The	O
Impact	O
of	O
Deployment	B-T052
on	O
Parental	B-T099
,	O
Family	B-T099
and	O
Child	B-T100
Adjustment	B-T055
in	O
Military Families	B-T099
Since	O
9/11,	O
military service	B-T097
in	O
the	O
United States	B-T083
has	O
been	O
characterized	O
by	O
wartime	B-T079
deployments	B-T052
and	O
reintegration	O
challenges	O
that	O
contribute	O
to	O
a	O
context	O
of	O
stress	B-T033
for	O
military families	B-T099
.	O
Research	B-T062
indicates	O
the	O
negative impact	B-T033
of	O
wartime	O
deployment	B-T052
on	O
the	O
well being	B-T078
of	O
service	B-T097
members	B-T098
,	O
military	B-T097
spouses	B-T099
,	O
and	O
children	B-T100
.	O
Yet,	O
few	O
studies	O
have	O
considered	O
how	O
parental	B-T099
deployments	B-T052
may	O
affect	O
adjustment	B-T055
in	O
young children	B-T100
and	O
their	O
families	B-T099
.	O
Using	O
deployment	B-T052
deployment records	B-T170
and	O
parent	B-T099
-	O
reported	B-T170
measures	O
from	O
primary	O
caregiving	B-T052
(N	O
=	O
680)	O
and	O
military	B-T097
(n	O
=	O
310)	O
parents	B-T099
,	O
we	O
examined	O
the	O
influence	O
of	O
deployment	B-T052
on	O
adjustment	B-T055
in	O
military families	B-T099
with	O
children	B-T100
ages	O
0-10	O
years.	O
Greater	O
deployment	B-T052
exposure	O
was	O
related	O
to	O
impaired	B-T169
family functioning	B-T054
and	O
marital	B-T033
instability	B-T033
.	O
Parental	B-T099
depressive	B-T048
and	O
posttraumatic stress symptoms	B-T048
were	O
associated with	B-T080
impairments	B-T169
in	O
social	B-T054
emotional	B-T033
adjustment	B-T055
in	O
young children	B-T100
,	O
increased	O
anxiety	B-T033
in	O
early	O
childhood	B-T079
,	O
and	O
adjustment	B-T055
problems	O
in	O
school-age children	B-T100
.	O
Conversely,	O
parental	B-T099
sensitivity	B-T041
was	O
associated with	B-T080
improved	O
social	B-T054
and	O
emotional outcomes	B-T033
across	O
childhood	B-T079
.	O
These	O
findings	B-T033
provide	O
guidance	O
to	O
developing	O
preventive	B-T080
approaches	O
for	O
military families	B-T099
with	O
young	O
children	B-T100
.	O

Beyond	O
neutral	B-T077
and	O
forbidden links	B-T077
:	O
morphological	B-T082
matches	B-T080
and	O
the	O
assembly	B-T078
of	O
mutualistic	B-T067
hawkmoth	B-T204
-	O
plant	B-T002
networks	B-T169
A	O
major	O
challenge	O
in	O
evolutionary ecology	B-T090
is	O
to	O
understand	O
how	O
co-evolutionary processes	B-T067
shape	O
patterns	B-T082
of	O
interactions	B-T169
between	O
species	B-T185
at	O
community	B-T096
level	B-T080
.	O
Pollination	B-T040
of	O
flowers	B-T002
with	O
long corolla tubes	B-T002
by	O
long-tongued hawkmoths	B-T204
has	O
been	O
invoked	O
as	O
a	O
showcase	O
model	B-T075
of	O
co-evolution	B-T045
.	O
Recently,	O
optimal	O
foraging	O
models	B-T075
have	O
predicted	O
that	O
there	O
might	O
be	O
a	O
close	O
association	B-T080
between	O
mouthparts' length	B-T081
and	O
the	O
corolla	B-T002
depth	B-T082
of	O
the	O
visited	O
flowers	B-T002
,	O
thus	O
favouring	O
trait	B-T032
convergence	B-T052
and	O
specialization	B-T090
at	O
community	B-T096
level.	O
Here,	O
we	O
assessed	B-T052
whether	O
hawkmoths	B-T204
more	O
frequently	O
pollinate plants	B-T002
with	O
floral tube	B-T185
lengths	B-T081
similar	O
to	O
their	O
proboscis	B-T204
lengths	B-T081
(	O
morphological	B-T082
match	B-T080
hypothesis	B-T078
)	O
against	O
abundance	B-T080
-based	O
processes	B-T067
(	O
neutral hypothesis	B-T078
)	O
and	O
ecological trait	B-T032
mismatches	B-T080
constraints	B-T057
(	O
forbidden links	B-T077
hypothesis	B-T078
),	O
and	O
how	O
these	O
processes	B-T067
structure	B-T082
hawkmoth	B-T204
-	O
plant	B-T002
mutualistic networks	B-T169
from	O
five	O
communities	B-T096
in	O
four	O
biogeographical regions	B-T083
of	O
South America	B-T083
.	O
We	O
found	O
convergence	B-T052
in	O
morphological	B-T082
traits	B-T032
across	O
the	O
five	O
communities	B-T096
and	O
that	O
the	O
distribution	B-T169
of	O
morphological	B-T082
differences	O
between	O
hawkmoths	B-T204
and	O
plants	B-T002
is	O
consistent	O
with	O
expectations	O
under	O
the	O
morphological	B-T082
match	B-T080
hypothesis	B-T078
in	O
three	O
of	O
the	O
five	O
communities	B-T096
.	O
In	O
the	O
two	O
remaining	O
communities	B-T096
,	O
which	O
are	O
ecotones	O
between	O
two	O
distinct	O
biogeographical areas	B-T083
,	O
interactions	B-T169
are	O
better	O
predicted	O
by	O
the	O
neutral hypothesis	B-T078
.	O
Our	O
findings	B-T169
are	O
consistent	O
with	O
the	O
idea	O
that	O
diffuse	O
co-evolution	B-T045
drives	O
the	O
evolution	B-T045
of	O
extremely	O
long proboscises	B-T204
and	O
flower tubes	B-T002
,	O
and	O
highlight	O
the	O
importance	O
of	O
morphological	B-T082
traits	B-T032
,	O
beyond	O
the	O
forbidden links	B-T077
hypothesis	B-T078
,	O
in	O
structuring	O
interactions	B-T169
between	O
mutualistic partners	B-T078
,	O
revealing	O
that	O
the	O
role	B-T077
of	O
niche-based processes	B-T067
can	O
be	O
much	O
more	O
complex	O
than	O
previously	O
known.	O

Nosocomial pneumonia	B-T047
caused	O
by	O
methicillin-resistant Staphylococcus aureus	B-T007
treated with	B-T061
linezolid	B-T109
or	O
vancomycin	B-T116
:	O
A	O
secondary	O
economic analysis	B-T057
of	O
resource use	B-T078
from	O
a	O
Spanish	B-T083
perspective	B-UnknownType
Adopting	O
a	O
unique	O
Spanish	B-T083
perspective	B-UnknownType
,	O
this	O
study	B-T062
aims	O
to	O
assess	O
healthcare resource utilization	B-T078
(	O
HCRU	B-T078
)	O
and	O
the	O
costs	B-T081
of	O
treating	B-T169
nosocomial pneumonia	B-T047
(	O
NP	B-T047
)	O
produced	O
by	O
methicillin-resistant Staphylococcus aureus	B-T007
(	O
MRSA	B-T007
)	O
in	O
hospitalized adults	B-T033
using	O
linezolid	B-T109
or	O
vancomycin	B-T116
.	O
An	O
evaluation	O
is	O
also	O
made	O
of	O
the	O
renal failure	B-T047
rate	B-T081
and	O
related	O
economic outcomes	B-T169
between	O
study groups	B-UnknownType
.	O
An	O
economic	O
post hoc evaluation	B-T058
of	O
a	O
randomized	B-T062
,	O
double-blind	B-T062
,	O
multicenter phase 4 study	B-T062
was	O
carried	O
out.	O
Nosocomial pneumonia	B-T047
due	O
to	O
MRSA	B-T007
in	O
hospitalized adults	B-T033
.	O
The	O
modified intent to treat	B-T169
(	O
mITT	B-T169
)	O
population	B-T098
comprised	O
224	O
linezolid	B-T109
-	O
and	O
224	O
vancomycin	B-T116
-	O
treated	B-T061
patients	B-T101
.	O
Costs	B-T081
and	O
HCRU	B-T078
were	O
evaluated	O
between	O
patients	B-T101
administered	B-T169
either	O
linezolid	B-T109
or	O
vancomycin	B-T116
,	O
and	O
between	O
patients	B-T101
who	O
developed	O
renal failure	B-T047
and	O
those	O
who	O
did	O
not.	O
Analysis	O
of	O
HCRU	B-T078
outcomes	B-T169
and	O
costs	B-T081
.	O
Total	O
costs	B-T081
were	O
similar	O
between	O
the	O
linezolid	B-T109
-	O
(€17,782±€9,615)	O
and	O
vancomycin	B-T116
-	O
treated	B-T061
patients	B-T101
(€17,423±€9,460)	O
(P=.69).	O
The	O
renal failure	B-T047
rate	B-T081
was	O
significantly	O
lower	O
in	O
the	O
linezolid	B-T109
-	O
treated	B-T061
patients	B-T101
(4%	O
vs.	O
15%;	O
P<.001).	O
The	O
total	O
costs	B-T081
tended	O
to	O
be	O
higher	O
in	O
patients	B-T101
who	O
developed	O
renal failure	B-T047
(€19,626±€10,840	O
vs.	O
€17,388±€9,369;	O
P=.14).	O
Among	O
the	O
patients	B-T101
who	O
developed	O
renal failure	B-T047
,	O
HCRU	B-T078
(	O
days	B-T079
on	O
mechanical ventilation	B-T061
:	O
13.2±10.7	O
vs.	O
7.6±3.6	O
days	B-T079
;	O
P=.21;	O
ICU stay	B-T079
:	O
14.4±10.5	O
vs.	O
9.9±6.6	O
days	B-T079
;	O
P=.30;	O
hospital stay	B-T079
:	O
19.5±9.5	O
vs.	O
16.1±11.0	O
days	B-T079
;	O
P=.26)	O
and	O
cost	B-T081
(€17,219±€8,792	O
vs.	O
€20,263±€11,350;	O
P=.51)	O
tended	O
to	O
be	O
lower	O
in	O
the	O
linezolid	B-T109
-	O
vs.	O
vancomycin	B-T116
-	O
treated	B-T061
patients	B-T101
.	O
There	O
were	O
no	O
statistically	O
significant	O
differences	O
in	O
costs	B-T081
per	O
patient	B-T101
-	O
day	B-T079
between	O
cohorts	B-T098
after	O
correcting	O
for	O
mortality	B-T081
(€1000	O
vs.	O
€1,010;	O
P=.98).	O
From	O
a	O
Spanish	B-T083
perspective	B-UnknownType
,	O
there	O
were	O
no	O
statistically	O
significant	O
differences	O
in	O
total	O
costs	B-T081
between	O
the	O
linezolid	B-T109
and	O
vancomycin	B-T116
pneumonia	B-T047
cohorts	B-T098
.	O
The	O
drug cost	B-T081
corresponding	O
to	O
linezolid	B-T109
was	O
partially	O
offset	B-T081
by	O
fewer	O
renal failure	B-T047
adverse events	B-T046
.	O

HERG1	B-T116
potassium channel	B-T116
expression	B-T045
in	O
potentially	B-T080
malignant disorders	B-T191
of	O
the	O
oral mucosa	B-T023
and	O
prognostic	B-T170
relevance	B-T080
in	O
oral squamous cell carcinoma	B-T191
HERG1	B-T116
potassium channel	B-T116
plays	O
a	O
critical	B-T080
role	B-T077
in	O
the	O
cell proliferation	B-T043
.	O
HERG1 protein	B-T116
expression	B-T045
was	O
analyzed	B-T062
by	O
immunohistochemistry	B-T060
(	O
IHC	B-T060
)	O
in	O
62	O
patients	B-T101
with	O
oral leukoplakias	B-T191
and	O
100	O
patients	B-T101
with	O
oral squamous cell carcinomas	B-T191
(	O
OSCC	B-T191
).	O
HERG1	B-T028
mRNA	B-T114
levels	B-T080
were	O
assessed	B-T052
by	O
real-time reverse transcriptase-polymerase chain reaction	B-T063
(	O
RT-PCR	B-T063
)	O
in	O
22	O
patients	B-T101
with	O
primary	B-T080
head and neck squamous cell carcinoma	B-T191
(	O
HNSCC	B-T191
).	O
Statistically significant	B-T081
associations	B-T080
were	O
found	O
between	O
HERG1	B-T116
expression	B-T045
and	O
tobacco consumption	B-T055
,	O
disease stage	B-T060
,	O
tumor	B-T191
differentiation	B-T043
,	O
tumor recurrence	B-T191
,	O
and	O
reduced	B-T080
survival	B-T052
.	O
There	O
was	O
no	B-T169
association	B-T080
between	O
HERG1	B-T116
expression	B-T045
and	O
the	O
risk	B-T078
of	O
progression	B-T191
from	O
oral leukoplakia	B-T191
to	O
OSCC	B-T191
.	O
In	O
addition,	O
a	O
high	B-T080
proportion	B-T081
of	O
tumors	B-T191
(80%)	O
showed	O
increased	B-T081
HERG1	B-T028
mRNA	B-T114
levels	B-T080
compared	B-T052
to	O
normal mucosa	B-T024
from	O
nononcologic patients	B-T101
.	O
Aberrant	B-T080
HERG1	B-T116
expression	B-T045
increases	B-T169
as	O
oral	O
tumorigenesis progresses	B-T191
from	O
oral hyperplasia	B-T046
to	O
OSCC	B-T191
.	O
Increased	B-T081
HERG1	B-T028
mRNA	B-T114
levels	B-T080
were	O
also	O
frequently	O
detected	B-T033
in	O
OSCC	B-T191
and	O
other	O
HNSCC	B-T191
subsites	B-T082
.	O
HERG1	B-T116
expression	B-T045
emerges	O
as	O
a	O
clinically	B-T080
relevant	B-T080
feature	B-T080
during	O
tumor progression	B-T191
and	O
a	O
potential	B-T080
poor	B-T080
prognostic	B-T170
biomarker	B-T201
for	O
OSCC	B-T191
.	O
©	O
2016	O
Wiley	O
Periodicals,	O
Inc.	O
Head	O
Neck	O
38:	O
1708-1716,	O
2016.	O

Nationwide	B-T082
reduction	B-T081
in	O
the	O
number	O
of	O
corneal transplantations	B-T061
for	O
keratoconus	B-T047
following	O
the	O
implementation	B-T052
of	O
cross-linking	B-T061
Keratoconus	B-T047
is	O
characterized	O
by	O
corneal ectasia	B-T047
and	O
irregular astigmatism	B-T047
,	O
which	O
can	O
lead	O
to	O
diminished vision	B-T047
and	O
corneal scarring	B-T033
.	O
Approximately	O
10-20%	O
of	O
patients	B-T101
with	O
keratoconus	B-T047
eventually	O
require	O
a	O
corneal transplant	B-T061
.	O
Corneal cross-linking	B-T061
(	O
CXL	B-T061
)	O
is	O
a	O
relatively	O
new	O
treatment	B-T061
that	O
may	O
help	O
prevent	O
the	O
need	O
for	O
corneal transplantation	B-T061
.	O
Here,	O
we	O
investigated	B-T169
whether	O
the	O
introduction	B-T169
of	O
CXL	B-T061
has	O
reduced	O
the	O
number	O
of	O
corneal transplants	B-T061
performed	B-T169
annually	B-T079
.	O
Data	B-T078
regarding	O
the	O
transplantation procedures	B-T061
performed	B-T169
in	O
patients	B-T101
under	O
the	O
age	B-T032
of	O
50	O
years	B-T079
were	O
extracted	O
from	O
the	O
Dutch National Organ Transplant Registry	B-T170
.	O
The	O
number	O
of	O
corneal transplants	B-T061
performed	B-T169
prior	O
to	O
(i.e.	O
in	O
2005	O
through	O
2007)	O
and	O
following	O
the	O
introduction	B-T169
of	O
CXL	B-T061
(i.e.	O
in	O
2012	O
through	O
2014)	O
were	O
compared	B-T052
.	O
Furthermore,	O
a	O
trend analysis	B-UnknownType
on	O
annual	B-T079
keratoplasties	B-T061
over	O
time	O
was	O
performed	B-T169
.	O
Approximately	O
25%	O
fewer	O
corneal transplants	B-T061
were	O
performed	B-T169
in	O
the	O
3-	O
year	B-T079
period	O
following	O
the	O
introduction	B-T169
of	O
CXL	B-T061
compared	B-T052
to	O
the	O
3-	O
year	B-T079
period	O
prior	O
to	O
the	O
introduction	B-T169
of	O
CXL	B-T061
(201	O
versus	O
269	O
transplants	B-T061
,	O
respectively;	O
p	O
=	O
0.005).	O
Age	B-T032
,	O
gender	B-T032
and	O
visual acuity	B-T201
were	O
similar	O
between	O
the	O
patient	B-T101
groups	O
in	O
the	O
two	O
time periods	B-T079
.	O
Trend analysis	B-UnknownType
also	O
demonstrated	O
a	O
significant	O
decrease	B-T081
in	O
the	O
amount	O
of	O
corneal transplants	B-T061
(p	O
=	O
0.001).	O
Significantly	O
fewer	O
corneal transplants	B-T061
were	O
performed	O
for	O
treating	O
keratoconus	B-T047
following	O
the	O
nationwide	B-T082
introduction	B-T169
of	O
CXL	B-T061
.	O
This	O
reduction	B-T081
suggests	O
that	O
corneal cross-linking	B-T061
can	O
significantly	O
reduce	B-T080
the	O
need	O
for	O
corneal transplantation	B-T061
.	O

Basal	B-T040
and	O
maximal	B-T080
metabolic rates	B-T039
differ	O
in	O
their	O
response	B-T032
to	O
rapid	O
temperature change	B-T080
among	O
avian	B-T012
species	B-T185
In	O
birds	B-T012
,	O
acclimation	B-T040
and	O
acclimatization	B-T040
to	O
temperature	B-T081
are	O
associated	O
with	O
changes	O
in	O
basal	B-T040
(	O
BMR	B-T040
),	O
summit	B-T039
(	O
Msum	B-T039
)	O
and	O
maximal	B-T080
(	O
MMR	B-T039
)	O
metabolic rates	B-T039
but	O
little	O
is	O
known	O
about	O
the	O
rate	B-T039
at	O
which	O
species	B-T185
adjust	O
their	O
phenotype	B-T032
to	O
short-term	B-T079
temperature	B-T081
variations	B-T080
.	O
Our	O
aims	B-T078
were	O
(1)	O
to	O
determine	O
the	O
pattern	B-T082
of	O
metabolic	B-T169
adjustments	O
following	O
a	O
rapid	O
temperature change	B-T080
,	O
(2)	O
to	O
determine	O
whether	O
performance	O
varies	O
at	O
similar	O
rates	B-T039
during	O
exposure to	B-T080
warm	B-T067
or	O
cold environments	B-T067
,	O
and	O
(3)	O
to	O
determine	O
if	O
BMR	B-T040
,	O
Msum	B-T039
and	O
MMR	B-T039
change	O
at	O
comparable	O
rates	B-T039
during	O
thermal	B-T070
acclimation	B-T040
.	O
We	O
measured	O
these	O
parameters	O
in	O
white-throated sparrows	B-T012
(	O
Zonotrichia albicollis	B-T012
),	O
black-capped chickadees	B-T012
(	O
Poecile atricapillus	B-T012
),	O
and	O
snow buntings	B-T012
(	O
Plectrophenax nivalis	B-T012
)	O
after	O
acclimation	B-T040
to	O
10	O
°C	O
(	O
day	B-T079
0)	O
and	O
on	O
the	O
4th	O
and	O
8th	O
days	B-T079
of	O
acclimation	B-T040
to	O
either	O
-5	O
or	O
28	O
°C.	O
Birds	B-T012
changed	O
their	O
metabolic	B-T169
phenotype	B-T032
within	O
8	O
days	B-T079
with	O
patterns	B-T082
differing	O
among	O
species	B-T185
.	O
Sparrows	B-T012
expressed	O
the	O
expected	O
metabolic	B-T169
increases	B-T169
in	O
the	O
cold	B-T067
and	O
decreases	O
at	O
thermoneutrality	B-T078
while	O
performance	O
in	O
chickadees	B-T012
and	O
buntings	B-T012
was	O
not	O
influenced	B-T077
by	O
temperature	B-T081
but	O
changed	O
over	O
time	O
with	O
inverse	O
patterns	B-T082
.	O
Our	O
results	B-T033
suggest	O
that	O
BMR	B-T040
varies	O
at	O
comparable	O
rates	B-T039
in	O
warm	B-T067
and	O
cold environments	B-T067
but	O
changes	O
faster	O
than	O
Msum	B-T039
and	O
MMR	B-T039
,	O
likely	O
due	O
to	O
limitations	B-T169
in	O
the	O
rate	B-T039
of	O
change	O
in	O
organ size	B-T032
and	O
function	B-T169
.	O
They	O
also	O
suggest	O
that	O
maximal	B-T080
metabolic	B-T169
capacity	B-T081
is	O
lost	B-T169
faster	O
in	O
a	O
warm environment	B-T067
than	O
it	O
is	O
gained	B-T081
in	O
a	O
cold environment	B-T067
.	O
With	O
the	O
expected	O
increase	O
in	O
temperature	B-T081
stochasticity	B-T081
at	O
northern latitudes	B-T083
,	O
a	O
loss	B-T081
of	O
thermogenic	B-T070
capacity	B-T081
during	O
warm	B-T067
winter	B-T079
days	B-T079
could,	O
therefore,	O
be	O
detrimental	O
if	O
birds	B-T012
are	O
slow	O
to	O
readjust	O
their	O
phenotype	B-T032
with	O
the	O
return	O
of	O
cold	B-T067
days	B-T079
.	O

A	O
prime	B-T041
a	O
day	O
keeps	O
calories	B-T081
away:	O
The	O
effects of	B-T080
supraliminal priming	B-T041
on	O
food consumption	B-T052
and	O
the	O
moderating role	B-T170
of	O
gender	B-T032
and	O
eating restraint	B-T170
The	O
link	O
between	O
intentions	B-T041
and	O
action	B-T052
in	O
weight control	B-T061
is	O
weaker	O
than	O
previously	O
thought,	O
so	O
recent	O
research	B-T062
has	O
called	O
for	O
further	O
investigation	O
of	O
ways	O
to	O
improve	O
weight control	B-T061
that	O
bypass	O
conscious	B-T041
intentions	B-T041
.	O
Priming	B-T041
has	O
been	O
shown	O
to	O
have	O
effects	O
on	O
individual	O
behavior	O
in	O
a	O
variety	O
of	O
contexts	O
by	O
influencing	O
subconscious	B-T041
cognition	B-T041
.	O
This	O
paper	O
investigates	O
the	O
effects of	B-T080
semantic priming	B-T169
using	O
healthy	B-T080
body image	B-T041
,	O
goal-oriented words	B-T170
on	O
food consumption	B-T052
.	O
The	O
moderating role	B-T170
of	O
both	O
restrained eating	B-T170
and	O
gender	B-T032
is	O
investigated.	O
161	O
participants	B-T098
were	O
involved	O
in	O
an	O
experiment	B-T062
using	O
a	O
novel	O
version	O
of	O
a	O
scrambled	O
sentence	B-T170
priming	B-T041
game	B-T056
.	O
The	O
outcome	O
measure	O
was	O
the	O
number	O
of	O
kilocalories	B-T081
consumed	B-T061
,	O
examined	O
using	O
a	O
between	O
subjects	O
ANCOVA	B-T081
with	O
priming	B-T041
,	O
gender	B-T032
,	O
restrained eating index	B-T170
,	O
self-reported	B-T062
BMI	B-T201
,	O
and	O
two	O
interaction	B-T169
terms	O
(	O
priming	B-T041
x	O
gender	B-T032
,	O
and	O
priming	B-T041
x	O
restrained eating index	B-T170
).	O
There	O
was	O
no	O
main	O
effect of	B-T080
priming	B-T041
but	O
there	O
was	O
an	O
interaction	B-T169
of	O
priming	B-T041
with	O
gender	B-T032
.	O
Females	B-T032
consumed	O
significantly	O
fewer	O
kilocalories	B-T081
after	O
being	O
exposed	O
to	O
priming	B-T041
words	B-T170
related	O
to	O
a	O
healthy	B-T080
body image	B-T041
(i.e.	O
"slim",	O
"fit,")	O
compared	O
to	O
females	B-T032
receiving	O
the	O
neutral	O
prime	B-T041
,	O
with	O
a	O
medium	O
effect	O
size	O
(d	O
=	O
0.58).	O
The	O
body image	B-T041
prime	B-T041
did	O
not	O
significantly	O
affect	O
food intake	B-T040
for	O
males	B-T032
,	O
nor	O
did	O
it	O
have	O
a	O
differential	O
effect	O
on	O
restrained eaters	B-T098
.	O
This	O
study	O
shows	O
that	O
priming	B-T041
can	O
be	O
an	O
effective	O
method	O
for	O
influencing	O
females	B-T032
to	O
reduce	O
food intake	B-T040
,	O
regardless	O
of	O
whether	O
they	O
are	O
restrained	B-T098
or	O
unrestrained eaters	B-T098
.	O
Future	O
studies	O
could	O
investigate	O
whether	O
different	O
priming	B-T041
words	B-T170
related	O
to	O
a	O
male's	B-T032
healthy	B-T080
body image	B-T041
goal	O
(i.e.	O
"buff,"	O
"	O
muscles	B-T024
,"	O
etc.)	O
would	O
similarly	O
reduce	O
food intake	B-T040
for	O
males	B-T032
.	O

Neurotrophins	B-T116
and	O
specific receptors	B-T116
in	O
the	O
oviduct tracts	B-T023
of	O
Japanese quail	B-T012
(	O
Coturnix coturnix japonica	B-T012
)	O
Neurotrophins	B-T116
(	O
NGF	B-T116
,	O
BDNF	B-T116
and	O
NT-3	B-T116
)	O
and	O
their	O
specific receptors	B-T116
(	O
TrkA	B-T116
,	O
TrkB	B-T116
and	O
TrkC	B-T116
)	O
were	O
studied	B-T062
in	O
the	O
oviduct	B-T023
of	O
egg laying	B-T040
quails	B-T012
.	O
Neurotrophins	B-T116
(	O
NTs	B-T116
)	O
are	O
mainly	O
involved	O
in	O
the	O
development	B-T169
and	O
maintenance	B-T169
of	O
neuronal populations	B-T025
in	O
the	O
central	B-T022
and	O
peripheral nervous system	B-T022
,	O
but	O
also	O
in	O
reproductive system	B-T022
.	O
In	O
this	O
survey,	O
we	O
first	O
studied	B-T062
the	O
morphological	B-T080
organization	B-T039
of	O
the	O
quail	B-T012
oviduct	B-T023
,	O
distinguished	O
in	O
infundibulum	B-T023
,	O
magnum	B-T023
,	O
isthmus	B-T023
,	O
uterus	B-T023
and	O
vagina	B-T023
,	O
and	O
then	O
we	O
analyzed	B-T062
the	O
expression	B-T045
and	O
localization	B-T043
of	O
NTs	B-T116
and	O
Trks receptors	B-T116
in	O
the	O
whole	O
tracts	B-T023
.	O
By	O
western blotting	B-T059
we	O
detected	O
that	O
the	O
investigated	B-T169
NTs	B-T116
and	O
Trks receptors	B-T116
are	O
expressed	B-T045
in	O
all	O
oviductal tracts	B-T023
.	O
By	O
immunohistochemistry	B-T060
we	O
were	O
able	O
to	O
define	O
the	O
distribution	B-T043
of	O
NTs	B-T116
and	O
Trks	B-T116
.	O
Specifically,	O
NGF	B-T116
,	O
BDNF	B-T116
and	O
NT3	B-T116
were	O
localized	O
in	O
lining	B-T082
and	O
ductal epithelial cells	B-T025
,	O
and	O
NGF	B-T116
was	O
also	O
detected	O
in	O
secretory cells	B-T025
of	O
tubular glands	B-T023
and	O
in	O
nervous fibers	B-T026
of	O
vessel wall	B-T023
.	O
TrkA	B-T116
and	O
TrkB	B-T116
were	O
present	O
in	O
the	O
lining	B-T082
and	O
ductal epithelium	B-T024
;	O
TrkA	B-T116
and	O
TrkC	B-T116
were	O
present	O
in	O
nervous fibers	B-T026
of	O
vessel wall	B-T023
in	O
all	O
oviductal tracts	B-T023
.	O
Furthermore,	O
we	O
also	O
observed	O
NGF	B-T116
and	O
BDNF	B-T116
co-localized	O
with	O
TrkA	B-T116
and	O
TrkB	B-T116
in	O
cells	B-T025
of	O
the	O
lining	B-T082
and	O
ductal epithelium	B-T024
,	O
suggesting	O
an	O
autocrine mechanism	B-T043
of	O
action	B-T052
.	O

The	O
influence	O
of	O
liposomal	B-T109
formulation	B-T077
on	O
the	O
incorporation	B-T169
and	O
retention	B-T169
of	O
PNA oligomers	B-T114
Liposomal	B-T109
formulations	B-T077
composed	O
of	O
phospholipids	B-T109
with	O
different	O
unsaturation degrees	B-T080
,	O
head groups	B-T169
and	O
at	O
different	O
cholesterol content have been tested	B-T059
for	O
the	O
encapsulation	B-T067
of	O
Peptide Nucleic Acid (PNA) oligomers	B-T114
.	O
The	O
best loading capability	B-T081
(177μg,	O
ER	B-T081
%=87.2)	O
was	O
obtained	O
for	O
pure	O
liposomes	B-T109
of	O
phosphatidylglycerol	B-T109
(	O
DOPG	B-T109
)	O
with	O
negatively charged	B-T196
head group	B-T169
.	O
The	O
insertion	B-T058
of	O
a	O
10-20%	O
of	O
cholesterol	B-T109
in	O
DOPG	B-T109
based	O
liposomes	B-T109
provides	O
a	O
slight	O
decrease	B-T081
(∼160μg)	O
of	O
the	O
PNA	B-T114
loading	B-T052
.	O
On	O
the	O
other	O
hand,	O
the	O
cholesterol	B-T109
addition	B-T169
(20-30%)	O
slows	O
down	O
the	O
PNA's	B-T114
release	B-T070
(∼27%)	O
in	O
fetal bovine serum	B-T130
from	O
the	O
liposomal	B-T109
formulation	B-T077
.	O
Based	O
on	O
the	O
encapsulation	B-T067
and	O
the	O
release properties	B-T070
,	O
PEGylated	B-T109
DOPG	B-T109
liposomes	B-T109
with	O
a	O
percentage	O
of	O
cholesterol	B-T109
of	O
10-20%	O
are	O
the	O
optimal formulation	B-T062
for	O
the	O
loading	B-T052
of	O
PNA-a210	B-T114
.	O

Histopathology	B-T091
of	O
the	O
filum terminale	B-T023
in	O
children	B-T100
with	O
and	O
without	B-T080
tethered cord syndrome	B-T047
with	O
attention	O
to	O
the	O
elastic tissue	B-T024
within	O
the	O
filum	B-T023
To	O
compare	B-T052
histologically	B-T169
transected	B-T169
fila	B-T023
from	O
pediatric	B-T080
patients	B-T101
with	O
tethered cord syndrome	B-T047
(	O
TCS	B-T047
),	O
with	O
and	O
without	B-T080
a	O
low	B-T029
conus	B-T023
,	O
with	O
controls,	O
focusing	O
on	O
collagenous	B-T024
and	O
elastic tissue	B-T024
.	O
Thirty	O
fila	B-T023
from	O
patients	B-T101
with	O
TCS	B-T047
,	O
including	O
5	O
where	O
minimal	B-T080
cautery	B-T061
was	O
used	O
prior	O
to	O
filum	B-T023
section	B-T059
,	O
were	O
compared	B-T052
with	O
fila	B-T023
from	O
27	O
pediatric	B-T080
cadavers	B-T017
without	B-T080
TCS	B-T047
(	O
controls	B-T096
).	O
Sections	B-T167
of	O
fila	B-T023
were	O
stained	B-T059
with	O
H&E	B-T059
,	O
Masson trichrome	B-T059
and	O
Verhoeff von Gieson elastic stains	B-T059
,	O
and	O
7	O
with	O
Gordon and Sweet's reticulin stain	B-T059
.	O
Fila	B-T023
from	O
controls	B-T096
showed	O
loose	B-T080
fibrous connective tissue	B-T024
(	O
FCT	B-T024
)	O
with	O
thin	B-T080
and	O
evenly dispersed	B-T169
elastic fibers	B-T024
(	O
EFs	B-T024
).	O
Reticulin fibers	B-T116
(	O
RFs	B-T116
)	O
were	O
seen	O
in	O
blood vessel walls	B-T023
and	O
nerve	B-T024
twigs.	O
Fat	B-T109
was	O
identified	B-T080
microscopically	B-T080
in	O
2	O
fila	B-T023
.	O
All	O
fila	B-T023
from	O
patients	B-T101
with	O
TCS	B-T047
had	O
dense FCT	B-T024
.	O
The	O
EFs	B-T024
were	O
in	O
normal	B-T080
numbers	O
in	O
17,	O
and	O
focally	B-T082
or	O
diffusely	B-T080
decreased	B-T081
in	O
13.	O
All	O
25	O
patients	B-T101
where	O
the	O
fila	B-T023
were	O
cauterized	B-T061
during	O
resection	B-T061
had	O
thick	B-T080
and	O
coiled	B-T082
EFs	B-T024
.	O
Coiling	B-T082
was	O
not	O
seen	O
when	O
minimal	B-T080
cautery	B-T061
was	O
applied.	O
RFs	B-T116
were	O
seen	O
in	O
blood vessel walls	B-T023
and	O
nerve	O
twigs.	O
Fat	B-T109
was	O
identified	B-T080
in	O
19	O
patients	B-T101
.	O
Findings	B-T033
were	O
similar	B-T080
,	O
whether	O
the	O
conus	B-T023
termination	O
was	O
normal	B-T080
or	O
low	B-T082
.	O
The	O
fila	B-T023
of	O
all	O
patients	B-T101
with	O
TCS	B-T047
,	O
whether	O
or	O
not	O
the	O
conus	B-T023
was	O
low	B-T082
,	O
showed	O
abnormal	B-T033
FCT	B-T024
.	O
EFs	B-T024
were	O
decreased	B-T081
in	O
48	O
%	O
of	O
patients	B-T101
;	O
however,	O
there	O
were	O
thick	B-T080
and	O
coiled	B-T082
EFs	B-T024
in	O
all	O
patients	B-T101
.	O
Coiling	B-T082
of	O
EFs	B-T024
,	O
initially	O
thought	O
to	O
be	O
an	O
abnormality	B-T033
in	O
patients	B-T101
,	O
is	O
considered	O
most	O
likely	O
to	O
be	O
a	O
result	B-T033
of	O
cautery	B-T061
(i.e.,	O
artifactual	B-T068
/	O
iatrogenic	B-T080
coiling	B-T082
).	O

Clinical value	B-T033
of	O
pathologic examination	B-T060
of	O
non-neoplastic kidney	B-T023
in	O
patients	B-T101
with	O
upper urinary tract	B-T022
malignancies	B-T191
While	O
surgical resection	B-T061
remains	O
the	O
standard	O
of	O
care	B-T052
in	O
the	O
treatment	B-T061
of	O
upper urinary tract	B-T022
malignancies	B-T191
,	O
nephrectomy	B-T061
is	O
a	O
risk factor	B-T033
for	O
the	O
development	B-T169
of	O
chronic kidney disease	B-T047
(	O
CKD	B-T047
).	O
The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
determine	O
whether	O
histologic	B-T169
evaluation	B-T058
of	O
non-neoplastic kidney	B-T023
could	O
enable	O
early identification	B-T061
of	O
unrecognized	O
kidney disease	B-T047
and	O
could	O
be	O
of	O
prognostic	B-T170
value	O
in	O
predicting	O
postoperative	B-T079
renal	B-T023
outcomes	B-T080
.	O
We	O
retrospectively analyzed	B-T062
51	O
patients	B-T101
with	O
upper urinary tract	B-T022
malignancies	B-T191
who	O
received	O
uninephrectomy	B-T061
or	O
uninephroureterectomy	B-T061
.	O
A	O
thorough	O
pathologic	B-T169
evaluation	B-T058
of	O
non-neoplastic kidney	B-T023
including	O
special stains	B-T061
,	O
immunofluorescence	B-T059
,	O
and	O
electron microscopic studies	B-T059
was	O
performed.	O
The	O
degree	B-T081
of	O
parenchymal	B-T023
changes	B-T169
was	O
graded	O
from	O
0	O
to	O
15.	O
Of	O
51	O
patients	B-T101
,	O
only	O
13	O
showed	O
normal	O
kidney	B-T023
pathology	B-T091
.	O
Fifteen	O
patients	B-T101
showed	O
glomerular abnormalities	B-T047
,	O
14	O
showed	O
diabetic nephropathy	B-T047
,	O
and	O
11	O
showed	O
vascular	B-T023
nephropathy	B-T061
.	O
There	O
was	O
one	O
case	O
each	O
of	O
reflux nephropathy	B-T047
and	O
chronic pyelonephritis	B-T047
.	O
The	O
median	O
histologic score	B-T081
was	O
5	O
points.	O
Only	O
25.4%	O
of	O
patients	B-T101
had	O
≤	O
3	O
points.	O
Score	B-T081
more	O
than	O
5	O
was	O
observed	O
in	O
47.1%	O
of	O
patients	B-T101
.	O
Postoperative	B-T079
estimated glomerular filtration rate	B-T059
(	O
eGFR	B-T059
)	O
at	O
3	O
to	O
36	O
months	B-T079
were	O
obtained	O
from	O
90.2%	O
of	O
patients	B-T101
,	O
and	O
of	O
those,	O
34.8%	O
had	O
de	O
novo	O
CKD	B-T047
.	O
Since	O
no	O
one	O
had	O
CKD	B-T047
in	O
partial	O
nephrectomized patients	B-T101
,	O
we	O
determined	O
risk factors	B-T033
for	O
CKD	B-T047
in	O
radical	O
nephrectomized patients	B-T101
.	O
Cox regression analysis	B-T170
revealed	O
that	O
postoperative	B-T079
AKI	B-T037
,	O
preoperative	B-T079
eGFR	B-T059
,	O
and	O
histologic	B-T169
score	O
of	O
non-neoplastic kidney	B-T023
were	O
the	O
independent	O
predictors	B-T078
for	O
CKD	B-T047
.	O
We	O
conclude	O
that	O
routine	O
pathologic	B-T169
evaluation	B-T058
of	O
non-neoplastic kidney	B-T023
provides	O
valuable	O
diagnostic	B-T169
and	O
prognostic	B-T170
information.	O

Concordant	O
but	O
Varied	O
Phenotypes	B-T032
among	O
Duchenne Muscular Dystrophy	B-T047
Patient	B-T101
-Specific	O
Myoblasts	B-T025
Derived	O
using	O
a	O
Human	B-T016
iPSC	B-T025
-Based	O
Model	B-T050
Duchenne muscular dystrophy	B-T047
(	O
DMD	B-T047
)	O
remains	O
an	O
intractable	O
genetic disease	B-T047
.	O
Althogh	O
there	O
are	O
several	O
animal models	B-T050
of	O
DMD	B-T047
,	O
there	O
is	O
no	O
human cell	B-T025
model	O
that	O
carries	O
patient	B-T101
-specific	O
DYSTROPHIN	B-T028
mutations	B-T045
.	O
Here,	O
we	O
present	O
a	O
human	B-T016
DMD	B-T047
model	B-T050
using	O
human induced pluripotent stem cells	B-T025
(	O
hiPSCs	B-T025
).	O
Our	O
model	O
reveals	O
concordant	O
disease	B-T047
-	O
related	B-T169
phenotypes	B-T032
with	O
patient	B-T101
-	O
dependent	B-T080
variation	B-T080
,	O
which	O
are	O
partially	O
reversed	O
by	O
genetic	B-T169
and	O
pharmacological	B-T169
approaches.	O
Our	O
"	O
chemical-compound	B-T103
-based"	O
strategy	B-T062
successfully	O
directs	O
hiPSCs	B-T025
into	O
expandable	O
myoblasts	B-T025
,	O
which	O
exhibit	O
a	O
myogenic transcriptional	B-T045
program	B-T169
,	O
forming	O
striated	B-T080
contractile	B-T026
myofibers	B-T026
and	O
participating	O
in	O
muscle regeneration	B-T033
in vivo	B-T082
.	O
DMD	B-T047
-	O
hiPSC	B-T025
-derived	O
myoblasts	B-T025
show	O
disease	B-T047
-	O
related	B-T169
phenotypes	B-T032
with	O
patient	B-T101
-to-	O
patient	B-T101
variability	B-T077
,	O
including	O
aberrant	B-T080
expression	O
of	O
inflammation	B-T046
or	O
immune-response genes	B-T028
and	O
collagens	B-T116
,	O
increased	O
BMP	B-T044
/	O
TGFβ signaling	B-T044
,	O
and	O
reduced	O
fusion	O
competence.	O
Furthermore,	O
by	O
genetic	B-T169
correction	B-T169
and	O
pharmacological	B-T169
"dual-	O
SMAD	B-T116
"	O
inhibition	B-T043
,	O
the	O
DMD	B-T047
-	O
hiPSC	B-T025
-derived	O
myoblasts	B-T025
and	O
genetically	B-T169
corrected	O
isogenic	B-T080
myoblasts	B-T025
form	O
"rescued"	O
multi	B-T081
-	O
nucleated	B-T080
myotubes	B-T025
.	O
In	O
conclusion,	O
our	O
findings	O
demonstrate	O
the	O
feasibility	O
of	O
establishing	O
a	O
human	B-T016
"	O
DMD	B-T047
-in-a-dish"	O
model	B-T050
using	O
hiPSC	B-T025
-based	O
disease modeling	B-T050
.	O

SNAI1	B-T116
promotes	B-T052
the	O
development	B-T169
of	O
HCC	B-T191
through	O
the	O
enhancement	B-T052
of	O
proliferation	B-T169
and	O
inhibition of apoptosis	B-T043
SNAI1	B-T116
,	O
a	O
zinc-finger transcription factor	B-T116
,	O
plays	O
an	O
important	O
role	O
in	O
the	O
induction	B-T169
of	O
epithelial-mesenchymal transition	B-T043
(	O
EMT	B-T043
)	O
in	O
various	O
cancers	B-T191
.	O
However,	O
the	O
possible	O
functions	O
of	O
SNAI1	B-T116
in	O
the	O
proliferation	B-T169
and	O
apoptosis	B-T043
of	O
hepatocellular carcinoma	B-T191
have	O
not	O
been	O
clearly	O
identified.	O
In	O
this	O
study	B-T062
,	O
we	O
investigated	O
the	O
effects	B-T080
and	O
mechanisms	B-T169
of	O
SNAI1	B-T116
in	O
the	O
proliferation	B-T169
and	O
apoptosis	B-T043
of	O
hepatocellular carcinoma	B-T191
using	O
clinical	B-T080
samples	B-T167
and	O
cell lines	B-T025
.	O
We	O
found	O
that	O
SNAI1	B-T116
is	O
highly	O
expressed	B-T045
in	O
the	O
tissues	B-T024
of	O
liver cancer	B-T191
compared	O
with	O
adjacent	O
nontumor tissues	B-T024
.	O
SNAI1	B-T116
is	O
also	O
highly	O
expressed	B-T045
in	O
the	O
hepatoma cell lines HepG2	B-T025
,	O
SMMC-7721	B-T025
,	O
and	O
BEL-7402	B-T025
compared	O
with	O
the	O
human normal liver cell line L02	B-T025
.	O
We	O
also	O
observed	O
that	O
SNAI1	B-T116
expression	B-T045
was	O
correlated	O
with	O
distal metastasis	B-T046
,	O
incomplete	O
tumor capsule formation	B-T191
,	O
and	O
histological differentiation	B-T201
in	O
hepatocellular carcinoma	B-T191
(	O
HCC	B-T191
).	O
Moreover,	O
we	O
demonstrated	O
that	O
knockdown	B-T063
of	O
SNAI1	B-T028
via	O
lentiviral	B-T005
vectors	B-T121
of	O
RNAi	B-T045
against	O
SNAI	B-T116
inhibited	O
cell proliferation	B-T169
by	O
inducing	O
G1 arrest	B-T043
,	O
which	O
was	O
accompanied	O
by	O
the	O
downregulation	B-T044
of	O
cyclin D1	B-T116
but	O
not	O
that	O
of	O
cyclin A	B-T116
.	O
In	O
addition,	O
knockdown	B-T063
of	O
SNAI1	B-T028
promoted	B-T052
apoptosis	B-T043
by	O
decreasing	O
the	O
expression	B-T045
of	O
Bcl-2	B-T116
.	O
In	O
conclusion,	O
our	O
findings	O
revealed	O
that	O
SNAI1	B-T116
is	O
involved	O
in	O
the	O
development	B-T169
of	O
hepatocellular carcinoma	B-T191
via	O
regulating the growth	B-T040
and	O
apoptosis	B-T043
of	O
tumor cells	B-T025
.	O

Quantitative assessment	B-T081
of	O
fluorescent proteins	B-T116
The	O
advent	O
of	O
fluorescent proteins	B-T116
(	O
FPs	B-T116
)	O
for	O
genetic labeling	B-T063
of	O
molecules	B-T167
and	O
cells	B-T025
has	O
revolutionized	O
fluorescence microscopy	B-T059
.	O
Genetic manipulations	B-T063
have	O
created	O
a	O
vast	O
array	O
of	O
bright	O
and	O
stable	O
FPs	B-T116
spanning	O
blue to red spectral regions	B-T082
.	O
Common	O
to	O
autofluorescent	B-T059
FPs	B-T116
is	O
their	O
tight	O
β-barrel structure	B-T087
,	O
which	O
provides	O
the	O
rigidity	B-T080
and	O
chemical	B-T103
environment	B-T082
needed	O
for	O
effectual	O
fluorescence	B-T070
.	O
Despite	O
the	O
common	O
structure	B-T085
,	O
each	O
FP	B-T116
has	O
unique	O
properties	B-T080
.	O
Thus,	O
there	O
is	O
no	O
single	O
'best'	O
FP	B-T116
for	O
every	O
circumstance,	O
and	O
each	O
FP	B-T116
has	O
advantages	O
and	O
disadvantages.	O
To	O
guide	O
decisions	O
about	O
which	O
FP	B-T116
is	O
right	O
for	O
a	O
given	O
application,	O
we	O
have	O
quantitatively	B-T081
characterized	O
the	O
brightness	B-T070
,	O
photostability	B-T033
,	O
pH	B-T081
stability	B-T080
and	O
monomeric	B-T104
properties	B-T080
of	O
more	O
than	O
40	O
FPs	B-T116
to	O
enable	O
straightforward	B-T080
and	O
direct	O
comparison	B-T052
between	O
them.	O
We	O
focus	O
on	O
popular	O
and/or	O
top-performing	O
FPs	B-T116
in	O
each	O
spectral region	B-T082
.	O

Consumption of fruits and vegetables	B-T040
associated with	B-T080
other	O
risk behaviors	B-T055
among	O
adolescents	B-T100
in	O
Northeast Brazil	B-T083
To	O
determine	O
the	O
prevalence	B-T081
of	O
consumption of fruits and vegetables	B-T040
and	O
identify	O
the	O
association with	B-T080
low	B-T080
level	B-T080
of	O
physical activity	B-T056
,	O
exposure to	B-T080
sedentary behavior	B-T033
,	O
consumption	B-T052
of	O
soft drinks	B-T168
and	O
overweight	B-T184
/	O
obesity	B-T047
in	O
adolescents	B-T100
.	O
This	O
is	O
a	O
cross-sectional school-based study	B-T062
with	O
a	O
representative	O
sample	B-T167
of	O
3992	O
students	B-T098
aged	O
14-19	O
years	B-T079
from	O
the	O
state of Sergipe	B-T083
,	O
Brazil	B-T083
.	O
The	O
outcome	B-T169
was	O
low	B-T080
consumption of fruits and vegetables	B-T040
(<5	O
servings/day	B-T079
).	O
Independent variables	B-T169
were:	O
level	B-T080
of	O
physical activity	B-T056
,	O
sedentary behavior	B-T033
,	O
consumption	B-T052
of	O
soft drinks	B-T168
,	O
and	O
overweight	B-T184
/	O
obesity	B-T047
.	O
Global Student Health Survey questionnaire	B-T170
and	O
body mass	B-T058
and	O
height	B-T032
measurements	B-T058
were	O
used,	O
as	O
well	O
as	O
chi-square test	B-T170
and	O
crude and adjusted binary logistic regression	B-T062
.	O
The	O
significance level	B-T062
adopted	O
was	O
5%.	O
The	O
prevalence	B-T081
of	O
inadequate	B-T080
consumption of fruits and vegetables	B-T040
was	O
high	B-T080
-	O
88.6%	O
(95%	O
CI	B-T081
=87.6-89.5).	O
Higher	B-T080
likelihood	O
of	O
low	B-T080
consumption of fruits and vegetables	B-T040
was	O
verified	O
among	O
boys	B-T100
who	O
were	O
exposed to	B-T080
sedentary behavior	B-T033
(	O
OR	B-T081
=1.63;	O
95%	O
CI	B-T081
=1.18-2.24),	O
who	O
consumed	B-T052
soft drinks	B-T168
(	O
OR	B-T081
=3.04;	O
95%	O
CI	B-T081
=2.10-4.40),	O
with	O
insufficiently	B-T080
physical activity	B-T056
(	O
OR	B-T081
=1.98;	O
95%	O
CI	B-T081
=1.43-2.73)	O
and	O
girls	B-T100
who	O
consumed	B-T052
soft drinks	B-T168
(	O
OR	B-T081
=1.88;	O
95%	O
CI	B-T081
=1.43-2.47)	O
and	O
those	O
with	O
overweight	B-T184
/	O
obesity	B-T047
(	O
OR	B-T081
=1.63;	O
95%	O
CI	B-T081
=1.19-2.23).	O
There	O
is	O
a	O
need	O
of	O
public policies	B-T064
aimed	O
at	O
encouraging	O
the	O
consumption of healthy foods	B-T052
among	O
adolescents	B-T100
.	O

Cobalamin	B-T114
Protection	B-T033
against	O
Oxidative Stress	B-T049
in	O
the	O
Acidophilic	B-T169
Iron-oxidizing Bacterium	B-T007
Leptospirillum Group II CF-1	B-T007
Members	O
of	O
the	O
genus	O
Leptospirillum	B-T007
are	O
aerobic	B-T080
iron-oxidizing bacteria	B-T007
belonging	O
to	O
the	O
phylum Nitrospira	B-T007
.	O
They	O
are	O
important	O
members	O
of	O
microbial	B-T001
communities	B-T070
that	O
catalyze	B-T070
the	O
biomining	B-T057
of	O
sulfidic ores	B-T104
,	O
thereby	O
solubilizing	O
metal ions	B-T196
.	O
These	O
microorganisms	B-T001
live	O
under	O
extremely	O
acidic	O
and	O
metal	B-T197
-loaded	O
environments	B-T082
and	O
thus	O
must	O
tolerate	O
high	O
concentrations	B-T081
of	O
reactive oxygen species	B-T123
(	O
ROS	B-T123
).	O
Cobalamin	B-T114
(	O
vitamin B12	B-T109
)	O
is	O
a	O
cobalt	B-T123
-containing	O
tetrapyrrole	B-T109
cofactor	B-T123
involved	O
in	O
intramolecular rearrangement reactions	B-T067
and	O
has	O
recently	O
been	O
suggested	O
to	O
be	O
an	O
intracellular	B-T082
antioxidant	B-T121
.	O
In	O
this	O
work,	O
we	O
investigated	B-T169
the	O
effect	B-T080
of	O
the	O
exogenous	B-T169
addition	O
of	O
cobalamin	B-T114
on	O
oxidative stress	B-T049
parameters	B-T077
in	O
Leptospirillum group II strain CF-1	B-T007
.	O
Our	O
results	O
revealed	B-T080
that	O
the	O
external supplementation	B-T168
of	O
cobalamin	B-T114
reduces	O
the	O
levels	O
of	O
intracellular	B-T082
ROSs	B-T123
and	O
the	O
damage	B-T169
to	O
biomolecules	B-T123
,	O
and	O
also	O
stimulates	B-T070
the	O
growth	B-T040
and	O
survival of cells	B-T043
exposed	O
to	O
oxidative stress	B-T049
exerted	O
by	O
ferric ion	B-T196
,	O
hydrogen peroxide	B-T121
,	O
chromate	B-T197
and	O
diamide	B-T109
.	O
Furthermore,	O
exposure	O
of	O
strain CF-1	B-T007
to	O
oxidative stress	B-T049
elicitors	O
resulted	O
in	O
the	O
transcriptional activation	B-T045
of	O
the	O
cbiA gene	B-T028
encoding	O
CbiA	B-T116
of	O
the	O
cobalamin	B-T114
biosynthetic pathway	B-T044
.	O
Altogether,	O
these	O
data	B-T078
suggest	O
that	O
cobalamin	B-T114
plays	O
an	O
important	O
role	O
in	O
redox	B-T044
protection	B-T033
of	O
Leptospirillum strain CF-1	B-T007
,	O
supporting	O
survival	O
of	O
this	O
microorganism	B-T001
under	O
extremely	O
oxidative	B-T169
environmental conditions	B-T080
.	O
Understanding	O
the	O
mechanisms	B-T169
underlying	O
the	O
protective	B-T033
effect	B-T080
of	O
cobalamin	B-T114
against	O
oxidative stress	B-T049
may	O
help	O
to	O
develop	O
strategies	O
to	O
make	O
biomining	B-T057
processes	B-T067
more	O
effective	B-T080
.	O

A	O
longitudinal study	B-T062
assessing	O
childcare	B-T057
services'	B-T057
adoption	O
of	O
obesity	B-T047
prevention policies and practices	B-T058
Despite	O
ongoing	O
investments	O
to	O
improve	O
the	O
obesogenic	B-T047
environments	B-T082
of	O
childcare	B-T057
settings,	O
little	O
is	O
known	O
regarding	O
how	O
these	O
services	B-T057
have	O
changed	O
their	O
physical activity	B-T056
and	O
nutrition-promoting practices	B-T062
.	O
This	O
study	O
aims	O
to	O
describe	O
changes	O
in	O
the	O
proportion	O
of	O
Australian	B-T098
childcare	B-T057
services	B-T057
that	O
have	O
adopted	O
best-practice	B-T058
healthy eating	B-T061
and	O
physical activity	B-T056
practices	B-T058
between	O
2006	O
and	O
2013	O
and	O
to	O
assess	O
whether	O
adoption	O
varied	O
by	O
socio-economic status	B-T080
and	O
locality	B-T082
.	O
A	O
randomly selected sample	B-T062
of	O
nominated	O
supervisors	B-T097
(n	O
=	O
358)	O
from	O
childcare	B-T057
services	B-T057
located	O
in	O
New South Wales	B-T083
,	O
Australia	B-T083
,	O
participated	O
in	O
a	O
telephone survey	B-T062
in	O
2006,	O
2009,	O
2010	O
and	O
2013.	O
Supervisors	B-T097
reported	O
on	O
their	O
service's	B-T057
adoption	O
of	O
six	O
practices	B-T058
:	O
(i)	O
having	O
written	O
nutrition	B-T062
and	O
physical activity	B-T056
policies	B-T170
;	O
(ii)	O
staff	B-T097
trained	O
in	O
physical activity	B-T056
and	O
nutrition	B-T062
in	O
the	O
past	O
year;	O
(iii)	O
scheduled	O
time	B-T079
for	O
fundamental	O
movement	B-T040
skills	B-T055
and	O
(iv)	O
outdoor play	B-T056
;	O
(v)	O
weekly	B-T079
or	O
less	O
screen time opportunitie	B-T033
s;	O
and	O
(vi)	O
serving	O
only	O
non-sweetened beverages	B-T168
.	O
A	O
significant	O
increase	O
in	O
the	O
prevalence	B-T081
of	O
services	B-T057
adopting	O
all	O
but	O
one	O
practice	B-T058
,	O
between	O
2006	O
and	O
2013	O
was	O
identified.	O
Ninety	O
one	O
percent	O
of	O
services	B-T057
adopted	O
four	O
or	O
more	O
practices	B-T058
,	O
a	O
significant	O
increase	O
from	O
38%	O
in	O
2006.	O
There	O
were	O
no	O
differences	O
in	O
the	O
proportion	O
of	O
services	B-T057
adopting	O
each	O
practice	B-T058
by	O
locality	B-T082
and	O
socio-economic status	B-T080
.	O
Government	B-T092
investment	B-T081
in	O
obesity	B-T047
prevention programmes	B-T058
can	O
equitably	O
improve	O
childcare	B-T057
service's	O
adoption	O
of	O
healthy eating	B-T061
and	O
physical activity	B-T056
promoting	O
practices	B-T058
on	O
a	O
jurisdiction	B-T170
-wide	O
basis.	O
The	O
establishment	O
of	O
a	O
routine	O
system	O
to	O
monitor	O
adoption	O
of	O
a	O
broader	O
range	O
of	O
practices	B-T058
by	O
childcare	B-T057
services	B-T057
is	O
warranted.	O

Isolation	B-T169
and	O
characterization	B-T052
of	O
Burkholderia sp. strain CCA53	B-T007
exhibiting	O
ligninolytic	B-T044
potential	B-T080
Microbial	B-T001
degradation	B-T040
of	O
lignin	B-T109
releases	O
fermentable sugars	B-T109
,	O
effective	B-T080
utilization	B-T169
of	O
which	O
could	O
support	O
biofuel	B-T109
production	B-T057
from	O
lignocellulosic	B-T109
biomass	B-T081
.	O
In	O
the	O
present	O
study	B-T062
,	O
a	O
lignin-degrading	B-T044
bacterium	B-T007
was	O
isolated	B-T169
from	O
leaf	B-T002
soil	B-T167
and	O
identified	O
as	O
Burkholderia sp.	B-T007
based	O
on	O
16S rRNA	B-T114
gene sequencing	B-T059
.	O
This	O
strain	B-T080
was	O
named	O
CCA53	B-T007
,	O
and	O
its	O
lignin-degrading	B-T044
capability	B-T080
was	O
assessed	B-T052
by	O
observing	O
its	O
growth	B-T040
on	O
medium	B-T130
containing	O
alkali lignin	B-T109
or	O
lignin	B-T109
-associated	O
aromatic monomers	B-T104
as	O
the	O
sole	O
carbon	B-T196
source	B-T033
.	O
Alkali lignin	B-T109
and	O
at	O
least	O
eight	O
lignin	B-T109
-associated	O
aromatic monomers	B-T104
supported	O
growth	B-T040
of	O
this	O
strain	B-T080
,	O
and	O
the	O
most	O
effective	B-T080
utilization	B-T169
was	O
observed	O
for	O
p-hydroxybenzene monomers	B-T104
.	O
These	O
findings	B-T033
indicate	O
that	O
Burkholderia sp. strain CCA53	B-T007
has	O
fragmentary activity	B-T052
for	O
lignin degradation	B-T044
.	O

Diagnostic	B-T169
utility	B-T169
of	O
additional	O
conventional	B-T081
techniques	B-T060
after	O
endobronchial ultrasonography	B-T060
guidance	B-T058
during	O
transbronchial biopsy	B-T060
Endobronchial ultrasonography	B-T060
with	O
a	O
guide sheath	B-T074
transbronchial biopsy	B-T060
(	O
EBUS	B-T060
-	O
GS	B-T074
TBB	B-T060
)	O
has	O
been	O
used	O
to	O
diagnose	B-T033
peripheral pulmonary lesions	B-T033
(	O
PPLs	B-T033
).	O
In	O
this	O
study	B-T062
,	O
we	O
evaluated	O
the	O
diagnostic	B-T169
utility	B-T169
of	O
conventional	B-T081
TBB	B-T060
after	O
EBUS	B-T060
-	O
GS	B-T074
TBB	B-T060
.	O
A	O
retrospective analysis	B-T062
of	O
patients	B-T101
who	O
underwent	O
conventional	B-T081
TBB	B-T060
after	O
EBUS	B-T060
-	O
GS	B-T074
TBB	B-T060
for	O
PPL	B-T033
between	O
August	O
1,	O
2012	O
and	O
December	O
31,	O
2014.	O
We	O
performed	O
multivariate analysis	B-T081
to	O
examine	O
the	O
association	B-T080
of	O
various	O
clinical	B-T080
factors	B-T169
,	O
including	O
EBUS	B-T060
probe	B-T074
distance	B-T081
and	O
sample size	B-T081
area	B-T082
,	O
with	O
diagnostic yield	B-T080
.	O
Of	O
88	O
eligible	O
patients	B-T101
,	O
57	O
(65%)	O
were	O
successfully	O
diagnosed	B-T033
by	O
EBUS	B-T060
-	O
GS	B-T074
TBB	B-T060
.	O
In	O
31	O
patients	B-T101
not	O
diagnosed	B-T033
by	O
EBUS	B-T060
-	O
GS	B-T074
TBB	B-T060
,	O
15	O
(48%)	O
were	O
successfully	O
diagnosed	B-T033
by	O
additional	O
conventional	B-T081
TBB	B-T060
.	O
Ground glass opacity	B-T033
(	O
GGO	B-T033
)	O
was	O
a	O
significant	B-T078
factor	B-T169
associated	O
with	O
the	O
diagnostic yield	B-T080
of	O
additional	O
conventional	B-T081
TBB	B-T060
following	O
EBUS	B-T060
-	O
GS	B-T074
TBB	B-T060
.	O
Multivariate analysis	B-T081
and	O
receiver operator curves	B-T081
revealed	O
that	O
distance	B-T081
between	O
the	O
PPL	B-T033
and	O
the	O
EBUS	B-T060
probe	B-T074
of	O
less	O
than	O
2.55	O
mm	O
favored	O
the	O
utility	B-T169
of	O
conventional	B-T081
TBB	B-T060
.	O
Additional	O
conventional	B-T081
TBB	B-T060
after	O
EBUS	B-T060
-	O
GS	B-T074
TBB	B-T060
could	O
be	O
a	O
useful	O
procedure	B-T060
for	O
the	O
diagnosis	B-T033
of	O
ground glass opacity	B-T033
PPLs	B-T033
and	O
in	O
cases	B-T169
of	O
a	O
distance	B-T081
of	O
less	O
than	O
2.55	O
mm	O
between	O
the	O
EBUS	B-T060
probe	B-T074
and	O
the	O
lesion	B-T033
.	O

Active	B-T169
diffusion	B-T070
and	O
microtubule-based transport	B-T043
oppose	O
myosin	B-T116
forces	B-T067
to	O
position	B-T082
organelles	B-T026
in	O
cells	B-T025
Even	O
distribution	B-T169
of	O
peroxisomes	B-T026
(	O
POs	B-T026
)	O
and	O
lipid droplets	B-T026
(	O
LDs	B-T026
)	O
is	O
critical	O
to	O
their	O
role	B-T077
in	O
lipid	B-T109
and	O
reactive oxygen species	B-T123
homeostasis	B-T038
.	O
How	O
even	O
distribution	B-T169
is	O
achieved	O
remains	O
elusive,	O
but	O
diffusive motion	B-T070
and	O
directed	O
motility	B-T040
may	O
play	O
a	O
role	B-T077
.	O
Here	O
we	O
show	O
that	O
in	O
the	O
fungus	B-T004
Ustilago maydis	B-T004
~95%	O
of	O
POs	B-T026
and	O
LDs	B-T026
undergo	O
diffusive motions	B-T070
.	O
These	O
movements	B-T040
require	O
ATP	B-T114
and	O
involve	O
bidirectional	B-T080
early	O
endosome	B-T026
motility	B-T040
,	O
indicating	O
that	O
microtubule	B-T026
-	O
associated	B-T080
membrane	B-T026
trafficking	B-T043
enhances	B-T052
diffusion	B-T070
of	O
organelles	B-T026
.	O
When	O
early	O
endosome transport	B-T043
is	O
abolished,	O
POs	B-T026
and	O
LDs	B-T026
drift	O
slowly	O
towards	O
the	O
growing cell end	B-T026
.	O
This	O
pole-ward drift	B-T043
is	O
facilitated	O
by	O
anterograde delivery	B-T043
of	O
secretory cargo	B-T116
to	O
the	O
cell tip	B-T026
by	O
myosin-5	B-T116
.	O
Modelling	B-T062
reveals	O
that	O
microtubule-based directed transport	B-T043
and	O
active	B-T169
diffusion	B-T070
support	O
distribution	B-T169
,	O
mobility	B-T043
and	O
mixing	O
of	O
POs	B-T026
.	O
In	O
mammalian	B-T015
COS-7 cells	B-T025
,	O
microtubules	B-T026
and	O
F-actin	B-T116
also	O
counteract	O
each	O
other	O
to	O
distribute	B-T169
POs	B-T026
.	O
This	O
highlights	O
the	O
importance	O
of	O
opposing	O
cytoskeletal	B-T026
forces	B-T067
in	O
organelle	B-T026
positioning	B-T082
in	O
eukaryotes	B-T204
.	O

The	O
role	O
of	O
catheter ablation	B-T061
in	O
the	O
management	B-T058
of	O
atrial fibrillation	B-T047
Atrial fibrillation	B-T047
is	O
driven	O
by	O
spontaneous	O
electrical activation	B-T040
emerging	O
from	O
the	O
pulmonary veins	B-T023
.	O
Catheter ablation	B-T061
using	O
either	O
radiofrequency	B-T061
or	O
cryothermal energy	B-T061
electrically	B-T169
isolates	B-T169
these	O
veins	B-T023
from	O
the	O
left atrium	B-T023
,	O
both	O
reducing	B-T080
the	O
burden	B-T078
of	O
atrial fibrillation	B-T047
episodes	B-T079
and	O
improving	O
the	O
patient's	B-T101
symptoms	B-T184
.	O
Catheter ablation	B-T061
is	O
superior	O
to	O
antiarryhthmic drugs	B-T121
when	O
patients	B-T101
are	O
carefully	O
selected.	O
Underlying	O
medical problems	B-T201
-	O
including	O
obesity	B-T047
,	O
hypertension	B-T047
and	O
obstructive sleep apnoea	B-T047
-	O
should	O
be	O
optimally	O
treated	B-T169
before	O
considering	O
ablation	B-T061
.	O
Although	O
this	O
treatment	B-T061
has	O
the	O
potential	B-T080
to	O
cure	B-T077
patients	B-T101
of	O
their	O
symptoms	B-T184
,	O
they	O
should	O
be	O
aware	O
of	O
the	O
important	O
associated	O
procedural complications	B-T033
.	O

The	O
Chinese Herbal	B-T080
Mixture	B-T167
Tien-Hsien Liquid	B-T109
Augments	B-T081
the	O
Anticancer	B-T080
Immunity	B-T039
in	O
Tumor Cell	B-T025
-	O
Vaccinated	B-T033
Mice	B-T015
Background	O
The	O
Chinese herbal	B-T080
mixture	B-T167
,	O
Tien-Hsien liquid	B-T109
(	O
THL	B-T109
),	O
has	O
been	O
used	O
as	O
an	O
anticancer	B-T080
dietary supplement	B-T168
for	O
more	O
than	O
20	O
years	B-T079
.	O
Our	O
previous	B-T079
studies	B-T062
have	O
shown	O
that	O
THL	B-T109
can	O
modulate	B-T082
immune response	B-T042
and	O
inhibit	B-T052
tumor growth	B-T191
.	O
In	O
this	O
study	B-T062
,	O
we	O
further	O
evaluated	B-T058
the	O
effect	B-T080
of	O
THL	B-T109
on	O
anticancer	B-T080
immune response	B-T042
in	O
mice	B-T015
vaccinated	B-T033
with	O
γ-ray	B-T070
-	O
irradiated	B-T070
tumor cells	B-T025
.	O
Methods	O
The	O
antitumor	B-T080
effect	B-T080
of	O
THL	B-T109
was	O
determined	B-T080
in	O
mice	B-T015
vaccinated	B-T033
with	O
low-tumorigenic CT-26-low colon cancer cells	B-T025
or	O
γ-ray-irradiated	B-T061
high-tumorigenic CT-26-high colon cancer cells	B-T025
.	O
The	O
number	B-T081
of	O
natural killer (NK) cells	B-T025
and	O
T lymphocytes	B-T025
in	O
the	O
spleen	B-T023
was	O
analyzed	B-T062
by	O
flow cytometry	B-T059
.	O
The	O
tumor	B-T191
-	O
killing	B-T043
activities	B-T052
of	O
NK cells	B-T025
and	O
cytotoxic T lymphocytes	B-T025
(	O
CTLs	B-T025
)	O
were	O
analyzed	B-T062
by	O
flow cytometry	B-T059
using	O
YAC-1	B-T025
and	O
CT-26-high cells	B-T025
,	O
respectively,	O
as	O
target	B-T169
cells	B-T025
.	O
The	O
levels	B-T080
of	O
IFN-γ	B-T116
,	O
IL-2	B-T116
,	O
and	O
TNF-α	B-T116
were	O
determined by	B-T080
ELISA	B-T059
.	O
Results	O
THL	B-T109
suppressed	B-T169
the	O
growth	B-T040
of	O
CT-26-high tumor	B-T025
in	O
mice	B-T015
previously	O
vaccinated	B-T033
with	O
low-tumorigenic CT-26-low cells	B-T025
or	O
γ-irradiated	B-T061
CT-26-high cells	B-T025
.	O
THL	B-T109
increased	B-T081
the	O
populations	O
of	O
NK cells	B-T025
and	O
CD4+ T lymphocytes	B-T025
in	O
the	O
spleen	B-T023
and	O
enhanced	B-T052
the	O
tumor	B-T191
-	O
killing	B-T043
activities	B-T052
of	O
NK cells	B-T025
and	O
CTL	B-T025
in	O
mice	B-T015
vaccinated	B-T033
with	O
γ-irradiated	B-T061
CT-26-high cells	B-T025
.	O
THL	B-T109
increased	B-T081
the	O
production	B-T169
of	O
IFN-γ	B-T116
,	O
IL-2	B-T116
,	O
and	O
TNF-α	B-T116
in	O
mice	B-T015
vaccinated	B-T033
with	O
γ-irradiated	B-T061
CT-26-high cells	B-T025
.	O
Conclusion	O
THL	B-T109
can	O
enhance	B-T052
the	O
antitumor	B-T080
immune responses	B-T042
in	O
mice	B-T015
vaccinated	B-T033
with	O
killed	B-T169
tumor cells	B-T025
.	O
These	O
results	B-T169
suggest	O
that	O
THL	B-T109
may	O
be	O
used	O
as	O
a	O
complementary medicine	B-T091
for	O
cancer	B-T191
patients	B-T101
previously	B-T079
treated	B-T169
with	O
killed tumor cell vaccines	B-T116
,	O
radiotherapy	B-T061
,	O
or	O
chemotherapy	B-T061
.	O

Timing	B-T079
of	O
False	O
Ring Formation	B-T039
in	O
Pinus halepensis	B-T002
and	O
Arbutus unedo	B-T002
in	O
Southern	B-T082
Italy	B-T083
:	O
Outlook	B-T201
from	O
an	O
Analysis	B-T062
of	O
Xylogenesis	B-T039
and	O
Tree-Ring	B-T002
Chronologies	B-T170
Mediterranean	B-T083
tree rings	B-T002
are	O
characterized	B-T052
by	O
intra-annual density fluctuations	B-T079
(	O
IADFs	B-T079
)	O
due	O
to	O
partly	O
climate-driven	B-T070
cambial activity	B-T039
.	O
IADFs	B-T079
are	O
used	O
as	O
structural	B-T082
signals	B-T078
to	O
gain	O
information	B-T078
on	O
relations	B-T080
between	B-T082
environmental	B-T082
conditions	B-T080
and	O
eco-physiological	B-T039
processes	B-T067
during	B-T079
xylogenesis	B-T039
,	O
with	O
intra-annual	B-T079
resolution	B-T077
.	O
To	O
reach	O
an	O
unbiased	B-T062
synchronization	B-T079
of	O
the	O
IADF	B-T079
position	B-T082
within	O
tree	B-T002
rings	B-T082
and	O
seasonal	B-T079
fluctuations	B-T184
in	O
environmental	B-T082
conditions	B-T080
,	O
it	O
is	O
necessary	O
to	O
know	O
the	O
timing	B-T079
of	O
cambial activity	B-T039
and	O
wood	B-T167
formation	B-T169
,	O
which	O
are	O
species-	B-T080
and	O
site-specific	B-T080
processes	B-T067
.	O
We	O
applied	B-T169
the	O
microcoring technique	B-T169
to	O
analyze	B-T062
xylogenesis	B-T039
in	O
Pinus halepensis	B-T002
and	O
Arbutus unedo	B-T002
.	O
To	O
the	O
best	O
of	O
our	O
knowledge,	O
this	O
is	O
the	O
first	O
attempt	B-T051
to	O
study	B-T062
xylogenesis	B-T039
in	O
a	O
hardwood	B-T167
species	B-T185
forming	O
frequent	B-T079
IADFs	B-T079
.	O
Both	O
species	B-T185
co-occur	B-T052
at	O
a	O
site	B-T082
in	O
southern	B-T082
Italy	B-T083
characterized	B-T052
by	O
a	O
Mediterranean	B-T083
climate	B-T070
.	O
To	O
facilitate	O
tree-ring dating	B-T062
and	O
identification	B-T080
of	O
IADFs	B-T079
,	O
we	O
performed	B-T169
traditional	B-T169
dendroecological	B-T080
analysis	B-T062
.	O
We	O
analyzed	B-T062
xylogenesis	B-T039
during	B-T079
summer	B-T079
,	O
which	O
is	O
considered	B-T078
a	O
constraint	B-T169
for	O
xylogenesis	B-T039
and	O
a	O
trigger	O
for	O
IADF	B-T079
formation	B-T169
.	O
We	O
followed	O
the	O
different	B-T080
phases	B-T079
of	O
cell development	B-T043
in	O
the	O
current	B-T079
wood	B-T167
increment	B-T081
with	O
the	O
aim	O
of	O
evaluating	O
whether	O
and	O
which	O
type	O
of	O
IADFs	B-T079
were	O
formed	B-T169
.	O
We	O
additionally	O
analyzed	B-T062
the	O
same	O
phases	B-T079
again	O
in	O
September	B-T079
and	O
in	O
winter	B-T079
to	O
verify	B-T169
the	O
possible	B-T033
formation	B-T169
of	O
IADFs	B-T079
in	O
fall	B-T079
and	O
whether	O
cell	B-T025
production	B-T039
and	O
differentiation	B-T043
was	O
completed	B-T080
by	O
the	O
end	O
of	O
the	O
calendar year	B-T079
.	O
Both	O
species	B-T185
formed	B-T169
the	O
same	O
type	O
of	O
IADFs	B-T079
(	O
earlywood	B-T167
-like	O
cells	B-T025
within	O
latewood	B-T167
),	O
due	O
to	O
temporary	B-T079
growth	B-T067
restoration	B-T033
triggered by	B-T080
rain	B-T070
events	B-T051
during	B-T079
the	O
period	B-T079
of	O
summer	B-T079
drought	B-T070
.	O
At	O
the	O
end	O
of	O
the	O
calendar year	B-T079
,	O
no	O
cells	B-T025
in	O
the	O
phases	B-T079
of	O
enlargement	B-T080
and	O
secondary cell wall	B-T026
deposition	B-T169
occurred	B-T052
.	O
A. unedo	B-T002
was	O
more	O
sensitive	B-T169
than	O
P. halepensis	B-T002
because	O
IADF	B-T079
s	O
were	O
formed	B-T169
earlier	B-T079
in	O
the	O
season	B-T079
and	O
were	O
more	O
frequent	B-T079
in	O
the	O
tree-ring	B-T002
series.	O
The	O
dendro-anatomical	B-T080
approach,	O
combining	O
analysis	B-T062
of	O
tree-ring	B-T002
series	O
and	O
of	O
xylogenesis	B-T039
,	O
helped	O
to	O
detect	B-T033
the	O
period	B-T079
of	O
IADF	B-T079
formation	B-T169
in	O
the	O
two	O
species	B-T185
.	O
Results	B-T169
are	O
discussed	O
in	O
functional	B-T169
terms	B-T078
,	O
highlighting	O
the	O
environmental	B-T082
conditions	B-T080
triggering	B-T080
IADFs	B-T079
,	O
and	O
also	O
in	O
methodological	B-UnknownType
terms	B-T078
,	O
evaluating	O
the	O
applicability	B-T169
of	O
xylogenesis	B-T039
analysis	B-T062
in	O
Mediterranean	B-T083
woods	B-T167
,	O
especially	O
when	O
the	O
formation	B-T169
of	O
IADFs	B-T079
is	O
not	O
uniform	B-T080
around	O
the	O
stem	B-T002
.	O

Emergence	B-T080
of	O
family medicine	B-T091
in	O
Ethiopia	B-T083
[corrected]:	O
an	O
international	B-T078
collaborative	B-T054
education model	B-T170
Family Medicine	B-T091
(	O
FM	B-T091
)	O
is	O
a	O
new	O
specialty	B-T091
in	O
Ethiopia	B-T083
.	O
The	O
first seven family physicians	B-T097
graduated	B-T098
in	O
February	B-T080
2016	O
from	O
the	O
inaugural	O
residency	B-T065
programme	B-T170
at	O
Addis Ababa University	B-T073
.	O
Cooperation	B-T054
amongst	O
Ethiopian	B-T098
and	O
expatriate	B-T033
decision-makers	B-T097
and	O
physicians	B-T097
was	O
needed	O
to	O
begin	B-T079
the	O
programme	B-T170
.	O
Intentional	B-T078
replacement	B-T169
of	O
expatriates	B-T033
with	O
Ethiopian	B-T098
family physicians	B-T097
has	O
begun	B-T079
.	O
Barriers	B-T080
include	O
lack of	B-T080
understanding	B-T041
of	O
FM	B-T091
and	O
the	O
human	B-T169
and	O
financial resources	B-T033
needed	O
for	O
scaling up	B-T081
the	O
programme	B-T170
.	O
Regular	B-T080
programme	B-T170
review	B-T080
with	O
resident physician	B-T097
involvement	B-T054
has	O
allowed	O
the	O
FM	B-T091
training programme	B-T065
to	O
adapt	B-T080
and	O
fit	B-T052
the	O
Ethiopian	B-T098
context	B-T078
.	O
Further	O
successes	B-T054
will	O
result	B-T169
from	O
ongoing	O
support	B-T054
and	O
advocacy	B-T054
from	O
the	O
Federal Ministry of Health	B-T057
and	O
other	O
Ethiopian	B-T098
,	O
African	B-T098
,	O
and	O
international	B-T078
international primary care organisations	B-T093
.	O

The	O
Experience	B-T041
of	O
Women	B-T098
Veterans	B-T098
Coming	O
Back	O
from	O
War	B-T052
Issues surrounding mental health	B-T048
are	O
common	O
for	O
women	B-T098
veterans	B-T098
who	O
have	O
served	O
in	O
Iraq	B-T083
and	O
Afghanistan	B-T083
wars	B-T052
.	O
The	O
goal	O
of	O
this	O
phenomenological	B-T078
study	B-T062
was	O
to	O
document	B-T170
themes	B-UnknownType
in	O
the	O
stories	B-T170
gathered	O
from	O
eight	O
women	B-T098
veterans	B-T098
who	O
had	O
come	O
back	O
from	O
war	B-T052
.	O
Themes	B-UnknownType
in	O
the	O
stories	B-T170
were:	O
arriving	O
with	O
mixed	O
sentiments	B-T055
;	O
evolving	O
to	O
a	O
changed	B-T169
view of self	B-T041
;	O
permeating aggravation	B-T033
;	O
confounding broken relationships	B-T054
,	O
frequent deployments	B-T033
,	O
and	O
change in military status	B-T033
;	O
remembering	B-T041
war	B-T052
experiences	B-T041
;	O
and	O
seeking opportunity for what is possible	B-T033
.	O
Mental health issues	B-T048
can	O
be	O
observed	O
in	O
the	O
themes	B-UnknownType
.	O
Including	O
story	B-T170
as	O
part	O
of	O
the	O
mental health	B-T041
visit	O
with	O
veterans	B-T098
may	O
be	O
beneficial	O
to	O
veterans	B-T098
as	O
they	O
deal	O
with	O
the	O
transition of coming back	B-T052
.	O

Trajectories	B-T082
of	O
Health	B-T078
and	O
Behavioral Health Services	B-T058
Use	B-T169
among	O
Community	B-T096
Corrections	B-T169
-Involved	O
Rural	B-T033
Adults	B-T100
This	O
article	O
seeks	O
to	O
establish	O
time-based	O
trajectories	B-T082
of	O
health	B-T078
and	O
behavioral health services	B-T058
utilization	B-T169
for	O
community corrections-involved	B-T078
(	O
CCI	B-T078
)	O
adults	B-T100
and	O
to	O
examine	O
demographic	B-T078
and	O
clinical	B-T080
correlates	O
associated	O
with	O
these	O
trajectories	B-T082
.	O
To	O
accomplish	O
this	O
aim,	O
the	O
authors	O
applied	O
a	O
latent class growth analysis	B-T062
(	O
LCGA	B-T062
)	O
to	O
services	B-T058
use	O
data	O
from	O
a	O
sample	O
of	O
rural	B-T033
CCI	B-T078
adults	B-T100
who	O
reported	O
their	O
medical	B-T169
,	O
mental health	B-T041
,	O
and	O
substance use	B-T078
treatment utilization	B-UnknownType
behavior	B-T053
every	O
60	O
days	B-T079
for	O
1.5	O
years	B-T079
.	O
LCGA	B-T062
established	O
1.5-year	B-T079
trajectories	B-T082
and	O
demographic	B-T078
correlates	O
of	O
health services	B-T058
among	O
rural	B-T033
CCI	B-T078
adults	B-T100
.	O
For	O
medical services	B-T058
,	O
three	O
classes	O
emerged	O
(stable-low	O
users	B-T098
,	O
13%;	O
stable-intermediate	O
users	B-T098
,	O
40%;	O
and	O
stable-high	O
users	B-T098
,	O
47%).	O
For	O
mental health	B-T041
and	O
substance use	B-T078
services	B-T058
,	O
three	O
classes	O
emerged	O
(stable-low,	O
69%	O
and	O
61%,	O
respectively;	O
low-baseline-increase,	O
10%	O
and	O
12%,	O
respectively;	O
high-baseline	O
decline,	O
21%	O
and	O
28%,	O
respectively).	O
Employment	B-T080
,	O
gender	B-T032
,	O
medication usage	B-T033
,	O
and	O
depression	B-T048
severity	B-T080
predicted	O
membership	B-T055
across	O
all	O
services	B-T058
.	O
Results	O
underscore	O
the	O
importance	O
of	O
social workers	B-T097
and	O
other	O
community services	B-T058
providers	B-T097
aligning	O
health services	B-T058
access	O
with	O
the	O
needs	O
of	O
the	O
CCI	B-T078
population,	O
and	O
highlight	O
CCI	B-T078
adults	B-T100
as	O
being	O
at	O
risk	B-T078
of	O
underservice	O
in	O
critical	O
prevention	B-T061
and	O
intervention domains	B-T061
.	O

Data set	B-T170
of	O
interactomes	B-T044
and	O
metabolic pathways	B-T169
of	O
proteins	B-T116
differentially	O
expressed	B-T045
in	O
brains	B-T023
with	O
Alzheimer׳s disease	B-T047
Alzheimer׳s disease	B-T047
is	O
one	O
of	O
the	O
main	O
causes	O
of	O
dementia	B-T048
in	O
the	O
elderly	B-T098
and	O
its	O
frequency	B-T079
is	O
on	O
the	O
rise	O
worldwide	B-T098
.	O
It	O
is	O
considered	O
the	O
result	O
of	O
complex	B-T080
interactions	B-T169
between	O
genetic	B-T080
and	O
environmental factors	B-T080
,	O
being	O
many	O
of	O
them	O
unknown.	O
Therefore,	O
there	O
is	O
a	O
dire	O
necessity	O
for	O
the	O
identification	O
of	O
novel	O
molecular players	B-T116
for	O
the	O
understanding	O
of	O
this	O
disease	B-T047
.	O
In	O
this	O
data	B-T078
article	B-T170
we	O
determined	O
the	O
protein expression	B-T045
profiles	O
of	O
whole	O
protein	B-T116
extracts	B-T167
from	O
cortex regions of brains	B-T029
from	O
patients	B-T101
with	O
Alzheimer׳s disease	B-T047
in	O
comparison	O
to	O
a	O
normal brain	B-T023
.	O
We	O
identified	B-T080
721	O
iTRAQ-labeled	B-T130
polypeptides	B-T116
with	O
more	O
than	O
95%	O
in	O
confidence.	O
We	O
analyzed	B-T062
all	O
proteins	B-T116
that	O
changed	O
in	O
their	O
expression level	B-T081
and	O
located	O
them	O
in	O
the	O
KEGG metabolic pathways	B-T170
,	O
as	O
well	O
as	O
in	O
the	O
mitochondrial complexes of the electron transport chain	B-T026
and	O
ATP synthase	B-T116
.	O
In	O
addition,	O
we	O
analyzed	B-T062
the	O
over- and sub-expressed polypeptides	B-T116
through	O
IPA software	B-T073
,	O
specifically	O
Core I and Biomarkers I modules	B-T170
.	O
Data	B-T078
in	O
this	O
article	B-T170
is	O
related	O
to	O
the	O
research	B-T062
article	B-T170
"Identification	O
of	O
proteins	B-T116
that	O
are	O
differentially	O
expressed	B-T045
in	O
brains	B-T023
with	O
Alzheimer's disease	B-T047
using	O
iTRAQ labeling	B-T059
and	O
tandem mass spectrometry	B-T063
"	O
(Minjarez	O
et	O
al.,	O
2016)	O
[1].	O

Emergency general surgery	B-T061
specific frailty index	B-T170
:	O
A	O
validation study	B-T062
Assessment	B-T058
of	O
operative risk	B-T078
in	O
geriatric patients	B-T101
undergoing	O
emergency general surgery	B-T061
(	O
EGS	B-T061
)	O
is	O
challenging.	O
Frailty	B-T033
is	O
an	O
established	O
measure	B-T081
for	O
risk assessment	B-T058
in	O
surgical cases	B-T077
.	O
The	O
aim	O
of	O
our	O
study	B-T062
was	O
to	O
validate	B-T062
a	O
modified	O
15	O
variable	B-T080
emergency general surgery specific frailty index	B-T058
(	O
EGSFI	B-T058
).	O
We	O
prospectively	O
collected	B-T078
geriatric	B-T080
(	O
age > 65	B-T100
)	O
emergency general surgery	B-T061
patients	B-T101
for	O
1-	O
year	B-T079
.	O
Post-operative complications	B-T046
were	O
collected	B-T078
.	O
Frailty Index	B-T170
was	O
calculated	B-T059
for	O
200	O
patients	B-T101
based	O
on	O
their	O
pre-admission	B-T079
condition	B-T080
using	O
50-	O
variable	B-T080
modified	O
Rockwood Frailty Index	B-T170
(	O
FI	B-T170
).	O
EGSFI	B-T058
was	O
developed	O
based	O
on	O
the	O
regression model	B-T170
for	O
complications	B-T046
and	O
the	O
most	O
significant	O
factors	O
in	O
the	O
FI	B-T170
.	O
ROC curve analysis	B-T081
was	O
performed	O
to	O
determine	O
cutoff	B-T169
for	O
frail	B-T033
status	B-T080
.	O
We	O
validated	B-T062
our	O
results	B-T169
using	O
60	O
patients	B-T101
for	O
predicting	B-T078
complications	B-T046
.	O
A	O
total	O
of	O
260	O
patients	B-T101
(200	O
developing,	O
60	O
Validation	B-T062
)	O
were	O
enrolled	B-T058
in	O
this	O
study	B-T062
.	O
Mean age	B-T032
was	O
71	O
±	O
11	O
years	B-T079
,	O
and	O
33%	O
developed	O
complications	B-T046
.	O
Most	O
common	B-T081
complications	B-T046
were	O
pneumonia	B-T047
(12%),	O
UTI	B-T047
(9%),	O
and	O
wound infection	B-T046
(7%).	O
Univariate analysis	B-T062
identified	O
15	O
variables	B-T080
significantly	O
associated with	B-T080
complications	B-T046
that	O
were	O
used	O
to	O
develop	O
the	O
EGSFI	B-T058
.	O
A	O
cutoff	B-T169
frailty score	B-T033
of	O
0.325	O
was	O
identified	O
using	O
ROC curve analysis	B-T081
for	O
frail	B-T033
status	B-T080
.Sixty-	O
patients	B-T101
(	O
frail	B-T033
:	O
18,	O
non-frail	B-T033
:	O
42)	O
were	O
enrolled	B-T058
in	O
the	O
validation	B-T062
cohort	B-T098
.	O
Frail	B-T033
patients	B-T101
were	O
more	O
likely	O
to	O
have	O
post-operative complications	B-T046
(47%	O
vs.	O
20%,	O
p	O
<	O
0.001)	O
compared	O
to	O
nonfrail patients	B-T101
.	O
Frail	B-T033
status	B-T080
based	O
on	O
EGSFI	B-T058
was	O
a	O
significant predictor	B-T078
of	O
post-operative complications	B-T046
(	O
OR	B-T081
=7.3,	O
95%	O
CI	B-T081
=	O
1.7	O
-	O
19.8;	O
p=0.006).	O
Age	B-T032
was	O
not	O
associated with	B-T080
postoperative complications	B-T046
(	O
OR	B-T081
=0.99,	O
95%	O
CI	B-T081
=	O
0.92	O
-1.06;	O
p=0.86).	O
The	O
15-	O
variable	B-T080
validated	B-T062
EGSFI	B-T058
is	O
a	O
simple	O
and	O
reliable	O
bedside tool	B-T073
to	O
determine	O
the	O
frailty status	B-T033
of	O
patients	B-T101
undergoing	O
emergency general surgery	B-T061
.	O
Frail	B-T033
status	B-T080
as	O
determined	O
by	O
Abstract	O
the	O
EGSFI	B-T058
is	O
an	O
independent predictor	B-T078
of	O
post-operative complications	B-T046
and	O
mortality	B-T081
in	O
geriatric	B-T080
emergency general surgery	B-T061
patients	B-T101
.	O
Level	O
II,	O
Prognostic Studies	B-T062
-	O
Investigating	B-T169
the	O
Effect	B-T080
of	O
a	O
Patient Characteristic	B-T201
on	O
the	O
Outcome of Disease	B-T033
.	O

Comparative	O
Epidemiologic	B-T169
Characteristics	B-T080
of	O
Pertussis	B-T047
in	O
10	O
Central	B-T083
and	O
Eastern European Countries	B-T083
,	O
2000-2013	O
We	O
undertook	O
an	O
epidemiological survey	B-T062
of	O
the	O
annual	B-T079
incidence	B-T081
of	O
pertussis	B-T047
reported	B-T058
from	O
2000	O
to	O
2013	O
in	O
ten	O
Central	B-T083
and	O
Eastern European countries	B-T083
to	O
ascertain	O
whether	O
increased	O
pertussis	B-T047
reports	B-T170
in	O
some	O
countries	B-T083
share	O
common	O
underlying	O
drivers	O
or	O
whether	O
there	O
are	O
specific	O
features	B-T080
in	O
each	O
country	B-T083
.	O
The	O
annual	B-T079
incidence	B-T081
of	O
pertussis	B-T047
in	O
the	O
participating	O
countries	B-T083
was	O
obtained	O
from	O
relevant	O
government institutions	B-T093
and/or	O
national surveillance systems	B-T093
.	O
We	O
reviewed	B-T080
the	O
changes	B-T169
in	O
the	O
pertussis	B-T047
incidence rates	B-T081
in	O
each	O
country	B-T083
to	O
explore	O
differences	B-T080
and/or	O
similarities	B-T080
between	O
countries	B-T083
in	O
relation	O
to	O
pertussis	B-T047
surveillance	B-T169
;	O
case definitions	B-T170
for	O
detection	B-T033
and	O
confirmation	B-T080
of	O
pertussis	B-T047
;	O
incidence	B-T081
and	O
number of cases	B-T081
of	O
pertussis	B-T047
by	O
year	B-T079
,	O
overall	O
and	O
by	O
age group	B-T100
;	O
population	B-T098
by	O
year	B-T079
,	O
overall	O
and	O
by	O
age group	B-T100
;	O
pertussis	B-T047
immunization schedule	B-T061
and	O
coverage	B-T169
,	O
and	O
switch	O
from	O
whole-cell pertussis vaccines	B-T121
(	O
wP	B-T121
)	O
to	O
acellular pertussis vaccines	B-T121
(	O
aP	B-T121
).	O
There	O
was	O
heterogeneity	B-T080
in	O
the	O
reported	B-T058
annual	B-T079
incidence rates	B-T081
and	O
trends	O
observed	O
across	O
countries	B-T083
.	O
Reported	B-T058
pertussis	B-T047
incidence rates	B-T081
varied	O
considerably,	O
ranging	O
from	O
0.01	O
to	O
96	O
per	O
100,000	O
population	B-T098
,	O
with	O
the	O
highest	B-T080
rates	B-T081
generally	O
reported	B-T058
in	O
Estonia	B-T083
and	O
the	O
lowest	B-T080
in	O
Hungary	B-T083
and	O
Serbia	B-T083
.	O
The	O
greatest	O
burden	B-T078
appears	O
for	O
the	O
most	O
part	O
in	O
infants	B-T100
(<1	O
year	B-T079
)	O
in	O
Bulgaria	B-T083
,	O
Hungary	B-T083
,	O
Latvia	B-T083
,	O
Romania	B-T083
,	O
and	O
Serbia	B-T083
,	O
but	O
not	O
in	O
the	O
other	O
participating	O
countries	B-T083
where	O
the	O
burden	B-T078
may	O
have	O
shifted	O
to	O
older children	B-T100
,	O
though	O
surveillance	B-T169
of	O
adults	B-T100
may	O
be	O
inappropriate.	O
There	O
was	O
no	O
consistent	O
pattern	O
associated with	B-T080
the	O
switch	O
from	O
wP	B-T121
to	O
aP vaccines	B-T121
on	O
reported	B-T058
pertussis	B-T047
incidence rates	B-T081
.	O
The	O
heterogeneity	B-T080
in	O
reported	B-T058
data	B-T078
may	O
be	O
related	O
to	O
a	O
number	O
of	O
factors	B-T169
including	O
surveillance	B-T169
system	B-T169
characteristics	B-T080
or	O
capabilities	B-T080
,	O
different	O
case definitions	B-T170
,	O
type	B-T080
of	O
pertussis	B-T047
confirmation tests	B-T059
used,	O
public	B-T092
awareness	B-T033
of	O
the	O
disease	B-T047
,	O
as	O
well	O
as	O
real	O
differences	B-T081
in	O
the	O
magnitude	B-T081
of	O
the	O
disease	B-T047
,	O
or	O
a	O
combination	O
of	O
these	O
factors	B-T169
.	O
Our	O
study	O
highlights	O
the	O
need	O
to	O
standardize	O
pertussis	B-T047
detection	B-T033
and	O
confirmation	B-T080
in	O
surveillance programs	B-T062
across	O
Europe	B-T083
,	O
complemented	O
with	O
carefully-designed	O
seroprevalence studies	B-T062
using	O
the	O
same	O
protocols	B-T170
and	O
methodologies	B-T062
.	O

Identification	B-T080
and	O
characterization	B-T052
of	O
Dichelobacter nodosus	B-T007
serogroup H	B-T170
from	O
ovine	B-T015
footrot	B-T047
in	O
India	B-T083
A	O
total	O
of	O
56	O
foot swabs	B-T167
were	O
collected	O
from	O
inter digital spaces	B-T030
of	O
sheep	B-T015
with	O
footrot	B-T047
lesions	B-T033
were	O
screened	B-T060
for	O
16	O
rRNA	B-T114
of	O
Dichelobacter nodosus	B-T007
by	O
PCR	B-T063
.	O
Out	O
of	O
the	O
56	O
samples	B-T077
,	O
38(67.85%)	O
were	O
found	O
to	O
be	O
positive	B-T033
.	O
All	O
the	O
positive	B-T033
samples	B-T077
were	O
subjected	O
to	O
multiplex PCR	B-T063
targeting fimA gene	B-T063
for	O
identification	B-T080
of	O
serogroups	B-T170
of	O
D. nodosus	B-T007
.	O
Serogroup H	B-T170
was	O
found	O
along	O
with	O
serogroup B	B-T170
in	O
12	O
(55.26%)	O
samples	B-T077
and	O
with	O
serogroup I	B-T170
in	O
8	O
(22.2%)	O
samples	B-T077
.	O
The	O
serogroup H	B-T170
was	O
identified	B-T080
for	O
the	O
first	O
time	O
from	O
the	O
Indian subcontinent	B-T083
.	O
The	O
phylogenetic analysis	B-T062
of	O
the	O
present	O
sequence	B-T086
with	O
the	O
available	O
serogroup H	B-T170
sequences	B-T086
of	O
GenBank	B-T170
revealed	O
to	O
be	O
in	O
close	O
association	O
with	O
the	O
serotype H1	B-T170
.	O

Conservation education	B-T065
and	O
habitat	B-T082
restoration	B-T169
for	O
the	O
endangered	B-T098
Sagalla caecilian	B-T011
(	O
Boulengerula niedeni	B-T011
)	O
in	O
Sagalla Hill	B-T083
,	O
Kenya	B-T083
The	O
Sagalla caecilian	B-T011
(	O
Boulengerula niedeni	B-T011
)	O
is	O
an	O
endangered	B-T098
amphibian	B-T011
endemic	B-UnknownType
to	O
Sagalla Hill	B-T083
in	O
the	O
Taita Hills	B-T083
.	O
This	O
burrowing worm	B-T204
-like	O
species	B-T185
prefers	O
soft	B-T080
soil	B-T167
with	O
high	B-T080
moisture	B-T167
and	O
organic matter	B-T167
.	O
The	O
major	B-T080
threats	B-T078
to	O
the	O
Sagalla caecilian	B-T011
are	O
soil erosion	B-T070
caused	B-T169
by	O
steep slopes	B-T082
,	O
bare	O
ground	B-T083
and	O
water siphoning	B-T067
/	O
soil hardening	B-T067
from	O
exotic eucalyptus trees	B-T002
.	O
The	O
purpose	O
of	O
this	O
study	B-T062
was	O
to	O
get	O
a	O
better	B-T080
understanding	B-T041
of	O
the	O
local	B-T082
people's	B-T098
attitude	B-T041
towards	O
this	O
species	B-T185
and	O
how	O
they	O
can	O
contribute	B-T052
to	O
its	O
continued	B-T078
conservation	B-T080
through	O
restoration	B-T169
of	O
its	O
remaining	B-T080
habitat	B-T082
.	O
In	O
this	O
study	B-T062
,	O
it	O
was	O
found	B-T033
that	O
96%	O
of	O
Sagalla	B-T083
people	B-T098
are	O
aware	B-T041
of	O
the	O
species	B-T185
,	O
its	O
habits	B-T055
and	O
its	O
association	O
with	O
soils	B-T167
high	B-T080
in	O
organic matter	B-T167
.	O
It	O
was	O
also	O
found	B-T033
that	O
96%	O
of	O
Sagalla	B-T083
people	B-T098
use	O
organic	B-T080
manure	B-T167
from	O
cow	B-T015
dung	B-T031
in	O
their	O
farms	B-T082
.	O
Habitat	B-T082
restoration	B-T169
through	O
planting	B-T052
of	O
indigenous	B-T082
plants	B-T002
was	O
found	B-T033
to	O
be	O
ongoing	B-T078
,	O
especially	B-T080
on	O
compounds	B-T103
of	O
public institutions	B-T092
as	O
well	O
as	O
on	O
private lands	B-UnknownType
.	O
Although	O
drought	B-T070
was	O
found	B-T033
to	O
be	O
a	O
challenge	O
for	O
seedlings	B-T002
development	B-T169
especially	O
on	O
the	O
low	B-T080
elevation	B-T082
sites	B-T082
,	O
destruction	B-T052
by	O
livestock	B-T008
especially	O
during	B-T079
the	O
dry	B-T080
season	B-T079
is	O
also	O
a	O
major	B-T080
threat	B-T078
.	O
In	O
this	O
study	B-T062
,	O
it	O
was	O
recommended	B-T078
that	O
any	O
future	B-T079
habitat	B-T082
restoration	B-T169
initiative	B-T041
should	O
include	B-T169
strong	B-T080
chain-link	B-T073
fencing	B-T052
to	O
protect	O
the	O
seedlings	B-T002
from	O
livestock	B-T008
activity	B-T052
.	O
Recognizing	O
that	O
the	O
preferred	B-T078
habitats	B-T082
for	O
the	O
species	B-T185
are	O
in	O
the	O
valleys	B-T082
,	O
systematic	B-T169
planting	B-T052
of	O
keystone plant	B-T002
species	B-T185
such	O
as	O
fig trees	B-T002
(	O
Ficus	B-T002
)	O
creates	B-T052
the	O
best	O
microhabitats	B-T082
.	O
These	O
are	O
better	B-T080
than	O
general	B-T082
woodlots	B-T082
of	O
indigenous	B-T082
trees	B-T002
.	O

The	O
clinical	B-T080
and	O
economic	B-T169
burden	B-T078
of	O
significant	B-T078
bleeding	B-T046
during	B-T079
lung resection surgery	B-T061
:	O
A	O
retrospective matched cohort analysis	B-T062
of	O
real	B-T080
-	O
world	B-T098
data	B-T078
The	O
objective	B-T080
of	O
this	O
retrospective study	B-T062
was	O
to	O
quantify	B-T081
the	O
clinical	B-T080
and	O
economic	B-T169
burden	B-T078
of	O
significant	B-T078
bleeding	B-T046
in	O
lung resection surgery	B-T061
in	O
the	O
US	B-T083
.	O
This	O
study	B-T062
utilized	B-T169
2009-2012	O
data	B-T078
from	O
the	O
Premier Perspective Database(TM)	B-T170
.	O
Adult	B-T100
patients	B-T101
with	O
primary pulmonary lobectomy	B-T061
or	O
segmentectomy procedures	B-T061
were	O
categorized	B-T052
by	O
the	O
surgical approach	B-T169
(	O
VATS	B-T061
vs	O
open	B-T061
)	O
and	O
primary diagnosis	B-T080
(	O
primary	B-T060
or	O
metastatic lung cancer	B-T060
vs	O
non-lung cancer	B-T060
).	O
Patients	B-T101
requiring	O
≥3	O
units	B-T081
of	O
blood products	B-T121
with	O
at least	B-T080
1	O
unit	B-T081
of	O
PRBCs	B-T116
:	O
"	O
significant	B-T078
bleeding	B-T046
"	O
cohort	B-T098
;	O
those	O
requiring	O
<3	O
units	B-T081
:	O
"	O
non-significant	B-T033
bleeding	B-T046
"	O
cohort	B-T098
;	O
and	O
those	O
not	O
requiring	O
blood products	B-T121
:	O
"	O
no	B-T169
bleeding	B-T046
"	O
cohort	B-T098
.	O
A	O
matched	O
cohort analysis	B-T062
was	O
performed	B-T169
between	O
the	O
"	O
significant	B-T078
bleeding	B-T046
"	O
and	O
the	O
"	O
no	B-T169
bleeding	B-T046
cohort	B-T098
"	O
using	O
matching variables	B-UnknownType
:	O
hospital	B-T073
,	O
lung cancer diagnosis	B-T060
,	O
year of surgery	B-T079
,	O
APR-DRG severity score	B-T081
,	O
procedure type	B-T201
and	O
approach	B-T169
,	O
age	B-T032
,	O
and	O
gender	B-T032
.	O
The	O
"	O
All	B-T081
-	O
patient	B-T101
"	O
cohort	B-T098
comprised	O
21,429	O
patients	B-T101
:	O
213	O
"	O
significant	B-T078
bleeding	B-T046
";	O
2,780	O
"	O
non-significant	B-T033
bleeding	B-T046
";	O
and	O
18,436	O
"	O
no	B-T169
bleeding	B-T046
".	O
Overall	B-T080
incidence	B-T081
of	O
significant	B-T078
chest	B-T029
bleeding	B-T046
was	O
0.99%.	O
Patients	B-T101
from	O
"	O
significant	B-T078
bleeding	B-T046
"	O
cohort	B-T098
and	O
"	O
non-significant	B-T033
bleeding	B-T046
"	O
cohort	B-T098
had	O
2.5	O
days	B-T079
and	O
2	O
days	B-T079
(p	O
<	O
0.0001)	O
longer	B-T080
length of stay	B-T079
in	O
the	O
hospital	B-T073
compared	B-T052
to	O
those	O
in	O
the	O
"	O
no	B-T169
bleeding	B-T046
"	O
cohort	B-T098
,	O
respectively.	O
Overall	B-T080
,	O
hospital costs	B-T081
for	O
"	O
significant	B-T078
bleeding	B-T046
"	O
cohort	B-T098
were	O
higher	B-T080
than	O
"	O
no	B-T169
bleeding	B-T046
"	O
cohort	B-T098
for	O
those	O
who	O
were	O
covered	B-T169
under	O
Medicare	B-T064
($59,871	O
vs	O
$23,641),	O
were	O
≥76	O
years of age	B-T079
($64,010	O
vs	O
$24,243),	O
had	O
greater	B-T081
severity of illness	B-T080
($97,813	O
vs	O
$51,871)	O
and	O
underwent	O
open	O
segmentectomy	B-T061
($74,220	O
vs	O
$21,903).	O
Hospital costs	B-T081
for	O
"	O
significant	B-T078
bleeding	B-T046
"	O
cohort	B-T098
and	O
"	O
non-significant	B-T033
bleeding	B-T046
"	O
were	O
significantly	B-T078
higher	B-T080
($11,589	O
and	O
$5,280,	O
respectively,	O
p	O
<	O
0.0001)	O
than	O
no	B-T169
bleeding	B-T046
cohort	B-T098
.	O
Although	O
significant	B-T078
bleeding	B-T046
during	B-T079
lung resection surgery	B-T061
is	O
rare	B-T080
,	O
patients	B-T101
with	O
such	O
complication	B-T046
could	O
stay	B-T079
longer	B-T080
at	O
the	O
hospital	B-T073
and	O
cost	B-T081
an	O
average	O
of	O
$13,103	O
more	O
than	O
those	O
without.	O

Laceration	B-T037
of	O
a	O
branch of	B-T082
the	O
profunda femoris artery	B-T023
caused	B-T169
by	O
a	O
spike	B-T033
of	O
the	O
displaced	B-T082
lesser trochanter	B-T023
in	O
an	O
inter-trochanteric	B-T030
femoral fracture	B-T037
.	O
A	O
case report	B-T170
Injury	B-T037
of	O
femoral vessels	B-T023
is	O
an	O
extremely	B-T080
rare	B-T080
complication	B-T046
in	O
intertrochanteric	B-T030
femoral fractures	B-T037
.	O
In	O
most	O
cases	B-T169
reported	B-T058
,	O
the	O
vascular lesion	B-T047
involves	B-T169
the	O
superficial femoral artery	B-T023
,	O
whereas	O
in	O
very	O
few	O
cases	B-T169
does	O
it	O
involve	B-T169
the	O
profunda femoris artery	B-T023
.	O
We	O
report	B-T170
a	O
case	B-T169
of	O
acute bleeding	B-T046
due	O
to	O
laceration	B-T037
of	O
a	O
perforating	B-T033
branch of	B-T082
the	O
profunda femoris artery	B-T023
caused	B-T169
by	O
a	O
sharp	B-T033
fragment of	B-T169
the	O
displaced	B-T082
lesser trochanter	B-T023
in	O
an	O
intertrochanteric	B-T030
femoral fracture	B-T037
;	O
the	O
lesion	B-T033
was	O
treated	B-T169
by	O
transcatheter embolization	B-T061
.	O
The	O
arterial injury	B-T037
may	O
be	O
iatrogenic	B-T080
,	O
occurring	B-T052
during	O
intramedullary	B-T082
internal fixation	B-T061
,	O
or	O
less	O
frequently	B-T079
,	O
the	O
injury	B-T037
may	O
be	O
due	O
to	O
the	O
fracture	B-T037
itself,	O
caused	B-T169
by	O
a	O
sharp	B-T033
bone fragment	B-T037
that	O
damages	B-T169
the	O
profunda femoris artery	B-T023
or	O
one	O
of	O
its	O
perforating	B-T033
branches	B-T082
.	O
We	O
believe	O
that	O
intertrochanteric	B-T030
femoral fractures	B-T037
with	O
avulsed	B-T037
lesser trochanter	B-T023
are	O
at risk	B-T080
for	O
femoral vessel	B-T023
injuries	B-T037
caused	B-T169
by	O
the	O
displaced	B-T082
bone	B-T023
spike	B-T033
,	O
and	O
we	O
advise	O
meticulous	B-T080
clinical	B-T080
and	O
laboratory monitoring	B-T058
pre-	B-T079
and	O
post-operatively	B-T079
to	O
prevent serious complications	B-T061
.	O

Direct	O
contact	O
with	O
perivascular	B-T023
tumor cells	B-T025
enhances	O
integrin αvβ3	B-T116
signaling	B-T044
and	O
migration	B-T043
of	O
endothelial cells	B-T025
The	O
secretion	B-T043
of	O
soluble	O
pro-angiogenic factors	B-T123
by	O
tumor cells	B-T025
and	O
stromal cells	B-T025
in	O
the	O
perivascular	B-T023
niche	O
promotes	O
the	O
aggressive angiogenesis	B-T191
that	O
is	O
typical	O
of	O
glioblastoma	B-T191
(	O
GBM	B-T191
).	O
Here,	O
we	O
show	O
that	O
angiogenesis	B-T191
also	O
can	O
be	O
promoted	O
by	O
a	O
direct	O
interaction	O
between	O
brain	B-T023
tumor cells	B-T025
,	O
including	O
tumor cells	B-T025
with	O
cancer stem	B-T025
-like	O
properties	O
(	O
CSCs	B-T025
),	O
and	O
endothelial cells	B-T025
(	O
ECs	B-T025
).	O
As	O
shown	O
in vitro	B-T080
,	O
this	O
direct	O
interaction	O
is	O
mediated	O
by	O
binding	B-T044
of	O
integrin αvβ3	B-T116
expressed	B-T045
on	O
ECs	B-T025
to	O
the	O
RGD-peptide	B-T116
in	O
L1CAM	B-T116
expressed	B-T045
on	O
CSCs	B-T025
.	O
It	O
promotes	O
both	O
EC	B-T025
network formation	B-T043
and	O
enhances	O
directed	O
migration	B-T043
toward	O
basic	O
fibroblast growth factor	B-T116
.	O
Activation	B-T052
of	O
αvβ3	B-T116
and	O
bone marrow tyrosine kinase on chromosome X	B-T116
(	O
BMX	B-T116
)	O
is	O
required	O
for	O
migration	B-T043
stimulated	O
by	O
direct	O
binding	B-T044
but	O
not	O
for	O
migration	B-T043
stimulated	O
by	O
soluble	O
factors.	O
RGD-peptide	B-T116
treatment	B-T169
of	O
mice	B-T015
with	O
established	O
intracerebral	B-T082
GBM	B-T191
xenografts	B-T122
significantly	O
reduced	O
the	O
percentage	O
of	O
Sox2	B-T116
-positive	O
tumor cells	B-T025
and	O
CSCs	B-T025
in	O
close	O
proximity	O
to	O
ECs	B-T025
,	O
decreased	O
integrin αvβ3	B-T116
and	O
BMX	B-T116
activation	O
and	O
p130CAS	B-T116
phosphorylation	B-T044
in	O
the	O
ECs	B-T025
,	O
and	O
reduced	O
the	O
vessel	B-T023
surface area	B-T082
.	O
These	O
results	O
reveal	O
a	O
previously	O
unrecognized	O
aspect	O
of	O
the	O
regulation	B-T038
of	O
angiogenesis	B-T191
in	O
GBM	B-T191
that	O
can	O
impact	O
therapeutic	B-T169
anti-angiogenic	B-T121
targeting.	O

The	O
use	O
of	O
Ocimum americanum	B-T002
essential oil	B-T109
against	O
the	O
pathogens	B-T001
Aeromonas hydrophila	B-T007
and	O
Gyrodactylus sp.	B-T204
in	O
silver catfish	B-T013
(	O
Rhamdia quelen	B-T013
)	O
The	O
bactericidal activity	B-T034
(	O
MIC-test	B-T059
)	O
of	O
Ocimum americanum	B-T002
(	O
inflorescences	B-T002
)	O
essential oil	B-T109
(	O
OAEO	B-T109
)	O
against	O
Aeromonas hydrophila	B-T007
was	O
determined	O
in	O
this	O
study.	O
It	O
was	O
also	O
investigated	O
the	O
potential	O
of	O
OAEO	B-T109
and	O
the	O
main	O
compound	B-T080
found	O
in	O
the	O
oil	B-T109
(	O
linalool	B-T109
)	O
at	O
subinhibitory	O
concentrations	O
to	O
be	O
inhibitors	B-T120
of	O
hemolysis	B-T046
caused	O
by	O
Aer. hydrophila	B-T007
in	O
fish	B-T013
erythrocytes	B-T025
.	O
An	O
in vivo experiment	B-T062
was	O
conducted	O
to	O
evaluate	O
survival	B-T052
of	O
fish	B-T013
(	O
Rhamdia quelen	B-T013
)	O
experimentally	B-T062
infected	B-T033
with	O
Aer. hydrophila	B-T007
and	O
exposed	B-T080
to	O
OAEO	B-T109
.	O
A	O
second	O
experiment	B-T062
was	O
conducted	O
to	O
evaluate	O
the	O
in vitro	B-T062
and	O
in vivo	B-T062
activity	O
of	O
OAEO	B-T109
(mix	O
from	O
inflorescences	B-T002
and	O
leaves	B-T002
)	O
against	O
the	O
parasite Gyrodactylus sp.	B-T204
The	O
OAEO	B-T109
showed	O
weak	B-T080
in vitro	B-T062
activity	O
against	O
Aer. hydrophila	B-T007
(6400	O
μg	O
ml(-1)).	O
At	O
subinhibitory	O
concentrations	O
OAEO	B-T109
(100	O
μg	O
ml(-1))	O
inhibited	B-T052
hemolysis	B-T046
(90%)	O
caused	O
by	O
Aer. hydrophila	B-T007
in	O
fish	B-T013
erythrocytes	B-T025
,	O
however,	O
linalool	B-T109
did	O
not present	B-T169
hemolysis	B-T046
inhibition activity	B-T052
.	O
At	O
low	O
concentrations	O
(10	O
and	O
20	O
mg	O
l(-1))	O
added	O
to	O
the	O
water	B-T121
OAEO	B-T109
promoted	B-T052
survival	B-T052
of	O
experimentally	O
infected	B-T033
fish	B-T013
with	O
Aer. hydrophila	B-T007
.	O
Lastly,	O
OAEO	B-T109
-mix	O
(50	O
mg	O
l(-1))	O
was	O
effective	B-T080
against	O
Gyrodactylus sp.	B-T204
significantly reducing	B-T081
(60%)	O
the	O
number	O
of	O
parasites	B-T204
in	O
the	O
fish	B-T013
.	O
This	O
article	O
is	O
protected	O
by	O
copyright.	O
All	O
rights	O
reserved.	O

Interleukin-1β	B-T116
induced	O
Stress Granules	B-T026
Sequester	B-T169
COX-2	B-T116
mRNA	B-T114
and	O
Regulates	B-T038
its	O
Stability	B-T080
and	O
Translation	B-UnknownType
in	O
Human	B-T016
OA	B-T047
Chondrocytes	B-T025
Enhanced	B-T052
and	O
immediate	O
expression	B-T045
of	O
cyclooxygenase-2	B-T028
(	O
COX-2	B-T028
)	O
mRNA	B-T114
is	O
observed	O
in	O
IL-1β	B-T116
-	O
stimulated	B-T061
OA	B-T047
chondrocytes	B-T025
but	O
the	O
synthesis of protein	B-T044
found	O
significantly	O
delayed	B-T079
.	O
Here	O
we	O
investigated	O
the	O
role	O
of	O
stress granules	B-T026
(	O
SGs	B-T026
),	O
ribonucleoprotein complexes	B-T026
that	O
regulate	B-T038
mRNA translation	B-UnknownType
,	O
in	O
the	O
delayed	B-T079
translation	B-UnknownType
of	O
COX-2	B-T028
mRNAs	B-T114
in	O
IL-1β	B-T116
-	O
stimulated	B-T061
OA	B-T047
chondrocytes	B-T025
.	O
Stimulation	B-T061
of	O
human	B-T016
chondrocytes	B-T025
with	O
IL-1β	B-T116
activated	O
the	O
stress response	B-T039
genes	B-T028
and	O
the	O
phosphorylation	B-T044
of	O
eIF2α	B-T116
that	O
triggered	B-T080
the	O
assembly of SGs	B-T045
.	O
Using	O
combined	O
immunofluorescence staining	B-T059
of	O
SGs	B-T026
markers	B-T201
and	O
COX-2 protein	B-T116
,	O
RNA	B-T114
fluorescence in situ hybridization	B-T063
and	O
RNA	B-T114
immunoprecipitation	B-T059
,	O
the	O
COX-2	B-T028
mRNAs	B-T114
were	O
found	O
sequestered	B-T169
in	O
SGs	B-T026
in	O
IL-1β	B-T116
-	O
stimulated	B-T061
OA	B-T047
chondrocytes	B-T025
.	O
No	B-T033
increase	B-T169
in	O
COX-2	B-T116
protein expression	B-T045
was	O
observed	O
during	O
the	O
persistence	B-T079
of	O
SGs	B-T026
but	O
enhanced	B-T052
expression	B-T045
of	O
COX-2 protein	B-T116
was	O
noted	O
upon	O
clearance	B-T080
of	O
the	O
SGs	B-T026
.	O
Inhibition	B-T052
of	O
SGs	B-T026
clearance	B-T080
blocked	B-T169
COX-2	B-T028
mRNA	B-T114
translation	B-UnknownType
whereas	O
blocking	B-T169
the	O
assembly of SGs	B-T045
by	O
TIA-1	B-T116
depletion	B-T169
resulted	O
in	O
rapid	O
and	O
increased	B-T081
production	B-T169
of	O
COX-2	B-T116
and	O
PGE2	B-T109
.	O
Our	O
findings	O
show	O
for	O
the	O
first	O
time	O
assembly of SGs	B-T045
and	O
sequestration	B-T169
of	O
COX-2	B-T028
mRNAs	B-T114
in	O
human	B-T016
OA	B-T047
chondrocytes	B-T025
under	O
pathological conditions	B-T184
.	O
Post-transcriptional regulation	B-T045
of	O
COX-2	B-T028
mRNAs translation	B-UnknownType
by	O
SGs	B-T026
indicates	O
a	O
role	O
in	O
IL-1β	B-T116
-mediated	O
catabolic	B-T169
response	B-T032
that	O
could	O
be	O
therapeutically	B-T061
targeted	O
in	O
OA	B-T047
.	O

Spatio-Temporal Distribution	B-T169
of	O
Bark	B-T002
and	O
Ambrosia	B-T002
Beetles	B-T204
in	O
a	O
Brazilian	B-T083
Tropical Dry Forest	B-T070
Bark	B-T002
and	O
the	O
ambrosia	B-T002
beetles	B-T204
dig	O
into	O
host plants	B-UnknownType
and	O
live	O
most	O
of	O
their	O
lives	O
in	O
concealed	O
tunnels	B-T082
.	O
We	O
assessed	B-T052
beetle	B-T204
community	B-T096
dynamics	B-T102
in	O
tropical dry forest	B-T070
sites	B-T082
in	O
early	B-T079
,	O
intermediate	B-T079
,	O
and	O
late	B-T079
successional stages	B-T079
,	O
evaluating	O
the	O
influence	O
of	O
resource	B-T078
availability	B-T169
and	O
seasonal variations	B-T079
in	O
guild structure	B-T080
.	O
We	O
collected	B-T078
a	O
total	O
of	O
763	O
beetles	B-T204
from	O
23	O
species	B-T185
,	O
including	O
14	O
bark	B-T002
beetle	B-T204
species	B-T185
,	O
and	O
9	O
ambrosia	B-T002
beetle	B-T204
species	B-T185
.	O
Local	B-T082
richness	B-T080
of	O
bark	B-T002
and	O
ambrosia	B-T002
beetles	B-T204
was	O
estimated	O
at	O
31	O
species	B-T185
.	O
Bark	B-T002
and	O
ambrosia	B-T002
composition	B-T078
was	O
similar	O
over	O
the	O
successional stages	B-T079
gradient	B-T081
,	O
and	O
beta diversity	B-T080
among	O
sites	B-T082
was	O
primarily	O
determined	O
by	O
species	B-T185
turnover,	O
mainly	O
in	O
the	O
bark	B-T002
beetle	B-T204
community	B-T096
.	O
Bark	B-T002
beetle	B-T204
richness	B-T080
and	O
abundance	B-T080
were	O
higher	O
at	O
intermediate stages	B-T079
;	O
availability of	B-T169
wood	B-T167
was	O
the	O
main	O
spatial mechanism	B-T169
.	O
Climate	B-T070
factors	B-T169
were	O
effectively	O
non-seasonal	B-T080
.	O
Ambrosia	B-T002
beetles	B-T204
were	O
not	O
influenced	O
by	O
successional stages	B-T079
,	O
however	O
the	O
increase	B-T169
in	O
wood	B-T167
resulted	O
in	O
increased	B-T081
abundance	B-T080
.	O
We	O
found	O
higher	O
richness	B-T080
at	O
the	O
end	O
of	O
the	O
dry	B-T079
and	O
wet seasons	B-T079
,	O
and	O
abundance	B-T080
increased	B-T081
with	O
air	B-T167
moisture	B-T167
and	O
decreased	O
with	O
higher	O
temperatures	B-T081
and	O
greater	O
rainfall	B-T070
.	O
In	O
summary,	O
bark	B-T002
beetle	B-T204
species	B-T185
accumulation	B-T169
was	O
higher	O
at	O
sites	B-T082
with	O
better	O
wood	B-T167
production	B-T052
,	O
while	O
the	O
needs	O
of	O
fungi	B-T004
(	O
host	B-UnknownType
and	O
air	B-T167
moisture	B-T167
),	O
resulted	O
in	O
a	O
favorable	O
conditions	B-T080
for	O
species	B-T185
accumulation	B-T169
of	O
ambrosia	B-T002
.	O
The	O
overall	O
biological	B-T080
pattern	B-T080
among	O
guilds	O
differed	O
from	O
tropical rain forests	B-T070
,	O
showing	O
patterns	O
similar	O
to	O
dry forest areas	B-T070
.	O

Detection	B-T061
and	O
Characterization	O
of	O
Flat Aberrant Crypt Foci (Flat ACF)	B-T047
in	O
the	O
Novel	O
A/J Min/+ Mouse	B-T050
Flat aberrant crypt foci	B-T047
(	O
flat ACF	B-T047
)	O
and	O
mucin-depleted foci	B-T047
(	O
MDF	B-T047
)	O
have	O
previously	O
been	O
described	O
as	O
preneoplastic colonic lesions	B-T047
.	O
We	O
used	O
the	O
novel	O
A/J Min/+ mouse model	B-T050
,	O
that	O
demonstrates	O
extensive	O
spontaneous	O
colon carcinogenesis	B-T191
to	O
refine	O
the	O
method	O
of	O
detection	B-T061
of	O
flat ACF	B-T047
and	O
further	O
characterize	O
and	O
define	O
them	O
as	O
early	O
lesions	B-T033
by	O
histological examination	B-T059
and	O
comparison	O
with	O
MDF	B-T047
.	O
Colons	B-T023
were	O
stained with methylene blue	B-T059
(	O
MB	B-T109
)	O
for	O
flat ACF	B-T047
detection	B-T061
and	O
restained	B-T059
with	O
high-iron diamine-alcian blue	B-T109
(	O
HID-AB	B-T109
)	O
for	O
MDF	B-T047
detection	B-T061
.	O
Optimal	O
flat ACF	B-T047
recognition	O
required	O
at	O
least	O
24	O
h	O
of	O
storage	O
post-	O
MB staining	B-T059
and	O
adherence	O
to	O
a	O
set	O
of	O
characteristics.	O
The	O
fraction of	B-T081
flat ACF	B-T047
corresponding	O
with	O
MDF	B-T047
was	O
93%.	O
Flat ACF	B-T047
/	O
MDF	B-T047
displayed	O
the	O
same	O
picture	O
of	O
severe dysplasia	B-T049
,	O
lack of	B-T080
mucus	B-T025
and	O
goblet cells	B-T025
and	O
accumulation	B-T033
of	O
cytoplasmic	B-T026
β-catenin	B-T116
.	O
The	O
easily	O
detectable	O
flat ACF	B-T047
are	O
reliable	O
surface	B-T026
biomarkers	B-T201
of	O
Apc	B-T028
-driven	O
colon carcinogenesis	B-T191
.	O

Transcriptional enhancement	B-T045
of	O
Smn	B-T028
levels	B-T034
in	O
motoneurons	B-T025
is	O
crucial	O
for	O
proper	O
axon	B-T026
morphology	B-T080
in	O
zebrafish	B-T013
An	O
unresolved	O
mystery	O
in	O
the	O
field	O
of	O
spinal muscular atrophy	B-T047
(	O
SMA	B-T047
)	O
is	O
why	O
a	O
reduction	O
of	O
the	O
ubiquitously	O
expressed	O
Smn protein	B-T116
causes	O
defects	B-T033
mostly	O
in	O
motoneurons	B-T025
.	O
We	O
addressed	O
the	O
possibility	O
that	O
this	O
restricted	O
vulnerability	O
stems	O
from	O
elevated	O
Smn expression	B-T045
in	O
motoneurons	B-T025
.	O
To	O
explore	O
this,	O
we	O
established	O
an	O
ex vivo zebrafish culture system	B-T074
zebrafish	B-T013
culture	O
system	O
of	O
GFP	B-T116
-	O
marked	B-T080
motoneurons	B-T025
to	O
quantitatively	O
measure	O
Smn protein	B-T034
and	O
smn mRNA	B-T114
levels	B-T081
as	O
well	O
as	O
promoter	O
activity	O
in	O
motoneurons	B-T025
versus	O
other	O
cell	B-T025
types.	O
Importantly,	O
we	O
uncovered	O
that	O
Smn levels	B-T034
are	O
elevated	O
in	O
motoneurons	B-T025
by	O
means	O
of	O
transcriptional activation	B-T045
.	O
In	O
addition,	O
we	O
identified	O
the	O
ETS family transcription factor Etv5b	B-T116
to	O
be	O
responsible	O
for	O
increased	O
smn transcription	B-T045
in	O
motoneurons	B-T025
.	O
Moreover,	O
we	O
established	O
that	O
the	O
additional	O
supply	O
of	O
Smn protein	B-T116
in	O
motoneurons	B-T025
is	O
necessary	O
for	O
proper	O
axonogenesis	B-T042
in	O
a	O
cell-autonomous manner	B-T043
.	O
These	O
findings	B-T034
demonstrate	O
the	O
reliance	O
of	O
motoneurons	B-T025
on	O
more	O
Smn	B-T116
,	O
thereby	O
adding	O
a	O
novel	O
piece	O
of	O
evidence	B-T078
for	O
their	O
increased	B-T081
vulnerability	B-T201
under	O
SMA conditions	B-T047
.	O

Evaluation	B-T058
of	O
response	O
from	O
axitinib	B-T109
per	O
Response Evaluation Criteria in Solid Tumors	B-T170
versus	O
Choi criteria	B-T170
in	O
previously	O
treated	B-T033
patients	B-T101
with	O
metastatic renal cell carcinoma	B-T191
Axitinib	B-T109
,	O
a	O
selective	O
and	O
potent	O
tyrosine kinase inhibitor	B-T121
of	O
vascular endothelial growth factor receptors	B-T116
,	O
was	O
available	O
to	O
patients	B-T101
from	O
Canada	B-T083
and	O
Australia	B-T083
,	O
prior	O
to	O
regulatory	O
approval	B-T170
of	O
axitinib	B-T109
in	O
these	O
countries	B-T083
,	O
for	O
treatment	B-T061
of	O
clear-cell metastatic renal cell carcinoma	B-T191
(	O
mRCC	B-T191
)	O
after	O
failure	O
of	O
one	O
prior	O
systemic	O
regimen	B-T061
.	O
This	O
single-arm	B-T062
,	O
open-label study	B-T062
of	O
axitinib	B-T109
evaluated	O
the	O
efficacy	B-T062
,	O
safety	B-T062
,	O
and	O
quality of life	B-T078
(	O
QoL	B-T078
)	O
in	O
patients	B-T101
with	O
mRCC	B-T191
whose	O
disease	B-T047
progressed	B-T046
after	O
one	O
prior	O
systemic	O
first-line regimen	B-T061
.	O
Primary	O
objective	O
was	O
objective	O
response rate	B-T079
evaluated	B-T058
per	O
Response Evaluation Criteria in Solid Tumors	B-T170
(	O
RECIST	B-T170
)	O
and	O
Choi criteria	B-T170
.	O
Progression-free survival	B-T081
,	O
overall survival	B-T081
,	O
safety	B-T062
,	O
and	O
QoL	B-T078
were	O
secondary	O
end	O
points.	O
Due	O
to	O
the	O
small	O
study	B-T062
size,	O
analyses	O
comprised	O
of	O
descriptive	O
statistics	B-T062
.	O
Fifteen	O
patients	B-T101
were	O
recruited,	O
five	O
from	O
Canada	B-T083
and	O
ten	O
from	O
Australia	B-T083
,	O
over	O
a	O
limited	O
recruitment	O
period.	O
Thirteen	O
patients	B-T101
received	O
sunitinib	B-T109
as	O
prior	O
therapy	B-T061
.	O
All	O
patients	B-T101
had	O
clear-cell carcinoma	B-T191
,	O
eleven	O
had	O
prior	O
nephrectomy	B-T061
.	O
Liver	B-T023
,	O
lung	B-T023
,	O
and	O
lymph nodes	B-T023
were	O
the	O
most	O
frequent	O
sites	O
of	O
metastases	B-T191
;	O
one	O
patient	B-T101
had	O
brain metastasis	B-T191
.	O
Median	B-T081
time	O
on	O
axitinib	B-T109
was	O
118.0	O
days	B-T079
(	O
range	B-T081
:	O
3.5-645.0	O
days	B-T079
);	O
estimated	O
survival	B-T052
probability	O
at	O
12	O
months	B-T079
was	O
57.8%.	O
Two	O
(13.3%)	O
patients	B-T101
had	O
objective	O
responses	B-T032
per	O
RECIST	B-T170
versus	O
nine	O
(60.0%)	O
per	O
Choi criteria	B-T170
.	O
Six	O
patients	B-T101
had	O
progressive	B-T046
disease	B-T047
based	O
on	O
RECIST	B-T170
versus	O
three	O
per	O
Choi criteria	B-T170
.	O
Nine	O
(60.0%)	O
events	O
of	O
progression	B-T046
or	O
death	B-T040
occurred	O
by	O
the	O
end	O
of	O
study	B-T062
,	O
and	O
three	O
patients	B-T101
continued	O
to	O
receive	O
the	O
study	B-T062
drug	B-T121
.	O
Fatigue	B-T184
(33%)	O
and	O
diarrhea	B-T184
(20%)	O
were	O
the	O
most	O
common	O
grade	O
≥3	O
all-causality,	O
treatment	B-T061
-emergent	O
adverse events	B-T046
.	O
The	O
mean	B-T081
change	O
in	O
European	B-T083
Quality of Life	B-T078
-	O
5	O
Dimensions	O
score	B-T081
from	O
baseline	B-T081
to	O
end	O
of	O
treatment	B-T061
was	O
-0.0837.	O
The	O
small	O
number	O
of	O
patients	B-T101
and	O
lack	O
of	O
a	O
comparator	O
arm	O
limit	O
the	O
ability	O
to	O
draw	O
definitive	B-T079
conclusions	B-T078
;	O
however,	O
safety	B-T062
and	O
efficacy	B-T062
profiles	O
of	O
axitinib	B-T109
were	O
consistent	O
with	O
reports	O
from	O
previous	O
studies	B-T062
in	O
patients	B-T101
with	O
mRCC	B-T191
,	O
and	O
patients	B-T101
generally	O
maintained	O
QoL	B-T078
.	O
The	O
sizeable	O
difference	O
observed	O
in	O
objective	O
response rate	B-T079
by	O
RECIST	B-T170
versus	O
Choi criteria	B-T170
merits	O
further	O
research	B-T062
.	O

Biochemical	B-T169
characteristics	B-T080
of	O
AtFAR2	B-T116
,	O
a	O
fatty acid reductase	B-T116
from	O
Arabidopsis thaliana	B-T002
that	O
reduces	O
fatty acyl-CoA	B-T114
and	O
-	O
ACP substrates	B-T116
into	O
fatty alcohols	B-T109
Fatty alcohols	B-T109
and	O
derivatives	B-T104
are	O
important	B-T080
for	O
proper	O
deposition	B-T169
of	O
a	O
functional	B-T169
pollen wall	B-T026
.	O
Mutations	B-T045
in	O
specific	O
genes	B-T028
encoding	O
fatty acid reductases	B-T116
(	O
FAR	B-T116
)	O
responsible	O
for	O
fatty alcohol	B-T109
production	B-T169
cause	O
abnormal	B-T033
development	B-T169
of	O
pollen	B-T002
.	O
A	O
disrupted	B-T080
AtFAR2 (MS2) gene	B-T028
in	O
Arabidopsis thaliana	B-T002
results	B-T169
in	O
pollen	B-T002
developing	B-T169
an	O
abnormal	B-T033
exine layer	B-T026
and	O
a	O
reduced fertility	B-T033
phenotype	B-T032
.	O
AtFAR2	B-T116
has	O
been	O
shown	O
to	O
be	O
targeted	B-T169
to	O
chloroplasts	B-T026
and	O
in	O
a	O
purified form	B-T080
to	O
be	O
specific	B-T080
for	O
acyl-ACP substrates	B-T116
.	O
Here,	O
we	O
present	O
data	B-T078
on	O
the	O
in vitro	B-T080
and	O
in	O
planta	B-T002
characterizations	B-T052
of	O
AtFAR2	B-T116
from	O
A. thaliana	B-T002
and	O
show	O
that	O
this	O
enzyme	B-T116
has	O
the	O
ability	O
to	O
use	O
both,	O
C16:0-ACP	B-T116
and	O
C16:0-CoA	B-T114
,	O
as	O
substrates	B-T120
to	O
produce	O
C16:0-alcohol	B-T109
.	O
Our	O
results	O
further	O
show	O
that	O
AtFAR2	B-T116
is	O
highly	O
similar	O
in	O
properties	B-T080
and	O
substrate	B-T120
specificity	B-T081
to	O
AtFAR6	B-T116
for	O
which	O
in vitro	B-T080
data	B-T078
has	O
been	O
published,	O
and	O
which	O
is	O
also	O
a	O
chloroplast	B-T026
localized	B-T082
enzyme	B-T116
.	O
This	O
suggests	O
that	O
although	O
AtFAR2	B-T116
is	O
the	O
major	O
enzyme	B-T116
responsible	O
for	O
exine layer	B-T026
functionality	B-T169
,	O
AtFAR6	B-T116
might	O
provide	O
functional	B-T169
redundancy	B-T169
to	O
AtFAR2	B-T116
.	O

Comparing	B-T052
Time Perception	B-T041
among	O
Morphine	B-T109
-	O
Derived	B-T080
Drugs	B-T121
Addicts	B-T101
and	O
Controls	B-T096
The	O
aim	B-T078
of	O
the	O
present	O
study	B-T062
is	O
to	O
compare	B-T052
time perception	B-T041
among	O
drug addicts	B-T033
and	O
controls	B-T096
.	O
30	O
drug addicts	B-T033
were	O
selected	B-T052
,	O
and	O
30	O
non-addict individuals	B-T098
were	O
selected	B-T052
as	O
the	O
control group	B-T096
.	O
The	O
two	O
groups	B-T078
performed	O
three	O
tests	B-T170
of	O
time	B-T079
reproduction	B-T040
,	O
time estimation	B-T079
,	O
and	O
time	B-T079
discrimination	B-T041
.	O
There	O
was	O
a	O
significant	B-T078
difference	B-T080
between	O
the	O
addicts	B-T101
group	B-T078
and	O
the	O
control group	B-T096
regarding	O
the	O
error	B-T080
of	O
time	B-T079
reproduction	B-T040
and	O
time estimation	B-T079
.	O
The	O
addict	B-T101
group	B-T078
in	O
comparison	B-T052
to	O
the	O
control group	B-T096
had	O
a	O
lower	B-T052
under-	O
reproduction	B-T040
and	O
a	O
higher	B-T080
over-	O
reproduction	B-T040
error	B-T080
,	O
and	O
also	O
a	O
lower	B-T052
under-	O
estimation	B-T041
and	O
higher	B-T080
over-	O
estimation	B-T041
error	B-T080
.	O
However,	O
regarding	O
time	B-T079
discrimination	B-T041
,	O
no	O
significant	B-T078
difference	B-T080
was	O
observed	O
between	O
the	O
errors	B-T080
committed	O
by	O
both	O
groups	B-T078
.	O
On	O
the	O
other	O
hand,	O
when	O
showing	O
images	B-T170
of	O
drug consumption	B-UnknownType
tools	B-T073
and	O
normal	B-T080
images	B-T170
with	O
same	O
durations	B-T079
,	O
the	O
normal	B-T080
group	B-T078
believed	O
that	O
the	O
images	B-T170
related	O
to	O
drug consumption	B-UnknownType
tools	B-T073
were	O
shown	O
for	O
a	O
shorter	B-T081
period	B-T079
of	O
time	B-T079
.	O
Time perception	B-T041
is	O
different	B-T080
between	O
morphine	B-T109
-	O
derived	B-T080
drugs	B-T121
addicts	B-T101
and	O
controls	B-T096
.	O

Co-delivery	B-T169
of	O
pemetrexed	B-T109
and	O
miR-21 antisense oligonucleotide	B-T114
by	O
lipid	B-T109
-	O
polymer	B-T104
hybrid nanoparticles	B-T073
and	O
effects	B-T080
on	O
glioblastoma	B-T191
cells	B-T025
Combination therapy	B-T061
using	O
anticancer drugs	B-T109
and	O
nucleic acid	B-T114
is	O
a	O
more	O
promising	O
strategy	O
to	O
overcome	O
multidrug resistance	B-T032
in	O
cancer	B-T191
and	O
to	O
enhance	O
apoptosis	B-T043
.	O
In	O
this	O
study	B-T062
,	O
lipid	B-T109
-	O
polymer	B-T104
hybrid nanoparticles	B-T073
(	O
LPNs	B-T122
),	O
which	O
contain	O
both	O
pemetrexed	B-T109
and	O
miR-21 antisense oligonucleotide	B-T114
(	O
anti-miR-21	B-T114
),	O
have	O
been	O
developed	O
for	O
treatment	B-T169
of	O
glioblastoma	B-T191
,	O
the	O
most	O
aggressive	B-T191
type	O
of	O
brain tumor	B-T191
.	O
Prepared	O
LPNs	B-T122
have	O
been	O
well	O
characterized	O
by	O
particle size	B-T081
distribution	B-T169
and	O
zeta potential	B-T067
measurements	B-T169
,	O
determination	O
of	O
encapsulation	B-T067
efficiency	B-T081
,	O
and	O
in vitro	B-T080
release experiments	B-T062
.	O
Morphology	B-T080
of	O
LPNs	B-T122
was	O
determined	O
by	O
transmission electron microscopy	B-T059
.	O
LPNs	B-T122
had	O
a	O
hydrodynamic	B-T070
size	B-T082
below	O
100	O
nm	O
and	O
exhibited	O
sustained release	B-T169
of	O
pemetrexed	B-T109
up	O
to	O
10	O
h.	O
Encapsulation	B-T067
of	O
pemetrexed	B-T109
in	O
LPNs	B-T122
increased	O
cellular uptake	B-T043
from	O
6%	O
to	O
78%.	O
Results	O
of	O
confocal microscopy analysis	B-T059
have	O
shown	O
that	O
co-delivery	B-T169
of	O
anti-miR-21	B-T114
significantly	O
improved	O
accumulation	B-T033
of	O
LPNs	B-T122
in	O
the	O
nucleus	B-T026
of	O
U87MG cells	B-T025
.	O
Nevertheless,	O
more	O
effective	O
cytotoxicity	B-T049
results	B-T169
could	O
not	O
be	O
obtained	O
due	O
to	O
low	O
concentration	B-UnknownType
of	O
anti-miR-21	B-T114
,	O
loaded	O
in	O
LPNs	B-T122
.	O
We	O
expect	O
that	O
the	O
effective	O
drug delivery systems	B-T074
can	O
be	O
obtained	O
with	O
higher	O
concentration	B-UnknownType
of	O
anti-miR-21	B-T114
for	O
the	O
treatment	B-T061
of	O
glioblastoma	B-T191
.	O

Expert	B-T097
position paper	B-T170
on	O
prolonged	B-T079
dual antiplatelet therapy	B-T061
in	O
secondary prevention	B-T061
following	O
myocardial infarction	B-T047
The	O
protective effect	B-T080
of	O
dual antiplatelet therapy	B-T061
(	O
DAPT	B-T061
)	O
following	O
acute coronary syndrome	B-T047
is	O
undisputed,	O
but	O
its	O
duration	B-T079
is	O
subject	O
of	O
debate	B-T052
.	O
Several	O
studies	B-T062
show	O
that	O
prolonged	B-T079
therapy	B-T061
provides	O
a	O
clinical	B-T080
benefit	B-T081
in	O
patients	B-T101
following	O
acute coronary syndrome	B-T047
.	O
The	O
aim	O
of	O
this	O
position paper	B-T170
authored	O
by	O
Austrian	B-T098
experts	B-T097
is	O
to	O
outline	O
the	O
current	B-T079
evidence	B-T078
and	O
provide	O
an	O
overview	O
of	O
recent	O
studies	B-T062
.	O
It	O
is	O
also	O
intended	O
to	O
serve	O
as	O
a	O
practical guide	B-T170
to	O
identify	O
those	O
patients	B-T101
who	O
may	O
benefit	B-T081
from	O
prolonged	B-T079
DAPT	B-T061
.	O

Medulloblastoma	B-T191
:	O
molecular pathways	B-T044
and	O
histopathological	B-T169
classification	B-T185
Malignant brain tumors	B-T191
are	O
the	O
leading	B-T169
cause	B-T169
of	O
cancer	B-T191
death	B-T033
among	O
pediatric	B-T080
patients	B-T101
,	O
and	O
medulloblastoma	B-T191
constitutes	O
20%	O
of	O
them.	O
Currently,	O
the	O
treatment	B-T061
is	O
risk-adapted.	O
Maximum	O
surgical resection	B-T061
is	O
recommended	B-T078
,	O
always	O
followed	O
by	O
chemotherapy	B-T061
and	O
neuroaxis	B-T022
radiotherapy	B-T061
.	O
In	O
spite	O
of	O
the	O
improving	B-T080
survival rate	B-T081
,	O
survivors	B-T101
succumb	O
to	O
treatment	B-T061
-	O
induced	B-T169
side effects	B-T046
.	O
To	O
reduce	B-T080
toxic effects	B-T037
,	O
molecular-targeted treatment	B-T061
is	O
proposed.	O
Medulloblastoma	B-T191
research	B-T062
is	O
very	O
robust	B-T080
,	O
and	O
new	O
articles	B-T170
on	O
the	O
subject	O
are	O
published	B-T057
daily.	O
In	O
the	O
current	O
review	B-T170
we	O
have	O
tried	O
to	O
bring	O
together	O
molecular	B-T080
pathophysiology	B-T169
of	O
the	O
neoplasm	B-T191
and	O
current	O
pathological	B-T169
classification	B-T185
,	O
thus	O
making	O
an	O
effort	O
to	O
relate	O
tumor biology	B-T062
and	O
the	O
histological picture	B-T201
.	O

Spatio-Temporal History	B-T062
of	O
HIV-1 CRF35_AD	B-T034
in	O
Afghanistan	B-T083
and	O
Iran	B-T083
HIV-1 Circulating Recombinant Form 35_AD	B-T005
(	O
CRF35_AD	B-T034
)	O
has	O
an	O
important	O
position	O
in	O
the	O
epidemiological	B-T091
profile	B-T169
of	O
Afghanistan	B-T083
and	O
Iran	B-T083
.	O
Despite	O
the	O
presence	O
of	O
this	O
clade	B-T001
in	O
Afghanistan	B-T083
and	O
Iran	B-T083
for	O
over	O
a	O
decade,	O
our	O
understanding	O
of	O
its	O
origin	O
and	O
dissemination	B-T080
patterns	O
is	O
limited.	O
In	O
this	O
study,	O
we	O
performed	O
a	O
Bayesian phylogeographic analysis	B-T081
to	O
reconstruct	O
the	O
spatio-temporal dispersion pattern	B-T080
of	O
this	O
clade	B-T001
using	O
eligible	O
CRF35_AD	B-T034
gag and pol sequences	B-T086
available	O
in	O
the	O
Los Alamos	B-T083
HIV database	B-T170
(432	O
sequences	B-T086
available	O
from	O
Iran	B-T083
,	O
16	O
sequences	B-T086
available	O
from	O
Afghanistan	B-T083
,	O
and	O
a	O
single	O
CRF35_AD	B-T034
-like	O
pol sequence	B-T086
available	O
from	O
USA	B-T083
).	O
Bayesian Markov Chain Monte Carlo algorithm	B-T170
was	O
implemented	O
in	O
BEAST v1.8.1	B-T073
.	O
Between-country	O
dispersion	O
rates	O
were	O
tested	O
with	O
Bayesian stochastic search variable selection method	B-T170
and	O
were	O
considered	O
significant	O
where	O
Bayes factor values	B-T081
were	O
greater	O
than	O
three.	O
The	O
findings	O
suggested	O
that	O
CRF35_AD	B-T034
sequences	B-T086
were	O
genetically	O
similar	O
to	O
parental sequences	B-T086
from	O
Kenya	B-T083
and	O
Uganda	B-T083
,	O
and	O
to	O
a	O
set	O
of	O
subtype A1	B-T034
sequences	B-T086
available	O
from	O
Afghan	B-T083
refugees	B-T098
living	O
in	O
Pakistan	B-T083
.	O
Our	O
results	O
also	O
showed	O
that	O
across	O
all	O
phylogenies	B-T078
,	O
Afghan	B-T083
and	O
Iranian	B-T083
CRF35_AD	B-T034
sequences	B-T086
formed	O
a	O
monophyletic cluster	B-T081
(posterior	O
clade	O
credibility>	O
0.7).	O
The	O
divergence	O
date	O
of	O
this	O
cluster	B-T081
was	O
estimated	O
to	O
be	O
between	O
1990	O
and	O
1992.	O
Within	O
this	O
cluster	B-T081
,	O
a	O
bidirectional	B-T080
dispersion	B-T080
of	O
the	O
virus	B-T005
was	O
observed	O
across	O
Afghanistan	B-T083
and	O
Iran	B-T083
.	O
We	O
could	O
not	O
clearly	O
identify	O
if	O
Afghanistan	B-T083
or	O
Iran	B-T083
first	O
established	O
or	O
received	O
this	O
epidemic	B-T047
,	O
as	O
the	O
root	O
location	O
of	O
this	O
cluster	B-T081
could	O
not	O
be	O
robustly	O
estimated.	O
Three	O
CRF35_AD	B-T034
sequences	B-T086
from	O
Afghan	B-T083
refugees	B-T098
living in	B-T082
Pakistan	B-T083
nested	O
among	O
Afghan	B-T083
and	O
Iranian	B-T083
CRF35_AD	B-T034
branches.	O
However,	O
the	O
CRF35_AD	B-T034
-like	O
sequence	B-T086
available	O
from	O
USA	B-T083
diverged	O
independently	O
from	O
Kenyan	B-T083
subtype A1	B-T034
sequences	B-T086
,	O
suggesting	O
it	O
not	O
to	O
be	O
a	O
true	O
CRF35_AD	B-T034
lineage.	O
Potential	B-T080
factors	B-T169
contributing	O
to	O
viral	B-T005
exchange	O
between	O
Afghanistan	B-T083
and	O
Iran	B-T083
could	O
be	O
injection	O
drug	O
networks	O
and	O
mass migration	B-T054
of	O
Afghan	B-T083
refugees	B-T098
and	O
labours	B-T055
to	O
Iran	B-T083
,	O
which	O
calls	O
for	O
extensive	B-T080
preventive	B-T080
efforts.	O

The	O
Benefits	B-T081
of	O
Combination Therapy	B-T061
with	O
Esomeprazole	B-T109
and	O
Rebamipide	B-T109
in	O
Symptom	B-T184
Improvement	B-T077
in	O
Reflux Esophagitis	B-T047
:	O
An	O
International	B-T078
Multicenter Study	B-T062
To	O
investigate	B-T169
the	O
effects	B-T080
of	O
esomeprazole	B-T109
and	O
rebamipide	B-T109
combination therapy	B-T061
on	O
symptomatic	B-T184
improvement	B-T077
in	O
patients	B-T101
with	O
reflux esophagitis	B-T047
.	O
A	O
total	O
of	O
501	O
patients	B-T101
with	O
reflux esophagitis	B-T047
were	O
randomized	B-T062
into	O
one	O
of	O
the	O
following	O
two	O
treatment regimens	B-T061
:	O
40	O
mg	O
esomeprazole	B-T109
plus	O
300	O
mg	O
rebamipide	B-T109
daily	B-T079
(	O
combination therapy	B-T061
group	B-T078
)	O
or	O
40	O
mg	O
esomeprazole	B-T109
daily	B-T079
(	O
monotherapy	B-T061
group	B-T078
).	O
We	O
used	O
a	O
symptom	B-T184
questionnaire	B-T170
that	O
evaluated	B-T169
heartburn	B-T184
,	O
acid regurgitation	B-T184
,	O
and	O
four	O
upper gastrointestinal symptoms	B-T047
.	O
The	O
primary	O
efficacy	B-T080
end	O
point	O
was	O
the	O
mean	O
decrease	B-T081
in	O
the	O
total	O
symptom score	B-T033
.	O
The	O
mean	O
decreases	B-T081
in	O
the	O
total	O
symptom score	B-T033
at	O
4	O
weeks	B-T079
were	O
estimated	O
to	O
be	O
-18.1±13.8	O
in	O
the	O
combination therapy	B-T061
group	B-T078
and	O
-15.1±11.9	O
in	O
the	O
monotherapy	B-T061
group	B-T078
(p=0.011).	O
Changes	O
in	O
reflux	B-T047
symptom	B-T184
s	O
from	O
baseline	B-T081
after	O
4	O
weeks	B-T079
of	O
treatment	B-T061
were	O
-8.4±6.6	O
in	O
the	O
combination therapy	B-T061
group	B-T078
and	O
-6.8±5.9	O
in	O
the	O
monotherapy	B-T061
group	B-T078
(p=0.009).	O
Over	O
a	O
4-	O
week	B-T079
treatment	B-T061
course,	O
esomeprazole	B-T109
and	O
rebamipide	B-T109
combination therapy	B-T061
was	O
more	O
effective	B-T080
in	O
decreasing	B-T033
the	O
symptoms	B-T184
of	O
reflux esophagitis	B-T047
than	O
esomeprazole	B-T109
monotherapy	B-T061
.	O

Integrating	B-T080
Palliative Care	B-T091
in	O
Pediatric Oncology	B-T091
:	O
Evidence	O
for	O
an	O
Evolving	B-T169
Paradigm	B-T062
for	O
Comprehensive	B-T058
Cancer Care	B-T061
The	O
demonstrated	O
benefit	O
of	O
integrating	B-T080
palliative care	B-T091
(	O
PC	B-T091
)	O
into	O
cancer treatment	B-T061
has	O
triggered	O
an	O
increased	B-T081
need	O
for	O
PC	B-T091
services.	O
The	O
trajectory	O
of	O
integrating	B-T080
PC	B-T091
in	O
comprehensive	B-T058
cancer centers,	B-T073
particularly	O
pediatric centers	B-T093
,	O
is	O
unknown.	O
We	O
describe	O
our	O
8-	O
year	B-T079
experience	O
of	O
initiating	O
and	O
establishing	B-T080
PC	B-T091
with	O
the	O
Quality of Life Service	B-T058
(	O
QoLS	B-T058
)	O
at	O
St. Jude Children's Research Hospital	B-T093
.	O
We	O
retrospectively	O
reviewed	O
records of patients	B-T170
seen	O
by	O
the	O
QoLS	B-T058
(n=615)	O
from	O
March	B-T079
2007	O
to	O
December	B-T080
2014.	O
Variables	B-T081
analyzed	O
for	O
each	O
year	B-T079
,	O
using	O
descriptive	O
statistics	B-T081
,	O
included	O
diagnostic groups	B-T170
,	O
QoLS	B-T058
encounters	B-T058
,	O
goals of care	B-T058
,	O
duration of survival	B-T201
,	O
and	O
location of death	B-T082
.	O
Total	O
QoLS	B-T058
patient	B-T101
encounters	B-T058
increased	B-T081
from	O
58	O
(2007)	O
to	O
1,297	O
(2014),	O
new	O
consults	B-T058
increased	B-T081
from	O
17	O
(2007)	O
to	O
115	O
(2014),	O
and	O
mean	O
encounters	B-T058
per	O
patient	B-T101
increased	B-T081
from	O
5.06	O
(2007)	O
to	O
16.11	O
(2014).	O
Goal of care	B-T058
at	O
initial consultation	B-T058
shifted	O
from	O
primarily	O
comfort	B-T041
to	O
an	O
increasing	B-T169
goal of cure	B-T170
.	O
The	O
median	O
number	O
of	O
days	O
from	O
initial consult	B-T058
to	O
death	B-T033
increased	B-T081
from	O
52	O
days	O
(2008)	O
to	O
223	O
days	O
(2014).	O
A	O
trend	O
toward	O
increased	B-T081
outpatient	B-T101
location of death	B-T082
was	O
noted	O
with	O
42%	O
outpatient	B-T101
deaths	B-T033
in	O
2007,	O
increasing	B-T169
to	O
a	O
majority	B-T080
in	O
each	O
subsequent	O
year	B-T079
(range,	O
51%-74%).	O
Hospital-wide	B-T080
,	O
patients	B-T101
receiving	O
PC	B-T091
services	O
before	O
death	B-T033
increased	B-T081
from	O
approximately	B-T080
50%	O
to	O
nearly	O
100%.	O
Since	O
its	O
inception,	O
the	O
QoLS	B-T058
experienced	O
a	O
dramatic	O
increase	B-T081
in	O
referrals	B-T058
and	O
encounters	B-T058
per	O
patient	B-T101
,	O
increased	B-T081
use	O
by	O
all	O
clinical services	B-T058
,	O
a	O
trend	O
toward	O
earlier	B-T079
consultation	B-T058
and	O
longer term	B-T079
follow-up	B-T058
,	O
increasing	B-T169
outpatient	B-T101
location of death	B-T082
,	O
and	O
near-	O
universal	B-T080
PC	B-T091
involvement	O
at	O
the	O
end-of-life	B-T058
.	O
The	O
successful	O
integration	B-T080
of	O
PC	B-T091
in	O
a	O
comprehensive	B-T058
cancer center	B-T073
,	O
and	O
the	O
resulting	O
potential	O
for	O
improved	O
care provision	B-T058
over	O
time	B-T079
,	O
can	O
serve	O
as	O
a	O
model	B-T170
for	O
other	O
programs	B-T058
on	O
a	O
broad	O
scale.	O

PROTECTIVE EFFECTS OF	B-T080
DIPEPTIDYL PEPTIDASE-4 INHIBITORS	B-T121
ON	O
PROGRESSION	B-T046
OF	O
DIABETIC RETINOPATHY	B-T047
IN	O
PATIENTS	B-T101
WITH	O
TYPE 2 DIABETES	B-T047
To	O
investigate	B-T169
the	O
effects of	B-T080
dipeptidyl peptidase-4 inhibitors	B-T121
(	O
DPP4	B-T121
)	O
on	O
the	O
progression	B-T046
of	O
diabetic retinopathy	B-T047
(	O
DR	B-T047
)	O
in	O
patients	B-T101
with	O
Type 2 diabetes	B-T047
based	O
on	O
the	O
DR	B-T047
severity scale	B-T081
.	O
The	O
medical records	B-T170
of	O
82	O
patients	B-T101
with	O
Type 2 diabetes	B-T047
enrolled	O
from	O
2005	O
to	O
2015	O
were	O
retrospectively	B-T080
reviewed	B-T080
.	O
Fundus photographs	B-T060
were	O
graded	B-T185
using	O
Early Treatment Diabetic Retinopathy Study methods	B-T170
.	O
The	O
associations	B-T080
between	O
baseline	B-T081
risk factors	B-T033
and	O
progression	B-T046
of	O
DR	B-T047
were	O
investigated	B-T169
.	O
Seven	O
of	O
28	O
patients	B-T101
treated	B-T169
with	O
DPP4 inhibitors	B-T121
and	O
26	O
of	O
54	O
treated	B-T169
with	O
other	O
hypoglycemic agents	B-T121
showed	O
progression	B-T046
of	O
retinopathy	B-T047
,	O
defined	O
as	O
one	O
or	O
more	O
steps	O
on	O
the	O
Early Treatment Diabetic Retinopathy Study scale	B-T081
(P	O
=	O
0.043).	O
Only	O
treatment	B-T169
with	O
DPP4 inhibitors	B-T121
significantly	O
reduced	B-T080
the	O
progression	B-T046
of	O
DR	B-T047
in	O
patients	B-T101
after	O
propensity score	B-T081
matching	O
(P	O
=	O
0.009).	O
Treatment	B-T169
with	O
DPP4 inhibitors	B-T121
was	O
associated with	B-T080
a	O
lower	B-T052
risk	B-T078
of	O
DR	B-T047
progression	B-T046
(P	O
=	O
0.011).	O
Treatment	B-T169
with	O
DPP4 inhibitors	B-T121
was	O
the	O
independent	B-T078
protective factor	B-T169
against	O
the	O
progression	B-T046
of	O
DR	B-T047
,	O
aside	O
from	O
improving glycemic control	B-T033
.	O
This	O
is	O
the	O
first	O
study	O
to	O
show	O
the	O
benefits	B-T081
of	O
DPP4 inhibitors	B-T121
in	O
reducing	B-T080
DR	B-T047
progression	B-T046
,	O
and	O
provides	O
encouraging	O
preliminary	B-T079
data	B-T078
for	O
further	O
evaluation	B-T058
of	O
DPP4 inhibitors	B-T121
in	O
the	O
progression	B-T046
of	O
DR	B-T047
in	O
a	O
randomized	B-T062
,	O
double-blind	B-T062
,	O
placebo-controlled trial	B-T062
.	O

Production	B-T057
of	O
Laccase	B-T116
by	O
Cochliobolus sp.	B-T004
Isolated	B-T169
from	O
Plastic	B-T167
Dumped Soils	B-T167
and	O
Their	O
Ability	B-T032
to	O
Degrade	B-UnknownType
Low Molecular Weight PVC	B-T109
One	O
of	O
the	O
utmost	O
man-made problems	B-T068
faced	O
today	O
has	O
been	O
the	O
ever	B-T079
-	O
increasing	B-T169
plastic	B-T167
waste	B-T167
filling	B-T052
the	O
world.	O
It	O
accounts	O
for	O
an	O
estimated	O
20-30%	O
(by	O
volume)	O
of	O
municipal solid waste	B-T167
in	O
landfill sites	B-T073
worldwide.	O
Research	O
on	O
plastic	B-T167
biodegradation	B-T070
has	O
been	O
steadily	O
growing	O
over	O
the	O
past	O
four	O
decades.	O
Several	O
fungi	B-T004
have	O
been	O
identified	O
that	O
produce	O
enzymes	B-T116
capable	O
of	O
plastic	B-T167
degradation	B-T070
in	O
various	O
laboratory conditions	B-T080
.	O
This	O
paper	O
presents	O
a	O
study	O
that	O
determined	O
the	O
ability	B-T032
of	O
fungi	B-T004
to	O
degrade	B-UnknownType
low molecular weight polyvinyl chloride	B-T109
(	O
PVC	B-T109
)	O
by	O
the	O
enzyme laccase	B-T116
.	O
We	O
have	O
isolated	B-T169
a	O
fungal	B-T004
species	B-T185
,	O
Cochliobolus sp.	B-T004
,	O
from	O
plastic	B-T167
dumped soils	B-T167
and	O
they	O
were	O
cultured	B-T059
on	O
Czapek Dox Agar slants	B-T130
at	O
30°C.	O
The	O
effectiveness	B-T080
of	O
this	O
fungal	B-T004
species	B-T185
on	O
the	O
degradation	B-T070
of	O
commercial	O
low molecular weight polyvinyl chloride	B-T109
(	O
PVC	B-T109
)	O
was	O
studied	O
under	O
laboratory conditions	B-T080
.	O
Significant	O
differences	O
were	O
observed	O
from	O
the	O
FTIR	B-T062
,	O
GC-MS	B-T059
,	O
and	O
SEM	B-T059
results	O
in	O
between	O
control	B-T167
and	O
Cochliobolus sp.	B-T004
treated	O
PVC	B-T109
.	O

Effects of	B-T080
Cerium	B-T130
and	O
Titanium Oxide	B-T121
Nanoparticles	B-T073
in	O
Soil	B-T167
on	O
the	O
Nutrient	B-T168
Composition	B-T201
of	O
Barley	B-T002
(	O
Hordeum vulgare L	B-T002
.)	O
Kernels	B-T168
The	O
implications	B-T169
of	O
metal nanoparticles	B-T073
(	O
MeNPs)	B-T073
are	O
still	O
unknown	B-T080
for	O
many	B-T081
food crops	B-T002
.	O
The	O
purpose	B-T169
of	O
this	O
study	B-T062
was	O
to	O
evaluate	O
the	O
effects of	B-T080
cerium oxide	B-T130
(	O
nCeO₂	B-T130
)	O
and	O
titanium oxide	B-T121
(	O
nTiO₂	B-T121
)	O
nanoparticles	B-T073
in	O
soil	B-T167
at	O
0,	O
500	O
and	O
1000	O
mg·kg(-1)	O
on	O
the	O
nutritional parameters	B-T080
of	O
barley	B-T002
(	O
Hordeum vulgare L.	B-T002
)	O
kernels	B-T168
.	O
Mineral nutrients	B-T197
,	O
amylose	B-T109
,	O
β-glucans	B-T109
,	O
amino acid	B-T116
and	O
crude protein	B-T116
(	O
CP	B-T116
)	O
concentrations were measured	B-T081
in	O
kernels	B-T168
.	O
Whole	B-T081
flour	B-T168
samples	O
were	O
analyzed	O
by	O
ICP-AES/MS	B-T059
,	O
HPLC	B-T059
and	O
Elemental CHNS Analyzer	B-T073
.	O
Results	O
showed	O
that	O
Ce	B-T109
and	O
Ti	B-T196
accumulation	B-T033
under	O
MeNPs	B-T073
treatments	B-T169
did	O
not	O
differ	O
from	O
the	O
control treatment	B-T169
.	O
However,	O
nCeO₂	B-T130
and	O
nTiO₂	B-T121
had	O
an	O
impact	B-T080
on	O
composition	B-T201
and	O
nutritional quality	B-T080
of	O
barley	B-T002
kernels	B-T168
in	O
contrasting ways	B-T080
.	O
Both	O
MeNPs	B-T073
left	O
β-glucans	B-T109
unaffected	B-T077
but	O
reduced	O
amylose	B-T109
content	O
by	O
approximately	O
21%.	O
Most	O
amino acids	B-T116
and	O
CP	B-T116
increased	B-T081
.	O
Among	O
amino acids	B-T116
,	O
lysine	B-T116
followed	O
by	O
proline	B-T116
saw	O
the	O
largest increase	B-T169
(51%	O
and	O
37%,	O
respectively).	O
Potassium	B-T123
and	O
S	B-T121
were	O
both	O
negatively impacted	B-T080
by	O
MeNPs	B-T073
,	O
while	O
B	O
was	O
only	O
affected	B-T169
by	O
500	O
mg	O
nCeO₂	B-T130
·kg(-1).	O
On	O
the	O
contrary	O
Zn	B-T059
and	O
Mn concentrations	B-T059
were	O
improved	O
by	O
500	O
mg	O
nTiO₂	B-T121
·kg(-1),	O
and	O
Ca	O
by	O
both	O
nTiO₂	B-T121
treatments	B-T169
.	O
Generally,	O
our	O
findings	O
demonstrated	B-T052
that	O
kernels	B-T168
are	O
negatively affected	B-T033
by	O
nCeO₂	B-T130
while	O
nTiO₂	B-T121
can	O
potentially	O
have	O
beneficial effects	B-T080
.	O
However,	O
both	O
MeNPs	B-T073
have	O
the	O
potential	O
to	O
negatively impact	B-T080
malt	B-T168
and	O
feed production	B-T090
.	O

Quantifying	B-T081
Nonlinear	O
Contributions	B-T052
to	O
Cortical Responses Evoked	B-T059
by	O
Continuous Wrist Manipulation	B-T061
Cortical responses	B-T059
to	O
continuous stimuli	B-T039
as	O
recorded	O
using	O
either	O
magneto-	B-T060
or	O
electroencephalography	B-T060
(	O
EEG	B-T060
)	O
have	O
shown	O
power	O
at	O
harmonics	O
of	O
the	O
stimulated frequency	B-T079
,	O
indicating	O
nonlinear behavior	B-T053
.	O
Even	O
though	O
the	O
selection	O
of	O
analysis	B-T062
techniques	B-T169
depends	O
on	O
the	O
linearity	B-T082
of	O
the	O
system	O
under	O
study,	O
the	O
importance	O
of	O
nonlinear	O
contributions	B-T052
to	O
cortical responses	B-T059
has	O
not	O
been	O
formally	O
addressed.	O
The	O
goal of this paper	B-T170
is	O
to	O
quantify	B-T081
the	O
nonlinear	O
contributions	B-T052
to	O
the	O
cortical response	B-T059
obtained	O
from	O
continuous	B-T078
sensory stimulation	B-T061
.	O
EEG	B-T060
was	O
used	O
to	O
record	O
the	O
cortical response evoked	B-T059
by	O
continuous movement of the wrist joint	B-T033
of	O
healthy	O
subjects	O
applied	O
with	O
a	O
robotic manipulator	B-T073
.	O
Multisine	O
stimulus signals	B-T067
(i.e.,	O
the	O
sum	O
of	O
several	B-T081
sinusoids	B-T030
)	O
elicit	O
a	O
periodic	B-T079
cortical response	B-T059
and	O
allow	O
to	O
assess	B-T052
the	O
nonlinear	O
contributions	B-T052
to	O
the	O
response.	O
Wrist dynamics	B-T061
(relation	O
between	O
joint angle	B-T030
and	O
torque	B-T067
)	O
were	O
successfully	O
linearized	B-T082
,	O
explaining	O
99%	O
of	O
the	O
response.	O
In	O
contrast,	O
the	O
cortical response	B-T059
revealed	O
a	O
highly	O
nonlinear	O
relation;	O
where	O
most	O
power	O
(∼	O
80	O
%)	O
occurred	O
at	O
non-stimulated	O
frequencies.	O
Moreover,	O
only	O
10%	O
of	O
the	O
response	O
could	O
be	O
explained	O
using	O
a	O
nonparametric linear model	B-T081
.	O
These	O
results	B-T033
indicate	O
that	O
the	O
recorded	O
evoked cortical responses	B-T059
are	O
governed	O
by	O
nonlinearities	O
and	O
that	O
linear	B-T082
methods	O
do	O
not	O
suffice	O
when	O
describing	O
the	O
relation	O
between	O
mechanical stimulus	B-T067
and	O
cortical response	B-T033
.	O

Using	B-T169
melanopsin	B-T116
to	O
study	B-T062
G protein signaling	B-T044
in	O
cortical	B-T023
neurons	B-T025
Our	O
understanding	B-T041
of	O
G protein-coupled receptors	B-T116
(	O
GPCRs	B-T116
)	O
in	O
the	O
central nervous system	B-T022
(	O
CNS	B-T022
)	O
has	O
been	O
hampered	O
by	O
the	O
limited	O
availability	O
of	O
tools	B-T073
allowing	O
for	O
the	O
study	B-T062
of	O
their	O
signaling	B-T038
with	O
precise temporal	B-T079
control	B-T169
.	O
To	O
overcome	B-T052
this,	O
we	O
tested	B-T169
the	O
utility	O
of	O
the	O
bistable	B-T080
mammalian	B-T015
opsin	B-T116
melanopsin	B-T116
to	O
examine	O
G protein signaling	B-T044
in	O
CNS	B-T022
neurons	B-T025
.	O
Specifically,	O
we	O
used	B-T169
biolistic	B-T063
(	O
gene gun	B-T075
)	O
approaches	O
to	O
transfect melanopsin	B-T116
into	O
cortical	B-T023
pyramidal cells	B-T025
maintained	B-T169
in	O
organotypic slice culture	B-T059
.	O
Whole cell recordings	B-T062
from	O
transfected neurons	B-T025
indicated	O
that	O
application	O
of	O
blue light	B-T070
effectively	B-T080
activated	B-T169
the	O
transfected melanopsin	B-T116
to	O
elicit	B-T080
the	O
canonical	O
biphasic	B-T079
modulation	B-UnknownType
of	O
membrane	B-T026
excitability	B-T184
previously	O
associated with	B-T080
the	O
activation	B-T169
of	O
GPCRs	B-T116
coupling	B-T169
to	O
Gαq-11	B-T116
Remarkably,	O
full	O
mimicry	O
of	O
exogenous	B-T169
agonist	B-T121
concentration	B-T081
could	O
be	O
obtained	B-T169
with	O
pulses	B-T067
as	O
short	O
as	O
a	O
few	B-T081
milliseconds	B-T079
,	O
suggesting	O
that	O
their	O
triggering	B-T080
required	O
a	O
single	B-T081
melanopsin	B-T116
activation-deactivation cycle	B-T079
.	O
The	O
resulting	B-T169
temporal control	B-T169
over	O
melanopsin	B-T116
activation	B-T169
allowed	O
us	O
to	O
compare	B-T052
the	O
activation	B-T169
kinetics	B-T070
of	O
different	O
components	O
of	O
the	O
electrophysiological	B-T042
response	B-T032
.	O
We	O
also	O
replaced	O
the	O
intracellular	B-T082
loops	B-T082
of	O
melanopsin	B-T116
with	O
those	O
of	O
the	O
5-HT2A receptor	B-T116
to	O
create	O
a	O
light-activated	B-T067
GPCR	B-T116
capable	O
of	O
interacting	B-T169
with	O
the	O
5-HT2A receptor	B-T116
interacting	B-T169
proteins	B-T116
.	O
The	O
resulting	B-T169
chimera	B-T116
expressed	B-T169
weak	B-T080
activity	B-T052
but	O
validated	B-T062
the	O
potential	B-T080
usefulness	B-T080
of	O
melanopsin	B-T116
as	O
a	O
tool	B-T073
for	O
the	O
study	B-T062
of	O
G protein signaling	B-T044
in	O
CNS	B-T022
neurons	B-T025
.	O

Maternal	B-T099
vitamin D	B-T109
levels	B-T080
and	O
the	O
risk	B-T078
of	O
perinatal death	B-T046
To	O
determine	O
the	O
association	B-T080
between	O
maternal	B-T099
vitamin D	B-T109
levels	B-T080
and	O
perinatal death	B-T046
.	O
A	O
retrospective	B-T080
cross-sectional study	B-T062
of	O
all	O
non-anomalous,	O
singleton	B-T099
births	B-T040
(≥24	O
weeks	B-T079
)	O
with	O
perinatal death	B-T046
compared	O
to	O
a	O
matched	O
control group	B-T096
.	O
Only	O
pregnancies	B-T040
with	O
a	O
recorded	O
vitamin D	B-T109
level	B-T080
at	O
booking	O
(8-19	O
weeks	B-T079
gestation	B-T040
)	O
were	O
included	O
for	O
analysis	B-T062
.	O
Maternal	B-T099
vitamin D	B-T109
levels	B-T080
were	O
categorized	O
into	O
normal	B-T080
,	O
deficient	B-T169
and	O
insufficient	B-T080
cohorts	B-T098
and	O
variables	B-T080
compared	O
between	O
the	O
three	O
groups	B-T098
.	O
There	O
were	O
31	O
perinatal deaths	B-T046
which	O
were	O
compared	O
to	O
111	O
controls	B-T096
.	O
Median	O
vitamin D	B-T109
levels	B-T080
were	O
lower	O
in	O
the	O
perinatal death	B-T046
cohort	B-T098
compared	O
to	O
the	O
control group	B-T096
(55	O
nmol/L	O
versus	O
64	O
nmol/L,	O
p	O
=	O
0.43).	O
There	O
was	O
no	O
significant	O
increase	O
in	O
deaths	B-T040
between	O
the	O
normal	B-T080
and	O
deficient	B-T169
(p	O
=	O
0.33)	O
or	O
insufficient	B-T080
(p	O
=	O
0.09)	O
groups	B-T098
.	O
Low	O
maternal	B-T099
vitamin D	B-T109
levels	B-T080
at	O
booking	O
were	O
not	O
associated with	B-T080
an	O
increased	O
risk	B-T078
of	O
perinatal demise	B-T046
.	O

Effect	B-T080
of	O
constitutive inactivation	B-T045
of	O
the	O
myostatin gene	B-T028
on	O
the	O
gain	B-T081
in	O
muscle strength	B-T042
during	O
postnatal growth	B-T040
in	O
two	O
murine	B-T015
models	B-T008
The	O
effect	B-T080
of	O
constitutive inactivation	B-T045
of	O
the	O
gene encoding myostatin	B-T028
on	O
the	O
gain	B-T081
in	O
muscle performance	B-T042
during	O
postnatal growth	B-T040
has	O
not	O
been	O
well	O
characterized.	O
We	O
analyzed	O
2	O
murine	B-T015
myostatin	B-T028
knockout (KO) models	B-T008
,	O
(i)	O
the	O
Lee model	B-T008
(	O
KO(Lee	B-T015
))	O
and	O
(ii)	O
the	O
Grobet model	B-T008
(	O
KO(Grobet)	B-T015
),	O
and	O
measured	B-T080
the	O
contraction	B-T039
of	O
tibialis anterior muscle	B-T023
in situ	B-T082
.	O
Absolute maximal isometric force	B-T042
was	O
increased	B-T081
in	O
6-month-old	O
KO(Lee)	B-T015
and	O
KO(Grobet) mice	B-T015
,	O
as	O
compared	B-T052
to	O
wild-type mice	B-T015
.	O
Similarly,	O
absolute maximal power	B-T042
was	O
increased	B-T081
in	O
6-month-old	O
KO(Lee) mice	B-T015
.	O
In	O
contrast,	O
specific	B-T080
maximal force	B-T042
(	O
relative	B-T080
maximal force	B-T042
per	O
unit	O
of	O
muscle	B-T024
mass	B-T033
was	O
decreased	B-T081
in	O
all	O
6-month-old	O
male	B-T032
and	O
female	B-T032
KO mice	B-T015
,	O
except	B-T169
in	O
6-month	B-T079
-old	O
female	B-T032
KO(Grobet) mice	B-T015
,	O
whereas	O
specific	B-T080
maximal power	B-T040
was	O
reduced	B-T080
only	O
in	O
male	B-T032
KO(Lee) mice	B-T015
.	O
Genetic inactivation	B-T045
of	O
myostatin	B-T028
increases	B-T169
maximal force	B-T042
and	O
power	B-T040
,	O
but	O
in	O
return	B-T080
it	O
reduces	B-T080
muscle	B-T024
quality	B-T080
,	O
particularly	O
in	O
male	B-T032
mice	B-T015
.	O
Muscle	O
Nerve	O
55:	O
254-261,	O
2017.	O

Methylation	B-T044
status	B-T080
of	O
the	O
promoter region	B-T114
of	O
the	O
human	B-T016
frizzled 9 gene	B-T028
in	O
acute myeloid leukemia	B-T191
The	O
FZD9 gene	B-T028
is	O
located	O
at	O
chromosome 7q11.23	B-T028
,	O
and	O
has	O
been	O
indicated	O
to	O
be	O
a	O
tumor suppressor gene	B-T028
.	O
The	O
present	O
study	B-T062
examined	B-T033
the	O
involvement	B-T169
of	O
FZD9	B-T028
promoter	B-T114
methylation	B-T044
in	O
the	O
downregulation	B-T044
of	O
FZD9	B-T028
expression	B-T045
in	O
leukemia	B-T191
cells	B-T025
.	O
The	O
expression	B-T045
of	O
the	O
FZD9 gene	B-T028
was	O
absent	B-T169
in	O
various	O
leukemic	B-T191
cell lines	B-T025
,	O
while	O
it	O
was	O
restored	O
following	O
treatment	B-T169
with	O
DNA demethylating agent	B-T109
5-aza-2'-deoxycytidine	B-T109
.	O
Bisulfite sequencing analysis	B-T063
of	O
the	O
FZD9	B-T028
promoter region	B-T114
showed	O
that	O
it	O
was	O
partially	O
methylated	B-T044
in	O
cell lines	B-T025
in	O
which	O
FZD9 gene	B-T028
was	O
not	O
expressed	B-T045
.	O
Thus,	O
DNA methylation	B-T044
in	O
the	O
promoter region	B-T114
may	O
lead	O
to	O
inactivation	B-T169
of	O
the	O
FZD9 gene	B-T028
,	O
which	O
may	O
represent	O
and	O
aberration	O
associated with	B-T080
leukemia	B-T191
,	O
since	O
DNA	B-T114
was	O
not	O
methylated	B-T044
in	O
normal	O
peripheral blood mononuclear cells	B-T025
.	O
Methylation	B-T044
-specific	O
polymerase chain reaction analysis	B-T063
revealed	O
that	O
the	O
promoter region	B-T114
of	O
the	O
FZD9 gene	B-T028
was	O
frequently	B-T079
methylated	B-T044
in	O
primary	B-T080
or	O
relapse	B-T067
acute myeloid leukemia	B-T191
(52.9%;	O
excluding	O
acute promyelocytic leukemia	B-T191
);	O
however,	O
methylation	B-T044
was	O
infrequent	O
in	O
B-cell	B-T025
acute lymphocytic leukemia	B-T191
(5.6%).	O
In	O
conclusion,	O
the	O
present	O
study	B-T062
indicated	O
that	O
the	O
methylation	B-T044
profile	B-T059
of	O
the	O
FZD9 gene	B-T028
corresponded	O
to	O
that	O
of	O
a	O
candidate	O
tumor-suppressor gene	B-T028
in	O
acute myeloid leukemia	B-T191
.	O

Identification	B-T080
of	O
a	O
group	B-T078
of	O
XTHs	B-T116
genes	B-T028
responding	O
to	O
heavy metal	B-T196
mercury	B-T131
,	O
salinity and drought stresses	B-T067
in	O
Medicago truncatula	B-T002
Xyloglucan endotransglucosylase/hydrolases	B-T116
(	O
XTH	B-T116
)	O
are	O
one	O
of	O
the	O
key	O
enzymes	B-T116
regulating	B-T038
cell wall construction	B-T043
,	O
extension	B-T169
and	O
metabolism	B-T025
.	O
In	O
the	O
study	B-T062
,	O
44	O
XTH protein	B-T116
genes	B-T028
from	O
Medicago truncatula	B-T002
genome	B-T028
were	O
identified	O
using	O
bioinformatics	B-T091
,	O
microarray	B-T073
and	O
RT-PCR	B-T063
.	O
Each	O
XTH	B-T116
was	O
showed	O
to	O
possess	O
a	O
highly conserved domain	B-T087
((D/N)-E-(I/L/F/V)-D-(F/I/L)-E-(F/L)-L-G),	O
and	O
most	O
of	O
XTHs	B-T116
possess	O
four	O
Cys	B-T116
in	O
the	O
C terminal region	B-T087
,	O
which	O
suggests	O
the	O
potential	B-T080
for	O
generating	O
disulfide bonds	B-T087
.	O
Based	O
on	O
the	O
XTH	B-T116
protein sequences	B-T087
,	O
these	O
XTHs	B-T116
can	O
be	O
classified	O
into	O
three	O
major	O
families	B-T116
and	O
each	O
family	B-T116
can	O
be	O
subdivided	O
into	O
more	O
groups	B-T078
.	O
Examination	O
of	O
the	O
genomic location	B-T082
of	O
XTH genes	B-T028
on	O
M. truncatula	B-T002
chromosomes	B-T026
showed	O
that	O
the	O
evolutional expansion	B-T038
of	O
the	O
genes	B-T028
was	O
possibly	O
attributed	O
to	O
localized	B-T082
gene duplications	B-T045
.	O
To	O
investigate	O
the	O
possible	O
involvement	B-T169
of	O
the	O
XTHs	B-T116
responding	O
to	O
heavy metals	B-T196
and	O
other	O
abiotic stresses	B-T067
,	O
the	O
XTH genes	B-T028
were	O
exposed	O
to	O
heavy metal	B-T196
(	O
Hg	B-T131
or	O
Cu	B-T121
),	O
salt and drought stresses	B-T067
.	O
There	O
were	O
28,	O
21	O
and	O
21	O
MtXTH genes	B-T028
found	O
to	O
respond	O
to	O
HgCl2	B-T121
,	O
salt and drought stresses	B-T067
,	O
respectively,	O
but	O
their	O
expression	B-T045
were	O
different	O
under	O
the	O
stresses	B-T067
.	O
Some	O
of	O
the	O
XTH genes	B-T028
were	O
well	O
confirmed	O
by	O
quantitative	B-T081
RT-PCR	B-T063
(	O
qRT-PCR	B-T063
).	O
We	O
further	O
specified	B-T080
expression	B-T045
of	O
a	O
XTH gene	B-T028
Medtr4g128580	B-T028
(	O
MtXTH3	B-T028
)	O
under	O
different	O
environmental stresses	B-T067
,	O
and	O
showed	O
that	O
MtXTH3	B-T028
was	O
induced	O
by	O
Hg	B-T131
exposure	B-T080
.	O
These	O
results	B-T169
indicated	O
that	O
a	O
group	B-T078
of	O
MtXTHs	B-T028
could	O
be	O
differentially	O
expressed	B-T045
under	O
the	O
environmental stresses	B-T067
.	O

Vestibular disorders	B-T047
and	O
nausea	B-T184
during	O
head	B-T191
and	O
neck	B-T191
intensity-modulated radiation therapy	B-T061
We	O
studied	O
whether	O
there	O
is	O
a	O
relationship	B-T080
between	O
nausea	B-T184
and	O
vestibular disorders	B-T047
in	O
patients	B-T101
treated with	B-T061
intensity modulated radiation therapy	B-T061
(	O
IMRT	B-T061
)	O
for	O
head	B-T191
and	O
neck cancer	B-T191
.	O
We	O
performed	O
a	O
prospective single-centre study	B-T062
that	O
enrolled	B-T058
31	O
patients	B-T101
.	O
A	O
videonystagmography	B-T061
was	O
carried	O
out	O
before	O
and	O
within	O
15	O
days	O
after	O
radiation therapy	B-T061
for	O
each	O
patient	B-T101
.	O
Nausea	B-T184
was	O
assessed	O
at	O
baseline	B-T081
,	O
every	O
week,	O
and	O
at	O
the	O
post-radiotherapy	B-T061
videonystagmography	B-T061
visit.	O
Twenty-six	O
patients	B-T101
had	O
benefited	O
from	O
a	O
complete	O
interpretable	O
videonystagmography	B-T061
.	O
For	O
14	O
of	O
these	O
patients	B-T101
vestibular damage	B-T033
was	O
diagnosed	B-T033
post-radiotherapy	B-T061
.	O
During	O
irradiation	B-T070
,	O
six	O
patients	B-T101
felt	O
nauseous	B-T184
,	O
but	O
without	O
dizziness	B-T184
.	O
In	O
univariate analysis	B-T062
,	O
we	O
found	O
a	O
relationship	B-T080
statistically significant	B-T081
between	O
the	O
average	O
dose	B-T081
received	O
by	O
the	O
vestibules	B-T030
and	O
vestibular disorder	B-T047
videonystagmography	B-T061
(P=0.001,	O
odds ratio	B-T081
[	O
OR	B-T081
]:	O
1.08	O
[1.025-.138]),	O
but	O
there	O
was	O
no	B-T033
relationship	B-T080
between	O
vestibular disorder	B-T047
videonystagmography	B-T061
and	O
nausea	B-T184
(P=0.701).	O
Irradiation	B-T070
of	O
the	O
vestibular system	B-T022
during	O
IMRT	B-T061
does	O
not	O
seem	O
to	O
explain	O
the	O
nausea	B-T184
.	O

Preventing	O
Youth	B-T100
Internalizing Symptoms	B-T048
Through	O
the	O
Familias Unidas	B-UnknownType
Intervention	B-UnknownType
:	O
Examining	O
Variation	B-T081
in	O
Response	B-T201
Prevention programs	B-T170
that	O
strengthen	O
parenting	B-T054
and	O
family functioning	B-T054
have	O
been	O
found	O
to	O
reduce	B-T061
poor behavioral	B-T184
outcomes	O
in	O
adolescents	B-T100
,	O
including	O
substance use	B-T048
,	O
HIV risk	B-T033
,	O
externalizing	O
and	O
internalizing problems	B-T048
.	O
However,	O
there	O
is	O
evidence	O
that	O
not	O
all	O
youth	B-T100
benefit	O
similarly	O
from	O
these	O
programs	B-T170
.	O
Familias Unidas	B-UnknownType
is	O
a	O
family-focused intervention	B-UnknownType
designed	O
to	O
prevent	O
substance use	B-T048
and	O
sexual risk	B-T033
among	O
Hispanic	B-T098
youth	B-T100
and	O
has	O
recently	O
demonstrated	O
unanticipated	O
reductions	B-T061
in	O
internalizing symptoms	B-T048
for	O
some	O
youth	B-T100
.	O
This	O
paper	O
examines	O
variation	O
in	O
intervention	B-UnknownType
response	O
for	O
internalizing symptoms	B-T048
using	O
individual-level data	B-UnknownType
pooled	O
across	O
four	O
distinct	O
Familias Unidas	B-UnknownType
trials	B-T062
:	O
(1)	O
266	O
eighth grade	B-T033
students	B-T098
recruited	O
from	O
the	O
general	O
school population	B-T098
;	O
(2)	O
160	O
ninth grade	B-T033
students	B-T098
from	O
the	O
general	O
school population	B-T098
;	O
(3)	O
213	O
adolescents	B-T100
with	O
conduct	B-T048
,	O
aggression	B-T055
,	O
and/or	O
attention problems	B-T033
;	O
and	O
(4)	O
242	O
adolescents	B-T100
with	O
a	O
delinquency	B-T048
history.	O
Causal inference growth mixture modeling	B-UnknownType
suggests	O
a	O
three-	O
class	B-T185
model	B-T170
.	O
The	O
two	O
largest	O
classes	B-T185
represent	O
youth	B-T100
with	O
low	B-T080
(60	O
%)	O
and	O
medium	B-T081
(27	O
%)	O
internalizing symptoms	B-T048
at	O
baseline	B-T081
,	O
and	O
both	O
intervention	B-UnknownType
and	O
control	B-T096
participants	B-T098
show	O
reductions	B-T061
in	O
internalizing symptoms	B-T048
.	O
The	O
third	O
class	B-T185
(13	O
%)	O
represents	O
youth	B-T100
with	O
high	B-T080
levels	B-T080
of	O
baseline	B-T081
internalizing symptoms	B-T048
who	O
remain	O
at	O
steady	B-T080
levels	B-T080
of	O
internalizing symptoms	B-T048
when	O
exposed to	B-T080
the	O
intervention	B-UnknownType
,	O
but	O
who	O
experience	O
an	O
increase	O
in	O
symptoms	B-T048
under	O
the	O
control condition	B-T080
.	O
Female gender	B-T032
,	O
low	B-T080
baseline	B-T081
levels	B-T080
of	O
parent	B-T099
-	O
adolescent	B-T100
communication	B-T054
,	O
and	O
older age	B-T098
were	O
associated	O
with	O
membership	O
in	O
the	O
high-risk	B-T033
class	B-T185
.	O
These	O
synthesis	O
analyses	O
involving	O
a	O
large	O
sample	O
of	O
youth	B-T100
with	O
varying	O
initial risk levels	B-T080
represent	O
a	O
further	O
step	O
toward	O
strengthening	O
our	O
knowledge	O
of	O
preventive intervention	B-UnknownType
response	B-T201
and	O
improving	O
preventive interventions	B-UnknownType
.	O

Acute Kidney Injury	B-T037
Severity	B-T080
and	O
Long-Term	B-T079
Readmission	B-T058
and	O
Mortality	B-T081
After	O
Cardiac Surgery	B-T061
Acute kidney injury	B-T037
(	O
AKI	B-T037
)	O
is	O
a	O
common	O
complication	B-T046
after	O
cardiac surgery	B-T061
.	O
While	O
AKI	B-T037
severity	B-T080
is	O
known	O
to	O
be	O
associated with	B-T080
increased	O
risk	B-T078
of	O
short-term	B-T079
outcomes,	O
its	O
long-term	B-T079
impact	O
is	O
less	O
well	O
understood.	O
Adult	O
patients	B-T101
undergoing	O
isolated	O
coronary artery bypass graft surgery	B-T061
at	O
eight	O
centers	O
were	O
enrolled	O
into	O
the	O
Northern New England biomarker registry	B-T170
(n	O
=	O
1,610).	O
Patients	B-T101
were	O
excluded	O
if	O
they	O
had	O
renal failure	B-T047
(n	O
=	O
15)	O
or	O
died	B-T033
during	O
index admission	B-T058
(n	O
=	O
38).	O
Severity	B-T080
of	O
AKI	B-T037
was	O
defined	O
using	O
the	O
Acute Kidney Injury Network	B-T185
(	O
AKIN	B-T185
).	O
We	O
linked	O
our	O
cohort	B-T081
to	O
national Medicare	B-T093
and	O
state all-payer claims	B-T170
to	O
ascertain	O
readmissions	B-T058
and	O
to	O
the	O
National Death Index	B-T170
to	O
ascertain	O
survival	B-T169
.	O
Kaplan-Meier	B-T081
and	O
multivariate Cox proportional hazards modeling	B-T081
was	O
conducted	O
for	O
time	O
to	O
readmission	B-T058
and	O
death	B-T033
over	O
5	O
years.	O
Within	O
5	O
years,	O
513	O
patients	B-T101
(33.8%)	O
had	O
AKI	B-T037
with	O
AKIN	B-T185
stage	O
1	O
(29.9%)	O
and	O
stage	O
2	O
to	O
3	O
(3.9%).	O
There	O
were	O
620	O
readmissions	B-T058
(39.9%)	O
and	O
370	O
deaths	B-T033
(23.8%).	O
After	O
adjustment,	O
stage	O
1	O
AKI	B-T037
patients	B-T101
had	O
a	O
31%	O
increased	O
risk	B-T078
of	O
readmission	B-T058
(95%	O
confidence interval	B-T081
[	O
CI	B-T081
]:	O
1.10	O
to	O
1.57),	O
whereas	O
stage	O
2	O
or	O
3	O
patients	B-T101
had	O
a	O
98%	O
increased	O
risk	B-T078
(95%	O
CI	B-T081
:	O
1.41	O
to	O
2.78)	O
compared	O
with	O
patients	B-T101
having	O
no	B-T033
AKI	B-T037
.	O
Relative	O
to	O
patients	B-T101
without	O
AKI	B-T037
,	O
stage	O
1	O
patients	B-T101
had	O
a	O
56%	O
increased	O
risk	B-T078
of	O
mortality	B-T081
(95%	O
CI	B-T081
:	O
1.14	O
to	O
2.13),	O
whereas	O
stage	O
2	O
or	O
3	O
patients	B-T101
had	O
a	O
3.5	O
times	O
higher	O
risk	B-T078
(95%	O
CI	B-T081
:	O
2.16	O
to	O
5.60).	O
Severity	B-T080
of	O
AKI	B-T037
using	O
the	O
AKIN	B-T185
stage	O
criteria	O
is	O
associated with	B-T080
a	O
significantly	O
increased	O
risk	B-T078
of	O
5-year	O
readmission	B-T058
and	O
mortality	B-T081
.	O
Our	O
findings	O
suggest	O
that	O
efforts	O
to	O
reduce	O
AKI	B-T037
in	O
the	O
perioperative period	B-T079
may	O
have	O
a	O
significant	O
long-term	B-T079
impact	O
on	O
patients	B-T101
and	O
payers	O
in	O
reducing	O
mortality	B-T081
and	O
health care utilization	B-T058
.	O

Association	B-T080
of	O
abdominal fat	B-T024
with	O
serum	B-T031
amylase	B-T116
in	O
an	O
older	B-T098
cohort	B-T098
:	O
The	O
Baltimore	B-T083
Longitudinal Study	B-T062
of	O
Aging	B-T040
Abdominal fat	B-T024
is	O
a	O
major	O
determinant	B-T169
of	O
metabolic diseases	B-T047
in	O
older	B-T098
individuals	B-T098
.	O
Obesity	B-T047
and	O
diabetes	B-T047
are	O
associated with	B-T080
low	B-T080
serum amylase (SA) levels	B-T033
,	O
but	O
the	O
association	B-T080
between	O
SA	B-T033
and	O
metabolic disease	B-T047
is	O
poorly	O
understood.	O
We	O
investigated	B-T169
the	O
association	B-T080
of	O
low	B-T080
SA	B-T033
with	O
diabetes	B-T047
and	O
sex	B-T032
-	O
specific	B-T080
associations	B-T080
of	O
serum	B-T031
amylase	B-T116
with	O
abdominal fat	B-T024
in	O
older adults	B-T100
.	O
In	O
community-dwelling	B-T056
volunteers	B-T098
from	O
the	O
Baltimore	B-T083
Longitudinal Study	B-T062
of	O
Aging	B-T040
(778	O
participants	B-T098
,	O
age	B-T032
66.8±13.6	O
years	B-T079
),	O
we	O
assessed	B-T052
abdominal fat	B-T024
by	O
computed tomography	B-T060
and	O
diabetes status	B-T033
using	O
the	O
American Diabetes Association	B-T094
criteria	B-T078
.	O
Linear regression analyses	B-T081
assessed	B-T052
the	O
cross-sectional associations	B-T080
between	O
abdominal fat	B-T024
and	O
SA	B-T033
,	O
and	O
logistic regression	B-T062
assessed	B-T052
the	O
odds	B-T081
of	O
diabetes	B-T047
,	O
given	O
low	B-T080
SA	B-T033
.	O
In	O
unadjusted analyses	B-T062
,	O
individuals	B-T098
in	O
the	O
lowest	B-T080
SA	B-T033
quartile	B-T080
(<48μ/L)	O
had	O
1.97	O
greater	O
odds	B-T081
of	O
diabetes	B-T047
,	O
(95%	O
CI	B-T081
,	O
1.01-3.83)	O
than	O
those	O
in	O
the	O
highest	O
quartile	B-T080
(⩾80μ/L).	O
This	O
association	B-T080
was	O
no	O
longer	O
significant	B-T078
after	O
adjusting	O
for	O
visceral adipose tissue area	B-T024
(	O
VAT	B-T024
,	O
dm(2)),	O
abdominal subcutaneous adipose tissue	B-T024
(	O
SAT	B-T024
,	O
dm(2))	O
or	O
BMI	B-T201
.	O
In	O
adjusted analyses	B-T062
,	O
VAT	B-T024
and	O
SAT	B-T024
were	O
significantly	B-T078
associated with	B-T080
SA	B-T033
in	O
both	O
sexes	B-T032
.	O
Among	O
women	B-T098
,	O
SA	B-T033
was	O
more	O
strongly	O
associated with	B-T080
VAT	B-T024
than	O
with	O
SAT	B-T024
or	O
BMI	B-T201
;	O
VAT	B-T024
(β=-0.117±0.048,	O
P<0.001),	O
SAT	B-T024
(β=-0.023±0.025,	O
P=0.346)	O
and	O
BMI	B-T201
(β=-0.0052±0.075,	O
P=0.49).	O
The	O
association	B-T080
between	O
SA	B-T116
and	O
diabetes	B-T047
was	O
explained	O
mainly	O
by	O
abdominal visceral fat	B-T024
.	O
In	O
women	B-T098
,	O
SA	B-T116
was	O
more	O
strongly	O
associated with	B-T080
VAT	B-T024
than	O
with	O
BMI	B-T201
or	O
SAT	B-T024
.	O
These	O
findings	O
provide	O
motivation	O
for	O
future	O
mechanistic studies	B-T089
on	O
SA's	B-T116
role	O
in	O
metabolic diseases	B-T047
.	O

Efficacy	B-T080
of	O
Intravenous	B-T082
Chlorothiazide	B-T109
for	O
Refractory	B-T169
Acute Decompensated Heart Failure	B-T047
Unresponsive	B-T169
to	O
Adjunct	B-T169
Metolazone	B-T109
To	O
assess	O
the	O
efficacy	B-T080
of	O
intravenous	B-T082
chlorothiazide	B-T109
in	O
patients	B-T101
with	O
acute decompensated heart failure	B-T047
(	O
ADHF	B-T047
)	O
who	O
were	O
determined	O
to	O
be	O
loop diuretic	B-T121
resistant	B-T169
and	O
refractory	B-T169
to	O
metolazone	B-T109
.	O
Retrospective cohort study	B-T062
with	O
patients	B-T101
serving	O
as	O
their	O
own	O
controls	B-T096
.	O
Large	B-T081
,	O
academic	B-T092
,	O
tertiary care hospital	B-T073
.	O
Forty-five	O
patients	B-T101
with	O
ADHF	B-T047
who	O
had	O
an	O
inadequate	B-T080
response	B-T032
to	O
high-dose	B-T081
loop diuretics	B-T121
and	O
then	O
received	O
at	O
least	O
one	O
dose	B-T081
of	O
oral	B-T082
metolazone	B-T109
5	O
mg	O
or	O
greater	B-T081
(	O
metolazone	B-T109
index dose	B-T081
)	O
followed	O
by	O
at	O
least	O
one	O
dose	B-T081
of	O
intravenous	B-T082
chlorothiazide	B-T109
500	O
mg	O
(	O
chlorothiazide	B-T109
index dose	B-T081
)	O
if	O
the	O
response	O
to	O
metolazone	B-T109
was	O
considered	O
inadequate	B-T080
,	O
according	O
to	O
the	O
institutional protocol	B-T170
,	O
between	O
February	O
4,	O
2013,	O
and	O
February	O
28,	O
2015,	O
were	O
included.	O
If	O
multiple	O
doses	B-T081
of	O
metolazone	B-T109
were	O
administered	B-T058
,	O
the	O
last	O
dose	B-T081
given	O
before	O
the	O
chlorothiazide	B-T109
index dose	B-T081
was	O
considered	O
the	O
index dose	B-T081
;	O
the	O
metolazone	B-T109
index dose	B-T081
had	O
to	O
have	O
been	O
administered	B-T058
more	O
than	O
2	O
hours	B-T079
before	O
the	O
chlorothiazide	B-T109
index dose	B-T081
.	O
Data	B-T078
for	O
a	O
total	O
of	O
90	O
diuretic	B-T121
doses	B-T081
(45	O
metolazone	B-T109
,	O
45	O
chlorothiazide	B-T109
)	O
were	O
included	O
in	O
the	O
analysis	B-T062
.	O
The	O
median	O
dose	B-T081
of	O
loop diuretic	B-T121
in	O
intravenous	B-T082
furosemide	B-T109
equivalents	O
given	O
over	O
the	O
24-	O
hour	B-T079
period	B-T079
before	O
the	O
metolazone	B-T109
index dose	B-T081
was	O
400	O
mg.	O
The	O
average	O
length	O
of	O
stay	B-T079
was	O
34.7	O
days	B-T079
,	O
and	O
in-hospital mortality	B-T080
was	O
35.6%	O
(16/45	O
patients	B-T101
).	O
The	O
primary	O
end point	B-T080
of	O
a	O
net-negative	B-T033
urine output	B-T201
of	O
500	O
ml	O
or	O
greater	O
during	O
the	O
12	O
hours	B-T079
after	O
the	O
index dose	B-T081
occurred	O
in	O
42.2%	O
(19/45	O
patients	B-T101
)	O
and	O
35.5%	O
(16/45	O
patients	B-T101
)	O
for	O
the	O
chlorothiazide	B-T109
and	O
metolazone	B-T109
doses	B-T081
,	O
respectively	O
(p=0.581).	O
The	O
median	O
12-	O
hour	B-T079
urine output	B-T201
following	O
administration	B-T081
of	O
metolazone	B-T109
was	O
810	O
ml	O
(	O
interquartile range	B-T081
[	O
IQR	B-T081
]	O
866	O
ml)	O
versus	O
1075	O
ml	O
(	O
IQR	B-T081
940	O
ml)	O
following	O
administration	B-T081
of	O
chlorothiazide	B-T109
(p=0.363).	O
Compared	B-T052
with	O
metolazone	B-T109
,	O
the	O
chlorothiazide	B-T109
doses	B-T081
did	O
not	O
result	O
in	O
an	O
increase	B-T169
in	O
urine output	B-T201
of	O
at	O
least	O
500	O
ml	O
during	O
the	O
12	O
hours	B-T079
following	O
the	O
dose	B-T081
relative	O
to	O
the	O
12	O
hours	B-T079
before	O
the	O
dose	B-T081
(31.1%	O
vs	O
22.2%,	O
p=0.754).	O
No	O
significant	O
difference	O
in	O
achievement	O
of	O
net-negative	B-T033
urine output	B-T201
of	O
500	O
ml	O
or	O
greater	O
during	O
the	O
12	O
hours	B-T079
following	O
the	O
chlorothiazide	B-T109
or	O
metolazone	B-T109
dose	B-T081
was	O
noted	O
(42.2%	O
for	O
chlorothiazide	B-T109
vs	O
35.5%	O
for	O
metolazone	B-T109
,	O
p=0.581).	O
The	O
addition	O
of	O
intravenous	B-T082
chlorothiazide	B-T109
did	O
not	O
result	O
in	O
improved	B-T033
diuresis	B-T042
in	O
patients	B-T101
with	O
ADHF	B-T047
determined	O
to	O
be	O
refractory	B-T169
to	O
loop diuretic	B-T121
s	O
and	O
adjunctive	B-T169
oral	B-T082
metolazone	B-T109
.	O

Comparisons	B-T052
of	O
Safety	B-T068
and	O
Clinical	B-T080
Outcomes	B-T169
Between	O
Multiple-level	B-T061
and	O
Single-level Cervical Disk Replacement	B-T061
for	O
Cervical Spondylosis	B-T047
:	O
A	O
Systematic Review	B-T170
and	O
Meta-analysis	B-T170
This	O
is	O
a	O
systematic review	B-T170
and	O
meta-analysis	B-T170
.	O
The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
evaluate	B-T169
the	O
efficacy	B-T080
and	O
safety	B-T068
of	O
multiple-level cervical disk replacement	B-T061
(	O
CDR	B-T061
)	O
over	O
single-level CDR	B-T061
for	O
the	O
treatment	B-T061
of	O
cervical spondylosis	B-T047
.	O
Some	O
authors	O
advocate	O
for	O
the	O
multiple-level CDR	B-T061
instead	O
of	O
anterior	B-T082
decompression	B-T061
and	O
fusion	B-T061
in	O
cervical multiple-level spondylosis	B-T047
.	O
However,	O
whether	O
the	O
efficacy	B-T080
and	O
safety	B-T068
of	O
multi-level CDR	B-T061
are	O
as	O
favorable	O
as	O
that	O
of	O
single-level CDR	B-T061
remains	O
controversial.	O
MEDLINE	B-T170
,	O
EMBASE	B-T170
,	O
and	O
Cochrane library databases	B-T170
were	O
searched	O
up	O
to	O
November	O
2015	O
for	O
controlled studies	B-T062
that	O
compared	B-T052
the	O
clinical	B-T080
outcomes	B-T169
of	O
single-level	B-T061
and	O
multiple-level CDR	B-T061
for	O
the	O
treatment	B-T061
of	O
cervical spondylosis	B-T047
.	O
The	O
following	O
outcomes	B-T169
were	O
extracted	O
and	O
analyzed	B-T062
:	O
prevalence	B-T081
of	O
heterotopic ossification	B-T046
and	O
reoperation	B-T061
,	O
preoperative	B-T079
and	O
postoperative	B-T079
Neck Disability Index scores	B-T033
,	O
preoperative	B-T079
and	O
postoperative	B-T079
Visual Analog Scale scores	B-T201
,	O
and	O
success	B-T080
rate	B-T081
using	O
the	O
Odom grading system	B-T185
.	O
Ten	O
studies	B-T062
involving	O
1402	O
patients	B-T101
were	O
included:	O
including	O
3	O
randomized controlled trials	B-T062
,	O
5	O
prospective studies	B-T062
,	O
and	O
3	O
retrospective studies	B-T062
.	O
No	O
significant	O
differences	O
between	O
single-level	B-T061
and	O
multiple-level	B-T061
groups	O
were	O
found	O
in	O
terms	O
of	O
the	O
prevalence	B-T081
of	O
heterotopic ossification	B-T046
and	O
reoperation	B-T061
rate	B-T081
,	O
Neck Disability Index score	B-T033
,	O
Visual Analog Scale score	B-T201
,	O
and	O
success	B-T080
rate	B-T081
using	O
the	O
Odom grading system	B-T185
.	O
On	O
the	O
basis	O
of	O
this	O
meta-analysis	B-T170
,	O
clinical	B-T080
outcomes	B-T169
of	O
multiple-level CDR	B-T061
are	O
similar	O
to	O
those	O
of	O
single-level CDR	B-T061
for	O
cervical spondylosis	B-T047
,	O
which	O
suggests	O
the	O
multiple-level CDR	B-T061
is	O
as	O
effective	B-T080
and	O
safe	B-T068
as	O
the	O
single-level CDR	B-T061
.	O
Nonetheless,	O
more	O
well-designed	O
studies	B-T062
are	O
needed	O
for	O
further	O
evaluation	B-T062
.	O

Evaluation	B-T058
of	O
the	O
Effects of	B-T080
Intravenous	B-T082
and	O
Percutaneous	B-T082
Low Level Laser Therapy	B-T061
in	O
the	O
Management	B-T061
of	O
Shoulder	B-T029
Myofascial Pain Syndrome	B-T047
Myofascial pain syndrome	B-T047
(	O
MPS	B-T047
)	O
treatment	B-T061
is	O
challenging	O
with	O
a	O
high	O
recurrence	O
rate	O
and	O
still	O
lacks	O
a	O
clear	O
treatment frame	B-T061
.	O
Therefore	O
research	O
on	O
new,	O
more	O
efficient	B-T080
and	O
long	O
lasting	O
effect	O
treatment	B-T061
modalities	B-T078
is	O
necessary.	O
This	O
study	O
looked	O
at	O
the	O
effects of	B-T080
intravenous	B-T082
laser therapy	B-T061
(	O
IVL	B-T061
)	O
and	O
percutaneous	B-T082
low level laser	B-T061
(	O
PLLL	B-T061
)	O
in	O
the	O
management	B-T061
of	O
shoulder	B-T029
MPS	B-T047
.	O
In	O
this	O
randomized controlled trial	B-T062
,	O
30	O
patients	B-T101
fulfilling	O
inclusion criteria	B-T080
were	O
randomly	O
equally	O
allocated	O
to	O
3	O
groups,	O
control	B-T096
,	O
IVL	B-T098
and	O
PLLL	B-T098
.	O
Control group	B-T096
received	O
12	O
sessions	O
of	O
placebo	B-T062
low level laser	B-T061
,	O
IVL group	B-T098
received	O
12	O
sessions	O
of	O
IVL therapy	B-T061
,	O
and	O
PLLL group	B-T098
received	O
12	O
sessions	O
of	O
PLLL therapy	B-T061
.	O
All	O
patients	B-T101
were	O
trained	O
for	O
better	B-T080
body posture	B-T032
,	O
body mechanics	B-T022
,	O
gentle massage	B-T061
of	O
trigger points	B-T029
,	O
stretching exercises	B-T061
of	O
affected	B-T169
muscle	B-T024
(	O
trapezius	B-T023
),	O
and	O
received	O
10	O
mg	O
of	O
oral	B-T082
nortriptyline	B-T109
regimen	B-T061
every	O
night	O
for	O
3	O
months.	O
Outcomes	O
included	O
pain severity	B-T080
,	O
functional disability	B-T033
,	O
and	O
quality of life	B-T078
.	O
Patients	B-T101
were	O
assessed	O
using	O
Numeric Rating Scale	B-T170
(	O
NRS	B-T170
),	O
Pain Disability Index	B-T170
(	O
PDI	B-T170
),	O
and	O
Short Form Health Survey	B-T170
(	O
SF-12	B-T170
).	O
Data collected	B-T033
were	O
analyzed	B-T062
using	O
analysis of variance	B-T081
(	O
ANOVA	B-T081
),	O
Mann-Whitney	B-T170
and	O
t tests	B-T170
.	O
The	O
mean	O
of	O
PDI	B-T170
and	O
maximum	O
pain intensity	B-T201
during	O
day	O
and	O
night	O
significantly	O
reduced	B-T080
in	O
both	O
PLLL	B-T098
and	O
IVL groups	B-T098
compared	O
to	O
control group	B-T096
.	O
Although	O
pain	O
severity	O
and	O
PDI	B-T170
reduction	O
was	O
more	O
pronounced	O
in	O
IVL group	B-T098
compared	O
to	O
PLLL group	B-T098
,	O
the	O
differences	O
were	O
not	O
statistically significant	B-T081
.	O
Also,	O
quality of life	B-T078
statistically significantly	B-T081
improved	O
in	O
both	O
IVL	B-T098
and	O
PLLL groups	B-T098
compared	O
to	O
control group	B-T096
was	O
more,	O
and	O
although	O
higher	O
in	O
IVL group	B-T098
,	O
the	O
difference	O
was	O
not	O
statistically significant	B-T081
when	O
compared	O
to	O
PLLL group	B-T098
.	O
No side effects	B-T033
were	O
observed	O
in	O
the	O
intervention groups	B-T098
.	O
Intravenous	B-T082
laser	B-T061
and	O
PLLL therapy	B-T061
had	O
a	O
positive	O
effect	B-T080
on	O
pain severity	B-T080
and	O
PDI	B-T170
reduction,	O
and	O
quality of life	B-T078
in	O
this	O
study.	O
Also	O
no adverse event	B-T033
was	O
recorded.	O
Thus,	O
intravenous	B-T082
lasers	B-T061
and	O
PLLL therapy	B-T061
seem	O
to	O
be	O
effective	B-T080
complementary	O
modalities	B-T078
in	O
managing	B-T061
patients	B-T101
with	O
shoulder	B-T029
MPS	B-T047
.	O

Structural	B-T082
Insights	B-T041
into	O
5-HT1A	B-T116
/	O
D4	B-T116
Selectivity	B-T070
of	O
WAY-100635	B-T109
Analogues	B-T104
:	O
Molecular Modeling	B-T062
,	O
Synthesis	B-T052
,	O
and	O
in Vitro	B-T080
Binding	B-T044
The	O
resurgence	O
of	O
interest	O
in	O
5-HT1A receptors	B-T116
as	O
a	O
therapeutic	B-T169
target	B-T169
requires	O
the	O
existence	O
of	O
highly	O
selective	B-T080
5-HT1A	B-T116
ligands	B-T103
.	O
To	O
date,	O
WAY-100635	B-T109
has	O
been	O
the	O
prototypical antagonist	B-T120
of	O
these	O
receptors	B-T116
.	O
However,	O
this	O
compound	B-T080
also	O
has	O
significant	O
affinity	B-UnknownType
for	O
and	O
activity	O
at	O
D4 dopamine receptors	B-T116
.	O
In	O
this	O
context,	O
this	O
work	O
was	O
aimed	O
at	O
better	O
understanding	O
the	O
5-HT1A	B-T116
/	O
D4	B-T116
selectivity	B-T070
of	O
WAY-100635	B-T109
and	O
analogues	B-T104
from	O
a	O
structural	B-T082
point	O
of	O
view.	O
In silico	B-T066
investigations	B-T169
revealed	O
two	O
key	O
interactions	B-T169
for	O
the	O
5-HT1A	B-T116
/	O
D4	B-T116
selectivity	B-T070
of	O
WAY-100635	B-T109
and	O
analogues	B-T104
.	O
First,	O
a	O
hydrogen bond	B-T070
only	O
found	O
with	O
the	O
Ser 7.36	B-T116
of	O
D4 receptor	B-T116
appeared	O
to	O
be	O
the	O
key	O
for	O
a	O
higher	O
D4	B-T116
affinity	B-UnknownType
for	O
newly	O
synthesized	B-T052
aza	B-T109
analogues	B-T104
.	O
The	O
role	O
of	O
Ser 7.36	B-T116
was	O
confirmed	O
as	O
the	O
affinity	B-UnknownType
of	O
aza	B-T109
analogues	B-T104
for	O
the	O
mutant	B-T049
D4 receptor S7.36A	B-T116
was	O
reduced.	O
Then,	O
the	O
formation	O
of	O
another	O
hydrogen bond	B-T070
with	O
the	O
conserved	O
Ser 5.42 residue	B-T116
appeared	O
to	O
be	O
also	O
critical	O
for	O
D4	B-T116
binding	B-T044
.	O

Genomic analysis	B-T059
of	O
nontypeable pneumococci	B-T007
causing	O
invasive pneumococcal disease	B-T047
in	O
South Africa	B-T083
,	O
2003-2013	O
The	O
capsular polysaccharide	B-T109
is	O
the	O
principal	O
virulence factor	B-T109
of	O
Streptococcus pneumoniae	B-T007
and	O
a	O
target	B-T169
for	O
current	O
pneumococcal vaccines	B-T121
.	O
However,	O
some	O
pathogenic	B-T033
pneumococci	B-T007
are	O
serologically nontypeable	B-T170
[	O
nontypeable pneumococci	B-T007
(	O
NTPn	B-T007
)].	O
Due	O
to	O
their	O
relative	O
rarity	B-T080
,	O
NTPn	B-T007
are	O
poorly	O
characterized	B-T052
,	O
and,	O
as	O
such,	O
limited	O
data	B-T078
exist	O
which	O
describe	O
these	O
organisms	B-T001
.	O
We	O
aimed	O
to	O
describe	O
disease	B-T047
and	O
genotypically	B-T032
characterize	B-T052
NTPn	B-T007
causing	O
invasive pneumococcal disease	B-T047
in	O
South Africa	B-T083
.	O
Isolates	B-T123
were	O
detected	O
through	O
national,	O
laboratory	B-T073
-	O
based	B-T078
surveillance	B-T169
for	O
invasive pneumococcal disease	B-T047
in	O
South Africa	B-T083
and	O
characterized	B-T052
by	O
whole	O
genome analysis	B-T059
.	O
We	O
predicted	O
ancestral	B-T169
serotypes	B-T170
(	O
serotypes	B-T170
from	O
which	O
NTPn	B-T007
may	O
have	O
originated)	O
for	O
Group I	B-T078
NTPn	B-T007
using	O
multilocus sequence typing	B-T062
and	O
capsular region	B-T082
sequence analyses	B-T059
.	O
Antimicrobial resistance	B-T201
patterns	B-T082
and	O
mutations	B-T045
potentially	B-T080
causing	O
nontypeability	B-T170
were	O
identified	B-T080
.	O
From	O
2003-2013,	O
39	O
(0.1	O
%,	O
39/32,824)	O
NTPn	B-T007
were	O
reported.	O
Twenty-two	B-T081
(56	O
%)	O
had	O
partial	B-T081
capsular genes	B-T028
(	O
Group I	B-T078
)	O
and	O
17	O
(44	O
%)	O
had	O
complete	B-T080
capsular deletion	B-T045
of	O
which	O
15	O
had	O
replacement	B-T169
by	O
other	O
genes	B-T028
(	O
Group II	B-T078
).	O
Seventy-nine	B-T081
percent	B-T081
(31/39)	O
of	O
our	O
NTPn	B-T007
isolates	B-T123
were	O
derived	O
from	O
encapsulated	B-T080
S. pneumoniae	B-T007
.	O
Ancestral	O
serotypes	B-T170
1	O
(27	O
%,	O
6/22)	O
and	O
8	O
(14	O
%,	O
3/22)	O
were	O
most	O
prevalent,	O
and	O
59	O
%	O
(13/22)	O
of	O
ancestral	B-T169
serotypes	B-T170
were	O
serotypes	B-T170
included	O
in	O
the	O
13-valent pneumococcal conjugate vaccine	B-T121
.	O
We	O
identified	O
a	O
variety	O
of	O
mutations	B-T045
within	O
the	O
capsular region	B-T082
of	O
Group I	B-T078
NTPn	B-T007
,	O
some	O
of	O
which	O
may	O
be	O
responsible	O
for	O
the	O
nontypeable	B-T170
phenotype	B-T032
.	O
Nonsusceptibility	B-T034
to	O
tetracycline	B-T109
and	O
erythromycin	B-T109
was	O
higher	O
in	O
NTPn	B-T007
than	O
encapsulated	B-T080
S. pneumoniae	B-T007
.	O
NTPn	B-T007
are	O
currently	O
a	O
rare	O
cause	O
of	O
invasive pneumococcal disease	B-T047
in	O
South Africa	B-T083
and	O
represent	O
a	O
genetically	O
diverse	O
collection	O
of	O
isolates.	O

Pre-hypertension	B-T047
,	O
pre-diabetes	B-T047
or	O
both:	O
which	O
is	O
best	O
at	O
predicting	B-T078
cardiovascular events	B-T033
in	O
the	O
long term	B-T079
?	O
The	O
present	O
study	B-T062
aimed	O
to	O
assess	O
the	O
value	O
of	O
pre-diabetes	B-T047
and	O
pre-hypertension	B-T047
in	O
predicting	B-T078
cardiovascular events	B-T033
.	O
A	O
population	B-T081
-based,	O
cross-sectional survey	B-T062
was	O
conducted,	O
representing	O
a	O
large	O
sample	O
of	O
the	O
general	O
Iranian	B-T098
population	B-T098
aged	O
35	O
years	B-T079
and	O
older	O
from	O
the	O
Isfahan Province	B-T083
and	O
determined	O
using	O
a	O
random, multistage cluster-sampling	B-T062
10-year	O
cohort	B-T098
.	O
The	O
five	O
end	O
points	O
considered	O
as	O
study outcome	B-T169
were	O
unstable angina	B-T047
(	O
UA	B-T047
),	O
acute	B-T079
occurrence	B-T079
of	O
myocardial infarction	B-T047
(	O
MI	B-T047
),	O
sudden cardiac death	B-T046
(	O
SCD	B-T046
),	O
brain stroke	B-T047
and	O
cardiovascular disease	B-T047
(	O
CVD	B-T047
).	O
Of	O
the	O
6323	O
subjects	O
scheduled	O
for	O
assessment	B-T058
of	O
diabetes state	B-T047
617	O
were	O
diabetics	B-T033
and	O
712	O
were	O
pre-diabetic	B-T033
.	O
In	O
addition,	O
of	O
these	O
subjects,	O
1754	O
had	O
hypertension	B-T047
and	O
2500	O
had	O
pre-hypertension	B-T047
.	O
Analysing	O
only	O
pre-hypertension	B-T047
,	O
pre-diabetes	B-T047
and	O
its	O
combination	O
and	O
adjusted	O
for	O
gender	B-T032
and	O
age	O
variables,	O
pre-hypertension	B-T047
and	O
pre-diabetes	B-T047
status	O
together,	O
could	O
only	O
effectively	O
predict	O
occurrence	B-T079
of	O
MI	B-T047
(	O
hazard ratio	B-T081
(	O
HR	B-T081
)=3.21,	O
95%	O
confidence interval	B-T081
(	O
CI	B-T081
):	O
1.06-9.76,	O
P=0.04).	O
In	O
the	O
same	O
COX regression models	B-T170
,	O
pre-hypertension	B-T047
status	O
could	O
predict	O
UA	B-T047
and	O
CVD	B-T047
occurrence	B-T079
(	O
HR	B-T081
=2.94,	O
95%	O
CI	B-T081
:	O
1.68-5.14,	O
P<0.001	O
and	O
HR	B-T081
=1.74,	O
95%	O
CI	B-T081
:	O
1.23-2.47,	O
P=0.002,	O
respectively).	O
However,	O
pre-diabetes	B-T047
status	O
could	O
not	O
predict	O
any	O
of	O
these	O
events	O
after	O
adjustment	O
for	O
gender	B-T032
and	O
age	B-T032
.	O
Our	O
data	B-T078
provide	O
valuable	O
evidence	B-T078
of	O
the	O
triggering	O
role	O
of	O
pre-hypertension	B-T047
and	O
pre-diabetes	B-T047
together,	O
on	O
appearance	B-T080
and	O
progression	B-T046
of	O
MI	B-T047
even	O
in	O
healthy individuals	B-T098
and	O
the	O
significant	O
predicting	B-T078
value	O
of	O
pre-hypertension	B-T047
on	O
the	O
occurrence	B-T079
of	O
UA	B-T047
and	O
CVD	B-T047
.	O
In	O
this	O
regard,	O
the	O
value	O
of	O
pre-hypertension	B-T047
and	O
pre-diabetes	B-T047
together,	O
and	O
the	O
pre-hypertension	B-T047
state	O
alone,	O
are	O
clearly	O
superior	O
to	O
pre-diabetes	B-T047
state	O
alone	O
in	O
predicting	B-T078
cardiovascular events	B-T033
.	O

Strategies	B-T065
for	O
Successful	B-T080
Clinical	B-T080
Teaching	B-T065
This	O
article	B-T170
is	O
one	O
in	O
a	O
series	O
on	O
the	O
roles	B-T077
of	O
adjunct clinical faculty	B-T097
and	O
preceptors	B-T097
,	O
who	O
teach	B-T065
nursing students	B-T097
and	O
new	B-T080
graduates	B-T098
to	O
apply	B-T169
knowledge	B-T170
in	O
clinical settings	B-T082
.	O
This	O
article	B-T170
describes	O
teaching strategies	B-T065
as	O
well	O
as	O
the	O
importance	O
of	O
the	O
learning environment	B-T082
.	O

Learned helplessness	B-T041
at	O
fifty:	O
Insights	B-T041
from	O
neuroscience	B-T091
Learned helplessness	B-T041
,	O
the	O
failure	B-T169
to	O
escape	B-T041
shock	B-T046
induced	B-T169
by	O
uncontrollable	O
aversive events	B-T169
,	O
was	O
discovered	O
half	O
a	O
century	O
ago.	O
Seligman and Maier	B-T016
(1967)	O
theorized	B-T078
that	O
animals	B-T008
learned	B-T041
that	O
outcomes	B-T169
were	O
independent of	B-T169
their	O
responses	B-T032
-that	O
nothing	O
they	O
did	O
mattered-and	O
that	O
this	O
learning	B-T041
undermined	O
trying	O
to	O
escape	B-T041
.	O
The	O
mechanism	O
of	O
learned helplessness	B-T041
is	O
now	O
very	O
well-charted biologically	B-T080
,	O
and	O
the	O
original	O
theory	B-T078
got	O
it	O
backward.	O
Passivity	B-T055
in	O
response	B-T032
to	O
shock	B-T046
is	O
not	O
learned	B-T041
.	O
It	O
is	O
the	O
default,	O
unlearned	O
response	B-T032
to	O
prolonged	B-T079
aversive events	B-T169
and	O
it	O
is	O
mediated	O
by	O
the	O
serotonergic activity	B-T044
of	O
the	O
dorsal raphe nucleus	B-T023
,	O
which	O
in	O
turn	O
inhibits	B-T052
escape	B-T041
.	O
This	O
passivity	B-T055
can	O
be	O
overcome	O
by	O
learning	B-T041
control	B-T080
,	O
with	O
the	O
activity	O
of	O
the	O
medial prefrontal cortex	B-T023
,	O
which	O
subserves	O
the	O
detection	B-T033
of	O
control	B-T080
leading	O
to	O
the	O
automatic	B-T169
inhibition	B-T052
of	O
the	O
dorsal raphe nucleus	B-T023
.	O
So	O
animals	B-T008
learn	B-T041
that	O
they	O
can	O
control	B-T080
aversive events	B-T169
,	O
but	O
the	O
passive	B-T080
failure	B-T169
to	O
learn	B-T041
to	O
escape	B-T041
is	O
an	O
unlearned	O
reaction	B-T169
to	O
prolonged	B-T079
aversive stimulation	B-T061
.	O
In	O
addition,	O
alterations	B-T078
of	O
the	O
ventromedial prefrontal cortex	B-T023
-	O
dorsal raphe	B-T023
pathway	B-T077
can	O
come	O
to	O
subserve	O
the	O
expectation	B-T078
of	O
control	B-T080
.	O
We	O
speculate	O
that	O
default	O
passivity	B-T055
and	O
the	O
compensating	B-T080
detection	B-T033
and	O
expectation	B-T078
of	O
control	B-T080
may	O
have	O
substantial	O
implications	O
for	O
how	O
to	O
treat	B-T169
depression	B-T048
.	O
(PsycINFO	O
Database	O
Record	O

A	O
peptide	B-T116
from	O
human β thymosin	B-T116
as	O
a	O
platform	O
for	O
the	O
development	O
of	O
new	O
anti-biofilm	B-T024
anti-biofilm agents	B-T121
for	O
Staphylococcus spp.	B-T007
and	O
Pseudomonas aeruginosa	B-T007
Conventional	O
antibiotics	B-T195
might	O
fail	O
in	O
the	O
treatment	O
of	O
biofilm	B-T007
-associated	O
infections	B-T046
causing	O
infection	B-T046
recurrence	B-T046
and	O
chronicity	B-T079
.	O
The	O
search	O
for	O
antimicrobial peptides	B-T116
has	O
been	O
performed	O
with	O
the	O
aim	O
to	O
discover	B-T052
novel	O
anti-infective agents	B-T121
active	B-T169
on	O
pathogens	B-T001
in	O
both	O
planktonic	B-T007
and	O
biofilm	B-T007
associated	O
forms.	O
The	O
fragment	B-T116
9-19	O
of	O
human thymosin β4	B-T116
was	O
studied	B-T062
through	O
1	O
μs	O
MD simulation	B-T066
.	O
Two	O
main	O
conformations of the peptide	B-T082
were	O
detected,	O
both	O
constituted	O
by	O
a	O
central hydrophobic core	B-T082
and	O
by	O
the	O
presence	O
of	O
peripheral	B-T082
charged	O
residues	B-T077
suggesting	O
a	O
possible	O
mechanism	O
of	O
interaction	B-T169
with	O
two	O
models	B-T170
of	O
biological membranes	B-T026
,	O
related	O
to	O
eukaryotic	B-T204
or	O
bacterial membrane	B-T026
respectively.	O
In	O
addition,	O
the	O
peptide	B-T116
was	O
chemically	O
synthesized	O
and	O
its	O
antimicrobial activity	B-T034
was	O
tested	O
in vitro	B-T062
against	O
planktonic	B-T007
and	O
biofilm	B-T007
form	O
of	O
a	O
group	B-T078
of	O
reference	O
strains	B-T001
of	O
Staphylococcus spp.	B-T007
and	O
one	O
P. aeruginosa	B-T007
strain	B-T001
.	O
The	O
human thymosin β4	B-T116
fragment	B-T116
EIEKFDKSKLK	B-T087
showed	O
antibacterial activity	B-T044
against	O
staphylococcal	B-T007
strains	B-T001
and	O
Pseudomonas aeruginosa	B-T007
ATCC	O
15442	O
at	O
concentrations	B-T081
from	O
12.5	O
to	O
6.2	O
mg/ml	O
and	O
inhibited	O
biofilm formation	B-T043
at	O
sub-inhibitory concentrations	B-T081
(3.1-0.75	O
mg/ml).	O
The	O
activity	B-T052
of	O
the	O
fragment	B-T116
in	O
inhibiting	O
biofilm formation	B-T043
,	O
could	O
be	O
due	O
to	O
the	O
conformations	B-T082
highlighted	O
by	O
the	O
MD simulations	B-T066
,	O
suggesting	O
its	O
interaction	B-T169
with	O
the	O
bacterial membrane	B-T026
.	O
Human thymosin β4	B-T116
fragment	B-T116
can	O
be	O
considered	O
a	O
promising	O
lead compound	B-T121
to	O
develop	O
novel	O
synthetic	O
or	O
recombinant derivatives	B-T116
with	O
improved	O
pharmaceutical	B-T091
potential.	O

Structural	B-T082
Basis	B-T169
for	O
Simvastatin	B-T109
Competitive Antagonism	B-T044
of	O
Complement Receptor 3	B-T116
The	O
complement system	B-T116
is	O
an	O
important	O
part	O
of	O
the	O
innate immune response	B-T032
to	O
infection	B-T047
but	O
may	O
also	O
cause	O
severe complications	B-T033
during	O
inflammation	B-T046
.	O
Small molecule	B-T109
antagonists	B-T120
to	O
complement receptor 3	B-T116
(	O
CR3	B-T116
)	O
have	O
been	O
widely	O
sought,	O
but	O
a	O
structural	B-T082
basis	B-T169
for	O
their	O
mode of action	B-T169
is	O
not	O
available.	O
We	O
report	B-T170
here	O
on	O
the	O
structure	B-T082
of	O
the	O
human	B-T016
CR3	B-T116
ligand-binding I domain	B-T087
in	O
complex	B-T104
with	O
simvastatin	B-T109
.	O
Simvastatin	B-T109
targets	B-T169
the	O
metal	B-T197
ion-dependent	B-T080
adhesion site	B-T082
of	O
the	O
open,	O
ligand-binding	B-T044
conformation	B-T082
of	O
the	O
CR3	B-T116
I domain	B-T087
by	O
direct	O
contact with	B-T169
the	O
chelated Mg(2+) ion	B-T109
.	O
Simvastatin	B-T109
antagonizes	B-T033
I domain binding	B-T087
to	O
the	O
complement fragments	B-T116
iC3b	B-T116
and	O
C3d	B-T116
but	O
not	O
to	O
intercellular adhesion molecule-1	B-T116
.	O
By	O
virtue	B-T078
of	O
the	O
I domain's	B-T087
wide	O
distribution	B-T082
in	O
binding kinetics	B-T039
to	O
ligands	B-T103
,	O
it	O
was	O
possible	B-T033
to	O
identify	O
ligand binding	B-T044
kinetics	B-T039
as	O
discriminator	O
for	O
simvastatin	B-T109
antagonism	B-T044
.	O
In	O
static	B-T080
cellular	B-T059
experiments	B-T062
,	O
15-25	O
μm	O
simvastatin	B-T109
reduced	B-T080
adhesion	B-T067
by	O
K562 cells	B-T025
expressing	B-T045
recombinant	B-T001
CR3	B-T116
and	O
by	O
primary	B-T080
human	B-T016
monocytes	B-T025
,	O
with	O
an	O
endogenous	B-T169
expression	B-T045
of	O
this	O
receptor	B-T116
.	O
Application	B-T058
of	O
force	B-T067
to	O
adhering	B-T067
monocytes	B-T025
potentiated	O
the	O
effects of	B-T080
simvastatin	B-T109
where	O
only	O
a	O
50-100	O
nm	O
concentration	B-T081
of	O
the	O
drug	B-T121
reduced	B-T080
the	O
adhesion	B-T067
by	O
20-40%	O
compared	B-T052
with	O
untreated	B-T080
cells	B-T025
.	O
The	O
ability	B-T032
of	O
simvastatin	B-T109
to	O
target	B-T169
CR3	B-T116
in	O
its	O
ligand binding	B-T044
-	O
activated	B-T052
conformation	B-T082
is	O
a	O
novel	B-T080
mechanism	B-T044
to	O
explain	O
the	O
known	O
anti-inflammatory effects	B-T080
of	O
this	O
compound	B-T103
,	O
in	O
particular	O
because	O
this	O
CR3	B-T116
conformation	B-T082
is	O
found	O
in	O
pro-inflammatory	B-T080
environments	B-T082
.	O
Our	O
report	B-T170
points	O
to	O
new	O
designs	B-T090
of	O
CR3	B-T116
antagonists	B-T120
and	O
opens	O
new	O
perspectives	O
and	O
identifies	B-T033
druggable	B-T080
receptors	B-T116
from	O
characterization	B-T052
of	O
the	O
ligand binding	B-T044
kinetics	B-T039
in	O
the	O
presence	B-T080
of	O
antagonists	B-T120
.	O

Common	B-T081
Laboratory	B-T073
Parameters	B-T033
for	O
Differentiating	B-T169
Between	O
Community-Acquired	B-T047
and	O
Healthcare-Associated Pneumonia	B-T047
The	O
correct	B-T080
diagnosis	B-T033
of	O
healthcare-associated pneumonia	B-T047
(	O
HCAP	B-T047
)	O
as	O
opposed	O
to	O
community-acquired pneumonia	B-T047
is	O
essential	B-T080
for	O
the	O
selection	B-T052
of	O
a	O
correct	B-T080
empirical	B-T080
antimicrobial	B-T121
approach,	O
reserving	O
the	O
broad-spectrum	B-T077
or	O
highly potent	B-T080
antimicrobial therapies	B-T061
for	O
resistant	B-T169
strains	B-T001
most	O
commonly	O
present	O
in	O
HCAP	B-T047
,	O
whereas	O
treating	B-T169
the	O
less	O
resistant	B-T169
strains	B-T001
,	O
most	O
commonly	O
associated with	B-T080
community	B-T096
and	O
long-term care facility	B-T073
-	O
acquired infections	B-T046
,	O
with	O
a	O
more	O
targeted	B-T169
empirical approach	B-T062
.	O
The	O
standard approach	B-T080
today	B-T079
is	O
to	O
differentiate	B-T169
between	O
the	O
two	O
based	O
on	O
the	O
medical history	B-T033
of	O
the	O
past	B-T079
90	O
days	B-T079
prior	O
to	O
admission	B-T058
.	O
Measurable	B-T169
,	O
quantitative	B-T081
assessment	B-T058
may	O
be	O
able	O
to	O
assist	B-T080
in	O
this	O
decision	B-T041
.	O
The	O
objective	O
of	O
this	O
study	O
is	O
to	O
find	O
a	O
measurable	B-T169
method	B-T170
of	O
differentiating	B-T169
between	O
community-acquired	B-T047
and	O
healthcare-associated pneumonias	B-T047
.	O
The	O
records	B-T170
of	O
126	O
patients	B-T101
admitted	B-T058
with	O
a	O
diagnosis	B-T033
of	O
pneumonia	B-T047
were	O
divided	O
into	O
two	O
groups	B-T078
based	O
on	O
the	O
probable	O
cause of their disease	B-UnknownType
,	O
in	O
accordance	O
with	O
common practice	B-T041
.	O
The	O
routine	B-T080
laboratory work	B-T059
taken	O
upon	O
admittance	B-T058
was	O
analyzed	B-T062
using	O
logistical regression	B-T062
and	O
Student's t-test	B-T081
.	O
We	O
have	O
found	O
that	O
the	O
red blood cell distribution width	B-T059
and	O
the	O
neutrophil	B-T025
neutrophil -to- lymphocyte ratio	B-T081
lymphocyte	B-T025
ratio,	O
both	O
routine parameters	B-T033
obtained	O
in	O
a	O
simple	O
blood count	B-T059
,	O
can	O
each	O
assist	B-T080
in	O
differentiating	B-T169
between	O
community-acquired	B-T047
and	O
healthcare-associated pneumonias	B-T047
.	O
We	O
have	O
found	O
two	O
statistically significant parameters	B-T081
that	O
may	O
be	O
used	O
as	O
adjuncts	O
to	O
the	O
medical history	B-T033
,	O
chest radiography	B-T060
and	O
other parameters	B-T033
in	O
forming	O
an	O
immediate	B-T079
clinical impression	B-T033
of	O
a	O
patient	B-T101
presenting	O
with	O
pneumonia	B-T047
.	O

A	O
quasi-experimental study	B-T062
of	O
a	O
reminiscence program	B-T061
focused	O
on	O
autobiographical memory	B-T041
in	O
institutionalized	O
older adults	B-T098
with	O
cognitive impairment	B-T048
Working	O
with	O
past memories	B-T041
through	O
reminiscence interventions	B-T061
has	O
been	O
practiced	O
for	O
several decades	B-T081
with	O
successful	O
outcomes	B-T169
on	O
mental health	B-T041
in	O
older adults	B-T098
.	O
Few	O
studies	B-T062
however	O
have	O
focused	O
on	O
autobiographical memory	B-T041
recall	B-T041
in	O
older individuals	B-T098
with	O
cognitive impairment	B-T048
.	O
This	O
study	B-T062
aims	O
to	O
analyze	O
the	O
impact	O
of	O
an	O
individual	B-T098
reminiscence program	B-T061
in	O
a	O
group	O
of	O
older persons	B-T098
with	O
cognitive decline	B-T046
living	O
in	O
nursing homes	B-T073
on	O
the	O
dimensions	O
of	O
cognition	B-T041
,	O
autobiographical memory	B-T041
,	O
mood	B-T041
,	O
behavior	B-T053
and	O
anxiety	B-T048
.	O
A	O
two-group	O
pre-test and post-test design	B-T170
with	O
single blinded assessment	B-T058
was	O
conducted.	O
Forty-one	O
participants	B-T098
were	O
randomized	O
to	O
an	O
experimental group	B-T098
(n=20)	O
and	O
a	O
control group	B-T096
(n=21).	O
The	O
first	O
group	O
attended	O
five	O
weekly	O
individual	B-T098
reminiscence	B-T041
sessions	B-T051
.	O
Changes	O
in	O
the	O
outcome measures	B-T081
were	O
examined	B-T033
for	O
cognition	B-T041
(	O
Montreal Cognitive Assessment	B-T170
;	O
Autobiographical Memory Test	B-T170
),	O
behavior	B-T053
(	O
Alzheimer Disease Assessment Subscale Non-Cog	B-T170
)	O
and	O
emotional status	B-T033
(	O
Cornell Scale for Depression	B-T170
in	O
Dementia	B-T048
;	O
Geriatric Depression Scale	B-T170
,	O
and	O
Geriatric Anxiety Inventory	B-T170
).	O
Participants	B-T098
attending	O
reminiscence sessions	B-T051
exhibited	O
better	O
outcomes	B-T169
compared	O
to	O
the	O
control group	B-T096
in	O
cognition	B-T041
,	O
anxiety	B-T048
and	O
depression	B-T048
(p<0.001),	O
and	O
presented	O
a	O
higher	O
number	O
of	O
retrieved	B-T041
autobiographical events	B-T051
,	O
specificity	O
of	O
evoked	O
memories	B-T041
and	O
positive	O
valence	O
of	O
events	B-T051
(p<0.001),	O
and	O
also	O
presented	O
lower	O
latency	O
time	O
for	O
recalling	B-T041
events	B-T051
,	O
and	O
lower	O
negative	O
recalled	B-T041
events	B-T051
(p<0.01).	O
This	O
study	O
supports	O
the	O
potential	O
value	O
of	O
reminiscence therapy	B-T061
in	O
improving	O
the	O
recall	B-T041
of	O
autobiographical memory	B-T041
.	O
Reminiscence therapy	B-T061
can	O
be	O
helpful	O
to	O
maintain	O
or	O
improve	O
cognitive function	B-T041
,	O
decrease	O
anxiety	B-T048
and	O
manage	O
depressive symptoms	B-T184
and	O
altered behavior	B-T055
,	O
but	O
further	O
investigation	O
is	O
needed	O
to	O
clarify	O
long-term	O
effects.	O

Economic Burden	B-T081
of	O
Illness	B-T184
Among	O
Patients	B-T101
with	O
Severe Asthma	B-T033
in	O
a	O
Managed	O
Care Setting	B-T073
Despite	O
intensive	O
pharmacotherapy	B-T061
,	O
a	O
considerable	O
number	B-T081
of	O
patients	B-T101
with	O
severe asthma	B-T033
have	O
inadequate	B-T080
disease	B-T047
control	B-T080
.	O
Patients	B-T101
with	O
severe asthma	B-T033
who	O
experience	B-T041
exacerbations	B-T033
consume	O
significant	O
health care resources	B-T081
.	O
To	O
assess	B-T052
health care resource	B-T081
utilization	B-T169
and	O
associated	O
costs	B-T081
among	O
patients	B-T101
with	O
persistent	B-T079
severe asthma	B-T033
who	O
experienced	B-T041
exacerbations	B-T033
compared	O
with	O
patients	B-T101
with	O
persistent	B-T079
but	O
nonsevere	O
asthma	B-T047
.	O
This	O
retrospective	B-T080
analysis	B-T062
of	O
a	O
national administrative claims database	B-T170
identified	B-T080
patients	B-T101
aged	B-T032
≥	O
12	O
years	B-T079
who	O
had	O
at	O
least	O
1	O
medical claim	B-UnknownType
with	O
an	O
asthma	B-T047
diagnosis	B-T033
in	O
2012	O
and	O
had	O
continuous	O
medical	B-T033
and	O
pharmacy coverage	B-T033
under	O
a	O
commercial	B-T170
or	O
Medicare Advantage plan	B-T064
from	O
January	O
1,	O
2012,	O
to	O
December	O
31,	O
2013.	O
Patients	B-T101
were	O
assigned	B-T169
to	O
1	O
of	O
2	O
mutually	O
exclusive	O
cohorts	B-T098
-	O
persistent asthma	B-T047
(	O
PA	B-T047
)	O
or	O
severe asthma	B-T033
(	O
SA	B-T033
)-according	O
to	O
an	O
established	O
algorithm	B-T170
based	O
on	O
asthma	B-T047
-related	O
health care resource	B-T081
use	B-T169
and	O
pharmacy claims	B-T033
for	O
controller medication	B-T121
.	O
SA	B-T033
patients	B-T101
were	O
required	O
to	O
meet	B-T067
PA	B-T047
criteria	B-T078
and	O
also	O
have	O
evidence	B-T078
of	O
≥2	O
asthma exacerbations	B-T033
in	O
2012.	O
Asthma	B-T047
-related	O
health care resource	B-T081
utilization	B-T169
and	O
costs	B-T081
were	O
computed	B-T052
from	O
asthma	B-T047
medication	B-T058
use	B-T169
(	O
rescue	B-T169
and	O
controller therapy	B-T169
)	O
and	O
medical claims	B-UnknownType
with	O
an	O
asthma	B-T047
diagnosis	B-T033
in	O
the	O
primary position	B-T082
in	O
2012	O
and	O
2013.	O
Adherence	B-T169
to	O
controller therapy	B-T169
was	O
assessed	B-T052
over	O
365	O
days	B-T079
by	O
using	O
the	O
proportion of days covered	B-T079
(	O
PDC	B-T079
),	O
starting	O
with	O
the	O
first	O
claim	B-UnknownType
for	O
controller therapy	B-T169
in	O
2012.	O
Differences	B-T080
between	O
the	O
PA	B-T047
and	O
SA	B-T033
cohorts	B-T098
were	O
analyzed	B-T062
by	O
t-test	B-T170
for	O
continuous variables	B-T080
and	O
chi-square test	B-T170
for	O
categorical variables	B-T080
.	O
Asthma	B-T047
-related	O
costs	B-T081
in	O
2013	O
were	O
also	O
analyzed	B-T062
using	O
a	O
generalized	O
linear model	B-T081
with	O
a	O
gamma distribution	B-T081
and	O
log link	B-T081
,	O
adjusted	B-T169
for	O
patient	B-T101
demographics	B-T185
(	O
age	B-T032
,	O
gender	B-T032
,	O
region	B-T083
,	O
and	O
insurance type	B-T170
)	O
and	O
Quan-Charlson comorbidity score	B-T081
.	O
A	O
total	O
of	O
65,359	O
patients	B-T101
were	O
included:	O
63,597	O
(97.3%)	O
PA	B-T047
patients	B-T101
and	O
1,762	O
SA	B-T033
patients	B-T101
(2.7%).	O
Compared	B-T052
with	O
the	O
PA	B-T047
cohort	B-T098
,	O
the	O
SA	B-T033
cohort	B-T098
was	O
older	B-T098
(	O
mean age	B-T032
=	O
50.8	O
years	B-T079
vs.	O
46.5	O
years	B-T079
,	O
P	O
<	O
0.001)	O
and	O
had	O
higher	O
mean	O
comorbidity score	B-T081
(1.47	O
vs.	O
1.31,	O
P<	O
0.001).	O
The	O
mean	O
count	O
of	O
all	O
asthma	B-T047
medications	B-T058
fills	O
was	O
2.2-fold	O
(2012)	O
and	O
2.1-fold	O
(2013)	O
higher	O
in	O
the	O
SA	B-T033
cohort,	B-T098
compared	B-T052
with	O
the	O
PA	B-T047
cohort	B-T098
(P<	O
0.001).	O
Mean	O
PDC	B-T079
for	O
all	O
oral	B-T122
and	O
inhaled	B-T040
controller therapy	B-T061
was	O
also	O
higher	O
in	O
the	O
SA	B-T033
cohort	B-T098
compared	B-T052
with	O
the	O
PA	B-T047
cohort	B-T098
(0.80	O
vs.	O
0.65,	O
P<	O
0.001).	O
SA	B-T033
patients	B-T101
had	O
a	O
significantly	O
greater mean count	B-T081
of	O
asthma	B-T047
-related	O
hospitalizations	B-T058
,	O
emergency room visits	B-T058
,	O
and	O
ambulatory visits	B-T033
in	O
2012	O
and	O
2013	O
(P<	O
0.001).	O
Unadjusted	O
mean	O
annual	O
asthma	B-T047
-related	O
costs	B-T081
in	O
the	O
SA	B-T033
versus	O
PA	B-T047
cohorts	B-T098
were	O
$6,496	O
versus	O
$2,739	O
(P	O
<	O
0.001)	O
in	O
2012	O
and	O
$5,174	O
versus	O
$1,775	O
(P<	O
0.001)	O
in	O
2013.	O
Higher	O
asthma	B-T047
-related	O
costs	B-T081
were	O
driven	O
by	O
greater	O
mean	O
annual	O
asthma	B-T047
medication	B-T058
costs	B-T081
in	O
2012	O
($4,545	O
vs.	O
$1,738,	O
P<	O
0.001)	O
and	O
2013	O
($4,068	O
vs.	O
$1,348,	O
P<	O
0.001).	O
Adjusted	B-T169
mean	O
annual	O
asthma	B-T047
-related	O
costs	B-T081
in	O
2013	O
were	O
$3,336	O
greater	O
(	O
cost ratio	B-T081
=2.878,	O
P<	O
0.001)	O
in	O
the	O
SA	B-T033
cohort	B-T098
,	O
and	O
adjusted	B-T169
mean	O
annual	O
asthma	B-T047
medication	B-T058
costs	B-T081
were	O
$2,672	O
higher	O
(cost	O
ratio=2.982,	O
P<	O
0.001)	O
in	O
the	O
SA	B-T033
cohort	B-T098
.	O
Patients	B-T101
with	O
SA	B-T033
who	O
experienced	B-T041
2	O
or	O
more	O
exacerbations	B-T033
had	O
2.1-fold	O
greater	O
use	B-T169
of	O
controller medications	B-T061
across	O
both	O
study	O
years	B-T079
and	O
were	O
more	O
adherent	B-T169
to	O
controller therapy	B-T169
than	O
patients	B-T101
with	O
PA	B-T047
.	O
Despite	O
more	O
intensive	O
pharmacotherapy	B-T061
,	O
SA	B-T033
patients	B-T101
incurred	O
2.9-fold	O
higher	O
adjusted	B-T169
asthma	B-T047
-related	O
costs	B-T081
and	O
3-fold	O
higher	O
adjusted	B-T169
asthma	B-T047
medication	B-T058
costs	B-T081
than	O
PA	B-T047
patients	B-T101
.	O
Patients	B-T101
with	O
SA	B-T033
consistently	B-T078
demonstrated	O
a	O
higher	O
rate	O
of	O
health care	B-T058
utilization	B-T169
.	O
Funding	B-T081
for	O
this	O
study	B-T062
(HO-14-14443)	O
was	O
provided	O
by	O
GlaxoSmithKline	B-T093
(	O
GSK	B-T093
).	O
All	O
listed	O
authors	B-T097
meet	B-T067
the	O
criteria	B-T078
for	O
authorship	B-T057
set	O
forth	O
by	O
the	O
International Committee for Medical Journal Editors	B-T096
.	O
Albers	B-T170
,	O
Forshag	B-T170
,	O
and	O
Yancey	B-T170
are	O
employees	B-T097
of	O
GSK	B-T093
and	O
hold	O
stock	O
in	O
GSK	B-T093
.	O
Dalal	B-T170
,	O
Nagar	B-T170
,	O
and	O
Ortega	B-T170
were	O
employees	B-T097
of	O
GSK	B-T093
at	O
the	O
time	B-T079
this	O
research	B-T062
was	O
conducted.	O
Chastek	B-T170
and	O
Korrer	B-T170
are	O
employees	B-T097
of	O
Optum	B-T093
,	O
which	O
received	O
consulting fees	B-T081
from	O
GSK	B-T093
for	O
research	B-T062
related	O
to	O
this	O
study	B-T062
.	O
Study concept	B-T078
and	O
design	B-T052
were	O
contributed	B-T052
by	O
Chastek	B-T170
,	O
Nagar	B-T170
,	O
and	O
Dalal	B-T170
.	O
Korrer	B-T170
took	O
the	O
lead	O
in	O
data collection	B-T062
,	O
along	O
with	O
Chastek	B-T170
,	O
and	O
data interpretation	B-T081
was	O
performed	O
by	O
Chastek	B-T170
,	O
Ortega	B-T170
,	O
Forshag	B-T170
,	O
and	O
Dalal	B-T170
.	O
The	O
manuscript	B-T073
was	O
written	O
by	O
Chastek	B-T170
and	O
Dalal	B-T170
and	O
revised	B-T169
by	O
Albers	B-T170
and	O
Yancy	B-T170
,	O
assisted	B-T080
by	O
the	O
other	O
authors	B-T097
.	O

Differential regulation	B-T042
of	O
spontaneous	B-T169
and	O
evoked	B-T080
inhibitory synaptic transmission	B-T042
in	O
somatosensory cortex	B-T023
by	O
retinoic acid	B-T109
Retinoic acid	B-T109
(	O
RA	B-T109
),	O
a	O
developmental	B-T080
morphogen	B-T121
,	O
has	O
emerged	O
in	O
recent	O
studies	O
as	O
a	O
novel	B-T080
synaptic	B-T043
signaling molecule	B-T123
that	O
acts	O
in	O
mature	B-T079
hippocampal	B-T023
neurons	B-T025
to	O
modulate	B-UnknownType
excitatory	B-T042
and	O
inhibitory synaptic transmission	B-T042
in	O
the	O
context	O
of	O
homeostatic	B-T038
synaptic plasticity	B-T042
.	O
However,	O
it	O
is	O
unclear	O
whether	O
RA	B-T109
is	O
capable	O
of	O
modulating	B-UnknownType
neural circuits	B-UnknownType
outside	B-T082
of	O
the	O
hippocampus	B-T023
,	O
and	O
if	O
so,	O
whether	O
the	O
mode of RA's action	B-T169
at	O
synapses	B-T030
is	O
similar	B-T080
to	O
that	O
within	B-T082
the	O
hippocampal	B-T023
network.	O
Here	O
we	O
explore	O
for	O
the	O
first	O
time	O
RA	B-T109
's	O
synaptic function	B-T043
outside	B-T082
the	O
hippocampus	B-T023
and	O
uncover	O
a	O
novel	B-T080
function	B-T169
of	O
all-trans retinoic acid	B-T109
at	O
inhibitory synapses	B-T026
.	O
Acute	B-T079
RA	B-T109
treatment	B-T169
increases	B-T169
spontaneous	B-T169
inhibitory synaptic transmission	B-T042
in	O
L2/3 pyramidal neurons	B-T025
of	O
the	O
somatosensory cortex	B-T023
,	O
and	O
this	O
effect	B-T080
requires	O
expression	B-T045
of	O
RA's receptor	B-T116
RARα	B-T116
both	O
pre- and post-synaptically	B-T043
.	O
Intriguingly,	O
RA	B-T109
does	O
not	O
seem	O
to	O
affect	O
evoked	B-T080
inhibitory transmission	B-T042
assayed	O
with	O
either	O
extracellular	B-T026
stimulation	O
or	O
direct	O
activation of action potentials	B-T043
in	O
presynaptic	B-T026
interneurons	B-T025
at	O
connected	O
pairs	O
of	O
interneurons	B-T025
and	O
pyramidal neurons	B-T025
.	O
Taken	O
together,	O
these	O
results	B-T033
suggest	O
that	O
RA's	B-T109
action	B-T052
at	O
synapses	B-T030
is	O
not	O
monotonous,	O
but	O
is	O
diverse	B-T080
depending	O
on	O
the	O
type	O
of	O
synaptic connection	B-T043
(	O
excitatory	B-T042
versus	O
inhibitory	B-T042
)	O
and	O
circuit	B-UnknownType
(	O
hippocampal	B-T023
versus	O
cortical)	B-T023
.	O
Thus,	O
synaptic signaling	B-T043
of	O
RA	B-T109
may	O
mediate	O
multi-faceted	O
regulation of synaptic plasticity	B-T042
.	O
In	O
addition	O
to	O
its	O
classic roles	B-T077
in	O
brain development	B-T042
,	O
retinoic acid	B-T109
(	O
RA	B-T109
)	O
has	O
recently	O
been	O
shown	O
to	O
regulate	B-T042
excitatory	B-T042
and	O
inhibitory transmission	B-T042
in	O
the	O
adult	B-T100
brain	B-T023
.	O
Here,	O
the	O
authors	B-T097
show	O
that	O
in	O
layer 2/3	B-T023
(	O
L2/3	B-T023
)	O
of	O
the	O
somatosensory cortex	B-T023
(	O
S1	B-T023
),	O
acute	B-T079
RA	B-T109
induces	B-T169
increases	B-T169
in	O
spontaneous	B-T169
but	O
not	O
action-potential	B-T043
evoked	B-T080
transmission	B-T043
,	O
and	O
that	O
this	O
requires	O
retinoic acid receptor	B-T116
(	O
RARα	B-T116
)	O
both	O
in	O
presynaptic	B-T026
PV	B-T116
-positive	O
interneurons	B-T025
and	O
postsynaptic	B-UnknownType
pyramidal (PN) neurons	B-T025
.	O

Utilization	B-T081
Pattern	B-T082
and	O
Drug Use	B-T041
of	O
Traditional Chinese Medicine	B-T091
Chinese	B-T091
Medicine,	O
Western Medicine	B-T091
,	O
and	O
Integrated Chinese-Western Medicine	B-T091
Treatments	B-T061
for	O
Allergic Rhinitis	B-T047
Under	O
the	O
National Health Insurance Program	B-T058
in	O
Taiwan	B-T083
Patients	B-T101
in	O
Taiwan	B-T083
with	O
allergic rhinitis	B-T047
seek	O
not	O
only	O
Western medicine	B-T091
treatment	B-T061
but	O
also	O
Traditional Chinese Medicine	B-T091
treatment	B-T061
or	O
integrated Chinese-Western medicine	B-T091
treatment	B-T061
.	O
Various	O
studies	O
have	O
conducted	O
pairwise comparison	B-T081
on	O
Traditional Chinese Medicine	B-T091
,	O
Western medicine	B-T091
,	O
and	O
integrated Chinese-Western medicine	B-T091
treatments	B-T061
.	O
However,	O
none	O
conducted	O
simultaneous	B-T079
analysis	B-T062
of	O
the	O
three	O
treatments	B-T061
.	O
This	O
study	O
analyzed	B-T062
patients	B-T101
with	O
allergic rhinitis	B-T047
receiving	O
the	O
three	O
treatments	B-T061
to	O
identify	O
differences	O
in	O
demographic	B-T090
characteristic	B-T080
and	O
medical	B-T169
use	B-T169
and	O
thereby	O
to	O
determine	O
drug use patterns	B-T041
of	O
different	O
treatments	B-T061
.	O
The	O
National Health Insurance Research Database	B-T170
was	O
the	O
data source	B-T081
,	O
and	O
included	O
patients	B-T101
were	O
those	O
diagnosed	B-T033
with	O
allergic rhinitis	B-T047
(	O
International Classification of Diseases, Ninth Revision	B-T170
,	O
Clinical Modification codes 470-478	B-T170
).	O
Chi-square test	B-T170
and	O
Tukey studentized range (honest significant difference) test	B-T170
were	O
conducted	O
to	O
investigate	B-T169
the	O
differences	O
among	O
the	O
three	O
treatments	B-T061
.	O
Visit frequency	B-T081
for	O
allergic rhinitis	B-T047
treatment	B-T061
was	O
higher	O
in	O
female	B-T098
than	O
male	B-T098
patients	B-T101
,	O
regardless	O
of	O
treatment	B-T061
with	O
Traditional Chinese Medicine	B-T091
,	O
Western medicine	B-T091
,	O
or	O
integrated Chinese-Western medicine	B-T091
.	O
Persons	B-T098
aged	O
0-19	O
years	O
ranked	O
the	O
highest	B-T080
in	O
proportion	B-T081
of	O
visits	B-T058
for	O
allergic rhinitis	B-T047
.	O
Traditional Chinese Medicine	B-T091
treatment	B-T061
had	O
more	O
medical	B-T169
items	O
per	O
person-time	B-T098
and	O
daily	B-T079
drug cost	B-T081
per	O
person-time	B-T098
and	O
had	O
the	O
lowest	B-T080
total	B-T080
expenditure	B-T081
per	O
person-time	B-T098
.	O
In	O
contrast,	O
Western medicine	B-T091
had	O
the	O
lowest	B-T080
daily	B-T079
drug cost	B-T081
per	O
person-time	B-T098
and	O
the	O
highest	B-T080
total	B-T080
expenditure	B-T081
per	O
person-time	B-T098
.	O
The	O
total	B-T080
expenditure	B-T081
per	O
person-time	B-T098
,	O
daily	B-T079
drug cost	B-T081
per	O
person-time	B-T098
,	O
and	O
medical	B-T169
items	B-T071
per	O
person-time	B-T098
of	O
integrated Chinese-Western medicine	B-T091
treatment	B-T061
lay	O
between	O
those	O
seen	O
with	O
Traditional Chinese Medicine	B-T091
and	O
Western medicine	B-T091
treatments	B-T061
.	O
Although	O
only	O
6.82	O
%	O
of	O
patients	B-T101
with	O
allergic rhinitis	B-T047
chose	O
integrated Chinese-Western medicine	B-T091
treatment	B-T061
,	O
the	O
visit frequency	B-T081
per	O
person-year	O
of	O
integrated Chinese-Western medicine	B-T091
ranked	O
highest	B-T080
.	O
In	O
addition,	O
multiple-composition	B-T081
medicines	B-T121
were	O
used	O
more	O
frequently	B-T079
than	O
single-composition	B-T081
medicines	B-T121
,	O
and	O
mar huang	B-T109
(	O
Ephedra sinica Stapf	B-T002
)	O
was	O
seldom	O
used	O
to	O
decrease	B-T081
the	O
risk of	B-T078
combining	O
medications	B-T121
.	O

TLR9	B-T028
Deficiency	B-T169
Leads	O
to	O
Accelerated	B-T169
Renal Disease	B-T047
and	O
Myeloid Lineage	B-T025
Abnormalities	B-T033
in	O
Pristane	B-T109
-Induced	O
Murine	B-T015
Lupus	B-T047
Systemic lupus erythematosus	B-T047
(	O
SLE)	B-T047
is	O
a	O
chronic	B-T079
,	O
life-threatening	B-T033
autoimmune disorder	B-T047
,	O
leading	O
to	O
multiple	O
organ	B-T023
pathologies	B-T091
and	O
kidney	B-T023
destruction	B-T052
.	O
Analyses	O
of	O
numerous	O
murine	B-T015
models	B-T050
of	O
spontaneous	O
SLE	B-T047
have	O
revealed	O
a	O
critical	O
role	O
for	O
endosomal	B-T026
TLRs	B-T116
in	O
the	O
production	O
of	O
autoantibodies	B-T116
and	O
development	O
of	O
other	O
clinical	B-T080
disease	B-T047
manifestations	B-T169
.	O
Nevertheless,	O
the	O
corresponding	O
TLR9	B-T028
-	O
deficient	B-T169
autoimmune	B-T046
-prone	O
strains	B-T001
consistently	O
develop	O
more	O
severe	O
disease	B-T047
pathology	B-T091
.	O
Injection	B-T061
of	O
BALB/c mice	B-T015
with	O
2,6,10,14-tetramethylpentadecane	B-T109
(	O
TMPD	B-T109
),	O
commonly	O
known	O
as	O
pristane	B-T109
,	O
also	O
results	O
in	O
the	O
development	O
of	O
SLE-like disease	B-T047
.	O
We	O
now	O
show	O
that	O
Tlr9(-/-)	B-T028
BALB/c mice	B-T015
injected i.p.	B-T061
with	O
TMPD	B-T109
develop	O
more	O
severe	O
autoimmunity	B-T046
than	O
do	O
their	O
TLR	B-T116
-sufficient	O
cohorts.	O
Early	O
indications	O
include	O
an	O
increased	O
accumulation	B-T033
of	O
TLR7	B-T028
-	O
expressing	B-T045
Ly6C(hi)	B-T129
inflammatory	B-T169
monocytes	B-T025
at	O
the	O
site of injection	B-T082
,	O
upregulation	B-T044
of	O
IFN	B-T116
-regulated	O
gene expression	B-T045
in	O
the	O
peritoneal cavity	B-T030
,	O
and	O
an	O
increased	O
production	O
of	O
myeloid lineage precursors	B-T025
(	O
common myeloid progenitors	B-T025
and	O
granulocyte	B-T025
myeloid precursors	B-T025
)	O
in	O
the	O
bone marrow	B-T024
.	O
TMPD	B-T109
-	O
injected	B-T061
Tlr9(-/-)	B-T028
BALB/c mice	B-T015
develop	O
higher	O
autoantibody	B-T116
titers	O
against	O
RNA	B-T114
,	O
neutrophil	B-T025
cytoplasmic	B-T026
Ags	B-T129
,	O
and	O
myeloperoxidase	B-T116
than	O
do	O
TMPD	B-T109
-	O
injected	B-T061
wild-type BALB/c mice	B-T015
.	O
The	O
TMP	B-T109
-	O
injected	B-T061
Tlr9(-/-)	B-T028
mice	B-T015
,	O
and	O
not	O
the	O
wild-type mice	B-T015
,	O
also	O
develop	O
a	O
marked	O
increase	O
in	O
glomerular IgG	B-T116
deposition	B-T169
and	O
infiltrating	O
granulocytes	B-T025
,	O
much	O
more	O
severe	O
glomerulonephritis	B-T047
,	O
and	O
a	O
reduced	B-T080
lifespan	B-T102
.	O
Collectively,	O
the	O
data	O
point	O
to	O
a	O
major	O
role	O
for	O
TLR7	B-T028
in	O
the	O
response	B-T032
to	O
self-antigens	B-T129
in	O
this	O
model	B-T050
of	O
experimental	O
autoimmunity	B-T046
.	O
Therefore,	O
the	O
BALB/c	B-T015
pristane	B-T109
model	B-T050
recapitulates	O
other	O
TLR7	B-T028
-driven	O
spontaneous	O
models	B-T050
of	O
SLE	B-T047
and	O
is	O
negatively	B-T033
regulated	O
by	O
TLR9	B-T028
.	O

Effect	B-T080
of	O
Xenotransplantation	B-T061
Site	B-T082
on	O
MicroRNA	B-T114
Expression	B-T045
of	O
Human	B-T016
Colon Cancer	B-T191
Stem Cells	B-T025
Cancer stem cells	B-T025
(	O
CSCs	B-T025
)	O
have	O
a	O
high	B-T080
tumorigenic	B-T191
ability	B-T032
to	O
form	O
patient-derived tumor xenografts	B-T050
(	O
PDXs	B-T050
).	O
PDXs	B-T050
are	O
an	O
attractive	B-T080
pre-clinical model	B-T170
,	O
but	O
gene expression	B-T045
and	O
biological behavior	B-T070
of	O
cancer cells	B-T025
in	O
the	O
tumor	B-T191
will	O
change	B-T169
during	O
establishment	B-T080
and	O
passage	O
of	O
PDXs	B-T050
.	O
Human	B-T016
colon cancer	B-T191
PDX	B-T050
was	O
established	B-T080
and	O
passaged	B-T059
either	O
subcutaneously	B-T082
or	O
orthotopically	B-T082
into	O
the	O
murine	B-T015
intestine	B-T023
.	O
Histology	B-T091
and	O
flow cytometric	B-T059
profile	B-T059
of	O
the	O
surgical	B-T061
specimen	B-T077
and	O
the	O
PDX	B-T050
were	O
analyzed	B-T062
.	O
CSCs	B-T025
were	O
then	O
isolated	B-T169
from	O
the	O
tumors	B-T191
and	O
their	O
microRNA	B-T114
(	O
miRNA	B-T114
)	O
expression	B-T045
was	O
analyzed	B-T062
by	O
semi-quantitative polymerase chain reaction	B-T059
.	O
The	O
surgical	B-T061
specimens	B-T077
and	O
PDXs	B-T050
were	O
histologically	B-T091
similar	B-T080
.	O
The	O
size	B-T082
of	O
CSC	B-T025
population	B-T098
increased	B-T081
and	O
expression	B-T045
of	O
miRNA	B-T114
s	O
in	O
CSCs	B-T025
changed	B-T169
in	O
the	O
passaged	B-T059
PDXs	B-T050
.	O
Expression	B-T045
of	O
oncogenic	B-T131
miRNAs	B-T114
was	O
highly	B-T080
up-regulated	B-T044
in	O
the	O
CSCs	B-T025
of	O
the	O
orthotopically	B-T082
passaged	B-T059
PDXs	B-T050
.	O
The	O
xenotransplantation	B-T061
site	B-T082
and	O
the	O
number	B-T081
of	O
tumor	B-T191
passages	B-T059
affect	B-T041
the	O
miRNA	B-T114
expression	B-T045
of	O
human	B-T016
colon	B-T023
CSCs	B-T025
.	O

Chemosensitivity	B-T033
,	O
Cardiovascular Risk	B-T033
,	O
and	O
the	O
Ventilatory Response	B-T201
to	O
Exercise	B-T056
in	O
COPD	B-T047
COPD	B-T047
is	O
associated	O
with	O
elevated	B-T080
cardiovascular risk	B-T033
and	O
a	O
potentiated	B-T080
ventilatory response	B-T201
to	O
exercise	B-T056
.	O
Enhanced	O
carotid	B-T023
chemoreceptor	B-T025
(	O
CC	B-T025
)	O
activity	B-T042
/	O
sensitivity	B-T042
sensitivity	B-T042
is	O
present	O
in	O
other	O
clinical conditions	B-T201
,	O
has	O
been	O
shown	O
to	O
contribute	O
to	O
sympathetic	B-T022
vasoconstrictor outflow	B-T046
,	O
and	O
is	O
predictive	B-T080
of	O
mortality	B-T033
.	O
CC	B-T025
activity	B-T042
/	O
sensitivity	B-T042
,	O
and	O
the	O
resulting	O
functional	B-T169
significance	B-T078
,	O
has	O
not been well examined	B-T080
in	O
COPD	B-T047
.	O
We	O
hypothesized	O
that	O
CC	B-T025
activity	B-T042
/	O
sensitivity	B-T042
would	O
be	O
elevated	B-T080
in	O
COPD	B-T047
,	O
and	O
related	O
to	O
increased	B-T081
pulse wave velocity	B-T081
(a	O
marker	B-T201
of	O
CV risk	B-T033
)	O
and	O
the	O
ventilatory response	B-T201
to	O
exercise	B-T056
.	O
30	O
COPD	B-T047
patients	B-T101
and	O
10	O
healthy	B-T080
age-matched	O
controls	B-T096
were	O
examined	B-T033
.	O
Participants	B-T098
performed	O
baseline	B-T081
cardiopulmonary exercise	B-T060
and	O
pulmonary function testing	B-T060
.	O
CC	B-T025
activity	B-T042
was	O
later	O
evaluated	B-T058
by	O
the	O
drop in	B-T033
ventilation	B-T039
with	O
breathing	B-T039
100%	O
O2	B-T121
,	O
and	O
CC	B-T025
sensitivity	B-T042
was	O
then	O
assessed	O
by	O
the	O
ventilatory response to hypoxia	B-T060
(ΔVE/ΔS	O
pO2	B-T059
).	O
Peripheral	B-T082
arterial stiffness	B-T039
was	O
subsequently	O
evaluated	B-T058
by	O
measurement	B-T169
of	O
pulse wave velocity	B-T081
(	O
PWV	B-T081
)	O
using	O
applanation tonometry	B-T060
while	O
the	O
subjects	O
were	O
breathing	B-T039
room air	B-T033
,	O
and	O
then	O
following	O
chemoreceptor	B-T025
inhibition	B-T052
by	O
breathing	B-T039
100%	B-T081
O2	B-T121
for	O
2	O
minutes.	O
CC	B-T025
activity	B-T042
,	O
CC	B-T025
sensitivity	B-T042
,	O
PWV	B-T081
and	O
the	O
ventilatory response	B-T201
to	O
exercise	B-T056
were	O
all	O
increased	O
in	O
COPD	B-T047
relative	O
to	O
controls	B-T096
.	O
CC	B-T025
sensitivity	B-T042
was	O
related	O
to	O
PWV	B-T081
;	O
however,	O
neither	O
CC	B-T025
activity	B-T042
nor	O
CC	B-T025
sensitivity	B-T042
was	O
related	O
to	O
the	O
ventilatory response	B-T201
to	O
exercise	B-T056
in	O
COPD	B-T047
.	O
CC	B-T025
inhibition	O
by	O
breathing	B-T039
100%	B-T081
O2	B-T121
normalized	O
PWV	B-T081
in	O
COPD	B-T047
,	O
while	O
no effect	B-T080
was	O
observed	O
in	O
controls	B-T096
.	O
CC	B-T025
activity	B-T042
and	O
sensitivity	B-T042
are	O
elevated	B-T080
in	O
COPD	B-T047
,	O
and	O
appear	O
related	O
to	O
cardiovascular risk	B-T033
;	O
however,	O
CC	B-T025
activity	B-T042
/	O
sensitivity	B-T042
does	O
not	O
contribute	O
to	O
the	O
potentiated	B-T080
ventilatory response	B-T201
to	O
exercise	B-T056
.	O

Isolation of Cells	B-T059
Specialized	B-T077
in	O
Anticancer	B-T109
Alkaloid Metabolism	B-T044
by	O
Fluorescence-Activated Cell Sorting	B-T059
Plant	B-T002
specialized	B-T077
metabolism	B-T040
often	O
presents	O
a	O
complex	B-T080
cell	B-T025
-	O
specific	B-T080
compartmentation	B-T043
essential	O
to	O
accomplish	O
the	O
biosynthesis	B-T169
of	O
valuable	O
plant	B-T002
natural products	B-T123
.	O
Hence,	O
the	O
disclosure	O
and	O
potential	O
manipulation	B-T169
of	O
such	O
pathways	B-T077
may	O
depend	O
on	O
the	O
capacity	O
to	O
isolate	B-T059
and	O
characterize	B-T052
specific	B-T080
cell types	B-T170
.	O
Catharanthus roseus	B-T002
is	O
the	O
source	O
of	O
several	O
medicinal	B-T121
terpenoid indole alkaloids	B-T109
,	O
including	O
the	O
low-level	O
anticancer	B-T109
vinblastine	B-T109
and	O
vincristine	B-T109
,	O
for	O
which	O
the	O
late	O
biosynthetic steps	B-T169
occur	O
in	O
specialized	B-T077
mesophyll cells	B-T025
called	O
idioblasts	B-T025
.	O
Here,	O
the	O
optical	B-T090
,	O
fluorescence	B-T070
,	O
and	O
alkaloid	B-T109
-	O
accumulating	B-T033
properties	O
of	O
C. roseus	B-T002
leaf	B-T002
idioblasts	B-T025
are	O
characterized	B-T052
,	O
and	O
a	O
methodology	B-T078
for	O
the	O
isolation	B-T059
of	O
idioblast	B-T025
protoplasts	B-T025
by	O
fluorescence-activated cell sorting	B-T059
is	O
established,	O
taking	O
advantage	O
of	O
the	O
distinctive	O
autofluorescence	B-T059
of	O
these	O
cells	B-T025
.	O
This	O
achievement	O
represents	O
a	O
crucial	O
step	O
for	O
the	O
development	O
of	O
differential	O
omic strategies	B-T062
leading	O
to	O
the	O
identification	B-T080
of	O
candidate genes	B-T028
putatively	O
involved	O
in	O
the	O
biosynthesis	B-T169
,	O
pathway	B-T077
regulation	B-T038
,	O
and	O
transmembrane transport	B-T043
leading	O
to	O
the	O
anticancer	B-T033
alkaloids	B-T109
from	O
C. roseus	B-T002
.	O

Interaction	B-T169
of	O
the	O
Antimicrobial Peptides	B-T116
Rhesus θ-Defensin	B-T116
and	O
Porcine	B-T015
Protegrin-1	B-T116
with	O
Anionic Phospholipid Monolayers	B-T109
A	O
combination	O
of	O
Langmuir isotherm	B-T170
,	O
Brewster angle microscopy	B-T059
(	O
BAM	B-T059
),	O
and	O
neutron reflectivity studies	B-T062
have	O
been	O
performed	O
to	O
gain	O
insight	O
into	O
the	O
effects	O
on	O
model	B-T170
bacterial cell membranes	B-T026
of	O
the	O
antimicrobial peptides	B-T116
,	O
Rhesus θ-defensin 1	B-T116
(	O
RTD-1	B-T116
),	O
and	O
porcine	B-T015
protegrin 1	B-T116
(	O
PG-1	B-T116
).	O
The	O
peptides	B-T116
were	O
interacted	B-T169
with	O
monolayers	B-T109
spread	O
at	O
the	O
air	B-T167
-	O
water	B-T121
interface	O
and	O
prepared	O
from	O
a	O
3:1	O
molar	O
mixture	O
of	O
phosphatidylethanolamine	B-T109
and	O
phosphatidylglycerol	B-T109
used	O
to	O
approximate	B-T080
the	O
cell membranes	B-T026
of	O
Gram positive bacteria	B-T007
.	O
The	O
Langmuir film	B-T167
balance	O
measurements	B-T169
show	O
that	O
both	O
peptides	B-T116
perturb	B-T169
the	O
lipid monolayers	B-T109
causing	O
an	O
increase	O
in	O
surface pressure	B-T070
,	O
and	O
the	O
BAM	B-T059
studies	O
show	O
that	O
each	O
results	O
in	O
the	O
formation	O
of	O
small domains	B-T087
within	O
the	O
lipid films	B-T170
,	O
around	O
5	O
μm	O
diameter.	O
The	O
overall	O
change	O
in	O
monolayer	B-T109
surface pressure	B-T070
caused	O
by	O
PG-1	B-T116
,	O
however,	O
is	O
a	O
little	O
more	O
pronounced	O
than	O
that	O
due	O
to	O
RTD-1	B-T116
(+8.5	O
mN·m(-1)	O
vs	O
+5.5	O
mN·m(-1)),	O
and	O
the	O
rate	O
of	O
its	O
initial	O
interaction	B-T169
with	O
the	O
monolayer	B-T109
is	O
a	O
little	O
more	O
rapid	O
than	O
that	O
for	O
RTD-1	B-T116
.	O
The	O
neutron reflectivity studies	B-T075
also	O
show	O
differences	O
for	O
PG-1	B-T116
and	O
RTD-1	B-T116
,	O
with	O
the	O
model	B-T170
fits	O
to	O
these	O
data	O
showing	O
that	O
the	O
more	O
amphiphilic	B-T121
PG-1	B-T116
becomes	O
fully	O
embedded	B-T059
within	O
the	O
lipid film	B-T170
-causing	O
an	O
extension	O
of	O
the	O
lipid acyl chains	B-T120
but	O
leaving	O
the	O
thickness	B-T080
of	O
the	O
lipid headgroup layer	B-T120
unaffected-while	O
RTD-1	B-T116
is	O
seen	O
to	O
insert	O
less	O
deeply-causing	O
the	O
same	O
extension	O
of	O
the	O
lipid acyl chains	B-T120
as	O
PG-1	B-T116
but	O
also	O
causing	O
a	O
significant	O
increase	O
in	O
thickness	B-T080
of	O
the	O
lipid headgroup layer	B-T120
.	O
The	O
various	O
differing	O
effects	O
of	O
the	O
two	O
peptides	B-T116
on	O
anionic lipid monolayers	B-T109
are	O
discussed	O
in	O
the	O
context	O
of	O
their	O
differing	O
hemolytic activities	B-T059
,	O
and	O
their	O
proposed	O
differing propensities	B-T081
to	O
form	O
transmembrane	B-T026
pores	B-T026
.	O

Development	B-T039
of	O
chrysin	B-T109
loaded	O
poloxamer	B-T109
micelles	O
and	O
toxicity	B-T080
evaluation	B-T058
in	O
fish	B-T013
embryos	B-T018
Poloxamer	B-T109
micelles	B-T109
micelles	B-T109
promise	O
safety	B-T068
and	O
efficacy	B-T080
for	O
many	O
water	B-T121
insoluble	B-T080
drugs	B-T121
.	O
Chrysin	B-T109
has	O
been	O
reported	O
to	O
have	O
anticancer	B-T080
,	O
anti-inflammatory	B-T080
,	O
antioxidant	B-T039
,	O
and	O
anti-aromatase activities	B-T044
but	O
its	O
water	B-T121
insoluble	B-T080
properties	B-T080
limit	O
its	O
pharmaceutical application	B-T091
.	O
In	O
the	O
present	O
study,	O
chrysin	B-T109
loaded	O
poloxamer	B-T109
micelles	B-T109
were	O
developed.	O
Two	O
types	O
of	O
poloxamers	B-T109
,	O
Pluronic F-68	B-T109
and	O
Pluronic F-127	B-T109
were	O
compared.	O
It	O
was	O
found	O
that	O
chrysin	B-T109
loaded	O
Pluronic F-68	B-T109
micelles	B-T109
(	O
CS-P68	B-T109
)	O
and	O
chrysin	B-T109
loaded	O
Pluronic F-127	B-T109
micelles	B-T109
(	O
CS-P127	B-T109
)	O
obviously	O
increase	B-T169
the	O
aqueous	B-T080
solubility	B-T080
of	O
chrysin	B-T109
.	O
The	O
results	B-T169
also	O
indicated	O
that	O
the	O
type	O
of	O
polymer	B-T104
and	O
ratio	O
of	O
drug	B-T121
to	O
polymer	B-T104
affected	O
size	B-T082
and	O
desirable	O
characteristics	B-T080
of	O
the	O
micelles	B-T109
.	O
The	O
micelle system	B-T109
of	O
CS-P68	B-T109
and	O
CS-P127	B-T109
formed	O
at	O
drug	B-T121
to	O
polymer	B-T104
ratios	B-T081
of	O
1:4	O
and	O
1:2,	O
respectively,	O
was	O
found	O
to	O
be	O
the	O
most	O
suitable	O
monodispersed	O
system	O
with	O
a	O
nanosize-range diameter	B-T081
.	O
The	O
in vivo study	B-T062
in	O
zebrafish	B-T013
eggs	B-T025
indicates	O
that	O
the	O
toxicity	B-T080
of	O
CS-P68	B-T109
and	O
CS-P127	B-T109
is	O
a	O
dose response	B-T078
.	O
CS-P68	B-T109
and	O
CS-P127	B-T109
at	O
a	O
drug dose	B-T081
of	O
10	O
ng/mL	O
or	O
less	B-T080
is	O
safe	O
for	O
zebrafish	B-T013
embryo	B-T018
growth	B-T040
.	O
The	O
results	O
of	O
this	O
study	B-T062
indicate	O
enhanced	B-T052
water solubility	B-T081
of	O
chrysin	B-T109
.	O
Chrysin	B-T109
loaded	O
poloxamer	B-T109
micelles	B-T109
are	O
promising	O
for	O
further	O
use	O
in	O
in vivo studies	B-T062
in	O
mammalian	B-T015
animals	B-T008
and	O
humans	B-T016
.	O

Adenoviral	B-T005
Delivery	B-T061
of	O
Tumor Necrosis Factor-α	B-T116
and	O
Interleukin-2	B-T116
Enables	O
Successful	O
Adoptive Cell Therapy	B-T061
of	O
Immunosuppressive	B-T121
Melanoma	B-T191
Adoptive T-cell transfer	B-T061
is	O
a	O
promising	O
treatment approach	B-UnknownType
for	O
metastatic cancer	B-T191
,	O
but	O
efficacy	B-T080
in	O
solid tumors	B-T191
has	O
only	O
been	O
achieved	O
with	O
toxic	B-T080
pre-	O
and	O
postconditioning	O
regimens.	O
Thus,	O
adoptive T-cell therapies	B-T061
would	O
benefit	B-T081
from	O
complementary	O
modalities	B-T078
that	O
enable	O
their	O
full	B-T080
potential	B-T080
without	O
excessive	B-T080
toxicity	B-T080
.	O
We	O
aimed	B-T078
to	O
improve	B-T080
the	O
efficacy	B-T080
and	O
safety	B-T080
of	O
adoptive T-cell transfer	B-T061
by	O
using	O
adenoviral vectors	B-T114
for	O
direct	O
delivery	B-T169
of	O
immunomodulatory	B-T061
murine	B-T015
cytokines	B-T116
into	O
B16.OVA	B-T025
melanoma tumors	B-T050
tumors	B-T191
with	O
concomitant	B-T079
T-cell receptor	B-T116
transgenic OT-I	B-T015
transgenic OT-I T-cell transfer	B-T061
.	O
Armed	O
adenoviruses	B-T005
expressed	O
high	O
local	O
and	O
low	O
systemic	O
levels	O
of	O
cytokine	B-T116
when	O
injected	B-T169
into	O
B16.OVA	B-T025
tumors	B-T191
,	O
suggesting	O
safety	B-T080
of	O
virus-mediated	B-T005
virus-mediated cytokine delivery	B-T061
cytokine	B-T116
delivery.	O
Antitumor	B-T080
efficacy	B-T080
was	O
significantly	O
enhanced	B-T052
with	O
adenoviruses	B-T005
coding	O
for	O
murine	B-T015
interleukin-2	B-T116
(	O
mIL-2	B-T116
)	O
and	O
tumor necrosis factor-α	B-T116
(	O
mTNFα	B-T116
)	O
when	O
compared	O
with	O
T-cell transfer	B-T061
alone	O
or	O
viruses	B-T005
alone.	O
Further	O
improvement	B-T077
in	O
efficacy	B-T080
was	O
achieved	O
with	O
a	O
triple	B-T081
combination	B-T080
of	O
mIL-2	B-T116
,	O
mTNFα	B-T116
,	O
and	O
OT-I T-cells	B-T025
.	O
Mechanistic studies	B-T169
suggest	O
that	O
mIL-2	B-T116
has	O
an	O
important	B-T080
role	B-T077
in	O
activating	B-T052
T-cells	B-T025
at	O
the	O
tumor	B-T191
,	O
while	O
mTNFα	B-T116
induces	O
chemokine	B-T116
expression	B-T045
.	O
Furthermore,	O
adenovirus	B-T005
treatments	B-T061
enhanced	B-T052
tumor	B-T191
-	O
infiltration	O
of	O
OT-I T-cells	B-T025
as	O
demonstrated	B-T052
by	O
SPECT/CT imaging	B-T060
of	O
(111)In-labeled cells	B-T025
.	O
Our	O
results	B-T169
suggest	B-T078
the	O
utility	O
of	O
cytokine-coding	B-T116
adenoviruses	B-T005
for	O
improving	B-T080
the	O
efficacy	B-T080
of	O
adoptive T-cell therapies	B-T061
.	O

The	O
Maternal	B-T033
Legacy	B-T081
:	O
Female	B-T032
Identity	B-T054
Predicts	O
Offspring	B-T099
Sex Ratio	B-T081
in	O
the	O
Loggerhead Sea Turtle	B-T014
In	O
organisms	B-T001
with	O
temperature-dependent	B-T081
sex determination	B-T038
,	O
the	O
incubation environment	B-T082
plays	O
a	O
key	O
role	O
in	O
determining	O
offspring	B-T099
sex ratios	B-T081
.	O
Given	O
that	O
global	B-T080
temperatures	B-T081
have	O
warmed	B-T070
approximately	O
0.6	O
°C	O
in	O
the	O
last	O
century,	O
it	O
is	O
necessary	O
to	O
consider	O
how	O
organisms	B-T001
will	O
adjust	B-T033
to	O
climate change	B-T070
.	O
To	O
better	O
understand	O
the	O
degree	B-T080
to	O
which	O
mothers	B-T099
influence	B-T077
the	O
sex ratios	B-T081
of	O
their	O
offspring	B-T099
,	O
we	O
use	O
24	O
years	B-T079
of	O
nesting data	B-T078
for	O
individual	B-T098
female	B-T032
loggerhead sea turtles	B-T014
(	O
Caretta caretta	B-T014
)	O
observed	O
on	O
Bald Head Island	B-T083
,	O
North Carolina	B-T083
.	O
We	O
find	O
that	O
maternal	B-T033
identity	B-T054
is	O
the	O
best	O
predictor	O
of	O
nest	B-T082
sex ratio	B-T081
in	O
univariate	B-T062
and	O
multivariate predictive models	B-T062
.	O
We	O
find	O
significant	O
variability	B-T077
in	O
estimated	O
nest	B-T082
sex ratios	B-T081
among	O
mothers	B-T099
,	O
but	O
a	O
high	O
degree	O
of	O
consistency	B-T080
within	O
mothers	B-T099
,	O
despite	O
substantial	O
spatial	B-T082
and	O
temporal	B-T079
thermal variation	B-T070
.	O
Our	O
results	O
suggest	O
that	O
individual	B-T098
differences	O
in	O
nesting preferences	B-T054
are	O
the	O
main	O
driver	O
behind	O
divergences	B-T082
in	O
nest	B-T082
sex ratios	B-T081
.	O
As	O
such,	O
a	O
female's	B-T032
ability	O
to	O
plastically	O
adjust	O
her	O
nest	B-T082
sex ratios	B-T081
in	O
response	O
to	O
environmental	B-T082
conditions	B-T080
is	O
constrained	B-T077
,	O
potentially	O
limiting	O
how	O
individuals	B-T098
behaviorally	O
mitigate	B-T067
the	O
effects	O
of	O
environmental change	B-T033
.	O
Given	O
that	O
many	O
loggerhead	B-T014
populations	B-T098
already	O
show	O
female-biased	B-T078
offspring	B-T099
sex ratios	B-T081
,	O
understanding	O
maternal behavioral	B-T054
responses	O
is	O
critical	B-T080
for	O
predicting	O
the	O
future	O
of	O
long-lived	O
species	B-T185
vulnerable	B-T169
to	O
extinction	B-T070
.	O

Increased	O
RhoA	B-T116
Activity	B-T044
Predicts	O
Worse	B-T033
Overall Survival	B-T081
in	O
Patients	B-T101
Undergoing	O
Surgical Resection	B-T061
for	O
Lauren	B-T185
Diffuse-Type Gastric Adenocarcinoma	B-T191
Several	O
studies	O
have	O
reported	O
a	O
high	O
rate	O
of	O
RHOA	B-T028
mutations	B-T045
in	O
the	O
Lauren	B-T185
diffuse-type gastric adenocarcinoma	B-T191
(	O
GA	B-T191
)	O
but	O
not	O
in	O
intestinal-type GA	B-T191
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
RhoA	B-T116
activity	B-T044
is	O
prognostic	B-T201
for	O
overall survival	B-T081
(	O
OS	B-T081
)	O
in	O
patients	B-T101
with	O
resectable	O
GA	B-T191
.	O
Retrospective review	B-T062
was	O
performed	O
on	O
a	O
prospective	O
database	O
of	O
GA	B-T191
patients	B-T101
who	O
underwent	O
potentially	O
curative resection	B-T061
between	O
2003	O
and	O
2012	O
at	O
a	O
single institution	B-T093
.	O
Tissue	B-T024
microarrays	B-T073
were	O
constructed	O
from	O
surgical specimens	B-T059
and	O
analyzed	O
for	O
phosphorylated	B-T116
RhoA	B-T116
,	O
a	O
marker	B-T201
of	O
inactive	O
RhoA	B-T116
signaling	B-T043
.	O
OS	B-T081
was	O
estimated	O
by	O
the	O
Kaplan-Meier method	B-T062
,	O
and	O
multivariate analysis	B-T081
was	O
performed	O
by	O
Cox proportional hazards regression modeling	B-T081
.	O
One	O
hundred	O
thirty-six	O
patients	B-T101
with	O
diffuse-type GA	B-T191
and	O
129	O
patients	B-T101
with	O
intestinal-type GA	B-T191
were	O
examined.	O
Compared	O
to	O
intestinal-type GA	B-T191
,	O
diffuse-type GA	B-T191
tumors	B-T191
were	O
significantly	O
associated with	B-T080
increased	O
tumor size	B-T082
and	O
advanced tumor, node, metastasis (TNM) classification system stage	B-T185
.	O
In	O
patients	B-T101
with	O
diffuse-type GA	B-T191
,	O
high	O
RhoA	B-T116
activity	B-T044
was	O
associated with	B-T080
significantly	O
worse	B-T033
OS	B-T081
when	O
compared	O
to	O
low	O
RhoA	B-T116
activity	B-T044
(5-year	O
OS	B-T081
52.5	O
vs.	O
81.0	O
%,	O
p	O
=	O
0.017).	O
This	O
difference	O
in	O
OS	B-T081
was	O
not	O
observed	O
in	O
patients	B-T101
with	O
intestinal-type GA	B-T191
(5-year	O
OS	B-T081
83.9	O
vs.	O
81.6	O
%,	O
p	O
=	O
0.766).	O
On	O
multivariate analysis	B-T081
of	O
diffuse-type GA	B-T191
patients	B-T101
,	O
high	O
RhoA	B-T116
activity	B-T044
was	O
an	O
independent	O
negative	O
prognostic factor	B-T201
for	O
OS	B-T081
(	O
hazard ratio	B-T081
2.38,	O
95	O
%	O
confidence interval	B-T081
1.07-5.28).	O
Increased	O
RhoA	B-T116
activity	B-T044
is	O
predictive	O
of	O
worse	B-T033
OS	B-T081
in	O
patients	B-T101
with	O
diffuse-type GA	B-T191
who	O
undergo	O
potentially	O
curative surgical resection	B-T061
.	O
Along	O
with	O
findings	O
from	O
genomic studies	B-T091
,	O
these	O
results	O
suggest	O
RhoA	B-T116
may	O
be	O
a	O
novel	O
therapeutic	B-T061
target	B-T169
in	O
diffuse-type GA	B-T191
.	O

Doxifluridine	B-T114
-	O
conjugated	B-T082
2-5A	B-T114
analog	B-T104
shows	O
strong	B-T080
RNase L	B-T116
activation	B-T045
ability	B-T080
and	O
tumor suppressive	B-T044
effect	B-T080
RNase L	B-T116
is	O
activated	B-T045
by	O
2',5'-oligoadenylates	B-T114
(	O
2-5A	B-T114
)	O
at	O
subnanomolar	B-T081
levels	B-T080
to	O
cleave	B-T082
single-stranded RNA	B-T114
.	O
We	O
previously	O
reported	B-T170
the	O
hypothesis	B-T078
that	O
the	O
introduction	B-T169
of	O
an	O
8-methyladenosine	B-T114
residue	O
at	O
the	O
2'-	O
terminus	B-T082
of	O
the	O
2-5A tetramer	B-T114
shifts	B-T169
the	O
2-5A	B-T114
binding site	B-T192
of	O
RNase L	B-T116
.	O
In	O
this	O
study	B-T062
,	O
we	O
synthesized	B-T052
various	O
5'-	O
modified	B-T169
2-5A	B-T114
analog	B-T104
s	O
with	O
8-methyladenosine	B-T114
at	O
the	O
2'-	O
terminus	B-T082
.	O
The	O
doxifluridine	B-T114
-	O
conjugated	B-T082
8-methyladenosine	B-T114
-	O
substituted	B-T052
2-5A	B-T114
analog	B-T104
was	O
significantly more	B-T081
effective	B-T080
as	O
an	O
activator	B-T052
of	O
RNase L	B-T116
than	O
the	O
parent	B-T077
5'-	O
monophophorylated	B-T044
2-5A tetramer	B-T114
and	O
showed	O
a	O
tumor suppressive	B-T044
effect	B-T080
against	B-T080
human	B-T016
cervical cancer	B-T191
cells	B-T025
.	O

Does	O
Video Laryngoscopy	B-T074
Offer	O
Advantages	B-T080
over	O
Direct Laryngoscopy	B-T060
during	B-T079
Cardiopulmonary Resuscitation	B-T061
?	O
Interruption	B-T079
of	O
chest compressions	B-T058
should	O
be	O
minimized	B-T080
because	O
of	O
its	O
negative	B-T033
effects	B-T080
on	O
survival	B-T081
.	O
This	O
randomized	B-T062
,	O
controlled	B-T169
,	O
cross-over study	B-T062
aimed	B-T078
to	O
analyze	B-T062
the	O
effectiveness	B-T080
of	O
Macintosh	B-T074
,	O
Miller	B-T074
,	O
McCoy	B-T074
and	O
McGrath laryngoscopes	B-T074
during	B-T079
with	O
or	O
without	O
chest compressions	B-T058
in	O
the	O
scope	B-T077
of	O
a	O
simulated	O
cardiopulmonary resuscitation	B-T061
scenario	B-T169
.	O
The	O
time	B-T079
required	B-T169
for	O
successful	B-T080
tracheal intubation	B-T061
,	O
number of attempts	B-T201
,	O
dental trauma	B-T037
severity	B-T080
and	O
the	O
need	B-T080
for	O
optimization	B-T052
manoeuvres	B-T052
were	O
recorded	B-T033
during	B-T079
cardiopulmonary resuscitation	B-T061
with	O
and	O
without	O
chest compressions	B-T058
.	O
The	O
experience	B-T041
with	O
computer games	B-T073
during	B-T079
the	O
last	O
10	O
years	B-T079
were	O
asked	O
to	O
the	O
participants	B-T098
and	O
recorded	B-T033
.	O
McCoy laryngoscope	B-T074
yielded	O
the	O
shortest time	B-T079
for	O
successful	B-T080
tracheal intubation	B-T061
both	O
in	O
the	O
presence	B-T033
of	O
and	O
without	O
chest compressions	B-T058
.	O
During	B-T079
the	O
use	B-T169
of	O
McCoy laryngoscopes	B-T074
,	O
fewer	B-T081
tracheal intubation	B-T061
attempts	B-T051
,	O
lower incidence	B-T081
of	O
dental trauma	B-T037
and	O
lower	B-T052
visual analogue scale scores	B-T201
on	O
the	O
ease	O
of	O
intubation	B-T061
were	O
recorded	B-T033
.	O
Participants	B-T098
who	O
are	O
experienced	B-T041
computer game	B-T073
players	B-T098
using	O
Macintosh	B-T074
,	O
McCoy	B-T074
and	O
McGrath	B-T074
achieved	B-T033
successful	B-T080
tracheal intubation	B-T061
in	O
a	O
significantly	B-T078
shorter time	B-T079
during	B-T079
resuscitation	B-T061
without	O
chest compressions	B-T058
.	O
Dental trauma	B-T037
incidence	B-T081
and	O
number	B-T081
of	O
tracheal intubation	B-T061
attempts	B-T051
did	O
not	O
show	O
any	O
significant	B-T078
difference	B-T080
between	O
the	O
four	B-T081
laryngoscopes	B-T074
being	O
related	O
to	O
the	O
rate	B-T081
of	O
playing	B-T052
computer games	B-T073
.	O
McGrath video laryngoscopes	B-T074
do	O
not	O
appear	O
to	O
have	O
advantages	B-T080
over	O
direct laryngoscopes	B-T060
for	O
securing	O
a	O
smooth	B-T080
and	O
successful	B-T080
tracheal intubation	B-T061
during	B-T079
rhythmic chest compressions	B-T058
.	O
We	O
believe	O
that	O
as	O
McCoy laryngoscope	B-T074
provided	B-T052
tracheal intubation	B-T061
in	O
a	O
shorter time	B-T079
and	O
with	O
fewer	B-T081
attempts	B-T051
,	O
this	O
laryngoscope	B-T074
may	O
increase	B-T169
the	O
success rate	B-T081
of	O
resuscitation	B-T061
.	O

The	O
nurse-patient communication	B-T054
:	O
voices	O
from	O
nursing students	B-T097
Effective communication skills	B-T032
have	O
been	O
found	O
to	O
be	O
one	O
of	O
the	O
pivotal factors	B-T169
in	O
building	O
positive interpersonal relationships	B-T054
.	O
Little	O
is	O
known	O
about	O
nursing undergraduates	B-T097
'	O
perspectives	B-UnknownType
on	O
communicating	B-T169
with	O
patients	B-T101
.	O
This	O
study	B-T062
aimed	O
to	O
explore	O
nursing students'	B-T097
perspectives	B-UnknownType
and	O
experiences	B-T041
of	O
nurse-patient communication	B-T054
in	O
their	O
clinical	B-T080
placement	B-T080
.	O
The	O
participants	B-T098
included	O
21	O
second-year undergraduates	B-T098
and	O
21	O
first-year master's students	B-T098
.	O
Interviews	B-T052
were	O
conducted	O
in	O
Cantonese	B-T171
and	O
then	O
transcribed	O
in	O
Chinese	B-T171
and	O
translated	O
into	O
English	B-T171
.	O
A	O
content analysis	B-T062
approach	B-T082
was	O
adopted	O
to	O
analyze	O
the	O
data	B-T078
.	O
Five	O
themes	B-UnknownType
emerged	O
from	O
the	O
interview data	B-T078
.	O
'The	O
necessity	O
of	O
nurse-patient communication	B-T054
'	O
reveals	B-T080
why	O
the	O
students	B-T098
valued	O
nurse-patient communication	B-T054
.	O
'The	O
conversation contents	B-T033
'	O
describes	O
the	O
content of the conversations	B-T033
that	O
students	B-T098
typically	O
had	O
with	O
patients	B-T101
.	O
The	O
third	O
theme	B-UnknownType
is	O
'	O
self-reflection	B-T033
on	O
the	O
nurse-patient communication	B-T054
'.	O
The	O
last	O
two	O
themes	B-UnknownType
,	O
'the	O
communication pattern in different	B-T033
hospital settings	B-T073
'	O
and	O
'the	O
obstacles	O
impeding	O
nurse-patient communication	B-T054
',	O
are	O
about	O
the	O
students'	B-T098
communication styles	B-T080
in	O
different	O
hospitals	B-T073
and	O
the	O
barriers	O
they	O
encounter	B-T053
.	O
To	O
improve	B-T033
students'	B-T098
communication skills	B-T032
,	O
educators	B-T097
and	O
clinical staff	B-T097
should	O
listen	O
to	O
students	B-T098
,	O
enhance	B-T052
students'	B-T098
reflective skills	B-T055
and	O
strengthen	O
their	O
confidence	B-T041
.	O
Through	O
understanding	B-T041
students'	B-T098
difficulties	B-T080
in	O
the	O
nurse-patient communication	B-T054
experience	B-T041
and	O
the	O
skills	B-T055
that	O
they	O
lack,	O
educators	B-T097
can	O
provide	O
them	O
with	O
helpful	O
recommendations	B-T078
to	O
improve	B-T033
their	O
communication skills	B-T032
in	O
clinical practice	B-T057
.	O
The	O
results	O
of	O
this	O
study	B-T062
reveal	B-T080
that	O
students'	B-T098
nurse-patient communication	B-T054
skills	B-T032
need	O
to	O
be	O
improved	B-T033
.	O

Early	O
hippocampal	B-T023
volume loss	B-T033
as	O
a	O
marker	B-T201
of	O
eventual	O
memory deficits	B-T048
caused	O
by	O
repeated stress	B-T033
Exposure to	B-T080
severe	B-T080
and	O
prolonged	B-T079
stress	B-T033
has	O
detrimental effects	B-T033
on	O
the	O
hippocampus	B-T023
.	O
However,	O
relatively	B-T080
little	B-T081
is	O
known	B-T080
about	O
the	O
gradual	B-T080
changes	B-T169
in	O
hippocampal structure	B-T023
,	O
and	O
its	O
behavioral	B-T053
consequences	B-T169
,	O
over	O
the	O
course	O
of	O
repeated stress	B-T033
.	O
Behavioral analyses	B-T058
during	O
10	O
days	O
of	O
chronic stress	B-UnknownType
pointed	O
to	O
a	O
delayed	O
decline	B-T081
in	O
spatial memory	B-T041
,	O
the	O
full	O
impact	B-T080
of	O
which	O
is	O
evident	O
only	O
after	O
the	O
end	O
of	O
stress	B-T033
.	O
In	O
contrast,	O
concurrent	B-T079
volumetric measurements	B-T081
in	O
the	O
same	O
animals	B-T008
revealed	O
significant	O
reduction	B-T080
in	O
hippocampal	B-T023
volumes	B-T081
in	O
stressed	B-T033
animals	B-T008
relative	O
to	O
their	O
unstressed counterparts	B-T033
,	O
as	O
early	O
as	O
the	O
third	O
day	O
of	O
stress	B-T033
.	O
Notably,	O
animals	B-T008
that	O
were	O
behaviorally	B-T053
the	O
worst	B-T080
affected	B-T169
at	O
the	O
end	O
of	O
chronic stress	B-UnknownType
suffered	B-T048
the	O
most	O
pronounced	O
early loss in hippocampal volume	B-T033
.	O
Together,	O
these	O
findings	O
support	O
the	O
view	O
that	O
not	O
only	O
is	O
smaller	O
hippocampal	B-T023
volume	B-T081
linked	O
to	O
stress	B-T033
-	O
induced	B-T169
memory deficits	B-T048
,	O
but	O
it	O
may	O
also	O
act	O
as	O
an	O
early	O
risk factor	B-T033
for	O
the	O
eventual	O
development	O
of	O
cognitive impairments	B-T048
seen	O
in	O
stress-related psychiatric disorders	B-T048
.	O

The	O
Association	B-T080
between	O
C9orf72	B-T028
Repeats	B-T086
and	O
Risk	B-T078
of	O
Alzheimer's Disease	B-T047
and	O
Amyotrophic Lateral Sclerosis	B-T047
:	O
A	O
Meta-Analysis	B-T062
C9orf72	B-T028
is	O
the	O
most	O
common	O
genetic	B-T169
cause	B-T169
of	O
amyotrophic lateral sclerosis	B-T047
(	O
ALS	B-T047
)	O
and	O
frontotemporal dementia	B-T047
(	O
FTD	B-T047
)	O
in	O
Caucasian populations	B-T098
.	O
However,	O
the	O
relationship	B-T080
between	O
C9orf72	B-T028
repeats	B-T086
and	O
Alzheimer's disease	B-T047
(	O
AD	B-T047
)	O
was	O
not clear	B-T033
.	O
Additionally,	O
there	O
were	O
few	O
articles	B-T170
assessing	B-T052
C9orf72	B-T028
in	O
other	O
ethnicities	B-T080
with	O
ALS	B-T047
.	O
In	O
this	O
meta-analysis	B-T062
,	O
we	O
aimed	O
to	O
investigate	B-T169
the	O
relationship	B-T080
between	O
C9orf72	B-T028
repeat expansions	B-T049
(≥30	O
repeats	B-T086
)	O
and	O
intermediate	B-T082
repeat copies	B-T086
(20-29	O
repeats	B-T086
)	O
and	O
AD	B-T047
or	O
ALS	B-T047
.	O
The	O
results	B-T169
suggested	O
positive	B-T033
correlations	B-T080
between	O
C9orf72	B-T028
repeat expansions	B-T049
and	O
the	O
risk	B-T078
of	O
Alzheimer's disease	B-T047
(	O
OR	B-T081
=	O
6.36,	O
95%	O
CI	B-T081
=	O
3.13-12.92,	O
and	O
p	B-T081
<	O
0.00001),	O
while	O
intermediate	B-T082
repeat copies	B-T086
of	O
C9orf72 gene	B-T028
were	O
not	O
associated with	B-T080
the	O
risk	B-T078
of	O
the	O
disease	B-T047
.	O
C9orf72	B-T028
repeat expansions	B-T049
were	O
positively	B-T033
correlated	B-T080
with	O
the	O
risk	B-T078
of	O
familial	B-T047
and	O
sporadic ALS	B-T047
(	O
OR	B-T081
=	O
293.25,	O
95%	O
CI	B-T081
=	O
148.17-580.38,	O
and	O
p	B-T081
<	O
0.00001;	O
OR	B-T081
=	O
35.57,	O
95%	O
CI	B-T081
=	O
19.61-64.51,	O
and	O
p	B-T081
<	O
0.00001).	O
There	O
was	O
a	O
positive	B-T033
correlation	B-T080
between	O
the	O
gene variations	B-T070
and	O
ALS	B-T047
risk	B-T078
among	O
Caucasians	B-T098
and	O
Asians	B-T098
(	O
OR	B-T081
=	O
57.56,	O
95%	O
CI	B-T081
=	O
36.73-90.22,	O
and	O
p	B-T081
<	O
0.00001;	O
OR	B-T081
=	O
6.35,	O
95%	O
CI	B-T081
=	O
1.39-29.02,	O
and	O
p	B-T081
=	O
0.02).	O

Demonstration	O
and	O
validation	B-T062
of	O
a	O
new	O
pressure	B-T067
-based	O
MRI	B-T074
-safe	O
pain tolerance	B-T033
device	B-T074
One	O
of	O
the	O
barriers	O
to	O
studying	O
the	O
behavioral	B-T053
and	O
emotional	B-T041
effects	B-T080
of	O
pain	B-T184
using	O
functional Magnetic Resonance Imaging	B-T060
(	O
fMRI	B-T060
)	O
is	O
the	O
absence	O
of	O
a	O
commercially	O
available,	O
MRI	B-T074
-	O
compatible	B-T080
,	O
pressure	B-T067
-based	O
algometer	B-T074
to	O
elicit	B-T080
pain	B-T184
.	O
The	O
present	O
study	O
sought	O
to	O
address	O
this	O
barrier	O
through	O
creation	O
and	O
validation	O
of	O
a	O
novel	O
MRI	B-T074
-safe	O
apparatus	B-T074
capable	O
of	O
delivering	O
incremental	B-T081
,	O
measurable	B-T169
amounts	O
of	O
pressure	B-T067
inside	O
a	O
scanning bore	B-T074
.	O
We	O
introduced	O
an	O
MR-safe	O
device	B-T074
used	O
to	O
administer	O
pressure	B-T067
-based	O
pain	B-T184
.	O
To	O
test	B-T059
against	O
a	O
commercially	O
available,	O
MRI	B-T074
-	O
incompatible	B-T080
algometer	B-T074
(	O
AlgoMed	B-T074
),	O
199	O
participants	O
reported	O
their	O
pain tolerance	B-T033
for	O
both	O
devices.	O
A	O
second	O
experiment	O
tested	B-T059
the	O
validity	O
of	O
pressure	B-T067
-based	O
pain	B-T184
in	O
an	O
MRI	B-T074
environment	B-T082
by	O
comparing	O
brain	B-T023
activation	B-T052
with	O
established	O
neural networks	B-T023
for	O
pain	B-T184
.	O
10	O
participants	O
performed	O
an	O
identical	O
procedure	O
to	O
test	B-T059
for	O
pain	B-T184
tolerance	O
while	O
being	O
scanned	B-T060
in	O
a	O
7T	O
MRI scanner	B-T074
.	O
Results	O
support	O
the	O
validity and reliability	B-T080
of	O
our	O
novel	O
device	B-T074
.	O
In	O
Study	O
1,	O
pain tolerance	B-T033
with	O
this	O
device	B-T074
was	O
strongly	O
correlated	O
with	O
pain tolerance	B-T033
as	O
measured	O
by	O
a	O
commercially	O
available	O
algometer	B-T074
(r=0.78).	O
In	O
Study	O
2,	O
this	O
device	B-T074
yielded	O
BOLD	B-T042
activation	O
within	O
the	O
insula	B-T023
(	O
BA 13	B-T023
)	O
and	O
anterior cingulate gyrus	B-T023
(	O
BA 24	B-T029
);	O
as	O
pressure	B-T067
increased	B-T081
,	O
activation	O
in	O
these	O
areas	O
parametrically	B-UnknownType
increased	B-T081
.	O
These	O
findings	O
correspond	O
to	O
other	O
studies	O
using	O
thermal	B-T061
,	O
electrical	B-T061
,	O
or	O
mechanical	B-T061
pain applications	B-T184
.	O
Behavioral	B-T053
and	O
functional	B-T169
data	B-T078
demonstrate	O
that	O
this	O
new	O
device	B-T074
is	O
a	O
valid	O
method	O
of	O
administering	B-T061
pressure	B-T067
-related	O
pain	B-T184
in	O
MRI	B-T074
environments	B-T082
.	O
Our	O
novel	O
MRI	B-T074
-safe	O
device	B-T074
is	O
a	O
valid	O
instrument	B-T074
to	O
measure	B-T169
and	O
administer	B-T169
pressure	B-T067
-based	O
pain	B-T184
.	O

Anti-Inflammatory Properties	B-T080
of	O
Menthol	B-T109
and	O
Menthone	B-T109
in	O
Schistosoma mansoni Infection	B-T047
Schistosomiasis	B-T047
is	O
a	O
parasitic disease	B-T047
caused	O
by	O
several	O
species	B-T185
of	O
trematode worms	B-T204
and	O
it	O
is	O
believed	O
that	O
more	O
than	O
261	O
million	O
people	B-T098
are	O
affected	B-T169
worldwide.	O
New	O
drug development	B-T091
has	O
become	O
essential	B-T080
because	O
there	O
is	O
a	O
risk	O
of	O
the	O
parasite	B-T204
becoming	O
resistant	B-T039
to	O
Praziquantel	B-T109
,	O
the	O
only	O
drug	B-T121
available	O
for	O
this	O
infection	B-T046
.	O
This	O
study	B-T062
evaluated	B-T058
parasitological	B-T080
,	O
immunological	B-T169
and	O
histological	B-T169
parameters	B-T033
in	O
mice	B-T015
infected	B-T033
with	O
Schistosoma mansoni	B-T204
and	O
treated with	B-T061
an	O
herbal commercial medicine	B-T121
.	O
This	O
drug	B-T121
consists	O
of	O
menthol	B-T109
(30-55%)	O
and	O
menthone	B-T109
(14-32%).	O
A	O
60	O
day	O
treatment regimen	B-T061
with	O
the	O
herbal medicine	B-T121
decreased	B-T081
the	O
number	O
of	O
S. mansoni	B-T204
eggs	B-T204
in	O
the	O
feces	B-T031
,	O
liver	B-T023
,	O
and	O
intestine	B-T023
and	O
reduced	B-T080
the	O
number	O
of	O
hepatic granulomas	B-T047
.	O
We	O
observed	B-T169
a	O
reduction	B-T061
of	O
84%	O
in	O
blood eosinophilia	B-T047
and	O
a	O
decrease	B-T081
in	O
the	O
IL-4	B-T116
and	O
IL-10	B-T116
blood levels	B-T031
after	O
treatment	B-T061
.	O
Therefore,	O
we	O
propose	O
that	O
schistosomiasis	B-T047
treatment	B-T061
with	O
this	O
herbal medicine	B-T121
for	O
60	O
days	O
has	O
an	O
immunomodulatory	B-T080
and	O
anti-inflammatory action	B-T080
in	O
this	O
animal model	B-T008
for	O
schistosomiasis	B-T047
thus	O
contributing	B-T052
to	O
the	O
decrease	B-T081
in	O
physio	O
pathological	B-T169
effects	B-T080
caused	O
by	O
S. mansoni infection	B-T047
.	O

Catastrophic	B-T047
health expenditure	B-T081
:	O
a	O
comparative analysis	B-T062
of	O
empty-nest	B-T078
and	O
non-empty-nest	B-T078
households	B-T099
with	O
seniors	B-T098
in	O
Shandong, China	B-T083
The	O
aim	B-T078
of	O
this	O
study	B-T062
was	O
to	O
compare	B-T052
the	O
catastrophic	B-T047
health expenditure	B-T081
(	O
CHE	B-T081
)	O
prevalence	B-T081
and	O
its	O
determinants	B-T169
between	O
empty-nest	B-T078
and	O
non-empty-nest	B-T078
elderly	B-T098
households	B-T099
.	O
Shandong province of China	B-T083
.	O
A	O
total	B-T080
of	O
2761	O
elderly	B-T098
households	B-T099
are	O
included	B-T169
in	O
the	O
analysis	B-T062
.	O
CHE	B-T081
incidence	B-T081
among	O
elderly	B-T098
households	B-T099
was	O
44.9%.	O
The	O
CHE	B-T081
incidence	B-T081
of	O
empty-nest	B-T078
singles	B-T033
(59.3%,	O
p=0.000,	O
OR=3.19)	O
and	O
empty-nest	B-T078
couples	B-T099
(52.9%,	O
p=0.000,	O
OR=2.45)	O
are	O
both	O
statistically	B-T081
higher	B-T080
than	O
that	O
of	O
non-empty-nest	B-T078
elderly	B-T098
households	B-T099
(31.4%).	O
An	O
inverse association	B-T077
was	O
observed	B-T169
between	O
CHE	B-T081
incidence	B-T081
and	O
income level	B-T080
in	O
all	O
elderly	B-T098
household	B-T099
types	B-T080
.	O
Factors	B-T169
including	B-T169
1	O
or	O
more	O
household	B-T099
elderly members	B-T098
with	O
non-communicable chronic diseases	B-T047
in	O
the	O
past	O
6	O
months,	O
1	O
or	O
more	O
elderly	B-T098
household members	B-T099
being	O
hospitalised	B-T033
in	O
the	O
past year	B-T079
and	O
lower	B-T052
household	B-T099
income	B-T081
,	O
are	O
significant	B-T078
risk factors	B-T033
for	O
CHE	B-T081
in	O
all	O
3	O
household	B-T099
types	B-T080
(p<0.05).	O
Health insurance	B-T058
status	B-T080
was	O
found	O
to	O
be	O
a	O
significant	B-T078
determinant	B-T169
of	O
CHE	B-T081
among	O
empty-nest	B-T078
singles	B-T033
and	O
non-empty-nest	B-T078
households	B-T099
(p<0.05).	O
CHE	B-T081
incidence	B-T081
among	O
elderly	B-T098
households	B-T099
is	O
high	B-T080
in	O
China	B-T083
.	O
Empty-nest	B-T078
households	B-T099
are	O
at	O
higher	B-T080
risk	B-T078
for	O
CHE	B-T081
than	O
non-empty-nest	B-T078
households	B-T099
.	O
Based	O
on	O
these	O
findings	B-T033
,	O
we	O
suggest	B-T078
that	O
special	B-T080
insurance	B-T058
be	O
developed	O
to	O
broaden	B-T082
the	O
coverage	B-T078
of	O
health services	B-T058
and	O
heighten	B-T080
the	O
reimbursement rate	B-T058
for	O
empty-nest	B-T078
elderly	B-T098
in	O
the	O
existing	O
health insurance	B-T058
schemes	B-T170
.	O
Financial	B-T080
and	O
social protection	B-T064
interventions	B-T058
are	O
also	O
essential	B-T080
for	O
identifie	B-T080
d	O
at-risk	B-T080
subgroups	B-T185
among	O
different	O
types	O
of	O
elderly	B-T098
households	B-T099
.	O

Role	O
of	O
agonistic autoantibodies	B-T116
against	O
type-1 angiotensin II receptor	B-T116
in	O
the	O
pathogenesis	B-T046
of	O
retinopathy	B-T047
in	O
preeclampsia	B-T046
To	O
investigate	B-T169
the	O
mechanism	B-T169
underlying	O
AT1-AA	B-T129
-induced	O
retinopathy	B-T047
in	O
severe	O
preeclampsia	B-T046
by	O
measuring	O
the	O
positive rate	B-T081
and	O
titer	B-T081
of	O
AT1-AA	B-T129
in	O
plasma	B-T031
from	O
women	B-T098
with	O
severe preeclampsia	B-T046
and	O
normal	O
pregnant women	B-T098
to	O
see	O
whether	O
AT1-AA	B-T129
titer	B-T081
was	O
correlated	B-T080
with	O
the	O
grade	O
of	O
retinopathy	B-T047
.	O
A	O
preeclampsia	B-T046
rat	B-T015
model	B-T008
was	O
also	O
established	O
by	O
intravenous injection	B-T169
of	O
AT1-AA	B-T129
extracted	O
from	O
the	O
plasma	B-T031
of	O
patient	B-T101
suffering	O
from	O
severe preeclampsia	B-T046
.	O
The	O
results	O
showed	O
that	O
the	O
plasma	B-T031
titer	B-T081
and	O
positive rate	B-T081
of	O
AT1-AA	B-T129
were	O
significantly	O
higher	O
in	O
women	B-T098
with	O
severe preeclampsia	B-T046
than	O
normal	O
pregnant women	B-T098
.	O
The	O
antibody	B-T116
titer	B-T081
in	O
cases	O
of	O
severe	O
preeclampsia	B-T046
was	O
associated	O
with	O
the	O
grade	O
of	O
retinopathy	B-T047
,	O
and	O
positively	O
correlated	B-T080
with	O
the	O
level	O
of	O
TNF-α	B-T116
and	O
VEGF	B-T116
.	O
The	O
animal experiment	B-T062
results	B-T169
showed	O
that	O
the	O
modeled rats	B-T015
presented	O
symptoms	B-T184
very	O
similar	O
to	O
symptoms	B-T184
of	O
human	B-T016
preeclampsia	B-T046
,	O
including	O
retinopathy	B-T047
.	O
Ocular fundus	B-T023
examination	B-T058
showed	O
retinal microvascular abnormalities	B-T033
,	O
hemorrhaging	B-T046
and	O
leakage	B-T033
in	O
the	O
severe preeclampsia	B-T046
.	O
Morphological changes	B-T082
included	O
edema	B-T184
,	O
thickening	B-T033
of	O
the	O
INL	B-T023
and	O
ONL	B-T023
,	O
and	O
pigment atrophy	B-T033
.	O
TNF-α	B-T116
and	O
VEGF	B-T116
levels	O
were	O
increased	O
in	O
the	O
vitreous humor	B-T031
and	O
retina	B-T023
of	O
the	O
model rats	B-T015
.	O
Our	O
studies	B-T062
results	B-T169
suggest	O
that	O
abnormal expression	B-T045
of	O
AT1-AA	B-T129
could	O
induce	O
damage	B-T169
to	O
retinal capillary endothelial cells	B-T025
and	O
increase	O
vascular permeability	B-T042
,	O
resulting in	B-T169
retinopathy	B-T047
.	O

Characterizing	B-T052
sexual function	B-T040
in	O
patients	B-T101
with	O
generalized anxiety disorder	B-T048
:	O
a	O
pooled analysis	B-T062
of	O
three	O
vilazodone	B-T109
studies	B-T062
Vilazodone	B-T109
has	O
been	O
shown	O
to	O
reduce	B-T080
core symptoms	B-T184
of	O
generalized anxiety disorder	B-T048
(	O
GAD	B-T048
)	O
in	O
three	O
randomized	B-T062
,	O
double-blind	B-T062
,	O
placebo-controlled trials	B-T062
.	O
Since	O
sexual dysfunction	B-T047
(	O
SD	B-T047
)	O
is	O
not	O
well	O
characterized	O
in	O
GAD	B-T048
,	O
a	O
post hoc analysis	B-T062
of	O
these	O
trials	B-T062
was	O
conducted	O
to	O
evaluate	B-T058
the	O
effects of	B-T080
vilazodone	B-T109
on	O
sexual functioning	B-T040
in	O
GAD	B-T048
patients	B-T101
.	O
Data	B-T078
were	O
pooled	B-T169
from	O
one	O
fixed-dose trial	B-T062
of	O
vilazodone	B-T109
20	O
and	O
40	O
mg/day	B-T081
(	O
NCT01629966	B-T170
)	O
and	O
two	O
flexible-dose studies	B-T062
of	O
vilazodone	B-T109
20-40	O
mg/day	B-T081
(	O
NCT01766401	B-T170
,	O
NCT01844115	B-T170
)	O
in	O
adults	B-T100
with	O
GAD	B-T048
.	O
Sexual functioning	B-T040
was	O
assessed	B-T052
using	O
the	O
Changes in Sexual Functioning Questionnaire	B-T170
(	O
CSFQ	B-T170
).	O
Outcomes	B-T062
included	O
mean change from baseline to end of treatment	B-T081
(	O
EOT	B-T080
)	O
in	O
CSFQ total score	B-T033
and	O
percentage	B-T081
of	O
patients	B-T101
shifting	B-T169
from	O
SD	B-T047
at	O
baseline	B-T081
(	O
CSFQ total score	B-T033
≤47	O
for	O
males	B-T098
,	O
≤41	O
for	O
females	B-T098
)	O
to	O
normal functioning	B-T033
at	O
EOT	B-T080
.	O
Treatment-emergent adverse events	B-T046
related	O
to	O
sexual functioning	B-T040
were	O
also	O
analyzed	B-T062
.	O
A	O
total	B-T080
of	O
1,373	O
patients	B-T101
were	O
included	O
in	O
the	O
analyses	B-T062
.	O
SD	B-T047
at	O
baseline	B-T081
was	O
more	O
common	O
in	O
females	B-T098
(	O
placebo	B-T122
,	O
46.4%;	O
vilazodone	B-T109
,	O
49%)	O
than	O
in	O
males	B-T098
(	O
placebo	B-T122
,	O
35.1%;	O
vilazodone	B-T109
,	O
40.9%).	O
CSFQ total score	B-T033
improvement	B-T077
was	O
found	O
in	O
both	O
females	B-T098
(	O
placebo	B-T122
,	O
+1.2;	O
vilazodone	B-T109
,	O
+1.6)	O
and	O
males	B-T098
(	O
placebo	B-T122
,	O
+2.1;	O
vilazodone	B-T109
,	O
+1.0),	O
with	O
no statistically significant differences	B-T033
between	O
treatment	B-T169
groups	B-T078
.	O
The	O
percentage	B-T081
of	O
patients	B-T101
who	O
shifted	B-T169
from	O
SD	B-T047
at	O
baseline	B-T081
to	O
normal	B-T080
sexual functioning	B-T040
at	O
EOT	B-T080
was	O
higher	O
in	O
males	B-T098
(	O
placebo	B-T122
,	O
40.6%;	O
vilazodone	B-T109
,	O
35.7%)	O
than	O
in	O
females	B-T098
(	O
placebo	B-T122
,	O
24.9%;	O
vilazodone	B-T109
,	O
34.9%);	O
no statistical testing	B-T033
was	O
performed.	O
Except	O
for	O
erectile dysfunction	B-T047
and	O
delayed ejaculation	B-T046
in	O
vilazodone	B-T109
-	O
treated	B-T169
males	B-T098
(2.4%	O
and	O
2.1%,	O
respectively),	O
no treatment-emergent adverse events	B-T033
related	O
to	O
sexual functioning	B-T040
occurred	B-T052
in	O
≥2%	O
of	O
patients	B-T101
in	O
either	O
treatment	B-T169
group	B-T078
.	O
Approximately	B-T080
35%-50%	O
of	O
patients	B-T101
in	O
the	O
vilazodone	B-T109
GAD	B-T048
studies	B-T062
had	O
SD	B-T047
at	O
baseline	B-T081
.	O
Vilazodone	B-T109
and	O
placebo	B-T122
had	O
similar	O
effects	B-T080
on	O
CSFQ	B-T170
outcomes	B-T062
in	O
both	O
females	B-T098
and	O
males	B-T098
,	O
indicating	O
a	O
limited	B-T169
adverse impact	B-T046
on	O
sexual functioning	B-T040
with	O
vilazodone	B-T109
.	O

Biogeochemical	B-T169
Controls	B-T080
of	O
Uranium	B-T196
Bioavailability	B-T081
from	O
the	O
Dissolved Phase	B-T080
in	O
Natural	B-T169
Freshwaters	B-T167
To	O
gain	O
insights	O
into	O
the	O
risks	B-T078
associated with	B-T080
uranium	B-T196
(	O
U	B-T196
)	O
mining	B-T057
and	O
processing	B-T052
,	O
we	O
investigated	B-T169
the	O
biogeochemical	B-T169
controls	B-T080
of	O
U	B-T196
bioavailability	B-T081
in	O
the	O
model	O
freshwater	B-T167
species	B-T185
Lymnaea stagnalis	B-T204
(	O
Gastropoda	B-T204
).	O
Bioavailability	B-T081
of	O
dissolved U(VI)	B-T196
was	O
characterized	B-T052
in	O
controlled	B-T169
laboratory	B-T073
experiments	B-T062
over	O
a	O
range	O
of	O
water	B-T121
hardness	B-T080
,	O
pH	B-T081
,	O
and	O
in	O
the	O
presence	B-T033
of	O
complexing ligands	B-T103
in	O
the	O
form	O
of	O
dissolved natural organic matter	B-T167
(	O
DOM	B-T167
).	O
Results	B-T034
show	O
that	O
dissolved U	B-T196
is	O
bioavailable	B-T080
under	O
all	O
the	O
geochemical conditions	B-T090
tested	B-T169
.	O
Uranium	B-T196
uptake	B-T039
rates	B-T081
follow	O
first order kinetics	B-UnknownType
over	O
a	O
range	O
encompassing	O
most	O
environmental	B-T082
concentrations	B-T081
.	O
Uranium	B-T196
uptake	B-T039
rates	B-T081
in	O
L. stagnalis	B-T204
ultimately	O
demonstrate	O
saturation	B-T070
uptake	B-T039
kinetics	B-T070
when	O
exposure	B-T080
concentrations	B-T081
exceed	O
100	O
nM,	O
suggesting	B-T078
uptake	B-T039
via	O
a	O
finite	O
number	O
of	O
carriers	O
or	O
ion channels	B-T116
.	O
The	O
lack	O
of	O
a	O
relationship	O
between	O
U	B-T196
uptake	B-T039
rate	O
constants	B-T081
and	O
Ca	B-T121
uptake	B-T039
rates	B-T081
suggest	B-T078
that	O
U	B-T196
does	O
not	O
exclusively	O
use	O
Ca	B-T121
membrane transporters	B-T116
.	O
In	O
general,	O
U	B-T196
bioavailability	B-T081
decreases	B-T033
with	O
increasing	B-T169
pH	B-T081
,	O
increasing	B-T169
Ca	B-T121
and	O
Mg	B-T123
concentrations	B-T081
,	O
and	O
when	O
DOM	B-T167
is	O
present	B-T033
.	O
Competing	O
ions	B-T196
did	O
not	O
affect	O
U	B-T196
uptake	B-T039
rates	B-T081
.	O
Speciation modeling	B-T062
that	O
includes	O
formation	B-T169
constants	B-T081
for	O
U	B-T196
ternary complexes	B-T104
reveals	B-T080
that	O
the	O
aqueous	B-T080
concentration	B-T081
of	O
dicarbonato U	B-T196
species	B-T185
(UO2(CO3)2(-2))	O
best	O
predicts	O
U	B-T196
bioavailability	B-T081
to	O
L. stagnalis	B-T204
,	O
challenging	O
the	O
free-ion activity	B-T052
model	O
postulate.	O

Interleukin-21	B-T116
plays	O
a	O
critical	O
role	O
in	O
the	O
pathogenesis	B-T046
and	O
severity	O
of	O
type I autoimmune hepatitis	B-T047
Recently,	O
the	O
number	O
of	O
follicular	B-T023
helper T (Tfh) cells	B-T025
expressing	O
interleukin (IL)-21	B-T116
was	O
found	O
to	O
increase	O
in	O
peripheral blood	B-T031
of	O
human	B-T016
and	O
murine	B-T015
models	B-T050
of	O
autoimmune hepatitis	B-T047
(	O
AIH	B-T047
).	O
IL-21	B-T116
,	O
the	O
most	O
recently	O
discovered	O
member	O
of	O
the	O
type-I cytokine family	B-T116
,	O
exerts	O
various	O
effects	O
on	O
the	O
immune system	B-T022
,	O
including	O
B cell activation	B-T043
,	O
plasma cell differentiation	B-T043
,	O
and	O
immunoglobulin production	B-T038
.	O
We	O
aimed	O
to	O
assess	O
the	O
relationship	O
of	O
serum	B-T031
IL-21	B-T116
levels	B-T080
in	O
patients	B-T101
with	O
type I AIH	B-T047
with	O
clinical	B-T080
and	O
laboratory	B-T073
parameters	B-T077
and	O
histology	B-T091
.	O
Ninety-two	O
Japanese	B-T098
patients	B-T101
with	O
liver disease	B-T047
(22	O
AIH	B-T047
,	O
20	O
primary biliary cholangitis	B-T047
,	O
19	O
drug-induced liver injury	B-T047
,	O
8	O
acute hepatitis B	B-T047
,	O
8	O
chronic hepatitis C	B-T047
,	O
10	O
non-alcoholic steatohepatitis	B-T047
,	O
5	O
viral hepatitis	B-T047
)	O
and	O
10	O
healthy volunteers	B-T098
were	O
recruited.	O
Serum	B-T031
IL-21	B-T116
levels	B-T080
were	O
detected	O
by	O
enzyme-linked immunosorbent assay	B-T059
.	O
Real-time polymerase chain reaction	B-T063
measured	O
mRNA	B-T114
levels	B-T080
of	O
Bcl-6	B-T028
,	O
IL-21	B-T028
,	O
and	O
CXCR5	B-T028
(	O
Tfh-related factors	B-T116
)	O
in	O
peripheral	B-T082
mononuclear cells	B-T025
.	O
Mean	O
age	O
at	O
diagnosis	B-T033
of	O
AIH	B-T047
was	O
58.6	O
years,	O
male-to-female ratio	B-T033
was	O
4:18,	O
18.2	O
%	O
of	O
participants	O
had	O
cirrhosis	B-T047
,	O
and	O
22.7	O
%	O
had	O
severe	B-T080
disease	B-T047
.	O
IL-21	B-T116
levels	B-T080
were	O
significantly	O
increased	B-T081
in	O
the	O
serum	B-T031
of	O
patients	B-T101
with	O
AIH	B-T047
compared	O
to	O
those	O
with	O
other liver diseases	B-UnknownType
and	O
controls	B-T096
(p	O
<	O
0.0001).	O
Particularly,	O
serum	B-T031
IL-21	B-T116
levels	B-T080
were	O
significantly	O
increased	B-T081
in	O
severe	B-T080
AIH	B-T047
cases	O
compared	O
to	O
non-severe	O
cases	O
(p	O
<	O
0.05).	O
Serum	B-T031
IL-21	B-T116
levels	B-T080
correlated	O
positively	O
with	O
total	O
serum	B-T031
bilirubin levels	B-T059
(r	O
=	O
0.46,	O
p	O
<	O
0.05),	O
grading of necroinflammatory activity	B-T033
(r	O
=	O
0.68,	O
p	O
<	O
0.005)	O
and	O
negatively	O
with	O
serum albumin levels	B-T034
in	O
patients	B-T101
with	O
AIH	B-T047
(r	O
=	O
-0.49,	O
p	O
<	O
0.05).	O
In	O
patients	B-T101
with	O
biochemical	B-T169
remission	B-T033
of	O
AIH	B-T047
,	O
serum	B-T031
IL-21	B-T116
levels	B-T080
remained	O
elevated	B-T080
and	O
correlated	B-T080
positively	B-T033
with	O
serum IgG levels	B-T059
(r	O
=	O
0.84,	O
p	O
<	O
0.01).	O
Expression	B-T045
of	O
Tfh-related factors	B-T116
,	O
such	O
as	O
Bcl-6	B-T116
and	O
IL-21	B-T116
,	O
in	O
peripheral blood mononuclear cells	B-T025
of	O
patients	B-T101
with	O
AIH	B-T047
was	O
significantly	O
higher	B-T080
than	O
that	O
in	O
healthy volunteers	B-T098
.	O
IL-21	B-T116
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	B-T046
and	O
severity	O
of	O
AIH	B-T047
,	O
and	O
may	O
present	O
a	O
promising	O
target	O
for	O
AIH	B-T047
therapy	B-T169
.	O

Resistance	B-T169
Exercise	B-T056
in	O
Pregnancy	B-T040
and	O
Outcome	B-T033
As	O
the	O
health benefits	B-T081
of	O
exercise	B-T056
are	O
increasingly	O
recognized,	O
the	O
traditional advice	B-T058
to	O
rest	B-T056
during	O
pregnancy	B-T040
has	O
changed	B-T169
toward	O
a	O
more	O
healthy	B-T080
and	O
active	B-T169
pregnancy	B-T040
,	O
therefore	O
different	O
forms	O
of	O
exercise	B-T056
have	O
been	O
integrated	O
into	O
the	O
life	B-T078
of	O
the	O
pregnant woman	B-T098
.	O
Although	O
the	O
benefits	B-T081
of	O
using	O
a	O
combination	B-T080
of	O
resistance	B-T169
and	O
aerobic exercises	B-T061
are	O
not	O
yet	O
determined,	O
studies	B-T062
about	O
resistance	B-T169
and	O
strengthen	O
training programs	B-T065
are	O
few	O
although	O
no adverse	B-T184
outcomes	B-T033
were	O
reported.	O

Custom	O
ocular prosthesis	B-T074
in	O
rehabilitation	B-T061
of	O
a	O
child	B-T100
operated	O
for	O
retinoblastoma	B-T191
A	O
maxillofacial prosthodontist	B-T061
forms	O
an	O
important	B-T080
link	O
in	O
the	O
interdisciplinary	O
management of a patient	B-T058
with	O
anopthalmosis	B-T019
.	O
Prosthetic management	B-T061
of	O
an	O
anopthalmic defect	B-T019
aims	O
to	O
deliver	O
a	O
well-fitting	O
ocular prosthesis	B-T074
that	O
can	O
mimic	O
the	O
original	O
eye	B-T023
as	O
closely	O
as	O
possible,	O
and	O
thus	O
restoring	O
the	O
patient's	B-T101
self-confidence	B-T041
and	O
thereby	O
rehabilitating	B-T169
them	O
in	O
the	O
society	B-T092
.	O
The	O
fabrication	B-T061
of	O
a	O
custom	O
ocular prosthesis	B-T074
is	O
a	O
demanding	O
art.	O
This	O
case report	B-T170
presents	O
a	O
simplified	O
technique	B-T169
for	O
the	O
fabrication	B-T061
of	O
a	O
custom	O
ocular prosthesis	B-T074
for	O
a	O
child	B-T100
who	O
had	O
lost	B-T169
his	O
eye	B-T023
to	O
enucleation	B-T061
following	O
retinoblastoma	B-T191
.	O
Early	O
and	O
effective	O
rehabilitation	B-T061
of	O
the	O
defect	O
goes	O
a	O
long	O
way	O
in	O
restoring	O
the	O
self-image	B-T058
of	O
a	O
child	B-T100
in	O
its	O
early	O
character	O
building	O
age.	O

Pulmonary function	B-T042
and	O
health-related quality of life	B-T078
1-	O
year	B-T079
follow up	B-T058
after	O
cardiac surgery	B-T061
Pulmonary function	B-T042
is	O
severely	B-T080
reduced	B-T080
in	O
the	O
early	B-T079
period	B-T079
after	O
cardiac surgery	B-T061
,	O
and	O
impairments	B-T046
have	O
been	O
described	O
up	O
to	O
4-6	O
months	B-T079
after surgery	B-T079
.	O
Evaluation	B-T058
of	O
pulmonary function	B-T042
in	O
a	O
longer	O
perspective	O
is	O
lacking	B-T080
.	O
In	O
this	O
prospective study	B-T062
pulmonary function	B-T042
and	O
health-related quality of life	B-T078
were	O
investigated	B-T169
1	O
year	B-T079
after	O
cardiac surgery	B-T061
.	O
Pulmonary function	B-T042
measurements	B-T169
,	O
health-related quality of life	B-T078
(	O
SF-36	B-T170
),	O
dyspnoea	B-T184
,	O
subjective	B-T080
breathing	B-T039
and	O
coughing	B-T184
ability	B-T032
and	O
pain	B-T184
were	O
evaluated	B-T058
before	B-T079
and	O
1	O
year	B-T079
after surgery	B-T079
in	O
150	O
patients	B-T101
undergoing	O
coronary artery bypass grafting	B-T061
,	O
valve surgery	B-T061
or	O
combined	O
surgery	B-T061
.	O
One	O
year	B-T079
after surgery	B-T079
the	O
forced vital capacity	B-T201
and	O
forced expiratory volume	B-T042
in	O
1	O
s	O
were	O
significantly	O
decreased	B-T081
(by	O
4-5	O
%)	O
compared	B-T052
to	O
preoperative	B-T079
values	B-T081
(p	O
<	O
0.05).	O
Saturation of peripheral oxygen	B-T042
was	O
unchanged	B-T033
1	O
year	B-T079
postoperatively	B-T079
compared	B-T052
to	O
baseline	B-T081
.	O
A	O
significantly	O
improved	B-T033
health-related quality of life	B-T078
was	O
found	O
1	O
year	B-T079
after surgery	B-T079
,	O
with	O
improvements	B-T077
in	O
all	O
eight	O
aspects	B-T080
of	O
SF-36	B-T170
(p	O
<	O
0.001).	O
Sternotomy	B-T061
-related	O
pain	B-T184
was	O
low	B-T080
1	O
year	B-T079
postoperatively	B-T079
at rest	B-T169
(median	O
0	O
[min-max;	O
0-7]),	O
while	O
taking	O
a	O
deep breath	B-T184
(0	O
[0-4])	O
and	O
while	O
coughing	B-T184
(0	O
[0-8]).	O
A	O
more	O
pronounced	O
decrease	O
in	O
pulmonary function	B-T042
was	O
associated with	B-T080
dyspnoea	B-T184
limitations	B-T169
and	O
impaired	B-T046
subjective	B-T080
breathing	B-T039
and	O
coughing	B-T184
ability	B-T032
.	O
One	O
year	B-T079
after	O
cardiac surgery	B-T061
static	B-T080
and	O
dynamic	B-T169
lung function measurements	B-T060
were	O
slightly	O
decreased	B-T081
,	O
while	O
health-related quality of life	B-T078
was	O
improved	B-T033
in	O
comparison	B-T052
to	O
preoperative	B-T079
values	B-T081
.	O
Measured	B-T080
levels	B-T080
of	O
pain	B-T184
were	O
low	B-T080
and	O
saturation of peripheral oxygen	B-T042
was	O
same	B-T080
as	O
preoperatively	B-T079
.	O

Impact	B-T080
of	O
Soil	B-T167
Salinity	B-T081
on	O
the	O
Structure	B-T082
of	O
the	O
Bacterial	B-T007
Endophytic	B-T004
Community	B-T096
Identified	B-T080
from	O
the	O
Roots	B-T002
of	O
Caliph Medic	B-T002
(	O
Medicago truncatula	B-T002
)	O
In	O
addition	O
to	O
being	O
a	O
forage crop	B-T002
,	O
Caliph medic	B-T002
(	O
Medicago truncatula	B-T002
)	O
is	O
also	O
a	O
model legume plant	B-T062
and	O
is	O
used	O
for	O
research	O
focusing	O
on	O
the	O
molecular characterization	B-T052
of	O
the	O
interaction	B-T169
between	O
rhizobia	B-T007
and	O
plants	B-T002
.	O
However,	O
the	O
endophytic microbiome	B-T001
in	O
this	O
plant	B-T002
is	O
poorly	O
defined.	O
Endophytic	B-T004
bacteria	B-T007
play	O
a	O
role	O
in	O
supplying	O
plants	B-T002
with	O
the	O
basic	O
requirements	B-T169
necessary	O
for	O
growth	B-T040
and	O
development	B-T040
.	O
Moreover,	O
these	O
bacteria	B-T007
also	O
play	O
a	O
role	O
in	O
the	O
mechanism	B-T169
of	O
salinity stress	B-T070
adaptation	B-T038
in	O
plants	B-T002
.	O
As	O
a	O
prelude	O
to	O
the	O
isolation	B-T059
and	O
utilization	B-T169
of	O
these	O
bacteria	B-T007
in	O
Caliph medic	B-T002
farming	B-T082
,	O
41	O
bacterial	B-T007
OTUs	B-T185
were	O
identified	B-T080
in	O
this	O
project	O
from	O
within	O
the	O
interior	B-T082
of	O
the	O
roots	B-T002
of	O
this	O
plant	B-T002
by	O
pyrosequencing	B-T059
of	O
the	O
small ribosomal subunit gene	B-T028
(	O
16S rDNA	B-T028
)	O
using	O
a	O
cultivation-independent approach	B-T059
.	O
In	O
addition,	O
the	O
differential	B-T080
abundance	B-T080
of	O
these	O
bacteria	B-T007
was	O
studied	O
following	O
exposure	O
of	O
the	O
plants	B-T002
to	O
salinity stress	B-T070
.	O
About	O
29,064	O
high-quality reads	B-T081
were	O
obtained	O
from	O
the	O
sequencing	B-T059
of	O
six	O
libraries	B-T028
prepared	O
from	O
control	B-T024
and	O
salinity-treated tissues	B-T024
.	O
Statistical analysis	B-T062
revealed	O
that	O
the	O
abundance	B-T080
of	O
~70%	O
of	O
the	O
OTUs	B-T185
was	O
significantly	O
(p	O
≤	O
0.05)	O
altered	O
in	O
roots	B-T002
that	O
were	O
exposed to	B-T080
salinity stress	B-T070
.	O
Sequence analysis	B-T059
showed	O
a	O
similarity	O
between	O
some	O
of	O
the	O
identified	B-T080
species	B-T185
and	O
other,	O
known,	O
growth-promoting bacteria	B-T007
,	O
marine	B-T001
and	O
salt-stressed soil-borne bacteria	B-T007
,	O
and	O
nitrogen-fixing bacterial	B-T007
isolates	B-T123
.	O
Determination	O
of	O
the	O
amendments	O
to	O
the	O
bacteria	B-T007
l	O
community	B-T096
due	O
to	O
salinity stress	B-T070
in	O
Caliph medic	B-T002
provides	O
a	O
crucial	O
step	O
toward	O
developing	O
an	O
understanding	O
of	O
the	O
association	B-T080
of	O
these	O
endophytes	B-T004
,	O
under	O
salt stress conditions	B-T070
,	O
in	O
this	O
model plant	B-T062
.	O
To	O
provide	O
direct	O
evidence	B-T078
regarding	O
their	O
growth promoting activity	B-T052
,	O
a	O
group	B-T078
of	O
endophytic	B-T004
bacteria	B-T007
were	O
isolated	B-T169
from	O
inside	O
of	O
plant roots	B-T002
using	O
a	O
cultivation-dependent approach	B-T059
.	O
Several	O
of	O
these	O
isolates	B-T123
were	O
able	O
to	O
produce	O
ACC-deaminase	B-T116
,	O
ammonia	B-T121
and	O
IAA	B-T109
;	O
and	O
to	O
solubilize	B-T169
Zn+2	B-T121
and	O
PO4-3	B-T121
.	O
This	O
data	B-T078
is	O
consistent	O
with	O
the	O
predicted	O
occurrence	B-T079
(based	O
on	O
cultivation-independent techniques	B-T059
)	O
of	O
these	O
bacteria	B-T007
and	O
provides	O
some	O
insight	O
into	O
the	O
importance	O
of	O
the	O
endophytic	B-T004
bacteria	B-T007
in	O
Caliph medic	B-T002
when	O
grown	O
under	O
normal	B-T080
and	O
saline	B-T167
conditions	B-T080
.	O

Eliminating	O
Cancer Stem Cells	B-T025
in	O
CML	B-T191
with	O
Combination	O
Transcriptional	B-T045
Therapy	B-T061
Leukemia	B-T191
stem cells	B-T025
(	O
LSCs	B-T025
)	O
are	O
resistant	O
to	O
current	O
therapies	B-T061
used	O
to	O
treat	O
chronic myeloid leukemia	B-T191
(	O
CML	B-T191
).	O
Abraham	O
et	O
al.	O
(2016)	O
have	O
identified	O
a	O
molecular network	B-T044
critical	B-T169
for	O
CML	B-T191
LSC	B-T025
survival	B-T043
and	O
propose	O
that	O
simultaneously	O
targeting	O
two	O
of	O
their	O
major	O
transcriptional regulators	B-T116
,	O
p53	B-T028
and	O
c-Myc	B-T116
,	O
may	O
facilitate	O
their	O
eradication	B-T045
.	O

Crocetin	B-T109
improves	B-T033
the	O
quality	B-T080
of	O
in vitro	B-T080
-	O
produced	B-T169
bovine	B-T015
embryos	B-T018
:	O
Implications	O
for	O
blastocyst development	B-T039
,	O
cryotolerance	B-T080
,	O
and	O
apoptosis	B-T043
The	O
aim	O
of	O
this	O
work	O
was	O
to	O
assess	B-T058
the	O
effect	B-T080
of	O
supplementation	B-T061
of	O
bovine	B-T015
culture medium	B-T130
with	O
the	O
natural antioxidant	B-T121
crocetin	B-T109
on	O
in vitro	B-T080
blastocyst development	B-T039
and	O
quality	B-T080
.	O
This	O
was	O
evaluated	B-T058
as	O
cryotolerance	B-T080
,	O
apoptosis index	B-T170
,	O
and	O
total cells number	B-T059
and	O
allocation	B-T052
.	O
Abattoir	B-T073
-derived	O
oocytes	B-T025
were	O
matured	B-T079
and	O
fertilized	B-T169
in vitro	B-T080
according	O
to	O
standard procedure	B-T077
.	O
Twenty	O
hours	B-T079
after	O
IVF	B-T061
,	O
presumptive	B-T080
zygotes	B-T018
were	O
cultured	B-T059
in	O
synthetic oviduct	B-T023
fluid medium	B-T167
,	O
supplemented	O
with	O
0,	O
1,	O
2.5,	O
and	O
5	O
μM	O
crocetin	B-T109
(experiment	O
1)	O
at	O
39	O
°C	O
under	O
humidified air	B-T061
with	O
5%	O
CO2	B-T123
,	O
7%	O
O2	B-T121
,	O
and	O
88%	O
N2	B-T123
.	O
On	O
Day	B-T079
7,	O
embryo yields	B-T081
were	O
assessed	B-T052
and	O
the	O
blastocysts	B-T018
were	O
vitrified	O
by	O
Cryotop method	B-T170
in	O
16.5%	O
ethylene glycol	B-T109
,	O
16.5%	O
DMSO	B-T109
,	O
and	O
0.5	O
M	O
sucrose	B-T109
.	O
Finally,	O
blastocysts	B-T018
produced	O
on	O
Day	B-T079
8	O
in	O
the	O
absence	B-T169
(	O
control	B-T096
)	O
and	O
presence	B-T033
of	O
1	O
μM	O
crocetin	B-T109
were	O
used	O
for	O
terminal deoxynucleotidyl transferase-mediated dUTP nick end labelling	B-T063
and	O
differential staining	B-T059
to	O
evaluate	B-T058
,	O
respectively,	O
the	O
apoptotic rate	B-T081
and	O
the	O
allocation	B-T052
of	O
cells	B-T025
into	O
inner cell mass	B-T018
(	O
ICM	B-T018
)	O
and	O
trophectoderm	B-T018
(	O
TE	B-T018
)	O
lineages	B-T077
(experiment	O
2).	O
Embryo development	B-T042
was	O
higher	O
in	O
the	O
1	O
μM	O
crocetin group	B-T078
compared	O
to	O
the	O
control	B-T096
,	O
both	O
in	O
terms	O
of	O
total	B-T080
embryo	B-T018
output	B-T033
(37.7	O
±	O
4.2%,	O
52.9	O
±	O
6.3%,	O
40.9	O
±	O
7.6%,	O
and	O
42.4	O
±	O
8.7%,	O
respectively,	O
with	O
0,	O
1,	O
2.5,	O
and	O
5	O
μM;	O
P	O
<	O
0.01)	O
and	O
grade 1	B-T185
and	O
2	B-T185
blastocysts	B-T018
(33.6	O
±	O
4.9%,	O
46.1	O
±	O
7.3%,	O
37.8	O
±	O
7.9%,	O
and	O
39.4	O
±	O
7.9%,	O
respectively,	O
with	O
0,	O
1,	O
2.5,	O
and	O
5	O
μM;	O
P	O
<	O
0.05).	O
Moreover,	O
the	O
percentage	B-T078
of	O
fast-developing embryos	B-T042
increased	B-T081
in	O
1	O
μM	O
crocetin group	B-T078
compared	O
to	O
the	O
control	B-T096
(23.4	O
±	O
4.7%,	O
32.7	O
±	O
6.6%,	O
27.2	O
±	O
6.6%,	O
and	O
30.1	O
±	O
7.2%,	O
respectively,	O
with	O
0,	O
1,	O
2.5,	O
and	O
5	O
μM;	O
P	O
<	O
0.05).	O
In	O
addition,	O
the	O
enrichment of culture medium	B-T130
with	O
1	O
μM	O
crocetin	B-T109
improved	B-T033
embryo	B-T018
cryotolerance	B-T080
compared	O
to	O
the	O
control	B-T096
,	O
as	O
indicated	O
by	O
higher	O
hatching	B-T040
rates	B-T081
recorded	O
after	O
48	O
hours	B-T079
postwarming culture	B-T130
(46.5%	O
vs.	O
60.4%;	O
P	O
<	O
0.05).	O
Furthermore,	O
1	O
μM	O
crocetin	B-T109
decreased	B-T081
both	O
the	O
average	O
number	O
(9.9	O
±	O
0.4	O
vs.	O
7.1	O
±	O
0.3)	O
and	O
the	O
percentage	B-T078
of	O
apoptotic	B-T080
cells	B-T025
(7.1	O
±	O
0.4	O
vs.	O
4.2	O
±	O
0.2)	O
in	O
blastocysts	B-T018
compared	O
to	O
the	O
control	B-T096
(P	O
<	O
0.01).	O
However,	O
no	O
differences	O
were	O
recorded	O
in	O
the	O
average	O
number	O
of	O
ICM	B-T018
,	O
TE	B-T018
,	O
and	O
total	B-T080
total	B-T080
cells	B-T025
between	O
1	O
μM	O
crocetin	B-T109
and	O
control	B-T096
groups.	O
In	O
conclusion,	O
the	O
enrichment of bovine culture medium	B-T130
with	O
1	O
μM	O
crocetin	B-T109
increased	B-T081
both	O
blastocyst yield	B-T081
and	O
quality	B-T080
,	O
as	O
indicated	O
by	O
the	O
improved	B-T033
chronology	B-T170
of	O
embryo development	B-T042
,	O
increased	B-T081
resistance	B-T169
to	O
cryopreservation	B-T059
,	O
and	O
reduced incidence	B-T081
of	O
apoptosis	B-T043
.	O

Matrix solid-phase dispersion	B-T059
combined	O
to	O
liquid chromatography-tandem mass spectrometry	B-T059
for	O
the	O
determination	B-T059
of	O
paraben	B-T109
preservatives	B-T122
in	O
mollusks	B-T204
A	O
method for the extraction	B-T170
and	O
determination	B-T059
of	O
seven	O
parabens	B-T109
,	O
esters	B-T109
of	O
4-hydroxybenzoic acid	B-T109
,	O
widely	O
used	O
as	O
preservatives	B-T122
in	O
personal care products	B-T167
,	O
pharmaceuticals	B-T121
,	O
etc.,	O
and	O
two	O
chlorinated derivatives	B-T109
(	O
mono-	B-T109
and	O
di-chloro methyl paraben	B-T109
)	O
from	O
mollusk	B-T204
samples	B-T077
was	O
developed	O
by	O
combining	O
matrix solid-phase dispersion	B-T059
(	O
MSPD	B-T059
)	O
and	O
liquid chromatography-tandem mass spectrometry	B-T059
.	O
MSPD parameters	B-T170
,	O
such	O
as	O
solvent	B-T130
,	O
solid support	B-T130
and	O
clean-up sorbent	B-T130
,	O
were	O
optimized	B-T052
.	O
Besides,	O
since	O
blank	O
problems	O
were	O
observed	O
for	O
some	O
parabens	B-T109
,	O
these	O
were	O
investigated	B-T169
and	O
blanks	O
were	O
tackled	O
by	O
precleaning	B-T052
all	O
sorbents	B-T130
prior	O
to	O
use.	O
Under	O
final	O
conditions,	O
0.5g	O
of	O
freeze-dried	B-T059
mollusk	B-T204
were	O
dispersed	B-T082
with	O
1.2g	O
of	O
silica	B-T122
and	O
packed	B-T052
into	O
a	O
cartridge	B-T170
containing	O
3g	O
of	O
C18	B-T109
,	O
as	O
on-line	O
clean-up sorbent	B-T130
.	O
This	O
cartridge	B-T170
was	O
eluted	O
with	O
10mL	O
of	O
acetonitrile	B-T109
,	O
evaporated	B-T070
and	O
reconstituted	B-T052
in	O
methanol	B-T109
for	O
analysis	B-T062
.	O
In	O
the	O
validation	B-T062
stage,	O
successful	O
linearity	O
(R(2)>0.999),	O
recoveries	B-T052
(between	O
71	O
and	O
117%	O
for	O
most	O
analytes	B-T167
),	O
precision	B-T080
(RSD	O
lower	O
than	O
21%)	O
and	O
limits of detection	B-T081
and	O
quantification	B-T081
(	O
LOD	B-T081
and	O
LOQ	B-T062
,	O
lower	O
than	O
0.4	O
and	O
1.4ngg(-1)	O
dry weight	B-T081
respectively)	O
levels	B-T080
were	O
achieved.	O
Finally,	O
the	O
new	O
methodology	B-T170
was	O
applied	O
to	O
mussel	B-T204
,	O
clam	B-T204
and	O
cockle	B-T204
samples	B-T077
.	O
Methyl paraben	B-T109
was	O
above	O
the	O
LOQ	B-T081
in	O
five	O
of	O
the	O
six	O
samples	B-T077
(not	O
found	O
in	O
one	O
clam	B-T204
sample	B-T077
)	O
at	O
concentrations	B-T081
up	O
to	O
7ngg(-1)	O
dry weight	B-T081
.	O
Ethyl paraben	B-T109
was	O
found	O
above	O
the	O
LOQ	B-T081
in	O
mussel	B-T204
and	O
cockle	B-T204
samples	B-T077
at	O
a	O
concentration level	B-T081
around	O
0.3ngg(-1).	O
n-Propyl paraben	B-T109
was	O
only	O
above	O
the	O
LOQ	B-T081
in	O
one	O
mussel	B-T204
sample	B-T077
.	O

Two-stage	O
reconstructive	B-T061
overlapping stent	B-T074
LEO+	B-T074
and	O
SILK	B-T074
for	O
treatment	B-T061
of	O
intracranial	B-T029
circumferential	B-T082
fusiform aneurysms	B-T190
in	O
the	O
posterior	B-T082
circulation	B-T039
Intracranial	B-T029
circumferential	B-T082
fusiform aneurysms	B-T190
of	O
the	O
posterior	B-T082
circulation	B-T039
involving	O
arterial branches	B-T023
or	O
perforating	B-T033
vessels	B-T023
vessels	B-T023
are	O
difficult	B-T080
to	O
treat	B-T169
.	O
This	O
article	O
shows	O
an	O
endovascular	B-T029
reconstruction technique	B-T061
not	O
yet	O
described,	O
using	O
a	O
telescoping self-expandable stent	B-T074
(	O
LEO+	B-T074
)	O
and	O
flow-diverter device	B-T074
(	O
SILK	B-T074
)	O
at	O
different	B-T080
surgical times	B-T079
.	O
Two	O
patients	B-T101
with	O
circumferential	B-T082
fusiform aneurysm	B-T190
,	O
one	O
being	O
an	O
aneurysm	B-T047
of	O
the	O
segments	O
P2	O
and	O
P3	O
of	O
the	O
posterior cerebral artery	B-T023
,	O
diagnosed	B-T033
after	O
a	O
headache	B-T184
,	O
and	O
the	O
other	O
a	O
partially	B-T081
thrombosed aneurysm	B-T047
of	O
the	O
lower	B-T029
basilar artery	B-T023
,	O
diagnosed	B-T033
following	O
ischemia	B-T046
of	O
the	O
brain stem	B-T023
.	O
Endovascular	B-T029
treatment	B-T061
was	O
performed	O
by	O
means	O
of	O
a	O
vascular	B-T023
reconstruction technique	B-T061
that	O
used	O
at	O
different	B-T080
surgical times	B-T079
:	O
overlapping; a telescoped self-expandable stent	B-T061
,	O
LEO+	B-T074
;	O
and	O
a	O
flow-diverter device	B-T074
,	O
SILK	B-T074
.	O
Angiographic	B-T060
control	B-T080
was	O
carried	O
out	O
at	O
6	O
and	O
12	O
months	B-T079
,	O
to	O
evaluate	O
arterial patency	B-T201
,	O
flow	B-T070
maintenance	B-T052
in	O
the	O
arterial branches	B-T023
and	O
perforating	B-T033
vessels	B-T023
,	O
and	O
thrombosis	B-T046
of	O
the	O
aneurysm	B-T047
.	O
The	O
combined	B-T080
use	O
at	O
different	B-T080
surgical times	B-T079
of	O
the	O
self-expandable stent	B-T074
and	O
flow-diverter device	B-T074
was	O
technically	O
successful	B-T080
in	O
both	O
patients	B-T101
.	O
There	O
were	O
no	O
complications	B-T046
during	O
the	O
procedure	B-T169
,	O
nor	O
in	O
the	O
long-term	B-T079
follow-up	B-T058
with	O
full	O
arterial	B-T023
vascular	B-T023
reconstruction	B-T061
,	O
maintenance	B-T052
of	O
cerebral perfusion	B-T061
and	O
complete	B-T080
aneurysm	B-T047
occlusion	B-T169
at	O
the	O
6-	O
and	O
12-	O
month	B-T079
angiographic	B-T060
follow-up	B-T058
.	O
There	O
was	O
no	O
aneurysm recanalization	B-T037
nor	O
intra-stent stenosis	B-T046
.	O
Circumferential	B-T082
fusiform aneurysm	B-T190
of	O
the	O
posterior	B-T082
circulation	B-T039
involving	O
arterial branches	B-T023
or	O
perforating	B-T033
vessels	B-T023
to	O
the	O
brain stem	B-T023
may	O
be	O
treated	B-T169
with	O
this	O
arterial	B-T023
reconstruction technique	B-T061
at	O
different	B-T080
surgical times	B-T079
,	O
using	O
the	O
self-expandable stent	B-T074
called	O
LEO+	B-T074
and	O
the	O
flow-diverter device	B-T074
SILK	B-T074
,	O
minimizing	B-T080
the	O
risk	B-T078
of	O
complications	B-T046
and	O
failure	B-T169
of	O
the	O
endovascular	B-T029
technique	B-T061
,	O
with	O
the	O
potential	B-T080
for	O
arterial reconstruction	B-T061
with	O
thrombosis	B-T046
of	O
the	O
aneurysmatic sac	B-T047
,	O
as	O
well	O
as	O
flow	B-T070
maintenance	B-T052
in	O
the	O
eloquent arteries	B-T023
,	O
in	O
this	O
type	O
of	O
cerebral aneurysm	B-T047
.	O

Polysaccharide	B-T109
-	O
Specific	B-T080
Memory B Cells	B-T025
Predict	O
Protection	B-T033
against	O
Experimental	B-T080
Human	B-T016
Pneumococcal	B-T007
Carriage	B-T033
We	O
have	O
previously	B-T079
demonstrated	O
that	O
experimental	B-T080
pneumococcal	B-T007
carriage	B-T033
enhances	B-T052
immunity	B-T039
and	O
protects	B-T033
healthy	B-T080
adults	B-T100
against	B-T080
carriage	B-T033
reacquisition	B-T052
after	O
rechallenge	B-T061
with	O
a	O
homologous	B-T032
strain	B-T001
.	O
To	O
investigate	O
the	O
role	O
of	O
naturally	B-T169
acquired	B-T080
pneumococcal protein	B-T116
and	O
polysaccharide	B-T109
(	O
PS	B-T109
)-	O
specific	B-T080
immunity	B-T039
in	O
protection	B-T033
against	B-T080
carriage	B-T033
acquisition	B-T052
using	O
a	O
heterologous challenge	B-T039
model.	O
We	O
identified	O
healthy volunteers	B-T098
that	O
were	O
naturally	B-T169
colonized	B-T025
with	O
pneumococcus	B-T007
and,	O
after	O
clearance	B-T080
of	O
their	O
natural	B-T169
carriage	B-T033
episode	B-T079
,	O
challenged	O
them	O
with	O
a	O
heterologous	B-T032
6B strain	B-T007
.	O
In	O
another	O
cohort	B-T098
of	O
volunteers	B-T098
we	O
assessed	O
6BPS	B-T109
-	O
specific	B-T080
,	O
PspA	B-T116
-	O
specific	B-T080
,	O
and	O
PspC	B-T116
-	O
specific	B-T080
IgG	B-T116
and	O
IgA	B-T116
plasma	B-T025
and	O
memory B-cell populations	B-T025
before	B-T079
and	O
7,	O
14,	O
and	O
35	O
days	O
after	B-T079
experimental	B-T080
pneumococcal	B-T007
inoculation	B-T061
.	O
Heterologous challenge	B-T039
with	O
6B	B-T007
resulted	O
in	O
50%	O
carriage	B-T033
among	O
volunteers	B-T098
with	O
previous	B-T079
natural	B-T169
pneumococcal	B-T007
carriage	B-T033
.	O
Protection	B-T033
from	O
carriage	B-T033
was	O
associated with	B-T080
a	O
high	B-T080
number	O
of	O
circulating	B-T169
6BPS	B-T109
IgG	B-T116
-	O
secreting	B-T043
memory B cells	B-T025
at	O
baseline	B-T081
.	O
There	O
were	O
no	O
associations	B-T080
between	O
protection	B-T033
from	O
carriage	B-T033
and	O
baseline	B-T081
levels	B-T080
of	O
6BPS	B-T109
IgG	B-T116
in	O
serum	B-T031
or	O
nasal wash	B-T031
,	O
PspA	B-T116
-	O
specific	B-T080
,	O
or	O
PspC	B-T116
-	O
specific	B-T080
memory B cells	B-T025
or	O
plasma cells	B-T025
.	O
In	O
volunteers	B-T098
who	O
did	O
not develop	B-T033
carriage	B-T033
,	O
the	O
number	O
of	O
circulating	B-T169
6BPS	B-T109
memory B cells	B-T025
decreased	B-T081
and	O
the	O
number	O
of	O
6BPS	B-T109
plasma cells	B-T025
increased	B-T081
postinoculation	B-T033
.	O
Our	O
data	O
indicate	O
that	O
naturally	B-T169
acquired	B-T080
PS	B-T109
-	O
specific	B-T080
memory B cells	B-T025
,	O
but	O
not levels	B-T033
of	O
circulating	B-T169
IgG	B-T116
at	O
time	O
of	O
pneumococcal	B-T007
exposure	B-T080
,	O
are	O
associated with	B-T080
protection	B-T033
against	B-T080
carriage	B-T033
acquisition	B-T052
.	O

Hounsfield unit	B-T081
recovery	B-T052
in	O
clinical	B-T080
cone beam CT	B-T060
images	B-T078
of	O
the	O
thorax	B-T029
acquired	O
for	O
image guided radiation therapy	B-T061
A	O
comprehensive	B-T080
artefact	B-T068
correction	B-T169
method	B-T170
for	O
clinical	B-T080
cone beam CT	B-T060
(	O
CBCT	B-T060
)	O
images	B-T078
acquired	O
for	O
image guided radiation therapy	B-T061
(	O
IGRT	B-T061
)	O
on	O
a	O
commercial	O
system	O
is	O
presented.	O
The	O
method	B-T170
is	O
demonstrated	O
to	O
reduce	B-T080
artefacts	B-T068
and	O
recover	B-T052
CT	B-T060
-like	O
Hounsfield units	B-T081
(	O
HU	B-T081
)	O
in	O
reconstructed	B-T066
CBCT	B-T060
images	B-T078
of	O
five	O
lung cancer	B-T191
patients	B-T101
.	O
Projection image	B-T078
based	O
artefact	B-T068
corrections	B-T169
of	O
image lag	B-T068
,	O
detector scatter	B-T068
,	O
body scatter	B-T068
and	O
beam hardening	B-T033
are	O
described	O
and	O
applied	O
to	O
CBCT	B-T060
images	B-T078
of	O
five	O
lung cancer	B-T191
patients	B-T101
.	O
Image quality	B-T080
is	O
evaluated	B-T058
through	O
visual	B-T169
appearance	B-T080
of	O
the	O
reconstructed	B-T066
images	B-T078
,	O
HU	B-T081
-correspondence	O
with	O
the	O
planning	O
CT	B-T060
images	B-T078
,	O
and	O
total volume	B-T081
HU	B-T081
error	B-T080
.	O
Artefacts	B-T068
are	O
reduced	B-T080
and	O
CT	B-T060
-like	O
HUs	B-T081
are	O
recovered	B-T052
in	O
the	O
artefact	B-T068
corrected	B-T080
CBCT	B-T060
images	B-T078
.	O
Visual inspection	B-T058
confirms	B-T033
that	O
artefacts	B-T068
are	O
indeed	O
suppressed	B-T169
by	O
the	O
proposed	O
method	B-T170
,	O
and	O
the	O
HU	B-T081
root mean square	B-T081
difference	B-T081
between	O
reconstructed	B-T066
CBCTs	B-T060
and	O
the	O
reference	B-T077
CT	B-T060
images	B-T078
are	O
reduced	B-T080
by	O
31%	O
when	O
using	O
the	O
artefact	B-T068
corrections	B-T169
compared	B-T052
to	O
the	O
standard	B-T080
clinical	B-T080
CBCT	B-T060
reconstruction	B-T066
.	O
A	O
versatile	O
artefact	B-T068
correction	B-T169
method	B-T170
for	O
clinical	B-T080
CBCT	B-T060
images	B-T078
acquired	O
for	O
IGRT	B-T061
has	O
been	O
developed.	O
HU	B-T081
values	B-T081
are	O
recovered	B-T052
in	O
the	O
corrected	B-T080
CBCT	B-T060
images	B-T078
.	O
The	O
proposed	O
method	B-T170
relies	O
on	O
post processing	B-T170
of	O
clinical	B-T080
projection images	B-T078
,	O
and	O
does	O
not	O
require	O
patient	B-T101
specific	B-T080
optimisation	B-T052
.	O
It	O
is	O
thus	O
a	O
powerful	O
tool	B-T170
for	O
image	B-T078
quality	B-T080
improvement	B-T077
of	O
large	B-T081
numbers	B-T081
of	O
CBCT	B-T060
images	B-T078
.	O

Risk Factors	B-T033
for	O
Infection	B-T046
After	O
Knee Arthroscopy	B-T060
:	O
Analysis	B-T062
of	O
595,083	O
Cases	B-T169
From	O
3	O
United States	B-T083
Databases	B-T170
To	O
identify	B-T080
and	O
quantify	B-T081
patient-	B-T033
and	O
procedure-related risk factors	B-T033
for	O
post-arthroscopic	B-T079
knee infections	B-T047
using	O
a	O
large	O
dataset	B-T170
.	O
An	O
administrative health care database	B-T170
including	O
8	O
years	B-T079
of	O
records	O
from	O
2	O
large	O
commercial	O
insurers	B-T092
and	O
Medicare	B-T064
(a	O
5%	O
random sample	B-T062
)	O
was	O
queried	O
to	O
identify	O
all	O
knee arthroscopies	B-T060
performed	B-T169
on	O
patients	B-T101
aged	B-T032
at	O
least	O
15	O
years	B-T079
using	O
Current Procedural Terminology (CPT) codes	B-T170
.	O
Each	O
CPT code	B-T170
was	O
designated	O
as	O
a	O
high-	B-T058
or	O
low-complexity procedure	B-T058
,	O
with	O
the	O
former	O
typically	O
requiring	O
accessory	O
incisions	B-T061
or	O
increased	O
operative time	B-T079
.	O
Deep	O
infections	B-T046
were	O
identified	O
by	O
a	O
CPT code	B-T170
for	O
incision	B-T061
and	O
drainage	B-T061
within	O
90	O
days	B-T079
of	O
surgery	B-T169
.	O
Superficial infections	B-T046
were	O
identified	O
by	O
International Classification of Diseases, Ninth Revision infection codes	B-T170
without	O
any	O
record	B-T170
of	O
incision	B-T061
and	O
drainage	B-T061
.	O
Patients	B-T101
were	O
compared	O
based	O
on	O
age	B-T032
,	O
sex	B-T032
,	O
body mass index	B-T201
,	O
tobacco use	B-T055
,	O
presence	B-T080
of	O
diabetes	B-T047
,	O
and	O
Charlson Comorbidity Index	B-T081
.	O
A	O
total	O
of	O
526,537	O
patients	B-T101
underwent	O
595,083	O
arthroscopic knee procedures	B-T060
.	O
Deep	O
postoperative infections	B-T046
occurred	O
at	O
a	O
rate	O
of	O
0.22%.	O
Superficial infections	B-T046
occurred	O
at	O
a	O
rate	O
of	O
0.29%.	O
Tobacco use	B-T055
and	O
morbid obesity	B-T047
were	O
the	O
largest	O
risk factors	B-T033
for	O
deep	B-T046
and	O
superficial infections	B-T046
,	O
respectively	O
(P	O
<	O
.001;	O
relative risk	B-T081
of	O
1.90	O
and	O
2.19,	O
respectively).	O
There	O
were	O
also	O
higher	O
infection rates	B-T046
among	O
patients	B-T101
undergoing	O
relatively	O
high-complexity arthroscopies	B-T060
,	O
men	B-T098
,	O
obese	B-T047
patients	B-T101
,	O
diabetic	B-T047
patients	B-T101
,	O
and	O
younger	B-T079
patients	B-T101
(in	O
order	O
of	O
decreasing	O
relative risk	B-T081
).	O
Increased	O
Charlson Comorbidity Index	B-T081
was	O
associated with	B-T080
superficial	B-T046
and	O
total infections	B-T046
(P	O
<	O
.001).	O
Post-arthroscopic	B-T079
knee infections	B-T047
were	O
more	O
frequent	O
among	O
morbidly obese	B-T047
patients	B-T101
,	O
tobacco users	B-T033
,	O
patients	B-T101
undergoing	O
relatively	O
complex procedures	B-T058
,	O
men	B-T098
,	O
obese patients	B-T101
,	O
diabetic patients	B-T101
,	O
relatively	O
young patients	B-T101
,	O
and	O
patients	B-T101
with	O
increased	O
comorbidity	B-T078
burdens	O
in	O
this	O
study	O
population	B-T081
.	O
This	O
knowledge	O
may	O
allow	O
more	O
informed	O
preoperative counseling	B-T058
,	O
aid surgeons	B-T097
in	O
patient selection	B-T062
,	O
and	O
facilitate	O
infection prevention	B-T061
by	O
targeting	O
individuals	B-T098
with	O
higher	O
inherent risk	B-T078
.	O
Level	O
IV,	O
cross-sectional study	B-T062
.	O

Association	B-T080
of	O
prenatal	B-T100
and	O
early	O
life	O
exposure to	B-T080
tetrachloroethylene	B-T109
(	O
PCE	B-T109
)	O
with	O
polycystic ovary syndrome	B-T047
and	O
other	O
reproductive disorders	B-T047
in	O
the	O
cape cod	B-T083
health study	B-T062
:	O
A	O
retrospective cohort study	B-T062
Tetrachloroethylene	B-T109
(	O
PCE	B-T109
)	O
is	O
an	O
organic	B-T080
lipophilic	B-T081
solvent	B-T130
with	O
possible	O
neuroendocrine	B-T022
toxicity	B-T080
.	O
The	O
objective	B-T170
of	O
this	O
study	B-T062
was	O
to	O
determine	O
the	O
association	B-T080
of	O
prenatal	B-T100
and	O
early childhood	B-T079
exposure to	B-T080
PCE	B-T109
-	O
contaminated	B-T169
drinking water	B-T167
and	O
development	B-T039
of	O
adult-onset	B-T033
Polycystic Ovary Syndrome	B-T047
(	O
PCOS	B-T047
),	O
endometriosis	B-T047
,	O
difficulty conceiving	B-T033
and	O
miscarriage	B-T046
.	O
Five-hundred	O
exposed	B-T080
and	O
331	O
unexposed	B-T098
female	B-T032
participants	B-T098
born	O
between	O
1969	O
and	O
1983	O
completed	B-T080
questionnaires	B-T170
on	O
demographic	B-T078
and	O
lifestyle	B-T054
characteristics	B-T080
,	O
and	O
reproductive disorders	B-T047
.	O
Residential locations	B-T082
from	O
the	O
prenatal	B-T100
period	B-T079
through	O
five	O
years	O
of	O
age	B-T032
were	O
used	O
to	O
estimate	B-T081
early	O
life	O
PCE	B-T109
exposure	B-T080
with	O
water modeling software	B-T073
.	O
For	O
any	O
early	O
life	O
exposure to	B-T080
PCE	B-T109
,	O
the	O
adjusted risk ratio	B-T081
for	O
PCOS	B-T047
was	O
0.9	O
(95%	O
CI	B-T081
:	O
0.5-1.6).	O
No	O
statistically significan	B-T081
t	O
associations	B-T080
were	O
observed	B-T169
for	O
increasing	B-T169
levels	B-T080
of	O
exposure	B-T080
with	O
PCOS	B-T047
or	O
the	O
other	O
reproductive disorders	B-T047
.	O
No	O
meaningful	O
associations	B-T080
were	O
found	B-T033
among	O
adult	B-T100
women	B-T098
with	O
early	O
life	O
exposure to	B-T080
PCE	B-T109
-	O
contaminated	B-T169
drinking water	B-T167
and	O
adult-onset	B-T033
reproductive disorders	B-T047
.	O

Host plant	B-T002
affects	O
the	O
sexual attractiveness	B-T001
of	O
the	O
female	B-T032
white-spotted longicorn beetle	B-T204
,	O
Anoplophora malasiaca	B-T204
Anoplophora malasiaca	B-T204
(	O
Coleoptera	B-T204
:	O
Cerambycidae	B-T204
)	O
is	O
a	O
serious	O
pest	O
that	O
destroys	O
various	O
landscape	B-T082
and	O
crop	B-T002
trees	B-T002
in	O
Japan	B-T083
.	O
We	O
evaluated	O
the	O
precopulatory	B-T080
responses	B-T032
of	O
three	O
different	O
A. malasiaca	B-T204
populations	B-T098
collected	O
from	O
mandarin orange	B-T002
,	O
willow	B-T002
and	O
blueberry trees	B-T002
.	O
Most	O
of	O
the	O
males	B-T032
accepted	O
mates	O
from	O
within	O
the	O
same	O
host plant	B-T002
population	B-T098
as	O
well	O
as	O
females	B-T032
from	O
the	O
willow	B-T002
and	O
blueberry	B-T002
populations	B-T081
.	O
However,	O
significant	O
number	O
of	O
males	B-T032
from	O
the	O
blueberry	B-T002
and	O
willow	B-T002
populations	B-T098
rejected	O
females	B-T032
from	O
the	O
mandarin orange	B-T002
population	B-T081
immediately	O
after	O
touching	O
them	O
with	O
their	O
antennae	B-T023
.	O
Because	O
all	O
three	O
of	O
the	O
female	B-T032
populations	B-T098
produced	O
contact	O
sex pheromones	B-T123
on	O
their	O
elytra	B-T023
,	O
the	O
females	B-T032
of	O
the	O
mandarin orange	B-T002
population	B-T081
were	O
predicted	O
to	O
possess	O
extra	O
chemicals	B-T103
that	O
repelled	O
the	O
males	B-T032
of	O
the	O
other	O
two	O
populations	B-T081
.	O
β-Elemene	B-T109
was	O
identified	O
as	O
a	O
key	O
component	O
that	O
was	O
only	O
found	O
in	O
mandarin orange	B-T002
-fed	O
females	B-T032
and	O
induced	O
a	O
rejection	B-T080
response	B-T032
in	O
willow	B-T002
-fed	O
males	B-T032
.	O
Our	O
results	O
represent	O
the	O
first	O
example	O
of	O
a	O
female	B-T032
-acquired	O
repellent	B-T131
against	O
conspecific	O
males	B-T032
of	O
different	O
host plant	B-T002
populations	B-T081
,	O
indicating	O
that	O
the	O
host plant	B-T002
greatly	O
affects	O
the	O
female's	B-T032
sexual attractiveness	B-T001
.	O

Molecular	B-T080
detection	B-T061
of	O
infection	B-T046
homogeneity	B-T080
and	O
impact	B-T080
of	O
miltefosine	B-T109
treatment	B-T169
in	O
a	O
Syrian golden hamster	B-T015
model	O
of	O
Leishmania donovani	B-T204
and	O
L. infantum	B-T204
visceral leishmaniasis	B-T047
Control	B-T169
of	O
visceral leishmaniasis	B-T047
caused	O
by	O
Leishmania infantum	B-T204
and	O
Leishmania donovani	B-T204
primarily	O
relies	O
on	O
chemotherapy	B-T061
using	O
an	O
increasingly	O
compromised	B-T033
repertoire	O
of	O
antileishmanial compounds	B-T121
.	O
For	O
evaluation	B-T058
of	O
novel	B-T080
drugs	B-T121
,	O
the	O
Syrian golden hamster	B-T015
is	O
considered	O
as	O
a	O
clinically	B-T080
relevant	B-T080
laboratory model	B-T170
.	O
In	O
this	O
study	B-T062
,	O
two	O
molecular parasite detection assays	B-T059
were	O
developed	O
targeting	B-T169
cathepsin-like cysteine protease B	B-T116
(	O
CPB	B-T116
)	O
DNA	B-T114
and	O
18S	O
rRNA	B-T114
to	O
achieve	O
absolute	B-T080
amastigote	B-T204
quantification	B-T081
in	O
the	O
major	O
target	B-T169
organs	B-T023
liver	B-T023
and	O
spleen	B-T023
.	O
Both	O
quantitative PCR	B-T063
(qPCR) techniques	B-T063
showed	O
excellent	O
agreement	O
with	O
a	O
strong	O
correlation	B-T080
with	O
the	O
conventional	O
microscopic reading	B-T059
of	O
Giemsa-stained	B-T059
tissue	B-T024
smears	B-T059
.	O
Using	O
multiple	B-T081
single	B-T081
tissue pieces	B-T024
and	O
all	O
three	O
detection	B-T033
methods	B-T170
,	O
we	O
confirmed	O
homogeneity	B-T080
of	O
infection	B-T046
in	O
liver	B-T023
and	O
spleen	B-T023
and	O
the	O
robustness	B-T080
of	O
extrapolating	O
whole organ burdens	B-T081
from	O
a	O
small	B-T081
single	B-T081
tissue piece	B-T024
.	O
Comparison	B-T052
of	O
pre	B-T079
-	O
and	O
post-treatment	B-T079
burdens	B-T078
in	O
infected	B-T033
hamsters	B-T015
using	O
the	O
three	O
detection	B-T033
methods	B-T170
consistently	O
revealed	B-T080
a	O
stronger	O
parasite	B-T204
reduction	B-T080
in	O
the	O
spleen	B-T023
compared	B-T052
to	O
the	O
liver	B-T023
,	O
indicating	O
an	O
organ	B-T023
-	O
dependent	B-T080
clearance	B-T080
efficacy	B-T080
for	O
miltefosine	B-T109
.	O
In	O
conclusion	B-T078
,	O
this	O
study	B-T062
in	O
the	O
hamster	B-T015
demonstrated	O
high	B-T080
homogeneity	B-T080
of	O
infection	B-T046
in	O
liver	B-T023
and	O
spleen	B-T023
and	O
advocates	O
the	O
use	O
of	O
molecular	B-T080
detection	B-T061
methods	B-T170
for	O
assessment	B-T058
of	O
low	B-T080
(	O
post-treatment	B-T079
)	O
tissue	B-T024
burdens	B-T078
.	O

Approximate	B-T080
Bayesian computation	B-T081
for	O
estimating	B-T081
number concentrations	B-T081
of	O
monodisperse	B-T080
nanoparticles	B-T073
in	O
suspension	B-T167
by	O
optical microscopy	B-T059
We	O
present	B-T078
an	O
approximate	B-T080
Bayesian computation	B-T081
scheme	B-T170
for	O
estimating	B-T081
number concentrations	B-T081
of	O
monodisperse	B-T080
diffusing	B-T070
nanoparticles	B-T073
in	O
suspension	B-T167
by	O
optical particle tracking microscopy	B-T059
.	O
The	O
method	B-T169
is	O
based	B-T078
on	O
the	O
probability distribution	B-T081
of	O
the	O
time	B-T079
spent	B-T081
by	O
a	O
particle	B-T104
inside	B-T082
a	O
detection	B-T061
region	B-T082
.	O
We	O
validate	O
the	O
method	B-T169
on	O
suspensions	B-T167
of	O
well-controlled	B-T169
reference	B-T077
particles	B-T104
.	O
We	O
illustrate	O
its	O
usefulness	B-T080
with	O
an	O
application	B-T169
in	O
gene therapy	B-T061
,	O
applying	B-T169
the	O
method	B-T169
to	O
estimate	B-T081
number concentrations	B-T081
of	O
plasmid	B-T114
DNA molecules	B-T114
and	O
the	O
average number	B-T081
of	O
DNA molecules	B-T114
complexed	B-T104
with	O
liposomal	B-T109
drug delivery	B-T074
particles	B-T104
.	O

Gestational age	B-T032
specific	O
stillbirth	B-T033
risk	B-T078
among	O
Indigenous	B-T102
and	O
non	B-T169
-	O
Indigenous	B-T102
women	B-T098
in	O
Queensland	B-T083
,	O
Australia	B-T083
:	O
a	O
population based study	B-T062
In	O
Australia	B-T083
,	O
significant	O
disparity	O
persists	O
in	O
stillbirth	B-T033
rates	B-T081
between	O
Aboriginal	B-T098
and	O
Torres Strait Islander	B-T098
(	O
Indigenous Australian	B-T098
)	O
and	O
non	B-T169
-	O
Indigenous	B-T102
women	B-T098
.	O
Diabetes	B-T047
,	O
hypertension	B-T047
,	O
antepartum haemorrhage	B-T046
and	O
small-for-gestational age	B-T046
(	O
SGA	B-T046
)	O
have	O
been	O
identified	B-T080
as	O
important	B-T080
contributors	O
to	O
higher	O
rates	B-T081
among	O
Indigenous	B-T102
women	B-T098
.	O
The	O
objective	O
of	O
this	O
study	B-T062
was	O
to	O
examine	O
gestational age	B-T032
specific	O
risk	B-T078
of	O
stillbirth	B-T033
associated with	B-T080
these	O
conditions	B-T080
among	O
Indigenous	B-T102
and	O
non	B-T169
-	O
Indigenous	B-T102
women	B-T098
.	O
Retrospective	B-T080
population-based study	B-T062
of	O
all	O
singleton	B-T099
births	B-T081
of	O
at	O
least	O
20	O
weeks	B-T079
gestation	B-T040
or	O
at	O
least	O
400	O
grams	B-T081
birthweight	B-T032
in	O
Queensland	B-T083
between	O
July	B-T080
2005	O
and	O
December	B-T080
2011	O
using	O
data	B-T078
from	O
the	O
Queensland	B-T083
Perinatal	B-T079
Data Collection	B-T062
,	O
which	O
is	O
a	O
routinely-maintained database	B-T170
that	O
collects	O
data	B-T078
on	O
all	O
births	B-T081
in	O
Queensland	B-T083
.	O
Multivariate logistic regression	B-T062
was	O
used	O
to	O
calculate	O
adjusted odds ratios	B-T081
(	O
aOR	B-T081
)	O
and	O
95	O
%	O
confidence intervals	B-T081
,	O
adjusting	O
for	O
maternal	B-T033
demographic	B-T078
and	O
pregnancy factors	B-T033
.	O
Of	O
360987	O
births	B-T081
analysed	B-T062
,	O
20273	O
(5.6	O
%)	O
were	O
to	O
Indigenous	B-T102
women	B-T098
and	O
340714	O
(94.4	O
%)	O
were	O
to	O
non	B-T169
-	O
Indigenous	B-T102
women	B-T098
.	O
Stillbirth	B-T033
rates	B-T081
were	O
7.9	O
(95	O
%	O
CI	B-T081
6.8-9.2)	O
and	O
4.1	O
(95	O
%	O
CI	B-T081
3.9-4.3)	O
per	O
1000	O
births	B-T081
,	O
respectively.	O
For	O
both	O
Indigenous	B-T102
and	O
non	B-T169
-	O
Indigenous	B-T102
women	B-T098
across	O
most	O
gestational	B-T079
age groups	B-T100
,	O
antepartum haemorrhage	B-T046
,	O
SGA	B-T046
,	O
pre-existing diabetes	B-T033
and	O
pre-existing hypertension	B-T033
were	O
associated with	B-T080
increased	B-T081
risk	B-T078
of	O
stillbirth	B-T033
.	O
There	O
were	O
mixed	O
results	O
for	O
pre-eclampsia	B-T046
and	O
eclampsia	B-T047
and	O
a	O
consistently	O
raised	O
risk	B-T078
of	O
stillbirth	B-T033
was	O
not	O
seen	O
for	O
gestational diabetes	B-T047
.	O
This	O
study	B-T062
highlights	O
gestational age	B-T032
specific	O
stillbirth	B-T033
risk	B-T078
for	O
Indigenous	B-T102
and	O
non	B-T169
-	O
Indigenous	B-T102
women	B-T098
;	O
and	O
disparity	O
in	O
risk	B-T078
at	O
term gestations	B-T040
.	O
Improving	O
access	O
to	O
and	O
utilisation	O
of	O
appropriate	B-T080
and	O
responsive	B-T169
healthcare	B-T058
may	O
help	O
to	O
address	O
disparities	O
in	O
stillbirth	B-T033
risk	B-T078
for	O
Indigenous	B-T102
women	B-T098
.	O

Defining	B-T058
,	O
Describing	B-T170
,	O
and	O
Categorizing	B-T052
Public Health Infrastructure	B-T058
Priorities	B-T079
for	O
Tropical Cyclone	B-T070
,	O
Flood	B-T070
,	O
Storm	B-T070
,	O
Tornado	B-T070
,	O
and	O
Tsunami-Related Disasters	B-T070
The	O
study	B-T062
aim	O
was	O
to	O
undertake	O
a	O
qualitative	O
research	O
literature review	B-T170
to	O
analyze	O
available	O
databases	B-T170
to	O
define	B-T058
,	O
describe	B-T170
,	O
and	O
categorize	B-T052
public health infrastructure	B-T058
(	O
PHI	B-T058
)	O
priorities	B-T079
for	O
tropical cyclone	B-T070
,	O
flood	B-T070
,	O
storm	B-T070
,	O
tornado	B-T070
,	O
and	O
tsunami-related disasters	B-T070
.	O
Five	O
electronic	O
publication databases	B-T170
were	O
searched	O
to	O
define	B-T058
,	O
describe	B-T170
,	O
or	O
categorize	B-T052
PHI	B-T058
and	O
discuss	B-T054
tropical cyclone	B-T070
,	O
flood	B-T070
,	O
storm	B-T070
,	O
tornado	B-T070
,	O
and	O
tsunami-related disasters	B-T070
and	O
their	O
impact	B-T080
on	O
PHI	B-T058
.	O
The	O
data	B-T078
were	O
analyzed	O
through	O
aggregation	B-T169
of	O
individual	O
articles	B-T170
to	O
create	O
an	O
overall	O
data	O
description.	O
The	O
data	B-T078
were	O
grouped	B-T169
into	O
PHI	B-T058
themes	B-UnknownType
,	O
which	O
were	O
then	O
prioritized	B-T079
on	O
the	O
basis	O
of	O
degree	O
of	O
interdependency.	O
Sixty-seven	O
relevant	O
articles	B-T170
were	O
identified.	O
PHI	B-T058
was	O
categorized	B-T052
into	O
13	O
themes	B-UnknownType
with	O
a	O
total	O
of	O
158	O
descriptors	B-T170
.	O
The	O
highest	O
priority	B-T079
PHI	B-T058
identified	O
was	O
workforce	B-T169
.	O
This	O
was	O
followed	O
by	O
water	B-T167
,	O
sanitation	B-T090
,	O
equipment	B-T073
,	O
communication	B-T054
,	O
physical structure	B-T073
,	O
power	B-T073
,	O
governance	B-T089
,	O
prevention	B-T080
,	O
supplies	B-T169
,	O
service	B-T057
,	O
transport	B-T073
,	O
and	O
surveillance	B-T169
.	O
This	O
review	B-T170
identified	O
workforce	B-T169
as	O
the	O
most	O
important	O
of	O
the	O
13	O
thematic areas	B-UnknownType
related	O
to	O
PHI	B-T058
and	O
disasters	B-T070
.	O
If	O
its	O
functionality	O
fails,	O
workforce	B-T169
has	O
the	O
greatest	O
impact	O
on	O
the	O
performance	O
of	O
health services	B-T058
.	O
If	O
addressed	O
post-disaster	B-T079
,	O
the	O
remaining	O
forms	O
of	O
PHI	B-T058
will	O
then	O
be	O
progressively	O
addressed.	O
These	O
findings	O
are	O
a	O
step	O
toward	O
providing	O
an	O
evidence	O
base	O
to	O
inform	O
PHI	B-T058
priorities	B-T079
in	O
the	O
disaster	B-T070
setting.	O
(Disaster	O
Med	O
Public	O
Health	O
Preparedness.	O
2016;10:598-610).	O

Fragment	B-T116
-Based	O
Discovery	B-T052
of	O
5-Arylisatin	B-T109
-Based	O
Inhibitors	B-T121
of	O
Matrix Metalloproteinases 2	B-T116
and	O
13	B-T116
Matrix metalloproteinases	B-T116
(	O
MMPs	B-T116
)	O
are	O
well-established	O
targets	O
for	O
several	O
pathologies	B-T046
.	O
In	O
particular,	O
MMP-2	B-T116
and	O
MMP-13	B-T116
play	O
a	O
prominent	O
role	O
in	O
cancer progression	B-T046
.	O
In	O
this	O
study	B-T062
,	O
a	O
structure-based screening	B-T058
campaign	O
was	O
applied	O
to	O
prioritize	O
metalloproteinase	B-T116
-oriented	O
fragments	B-T116
.	O
This	O
computational model	B-T066
was	O
applied	O
to	O
a	O
representative	O
fragment	B-T116
set	B-T077
from	O
the	O
publically	O
available	O
EDASA Scientific compound library	B-T170
.	O
These	O
fragments	B-T116
were	O
prioritized,	O
and	O
the	O
top-ranking	O
hits	O
were	O
tested	O
in	O
a	O
biological assay	B-T059
to	O
validate	B-T062
the	O
model	B-T066
.	O
Two	O
scaffolds	B-T116
showed	O
consistent	O
activity	B-T052
in	O
the	O
assay	B-T059
,	O
and	O
the	O
isatin-based compounds	B-T109
were	O
the	O
most	O
interesting.	O
These	O
latter	O
fragments	B-T116
have	O
significant	O
potential	O
as	O
tools	O
for	O
the	O
design	B-T052
and	O
realization	O
of	O
novel	O
MMP inhibitors	B-T121
.	O
In	O
addition	O
to	O
their	O
micromolar activity	B-T052
,	O
the	O
chemical synthesis	B-T070
affords	O
flexible	B-T080
and	O
creative access	B-T082
to	O
their	O
analogues	B-T104
.	O

Incidence	B-T081
of	O
environmental	B-T080
and	O
genetic factors	B-T080
causing	O
congenital cataract	B-T019
in	O
Children	B-T100
of	O
Lahore	B-UnknownType
To	O
check	O
the	O
incidence	B-T081
of	O
environmental	B-T080
and	O
genetic factors	B-T080
causing	O
congenital cataract	B-T019
in	O
infants	B-T100
.	O
The	O
descriptive study	B-T062
was	O
conducted	O
at	O
Layton Rahmatullah Benevolent Trust	B-T093
,	O
Lahore	B-UnknownType
,	O
Pakistan	B-T083
,	O
from	O
October	O
2013	O
to	O
April	O
2014,	O
and	O
comprised	O
children	B-T100
under	O
15	O
years	B-T079
of	O
age	B-T032
who	O
had	O
rubella syndrome	B-T047
,	O
herpes simplex	B-T047
,	O
birth trauma	B-T033
,	O
trisomy 21	B-T049
,	O
Nance-Horan syndrome	B-T047
or	O
Lowe's syndrome	B-T047
.	O
Of	O
the	O
38,000	O
cases	B-T081
examined,	O
120(0.3%)	O
patients	B-T101
were	O
diagnosed	B-T033
with	O
congenital cataract	B-T019
.	O
Of	O
them,	O
52(43.33%)were	O
aged	B-T032
between	O
2	O
and	O
5	O
years	B-T079
,22(18.33%)	O
<11	O
years	B-T079
and	O
10(8.33%)	O
?15	O
years	B-T079
.	O
Bilateral congenital cataract	B-T047
was	O
observed	O
in	O
91(75.83%)	O
patients	B-T101
and	O
unilateral congenital cataract	B-T047
in	O
29(24.17%).	O
Environmental factors	B-T080
caused	O
72(62.07%)	O
cases	B-T081
and	O
genetic factors	B-T080
caused	O
44(37.93%)..	O
Congenital cataract	B-T019
predominated	B-T080
in	O
boys	B-T100
compared	O
to	O
girls	B-T100
.	O
Early	O
diagnosis	B-T033
and	O
adequate	O
therapy	B-T061
requires	O
specific	O
technology	B-T090
,	O
as	O
well	O
as	O
long-term	B-T079
and	O
permanent	B-T079
care	B-T052
..	O

Transcriptome	B-T086
and	O
Metabolome	B-T070
Analyses	B-T062
of	O
Glucosinolates	B-T109
in	O
Two	O
Broccoli Cultivars	B-T002
Following	O
Jasmonate	B-T109
Treatment	B-T169
for	O
the	O
Induction	B-T169
of	O
Glucosinolate	B-T109
Defense	B-T077
to	O
Trichoplusia ni	B-T204
(	O
Hübner	B-T170
)	O
Lepidopteran	B-T204
larvae	B-T204
growth	B-T040
is	O
influenced	B-T077
by	O
host	B-T001
plant	B-T002
glucosinolate	B-T109
(	O
GS	B-T109
)	O
concentrations	B-T081
,	O
which	O
are,	O
in	O
turn,	O
influenced	B-T077
by	O
the	O
phytohormone	B-T116
jasmonate	B-T109
(	O
JA	B-T109
).	O
In	O
order	O
to	O
elucidate	O
insect	B-T204
resistance	B-T169
biomarkers	B-T045
to	O
lepidopteran	B-T204
pests	B-T008
,	O
transcriptome	B-T086
and	O
metabolome	B-T070
analyses	B-T062
following	O
JA	B-T109
treatments	B-T169
were	O
conducted	O
with	O
two	O
broccoli cultivars	B-T002
,	O
Green Magic	B-T002
and	O
VI-158	B-T002
,	O
which	O
have	O
differentially	O
induced	B-T169
indole GSs	B-T109
,	O
neoglucobrassicin	B-T109
and	O
glucobrassicin	B-T109
,	O
respectively.	O
To	O
test	B-T169
these	O
two	O
inducible	B-T169
GSs	B-T109
on	O
growth	B-T040
of	O
cabbage looper	B-T204
(	O
Trichoplusia ni	B-T204
),	O
eight	O
neonate	O
cabbage looper larvae	B-T204
were	O
placed	O
onto	O
each	O
of	O
three	O
plants	B-T002
per	O
JA	B-T109
treatments	B-T169
(0,	O
100,	O
200,	O
400	O
µM)	O
three	O
days	B-T079
after	O
treatment	B-T169
.	O
After	O
five	O
days	B-T079
of	O
feeding	B-T052
,	O
weight	B-T081
of	O
larvae	B-T204
and	O
their	O
survival rate	B-T081
was	O
found	O
to	O
decrease	B-T081
with	O
increasing	B-T169
JA	B-T109
concentrations	B-T081
in	O
both	O
broccoli cultivars	B-T002
.	O
JA	B-T109
-	O
inducible	B-T169
GSs	B-T109
were	O
measured	B-T080
by	O
high performance liquid chromatography	B-T059
.	O
Neoglucobrassicin	B-T109
in	O
Green Magic	B-T002
and	O
glucobrassicin	B-T109
in	O
VI-158	B-T002
leaves	B-T002
were	O
increased	B-T081
in	O
a	O
dose-dependent	B-T081
manner.	O
One	O
or	O
both	O
of	O
these	O
glucosinolates	B-T109
and/or	O
their	O
hydrolysis	B-T070
products	B-T071
showed	O
significant	O
inverse	B-T080
correlations	B-T080
with	O
larval	B-T204
weight	B-T081
and	O
survival	B-T052
(five	O
days	B-T079
after	O
treatment	B-T169
)	O
while	O
being	O
positively	B-T033
correlated	B-T080
with	O
the	O
number	O
of	O
days	B-T079
to	O
pupation	B-T040
.	O
This	O
implies	O
that	O
these	O
two	O
JA	B-T109
-	O
inducible	B-T169
glucosinolates	B-T109
can	O
influence	B-T077
the	O
growth	B-T040
and	O
survival	B-T052
of	O
cabbage looper larvae	B-T204
.	O
Transcriptome profiling	B-T059
supported	O
the	O
observed	O
changes	B-T169
in	O
glucosinolate	B-T109
and	O
their	O
hydrolysis	B-T070
product	B-T071
concentrations	B-T081
following	O
JA	B-T109
treatments	B-T169
.	O
Several	O
genes	B-T028
related	O
to	O
GS	B-T109
metabolism	B-T040
differentiate	B-T169
the	O
two	O
broccoli cultivars	B-T002
in	O
their	O
pattern	B-T082
of	O
transcriptional	B-T045
response	B-T032
to	O
JA	B-T109
treatments	B-T169
.	O
Indicative	O
of	O
the	O
corresponding	O
change	B-T169
in	O
indole GS	B-T109
concentrations	B-T081
,	O
transcripts	B-T114
of	O
the	O
transcription factor	B-T116
MYB122	B-T116
,	O
core	O
structure	O
biosynthesis	B-T169
genes	B-T028
(	O
CYP79B2	B-T028
,	O
UGT74B1	B-T028
,	O
SUR1	B-T028
,	O
SOT16	B-T028
,	O
SOT17	B-T028
,	O
and	O
SOT18	B-T028
),	O
an	O
indole glucosinolate	B-T104
side	O
chain	O
modification	B-T033
gene	B-T028
(	O
IGMT1	B-T028
),	O
and	O
several	O
glucosinolate	B-T109
hydrolysis	B-T070
genes	O
(	O
TGG1	B-T028
,	O
TGG2	B-T028
,	O
and	O
ESM1	B-T028
)	O
were	O
significantly	O
increased	B-T081
in	O
Green Magic	B-T002
(statistically	O
significant	O
in	O
most	O
cases	O
at	O
400	O
µM)	O
while	O
UGT74B1	B-T028
and	O
MYB122	B-T028
were	O
significantly	O
increased	B-T081
in	O
VI-158	B-T002
.	O
Therefore,	O
these	O
metabolite	B-T123
and	O
transcript	B-T114
biomarker	B-T045
results	O
indicate	O
that	O
transcriptome profiling	B-T059
can	O
identify	B-T080
genes	B-T028
associated	O
with	O
the	O
formation	B-T169
of	O
two	O
different	O
indole GS	B-T109
and	O
their	O
hydrolysis	B-T070
products	B-T071
.	O
Therefore,	O
these	O
metabolite	B-T123
and	O
transcript	B-T114
biomarkers	B-T045
could	O
be	O
useful	O
in	O
an	O
effective	B-T080
marker	B-T045
-	O
assisted	B-T080
breeding	B-T040
strategy	O
for	O
resistance	B-T169
to	O
generalist	O
lepidopteran	B-T204
pests	B-T008
in	O
broccoli	B-T002
and	O
potentially	O
other	O
Brassica vegetables	B-T168
.	O

The	O
clinical prognosis	B-T033
of	O
implants	B-T074
that	O
are	O
placed	O
against	O
super-erupted	B-T047
opposing	O
dentition	B-T023
If	O
teeth	B-T023
are	O
missing	B-T020
,	O
super-eruption of teeth	B-T047
in	O
the	O
opposing arch	B-T082
can	O
occur	O
in	O
the	O
area	B-T082
and	O
can	O
change	O
the	O
occlusal plane	B-T042
.	O
When	O
missing teeth	B-T020
are	O
replaced	O
with	O
implants	B-T074
,	O
the	O
oral surgeon	B-T097
must	O
determine	O
whether	O
or	O
not	O
the	O
super-erupted teeth	B-T023
need	O
to	O
be	O
treated	B-T169
in	O
order	O
to	O
normalize	B-T062
the	O
occlusal plane	B-T042
.	O
In	O
this	O
study	B-T062
,	O
we	O
evaluated	B-T058
the	O
clinical prognosis	B-T033
of	O
dentition	B-T023
after	O
implant placement	B-T061
and	O
prosthetic treatment	B-T061
were	O
completed	B-T080
in	O
an	O
occlusal plane	B-T042
altered	O
by	O
super-erupted teeth	B-T023
in	O
the	O
opposing arch	B-T082
without	O
additional	O
treatment	B-T169
of	O
the	O
super-erupted teeth	B-T023
.	O
Twenty-two	O
patients	B-T101
(9	O
males	B-T032
,	O
13	O
females	B-T032
)	O
were	O
treated	B-T169
with	O
implants	B-T074
and	O
prosthetics	B-T074
without	O
addressing	O
the	O
super-erupted	B-T047
opposing	O
dentition	B-T023
from	O
April	O
2004	O
to	O
August	O
2012	O
at	O
Seoul	B-T083
National University Bundang Hospital	B-T073
.	O
A	O
total	O
of	O
33	O
implants	B-T074
were	O
placed.	O
Values	O
of	O
crestal bone loss	B-T047
,	O
survival rates	B-T081
,	O
and	O
surgical	B-T046
and	O
prosthetic complications	B-T046
for	O
an	O
average	O
of	O
29.6	O
months	B-T079
after	O
prosthetic loading	B-T061
were	O
recorded.	O
In	O
one	O
case	B-T077
,	O
the	O
cover screw	B-T074
was	O
exposed	O
after	O
implant surgery	B-T061
.	O
The	O
mean	O
crestal bone loss	B-T047
was	O
0.09±0.30	O
mm.	O
Of	O
the	O
33	O
implants	B-T074
,	O
31	O
survived	B-T067
,	O
a	O
survival rate	B-T081
of	O
93.94%.	O
A	O
prosthetic complication	B-T046
occurred	O
in	O
one	O
case	B-T077
but	O
functioned	O
well	O
after	O
correction.	O
Favorable	O
clinical results	B-T034
from	O
prosthetic complications	B-T046
,	O
crestal bone loss	B-T047
,	O
and	O
implant	B-T074
survival rates	B-T081
were	O
exhibited	O
in	O
implants	B-T074
next	O
to	O
a	O
super-erupted opposing tooth	B-T023
.	O

Evaluation	B-T080
of	O
Mathisen's technique	B-T169
for	O
ureteral reimplantation	B-T061
in	O
children	B-T100
with	O
primary	B-T080
vesicoureteral reflux	B-T047
Although	O
cross-trigonal ureteral reimplantation (Cohen)	B-T061
is	O
a	O
commonly	O
used	O
technique	B-T169
in	O
children	B-T100
,	O
it	O
represents	O
a	O
non-physiological transfer	B-T041
of	O
the	O
ureteral orifices	B-T030
and	O
may	O
prove	O
challenging	O
with	O
regard	O
to	O
endoscopic ureteral operations	B-T061
in	O
later	B-T079
life	B-T078
.	O
In	O
1964,	O
Mathisen	O
described	B-T078
an	O
alternative	B-T077
method	B-T169
of	O
ureteral reimplantation	B-T061
with	O
lateralization	B-T169
of	O
the	O
neohiatus	B-T082
,	O
creating	O
an	O
orthotopic	B-T082
course	B-T079
of	O
the	O
submucosal ureter	B-T023
.	O
We	O
have	O
evaluated	B-T052
success	B-T080
and	O
complication	B-T078
rates	B-T081
of	O
both	O
techniques	B-T169
that	O
were	O
applied	B-T169
sequentially	B-T169
at	O
our	O
departments	B-T092
.	O
Forty-eight	O
consecutive	B-T080
patients	B-T101
(83	O
ureters	B-T098
,	O
24	O
males	B-T098
/24	O
females	B-T098
)	O
following	O
Mathisen reimplantation	B-T061
were	O
compared	B-T052
with	O
53	O
consecutive	B-T080
patients	B-T101
(98	O
ureters	B-T098
,	O
30	O
males	B-T098
/23	O
females	B-T098
)	O
following	O
Cohen reimplantation	B-T061
.	O
Inclusion	B-T080
criteria	B-T078
were	O
primary	B-T080
vesicoureteral reflux	B-T047
(	O
VUR	B-T047
)	O
and	O
no	O
previous	B-T079
intervention	B-T061
.	O
Reflux	B-T047
grades	B-T185
(Mathisen	O
58	O
ureters	B-T098
/69.9%	O
VUR ≥ III	B-T033
;	O
Cohen	O
66	O
ureters	B-T098
/66.7%	O
VUR ≥ III	B-T033
)	O
and	O
the	O
occurence	O
of	O
other	O
complicating	B-T169
factors	B-T169
(	O
ureteroceles	B-T020
,	O
megaureters	B-T190
,	O
posterior urethral valves	B-T019
)	O
in	O
both	O
groups	B-T078
were	O
comparable	B-T052
.	O
After	O
Cohen's reimplantation	B-T061
there	O
were	O
no	O
immediate	B-T079
complications	B-T046
requiring	O
intervention	B-T061
;	O
during	B-T079
follow-up	B-T058
(	O
mean	B-T081
28.2	O
months	B-T079
)	O
three	O
patients	B-T101
(5.6%)	O
suffered	B-T048
febrile urinary tract infections	B-T047
(	O
UTIs	B-T047
),	O
of	O
which	O
one	O
(1.8%)	O
was	O
diagnosed	B-T033
with	O
a	O
persisting	B-T078
VUR	B-T047
.	O
Persistent	B-T078
hydronephroses	B-T047
(≥II	O
SFU	B-T047
)	O
were	O
recorded	O
in	O
six	O
patients	B-T101
(13.2%).	O
After	O
reimplantation	B-T061
using	O
Mathisen's technique	B-T169
,	O
two	O
patients	B-T101
(4.1%)	O
suffered	B-T048
significant	B-T078
intravesical bleeding	B-T047
;	O
during	O
follow-up	B-T058
(	O
mean	B-T081
23.06	O
months	B-T079
)	O
four	O
patients	B-T101
(8.3%)	O
suffered	B-T048
febrile UTIs	B-T047
,	O
and	O
seven	O
patients	B-T101
(14.5%)	O
were	O
diagnosed	B-T033
with	O
persisting	B-T078
VUR	B-T047
after	O
a	O
mean	B-T081
follow-up	B-T058
of	O
10.8	O
months	B-T079
.	O
The	O
patients	B-T101
with	O
persistent	B-T078
VUR	B-T047
had	O
more	O
commonly	O
high-grade	B-T080
(IV	O
and	O
V)	O
VUR	B-T047
initially,	O
compared	B-T052
to	O
the	O
whole group	B-T078
.	O
Two	O
patients	B-T101
(4.1%)	O
had	O
persistent	B-T078
hydronephroses	B-T047
(≥II	O
SFU	B-T047
).	O
Mathisen's technique	B-T169
for	O
ureteral reimplantation	B-T061
yielded	O
a	O
significantly	B-T078
(p	O
=	O
0.0256	O
patients	B-T101
,	O
p	O
=	O
0.006	O
ureterorenal units	B-T081
)	O
lower	B-T082
success	B-T080
rate	B-T081
(85.5%	O
patients	B-T101
,	O
89.2%	O
ureterorenal units	B-T081
)	O
in	O
comparison	B-T052
with	O
Cohen's technique	B-T169
(98.2%	O
patients	B-T101
,	O
99%	O
ureterorenal units	B-T081
).	O
Although	O
there	O
was	O
no	O
intervention	B-T061
for	O
obstruction	B-T046
,	O
persistent	B-T078
hydronephrosis	B-T047
was	O
more	O
common	O
in	O
the	O
Cohen group	B-T078
(13.2%	O
vs.	O
4.1%,	O
n.s.).	O
Despite	O
the	O
advantages	O
of	O
an	O
orthotopic	B-T082
ureteral orifice	B-T030
close	O
to	O
the	O
bladder neck	B-T023
,	O
as	O
achieved	O
by	O
Mathisen's reimplantation	B-T061
,	O
cross-trigonal ureteral reimplantation	B-T061
proved	O
more	O
reliable	B-T170
for	O
VUR	B-T047
correction	B-T169
.	O
As	O
regards	O
optimizing	O
the	O
results,	O
patient selection	B-T062
for	O
either	O
technique	B-T169
could	O
prove essential	B-T080
.	O
Nevertheless,	O
as	O
regards	O
the	O
difficulties	B-T080
with	O
ectopic	B-T082
ureteral orifices	B-T030
in	O
the	O
Cohen technique	B-T169
in	O
the	O
long-term	B-T079
follow-up	B-T058
,	O
the	O
concept	B-T078
of	O
anatomic	B-T080
,	O
orthotopic	B-T082
ureteral reimplantation	B-T061
should	O
be	O
pursued	O
and	O
the	O
technique	B-T169
should	O
be	O
further	O
refined.	O

The	O
use of	B-T169
neonatal	B-T079
extracorporeal life support	B-T061
in	O
pediatric	B-T080
cardiac intensive care unit	B-T073
The	O
aim	O
of	O
the	O
study	O
is	O
to	O
evaluate	B-T058
extracorporeal life support system	B-T061
(	O
ECLS	B-T061
)	O
employed	O
in	O
neonates	B-T100
in	O
pediatric	B-T080
cardiac intensive care unit	B-T073
.	O
Twenty-five	O
neonates	B-T100
that	O
required	O
ECLS	B-T061
in	O
between	O
November	O
2010	O
and	O
November	O
2015	O
were	O
evaluated	B-T058
.	O
The	O
median	B-T081
age	B-T032
was	O
12	O
days	B-T079
(	O
range	B-T081
3-28	O
days	B-T079
)	O
and	O
the	O
median	B-T081
body weight	B-T032
was	O
3	O
kg	O
(	O
range	B-T081
2.5-5	O
kg).	O
Venoarterial	B-T082
ECLS	B-T061
was	O
performed	B-T169
in	O
all	O
of	O
the	O
cases.	O
Ascendan aorta	B-T023
-	O
right atrial	B-T023
cannulation	B-T061
in	O
22	O
patients	B-T101
and	O
neck	B-T029
cannulation	B-T061
in	O
three	O
patients	B-T101
were	O
performed	B-T169
.	O
The	O
reason	O
for	O
ECLS	B-T061
was	O
E-CPR	B-T061
in	O
two	O
patients	B-T101
,	O
inability to wean	B-T033
from	O
cardiopulmonary bypass	B-T061
(	O
CPB	B-T061
)	O
in	O
seven	O
patients	B-T101
,	O
respiratory insufficiency	B-T046
and	O
hypoxia	B-T046
in	O
nine	O
patients	B-T101
,	O
low cardiac output	B-T046
(	O
LCOS	B-T046
)	O
in	O
seven	O
patients	B-T101
.	O
Median	B-T081
duration	B-T079
of	O
ECLS	B-T061
was	O
four	O
days	B-T079
(	O
range	B-T081
1-15).	O
Hemorrhagic	B-T080
complications	B-T046
developed	O
in	O
15,	O
renal complications	B-T046
in	O
13,	O
pulmonary complications	B-T046
in	O
12,	O
infectious	B-T047
complications	B-T046
in	O
11,	O
neurologic complications	B-T046
in	O
three	O
and	O
mechanical complications	B-T046
in	O
two	O
of	O
the	O
patients	B-T101
.	O
Weaning	B-T033
was	O
successful	B-T080
in	O
15	O
of	O
the	O
patients	B-T101
.	O
Eleven	O
patients	B-T101
were	O
successfully	B-T080
discharged	B-T058
.	O
ECLS	B-T061
is	O
an	O
important	B-T080
treatment option	B-T061
that	O
is	O
performed	B-T169
successfully	B-T080
in	O
many	O
centers	B-T073
around	O
the	O
world	B-T098
to	O
maintain	B-T052
life support	B-T061
in	O
patients	B-T101
unresponsive to medical treatment	B-T169
.	O
The	O
utilization	B-T169
of	O
this	O
modality	B-T078
especially	O
in	O
newborns	B-T100
with	O
congenital heart disease	B-T019
should	O
be	O
taken	O
into	O
consideration.	O

Medicare	B-T064
claims	B-T170
indicators	B-T169
of	O
healthcare	B-T058
utilization	B-T169
differences	B-T080
after	O
hospitalization	B-T058
for	O
ischemic stroke	B-T047
:	O
Race	B-T098
,	O
gender	B-T032
,	O
and	O
caregiving	B-T052
effects	B-T080
Background	B-T077
Differences	B-T080
in	O
healthcare	B-T058
utilization	B-T169
after	O
stroke	B-T047
may	O
partly	O
explain	O
race	B-T098
or	O
gender	B-T032
differences	B-T080
in	O
stroke	B-T047
outcomes	O
and	O
identify	O
factors	B-T169
that	O
might	O
reduce	B-T080
post	B-T079
-	O
acute stroke	B-T047
care costs	B-T081
.	O
Aim	O
To	O
examine	O
systematic	B-T169
differences	B-T080
in	O
Medicare	B-T064
claims	B-T170
for	O
healthcare	B-T058
utilization	B-T169
after	O
hospitalization	B-T058
for	O
ischemic stroke	B-T047
in	O
a	O
US	B-T083
population	B-T098
-based	O
sample	B-T096
.	O
Methods	O
Claims	B-T170
were	O
examined	B-T033
over	O
a	O
six-month	B-T079
period	B-T079
after	O
hospitalization	B-T058
for	O
279	O
ischemic stroke	B-T047
survivors	B-T101
65	O
years	B-T079
or	O
older	B-T098
from	O
the	O
REasons	B-T078
for	O
Geographic	B-T078
And	O
Racial Differences	B-T033
in	O
Stroke	B-T047
(	O
REGARDS	B-T047
)	O
study.	O
Statistical analyses	B-T062
examined	B-T033
differences	B-T080
in	O
post	B-T079
-	O
acute healthcare	B-T058
utilization	B-T169
,	O
adjusted	O
for	O
pre	B-T079
-	O
stroke	B-T047
utilization	B-T169
,	O
as	O
a	O
function	B-T169
of	O
race	B-T098
(	O
African-American	B-T098
vs.	O
White	B-T098
),	O
gender	B-T032
,	O
age	B-T032
,	O
stroke belt	B-UnknownType
residence	B-T082
,	O
income	B-T081
,	O
Medicaid dual-eligibility	B-T064
,	O
Charlson comorbidity index	B-T170
,	O
and	O
whether	O
the	O
person	B-T098
lived	B-T052
with	O
an	O
available	B-T169
caregiver	B-T097
.	O
Results	O
After	O
adjusting	O
for	O
covariates,	O
women	B-T098
were	O
more	O
likely	O
than	O
men	B-T098
to	O
receive	B-T080
home health care	B-T058
and	O
to	O
use	O
emergency department services	B-T058
during	O
the	O
post	B-T079
-	O
acute care	B-T058
period	B-T079
.	O
These	O
effects	B-T080
were	O
maintained	B-T169
even	O
after	O
further	B-T082
adjustment	B-T169
for	O
acute stroke	B-T047
severity	B-T080
.	O
African-Americans	B-T098
had	O
more	O
home health care	B-T058
visits	B-T058
than	O
Whites	B-T098
among	O
patients	B-T101
who	O
received	B-T080
some	O
home health care	B-T058
.	O
Having	O
a	O
co-residing	B-T052
caregiver	B-T097
was	O
associated with	B-T080
reduced	B-T080
acute hospitalization	B-T058
length of stay	B-T079
and	O
fewer	O
post	B-T079
-	O
acute emergency department	B-T058
and	O
primary care physician visits	B-T058
.	O
Conclusions	O
Underutilization of healthcare	B-T055
after	O
stroke	B-T047
does	O
not	O
appear	O
to	O
explain	O
poorer	O
long-term	B-T079
stroke	B-T047
outcomes	O
for	O
women	B-T098
and	O
African-Americans	B-T098
in	O
this	O
epidemiologically	B-T169
-derived	O
sample	B-T096
.	O
Caregiver	B-T097
availability	B-T169
may	O
contribute	B-T052
to	O
reduced	B-T080
formal care	B-T052
and	O
cost	B-T081
during	O
the	O
post	B-T079
-	O
acute	B-T058
period	B-T079
.	O

Do	O
dynamic global vegetation models	B-T170
capture	O
the	O
seasonality	B-T079
of	O
carbon fluxes	B-T070
in	O
the	O
Amazon basin	B-T083
?	O
A	O
data	B-T078
-	O
model	B-T170
intercomparison	B-UnknownType
To	O
predict	O
forest	B-T070
response	B-T032
to	O
long-term	B-T079
climate change	B-T070
with	O
high	O
confidence	O
requires	O
that	O
dynamic global vegetation models	B-T170
(	O
DGVMs	B-T170
)	O
be	O
successfully	O
tested	O
against	O
ecosystem	B-T070
response	B-T032
to	O
short-term	B-T079
variations	B-T079
in	O
environmental drivers	B-T082
,	O
including	O
regular	O
seasonal patterns	B-T079
.	O
Here,	O
we	O
used	O
an	O
integrated	O
dataset	B-T170
from	O
four	O
forests	B-T070
in	O
the	O
Brasil flux network	B-T170
,	O
spanning	O
a	O
range	O
of	O
dry-season	B-T079
intensities	B-T080
and	O
lengths	B-T081
,	O
to	O
determine	O
how	O
well	O
four	O
state-of-the-art	O
models	B-T170
(	O
IBIS	B-T170
,	O
ED2	B-T170
,	O
JULES	B-T170
,	O
and	O
CLM3.5	B-T170
)	O
simulated	O
the	O
seasonality	B-T079
of	O
carbon exchanges	B-T070
in	O
Amazonian	B-T083
tropical forests	B-T070
.	O
We	O
found	O
that	O
most	O
DGVMs	B-T170
poorly	O
represented	O
the	O
annual	O
cycle	O
of	O
gross primary productivity	B-T081
(	O
GPP	B-T081
),	O
of	O
photosynthetic capacity	B-T081
(	O
Pc	B-T081
),	O
and	O
of	O
other	O
fluxes	B-T070
and	O
pools.	O
Models	B-T170
simulated	O
consistent	O
dry-season	B-T079
declines	B-T081
in	O
GPP	B-T081
in	O
the	O
equatorial Amazon	B-T083
(	O
Manaus K34	B-T083
,	O
Santarem K67	B-T083
,	O
and	O
Caxiuanã CAX	B-T083
);	O
a	O
contrast	O
to	O
observed	O
GPP	B-T081
increases.	O
Model	B-T170
simulated	O
dry-season	B-T079
GPP	B-T081
reductions	B-T080
were	O
driven	O
by	O
an	O
external	O
environmental	B-T082
factor	B-T169
,	O
'	O
soil water stress	B-T033
'	O
and	O
consequently	O
by	O
a	O
constant	O
or	O
decreasing	O
photosynthetic infrastructure	B-T070
(	O
Pc	B-T081
),	O
while	O
observed	O
dry-season	B-T079
GPP	B-T081
resulted	O
from	O
a	O
combination	O
of	O
internal	O
biological	B-T080
(	O
leaf	B-T002
-flush	O
and	O
abscission	B-T040
and	O
increased	O
Pc	B-T081
)	O
and	O
environmental	B-T082
(incoming	O
radiation	B-T070
)	O
causes.	O
Moreover,	O
we	O
found	O
models	B-T170
generally	O
overestimated	O
observed	O
seasonal	O
net ecosystem exchange	B-T081
(	O
NEE	B-T081
)	O
and	O
respiration	B-T039
(	O
Re	B-T039
)	O
at	O
equatorial	O
locations.	O
In	O
contrast,	O
a	O
southern Amazon	B-T083
forest	B-T070
(Jarú	O
RJA)	O
exhibited	O
dry-season	B-T079
declines	B-T081
in	O
GPP	B-T081
and	O
Re	B-T039
consistent	O
with	O
most	O
DGVMs	B-T170
simulations	B-T062
.	O
While	O
water	O
limitation	O
was	O
represented	O
in	O
models	B-T170
and	O
the	O
primary	O
driver	O
of	O
seasonal	O
photosynthesis	B-T070
in	O
southern Amazonia	B-T083
,	O
changes	O
in	O
internal	O
biophysical processes	B-T038
,	O
light-harvesting	B-T044
adaptations	B-T070
(e.g.,	O
variations	O
in	O
leaf area index	B-T170
(	O
LAI	B-T170
)	O
and	O
increasing	O
leaf	B-T002
-level	O
assimilation	B-T038
rate	B-T081
related	O
to	O
leaf demography	B-T090
),	O
and	O
allocation	O
lags	O
between	O
leaf	B-T002
and	O
wood	B-T002
,	O
dominated	O
equatorial Amazon	B-T083
carbon flux	B-T070
dynamics	O
and	O
were	O
deficient	O
or	O
absent	O
from	O
current	O
model	B-T170
formulations.	O
Correctly	O
simulating	O
flux	B-T070
seasonality	B-T079
at	O
tropical forests	B-T070
requires	O
a	O
greater	O
understanding	O
and	O
the	O
incorporation	O
of	O
internal	O
biophysical mechanisms	B-T044
in	O
future	O
model developments	B-T170
.	O

Blood Pressure	B-T040
and	O
All-Cause Mortality	B-T033
by	O
Level	B-T080
of	O
Cognitive Function	B-T041
in	O
the	O
Elderly	B-T098
:	O
Results	B-T033
From	O
a	O
Population-Based Study	B-T062
in	O
Rural Greece	B-T083
This	O
study	B-T062
aimed	B-T078
to	O
investigate	B-T169
whether	O
the	O
effect	B-T080
of	O
blood pressure	B-T040
(	O
BP	B-T040
)	O
on	O
mortality	B-T033
differs	O
by	O
levels	B-T080
of	O
cognitive function	B-T041
.	O
The	O
associations	B-T080
of	O
brachial	B-T082
systolic BP	B-T201
,	O
diastolic BP	B-T201
,	O
mean arterial pressure	B-T033
(	O
MAP	B-T033
),	O
and	O
pulse pressure	B-T040
with	O
all-cause mortality	B-T033
were	O
prospectively explored	B-T033
(	O
follow-up	B-T058
7.0±2.2	O
years	B-T079
)	O
in	O
660	O
community-dwelling	B-T056
individuals	B-T098
(	O
≥60 years	B-T033
)	O
using	O
adjusted Cox models	B-T081
,	O
stratified	B-T080
by	O
cognitive impairment	B-T048
(	O
Mini-Mental State Examination	B-T060
[	O
MMSE	B-T060
]	O
<24).	O
No association	B-T080
between	O
brachial	B-T082
BP	B-T040
variables	B-T080
and	O
mortality	B-T033
was	O
shown	O
for	O
the	O
total	B-T080
sample	B-T167
in	O
quartiles analysis	B-T062
;	O
however,	O
MAP	B-T033
in	O
the	O
highest quartile	B-T080
,	O
compared	B-T052
with	O
the	O
second	B-T081
,	O
was	O
associated with	B-T080
mortality	B-T033
(	O
hazard ratio	B-T081
,	O
1.85;	O
95%	O
confidence intervals	B-T081
,	O
1.09-3.12)	O
among	O
cognitively impaired	B-T048
individuals	B-T098
.	O
The	O
fractional-polynomials approach	B-T062
for	O
BP	B-T040
confirmed	B-T033
this	O
finding	B-T033
and	O
further	B-T082
showed,	O
solely	B-T081
in	O
the	O
MMSE	B-T060
<24	O
subcohort	B-T081
,	O
U-shaped trends	B-T079
of	O
MAP	B-T033
and	O
systolic BP	B-T201
,	O
with	O
increased	B-T081
mortality risk	B-T078
in	O
extremely	B-T080
low or high values	B-T080
;	O
no	O
such	O
pattern	B-T082
was	O
evident	B-T078
for	O
patients	B-T101
with	O
MMSE	B-T060
≥24.	O
Elderly	B-T098
individuals	B-T098
with	O
cognitive impairment	B-T048
might	O
be	O
more	B-T081
susceptible	B-T169
to	O
the	O
detrimental effects	B-T046
of	O
low	B-T080
and	O
elevated	B-T080
MAP	B-T033
and	O
systolic BP	B-T201
.	O

Hypovitaminosis D	B-T047
and	O
Associated	O
Cardiometabolic Risk	B-T078
in	O
Women	B-T098
with	O
PCOS	B-T047
Women	B-T098
with	O
Polycystic Ovary Syndrome	B-T047
(	O
PCOS	B-T047
)	O
frequently	O
suffer	O
from	O
metabolic disturbances	B-T047
like	O
insulin resistance	B-T046
,	O
hypertension	B-T047
and	O
atherogenic dyslipidemia	B-T047
.	O
Accumulating	B-T033
evidences	O
suggest	O
that	O
Vitamin D deficiency	B-T047
is	O
common	O
in	O
PCOS	B-T047
and	O
may	O
be	O
associated with	B-T080
metabolic	B-T047
and	O
endocrinal dysfunctions	B-T047
in	O
PCOS	B-T047
.	O
Thus	O
women	B-T098
with	O
PCOS	B-T047
may	O
be	O
at	O
elevated	O
risk	B-T078
of	O
cardiovascular disease	B-T047
.	O
Present	O
study	B-T062
aims	O
to	O
evaluate	O
Vitamin D	B-T109
status	O
and	O
to	O
assess	O
its	O
association	O
with	O
metabolic	B-T047
and	O
endocrinal dysregulations	B-T047
in	O
women	B-T098
with	O
PCOS	B-T047
,	O
which	O
might	O
help	O
in	O
early identification	B-T061
and	O
prevention	B-T061
of	O
future	O
symptomatic	B-T169
cardiac disease	B-T047
.	O
A	O
total	O
of	O
44	O
women	B-T098
with	O
PCOS	B-T047
,	O
diagnosed	O
by	O
Rotterdam criteria	B-T170
and	O
45	O
healthy control	B-T080
without	O
PCOS	B-T047
,	O
were	O
evaluated	O
for	O
Vitamin D	B-T109
and	O
cardiometabolic risk factors	B-T033
,	O
including	O
fasting plasma glucose	B-T034
,	O
insulin resistance	B-T046
,	O
dyslipidemia	B-T047
,	O
hs-CRP	B-T033
.	O
That	O
apart,	O
several	O
endocrinal	B-T169
parameters	B-T077
of	O
hyperandrogenism	B-T047
were	O
also	O
examined.	O
Several	O
correlation studies	B-T062
were	O
determined	O
to	O
establish	O
the	O
role	O
of	O
Vitamin D	B-T109
as	O
a	O
cardiometabolic risk factor	B-T033
in	O
PCOS	B-T047
.	O
Results	O
were	O
expressed	O
as	O
mean±SD	O
and	O
were	O
statistically analysed	B-T062
using	O
SPSS software version 16	B-T073
,	O
unpaired student's t-test	B-T170
and	O
Pearson's correlation coefficient	B-T081
.	O
We	O
found	O
lower	O
levels	O
of	O
Vitamin D	B-T109
,	O
which	O
was	O
statistically	O
significant	O
as	O
compared	O
to	O
healthy controls	B-T080
.	O
Hyperinsulinemia	B-T047
,	O
rise	O
in	O
insulin resistance	B-T046
and	O
marked	O
dyslipidemia	B-T047
was	O
observed	O
in	O
the	O
present	O
study	B-T062
.	O
Another	O
relevant	O
finding	O
was	O
significant	O
correlation	O
of	O
Vitamin D	B-T109
with	O
insulin	B-T116
and	O
Homeostatic Model of Assessment- Insulin Resistance Index	B-T059
(	O
HOMA-IR	B-T059
).	O
Hypovitaminosis D	B-T047
was	O
prevalent	O
in	O
PCOS	B-T047
.	O
This	O
was	O
related	O
to	O
metabolic	B-T047
and	O
hormonal disorders	B-T033
in	O
PCOS	B-T047
.	O
Possibly	O
this	O
combined	O
with	O
impaired fasting glucose	B-T033
,	O
IR	B-T046
and	O
dyslipidemia	B-T047
,	O
could	O
account	O
for	O
Cardio vascular risks	B-T078
in	O
PCOS	B-T047
.	O
Further	O
prospective	O
observational studies	B-T170
and	O
randomized control trials	B-T062
are	O
required	O
to	O
explore	O
the	O
above	O
hypothesis	B-T078
.	O

Family	B-T099
close	B-T033
but	O
friends	B-T098
closer	B-T033
:	O
exploring	O
social support	B-T054
and	O
resilience	B-T055
in	O
older	B-T098
spousal	B-T099
dementia	B-T048
carers	B-T097
Spousal	B-T099
dementia	B-T048
carers	B-T097
have	O
unique	O
support	B-T054
needs	B-T080
;	O
they	O
are	O
likely	O
to	O
disengage	B-T080
from	O
their	O
existing	B-T077
social networks	B-T098
as	O
they	O
need	O
to	O
devote	O
more	O
time	B-T079
to	O
caring	B-T055
as	O
the	O
disease progresses	B-T046
.	O
Previously	O
we	O
showed	O
that	O
support	B-T054
resources	B-T078
can	O
facilitate	O
resilience	B-T055
in	O
carers	B-T097
,	O
but	O
the	O
relationship	B-T080
is	O
complex	B-T080
and	O
varies	O
by	O
relationship type	B-T169
.	O
The	O
current	O
paper	O
aims	O
to	O
explore	O
social support	B-T054
as	O
a	O
key	O
component	O
of	O
resilience	B-T055
to	O
identify	O
the	O
availability	B-T169
,	O
function	B-T169
and	O
perceived functional aspects	B-T169
of	O
support	B-T054
provided	O
to	O
older	B-T098
spousal	B-T099
dementia	B-T048
carers	B-T097
.	O
We	O
conducted	O
23	O
in-depth qualitative interviews	B-T052
with	O
spousal	B-T099
carers	B-T097
from	O
two	O
carer	B-T097
support groups	B-T095
and	O
a	O
care	O
home	O
in	O
North West England	B-T083
.	O
Family	B-T099
and	O
friends	B-T098
served	O
a	O
wide	O
range	O
of	O
functions	B-T169
but	O
were	O
equally	O
available	O
to	O
resilient	B-T098
and	O
non-resilient participants	B-T098
.	O
Family support	B-T061
was	O
perceived	B-T041
as	O
unhelpful	O
if	O
it	O
created	B-T052
feelings	B-T041
of	O
over-dependence	B-T080
.	O
Participants	B-T098
were	O
less	O
likely	O
to	O
resist involvement	B-T169
of	O
grandchildren	B-T099
due	O
to	O
their	O
relatively	O
narrow and low-level support functions	B-T054
.	O
Friend	B-T098
support	B-T054
was	O
perceived	B-T041
as	O
most	O
helpful	B-T080
when	O
it	O
derived	O
from	O
those	O
in	O
similar	O
circumstances	B-T080
.	O
Neighbours	B-T098
played	O
a	O
functionally	O
unique	O
role	O
of	O
crisis management	B-T061
.	O
These	O
perceptions	B-T041
may	O
moderate	B-T080
the	O
effect	B-T080
of	O
support	B-T054
on	O
resilience	B-T055
.	O
Family	B-T061
and	O
friend	B-T098
support	B-T054
is	O
not	O
always	O
sufficient	B-T080
to	O
facilitate	O
resilience	B-T055
.	O
Support functions	B-T054
facilitate	O
resilience	B-T055
only	O
if	O
they	O
are	O
perceived	B-T041
to	O
match	O
need	B-T080
.	O
Implications	B-T033
of	O
these	O
findings	B-T169
are	O
discussed.	O

Measure Up Pressure Down: Provider Toolkit	B-T058
to	O
Improve	B-T077
Hypertension	B-T047
Control	B-T040
Hypertension	B-T047
is	O
one	O
of	O
the	O
most	O
important	O
risk factors	B-T033
for	O
heart disease	B-T047
,	O
stroke	B-T047
,	O
kidney failure	B-T047
,	O
and	O
diabetes complications	B-T047
.	O
Nearly	O
one	O
in	O
three	O
Americans	B-T098
adults	B-T100
has	O
high blood pressure	B-T047
,	O
and	O
the	O
cost	B-T081
associated with	B-T080
treating	B-T061
this	O
condition	B-T047
is	O
staggering.	O
The	O
Measure Up Pressure Down: Provider Toolkit	B-T058
to	O
Improve	B-T077
Hypertension	B-T047
Control	B-T040
is	O
a	O
resource	B-T078
developed	B-T169
by	O
the	O
American Medical Group Foundation	B-T093
in	O
partnership	B-T092
with	O
the	O
American Medical Group Association	B-T093
.	O
The	O
goal	B-T170
of	O
this	O
toolkit	B-T170
is	O
to	O
mobilize	O
health care practitioners	B-T097
to	O
work	B-T057
together	B-T080
through	O
team	B-T096
-based	O
approaches	O
to	O
achieve	O
an	O
80%	O
control	B-T040
rate	B-T081
of	O
high blood pressure	B-T047
among	O
their	O
patient population	B-T101
.	O
The	O
toolkit	B-T170
can	O
be	O
used	O
by	O
health educators	B-T097
,	O
clinic administrators	B-T097
,	O
physicians	B-T097
,	O
students	B-T098
,	O
and	O
other	O
clinic staff	B-T097
as	O
a	O
step-by-step	O
resource	B-T078
for	O
developing	B-T169
the	O
infrastructure	B-T062
needed	O
to	O
better	O
identify	O
and	O
treat	B-T061
individuals	B-T098
with	O
high blood pressure	B-T047
or	O
other	O
chronic conditions.	B-T047

Potentiation	B-T061
of	O
LPS	B-T109
-	O
Induced	B-T046
Apoptotic Cell Death	B-T043
in	O
Human Hepatoma HepG2 Cells	B-T025
by	O
Aspirin	B-T109
via	O
ROS	B-T123
and	O
Mitochondrial Dysfunction	B-T033
:	O
Protection	B-T033
by	O
N-Acetyl Cysteine	B-T116
Cytotoxicity	B-T049
and	O
inflammation	B-T046
-	O
associated	B-T046
toxic	B-T080
responses	B-T032
have	O
been	O
observed	B-T169
to	O
be	O
induced	B-T169
by	O
bacterial	B-T080
lipopolysaccharides	B-T109
(	O
LPS	B-T109
)	O
in vitro	B-T080
and	O
in vivo	B-T082
respectively.	O
Use	O
of	O
nonsteroidal anti-inflammatory drugs	B-T121
(	O
NSAIDs	B-T121
),	O
such	O
as	O
aspirin	B-T109
,	O
has	O
been	O
reported	B-T058
to	O
be	O
beneficial	O
in	O
inflammation	B-T046
-	O
associated diseases	B-T046
like	O
cancer	B-T191
,	O
diabetes	B-T047
and	O
cardiovascular disorders	B-T047
.	O
Their	O
precise	O
molecular	B-T080
mechanisms	B-T169
,	O
however,	O
are	O
not	O
clearly	O
understood.	O
Our	O
previous	O
studies	B-T062
on	O
aspirin	B-T109
treated	B-T061
HepG2 cells	B-T025
strongly	O
suggest	O
cell cycle arrest	B-T043
and	O
induction	B-T169
of	O
apoptosis	B-T043
associated with	B-T080
mitochondrial dysfunction	B-T033
.	O
In	O
the	O
present	O
study	B-T062
,	O
we	O
have	O
further	O
demonstrated	O
that	O
HepG2 cells	B-T025
treated with	B-T061
LPS	B-T109
alone	O
or	O
in	O
combination	B-T080
with	O
aspirin	B-T109
induces	B-T169
subcellular	B-T026
toxic responses	B-T043
which	O
are	O
accompanied	O
by	O
increase	B-T169
in	O
reactive oxygen species	B-T123
(	O
ROS	B-T123
)	O
production,	O
oxidative stress	B-T049
,	O
mitochondrial respiratory dysfunction	B-T033
and	O
apoptosis	B-T043
.	O
The	O
LPS	B-T109
/	O
Aspirin	B-T109
induced	B-T169
toxicity	B-T037
was	O
attenuated	B-T052
by	O
pre-treatment	B-T079
of	O
cells	B-T025
with	O
N-acetyl cysteine	B-T116
(	O
NAC	B-T116
).	O
Alterations	O
in	O
oxidative stress	B-T049
and	O
glutathione	B-T116
-	O
dependent	B-T080
redox-homeostasis	B-T043
were	O
more	O
pronounced	O
in	O
mitochondria	B-T026
compared	B-T052
to	O
extra	B-T082
-	O
mitochondrial	B-T026
cellular compartments	B-T026
.	O
Pre-treatment	B-T079
of	O
HepG2 cells	B-T025
with	O
NAC	B-T116
exhibited	O
a	O
selective	O
protection	B-T033
in	O
redox homeostasis	B-T043
and	O
mitochondrial dysfunction	B-T033
.	O
Our	O
results	B-T033
suggest	O
that	O
the	O
altered	B-T169
redox metabolism	B-T043
,	O
oxidative stress	B-T049
and	O
mitochondrial	B-T026
function	B-T169
in	O
HepG2 cells	B-T025
play	O
a	O
critical	O
role	O
in	O
LPS	B-T109
/	O
aspirin	B-T109
-	O
induced	B-T169
cytotoxicity	B-T049
.	O
These	O
results	B-T033
may	O
help	O
in	O
better	O
understanding	O
the	O
pharmacological	B-T169
,	O
toxicological	B-T169
and	O
therapeutic properties	B-T169
of	O
NSAIDs	B-T121
in	O
cancer cells	B-T025
exposed	B-T080
to	O
bacterial endotoxins	B-T109
.	O

Placental	B-T018
Pathologic	B-T169
Associations	B-T080
with	O
Morbidly Adherent Placenta	B-T046
:	O
Potential	O
insights	O
into	O
Pathogenesis	B-T046
The	O
pathology	B-T169
that	O
underlies	O
morbidly adherent placenta	B-T046
(	O
MAP	B-T046
)	O
is	O
poorly	O
understood.	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
describe	O
the	O
placental	B-T018
pathology	B-T169
,	O
especially	O
implantation site	B-T082
pathology	B-T169
,	O
associated with	B-T080
MAP	B-T046
.	O
This	O
was	O
a	O
single	B-T081
institution	B-T093
,	O
retrospective case-control study	B-T062
design	O
examining	O
placentas	B-T018
of	O
patients	B-T101
who	O
delivered	B-T033
between	O
January	O
2008	O
and	O
September	O
2013.	O
MAP	B-T046
cases	B-T077
were	O
defined	O
by	O
the	O
need	O
for	O
clinical	B-T080
intervention	B-T058
at	O
delivery	B-T061
beyond	O
spontaneous	B-T169
placental delivery	B-T061
or	O
simple	O
manual extraction	B-T061
of	O
the	O
placenta	B-T018
.	O
Controls	B-T096
consisted	O
of	O
patients	B-T101
with	O
placentas	B-T018
sent	O
for	O
examination	B-T058
due	O
to	O
a	O
history	B-T033
of	O
maternal	B-T099
malignancy	B-T191
with	O
no	B-T033
clinical	B-T080
suspicion	B-T078
of	O
accreta	B-T046
.	O
Placental	B-T018
pathologic findings	B-T033
of	O
maternal vascular underperfusion	B-T047
(	O
MVU	B-T047
),	O
acute inflammation	B-T033
,	O
chronic inflammation	B-T046
,	O
fetal	B-T018
vascular obstruction	B-T047
and	O
hemorrhage	B-T046
were	O
recorded	O
and	O
compared	O
using	O
bivariable and multivariable analyses	B-UnknownType
.	O
Three	O
categories	B-T170
of	O
pathologic	B-T169
changes	B-T169
were	O
seen	O
more	O
commonly	O
in	O
MAP	B-T046
placentas	B-T018
(N=101)	O
than	O
control	B-T096
placentas	B-T018
(N=110):	O
chronic basal inflammation	B-T046
,	O
villous	O
changes	B-T169
of	O
MVU	B-T047
and	O
retromembranous	O
and	O
retromembranous	B-T046
/	O
intervillous hemorrhage	B-T046
.	O
In	O
multivariable analyses	B-T081
adjusted	O
for	O
confounders	B-T169
,	O
chronic basal villitis	B-T047
(	O
aOR	B-T081
5.6,	O
1.73-18.18),	O
plasma cell deciduitis	B-T033
(	O
aOR	B-T081
2.63,	O
1.08-6.39),	O
increased syncytial knots	B-T033
(	O
aOR	B-T081
3.92,	O
1.57-9.75),	O
villous	O
agglutination	O
(	O
aOR	B-T081
24.85,	O
2.78-221.75),	O
increased perivillous fibrin	B-T033
(	O
aOR	B-T081
5.08,	O
1.49-17.34),	O
and	O
the	O
presence	O
of	O
subchorionic	B-T046
/	O
intervillous thrombi	B-T033
(	O
aOR	B-T081
4.01,	O
1.63-9.86)	O
remained	O
associated with	B-T080
MAP	B-T046
.	O
MAP	B-T046
is	O
highly	O
associated with	B-T080
evidence	O
of	O
intraparenchymal placental hemorrhage	B-T046
villous	B-T080
changes	B-T169
of	O
MVU	B-T047
,	O
and	O
a	O
lymphoplasmacytic infiltrate	B-T033
at	O
the	O
implantation site	B-T082
.	O
The	O
contribution	O
of	O
this	O
basal chronic inflammatory infiltrate	B-T033
to	O
MAP	B-T046
requires	O
further	O
investigation.	O

An	O
ion-gating	O
multinanochannel	O
system	O
based	O
on	O
a	O
copper	B-T121
-	O
responsive	B-T169
self	B-T078
-	O
cleaving	B-T082
DNAzyme	B-T114
We	O
developed	O
an	O
ion-gating	O
nanochannel	O
composite	O
system	O
by	O
immobilizing	B-T169
a	O
Cu(2+)	B-T121
-	O
responsive	B-T169
self	B-T078
-	O
cleaving	B-T082
DNAzyme	B-T114
into	O
PET	B-T109
conical multinanochannels	B-T122
,	O
which	O
could	O
control	B-T169
the	O
ion transport	B-T043
by	O
regulating	B-T038
the	O
surface	B-T082
charge	B-T032
density	B-T081
of	O
the	O
channels	B-T122
.	O

High-Intensity Intermittent Training	B-T056
Positively	B-T033
Affects	B-T080
Aerobic	B-T061
and	O
Anaerobic Performance	B-T056
in	O
Judo	B-T056
Athletes	B-T097
Independently	O
of	O
Exercise Mode	B-T056
The	O
present	O
study	O
investigated	O
the	O
effects	B-T080
of	O
high-intensity intermittent training	B-T056
(	O
HIIT	B-T056
)	O
on	O
lower	B-T023
-	O
and	O
upper-body	B-T023
graded exercise	B-T056
and	O
high-intensity intermittent exercise	B-T056
(	O
HIIE	B-T056
,	O
four	O
Wingate	O
bouts)	O
performance	B-T052
,	O
and	O
on	O
physiological	B-T169
and	O
muscle damage	B-T020
markers responses	B-T033
in	O
judo	B-T056
athletes	B-T097
.	O
Thirty-five	O
subjects	B-T098
were	O
randomly allocated	B-T062
to	O
a	O
control group	B-T096
(n	O
=	O
8)	O
or	O
to	O
one	O
of	O
the	O
following	O
HIIT	B-T056
groups	B-T078
(n	O
=	O
9	O
for	O
each)	O
and	O
tested pre- and post	B-T170
-four	O
weeks	O
(2	O
training	O
d·wk(-1)):	O
(1)	O
lower-body	B-T023
cycle-ergometer	B-T061
;	O
(2)	O
upper-body	O
cycle-ergometer	B-T061
;	O
(3)	O
uchi-komi	B-T169
(	O
judo technique entrance	B-T169
).	O
All	O
HIIT	B-T056
were	O
constituted	O
by	O
two	O
blocks	O
of	O
10	O
sets	O
of	O
20	O
s	O
of	O
all	O
out	O
effort	O
interspersed	O
by	O
10	O
s	O
set	O
intervals	O
and	O
5-min	O
between	O
blocks.	O
For	O
the	O
upper-body	B-T023
group	B-T078
there	O
was	O
an	O
increase	B-T169
in	O
maximal aerobic power	B-T201
in	O
graded	O
upper-body	B-T023
exercise test	B-T033
(12.3%).	O
The	O
lower-body	B-T023
group	B-T078
increased	B-T169
power	B-T201
at	O
onset blood lactate	B-T109
in	O
graded	O
upper-body	B-T023
exercise test	B-T033
(22.1%).	O
The	O
uchi-komi group	B-T078
increased	B-T169
peak	O
power	O
in	O
upper	B-T023
-	O
(16.7%)	O
and	O
lower-body	B-T023
(8.5%),	O
while	O
the	O
lower-body	B-T023
group	O
increased	B-T169
lower-body	B-T023
mean	O
power	O
(14.2%)	O
during	O
the	O
HIIE	B-T056
.	O
There	O
was	O
a	O
decrease	B-T081
in	O
the	O
delta blood lactate	B-T109
for	O
the	O
uchi-komi training	B-T065
group	B-T078
and	O
in	O
the	O
third	O
and	O
fourth	O
bouts	O
for	O
the	O
upper-body	B-T023
training	B-T065
group	B-T078
.	O
Training	B-T065
induced	O
testosterone-cortisol	B-T081
ratio	B-T081
increased	B-T169
in	O
the	O
lower-body	B-T023
HIIE	B-T056
for	O
the	O
lower-body	B-T023
(14.9%)	O
and	O
uchi-komi (61.4%) training	B-T065
groups	B-T078
.	O
Thus,	O
short-duration	B-T080
low-volume	O
HIIT	B-T056
added	O
to	O
regular judo training	B-T065
was	O
able	O
to	O
increase	B-T169
upper-body	B-T023
aerobic power	B-T201
,	O
lower	B-T023
-	O
and	O
upper-body	B-T023
HIIE	B-T056
performance	B-T052
.	O

Microbiomes	B-T001
of	O
Muricea californica	B-T204
and	O
M. fruticosa	B-T204
:	O
Comparative Analyses	B-T062
of	O
Two	O
Co-occurring	O
Eastern Pacific	B-T083
Octocorals	B-T204
Octocorals	B-T204
are	O
sources	O
of	O
novel	O
but	O
understudied	B-T062
microbial	B-T001
diversity	B-T080
.	O
Conversely,	O
scleractinian	B-T204
or	O
reef-building coral microbiomes	B-T001
have	O
been	O
heavily	O
examined	B-T033
in	O
light	O
of	O
the	O
threats	B-T078
of	O
climate change	B-T070
.	O
Muricea californica	B-T204
and	O
Muricea fruticosa	B-T204
are	O
two	O
co-occurring species	B-T185
of	O
gorgonian octocoral	B-T204
abundantly found	B-T033
in	O
the	O
kelp	B-T204
forests	B-T070
of	O
southern California	B-T083
,	O
and	O
thus	O
provide	O
an	O
excellent basis	B-T169
to	O
determine	O
if	O
octocoral	B-T204
microbiomes	B-T001
are	O
host	B-T001
specific	B-T080
.	O
Using	O
Illumina MiSeq amplicon sequencing	B-T170
and	O
replicate samples	B-T169
,	O
we	O
evaluated	O
the	O
microbiomes	B-T001
collected	O
from	O
multiple colonies	B-T081
of	O
both	O
species	B-T185
of	O
Muricea	B-T204
to	O
measure	B-T081
both	O
inter-	B-T025
and	O
intra-colony	B-T025
microbiome	B-T001
variabilities	B-T077
.	O
In	O
addition,	O
microbiomes	B-T001
from	O
overlying	O
sea water	B-T167
and	O
nearby	O
zoanthids	B-T204
(another	O
benthic invertebrate	B-T204
)	O
were	O
also	O
included	O
in	O
the	O
analysis	B-T062
to	O
evaluate	O
whether	O
bacterial taxa	B-T170
specifically	O
associate with	B-T080
octocorals	B-T204
.	O
This	O
is	O
also	O
the	O
first report	B-T170
of	O
microbiomes	B-T001
from	O
these	O
species	B-T185
of	O
Muricea	B-T204
.	O
We	O
show	O
that	O
microbiomes	B-T001
isolated	B-T169
from	O
each	O
sample type	B-T080
are	O
distinct	B-T080
,	O
and	O
specifically,	O
that	O
octocoral	B-T204
species	B-T185
type	B-T080
had	O
the	O
greatest	O
effect	O
on	O
predicting	B-T078
the	O
composition	B-T201
of	O
the	O
Muricea	B-T204
microbiome	B-T001
.	O
Bacterial taxa	B-T170
contributing	O
to	O
compositional differences	B-T081
include	O
distinct	B-T080
strains	B-T001
of	O
Mycoplasma	B-T007
associated with	B-T080
either	O
M. californica	B-T204
or	O
M. fruticosa	B-T204
,	O
an	O
abundance	B-T080
of	O
Spirochaetes	B-T007
observed	B-T169
on	O
M. californica	B-T204
,	O
and	O
a	O
greater	B-T081
diversity	B-T080
of	O
γ-Proteobacteria	B-T007
associated with	B-T080
M. fruticosa	B-T204
.	O
Many	O
of	O
the	O
bacterial taxa	B-T170
contributing	O
to	O
these	O
differences	B-T081
are	O
known	O
for	O
their	O
presence	B-T033
in	O
photosymbiont-containing invertebrate	B-T204
microbiomes	B-T001
.	O

2,8-Dihydroxyadenine	B-T114
Nephropathy	B-T047
Identified	O
as	O
Cause	B-T169
of	O
End-Stage Renal Disease	B-T047
After	O
Renal Transplant	B-T061
Adenine phosphoribosyltransferase	B-T116
Adenine phosphoribosyltransferase deficiency	B-T047
is	O
a	O
rare	O
autosomal recessive disorder	B-T047
of	O
uric acid	B-T109
metabolism	B-T040
that	O
leads	O
to	O
formation	B-T169
and	O
excretion	B-T039
of	O
2,8-dihydroxyadenine	B-T114
into	O
urine	B-T031
.	O
The	O
low	O
solubility	B-T080
of	O
2,8-dihydroxyadenine	B-T114
results	O
in	O
precipitation	B-T070
and	O
formation	B-T169
of	O
urinary crystals	B-T034
and	O
renal stones	B-T047
.	O
Patients	B-T101
with	O
this	O
disorder	B-T047
usually	O
have	O
recurrent nephrolithiasis	B-T047
and	O
can	O
develop	O
nephropathy secondary	B-T047
to	O
crystal	B-T031
precipitation	B-T070
in	O
the	O
renal parenchyma	B-T023
.	O
The	O
disease	B-T047
is	O
most	O
often	O
underdiagnosed	B-T033
and	O
can	O
recur	B-T067
in	O
renal transplant	B-T061
,	O
causing	B-T169
graft failure	B-T046
.	O
Lack	O
of	O
specific	O
clinical	B-T080
manifestations	B-T169
,	O
chemical	B-T070
and	O
radiologic features	B-T033
identical	O
to	O
those	O
shown	O
with	O
uric acid	B-T109
uric acid stones	B-T031
,	O
and	O
lack of awareness	B-T033
among	O
clinicians	B-T097
are	O
among	O
the	O
causes	B-T169
for	O
the	O
underdiagnoses	B-T033
of	O
this	O
treatable	B-T169
disease	B-T047
.	O
Allopurinol	B-T109
,	O
a	O
xanthine dehydrogenase	B-T116
inhibitor	B-T121
,	O
is	O
the	O
mainstay	O
of	O
treatment	B-T169
,	O
supported	O
by	O
high	O
fluid intake	B-T201
and	O
dietary modifications	B-T061
.	O
The	O
possibility	O
of	O
adenine phosphoribosyl transferase	B-T116
adenine phosphoribosyl transferase deficiency	B-T047
should	O
be	O
considered	O
in	O
all	O
cases	O
of	O
urolithiasis	B-T047
in	O
children	B-T100
,	O
patients	B-T101
with	O
recurrent urolithiasis	B-UnknownType
,	O
and	O
patients	B-T101
with	O
urolithiasis	B-T047
associated with	B-T080
renal failure	B-T047
of	O
unknown	O
cause	B-T169
,	O
including	O
patients	B-T101
with	O
end-stage renal disease	B-T047
and	O
renal transplant recipients	B-T101
.	O
Here,	O
we	O
report	O
a	O
case	O
of	O
a	O
41-year-old	O
female patient	B-T032
who	O
had	O
a	O
late diagnosis	B-T080
of	O
2,8-dihydroxyadenine	B-T114
nephropathy	B-T047
-induced	O
end-stage renal disease	B-T047
,	O
made	O
on	O
the	O
native	B-T169
nephrectomy	B-T061
that	O
accompanied	O
the	O
renal transplant	B-T061
,	O
and	O
who	O
had	O
a	O
timely	O
intervention	O
that	O
prevented	B-T080
recurrence	B-T046
in	O
the	O
graft	B-T061
.	O

Social capital	B-T169
and	O
healthy	B-T080
ageing	B-T040
in	O
Indonesia	B-T083
A	O
large	B-T081
international	B-T078
literature	B-T170
has	O
found	O
a	O
positive	B-T033
association	B-T080
between	O
social capital	B-T169
and	O
measures	B-T081
of	O
physical	B-T033
and	O
mental health	B-T041
.	O
However,	O
there	O
is	O
a	O
paucity	O
of	O
research	B-T062
on	O
the	O
links	B-T080
between	O
social capital	B-T169
and	O
healthy	B-T080
ageing	B-T040
in	O
a	O
developing country	B-T080
environment	B-T082
,	O
where	O
universal social security coverage	B-T064
is	O
absent	B-T169
and	O
health infrastructure	B-T078
is	O
poor	B-T080
.	O
In	O
this	O
paper,	O
we	O
develop	O
and	O
empirically	O
test	B-T169
a	O
model	B-T170
of	O
the	O
linkages	B-T185
between	O
social capital	B-T169
and	O
the	O
health outcomes	B-T170
for	O
older adults	B-T098
in	O
Indonesia	B-T083
,	O
using	O
data	B-T078
from	O
the	O
Indonesian Family Life Survey-East	B-T170
(	O
IFLS-East	B-T170
),	O
conducted	O
in	O
2012.	O
Using	O
multivariate regression analysis	B-T170
,	O
we	O
examine	O
whether	O
social capital	B-T169
plays	O
a	O
role	B-T077
in	O
mitigating	B-T080
poor health	B-T033
among	O
older	B-T098
individuals	B-T098
aged	B-T032
50	O
years	B-T079
and	O
above	O
in	O
Indonesia	B-T083
's	O
most	O
vulnerable provinces	B-T083
.	O
We	O
test	B-T169
the	O
robustness	B-T080
of	O
these	O
social capital	B-T169
variables	B-T080
across	O
different	O
health	B-T078
measures	B-T081
(	O
self-assessed	B-T052
health	B-T078
,	O
Activities of Daily Living	B-T056
(	O
ADL	B-T056
),	O
measures	B-T081
of	O
chronic illness	B-T047
and	O
mental health	B-T041
measures	B-T081
),	O
as	O
well	O
as	O
across	O
different	O
demographic	B-T090
groups	B-T078
,	O
after	O
controlling	B-T169
for	O
an	O
array	B-T082
of	O
socio-economic	B-T080
,	O
demographic	B-T090
and	O
geographic	B-T082
characteristics	B-T080
.	O
Our	O
findings	B-T033
show	O
that	O
access	B-T082
to	O
better	O
social capital	B-T169
(using	O
measures	B-T081
of	O
neighbourhood	B-T098
trust	B-T054
and	O
community participation	B-T054
)	O
is	O
associated with	B-T080
a	O
higher	B-T080
degree	B-T081
of	O
physical mobility	B-T040
,	O
independence	B-T078
,	O
and	O
mental well-being	B-T041
among	O
older	B-T098
individuals	B-T098
but	O
has	O
no	O
influence	B-T077
on	O
chronic illnesses	B-T047
.	O
These	O
results	B-T169
are	O
consistent	B-T078
when	O
we	O
estimate	B-T081
samples	B-T096
disaggregated	O
by	O
gender	B-T032
,	O
rural	B-T033
/	O
urban	B-T080
residence	B-T082
,	O
and	O
by	O
age	B-T032
categories	B-T170
.	O
From	O
a	O
policy	B-T170
perspective	O
these	O
results	B-T169
point	O
to	O
the	O
importance	O
of	O
social capital	B-T169
measures	B-T169
in	O
moderating	B-T080
the	O
influence	B-T077
of	O
poor health	B-T033
,	O
particularly	O
in	O
the	O
Activities of Daily Living	B-T056
.	O

Modulation	B-T082
of	O
Interleukins	B-T116
in	O
Sepsis	B-T047
-	O
Associated	B-T080
Clotting Disorders	B-T047
:	O
Interplay	O
With	O
Hemostatic Derangement	B-T047
Interleukins	B-T116
play	O
a	O
central	B-T082
role	B-T077
in	O
the	O
immune system	B-T022
and	O
are	O
involved	B-T169
in	O
a	O
variety	O
of	O
immunological	B-T047
,	O
inflammatory	B-T047
,	O
and	O
infectious disease	B-T047
states	B-T169
including	O
sepsis syndrome	B-T047
.	O
Levels	B-T080
of	O
interleukins	B-T116
may	O
correlate	B-T080
with	O
overall survival	B-T081
and	O
may	O
directly	B-T080
or	O
indirectly	B-T080
affect	B-T041
some	O
of	O
the	O
regulators	B-T121
of	O
coagulation	B-T042
and	O
fibrinolysis	B-T039
,	O
thereby	O
disrupting	O
hemostasis	B-T042
and	O
thrombosis	B-T046
.	O
Our	O
hypothesis	B-T078
is	O
that	O
in	O
sepsis-associated coagulopathies	B-T047
(	O
SACs	B-T047
),	O
interleukins	B-T116
may	O
be	O
upregulated	B-T044
,	O
leading	O
to	O
hemostatic imbalance	B-T047
by	O
generating	O
thrombogenic mediators	B-T123
.	O
We	O
profiled	B-T169
the	O
levels	B-T080
of	O
interleukins	B-T116
IL-1α	B-T116
,	O
IL-1β	B-T116
,	O
IL-2	B-T116
,	O
IL-4	B-T116
,	O
IL-6	B-T116
,	O
IL-8	B-T116
,	O
and	O
IL-10	B-T116
in addition to	B-T169
d-dimer	B-T116
(	O
DD	B-T116
)	O
in	O
patients	B-T101
with	O
SAC	B-T047
and	O
in	O
normal	B-T080
donors	B-T098
.	O
We	O
observed	B-T169
the	O
highest	B-T080
increase	B-T169
in	O
interleukins	B-T116
IL-6	B-T116
(	O
322-fold	B-T081
),	O
IL-8	B-T116
(	O
48-fold	B-T081
),	O
IL-10	B-T116
(	O
72-fold	B-T081
),	O
and	O
DD	B-T116
(	O
18-fold	B-T081
).	O
This	O
suggests	B-T078
that	O
interleukins	B-T116
such	O
as	O
IL-6	B-T116
and	O
IL-10	B-T116
have	O
a	O
close	O
association with	B-T080
coagulopathy	B-T047
and	O
fibrinolytic dysregulation	B-UnknownType
in	O
sepsis	B-T047
and	O
can	O
be	O
considered	B-T078
as	O
candidates	B-T116
for	O
potential	B-T080
therapeutic	B-T169
targets	B-T169
in	O
SAC	B-T047
.	O

Thymosin β4	B-T116
:	O
Roles	O
in	O
Development	B-T169
,	O
Repair	B-T040
,	O
and	O
Engineering	B-T169
of	O
the	O
Cardiovascular System	B-T022
The	O
burden	O
of	O
cardiovascular disease	B-T047
is	O
a	O
growing	O
worldwide	O
issue	O
that	O
demands	O
attention.	O
While	O
many	O
clinical trials	B-T062
are	O
ongoing	O
to	O
test	B-T169
therapies	B-T061
for	O
treating	B-T169
the	O
heart	B-T023
after	O
myocardial infarction	B-T047
(	O
MI	B-T047
)	O
and	O
heart failure	B-T047
,	O
there	O
are	O
few	O
options	O
doctors	B-T097
able	O
to	O
currently	O
give	O
patients	B-T101
to	O
repair the heart	B-T061
.	O
This	O
eventually	O
leads	O
to	O
decreased	O
ventricular contractility	B-T042
and	O
increased	O
systemic disease	B-T047
,	O
including	O
vascular disorders	B-T047
that	O
could	O
result	O
in	O
stroke	B-T047
.	O
Small	O
peptides	B-T116
such	O
as	O
thymosin β4	B-T116
(	O
Tβ4	B-T116
)	O
are	O
upregulated	O
in	O
the	O
cardiovascular	B-T029
niche	B-T030
during	O
fetal development	B-T042
and	O
after	O
injuries	B-T037
such	O
as	O
MI	B-T047
,	O
providing	O
increased	O
neovasculogenesis	B-T191
and	O
paracrine signals	B-T043
for	O
endogenous	B-T169
endogenous stem cell	B-T025
recruitment	O
to	O
aid	O
in	O
wound repair	B-T040
.	O
New	O
research	B-T062
is	O
looking	O
into	O
the	O
effects	O
of	O
in vivo	B-T082
administration	B-T061
of	O
Tβ4	B-T116
through	O
injections	B-T061
and	O
coatings	B-T121
on	O
implants	B-T074
,	O
as	O
well	O
as	O
its	O
effect	O
on	O
cell differentiation	B-T043
.	O
Results	O
so	O
far	O
demonstrate	O
Tβ4	B-T116
administration	B-T061
leads	O
to	O
robust	O
increases	O
in	O
angiogenesis	B-T042
and	O
wound healing	B-T040
in	O
the	O
heart	B-T023
after	O
MI	B-T047
and	O
the	O
brain	B-T023
after	O
stroke	B-T047
,	O
and	O
can	O
differentiate	O
adult stem cells	B-T025
toward	O
the	O
cardiac	B-T023
lineage	B-T078
for	O
implantation	B-T061
to	O
the	O
heart	B-T023
to	O
increase	O
contractility	B-T042
and	O
survival	B-T169
.	O
Future	O
work,	O
some	O
of	O
which	O
is	O
currently	O
in	O
clinical trials	B-T062
,	O
will	O
demonstrate	O
the	O
in vivo	B-T082
effect	B-T080
of	O
these	O
therapies	B-T061
on	O
human	B-T016
patients	B-T101
,	O
with	O
the	O
goal	B-T170
of	O
helping	O
the	O
millions	O
of	O
people	B-T098
worldwide	O
affected	O
by	O
cardiovascular disease	B-T047
.	O

Yersinia ruckeri	B-T007
Isolates	B-T123
Recovered from	B-T080
Diseased	B-T047
Atlantic Salmon	B-T013
(	O
Salmo salar	B-T013
)	O
in	O
Scotland	B-T083
Are	O
More	O
Diverse	O
than	O
Those	O
from	O
Rainbow Trout	B-T013
(	O
Oncorhynchus mykiss	B-T013
)	O
and	O
Represent	B-T052
Distinct	O
Subpopulations	B-T098
Yersinia ruckeri	B-T007
is	O
the	O
etiological agent	B-T169
of	O
enteric redmouth	B-T047
(	O
ERM	B-T047
)	O
disease	B-T047
of	O
farmed	O
salmonids	B-T013
.	O
Enteric redmouth disease	B-T047
is	O
traditionally	O
associated with	B-T080
rainbow trout	B-T013
(	O
Oncorhynchus mykiss	B-T013
,	O
Walbaum	B-T013
),	O
but	O
its	O
incidence	B-T081
in	O
Atlantic salmon	B-T013
(	O
Salmo salar	B-T013
)	O
is	O
increasing	B-T169
.	O
Yersinia ruckeri	B-T007
isolates	B-T123
recovered from	B-T080
diseased	B-T047
Atlantic salmon	B-T013
have	O
been	O
poorly characterized	B-T052
,	O
and	O
very	O
little	O
is	O
known	O
about	O
the	O
relationship	B-T080
of	O
the	O
isolates	B-T123
associated with	B-T080
these	O
two	O
species	B-T185
.	O
Phenotypic	B-T032
approaches	O
were	O
used	O
to	O
characterize	O
109	O
Y. ruckeri	B-T007
isolates	B-T123
recovered	O
over	O
a	O
14-year	O
period	O
from	O
infected	B-T033
Atlantic salmon	B-T013
in	O
Scotland	B-T083
;	O
26	O
isolates	B-T123
from	O
infected	B-T033
rainbow trout	B-T013
were	O
also	O
characterized	B-T052
.	O
Biotyping	B-T059
,	O
serotyping	B-T059
,	O
and	O
comparison	B-T052
of	O
outer membrane	B-T026
protein profiles	B-T034
identified	O
19	O
Y. ruckeri	B-T007
clones	B-T024
associated with	B-T080
Atlantic salmon	B-T013
but	O
only	O
five	O
associated with	B-T080
rainbow trout	B-T013
;	O
none	O
of	O
the	O
Atlantic salmon	B-T013
clones	B-T024
occurred	O
in	O
rainbow trout	B-T013
and	O
vice	O
versa	O
These	O
findings	B-T033
suggest	O
that	O
distinct	O
subpopulations	B-T098
of	O
Y. ruckeri	B-T007
are	O
associated with	B-T080
each	O
species	B-T185
.	O
A	O
new	O
O serotype	B-T170
(designated	O
O8)	O
was	O
identified	O
in	O
56 biotype 1	B-T170
Atlantic salmon	B-T013
isolates	B-T123
and	O
was	O
the	O
most	O
common	O
serotype	B-T170
identified	O
from	O
2006	O
to	O
2011	O
and	O
in	O
2014,	O
suggesting	O
an	O
increased prevalence	B-T081
during	O
the	O
time	O
period	O
sampled.	O
Rainbow trout	B-T013
isolates	B-T123
were	O
represented	B-T052
almost	O
exclusively	O
by	O
the	O
same	O
biotype 2	B-T170
,	O
serotype O1	B-T170
clone	O
that	O
has	O
been	O
responsible	O
for	O
the	O
majority	O
of	O
ERM	B-T047
outbreaks	O
in	O
this	O
species	B-T185
within	O
the	O
United Kingdom	B-T083
since	O
the	O
1980s.	O
However,	O
the	O
identification	O
of	O
two	O
biotype 2	B-T170
,	O
serotype O8	B-T170
isolates	B-T123
in	O
rainbow trout	B-T013
suggests	O
that	O
vaccines	B-T121
containing	O
serotypes O1 and O8	B-T170
should	O
be	O
evaluated	O
in	O
both	O
rainbow trout	B-T013
and	O
Atlantic salmon	B-T013
for	O
application	O
in	O
Scotland	B-T083
.	O
Vaccination	B-T061
plays	O
an	O
important	O
role	O
in	O
protecting	O
Atlantic salmon	B-T013
against	O
the	O
bacterial	B-T007
pathogen	O
Yersinia ruckeri	B-T007
,	O
but,	O
in	O
recent	O
years,	O
there	O
has	O
been	O
an	O
increasing	B-T169
incidence	B-T081
of	O
vaccine	B-T121
breakdown	O
in	O
salmon	B-T013
.	O
This	O
is	O
largely	O
because	O
current	O
vaccines	B-T121
are	O
aimed	O
at	O
rainbow trout	B-T013
and	O
are	O
based	O
on	O
serotypes	B-T170
specific	O
for	O
this	O
species	B-T185
.	O
A	O
wider	O
range	O
of	O
serotypes	B-T170
is	O
responsible	O
for	O
infection	B-T046
in	O
Atlantic salmon	B-T013
,	O
but	O
very	O
little	O
is	O
known	O
about	O
the	O
diversity	O
of	O
these	O
strains	B-T013
and	O
their	O
relationships	B-T080
to	O
those	O
recovered from	B-T080
rainbow trout	B-T013
.	O
In	O
the	O
present	O
study,	O
we	O
demonstrate	O
that	O
Y. ruckeri	B-T007
isolates	B-T123
recovered from	B-T080
diseased	B-T047
Atlantic salmon	B-T013
in	O
Scotland	B-T083
are	O
more	O
diverse	O
than	O
those	O
from	O
rainbow trout	B-T013
;	O
furthermore,	O
isolates	B-T123
from	O
the	O
two	O
species	B-T185
represent	B-T052
distinct	O
subpopulations	B-T098
.	O
In	O
addition,	O
a	O
new	O
O serotype	B-T170
was	O
identified	O
that	O
is	O
responsible	O
for	O
a	O
significant	B-T078
proportion	B-T081
of	O
the	O
disease	B-T047
in	O
Atlantic salmon	B-T013
.	O
Our	O
findings	B-T033
are	O
likely	O
to	O
have	O
important	O
implications	O
for	O
the	O
development of improved vaccines	B-T062
against	O
Y. ruckeri	B-T007
.	O

CD84	B-T116
mediates	O
CLL	B-T191
-	O
microenvironment	B-T070
interactions	B-T043
Chronic lymphocytic leukemia	B-T191
(	O
CLL	B-T191
)	O
is	O
a	O
malignant disease	B-T047
of	O
small	O
mature lymphocytes	B-T025
.	O
Signals	B-T067
from	O
the	O
CLL	B-T191
microenvironment	B-T070
promote	B-T052
progression of the disease	B-T046
and	O
induce	B-T169
drug resistance	B-T038
.	O
This	O
phenomenon	B-T067
is	O
largely	O
dependent	B-T080
on	O
direct	O
contact	O
between	O
the	O
malignant B cells	B-T191
and	O
stromal cells	B-T025
.	O
CD84	B-T116
belongs	O
to	O
the	O
signaling lymphocyte activation molecule family	B-T116
of	O
immunoreceptors	B-T116
,	O
which	O
self-associates	B-T044
,	O
forming	O
an	O
orthogonal homophilic dimer	B-T104
.	O
We	O
therefore	O
hypothesized	O
that	O
CD84	B-T116
may	O
bridge	O
between	O
CLL	B-T191
cells	B-T025
and	O
their	O
microenvironment	B-T070
,	O
promoting	B-T052
cell survival	B-T043
.	O
Our	O
in vitro	B-T080
results	B-T169
show	O
that	O
CD84 expressed	B-T045
on	O
CLL	B-T191
cells	B-T025
interact	B-T169
with	O
CD84 expressed	B-T045
on	O
cells	B-T025
in	O
their	O
microenvironment	B-T070
,	O
inducing	B-T169
cell survival	B-T043
in	O
both	O
sides.	O
Blocking	B-T169
CD84	B-T116
in vitro	B-T080
and	O
in vivo	B-T082
disrupt	B-T080
the	O
interaction	B-T169
of	O
CLL	B-T191
cells	B-T025
with	O
their	O
microenvironment	B-T070
,	O
resulting in	B-T169
induced	B-T169
cell death	B-T043
.	O
Thus,	O
our	O
findings	B-T033
suggest	O
novel	B-T080
therapeutic	B-T169
strategies	O
based	O
on	O
the	O
blockade	B-T121
of	O
this	O
CD84	B-T116
-	O
dependent	B-T080
survival	B-T043
pathway	B-T044
.	O

Aurantimonas endophytica sp. nov.	B-T007
,	O
a	O
novel	O
endophytic bacterium	B-T004
isolated	O
from	O
roots	B-T002
of	O
Anabasis elatior (C. A. Mey.) Schischk	B-T002
An	O
orange-coloured	B-T080
,	O
aerobic	B-T080
,	O
motile	B-T033
and	O
short-rods bacterial strain	B-T007
,	O
designated	O
EGI 6500337T	B-T007
,	O
was	O
isolated	O
from	O
the	O
surface-sterilized	O
root	B-T002
of	O
a	O
halophyte	B-T002
Anabasis elatior (C. A. Mey.) Schischk	B-T002
collected	O
from	O
Urumqi	B-T083
,	O
Xinjiang province	B-T083
,	O
north-west China	B-T083
.	O
Growth	B-T040
occurred	O
at	O
5-35	O
°C	O
(optimum	O
30	O
°C),	O
at	O
pH	B-T081
6.0-9.0	O
(optimum	O
pH	B-T081
7.0),	O
and	O
in	O
the	O
presence	O
of	O
0-6	O
%	O
NaCl	B-T121
(w/v)	O
(optimum	O
0-1	O
%).	O
Phylogenetic tree	B-T080
based	O
on	O
16S rRNA	B-T114
gene sequences	B-T086
indicated	O
that	O
strain EGI 6500337T	B-T007
formed	O
a	O
distinct	O
lineage	O
in	O
the	O
cluster	O
that	O
comprised	O
the	O
genera Aurantimonas	B-T007
and	O
Aureimonas	B-T007
in	O
the	O
family Aurantimonadaceae	B-T007
.	O
The	O
16S rRNA	B-T114
gene sequence	B-T086
of	O
strain EGI 6500337T	B-T007
shared	O
the	O
highest	O
similarities	O
to	O
those	O
of	O
Aurantimonas coralicida DSM 14790T	B-T007
(97.15	O
%)	O
and	O
Aurantimonas manganoxydans DSM 21871T	B-T007
(97.15	O
%).	O
Strain EGI 6500337T	B-T007
contained	O
Q-10	B-T109
as	O
the	O
dominant	O
isoprenoid quinone	B-T109
.	O
The	O
major	O
cellular	O
fatty acids	B-T109
were	O
C18:1 7c	B-T109
(66.4	O
%)	O
and	O
C19:0 8c cyclo	B-T109
(23.3	O
%).	O
The	O
polar	O
lipid profile	B-T109
of	O
strain EGI 6500337T	B-T007
contained	O
diphosphatidylglycerol	B-T109
,	O
phosphatidylglycerol	B-T109
,	O
phosphatidylcholine	B-T109
,	O
phosphatidylethanolamine	B-T109
as	O
major	O
components,	O
similarly	O
to	O
the	O
members	O
of	O
the	O
genus Aurantimonas	B-T007
.	O
The	O
DNA	B-T114
G+C content	B-T081
of	O
strain EGI 6500337T	B-T007
was	O
66.8	O
mol%.	O
The	O
DNA	B-T114
-	O
DNA	B-T114
relatedness	O
between	O
strain EGI 6500337T	B-T007
and	O
Aurantimonas coralicida DSM 14790T	B-T007
was	O
24.7	O
±	O
2.9	O
%.	O
On	O
the	O
basis	O
of	O
the	O
phylogenetic analysis	B-T062
,	O
chemotaxonomic data	B-T078
and	O
phenotypic characteristics	B-T032
,	O
strain EGI 6500337T	B-T007
represents	O
a	O
novel	O
species	O
of	O
the	O
genus Aurantimonas	B-T007
,	O
for	O
which	O
the	O
name	O
Aurantimonas endophytica sp. nov.	B-T007
is	O
proposed.	O
The	O
type	O
strain	B-T007
is	O
EGI 6500337T	B-T007
(=	O
KCTC 52296T	B-T007
=	O
CPCC 100904T	B-T007
).	O

Assessment	B-T058
and	O
classification	B-T185
of	O
protocol deviations	B-T033
Deviations	B-T033
from	O
the	O
approved	O
trial protocol	B-T170
are	O
common	O
during	O
clinical trials	B-T062
.	O
They	O
have	O
been	O
conventionally	O
classified	B-T185
as	O
deviations	B-T033
or	O
violations	B-T062
,	O
depending	O
on	O
their	O
impact	B-T080
on	O
the	O
trial	B-T062
.	O
A	O
new	O
method	O
has	O
been	O
proposed	O
by	O
which	O
deviations	B-T033
are	O
classified	B-T185
in	O
five	O
grades from 1 to 5	B-T185
.	O
A	O
deviation	B-T033
of	O
Grade 1	B-T033
has	O
no	B-T033
impact	B-T080
on	O
the	O
subjects'	B-T098
well-being	B-T033
or	O
on	O
the	O
quality of data	B-T080
.	O
At	O
the	O
maximum,	O
a	O
deviation	B-T033
Grade 5	B-T185
leads	O
to	O
the	O
death	B-T033
of	O
the	O
subject	B-T098
.	O
This	O
method	O
of	O
classification	B-T185
was	O
applied	O
to	O
deviations	B-T033
noted	O
in	O
the	O
center	O
over	O
the	O
last	O
3	O
years.	O
It	O
was	O
observed	O
that	O
most	O
deviations	B-T033
were	O
of	O
Grades 1 and 2	B-T185
,	O
with	O
fewer	O
falling	O
in	O
Grades 3 and 4	B-T185
.	O
There	O
were	O
no	O
deviations	B-T033
that	O
led	O
to	O
the	O
death of the subject	B-T033
(Grade	O
5).	O
This	O
method	O
of	O
classification	B-T185
would	O
help	O
trial	B-T062
managers	B-T097
decide	O
on	O
the	O
action	O
to	O
be	O
taken	O
on	O
the	O
occurrence	B-T079
of	O
deviations	B-T033
,	O
which	O
would	O
be	O
based	O
on	O
their	O
impact	B-T080
.	O

Fabrication	B-T067
and	O
modelling	B-T062
of	O
fractal	B-T082
,	O
biomimetic	B-T082
,	O
micro	B-T082
and	O
nano-topographical surfaces	B-T082
Natural	B-T169
surface topographies	B-UnknownType
are	O
often	O
self-similar	O
with	O
hierarchical features	B-T080
at	O
the	O
micro	B-T077
and	O
nanoscale	B-T077
,	O
which	O
may	O
be	O
mimicked	O
to	O
overcome	O
modern	B-T079
tissue engineering	B-T061
and	O
biomaterial	B-T122
design	B-T052
limitations	B-T169
.	O
Specifically,	O
a	O
cell's microenvironment	B-T070
within	O
the	O
human body	B-T016
contains	O
highly	O
optimised,	O
fractal topographical cues	B-T029
,	O
which	O
directs	O
precise	O
cell	B-T025
behaviour	B-T053
.	O
However,	O
recreating	B-T169
biomimetic	B-T082
,	O
fractal topographies	B-T082
in vitro	B-T080
is	O
not	O
a	O
trivial process	B-T067
and	O
a	O
number	O
of	O
fabrication methods	B-T067
have	O
been	O
proposed	O
but	O
often	O
fail	B-T169
to	O
precisely	O
control	B-T080
the	O
spatial resolution	B-T082
of	O
features	B-T080
at	O
different	B-T080
lengths	B-T081
scales	B-T074
and	O
hence,	O
to	O
provide	O
true	O
biomimetic properties	B-T080
.	O
Here,	O
we	O
propose	O
a	O
method	B-T170
of	O
accurately	B-T080
reproducing	B-T169
the	O
self-similar,	O
micro	B-T082
and	O
nanoscale topography	B-T082
of	O
a	O
human	B-T016
biological tissue	B-T024
into	O
a	O
synthetic polymer	B-T109
through	O
an	O
innovative	O
fabrication process	B-T067
.	O
The	O
biological tissue	B-T024
surface	B-T082
was	O
characterised	B-T052
using	O
atomic force microscopy	B-T059
(	O
AFM	B-T059
)	O
to	O
obtain	O
spatial	B-T082
data	B-T078
in	O
X,	O
Y	O
and	O
Z,	O
which	O
was	O
converted	O
into	O
a	O
grayscale 'digital photomask'	B-T071
.	O
As	O
a	O
result	O
of	O
maskless grayscale optical lithography	B-T057
followed	O
by	O
modified deep reactive ion etching	B-T067
and	O
replica molding	B-T067
,	O
we	O
were	O
able	O
to	O
accurately	B-T080
reproduce	O
the	O
fractal topography	B-T082
of	O
acellular dermal matrix	B-T024
(	O
ADM	B-T024
)	O
into	O
polydimethylsiloxane	B-T109
(	O
PDMS	B-T109
).	O
Characterisation	B-T052
using	O
AFM	B-T059
at	O
three	O
different	B-T080
length	B-T081
scales	B-T074
revealed	O
that	O
the	O
nano	B-T082
and	O
micro-topographical	B-T082
features	B-T080
,	O
in	O
addition	O
to	O
the	O
fractal dimension	B-T081
,	O
of	O
native	B-T169
ADM	B-T024
were	O
reproduced	B-T169
in	O
PDMS	B-T109
.	O
In	O
conclusion,	O
it	O
has	O
been	O
shown	O
that	O
the	O
fractal topography	B-T082
of	O
biological surfaces	B-T082
can	O
be	O
mimicked	O
in	O
synthetic materials	B-T073
using	O
the	O
novel	B-T080
fabrication process	B-T067
outlined,	O
which	O
may	O
be	O
applied	O
to	O
significantly	O
enhance	O
medical device	B-T074
biocompatibility	B-T044
and	O
performance	B-T052
.	O

Investigating	B-T169
Effects of	B-T080
Acidic pH	B-T081
on	O
Proliferation	B-T043
,	O
Invasion	B-T046
and	O
Drug	B-T121
-	O
Induced	B-T169
Apoptosis	B-T043
in	O
Lymphoblastic Leukemia	B-T191
Some	O
studies	O
have	O
shown	O
that	O
extracellular	B-T030
pH	B-T081
in	O
tumors	B-T191
,	O
which	O
results	O
in	O
tumor progression	B-T191
,	O
is	O
less	O
than	O
that	O
in	O
normal	B-T080
tissues	B-T024
.	O
The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
investigate	B-T169
the	O
effects of	B-T080
extracellular	B-T030
acidic pH	B-T081
on	O
proliferation	B-T043
,	O
invasion	B-T046
,	O
and	O
drug	B-T121
-	O
induced	B-T169
apoptosis	B-T043
in	O
acute lymphoblastic cells	B-T025
.	O
The	O
cells	B-T025
were	O
cultured	O
in	O
different	B-T080
pH	B-T081
(	O
pH	B-T081
6.6	O
and	O
pH	B-T081
7.4)	O
for	O
12	O
days	B-T079
.	O
Cell proliferation	B-T043
was	O
assessed	B-T052
by	O
MTT assay	B-T062
and	O
cell invasion	B-T046
was	O
assayed	O
by	O
invasion assay	B-T059
and	O
gene expression analysis	B-T063
of	O
MMP-9	B-T116
.	O
Drug	B-T121
-	O
induced	B-T169
apoptosis	B-T043
was	O
evaluated	O
after	O
exposure to	B-T080
doxorubicin	B-T109
for	O
24	O
hours	O
by	O
annexin V	B-T116
/	O
PI	B-T109
staining	B-T059
and	O
gene expression analysis	B-T063
of	O
BAX pro-apoptotic protein	B-T116
.	O
The	O
results	O
indicated	O
the	O
enhanced	O
growth	B-T043
and	O
invasion	B-T046
of	O
leukemic	B-T191
cells	B-T025
at	O
pH	B-T081
6.6	O
(P	O
≤	O
0.05).	O
Furthermore,	O
the	O
cells	B-T025
at	O
pH	B-T081
6.6	O
were	O
resistant	B-T169
to	O
apoptosis	B-T043
by	O
doxorubicin	B-T109
(P	O
≤	O
0.05).	O
It	O
can	O
be	O
concluded	O
that	O
acidic pH	B-T081
increases	B-T169
the	O
proliferation	B-T043
,	O
invasion	B-T046
and	O
reduces	B-T080
the	O
drug	B-T121
-	O
induced	B-T169
apoptosis	B-T043
in	O
acute lymphoblastic leukemia	B-T191
.	O
Extracellular	B-T030
acidity	B-T081
can	O
influence	O
the	O
behavior	O
of	O
leukemic	B-T191
cells	B-T025
and	O
therefore,	O
the	O
manipulation	B-T169
of	O
extracellular liquid	B-T031
can	O
be	O
selected	O
as	O
a	O
therapeutic strategy	B-T061
for	O
leukemia	B-T191
,	O
especially	O
for	O
acute lymphoblastic leukemia	B-T191
.	O

Gold	B-T121
-	O
Nanosponge	B-T074
-Based	O
Multistimuli-Responsive Drug Vehicles	B-T122
for	O
Targeted	B-T169
Chemo-Photothermal Therapy	B-T061
Gold	B-T121
-	O
nanosponge	B-T074
-based	O
multistimuli-responsive drug vehicles	B-T122
are	O
constructed	O
for	O
combined	O
chemo-photothermal therapy	B-T061
with	O
pinpointed	O
drug	B-T121
delivery	B-T169
and	O
release	B-T169
capabilities	O
and	O
minimized	O
nonspecific	B-T078
systemic	B-T169
spread	B-T080
of	O
drugs	B-T121
,	O
remarkably	O
enhancing	B-T052
the	O
therapeutic efficiency	B-T080
while	O
minimizing	O
acute	B-T079
side effects	B-T046
.	O

Hemodynamic	B-T042
correlates	O
of	O
transient cognitive impairment	B-T048
after	O
transient ischemic attack	B-T047
and	O
minor stroke	B-T047
:	O
A	O
transcranial Doppler study	B-T060
Transient cognitive impairment	B-T048
(	O
TCI	B-T048
)	O
on	O
the	O
Mini Mental State Evaluation	B-T060
score	B-T081
is	O
common	O
after	O
transient ischemic attack	B-T047
/	O
minor stroke	B-T047
and	O
might	O
identify	B-T080
patients	B-T101
at	O
increased	O
risk	B-T078
of	O
dementia	B-T048
.	O
We	O
aimed	B-T078
to	O
replicate	B-T080
TCI	B-T048
using	O
the	O
Montreal Cognitive Assessment	B-T170
(	O
MoCA	B-T170
),	O
compare	B-T052
it	O
with	O
persistent Mild Cognitive Impairment	B-T048
(	O
PMCI	B-T048
),	O
and	O
to	O
determine	O
whether	O
global	B-T080
cerebral	B-T023
hemodynamic	B-T042
changes	B-T169
could	O
explain	O
transient	B-T079
impairment	B-T169
.	O
Consecutive	O
patients	B-T101
with	O
transient ischemic attack	B-T047
/	O
minor stroke	B-T047
(NIHSS	O
≤	O
3)	O
were	O
assessed	B-T052
with	O
the	O
MoCA	B-T170
and	O
transcranial Doppler ultrasound	B-T060
acutely	B-T079
and	O
at	O
1	O
month.	O
We	O
compared	B-T052
patients	B-T101
with	O
TCI	B-T048
(	O
baseline	B-T081
MoCA	B-T170
<	O
26	O
with	O
≥	O
2	O
points	B-T081
increase	B-T169
at	O
1	O
month),	O
PMCI	B-T048
(	O
MoCA	B-T170
<	O
26	O
with	O
<	O
2	O
points	B-T081
increase	B-T169
),	O
and	O
no cognitive impairment	B-T033
(	O
NCI	B-T033
;	O
MoCA	B-T170
≥	O
26).	O
Of	O
326	O
patients	B-T101
,	O
46	O
(14.1%)	O
had	O
PMCI	B-T048
,	O
98	O
(30.1%)	O
TCI	B-T048
,	O
and	O
182	O
(55.8%)	O
NCI	B-T033
.	O
At	O
baseline	B-T081
,	O
TCI	B-T048
patients	B-T101
had	O
higher systolic blood pressure	B-T033
(150.95	O
±	O
21.52	O
vs	O
144.86	O
±	O
22.44	O
mmHg,	O
p	O
=	O
0.02)	O
and	O
lower	B-T080
cerebral blood flow velocities	B-T081
,	O
particularly	O
end-diastolic velocity	B-T081
(30.16	O
±	O
9.63	O
vs	O
35.02	O
±	O
9.01	O
cm/s,	O
p	O
<	O
0.001)	O
and	O
mean flow velocity	B-T033
(48.95	O
±	O
12.72	O
vs	O
54	O
±	O
12.46	O
cm/s,	O
p	O
=	O
0.001)	O
than	O
those	O
with	O
NCI	B-T033
,	O
but	O
similar	O
clinical	B-T080
and	O
hemodynamic	B-T042
profiles	B-T059
to	O
those	O
with	O
PMCI	B-T048
.	O
Systolic BP fell	B-T033
between	O
baseline	B-T081
and	O
1	O
month	O
(	O
mean	B-T081
reduction	B-T061
=	O
14.01	O
±	O
21.26	O
mmHg)	O
and	O
end-diastolic velocity	B-T081
and	O
mean flow velocity	B-T033
increased	B-T169
(	O
mean	B-T081
increase	B-T169
=	O
+	O
2.42	O
±	O
6.41	O
and	O
1.89	O
±	O
8.77	O
cm/s,	O
respectively),	O
but	O
these	O
changes	B-T169
did	O
not differ	B-T033
between	O
patients	B-T101
with	O
TCI	B-T048
,	O
PMCI	B-T048
,	O
and	O
NCI	B-T033
.	O
TCI	B-T048
is	O
detectable	B-T201
with	O
the	O
MoCA	B-T170
after	O
transient ischemic attack	B-T047
and	O
minor stroke	B-T047
and	O
has	O
similar	O
clinical	B-T080
and	O
hemodynamic	B-T042
profile	B-T059
to	O
PMCI	B-T048
.	O
However,	O
TCI	B-T048
does	O
not appear	B-T169
to	O
be	O
due	O
to	O
exaggerated	B-T080
acute	B-T079
reversible	B-T169
global	B-T080
hemodynamic	B-T042
changes	B-T169
.	O

Apixaban	B-T109
5	O
mg	O
Twice	B-T081
Daily	B-T079
and	O
Clinical	B-T080
Outcomes	B-T169
in	O
Patients	B-T101
With	O
Atrial Fibrillation	B-T047
and	O
Advanced	B-T080
Age	B-T032
,	O
Low	B-T080
Body Weight	B-T032
,	O
or	O
High	B-T080
Creatinine	B-T109
:	O
A	O
Secondary Analysis	B-UnknownType
of	O
a	O
Randomized Clinical Trial	B-T062
In	O
the	O
Apixaban	B-T109
for	O
Reduction	B-T080
of	O
Stroke	B-T047
and	O
Other	O
Thromboembolic Complications	B-T046
in	O
Atrial Fibrillation	B-T047
(	O
ARISTOTLE	B-T062
)	O
trial	B-T062
,	O
the	O
standard	O
dose	B-T081
of	O
apixaban	B-T109
was	O
5	O
mg	O
twice	B-T081
daily	B-T079
;	O
patients	B-T101
with	O
at	O
least	O
2	O
dose	B-T081
-	O
reduction	B-T080
criteria-80	O
years	B-T079
or	O
older,	O
weight	B-T032
60	O
kg	O
or	O
less,	O
and	O
creatinine level	B-T033
level	B-T080
1.5	O
mg/dL	O
or	O
higher-received	O
a	O
reduced	B-T080
dose	B-T081
of	O
apixaban	B-T109
of	O
2.5	O
mg	O
twice	B-T081
daily	B-T079
.	O
Little	O
is	O
known	O
about	O
patients	B-T101
with	O
1	O
dose	B-T081
-	O
reduction	B-T080
criterion	O
who	O
received	O
the	O
5	O
mg	O
twice	B-T081
daily	B-T079
dose	B-T081
of	O
apixaban	B-T109
.	O
To	O
determine	O
the	O
frequency	B-T079
of	O
1	O
dose	B-T081
-	O
reduction	B-T080
criterion	O
and	O
whether	O
the	O
effects of	B-T080
the	O
5	O
mg	O
twice	B-T081
daily	B-T079
dose	B-T081
of	O
apixaban	B-T109
on	O
stroke	B-T047
or	O
systemic embolism	B-UnknownType
and	O
bleeding	B-T046
varied	O
among	O
patients	B-T101
with	O
1	O
or	O
no	O
dose	B-T081
-	O
reduction	B-T080
criteria.	O
Among	O
18	O
201	O
patients	B-T101
in	O
the	O
ARISTOTLE trial	B-T062
,	O
17	O
322	O
were	O
included	O
in	O
this	O
analysis	B-T062
.	O
Annualized	O
event	O
rates	O
of	O
stroke	B-T047
or	O
systemic embolism	B-UnknownType
and	O
major	O
bleeding	B-T046
and	O
hazard ratios	B-T081
(	O
HRs	B-T081
)	O
and	O
95%	O
CIs	B-T081
were	O
evaluated	B-T058
.	O
Interactions	B-T169
between	O
the	O
effects of	B-T080
apixaban	B-T109
vs	O
warfarin	B-T109
and	O
the	O
presence	O
of	O
1	O
or	O
no	O
dose	B-T081
-	O
reduction	B-T080
criteria	O
were	O
assessed	B-T052
.	O
The	O
first	O
patient	B-T101
was	O
enrolled	O
in	O
the	O
ARISTOTLE trial	B-T062
on	O
December	O
19,	O
2006,	O
and	O
follow-up	B-T058
was	O
completed	O
on	O
January	O
30,	O
2011.	O
Data	B-T078
were	O
analyzed	O
from	O
January	O
2015	O
to	O
May	O
30,	O
2016.	O
Analysis	B-T062
of	O
major	O
bleeding	B-T046
included	O
events	O
during	O
study	B-T062
drug treatment	B-T061
.	O
Analysis	B-T062
of	O
stroke	B-T047
or	O
systemic embolism	B-UnknownType
was	O
based	O
on	O
intention	B-T080
to	O
treat	B-T169
.	O
Of	O
the	O
patients	B-T101
with	O
1	O
or	O
no	O
dose	B-T081
-	O
reduction	B-T080
criteria	O
assigned	O
to	O
receive	O
the	O
5	O
mg	O
twice	B-T081
daily	B-T079
dose	B-T081
of	O
apixaban	B-T109
or	O
warfarin	B-T109
,	O
3966	O
had	O
1	O
dose	B-T081
-	O
reduction	B-T080
criterion;	O
these	O
patients	B-T101
had	O
higher	O
rates	O
of	O
stroke	B-T047
or	O
systemic embolism	B-UnknownType
(	O
HR	B-T081
,	O
1.47;	O
95%	O
CI	B-T081
,	O
1.20-1.81)	O
and	O
major	O
bleeding	B-T046
(	O
HR	B-T081
,	O
1.89;	O
95%	O
CI	B-T081
,	O
1.62-2.20)	O
compared	O
with	O
those	O
with	O
no	O
dose	B-T081
-	O
reduction	B-T080
criteria	O
(n	O
=	O
13	O
356).	O
The	O
benefit	B-T081
of	O
the	O
5	O
mg	O
twice	B-T081
daily	B-T079
dose	B-T081
of	O
apixaban	B-T109
(n	O
=	O
8665)	O
compared	O
with	O
warfarin	B-T109
(n	O
=	O
8657)	O
on	O
stroke	B-T047
or	O
systemic embolism	B-UnknownType
in	O
patients	B-T101
with	O
1	O
dose	B-T081
-	O
reduction	B-T080
criterion	O
(	O
HR	B-T081
,	O
0.94;	O
95%	O
CI	B-T081
,	O
0.66-1.32)	O
and	O
no	O
dose	B-T081
-	O
reduction	B-T080
criterion	O
(	O
HR	B-T081
,	O
0.77;	O
95%	O
CI	B-T081
,	O
0.62-0.97)	O
were	O
similar	O
(P	O
for	O
interaction	O
=	O
.36).	O
Similarly,	O
the	O
benefit	B-T081
of	O
5	O
mg	O
twice	B-T081
daily	B-T079
dose	B-T081
of	O
apixaban	B-T109
compared	O
with	O
warfarin	B-T109
on	O
major	O
bleeding	B-T046
in	O
patients	B-T101
with	O
1	O
dose	B-T081
-	O
reduction	B-T080
criterion	O
(	O
HR	B-T081
,	O
0.68;	O
95%	O
CI	B-T081
,	O
0.53-0.87)	O
and	O
no	O
dose	B-T081
-	O
reduction	B-T080
criterion	O
(	O
HR	B-T081
,	O
0.72;	O
95%	O
CI	B-T081
,	O
0.60-0.86)	O
were	O
similar	O
(P	O
for	O
interaction	O
=	O
.71).	O
Similar	O
patterns	O
were	O
seen	O
for	O
each	O
dose	B-T081
-	O
reduction	B-T080
criterion	O
and	O
across	O
the	O
spectrum	O
of	O
age	B-T032
,	O
body weight	B-T032
,	O
creatinine level	B-T033
level	B-T080
,	O
and	O
creatinine	B-T109
clearance	B-T201
.	O
Patients	B-T101
with	O
atrial fibrillation	B-T047
and	O
isolated	O
advanced	O
age	B-T032
,	O
low	O
body weight	B-T032
,	O
or	O
renal dysfunction	B-T033
have	O
a	O
higher	O
risk	B-T078
of	O
stroke	B-T047
or	O
systemic embolism	B-UnknownType
and	O
major	O
bleeding	B-T046
but	O
show	O
consistent	O
benefits	B-T081
with	O
the	O
5	O
mg	O
twice	B-T081
daily	B-T079
dose	B-T081
of	O
apixaban	B-T109
vs	O
warfarin	B-T109
compared	O
with	O
patients	B-T101
without	O
these	O
characteristics.	O
The	O
5	O
mg	O
twice	B-T081
daily	B-T079
dose	B-T081
of	O
apixaban	B-T109
is	O
safe,	O
efficacious,	O
and	O
appropriate	O
for	O
patients	B-T101
with	O
only	O
1	O
dose	B-T081
-	O
reduction	B-T080
criterion.	O
clinicaltrials.gov	O
Identifier:	O
NCT00412984.	O

Transition	B-T052
From	O
Hospital	B-T073
to	O
Home	B-T082
in	O
Preterm Infants	B-T100
and	O
Their	O
Families	B-T099
When	O
the	O
day	B-T079
of	O
discharge	B-T058
from	O
a	O
neonatal intensive care unit	B-T073
(	O
NICU	B-T073
)	O
comes	O
for	O
the	O
parents	B-T099
of	O
newborn infants	B-T100
,	O
they	O
are	O
filled	O
with	O
long-awaited	O
joy	B-T041
and	O
happiness	B-T041
.	O
They	O
go	O
home	B-T082
feeling	B-T041
as	O
parents	B-T099
,	O
away	O
from	O
scheduled routines	B-T080
of	O
the	O
hospital	B-T073
,	O
monitor alarms	B-T033
,	O
clinical rounds	B-T033
,	O
numerous	B-T081
tests	B-T059
,	O
and	O
so	O
on.	O
What	O
do	O
we	O
know	O
about	O
what	O
happens	B-T052
after	O
these	O
little patients	B-T101
and	O
their	O
families	B-T099
leave	B-T052
the	O
NICU	B-T073
?	O
What	O
happens	B-T052
from	O
the	O
point	O
of	O
leaving	B-T052
the	O
hospital	B-T073
until	O
when	O
things	O
get	O
settled	O
and	O
life	B-T078
becomes	O
perceived	B-T041
as	O
normal	B-T080
?	O
This	O
article	B-T170
presents	O
a	O
short	O
summary	B-T170
of	O
research	B-T062
conducted	O
with	O
the	O
vulnerable population	B-T098
of	O
high-risk	B-T033
and	O
preterm infants	B-T100
and	O
their	O
families	B-T099
postdischarge	B-T058
.	O
Available	O
evidence	B-T078
suggests	O
that	O
transition	B-T052
to	O
home	B-T082
after	O
hospital discharge	B-T058
,	O
a	O
phenomenon	B-T067
that	O
many	O
families	B-T099
experience	B-T041
,	O
is	O
challenging	B-T080
and	O
requires	O
attention	B-T058
from	O
clinicians	B-T097
and	O
researchers	B-T097
if	O
we	O
are	O
to	O
provide	O
effective	B-T080
,	O
efficient	B-T080
,	O
and	O
high-quality care	B-T058
.	O

Visual Analytics	B-T060
for	O
Pattern Discovery	B-T041
in	O
Home Care	B-T058
.	O
Clinical Relevance	B-T080
for	O
Quality Improvement	B-T057
Visualization	B-T041
can	O
reduce	O
the	O
cognitive load of information	B-T081
,	O
allowing	O
users	O
to	O
easily	O
interpret	B-T169
and	O
assess large amounts of data	B-T058
.	O
The	O
purpose	O
of	O
our	O
study	O
was	O
to	O
examine	O
home health data	B-T170
using	O
visual analysis techniques	B-T060
to	O
discover	O
clinically salient	B-T080
associations	B-T078
between	O
patient characteristics	B-T201
with	O
problem-oriented health outcomes	B-T170
of	O
older adult home health patients	B-T058
during	O
the	O
home health service	B-T058
period.	O
Knowledge	B-T170
,	O
Behavior	B-T053
and	O
Status ratings	B-T081
at	O
discharge	B-T058
as	O
well	O
as	O
change	O
from	O
admission	B-T058
to	O
discharge	B-T058
that	O
was	O
coded	O
using	O
the	O
Omaha System	B-T170
was	O
collected	O
from	O
a	O
dataset	B-T170
on	O
988	O
de-identified	O
patient data	B-T170
from	O
15	O
home health agencies	B-T093
.	O
SPSS Visualization Designer v1.0	B-T170
was	O
used	O
to	O
visually analyze patterns	B-T060
between	O
independent	O
and	O
outcome	O
variables	O
using	O
heat maps	B-T078
and	O
histograms	B-T073
.	O
Visualizations	B-T041
suggesting	O
clinical salience	B-T033
were	O
tested	B-T169
for	O
significance	O
using	O
correlation analysis	B-T062
.	O
The	O
mean	O
age	O
of	O
the	O
patients	B-T101
was	O
80	O
years,	O
with	O
the	O
majority	O
female	B-T032
(66%).	O
Of	O
the	O
150	O
visualizations	B-T041
,	O
69	O
potentially	O
meaningful patterns	B-T078
were	O
statistically	O
evaluated	O
through	O
bivariate associations	B-UnknownType
,	O
revealing	O
21	O
significant	O
associations	B-T078
.	O
Further,	O
14	O
associations	B-T078
between	O
episode	O
length	O
and	O
Charlson co-morbidity index	B-T170
mainly	O
with	O
urinary	B-T080
related	O
diagnoses and problems	B-T047
remained	O
significant	O
after	O
adjustment	O
analyses.	O
Through	O
visual analysis	B-T060
,	O
the	O
adverse	O
association	B-T078
of	O
the	O
longer	O
home health episode	B-T058
length	O
and	O
higher	O
Charlson co-morbidity index	B-T170
with	O
behavior or status outcomes	B-T033
for	O
patients	B-T101
with	O
impaired urinary function	B-T047
was	O
revealed.	O
We	O
have	O
demonstrated	O
the	O
use	O
of	O
visual analysis	B-T060
to	O
discover	O
novel	O
patterns	O
that	O
described	O
high-needs	O
subgroups	B-T185
among	O
the	O
older home health patient population	B-T081
.	O
The	O
effective	O
presentation	O
of	O
these	O
data patterns	B-T078
can	O
allow	O
clinicians	B-T097
to	O
identify	O
areas	O
of	O
patient improvement	B-T057
,	O
and	O
time	O
periods	O
that	O
are	O
most	O
effective	O
for	O
implementing	O
home health interventions	B-T058
to	O
improve	O
patient outcomes	B-T058
.	O

Transforming Growth Factor Beta 1	B-T116
(	O
TGF-β1	B-T116
)	O
in	O
Thyroid Cancer	B-T191
Patients	B-T101
:	O
a	O
View	O
from	O
the	O
Peripheral Blood	B-T031
Transforming growth factor beta	B-T116
(	O
TGF-β	B-T116
)	O
plays	O
an	O
important	O
role	O
in	O
many	O
pathophysiological	B-T169
conditions	B-T080
,	O
including	O
cancer	B-T191
.	O
The	O
level	B-T080
of	O
TGF-β	B-T116
in	O
patients	B-T101
with	O
differentiated thyroid cancer	B-T191
(	O
DTC	B-T191
)	O
has	O
not	O
been	O
examined	B-T033
so	O
far.	O
The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
measure	O
TGF-β	B-T116
concentration	B-T081
in	O
serum samples	B-T031
and	O
in	O
PHA	B-T116
-	O
stimulated	B-T044
whole blood	B-T031
culture	B-T059
in vitro	B-T080
and	O
to	O
analyze	B-T062
possible	O
associations	O
of	O
TGF-β1	B-T116
levels	B-T080
with	O
leukocyte	B-T025
,	O
lymphocyte	B-T025
and	O
platelets	B-T025
counts	B-T059
,	O
the	O
histological	B-T169
type	O
of	O
thyroid cancer	B-T191
,	O
and	O
stage of disease	B-T060
.	O
TGF-β1	B-T116
was	O
measured	O
in	O
22	O
DTC	B-T191
patients	B-T101
and	O
20	O
healthy	B-T080
controls	B-T096
using	O
the	O
duoSet ELISA Development kit	B-T074
for	O
human TGF-β1	B-T116
.	O
The	O
concentration	B-T081
of	O
TGF-β1	B-T116
in	O
serum samples	B-T031
from	O
both	O
groups	B-T098
correlated	O
positively	O
with	O
the	O
platelet	B-T025
counts	B-T059
.	O
There	O
was	O
no	O
statistically significant	B-T081
difference	O
in	O
the	O
serum concentrations	B-T081
of	O
TGF-β1	B-T116
between	O
DTC	B-T191
patients	B-T101
and	O
control subjects	B-T096
,	O
but	O
PHA	B-T116
stimulated	B-T044
whole blood	B-T031
cultures	B-T059
of	O
DTC	B-T191
patients	B-T101
produced	O
less	O
TGF-β1	B-T116
than	O
those	O
from	O
controls	B-T096
.	O
Additional	O
studies	B-T062
are	O
needed	O
to	O
determine	O
the	O
significance	B-T078
of	O
these	O
in vitro	B-T080
findings	B-T033
.	O

P-glycoprotein	B-T116
traffics	B-T169
from	O
the	O
nucleus	B-T026
to	O
the	O
plasma membrane	B-T026
in	O
rat brain	B-T023
endothelium	B-T024
during	O
inflammatory pain	B-T184
P-glycoprotein	B-T116
(	O
PgP	B-T116
),	O
a	O
drug	B-T121
efflux pump	B-T024
in	O
blood-brain barrier	B-T023
endothelial cells	B-T025
,	O
is	O
a	O
major	O
clinical	B-T080
obstacle	B-T080
for	O
effective	O
central nervous system	B-T022
drug delivery	B-T061
.	O
Identifying	B-T058
PgP	B-T116
regulatory pathways	B-T169
that	O
can	O
be	O
exploited	O
clinically	O
is	O
critical	O
for	O
improving	O
central nervous system	B-T022
drug delivery	B-T061
.	O
We	O
previously	O
found	O
that	O
PgP activity	B-T044
increases	B-T169
in	O
rat brain	B-T023
microvessels	B-T023
concomitant	B-T079
with	O
decreased	B-T081
central nervous system	B-T022
drug delivery	B-T061
in	O
response	O
to	O
acute	B-T079
peripheral	B-T082
inflammatory pain	B-T184
.	O
In	O
the	O
current	O
study,	O
we	O
tested	O
the	O
hypothesis	O
that	O
PgP	B-T116
traffics	B-T169
to	O
the	O
luminal	B-T082
plasma membrane	B-T026
of	O
the	O
microvessel	B-T023
endothelial cells	B-T025
from	O
intracellular	B-T082
stores	B-T169
during	O
peripheral	B-T082
inflammatory pain	B-T184
.	O
Using	O
immunofluorescence microscopy	B-T059
,	O
we	O
detected	B-T033
PgP	B-T116
in	O
endothelial cell	B-T025
nuclei	B-T026
and	O
in	O
the	O
luminal	B-T082
plasma membrane	B-T026
in	O
control animals	B-T008
.	O
Following	O
peripheral	B-T082
inflammatory pain	B-T184
,	O
luminal	B-T082
PgP	B-T116
staining	B-T059
increased	B-T081
while	O
staining	B-T059
in	O
the	O
nucleus	B-T026
decreased	B-T081
.	O
Biochemical analysis	B-T059
of	O
nuclear	B-T026
PgP	B-T116
content	B-T077
confirmed	O
our	O
visual observations	B-T169
.	O
Peripheral	B-T082
inflammatory pain	B-T184
also	O
increased	B-T081
endothelial cell	B-T025
luminal	B-T082
staining	B-T059
of	O
polymerase 1 and transcript release factor	B-T028
/	O
cavin1	B-T028
and	O
serum deprivation response protein	B-T028
/	O
cavin2	B-T028
,	O
two	O
caveolar scaffold proteins	B-T116
,	O
without	O
changing	O
caveolin1	B-T116
or	O
protein kinase C delta binding protein	B-T028
/	O
cavin3	B-T028
location	B-T082
.	O
Our	O
data	B-T078
(a)	O
indicate	O
that	O
PgP	B-T116
traffics	B-T169
from	O
stores	B-T169
in	O
the	O
nucleus	B-T026
to	O
the	O
endothelial cell	B-T025
luminal membrane	B-T026
in	O
response	O
to	O
peripheral	B-T082
inflammatory pain	B-T184
;	O
(b)	O
provide	O
an	O
explanation	O
for	O
our	O
previous	O
observation	B-T062
that	O
peripheral	B-T082
inflammatory pain	B-T184
inhibits	B-T052
central nervous system	B-T022
drug	B-T121
uptake	B-T039
;	O
and	O
(c)	O
suggest	O
a	O
novel	B-T080
regulatory mechanism	B-T033
for	O
PgP activity	B-T044
in	O
rat brain	B-T023
.	O

Functional	B-T169
Impairment	B-T169
in	O
Children	B-T100
With	O
Externalizing Behavior Disorders	B-T048
:	O
Psychometric	B-T060
Properties	B-T080
of	O
the	O
Weiss Functional Impairment Rating Scale-Parent Report	B-T170
in	O
a	O
German	B-T083
Clinical Sample	B-T167
To	O
examine	O
the	O
psychometric	B-T060
properties	B-T080
of	O
a	O
German	B-T083
adaptation	O
of	O
the	O
Weiss Functional Impairment Rating Scale-Parent Report	B-T170
(	O
WFIRS-P	B-T170
)	O
in	O
a	O
clinical sample	B-T167
of	O
children	B-T100
(4-12	O
years	B-T079
)	O
with	O
externalizing behavior disorders	B-T048
.	O
Data	B-T078
were	O
collected	B-T169
within	O
two	O
clinical trials	B-T062
(N	O
=	O
264).	O
Factorial validity	B-T080
,	O
reliability	B-T081
,	O
and	O
divergent validity	B-T081
from	O
symptoms	B-T184
of	O
ADHD	B-T048
and	O
oppositional defiant disorder	B-T048
(	O
ODD	B-T048
)	O
were	O
assessed	B-T052
.	O
Confirmatory factor analyses	B-T080
revealed	B-T080
that	O
a	O
bifactor model	B-T170
consistent with	B-T078
the	O
theoretical assumption	B-T078
of	O
a	O
general construct	B-T185
of	O
impairment	B-T169
(total	O
scale)	O
and	O
additional	B-T169
specific factors	B-T169
(subscales)	O
provided	O
satisfactory	B-T080
data fit	B-T078
.	O
Model	B-T170
-based	O
reliability	B-T081
estimates	B-T081
showed	O
that	O
both	O
the	O
general construct	B-T185
and	O
specific factors	B-T169
accounted	O
for	O
item	O
variance	B-T080
.	O
Internal	O
consistencies	B-T080
were	O
>.70,	O
part-whole	O
corrected	O
item-scale	O
correlations	B-T080
mostly	O
>.30.	O
Correlations	B-T080
between	O
the	O
WFIRS-P Scales	B-T170
and	O
ADHD	B-T048
and	O
ODD	B-T048
symptoms	B-T184
were	O
low	B-T080
to	O
moderate	B-T080
.	O
The	O
results	B-T169
support	O
the	O
factorial validity	B-T080
,	O
reliability	B-T081
,	O
and	O
divergent validity	B-T081
of	O
the	O
WFIRS-P	B-T170
.	O

What	O
can	O
the	O
Canadians	B-T098
and	O
Americans	B-T098
learn	B-T041
from	O
each	O
other's	O
health care systems	B-T093
?	O
Numerous	O
papers	B-T170
have	O
been	O
written	O
comparing	B-T052
the	O
Canadian	B-T098
and	O
US	B-T083
healthcare systems	B-T093
,	O
and	O
a	O
number	O
of	O
health policy	B-T089
experts	B-T097
have	O
recommended	B-T078
that	O
the	O
Americans	B-T098
implement	B-T052
their	O
single-payer system	B-T058
to	O
save	O
12-20%	O
of	O
its	O
healthcare expenditures	B-T081
.	O
This	O
paper	B-T170
is	O
different	O
in	O
that	O
it	O
assumes	O
that	O
neither	O
country	B-T083
will	O
undertake	O
a	O
significant	B-T078
philosophic	B-T080
or	O
structural	B-T082
change	B-T169
in	O
their	O
healthcare system	B-T093
,	O
but	O
there	O
are	O
lessons	O
to	O
be	O
learned	B-T041
that	O
are	O
inherent	O
in	O
one	O
that	O
could	O
be	O
a	O
major	O
breakthrough	B-T080
for	O
the	O
other.	O
Following	O
the	O
model	B-T083
in	O
Canada	B-T083
and	O
in	O
Western Europe	B-T083
,	O
the	O
USA	B-T083
could	O
implement	B-T052
universal	B-T080
health insurance	B-T058
so	O
that	O
the	O
32.0	O
million	O
(2015)	O
Americans	B-T098
still	O
uninsured	B-T098
would	O
have	O
at	O
least	O
minimal	B-T080
coverage	B-T078
when	O
incurring	O
medical expenditures	B-T081
.	O
Also,	O
the	O
USA	B-T083
could	O
use	O
smart cards	B-T073
to	O
evaluate eligibility	B-T058
and	O
to	O
process	B-T067
health insurance claims	B-T058
;	O
these	O
changes	O
resulting in	B-T169
an	O
estimated	B-T081
15%	O
reduction	B-T080
in	O
US	B-T083
health expenditures	B-T081
without	O
adversely	O
effecting	B-T080
access	B-T080
or	O
quality of care	B-T058
.	O
Such	O
a	O
strategy	O
would	O
result	B-T169
in	O
the	O
eventual	O
loss	B-T081
of	O
2.5	O
million	O
white-collar jobs	B-T090
at	O
hospitals	B-T073
,	O
physician offices	B-T073
and	O
insurance companies	B-T078
,	O
a	O
long-term	B-T079
economic	B-T169
gain	B-T081
.	O
Only	O
a	O
few	O
would	O
agree	O
with	O
the	O
statement	O
that	O
Canada	B-T083
already	O
functions	B-T169
with	O
a	O
multi-payer	B-T092
reimbursement system	B-T170
as	O
evidenced	O
by	O
(1)	O
a	O
federal	B-T092
-	O
provincial	B-T083
,	O
tax	B-T081
-	O
supported	B-T077
plan	B-T058
,	O
administered	O
by	O
each	O
of	O
the	O
provinces	B-T083
,	O
providing	O
universal coverage	B-T078
for	O
hospital	B-T073
and	O
physician services	B-T058
and	O
(2)	O
roughly	O
60%	O
of	O
its	O
residents	B-T098
receiving	O
employer-paid	B-T081
health insurance	B-T058
benefits	B-T081
,	O
underwritten	O
primarily	O
by	O
investor-owned	O
plans,	O
that	O
are	O
less	O
than	O
effective	B-T080
to	O
reimburse	B-T080
for	O
pharmaceuticals	B-T058
,	O
dental	B-T058
and	O
other	O
healthcare services	B-T058
.	O
What	O
could	O
be	O
learned	O
from	O
the	O
USA	B-T083
and	O
particularly	O
from	O
Western European countries	B-T083
is	O
possibly	O
implementing	B-T052
an	O
approach,	O
whereby	O
at	O
least	O
upper-income	B-T080
Canadians	B-T098
could	O
opt	O
out	O
of	O
their	O
federal	B-T092
-	O
provincial	B-T083
plan	B-T058
and	O
purchase	O
private	B-T092
insurance coverage	B-T078
-	O
being	O
eligible	O
for	O
far	O
more	O
comprehensive	O
"private"	O
benefits	O
for	O
hospital	B-T073
,	O
physician	B-T058
,	O
pharmaceutical	B-T058
,	O
dental	B-T058
and	O
other	O
healthcare services	B-T058
.	O
Aside	O
from	O
generating	O
billions	O
of	O
additional	O
needed	O
revenues	B-T081
from	O
the	O
private sector	B-T098
,	O
it	O
could	O
(1)	O
help	O
eliminate	B-T052
long	O
waits	O
for	O
non-emergent	O
physicians'	O
care	O
by	O
appointing	O
newly	O
minted	O
specialists	B-T097
to	O
their	O
medical staffs	B-T097
;	O
(2)	O
offer	O
prompt	B-T169
admissions	B-T058
for	O
elective cases	B-T033
to	O
"	O
private	B-T073
"	O
wings of hospitals	B-T073
;	O
(3)	O
increase	B-T081
available	O
funding	B-T081
for	O
what	O
is	O
currently	B-T079
an	O
undercapitalized	B-T033
system	B-T169
;	O
(4)	O
enhance	B-T052
the	O
system's	O
sluggish	B-T033
operations	B-T052
;	O
and	O
(5)	O
encourage	O
more	O
competition	B-T057
among	O
various	O
providers.	O
Although	O
such	O
a	O
two-tier approach	B-T170
,	O
such	O
as	O
available	O
in	O
the	O
USA	B-T083
and	O
elsewhere,	O
is	O
politically	O
dead	O
on	O
arrival	O
in	O
Canada	B-T083
today,	O
private insurance	B-T064
being	O
already	O
legal	B-T169
and	O
commonly	O
available	O
there.	O
Interestingly,	O
this	O
recommended	B-T078
solution	O
is	O
utilized	O
in	O
most	O
western European countries	B-T083
where	O
there	O
is	O
a	O
higher	O
percentagea	B-T081
than	O
in	O
Canada	B-T083
of	O
public	B-T092
(versus	O
private)	O
funding	B-T081
of	O
their	O
total	O
health expenditures	B-T081
.	O
Because	O
of	O
various	O
vested	O
interests,	O
attempts	B-T051
to	O
implement	B-T052
any	O
of	O
the	O
aforementioned	O
proposals	O
will	O
undoubtedly	O
result	B-T169
in	O
considerable	O
political	B-T057
rancor	B-T041
.	O
There	O
is	O
greater	O
likelihood,	O
however,	O
that	O
the	O
Canadians	B-T098
because	O
their	O
need	O
to	O
be	O
more	O
effective	B-T080
and	O
efficient	B-T080
in	O
their	O
delivery of care	B-T058
,	O
and	O
their	O
overall	O
long-term	B-T079
fiscal	B-T064
outlook	O
will	O
agree	B-T033
to	O
the	O
further	O
privatization	B-T064
of	O
their	O
healthcare system	B-T093
before	O
the	O
Americans	B-T098
will	O
mandate	O
universal	O
access,	O
use	O
the	O
smart card	B-T073
to	O
process	O
insurance eligibility	B-UnknownType
and	O
claims	O
or	O
will	O
impose	O
price	O
controls	B-T169
on	O
high-tech	O
services	O
and	O
on	O
pharmaceuticals	B-T121
.	O
Copyright	O
©	O
2016	O
John	O
Wiley	O
&	O
Sons,	O
Ltd.	O

Optimal	B-T080
Duration	B-T079
of	O
Coronary Ligation	B-T061
and	O
Reperfusion	B-T061
for	O
Reperfusion Injury	B-T037
Study	B-T062
in	O
a	O
Rat	B-T015
Model	B-T075
Reperfusion injury	B-T037
(	O
RI	B-T037
)	O
has	O
an	O
important	B-T080
impact	B-T080
on	O
the	O
clinical	B-T080
prognosis	B-T201
for	O
patients	B-T101
with	O
acute myocardial injury	B-T037
who	O
had	O
their	O
coronary	B-T082
blood flow	B-T039
reestablished	B-T080
.	O
However,	O
no	O
studies	B-T062
to	O
date	O
have	O
investigated	B-T169
the	O
timeframe	B-T079
of	O
coronary occlusion	B-T047
and	O
reperfusion	B-T061
effects	B-T080
on	O
RI	B-T037
.	O
A	O
total	O
of	O
100	O
rats	B-T015
were	O
divided	O
into	O
4	O
groups	B-T078
based	O
on	O
the	O
coronary ligation	B-T061
period	B-T079
:	O
30,	O
60,	O
120,	O
and	O
180	O
min,	O
and	O
each	O
group	B-T078
was	O
further	O
divided	O
into	O
5	O
subgroups	B-T078
with	O
different	B-T080
reperfusion	B-T061
periods	B-T079
:	O
0,	O
30,	O
60,	O
120,	O
and	O
180	O
min.	O
R0	O
was	O
the	O
baseline	B-T081
of	O
each	O
subgroup	B-T078
.	O
All	O
animals	B-T008
received	O
the	O
same	O
protocols	B-T170
for	O
designed	B-T052
ligation	B-T061
and	O
reperfusion	B-T061
periods	B-T079
.	O
Evans blue	B-T109
and	O
2,3,5-triphenyltetrazolium chloride	B-T109
were	O
used	O
to	O
distinguish	O
different	B-T080
myocardial injury	B-T037
areas	B-T082
:	O
area	B-T082
at risk	B-T080
(	O
AAR	B-T082
)	O
and	O
myocardial necrosis	B-T047
.	O
The	O
differences	B-T080
of	O
the	O
ratios	B-T081
of	O
the	O
necrotic	B-T042
area	B-T082
to	O
AAR	B-T082
between	O
each	O
subgroup	B-T078
and	O
baseline	B-T081
were	O
further	O
averaged	B-T081
to	O
calculate	B-T052
an	O
overall	B-T080
value	B-T081
of	O
each	O
heart	B-T023
.	O
The	O
relative	O
RI	B-T037
percentages	B-T081
showed	O
significant	B-T078
differences	B-T080
(0.8	O
±	O
2.3%,	O
4.9	O
±	O
3.3%,	O
10.8	O
±	O
3.1%,	O
and	O
20.3	O
±	O
3.6%	O
respectively,	O
p	O
<	O
0.001)	O
at	O
different	B-T080
time points	B-T079
of	O
reperfusion	B-T061
but	O
not	O
at	O
different	B-T080
time points	B-T079
of	O
ligation	B-T061
(p	O
=	O
0.593).	O
The	O
effects	B-T080
of	O
different	B-T080
time courses	B-T079
in	O
RI	B-T037
showed	O
that	O
the	O
L120R180	O
group	B-T078
(43.4	O
±	O
2.3%)	O
had	O
the	O
highest	B-T080
RI	B-T037
difference	B-T080
with	O
the	O
baseline	B-T081
group	B-T078
.	O
Maximal	B-T080
RI	B-T037
occurred	O
at	O
the	O
timeframe	B-T079
of	O
L120R180	O
in	O
our	O
animal model	B-T075
.	O
This	O
result	B-T169
may	O
be	O
utilized	O
to	O
assess	B-T052
the	O
substantial	O
benefits	B-T081
of	O
RI therapies	B-T061
in	O
an	O
experimental rat model	B-T050
setting.	O

Derivation	B-T080
of	O
a	O
Predictive	B-T080
Score	B-T081
for	O
Hemorrhagic	B-T046
Progression	B-T169
of	O
Cerebral Contusions	B-T037
in	O
Moderate	B-T037
and	O
Severe Traumatic Brain Injury	B-T037
After	O
traumatic brain injury	B-T037
(	O
TBI	B-T037
),	O
hemorrhagic	B-T046
progression	B-T169
of	O
contusions	B-T037
(	O
HPCs	B-T037
)	O
occurs	O
frequently	B-T079
.	O
However,	O
there	O
is	O
no	O
established	B-T080
predictive	B-T080
score	B-T081
to	O
identify	O
high-risk	B-T033
patients	B-T101
for	O
HPC	B-T037
.	O
Consecutive	B-T080
patients	B-T101
who	O
were	O
hospitalized	B-T033
(2008-2013)	O
with	O
non-penetrating	O
moderate	B-T037
or	O
severe TBI	B-T037
were	O
studied.	O
The	O
primary outcome	B-T080
was	O
HPC	B-T037
,	O
defined	O
by	O
both	O
a	O
relative	O
increase	B-T169
in	O
contusion	B-T037
volume	B-T081
by	O
≥30	O
%	O
and	O
an	O
absolute	B-T080
increase	B-T169
by	O
≥10	O
mL	O
on	O
serial imaging	B-UnknownType
.	O
Logistic regression models	B-T081
were	O
created	B-T052
to	O
identify	O
independent	O
risk factors	B-T033
for	O
HPC	B-T037
.	O
The	O
HPC	B-T037
Score	B-T081
was	O
then	O
derived	B-T080
based	O
on	O
the	O
final model	B-T170
.	O
Among	O
a	O
total	O
of	O
286	O
eligible	O
patients	B-T101
,	O
61	O
(21	O
%)	O
patients	B-T101
developed	O
HPC	B-T037
.	O
On	O
univariate analyses	B-T062
,	O
HPC	B-T037
was	O
associated with	B-T080
older age	B-T032
,	O
higher initial blood pressure	B-T033
,	O
antiplatelet medications	B-T121
,	O
anticoagulants	B-T121
,	O
subarachnoid hemorrhage	B-T047
(	O
SAH	B-T047
)	O
subdural hematoma	B-T046
(	O
SDH	B-T046
),	O
skull fracture	B-T037
,	O
frontal	B-T023
contusion	B-T037
,	O
larger	B-T081
contusion	B-T037
volume	B-T081
,	O
and	O
shorter interval	B-T079
from	O
injury	B-T037
to	O
initial CT	B-T060
.	O
In	O
the	O
final model	B-T170
,	O
SAH	B-T047
(	O
OR	B-T081
6.33,	O
95	O
%	O
CI	B-T081
,	O
1.80-22.23),	O
SDH	B-T046
(	O
OR	B-T081
3.46,	O
95	O
%	O
CI	B-T081
,	O
1.39-8.63),	O
and	O
skull fracture	B-T037
(	O
OR	B-T081
2.67,	O
95	O
%	O
CI	B-T081
,	O
1.28-5.58)	O
were	O
associated with	B-T080
HPC	B-T037
.	O
Based	O
on	O
these	O
factors	B-T169
,	O
the	O
HPC	B-T037
Score	B-T081
was	O
derived	B-T080
(	O
SAH	B-T047
=	O
2	O
points,	O
SDH	B-T046
=	O
1	O
point,	O
and	O
skull fracture	B-T037
=	O
1	O
point).	O
This	O
score	B-T081
had	O
an	O
area	O
under	O
the	O
receiver operating curve	B-T081
of	O
0.77.	O
Patients	B-T101
with	O
a	O
score	B-T081
of	O
0-2	O
had	O
a	O
4.0	O
%	O
incidence	B-T081
of	O
HPC	B-T037
,	O
while	O
patients	B-T101
with	O
a	O
score	B-T081
of	O
3-4	O
had	O
a	O
34.6	O
%	O
incidence	B-T081
of	O
HPC	B-T037
.	O
A	O
simple	O
HPC	B-T037
Score	B-T081
was	O
developed	O
for	O
early	O
risk	B-T078
stratification	B-T169
of	O
HPC	B-T037
in	O
patients	B-T101
with	O
moderate	B-T037
or	O
severe TBI	B-T037
.	O

Expressing	B-T055
sexuality	B-T053
in	O
nursing homes	B-T073
.	O
The	O
experience	B-T055
of	O
older women	B-T098
:	O
A	O
qualitative study	B-T062
In	O
nursing homes	B-T073
,	O
a	O
number	O
of	O
barriers	B-T080
to	O
the	O
expression	B-T055
of	O
sexuality	B-T053
exist	B-T077
,	O
such	O
as	O
the	O
lack of privacy	B-T033
,	O
certain	O
attitudes	B-T041
on	O
behalf	O
of	O
the	O
staff	B-T097
and	O
the	O
family	B-T099
,	O
the	O
lack	O
of	O
a	O
sexual partner	B-T098
,	O
and	O
physical limitations	B-T033
.	O
The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
describe	O
the	O
lived experience	B-T055
of	O
sexuality	B-T053
in	O
elderly Spanish women	B-T098
residing	O
in	O
nursing homes	B-T073
.	O
A	O
qualitative phenomenological approach	B-T062
was	O
followed.	O
Data	B-T078
were	O
collected	B-T062
over	O
an	O
18-	O
month period	B-T079
between	O
2013	O
and	O
2015.	O
Purposeful	O
sampling	B-T078
was	O
conducted	O
with	O
Spanish residents	B-T098
in	O
nursing homes	B-T073
in	O
Madrid	B-T083
.	O
Data	B-T078
were	O
collected	O
using	O
unstructured and semi-structured interviews	B-T052
.	O
The	O
data	B-T078
were	O
analyzed	B-T062
using	O
thematic analysis	B-T062
.	O
Twenty	O
female	B-T032
residents	B-T098
participated.	O
Three	O
main	O
themes	B-UnknownType
emerged	O
from	O
the	O
data	B-T078
:	O
a)	O
expressing	B-T055
sexuality	B-T053
,	O
b)	O
sexuality	B-T053
as	O
a	O
duty	B-T058
and	O
c)	O
respecting	O
vows	B-T079
.	O
Female	B-T032
residents	B-T098
reported	O
key	O
elements	O
influencing	O
how	O
they	O
manage	B-T058
their	O
sexuality	B-T053
in	O
Nursing Homes	B-T073
.	O
These	O
results	O
serve	O
to	O
improve	O
our	O
understanding	O
regarding	O
the	O
expression	B-T055
of	O
sexuality	B-T053
in	O
older female	B-T032
nursing home	B-T073
residents	B-T098
.	O

Xylan-based	B-T109
temperature	B-T081
/	O
pH	B-T081
sensitive	B-T169
hydrogels	B-T122
for	O
drug controlled release	B-T122
Xylan-based	B-T109
temperature	B-T081
/	O
pH	B-T081
sensitive	B-T169
hydrogels	B-T122
were	O
prepared	O
by	O
the	O
crosslinking copolymerization	B-T044
of	O
xylan	B-T109
with	O
N-isopropylacrylamide	B-T109
(	O
NIPAm	B-T109
)	O
and	O
acrylic acid	B-T109
(	O
AA	B-T109
)	O
using	O
N,Ń-methylenebis-acrylamide	B-T109
(	O
MBA	B-T109
)	O
as	O
a	O
cross-linker	B-T130
and	O
2,2-dimethoxy-2-phenylacetophenone	B-T109
as	O
a	O
photoinitiator	B-T109
via	O
ultraviolet irradiation	B-T070
.	O
The	O
influence	B-T077
of	O
the	O
NIPAm	B-T109
,	O
AA	B-T109
and	O
MBA	B-T109
amount	O
on	O
properties	O
of	O
xylan-based	B-T109
hydrogels	B-T122
was	O
discussed.	O
The	O
morphology	B-T080
and	O
interactions	B-T169
of	O
hydrogels	B-T122
were	O
characterized	B-T052
by	O
SEM	B-T059
and	O
FTIR	B-T062
.	O
The	O
lower critical solution temperature	B-T081
(	O
LCST	B-T081
)	O
of	O
hydrogels	B-T122
was	O
investigated	B-T169
by	O
DSC	B-T059
.	O
The	O
results	B-T033
indicated	O
that	O
the	O
LCST	B-T081
of	O
hydrogels	B-T122
emerged	O
at	O
around	O
34°C	O
and	O
increased	O
with	O
increasing	O
the	O
AA	B-T109
content.	O
The	O
drug	B-T121
encapsulation	B-T067
efficiency	B-T081
of	O
as-prepared	O
hydrogels	B-T122
reached	O
to	O
97.60%	O
and	O
the	O
cumulative	B-T080
release	B-T070
rate	B-T081
of	O
acetylsalicylic acid	B-T109
was	O
90.12%	O
and	O
26.35%	O
in	O
the	O
intestinal	B-T023
and	O
gastric fluid	B-T031
,	O
respectively.	O
Xylan-based	B-T109
hydrogels	B-T122
were	O
proved	O
to	O
be	O
biocompatible	B-T080
with	O
NIH3T3 cell	B-T025
by	O
MTT assay	B-T062
and	O
showed	O
the	O
promising	O
application	O
as	O
drug carriers	B-T122
for	O
the	O
intestinal	B-T023
-	O
targeted	B-T169
oral drug delivery	B-T061
.	O

Isolation	B-T059
and	O
prebiotic	B-T109
activity	B-T169
of	O
water-soluble	B-T130
polysaccharides	B-T109
fractions	B-T081
from	O
the	O
bamboo shoots	B-T168
(	O
Phyllostachys praecox	B-T002
)	O
The	O
water-soluble	B-T130
polysaccharides	B-T109
from	O
bamboo shoots	B-T168
(	O
Phyllostachys praecox	B-T002
)	O
(	O
WBP	B-T109
)	O
were	O
isolated	B-T169
,	O
and	O
the	O
characterizations	B-T185
as	O
well	O
as	O
prebiotic	B-T109
activities	B-T169
were	O
investigated	B-T169
.	O
The	O
yield	B-T081
of	O
WBP	B-T109
was	O
7.58±0.31%	O
under	O
optimal	O
hot-water	B-T197
extraction	B-T059
conditions.	O
Two	O
fractions	B-T081
,	O
i.e.,	O
WBP-1	B-T109
and	O
WBP-2	B-T109
with	O
molecular weight	B-T081
of	O
83.50kDa	O
and	O
80.08kDa,	O
respectively,	O
were	O
purified	O
by	O
chromatography	B-T059
.	O
Both	O
the	O
polysaccharides	B-T109
fractions	B-T081
were	O
identified	O
as	O
heteropolysaccharides-protein complexes	B-T104
composed	O
of	O
15	O
kinds	O
of	O
common	O
amino acids	B-T116
in	O
protein	B-T116
part	O
and	O
rhamnose	B-T109
,	O
arabinose	B-T109
,	O
xylose	B-T109
,	O
mannose	B-T109
,	O
glucose	B-T109
and	O
galactose	B-T109
in	O
different	O
molar ratios	B-T081
in	O
polysaccharide	B-T109
part.	O
The	O
existence	O
of	O
α-	B-T078
and	O
β-glycosidic linkages	B-T078
between	O
the	O
sugar	B-T109
units	O
was	O
confirmed	O
by	O
FTIR	B-T062
and	O
NMR spectra	B-T060
.	O
Compared	O
with	O
the	O
blank	O
control	O
and	O
the	O
reference	O
of	O
FOS,	O
WBP-1	B-T109
and	O
WBP-2	B-T109
significantly	O
increased	O
the	O
numbers	O
of	O
Bifidobacterium adolescentis	B-T007
and	O
Bifidobacterium bifidum	B-T007
(P<0.05),	O
which	O
contributed	O
to	O
the	O
production	B-T169
of	O
organic acids	B-T109
,	O
suggesting	O
that	O
the	O
polysaccharides	B-T109
have	O
potential	B-T080
prebiotic	B-T109
properties	B-T080
.	O

Evaluation	O
of	O
nutraceutical	B-T033
and	O
antinutritional properties	B-T033
in	O
barnyard	B-T002
and	O
finger millet	B-T168
varieties	B-T077
grown	O
in	O
Himalayan region	B-UnknownType
Five	O
elite	O
varieties	B-T077
of	O
barnyard	B-T002
(	O
Echinochloa frumentacea	B-T002
)	O
and	O
finger	B-T002
(	O
Eleusine coracana	B-T002
)	O
growing	O
at	O
northwestern Himalaya	B-UnknownType
were	O
investigated	B-T169
for	O
nutraceutical	B-T033
and	O
antinutritional properties	B-T033
.	O
Barnyard millet	B-T168
contained	O
higher	O
amount	B-T081
of	O
crude fiber	B-T109
,	O
total dietary fiber	B-T168
,	O
tryptophan	B-T116
content	B-T077
,	O
total carotenoids	B-T109
,	O
α-tocopherol	B-T109
compared	O
to	O
the	O
finger millet	B-T168
whereas	O
the	O
finger millet	B-T168
contains	O
higher	O
amount	B-T081
of	O
methionine	B-T116
and	O
ascorbic acid	B-T109
as	O
compared	O
to	O
the	O
barnyard millet	B-T168
.	O
The	O
secondary metabolites	B-T123
of	O
biological functions	B-T038
were	O
analyzed	O
and	O
found	O
that	O
barnyard millet	B-T168
contained	O
the	O
higher	O
amount	B-T081
of	O
polyphenols	B-T109
,	O
tannins	B-T109
and	O
ortho-dihydroxy phenol	B-T109
content	B-T077
compared	O
to	O
finger millet	B-T168
.	O
Among	O
antinutitional compounds	B-T109
barnyard millet	B-T168
contained	O
lower	O
phytic acid	B-T109
content	B-T077
compare	O
to	O
finger millet	B-T168
whereas	O
no significant difference	B-T033
in	O
trypsin inhibition activity	B-T044
of	O
barnyard millet	B-T168
and	O
finger millet	B-T168
varieties	B-T077
were	O
found.	O
Barnyard millet	B-T168
contained	O
higher	O
acid phosphatase	B-T116
,	O
α-galactosidase	B-T116
and	O
α-amylase inhibitor activity	B-T044
compared	O
to	O
finger millet	B-T168
.	O
Finger millet seeds	B-T168
contained	O
about	O
10-13	O
folds	O
higher	O
calcium	B-T121
content	B-T077
and	O
double	O
amount	B-T081
of	O
manganese	B-T123
content	B-T077
in	O
comparison	O
to	O
barnyard millet seeds	B-T168
.	O
Present	O
study	O
suggests	O
that	O
barnyard millet	B-T168
varieties	B-T077
studied	O
under	O
present	O
investigation	O
were	O
found	O
nutritionally	O
superior	O
compared	O
to	O
finger millet	B-T168
varieties	B-T077
.	O

Polymorphisms	B-T086
in	O
Inflammatory	B-T169
Mediator Genes	B-T028
and	O
Risk	B-T078
of	O
Preeclampsia	B-T046
in	O
Taiyuan	B-UnknownType
,	O
China	B-T083
Excessive	B-T080
maternal	B-T033
inflammatory response	B-T046
is	O
involved	O
in	O
the	O
pathogenesis	B-T046
of	O
preeclampsia	B-T046
.	O
Few	O
epidemiologic studies	B-T062
have	O
investigated	B-T169
the	O
associations	B-T080
between	O
genetic variations	B-T070
in	O
the	O
inflammatory	B-T169
mediator genes	B-T028
and	O
preeclampsia	B-T046
risk	B-T078
,	O
and	O
these	O
studies	B-T062
have	O
reached	O
inconsistent	O
results.	O
We	O
examined	O
31	O
single-nucleotide polymorphisms	B-T086
in	O
IL-1A	B-T028
,	O
IL-1B	B-T028
,	O
IL-1R1	B-T116
,	O
IL-2RA	B-T116
,	O
IL-5RA	B-T116
,	O
IL-6	B-T028
,	O
IL-6R	B-T116
,	O
TNFSF11	B-T028
,	O
TNFRSF11A	B-T028
,	O
IL-28RA	B-T028
,	O
IRAK4	B-T028
,	O
and	O
KIT genes	B-T028
and	O
the	O
risk	B-T078
of	O
preeclampsia	B-T046
and	O
its	O
clinical	B-T080
subtypes	B-T185
in	O
a	O
nested case-control study	B-T062
including	O
203	O
preeclampsia	B-T046
cases	B-T077
and	O
233	O
controls	B-T096
.	O
We	O
found	O
that	O
IL-1R1	B-T116
,	O
IL-5RA	B-T116
,	O
IL-6R	B-T116
,	O
and	O
TNFSF11	B-T028
were	O
associated with	B-T080
the	O
risk	B-T078
of	O
preeclampsia	B-T046
.	O
Although	O
the	O
significant	B-T078
associations	B-T080
observed	O
for	O
preeclampsia	B-T046
overall	B-T080
were	O
mainly	O
seen	O
for	O
late-onset	B-T079
preeclampsia	B-T046
and	O
severe	B-T080
preeclampsia	B-T046
,	O
IL-6R	B-T116
(	O
rs2229238	B-T170
)	O
and	O
TNFSF11	B-T028
(	O
rs9525643	B-T170
)	O
polymorphisms	B-T086
were	O
associated with	B-T080
the	O
risk	B-T078
of	O
early-onset	O
preeclampsia	B-T046
.	O
TNFSF11	B-T028
(	O
rs2200287	B-T170
and	O
rs2148072	B-T170
)	O
polymorphisms	B-T086
were	O
associated with	B-T080
risk	B-T078
of	O
mild	O
preeclampsia	B-T046
.	O
Our	O
study	B-T062
provided	O
the	O
first	O
evidence	B-T078
that	O
genetic variations	B-T070
in	O
inflammatory	B-T169
mediator genes	B-T028
IL-1R1	B-T116
,	O
IL-6R	B-T116
,	O
TNFSF11	B-T028
,	O
and	O
IL-5RA	B-T116
were	O
associated with	B-T080
preeclampsia	B-T046
risk	B-T078
,	O
and	O
the	O
risk	B-T078
varied	O
by	O
preeclampsia	B-T046
subtypes	B-T185
.	O

A	O
closer	O
look	O
at	O
school	B-T073
bonding	B-T041
among	O
African American	B-T098
adolescents	B-T100
in	O
low-income communities	B-T098
:	O
A	O
latent class analysis	B-T062
Positive	B-T033
school	B-T073
bonding	B-T041
is	O
a	O
significant	B-T078
precursor	B-T078
to	O
students	B-T098
'	O
school	B-T073
success	B-T054
.	O
However,	O
African American	B-T098
youth	B-T100
report	O
lower	B-T080
school	B-T073
success	B-T054
compared	O
with	O
their	O
White counterparts	B-T098
.	O
This	O
study	B-T062
examined	O
correlates	B-T080
of	O
school	B-T073
bonding	B-T041
among	O
633	O
African American	B-T098
youth	B-T100
who	O
were	O
recruited	B-T052
from	O
community settings	B-T096
in	O
Chicago	B-T083
.	O
Major	B-T080
findings	B-T033
indicated	O
that	O
negative peer norms	B-T033
,	O
exposure to	B-T080
community violence	B-T033
,	O
and	O
poor	B-T080
mental health	B-T041
were	O
negatively	B-T033
correlated	B-T080
with	O
school	B-T073
bonding	B-T041
,	O
while	O
parental monitoring	B-UnknownType
,	O
positive self-regard	B-T033
,	O
and	O
future	B-T079
orientation	B-T041
were	O
correlated	B-T080
with	O
higher	B-T080
school	B-T073
motivation	B-T041
.	O
Students	B-T098
classified	B-T185
as	O
having	O
high	B-T080
or	O
moderate	B-T080
school	B-T073
bonding	B-T041
were	O
more	O
likely	O
to	O
live	B-T052
with	O
both	O
parents	B-T099
,	O
experience	B-T041
higher	B-T080
levels	B-T080
of	O
parental monitoring	B-UnknownType
,	O
and	O
exhibit positive self-regard	B-T033
.	O
Implications	O
are	O
discussed	O
in	O
view	O
of	O
these	O
findings	B-T033
.	O

DEPRESSION	B-T048
,	O
ANXIETY	B-T048
,	O
STRESS	B-T048
,	O
AND	O
THEIR	O
ASSOCIATED	B-T080
FACTORS	B-T169
AMONG	O
CORPS MEMBERS	B-T098
SERVING	O
IN	O
KEBBI STATE	B-UnknownType
Depression	B-T048
,	O
anxiety	B-T048
and	O
stress	B-T048
,	O
are	O
not	O
only	O
health problems	B-T033
by	O
themselves,	O
but	O
also	O
associated with	B-T080
other	O
negative	B-T033
health	B-T078
consequences	B-T169
.	O
The	O
national youth service	B-T092
is	O
usually	O
characterized	B-T052
by	O
a	O
number	O
of	O
new	O
challenges	O
and	O
experiences	B-T041
which	O
may	O
require	O
life style	B-T054
adjustments	B-T055
by	O
the	O
corps member	B-T098
.	O
However,	O
no	O
previous	O
study	O
on	O
psychological factors	B-T041
has	O
been	O
conducted	O
among	O
corps members	B-T098
.	O
This	O
study	B-T062
was	O
conducted	O
to	O
determine	O
the	O
prevalence	B-T081
of	O
depression	B-T048
,	O
anxiety	B-T048
and,	O
stress	B-T048
and	O
their	O
associated	B-T080
factors	B-T169
among	O
corps members	B-T098
serving	O
in	O
Kebbi state	B-UnknownType
.	O
A	O
cross-sectional study	B-T062
was	O
conducted	O
among	O
264	O
corps members	B-T098
from	O
four	O
local government areas	B-UnknownType
of	O
the	O
state	B-T083
.	O
Selection	O
of	O
the	O
local government areas	B-UnknownType
and	O
the	O
individual	O
participants	B-T098
was	O
by	O
simple random sampling	B-T062
.	O
Data	B-T078
was	O
collected	O
from	O
May	B-T079
to	O
June	B-T079
2014	O
using	O
a	O
self-administered questionnaire	B-T170
.	O
Data analysis	B-T057
used	O
chi-square test	B-T170
to	O
identify	O
the	O
relationship	B-T080
between	O
categorical variables	B-T080
and	O
multivariate logistic regression	B-T062
to	O
identify	O
the	O
independent	O
factors	B-T169
for	O
depression	B-T048
,	O
anxiety	B-T048
and	O
stress	B-T048
each.	O
The	O
response rate	B-T079
was	O
97%.	O
Most	O
of	O
the	O
respondents	B-T098
were	O
males	B-T032
(63.6%),	O
single	B-T098
(85.5%),	O
and	O
above	O
20	O
years	B-T079
of	O
age	B-T032
(71.6%).	O
The	O
overall	O
prevalences	B-T081
of	O
depression	B-T048
,	O
anxiety	B-T048
and	O
stress	B-T048
among	O
the	O
respondents	B-T098
were	O
36.4%,	O
54.5%	O
and	O
18.2%	O
respectively.	O
The	O
independent	O
factors	B-T169
for	O
depression	B-T048
were;	O
being	O
from	O
the	O
North central	B-T083
(	O
OR	B-T081
=	O
5.99;	O
95%	O
CI	B-T081
:	O
2.194-16.354)	O
or	O
South-south	B-T083
;	O
and	O
the	O
perception	B-T041
of	O
earning	B-T081
enough	O
income	B-T081
(	O
OR	B-T081
=	O
2.987;	O
95%	O
CI	B-T081
CI	B-T081
:	O
1.062-8.400).	O
For	O
anxiety	B-T048
,	O
male gender	B-T032
(	O
OR	B-T081
=	O
0.411;	O
95%	O
CI	B-T081
:	O
0.169-0.999);	O
and	O
being	O
from	O
the	O
North central	B-T083
were	O
significant	O
risk factors	B-T033
(	O
OR	B-T081
=	O
3.731;	O
95%	O
CI	B-T081
:	O
1.450-9.599).	O
Being	O
above	O
26	O
years	B-T079
of	O
age	B-T032
was	O
an	O
independent	O
risk factor	B-T033
for	O
stress	B-T048
(	O
OR	B-T081
=	O
0.083;	O
95%	O
CI	B-T081
:	O
0.018-0.381).	O
Also,	O
those	O
who	O
had	O
ever	O
schooled	B-T033
outside	O
their	O
towns	B-T083
of	O
residence	B-T082
were	O
less	O
likely	O
to	O
be	O
stressed	B-T041
compared	O
to	O
those	O
who	O
had	O
never	O
(	O
OR	B-T081
=	O
0.30;	O
95%	O
CI	B-T081
:	O
0.110-0.855).	O
All	O
other	O
factors	B-T169
did	O
not	O
show	O
any	O
significant association	B-T080
with	O
any	O
of	O
the	O
outcome variables	B-T080
in	O
multivariate analysis	B-T081
.	O
In	O
conclusion	B-T078
,	O
the	O
prevalences	B-T081
of	O
depression	B-T048
,	O
anxiety	B-T048
and	O
stress	B-T048
are	O
high	B-T080
among	O
corps members	B-T098
serving	O
in	O
Kebbi state	B-UnknownType
.	O
There	O
is	O
need	O
to	O
expand	O
the	O
scope	O
of	O
this	O
study	B-T062
to	O
a	O
national level	B-T082
so	O
as	O
to	O
get	O
a	O
bigger	O
picture	O
of	O
the	O
problem	B-T033
.	O

Trans-oral	B-T082
fine needle aspiration cytology	B-T060
in	O
cervical (C1 and C2) vertebral	B-T023
lesions	B-T033
:	O
a	O
novel	O
diagnostic approach	B-T060
Fine needle aspiration (FNA) cytology	B-T060
is	O
a	O
relatively	O
non-invasive	B-T169
method	O
for	O
diagnosing	B-T033
both	O
superficial	B-T033
and	O
deep-seated neoplastic	B-T191
and	O
non-neoplastic lesions	B-T033
.	O
In	O
this	O
study,	O
we	O
evaluated	O
the	O
diagnostic utility	B-T169
of	O
trans-oral	B-T082
FNA	B-T060
in	O
cervical (C1 and C2) vertebral	B-T023
and	O
paravertebral	B-T029
lesions	B-T033
.	O
Eighteen	O
FNA	B-T060
cases	O
of	O
cervical vertebral	B-T023
and	O
paravertebral	B-T029
lesions	B-T033
performed	O
by	O
a	O
trans-oral route	B-T082
without	O
any	O
image-guidance	B-T058
between	O
1995	O
and	O
2014	O
were	O
retrieved	O
from	O
the	O
archives	O
of	O
the	O
cytology	B-T091
department	B-T092
at	O
PGIMER	B-T092
,	O
Chandigarh	B-UnknownType
and	O
reviewed.	O
Out	O
of	O
18	O
cases,	O
a	O
definite	O
diagnosis	B-T033
was	O
given	O
in	O
15	O
cases	O
(83.3%).	O
The	O
commonest	O
diagnosis	B-T033
seen	O
was	O
granulomatous inflammation	B-T046
consistent	O
with	O
tuberculosis	B-T047
(33.3%).	O
Trans-oral	B-T082
FNA	B-T060
is	O
a	O
quick,	O
inexpensive	O
and	O
relatively	O
safe	O
outpatient procedure	B-T061
for	O
sampling	O
C1 and C2 vertebral	B-T023
and	O
paravertebral	B-T029
lesions	B-T033
,	O
which	O
are	O
clinically	B-T201
and	O
radiologically	B-T091
difficult	O
to	O
approach.	O
It	O
helps	O
in	O
the	O
early diagnosis	B-T060
and	O
management of these patients	B-T058
.	O

Neonatal infections	B-T047
:	O
Case definition	B-T170
and	O
guidelines	B-T170
for	O
data collection	B-T062
,	O
analysis	B-T062
,	O
and	O
presentation	B-T078
of	O
immunisation	B-T061
safety data	B-T078
Maternal	B-T033
vaccination	B-T061
is	O
an	O
important	O
area	O
of	O
research	B-T062
and	O
requires	O
appropriate	O
and	O
internationally	O
comparable	O
definitions	B-T170
and	O
safety standards	B-T170
.	O
The	O
GAIA group	B-T097
,	O
part	O
of	O
the	O
Brighton Collaboration	B-T097
was	O
created	O
with	O
the	O
mandate	O
of	O
proposing	O
standardised	O
definitions	B-T170
applicable	O
to	O
maternal	B-T033
vaccine	B-T121
research	B-T062
.	O
This	O
study	B-T062
proposes	O
international	O
definitions	B-T170
for	O
neonatal infections	B-T047
.	O
The	O
neonatal infections	B-T047
GAIA	B-T097
working group	B-T098
performed	O
a	O
literature	B-T170
review	B-T169
using	O
Medline	B-T170
,	O
EMBASE	B-T170
and	O
the	O
Cochrane collaboration	B-T169
and	O
collected	O
definitions	B-T170
in	O
use	O
in	O
neonatal	B-T169
and	O
public health networks	B-T169
.	O
The	O
common	O
criteria	B-T078
derived	B-T080
from	O
the	O
extensive	O
search	O
formed	O
the	O
basis	O
for	O
a	O
consensus process	B-T054
that	O
resulted	O
in	O
three	O
separate	O
definitions	B-T170
for	O
neonatal	B-T100
blood stream infections	B-T046
(	O
BSI	B-T046
),	O
meningitis	B-T047
and	O
lower respiratory tract infections	B-T047
(	O
LRTI	B-T047
).	O
For	O
each	O
definition	B-T170
three	O
levels	O
of	O
evidence	O
are	O
proposed	O
to	O
ensure	O
the	O
applicability	O
of	O
the	O
definitions	B-T170
to	O
different	O
settings.	O
Recommendations	O
about	O
data collection	B-T062
,	O
analysis	B-T062
and	O
presentation	B-T078
are	O
presented	O
and	O
harmonized	B-T062
with	O
the	O
Brighton Collaboration	B-T097
and	O
GAIA	B-T097
format	B-T170
and	O
other	O
existing	O
international standards	B-T170
for	O
study	B-T062
reporting	B-T062
.	O

Beneficial	B-T081
effects	B-T080
of	O
dark chocolate	B-T168
on	O
exercise	B-T056
capacity	B-T081
in	O
sedentary	B-T080
subjects	B-T098
:	O
underlying	O
mechanisms	B-T169
.	O
A	O
double blind	B-T062
,	O
randomized	B-T062
,	O
placebo controlled	B-T062
trial	B-T062
In	O
heart failure	B-T047
patients	B-T101
the	O
consumption	B-T039
of	O
(-)-epicatechin	B-T121
(	O
(-)-Epi	B-T121
)-rich	O
cocoa	B-T168
can	O
restore	O
skeletal muscle	B-T024
(	O
SkM	B-T024
)	O
mitochondrial	B-T026
structure	B-T082
and	O
decrease	B-T081
biomarkers	B-T201
of	O
oxidative stress	B-T049
.	O
However,	O
nothing	O
is	O
known	O
about	O
its	O
effects	B-T080
on	O
exercise	B-T056
capacity	B-T081
and	O
underlying	O
mechanisms	B-T169
in	O
normal	B-T080
,	O
sedentary	B-T080
subjects	B-T098
.	O
Twenty	O
normal	B-T080
,	O
sedentary	B-T080
subjects	B-T098
(∼50	O
years old	B-T100
)	O
were	O
randomized	B-T062
to	O
placebo	B-T061
or	O
dark chocolate	B-T168
(	O
DC	B-T168
)	O
groups	B-T078
and	O
consumed	B-T052
20	O
g	O
of	O
the	O
products	O
for	O
3	O
months	B-T079
.	O
Subjects	B-T098
underwent	O
before	O
and	O
after	O
treatment	B-T061
,	O
bicycle ergometry	B-T060
to	O
assess	B-T058
VO2 max	B-T033
and	O
work	B-T057
,	O
SkM biopsy	B-T060
to	O
assess	B-T058
changes	O
in	O
mitochondrial	B-T026
density	B-T081
,	O
function	B-T169
and	O
oxidative stress	B-T049
and	O
blood sampling	B-T060
to	O
assess	B-T058
metabolic	B-T169
endpoints	B-T080
.	O
Seventeen	O
subjects	B-T098
completed	O
the	O
trial	B-T062
.	O
In	O
the	O
DC	B-T168
group	O
(n	O
=	O
9),	O
VO2 max	B-T033
increased	B-T169
(17%	O
increase	B-T169
,	O
p	O
=	O
0.056)	O
as	O
well	O
as	O
maximum	O
work	B-T057
(	O
watts	B-T081
)	O
achieved	O
(p	O
=	O
0.026)	O
with	O
no	O
changes	O
with	O
placebo	B-T061
(n	O
=	O
8).	O
The	O
DC	B-T168
group	O
evidenced	O
increases	B-T169
in	O
HDL	B-T116
levels	O
(p	O
=	O
0.005)	O
and	O
decreased	B-T081
triglycerides	B-T109
(p	O
=	O
0.07).	O
With	O
DC	B-T168
,	O
SkM	B-T024
evidenced	O
significant	B-T078
increases	B-T169
in	O
protein	B-T116
levels	O
for	O
LKB1	B-T116
,	O
AMPK	B-T116
and	O
PGC1α	B-T116
and	O
in	O
their	O
active	B-T169
forms	O
(	O
phosphorylated	B-T044
AMPK	B-T116
and	O
LKB1	B-T116
)	O
as	O
well	O
as	O
in	O
citrate synthase activity	B-T044
while	O
no	O
changes	O
were	O
observed	O
in	O
mitochondrial	B-T026
density	B-T081
.	O
With	O
DC	B-T168
,	O
significant	B-T078
increases	B-T169
in	O
SkM	B-T024
reduced	O
glutathione	B-T116
levels	O
and	O
decreases	B-T081
in	O
protein carbonylation	B-T044
were	O
observed.	O
Improvements	O
in	O
maximum	O
work	B-T057
achieved	O
and	O
VO2 max	B-T033
may	O
be	O
due	O
to	O
DC	B-T168
activation	B-T052
of	O
upstream	O
control	O
systems	O
and	O
enhancement	O
of	O
SkM	B-T024
mitochondria	B-T026
efficiency	B-T081
.	O
Larger	O
clinical studies	B-T062
are	O
warranted	O
to	O
confirm	O
these	O
observations	B-T062
.	O

Reduction	B-T080
in	O
Hospital-Wide	B-T073
Clinical Laboratory Specimen Identification	B-T059
Errors	B-T080
following	O
Process Interventions	B-UnknownType
:	O
A	O
10-	O
Year	B-T079
Retrospective Observational Study	B-T062
Accurate	B-T080
patient identification	B-T058
and	O
specimen labeling	B-T058
at	O
the	O
time	O
of	O
collection	O
are	O
crucial steps	B-T077
in	O
the	O
prevention	B-T062
of	O
medical errors	B-T080
,	O
thereby	O
improving	B-T080
patient safety	B-T058
.	O
All	O
patient specimen	B-T031
identification	B-T080
errors	B-T080
that	O
occurred	B-T052
in	O
the	O
outpatient department	B-T082
(	O
OPD	B-T082
),	O
emergency department	B-T073
(	O
ED	B-T073
),	O
and	O
inpatient department	B-T082
(	O
IPD	B-T082
)	O
of	O
a	O
3,800-	O
bed	B-T073
academic medical center	B-T073
in	O
Taiwan	B-T083
were	O
documented	B-T058
and	O
analyzed	B-T058
retrospectively	O
from	O
2005	O
to	O
2014.	O
To	O
reduce	B-T080
such	O
errors	B-T080
,	O
the	O
following	O
series	B-T081
of	O
strategies	B-T170
were	O
implemented:	O
a	O
restrictive specimen acceptance policy	B-T089
for	O
the	O
ED	B-T073
and	O
IPD	B-T082
in	O
2006;	O
a	O
computer-assisted	B-T059
barcode	B-T170
positive patient identification system	B-T073
for	O
the	O
ED	B-T073
and	O
IPD	B-T082
in	O
2007	O
and	O
2010,	O
and	O
automated	B-T169
sample labeling	B-T058
combined	B-T080
with	O
electronic identification systems	B-T058
introduced	B-T169
to	O
the	O
OPD	B-T082
in	O
2009.	O
Of	O
the	O
2000345	O
specimens	B-T031
collected	B-T169
in	O
2005,	O
1023	O
(0.0511%)	O
were	O
identified	B-T033
as	O
having	O
patient identification	B-T058
errors	B-T080
,	O
compared	O
with	O
58	O
errors	B-T080
(0.0015%)	O
among	O
3761238	O
specimens	B-T031
collected	B-T169
in	O
2014,	O
after	O
serial	O
interventions	B-T058
;	O
this	O
represents	O
a	O
97%	O
relative	B-T080
reduction	B-T080
.	O
The	O
total number	B-T081
(	O
rate	B-T081
)	O
of	O
institutional identification	B-T058
errors	B-T080
contributed	O
from	O
the	O
ED	B-T073
,	O
IPD	B-T082
,	O
and	O
OPD	B-T082
over	O
a	O
10-	O
year	B-T079
period	B-T079
were	O
423	O
(0.1058%),	O
556	O
(0.0587%),	O
and	O
44	O
(0.0067%)	O
errors	B-T080
before	B-T079
the	O
interventions	B-T058
,	O
and	O
3	O
(0.0007%),	O
52	O
(0.0045%)	O
and	O
3	O
(0.0001%)	O
after	B-T079
interventions	B-T058
,	O
representing	O
relative	B-T080
99%,	O
92%	O
and	O
98%	O
reductions	B-T080
,	O
respectively.	O
Accurate	B-T080
patient identification	B-T058
is	O
a	O
challenge	O
of	O
patient safety	B-T058
in	O
different	O
health	B-T078
settings	B-T081
.	O
The	O
data collected	B-T033
in	O
our	O
study	B-T062
indicate	O
that	O
a	O
restrictive specimen acceptance policy	B-T089
,	O
computer-generated	B-T059
positive identification systems	B-T073
,	O
and	O
interdisciplinary	O
cooperation	O
can	O
significantly	O
reduce	B-T080
patient identification	B-T058
errors	B-T080
.	O

Management	B-T058
of	O
skin and soft-tissue infections	B-T047
at	O
a	O
community	O
teaching hospital	B-T073
using	O
a	O
severity-of-illness tool	B-T169
Skin and soft-tissue infections	B-T047
(	O
SSTIs	B-T047
)	O
encompass	O
a	O
diverse	B-T080
range	B-T081
of	O
infections	B-T046
of	O
varying	O
severity	B-T080
.	O
The	O
Clinical Resource Efficiency Support Team (CREST) scoring system	B-T170
stratifies	B-T185
patients	B-T101
into	O
four	O
classes	B-T185
(I	O
=	O
least	O
severe	B-T080
to	O
IV	O
=	O
most	O
severe	B-T080
)	O
based	O
on	O
the	O
Standardized Early Warning Score	B-T170
(	O
SEWS	B-T170
).	O
The	O
objective	B-T078
of	O
this	O
study	B-T062
was	O
to	O
apply	O
CREST	B-T170
to	O
hospitalized patients	B-T101
with	O
SSTIs	B-T047
in	O
order	O
to	O
quantify	O
disease severity	B-T080
and	O
evaluate	B-T058
appropriateness	O
of	O
antibiotic	B-T195
management.	O
This	O
was	O
a	O
retrospective	B-T062
,	O
hypothesis	B-T078
-generating,	O
single-centre	O
evaluation	B-T058
of	O
hospitalized patients	B-T101
with	O
SSTIs	B-T047
admitted	B-T058
in	O
2011.	O
Based	O
on	O
CREST	B-T170
classification,	O
the	O
empirical	B-T080
antimicrobial	B-T121
choices	O
were	O
categorized	B-T052
as	O
appropriate,	O
over-treatment	B-T058
or	O
under-treatment	B-T061
.	O
A	O
total	O
of	O
369	O
patients	B-T101
were	O
screened	O
and	O
200	O
met	O
the	O
inclusion criteria	B-T080
.	O
The	O
majority	O
of	O
patients	B-T101
were	O
classified	B-T185
as	O
either	O
CREST	B-T170
class I	B-T185
(n	O
=	O
68)	O
or	O
class I	B-T185
I	O
(n	O
=	O
102).	O
Over-treatment	B-T058
was	O
more	O
common	O
in	O
the	O
less	O
severe	B-T080
classes	B-T185
(88%	O
and	O
32%	O
in	O
class I	B-T185
and	O
class II	B-T185
,	O
respectively;	O
P	O
<	O
0.05).	O
Sixty-three	O
percent	B-T081
of	O
class I	B-T185
(n	O
=	O
43)	O
were	O
over-treated	B-T058
due	O
to	O
both	O
the	O
use	O
of	O
intravenous	B-T169
antibiotic	B-T195
s	O
when	O
oral therapy	B-T061
was	O
sufficient	O
and	O
use	O
of	O
unnecessarily	O
broad-spectrum antibiotics	B-T195
.	O
In	O
contrast,	O
25%	O
(n	O
=	O
26)	O
of	O
class II	B-T185
were	O
over-treated	B-T058
due	O
to	O
use	O
of	O
unnecessarily	O
broad-spectrum antibiotics	B-T195
.	O
Overall	O
clinical failure	B-T033
rates	O
remained	O
low	O
with	O
only	O
1%,	O
4%	O
and	O
17%	O
of	O
patients	B-T101
unable	O
to	O
achieve	O
initial	O
response	B-T201
in	O
class II	B-T185
,	O
class III	B-T185
and	O
class IV	B-T185
.	O
Retrospective	B-T080
application	B-T058
of	O
CREST	B-T170
identified	O
opportunities	O
to	O
improve	O
the	O
management	B-T058
of	O
SSTIs	B-T047
.	O
CREST	B-T170
can	O
be	O
of	O
great	O
value	O
in	O
discriminating	O
less-	O
severe	B-T080
SSTIs	B-T047
,	O
which	O
can	O
be	O
treated	B-T061
on	O
an	O
outpatient	B-T101
basis.	O

Breakthrough	B-T080
viridans streptococcal bacteremia	B-T047
in	O
allogeneic hematopoietic stem cell transplant	B-T061
recipients	B-T101
receiving	B-T080
levofloxacin	B-T109
prophylaxis	B-T061
in	O
a	O
Japanese	B-T083
hospital	B-T073
Breakthrough	B-T080
viridans streptococcal bacteremia	B-T047
(	O
VSB	B-T047
)	O
in	O
patients	B-T101
with	O
hematological malignancy	B-T191
receiving	B-T080
levofloxacin	B-T109
prophylaxis	B-T061
is	O
a	O
major	B-T080
blood stream infection	B-T047
(	O
BSI	B-T047
)	O
occurring	B-T052
during	B-T079
febrile neutropenia	B-T047
.	O
However,	O
clinical data	B-T170
focused	B-T169
on	O
VSB	B-T047
in	O
allogeneic hematopoietic stem cell transplant	B-T061
(	O
allo-HSCT	B-T061
)	O
recipients	B-T101
are	O
lacking	B-T080
.	O
The	O
medical records	B-T170
of	O
allo-HSCT	B-T061
recipients	B-T101
who	O
received	B-T080
oral	B-T169
levofloxacin	B-T109
prophylaxis	B-T061
between	O
January	O
2011	O
and	O
August	O
2013	O
at	O
Toranomon Hospital	B-T073
were	O
reviewed	B-T080
to	O
evaluate	B-T058
breakthrough	B-T080
VSB	B-T047
.	O
Stored	O
viridans streptococcal	B-T007
(	O
VGS	B-T007
)	O
species	B-T185
were	O
identified	B-T080
by	O
using	B-T169
sodA gene	B-T028
sequencing	B-T059
,	O
and	O
were	O
assessed	B-T052
for	O
drug susceptibility	B-T038
.	O
Among	O
the	O
184	O
allo-HSCT	B-T061
recipients	B-T101
on	O
levofloxacin	B-T109
prophylaxis	B-T061
,	O
28	O
(15.2	O
%)	O
experienced	O
breakthrough	B-T080
VSB	B-T047
.	O
All	O
of	O
the	O
28	O
recipients	B-T101
with	O
VSB	B-T047
were	O
treated	B-T169
with	O
a	O
cefepime	B-T109
-	O
based	B-T169
or	O
piperacillin/tazobactam	B-T121
-	O
based	B-T169
regimen	B-T061
.	O
The	O
susceptibility	B-T038
rates	B-T081
of	O
the	O
VGS	B-T007
strains	B-T001
for	O
levofloxacin	B-T109
,	O
cefepime	B-T109
,	O
piperacillin/tazobactam	B-T121
,	O
meropenem	B-T109
,	O
and	O
vancomycin	B-T116
were	O
0	O
%,	O
95	O
%,	O
100	O
%,	O
100	O
%,	O
and	O
100	O
%,	O
respectively.	O
Both	O
the	O
MIC50	B-T059
(	O
minimum inhibitory concentration	B-T059
)	O
and	O
the	O
MIC90	B-T059
of	O
ceftazidim	B-T109
(0.5	O
μg/mL	O
and	O
2	O
μg/mL,	O
respectively)	O
were	O
higher	B-T080
than	O
the	O
MIC90	B-T059
of	O
all	O
the	O
other	O
anti-pseudomonal beta-lactams	B-T121
(	O
APBLs	B-T121
).	O
Only	O
1	O
VGS	B-T007
strain	B-T001
had	O
a	O
penicillin	B-T109
MIC	B-T059
≥	O
2	O
μg/mL	O
by	O
the	O
Etest	B-T059
(3.6	O
%).	O
There	O
were	O
no	B-T169
cases	B-T169
with	O
acute respiratory distress syndrome	B-T033
(	O
ARDS	B-T033
)	O
that	O
was	O
associated with	B-T080
VSB	B-T047
,	O
although	O
the	O
rate	B-T081
of	O
viridans group streptococcal shock syndrome	B-T047
was	O
high	B-T080
(26	O
%).	O
The	O
crude	O
30-day	B-T079
mortality rate	B-T081
in	O
the	O
VSB	B-T047
group	B-UnknownType
(10.7	O
%)	O
did	O
not	B-T169
differ	B-T080
significantly	B-T078
from	O
that	O
in	O
the	O
BSI	B-T047
without	B-T080
VSB	B-T047
group	B-UnknownType
(9.3	O
%)	O
or	O
non	B-T169
-	O
BSI	B-T047
group	B-UnknownType
(7.0	O
%)	O
(P	O
=	O
0.77).	O
Also,	O
VSB	B-T047
was	O
not	B-T169
a	O
risk factor	B-T033
for	O
all-cause	O
mortality	B-T081
up	O
to	O
60 days	B-T079
following	B-T079
allo-HSCT	B-T061
(P	O
=	O
0.43).	O
APBL	B-T121
with	O
increased	B-T081
anti-VGS activity	B-T033
(	O
APBL-VA	B-T033
)	O
monotherapy	B-T061
would	O
typically	O
be	O
optimal	B-T080
for	O
treating	B-T169
the	O
VGS	B-T007
strains	B-T001
in	O
this	O
setting.	O
Indication	O
of	O
adding	O
an	O
empiric	O
anti-gram-positive agent	B-T121
to	O
APBL-VA	B-T033
for	O
treating	B-T169
VSB	B-T047
should	O
depend	O
on	O
local	B-T082
factors	B-T169
,	O
such	O
as	O
the	O
susceptibility	B-T038
results	B-T169
.	O
In	O
addition,	O
breakthrough	B-T080
VSB	B-T047
is	O
probably	O
not	B-T169
a	O
major	B-T080
cause of death	B-T033
in	O
allo-HSCT	B-T061
settings,	O
where	O
beta-lactam	B-T109
non-susceptible VGS	B-T007
and	O
the	O
ARDS	B-T033
are	O
rare	B-T080
.	O

The	O
lost	O
art	O
of	O
the	O
splenorrhaphy	B-T061
In	O
the	O
case	O
of	O
the	O
hemodynamically unstable	B-T047
child	B-T100
,	O
splenorrhaphy	B-T061
is	O
preferred	O
to	O
splenectomy	B-T061
to	O
avert	O
postsplenectomy	B-T046
sepsis	B-T047
.	O
However,	O
successful	O
splenorrhaphy	B-T061
requires	O
familiarity	B-T041
with	O
the	O
procedure	B-T061
.	O
We	O
sought	O
to	O
determine	O
how	O
many	O
splenectomies	B-T061
or	O
splenorrhaphies	B-T061
for	O
trauma	B-T037
the	O
average	O
pediatric surgeon	B-T097
can	O
be	O
expected	O
to	O
perform	B-T169
during	O
their	O
career	B-T057
.	O
The	O
Pediatric Health Information System (PHIS) Database	B-T170
was	O
queried	O
for	O
patients	B-T101
≤18	O
years	B-T079
coded	O
with	O
an	O
International Classification of Diseases 9th Edition	B-T170
diagnosis code	B-T170
of	O
a	O
splenic injury	B-T037
from	O
2004	O
to	O
2013.	O
Age	B-T032
,	O
gender	B-T032
,	O
grade	B-T185
of	O
splenic injury	B-T037
,	O
and	O
operations	B-T061
performed	B-T169
were	O
extracted	B-T078
.	O
Numbers	O
of	O
pediatric surgeons	B-T097
per	O
hospital	B-T073
were	O
obtained.	O
9567	O
children	B-T100
were	O
identified	B-T080
.	O
2.1%	O
underwent	O
a	O
splenectomy	B-T061
and	O
0.8%	O
underwent	O
a	O
splenorrhaphy	B-T061
.	O
The	O
average	O
surgeon	B-T097
performed	B-T169
0.6	O
(SD=0.6)	O
splenectomies	B-T061
and	O
0.2	O
(SD=0.4)	O
splenorrhaphies	B-T061
for	O
trauma	B-T037
.	O
If	O
these	O
rates	B-T081
remain	O
constant	B-T080
over	O
time,	O
the	O
average	O
surgeon	B-T097
would	O
perform	B-T169
1.8	O
(SD	O
=1.7)	O
splenectomies	B-T061
and	O
0.6	O
(SD	O
=1.1)	O
splenorrhaphies	B-T061
for	O
trauma	B-T037
over	O
a	O
30-	O
year	B-T079
surgical career	B-T057
.	O
Nonoperative management	B-T061
is	O
associated	O
with	O
a	O
host	O
of	O
benefits,	O
but	O
has	O
resulted	O
in	O
a	O
decrease	O
in	O
the	O
experience level	B-T080
of	O
the	O
pediatric surgeons	B-T097
expected	O
to	O
perform	B-T169
an	O
emergency	O
splenectomy	B-T061
or	O
splenorrhaphy	B-T061
when	O
the	O
unusual	O
occasion	O
arises.	O

Vestibular	B-T030
-dependent	O
inter-stimulus interval	B-T079
effects	B-T080
on	O
sound evoked potentials	B-T042
of	O
central	B-T082
origin	B-T079
Todd	O
et	O
al.	O
(2014ab)	O
have	O
recently	O
demonstrated	O
the	O
presence	B-T033
of	O
vestibular	B-T030
-dependent	O
contributions	B-T052
to	O
auditory evoked potentials	B-T042
(	O
AEPs	B-T042
)	O
when	O
passing	O
through	O
the	O
vestibular	B-T030
threshold	B-T081
as	O
determined	O
by	O
vestibular evoked myogenic potentials	B-T034
(	O
VEMPs	B-T034
),	O
including	O
a	O
particular	O
deflection	B-T082
labeled	B-T080
as	O
an	O
N42/P52	O
prior	B-T079
to	O
the	O
long	B-T080
-	O
latency	B-T079
AEPs	B-T042
N1	O
and	O
P2.	O
In	O
this	O
paper	O
we	O
report	B-T058
the	O
results	B-T033
of	O
an	O
experiment	B-T062
to	O
determine	O
the	O
effect of	B-T080
inter-stimulus interval	B-T079
(	O
ISI	B-T079
)	O
and	O
regularity	B-T080
on	O
potentials	B-T042
recorded	O
above	B-T082
and	O
below	B-T082
VEMP	B-T034
threshold	B-T081
.	O
Five	O
healthy	B-T080
,	O
right-handed	B-T032
subjects	B-T098
were	O
recruited	O
and	O
evoked potentials	B-T042
were	O
recorded	O
to	O
binaurally	O
presented	O
sound stimulation	B-T061
,	O
above	B-T082
and	O
below	B-T082
vestibular	B-T030
threshold	B-T081
,	O
at	O
seven	O
stimulus	B-T067
rates	B-T081
with	O
ISIs	B-T079
of	O
212,	O
300,	O
424,	O
600,	O
848,	O
1200	O
and	O
1696	O
ms.	O
The	O
inner	O
five	O
intervals	B-T079
,	O
i.e.	O
300,	O
424,	O
600,	O
848,	O
1200	O
ms,	O
were	O
presented	B-T078
twice	O
in	O
both	O
regular	B-T080
and	O
irregular	B-T080
conditions.	O
ANOVA	B-T081
on	O
the	O
global field power	B-T081
(	O
GFP	B-T081
)	O
were	O
conducted	O
for	O
each	O
of	O
four	O
waves,	O
N42,	O
P52,	O
N1	O
and	O
P2	O
with	O
factors	O
of	O
intensity	B-T081
,	O
ISI	B-T079
and	O
regularity	B-T080
.	O
Both	O
N42	O
and	O
P52	O
waves	O
showed	O
significant	B-T078
ANOVA	B-T081
effects of	B-T080
intensity	B-T081
but	O
no	O
other	O
main	O
effects	B-T080
or	O
interactions	B-T169
.	O
In	O
contrast	O
both	O
N1	O
and	O
P2	O
showed	O
additional	B-T169
effects of	B-T080
ISI	B-T079
,	O
as	O
well	O
as	O
intensity	B-T081
,	O
and	O
evidence of	B-T169
non	B-T169
-	O
linear	B-T082
interactions	B-T169
between	O
ISI	B-T079
and	O
intensity	B-T081
.	O
A	O
source analysis	B-T062
was	O
carried	O
out	O
consistent with	B-T078
prior	B-T079
work	O
suggesting	O
that	O
when	O
above	B-T082
vestibular	B-T030
threshold	B-T081
,	O
in addition to	B-T169
bilateral	B-T082
superior	B-T082
temporal cortex	B-T023
,	O
ocular	B-T023
,	O
cerebellar	B-T023
and	O
cingulate	B-T023
sources	B-T033
are	O
recruited.	O
Further	O
statistical analysis	B-T062
of	O
the	O
source	B-T033
currents	B-T070
indicated	O
that	O
the	O
origin	O
of	O
the	O
interactions	B-T169
with	O
intensity	B-T081
may	O
be	O
the	O
ISI	B-T079
sensitivity	B-T081
of	O
the	O
vestibular	B-T030
-dependent	O
sources	B-T033
.	O
This	O
in	O
turn	O
may	O
reflect	O
a	O
specific	B-T080
vestibular	B-T030
preference	B-T078
for	O
stimulus	B-T067
rates	B-T081
associated with	B-T080
locomotion	B-T040
,	O
i.e.	O
rates	B-T081
close	O
to	O
2	O
Hz,	O
or	O
ISIs	B-T079
close	O
to	O
500	O
ms,	O
where	O
saccular	B-T082
afferents	B-T082
show	O
increased	B-T081
gain	B-T081
and	O
the	O
corresponding	O
reflexes	B-T042
are	O
most	O
sensitive	B-T169
.	O

A	O
Systematic Review	B-T170
of	O
the	O
Diagnostic	B-T169
and	O
Prognostic Value	B-T080
of	O
Urinary	B-T080
Protein	B-T116
Biomarkers	B-T201
in	O
Urothelial Bladder Cancer	B-T191
For	O
over	O
80	O
years,	O
cystoscopy	B-T060
has	O
remained	O
the	O
gold-standard	B-T080
for	O
detecting	B-T033
tumours	B-T191
of	O
the	O
urinary bladder	B-T023
.	O
Since	O
bladder tumours	B-T191
have	O
a	O
tendency	O
to	O
recur	B-T067
and	O
progress	B-T046
,	O
many	O
patients	B-T101
are	O
subjected	O
to	O
repeated	O
cystoscopies	B-T060
during	O
long-term	B-T079
surveillance	B-T058
,	O
with	O
the	O
procedure	B-T061
being	O
both	O
unpleasant	O
for	O
the	O
patient	B-T101
and	O
expensive	O
for	O
healthcare providers	B-T097
.	O
The	O
identification	B-T080
and	O
validation	B-T062
of	O
bladder tumour	B-T191
specific	O
molecular markers	B-T201
in	O
urine	B-T031
could	O
enable	O
tumour	B-T191
detection	B-T033
and	O
reduce	O
reliance	B-T055
on	O
cystoscopy	B-T060
,	O
and	O
numerous	O
classes	O
of	O
biomarkers	B-T201
have	O
been	O
studied.	O
Proteins	B-T116
represent	O
the	O
most	O
intensively	O
studied class of biomolecule	B-UnknownType
in	O
this	O
setting.	O
As	O
an	O
aid	O
to	O
researchers	B-T097
searching	O
for	O
better	O
urinary	B-T080
biomarkers	B-T201
,	O
we	O
report	O
a	O
comprehensive systematic review	B-T170
of	O
the	O
literature	B-T170
and	O
a	O
searchable	O
database	B-T170
of	O
proteins	B-T116
that	O
have	O
been	O
investigated	B-T058
to	O
date.	O
Our	O
objective	O
was	O
to	O
classify	O
these	O
proteins	B-T116
as:	O
1)	O
those	O
with	O
robustly	O
characterised	O
sensitivity and specificity	B-T081
for	O
bladder cancer	B-T191
detection	B-T033
;	O
2)	O
those	O
that	O
show	O
potential	O
but	O
further	O
investigation	B-T058
is	O
required;	O
3)	O
those	O
unlikely	O
to	O
warrant	O
further	O
investigation	B-T058
;	O
and	O
4)	O
those	O
investigated	B-T058
as	O
prognostic markers	B-T080
.	O
This	O
work	O
should	O
help	O
to	O
prioritise	O
certain	O
biomarkers	B-T201
for	O
rigorous validation	B-T062
,	O
whilst	O
preventing	B-T169
wasted	O
effort	O
on	O
proteins	B-T116
that	O
have	O
shown	O
no	O
association	O
whatsoever	O
with	O
the	O
disease	B-T047
,	O
or	O
only	O
modest	O
biomarker	B-T201
performance	O
despite	O
large-scale efforts	B-UnknownType
at	O
validation	B-T062
.	O

Well,	O
I	O
Wouldn't	O
be	O
Any	O
Worse	O
Off,	O
Would	O
I,	O
Than	O
I	O
am	O
Now?	O
A	O
Qualitative Study	B-T062
of	O
Decision-Making	B-T041
,	O
Hopes	B-T041
,	O
and	O
Realities	B-T078
of	O
Adults	B-T100
With	O
Type 1 Diabetes	B-T047
Undergoing	O
Islet Cell Transplantation	B-T061
For	O
selected	O
individuals	B-T098
with	O
type 1 diabetes	B-T047
,	O
pancreatic islet transplantation	B-T061
(	O
IT	B-T061
)	O
prevents	O
recurrent	O
severe	O
hypoglycemia	B-T047
and	O
optimizes glycemia	B-T061
,	O
although	O
ongoing	O
systemic immunosuppression	B-T061
is	O
needed.	O
Our	O
aim	O
was	O
to	O
explore	O
candidates	B-T098
and	O
recipients	B-T101
'	O
expectations	O
of	O
transplantation	B-T061
,	O
their	O
experience	O
of	O
being	O
on	O
the	O
waiting list	B-T033
,	O
and	O
(for	O
recipients	B-T101
)	O
the	O
procedure	O
and	O
life	O
posttransplant	B-T079
.	O
Cross-sectional	O
qualitative	B-T080
research design	B-T062
using	O
semistructured	O
interviews	B-T058
with	O
16	O
adults	B-T100
(8	O
pretransplant	B-T079
,	O
8	O
posttransplant	B-T079
;	O
from	O
4	O
UK	B-T083
centers	B-T073
(n	O
=	O
13)	O
and	O
1	O
Canadian	B-T083
center	B-T073
(n	O
=	O
3)).	O
Interviews	B-T058
were	O
audio-recorded	B-T058
,	O
transcribed,	O
and	O
underwent	O
inductive thematic analysis	B-T062
.	O
Interviewees	B-T098
were	O
aged	O
(mean	O
±	O
SD)	O
52	O
±	O
10	O
years	B-T079
(range,	O
30-64);	O
duration	B-T079
of	O
diabetes	B-T047
,	O
36	O
±	O
9	O
years	B-T079
(range,	O
21-56);	O
12	O
(75%)	O
were	O
women	B-T098
.	O
Narrative	O
accounts	O
centered	O
on	O
expectations	B-T078
,	O
hopes	B-T041
,	O
and	O
realities	B-T078
;	O
decision-making	B-T041
;	O
waiting	O
and	O
uncertainty;	O
the	O
procedure,	O
hospital stay	B-T079
,	O
and	O
follow-up	B-T058
.	O
Expected	O
benefits	O
included	O
fewer	O
severe	O
hypoglycemic episodes	B-T047
,	O
reduced	B-T080
need	O
for	O
insulin	B-T116
,	O
preventing	O
onset/progression	O
of	O
complications	B-T046
and	O
improved	O
psychological well-being	B-T033
.	O
These	O
were	O
realized	O
for	O
most,	O
at	O
least	O
in	O
the	O
short	O
term.	O
Most	O
interviewees	B-T098
described	O
well-informed,	O
shared	O
decision-making	B-T041
with	O
clinicians	B-T097
and	O
family	B-T099
,	O
and	O
managing	O
their	O
expectations.	O
Although	O
life	O
"on	O
the	O
list"	O
could	O
be	O
stressful	B-T169
,	O
and	O
immunosuppressant	B-T121
side effects	B-T046
were	O
severe	B-T080
,	O
interviewees	B-T098
reported	O
"	O
no	B-T033
regrets	B-T041
."	O
Posttransplant	B-T079
,	O
interviewees	B-T098
experienced	O
increased	O
confidence	B-T041
,	O
through	O
freedom from hypoglycemia	B-T033
and	O
regained	O
glycemic control	B-T061
,	O
which	O
tempered	O
any	O
disappointment	O
about	O
continued	O
reliance	O
on	O
insulin	B-T116
.	O
Most	O
viewed	O
their	O
transplant	B-T061
as	O
a	O
success,	O
though	O
several	O
reflected	O
upon	O
setbacks	O
and	O
hidden	O
hopes	B-T041
for	O
becoming	O
"	O
insulin-free	B-T033
."	O
Independently	O
undertaken	O
interviews	B-T058
demonstrated	O
realistic	O
and	O
balanced	O
expectations	O
of	O
IT	B-T061
and	O
indicate	O
how	O
to	O
optimize	O
the	O
process	O
and	O
support	O
for	O
future	O
IT	B-T061
candidates	B-T098
.	O

The	O
nanocomposite	B-T080
nature	O
of	O
bone	B-T023
drives	O
its	O
strength	B-T081
and	O
damage	B-T169
resistance	B-T169
In	O
human bone	B-T023
,	O
an	O
amorphous	B-T080
mineral	B-T197
serves	O
as	O
a	O
precursor	B-T078
to	O
the	O
formation	B-T169
of	O
a	O
highly	O
substituted	O
nanocrystalline	B-T073
apatite	B-T197
.	O
However,	O
the	O
precise	O
role	O
of	O
this	O
amorphous	B-T080
mineral	B-T197
remains	O
unknown.	O
Here,	O
we	O
show	O
by	O
using	O
transmission electron microscopy	B-T059
that	O
100-300	O
nm	O
amorphous	B-T080
calcium phosphate	B-T121
regions	B-T029
are	O
present	O
in	O
the	O
disordered phase	B-T082
of	O
trabecular bone	B-T024
.	O
Nanomechanical experiments	B-T062
on	O
cylindrical	B-T082
samples	B-T167
,	O
with	O
diameters	B-T081
between	O
250	O
nm	O
and	O
3,000	O
nm,	O
of	O
the	O
bone's	B-T023
ordered	B-T082
and	O
disordered phases	B-T082
revealed	O
a	O
transition	B-T052
from	O
plastic	B-T070
deformation	B-T033
to	O
brittle	B-T033
failure	B-T037
and	O
at	O
least	O
a	O
factor-of-2	O
higher	O
strength	B-T081
in	O
the	O
smaller	B-T080
samples	B-T167
.	O
We	O
postulate	O
that	O
this	O
transition	B-T052
in	O
failure	B-T169
mechanism	B-T169
is	O
caused	O
by	O
the	O
suppression	B-T169
of	O
extrafibrillar	B-T026
shearing	B-T061
in	O
the	O
smaller	O
samples	B-T167
,	O
and	O
that	O
the	O
emergent	O
smaller	B-T080
-is-	O
stronger	B-T080
size effect	B-T081
is	O
related	O
to	O
the	O
sample-size	B-T081
scaling	B-T052
of	O
the	O
distribution	O
of	O
flaws.	O
Our	O
findings	B-T033
should	O
help	O
in	O
the	O
understanding	O
of	O
the	O
multi-scale nature	B-T078
of	O
bone	B-T023
and	O
provide	O
insights	O
into	O
the	O
biomineralization	B-T042
process	B-T067
.	O

Assessing	B-T052
the	O
physiological	B-T169
relevance	B-T080
of	O
alternate	O
architectures	B-T082
of	O
the	O
p7 protein	B-T116
of	O
hepatitis C virus	B-T005
in	O
different	O
environments	B-T082
The	O
viroporin	B-T038
p7	B-T116
of	O
the	O
hepatitis C virus	B-T005
forms	O
multimeric channels	B-T116
eligible	O
for	O
ion transport	B-T043
across	O
the	O
endoplasmic reticulum membrane	B-T026
.	O
Currently	O
the	O
subject	B-T078
of	O
many	O
studies	B-T062
and	O
discussion,	O
the	O
molecular assembly	B-T044
of	O
the	O
ion channel	B-T116
and	O
the	O
structural	B-T082
characteristics	B-T080
of	O
the	O
p7	B-T116
monomer	B-T104
are	O
not	O
yet	O
fully	O
understood.	O
Structural	B-T082
investigation	B-T169
of	O
p7	B-T116
has	O
been	O
carried	O
out	O
only	O
in	O
detergent	B-T120
environments	B-T082
,	O
making	O
the	O
interpretation	O
of	O
the	O
experimental	O
results	O
somewhat	O
questionable.	O
Here,	O
we	O
analyze	B-T062
by	O
means	O
of	O
molecular dynamics simulations	B-T066
the	O
structure	B-T082
of	O
the	O
p7	B-T116
monomer	B-T104
as	O
a	O
function	O
of	O
its	O
sequence	B-T087
,	O
initial	O
conformation	B-T082
and	O
environment	B-T082
.	O
We	O
investigate	O
the	O
conductance	B-UnknownType
properties	O
of	O
three	O
models	B-T075
of	O
a	O
hexameric	B-T104
p7	B-T116
ion channel	B-T116
by	O
examining	O
ion translocation	B-T043
in	O
a	O
pure	O
lipid bilayer	B-T026
.	O
It	O
is	O
noteworthy	O
that	O
although	O
none	O
of	O
the	O
models	B-T075
reflects	O
the	O
experimentally	O
observed	O
trend	O
to	O
conduct	O
preferentially	O
cations	B-T104
,	O
we	O
were	O
able	O
to	O
identify	O
the	O
position	B-T082
and	O
orientation	B-T082
of	O
titratable	O
acidic or basic residues	B-T077
playing	O
a	O
crucial	O
role	O
in	O
ion	B-T196
selectivity	B-T052
and	O
in	O
the	O
overall	O
conductance	B-UnknownType
of	O
the	O
channel	B-T116
.	O
In	O
addition,	O
too	O
compact	O
a	O
packing	B-T044
of	O
the	O
monomers	B-T104
leads	O
to	O
channel	B-T116
collapse	B-T067
rather	O
than	O
formation	O
of	O
a	O
reasonable	O
pore	B-T026
,	O
amenable	O
to	O
ion translocation	B-T043
.	O
The	O
present	O
findings	O
are	O
envisioned	O
to	O
help	O
assess	O
the	O
physiological	B-T169
relevance	B-T080
of	O
p7	B-T116
ion channel	B-T116
models	B-T075
consisting	O
of	O
multimeric structures	B-T082
obtained	O
in	O
non-native	O
environments	B-T082
.	O

The	O
genome	B-T028
-scale	O
DNA-binding	B-T045
profile	B-T059
of	O
BarR	B-T116
,	O
a	O
β-alanine	B-T116
responsive	B-T169
transcription factor	B-T116
in	O
the	O
archaeon	B-T194
Sulfolobus acidocaldarius	B-T194
The	O
Leucine-responsive Regulatory Protein	B-T116
(	O
Lrp	B-T116
)	O
family	B-T116
is	O
a	O
widespread	O
family	B-T116
of	O
regulatory transcription factors	B-T116
in	O
prokaryotes	B-T001
.	O
BarR	B-T116
is	O
an	O
Lrp	B-T116
-like	O
transcription factor	B-T116
in	O
the	O
model	O
archaeon	B-T194
Sulfolobus acidocaldarius	B-T194
that	O
activates	B-T052
the	O
expression	B-T045
of	O
a	O
β-alanine aminotransferase gene	B-T028
,	O
which	O
is	O
involved	O
in	O
β-alanine degradation	B-T044
.	O
In	O
contrast	O
to	O
classical	O
Lrp	B-T116
-like	O
transcription factors	B-T116
,	O
BarR	B-T116
is	O
not responsive	B-T033
to	O
any	O
of	O
the	O
α-amino acids	B-T116
but	O
interacts	O
specifically	O
with	O
β-alanine	B-T116
.	O
Besides	O
the	O
juxtaposed	O
β-alanine aminotransferase gene	B-T028
,	O
other	O
regulatory	O
targets	O
of	O
BarR	B-T116
have	O
not	O
yet	O
been	O
identified	O
although	O
β-alanine	B-T116
is	O
the	O
precursor	B-T116
of	O
coenzyme A	B-T114
and	O
thus	O
an	O
important	O
central	O
metabolite	B-T123
.	O
The	O
aim	B-T078
of	O
this	O
study	B-T062
is	O
to	O
extend	O
the	O
knowledge	O
of	O
the	O
DNA-binding	B-T045
characteristics	B-T080
of	O
BarR	B-T116
and	O
of	O
its	O
corresponding	O
regulon	B-T028
from	O
a	O
local	B-T082
to	O
a	O
genome	B-T028
-wide	O
perspective.	O
We	O
characterized	O
the	O
genome-wide binding profile	B-T059
of	O
BarR	B-T116
using	O
chromatin immunoprecipation	B-T059
combined	O
with	O
high-throughput sequencing	B-T063
(	O
ChIP-seq	B-T063
).	O
This	O
revealed	O
21	O
genomic	B-T028
binding	B-T044
loci	B-T082
.	O
High-enrichment	O
binding regions	B-T045
were	O
validated	O
to	O
interact	O
with	O
purified	O
BarR protein	B-T116
in vitro	B-T080
using	O
electrophoretic mobility shift assays	B-T059
and	O
almost	O
all	O
targets	O
were	O
also	O
shown	O
to	O
harbour	O
a	O
conserved	B-T086
semi-palindromic	B-T114
binding motif	B-T087
.	O
Only	O
a	O
small	O
subset	O
of	O
enriched	O
genomic sites	B-T028
are	O
located	O
in	O
intergenic regions	B-T114
at	O
a	O
relative	O
short	O
distance	O
to	O
a	O
promoter	B-T114
,	O
and	O
qRT-PCR analysis	B-T059
demonstrated	O
that	O
only	O
one	O
additional	O
operon	B-T028
is	O
under	O
activation	B-T045
of	O
BarR	B-T116
,	O
namely	O
the	O
glutamine synthase operon	B-T028
.	O
The	O
latter	O
is	O
also	O
a	O
target	O
of	O
other	O
Lrp	B-T116
-like	O
transcription factors	B-T116
.	O
Detailed	O
inspection	O
of	O
the	O
BarR	B-T116
ChIP-seq profile	B-T034
at	O
the	O
β-alanine aminotransferase promoter region	B-T114
in	O
combination	B-T080
with	O
binding motif	B-T087
predictions	O
indicate	O
that	O
the	O
operator structure	B-T114
is	O
more	O
complicated	B-T169
than	O
previously	O
anticipated,	O
consisting	O
of	O
multiple (major and auxiliary) operators	B-T114
.	O
BarR	B-T116
has	O
a	O
limited	B-T169
regulon	B-T028
,	O
and	O
includes	O
also	O
glutamine synthase genes	B-T028
besides	O
the	O
previously	O
characterized	O
β-alanine aminotransferase	B-T028
.	O
Regulation	B-T038
of	O
glutamine synthase	B-T116
is	O
suggestive	O
of	O
a	O
link	O
between	O
β-alanine	B-T044
and	O
α-amino acid metabolism	B-T044
in	O
S. acidocaldarius	B-T194
.	O
Furthermore,	O
this	O
work	O
reveals	O
that	O
the	O
BarR	B-T116
regulon	B-T028
overlaps	O
with	O
that	O
of	O
other	O
Lrp	B-T116
-like	O
regulators	B-T077
.	O

GH32 family	B-T116
activity	B-T044
:	O
a	O
topological	B-T082
approach	O
through	O
protein contact networks	B-T169
The	O
application	O
of	O
Protein Contact Networks methodology	B-T169
allowed	O
to	O
highlight	O
a	O
novel	O
response	O
of	O
border region	B-T082
between	O
the	O
two	O
domains to substrate binding	B-T087
.	O
Glycoside hydrolases	B-T116
(	O
GH	B-T116
)	O
are	O
enzymes	B-T116
that	O
mainly	O
hydrolyze	B-T070
the	O
glycosidic bond	B-T044
between	O
two	O
carbohydrates	B-T109
or	O
a	O
carbohydrate	B-T109
and	O
a	O
non-carbohydrate moiety	B-T104
.	O
These	O
enzymes	B-T116
are	O
involved	O
in	O
many	O
fundamental	O
and	O
diverse	O
biological processes	B-T038
in	O
plants	B-T002
.	O
We	O
have	O
focused	O
on	O
the	O
GH32 family	B-T116
,	O
including	O
enzymes	B-T116
very	O
similar	O
in	O
both	O
sequence	B-T087
and	O
structure	B-T116
,	O
each	O
having	O
however	O
clear	O
specificities	O
of	O
substrate	B-T120
preferences	B-T078
and	O
kinetic properties	B-T169
.	O
Structural	B-T116
and	O
topological	B-T082
differences	O
among	O
proteins	B-T116
of	O
the	O
GH32 family	B-T116
have	O
been	O
here	O
identified	O
by	O
means	O
of	O
an	O
emerging	O
approach	O
(	O
Protein Contact network	B-T169
,	O
PCN	B-T169
)	O
based	O
on	O
the	O
formalization	O
of	O
3D structures	B-T082
as	O
contact networks	B-T169
among	O
amino-acid residues	B-T087
.	O
The	O
PCN	B-T169
approach	O
proved	O
successful	O
in	O
both	O
reconstructing	O
the	O
already	O
known	O
functional	B-T169
domains	B-T087
and	O
in	O
identifying	O
the	O
structural	B-T116
counterpart	O
of	O
the	O
properties	O
of	O
GH32 enzymes	B-T116
,	O
which	O
remain	O
uncertain,	O
like	O
their	O
allosteric	B-T169
character.	O
The	O
main	O
outcome	O
of	O
the	O
study	O
was	O
the	O
discovery	O
of	O
the	O
activation	B-T044
upon	O
binding of the border (cleft) region	B-T044
between	O
the	O
two	O
domains	B-T087
.	O
This	O
reveals	O
the	O
allosteric	B-T169
nature	O
of	O
the	O
enzymatic activity	B-T044
for	O
all	O
the	O
analyzed	O
forms	O
in	O
the	O
GH32 family	B-T116
,	O
a	O
character	O
yet	O
to	O
be	O
highlighted	O
in	O
biochemical studies	B-T059
.	O
Furthermore,	O
we	O
have	O
been	O
able	O
to	O
recognize	O
a	O
topological signature	B-T082
(graph	O
energy)	O
of	O
the	O
different	O
affinity	B-T070
of	O
the	O
enzymes	B-T116
towards	O
small	O
and	O
large	O
substrates	B-T120
.	O

Grasping	B-T040
At	O
The	O
Moon	B-T083
:	O
Enhancing	B-T052
Access	B-T082
To	O
Careers	B-T057
In	O
The	O
Health Professions	B-T091
A	O
former	B-T078
HHS	B-T093
secretary	B-T097
reflects	B-T041
on	O
what's	O
needed	O
to	O
enable	O
more	O
minorities	B-T098
to	O
become	O
doctors	B-T097
and	O
other	O
health professionals	B-T097
.	O

Multivariate	B-T081
Imaging	B-T060
Genetics Study	B-T062
of	O
MRI	B-T060
Gray Matter	B-T024
Volume	B-T081
and	O
SNPs	B-T086
Reveals	O
Biological	B-T080
Pathways	B-T077
Correlated	B-T080
with	O
Brain	B-T023
Structural	B-T082
Differences	B-T081
in	O
Attention Deficit Hyperactivity Disorder	B-T048
Attention deficit hyperactivity disorder	B-T048
(	O
ADHD	B-T048
)	O
is	O
a	O
prevalent	B-T081
neurodevelopmental disorder	B-T048
affecting	B-T169
children	B-T100
,	O
adolescents	B-T100
,	O
and	O
adults	B-T100
.	O
Its	O
etiology	B-T169
is	O
not	O
well	O
understood,	O
but	O
it	O
is	O
increasingly	O
believed	O
to	O
result	B-T169
from	O
diverse	B-T080
pathophysiologies	B-T046
that	O
affect	B-T169
the	O
structure	B-T082
and	O
function	B-T169
of	O
specific	B-T080
brain circuits	B-UnknownType
.	O
Although	O
one	O
of	O
the	O
best-studied	O
neurobiological abnormalities	B-T047
in	O
ADHD	B-T048
is	O
reduced	B-T080
fronto-striatal-cerebellar gray matter	B-T023
(	O
GM	B-T024
)	O
volume	B-T081
,	O
its	O
specific	O
genetic	B-T169
correlates	B-T080
are	O
largely	O
unknown	B-T080
.	O
In	O
this	O
study	B-T062
,	O
T1-weighted MR images of brain structure	B-T060
were	O
collected	O
from	O
198	O
adolescents	B-T100
(63	O
ADHD	B-T048
-	O
diagnosed	B-T033
).	O
A	O
multivariate parallel independent component analysis	B-T081
(	O
Para-ICA	B-T081
)	O
technique	B-T169
-identified	O
imaging	B-T060
genetic	B-T169
relationships	B-T080
between	O
regional	B-T082
GM	B-T024
volume	B-T081
and	O
single nucleotide polymorphism	B-T086
data	B-T078
.	O
Para-ICA analyses	B-T081
extracted	O
14	O
components	O
from	O
genetic data	B-T170
and	O
9	O
from	O
MR	B-T060
data	B-T078
.	O
An	O
iterative cross-validation	B-T062
using	O
randomly	O
chosen	O
subsamples	O
indicated	O
acceptable	O
stability	B-T080
of	O
these	O
ICA	B-T081
solutions	B-T077
.	O
A	O
series	O
of	O
partial correlation analyses	B-UnknownType
controlling	B-T067
for	O
age	B-T032
,	O
sex	B-T032
,	O
and	O
ethnicity	B-T080
revealed	O
two	O
genotype-phenotype	B-T032
component	B-T077
pairs	B-T080
significantly	O
differed	O
between	O
ADHD	B-T048
and	O
non-ADHD	B-T033
groups	B-T078
,	O
after	O
a	O
Bonferroni correction	B-T081
for	O
multiple	B-T081
comparisons	B-T052
.	O
The	O
brain	B-T023
phenotype	B-T032
component	B-T077
not	O
only	O
included	O
structures	B-T082
frequently	O
found	O
to	O
have	O
abnormally low	B-T080
volume	B-T081
in	O
previous	O
ADHD	B-T048
studies	B-T062
but	O
was	O
also	O
significantly	O
associated with	B-T080
ADHD	B-T048
differences	O
in	O
symptom severity	B-T033
and	O
performance	B-T052
on	O
cognitive tests	B-T170
frequently	O
found	O
to	O
be	O
impaired	O
in	O
patients	B-T101
diagnosed	B-T033
with	O
the	O
disorder	B-T047
.	O
Pathway analysis	B-T170
of	O
the	O
genotype	B-T032
component	B-T077
identified	O
several	O
different	O
biological	B-T080
pathways	B-T077
linked	O
to	O
these	O
structural	B-T082
abnormalities	B-T033
in	O
ADHD	B-T048
.	O
Some	O
of	O
these	O
pathways	B-T077
implicate	O
well-known	O
dopaminergic neurotransmission	B-T042
and	O
neurodevelopment	B-T042
hypothesized	B-T078
to	O
be	O
abnormal	B-T033
in	O
ADHD	B-T048
.	O
Other	O
more	O
recently	O
implicated	O
pathways	B-T077
included	O
glutamatergic	B-T043
and	O
GABA-eric physiological systems	B-T042
;	O
others	O
might	O
reflect	O
sources	O
of	O
shared	O
liability	O
to	O
disturbances	O
commonly	O
found	O
in	O
ADHD	B-T048
,	O
such	O
as	O
sleep abnormalities	B-T184
.	O

Clinicopathological	B-T058
and	O
Immunohistochemical	B-T059
Characteristics	O
of	O
Verruciform Xanthoma	B-T047
of	O
the	O
Lower Gingiva	B-T023
:	O
A	O
Case Report	B-T170
Verruciform xanthoma	B-T047
(	O
VX	B-T047
)	O
is	O
a	O
rare	O
benign lesion	B-T191
and	O
mainly	O
effects	O
the	O
oral mucosa	B-T023
.	O
This	O
slow-growing	B-T033
asymptomatic	B-T033
lesion	B-T191
typically	O
develops	O
along	O
the	O
gingival margin	B-T029
of	O
the	O
masticatory	B-T169
mucosa	B-T024
,	O
followed	O
by	O
the	O
hard palate	B-T023
,	O
tongue	B-T023
,	O
buccal mucosa	B-T023
,	O
floor of the mouth	B-T029
,	O
alveolar mucosa	B-T029
,	O
soft palate	B-T023
and	O
junction	B-T082
between	O
the	O
hard	B-T023
and	O
soft palate	B-T023
.	O
Moreover,	O
this	O
lesion	B-T191
can	O
also	O
affect	O
the	O
skin	B-T022
and	O
genital organs	B-T023
.	O
Clinically	B-T080
,	O
VX	B-T047
generally	O
presents	O
a	O
sessile	B-T033
or	O
pedunculated appearance	B-T033
,	O
forming	O
a	O
papule	B-T033
or	O
single plaque	B-T033
with	O
verrucous	B-T191
or	O
papillomatous	B-T191
mucosal	B-T024
growth	B-T042
.	O
The	O
colour	B-T080
(	O
white	B-T080
,	O
pink	B-T080
,	O
grey	B-T080
,	O
or	O
yellow	B-T080
)	O
depends	O
on	O
the	O
thickness	B-T080
of	O
the	O
overlying	O
epidermis	B-T024
.	O
In	O
fact,	O
the	O
clinical	B-T080
findings	B-T033
of	O
VX	B-T047
are	O
similar	O
to	O
those	O
of	O
verrucous carcinoma	B-T191
and	O
other	O
benign tumours	B-T191
,	O
such	O
as	O
squamous papilloma	B-T191
,	O
verruca vulgaris	B-T047
and	O
mucosal fibroma	B-T191
.	O
For	O
this	O
reason,	O
clinical	B-T080
and	O
histopathological	B-T169
examinations	B-T058
are	O
essential	O
for	O
accurate differential diagnosis	B-T060
.	O
Histologically	B-T169
,	O
VX	B-T047
is	O
characterized	O
by	O
parakeratosis	B-T047
,	O
rete ridges	B-T024
of	O
uniform	O
depth	O
and	O
the	O
accumulation	B-T033
of	O
foam cells	B-T025
,	O
which	O
are	O
also	O
called	O
"	O
xanthoma cells	B-T025
".	O
Here,	O
we	O
describe	O
the	O
clinicopathological	B-T058
and	O
immunohistochemical	B-T059
findings	B-T033
of	O
a	O
VX	B-T047
located	O
on	O
the	O
lower gingiva	B-T023
of	O
a	O
64-year-old	O
male patient	B-T032
.	O

MicroRNA 101b	B-T028
Is	O
Downregulated	B-T044
in	O
the	O
Prefrontal Cortex	B-T023
of	O
a	O
Genetic Model	B-T170
of	O
Depression	B-T048
and	O
Targets	B-T169
the	O
Glutamate Transporter	B-T116
SLC1A1	B-T116
(	O
EAAT3	B-T116
)	O
in Vitro	B-T080
MicroRNAs	B-T114
(	O
miRNAs	B-T114
)	O
are	O
small	B-T081
regulatory	B-T077
molecules	B-T167
that	O
cause	O
translational repression	B-T045
by	O
base pairing with target mRNAs	B-T044
.	O
Cumulative	B-T080
evidence	B-T078
suggests	O
that	O
changes	B-T169
in	O
miRNA	B-T028
expression	B-T045
may	O
in	O
part	O
underlie	O
the	O
pathophysiology	B-T169
and	O
treatment	B-T061
of	O
neuropsychiatric disorders	B-T047
,	O
including	O
major depressive disorder	B-T048
(	O
MDD	B-T048
).	O
A	O
miRNA	B-T028
expression	B-T045
assay	B-T059
that	O
can	O
simultaneously	B-T079
detect	O
423	O
rat	O
miRNAs	B-T028
(miRBase	O
v.17)	O
was	O
used	O
to	O
profile	B-T059
the	O
prefrontal cortex	B-T023
(	O
PFC	B-T023
)	O
of	O
a	O
genetic rat model	B-T170
of	O
MDD	B-T048
(the	O
Flinders Sensitive Line	B-T170
[	O
FSL	B-T170
])	O
and	O
the	O
controls	B-T096
,	O
the	O
Flinders Resistant Line	B-T170
(	O
FRL	B-T170
).	O
Gene expression	B-T045
data	B-T078
from	O
the	O
PFC	B-T023
of	O
FSL	B-T170
/	O
FRL	B-T170
animals	B-T008
(GEO	O
accession	O
no.	O
GSE20388)	O
were	O
used	O
to	O
guide	O
mRNA	B-T114
target	B-T169
selection	B-T052
.	O
Luciferase reporter assays	B-T059
were	O
used	O
to	O
verify	B-T169
miRNA	B-T028
targets	B-T169
in vitro	B-T080
.	O
We	O
identified	B-T080
23	O
miRNAs	B-T028
that	O
were	O
downregulated	B-T044
in	O
the	O
PFC	B-T023
of	O
the	O
FSL model	B-T170
compared	B-T052
with	O
controls	B-T096
.	O
Interestingly,	O
one	O
of	O
the	O
identified	B-T080
miRNAs	B-T028
(	O
miR-101b	B-T028
)	O
is	O
highly	O
conserved	B-T080
between	O
rat	B-T015
and	O
human	B-T016
and	O
was	O
recently	O
found	O
to	O
be	O
downregulated	B-T044
in	O
the	O
PFC	B-T023
of	O
depressed	B-T184
suicide	B-T033
subjects	B-T096
.	O
Using	O
a	O
combination	B-T080
of	O
in silico	B-T066
and	O
in vitro	B-T080
analyses	B-T062
,	O
we	O
found	O
that	O
miR-101b	B-T028
targets	B-T169
the	O
neuronal	B-T025
glutamate transporter	B-T116
SLC1A1	B-T116
(also	O
known	O
as	O
EAAC1	B-T116
or	O
EAAT3	B-T116
).	O
Accordingly,	O
both	O
mRNA	B-T114
and	O
protein levels	B-T034
of	O
SLC1A1	B-T116
were	O
found	O
to	O
be	O
upregulated	B-T044
in	O
the	O
PFC	B-T023
of	O
the	O
FSL model	B-T170
.	O
Besides	O
providing	O
a	O
list	O
of	O
novel	O
miRNAs	B-T028
associated with	B-T080
depression-like states	B-T033
,	O
this	O
preclinical study	B-T062
replicated	B-T169
the	O
human	B-T016
association	B-T080
of	O
miR-101	B-T028
with	O
depression	B-T048
.	O
In	O
addition,	O
since	O
one	O
of	O
the	O
targets	B-T169
of	O
miR-101b	B-T028
appears	O
to	O
be	O
a	O
glutamate transporter	B-T116
,	O
our	O
preclinical	B-T080
data	B-T078
support	O
the	O
hypothesis	B-T078
of	O
a	O
glutamatergic	B-T121
dysregulation	B-T033
being	O
implicated	O
in	O
the	O
etiology	B-T169
of	O
depression	B-T048
.	O

A	O
Practical Guide	B-T097
to	O
Forensic Nursing	B-T091
:	O
Incorporating	B-T169
forensic	B-T091
principles	B-T081
into	O
nursing practice	B-T058
Amar Angela F	B-T016
and	O
Sekula L Kathleen	B-T016
A	O
Practical Guide	B-T097
to	O
Forensic Nursing	B-T091
:	O
Incorporating	O
forensic	B-T091
principles	B-T081
into	O
nursing practice	B-T058
392pp	O
US$59.95	O
Sigma	O
Theta	O
Tau	O
International	O
Honor	O
Society	O
of	O
Nursing	O
9781940446349	O
1940446341	O
[Formula:	O
see	O
text	O
George Bernard Shaw	B-T016
described	O
Britons	B-T098
and	O
Americans	B-T098
as	O
'	O
divided	B-T169
by	O
a	O
common language	B-T171
',	O
and	O
that	O
is	O
made	O
very	O
clear	O
in	O
this	O
fascinating publication	B-T073
that	O
describes	O
in	O
depth	O
the	O
roles and responsibilities	B-T170
of	O
forensic nurses	B-T097
in	O
the	O
US	B-T083
.	O

Incidence	B-T081
of	O
Diabetes Mellitus	B-T047
and	O
Obesity	B-T047
and	O
the	O
Overlap	B-T079
of	O
Comorbidities	B-T078
in	O
HIV+	B-T034
Hispanics	B-T098
Initiating	B-T169
Antiretroviral Therapy	B-T061
Cardiovascular disease	B-T047
(	O
CVD	B-T047
)	O
is	O
a	O
leading	O
health	B-T078
threat	B-T078
for	O
HIV+	B-T034
patients	B-T101
on	O
antiretroviral therapy	B-T061
(	O
ART	B-T061
);	O
cardiometabolic	B-T047
comorbidities	B-T078
are	O
key	O
predictors of risk	B-T033
.	O
Data	B-T078
are	O
limited	O
on	O
incidence	B-T081
of	O
metabolic	B-T169
comorbidities	B-T078
in	O
HIV+	B-T034
individuals	B-T098
initiating	B-T169
ART	B-T061
in	O
low	B-T080
and	O
middle income	B-T080
countries	B-T083
(	O
LMICs	B-T083
),	O
particularly	B-T080
for	O
Hispanics	B-T098
.	O
We	O
examined	B-T033
incidence	B-T081
of	O
diabetes	B-T047
and	O
obesity	B-T047
in	O
a	O
prospective cohort	B-T098
of	O
those	O
initiating	B-T169
ART	B-T061
in	O
the	O
Dominican Republic	B-T083
.	O
Participants	B-T098
≥18	O
years	B-T079
,	O
initiating	B-T169
ART	B-T061
<90	O
days	B-T079
prior	O
to	O
study	B-T062
enrollment	B-T058
,	O
were	O
examined	B-T033
for	O
incidence	B-T081
of	O
impaired fasting glucose	B-T033
(	O
IFG	B-T033
),	O
diabetes mellitus	B-T047
(	O
DM	B-T047
),	O
overweight, and obesity	B-T047
.	O
Fasting plasma glucose	B-T059
(	O
FPG	B-T059
)	O
100-125mg/dl	O
defined	O
IFG	B-T033
;	O
FPG	B-T059
≥126	O
mg/dl,	O
diagnosis	B-T062
per	O
medical record	B-T170
,	O
or	O
use	O
of	O
hypoglycemic medication	B-T121
defined	O
DM	B-T047
.	O
Overweight and obesity	B-T047
were	O
BMI	B-T201
25-30	O
and	O
≥30kg/m2,	O
respectively.	O
Dyslipidemia	B-T047
was	O
total cholesterol	B-T109
≥240mg/dl	O
or	O
use of	B-T169
lipid-lowering medication	B-T121
.	O
Framingham risk equation	B-T170
was	O
used	B-T033
to	O
determine	B-T080
ten-year	B-T079
CVD	B-T047
risk	B-T058
at	O
the	O
end of observation	B-T062
.	O
Of	O
153	O
initiating	B-T169
ART	B-T061
,	O
8	O
(6%)	O
had	O
DM	B-T047
and	O
23	O
(16%)	O
had	O
IFG	B-T033
at	O
baseline	B-T081
,	O
6	O
developed	O
DM	B-T047
(28/1000	O
person	B-T098
-	O
years	B-T079
follow up	B-T058
[	O
PYFU	B-T058
])	O
and	O
46	O
developed	O
IFG	B-T033
(329/1000	O
PYFU	B-T058
).	O
At	O
baseline	B-T081
,	O
24	O
(18%)	O
were	O
obese	B-T047
and	O
36	O
(27%)	O
were	O
overweight	B-T184
,	O
15	O
became	O
obese	B-T047
(69/1000	O
PYFU	B-T058
)	O
and	O
22	O
became	O
overweight	B-T184
(163/1000	O
PYFU	B-T058
).	O
Median	B-T082
observation	B-T058
periods	B-T079
for	O
the	O
diabetes	B-T047
and	O
obesity	B-T047
analyses	B-T062
were	O
23.5	O
months	B-T079
and	O
24.3	O
months	B-T079
,	O
respectively.	O
Increased	B-T081
CVD	B-T047
risk	B-T058
(≥10%	O
10-year Framingham risk score	B-T033
)	O
was	O
present	B-T033
for	O
13%	O
of	O
the	O
cohort	B-T098
;	O
79%	O
of	O
the	O
cohort	B-T098
had	O
≥1	O
cardiometabolic comorbidity	B-T078
,	O
48%	O
had	O
≥2,	O
and	O
13%	O
had	O
all	O
three.	O
In	O
this	O
Hispanic	B-T098
cohort	B-T098
in	O
an	O
LMIC	B-T083
,	O
incidences	B-T081
of	O
IFG	B-T033
/	O
DM	B-T047
and	O
overweight	B-T184
/	O
obesity	B-T047
were	O
similar	B-T080
to	O
or	O
higher than	B-T080
that	O
found	B-T033
in	O
high income	B-T033
countries	B-T083
,	O
and	O
cardiometabolic disorders	B-T047
affected	B-T169
three-quarters	O
of	O
those	O
initiating	B-T169
ART	B-T061
.	O
Care models	B-T170
incorporating	O
cardiovascular risk	B-T047
reduction	B-T061
into	O
HIV	B-T047
treatment programs	B-T058
are	O
needed	B-T080
to	O
prevent	B-T169
CVD	B-T047
-	O
associated	B-T080
mortality	B-T081
in	O
this	O
vulnerable population	B-T098
.	O

Laparoscopic Approach	B-T060
for	O
Thermoablation Microwave	B-T061
in	O
the	O
Treatment	B-T061
of	O
Hepatocellular Carcinoma	B-T191
:	O
A	O
Single	O
Center	O
Experience	B-T041
The	O
surgical therapy	B-T061
of	O
choice	O
for	O
hepatocellular carcinoma	B-T191
(	O
HCC	B-T191
)	O
is	O
liver transplantation	B-T061
(	O
LT	B-T061
)	O
or	O
hepatic resection	B-T061
,	O
although	O
only	O
a	O
small	B-T081
percentage	B-T081
of	O
patients	B-T101
can	O
undergo	O
these	O
procedures	B-T169
.	O
Microwave thermal ablation	B-T061
(	O
MWTA	B-T061
)	O
can	O
be	O
an	O
effective	B-T080
alternative	B-T077
treatment	B-T061
for	O
HCC	B-T191
that	O
complicates	B-T169
a	O
cirrhotic liver disease	B-T047
,	O
either	O
as	O
a	O
final	B-T079
procedure	B-T169
or	O
for	O
downstaging	B-T060
patients	B-T101
on	O
the	O
waiting	O
list	O
for	O
LT	B-T061
,	O
or	O
in	O
combination	B-T080
with	O
resective	B-T061
surgery	B-T061
to	O
achieve	O
oncological	B-T191
radicality	B-T080
.	O
The	O
purpose	O
of	O
this	O
retrospective study	B-T062
was	O
to	O
evaluate	B-T058
experience	B-T041
with	O
the	O
laparoscopic approach	B-T060
of	O
MWTA	B-T061
at	O
our	O
center.	O
In	O
a	O
cohort	B-T098
of	O
35	O
consecutive	B-T080
patients	B-T101
undergoing	O
MWTA	B-T061
with	O
laparoscopic approach	B-T060
between	O
January,	O
2013	O
and	O
May,	O
2016,	O
we	O
reviewed	O
the	O
demographic data	B-T062
,	O
the	O
Barcelona clinic liver cancer stage	B-T185
,	O
the	O
severity	B-T080
of	O
cirrhotic liver disease	B-T047
,	O
the	O
size	B-T082
of	O
the	O
ablated	B-T061
lesion	B-T033
,	O
the	O
duration	B-T079
of	O
the	O
procedure	B-T169
,	O
and	O
complications	B-T169
occurring	O
within	O
90	O
days	B-T079
of	O
surgery	B-T061
.	O
MWTA	B-T061
was	O
performed	O
by	O
applying	O
one	O
to	O
three	O
hepatic	B-T029
parenchymal	B-T024
insertions	B-T058
(	O
mean	B-T081
1.8)	O
per	O
patient	B-T101
.	O
The	O
mean	B-T081
duration	B-T079
of	O
surgery	B-T061
was	O
163	O
±	O
18	O
minutes	B-T079
.	O
There	O
was	O
no	O
blood loss	B-T033
in	O
any	O
of	O
the	O
procedures	B-T169
.	O
Complete	O
necrosis	B-T042
on	O
CT scan	B-T060
was	O
achieved	O
in	O
26/35	O
patients	B-T101
(75%).	O
The	O
mean	B-T081
hospital stay	B-T079
was	O
4.6	O
(range	O
2-7)	O
days	B-T079
;	O
major	O
complications	B-T169
were	O
postablation	B-T079
syndrome	B-T047
in	O
2/35	O
(5.7%),	O
peritoneal fluid	B-T031
in	O
4/35	O
(11.4%),	O
and	O
transient	B-T079
jaundice	B-T047
in	O
1/35	O
(2.8%)	O
patients	B-T101
.	O
There	O
was	O
no mortality	B-T033
.	O
Laparoscopic	B-T060
MWTA	B-T061
is	O
a	O
safe	O
and	O
effective	B-T080
treatment	B-T061
for	O
unresectable	B-T201
HCC	B-T191
and	O
when	O
a	O
percutaneous	B-T082
procedure	B-T169
is	O
not	O
feasible.	O

Structured	B-T082
Instruction	B-T170
With	O
Modified	B-T169
Storybooks	B-UnknownType
to	O
Teach	B-T065
Morphosyntax	B-T090
and	O
Vocabulary	B-T170
to	O
Preschoolers	B-T100
Who	O
are	O
Deaf	B-T101
/	O
Hard of Hearing	B-T101
Children	B-T100
who	O
are	O
deaf	B-T101
/	O
hard of hearing	B-T101
(	O
D	B-T101
/	O
HH	B-T101
)	O
are	O
at risk	B-T080
for	O
diminished	B-T081
morphosyntactical	B-T090
and	O
vocabulary	B-T170
development	B-T169
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
effects of	B-T080
repeated	B-T169
reading	B-T056
combined	B-T080
with	O
structured	B-T082
instruction	B-T170
.	O
Targets	B-T169
were	O
a	O
morphosyntactical form	B-T090
and	O
novel	O
vocabulary words	B-T170
.	O
Participants	B-T098
were	O
3	O
preschoolers	B-T100
who	O
are	O
D	B-T101
/	O
HH	B-T101
who	O
were	O
receiving	B-T080
instruction	B-T170
with	O
an	O
oral	B-T082
approach.	O
Data	B-T078
from	O
a	O
multiple	B-T081
baseline design	B-T062
indicated	O
that	O
all	O
children	B-T100
acquired	B-T052
the	O
targeted	B-T169
skills	B-T055
and	O
demonstrated	O
high	O
levels	O
of	O
generalization	B-T041
of	O
these	O
skills	B-T055
to	O
untrained	B-T033
context	B-T078
.	O
Implications	B-T080
for	O
teaching	B-T065
young	B-T079
children	B-T100
who	O
are	O
D	B-T101
/	O
HH	B-T101
using	B-T169
repeated	B-T169
storybook	B-UnknownType
reading	B-T056
are	O
discussed.	O

Application	B-T058
of	O
BRAF V600E	B-T033
mutation	B-T045
-	O
specific	B-T080
immunohistochemistry	B-T060
in	O
diagnosis	B-T033
of	O
gastrointestinal stromal tumors	B-T191
To	O
evaluate	B-T058
the	O
utility	O
of	O
BRAF V600E	B-T033
allele	B-T028
-	O
specific	B-T080
antibody	B-T116
in	O
the	O
diagnosis	B-T033
of	O
gastrointestinal stromal tumors	B-T191
(	O
GISTs	B-T191
).	O
BRAF V600E	B-T033
mutation	B-T045
-	O
specific	B-T080
immunohistochemistry	B-T060
and	O
BRAF	B-T028
sequencing	B-T169
were	O
performed	O
in	O
24	O
consecutive	B-T080
GISTs	B-T191
,	O
including	O
14	O
cases	B-T169
of	O
KIT	B-T049
or	O
PDGFRA mutations	B-T049
and	O
10	O
cases	B-T169
of	O
KIT	B-T028
/	O
PDGFRA wild	B-T028
GISTs	B-T191
.	O
GISTs	B-T191
of	O
11	O
men	B-T098
and	O
13	O
women	B-T098
with	O
a	O
mean	B-T081
age	B-T032
54	O
years(range	O
29-75	O
years)	O
were	O
included	O
with	O
tumors	B-T191
arising	O
from	O
stomach	B-T023
(16	O
cases	B-T169
),	O
small bowel	B-T023
(7	O
cases	B-T169
),	O
and	O
peritoneal cavity	B-T030
(1	O
case	B-T169
).	O
Strong	B-T080
and	O
diffuse	B-T082
cytoplasmic	B-T026
BRAF	B-T116
staining	B-T033
was	O
noted	B-T080
in	O
4	O
of	O
24	O
cases	B-T169
(17%),	O
while	O
1	O
of	O
24	O
cases	B-T169
(4%)	O
showed	O
weak	B-T080
staining	B-T033
,	O
and	O
19	O
of	O
24	O
cases	B-T169
(79%)	O
had	O
no	B-T169
staining	B-T033
.	O
The	O
four	O
cases	B-T169
with	O
strong	B-T080
BRAF	B-T116
immunostain	B-T130
were	O
confirmed	B-T080
to	O
have	O
BRAF mutations	B-T049
,	O
including	O
3	O
cases	B-T169
in	O
the	O
stomach	B-T023
and	O
1	O
case	B-T169
in	O
the	O
small intestine	B-T023
.	O
All	O
tumors	B-T191
showed	O
spindle cell	B-T025
morphology	B-T080
.	O
Only	O
one	O
case	B-T169
had	O
progressive disease	B-T047
.	O
No	B-T169
BRAF mutations	B-T049
were	O
detected	B-T033
in	O
cases	B-T169
with	O
weak	B-T080
or	O
negative	B-T033
BRAF	B-T116
immunostain	B-T130
.	O
BRAF V600E	B-T033
mutation	B-T045
-	O
specific	B-T080
immunohistochemistry	B-T060
is	O
a	O
highly sensitive	B-T080
and	O
specific	B-T080
marker	B-T201
for	O
detecting	B-T033
BRAF-mutated	B-T049
GISTs	B-T191
.	O

Efficacy	O
of	O
pegylated liposomal etoposide nanoparticles	B-T109
on	O
breast cancer cell lines	B-T025
This	O
study	O
aimed	O
to	O
investigate	O
the	O
efficacy of	B-T080
pegylated liposomal etoposide nanoparticles	B-T109
(NPs)	O
against	O
T-47D	B-T050
and	O
MCF-7 breast cancer cell lines	B-T025
.	O
Pegylated liposomal etoposide NPs	B-T109
were	O
prepared	O
by	O
reverse phase evaporation method	B-T070
.	O
The	O
size	B-T082
,	O
size distribution	B-T082
,	O
and	O
zeta potential	B-T067
of	O
the	O
NPs	B-T109
was	O
measured	O
by	O
a	O
Zetasizer instrument	B-T074
.	O
The	O
cytotoxicity	B-T049
of	O
NPs	B-T109
was	O
inspected	O
by	O
methyl thiazol tetrazolium assay	B-T062
.	O
The	O
release pattern of the drug from the vesicles	B-UnknownType
was	O
studied	O
by	O
the	O
dialysis method	B-T061
.	O
Drug loading	B-UnknownType
and	O
encapsulation efficiency	B-T067
(	O
EE	B-T067
)	O
were	O
also	O
measured.	O
The	O
mean size	B-T082
,	O
size distribution	B-T082
,	O
and	O
zeta potential	B-T067
of	O
pegylated liposomal etoposide NPs	B-T109
were	O
491	O
±	O
15.5	O
nm,	O
0.504	O
±	O
0.14,	O
and	O
-35.8	O
±	O
2.5	O
mV,	O
respectively.	O
Drug loading	B-UnknownType
and	O
EE	B-T067
were	O
10.3	O
±	O
1.6%	O
and	O
99.1	O
±	O
2.8%,	O
respectively.	O
The	O
etoposide release in the formulation	B-T073
was	O
estimated	O
at	O
about	O
3.48%	O
after	O
48	O
h.	O
The	O
cytotoxicity effect	B-T049
of	O
etoposide NPs	B-T109
on	O
T-47D	B-T050
and	O
MCF-7 cell lines of breast cancer	B-T025
showed	O
higher	O
antitumor activity	B-T080
as	O
compared	O
with	O
those	O
of	O
the	O
free drug	B-T081
.	O
Liposome-based NPs	B-T109
may	O
hold	O
great	O
potential	O
as	O
a	O
drug delivery system	B-T074
.	O

The	O
Bindex(®) ultrasound device	B-T074
:	O
reliability	B-T081
of	O
cortical bone	B-T023
thickness	B-T080
measures	B-T081
and	O
their	O
relationship	B-T080
to	O
regional	B-T082
bone mineral density	B-T201
The	O
Bindex(®) quantitative ultrasound (QUS) device	B-T074
is	O
currently	O
available	O
and	O
this	O
study	B-T062
analyzed	B-T062
(I)	O
its	O
relative	B-T080
and	O
absolute	B-T080
intra- and inter-session reliability	B-T081
and	O
(II)	O
the	O
relationship	B-T080
between	O
the	O
data	B-T078
provided	O
by	O
Bindex(®)-QUS	B-T074
and	O
the	O
bone mineral density	B-T201
(	O
BMD	B-T201
)	O
measured	B-T080
by	O
dual-energy x-ray absorptiometry	B-T060
at	O
corresponding	O
skeletal sites	B-T082
in	O
young	B-T098
and	O
healthy subjects	B-T098
(	O
age	B-T032
:	O
25.0	O
±	O
3.6	O
years	B-T079
).	O
Bindex(®)-QUS	B-T074
calculates	B-T052
a	O
density index	B-T201
on	O
the	O
basis	O
of	O
the	O
thickness	B-T080
of	O
cortical bone	B-T023
measured	B-T080
at	O
the	O
distal radius	B-T023
and	O
the	O
distal	B-T023
plus	O
proximal tibia	B-T023
.	O
The	O
data	B-T078
show	O
a	O
very	O
good	O
relative	B-T080
and	O
absolute	B-T080
intra-	B-T081
(	O
ICC	B-T081
=	O
0.977,	O
CV	B-T081
=	O
1.5%)	O
and	O
inter-session reliability	B-T081
(	O
ICC	B-T081
=	O
0.978,	O
CV	B-T081
=	O
1.4%)	O
for	O
the	O
density index	B-T201
.	O
The	O
highest	B-T080
positive	B-T033
correlations	B-T080
were	O
found	O
between	O
cortical	B-T023
thickness	B-T080
and	O
BMD	B-T201
for	O
the	O
distal radius	B-T023
and	O
distal tibia	B-T023
(r	O
⩾	O
0.71,	O
p	O
<	O
0.001).	O
The	O
data	B-T078
indicate	O
that	O
the	O
Bindex(®)-QUS	B-T074
parameters	B-T033
are	O
repeatable	O
within	O
and	O
between	O
measurement	B-T169
sessions	B-T077
.	O
Furthermore,	O
the	O
measurements	B-T169
reflect	O
the	O
BMD	B-T201
at	O
specific	B-T080
skeletal sites	B-T082
.	O
Bindex(®)-QUS	B-T074
might	O
be	O
a	O
useful	O
tool	O
for	O
the	O
measurement	B-T169
of	O
skeletal adaptations	B-T039
.	O

Botulinum Toxin	B-T116
Use	O
in	O
Refractory Pain	B-T184
and	O
Other	O
Symptoms	B-T184
in	O
Parkinsonism	B-T047
Parkinson's disease	B-T047
(	O
PD	B-T047
)	O
and	O
other	O
parkinsonian syndromes	B-T047
are	O
chronic	B-T079
,	O
progressive	B-T169
neurodegenerative diseases	B-T047
.	O
With	O
advancing	O
disease	B-T047
,	O
both	O
motor	B-T184
and	O
non-motor symptoms	B-T184
represent	O
a	O
considerable	O
burden	B-T078
and	O
symptom	B-T184
relief	B-T033
and	O
quality of life	B-T078
improvement	B-T077
become	O
the	O
main	O
goal	B-T170
of	O
treatment	B-T061
.	O
Botulinum toxins	B-T116
(	O
BTX	B-T116
)	O
are	O
an	O
effective	B-T080
treatment	B-T061
modality	B-T078
for	O
many	O
neurological conditions	B-T047
.	O
To	O
understand	O
the	O
potential	B-T080
usefulness	B-T080
of	O
BTX	B-T116
in	O
this	O
population	B-T098
,	O
we	O
performed	B-T169
a	O
retrospective	B-T080
chart review	B-T058
of	O
all	O
patients	B-T101
with	O
a	O
clinical diagnosis	B-T060
of	O
idiopathic PD	B-T047
and	O
atypical parkinsonism	B-T047
who	O
received	O
treatment	B-T169
with	O
BTX injections	B-T061
in	O
our	O
center	B-T093
from	O
1995	O
to	O
2014	O
for	O
a	O
variety	O
of	O
symptoms	B-T184
.	O
Response	B-T032
to	O
BTX	B-T116
was	O
assessed	B-T052
using	O
a	O
subjective Clinical Global Impression	B-T170
.	O
Records	B-T170
of	O
160	O
patients	B-T101
were	O
reviewed	B-T080
.	O
Probable	O
idiopathic PD	B-T047
was	O
the	O
diagnosis	B-T033
in	O
117	O
patients	B-T101
(73.1%).	O
The	O
main	O
indication	B-T078
for	O
BTX	B-T116
treatment	B-T061
was	O
pain	B-T184
(50.6%	O
of	O
cases).	O
Other	O
indications	B-T078
were	O
the	O
treatment	B-T061
of	O
functional impairment	B-T033
resulting	B-T169
from	O
dystonia	B-T184
(26.25%),	O
sialorrhea	B-T047
(18.75%),	O
freezing of gait	B-T184
,	O
and	O
camptocormia	B-T020
.	O
Considering	O
pain	B-T184
as	O
indication	B-T078
,	O
81%	O
of	O
all	O
patients	B-T101
with	O
PD	B-T047
reported	B-T058
benefits	B-T081
after	O
the	O
first	O
BTX injections	B-T061
.	O
This	O
benefit	B-T081
was	O
maintained	B-T169
after	O
the	O
last recorded visit	B-T058
without	O
significant	O
difference	B-T080
in	O
outcome	B-T169
compared	B-T052
with	O
the	O
first	O
injection	B-T061
(p=0.067).	O
Similar	O
results	B-T169
were	O
observed	O
in	O
patients	B-T101
with	O
atypical parkinsonism	B-T047
.	O
Our	O
results	B-T169
confirm	O
the	O
safety	O
and	O
efficacy	B-T080
of	O
different	B-T080
uses	B-T169
of	O
BTX	B-T116
in	O
the	O
symptomatic	B-T169
treatment	B-T169
of	O
patients	B-T101
with	O
parkinsonism	B-T047
even	O
in	O
advanced	B-T080
stages	B-T079
of	O
the	O
disease	B-T047
,	O
and	O
suggest	B-T078
BTX	B-T116
treatment	B-T061
could	O
have	O
a	O
safe	O
and	O
useful	O
role	B-T077
in	O
the	O
treatment	B-T169
of	O
pain	B-T184
in	O
this	O
population	B-T098
.	O

Chronic exposure to	B-T033
haloperidol	B-T109
and	O
olanzapine	B-T109
leads	O
to	O
common	O
and	O
divergent	O
shape changes	B-T033
in	O
the	O
rat	B-T015
hippocampus	B-T023
in	O
the	O
absence	O
of	O
grey-matter	B-T024
volume loss	B-T169
One	O
of	O
the	O
most	O
consistently	O
reported	O
brain abnormalities	B-T190
in	O
schizophrenia	B-T048
(	O
SCZ	B-T048
)	O
is	O
decreased	O
volume and shape deformation	B-T033
of	O
the	O
hippocampus	B-T023
.	O
However,	O
the	O
potential	O
contribution	O
of	O
chronic antipsychotic medication	B-T121
exposure	B-T033
to	O
these	O
phenomena	O
remains	O
unclear.	O
We	O
examined	O
the	O
effect	O
of	O
chronic exposure	B-T033
(8	O
weeks)	O
to	O
clinically	O
relevant doses	B-T081
of	O
either	O
haloperidol	B-T109
(	O
HAL	B-T109
)	O
or	O
olanzapine	B-T109
(	O
OLZ	B-T109
)	O
on	O
adult	O
rat	B-T015
hippocampal	B-T029
volume and shape	B-T033
using	O
ex vivo	B-T169
structural MRI	B-T060
with	O
the	O
brain retained inside the cranium	B-T023
to	O
prevent	O
distortions	B-T190
due	O
to	O
dissection	B-T061
,	O
followed	O
by	O
tensor-based morphometry	B-T059
(	O
TBM	B-T059
)	O
and	O
elastic surface-based shape deformation analysis	B-T062
.	O
The	O
volume	O
of	O
the	O
hippocampus	B-T023
was	O
also	O
measured	O
post-mortem	B-T060
from	O
brain tissue	B-T023
sections	O
in	O
each	O
group.	O
Chronic exposure	B-T033
to	O
either	O
HAL	B-T109
or	O
OLZ	B-T109
had	O
no	O
effect	O
on	O
the	O
volume	O
of	O
the	O
hippocampus	B-T023
,	O
even	O
at	O
exploratory thresholds	B-T060
,	O
which	O
was	O
confirmed	O
post-mortem	B-T060
.	O
In	O
contrast,	O
shape deformation analysis	B-T062
revealed	O
that	O
chronic	O
HAL	B-T109
and	O
OLZ	B-T109
exposure	B-T033
lead	O
to	O
both	O
common	O
and	O
divergent shape deformations	B-T033
(q	O
=	O
0.05,	O
FDR-corrected)	O
in	O
the	O
rat	B-T015
hippocampus	B-T023
.	O
In	O
particular,	O
in	O
the	O
dorsal hippocampus	B-T023
,	O
HAL	B-T109
exposure	B-T033
led	O
to	O
inward shape deformation	B-T033
,	O
whereas	O
OLZ	B-T109
exposure	B-T033
led	O
to	O
outward shape deformation	B-T033
.	O
Interestingly,	O
outward shape deformations	B-T033
that	O
were	O
common	O
to	O
both	O
drugs	B-T121
occurred	O
in	O
the	O
ventral hippocampus	B-T023
.	O
These	O
effects	O
remained	O
significant	O
after	O
controlling	O
for	O
hippocampal	B-T023
volume	O
suggesting	O
true	O
shape changes	B-T033
.	O
Chronic exposure	B-T033
to	O
either	O
HAL	B-T109
or	O
OLZ	B-T109
leads	O
to	O
both	O
common	O
and	O
divergent	O
effects	O
on	O
rat	B-T015
hippocampal shape	B-T023
in	O
the	O
absence	O
of	O
volume	O
change.	O
The	O
implications	O
of	O
these	O
findings	O
for	O
the	O
clinic	O
are	O
discussed.	O

Shear	B-T070
and	O
extensional properties	B-T070
of	O
kefiran	B-T109
Kefiran	B-T109
is	O
a	O
neutral polysaccharide	B-T109
constituted	O
by	O
glucose	B-T109
and	O
galactose	B-T109
produced	O
by	O
Lactobacillus kefiranofaciens	B-T007
.	O
It	O
is	O
included	O
into	O
kefir grains	B-T168
and	O
has	O
several	O
health promoting properties	B-T070
.	O
In	O
the	O
present	O
work,	O
shear	B-T070
and	O
extensional properties	B-T070
of	O
different	B-T080
kefiran	B-T109
aqueous dispersions	B-T167
(0.5,	O
1	O
and	O
2%	O
wt.)	O
were	O
assessed	B-T052
and	O
compared	B-T052
to	O
other	O
neutral gums	B-T109
commonly	O
used	O
in	O
food	B-T168
,	O
cosmetic	B-T073
and	O
pharmaceutics industries	B-T093
(	O
methylcellulose	B-T109
,	O
locust bean gum	B-T200
and	O
guar gum	B-T109
).	O
Kefiran	B-T109
showed	O
shear flow characteristics	B-T070
similar	O
to	O
that	O
displayed	O
by	O
other	O
representative	O
neutral gums	B-T109
,	O
although	O
it	O
always	O
yielded	O
lower	B-T080
viscosities	B-T070
at	O
a	O
given	O
concentration	B-T081
.	O
For	O
each	O
gum	B-T109
system	B-T169
it	O
was	O
possible	O
to	O
find	O
a	O
correlation	B-T080
between	O
dynamic and steady shear properties	B-T070
by	O
a	O
master curve	B-T082
including	O
both	O
the	O
apparent	B-T078
and	O
complex	B-T080
viscosities	B-T070
.	O
When	O
studying	O
extensional properties	B-T070
of	O
selected	O
gums	B-T109
at	O
2%	O
wt.	O
by	O
means	O
of	O
a	O
capillary break-up rheometer	B-T073
,	O
kefiran	B-T109
solutions	B-T167
did	O
not	O
show	O
important	O
extensional properties	B-T070
,	O
displaying	O
a	O
behaviour	B-T080
close	O
the	O
Newtonian	B-T080
.	O

Air	B-T167
tamponade	B-T169
of	O
the	O
heart	B-T023
Pneumopericardium	B-T047
is	O
a	O
rare disease	B-T047
defined	O
as	O
the	O
presence	B-T033
of	O
air	B-T167
or	O
gas	B-T104
in	O
the	O
pericardial sac	B-T023
.	O
Among	O
the	O
etiological factors	B-T169
,	O
the	O
following	O
stand	O
out:	O
chest trauma	B-T037
,	O
barotrauma	B-T037
,	O
air	B-T167
-containing	O
fistulas	B-T190
between	O
the	O
pericardium	B-T023
and	O
the	O
surrounding	B-T082
structures	B-T082
,	O
secondary gas production	B-T169
by	O
microorganisms	B-T001
growing	O
in	O
the	O
pericardial sac	B-T023
,	O
and	O
iatrogenic	B-T080
factors	B-T169
.	O
Until	O
now,	O
spontaneous	B-T169
pneumopericardium	B-T047
has	O
been	O
considered	B-T078
a	O
harmless	B-T080
and	O
temporary	B-T079
state	B-T169
,	O
but	O
a	O
review of	B-T169
clinical cases	B-T077
indicates	O
that	O
the	O
presence	B-T033
of	O
air	B-T167
in	O
the	O
pericardium	B-T023
can	O
lead	O
to	O
cardiac tamponade	B-T047
and	O
life-threatening	B-T033
hemodynamic	B-T042
disturbances	B-T080
.	O
We	O
present	B-T033
the	O
case	O
of	O
an	O
80-	O
year-old	B-T079
patient	B-T101
with	O
a	O
chronic	B-T079
bronchopericardial	B-T023
fistula	B-T190
,	O
who	O
suffered	O
from	O
a	O
cardiac arrest	B-T047
due	O
to	O
air	B-T167
tamponade	B-T169
of	O
the	O
heart	B-T023
.	O

The	O
Complete	B-T080
Chloroplast Genome	B-T028
Sequence	B-T086
of	O
the	O
Medicinal Plant	B-T002
Swertia mussotii	B-T002
Using	O
the	O
PacBio RS II Platform	B-T074
Swertia mussotii	B-T002
is	O
an	O
important	O
medicinal plant	B-T002
that	O
has	O
great	B-T081
economic	B-T081
and	O
medicinal value	B-T121
and	O
is	O
found	O
on	O
the	O
Qinghai Tibetan Plateau	B-UnknownType
.	O
The	O
complete	B-T080
chloroplast (cp) genome	B-T028
of	O
S. mussotii	B-T002
is	O
153,431	O
bp	O
in	O
size	B-T081
,	O
with	O
a	O
pair	B-T080
of	O
inverted repeat (IR) regions	B-T114
of	O
25,761	O
bp	O
each	O
that	O
separate	B-T080
an	O
large single-copy (LSC) region	B-T086
of	O
83,567	O
bp	O
and	O
an	O
a	O
small single-copy (SSC) region	B-T086
of	O
18,342	O
bp.	O
The	O
S. mussotii	B-T002
cp genome	B-T028
encodes	B-T052
84	O
protein-coding genes	B-T028
,	O
37	O
transfer RNA	B-T114
(	O
tRNA	B-T114
)	O
genes	B-T028
,	O
and	O
eight	O
ribosomal RNA (rRNA) genes	B-T028
.	O
The	O
identity,	O
number,	O
and	O
GC content	B-T081
of	O
S. mussotii	B-T002
cp genes	B-T028
were	O
similar	O
to	O
those	O
in	O
the	O
genomes	B-T028
of	O
other	O
Gentianales	B-T002
species	B-T185
.	O
Via	O
analysis	B-T062
of	O
the	O
repeat structure	B-T086
,	O
11	O
forward	O
repeats	B-T086
,	O
eight	O
palindromic repeats	B-T114
,	O
and	O
one	O
reverse	O
repeat	O
were	O
detected	B-T033
in	O
the	O
S. mussotii	B-T002
cp genome	B-T028
.	O
There	O
are	O
45	O
SSRs	B-T114
in	O
the	O
S. mussotii	B-T002
cp genome	B-T028
,	O
the	O
majority	B-T080
of	O
which	O
are	O
mononucleotides	B-T114
found	O
in	O
all	O
other	O
Gentianales	B-T002
species	B-T185
.	O
An	O
entire	B-T081
cp genome	B-T028
comparison study	B-T062
of	O
S. mussotii	B-T002
and	O
two	O
other	O
species	B-T185
in	O
Gentianaceae	B-T002
was	O
conducted.	O
The	O
complete	B-T080
cp genome	B-T028
sequence	B-T086
provides	O
intragenic	B-T028
information	B-T078
for	O
the	O
cp	B-T026
genetic engineering	B-T063
of	O
this	O
medicinal plant	B-T002
.	O

Meta-Analysis	B-T062
of	O
29	O
Experiments	B-T062
Evaluating	B-T058
the	O
Effects of	B-T080
Rapamycin	B-T109
on	O
Life Span	B-T102
in	O
the	O
Laboratory Mouse	B-T015
Rapamycin	B-T109
has	O
favorable	O
effects	B-T080
on	O
aging	B-T040
in	O
mice	B-T015
and	O
may	O
eventually	O
be	O
applied	B-T169
to	O
encourage	O
"	O
healthy	B-T080
aging	B-T040
"	O
in	O
humans	B-T016
.	O
This	O
study	B-T062
analyzed	B-T062
raw	B-T080
data	B-T078
from	O
29	O
survival studies	B-T062
of	O
rapamycin	B-T109
-	O
and	O
control	B-T167
-	O
treated	B-T169
mice	B-T015
,	O
with	O
the	O
goals	B-T170
of	O
estimating	B-T081
summary	B-T170
statistics	B-T170
and	O
identifying	B-T080
factors	B-T169
associated with	B-T080
effect size	B-T081
heterogeneity	B-T080
.	O
Meta-analysis	B-T062
demonstrated	B-T080
significant	B-T078
heterogeneity	B-T080
across	O
studies	B-T059
,	O
with	O
hazard ratio	B-T081
(HR)	B-T081
estimates	B-T081
ranging	B-T081
from	O
0.22	O
(95%	O
confidence interval	B-T081
[CI]	B-T081
:	O
0.06-0.82)	O
to	O
0.92	O
(95%	O
CI	B-T081
:	O
0.65-1.28).	O
Sex	B-T032
was	O
the	O
major	B-T080
factor	B-T169
accounting	B-T169
for	O
effect size	B-T081
variation	B-T080
,	O
and	O
mortality	B-T081
was	O
decreased	B-T081
more	B-T081
in	O
females	B-T032
(	O
HR	B-T081
=	O
0.41;	O
95%	O
CI	B-T081
:	O
0.35-0.48)	O
as	O
compared	B-T052
with	O
males	B-T032
(	O
HR	B-T081
=	O
0.63;	O
95%	O
CI	B-T081
:	O
0.55-0.71).	O
Rapamycin	B-T109
effects	B-T080
were	O
also	O
genotype	B-T032
dependent	B-T080
,	O
however,	O
with	O
stronger	B-T080
survivorship	B-T079
increases	B-T169
in	O
hybrid	B-T001
mice	B-T015
(14.4%;	O
95%	O
CI	B-T081
:	O
12.5-16.3%)	O
relative	B-T080
to	O
pure	B-T001
inbred strains	B-T015
(8.8%;	O
95%	O
CI	B-T081
:	O
6.2-11.6%).	O
Number	B-T081
needed	B-T169
to	O
treat	B-T169
was	O
applied	B-T169
as	O
an	O
effect size	B-T081
metric	B-T081
,	O
which	O
consistently	O
identified	B-T080
early	O
senescence	B-T033
as	O
the	O
age	B-T032
of	O
peak	B-T080
treatment	B-T169
benefit	B-T081
.	O
These	O
results	B-T169
provide	B-T052
synthesis	B-T052
of	O
existing	B-T077
data	B-T078
to	O
support	B-T077
the	O
potential	O
translation	B-T062
of	O
findings	B-T033
from	O
mouse	B-T015
to	O
primate species	B-T015
.	O
Because	O
rapamycin's	B-T109
effect	B-T080
on	O
survival	B-T052
depends	B-T080
on	O
sex	B-T032
and	O
genotype	B-T032
,	O
further	O
work	O
is	O
justified	O
to	O
understand	O
how	O
these	O
factors	B-T169
shape	O
treatment	B-T169
response	B-T032
.	O

Transfusion medicine	B-T091
in	O
medical education	B-T065
:	O
an	O
analysis	B-T062
of	O
curricular grids	B-UnknownType
in	O
Brazil	B-T083
and	O
a	O
review	B-T078
of	O
the	O
current literature	B-T170
Blood transfusions	B-T061
are	O
one	O
of	O
the	O
most	O
performed	O
medical procedures	B-T058
in	O
the	O
world	B-T098
.	O
Thus,	O
as	O
education	B-T065
in	O
transfusion medicine	B-T091
is	O
vital	B-T080
to	O
medical care	B-T033
,	O
it	O
should	O
aim	O
to	O
promote	B-T052
a	O
responsible	O
practice	B-T057
with	O
the	O
rational	O
use	O
of	O
blood	B-T031
by	O
doctors	B-T097
.	O
This	O
study	O
aims	O
to	O
investigate	B-T169
the	O
situation	O
of	O
the	O
teaching	B-T065
of	O
transfusion medicine	B-T091
in	O
medical schools	B-T073
in	O
Brazil	B-T083
.	O
The	O
websites	B-T170
of	O
the	O
249	O
Brazilian	B-T098
medical schools	B-T073
in	O
operation	B-T052
in	O
June	O
2015	O
were	O
visited	O
and	O
the	O
curricula	B-T170
of	O
the	O
medical courses	B-T065
were	O
investigated	B-T169
in	O
respect	O
to	O
the	O
presence	O
or	O
absence	O
of	O
a	O
transfusion medicine discipline	B-T091
.	O
When	O
available,	O
the	O
subject	O
grids	O
were	O
analyzed	B-T062
to	O
verify	O
whether	O
a	O
description of content	B-T170
regarding	O
transfusion medicine	B-T091
was	O
given	O
within	O
other	O
disciplines	B-T090
.	O
Of	O
the	O
249	O
medical school	B-T073
sites	O
visited,	O
information	B-T078
on	O
the	O
curriculum	B-T170
was	O
obtained	O
from	O
178.	O
Of	O
the	O
medical schools	B-T073
that	O
published	B-T057
their	O
curriculum	B-T170
,	O
132	O
(74.1%)	O
did	O
not	O
have	O
disciplines of transfusion medicine	B-T091
or	O
hematology	B-T091
and	O
only	O
seven	O
(3.9%)	O
had	O
a	O
discipline of transfusion medicine	B-T091
in	O
the	O
curricular grid	B-UnknownType
.	O
Education	B-T065
on	O
transfusion medicine	B-T091
is	O
of	O
fundamental importance	B-T080
for	O
safe and efficient transfusion practices	B-T061
.	O
Deficiencies	B-T169
in	O
medical	B-T169
knowledge	B-T170
of	O
this	O
subject	O
have	O
been	O
found	O
worldwide.	O
The	O
results	O
of	O
this	O
study	O
indicate	O
a	O
possible	O
deficiency	B-T169
in	O
teaching	B-T065
the	O
basics	B-T169
of	O
this	O
specialty.	O
Thus,	O
additional	O
prospective studies	B-T062
to	O
assess	B-T058
the	O
knowledge	B-T170
and	O
practice	O
of	O
transfusion medicine	B-T091
in	O
Brazilian	B-T098
medical schools	B-T073
are	O
warranted,	O
which	O
could	O
prompt	O
a	O
discussion	O
on	O
the	O
importance	B-T080
of	O
offering	O
training	B-T065
in	O
transfusion medicine	B-T091
to	O
medical students	B-T097
.	O

Advanced	B-T080
interlocking systems	B-T074
to	O
improve	B-T033
heavy	B-T080
-	O
load-bearing	B-T032
characteristics	B-T080
of	O
flexible	B-T080
intramedullary nailing	B-T061
Flexible	B-T080
intramedullary nailing	B-T061
(	O
FIN	B-T061
)	O
is	O
a	O
minimally invasive	B-T061
and	O
widespread	B-T082
standard	B-T080
method	B-T061
for	O
osteosynthesis	B-T061
of	O
pediatric	B-T080
long bone fractures	B-T033
.	O
In	O
the	O
case	O
of	O
unstable fractures	B-T037
of	O
the	O
lower extremity	B-T023
,	O
interlocking systems	B-T074
need	O
to	O
be	O
used	O
to	O
prevent	O
axial	B-T082
shortening	B-T061
and	O
subsequent	B-T079
perforation	B-T046
of	O
the	O
nail	B-T074
at	O
its	O
insertion site	B-T082
.	O
In	O
the	O
present	O
study	B-T062
,	O
four	O
different	O
screw	B-T074
-fixed	O
interlocking systems	B-T074
for	O
FINs	B-T061
(	O
Hofer TwinPlug	B-T074
with	O
two	O
3-mm	O
titanium	B-T196
interlocking screws	B-T074
,	O
Hofer FixPlug	B-T074
with	O
3-mm	O
titanium	B-T196
interlocking screw	B-T074
,	O
Hofer Plug	B-T074
with	O
3.5-mm	O
titanium	B-T196
interlocking screw	B-T074
,	O
and	O
Hofer Plug	B-T074
with	O
3-mm	O
titanium	B-T196
interlocking screw	B-T074
)	O
in	O
comparison	B-T052
with	O
the	O
commonly	O
used	O
Ender	O
stainless steel	B-T122
nails	B-T074
(locked	O
with	O
3.5-mm	O
screw	B-T074
)	O
were	O
experimentally investigated	B-T169
in	O
cadaveric	B-T017
lamb	B-T015
tibiae	B-T023
,	O
regarding	O
their	O
load	B-T052
characteristics	B-T080
and	O
failure	B-T066
modes	B-T169
in	O
the	O
case	O
of	O
heavy	B-T080
loading	B-T052
.	O
The	O
specimens	B-T167
were	O
subjected	O
to	O
sequential	B-T080
axial	B-T082
cyclic	B-T079
loading	B-T052
of	O
5000	O
cycles	B-T079
with	O
stepwise increase	B-T169
of	O
the	O
load	B-T052
amplitude	B-T082
until	O
failure	B-T066
.	O
Migration	B-T067
of	O
locking screws	B-T074
and	O
internal	B-T082
damage	B-T037
of	O
bone tissue	B-T024
was	O
quantified	O
by	O
micro-computed tomography (CT) imaging	B-T060
.	O
Ender nails	B-T074
failed	B-T169
on	O
average	B-T081
at	O
a	O
peak	B-T080
load	B-T052
of	O
800	O
N,	O
TwinPlugs	B-T074
at	O
1367	O
N,	O
FixPlugs	B-T074
at	O
1222	O
N,	O
Plugs	B-T074
3.5mm	O
at	O
1225	O
N	O
and	O
Plugs	B-T074
3.0mm	O
at	O
971	O
N.	O
TwinPlugs	B-T074
,	O
FixPlugs	B-T074
,	O
and	O
Plugs	B-T074
3.5mm	O
failed	B-T169
in	O
a	O
slow	O
manner	O
over	O
several	O
hundred	O
loading	B-T052
cycles	B-T079
,	O
whereas	O
Ender nails	B-T074
and	O
Plugs	B-T074
3.0mm	O
exhibited	O
abrupt	B-T080
failure	B-T066
without	O
any	O
prior	B-T079
indication	B-T078
.	O
Our	O
results	O
confirm	O
that	O
axial	B-T082
stability	B-T080
of	O
FIN	B-T061
can	O
be	O
further	O
improved	B-T033
by	O
screw	B-T074
-fixed	O
plugs	B-T074
by	O
simultaneously	B-T079
avoiding	O
shortcomings	O
of	O
an	O
eye-locked system	B-T073
,	O
which	O
the	O
Ender nails	B-T074
are.	O
Considering	O
biomechanical	B-T070
results	B-T033
,	O
plug	B-T074
interlocking systems	B-T074
with	O
3.5-mm	O
screws	B-T074
should	O
be	O
favored	O
over	O
conventional	B-T080
Ender nails	B-T074
and	O
plugs	B-T074
with	O
3-mm	O
screws	B-T074
.	O

Surgical	B-T061
Guidance	B-T061
via	O
Multiplexed Molecular Imaging	B-T060
of	O
Fresh	O
Tissues	B-T024
Labeled	B-T130
with	O
SERS	B-T070
-Coded	O
Nanoparticles	B-T073
The	O
imaging	B-T060
of	O
dysregulated	O
cell-surface receptors	B-T116
(or	O
biomarkers)	B-T201
is	O
a	O
potential	O
means	O
of	O
identifying	O
the	O
presence	B-T033
of	O
cancer	B-T191
with	O
high	O
sensitivity	B-T169
and	O
specificity	B-T081
.	O
However,	O
due	O
to	O
heterogeneities	B-T080
in	O
the	O
expression of protein	B-T045
biomarkers	B-T123
in	O
tumors	B-T191
,	O
molecular imaging	B-T060
technologies	B-T058
should	O
ideally	O
be	O
capable	O
of	O
visualizing	O
a	O
multiplexed panel	B-T130
of	O
cancer biomarkers	B-T123
.	O
Recently,	O
surface-enhanced Raman-scattering	B-T070
(	O
SERS	B-T070
)	O
nanoparticles	B-T073
(	O
NPs	B-T073
)	O
have	O
attracted	O
wide	O
interest	O
due	O
to	O
their	O
potential	O
for	O
sensitive	B-T169
and	O
multiplexed biomarker	B-T130
detection	B-T061
.	O
In	O
this	O
review	B-T170
,	O
we	O
focus	O
on	O
the	O
most	O
recent	O
advances	O
in	O
tumor	B-T191
imaging	B-T060
using	O
SERS	B-T070
-coded	O
NPs	B-T073
.	O
A	O
brief	O
introduction	O
of	O
the	O
structure	B-T082
and	O
optical properties	B-T070
of	O
SERS	B-T070
NPs	B-T073
is	O
provided,	O
followed	O
by	O
a	O
detailed	O
discussion	O
of	O
key	O
imaging	B-T060
issues	O
such	O
as	O
the	O
administration	B-T169
of	O
NPs	B-T073
in	O
tissue	B-T024
(	O
topical	B-T082
versus	O
systemic	B-T169
),	O
the	O
optical configuration	B-UnknownType
and	O
imaging	B-T060
approach	O
of	O
Raman imaging systems	B-T059
,	O
spectral demultiplexing methods	B-T060
for	O
quantifying	B-T081
NP	B-T073
concentrations	B-T081
,	O
and	O
the	O
disambiguation	B-T080
of	O
specific	B-T080
vs.	O
nonspecific	B-T078
sources	O
of	O
contrast	O
through	O
ratiometric imaging	B-T060
of	O
targeted	B-T169
and	O
untargeted	B-T167
(	O
control	B-T167
)	O
NP	B-T073
pairs.	O
Finally,	O
future	O
challenges	O
and	O
directions	O
are	O
briefly	O
outlined.	O

Expression	B-T045
and	O
methylation	B-T044
in	O
posttraumatic stress disorder	B-T048
and	O
resilience	B-T055
;	O
evidence	B-T078
of	O
a	O
role	B-T077
for	O
odorant receptors	B-T116
Post-traumatic stress disorder	B-T048
(	O
PTSD	B-T048
)	O
is	O
a	O
common	O
and	O
potentially	B-T080
disabling disorder	B-T047
that	O
develops	O
in	O
1/5	O
to	O
1/3	O
of	O
people	B-T098
exposed to	B-T080
severe	B-T080
trauma	B-T037
.	O
Twin studies	B-T170
indicate	O
that	O
genetic	B-T169
factors	B-T169
account	O
for	O
at	O
least	O
one	O
third	O
of	O
the	O
variance	B-T080
in	O
the	O
risk	O
for	O
developing	O
PTSD	B-T048
,	O
however,	O
the	O
specific	B-T080
role	B-T077
for	O
genetic	B-T169
factors	B-T169
in	O
the	O
pathogenesis	B-T046
of	O
PTSD	B-T048
is	O
not	O
well	O
understood.	O
We	O
studied	O
genome-wide	B-T063
gene expression	B-T045
and	O
DNA methylation	B-T044
profiles	B-T081
in	O
12	O
participants	B-T098
with	O
PTSD	B-T048
and	O
12	O
participants	B-T098
who	O
were	O
resilient	B-T055
to	O
similar	O
severity	B-T080
trauma	B-T037
exposure	B-T080
.	O
Close	O
to	O
4000	O
genes	B-T028
were	O
differentially	B-T080
expressed	B-T045
with	O
adjusted	B-T169
p<0.05,	O
fold-change	B-T081
>2,	O
with	O
all	O
but	O
3	O
upregulated	B-T044
with	O
PTSD	B-T048
.	O
Eight	O
odorant/olfactory receptor	B-T116
related	O
genes	B-T028
were	O
up-regulated	B-T044
with	O
PTSD	B-T048
as	O
well	O
as	O
genes	B-T028
related	O
to	O
immune activation	B-T043
,	O
the	O
Gamma-Aminobutyric Acid A (GABAA) receptor	B-T116
,	O
and	O
vitamin D synthesis	B-T044
.	O
No	O
differences	O
with	O
adjusted	B-T169
significance	B-T078
for	O
DNA methylation	B-T044
were	O
found.	O
We	O
conclude	O
that	O
increased	B-T081
gene expression	B-T045
may	O
play	O
an	O
important	B-T080
role	B-T077
in	O
PTSD	B-T048
and	O
this	O
expression	B-T045
may	O
not	O
be	O
a	O
consequence of	B-T169
DNA methylation	B-T044
.	O
The	O
role	B-T077
of	O
odorant receptor	B-T116
expression	B-T045
warrants	O
independent	B-T169
replication	B-T045
.	O

Absorption Characteristics	B-T169
of	O
Vertebrate	B-T010
Non	B-T169
-	O
Visual	B-T169
Opsin, Opn3	B-T116
Most	O
animals	B-T008
possess	B-T078
multiple	B-T081
opsins	B-T116
which	O
sense	B-T040
light	B-T070
for	O
visual	B-T169
and	O
non	B-T169
-	O
visual functions	B-T040
.	O
Here,	O
we	O
show	O
spectral	B-T081
characteristics	B-T080
of	O
non	B-T169
-	O
visual	B-T169
opsins	B-T116
,	O
vertebrate	B-T010
Opn3s	B-T116
,	O
which	O
are	O
widely	O
distributed	B-T169
among	O
vertebrates	B-T010
.	O
We	O
successfully	B-T080
expressed	B-T045
zebrafish	B-T013
Opn3	B-T116
in	O
mammalian	B-T015
cultured cells	B-T025
and	O
measured	B-T080
its	O
absorption spectrum spectroscopically	B-T059
.	O
When	O
incubated	B-T059
with	O
11-cis retinal	B-T109
,	O
zebrafish	B-T013
Opn3	B-T116
formed	O
a	O
blue-sensitive photopigment	B-T109
with	O
an	O
absorption	B-T043
maximum	B-T081
around	O
465	O
nm.	O
The	O
Opn3	B-T116
converts	B-T169
to	O
an	O
all-trans retinal-bearing	B-T109
photoproduct	B-T167
with	O
an	O
absorption spectrum	B-T059
similar	B-T080
to	O
the	O
dark state	B-T042
following	O
brief	B-T079
blue-light	B-T070
irradiation	B-T070
.	O
The	O
photoproduct	B-T167
experienced	O
a	O
remarkable	O
blue-shift	B-T081
,	O
with	O
changes	O
in position	B-T082
of	O
the	O
isosbestic point	B-T081
,	O
during	O
further	O
irradiation	B-T070
.	O
We	O
then	O
used	O
a	O
cAMP	B-T114
-	O
dependent	B-T169
luciferase	B-T116
reporter	B-T130
assay	B-T059
to	O
investigate	B-T169
light	B-T070
-	O
dependent	B-T169
cAMP	B-T114
responses	B-T043
in	O
cultured cells	B-T025
expressing	B-T045
zebrafish	B-T013
,	O
pufferfish	B-T013
,	O
anole	B-T014
and	O
chicken	B-T012
Opn3	B-T116
.	O
The	O
wild type	B-T028
opsins	B-T116
did	O
not	O
produce	O
responses	B-T043
,	O
but	O
cells	B-T025
expressing	B-T045
chimera	B-T001
mutants	B-T116
(	O
WT Opn3s	B-T116
in	O
which	O
the	O
third intracellular	B-T082
loops	B-T087
were	O
replaced	B-T169
with	O
the	O
third intracellular	B-T082
loop	B-T087
of	O
a	O
Gs-coupled	B-T116
jellyfish	B-T204
opsin	B-T116
)	O
displayed	B-T169
light	B-T070
-	O
dependent	B-T169
changes	B-T081
in	O
cAMP	B-T114
.	O
The	O
results	O
suggest	O
that	O
Opn3	B-T116
is	O
capable	O
of	O
activating	B-T045
G protein(s)	B-T116
in	O
a	O
light	B-T070
-	O
dependent	B-T169
manner.	O
Finally,	O
we	O
used	O
this	O
assay	B-T059
to	O
measure	B-T081
the	O
relative	B-T080
wavelength	B-T081
-	O
dependent	B-T169
response	B-T032
of	O
cells	B-T025
expressing	B-T045
Opn3	B-T116
chimeras	B-T001
to	O
multiple	B-T081
quantally	B-T170
-	O
matched	B-T080
stimuli	B-T067
.	O
The	O
inferred	B-T078
spectral sensitivity	B-T041
curve	B-T082
of	O
zebrafish	B-T013
Opn3	B-T116
accurately	B-T080
matched	B-T080
the	O
measured	B-T080
absorption spectrum	B-T059
.	O
We	O
were	O
unable	O
to	O
estimate	O
the	O
spectral sensitivity	B-T041
curve	B-T082
of	O
mouse	B-T015
or	O
anole	B-T014
Opn3	B-T116
,	O
but,	O
like	O
zebrafish	B-T013
Opn3	B-T116
,	O
the	O
chicken	B-T012
and	O
pufferfish	B-T013
Opn3-JiL3	B-T116
chimeras	B-T001
also	O
formed	O
blue-sensitive pigments	B-T116
.	O
These	O
findings	O
suggest	O
that	O
vertebrate	B-T010
Opn3s	B-T116
may	O
form	O
blue-sensitive G protein-coupled pigments	B-T116
.	O
Further,	O
we	O
suggest	O
that	O
the	O
method	O
described	O
here,	O
combining	O
a	O
cAMP	B-T114
-	O
dependent	B-T169
luciferase	B-T116
reporter	B-T130
assay	B-T059
with	O
chimeric	B-T001
opsins	B-T116
possessing	O
the	O
third intracellular	B-T082
loop	B-T087
of	O
jellyfish	B-T204
opsin	B-T116
,	O
is	O
a	O
versatile	O
approach	O
for	O
estimating	B-T081
absorption spectra	B-T059
of	O
opsins	B-T116
with	O
unknown	O
signaling cascades	B-T043
or	O
for	O
which	O
absorption spectra	B-T059
are	O
difficult	B-T080
to	O
obtain.	O

Effectiveness	B-T080
of	O
offloading	B-T061
methods	B-T061
in	O
preventing	B-T061
primary	B-T080
diabetic foot ulcers	B-T047
in	O
adults	B-T100
with	O
diabetes	B-T047
:	O
a	O
systematic review	B-T170
The	O
incidence	B-T081
of	O
foot ulceration	B-T047
related	O
to	O
diabetes	B-T047
is	O
increasing	B-T169
.	O
Many	O
foot care	B-T061
professionals	B-T097
recommend	O
offloading	B-T061
measures	O
as	O
part	O
of	O
management strategies	B-T058
for	O
modulating	O
excess	B-T080
pressure	B-T081
to	O
prevent	B-T061
development	O
of	O
diabetic foot ulcers	B-T047
(	O
DFUs	B-T047
).	O
These	O
measures	B-T081
may	O
include	O
padding	B-T061
,	O
insoles	B-T074
/	O
orthotic devices	B-T074
and	O
footwear	B-T073
.	O
There	O
is	O
a	O
lack	O
of	O
evidence	B-T078
-based	O
guidance	O
on	O
the	O
effectiveness	B-T080
of	O
the	O
different	O
offloading	B-T061
options	O
for	O
preventing	B-T061
primary	B-T080
ulceration	B-T047
in	O
those	O
with	O
diabetes	B-T047
.	O
To	O
identify,	O
critically	O
appraise	O
and	O
synthesize	O
the	O
best	O
available	O
evidence	B-T078
on	O
methods	B-T061
of	O
offloading	B-T061
to	O
prevent	B-T061
the	O
development	B-T169
,	O
and	O
reduce	B-T080
the	O
risk	B-T078
,	O
of	O
primary	B-T080
foot ulceration	B-T047
in	O
adults	B-T100
with	O
diabetes	B-T047
.The	O
question	B-T078
addressed	B-T170
by	O
the	O
review	B-T170
was:	O
what	O
is	O
the	O
effectiveness	B-T080
of	O
methods	B-T061
of	O
offloading	B-T061
in	O
preventing	B-T061
primary	B-T080
DFUs	B-T047
in	O
adults	B-T100
with	O
diabetes	B-T047
?	O
Adults	B-T100
18	O
years	B-T079
and	O
older	O
with	O
diabetes mellitus	B-T047
,	O
regardless	O
of	O
age	B-T032
,	O
gender	B-T032
,	O
ethnicity	B-T080
,	O
duration	B-T079
or	O
type	B-T080
of	O
diabetes	B-T047
,	O
with	O
no	O
history	B-T033
of	O
DFUs	B-T047
and	O
in	O
any	O
clinical setting	B-T082
will	O
be	O
included.	O
Interventions	B-T061
will	O
include	O
all	O
external	O
methods	B-T061
of	O
offloading	B-T061
.	O
All	O
comparators	O
will	O
be	O
considered.	O
Studies	B-T062
that	O
utilize	O
interventions	B-T061
not	O
considered	O
usual	B-T080
practice	B-T061
in	O
the	O
prevention	B-T061
of	O
DFUs	B-T047
will	O
be	O
excluded	B-T078
.	O
The	O
primary	B-T080
outcome	B-T169
will	O
be	O
primary	B-T080
foot ulceration	B-T047
.	O
The	O
secondary	B-T081
outcome	B-T169
will	O
be	O
indications	O
of	O
changes	O
in	O
plantar	B-T029
pressure	B-T081
.	O
This	O
review	B-T170
will	O
consider	O
all	O
quantitative	B-T081
study designs	B-T062
.	O
A	O
three-step	O
strategy	O
for	O
published	O
and	O
unpublished	O
literature	B-T170
will	O
be	O
used.	O
Fourteen	O
databases	B-T170
will	O
be	O
searched	O
for	O
studies	B-T062
in	O
English	B-T171
up	O
to	O
November	O
2013.	O
The	O
JBI-MAStARI extraction tool	B-T170
was	O
used	O
to	O
extract	O
relevant	O
data	B-T078
.	O
Results	B-T169
were	O
summarized	B-T170
using	O
narrative	B-UnknownType
and	O
tables	B-T170
.	O
Three	O
studies	B-T062
which	O
examined	O
the	O
effectiveness	B-T080
of	O
four	O
different	O
offloading	B-T061
interventions	B-T061
met	O
the	O
inclusion criteria	B-T080
.	O
There	O
is	O
limited	O
evidence	B-T078
that	O
use	O
of	O
a	O
footwear	B-T073
system	O
(	O
prototype shoe plus polyurethane	B-T073
or	O
cork insole	B-T073
)	O
may	O
prevent	B-T061
a	O
break	O
in	O
the	O
skin	B-T022
;	O
use	O
of	O
customized	O
rigid	O
orthotic devices	B-T074
may	O
contribute	O
to	O
a	O
reduction	B-T080
in	O
the	O
grade	B-T080
and	O
number	B-T081
of	O
calluses	B-T020
;	O
and	O
a	O
manufactured	O
shoe plus	B-T073
customized	O
insole	B-T073
may	O
reduce	O
plantar	B-T029
pressure	B-T081
and	O
therefore	O
reduce	O
the	O
potential	O
risk	B-T078
of	O
skin ulceration	B-T047
.	O
There	O
is	O
limited	O
and	O
low-quality	O
evidence	B-T078
that	O
in	O
a	O
population	B-T098
of	O
adults	B-T100
with	O
diabetes	B-T047
with	O
no	O
history	B-T033
of	O
DFU	B-T047
,	O
the	O
use	O
of	O
footwear	B-T073
with	O
customized	O
or	O
prefabricated	O
orthotic devices	B-T074
may	O
provide	O
some	O
reduction	O
in	O
plantar	B-T029
pressure	B-T081
and	O
therefore	O
help	O
to	O
prevent	B-T061
a	O
primary	B-T080
DFU	B-T047
.	O
There	O
is	O
a	O
lack	O
of	O
evidence	B-T078
on	O
the	O
relative	O
effectiveness	B-T080
of	O
different	O
offloading	B-T061
options.	O

Punch	B-T048
injury	B-T037
self-harm	B-T037
in	O
young people	B-T100
Punch	B-T048
injuries	B-T037
are	O
a	O
form	B-T080
of	O
self-harm	B-T037
characterised	B-T052
by	O
the	O
intentional	B-T080
act of striking	B-T052
an	O
object	B-T072
with	O
a	O
closed	B-T169
fist	B-T072
.	O
We	O
aimed	B-T078
to	O
describe	O
the	O
characteristics	B-T080
and	O
trends	B-T079
in	O
young people	B-T100
presenting	B-T078
with	O
injuries	B-T037
sustained	B-T169
via	O
the	O
punch	B-T048
mechanism	B-T169
.	O
A	O
comprehensive	B-T080
retrospective review	B-T062
of	O
medical records	B-T170
was	O
completed	B-T080
of	O
all	O
young people	B-T100
aged	B-T032
10-18	O
years	B-T079
presenting	B-T078
to	O
our	O
Central London Emergency Department	B-T093
over	O
a	O
12-month period	B-T079
.	O
A	O
subset of the total group	B-T185
was	O
identified	B-T080
as	O
the	O
punch	B-T048
injury	B-T037
subgroup	B-T185
.	O
A	O
total	O
of	O
78	O
punch	B-T048
injury	B-T037
presentations	B-T078
were	O
identified	B-T080
.	O
In	O
this	O
subgroup	B-T185
,	O
the	O
male	B-T032
:	O
female	B-T032
ratio	B-T081
is	O
4.57:1;	O
37.18%	O
of	O
presentations	B-T078
were	O
associated with	B-T080
a	O
fracture	B-T037
(n	O
=	O
29)	O
and	O
35.90%	O
(n	O
=	O
28)	O
of	O
patients	B-T101
re-presented	B-T078
following	O
another	O
punch	B-T048
injury	B-T037
,	O
as	O
a	O
victim of violence	B-T033
,	O
or	O
by	O
other	O
psychiatric	B-T169
presentation	B-T078
.	O
In	O
conclusion	B-T078
,	O
a	O
male preponderance	B-T033
was	O
observed	B-T169
,	O
with	O
frequent	B-T079
re-presentations	B-T078
,	O
often	O
in	O
high-risk	B-T033
circumstances	B-T169
.	O
An	O
opportunity	O
for	O
screening	B-T058
,	O
including	O
mental health	B-T041
,	O
social	B-T169
and	O
substance misuse	B-T033
,	O
was	O
identified	B-T080
.	O
Further	O
research	B-T062
is	O
needed	B-T080
to	O
enable	O
targeted	B-T169
effective	B-T080
interventions	B-T058
in	O
this	O
group	B-T100
.	O

Delayed	B-T079
Recognition	B-T041
of	O
Deterioration	B-T033
of	O
Patients	B-T101
in	O
General Wards	B-T073
Is	O
Mostly	O
Caused	O
by	O
Human	B-T016
Related	O
Monitoring	B-T058
Failures	B-T169
:	O
A	O
Root Cause Analysis	B-T080
of	O
Unplanned	O
ICU Admissions	B-T058
An	O
unplanned	O
ICU admission	B-T058
of	O
an	O
inpatient	B-T101
is	O
a	O
serious adverse event	B-T033
(	O
SAE	B-T033
).	O
So	O
far,	O
no	O
in	O
depth-study	O
has	O
been	O
performed	O
to	O
systematically	O
analyse	O
the	O
root causes	B-T080
of	O
unplanned	O
ICU-admissions	B-T058
.	O
The	O
primary	O
aim	O
of	O
this	O
study	O
was	O
to	O
identify	O
the	O
healthcare worker	B-T097
-,	O
organisational	B-T080
-,	O
technical	B-T097
,-	O
disease	B-T047
-	O
and	O
patient	B-T101
-	O
related	O
causes	O
that	O
contribute	O
to	O
acute	O
unplanned	O
ICU admissions	B-T058
from	O
general wards	B-T073
using	O
a	O
Root-Cause Analysis Tool	B-T080
called	O
PRISMA-medical	B-T058
.	O
Although	O
a	O
Track and Trigger System (MEWS)	B-T057
was	O
introduced	O
in	O
our	O
hospital	B-T073
a	O
few	O
years	O
ago,	O
it	O
was	O
implemented	O
without	O
a	O
clear	O
protocol	B-T061
.	O
Therefore,	O
the	O
secondary	O
aim	O
was	O
to	O
assess	O
the	O
adherence	O
to	O
a	O
Track and Trigger system	B-T057
to	O
identify	O
deterioration	B-T033
on	O
general hospital wards	B-T073
in	O
patients	B-T101
eventually	O
transferred	O
to	O
the	O
ICU	B-T073
.	O
Retrospective observational study	B-T062
in	O
49	O
consecutive	O
adult	O
patients	B-T101
acutely	O
admitted	B-T058
to	O
the	O
Intensive Care Unit	B-T073
from	O
a	O
general nursing ward	B-T058
.	O
1.	O
PRISMA-analysis	B-T062
on	O
root causes	B-T080
of	O
unplanned	O
ICU admissions	B-T058
2.	O
Assessment	O
of	O
protocol	B-T061
adherence	O
to	O
the	O
early warning score system	B-T033
.	O
Out	O
of	O
49	O
cases,	O
156	O
root causes	B-T080
were	O
identified.	O
The	O
most	O
frequent	O
root causes	B-T080
were	O
healthcare worker	B-T097
related	O
(46%),	O
which	O
were	O
mainly	O
failures	B-T169
in	O
monitoring	B-T058
the	O
patient	B-T101
.	O
They	O
were	O
followed	O
by	O
disease	B-T047
-related	O
(45%),	O
patient	B-T101
-related	O
causes	O
(7,	O
5%),	O
and	O
organisational	B-T080
root causes	B-T080
(3%).	O
In	O
only	O
40%	O
of	O
the	O
patients	B-T101
vital parameters	B-T077
were	O
monitored	O
as	O
was	O
instructed	O
by	O
the	O
doctor	B-T097
.	O
477	O
vital parameter	B-T077
sets	O
were	O
found	O
in	O
the	O
48	O
hours	O
before	O
ICU admission	B-T058
,	O
in	O
only	O
1%	O
a	O
correct	O
MEWS	B-T057
was	O
explicitly	O
documented	B-T058
in	O
the	O
record.	O
This	O
in-depth analysis	B-T062
demonstrates	O
that	O
almost	O
half	O
of	O
the	O
unplanned	O
ICU admissions	B-T058
from	O
the	O
general ward	B-T073
had	O
healthcare worker	B-T097
related	O
root causes	B-T080
,	O
mostly	O
due	O
to	O
monitoring	B-T058
failures	B-T169
in	O
clinically deteriorating	B-T033
patients	B-T101
.	O
In	O
order	O
to	O
reduce	O
unplanned	O
ICU admissions	B-T058
,	O
improving	O
the	O
monitoring	B-T058
of	O
patients	B-T101
is	O
therefore	O
warranted.	O

Effects	O
of	O
a	O
novel	O
phosphodiesterase 10A inhibitor	B-T121
in	O
non-human primates	B-T015
:	O
A	O
therapeutic approach	B-T169
for	O
schizophrenia	B-T048
with	O
improved	O
side effect profile	B-T046
Schizophrenia	B-T048
symptoms	B-T184
are	O
associated with	B-T080
alterations in basal ganglia-cortical networks	B-T047
that	O
include	O
the	O
cyclic nucleotides	B-T114
(	O
cAMP	B-T114
/	O
cGMP	B-T114
)	O
signaling pathways	B-T044
.	O
Phosphodiesterase 10A (PDE10A) inhibitors	B-T121
have	O
been	O
considered	O
as	O
therapeutic agents	B-T121
for	O
schizophrenia	B-T048
because	O
the	O
regulation of cAMP	B-T044
and	O
cGMP	B-T044
in	O
the	O
striatum	B-T023
by	O
PDE10A	B-T116
plays	O
an	O
important	O
role	O
in	O
the	O
signaling mechanisms	B-T044
of	O
the	O
striatal-cortical network	B-UnknownType
,	O
and	O
thereby	O
in	O
cognitive function	B-T041
.	O
In	O
the	O
present	O
study	O
we	O
assessed	O
in	O
non-human primates	B-T015
(	O
NHPs	B-T015
)	O
the	O
effects	O
of	O
a	O
novel	O
PDE10A inhibitor	B-T121
(	O
FRM-6308	B-T121
)	O
that	O
has	O
demonstrated	O
high potency	B-T121
and	O
selectivity	O
for	O
human recombinant PDE10A	B-T116
in vitro	B-T062
.	O
The	O
behavioral effects	B-T033
of	O
FRM-6308	B-T121
in	O
a	O
dose range	B-T081
were	O
determined	O
in	O
rhesus monkeys	B-T015
using	O
a	O
standardized motor disability scale	B-T033
for	O
primates	B-T015
,	O
motor tasks	B-T061
,	O
and	O
the	O
"	O
drug effects on the nervous system" (DENS) scale	B-UnknownType
.	O
The	O
neuronal	B-T129
metabolic effects	B-T039
of	O
FRM-6308	B-T121
were	O
determined	O
with	O
[(18)F]-fluorodeoxyglucose PET imaging	B-T060
.	O
Results	O
showed	O
that	O
FRM-6308	B-T121
did	O
not	O
have	O
any	O
specific	O
effects	O
on	O
the	O
motor system	B-UnknownType
at	O
s.c. doses	B-T169
up	O
to	O
0.32	O
mg/kg	O
in	O
NHPs	B-T015
,	O
which	O
induced	O
a	O
significant	O
increase	O
in	O
the	O
FDG	B-T109
-	O
SUV	B-T081
in	O
striatum	B-T023
(F	O
16.069,	O
p	O
<	O
0.05)	O
and	O
cortical	B-T029
(F	O
15.181,	O
p	O
<	O
0.05)	O
regions.	O
Higher doses	B-T081
induced	O
sedation	B-T033
and	O
occasional involuntary movements	B-T184
with	O
clear	O
development	O
of	O
tolerance after repeated exposures	B-T033
.	O
These	O
findings	O
suggest	O
that	O
FRM-6308	B-T121
has	O
the	O
adequate pharmacological profile	B-T061
to	O
advance	O
testing	O
in	O
clinical trials	B-T062
and	O
demonstrate	O
antipsychotic efficacy	B-T039
of	O
PDE10A	B-T116
inhibition	B-T052
for	O
the	O
treatment	B-T169
of	O
schizophrenia	B-T048
patients	B-T101
.	O

Agglomeration	B-T081
of	O
Luminescent	B-T070
Porous	B-T082
Silicon	B-T196
Nanoparticles	B-T073
in	O
Colloidal Solutions	B-T122
We	O
have	O
prepared	B-T033
colloidal solutions	B-T122
of	O
clusters	B-T081
composed	O
from	O
porous	B-T082
silicon	B-T196
nanoparticles	B-T073
in	O
methanol	B-T109
,	O
water	B-T121
and	O
phosphate-buffered saline	B-T167
(	O
PBS	B-T167
).	O
Even	O
if	O
the	O
size	B-T082
of	O
the	O
nanoclusters	B-T081
is	O
between	O
60	O
and	O
500	O
nm,	O
due	O
to	O
their	O
highly	B-T080
porous	B-T082
"cauliflower"-like structure	B-T082
,	O
the	O
porous	B-T082
silicon	B-T196
nanoparticles	B-T073
are	O
composed	O
of	O
interconnected	B-T082
nanocrystals	B-T073
having	O
around	O
2.5	O
nm	O
in	O
size	B-T082
and	O
showing	O
strong	B-T080
visible	B-T080
luminescence	B-T070
in	O
the	O
orange	B-T080
-	O
red	B-T080
spectral	B-T077
region	B-T082
(centred	O
at	O
600-700	O
nm).	O
Hydrophilic behaviour	B-T080
and	O
good	B-T080
solubility	B-T080
of	O
the	O
nanoclusters	B-T081
in	O
water	B-T121
and	O
water	B-T121
-	O
based	B-T078
solutions	B-T167
were	O
obtained	B-T169
by	O
adding	O
hydrogen peroxide	B-T121
into	O
the	O
etching	B-T070
solution	B-T167
during	O
preparation	B-T052
and	O
16	O
min	O
long	O
after-bath	B-T169
in	O
hydrogen peroxide	B-T121
.	O
By	O
simple	B-T080
filtration	B-T068
of	O
the	O
solutions	B-T167
with	O
syringe filters	B-T074
,	O
we	O
have	O
extracted	B-T080
smaller	B-T081
nanoclusters	B-T081
with	O
sizes	B-T082
of	O
approx	B-T080
.	O
60-70	O
nm;	O
however,	O
these	O
nanoclusters	B-T081
in	O
water	B-T121
and	O
PBS solution	B-T167
(	O
pH neutral	B-T080
)	O
are	O
prone	B-T169
to	O
agglomeration	B-T081
,	O
as	O
was	O
confirmed	B-T033
by	O
zeta potential	B-T067
measurements	B-T169
.	O
When	O
the	O
samples	B-T167
were	O
left	O
at	O
ambient conditions	B-T080
for	O
several	B-T081
weeks,	O
the	O
typical	B-T080
nanocluster	B-T081
size	B-T082
increased	B-T081
to	O
approx	B-T080
.	O
330-400	O
nm	O
and	O
then	O
remained	O
stable	B-T080
.	O
However,	O
both	O
freshly	B-T080
filtered	B-T077
and	O
aged	B-T079
samples	B-T167
(with	O
agglomerated	B-T081
porous	B-T082
silicon	B-T196
nanoparticles	B-T073
)	O
of	O
porous	B-T082
silicon	B-T196
in	O
water	B-T121
and	O
PBS solutions	B-T167
can	O
be	O
further	O
used	O
for	O
biological	B-T080
studies	B-T062
or	O
as	O
luminescent	B-T070
markers	B-T201
in	O
living cells	B-T025
.	O

Development	B-T169
of	O
a	O
liquid chromatography-tandem mass spectrometry	B-T059
method	B-T169
for	O
quantitative analysis	B-UnknownType
of	O
trace	B-T081
d-amino acids	B-T116
d-Amino acids	B-T116
have	O
recently	B-T079
attracted	O
much	O
attention	B-T041
in	O
various	O
research fields	B-T062
including	B-T169
medical	B-T169
,	O
clinical	B-T080
and	O
food industry	B-T057
due	O
to	O
their	O
important	B-T080
biological functions	B-T038
that	O
differ	O
from	O
l-amino acid	B-T116
.	O
Most	O
chiral	B-T067
amino acid	B-T116
separation	B-T059
techniques	B-T169
require	B-T169
complicated	B-T169
derivatization	B-T067
procedures	B-T169
in	O
order	O
to	O
achieve	O
the	O
desirable	B-T080
chromatographic	B-T080
behavior	O
and	O
detectability	B-T033
.	O
Thus,	O
the	O
aim	B-T078
of	O
this	O
research	B-T062
is	O
to	O
develop	B-T169
a	O
highly sensitive	B-T080
analytical method	B-T170
for	O
the	O
enantioseparation	B-T059
of	O
chiral	B-T067
amino acids	B-T116
without	O
any	O
derivatization	B-T067
process	B-T067
using	O
liquid chromatography-tandem mass spectrometry	B-T059
(	O
LC-MS/MS	B-T059
).	O
By	O
optimizing	B-T052
MS/MS	B-T059
parameters	B-T077
,	O
we	O
established	B-T080
a	O
quantification	B-T081
method	B-T169
that	O
allowed	O
the	O
simultaneous	B-T079
analysis	B-T062
of	O
18	O
d-amino acids	B-T116
with	O
high sensitivity	B-T067
and	O
reproducibility	B-T080
.	O
Additionally,	O
we	O
applied	B-T169
the	O
method	B-T169
to	O
food sample	B-T167
(	O
vinegar	B-T109
)	O
for	O
the	O
validation	B-T062
,	O
and	O
successfully	O
quantified	B-T081
trace levels	B-T081
of	O
d-amino acids	B-T116
in	O
samples	B-T167
.	O
These	O
results	B-T034
demonstrated	O
the	O
applicability	B-T080
and	O
feasibility	B-T080
of	O
the	O
LC-MS/MS	B-T059
method	B-T169
as	O
a	O
novel	B-T080
,	O
effective	B-T080
tool	O
for	O
d-amino acid	B-T116
measurement	B-T169
in	O
various	O
biological samples	B-T077
.	O

The	O
Multi-center Evaluation of the Accuracy of the Contrast MEdium INduced Pd/Pa RaTiO	B-T170
in	O
Predicting	O
FFR	B-T201
(	O
MEMENTO	B-T170
-	O
FFR	B-T201
)	O
Study	B-T062
Adenosine	B-T114
administration	B-T061
is	O
needed	O
for	O
the	O
achievement	O
of	O
maximal	B-T080
hyperaemia	B-T047
fractional flow reserve	B-T201
(	O
FFR	B-T201
)	O
assessment	B-T058
.	O
The	O
objective	O
was	O
to	O
test	O
the	O
accuracy	B-T080
of	O
Pd	B-T034
/	O
Pa	B-T034
ratio	B-T081
registered	O
during	O
submaximal	B-T080
hyperaemia	B-T047
induced	O
by	O
non-ionic contrast medium	B-T130
(	O
contrast FFR	B-T201
[	O
cFFR	B-T201
])	O
in	O
predicting	O
FFR	B-T201
and	O
comparing	O
it	O
to	O
the	O
performance	O
of	O
resting	B-T033
Pd	B-T034
/	O
Pa	B-T034
in	O
a	O
collaborative	B-T062
registry	O
of	O
926	O
patients	B-T101
enrolled	O
in	O
10	O
hospitals	B-T073
from	O
four	B-T081
European countries	B-UnknownType
(	O
Italy	B-T083
,	O
Spain	B-T083
,	O
France	B-T083
and	O
Portugal	B-T083
).	O
Resting	B-T033
Pd	B-T034
/	O
Pa	B-T034
,	O
cFFR	B-T201
and	O
FFR	B-T201
were	O
measured	O
in	O
1,026	O
coronary stenoses	B-T047
functionally	B-T169
evaluated	O
using	O
commercially	O
available	O
pressure wires	B-T074
.	O
cFFR	B-T201
was	O
obtained	O
after	O
intracoronary injection	B-T169
of	O
contrast medium	B-T130
,	O
while	O
FFR	B-T201
was	O
measured	O
after	O
administration	B-T061
of	O
adenosine	B-T114
.	O
Resting	B-T033
Pd	B-T034
/	O
Pa	B-T034
and	O
cFFR	B-T201
were	O
significantly	O
higher	B-T080
than	O
FFR	B-T201
(0.93±0.05	O
vs.	O
0.87±0.08	O
vs.	O
0.84±0.08,	O
p<0.001).	O
A	O
strong	O
correlation	B-T080
and	O
a	O
close	O
agreement	O
at	O
Bland-Altman analysis	B-T170
between	O
cFFR	B-T201
and	O
FFR	B-T201
were	O
observed	O
(r=0.90,	O
p<0.001	O
and	O
95%	O
CI	B-T081
of	O
disagreement:	O
from	O
-0.042	O
to	O
0.11).	O
ROC curve	B-T081
analysis	B-T062
showed	O
an	O
excellent	O
accuracy	B-T080
(89%)	O
of	O
the	O
cFFR	B-T201
cut-off	O
of	O
≤0.85	O
in	O
predicting	O
an	O
FFR	B-T201
value	O
≤0.80	O
(AUC	O
0.95	O
[95%	O
CI	B-T081
:	O
0.94-0.96]),	O
significantly	O
better	O
than	O
that	O
observed	O
using	O
resting	B-T033
Pd	B-T034
/	O
Pa	B-T034
(AUC:	O
0.90,	O
95%	O
CI	B-T081
:	O
0.88-0.91;	O
p<0.001).	O
A	O
cFFR	B-T201
/	O
FFR	B-T201
hybrid approach	B-T170
showed	O
a	O
significantly	O
lower	B-T080
number	O
of	O
lesions	B-T033
requiring	O
adenosine	B-T114
than	O
a	O
resting	B-T033
Pd	B-T034
/	O
Pa	B-T034
/	O
FFR	B-T201
hybrid approach	B-T170
(22%	O
vs.	O
44%,	O
p<0.0001).	O
cFFR	B-T201
is	O
accurate	B-T080
in	O
predicting	O
the	O
functional	B-T169
significance	O
of	O
coronary stenosis	B-T047
.	O
This	O
could	O
allow	O
limiting	O
the	O
use	O
of	O
adenosine	B-T114
to	O
obtain	O
FFR	B-T201
to	O
a	O
minority	O
of	O
stenoses	B-T046
with	O
considerable	O
savings	O
of	O
time	B-T079
and	O
costs	B-T081
.	O

Transfemoral aortic valve implantation	B-T061
with	O
the	O
repositionable Lotus valve	B-T074
for	O
treatment	B-T061
of	O
patients	B-T101
with	O
symptomatic	B-T169
severe	B-T080
aortic stenosis	B-T047
:	O
results	B-T169
from	O
a	O
single-centre experience	B-T041
The	O
aim	O
of	O
the	O
study	B-T062
was	O
to	O
evaluate	B-T058
the	O
procedural	O
and	O
30-	O
day	B-T079
results	B-T169
for	O
the	O
repositionable Lotus valve	B-T074
in	O
patients	B-T101
undergoing	O
transfemoral aortic valve implantation	B-T061
in	O
a	O
single-centre experience	B-T041
.	O
We	O
prospectively	O
enrolled	O
110	O
patients	B-T101
with	O
severe	B-T080
symptomatic	B-T169
aortic stenosis	B-T047
(	O
NCT02162069	B-T170
).	O
All	O
procedures	B-T169
were	O
performed	O
without	O
general anaesthesia	B-T061
by	O
the	O
transfemoral approach	B-T061
.	O
Patients	B-T101
were	O
followed	O
for	O
30	O
days	B-T079
.	O
Patients	B-T101
received	B-T080
the	O
23	O
mm	O
(n=20),	O
25	O
mm	O
(n=43)	O
or	O
27	O
mm	O
(n=47)	O
Lotus device	B-T074
.	O
Mean oversizing	B-T081
in	O
relation	O
to	O
annulus	B-T026
or	O
left ventricular outflow tract	B-T023
(	O
LVOT	B-T023
)	O
did	O
not	O
differ	O
among	O
groups	B-T078
.	O
There	O
was	O
no residual	B-UnknownType
moderate	B-T080
or	O
severe	B-T080
aortic regurgitation	B-T047
.	O
The	O
rate of mild aortic regurgitation	B-T081
aortic regurgitation	B-T047
was	O
low	O
at	O
9.1%.	O
There	O
was	O
no	O
valve	B-T023
embolisation	B-T061
,	O
no	O
need	O
for	O
a	O
second	B-T081
valve	B-T023
and	O
no conversion	B-T033
to	O
surgery	B-T061
.	O
The	O
need	O
for	O
a	O
new	O
pacemaker implantation	B-T061
due	O
to	O
complete	B-T047
(	O
third degree	B-T047
)	O
or	O
type II (Mobitz) second degree atrioventricular block	B-T047
was	O
24.1%,	O
excluding	O
patients	B-T101
with	O
previously	O
implanted devices	B-T061
.	O
Within	O
30	O
days	B-T079
the	O
rates	B-T081
of	O
all-cause mortalit	B-T081
y	O
and	O
stroke	B-T047
were	O
low	B-T080
.	O
In	O
patients	B-T101
with	O
severe	B-T080
aortic stenosis	B-T047
,	O
transfemoral TAVI	B-T061
with	O
the	O
repositionable Lotus valve	B-T074
was	O
associated with	B-T080
a	O
high	B-T080
rate	B-T081
of	O
device	B-T074
success	B-T080
,	O
no	O
moderate	B-T080
or	O
severe	B-T080
residual	B-T080
aortic regurgitation	B-T047
,	O
low	B-T080
rates	B-T081
of	O
major	B-T080
vascular complications	B-T047
and	O
mortality	B-T081
within	O
30	O
days	B-T079
.	O

A	O
Comparison	B-T052
Between	O
Measured	B-T080
Concentration	B-T081
of	O
3H	B-T196
in	O
Kalpakkam Environment	B-UnknownType
with	O
Predicted Atmospheric Dispersion Model	B-T075
The	O
field	B-T082
measurements	B-T169
of	O
3H	B-T196
in	O
the	O
form	O
of	O
HTO	B-T197
present	O
in	O
air	B-T070
moisture	B-T167
carried	O
out	O
around	O
Madras Atomic Power Station	B-T073
were	O
compared	B-T052
with	O
predicted	O
values	O
using	O
atmospheric dispersion modeling	B-T075
.	O
Air 3H samples	B-T167
were	O
collected	B-T078
from	O
different	O
sectors	B-T083
at	O
the	O
site	B-T082
boundary	B-T185
of	O
the	O
operating	B-T052
reactors	B-T073
for	O
the	O
period	B-T079
of	O
2	O
y	B-T079
and	O
compared	B-T052
with	O
Gaussian Plume model	B-T075
.	O
The	O
predictions	B-T078
were	O
comparable	O
with	O
the	O
measured	B-T080
value	B-T081
.	O
The	O
slight	B-T080
variation	B-T080
observed	B-T169
between	O
the	O
two	O
methods	B-T170
is	O
attributed	O
to	O
the	O
uncertainty	B-T033
involved	O
in	O
the	O
measurement	B-T169
of	O
air	B-T167
3H	B-T196
concentration	B-T081
and	O
in	O
the	O
measurement	B-T169
of	O
site-specific	B-T082
meteorological parameters	B-T070
.	O
The	O
radiation dose	B-T081
imparted	B-T169
to	O
members of public	B-T092
due	O
to	O
the	O
levels	B-T080
observed	B-T169
is	O
well	O
within	O
station	B-T073
technical specification limit	B-T169
for	O
3H	B-T196
.	O

The	O
four-component	O
aureocin A70	B-T116
as	O
a	O
promising agent	B-T120
for	O
food biopreservation	B-T057
Aureocin A70	B-T116
is	O
the	O
only	O
four-component	O
bacteriocin	B-T116
described	O
to	O
date.	O
As	O
it	O
inhibits the growth	B-T040
of	O
a	O
wide	O
range	O
of	O
Gram-positive bacteria	B-T007
,	O
including	O
Listeria monocytogenes	B-T007
strains	B-T001
isolated	O
from	O
food	B-T168
,	O
its	O
potential	O
for	O
improving	O
food safety	B-T057
was	O
investigated	O
in	O
this	O
study.	O
Aureocin A70	B-T116
(10,240AU/mL)	O
proved	O
to	O
be	O
bactericidal	B-T195
,	O
but	O
not	O
extensively	O
lytic	B-T080
,	O
against	O
listerial	B-T007
strains	B-T001
.	O
The	O
antibacterial activity	B-T052
of	O
aureocin A70	B-T116
(16AU/mL)	O
was	O
then	O
tested	O
in	O
UHT-treated	B-T061
skimmed milk	B-T168
inoculated	B-T059
with	O
the	O
food	B-T168
-associated	O
L. monocytogenes L12 strain	B-T007
(4-log	O
CFU/mL)	O
during	O
storage	B-T169
at	O
4°C	O
for	O
one	O
week.	O
Aureocin A70	B-T116
caused	O
a	O
time-dependent	O
reduction	B-T070
in	O
the	O
listerial	B-T007
viable cell counts	B-T059
(5.51-log	O
units)	O
up	O
to	O
7days	O
of	O
incubation	B-T059
.	O
Aureocin A70	B-T116
was	O
neither	O
toxic	B-T080
to	O
the	O
Vero	B-T025
and	O
the	O
L-929 cell lines	B-T025
nor	O
exhibited	O
a	O
hemolytic activity	B-T049
against	O
sheep	B-T015
red blood cells	B-T025
.	O
Aureocin A70	B-T116
proved	O
to	O
be	O
completely	O
stable	O
for	O
one	O
month	O
at	O
25°C,	O
16weeks	O
at	O
4°C	O
and	O
20weeks	O
at	O
-20°C.	O
Aureocin A70	B-T116
exhibited	O
a	O
time-dependent	O
susceptibility	B-T081
to	O
simulated	B-T070
gastric juice	B-T031
and	O
bile salts	B-T109
mimicking	O
gastrointestinal conditions	B-T033
.	O
The	O
entrapment	B-T044
of	O
aureocin A70	B-T116
in	O
an	O
alginate	B-T109
/	O
gelatin matrix	B-T116
revealed	O
that	O
this	O
bacteriocin	B-T116
can	O
be	O
released	O
from	O
this	O
matrix.	O
Moreover,	O
it	O
remained	O
adsorbed	O
to	O
and	O
active	O
on	O
a	O
low-density polyethylene plastic	B-T109
surface	O
suggesting	O
that	O
aureocin A70	B-T116
may	O
be	O
employed	O
in	O
bioactive	B-T167
packaging	B-T052
to	O
control the growth	B-T040
of	O
undesirable	O
bacteria	B-T007
.	O
Taken	O
together	O
these	O
results	O
suggest	O
that	O
aureocin A70	B-T116
is	O
a	O
promising alternative	B-T120
to	O
be	O
used	O
in	O
food applications	B-T057
.	O

Folate	B-T109
-	O
conjugated	B-T082
gene	B-T028
-	O
carrying	B-T045
microbubbles	B-T074
with	O
focused ultrasound	B-T061
for	O
concurrent	B-T079
blood-brain barrier	B-T023
opening	B-T082
and	O
local	B-T082
gene delivery	B-T045
Previous	B-T079
studies	B-T062
have	O
demonstrated	O
that	O
circulating	B-T169
DNA	B-T114
-	O
encapsulated	B-T080
microbubbles	B-T074
(	O
MBs	B-T074
)	O
combined	B-T080
with	O
focused ultrasound	B-T061
(	O
FUS	B-T061
)	O
can	O
be	O
used	B-T169
for	O
local	B-T082
blood-brain barrier	B-T023
(	O
BBB	B-T023
)	O
opening	B-T082
and	O
gene delivery	B-T045
.	O
However,	O
few	O
studies	B-T062
focused	B-T169
on	O
how	O
to	O
increase	B-T169
the	O
efficiency	B-T081
of	O
gene delivery	B-T045
to	O
brain tumors	B-T191
after	O
the	O
released	B-T169
gene	B-T028
penetrating	B-T169
the	O
BBB	B-T023
.	O
Here,	O
we	O
proposed	O
the	O
use of	B-T169
folate	B-T109
-	O
conjugated	O
DNA	O
-	O
loaded	O
cationic MBs	B-T074
(	O
FCMBs	B-T074
).	O
When	O
combined	B-T080
with	O
FUS	B-T061
as	O
a	O
trigger	B-T080
for	O
BBB	B-T023
opening,	O
FCMBs	B-T074
were	O
converted	O
into	O
nanometer	B-T081
-	O
sized	B-T082
vesicles	B-T026
that	O
were	O
transported	B-T043
to	O
the	O
brain	B-T023
parenchyma	B-T023
.	O
The	O
FCMBs	B-T074
can	O
selectively	O
aggregate	B-T080
around	O
tumor cells	B-T025
that	O
overexpressed	B-T045
the	O
folate receptor	B-T116
,	O
thus	O
enhancing	B-T052
gene delivery	B-T045
via	O
folate	B-T116
-	O
stimulated	B-T070
endocytosis	B-T043
.	O
Our	O
results	B-T169
confirmed	B-T080
that	O
FCMBs	B-T074
can	O
carry	B-T045
DNA	B-T114
on	O
the	O
surface	B-T082
of	O
the	O
MB	B-T074
shell	B-T080
and	O
have	O
good	B-T080
targeting	B-T169
ability	B-T081
on	O
C6 glioma cells	B-T025
.	O
In	O
addition,	O
the	O
optimized	O
FUS	B-T061
parameters	B-T077
for	O
FCMBs	B-T074
-	O
enhanced	B-T052
gene delivery	B-T045
were	O
confirmed by	B-T080
cell	B-T025
experiments	B-T062
(	O
center frequency	B-T081
=	O
1	O
MHz;	O
acoustic pressure	B-T081
=	O
700	O
kPa;	O
pulse	B-T067
repetition	B-T169
frequency	B-T081
=	O
5	O
Hz;	O
cycle	B-T079
number	B-T081
=	O
10000;	O
exposure	B-T080
time	B-T079
=	O
1	O
min;	O
FCMBs	B-T074
concentration	B-T081
=	O
4	O
×	O
10(7)	O
MB/mL).	O
In vivo	B-T082
data	B-T078
also	O
indicated	B-T033
that	O
FCMBs	B-T074
show	O
better	B-T080
gene	B-T028
transfection	B-T045
efficiency	B-T081
than	O
MBs	B-T074
without	B-T080
folate	B-T116
conjugation	B-T043
and	O
the	O
traditional	B-T169
approach	B-T082
of	O
directly	B-T080
injecting	B-T061
the	O
gene	B-T028
.	O
This	O
study	B-T062
described	O
our	O
novel	B-T080
development	B-T169
of	O
multifunctional	B-T169
MBs	B-T074
for	O
FUS	B-T061
-	O
triggered	B-T080
gene delivery	B-T045
/	O
therapy	B-T061
.	O

Modulation	B-T082
of	O
IL-6	B-T116
induced	B-T169
RANKL	B-T116
expression	B-T045
in	O
arthritic	B-T047
synovium	B-T023
by	O
a	O
transcription factor SOX5	B-T116
Receptor activator of nuclear factor κB ligand	B-T116
(	O
RANKL	B-T116
)	O
is	O
critically	B-T080
involved	O
in	O
bone erosion	B-T046
of	O
rheumatoid arthritis	B-T047
(	O
RA	B-T047
).	O
We	O
previously	B-T079
reported	O
association	O
between	O
younger age	B-T032
at	O
onset	O
of	O
RA	B-T047
and	O
a	O
RANKL	B-T116
promoter	O
SNP	B-T086
that	O
conferred	O
an	O
elevated	B-T080
promoter	O
activity	O
via	O
binding	B-T052
to	O
a	O
transcription factor SOX5	B-T116
.	O
Here	O
we	O
study	B-T062
the	O
regulation	B-T043
of	O
SOX5	B-T116
levels	O
in	O
relation	O
to	O
RANKL	B-T116
expression	B-T045
in	O
RA	B-T047
synovial	B-T023
fibroblasts	B-T025
(	O
SF	B-T025
)	O
and	O
the	O
development	B-T169
of	O
bone erosion	B-T046
in	O
the	O
collagen-induced arthritis	B-T050
(	O
CIA	B-T050
)	O
mouse	B-T015
.	O
Our	O
data	B-T170
indicated	B-T033
SOX5	B-T116
levels	O
were	O
higher	O
in	O
synovium	B-T023
and	O
synovial fluid	B-T031
from	O
RA	B-T047
compared	B-T052
to	O
osteoarthritis	B-T047
patients	B-T101
.	O
Pro-inflammatory	B-T169
cytokines	B-T116
upregulated	B-T044
SOX5	B-T116
and	O
RANKL	B-T116
expression	B-T045
in	O
both	O
primary	O
RA	B-T047
SF	B-T025
and	O
the	O
rheumatoid	O
synovial	O
fibroblast cell line	B-UnknownType
,	O
MH7A	B-T025
.	O
Overexpression	B-T045
of	O
SOX5	B-T116
resulted	B-T169
in	O
significantly increased	B-T081
RANKL	B-T116
levels,	O
while	O
knockdown	B-T063
of	O
SOX5	B-T028
resulted	B-T169
in	O
diminished	B-T081
IL-6	B-T116
mediated	O
RANKL	B-T116
upregulation	B-T044
in	O
MH7A cells	B-T025
.	O
Chromatin immunoprecipitation	B-T059
(	O
ChIP	B-T059
)	O
showed	O
approximately	B-T080
3-fold	O
enrichment	O
of	O
RANKL-specific DNA	B-T114
in	O
anti-SOX5 immunoprecipitate	B-T129
in	O
IL-6	B-T116
treated	B-T169
MH7A cells	B-T025
as	O
compared	B-T052
to	O
untreated cells	B-T033
.	O
Locally	O
silencing	B-T045
SOX5 gene	B-T028
significantly diminished	B-T081
RANKL	B-T116
positive	B-T033
cells	B-T025
and	O
bone erosion	B-T046
in	O
CIA	B-T050
mice	B-T015
.	O
These	O
findings	B-T033
suggest	B-T078
SOX5	B-T116
is	O
an	O
important	O
regulator	B-T077
of	O
IL-6	B-T116
-	O
induced	B-T169
RANKL	B-T116
expression	B-T045
in	O
RA	B-T047
SF	B-T025
.	O

Intracameral	B-T082
cefuroxime	B-T109
in	O
the	O
prevention	B-T061
of	O
postoperative endophthalmitis	B-T047
:	O
an	O
experience	B-T041
from	O
Hong Kong	B-T083
The	O
purpose	O
was	O
to	O
study	B-T062
the	O
effect	B-T080
of	O
introducing	B-T169
intracameral	B-T082
cefuroxime	B-T109
,	O
which	O
was	O
compounded	B-T058
by	O
a	O
hospital pharmacy	B-T093
,	O
on	O
postoperative endophthalmitis	B-T047
in	O
a	O
tertiary eye centre	B-T093
in	O
Hong Kong	B-T083
.	O
All	O
cases	O
that	O
underwent	O
cataract surgeries	B-T061
over	O
a	O
12-year	O
period	O
(January	O
2004	O
to	O
December	O
2015)	O
were	O
included.	O
The	O
routine	B-T080
use	B-T169
of	O
intracameral	B-T082
cefuroxime	B-T109
at	O
the	O
end	O
of	O
cataract surgery	B-T061
was	O
introduced	O
at	O
our	O
centre	O
after	O
April	O
2010.	O
All	O
cefuroxime	B-T109
aliquots	B-T081
were	O
prepared	O
by	O
the	O
hospital pharmacy	B-T093
using	O
an	O
aseptic	B-T080
aseptic compounding	B-T058
technique.	O
The	O
rates	B-T081
of	O
postoperative endophthalmitis	B-T047
before	O
April	O
2010	O
(	O
Group	B-UnknownType
1,	O
no	B-T169
intracameral	B-T082
cefuroxime	B-T109
)	O
and	O
after	O
April	O
2010	O
(	O
Group	B-UnknownType
2,	O
routine	O
use	O
of	O
intracameral	B-T082
cefuroxime	B-T109
)	O
were	O
compared.	O
A	O
total	O
of	O
30,428	O
eyes	B-T023
(7,332	O
in	O
Group	B-UnknownType
1	O
and	O
23,096	O
in	O
Group	B-UnknownType
2)	O
were	O
studied.	O
Eight	O
cases	O
developed	O
postoperative endophthalmitis	B-T047
(1.09	O
in	O
1000;	O
0.11	O
%)	O
in	O
Group	B-UnknownType
1	O
whereas	O
no	O
cases	O
developed	O
endophthalmitis	B-T047
(0	O
%)	O
in	O
Group	B-UnknownType
2.	O
The	O
rate	B-T081
of	O
reduction	B-T080
was	O
statistically significant	B-T081
(p	O
<	O
0.0001).	O
Seven	O
out	O
of	O
eight	O
cases	O
of	O
endophthalmitis	B-T047
were	O
confirmed	O
by	O
positive culture	B-T033
.	O
Organisms	B-T001
identified	O
were	O
Group G Streptococcus	B-T007
(two	O
cases),	O
Group B Streptococcus	B-T007
,	O
Staphylococcus aureus	B-T007
,	O
Serratia marcescens	B-T007
,	O
and	O
coagulase-negative Staphylococcus	B-T007
(two	O
cases).	O
Antibiotic susceptibility	B-T033
testing results	B-T034
were	O
available	O
in	O
six	O
cases.	O
Four	O
out	O
of	O
six	O
organisms	B-T001
were	O
susceptible	B-T169
to	O
the	O
penicillin group	B-T109
.	O
No adverse events	B-T033
related	O
to	O
the	O
use	B-T169
of	O
intracameral	B-T082
cefuroxime	B-T109
were	O
encountered.	O
The	O
use	B-T169
of	O
intracameral	B-T082
cefuroxime	B-T109
could	O
significantly	O
reduce	B-T081
the	O
rate	B-T081
of	O
postoperative endophthalmitis	B-T047
in	O
a	O
tertiary centre	B-T093
in	O
Hong Kong	B-T083
.	O
The	O
use	B-T169
of	O
aseptic	B-T080
aseptic compounding	B-T058
to	O
prepare	O
cefuroxime	B-T109
aliquots	B-T081
by	O
hospital pharmacy	B-T093
appeared	O
to	O
be	O
safe	O
and	O
efficacious.	O

A	O
standardized	O
approach	O
for	O
the	O
assessment	B-T058
and	O
treatment	B-T061
of	O
internationally	B-T078
adopted children	B-T099
with	O
a	O
previously	O
repaired	O
anorectal malformation	B-T190
(	O
ARM	B-T190
)	O
A	O
significant	O
number	O
of	O
internationally	B-T078
adopted children	B-T099
have	O
congenital birth defects	B-T019
.	O
As	O
a	O
specialist	O
center	O
for	O
colorectal	B-T082
diagnoses	B-T060
,	O
we	O
evaluate	O
such	O
children	B-T100
with	O
an	O
anorectal malformation	B-T190
(	O
ARM	B-T190
)	O
and	O
have	O
found	O
that	O
a	O
significant	O
number	O
need	O
a	O
reoperation	B-T061
.	O
Knowledge	B-T033
of	O
the	O
common	O
complications	B-T046
following	O
ARM	B-T190
surgery	B-T061
has	O
led	O
us	O
to	O
develop	O
treatment	B-T061
algorithms	B-T170
for	O
patients	B-T101
with	O
unknown	O
past medical	B-T033
and	O
surgical history	B-T033
,	O
a	O
situation	O
typically	O
encountered	O
in	O
the	O
adopted	B-T033
population	B-T098
.	O
The	O
results	O
of	O
investigations	B-T058
,	O
indications	B-T078
,	O
and	O
rate	B-T081
of	O
reoperation	B-T061
were	O
assessed	O
for	O
adopted children	B-T099
with	O
an	O
ARM	B-T190
evaluated	O
between	O
2014	O
and	O
2016.	O
56	O
patients	B-T101
(28	O
males	B-T032
)	O
were	O
identified.	O
76.8%	O
required	O
reoperative surgery	B-T061
.	O
Mislocation	O
of	O
the	O
anus	B-T023
outside	B-T082
the	O
sphincter	B-T023
complex	O
was	O
seen	O
in	O
50%	O
of	O
males	B-T032
and	O
39.3%	O
of	O
females	B-T032
.	O
Anal stricture	B-T019
,	O
rectal prolapse	B-T047
,	O
retained	B-T169
vaginal septum	B-T019
,	O
and	O
a	O
strictured	B-T046
vaginal introitus	B-T030
were	O
also	O
common.	O
The	O
reoperative surgery	B-T061
rate	B-T081
in	O
the	O
internationally	B-T078
adopted child	B-T099
with	O
an	O
ARM	B-T190
is	O
high.	O
Complete,	O
systematic	O
evaluation	O
of	O
these	O
children	B-T100
is	O
required	O
to	O
identify	O
complications	B-T046
following	O
initial	O
repair	B-T058
.	O
Development	O
of	O
mechanisms	O
to	O
improve	O
the	O
primary	O
surgical care	B-T058
these	O
children	B-T100
receive	O
is	O
needed.	O

Highly	O
fluorescent	B-T070
gold	B-T121
nanoclusters	B-T073
stabilized	O
by	O
food proteins	B-T116
:	O
From	O
preparation	O
to	O
application	O
in	O
detection	B-T061
of	O
food	B-T168
contaminants	B-T167
and	O
bioactive nutrients	B-T167
Applications	O
of	O
nanotechnology	B-T090
in	O
food	B-T168
have	O
rapidly	O
increased	O
in	O
the	O
past	O
decades.	O
Ultra-small gold nanoclusters	B-T073
(	O
Au NCs	B-T073
),	O
composed	O
of	O
several	O
to	O
roughly	O
a	O
hundred	O
atoms,	O
represent	O
a	O
kind	O
of	O
novel	O
nanomaterials	B-T073
.	O
The	O
Au NCs	B-T073
directed	O
by	O
food proteins	B-T116
have	O
drawn	O
considerable	O
research	O
attention	O
due	O
to	O
their	O
environmentally friendly preparation	B-T057
,	O
strong	O
fluorescence	B-T070
,	O
excellent	O
photo-stability	B-T080
and	O
favorable	O
biocompatibility	B-T044
.	O
These	O
interesting	O
protein-Au hybrids	B-T073
have	O
opened	O
up	O
a	O
new	O
area	O
at	O
the	O
nano-bio-food interface	B-T093
,	O
not	O
only	O
did	O
they	O
provide	O
the	O
missing	O
link	O
between	O
single metal atoms	B-T196
and	O
plasmonic	B-T062
metal nanoparticles	B-T073
,	O
but	O
also	O
developed	O
the	O
hybrid system	B-T122
between	O
biomacromolecule	B-T167
and	O
inorganic	B-T077
ions	B-T196
.	O
In	O
this	O
review,	O
we	O
highlighted	O
the	O
synthesis	B-T052
strategies	O
and	O
optical properties	B-T080
of	O
the	O
Au NCs	B-T073
stabilized	O
by	O
typical	O
food proteins	B-T116
as	O
well	O
as	O
their	O
applications	O
in	O
detection	B-T061
of	O
food	B-T168
contaminants	B-T167
or	O
bioactive nutrients	B-T167
.	O
In	O
addition,	O
we	O
discussed	O
current	O
challenges	O
and	O
future	O
development	O
in	O
food proteins	B-T116
directed	O
gold nanoclusters	B-T073
for	O
size-controlled	O
synthesis	B-T052
and	O
multifunctional	O
applications.	O

Sub-lethal effects	B-T033
of	O
dietary	B-T168
neonicotinoid insecticide	B-T131
exposure	B-T080
on	O
honey bee queen	B-T204
fecundity	B-T040
and	O
colony	B-T025
development	B-T039
Many	O
factors	B-T169
can	O
negatively	B-T033
affect	O
honey bee	B-T204
(	O
Apis mellifera L.	B-T204
)	O
health	B-T078
including	O
the	O
pervasive	B-T082
use	O
of	O
systemic	B-T169
neonicotinoid insecticides	B-T131
.	O
Through	O
direct	O
consumption	B-T039
of	O
contaminated	B-T169
nectar	B-T123
and	O
pollen	B-T002
from	O
treated	B-T169
plants	B-T002
,	O
neonicotinoids	B-T131
can	O
affect	O
foraging	B-T055
,	O
learning	B-T041
,	O
and	O
memory	B-T041
in	O
worker bees	B-T204
.	O
Less	O
well	O
studied	O
are	O
the	O
potential	O
effects	O
of	O
neonicotinoids	B-T131
on	O
queen bees	B-T204
,	O
which	O
may	O
be	O
exposed	O
indirectly	O
through	O
trophallaxis	B-T054
,	O
or	O
food	B-T168
-	O
sharing	B-T054
.	O
To	O
assess	B-T058
effects	O
on	O
queen	B-T204
productivity	B-T081
,	O
small	B-T081
colonies	B-T025
of	O
different	O
sizes	B-T082
(1500,	O
3000,	O
and	O
7000	O
bees	B-T204
)	O
were	O
fed	B-T052
imidacloprid	B-T109
(0,	O
10,	O
20,	O
50,	O
and	O
100	O
ppb)	O
in	O
syrup	B-T168
for	O
three	O
weeks	B-T079
.	O
We	O
found	O
adverse effects	B-T046
of	O
imidacloprid	B-T109
on	O
queens	B-T204
(	O
egg-laying	B-T040
and	O
locomotor activity	B-T040
),	O
worker bees	B-T204
(	O
foraging	B-T055
and	O
hygienic	B-T091
activities	B-T052
),	O
and	O
colony	B-T025
development	B-T040
(	O
brood	B-T204
production	O
and	O
pollen	B-T002
stores)	O
in	O
all	O
treated	B-T169
colonies	B-T025
.	O
Some	O
effects	O
were	O
less	B-T080
evident	O
as	O
colony	B-T025
size	B-T082
increased	B-T081
,	O
suggesting	O
that	O
larger	B-T081
colony	B-T025
populations	B-T098
may	O
act	O
as	O
a	O
buffer	O
to	O
pesticide exposure	B-T033
.	O
This	O
study	B-T062
is	O
the	O
first	O
to	O
show	O
adverse effects	B-T046
of	O
imidacloprid	B-T109
on	O
queen bee	B-T204
fecundity	B-T040
and	O
behavior	B-T053
and	O
improves	B-T080
our	O
understanding	B-T041
of	O
how	O
neonicotinoids	B-T131
may	O
impair	B-T169
short-term	O
colony	B-T025
functioning	B-T169
.	O
These	O
data	B-T078
indicate	O
that	O
risk-mitigation efforts	B-T170
should	O
focus	O
on	O
reducing	B-T080
neonicotinoid	B-T131
exposure	B-T080
in	O
the	O
early spring	B-T079
when	O
colonies	B-T025
are	O
smallest	B-T081
and	O
queens	B-T204
are	O
most	O
vulnerable	B-T169
to	O
exposure	B-T080
.	O

Therapeutic applications	B-T169
of	O
CRISPR	B-T114
RNA-guided	B-T114
genome editing	B-T063
The	O
rapid	O
development	O
of	O
programmable nuclease	B-T116
-based	O
genome editing	B-T063
technologies	B-T090
has	O
enabled	O
targeted	B-T169
gene	B-T028
disruption	B-T169
and	O
correction	B-T061
both	O
in vitro	B-T080
and	O
in vivo	B-T082
This	O
revolution	O
opens	O
up	O
the	O
possibility	O
of	O
precise	O
genome editing	B-T063
at	O
target	B-T169
genomic sites	B-T082
to	O
modulate	O
gene function	B-T045
in	O
animals	B-T008
and	O
plants	B-T002
.	O
Among	O
several	O
programmable nucleases	B-T116
,	O
the	O
type II clustered regularly interspaced short palindromic repeats	B-T114
(	O
CRISPR	B-T114
)-	O
CRISPR-associated nuclease 9 (Cas9) system	B-T044
has	O
progressed	O
remarkably	O
in	O
recent	O
years,	O
leading	O
to	O
its	O
widespread	O
use	O
in	O
research	B-T062
,	O
medicine	B-T091
and	O
biotechnology	B-T091
.	O
In	O
particular,	O
CRISPR-Cas9	B-T044
shows	O
highly	O
efficient	O
gene editing	B-T063
activity	O
for	O
therapeutic purposes	B-T169
in	O
systems	O
ranging	O
from	O
patient	B-T101
stem cells	B-T025
to	O
animal models	B-T008
.	O
However,	O
the	O
development	O
of	O
therapeutic approaches	B-T169
and	O
delivery methods	B-T061
remains	O
a	O
great	O
challenge	O
for	O
biomedical	B-T091
applications	B-T169
.	O
Herein,	O
we	O
review	O
therapeutic applications	B-T169
that	O
use	O
the	O
CRISPR-Cas9 system	B-T044
and	O
discuss	O
the	O
possibilities	O
and	O
challenges	O
ahead.	O

Design	B-T052
and	O
characteristics	B-T080
of	O
cytotoxic	B-T169
fibroblast growth factor 1	B-T116
conjugate	B-T121
for	O
fibroblast growth factor receptor	B-T116
-	O
targeted cancer therapy	B-T061
Fibroblast growth factor receptors	B-T116
(	O
FGFRs	B-T116
)	O
are	O
attractive	O
candidate	O
cancer therapy	B-T061
targets	B-T169
as	O
they	O
are	O
overexpressed	B-T045
in	O
multiple	B-T081
types	O
of	O
tumors	B-T191
,	O
such	O
as	O
breast	B-T191
,	O
prostate	B-T191
,	O
bladder	B-T191
,	O
and	O
lung cancer	B-T191
.	O
In	O
this	O
study,	O
a	O
natural ligand	B-T044
of	O
FGFR	B-T116
,	O
an	O
engineered variant	B-T116
of	O
fibroblast growth factor 1	B-T116
(	O
FGF1V	B-T116
),	O
was	O
conjugated	B-T082
to	O
a	O
potent cytotoxic drug	B-T121
,	O
monomethyl auristatin E	B-T116
(	O
MMAE	B-T116
),	O
and	O
used	O
as	O
a	O
targeting agent	B-T043
for	O
cancer cells	B-T025
overexpressing	B-T045
FGFRs	B-T116
,	O
similar	O
to	O
antibodies	B-T116
in	O
antibody-drug conjugates	B-T061
.	O
The	O
FGF1V-valine-citrulline-MMAE conjugate	B-T121
showed	O
a	O
favorable	O
stability profile	B-T044
,	O
bound	B-T044
FGFRs	B-T116
on	O
the	O
cell surface	B-T026
specifically	B-T080
,	O
and	O
efficiently	B-T080
released	B-T169
the	O
drug (MMAE)	B-T116
upon	O
cleavage	B-T044
by	O
the	O
lysosomal protease cathepsin B	B-T116
.	O
Importantly,	O
the	O
conjugate	B-T121
showed	O
a	O
prominent	B-T080
cytotoxic effect	B-T049
toward	O
cell lines	B-T025
expressing	B-T045
FGFR	B-T116
.	O
FGF1V-vcMMAE	B-T121
was	O
highly	O
cytotoxic	B-T169
at	O
concentrations	B-T081
even	O
an	O
order	O
of	O
magnitude	O
lower	B-T052
than	O
those	O
found	O
for	O
free	O
MMAE	B-T116
.	O
This	O
effect	O
was	O
FGFR	B-T116
-specific	O
as	O
cells	B-T025
lacking	B-T080
FGFR	B-T116
did not show	B-T033
any	O
increased	B-T081
mortality	B-T043
.	O

Effects	O
of	O
morphology	B-T080
and	O
surface hydroxyl	B-T197
on	O
the	O
toxicity	B-T037
of	O
BiOCl	B-T121
in	O
human	B-T016
HaCaT cells	B-T025
Recently,	O
bismuth oxychloride	B-T121
nanomaterials	B-T185
(	O
BiOCls	B-T121
)	O
are	O
showing	O
great	O
promise	O
in	O
pollutant	B-T131
removal	B-T052
.	O
Residues	B-T131
from	O
these	O
environmental remediations	B-T069
are	O
potential	O
hazardous materials	B-T131
.	O
Unfortunately,	O
human	B-T016
health risks	B-T058
of	O
BiOCls	B-T121
are	O
still	O
unexplored	O
widely.	O
In	O
the	O
present	O
study	B-T062
,	O
we	O
focused	O
on	O
the	O
influence	O
of	O
physicochemical properties	B-T080
on	O
the	O
cytotoxicity	B-T049
of	O
BiOCls	B-T121
toward	O
a	O
human	B-T016
skin	B-T022
derived	O
cell line	B-T025
(	O
HaCaT	B-T025
).	O
Results	O
showed	O
that	O
morphology	B-T080
and	O
surface hydroxyl	B-T197
both	O
had	O
a	O
profound	O
effect	O
on	O
the	O
toxicity	B-T037
of	O
BiOCls	B-T121
.	O
Microsphere-shaped	B-T082
BiOCl	B-T121
caused	O
less	O
toxicity	B-T037
than	O
nanosheet-shaped	B-T082
BiOCl	B-T121
because	O
of	O
weaker particle-membrane interactions	B-T043
,	O
while	O
the	O
presence	O
of	O
surface hydroxyl	B-T197
on	O
microsphere-shaped	B-T082
BiOCl	B-T121
significantly	O
raised	O
the	O
toxicity	B-T037
owing	O
to	O
the	O
increased	O
interaction	B-T043
with	O
cell membrane	B-T026
.	O
Both	O
microsphere-shaped	B-T082
BiOCl	B-T121
with	O
surface hydroxyl	B-T197
and	O
nanosheet-shaped	B-T082
BiOCl	B-T121
caused	O
significant	O
cell membrane	B-T026
damage	B-T049
(	O
PI	B-T109
PI uptake	B-T059
and	O
LDH	B-T116
LDH release	B-T059
),	O
however,	O
based	O
on	O
the	O
different	O
mechanism	B-T043
.	O
The	O
former	O
may	O
be	O
a	O
predominant	O
"chemical" mechanism	B-T043
involved	O
an	O
oxidative stress paradigm	B-T062
,	O
as	O
manifested	O
by	O
elevated	O
ROS	B-T123
and	O
depleted	O
GSH	B-T116
,	O
while	O
the	O
latter	O
is	O
mainly	O
due	O
to	O
a	O
direct	O
"	O
physical	B-T169
"	O
damage	B-T049
to	O
cell membrane	B-T026
.	O
Both	O
"	O
physical	B-T043
"	O
and	O
"chemical" response	B-T043
led	O
to	O
cell death	B-T043
.	O
Furthermore,	O
a	O
set	O
of	O
experiments	B-T062
including	O
MMP	B-T043
collapse,	O
cell cycle arrest	B-T043
,	O
and	O
apoptosis	B-T043
/	O
necrosis	B-T042
were	O
conducted	O
to	O
propose	O
a	O
scenario	O
for	O
toxicological aspects	B-T080
of	O
BiOCls	B-T121
.	O
Data	B-T078
presented	O
here	O
would	O
help	O
to	O
enable	O
the	O
rational design	B-T052
of	O
BiOCls	B-T121
for	O
either	O
reducing	O
their	O
unintended consequences	B-T080
or	O
increasing	O
their	O
application potentials	B-T080
.	O

Reduced	B-T080
haemodynamic coupling	B-T042
and	O
exercise	B-T056
are	O
associated with	B-T080
vascular stiffening	B-T046
in	O
pulmonary arterial hypertension	B-T047
Inadequate	B-T080
right ventricular	B-T023
(	O
RV	B-T023
)	O
and	O
pulmonary arterial	B-T023
(	O
PA	B-T023
)	O
functional	B-T169
responses	B-T169
to	O
exercise	B-T056
are	O
important	O
yet	O
poorly	O
understood	O
features	O
of	O
pulmonary arterial hypertension	B-T047
(	O
PAH	B-T047
).	O
This	O
study	B-T062
combined	O
invasive	B-T061
catheterisation	B-T061
with	O
echocardiography	B-T060
to	O
assess	B-T052
RV	B-T023
afterload,	O
RV function	B-T042
and	O
ventricular	B-T023
-	O
vascular	B-T023
coupling	B-T042
in	O
subjects	B-T098
with	O
PAH	B-T047
.	O
Twenty-six	O
subjects	B-T098
with	O
PAH	B-T047
were	O
prospectively	O
recruited	O
to	O
undergo	O
right heart	B-T029
catheterisation	B-T061
and	O
Doppler echocardiography	B-T060
at	O
rest	B-T056
and	O
during	O
incremental	B-T081
exercise	B-T056
,	O
and	O
cardiac MRI	B-T060
at	O
rest	B-T056
.	O
Measurements	B-T169
at	O
rest	B-T056
included	O
basic	O
haemodynamics	B-T042
,	O
RV function	B-T042
and	O
coupling efficiency	B-T081
(	O
η	B-T081
).	O
Measurements	B-T169
during	O
incremental	B-T081
exercise	B-T056
included	O
pulmonary vascular resistance	B-T033
(	O
Z0	B-T033
),	O
characteristic impedance	B-T060
(	O
ZC	B-T060
,	O
a	O
measure	B-T169
of	O
proximal	B-T082
PA	B-T023
stiffness	B-T039
)	O
and	O
proximal	B-T082
and	O
distal	B-T082
PA	O
compliance	O
(CPA).	O
In	O
patients	B-T101
with	O
PAH	B-T047
,	O
the	O
proximal	B-T082
PAs	B-T023
were	O
significantly	B-T078
stiffer	B-T033
at	O
maximum	B-T081
exercise	B-T056
(	O
ZC	B-T060
=2.31±0.38	O
vs	O
1.33±0.15	O
WU×m(2)	O
at	O
rest	B-T056
;	O
p=0.003)	O
and	O
PA	O
compliance	O
was	O
decreased	B-T081
(CPA	O
=0.88±0.10	O
vs	O
1.32±0.17	O
mL/mm	O
Hg/m(2)	O
at	O
rest	B-T056
;	O
p=0.0002).	O
Z0	B-T033
did	O
not	O
change	O
with	O
exercise	B-T056
.	O
As	O
a	O
result,	O
the	O
resistance-compliance (RC) time	B-T081
decreased	B-T081
with	O
exercise	B-T056
(0.67±0.05	O
vs	O
1.00±0.07	O
s	O
at	O
rest	B-T056
;	O
p<10(-6)).	O
When	O
patients	B-T101
were	O
grouped	O
according	O
to	O
resting	B-T056
coupling efficiency	B-T081
,	O
those	O
with	O
poorer	O
η	B-T081
exhibited	O
stiffer	B-T033
proximal	B-T082
PAs	B-T023
at	O
rest	B-T056
,	O
a	O
lower	O
maximum	B-T081
exercise	B-T056
level	B-T080
,	O
and	O
more	O
limited	O
CPA	O
reduction	B-T080
at	O
maximum	B-T081
exercise	B-T056
.	O
In	O
PAH	B-T047
,	O
exercise	B-T056
causes	O
proximal	B-T082
and	O
distal	B-T082
PA	B-T023
stiffening	B-T039
,	O
which	O
combined	O
with	O
preserved	O
Z0	B-T033
results	O
in	O
decreased	B-T081
RC time	B-T081
with	O
exercise	B-T056
.	O
Stiff PAs	B-T023
at	O
rest	B-T056
may	O
also	O
contribute	O
to	O
poor	O
haemodynamic coupling	B-T042
,	O
reflecting	O
reduced	B-T080
pulmonary vascular	B-T023
reserve	O
that	O
contributes	B-T052
to	O
limit	O
the	O
maximum	B-T081
exercise	B-T056
level	B-T080
tolerated.	O

Altered pH gradient	B-T081
at	O
the	O
plasma membrane	B-T026
of	O
osteosarcoma	B-T191
cells	B-T025
is	O
a	O
key	O
mechanism	B-T169
of	O
drug resistance	B-T038
Current	O
therapy	B-T061
of	O
osteosarcoma	B-T191
(	O
OS	B-T191
),	O
the	O
most	O
common	O
primary bone malignancy	B-T191
,	O
is	O
based	O
on	O
a	O
combination of surgery and chemotherapy	B-T061
.	O
Multidrug resistance	B-T032
mediated	O
by	O
P-glycoprotein	B-T116
(	O
P-gp	B-T116
)	O
overexpression	B-T045
has	O
been	O
previously	O
associated	O
with	O
treatment failure	B-T033
and	O
progression	B-T046
of	O
OS	B-T191
,	O
although	O
other	O
mechanisms	B-T169
may	O
also	O
play	O
a	O
role.	O
We	O
considered	O
the	O
typical	O
acidic extracellular pH	B-T081
(	O
pHe	B-T081
)	O
of	O
sarcomas	B-T191
,	O
and	O
found	O
that	O
doxorubicin	B-T109
(	O
DXR	B-T109
)	O
cytotoxicity	B-T049
is	O
reduced	B-T080
in	O
P-gp	B-T028
negative	O
OS	B-T191
cells cultured	B-T025
at	O
pHe	B-T081
6.5	O
compared	O
to	O
standard	O
7.4.	O
Short-time	B-T079
(24-48	O
hours)	O
exposure to	B-T080
low	O
pHe	B-T081
significantly increased	B-T081
the	O
number	O
and	O
acidity	B-T034
of	O
lysosomes	B-T026
,	O
and	O
the	O
combination	B-T080
of	O
DXR	B-T109
with	O
omeprazole	B-T109
,	O
a	O
proton pump inhibitor	B-T121
targeting	O
lysosomal acidity	B-T043
,	O
significantly enhanced	B-T081
DXR	B-T109
cytotoxicity	B-T049
.	O
In	O
OS	B-T191
xenografts	B-T122
,	O
the	O
combination treatment	B-T061
of	O
DXR	B-T109
and	O
omeprazole	B-T109
significantly reduced	B-T038
tumor volume	B-T081
and	O
body weight loss	B-T033
.	O
The	O
impaired toxicity	B-T037
of	O
DXR	B-T109
at	O
low	O
pHe	B-T081
was	O
not	O
associated	O
with	O
increased	B-T081
autophagy	B-T043
or	O
lysosomal acidification	B-T043
,	O
but	O
rather,	O
as	O
shown	O
by	O
SNARF	B-T130
staining	B-T059
,	O
with	O
a	O
reversal	B-T169
of	O
the	O
pH gradient	B-T081
at	O
the	O
plasma membrane	B-T026
(	O
ΔpHcm	B-T081
),	O
eventually	O
leading	O
to	O
a	O
reduced	B-T080
DXR	B-T109
intracellular	B-T082
accumulation	B-T033
.	O
Finally,	O
the	O
reversal	B-T169
of	O
ΔpHcm	B-T081
in	O
OS	B-T191
cells	B-T025
promoted	O
resistance	B-T169
not	O
only	O
to	O
DXR	B-T109
,	O
but	O
also	O
to	O
cisplatin	B-T121
and	O
methotrexate	B-T109
,	O
and,	O
to	O
a	O
lesser	O
extent,	O
to	O
vincristine	B-T109
.	O
Altogether,	O
our	O
findings	O
show	O
that,	O
in	O
OS	B-T191
cells	B-T025
,	O
short-term	B-T079
acidosis	B-T046
induces	O
resistance	B-T169
to	O
different	O
chemotherapeutic drugs	B-T109
by	O
a	O
reversal	B-T169
of	O
ΔpHcm	B-T081
,	O
suggesting	O
that	O
buffer	B-T121
therapies	B-T061
or	O
regimens	B-T170
including	O
proton pump inhibitors	B-T121
in	O
combination	B-T080
to	O
low	O
concentrations	B-T081
of	O
conventional	O
anticancer agents	B-T109
may	O
offer	O
novel	B-T080
solutions	O
to	O
overcome	B-T052
drug resistance	B-T038
.	O

Boston Keratoprosthesis Type 1	B-T074
:	O
A	O
Randomized Controlled Trial	B-T062
of	O
Fresh	B-T080
versus	O
Frozen	B-T080
Corneal Donor Carriers	B-T101
with	O
Long-Term	B-T079
Follow-up	B-T058
To	O
compare	B-T052
the	O
long-term	B-T079
clinical outcomes	B-T169
of	O
fresh	B-T080
versus	O
frozen	B-T080
corneal graft carriers	B-T101
for	O
the	O
Boston Keratoprosthesis type 1	B-T074
(	O
B-KPro	B-T074
).	O
Prospective,	O
single-center,	O
nonblinded	B-T077
,	O
randomized controlled trial.	B-T062
All	O
participants	B-T098
were	O
followed	O
through	O
the	O
initial	B-T079
study protocol	B-T170
of	O
24	O
months	B-T079
and	O
were	O
approached	O
to	O
enter	O
an	O
extension	B-T169
phase	B-T079
,	O
with	O
continuing	O
follow-up visits	B-T058
to	O
60	O
months	B-T079
.	O
All	O
patients	B-T101
undergoing	O
B-KPro surgery	B-T061
between	O
October	O
2008	O
and	O
December	O
2009	O
by	O
a	O
single	O
experienced surgeon	B-T097
at	O
the	O
Centre	O
Hospitalier de l'Université de Montréal	B-T073
using	O
an	O
allograft carrier	B-T024
were	O
considered.	O
Patients	B-T101
were	O
excluded	B-T052
if	O
they	O
had	O
previously	B-T079
undergone	O
B-KPro	B-T074
implantation	B-T061
.	O
Participants	B-T098
were	O
randomized	B-T033
individually	O
to	O
receive	B-T080
a	O
B-KPro	B-T074
using	O
a	O
frozen	B-T080
or	O
a	O
fresh	B-T080
corneal graft carrier	B-T024
on	O
the	O
basis	O
of	O
tissue	B-T024
availability	B-T169
on	O
the	O
day	B-T079
of	O
surgery	B-T061
,	O
as	O
determined	O
by	O
the	O
local	O
eye bank	B-T073
.	O
The	O
primary	O
outcome measure	B-T081
was	O
device retention	B-T033
at	O
24	O
and	O
60	O
months	B-T079
.	O
Secondary	O
outcome	O
measures	O
included	O
surgical feasibility	B-T033
,	O
visual acuity	B-T201
(	O
VA	B-T201
),	O
and	O
complications	B-T046
.	O
Thirty-seven	O
eyes	B-T023
of	O
37	O
patients	B-T101
were	O
enrolled	O
in	O
the	O
initial	B-T079
study protocol	B-T170
,	O
with	O
19	O
eyes	B-T023
randomized	B-T062
to	O
fresh	B-T080
and	O
18	O
to	O
frozen	B-T080
carrier grafts	B-T024
.	O
Thirty-six	O
eyes	B-T023
were	O
followed	O
through	O
to	O
24	O
months	B-T079
,	O
with	O
1	O
lost	O
to	O
follow-up	B-T058
.	O
Of	O
these,	O
26	O
were	O
enrolled	O
in	O
the	O
extension	B-T169
(11	O
eyes	B-T023
with	O
a	O
frozen	B-T080
and	O
15	O
eyes	B-T023
with	O
a	O
fresh	B-T080
carrier graft	B-T024
).	O
There	O
were	O
no differences	B-T033
in	O
the	O
baseline	B-T081
characteristics	B-T080
of	O
patients	B-T101
enrolled	O
in	O
the	O
extension	B-T169
phase	B-T079
versus	O
those	O
who	O
were	O
not.	O
At	O
60	O
months	B-T079
,	O
median	O
corrected	O
distance	O
VA	B-T201
)	O
in	O
the	O
fresh group	B-T078
had	O
improved	B-T033
to	O
20/150	O
from	O
a	O
baseline	B-T081
of	O
counting	O
fingers,	O
whereas	O
the	O
frozen group	B-T078
improved	B-T033
to	O
20/400	O
from	O
a	O
baseline	B-T081
of	O
hand	O
motions.	O
Device retention	B-T033
was	O
100%	O
at	O
24	O
months	B-T079
and	O
96%	O
at	O
60	O
months	B-T079
.	O
There	O
were	O
no	O
significant	O
differences	B-T080
in	O
the	O
rate	B-T081
of	O
complications	B-T046
between	O
groups	B-T078
.	O
Fresh	B-T080
and	O
frozen	B-T080
corneal donors	B-T098
offer	O
similar	O
clinical outcomes	B-T169
when	O
used	O
as	O
carriers	B-T024
for	O
the	O
B-KPro	B-T074
,	O
with	O
no	O
significant	O
differences	B-T080
in	O
device retention	B-T033
,	O
visual rehabilitation	B-T033
,	O
or	O
rates	B-T081
of	O
complications	B-T046
at	O
24	O
or	O
60	O
months	B-T079
.	O

Impact	B-T080
of	O
an	O
Educational Intervention	B-T061
to	O
Improve	B-T033
Antibiotic	B-T195
Prescribing	B-T058
for	O
Nurse Practitioners	B-T097
in	O
a	O
Pediatric	B-T100
Urgent Care Center	B-T073
Up	O
to	O
21%	O
of	O
pediatric visits	B-T058
result	O
in	O
an	O
antibiotic	B-T195
prescription	B-T058
,	O
and	O
a	O
large	O
portion	O
of	O
these	O
are	O
unnecessary.	O
To	O
determine	O
if	O
educational sessions	B-T065
would	O
reduce	B-T080
inappropriate	B-T080
antibiotic	B-T195
use	B-T169
.	O
Intervention study	B-T170
evaluating	B-T058
antibiotic	B-T195
prescribing	B-T058
following	O
educational sessions	B-T065
for	O
urinary tract infection	B-T047
,	O
skin	B-T047
and	O
soft tissue infection	B-T047
,	O
pharyngitis	B-T047
,	O
upper respiratory tract infection	B-T047
,	O
acute otitis media	B-T047
,	O
and	O
acute bacterial sinusitis	B-T047
.	O
A	O
total	O
of	O
26	O
out	O
of	O
43	O
(60%)	O
nurse practitioners	B-T097
in	O
4	O
urgent care centers	B-T073
were	O
enrolled	B-T058
in	O
the	O
study	B-T062
.	O
The	O
rate	B-T081
of	O
inappropriate	B-T080
antibiotic	B-T195
use	B-T169
among	O
all	O
conditions	O
was	O
10%	O
before	O
and	O
8%	O
after	O
the	O
intervention	B-T061
(p	O
=	O
.02).	O
A	O
decrease	B-T081
in	O
inappropriate	B-T080
antibiotic	B-T195
prescribing	B-T058
was	O
seen	O
after	O
the	O
educational session	B-T065
(p	O
<	O
.01).	O
The	O
most	O
common	O
reasons	O
for	O
inappropriate	B-T080
antibiotic	B-T195
prescribing	B-T058
were	O
too	O
broad	O
(41%),	O
wrong dosage	B-T033
(22%),	O
and	O
not indicated	B-T033
(17%).	O
Educational sessions	B-T065
led	O
to	O
improvement	B-T077
in	O
overall	O
inappropriate	B-T080
antibiotic	B-T195
use	B-T169
.	O
Additional	O
stewardship	B-T170
interventions	B-T061
are	O
needed	O
to	O
further	O
reduce	B-T080
unnecessary	O
antibiotic	B-T195
use	B-T169
.	O

Zika Virus	B-T005
Disrupts	B-T080
Phospho-TBK1	B-T116
Localization	B-T043
and	O
Mitosis	B-T043
in	O
Human	B-T016
Neuroepithelial	B-T080
Stem Cells	B-T025
and	O
Radial Glia	B-T025
The	O
mechanisms	B-T169
underlying	O
Zika virus	B-T005
(	O
ZIKV	B-T005
)-related	O
microcephaly	B-T019
and	O
other	O
neurodevelopment	B-T042
defects	B-T169
remain	O
poorly	B-T080
understood	B-T041
.	O
Here,	O
we	O
describe	O
the	O
derivation	B-T080
and	O
characterization	B-T052
,	O
including	O
single-cell RNA-seq	B-T086
,	O
of	O
neocortical	B-T023
and	O
spinal cord	B-T023
neuroepithelial	B-T080
stem (NES) cells	B-T025
to	O
model	O
early	B-T079
human	B-T016
neurodevelopment	B-T042
and	O
ZIKV	B-T005
-related	O
neuropathogenesis	B-T047
.	O
By	O
analyzing	O
human	B-T016
NES cells	B-T025
,	O
organotypic	B-T080
fetal	B-T018
brain	B-T023
slices	B-T167
,	O
and	O
a	O
ZIKV	B-T005
-	O
infected	B-T033
micrencephalic	B-T019
brain	B-T023
,	O
we	O
show	O
that	O
ZIKV	B-T005
infects	B-T033
both	O
neocortical	B-T023
and	O
spinal	B-T023
NES cells	B-T025
as	O
well	O
as	O
their	O
fetal	B-T018
homolog,	O
radial glial cells	B-T025
(	O
RGCs	B-T025
),	O
causing	O
disrupted	B-T080
mitoses	B-T043
,	O
supernumerary	B-T081
centrosomes	B-T026
,	O
structural	B-T082
disorganization	B-T033
,	O
and	O
cell death	B-T043
.	O
ZIKV infection	B-T047
of	O
NES cells	B-T025
and	O
RGCs	B-T025
causes	O
centrosomal	B-T026
depletion	B-T169
and	O
mitochondrial	B-T026
sequestration	B-T169
of	O
phospho-TBK1	B-T116
during	O
mitosis	B-T043
.	O
We	O
also	O
found	O
that	O
nucleoside analogs	B-T114
inhibit	B-T052
ZIKV	B-T005
replication	B-T043
in	O
NES cells	B-T025
,	O
protecting	O
them	O
from	O
ZIKV	B-T005
-	O
induced	B-T169
pTBK1	B-T116
relocalization	B-T043
and	O
cell death	B-T043
.	O
We	O
established	B-T080
a	O
model system	B-T170
of	O
human	B-T016
neural stem cells	B-T025
to	O
reveal	O
cellular	B-T025
and	O
molecular	B-T080
mechanisms	B-T169
underlying	O
neurodevelopmental	B-T042
defects	B-T169
associated with	B-T080
ZIKV infection	B-T047
and	O
its	O
potential	B-T080
treatment	B-T061
.	O

Prevalence	B-T081
of	O
HPV	B-T005
genotypes	B-T032
in	O
cervical adenocarcinoma	B-T191
:	O
a	O
study	B-T062
in	O
Greek	B-T098
women	B-T098
To	O
study	B-T062
the	O
prevalence	B-T081
of	O
human papillomavirus	B-T005
(	O
HPV	B-T005
)	O
genotypes	B-T032
among	O
cervical adenocarcinomas	B-T191
in	O
Greek	B-T098
women	B-T098
.	O
The	O
study group	B-UnknownType
comprised	O
78	O
adenocarcinoma	B-T191
cases	B-T077
(20	O
in situ	B-T191
and	O
58	O
invasive	B-T191
).	O
HPV DNA	B-T114
was	O
amplified	B-T045
using	O
polymerase chain reaction	B-T063
(	O
PCR	B-T063
)	O
and	O
HPV	B-T005
genotypes	B-T032
were	O
identified	B-T080
by	O
reverse hybridization	B-T063
.	O
There	O
was	O
a	O
high prevalence	B-T081
of	O
HPV infection	B-T047
both	O
for	O
in situ	B-T191
(95%)	O
or	O
invasive (94.83%) adenocarcinomas	B-T191
,	O
comprising	O
also	O
cancers	B-T191
of	O
unusual morphology	B-T080
.	O
HPV 16	B-T005
was	O
the	O
commonest	B-T081
strain	B-T001
(N=57,	O
73.08%)	O
followed	O
by	O
HPV 18	B-T005
(N=28,	O
35.90%).	O
Interestingly,	O
13	O
cases	B-T077
(16.67%)	O
were	O
also	O
HPV 52 positive	B-T005
(as	O
co-infection	B-T047
with	O
HPV 16	B-T005
or	O
18	B-T005
).	O
All	O
other	O
strains	B-T001
with	O
the	O
exception	B-T077
of	O
HPV 66	B-T005
were	O
found	O
only	O
as	O
co-infections	B-T047
.	O
No	O
significant	O
age difference	B-T100
was	O
noted	O
in	O
terms	O
of	O
any	O
HPV	B-T005
strain	B-T001
positivity	B-T033
.	O
HPV DNA	B-T114
was	O
found	O
in	O
the	O
large majority	B-T054
of	O
cervical adenocarcinomas	B-T191
.	O
As	O
opposed	O
to	O
other	O
studies	B-T062
,	O
HPV 52	B-T005
was	O
the	O
third	O
most	O
commonly	B-T081
encountered	B-T058
strain	B-T001
after	O
HPV 16	B-T005
and	O
HPV 18	B-T005
.	O
The	O
above	O
findings	O
would	O
probably	O
be	O
of	O
help	B-T080
in	O
decision making	B-T041
concerning	O
vaccination	B-T061
policy	B-T170
for	O
the	O
prevention	B-T080
of	O
HPV infection	B-T047
in	O
Greece	B-T083
.	O

Glucose metabolism	B-T044
-	O
weighted imaging	B-T060
with	O
chemical exchange-sensitive MRI	B-T060
of	O
2-deoxyglucose	B-T109
(	O
2DG	B-T109
)	O
in	O
brain	B-T023
:	O
Sensitivity	B-T081
and	O
biological	B-T080
sources	B-T033
Recent proof-of-principle studies	B-T062
have	O
demonstrated	O
the	O
feasibility	O
of	O
measuring	O
the	O
uptake	B-T039
and	O
metabolism	B-T040
of	O
non-labeled	O
2-deoxy-D-glucose	B-T109
(	O
2DG	B-T109
)	O
by	O
a	O
chemical exchange-sensitive spin-lock (CESL) MRI approach	B-T060
.	O
In	O
order	O
to	O
gain	O
better	O
understanding	O
of	O
this	O
new	O
approach,	O
we	O
performed	O
dynamic	B-T169
in vivo	B-T082
CESL MRI	B-T060
on	O
healthy	B-T080
rat	B-T015
brains	B-T023
with	O
an	O
intravenous injection	B-T169
of	O
2DG	B-T109
under	O
various	O
conditions	O
at	O
9.4T.	O
For	O
three	O
2DG	B-T109
doses	B-T081
of	O
0.25,	O
0.5	O
and	O
1g/kg,	O
we	O
found	O
that	O
2DG	B-T109
-	O
CESL	B-T060
signals	B-T067
increased	B-T081
linearly	O
with	O
injection	B-T061
dose	B-T081
at	O
the	O
initial	O
(<20min)	O
but	O
not	O
the	O
later	O
period	O
(>40min)	O
suggesting	O
time-dependent	O
differential	O
weightings	O
of	O
2DG	B-T109
transport	B-T043
and	O
metabolism	B-T040
.	O
Remaining	O
2DG	B-T109
-	O
CESL	B-T060
studies	O
were	O
performed	O
with	O
0.25g/kg	O
2DG	B-T109
.	O
Since	O
a	O
higher	B-T080
isoflurane	B-T109
level	B-T080
reduces	B-T080
glucose metabolism	B-T044
and	O
increases	B-T169
blood flow	B-T039
,	O
2DG	B-T109
-	O
CESL	B-T060
was	O
measured	B-T080
under	O
0.5%,	O
1.5%	O
and	O
2.2%	O
isoflurane	B-T109
.	O
The	O
2DG	B-T109
-	O
CESL	B-T060
signal	B-T067
was	O
reduced	B-T080
at	O
higher	B-T080
isoflurane	B-T109
levels	O
correlating	O
well	O
with	O
the	O
2DG	B-T109
phosphorylation	B-T044
in	O
the	O
intracellular space	B-T030
.	O
To	O
detect	O
regional heterogeneities	B-T102
of	O
glucose metabolism	B-T044
,	O
2DG	B-T109
-	O
CESL	B-T060
with	O
0.33×0.33×1.50mm(3)	O
resolution	O
was	O
obtained,	O
which	O
indeed	O
showed	O
a	O
higher	B-T080
response	O
in	O
the	O
cortex	B-T023
compared	O
to	O
the	O
corpus callosum	B-T023
.	O
Lastly,	O
unlike	O
CESL MRI	B-T060
with	O
the	O
injection	B-T061
of	O
non-transportable mannitol	B-T109
,	O
the	O
2DG	B-T109
-	O
CESL	B-T060
response	O
decreased	B-T081
with	O
an	O
increased	B-T081
spin-lock pulse power	B-T081
confirming	O
that	O
2DG	B-T109
-	O
CESL	B-T060
is	O
dominated	O
by	O
chemical	B-T103
exchange	B-T201
processes	B-T067
in	O
the	O
extravascular space	B-T082
.	O
Taken	O
together,	O
our	O
results	O
showed	O
that	O
2DG	B-T109
-	O
CESL MRI	B-T060
signals	B-T067
mainly	O
indicate	O
glucose transport	B-T043
and	O
metabolism	B-T044
and	O
may	O
be	O
a	O
useful	O
biomarker	B-T201
for	O
metabolic	B-T169
studies	B-T062
of	O
normal	B-T023
and	O
diseased	B-T047
brains	B-T023
.	O

Parental	B-T099
perceptions	B-T041
of	O
children´s agency	B-T092
:	O
Parental warmth	B-UnknownType
,	O
school achievement	B-T055
and	O
adjustment	B-T055
The	O
present	O
study	B-T062
examined	O
Swedish	B-T098
mothers'	B-T099
and	O
fathers'	B-T099
warmth	B-UnknownType
towards	O
their	O
children	B-T100
in	O
relation	O
to	O
their	O
children´s agency	B-T092
.	O
It	O
also	O
examined	O
the	O
longitudinal	O
relation	O
between	O
agency	B-T092
and	O
children's	B-T100
externalizing,	O
internalizing,	O
and	O
school achievement	B-T055
.	O
Swedish	B-T098
children's	B-T100
mothers	B-T099
and	O
fathers	B-T099
(N	O
=	O
103)	O
were	O
interviewed	B-T052
at	O
three	O
time points	B-T079
(when	O
children	B-T100
were	O
8,	O
9,	O
and	O
10	O
years	B-T079
old)	O
about	O
their	O
warmth	B-UnknownType
towards	O
their	O
children	B-T100
,	O
children's agency	B-T092
,	O
and	O
children's	B-T100
externalizing	O
and	O
internalizing	O
behaviors	O
and	O
school achievement	B-T055
.	O
Parental warmth	B-UnknownType
at	O
Time	B-T079
1	O
was	O
significantly	O
correlated	B-T080
with	O
child agency	B-T092
at	O
Time	B-T079
2,	O
which	O
was	O
significantly	O
correlated	B-T080
with	O
child	B-T100
externalizing	O
and	O
internalizing	O
behaviors	O
and	O
academic achievement	B-T055
at	O
Time	B-T079
3.	O
There	O
were	O
no	O
differences	O
between	O
girls	B-T100
and	O
boys	B-T100
.	O
Results	O
from	O
this	O
study	B-T062
indicate	O
that	O
Swedish	B-T098
parents' warmth	B-UnknownType
is	O
directly	O
related	O
to	O
subsequent	O
perceptions	B-T041
of	O
children's agency	B-T092
,	O
which	O
in	O
turn	O
are	O
related	O
to	O
subsequently	O
lower	O
child	B-T100
externalizing	O
and	O
internalizing	O
problems	B-T033
and	O
higher	O
academic achievement	B-T055
.	O
These	O
findings	B-T033
held	O
in	O
the	O
context	O
of	O
a	O
three-	O
year	B-T079
longitudinal study	B-T062
and	O
for	O
both	O
boys	B-T100
and	O
girls	B-T100
,	O
suggesting	O
the	O
importance	O
of	O
child agency	B-T092
in	O
the	O
link	O
between	O
parental warmth	B-UnknownType
and	O
children's	B-T100
adjustment	B-T055
.	O

Vasopressin	B-T116
regulates the growth	B-T043
of	O
the	O
biliary epithelium	B-T025
in	O
polycystic liver disease	B-T019
The	O
neurohypophysial hormone	B-T116
arginine vasopressin	B-T116
(	O
AVP	B-T116
)	O
acts	O
by	O
three	O
distinct	O
receptor	B-T116
subtypes:	O
V1a	B-T116
,	O
V1b	B-T116
,	O
and	O
V2	B-T116
.	O
In	O
the	O
liver	B-T023
,	O
AVP	B-T116
is	O
involved	B-T169
in	O
ureogenesis	B-T044
,	O
glycogenolysis	B-T044
,	O
neoglucogenesis	B-T044
and	O
regeneration	B-T042
.	O
No	O
data	O
exist	O
about	O
the	O
presence	B-T033
of	O
AVP	B-T116
in	O
the	O
biliary epithelium	B-T025
.	O
Cholangiocytes	B-T025
are	O
the	O
target cells	B-T025
in	O
a	O
number	O
of	O
animal models	B-T050
of	O
cholestasis	B-T047
,	O
including	O
bile duct	B-T023
ligation	B-T061
(	O
BDL	B-T061
),	O
and	O
in	O
several	O
human	B-T016
pathologies	B-T091
,	O
such	O
as	O
polycystic liver disease	B-T019
characterized	B-T052
by	O
the	O
presence	B-T033
of	O
cysts	B-T047
that	O
bud	O
from	O
the	O
biliary epithelium	B-T025
.	O
In vivo	B-T082
,	O
liver	B-T023
fragments	B-T031
from	O
normal	O
and	O
BDL	B-T061
mice	B-T015
and	O
rats	B-T015
as	O
well	O
as	O
liver samples	B-T024
from	O
normal	O
and	O
ADPKD	B-T019
patients	B-T101
were	O
collected	O
to	O
evaluate:	O
(i)	O
intrahepatic	B-T082
bile duct	B-T023
mass	B-T033
by	O
immunohistochemistry	B-T060
for	O
cytokeratin-19	B-T116
;	O
and	O
(ii)	O
expression	B-T045
of	O
V1a	B-T116
,	O
V1b	B-T116
and	O
V2	B-T116
by	O
immunohistochemistry	B-T060
,	O
immunofluorescence	B-T059
and	O
real-time PCR	B-T063
.	O
In vitro	B-T080
,	O
small	O
and	O
large	O
mouse	B-T015
cholangiocytes	B-T025
,	O
H69	B-T025
(	O
non-malignant	B-T080
human	B-T016
cholangiocytes	B-T025
)	O
and	O
LCDE	B-T025
(	O
human	B-T016
cholangiocytes	B-T025
from	O
the	O
cystic epithelium	B-T190
)	O
were	O
stimulated	B-T044
with	O
vasopressin	B-T116
in	O
the	O
absence/	O
presence	B-T033
of	O
AVP antagonists	B-T116
such	O
as	O
OPC-31260	B-T109
and	O
Tolvaptan	B-T109
,	O
before	O
assessing	O
cellular growth	B-T043
by	O
MTT assay	B-T059
and	O
cAMP	B-T114
levels.	O
Cholangiocytes	B-T025
express	O
V2 receptor	B-T116
that	O
was	O
upregulated	B-T044
following	O
BDL	B-T061
and	O
in	O
ADPKD	B-T019
liver samples	B-T024
.	O
Administration	B-T061
of	O
AVP	B-T116
increased	B-T081
proliferation	B-T043
and	O
cAMP	B-T114
levels	O
of	O
small	O
cholangiocytes	B-T025
and	O
LCDE cells	B-T025
.	O
We	O
found	O
no effect	B-T080
in	O
the	O
proliferation	B-T043
of	O
large	O
mouse	B-T015
cholangiocytes	B-T025
and	O
H69 cells	B-T025
.	O
Increases	B-T169
were	O
blocked	B-T169
by	O
preincubation	B-T059
with	O
the	O
AVP antagonists	B-T116
.	O
These	O
results	B-T169
showed	O
that	O
AVP	B-T116
and	O
its	O
receptors	B-T116
may	O
be	O
important	O
in	O
the	O
modulation	B-UnknownType
of	O
the	O
proliferation rate	B-T034
of	O
the	O
biliary epithelium	B-T025
.	O

Central Corneal Thickness	B-T201
Reproducibility	B-T081
among	O
Ten	O
Different	O
Instruments	B-T073
To	O
assess	B-T058
agreement	O
between	O
one	O
ultrasonic	B-T074
(	O
US	B-T074
)	O
and	O
nine	O
optical instruments	B-T073
for	O
the	O
measurement	B-T169
of	O
central corneal thickness	B-T201
(	O
CCT	B-T201
),	O
and	O
to	O
evaluate	B-T058
intra- and inter-operator reproducibility	B-T081
.	O
In	O
this	O
observational	O
cross-sectional study	B-T062
,	O
two	O
masked	O
operators	O
measured	O
CCT	B-T201
thickness	O
twice	O
in	O
28	O
healthy	B-T080
eyes	B-T023
.	O
We	O
used	O
seven	O
spectral-domain optical coherence tomography (SD-OCT) devices	B-T074
,	O
one time-domain OCT	B-T074
,	O
one	O
Scheimpflug camera	B-T074
,	O
and	O
one	O
US-based instrument	B-T074
.	O
Inter- and intra-operator reproducibility	B-T080
was	O
evaluated	B-T058
by	O
intraclass correlation coefficient	B-T081
(	O
ICC	B-T081
),	O
coefficient of variation	B-T081
(	O
CV	B-T081
),	O
and	O
Bland-Altman test	B-T170
analysis	B-T062
.	O
Instrument	B-T074
-to-	O
instrument	B-T074
reproducibility	B-T081
was	O
determined	O
by	O
ANOVA	B-T081
for	O
repeated	O
measurements.	O
We	O
also	O
tested	B-T169
how	O
the	O
devices	B-T074
disagreed	O
regarding	O
systemic	B-T169
bias	B-T078
and	O
random	B-T080
error	B-T080
using	O
a	O
structural equation model	B-T062
.	O
Mean	O
CCT	B-T201
of	O
all	O
instruments	B-T074
ranged	O
from	O
536	O
±	O
42	O
μm	O
to	O
577	O
±	O
40	O
μm.	O
An	O
instrument	B-T074
-to-	O
instrument	B-T074
correlation test	B-T170
showed	O
high	B-T080
values	B-T080
among	O
the	O
10	O
investigated	B-T169
devices	B-T074
(	O
correlation coefficient	B-T081
range	B-T081
0.852-0.995;	O
p values	B-T081
<0.0001	O
in	O
all	O
cases).	O
The	O
highest	O
correlation	O
coefficient	O
values	O
were	O
registered	O
between	O
3D	O
OCT-2000	O
Topcon-Spectral OCT/SLO Opko	B-T073
(0.995)	O
and	O
Cirrus HD-OCT Zeiss-RS-3000 Nidek	B-T073
(0.995),	O
whereas	O
the	O
lowest	O
were	O
seen	O
between	O
SS-1000 CASIA	B-T073
and	O
Spectral OCT/SLO Opko	B-T073
(0.852).	O
ICC	B-T081
and	O
CV	B-T081
showed	O
excellent	O
inter- and intra-operator reproducibility	B-T080
for	O
all	O
optic	B-T090
-based	O
devices	B-T074
,	O
except	O
for	O
the	O
US	B-T074
-based	O
device	B-T074
.	O
Bland-Altman	B-T170
analysis	B-T062
demonstrated	O
low	O
mean	O
biases	B-T078
between	O
operators.	O
Despite	O
highlighting	O
good	O
intra- and inter-operator reproducibility	B-T080
,	O
we	O
found	O
that	O
a	O
scale	B-T170
bias	B-T078
between	O
instruments	B-T074
might	O
interfere with	B-T169
thorough	O
CCT	B-T201
monitoring	B-T058
.	O
We	O
suggest	O
that	O
optimal	B-T080
monitoring	B-T058
is	O
achieved	O
with	O
the	O
same	O
operator	O
and	O
the	O
same	O
device	B-T074
.	O

Predictors	B-T078
of	O
neurologic	B-T046
and	O
nonneurologic death	B-T033
in	O
patients	B-T101
with	O
brain metastasis	B-T191
initially	O
treated	B-T169
with	O
upfront stereotactic radiosurgery	B-T061
without	O
whole-brain radiation therapy	B-T061
In	O
this	O
study	B-T062
we	O
attempted	O
to	O
discern	O
the	O
factors	B-T169
predictive	B-T080
of	O
neurologic death	B-T046
in	O
patients	B-T101
with	O
brain metastasis	B-T191
treated	B-T169
with	O
upfront stereotactic radiosurgery	B-T061
(	O
SRS	B-T061
)	O
without	O
whole brain radiation therapy	B-T061
(	O
WBRT	B-T061
)	O
while	O
accounting	O
for	O
the	O
competing risk	B-T078
of	O
nonneurologic death	B-T033
.	O
We	O
performed	O
a	O
retrospective	B-T080
single-institution	B-T093
analysis	B-T062
of	O
patients	B-T101
with	O
brain metastasis	B-T191
treated	B-T169
with	O
upfront	O
SRS	B-T061
without	O
WBRT	B-T061
.	O
Competing risks analysis	B-T080
was	O
performed	O
to	O
estimate	O
the	O
subdistribution	O
hazard ratios	B-T081
(	O
HRs	B-T081
)	O
for	O
neurologic	B-T046
and	O
nonneurologic death	B-T033
for	O
predictor	B-T078
variables	O
of	O
interest.	O
Of	O
738	O
patients	B-T101
treated	B-T169
with	O
upfront SRS	B-T061
alone,	O
neurologic death	B-T046
occurred	O
in	O
226	O
(30.6%),	O
while	O
nonneurologic death	B-T033
occurred	O
in	O
309	O
(41.9%).	O
Multivariate competing risks analysis	B-T081
identified	O
an	O
increased	B-T081
hazard	B-T081
of	O
neurologic death	B-T046
associated	O
with	O
diagnosis-specific graded prognostic assessment	B-T170
(	O
DS-GPA	B-T170
)	O
≤	O
2	O
(P	O
=	O
.005),	O
melanoma	B-T191
histology	B-T059
(P	O
=	O
.009),	O
and	O
increased	B-T081
number	O
of	O
brain metastases	B-T191
(P<.001),	O
while	O
there	O
was	O
a	O
decreased	B-T081
hazard	B-T081
associated	O
with	O
higher	O
SRS	B-T061
dose	B-T081
(P	O
=	O
.004).	O
Targeted agents	B-T121
were	O
associated	O
with	O
a	O
decreased	B-T081
HR	B-T081
of	O
neurologic death	B-T046
in	O
the	O
first	O
1.5	O
years	B-T079
(P	O
=	O
.04)	O
but	O
not	O
afterwards.	O
An	O
increased	B-T081
hazard	B-T081
of	O
nonneurologic death	B-T033
was	O
seen	O
with	O
increasing	O
age	B-T032
(P	O
=.03),	O
nonmelanoma histology	B-T059
(P<.001),	O
presence	O
of	O
extracranial disease	B-T047
(P<.001),	O
and	O
progressive	B-T169
systemic disease	B-T047
(P	O
=.004).	O
Melanoma	B-T191
,	O
DS-GPA	B-T170
,	O
number	B-T081
of	O
brain metastases	B-T191
,	O
and	O
SRS	B-T061
dose	B-T081
are	O
predictive	B-T080
of	O
neurologic death	B-T046
,	O
while	O
age	B-T032
,	O
nonmelanoma histology	B-T059
,	O
and	O
more	O
advanced	O
systemic disease	B-T047
are	O
predictive	B-T080
of	O
nonneurologic death	B-T033
.	O
Targeted agents	B-T121
appear	O
to	O
delay	B-T079
neurologic death	B-T046
.	O

Pharmacological Actions	B-T038
of	O
Glucagon-Like Peptide-1	B-T116
,	O
Gastric Inhibitory Polypeptide	B-T116
,	O
and	O
Glucagon	B-T116
Glucagon family	B-T116
of	O
peptide hormones	B-T116
is	O
a	O
group	O
of	O
structurally	O
related	O
brain-gut peptides	B-T116
that	O
exert	O
their	O
pleiotropic actions	B-T045
through	O
interactions	B-T045
with	O
unique members of class B1	B-T185
G protein-coupled receptors	B-T116
(	O
GPCRs	B-T116
).	O
They	O
are	O
key	O
regulators	B-T077
of	O
hormonal	B-T080
homeostasis	B-T038
and	O
are	O
important	O
drug targets	B-T074
for	O
metabolic disorders	B-T047
such	O
as	O
type-2 diabetes mellitus	B-T047
(	O
T2DM	B-T047
),	O
obesity	B-T047
,	O
and	O
dysregulations of the nervous systems	B-T047
such	O
as	O
migraine	B-T047
,	O
anxiety	B-T048
,	O
depression	B-T048
,	O
neurodegeneration	B-T049
,	O
psychiatric disorders	B-T048
,	O
and	O
cardiovascular diseases	B-T047
.	O
The	O
current	O
review	O
aims	O
to	O
provide	O
a	O
detailed	O
overview	B-T170
of	O
the	O
current	O
understanding	O
of	O
the	O
pharmacological actions	B-T038
and	O
therapeutic advances	B-T061
of	O
three	O
members	O
within	O
this	O
family	O
including	O
glucagon-like peptide-1	B-T116
(	O
GLP-1	B-T116
),	O
gastric inhibitory polypeptide	B-T116
(	O
GIP	B-T116
),	O
and	O
glucagon	B-T116
.	O

Endemic	B-T082
hydrothermal vent	B-T070
species	B-T185
identified	B-T080
in	O
the	O
open	O
ocean	B-T170
seed bank	B-T002
Hydrothermal vent	B-T070
systems	B-T169
host	O
microbial	B-T001
communities	B-T096
among	O
which	O
several	B-T081
microorganisms	B-T001
have	O
been	O
considered	B-T078
endemic	B-T082
to	O
this	O
type	O
of	O
habitat	B-T082
.	O
It	O
is	O
still	O
unclear	B-T033
how	O
these	O
organisms	B-T001
colonize	B-T033
geographically	B-T083
distant	B-T082
hydrothermal	B-T080
environments	B-T082
.	O
Based	O
on	O
16S rRNA	B-T114
gene sequences	B-T086
,	O
we	O
compare	B-T052
the	O
bacterial	B-T080
communities	B-T096
of	O
sixteen	O
Atlantic	B-T083
hydrothermal vent	B-T070
samples	B-T077
with	O
our	O
own	O
and	O
publicly	O
available	B-T169
global	B-T080
open	O
ocean	B-T170
samples	B-T167
.	O
Analysing	B-T062
sequences	B-T086
obtained	B-T169
from	O
63	O
million	O
16S rRNA	B-T114
genes	B-T028
,	O
the	O
genera	B-T185
we	O
could	O
identify	O
in	O
the	O
open	O
ocean waters	B-T170
contained	B-T169
99.9%	O
of	O
the	O
vent	B-T070
reads.	O
This	O
suggests	B-T078
that	O
previously	B-T079
observed	B-T169
vent	B-T070
exclusiveness	B-T033
is,	O
in	O
most	O
cases	B-T169
,	O
probably	B-T078
an	O
artefact	B-T033
of	O
lower	B-T052
sequencing	B-T059
depth	B-T080
.	O
These	O
findings	B-T033
are	O
a	O
further	O
step	O
towards	O
elucidating	O
the	O
role	B-T170
of	O
the	O
open	O
ocean	B-T170
as	O
a	O
seed bank	B-T002
.	O
They	O
can	O
explain	O
the	O
predicament	B-T033
of	O
how	O
species	B-T185
expected	B-T170
to	O
be	O
endemic	B-T082
to	O
vent	B-T070
systems	B-T169
are	O
able	B-T033
to	O
colonize	B-T033
geographically	B-T083
distant	B-T082
hydrothermal	B-T080
habitats	B-T082
and	O
contribute	B-T052
to	O
our	O
understanding	B-T041
of	O
whether	O
'everything	O
is	O
really	O
everywhere'.	O

Cerebral toxoplasmosis	B-T047
in	O
patients	B-T101
with	O
acquired immune deficiency syndrome	B-T047
in	O
the	O
neurological emergency department	B-T073
of	O
a	O
tertiary hospital	B-T073
Cerebral toxoplasmosis	B-T047
is	O
the	O
most	O
common	O
cause	B-T169
of	O
space	B-T082
occupying	O
brain lesion	B-T047
in	O
patients	B-T101
with	O
HIV/AIDS	B-T047
in	O
Brazil	B-T083
.	O
In	O
the	O
post-HAART era	B-T079
,	O
it	O
is	O
responsible	O
for	O
high	B-T080
rates	B-T081
of	O
morbidity	B-T081
and	O
mortality	B-T081
worldwide.	O
This	O
study	B-T062
consists	O
of	O
a	O
case series	B-T062
of	O
56	O
patients	B-T101
diagnosed	B-T033
with	O
cerebral toxoplasmosis	B-T047
whose	O
clinical	B-T080
features	B-T080
,	O
brain imaging	B-T060
and	O
cerebrospinal fluid	B-T031
aspects	B-T080
were	O
analyzed	B-T062
.	O
Cerebral toxoplasmosis	B-T047
led	O
to	O
the	O
diagnosis	B-T033
of	O
infection	B-T046
by	O
the	O
human immunodeficiency virus	B-T005
(	O
HIV	B-T005
)	O
in	O
27	O
(48.2%)	O
of	O
the	O
patients	B-T101
,	O
while	O
29	O
(51.2%)	O
others	O
already	O
knew	O
to	O
be	O
HIV seropositive	B-T034
.	O
However,	O
at	O
the	O
time	B-T079
of	O
diagnosis	B-T033
of	O
cerebral toxoplasmosis	B-T047
,	O
only	O
9	O
(16.6%)	O
reported	B-T058
being	O
under	O
antiretroviral therapy	B-T061
and	O
5	O
(8.9%)	O
were	O
receiving	B-T080
primary	B-T080
prophylaxis	B-T061
for	O
toxoplasmosis	B-T047
.	O
Headache	B-T184
,	O
strength deficit	B-T184
and	O
fever	B-T184
were	O
the	O
most	O
frequent	O
signs and symptoms	B-T184
throughout	O
the	O
study	B-T062
.	O
Fifty-three	O
patients	B-T101
showed	O
changes	B-T169
consistent with	B-T078
toxoplasmosis	B-T047
in	O
CT	B-T060
or	O
MRI	B-T060
.	O
Thirty-four	O
(60.7%)	O
CSF samples	B-T031
were	O
positive	B-T033
in	O
the	O
indirect haemagglutination test	B-T059
and	O
for	O
the	O
reaction	B-T169
of	O
Toxoplasma gondii IgG	B-T116
ELISA	B-T059
,	O
while	O
31	O
(55.4%)	O
were	O
positive	B-T033
in	O
the	O
direct haemagglutination test	B-T059
.	O
Fifty	O
(89.3%)	O
patients	B-T101
underwent	O
first-line treatment	B-T061
for	O
toxoplasmosis	B-T047
.	O
Cerebral toxoplasmosis	B-T047
is	O
still	O
a	O
very	O
relevant	B-T080
neurological disease	B-T047
in	O
individuals	B-T098
with	O
AIDS	B-T047
admitted	B-T058
to	O
neurology	B-T091
emergency departments	B-T073
.	O
Early diagnosis	B-T060
and	O
initiation	B-T169
of	O
empiric treatment	B-T033
and	O
antiretroviral therapy	B-T061
are	O
important	O
for	O
good	O
prognosis	B-T058
.	O

Maf1	B-T028
-mediated	O
regulation	B-T038
of	O
yeast	B-T004
RNA polymerase III	B-T116
is	O
correlated	B-T080
with	O
CCA addition at the 3' end of tRNA	B-T045
tRNA precursors	B-T114
In	O
eukaryotic cells	B-T025
tRNA synthesis	B-T045
is	O
negatively	B-T033
regulated	B-T038
by	O
the	O
protein Maf1	B-T116
,	O
conserved	O
from	O
yeast	B-T004
to	O
humans	B-T016
.	O
Maf1	B-T028
from	O
yeast	B-T004
Saccharomyces cerevisiae	B-T004
mediates	O
repression	B-T045
of	O
trna transcription	B-T045
when	O
cells	B-T025
are	O
transferred	O
from	O
medium	B-T130
with	O
glucose	B-T109
to	O
medium	B-T130
with	O
glycerol	B-T109
,	O
a	O
non-fermentable	B-T044
carbon	B-T196
source	B-T033
.	O
The	O
strain	B-T001
with	O
deleted	B-T033
gene	B-T028
encoding	B-T052
Maf1	B-T028
(	O
maf1Δ	B-T028
)	O
is	O
viable	B-T080
but	O
accumulates	O
tRNA precursors	B-T114
.	O
In	O
this	O
study	B-T062
tRNA precursors	B-T114
were	O
analysed	B-T062
by	O
RNA-Seq	B-T059
and	O
Northern hybridization	B-T059
in	O
wild type	B-T028
strain	B-T001
and	O
maf1Δ	B-T028
mutant	B-T028
grown	O
in	O
glucose	B-T109
medium	B-T130
or	O
upon	O
shift	O
to	O
repressive conditions	B-T080
.	O
A	O
negative	B-T033
effect	B-T080
of	O
maf1Δ	B-T028
mutant	B-T028
on	O
the	O
addition of the auxiliary CCA nucleotides to the 3' end of pre-tRNAs	B-T045
was	O
observed	O
in	O
cells	B-T025
shifted	O
to	O
unfavourable	O
growth	B-T040
conditions	B-T080
.	O
This	O
effect	B-T080
was	O
reduced	B-T080
by	O
overexpression	B-T045
of	O
the	O
yeast	B-T004
CCA1 gene	B-T028
encoding	B-T052
ATP(CTP):tRNA nucleotidyltransferase	B-T116
.	O
The	O
CCA sequence	B-T086
at	O
the	O
3'	O
end	O
is	O
important	O
for	O
export	B-T067
of	O
tRNA precursors	B-T114
from	O
the	O
nucleus	B-T026
and	O
essential	O
for	O
tRNA charging	B-T045
with	O
amino acids	B-T116
.	O
Data	B-T078
presented	O
here	O
indicate	O
that	O
CCA-addition to intron -containing end-processed tRNA precursors	B-T045
intron	B-T114
-containing	O
end-processed	O
tRNA	O
precursors	O
is	O
a	O
limiting step	B-T077
in	O
tRNA maturation	B-T045
when	O
there	O
is	O
no	O
Maf1	B-T028
mediated	O
RNA polymerase III	B-T116
(	O
Pol III	B-T116
)	O
repression	B-T045
.	O
The	O
correlation	B-T080
between	O
CCA	B-T086
synthesis	B-T044
and	O
Pol III	B-T116
regulation	B-T038
by	O
Maf1	B-T028
could	O
be	O
important	O
in	O
coordination	B-T169
of	O
tRNA transcription	B-T045
,	O
processing	B-T045
and	O
regulation of translation	B-T043
.	O

Pre-existing	B-T080
renal	B-T023
lesions	B-T033
revealed	O
after	O
renal	B-T023
trauma	B-T037
,	O
Difficulties	O
in	O
diagnosis	B-T062
and	O
accountability	B-T078
:	O
About	O
14	O
cases	B-T077
Pre-existing	B-T080
renal	B-T023
lesions	B-T033
(	O
PERL	B-T033
)	O
may	O
interfere	O
with	O
the	O
patho-physiology	B-T169
of	O
trauma	B-T037
,	O
alter	O
the	O
radiographic imaging	B-T060
and	O
influence	B-T077
the	O
therapeutic	B-T061
approach.	O
The	O
aims	B-T078
of	O
this	O
study	B-T062
were	O
to	O
record	O
the	O
PERL	B-T033
found	O
incidentally	O
during	O
blunt	B-T080
renal	B-T023
trauma	B-T037
,	O
to	O
specify	O
the	O
place	O
for	O
effective	O
conservative management	B-T061
and	O
to	O
determin	O
the	O
estimated	O
partial permanent disability	B-T033
(	O
PPD	B-T033
).	O
The	O
medical records	B-T170
of	O
14	O
patients	B-T101
with	O
PERL	B-T033
and	O
blunt	B-T080
renal	B-T023
trauma	B-T037
were	O
reviewed.	O
In	O
each	O
patient	B-T101
,	O
pre-existing	B-T080
renal	B-T023
abnormalities,	O
clinical	B-T080
symptoms	B-T184
,	O
CT scan	B-T060
study	B-T062
findings	B-T033
,	O
associated	O
injuries	B-T037
,	O
therapeutic	B-T061
approach,	O
the	O
accountability	B-T078
criteria	O
and	O
the	O
estimated	O
PPD	B-T033
were	O
recorded.	O
There	O
were	O
11	O
men	B-T098
and	O
3	O
women	B-T098
with	O
a	O
mean	B-T081
age	B-T032
of	O
35,6	O
years	B-T079
(range	O
19-66	O
years	B-T079
).	O
Renal	B-T023
trauma	B-T037
was	O
due	O
to	O
a	O
traffic accident	B-T037
in	O
8	O
patients	B-T101
.	O
Renal	B-T023
damage	O
appeared	O
to	O
be	O
disproportionate	O
to	O
the	O
severity	B-T080
of	O
the	O
trauma	B-T037
(minor	O
trauma	B-T037
).	O
They	O
had	O
a	O
lower	O
rate	O
of	O
associated	O
trauma	B-T037
to	O
other	O
abdominal organs	B-T023
(four	O
patients	B-T101
only).	O
Urinary stones	B-T031
were	O
present	O
in	O
5	O
patients	B-T101
,	O
pelvi-ureteric junction obstruction	B-T046
in	O
3,	O
horseshoe kidny	B-T019
in	O
3,	O
ectopic kidney	B-T019
in	O
2	O
and	O
upper	O
urinary tract carcinoma	B-T191
in	O
one	O
case.	O
Early	O
nephrectomy	B-T061
was	O
required	O
in	O
three	O
cases	B-T077
for	O
hemodynamic instability	B-T047
.	O
Ureteral stenting	B-T074
was	O
indicated	O
in	O
3	O
cases	B-T077
.	O
Six	O
patients	B-T101
were	O
operated	B-T061
later	O
because	O
of	O
their	O
underlying	O
renal	B-T023
pathology	B-T059
.	O
A	O
conservative treatment	B-T061
was	O
possible	O
only	O
in	O
7	O
of	O
cases	B-T077
.	O
The	O
PPD	B-T033
related	O
to	O
renal	B-T023
trauma	B-T037
varide	O
from	O
0	O
to	O
13%	O
in	O
all	O
cases	B-T077
.	O
PERL	B-T033
may	O
complicate	O
a	O
negligible	O
renal	B-T023
trauma	B-T037
while	O
in	O
some	O
cases	B-T077
they	O
may	O
be	O
of	O
vital	O
importance	O
for	O
the	O
patient's	B-T101
final	O
outcome.	O
The	O
imaging	O
findings	B-T033
are	O
crucial	O
but	O
may	O
be	O
confusing.	O
The	O
therapeutic	B-T061
approach	O
is,	O
to	O
a	O
large	O
extent,	O
dependent	O
on	O
the	O
type	O
of	O
PERL	B-T033
and	O
the	O
severity	B-T080
of	O
damage	B-T169
,	O
and	O
is	O
often	O
conservative	O
in	O
the	O
hemo-dynamically stable	B-T033
patient	B-T101
.	O
Accountability	B-T078
link	O
may	O
be	O
difficult	O
to	O
establish	O
and	O
the	O
PPD	B-T033
depends	O
on	O
the	O
PERL	B-T033
and	O
the	O
renal injuries	B-T037
severity	B-T080
.	O
We	O
have	O
no	O
involvement	O
with	O
funding	O
in	O
this	O
case.	O
Ethical	O
approval:	O
Not	O
required	O
Conflicts	O
of	O
interest:	O
None.	O

Polymeric	B-T104
Nanostructure	B-T073
Compiled	O
with	O
Multifunctional Components	B-T077
To	O
Exert	O
Tumor	B-T191
-	O
Targeted Delivery	B-T063
of	O
Antiangiogenic	B-T039
Gene	B-T028
for	O
Tumor Growth	B-T191
Suppression	B-T080
Nucleic acid-based	B-T114
therapy	B-T061
has	O
emerged	O
as	O
a	O
revolutionary methodology	B-T078
for	O
treatment	B-T169
of	O
the	O
diseases	B-T047
related	O
to	O
protein	B-T116
dysfunction	B-T077
;	O
however,	O
lack of	B-T080
systemically	B-T169
applicable	B-T080
synthetic delivery systems	B-T063
limits	O
its	O
current	O
usage	O
in	O
local applications	B-T046
,	O
particularly	O
for	O
DNA-based	B-T114
therapy	B-T061
with	O
regard	O
to	O
the	O
poor bioavailability	B-T081
in	O
the	O
systemic administrations	B-UnknownType
.	O
To	O
overcome	O
this	O
obstacle,	O
we	O
compiled	O
multiple	B-T081
chemistry-based strategies	B-T059
into	O
the	O
manufacture	B-T057
of	O
the	O
gene delivery formulations	B-T063
to	O
pursue	O
improved	B-T033
tolerability	B-T080
of	O
DNA	B-T114
to	O
the	O
enzymatic	B-T044
degradation	B-T044
in	O
the	O
biological	B-T080
milieu	B-T082
and	O
prolonged retention	B-T043
in	O
the	O
systemic	O
circulation.	O
Here,	O
we	O
constructed	O
a	O
distinctive multilayered	B-T080
functional	B-T169
architecture	B-T082
:	O
plasmid DNA	B-T114
(	O
pDNA	B-T114
)	O
was	O
electrostatically complexed	B-T067
with	O
cationic	B-T104
poly(lysine)	B-T116
(	O
polyplex	B-T104
)	O
as	O
the	O
interior	B-T082
pDNA	B-T114
reservoir	B-T082
,	O
which	O
was	O
further	O
cross-linked	B-T070
by	O
redox	B-T044
-	O
responsive	B-T169
disulfide	B-T104
cross-linking	B-T169
to	O
minimize	O
the	O
occurrence	B-T079
of	O
polyplex	B-T104
disassembly	B-T052
through	O
exchange reaction	B-T044
with	O
the	O
biological	B-T080
charged components	B-T196
.	O
Still,	O
the	O
pDNA	B-T114
reservoir	B-T082
was	O
spatially	O
protected	O
by	O
a	O
sequential	B-T080
thermoresponsive	B-T169
poly(N-isopropylacrylamide)	B-T109
palisade	B-T033
as	O
the	O
intermediate barrier	B-T033
and	O
a	O
biocompatible	B-T122
hydrophilic	B-T080
poly(ethylene glycol)	B-T109
(	O
PEG	B-T109
)	O
shell	B-T080
with	O
the	O
aim	O
of	O
preventing	O
the	O
accessibility	B-T080
of	O
the	O
biological	B-T080
species	B-T185
,	O
particularly	O
the	O
nuclease	B-T116
degradation	B-T169
to	O
the	O
pDNA	B-T114
payload.	O
Subsequent	O
investigations	B-T058
validated	O
the	O
utilities	O
of	O
these	O
strategies	B-T041
in	O
accomplishing	O
prolonged	O
blood	B-T031
retention	B-T046
.	O
In	O
an	O
attempt	O
to	O
apply	O
this	O
method	B-T170
for	O
tumor	O
therapy	B-T061
,	O
ligand cyclic (Arg-Gly-Asp) peptide	B-T116
was	O
attached	O
at	O
the	O
distal	O
end	O
of	O
PEG	B-T109
,	O
validating	O
prompted	O
tumor	B-T191
-	O
targeted	B-T169
delivery	B-T077
and	O
gene expression	B-T045
of	O
the	O
loaded	O
antiangiogenic	B-T039
gene	B-T028
at	O
the	O
targeted	B-T169
tumor cells	B-T025
and	O
accordingly	O
exerting	B-T040
antiangiogenesis	B-T039
of	O
the	O
tumors	B-T191
for	O
abrogation	B-T079
of	O
tumor growth	B-T191
.	O
Together	O
with	O
its	O
excellent	O
safe	O
profile,	O
the	O
proposed	O
formulation	O
suggests	O
potential	B-T080
utility	O
as	O
a	O
practical	O
gene delivery system	B-T063
for	O
treatment	B-T169
of	O
intractable	B-T169
diseases	B-T047
.	O

Evaluation	B-T058
of	O
the	O
VIDAS Anti-HCV Assay	B-T059
for	O
Detection	B-T061
of	O
Hepatitis C Virus Infection	B-T047
Anti-hepatitis C virus antibody	B-T116
(	O
anti-HCV	B-T116
)	O
assays	B-T059
are	O
recommended	O
for	O
screening	B-T058
HCV	B-T005
HCV -infected persons	B-T098
.	O
The	O
VIDAS Anti-HCV Assay	B-T059
(bioMérieux,	O
France	B-T083
),	O
based	O
on	O
the	O
enzyme-linked fluorescence test	B-T059
principle	B-T078
,	O
was	O
recently	O
introduced	O
in	O
Korea	B-T083
.	O
We	O
evaluated	O
the	O
clinical	B-T080
performance	B-T052
of	O
the	O
VIDAS assay	B-T059
.	O
One	O
hundred	O
HCV-positive	B-T034
and	O
1,002	O
HCV-negative	B-T034
blood samples	B-T031
confirmed	O
by	O
Architect anti-HCV	B-T059
(	O
Abbott Laboratories	B-T093
,	O
USA	B-T083
)	O
and	O
COBAS TaqMan HCV real-time PCR	B-T063
(	O
Roche Diagnostics	B-T092
,	O
USA	B-T083
)	O
or	O
the	O
Procleix Ultrio Plus Assay	B-T059
(Gen-Probe	O
Incorporated,	O
USA	B-T083
)	O
were	O
obtained	O
from	O
the	O
Human Serum Bank	B-T093
(	O
HSB	B-T093
)	O
and	O
tested	O
by	O
VIDAS	B-T059
.	O
In	O
case	O
of	O
discrepant results	B-T033
,	O
we	O
conducted	O
a	O
recombinant immunoblot assay	B-T059
(	O
RIBA	B-T059
).	O
The	O
agreement rates	B-T081
for	O
known	O
HCV-positive	B-T034
and	O
HCV-negative	B-T034
samples	B-T031
between	O
the	O
VIDAS assay	B-T059
and	O
the	O
HSB	B-T093
testing	O
were	O
100%	O
(95%	O
confidence interval	B-T081
[	O
CI	B-T081
]:	O
96.4-100%)	O
and	O
99.5%	O
(95%	O
CI	B-T081
:	O
98.8-99.8%),	O
respectively.	O
One	O
of	O
the	O
five	O
discrepant	B-T033
samples	B-T031
was	O
positive	B-T033
for	O
Core 2+	B-T129
and	O
NS3-2 2+	B-T129
reactivity,	O
two	O
samples	B-T031
were	O
negative	B-T033
,	O
and	O
the	O
other	O
two	O
were	O
indeterminate	O
regarding	O
NS4 2+	B-T129
reactivity	O
in	O
RIBA	B-T059
.	O
We	O
observed	O
a	O
significant	O
but	O
weak	O
positive	O
correlation	B-T080
between	O
the	O
titers	B-T081
of	O
VIDAS	B-T059
and	O
Architect assays	B-T059
(r=0.315,	O
P<0.001).	O
The	O
VIDAS anti-HCV assay	B-T059
,	O
developed	O
on	O
the	O
VIDAS	B-T059
automated immunoassay platform	B-T059
based	O
on	O
the	O
ready-to-use,	O
single-sample	O
test	O
concept	O
may	O
be	O
useful	O
in	O
small-to-medium-sized	O
laboratories	B-T073
.	O
It	O
showed	O
good	O
agreement	O
with	O
Architect anti-HCV	B-T059
and	O
COBAS PCR assays	B-T063
and	O
is	O
therefore	O
useful	O
for	O
detection	O
of	O
HCV infection	B-T047
.	O
Weakly test-positive (ambiguous)	B-T034
samples	B-T031
require	O
additional	O
testing	O
by	O
another	O
anti-HCV	B-T116
,	O
RIBA	B-T059
,	O
or	O
HCV RNA assay	B-T059
.	O

Reassembly of Excitable Domains	B-T042
after	O
CNS	B-T022
Axon Regeneration	B-T042
Action potential initiation	B-T043
and	O
propagation	B-T043
in	O
myelinated axons	B-UnknownType
require	O
ion channel clustering	B-T043
at	O
axon initial segments	B-T026
(AIS	B-T026
)	O
and	O
nodes of Ranvier	B-T030
.	O
Disruption	B-T169
of	O
these	O
domains	O
after	O
injury	B-T037
impairs	B-T169
nervous system function	B-T042
.	O
Traditionally,	O
injured	B-T169
CNS	B-T022
axons	B-T026
are	O
considered	O
refractory	B-T040
to	O
regeneration	B-T042
,	O
but	O
some	O
recent	O
approaches	O
challenge	O
this	O
view	O
by	O
showing	O
robust	B-T080
long-distance	B-T081
regeneration	B-T042
.	O
However,	O
whether	O
these	O
approaches	O
allow	O
remyelination	B-T042
and	O
promote	O
the	O
reestablishment	B-T042
of	O
AIS	B-T026
and	O
nodes of Ranvier	B-T030
is	O
unknown	B-T080
.	O
Using	O
mouse	B-T015
optic nerve	B-T023
crush	B-T037
as	O
a	O
model	B-T050
for	O
CNS	B-T022
traumatic injury	B-T037
,	O
we	O
performed	O
a	O
detailed	O
analysis	B-T062
of	O
AIS	B-T026
and	O
node	B-T030
disruption	B-T169
after	O
nerve crush	B-T037
.	O
We	O
found	O
significant	O
disruption	B-T169
of	O
AIS	B-T026
and	O
loss	B-T081
of	O
nodes	B-T030
within	O
days	O
of	O
the	O
crush	B-T037
,	O
and	O
complete	O
loss	B-T081
of	O
nodes	B-T030
1	O
week	O
after	O
injury	B-T037
.	O
Genetic deletion	B-T045
of	O
the	O
tumor suppressor phosphatase and tensin homolog	B-T028
(	O
Pten	B-T028
)	O
in	O
retinal ganglion cells	B-T025
(	O
RGCs	B-T025
),	O
coupled	O
with	O
stimulation	B-T043
of	O
RGCs	B-T025
by	O
inflammation	B-T046
and	O
cAMP	B-T114
,	O
dramatically	O
enhanced	O
regeneration	B-T042
.	O
With	O
this	O
treatmen	B-T062
t,	O
we	O
found	O
significant	O
reestablishment	B-T042
of	O
RGC	B-T025
AIS	B-T026
,	O
remyelination	B-T042
,	O
and	O
even	O
reassembly	B-T042
of	O
nodes	B-T030
in	O
regions proximal	B-T082
,	O
within	B-T082
,	O
and	O
distal	B-T082
to	O
the	O
crush	B-T037
site	B-T029
.	O
Remyelination	B-T042
began	O
near the retina	B-T029
,	O
progressed	B-T169
distally	B-T082
,	O
and	O
was	O
confirmed	O
by	O
electron microscopy	B-T059
.	O
Although	O
axons	B-T026
grew	B-T043
rapidly	B-T080
,	O
remyelination	B-T042
and	O
nodal ion channel clustering	B-T043
was	O
much	O
slower	B-T080
.	O
Finally,	O
genetic deletion	B-T045
of	O
ankyrinG	B-T116
from	O
RGCs	B-T025
to	O
block	B-T169
AIS	B-T026
reassembly	B-T042
did	O
not	O
affect	O
axon regeneration	B-T042
,	O
indicating	O
that	O
preservation	O
of	O
neuronal polarity	B-T082
is	O
not required	B-T033
for	O
axon regeneration	B-T042
.	O
Together,	O
our	O
results	O
demonstrate,	O
for	O
the	O
first	O
time,	O
that	O
regenerating	B-T042
CNS	B-T022
axons	B-T026
can	O
be	O
remyelinated	B-T042
and	O
reassemble	B-T042
new	O
AIS	B-T026
and	O
nodes of Ranvier	B-T030
.	O
We	O
show,	O
for	O
the	O
first	O
time,	O
that	O
regenerated	B-T042
CNS	B-T022
axons	B-T026
have	O
the	O
capacity	B-T081
to	O
both	O
remyelinate	B-T042
and	O
reassemble	B-T042
the	O
axon initial segments	B-T026
and	O
nodes of Ranvier	B-T030
necessary	O
for	O
rapid	B-T080
and	O
efficient	B-T080
action potential propagation	B-T043
.	O

Clinicopathological	B-T091
relevance	O
of	O
kinesin family member 18A	B-T116
expression	B-T045
in	O
invasive breast cancer	B-T191
Recently,	O
kinesin	B-T116
motor proteins	B-T116
have	O
been	O
focused	O
on	O
as	O
targets	B-T169
for	O
cancer therapy	B-T061
.	O
Kinesins	B-T116
are	O
microtubule	B-T116
-based	O
motor proteins	B-T116
that	O
mediate	O
diverse functions	B-T169
within	O
the	O
cell	B-T025
,	O
including	O
the	O
transport	B-T043
of	O
vesicles	B-T026
,	O
organelles	B-T026
,	O
chromosomes	B-T026
and	O
protein complexes	B-T116
,	O
as	O
well	O
as	O
the	O
movement of microtubules	B-T043
.	O
In	O
the	O
current	O
study,	O
the	O
expression	B-T045
of	O
kinesin family member 18A	B-T116
(	O
KIF18A	B-T116
),	O
a	O
member of kinesin superfamily	B-T116
,	O
was	O
investigated	B-T169
in	O
breast cancer	B-T191
using	O
immunohistochemistry	B-T060
,	O
and	O
its	O
effect	O
on	O
breast cancer	B-T191
prognosis	O
was	O
examined.	O
KIF18A	B-T116
expression level	B-T081
was	O
significantly	O
associated with	B-T080
lymph node metastasis	B-T191
(P=0.047).	O
In	O
patients	B-T101
with	O
high	O
levels	O
of	O
KIF18A	B-T116
expression	B-T045
,	O
survival	B-T052
was	O
significantly	O
poorer	O
compared	O
to	O
patients	B-T101
with	O
low	O
levels	O
of	O
KIF18A	B-T116
expression	B-T045
(	O
disease-free survival	B-T081
,	O
P=0.030).	O
Multivariate analysis	B-T081
revealed	O
that	O
venous invasion	B-T033
(	O
hazard ratio	B-T081
,	O
9.22;	O
95%	O
confidence interval	B-T081
,	O
3.90-23.66;	O
P<0.001)	O
and	O
KIF18A	B-T116
expression	B-T045
(	O
hazard ratio	B-T081
,	O
3.20;	O
95%	O
confidence interval	B-T081
,	O
1.34-6.09;	O
P=0.010)	O
were	O
independent	O
predictive factors	B-T170
for	O
lymph node metastasis	B-T191
.	O
KIF18A	B-T116
may	O
be	O
a	O
useful	O
predictive	B-T170
marker	B-T201
for	O
lymph node metastasis	B-T191
in	O
breast cancer	B-T191
,	O
which	O
could	O
facilitate	O
curative adjuvant	B-T033
treatment	B-T061
.	O

The	O
underlying	O
inflammatory chronic disease	B-T047
influences	B-T077
infliximab	B-T116
pharmacokinetics	B-T169
Infliximab	B-T116
is	O
an	O
anti-tumor necrosis factor	B-T121
monoclonal antibody	B-T116
approved	O
in	O
chronic inflammatory diseases	B-T047
such	O
as	O
rheumatoid arthritis	B-T047
(	O
RA	B-T047
),	O
psoriatic arthritis	B-T047
(	O
PsA	B-T047
),	O
ankylosing spondylitis	B-T047
(	O
AS	B-T047
),	O
Crohn's disease	B-T047
(	O
CD	B-T047
)	O
and	O
ulcerative colitis	B-T047
(	O
UC	B-T047
).	O
Infliximab	B-T116
pharmacokinetics	B-T169
is	O
variable	O
between	O
patients	B-T101
,	O
but	O
influence	B-T077
of	O
the	O
underlying disease	B-T047
was	O
never	O
assessed	B-T052
.	O
This	O
study	O
aimed	O
at	O
assessing	O
this	O
influence	B-T077
using	O
a	O
cohort	B-T098
of	O
patients monitored	B-T058
in	O
a	O
single	O
center	O
and	O
with	O
the	O
same	O
assay	B-T059
.	O
Infliximab	B-T116
trough	O
concentrations	B-T081
were	O
determined	B-T080
on	O
samples collected	B-T059
between	O
weeks	O
0	O
and	O
22	O
after	O
treatment	B-T169
initiation	B-T169
in	O
218	O
patients	B-T101
treated	B-T169
for	O
RA	B-T047
,	O
PsA	B-T047
,	O
AS	B-T047
,	O
CD	B-T047
or	O
UC	B-T047
.	O
Infliximab	B-T116
pharmacokinetics	B-T169
was	O
analyzed	B-T062
by	O
a	O
one-compartment	O
population	B-T098
model	O
with	O
first-order	O
elimination	B-T033
rate constant	B-T081
.	O
In	O
AS	B-T047
patients	B-T101
,	O
volume of distribution	B-T081
(	O
V	B-T081
)	O
and	O
elimination	B-T033
clearance	B-T080
(	O
CL	B-T080
)	O
were	O
5.4	O
L	O
and	O
0.24	O
L/day,	O
respectively.	O
In	O
CD	B-T047
and	O
UC	B-T047
patients	B-T101
,	O
V	O
was	O
49%	O
and	O
52%	O
higher	O
than	O
in	O
AS	B-T047
,	O
respectively,	O
and	O
CL	B-T080
was	O
47%	O
and	O
60%	O
higher	O
than	O
in	O
AS	B-T047
,	O
respectively.	O
In	O
RA	B-T047
patients	B-T101
,	O
CL	B-T080
was	O
49%	O
higher	O
than	O
in	O
AS	B-T047
patients	B-T101
.	O
Simulations	B-T062
showed	O
that	O
without	O
methotrexate	B-T109
,	O
a	O
3	O
mg/kg	O
dosing	B-T081
regimen	B-T061
would	O
lead	O
only	O
16%	O
of	O
RA	B-T047
patients	B-T101
to	O
reach	O
the	O
target	B-T169
concentration	B-T081
(2.5	O
mg/L)	O
at	O
week	O
22,	O
whereas	O
target	B-T169
concentrations	B-T081
would	O
be	O
reached	O
in	O
approximately	B-T080
half	O
of	O
RA	B-T047
patients	B-T101
cotreated	B-T169
with	O
methotrexate	B-T109
,	O
as	O
well	O
as	O
half	O
of	O
CD	B-T047
(3.5	O
mg/L)	O
and	O
UC	B-T047
(3.7	O
mg/L)	O
patients	B-T101
.	O
The	O
suboptimality	O
of	O
approved	O
dosing	B-T081
regimens	B-T061
supports	O
the	O
development	B-T169
of	O
dosing	B-T081
optimization	B-T052
based	O
on	O
concentration measurements	B-T081
.	O

International	B-T078
validation	B-T062
of	O
a	O
urinary	B-T031
biomarker	B-T201
panel	B-T059
for	O
identification	O
of	O
active	B-T169
lupus nephritis	B-T047
in	O
children	B-T100
Conventional	O
markers	B-T201
of	O
juvenile-onset systemic lupus erythematosus	B-T047
(	O
JSLE	B-T047
)	O
disease activity	B-T060
fail	O
to	O
adequately	O
identify	O
lupus nephritis	B-T047
(	O
LN	B-T047
).	O
While	O
individual	O
novel	B-T080
urine	B-T031
biomarkers	B-T201
are	O
good	O
at	O
detecting	B-T061
LN	B-T047
flares	B-T184
,	O
biomarker	B-T201
panels	B-T059
may	O
improve	O
diagnostic accuracy	B-T080
.	O
The	O
aim	B-T078
of	O
this	O
study	B-T062
was	O
to	O
assess	B-T052
the	O
performance	O
of	O
a	O
biomarker	B-T201
panel	B-T059
to	O
identify	O
active	B-T169
LN	B-T047
in	O
two	O
international	B-T078
JSLE	B-T047
cohorts	B-T098
.	O
Novel	O
urinary	B-T031
biomarkers	B-T201
,	O
namely	O
vascular cell adhesion molecule-1	B-T116
(	O
VCAM-1	B-T116
),	O
monocyte chemoattractant protein 1	B-T116
(	O
MCP-1	B-T116
),	O
lipocalin-like prostaglandin D synthase	B-T116
(	O
LPGDS	B-T116
),	O
transferrin	B-T116
(	O
TF	B-T116
),	O
ceruloplasmin	B-T116
,	O
alpha-1-acid glycoprotein	B-T116
(	O
AGP	B-T116
)	O
and	O
neutrophil gelatinase-associated lipocalin	B-T116
(	O
NGAL	B-T116
),	O
were	O
quantified	B-T081
in	O
a	O
cross-sectional study	B-T062
that	O
included	O
participants	B-T098
of	O
the	O
UK	B-T083
JSLE	B-T047
Cohort Study	B-T081
(	O
Cohort 1	B-T098
)	O
and	O
validated	O
within	O
the	O
Einstein Lupus	B-T093
Cohort	B-T098
(	O
Cohort 2	B-T098
).	O
Binary	B-T080
logistic regression modelling	B-T062
and	O
receiver operating characteristic	B-T081
curve analysis	B-T081
[	O
area under the curve	B-T081
(	O
AUC	B-T081
)]	O
were	O
used	O
to	O
identify	O
and	O
assess	B-T052
combinations	B-T080
of	O
biomarkers	B-T201
for	O
diagnostic accuracy	B-T080
.	O
A	O
total	O
of	O
91	O
JSLE	B-T047
patients	B-T101
were	O
recruited	O
across	O
both	O
cohorts	B-T098
,	O
of	O
whom	O
31	O
(34	O
%)	O
had	O
active	B-T169
LN	B-T047
and	O
60	O
(66	O
%)	O
had	O
no	O
LN	B-T047
.	O
Urinary	B-T031
AGP	B-T116
,	O
ceruloplasmin	B-T116
,	O
VCAM-1	B-T116
,	O
MCP-1	B-T116
and	O
LPGDS	B-T116
levels	B-T080
were	O
significantly higher	B-T081
in	O
those	O
patients	B-T101
with	O
active	B-T169
LN	B-T047
than	O
in	O
non	B-T169
-	O
LN	B-T047
patients	B-T101
[all	O
corrected	O
p	O
values	O
(p	O
c)	O
<	O
0.05]	O
across	O
both	O
cohorts	B-T098
.	O
Urinary	B-T031
TF	B-T116
also	O
differed	O
between	O
patient	B-T101
groups	O
in	O
Cohort 2	B-T098
(p	O
c	O
=	O
0.001).	O
Within	O
Cohort 1	B-T098
,	O
the	O
optimal	B-T080
biomarker	B-T201
panel	B-T059
included	O
AGP	B-T116
,	O
ceruloplasmin	B-T116
,	O
LPGDS	B-T116
and	O
TF	B-T116
(	O
AUC	B-T081
0.920	O
for	O
active	B-T169
LN	B-T047
identification).	O
These	O
results	O
were	O
validated	O
in	O
Cohort 2	B-T098
,	O
with	O
the	O
same	O
markers	B-T201
resulting	O
in	O
the	O
optimal	B-T080
urine	B-T031
biomarker	B-T201
panel	B-T059
(	O
AUC	B-T081
0.991).	O
In	O
two	O
international	B-T078
JSLE	B-T047
cohorts	B-T098
,	O
urinary	B-T031
AGP	B-T116
,	O
ceruloplasmin	B-T116
,	O
LPGDS	B-T116
and	O
TF	B-T116
demonstrate	O
an	O
'excellent'	O
ability	O
for	O
accurately	O
identifying	O
active	B-T169
LN	B-T047
in	O
children	B-T100
.	O

Fine	O
structure	O
of	O
interleukin 18 (IL-18) receptor	B-T116
-	O
immunoreactive	B-T022
neurons	B-T025
in	O
the	O
retrosplenial cortex	B-T023
and	O
its	O
changes	O
in	O
IL18	B-T028
knockout mice	B-T015
Interleukin 18	B-T116
(	O
IL-18	B-T116
)	O
participates	O
in	O
the	O
inflammatory	B-T169
immune response	B-T042
immune response	B-T042
of	O
lymphocytes	B-T025
.	O
Delay in learning or memory	B-T079
are	O
common	O
in	O
the	O
IL-18	B-T028
knockout mouse	B-T015
.	O
Many	O
IL-18	B-T116
-	O
immunoreactive	B-T022
neurons	B-T025
are	O
found	O
in	O
the	O
retrosplenial cortex	B-T023
(	O
RSC	B-T023
)	O
and	O
the	O
subiculum	B-T023
.	O
These	O
neurons	B-T025
also	O
contain	O
the	O
IL-18 receptor	B-T116
.	O
We	O
determined	O
the	O
location	O
and	O
the	O
ultrastructure	B-T078
of	O
the	O
IL-18 receptor	B-T116
-	O
immunoreactive	B-T022
neurons	B-T025
in	O
the	O
RSC	B-T023
and	O
observed	O
changes	O
in	O
the	O
IL-18 receptor	B-T116
-	O
immunoreactive	B-T022
neurons	B-T025
of	O
the	O
IL-18	B-T028
knockout mouse	B-T015
.	O
The	O
IL-18 receptor	B-T116
-	O
immunoreactive	B-T022
neurons	B-T025
were	O
found	O
specifically	O
in	O
layer V of the granular RSC	B-T029
.	O
They	O
were	O
medium-sized	O
neurons	B-T025
with	O
a	O
light	O
oval nucleus	B-T026
and	O
had	O
little	O
cytoplasm	B-T026
with	O
many	O
free ribosomes	B-T026
,	O
rough	O
endoplasmic reticulum	B-T026
and	O
many	O
mitochondria	B-T026
,	O
but	O
no	O
Nissl bodies	B-T026
.	O
The	O
number	O
of	O
axosomatic terminals	B-T030
was	O
about	O
six	O
per	O
section.	O
The	O
IL-18 receptor	B-T116
-	O
immunoreactive	B-T022
neurons	B-T025
were	O
not	O
found	O
in	O
the	O
RSC	B-T023
in	O
the	O
IL-18	B-T028
knockout mouse	B-T015
at	O
5	O
or	O
9	O
weeks	O
of	O
age.	O
However,	O
many	O
small electron-dense	B-T085
neurons	B-T025
were	O
found	O
in	O
layer V	B-T029
.	O
Both	O
the	O
nucleus	B-T026
and	O
cytoplasm	B-T026
were	O
electron-dense	B-T085
,	O
but	O
not	O
necrotic.	O
The	O
mitochondria	B-T026
and	O
rough endoplasmic reticulum	B-T026
were	O
swollen	B-T033
.	O
The	O
IL-18 receptor	B-T116
-	O
immunoreactive	B-T022
neurons	B-T025
were	O
presumed	O
to	O
be	O
degenerating	B-T033
.	O
The	O
degeneration	B-T049
of	O
the	O
IL18-receptor	B-T116
-	O
immunoreactive	B-T022
neurons	B-T025
in	O
the	O
RSC	B-T023
may	O
cause	O
the	O
abnormal behaviors	B-T048
of	O
the	O
IL-18	B-T028
knockout mice	B-T015
.	O

Exploring	O
the	O
genetic	B-T169
variability	B-T077
in	O
water	B-T121
use	B-T169
efficiency	B-T081
:	O
Evaluation	O
of	O
inter	B-T079
and	O
intra cultivar	B-T002
genetic diversity	B-T070
in	O
grapevines	B-T002
Genetic	B-T169
improvement	B-T077
of	O
crop	B-T002
Water	B-T121
Use	B-T169
Efficiency	B-T081
(	O
WUE	B-T081
)	O
is	O
a	O
general	O
goal	B-T078
because	O
the	O
increasing	B-T169
water	B-T121
scarcity	B-T169
and	O
the	O
trend	O
to	O
a	O
more	O
sustainable	B-T169
agriculture	B-T090
.	O
For	O
grapevines	B-T002
,	O
this	O
subject	B-T078
is	O
relevant	B-T080
and	O
need	O
an	O
urgent	O
response	O
because	O
their	O
wide	O
distribution	B-T169
in	O
semi-arid	B-T070
areas	B-T082
.	O
New	O
cultivars	B-T002
are	O
difficult	B-T080
to	O
introduce	B-T169
in	O
viticulture	B-UnknownType
due	O
to	O
the	O
narrow	O
dependency	O
of	O
consumer	B-T098
appreciation	B-T077
often	O
linked	O
to	O
a	O
certain	O
particular	O
wine	B-T168
taste	B-T081
.	O
Clones	B-T024
of	O
reputed	O
cultivars	B-T002
would	O
presumably	O
be	O
more	O
accepted	B-T080
but	O
little	O
is	O
known	O
on	O
the	O
intra-cultivar	B-T002
genetic	B-T169
variability	B-T077
of	O
the	O
WUE	B-T081
.	O
The	O
present	O
work	O
compares	B-T052
,	O
on	O
the	O
basis	O
of	O
two	O
field	B-T090
assays,	O
the	O
variability	B-T077
of	O
intrinsic	O
water	B-T121
use	B-T169
efficiency	B-T081
(	O
WUEi	B-T081
)	O
in	O
a	O
large	O
collection	B-T169
of	O
cultivars	B-T002
in	O
contrast	B-T080
with	O
a	O
collection	B-T169
of	O
clones	B-T024
of	O
Tempranillo cultivar	B-T002
.	O
The	O
results	B-T169
show	O
that	O
clonal	B-T080
variability	B-T077
of	O
WUEi	B-T081
was	O
around	B-T078
80%	O
of	O
the	O
inter-cultivar	B-T002
,	O
thus	O
providing	O
a	O
first	O
assessment	B-T052
on	O
the	O
opportunity	O
for	O
clonal	B-T080
selection	B-T052
by	O
WUE	B-T081
.	O
Plotting	O
the	O
WUEi	B-T081
data	B-T078
against	O
stem	B-T002
water	B-T121
potential	B-T080
or	O
stomatal conductance	B-T039
it	O
was	O
possible	B-T033
to	O
identify	B-T080
cultivars	B-T002
and	O
clones	B-T024
out	O
of	O
the	O
confidence intervals	B-T081
of	O
this	O
linear regression	B-T081
thus	O
with	O
significantly higher	B-T081
and	O
lower	B-T081
WUEi	B-T081
values	B-T081
.	O
The	O
present	O
results	B-T169
contribute	B-T052
to	O
open	O
the	O
expectative	O
for	O
a	O
genetic	B-T169
improvement	B-T077
of	O
grapevine	B-T002
WUE	B-T081
.	O

Comparison	O
of	O
methods	O
for	O
isolating	B-T059
primary	B-T080
hepatocytes	B-T025
from	O
mini pigs	B-T015
Successful	O
porcine	B-T015
hepatocyte	B-T025
isolation	B-T059
is	O
crucial	O
for	O
the	O
development	B-T169
of	O
bioartificial liver devices	B-T074
and	O
hepatocyte transplantation	B-T061
.	O
Serva collagenase NB grades	B-T116
are	O
formulated	O
collagenases	B-T116
that	O
are	O
suitable	O
for	O
various	O
tissue	B-T024
isolation	B-T059
applications.	O
N-acetylcysteine	B-T116
(	O
NAC	B-T116
)	O
can	O
improve	O
the	O
viability	B-T080
of	O
human	B-T016
hepatocytes	B-T025
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
effectiveness	B-T080
of	O
two	O
collagenases	B-T116
and	O
effect of	B-T080
NAC	B-T116
on	O
hepatocyte	B-T025
isolation	B-T059
from	O
porcine	B-T015
liver tissue	B-T023
.	O
Porcine	B-T015
hepatocytes	B-T025
were	O
isolated	B-T059
using	O
the	O
perfusion method	B-T061
from	O
Bama	O
mini pigs	B-T015
assigned	O
to	O
the	O
Serva NB 4	B-T116
group	B-T078
(n=6),	O
the	O
Serva NB 8	B-T116
group	B-T078
(n=6),	O
or	O
the	O
NB 8	B-T116
+	O
NAC	B-T116
group	B-T078
(n=6).	O
Viability	B-T080
and	O
yield	O
were	O
defined	O
as	O
fresh	O
hepatocytes	B-T025
and	O
their	O
spheroids formation	B-T033
after	O
24-hour	O
rocker culture	B-T059
in	O
serum-free medium	B-T130
.	O
Metabolic function	B-T040
was	O
assessed	O
by	O
gene expression	B-T045
,	O
albumin	B-T116
,	O
and	O
urea	B-T109
synthesis	B-T038
.	O
All	O
procedures	O
resulted	O
in	O
successful	O
hepatocyte	B-T025
isolation	B-T059
.	O
Cells	B-T025
from	O
the	O
NB 8	B-T116
+	O
NAC	B-T116
group	B-T078
had	O
(97.8±1.9)%	O
viability	B-T080
,	O
which	O
was	O
higher	O
than	O
the	O
NB 8	B-T116
group	B-T078
with	O
(94.4±2.4)%	O
and	O
the	O
NB 4	B-T116
group	B-T078
with	O
(94.5±3.2)%	O
(P<.001).	O
The	O
final	O
cell	B-T025
yield	O
reached	O
(11.8±1.0)×10(9)	O
cells	B-T025
in	O
the	O
NB 8	B-T116
+	O
NAC	B-T116
group	B-T078
,	O
compared	O
to	O
(9.5±2.1)×10(9)	O
cells	B-T025
in	O
the	O
NB 8	B-T116
group	B-T078
(P<.01)	O
and	O
(9.1±1.1)	O
×10(9)	O
cells	B-T025
in	O
the	O
NB 4	B-T116
group	B-T078
(P<.001).	O
The	O
secretion	B-T038
of	O
albumin	B-T116
was	O
superior	O
in	O
the	O
NB 8	B-T116
+	O
NAC	B-T116
group	B-T078
at	O
a	O
concentration	O
of	O
(425.8±35.3)	O
ng/mL	O
compared	O
to	O
the	O
NB 8	B-T116
group	B-T078
(339.1±32.6)	O
ng/mL	O
(P	O
<.001)	O
and	O
NB 4	B-T116
group	B-T078
(293.6±43.3)	O
ng/mL	O
(P	O
<.01).	O
The	O
injury	B-T037
of	O
hepatocytes	B-T025
also	O
decreased	O
in	O
the	O
NB 8	B-T116
+	O
NAC	B-T116
group	B-T078
(P<.01).	O
The	O
data	O
are	O
presented	O
as	O
means ± SD	B-T081
.	O
Formulated	O
collagenase Serva NB 8	B-T116
and	O
NAC	B-T116
could	O
improve	O
the	O
porcine	B-T015
hepatocyte	B-T025
isolation	B-T059
,	O
resulting	O
in	O
higher	O
yields	O
of	O
viable cells	B-T025
.	O

Endothermal venous ablation	B-T061
of	O
the	O
saphenous vein	B-T023
on	O
patients	B-T101
who	O
are	O
on	O
anticoagulation therapy	B-T061
The	O
purpose	O
of	O
this	O
study	B-T062
was	O
to	O
evaluate	O
the	O
risks	B-T078
of	O
bleeding	B-T046
,	O
deep venous thrombosis	B-T047
(	O
DVT	B-T047
),	O
endovenous heat induced thrombosis	B-T046
(	O
EHIT	B-T046
)	O
and	O
failure	B-T169
of	O
ablation	B-T061
on	O
patients	B-T101
who	O
undergo	O
ablation	B-T061
while	O
on	O
oral anticoagulation	B-T061
.	O
We	O
compared	B-T052
378	O
(3.4%)	O
out	O
of	O
11252	O
patients	B-T101
(	O
group A	B-T185
)	O
who	O
had	O
undergone	O
724	O
endovenous ablation	B-T061
of	O
the	O
saphenous veins	B-T023
from	O
January	O
1,	O
2011	O
to	O
September	O
30,	O
2014	O
while	O
on	O
oral anticoagulation	B-T061
to	O
a	O
randomly	O
selected	O
375	O
patients	B-T101
(	O
group B	B-T185
)	O
who	O
underwent	O
641	O
endovenous ablation	B-T061
in	O
the	O
same	O
time period	B-T079
but	O
were	O
not	O
on	O
anticoagulation	B-T061
.	O
The	O
demographic data	B-T081
,	O
history of	B-T033
DVT	B-T047
,	O
the	O
Clinical	B-T080
,	O
Etiologic	B-T080
,	O
Anatomic	B-T080
,	O
Pathologic	B-T169
(	O
CEAP	B-T080
)	O
classification	B-T185
and	O
the	O
VCSS	B-T081
(	O
Venous Clinical Severity Score	B-T081
)	O
scores	O
were	O
analyzed.	O
The	O
indications	B-T078
for	O
anticoagulation	B-T061
,	O
the	O
anticoagulants	B-T121
used	O
were	O
recorded.	O
The	O
primary	O
endpoints	O
were	O
bleeding	B-T046
,	O
development	O
of	O
DVT	B-T047
or	O
EHIT	B-T046
,	O
and	O
failure	B-T169
of	O
ablation	B-T061
.	O
Patients	B-T101
in	O
group A	B-T185
were	O
older	B-T098
,	O
had	O
more	O
men	B-T098
,	O
more	O
history	O
of	O
DVT	B-T047
and	O
PE	B-T047
,	O
had	O
higher	O
CEAP	B-T080
and	O
VCSS	B-T081
scores	O
compared	O
to	O
group B	B-T185
.	O
The	O
type	O
of	O
anticoagulation	B-T061
used	O
was	O
warfarin	B-T109
in	O
77.2%	O
direct oral inhibitors	B-T121
(	O
DOIs	B-T121
)	O
in	O
22.8%.	O
The	O
rate	B-T081
of	O
failure	B-T169
of	O
ablation	B-T061
at	O
3	O
days	B-T079
was	O
39	O
(5.6%)	O
for	O
Group A	B-T185
and	O
3	O
(0.5%)	O
for	O
Group B	B-T185
(P<0.0001)	O
and	O
at	O
one month	B-T079
it	O
was	O
46	O
(10.1%)	O
vs.	O
27	O
(6.7%)	O
(P=0.086).	O
The	O
number	O
of	O
EHIT	B-T046
cases	B-T169
in	O
group A	B-T185
at	O
3	O
days	B-T079
was	O
2	O
(0.3%),	O
compared	O
to	O
6	O
(0.9%)	O
in	O
group B	B-T185
(P=0.016)	O
and	O
at	O
1 month	B-T079
it	O
was	O
0	O
compared	O
to	O
4	O
(1.0%)	O
(P=0.0483).	O
The	O
DVT	B-T047
,	O
SVT	B-T047
,	O
hematoma	B-T046
and	O
wound infection	B-T046
rates	B-T081
were	O
similar	O
in	O
the	O
two	O
groups	B-T078
.	O
Ablation	B-T061
of	O
the	O
saphenous veins	B-T023
in	O
patients	B-T101
who	O
are	O
on	O
oral anticoagulation	B-T061
is	O
safe	O
and	O
does	O
not	O
increase	O
the	O
risk	B-T078
of	O
bleeding	B-T046
or	O
hematoma	B-T046
,	O
but	O
it	O
may	O
slightly	O
lower	O
the	O
incidence	B-T081
of	O
EHIT	B-T046
and	O
increase	O
the	O
incidence	B-T081
of	O
failure	B-T169
of	O
ablation	B-T061
.	O

Variation analysis	B-T062
of	O
PRIM1 gene	B-T028
in	O
Chinese	B-T098
patients	B-T101
with	O
primary ovarian insufficiency	B-T047
Insights	O
into	O
common	O
genetic susceptibility	B-T032
between	O
primary ovarian insufficiency	B-T047
(	O
POI	B-T047
)	O
and	O
natural	B-T040
or	O
early menopause	B-T047
have	O
delivered	B-T169
an	O
innovative	O
way	O
of	O
assessing	O
the	O
genetic mechanisms	B-T169
involved	O
in	O
POI	B-T047
.	O
PRIM1	B-T028
plays	O
a	O
crucial	O
role	O
in	O
DNA replication	B-T045
by	O
synthesizing	B-T052
RNA primers	B-T114
for	O
Okazaki fragments	B-T114
.	O
It	O
is	O
closely	O
associated with	B-T080
age	B-T032
at	O
natural menopause	B-T040
,	O
early menopause	B-T047
and	O
POI	B-T047
in	O
European	B-T098
women	B-T098
.	O
In	O
this	O
study	B-T062
,	O
we	O
aimed	O
to	O
investigate	B-T169
whether	O
mutations	B-T045
in	O
PRIM1	B-T028
contribute	O
to	O
POI	B-T047
in	O
Chinese	B-T098
women	B-T098
.	O
All	O
exons	B-T114
and	O
exon-intron boundaries	B-T114
of	O
PRIM1 gene	B-T028
were	O
sequenced	B-T059
in	O
192	O
Han Chinese	B-UnknownType
women	B-T098
with	O
non-syndromic	O
POI	B-T047
.	O
No	O
plausible	O
mutations	B-T045
were	O
identified	B-T080
.	O
The	O
results	O
suggest	O
that	O
the	O
perturbations	B-T169
in	O
PRIM1 gene	B-T028
are	O
not	O
a	O
common	O
explanation	O
for	O
POI	B-T047
in	O
Chinese	B-T098
women	B-T098
.	O

Selection	B-T052
of	O
a	O
marker gene	B-T028
to	O
construct	O
a	O
reference library	B-T073
for	O
wetland	B-T070
plants	B-T002
,	O
and	O
the	O
application	O
of	O
metabarcoding	B-T062
to	O
analyze	B-T062
the	O
diet	B-T168
of	O
wintering	B-T079
herbivorous	B-T008
waterbirds	B-T012
Food	B-T168
availability	B-T169
and	O
diet	B-T168
selection	B-T052
are	O
important	O
factors	B-T169
influencing	B-T077
the	O
abundance	B-T080
and	O
distribution	B-T169
of	O
wild	B-T170
waterbirds	B-T012
.	O
In	O
order	O
to	O
better	O
understand	O
changes	B-T169
in	O
waterbird	B-T012
population	B-T081
,	O
it	O
is	O
essential	O
to	O
figure	O
out	O
what	O
they	O
feed on	B-T052
.	O
However,	O
analyzing	B-T062
their	O
diet	B-T168
could	O
be	O
difficult	B-T080
and	O
inefficient	B-T169
using	O
traditional	O
methods	B-T169
such	O
as	O
microhistologic observation	B-T059
.	O
Here,	O
we	O
addressed	O
this	O
gap	O
of	O
knowledge	O
by	O
investigating	O
the	O
diet	B-T168
of	O
greater white-fronted goose Anser albifrons	B-T012
and	O
bean goose Anser fabalis	B-T012
,	O
which	O
are	O
obligate herbivores	B-T008
wintering	B-T079
in	O
China	B-T083
,	O
mostly	O
in	O
the	O
Middle	B-T083
and	O
Lower Yangtze River floodplain	B-T083
.	O
First,	O
we	O
selected	B-T052
a	O
suitable	B-T080
and	O
high-resolution	O
marker gene	B-T028
for	O
wetland	B-T070
plants	B-T002
that	O
these	O
geese	B-T012
would	O
consume	O
during	O
the	O
wintering period	B-T079
.	O
Eight	O
candidate genes	B-T028
were	O
included:	O
rbcL	B-T028
,	O
rpoC1	B-T028
,	O
rpoB	B-T028
,	O
matK	B-T028
,	O
trnH-psbA	B-T087
,	O
trnL	B-T028
(	O
UAA	B-T086
),	O
atpF-atpH	B-T087
,	O
and	O
psbK-psbI	B-T087
.	O
The	O
selection	B-T052
was	O
performed	O
via	O
analysis	B-T062
of	O
representative	B-T052
sequences	B-T086
from	O
NCBI	B-T092
and	O
comparison	B-T052
of	O
amplification	B-T045
efficiency	B-T081
and	O
resolution	O
power	O
of	O
plant	B-T002
samples	B-T167
collected	O
from	O
the	O
wintering area	B-T083
.	O
The	O
trnL gene	B-T028
was	O
chosen	O
at	O
last	O
with	O
c/h primers	B-T114
,	O
and	O
a	O
local	B-T082
plant	B-T002
reference library	B-T073
was	O
constructed	B-T185
with	O
this	O
gene	B-T028
.	O
Then,	O
utilizing	O
DNA metabarcoding	B-T062
,	O
we	O
discovered	B-T052
15	O
food items	B-T168
in	O
total	O
from	O
the	O
feces	B-T031
of	O
these	O
birds	B-T012
.	O
Of	O
the	O
15	O
unique	O
dietary	B-T168
sequences	B-T086
,	O
10	O
could	O
be	O
identified	O
at	O
specie	B-T185
level	B-T080
.	O
As	O
for	O
greater white-fronted goose	B-T012
,	O
73%	O
of	O
sequences	B-T086
belonged	O
to	O
Poaceae spp.	B-T002
,	O
and	O
26%	O
belonged	O
to	O
Carex spp	B-T002
.	O
In	O
contrast,	O
almost	O
all	O
sequences	B-T086
of	O
bean goose	B-T012
belonged	O
to	O
Carex spp	B-T002
.	O
(99%).	O
Using	O
the	O
same	O
samples	B-T167
,	O
microhistology	B-T059
provided	O
consistent	B-T078
food composition	B-T168
with	O
metabarcoding	B-T062
results	B-T169
for	O
greater white-fronted goose	B-T012
,	O
while	O
13%	O
of	O
Poaceae	B-T002
was	O
recovered	O
for	O
bean goose	B-T012
.	O
In	O
addition,	O
two	O
other	O
taxa	B-T077
were	O
discovered	B-T052
only	O
through	O
microhistologic analysis	B-T059
.	O
Although	O
most	O
of	O
the	O
identified	O
taxa	B-T077
matched	B-T080
relatively	O
well	O
between	O
the	O
two	O
methods	B-T169
,	O
DNA metabarcoding	B-T062
gave	O
taxonomically	B-T169
more	O
detailed information	B-T078
.	O
Discrepancies	B-T033
were	O
likely	O
due	O
to	O
biased	B-T078
PCR	B-T063
amplification	B-T045
in	O
metabarcoding	B-T062
,	O
low	O
discriminating	B-T054
power	B-T081
of	O
current	O
marker genes	B-T028
for	O
monocots	B-T002
,	O
and	O
biases	B-T078
in	O
microhistologic analysis	B-T059
.	O
The	O
diet	B-T168
differences	B-T080
between	O
two	O
geese	B-T012
species	B-T185
might	O
indicate	O
deeper	O
ecological	B-T070
significance	B-T078
beyond	O
the	O
scope	O
of	O
this	O
study	B-T062
.	O
We	O
concluded	O
that	O
DNA metabarcoding	B-T062
provides	O
new	O
perspectives	B-T170
for	O
studies	B-T062
of	O
herbivorous	B-T008
waterbird	B-T012
diets	B-T168
and	O
inter-specific interactions	B-T169
,	O
as	O
well	O
as	O
new	O
possibilities	O
to	O
investigate	B-T169
interactions	B-T169
between	O
herbivores	B-T008
and	O
plants	B-T002
.	O
In	O
addition,	O
microhistologic analysis	B-T059
should	O
be	O
used	O
together	O
with	O
metabarcoding methods	B-T062
to	O
integrate	O
this	O
information	B-T078
.	O

Expressions	B-T045
of	O
CD8	B-T129
+	O
TILs	B-T025
,	O
PD-L1	B-T116
and	O
Foxp3	B-T116
+	O
TILs	B-T025
in	O
stage I NSCLC	B-T191
guiding	O
adjuvant chemotherapy	B-T061
decisions	B-T041
Currently,	O
adjuvant chemotherapy	B-T061
is	O
recommended	B-T078
for	O
patients	B-T101
with	O
high risk	B-T033
stage I non-small cell lung cancer	B-T191
(	O
NSCLC	B-T191
).	O
However,	O
identifying	B-T080
high risk	B-T033
patients	B-T101
remains	O
a	O
challenge.	O
This	O
study	B-T062
aims	B-T078
to	O
identify	B-T080
the	O
patient	B-T101
cohorts	B-T098
more	O
likely	O
to	O
benefit	O
from	O
adjuvant chemotherapy	B-T061
based	O
on	O
the	O
tumor	B-T191
micro-immune	B-T169
environment	B-T082
.	O
CD8	B-T129
+	O
TILs	B-T025
significantly associated with	B-T080
disease-free survival	B-T081
(	O
DFS	B-T081
)	O
and	O
overall survial	B-T081
(	O
OS	B-T081
)	O
(p=0.002;	O
0.040).	O
Patients	B-T101
with	O
high risk factors	B-T033
may	O
also	O
predict	O
shorter	O
DFS	B-T081
(P=0.056).	O
When	O
compared	B-T052
together,	O
patients	B-T101
with	O
high	B-T080
-	O
CD8	B-T129
+	O
TILs	B-T025
showed	O
better	O
DFS	B-T081
than	O
patients	B-T101
with	O
low	B-T080
-	O
CD8	B-T129
+	O
TILs	B-T025
,	O
no	O
matter	O
their	O
risk factors	B-T033
status.	O
There's	O
no correlation	B-T033
between	O
PD-L1	B-T116
expressions	B-T045
and	O
survival	B-T169
.	O
PD-L1	B-T116
was	O
highly	B-T080
expressed	B-T045
in	O
men	B-T098
,	O
squamous	B-T080
and	O
well differentiated	B-T080
carcinoma	B-T191
.	O
In	O
addition,	O
Foxp3	B-T116
+	O
TILs	B-T025
alone	O
didn't	O
show	O
any	O
prognostic	O
effects,	O
but	O
low	B-T080
-	O
Foxp3	B-T116
/	O
high	B-T080
-	O
CD8	B-T129
+	O
TILs	B-T025
were	O
associated with	B-T080
prolonged	B-T079
DFS	B-T081
(p=0.031).	O
A	O
total	O
of	O
126	O
patients	B-T101
with	O
surgically resected	B-T080
stage I NSCLC	B-T191
were	O
included	B-T169
to	O
perform	O
immunohistochemistry	B-T060
of	O
CD8	B-T129
+	O
tumor infiltrating lymphocytes	B-T025
(	O
TILs	B-T025
),	O
programmed death ligand-1	B-T116
(	O
PD-L1	B-T116
)	O
and	O
forkhead box P3	B-T116
(	O
Foxp3	B-T116
)+	O
TILs	B-T025
.	O
CD8	B-T129
+	O
TILs	B-T025
are	O
effective	B-T080
prognostic	O
predictors.	O
Patients	B-T101
with	O
surgically resected	B-T080
stage I NSCLC	B-T191
showing	O
low	O
CD8	B-T129
+	O
TILs	B-T025
could	O
be	O
considered	O
for	O
adjuvant chemotherapy	B-T061
,	O
even	O
if	O
they	O
have	O
no	O
high risk	B-T033
features.	O

Unaffected	O
twins discordant	B-T046
for	O
affective disorders	B-T048
show	O
changes	O
in	O
anterior callosal	B-T023
white matter	B-T024
microstructure	B-T082
The	O
neurobiological	B-T091
mechanisms	B-T169
mediating	O
an	O
increased	O
risk	B-T078
to	O
develop	O
affective disorders	B-T048
remain	O
poorly	O
understood.	O
In	O
a	O
group of individuals	B-T098
with	O
a	O
family history	B-T033
of	O
major depressive	B-T048
(	O
MDD	B-T048
)	O
or	O
bipolar disorder	B-T048
(	O
BD	B-T048
),	O
we	O
investigated	O
the	O
microstructural	O
properties	O
of	O
white matter	B-T024
fiber tracts	B-T023
,	O
that	O
is,	O
cingulum bundle	B-T023
,	O
uncinate fasciculus	B-T023
,	O
anterior limb of the internal capsule	B-T023
,	O
and	O
corpus callosum	B-T023
,	O
that	O
facilitate	O
the	O
communication	O
between	O
brain regions	B-T029
implicated	O
in	O
affective disorders	B-T048
.	O
Eighty-nine	O
healthy	O
mono	B-T099
-	O
or	O
dizygotic twins	B-T099
with	O
a	O
co-twin	B-T099
diagnosed	B-T033
with	O
MDD	B-T048
or	O
BD	B-T048
(	O
high-risk	B-T098
)	O
and	O
57	O
healthy	B-T080
twins	B-T099
with	O
a	O
co-twin	B-T099
with	O
no familial history of	B-T033
affective disorders	B-T048
(low-risk)	O
were	O
included	O
in	O
a	O
diffusion tensor imaging study	B-T060
.	O
The	O
high-risk group	B-T098
showed	O
decreased	O
fractional anisotropy	B-T060
(	O
FA	B-T060
),	O
a	O
measure	O
of	O
water	B-T121
diffusion	B-T070
directionality	B-T169
,	O
and	O
increased	O
radial	B-T077
diffusivity	B-T077
in	O
the	O
anterior region of corpus callosum	B-T023
compared	O
to	O
the	O
low-risk group	B-T098
.	O
This	O
abnormality	B-T033
was	O
not	O
associated	O
with	O
zygosity	B-T169
or	O
type	O
of	O
depressive disorder	B-T048
of	O
co-twin	B-T099
.	O
The	O
observed	O
decreased	O
anterior callosal fiber	B-T023
FA	B-T060
in	O
the	O
high-risk group	B-T098
may	O
be	O
indicative	O
of	O
a	O
compromised	O
interhemispheric communication	B-T041
between	O
left	B-T023
and	O
right frontal regions	B-T023
critically	O
involved	O
in	O
mood regulation	B-T041
.	O
Reduced	O
anterior callosal	B-T023
FA	B-T060
may	O
act	O
as	O
a	O
vulnerability	B-UnknownType
marker	B-T201
for	O
affective disorders	B-T048
in	O
individuals	B-T098
at	O
familial risk	B-T078
.	O

A	O
Window	O
on	O
the	O
Study of Aversive	B-T061
Instrumental Learning	B-T041
:	O
Strains	B-T001
,	O
Performance	B-T052
,	O
Neuroendocrine	B-T022
,	O
and	O
Immunologic Systems	B-T022
The	O
avoidance	B-T041
response	B-T032
is	O
present	O
in	O
pathological	B-T169
anxiety	B-T033
and	O
interferes	O
with	O
normal daily functions	B-T169
.	O
The	O
aim	O
of	O
this	O
article	O
is	O
to	O
shed	O
light	O
on	O
performance	B-T052
markers	O
of	O
active avoidance	B-T041
(	O
AA	B-T041
)	O
using	O
two	O
different	O
rat strains	B-T015
,	O
Sprague-Dawley	B-T015
(	O
SD	B-T015
)	O
and	O
Wistar	B-T015
.	O
Specifically,	O
good	O
and	O
poor	O
performers	B-T169
were	O
evaluated	B-T058
regarding	O
anxiety	B-T033
traits	B-T032
exhibited	O
in	O
the	O
elevated plus maze	B-T073
(	O
EPM	B-T073
)	O
and	O
corticosterone levels	B-T059
and	O
motor activity	B-T038
in	O
the	O
open field test	B-T059
.	O
In	O
addition,	O
the	O
plasma levels	B-T059
of	O
Interleukin-6	B-T116
(	O
IL-6	B-T116
),	O
Interleukin-1Beta	B-T116
(	O
IL-1beta	B-T116
),	O
Nerve Growth Factor Beta	B-T116
(	O
NGF-beta	B-T116
),	O
Tumor Necrosis Factor-Alpha	B-T116
(	O
TNF-alpha	B-T116
)	O
and	O
cytokine-induced neutrophil chemoattractant 1	B-T116
(	O
CINC-1	B-T116
)	O
were	O
compared	O
in	O
the	O
good	O
and	O
poor	O
performers	B-T169
to	O
better	O
understand	O
the	O
role	O
of	O
the	O
immunologic system	B-T022
in	O
aversive learning	B-T061
.	O
Behavioral criteria	B-T170
were	O
employed	O
to	O
identify	O
subpopulations	B-T098
of	O
SD	B-T015
and	O
Wistar rats	B-T015
based	O
on	O
their	O
behavioral scores	B-T170
during	O
a	O
two-way	O
AA	B-T041
test	B-T170
.	O
The	O
animals	B-T008
were	O
tested	B-T170
for	O
anxiety	B-T033
-like	O
behavior	B-T053
in	O
the	O
EPM	B-T073
and	O
motor activity	B-T038
in	O
the	O
open-field test	B-T059
.	O
Plasma corticosterone levels	B-T059
were	O
measured	B-T080
at	O
the	O
end	O
of	O
the	O
avoidance	B-T041
test	B-T170
.	O
Cytokine levels	B-T059
of	O
IL-6	B-T116
,	O
IL-1beta	B-T116
,	O
NGF-beta	B-T116
,	O
TNF-alpha	B-T116
,	O
and	O
CINC-1	B-T116
were	O
measured	B-T080
in	O
the	O
plasma	B-T031
of	O
the	O
Wistar rats	B-T015
.	O
Sixty-six	O
percent	O
of	O
the	O
Wistar rats	B-T015
and	O
35%	O
of	O
the	O
SD rats	B-T015
exhibited	O
a	O
poor	O
performance	B-T052
.	O
This	O
feature	O
was	O
associated with	B-T080
a	O
decrease	O
in	O
anxiety	B-T033
-like	O
behavior	B-T053
in	O
the	O
EPM	B-T073
.	O
The	O
poor	O
and	O
good	O
performers	B-T169
exhibited	O
lower	O
levels of corticosterone	B-T059
compared	O
with	O
the	O
control animals	B-T008
,	O
which	O
suggests	O
that	O
training	O
alters	O
corticosterone levels	B-T059
,	O
thereby	O
leading	O
to	O
hypocortisolism	B-T047
,	O
independent	O
of	O
the	O
performance	B-T052
.	O
The	O
CINC-1	B-T116
levels	B-T080
were	O
increased	O
in	O
the	O
poor	O
performers	B-T169
,	O
which	O
reinforces	O
the	O
role	O
of	O
immunologic system	B-T022
activation	B-T052
in	O
learning deficits	B-T048
.	O
Our	O
study	O
provides	O
a	O
better	O
understanding	O
of	O
the	O
complex	B-T080
interactions	B-T169
that	O
underlie	O
neuroimmune	B-UnknownType
consequences	B-T169
and	O
their	O
implications	O
for	O
performance	B-T052
.	O

Costing	B-T169
'	O
healthy' food baskets	B-T168
in	O
Australia	B-T083
-	O
a	O
systematic review	B-T170
of	O
food	B-T168
price	B-T081
and	O
affordability	B-T081
monitoring tools	B-T170
,	O
protocols	B-T170
and	O
methods	B-T170
To	O
undertake	O
a	O
systematic review	B-T170
to	O
determine	O
similarities	B-T080
and	O
differences	B-T080
in	O
metrics	B-T081
and	O
results	B-T169
between	O
recently	B-T079
and/or	O
currently	B-T079
used	O
tools	B-T170
,	O
protocols	B-T170
and	O
methods	B-T170
for	O
monitoring	B-T058
Australian	B-T083
healthy food	B-T168
prices	B-T081
and	O
affordability	B-T081
.	O
Electronic databases	B-T170
of	O
peer-reviewed literature	B-T170
and	O
online grey literature	B-T170
were	O
systematically	B-T169
searched	B-T052
using	O
the	O
PRISMA	B-T062
approach	O
for	O
articles	B-T170
and	O
reports	B-T170
relating	O
to	O
healthy food	B-T168
and	O
diet price assessment tools	B-T170
,	O
protocols	B-T170
,	O
methods	B-T170
and	O
results	B-T169
that	O
utilised	O
retail pricing	B-T081
.	O
National	B-UnknownType
,	O
state	B-T083
,	O
regional	B-T082
and	O
local areas	B-T083
of	O
Australia	B-T083
from	O
1995	O
to	O
2015.	O
Assessment tools	B-T170
,	O
protocols	B-T170
and	O
methods	B-T170
to	O
measure	B-T081
the	O
price	B-T081
of	O
'healthy' foods	B-T168
and	O
diets	B-T168
.	O
The	O
search	O
identified	B-T080
fifty-nine	O
discrete	O
surveys	B-T170
of	O
'	O
healthy' food	B-T168
pricing	B-T081
incorporating	O
six	O
major	O
food pricing tools	B-T170
(those	O
used	O
in	O
multiple areas	B-T082
and	O
time periods	B-T079
)	O
and	O
five	O
minor	B-T080
food pricing tools	B-T170
(those	O
used	O
in	O
a	O
single survey area	B-T082
or	O
time period	B-T079
).	O
Analysis	B-T062
demonstrated	O
methodological	B-T078
differences	B-T080
regarding:	O
included	B-T169
foods	B-T168
;	O
reference households	B-T099
;	O
use	O
of	O
availability	B-T169
and/or	O
quality measures	B-T170
;	O
household income	B-T033
sources	B-T033
;	O
store	B-T073
sampling methods	B-T170
;	O
data collection	B-T062
protocols	B-T170
;	O
analysis methods	B-T062
;	O
and	O
results	B-T169
.	O
'	O
Healthy' food	B-T168
price	B-T081
assessment	B-T052
methods	B-T170
used	O
in	O
Australia	B-T083
lack	B-T080
comparability	B-T052
across	O
all	O
metrics	B-T081
and	O
most	O
do	O
not	O
fully	O
align	O
with	O
a	O
'	O
healthy' diet	B-T168
as	O
recommended	B-T078
by	O
the	O
current	O
Australian Dietary Guidelines	B-T170
.	O
None	O
have	O
been	O
applied	O
nationally.	O
Assessment	B-T052
of	O
the	O
price	B-T081
,	O
price differential	B-T078
and	O
affordability	B-T081
of	O
healthy	B-T061
(	O
recommended	B-T078
)	O
and	O
current	B-T079
(unhealthy) diets	B-T055
would	O
provide	B-T052
more	O
robust	B-T080
and	O
meaningful	O
data	B-T078
to	O
inform	O
health and fiscal policy	B-T064
in	O
Australia	B-T083
.	O
The	O
INFORMAS	B-T170
'	O
optimal	B-T080
'	O
approach	O
provides	O
a	O
potential	B-T080
framework	O
for	O
development	B-T169
of	O
these	O
methods	B-T170
.	O

Consecutive	B-T080
Endovascular Treatment	B-T061
of	O
20	O
Ruptured	B-T169
Very	O
Small	B-T081
(<3	O
mm)	O
Anterior Communicating Artery Aneurysms	B-T047
Small	B-T081
aneurysms	B-T047
located	O
at	O
the	O
anterior communicating artery	B-T023
carry	O
significant	O
procedural	O
challenges	O
due	O
to	O
a	O
complex	O
anatomy	B-T017
.	O
Recent	O
advances	O
in	O
endovascular technologies	B-T061
have	O
expanded	O
the	O
use	O
of	O
coil embolization	B-T061
for	O
small	B-T081
aneurysm	B-T047
treatment	B-T169
.	O
However,	O
limited	O
reports	O
describe	O
their	O
safety	B-T068
and	O
efficacy	B-T080
profiles	O
in	O
very	O
small	B-T081
anterior communicating artery aneurysms	B-T047
.	O
We	O
sought	O
to	O
review	O
and	O
report	O
the	O
immediate	O
and	O
long-term clinical	B-T080
as	O
well	O
as	O
radiographic outcomes	B-T080
of	O
consecutive	B-T080
patients	B-T101
with	O
ruptured	B-T169
very	O
small	B-T081
anterior communicating artery aneurysms	B-T047
treated	O
with	O
current	O
endovascular coil embolization techniques	B-T061
.	O
A	O
prospectively	O
maintained	O
single-institution	O
neuroendovascular database	B-T170
was	O
accessed	O
to	O
identify	O
consecutive	O
cases	O
of	O
very	O
small	B-T081
(<3	O
mm)	O
ruptured	B-T169
anterior communicating artery aneurysms	B-T047
treated	O
endovascularly	O
between	O
2006	O
and	O
2013.	O
A	O
total	O
of	O
20	O
patients	B-T101
with	O
ruptured	B-T169
very	O
small	B-T081
(<3	O
mm)	O
anterior communicating artery aneurysms	B-T047
were	O
consecutively	B-T080
treated	O
with	O
coil embolization	B-T061
.	O
The	O
average	O
maximum	O
diameter	B-T081
was	O
2.66	O
±	O
0.41	O
mm.	O
Complete	O
aneurysm occlusion	B-T061
was	O
achieved	O
for	O
17	O
(85%)	O
aneurysms	B-T047
and	O
near-complete	O
aneurysm occlusion	B-T061
for	O
3	O
(15%)	O
aneurysms	B-T047
.	O
Intraoperative	B-T079
perforation	B-T033
was	O
seen	O
in	O
2	O
(10%)	O
patients	B-T101
without	O
any	O
clinical worsening	B-T078
or	O
need	O
for	O
an	O
external ventricular drain	B-T061
.	O
A	O
thromboembolic event	B-T046
occurred	O
in	O
1	O
(5	O
%)	O
patient	B-T101
without	O
clinical worsening	B-T078
or	O
radiologic infarct	B-T046
.	O
Median	O
clinical	O
follow-up	B-T058
was	O
12	O
(±14.1)	O
months	B-T079
and	O
median	O
imaging	O
follow-up	B-T058
was	O
12	O
(±18.4)	O
months	B-T079
.	O
This	O
report	O
describes	O
the	O
largest	O
series	O
of	O
consecutive	B-T080
endovascular treatments	B-T061
of	O
ruptured	B-T169
very	O
small	B-T081
anterior communicating artery aneurysms	B-T047
.	O
These	O
findings	O
suggest	O
that	O
coil embolization	B-T061
of	O
very	O
small	B-T081
aneurysms	B-T047
in	O
this	O
location	B-T082
can	O
be	O
performed	O
with	O
acceptable	O
rates	O
of	O
complications	B-T046
and	O
recanalization	B-T061
.	O

Factors	B-T169
affecting	B-T169
the	O
formation	B-T169
of	O
nitrogenous disinfection	B-T061
by-products	B-T104
during	O
chlorination	B-T057
of	O
aspartic acid	B-T116
in	O
drinking water	B-T167
The	O
formation	B-T169
of	O
emerging	O
nitrogenous disinfection	B-T061
by-products	B-T104
(	O
N-DBPs	B-T104
)	O
from	O
the	O
chlorination	B-T057
of	O
aspartic acid	B-T116
(	O
Asp	B-T116
)	O
was	O
investigated	B-T169
.	O
The	O
yield	O
of	O
dichloroacetonitrile	B-T109
(	O
DCAN	B-T109
)	O
was	O
higher	O
than	O
other	O
N-DBPs	B-T104
,	O
such	O
as	O
dichloroacetamide	B-T109
(	O
DCAcAm	B-T109
)	O
and	O
chloropicrin	B-T109
(	O
TCNM	B-T109
)	O
during	O
the	O
chlorination	B-T057
of	O
Asp	B-T116
.	O
The	O
formation	B-T169
of	O
DCAN	B-T109
,	O
DCAcAm	B-T109
,	O
and	O
TCNM	B-T109
all	O
showed	O
a	O
trend	O
of	O
first	O
increasing	B-T169
and	O
then	O
decreasing	B-T033
during	O
the	O
chlorination	B-T057
of	O
Asp	B-T116
with	O
increasing	B-T169
contact time	B-T079
.	O
The	O
dosage	B-T081
of	O
chlorine	B-T131
had	O
an	O
impact	O
on	O
the	O
formation	B-T169
of	O
DCAN	B-T109
,	O
DCAcAm	B-T109
,	O
and	O
TCNM	B-T109
.	O
The	O
highest	O
yields	B-T081
of	O
DCAN	B-T109
and	O
DCAcAm	B-T109
appeared	O
when	O
the	O
Cl2	B-T131
/	O
Asp	B-T116
molar ratio	B-T081
was	O
about	O
20,	O
the	O
yield	B-T081
of	O
TCNM	B-T109
increased	B-T081
with	O
increasing	B-T169
the	O
Cl2	B-T131
/	O
Asp	B-T116
molar ratio	B-T081
from	O
5	O
to	O
30	O
and	O
TCNM	B-T109
was	O
not	O
produced	O
when	O
the	O
ratio	B-T081
was	O
less	O
than	O
5.	O
Cyanogen chloride	B-T109
(	O
CNCl	B-T109
)	O
was	O
detected	O
when	O
the	O
Cl2	B-T131
/	O
Asp	B-T116
molar ratio	B-T081
was	O
lower	O
than	O
5.	O
N-DBPs	B-T104
formation	B-T169
was	O
influenced	O
by	O
pH	B-T081
.	O
DCAN	B-T109
formation	B-T169
increased	B-T081
with	O
increasing	B-T169
pH	B-T081
from	O
5	O
to	O
6	O
and	O
then	O
decreased	B-T081
with	O
increasing	B-T169
pH	B-T081
from	O
6	O
to	O
9,	O
but	O
DCAcAm	B-T109
and	O
TCNM	B-T109
increased	B-T081
with	O
increasing	B-T169
pH	B-T081
from	O
5	O
to	O
8	O
and	O
then	O
decreased	B-T081
.	O
Higher	O
temperatures	B-T081
reduced	B-T080
the	O
formation	B-T169
of	O
DCAN	B-T109
and	O
DCAcAm	B-T109
,	O
but	O
increased	B-T081
TCNM	B-T109
formation	B-T169
.	O
DCAN	B-T109
and	O
DCAcAm	B-T109
formation	B-T169
decreased	B-T081
,	O
and	O
relatively	O
stable	B-T080
TCNM	B-T109
formation	B-T169
increased	B-T081
,	O
with	O
increasing	B-T169
free	O
chlorine	B-T131
contact time	B-T079
during	O
chloramination	B-T067
.	O
N-nitrosodimethylamine	B-T109
(	O
NDMA	B-T109
)	O
was	O
produced	O
during	O
chloramination	B-T067
of	O
Asp	B-T116
and	O
increased	B-T081
with	O
prolonged	B-T079
chloramination	B-T067
contact time	B-T079
.	O
The	O
presence	O
of	O
bromide ions	B-T121
enhanced	B-T052
the	O
yields	B-T081
of	O
haloacetonitriles	B-T109
and	O
shifted	O
N-DBPs	B-T104
to	O
more	O
brominated species	B-T109
.	O

Midodrine	B-T109
and	O
tolvaptan	B-T109
in	O
patients	B-T101
with	O
cirrhosis	B-T047
and	O
refractory	B-T033
or	O
recurrent ascites	B-UnknownType
:	O
a	O
randomised	B-T062
pilot study	B-T062
Splanchnic arterial vasodilatation	B-T042
and	O
subsequent	O
sodium	B-T047
and	O
water retention	B-T033
play	O
an	O
important	O
role	O
in	O
cirrhotic ascites	B-T047
.	O
Midodrine	B-T109
and	O
tolvaptan	B-T109
have	O
been	O
used	O
separately	O
in	O
these	O
patients	B-T101
.	O
However,	O
there	O
are	O
no	O
reports	O
on	O
the	O
use	O
of	O
combination	B-T061
of	O
midodrine	B-T109
and	O
tolvaptan	B-T109
in	O
the	O
control	O
of	O
ascites	B-T047
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	B-T058
the	O
safety	B-T068
and	O
efficacy	B-T080
of	O
midodrine	B-T109
,	O
tolvaptan	B-T109
and	O
their	O
combination	B-T061
in	O
control	O
of	O
refractory	B-T033
or	O
recurrent ascites	B-UnknownType
in	O
cirrhotics	B-T047
.	O
Fifty	O
cirrhotic	B-T080
patients	B-T101
with	O
refractory	B-T033
or	O
recurrent ascites	B-UnknownType
were	O
randomised	B-T062
to	O
receive	O
midodrine	B-T109
(n=13),	O
tolvaptan	B-T109
(n=12)	O
or	O
both	O
(n=13)	O
plus	O
standard	O
medical therapy	B-T061
(	O
SMT	B-T061
)	O
or	O
SMT	B-T061
alone	O
(n=12).	O
A	O
significant increase in urinary volume	B-T033
and	O
urinary sodium	B-T047
at	O
1	O
and	O
3	O
months	B-T079
(P<.05)	O
was	O
observed	O
in	O
all	O
groups	B-T098
except	O
SMT	B-T061
.	O
There	O
was	O
no	O
worsening	B-T080
of	O
renal	B-T033
or	O
hepatic function	B-T042
in	O
any	O
group	B-T098
.	O
There	O
was	O
deterioration	B-T067
of	O
model for end-stage liver disease	B-T185
(	O
MELD	B-T185
)	O
in	O
SMT.	O
Midodrine	B-T109
as	O
well	O
as	O
combination	B-T061
of	O
midodrine	B-T109
and	O
tolvaptan	B-T109
but	O
not	O
tolvaptan	B-T109
alone	O
was	O
superior	O
to	O
SMT	B-T061
in	O
control	O
of	O
ascites	B-T047
at	O
3	O
months	B-T079
(P<.05).	O
The	O
combination therapy	B-T061
was	O
also	O
superior	O
to	O
midodrine	B-T109
in	O
the	O
control	O
of	O
ascites	B-T047
at	O
1	O
month	B-T079
.	O
The	O
morbidity	B-T081
and	O
mortality	B-T081
were	O
similar	O
in	O
all	O
the	O
groups	B-T098
except	O
SMT	B-T061
.	O
The	O
results	O
of	O
this	O
pilot study	B-T062
suggest	O
that	O
midodrine	B-T109
and	O
combination	B-T061
with	O
tolvaptan	B-T109
better	O
controls	O
ascites	B-T047
without	O
any	O
renal	B-T047
or	O
hepatic dysfunction	B-T046
.	O
The	O
combination therapy	B-T061
rapidly	O
controls	O
ascites	B-T047
as	O
compared	O
to	O
midodrine	B-T109
or	O
tolvaptan	B-T109
alone.	O

Acute Complicated Sinusitis	B-T047
:	O
Ten	O
Years	B-T079
Experience	B-T041
from	O
the	O
University Hospital	B-T073
of	O
the	O
West Indies	B-T083
Complicated sinusitis	B-T047
is	O
rare	B-T047
.	O
It	O
might	O
not	O
be	O
identified	O
early	O
and	O
might	O
expose	O
the	O
patient	B-T101
to	O
an	O
unfavourable outcome	B-T169
.	O
There	O
is	O
a	O
paucity	O
of	O
data	B-T078
regarding	O
this	O
condition	B-T047
in	O
the	O
Caribbean	B-T083
.	O
This	O
study	B-T062
was	O
undertaken	O
to	O
describe	O
the	O
clinical characteristics	B-T201
and	O
treatment outcomes	B-T080
of	O
patients	B-T101
admitted	B-T058
with	O
this	O
condition	B-T047
.	O
A	O
retrospective	B-T080
chart review	B-UnknownType
was	O
performed	O
on	O
patients	B-T101
admitted	B-T058
to	O
the	O
University Hospital of the West Indies	B-T073
(	O
UHWI	B-T073
)	O
with	O
complicated sinusitis	B-T047
between	O
1999	O
to	O
2011.	O
The	O
data	B-T078
was	O
analysed	B-T062
using	O
SPSS statistics 22 software	B-T170
.	O
There	O
were	O
30	O
patients	B-T101
(23	O
males	B-T032
and	O
7	O
females	B-T032
).	O
The	O
mean	B-T081
(	O
SD	B-T081
)	O
age	B-T032
was	O
19	O
(13.96)	O
years	B-T079
.	O
Twenty-two	O
had	O
orbital	B-T030
complications	B-T046
,	O
two	O
had	O
intracranial	B-T029
complications	B-T046
and	O
one	O
had	O
both.	O
The	O
most	O
common	B-T081
organisms	B-T001
isolated	B-T169
were	O
streptococcus	B-T007
and	O
the	O
most	O
common	B-T081
sensitivity	B-T032
was	O
to	O
amoxicillin	B-T109
and	O
clavulinic acid	B-T109
.	O
Sixteen	O
patients	B-T101
who	O
had	O
an	O
external	B-T082
surgical approach	B-T169
had	O
a	O
mean	B-T081
(	O
SD	B-T081
)	O
hospital stay	B-T079
of	O
8.8	O
(3.71)	O
days	B-T079
compared	O
to	O
three	O
patients	B-T101
who	O
had	O
a	O
purely	O
endoscopic approach	B-T082
who	O
had	O
a	O
mean	B-T081
(	O
SD	B-T081
)	O
hospital stay	B-T079
of	O
7.67	O
(0.577)	O
days	B-T079
.	O
There	O
was	O
no	B-T033
statistical difference	B-T081
in	O
mean	B-T081
hospital stay	B-T079
between	O
these	O
two	O
groups	B-T078
(95%	O
CI,-3.49-5.78;	O
p	O
=	O
0.609).	O
The	O
mean	B-T081
duration	B-T079
of	O
hospital stay	B-T079
for	O
those	O
treated medically	B-T058
was	O
six	O
days	B-T079
versus	O
ten	O
days	B-T079
for	O
the	O
surgical	B-T169
group	B-T078
.	O
The	O
mean	B-T081
difference	B-T081
was	O
three	O
days	B-T079
(95%	O
CI,	O
0.193-6.595;	O
p	O
=	O
0.039).	O
Acute complicated sinusitis	B-T047
is	O
seen	O
more	O
commonly	B-T081
in	O
adolescent males	B-T100
.	O
The	O
most	O
common	B-T081
complication	B-T046
was	O
orbital	B-T030
.	O
Surgical treatment	B-T061
is	O
indicated	O
for	O
those	O
patients	B-T101
who	O
fail	B-T169
medical	B-T169
management	B-T057
and	O
should	O
consist	O
of	O
an	O
endoscopic approach	B-T082
which	O
may	O
be	O
combined	O
with	O
open	O
approaches	O
if	O
indicated.	O

Comparative	O
proteomic analysis	B-T059
reveals	O
alterations	B-T078
in	O
development	B-T040
and	O
photosynthesis	B-T070
-related	O
proteins	B-T116
in	O
diploid	B-T032
and	O
triploid	B-T049
rice	B-T002
Polyploidy	B-T049
has	O
pivotal	O
influences	B-T077
on	O
rice	B-T002
(	O
Oryza sativa L.	B-T002
)	O
morphology	B-T080
and	O
physiology	B-T039
,	O
and	O
is	O
very	O
important	O
for	O
understanding	O
rice	B-T002
domestication	B-T078
and	O
improving	O
agricultural traits	B-T032
.	O
Diploid	B-T032
(	O
DP	B-T032
)	O
and	O
triploid	B-T049
(	O
TP	B-T049
)	O
rice	B-T002
shows	O
differences	B-T080
in	O
morphological	B-T080
parameters	B-T033
,	O
such	O
as	O
plant	B-T002
height	B-T032
,	O
leaf	B-T002
length	B-T081
,	O
leaf	B-T002
width	B-T081
and	O
the	O
physiological	B-T169
index	B-T170
of	O
chlorophyll	B-T109
content	B-T077
.	O
However,	O
the	O
underlying	O
mechanisms	B-T169
determining	O
these	O
morphological	B-T080
differences	B-T080
are	O
remain	O
to	O
be	O
defined.	O
To	O
better	O
understand	O
the	O
proteomic	B-T116
changes	B-T169
between	O
DP	B-T032
and	O
TP	B-T049
,	O
tandem mass tags (TMT) mass spectrometry (MS)	B-T059
/	O
MS	B-T059
was	O
used	O
to	O
detect	O
the	O
significant	O
changes	B-T169
to	O
protein expression	B-T045
between	O
DP	B-T032
and	O
TP	B-T049
.	O
Results	O
indicated	O
that	O
both	O
photosynthesis	B-T070
and	O
metabolic pathways	B-T169
were	O
highly	O
significantly	O
associated with	B-T080
proteomic alteration	B-T044
between	O
DP	B-T032
and	O
TP	B-T049
based	O
on	O
biological process	B-T038
and	O
pathway enrichment analysis	B-T059
,	O
and	O
13	O
higher	O
abundance	B-T080
chloroplast proteins	B-T116
involving	O
in	O
these	O
two	O
pathways	B-T044
were	O
identified	B-T080
in	O
TP	B-T049
.	O
Quantitative real-time PCR analysis	B-T063
demonstrated	O
that	O
5	O
of	O
the	O
13	O
chloroplast proteins	B-T116
ATPF	B-T116
,	O
PSAA	B-T116
,	O
PSAB	B-T116
,	O
PSBB	B-T116
and	O
RBL	B-T116
in	O
TP	B-T049
were	O
higher	O
abundance	B-T080
compared	O
with	O
those	O
in	O
DP	B-T032
.	O
This	O
study	B-T062
integrates	O
morphology	B-T080
,	O
physiology	B-T039
and	O
proteomic profiling	B-T059
alteration	B-T078
of	O
DP	B-T032
and	O
TP	B-T049
to	O
address	O
their	O
underlying	O
different	O
molecular mechanisms	B-T044
.	O
Our	O
finding	O
revealed	O
that	O
ATPF	B-T116
,	O
PSAA	B-T116
,	O
PSAB	B-T116
,	O
PSBB	B-T116
and	O
RBL	B-T116
can	O
induce	O
considerable	O
expression	B-T045
changes	B-T169
in	O
TP	B-T049
and	O
may	O
affect	O
the	O
development	B-T040
and	O
growth	B-T040
of	O
rice	B-T002
through	O
photosynthesis	B-T070
and	O
metabolic pathways	B-T169
.	O

Correlation	B-T080
of	O
cardiopulmonary exercise testing	B-T060
parameters	B-T077
with	O
quality of life	B-T078
in	O
stable	B-T033
COPD	B-T047
patients	B-T101
The	O
precise	O
head	O
to	O
head	O
relationships	B-T080
between	O
Cardio-pulmonary exercise testing	B-T060
(	O
CPET	B-T060
)	O
parameters	B-T077
and	O
patients	B-T101
'	O
daily symptoms	B-T033
/	O
activities	B-T056
and	O
the	O
disease	B-T047
social	B-T080
/	O
emotional impact	B-T201
are	O
less	O
well	O
defined.	O
In	O
this	O
study,	O
the	O
correlation	B-T080
of	O
COPD	B-T047
daily symptoms	B-T033
and	O
quality of life	B-T078
[assessed	O
by	O
St. George's Respiratory Questionnaire	B-T170
(	O
SGRQ	B-T170
)]	O
and	O
COPD	B-T047
severity index	B-T170
(	O
BODE-index	B-T170
)	O
with	O
CPET	B-T060
parameters	B-T077
were	O
investigated.	O
Symptom	B-T184
-limited	O
CPET	B-T060
was	O
performed	O
in	O
37	O
consecutive	B-T080
COPD	B-T047
(	O
GOLD I-III	B-T060
)	O
subjects	O
during	O
non-	O
exacerbation	B-T047
phase	B-T079
.	O
The	O
SGRQ	B-T170
was	O
also	O
completed	O
by	O
each	O
patient	B-T101
.	O
SGRQ-score	B-T201
correlated	B-T080
negatively	B-T033
with	O
FEV1	B-T060
(r=-0.49,	O
P<0.01),	O
predicted	B-T078
maximal work-rate	B-T033
(	O
%WR-max	B-T033
)	O
(r=-0.44,	O
P<0.01),	O
V'O2	B-T033
/	O
WR	B-T201
(r=-0.52,	O
P<0.01)	O
and	O
breathing reserve	B-T081
(r=-0.50,	O
P<0.01).	O
However	O
it	O
did not correlate	B-T033
with	O
Peak-V'O2	B-T033
%	O
predicted	O
(r=-0.27,	O
P=0.10).	O
In	O
20	O
(54.1%)	O
subjects	O
in	O
which	O
leg fatigue was the main cause for stopping the test	B-T033
,	O
Peak-V'O2	B-T033
,	O
%WR-max	B-T033
,	O
HR-Reserve	B-T081
and	O
Breathing reserve	B-T081
were	O
higher	O
(P=0.04,	O
<0.01,	O
0.04	O
and	O
<0.01	O
respectively)	O
than	O
the	O
others.	O
There	O
was	O
also	O
a	O
significant	B-T081
correlation	B-T080
between	O
BODE-index	B-T170
and	O
∆VO2	B-T033
/	O
∆WR	B-T201
(r=-0.64,	O
P<0.001)	O
and	O
breathing-reserve	B-T081
(r=-0.38,	O
P=0.018).	O
The	O
observed	O
relationships	B-T080
between	O
CPET	B-T060
parameter	B-T077
and	O
daily	B-T079
subjective complaints	B-T041
in	O
COPD	B-T047
were	O
not	O
strong.	O
Those	O
who	O
discontinued	O
the	O
CPET	B-T060
because of leg fatigue	B-T033
were	O
in	O
the	O
earlier stages	B-T079
of	O
COPD	B-T047
.	O
Significant	O
negative	B-T033
correlation	B-T080
between	O
∆VO2	B-T033
/	O
∆WR	B-T201
and	O
BODE-index	B-T170
suggests	O
that	O
along	O
with	O
COPD	B-T047
progression	B-T046
,	O
regardless	O
of	O
negative past history	B-T033
,	O
other	O
comorbidities	B-T078
such	O
as	O
cardiac	B-T033
/	O
musculoskeletal problems	B-T033
should	O
be	O
sought.	O

Intrapartum	B-T079
Cervical Laceration	B-T037
and	O
Subsequent	O
Pregnancy Outcomes	B-T033
The	O
objective	B-T170
of	O
this	O
study	B-T062
was	O
to	O
describe	O
pregnancy outcomes	B-T033
,	O
including	O
cervical insufficiency	B-T047
and	O
preterm birth	B-T033
,	O
in	O
the	O
subsequent	O
pregnancy	B-T040
following	B-T079
an	O
intrapartum	B-T079
cervical laceration	B-T037
.	O
Retrospective	O
cohort	B-T098
of	O
women	B-T098
with	O
their	O
first	O
two	O
consecutive	B-T080
singleton pregnancies	B-T040
carried	O
to	O
≥	O
20(0/7)	O
weeks	B-T079
'	O
gestation	B-T040
within	O
a	O
tertiary health care system	B-T093
from	O
2002	O
to	O
2012.	O
Cervical laceration	B-T037
cases	B-T077
were	O
identified	B-T080
by	O
ICD9 codes	B-T170
and	O
included	B-T169
if	O
suture repair	B-T061
was	O
required	B-T169
.	O
In	O
this	O
study	B-T062
,	O
55	O
women	B-T098
were	O
confirmed	B-T033
to	O
have	O
a	O
cervical laceration	B-T037
in	O
the	O
first	O
delivery	B-T040
;	O
43	O
lacerations	B-T037
after	O
vaginal delivery	B-T061
(VD)	B-T061
and	O
12	O
after	O
cesarean delivery	B-T061
(CD)	B-T061
.	O
The	O
median	B-T081
gestational age	B-T032
of	O
the	O
first	O
delivery	B-T040
was	O
40(0/7)	O
weeks	B-T079
and	O
the	O
median	B-T081
birth weight	B-T032
3,545	O
g;	O
these	O
did	O
not	O
differ	B-T080
between	O
VD	B-T061
and	O
CD	B-T061
.	O
In	O
the	O
second	O
pregnancy	B-T040
,	O
2	O
of	O
55	O
women	B-T098
(4.6%)	O
had	O
a	O
prophylactic	B-T169
cerclage	B-T061
placed;	O
1	O
carried	B-T052
to	O
term	B-T040
and	O
the	O
other	O
delivered	B-T033
at	O
35(6/7)	O
weeks	B-T079
.	O
In	O
total	B-T080
,	O
four	O
women	B-T098
(9.3%)	O
delivered	B-T033
the	O
second	O
pregnancy	B-T040
<	O
37	O
weeks	B-T079
:	O
three	O
had	O
a	O
prior	B-T079
term	B-T040
VD	B-T061
and	O
one	O
had	O
a	O
prior	B-T079
34	O
weeks	B-T079
VD	B-T061
.	O
There	O
was	O
only	O
one	O
case	B-T077
of	O
recurrent	B-T079
cervical laceration	B-T037
,	O
occurring	B-T052
in	O
the	O
setting	B-T169
of	O
vaginal deliveries	B-T061
.	O
Obstetric	B-T169
cervical lacerations	B-T037
are	O
uncommon	B-T080
.	O
Complications	B-T046
in	O
the	O
following	B-T079
pregnancy	B-T040
were	O
low	B-T080
,	O
despite	O
lack	B-T080
of	O
additional	O
prophylactic	B-T169
cerclage	B-T061
use.	O

A	O
Wnt Pathway	B-T044
Activator	B-T109
Induces Apoptosis	B-T043
and	O
Cell Death	B-T043
in	O
Mouse Monocytic Leukemia	B-T191
Cells	B-T025
A	O
Wnt agonist,	B-T109
2-amino-4-[3,4-(methylenedioxy)benzylamino]-6-(3-methoxyphenyl) pyrimidine	B-T109
,	O
is	O
a	O
cell-permeable	B-T043
pyrimidine compound	B-T109
that	O
has	O
been	O
shown	O
to	O
mimic	O
the	O
effect	O
of	O
Wnt	B-T116
.	O
In	O
this	O
study,	O
leukemic mouse cell lines	B-T025
,	O
RAW 264.7	B-T025
and	O
J774.1	B-T025
,	O
were	O
incubated	O
with	O
the	O
Wnt agonist	B-T109
.	O
The	O
Wnt agonist	B-T109
showed	O
cell death	B-T043
in	O
the	O
concentration	O
of	O
1-10	O
μM.	O
The	O
Wnt agonist	B-T109
did	O
not	O
show	O
inhibition	B-T052
of	O
GSK-3β	B-T116
activity	B-T044
but	O
induced	B-T169
β-catenin accumulation	B-T044
in	O
the	O
nucleus	B-T026
.	O
The	O
Wnt agonist	B-T109
showed	O
caspase-independent cell death	B-T043
,	O
but	O
no	O
further	O
involvement	O
in	O
cell death ER stress signaling	B-T043
.	O
Here	O
we	O
discuss	O
the	O
possible	O
mechanism	O
of	O
Wnt agonist	B-T109
-	O
induced apoptotic cell death	B-T043
in	O
RAW 264.7 cells	B-T025
.	O

Extracorporeal membrane oxygenation	B-T061
outcomes	B-T169
in	O
children	B-T100
with	O
hemophagocytic lymphohistiocytosis	B-T047
Pediatric	B-T080
patients	B-T101
with	O
hemophagocytic lymphohistiocytosis	B-T047
(	O
HLH	B-T047
)	O
may	O
develop	O
refractory	B-T169
respiratory	B-T047
or	O
cardiac failure	B-T047
that	O
warrants	O
consideration	B-T033
for	O
extracorporeal membrane oxygenation	B-T061
(	O
ECMO	B-T061
)	O
support	B-T074
.	O
The	O
purposes	B-T169
of	O
this	O
study	B-T062
were	O
to	O
describe	O
the	O
use	B-T169
and	O
outcomes	B-T080
of	O
ECMO	B-T061
in	O
pediatric	B-T080
HLH	B-T047
patients	B-T101
,	O
to	O
identify	B-T080
risk factors	B-T033
for	O
hospital mortality	B-T080
and	O
to	O
compare	B-T052
their	O
ECMO	B-T061
use	B-T169
and	O
outcomes	B-T080
to	O
the	O
ECMO	B-T061
population	B-T098
as	O
a	O
whole.	O
Pediatric	B-T080
patients	B-T101
(⩽	O
18	O
years	B-T079
)	O
with	O
a	O
diagnosis	B-T033
of	O
HLH	B-T047
in	O
the	O
Extracorporeal Life Support Organization	B-T058
(	O
ELSO	B-T058
)	O
Registry	B-T170
were	O
included	B-T169
.	O
Between	O
1983	O
and	O
2014,	O
data	B-T078
for	O
30	O
children	B-T100
with	O
HLH	B-T047
were	O
available	O
in	O
the	O
ELSO	B-T058
registry	B-T170
and	O
all	O
were	O
included	B-T169
in	O
this	O
study	B-T062
.	O
All	O
cases	B-T077
occurred	B-T052
in	O
the	O
last	B-T079
decade	B-T081
.	O
Of	O
the	O
30	O
HLH	B-T047
patients	B-T101
,	O
24	O
(80%)	O
had	O
a	O
respiratory	B-T047
indication	B-T078
for	O
ECMO	B-T061
and	O
six	O
(20%)	O
had	O
a	O
cardiac	B-T047
indication	B-T078
(of	O
which	O
4	O
were	O
E	B-T082
-	O
CPR	B-T061
and	O
2	O
cardiac failure	B-T047
).	O
Of	O
the	O
24	O
respiratory	B-T047
ECMO	B-T061
patients	B-T101
,	O
63%	O
were	O
placed	O
on	O
VA ECMO	B-T061
.	O
Compared	B-T052
with	O
all	O
pediatric	B-T080
patients	B-T101
in	O
the	O
ELSO	B-T058
registry	B-T170
during	O
the	O
study period	B-T079
(n=17,007),	O
HLH	B-T047
patients	B-T101
had	O
worse	O
hospital survival	B-T169
(non-HLH	O
59%	O
vs	O
HLH	B-T047
30%,	O
p	B-T081
=0.001).	O
In	O
pediatric	B-T080
HLH	B-T047
patients	B-T101
,	O
no	O
pre-	O
ECMO	B-T061
risk factors	B-T033
for	O
mortality	B-T081
were	O
identified	B-T080
.	O
The	O
development	B-T169
of	O
a	O
hemorrhagic	B-T080
complication	B-T046
on	O
ECMO	B-T061
was	O
associated with	B-T080
decreased	B-T081
mortality	B-T081
(	O
p	B-T081
=0.01).	O
Comparing	B-T052
HLH	B-T047
patients	B-T101
with	O
respiratory failure	B-T047
to	O
patients	B-T101
with	O
other	O
immune compromised conditions	B-T201
,	O
the	O
overall	O
survival rate	B-T081
is	O
similar	O
(	O
HLH	B-T047
38%	O
vs.	O
non-HLH	O
immune compromised	B-T201
31%,	O
p	B-T081
=0.64).	O
HLH	B-T047
is	O
an	O
uncommon	B-T080
indication	B-T078
for	O
ECMO	B-T061
and	O
these	O
patients	B-T101
have	O
increased	B-T081
mortality	B-T081
compared	B-T052
to	O
the	O
overall	O
pediatric	B-T080
ECMO	B-T061
population	B-T098
.	O
These	O
data	B-T078
should	O
be	O
factored	O
into	O
decision-making	B-T041
when	O
considering	O
ECMO	B-T061
for	O
pediatric	B-T080
HLH	B-T047
patients	B-T101
.	O

Gut microbiome	B-T001
alterations	B-T078
in	O
patients	B-T101
with	O
stage 4	B-T080
hepatitis C	B-T047
Hepatitis C virus	B-T005
(	O
HCV	B-T005
)	O
causes	O
debilitating	O
liver diseases	B-T047
,	O
which	O
may	O
progress	O
to	O
cirrhosis	B-T047
and	O
cancer	B-T191
,	O
and	O
claims	O
500,000	O
annual	O
lives	O
worldwide	B-T078
.	O
While	O
HCV	B-T005
epidemiology	B-T062
,	O
pathophysiology	B-T046
,	O
and	O
therapy	B-T169
are	O
being	O
deeply	O
studied,	O
rare	O
attention	O
is	O
given	O
to	O
reciprocal interactions	B-T040
between	O
HCV infection	B-T047
,	O
HCV	B-T005
-induced	O
chronic liver diseases	B-T047
,	O
and	O
the	O
human	B-T016
gut microbiome	B-T001
.	O
As	O
Egypt	B-T083
has	O
the	O
world's	B-T098
highest prevalence	B-T081
of	O
HCV infections	B-T047
,	O
we	O
launched	O
this	O
study	B-T062
to	O
monitor	O
differences	O
in	O
the	O
gut microbial community	B-T001
composition	B-T201
of	O
Egyptian	B-T098
HCV	B-T005
patients	B-T101
that	O
may	O
affect,	O
or	O
result	O
from,	O
the	O
patients	B-T101
'	O
liver	B-T023
state	B-T169
.	O
To	O
this	O
end,	O
we	O
analyzed	O
stool samples	B-T031
from	O
six	O
stage 4	B-T080
-	O
HCV	B-T005
patients	B-T101
and	O
eight	O
healthy individuals	B-T098
by	O
high-throughput	B-T060
16S rRNA gene sequencing	B-T059
using	O
Illumina MiSeq	B-T074
.	O
Overall,	O
the	O
alpha-diversity	B-T080
of	O
the	O
healthy persons'	B-T098
gut microbiomes	B-T001
was	O
higher	B-T080
than	O
those	O
of	O
the	O
HCV	B-T005
patients	B-T101
.	O
Whereas	O
members	O
of	O
phylum Bacteroidetes	B-T007
were	O
more	O
abundant	O
in	O
HCV	B-T005
patients	B-T101
,	O
healthy individuals	B-T098
had	O
higher	B-T080
abundance	B-T080
of	O
Firmicutes	B-T007
,	O
Proteobacteria	B-T007
,	O
and	O
Actinobacteria	B-T007
.	O
Genus	B-T185
-level	O
analysis	B-T062
showed	O
differential	O
abundance	B-T080
of	O
Prevotella	B-T007
and	O
Faecalibacterium	B-T007
(	O
higher	B-T080
in	O
HCV	B-T005
patients	B-T101
)	O
vs.	O
Ruminococcus	B-T007
and	O
Clostridium	B-T007
(	O
healthy group	B-T078
),	O
indicating	O
that	O
the	O
higher	B-T080
abundance	B-T080
of	O
Bacteroidetes	B-T007
in	O
HCV	B-T005
patients	B-T101
is	O
most	O
likely	O
due	O
to	O
Prevotella	B-T007
overabundance	B-T080
.	O
The	O
probiotic genus	B-T007
,	O
Bifidobacterium	B-T007
,	O
was	O
only	O
observed	O
in	O
the	O
microbiotas	B-T001
of	O
healthy individuals	B-T098
.	O
To	O
the	O
best	O
of	O
our	O
knowledge,	O
this	O
study	B-T062
provides	O
a	O
first	O
overview	O
of	O
major	O
phyla	B-T185
and	O
genera	B-T185
differentiating	O
stage 4	B-T080
-	O
HCV	B-T005
patients	B-T101
from	O
healthy individuals	B-T098
and	O
suggests	O
possible	O
microbiome	B-T001
remodeling	O
in	O
chronic hepatitis C	B-T047
,	O
possibly	O
shaped	O
by	O
bacterial translocation	B-T043
as	O
well	O
as	O
the	O
liver's	B-T023
impaired role	B-T033
in	O
digestion	B-T040
and	O
protein synthesis	B-T044
.	O
Future	O
studies	O
will	O
investigate	O
the	O
microbiome	B-T001
composition	B-T201
and	O
functional	O
capabilities	B-T080
in	O
more	O
patients	B-T101
while	O
tracing	O
some	O
potential	O
biomarker	B-T201
taxa	O
(e.g.,	O
Prevotella	B-T007
,	O
Faecalibacterium	B-T007
vs.	O
Bifidobacterium	B-T007
).	O

Peptide	B-T116
-Mediated	O
Interference	B-T070
of	O
PB2	B-T116
-	O
eIF4G1	B-T116
Interaction	B-T044
Inhibits	B-T052
Influenza A Viruses	B-T005
'	O
Replication	B-T043
in Vitro	B-T062
and	O
in Vivo	B-T062
Influenza viruses	B-T005
are	O
obligate parasites	B-T204
that	O
hijack the host cellular system	B-T043
.	O
Previous	O
results	O
have	O
shown	O
that	O
the	O
influenza virus PB2	B-T116
subunit	O
confers	O
a	O
dependence	O
of	O
host eukaryotic translation initiation factor 4-γ 1	B-T116
(	O
eIF4G1	B-T116
)	O
for	O
viral mRNA translation	B-T046
.	O
Here,	O
we	O
demonstrated	O
that	O
peptide	B-T116
-mediated	O
interference	B-T070
of	O
the	O
PB2	B-T116
-	O
eIF4G1	B-T116
interaction	B-T044
inhibited	B-T052
virus replication	B-T043
in vitro	B-T062
and	O
in vivo	B-T062
.	O
Remarkably,	O
intranasal administration	B-T061
of	O
the	O
peptide	B-T116
provided	O
100%	O
protection	B-T033
against	O
lethal	B-T033
challenges	B-T058
of	O
influenza A viruses	B-T005
in	O
BALB/c mice	B-T015
,	O
including	O
H1N1	B-T005
,	O
H5N1	B-T005
,	O
and	O
H7N9 influenza virus subtypes	B-T005
.	O
Mapping	B-T063
of	O
the	O
PB2 protein	B-T116
indicated	O
that	O
the	O
eIF4G1	B-T116
binding sites	B-T192
resided	O
within	O
the	O
PB2 cap	B-T116
-	O
binding domain	B-T044
.	O
Virtual docking analysis	B-T170
suggested	O
that	O
the	O
inhibitory	B-T052
peptide	B-T116
associated with	B-T080
the	O
conserved	O
amino acid residues	B-T116
that	O
were	O
essential	O
to	O
PB2	B-T116
cap-binding activity	B-T059
.	O
Overall,	O
our	O
results	O
identified	O
the	O
PB2	B-T116
-	O
eIF4G1	B-T116
interactive site	B-T192
as	O
a	O
druggable	B-T121
target	O
for	O
influenza	B-T047
therapeutics	B-T061
.	O

DRG1	B-T028
is	O
a	O
potential	O
oncogene	B-T028
in	O
lung adenocarcinoma	B-T191
and	O
promotes	B-T052
tumor progression	B-T191
via	O
spindle checkpoint signaling	B-T043
regulation	B-T038
Developmentally	O
regulated	O
GTP binding protein 1	B-T116
(	O
DRG1	B-T116
),	O
a	O
member	O
of	O
the	O
DRG family	B-T116
,	O
plays	O
important	O
roles	O
in	O
regulating cell growth	B-T043
.	O
However,	O
the	O
molecular basis	B-T078
of	O
DRG1	B-T116
in	O
cell proliferation regulation	B-T043
and	O
the	O
relationship	O
between	O
DRG1	B-T116
and	O
tumor progression	B-T191
remain	O
poorly	O
understood.	O
Here,	O
we	O
demonstrate	O
that	O
DRG1	B-T116
is	O
elevated	O
in	O
lung adenocarcinomas	B-T191
while	O
weakly	O
expressed	B-T045
in	O
adjacent	O
lung	B-T023
tissues	B-T024
.	O
DRG1	B-T028
knockdown	B-T063
causes	O
growth inhibition	B-T043
of	O
tumor cells	B-T025
by	O
significantly	O
increasing	O
the	O
proportion	O
of	O
cells	B-T025
in	O
M phase	B-T043
.	O
Overexpression	B-T045
of	O
DRG1	B-T116
leads	O
to	O
chromosome	B-T026
missegregation	B-T045
which	O
is	O
an	O
important	O
index	O
for	O
tumorigenesis	B-T191
.	O
Interestingly,	O
ectopic	B-T045
of	O
DRG1	B-T028
reduces	O
taxol	B-T109
induced	B-T169
apoptosis	B-T043
of	O
lung adenocarcinoma	B-T191
cells	B-T025
.	O
Mechanistic	B-T022
analyses	B-T062
confirm	O
that	O
DRG1	B-T116
localizes	B-T082
at	O
mitotic spindles	B-T026
in	O
dividing cells	B-T025
and	O
binds	B-T044
to	O
spindle checkpoint signaling	B-T043
proteins	B-T116
in vivo	B-T082
.	O
These	O
studies	B-T062
highlight	O
the	O
expanding	O
role	O
of	O
DRG1	B-T028
in	O
tumorigenesis	B-T191
and	O
reveal	O
a	O
mechanism	B-T169
of	O
DRG1	B-T028
in	O
taxol	B-T109
resistance.	O

Gelsolin	B-T116
in	O
Onychophora	B-T204
and	O
Tardigrada	B-T204
with	O
notes	O
on	O
its	O
variability	B-T077
in	O
the	O
Ecdysozoa	B-T204
Rearrangements	B-T067
of	O
the	O
filamentous actin network	B-T116
involve	O
a	O
broad	O
range	B-T081
of	O
actin binding proteins	B-T116
.	O
Among	O
these,	O
the	O
gelsolin proteins	B-T116
sever	O
actin filaments	B-T026
,	O
cap	O
their	O
fast growing	B-T033
end	O
and	O
nucleate	B-T044
actin assembly	B-T043
in	O
a	O
calcium	B-T121
-	O
dependent	B-T080
manner.	O
Here,	O
we	O
focus	O
on	O
the	O
gelsolin	B-T116
of	O
the	O
onychophoran	B-T204
Peripatoides novaezealandiae	B-T204
and	O
the	O
eutardigrade	B-T204
Hypsibius dujardini	B-T204
.	O
From	O
the	O
cDNA	B-T114
of	O
P. novaezealandiae	B-T204
we	O
obtained	B-T169
the	O
complete	O
coding sequence	B-T028
with	O
an	O
open reading frame	B-T028
of	O
2178	O
bp	B-T044
.	O
It	O
encodes	B-T052
a	O
protein	B-T116
of	O
726	O
amino acids	B-T116
with	O
a	O
calculated	B-T052
molecular mass	B-T081
of	O
82,610.9Da	O
and	O
a	O
pI	O
of	O
5.57.	O
This	O
sequence	B-T087
is	O
comprised	B-T052
of	O
six	O
segments	B-T082
(S1-S6).	O
However,	O
analysis	B-T062
of	O
data	B-T078
from	O
TardiBase	B-T170
reveals	B-T080
that	O
the	O
gelsolin	B-T116
of	O
the	O
eutardigrade	B-T204
Hypsibius dujardini	B-T204
has	O
only	O
three	O
segments	B-T082
(S1-S3).	O
The	O
coding sequence	B-T028
consist	O
of	O
1119	O
bp	B-T044
for	O
373	O
amino acids	B-T116
with	O
a	O
calculated	B-T052
molecular mass	B-T081
of	O
42,440.95Da	O
and	O
a	O
pI	O
of	O
6.17.	O
The	O
Peripatoides	B-T204
and	O
Hypsibius	B-T204
gelsolin	B-T116
revealed	B-T080
both	O
conserved	B-T086
binding motifs	B-T116
for	O
G-actin	B-T116
,	O
F-actin	B-T116
and	O
phosphatidylinositol 4,5-bisphosphate	B-T109
(	O
PIP2	B-T109
),	O
along	O
with	O
a	O
full	O
set	O
of	O
type-1	B-T192
and	O
type-2	B-T192
Ca(2+)	B-T121
-	O
binding sites	B-T192
which	O
could	O
result	B-T169
in	O
the	O
binding	B-T044
of	O
eight	O
and	O
four	O
calcium ions	B-T121
,	O
respectively.	O
Both	O
gelsolin proteins	B-T116
lack	B-T080
a	O
C-terminal	B-T087
latch-helix	B-T082
indicating	O
a	O
more	O
rapid	B-T080
activation	B-T052
in	O
the	O
submicromolar	O
Ca(2+) range	B-T059
.	O
We	O
suggest	O
that	O
a	O
gelsolin	B-T116
with	O
three	O
segments	B-T082
was	O
present	B-T033
in	O
the	O
last	O
common	O
ancestor	B-T099
of	O
the	O
ecdysozoan	B-T204
clade	O
Panarthropoda	B-T204
(	O
Onychophora	B-T204
,	O
Tardigrada	B-T204
,	O
Arthropoda	B-T204
),	O
primarily	B-T080
because	O
the	O
gelsolin	B-T116
of	O
all	O
non-Ecdysozoa	O
studied	B-T062
so	O
far	O
(except	O
Chordata	B-T008
)	O
reveals	B-T080
this	O
number	O
of	O
segments	B-T082
.	O
Mapping	B-T059
of	O
our	O
molecular data	B-T170
onto	O
a	O
well-established	B-T080
phylogeny	B-T078
revealed	B-T080
that	O
the	O
number	O
of	O
gelsolin	B-T116
segments	B-T082
does	O
not	O
correlate	B-T080
with	O
the	O
phylogenetic	B-T078
lineage	B-T077
but	O
rather	O
with	O
particular	O
functional	B-T169
demands	O
to	O
alter	B-T169
the	O
kinetics	B-T070
of	O
actin polymerization	B-T043
.	O

MiR-424-5p	B-T028
participates	B-T169
in	O
esophageal squamous cell carcinoma	B-T191
invasion	B-T046
and	O
metastasis	B-T191
via	O
SMAD7	B-T028
pathway	B-T044
mediated	O
EMT	B-T043
ESCC	B-T191
is	O
a	O
life-threatening	B-T033
disease	B-T047
due	O
to	O
invasion	B-T046
and	O
metastasis	B-T191
in	O
the	O
early stage	B-T079
.	O
Great	O
efforts	O
had	O
been	O
made	O
to	O
detect	B-T033
the	O
molecular	B-T080
mechanisms	B-T169
which	O
led	O
to	O
the	O
invasion	B-T046
and	O
metastasis	B-T191
in	O
ESCC	B-T191
.	O
Recent	O
evidence	B-T078
had	O
suggested	O
that	O
deregulation	B-T052
of	O
miR-424-5p	B-T028
took	O
an	O
important	O
role	B-T077
in	O
cancers	B-T191
.	O
However,	O
its	O
role	B-T077
and	O
functional	B-T169
mechanism	B-T169
in	O
ESCC	B-T191
had	O
seldom	B-T080
been	O
elucidated.	O
The	O
expression levels	B-T081
of	O
miR-424-5p	B-T028
were	O
detected	B-T033
in	O
ESCC	B-T191
tissues	B-T024
and	O
cell lines	B-T025
by	O
real-time PCR methods	B-T063
.	O
Then,	O
the	O
invasion	B-T046
,	O
metastasis	B-T191
and	O
proliferation	B-T043
ability	O
of	O
ESCC	B-T191
cell lines	B-T025
transfected	B-T045
with	O
miR-424-5p	B-T028
mimics	O
were	O
analyzed	B-T062
separately	O
by	O
transwell invasion assay	B-T059
,	O
wound healing assay	B-T059
and	O
cell proliferation assay	B-T062
.	O
Finally,	O
the	O
target gene	B-T028
of	O
miR-424-5p	B-T028
was	O
studied	O
and	O
verified	B-T169
by	O
luciferase activity assay	B-T059
.	O
And	O
the	O
role	B-T077
of	O
miR-424-5p	B-T028
in	O
EMT	B-T043
was	O
also	O
investigated	B-T169
by	O
real-time PCR	B-T063
and	O
western blot assay	B-T059
.	O
We	O
showed	O
that	O
the	O
expression levels	B-T081
of	O
miR-424-5p	B-T028
were	O
decreased	B-T081
both	O
in	O
ESCC	B-T191
tissues	B-T024
and	O
cell lines	B-T025
.	O
Furthermore,	O
the	O
expression levels	B-T081
of	O
miR-424-5p	B-T028
were	O
negatively	O
linked	O
to	O
lymph node	B-T023
metastasis	B-T191
in	O
ESCC	B-T191
tissues	B-T024
.	O
Restoration	O
of	O
miR-424-5p	B-T028
in	O
EC-1 cells	B-T025
by	O
using	O
miR-424-5p	B-T028
mimics	O
could	O
decrease	B-T081
the	O
invasion	B-T046
,	O
metastasis	B-T191
and	O
proliferation	B-T043
of	O
EC-1 cells	B-T025
,	O
indicating	O
its	O
role	B-T077
in	O
inhibition	B-T052
on	O
the	O
invasion	B-T046
and	O
metastasis	B-T191
ability	O
of	O
ESCC	B-T191
cells	B-T025
and	O
tissues	B-T024
.	O
In	O
addition,	O
we	O
demonstrated	O
that	O
SMAD7	B-T028
was	O
a	O
specific	O
target gene	B-T028
for	O
miR-424-5p	B-T028
by	O
luciferase activity assay	B-T059
and	O
miR-424-5p	B-T028
could	O
not	O
only	O
negatively	B-T033
regulate	B-T045
SMAD7	B-T028
expression	B-T045
but	O
also	O
participate	O
in	O
EMT	B-T043
via	O
SMAD7	B-T028
,	O
because	O
overexpression	B-T045
of	O
SMAD7	B-T028
could	O
partly	O
enhance	B-T052
the	O
miR-424-5p	B-T028
anti-EMT	B-T033
function	B-T169
.	O
Our	O
results	B-T169
described	O
that	O
miR-424-5p	B-T028
-	O
SMAD7	B-T028
pathway	B-T044
contributed	O
to	O
ESCC	B-T191
invasion	B-T046
and	O
metastasis	B-T191
and	O
up-regulation	B-T044
of	O
miR-424-5p	B-T028
perhaps	O
provided	O
a	O
strategy	O
for	O
preventing	B-T169
tumor invasion	B-T033
,	O
metastasis	B-T191
.	O

Double-Network Hydrogel	B-T109
with	O
Tunable	B-T080
Mechanical Performance	B-T052
and	O
Biocompatibility	B-T044
for	O
the	O
Fabrication	B-T170
of	O
Stem Cells	B-T025
-	O
Encapsulated Fibers	B-T109
and	O
3D Assemble	B-T082
Fabrication	B-T170
of	O
cell	B-T025
-	O
encapsulated fibers	B-T109
could	O
greatly	O
contribute	B-T052
to	O
tissue engineering	B-T061
and	O
regenerative medicine	B-T091
.	O
However,	O
existing	B-T080
methods	B-T169
suffered	O
from	O
not	O
only	O
unavoidability	B-T080
of	O
cell damaging	B-T049
conditions	B-T080
and/or	O
sophisticated equipment	B-T073
,	O
but	O
also	O
unavailability	B-T080
of	O
proper	O
materials	B-T167
to	O
satisfy	O
both	O
mechanical	B-T169
and	O
biological	B-T080
expectations	B-T078
.	O
In	O
this	O
work	B-T057
,	O
a	O
simple	B-T080
method	B-T169
is	O
proposed	B-T080
to	O
prepare	B-T052
cell	B-T025
-	O
encapsulated fibers	B-T109
with	O
tunable	B-T080
mechanical strength	B-T081
and	O
stretching behavior	B-T080
as	O
well	O
as	O
diameter	B-T081
and	O
microstructure	B-T104
.	O
The	O
hydrogel	B-T109
fibers	B-T109
are	O
made	O
from	O
optimal	B-T080
combination	B-T080
of	O
alginate	B-T109
and	O
poly(N-iso-propylacrylamide)-poly(ethylene glycol)	B-T122
,	O
characteristics	O
of	O
double-network hydrogel	B-T109
,	O
with	O
enough	O
stiffness	B-T184
and	O
flexibility	B-T080
to	O
create	B-T052
a	O
variety	B-T077
of	O
three dimensional structures	B-T082
like	O
parallel helical	B-T082
and	O
different	B-T080
knots without crack	B-T082
.	O
Furthermore,	O
such	O
hydrogel	B-T109
fibers	B-T109
exhibit	O
better	B-T080
compatibility	B-T044
as	O
indicated	B-T033
by	O
the	O
viability	B-T080
,	O
proliferation	B-T169
and	O
expression	B-T169
of	O
pluripotency	B-T169
markers	B-T201
of	O
embryonic stem cells	B-T025
encapsulated	B-T080
after	O
4-day	B-T033
culture	B-T059
.	O
The	O
double-network hydrogel	B-T109
possesses	B-T048
specific	B-T080
quick	B-T080
responses	B-T032
to	O
either	O
of	O
alginate lyase	B-T116
,	O
EDTA	B-T109
or	O
lower	O
environmental temperature	B-T081
which	O
facilitate	O
the	O
optional	O
degradation	B-T169
of	O
fibers	B-T109
or	O
fibrous assemblies	B-T082
to	O
release	O
the	O
cells	B-T025
encapsulated	B-T080
for	O
subsequent	B-T079
assay	B-T059
or	O
treatment	B-T061
.	O

Synchronous	B-T079
vitellogenin	B-T116
expression	B-T045
and	O
sexual maturation	B-T040
during	O
migration	B-T039
are	O
negatively	B-T033
correlated	B-T080
with	O
juvenile hormone	B-T125
levels	B-T080
in	O
Mythimna separata	B-T204
Annual	O
migration	B-T039
of	O
pests	B-T008
between	O
different	B-T080
seasonal	B-T079
habitats	B-T082
can	O
lead	B-T169
to	O
serious	O
crop	B-T002
damage	B-T169
.	O
Reproductive	B-T040
immaturity	B-T080
is	O
generally	O
associated	O
with	O
the	O
migratory process	B-T039
(	O
oogenesis	B-T042
-	O
flight syndrome	B-T047
),	O
but	O
the	O
mechanism	B-T169
of	O
reproductive development	B-T040
during	O
migration	B-T039
migration	B-T039
varies	O
unpredictably	B-T033
.	O
Here,	O
the	O
vitellogenin gene	B-T028
(	O
MsVg	B-T028
)	O
and	O
three	O
key	B-T077
regulatory enzyme genes	B-T028
(	O
MsJhamt	B-T028
,	O
MsJheh	B-T028
and	O
MsJhe	B-T028
)	O
related	O
to	O
juvenile hormone	B-T125
(	O
JH	B-T125
)	O
synthesis	B-T052
and	O
degradation	B-T044
were	O
identified	B-T080
and	O
characterized	B-T052
in	O
Mythimna separata	B-T204
.	O
The	O
relative expression	B-T045
of	O
MsVg	B-T028
varied	O
significantly	O
in	O
response	B-T032
to	O
seasonal	B-T079
changes	B-T169
and	O
was	O
significantly	O
correlated	B-T080
with	O
stages	B-T079
of	O
ovarian development	B-T042
.	O
The	O
relatively	O
low levels	B-T080
of	O
JH	B-T125
titer	B-T081
did	O
not differ	B-T033
significantly	O
in	O
male	B-T032
moths	B-T204
but	O
slightly	O
increased	B-T081
in	O
female adults	B-T098
during	O
the	O
migratory season	B-T039
,	O
which	O
was	O
consistent with	B-T078
changes	B-T169
in	O
mRNA	B-T114
levels	B-T080
for	O
MsJhamt	B-T028
,	O
MsJheh	B-T028
and	O
MsJhe	B-T028
.	O
JH	B-T125
titer	B-T081
was	O
negatively	B-T033
associated	O
with	O
relative	O
seasonal	B-T079
levels	B-T080
of	O
vitellogenin	B-T116
mRNA	B-T114
transcripts	B-T114
and	O
with	O
ovarian development	B-T042
in	O
migrating	B-T039
M. separata	B-T204
.	O
The	O
synchrony	B-T079
of	O
MsVg expression	B-T045
with	O
sexual maturation	B-T040
highlighted	O
the	O
potential	B-T080
of	O
MsVg	B-T028
transcript	B-T114
levels	B-T080
to	O
serve	O
as	O
an	O
index	B-T170
to	O
monitor	O
the	O
adult	B-T100
reproductive	B-T040
status	B-T080
.	O
In	O
addition,	O
the	O
level	B-T080
of	O
JH	B-T125
and	O
sexual maturity	B-T040
were	O
correlated	B-T080
with	O
the	O
extent	O
of	O
JH	B-T125
in	O
regulating	B-T038
the	O
MsVg expression	B-T045
and	O
reproduction	B-T040
during	O
seasonal	B-T079
northern and southern migration	B-T039
migration	B-T039
.	O

Functional Result	B-T169
After	O
Cochlear Implantation	B-T061
in	O
Children	B-T100
and	O
Adults	B-T100
With	O
Single-sided Deafness	B-T047
Patients	B-T101
with	O
single-sided deafness	B-T047
(	O
SSD	B-T047
)	O
suffer	O
from	O
reduced	B-T080
binaural hearing	B-T042
(i.e.,	O
sound localization	B-T041
and	O
speech	B-T040
in	O
noise discrimination	B-T041
).	O
Cochlear implantation	B-T061
has	O
recently	O
been	O
introduced	O
for	O
patients	B-T101
with	O
SSD	B-T047
,	O
as	O
an	O
alternative	B-T077
to	O
hearing devices	B-T074
that	O
employ	O
contralateral	B-T082
routing	O
of	O
the	O
signal	B-T067
.	O
Application	B-T058
to	O
children	B-T100
has	O
also	O
been	O
started.	O
We	O
retrospectively	B-T062
analyze	O
a	O
case	O
series	O
of	O
4	O
children	B-T100
and	O
17	O
adults	B-T100
with	O
SSD	B-T047
,	O
treated with	B-T061
cochlear implantation	B-T061
.	O
The	O
outcome	B-T169
of	O
adult	B-T100
patients	B-T101
was	O
compared	O
with	O
a	O
control group	B-T096
of	O
27	O
patients	B-T101
with	O
bilateral profound hearing loss	B-T047
using	O
a	O
cochlear implant	B-T074
.	O
During	O
12	O
months,	O
the	O
mean	B-T033
speech recognition	B-T041
score	B-T081
increased	O
from	O
30	O
to	O
41%	O
for	O
monosyllabic	B-T170
monosyllabic words	B-T170
in	O
adults	B-T100
,	O
and	O
from	O
58	O
to	O
89%	O
for	O
multisyllabic	B-T170
numbers.	O
The	O
cochlear implant	B-T074
(	O
CI	B-T074
)	O
improved hearing	B-T033
in	O
noise	B-T067
in	O
all	O
SSD	B-T047
patients	B-T101
,	O
as	O
was	O
demonstrated	O
by	O
a	O
significant	O
improvement	B-T077
of	O
the	O
speech reception threshold	B-T201
in	O
different	O
speech	O
and	O
noise	O
configurations.	O
Sound localization	B-T041
-correlated	O
angle detection error	B-T170
improved	B-T077
with	O
CI	B-T074
use	O
at	O
every	O
time	O
point.	O
The	O
maximum	O
word recognition	B-T041
score	B-T081
for	O
monosyllabic	B-T170
monosyllabic words	B-T170
in	O
quiet	O
correlated	O
with	O
the	O
logarithm	B-T081
of	O
the	O
duration of deafness	B-T079
deafness	B-T033
;	O
improvement	B-T077
of	O
the	O
speech reception threshold	B-T201
and	O
RMS angle detection error	B-T170
by	O
the	O
CI	B-T074
did	O
not.	O
All	O
SSD	B-T047
patients	B-T101
benefitted	O
from	O
the	O
CI	B-T074
in	O
different	O
hearing	B-T039
situations	B-T080
.	O
Patients	B-T101
with	O
SSD	B-T047
for	O
a	O
long	O
period	O
can	O
improve	B-T080
after	O
cochlear implantation	B-T061
.	O

CHOROIDAL VASCULARITY INDEX	B-T081
:	O
A	O
Novel	O
Optical Coherence Tomography	B-T060
Based	O
Parameter	B-T077
in	O
Patients	B-T101
With	O
Exudative Age-Related Macular Degeneration	B-T047
To	O
evaluate	O
choroidal	B-T023
structural	B-T082
changes	O
in	O
exudative age-related macular degeneration	B-T047
(	O
AMD	B-T047
)	O
using	O
choroidal vascularity index	B-T081
computed	B-T052
from	O
image	O
binarization	O
on	O
spectral domain optical coherence tomography	B-T060
with	O
enhanced	O
depth imaging	B-T060
.	O
This	O
prospective	O
case series	B-T062
included	O
42	O
consecutive	B-T080
patients	B-T101
with	O
unilateral	B-T082
exudative AMD	B-T047
.	O
Choroidal	B-T023
images	B-T060
were	O
segmented	O
into	O
luminal	B-T082
area	B-T082
and	O
stromal	O
area.	O
Choroidal vascularity index	B-T081
was	O
defined	O
as	O
the	O
ratio	B-T081
of	O
luminal	B-T082
area	B-T082
to	O
total	O
choroid	O
area	B-T082
.	O
Mean	B-T081
choroidal vascularity index	B-T081
and	O
mean	B-T081
choroidal thickness	B-T081
between	O
study	B-T062
and	O
fellow	O
eyes	B-T023
of	O
the	O
same	O
patient	B-T101
with	O
dry	O
AMD	B-T047
were	O
compared	O
using	O
Student's t-test	B-T081
.	O
There	O
was	O
a	O
significantly lower	B-T081
choroidal vascularity index	B-T081
in	O
eyes	B-T023
with	O
exudative AMD	B-T047
(60.14	O
±	O
4.55	O
vs.	O
62.75	O
±	O
4.82,	O
P	O
<	O
0.01).	O
Luminal area	B-T082
(P	O
<	O
0.01)	O
was	O
decreased	B-T081
in	O
eyes	B-T023
with	O
exudative AMD	B-T047
but	O
there	O
was	O
no significant difference	B-T033
in	O
total	O
choroid	O
area	B-T082
(P	O
=	O
0.05)	O
and	O
choroidal	O
thickness	O
(P	O
=	O
0.93)	O
between	O
study	B-T062
and	O
fellow	O
eyes	B-T023
.	O
Eyes	B-T023
with	O
exudative AMD	B-T047
demonstrated	O
reduced	B-T080
choroidal vascularity index	B-T081
but	O
insignificant	O
differences	B-T080
in	O
choroidal	O
thickness	O
compared	O
with	O
their	O
fellow	O
eyes	B-T023
.	O
Choroidal vascularity index	B-T081
may	O
be	O
a	O
potential	B-T080
noninvasive tool	B-T033
for	O
studying	B-T062
structural	B-T082
changes	O
in	O
choroid	B-T023
and	O
monitoring	O
choroidal disease	B-T047
in	O
exudative AMD	B-T047
.	O

Comparison	B-T052
of	O
Esophageal	B-T201
,	O
Rectal	B-T033
,	O
and	O
Gastrointestinal	B-T029
Temperatures	B-T081
During	O
Passive Rest	B-T056
After	O
Exercise	B-T056
in	O
The	O
Heat	B-T070
:	O
The	O
Influence	B-T077
of	O
Hydration	B-T033
It	O
is	O
unknown	O
how	O
valid	O
esophageal	B-T201
,	O
rectal	B-T033
,	O
and	O
gastrointestinal	B-T029
temperatures	B-T081
(	O
TES	B-T201
,	O
TRE	B-T033
,	O
and	O
TGI	B-T081
)	O
compare	O
after	O
exercise-induced	B-T184
hyperthermia	B-T184
in	O
various	O
hydration states	B-T033
.	O
The	O
purpose	O
of	O
this	O
study	B-T062
was	O
to	O
examine	O
the	O
differences	O
between	O
TES	B-T201
,	O
TRE	B-T033
,	O
and	O
TGI	B-T081
during	O
passive rest	B-T056
following	O
exercise-induced	B-T184
hyperthermia	B-T184
under	O
two	O
different	O
hydration states	B-T033
:	O
euhydrated	B-T033
(	O
EU	B-T033
)	O
and	O
hypohydrated	B-T047
(	O
HY	B-T047
).	O
Randomized-crossover design	B-T062
.	O
Controlled	B-T067
laboratory setting	B-T073
.	O
Nine	O
recreationally	B-T056
active	B-T169
male	B-T032
participants	B-T098
(mean±	O
SD	B-T081
;	O
age	B-T032
,	O
24±4;	O
height	B-T032
,	O
177.3±9.9cm;	O
body mass	B-T032
,	O
76.7±11.6kg;	O
body fat	B-T201
,	O
14.7±5.8%).	O
Participants	B-T098
completed	O
two	O
trials	B-T062
(	O
EU	B-T033
and	O
HY	B-T047
)	O
consisting	O
of	O
a	O
bout	B-T079
of	O
treadmill exercise	B-T056
(a	O
10	O
minute	O
walk	O
ranging	B-T081
4.8-7.2km·hr(-1)	O
at	O
a	O
5%	O
grade	B-T185
followed	O
by	O
a	O
20	O
minute	B-T079
jog	B-T056
ranging	B-T081
8.0-12.1km·hr(-1)	O
at	O
a	O
1%	O
grade)	O
in	O
a	O
hot environment	B-T067
(	O
ambient temperature	B-T070
,	O
39.3±1.0°C;	O
relative humidity	B-T081
,	O
37.6±6.0%;	O
wet bulb globe temperature	B-T169
,	O
31.3±1.5°C)	O
followed	O
by	O
passive rest	B-T056
.	O
Root mean squared difference	B-T081
(	O
RMSD	B-T081
)	O
was	O
used	O
to	O
compare	O
the	O
variance	B-T080
of	O
temperature readings	B-T032
at	O
corresponding	O
time points	B-T079
for	O
TRE	B-T033
vs	O
TGI	B-T081
,	O
TRE	B-T033
vs	O
TES	B-T201
,	O
and	O
TGI	B-T081
vs	O
TES	B-T201
in	O
EU	B-T033
and	O
HY	B-T047
.	O
RMSD	B-T081
values	O
were	O
compared	O
using	O
three-way repeated measures ANOVA	B-T081
.	O
Post	O
hoc	O
analysis	B-T062
of	O
significant	O
main	O
effects	B-T080
was	O
done	O
using	O
Tukey's HSD	B-T170
with	O
significance	O
set	O
at	O
p<0.05.	O
RMSD values	B-T081
(°C)	O
for	O
all	O
device	B-T074
comparisons	B-T052
were	O
significantly	B-T081
different	O
in	O
EU	B-T033
(	O
TRE	B-T033
-	O
TGI	B-T081
,	O
0.11±0.12;	O
TRE	B-T033
-	O
TES	B-T201
,	O
1.58±1.01;	O
TGI	B-T081
-	O
TES	B-T201
,	O
2.04±1.19)	O
than	O
HY	B-T047
(	O
TRE	B-T033
-	O
TGI	B-T081
,	O
0.22±0.28;	O
TRE	B-T033
-	O
TES	B-T201
,	O
1.27±0.61;	O
TGI	B-T081
-	O
TES	B-T201
,	O
1.16±0.76)	O
(p<0.01).	O
Across	O
the	O
45-	O
minute	B-T079
bout	B-T079
of	O
passive rest	B-T056
,	O
there	O
were	O
no	O
differences	O
in	O
TRE	B-T033
,	O
TGI	B-T081
and	O
TES	B-T201
between	O
EU	B-T033
and	O
HY	B-T047
trials	B-T062
(p=0.468).	O
During	O
passive rest	B-T056
after	O
exercise	B-T056
in	O
the	O
heat	B-T070
,	O
TRE	B-T033
and	O
TGI	B-T081
were	O
in	O
good	O
agreement	O
when	O
tracking	O
body temperature	B-T032
,	O
with	O
a	O
better	O
agreement	O
appearing	O
in	O
those	O
maintaining	O
a	O
state	O
of	O
euhydration	B-T033
versus	O
those	O
who	O
became	O
hypohydrated	B-T047
during	O
exercise	B-T056
;	O
however,	O
this	O
small	O
difference	O
does	O
not	O
appear	O
to	O
be	O
of	O
clinical significance	B-T033
.	O

Annexin A1	B-T116
restores	O
Aβ1-42	B-T116
-induced	O
blood-brain barrier disruption	B-T061
through	O
the	O
inhibition	B-T044
of	O
RhoA-ROCK signaling pathway	B-T044
The	O
blood-brain barrier	B-T023
(	O
BBB	B-T023
)	O
is	O
composed	O
of	O
brain capillary	B-T023
endothelial cells	B-T025
and	O
has	O
an	O
important	O
role	O
in	O
maintaining	O
homeostasis	B-T038
of	O
the	O
brain	B-T023
separating	O
the	O
blood	B-T031
from	O
the	O
parenchyma	B-T023
of	O
the	O
central nervous system	B-T022
(	O
CNS	B-T022
).	O
It	O
is	O
widely	O
known	O
that	O
disruption of the BBB	B-T061
occurs	O
in	O
various	O
neurodegenerative diseases	B-T047
,	O
including	O
Alzheimer's disease	B-T047
(	O
AD	B-T047
).	O
Annexin A1	B-T116
(	O
ANXA1	B-T116
),	O
an	O
anti-inflammatory messenger	B-T116
,	O
is	O
expressed	B-T045
in	O
brain endothelial cells	B-T025
and	O
regulates	O
the	O
BBB	B-T023
integrity.	O
However,	O
its	O
role	O
and	O
mechanism	B-T044
for	O
protecting	O
BBB	B-T023
in	O
AD	B-T047
have	O
not	O
been	O
identified.	O
We	O
found	O
that	O
β-Amyloid 1-42	B-T116
(	O
Aβ42	B-T116
)-induced	O
BBB disruption	B-T061
was	O
rescued	O
by	O
human recombinant ANXA1	B-T116
(	O
hrANXA1	B-T116
)	O
in	O
the	O
murine	B-T109
brain endothelial cell line bEnd.3.	B-T025
Also,	O
ANXA1	B-T116
was	O
decreased	O
in	O
the	O
bEnd.3 cells	B-T025
,	O
the	O
capillaries	B-T023
of	O
5XFAD mice	B-T001
,	O
and	O
the	O
human serum	B-T031
of	O
patients	B-T101
with	O
AD	B-T047
.	O
To	O
find	O
out	O
the	O
mechanism	B-T044
by	O
which	O
ANXA1	B-T116
recovers	O
the	O
BBB	B-T023
integrity	O
in	O
AD	B-T047
,	O
the	O
RhoA-ROCK signaling pathway	B-T044
was	O
examined	O
in	O
both	O
Aβ42	B-T116
-treated	O
bEnd.3 cells	B-T025
and	O
the	O
capillaries	B-T023
of	O
5XFAD mice	B-T001
as	O
RhoA	B-T116
was	O
activated	B-T045
in	O
both	O
cases.	O
RhoA inhibitors	B-T080
alleviated	O
Aβ42	B-T116
-induced	O
BBB disruption	B-T061
and	O
constitutively	O
overexpressed	B-T045
RhoA-GTP	B-T116
(active	O
form	O
of	O
RhoA	B-T116
)	O
attenuated	O
the	O
protective	O
effect	O
of	O
ANXA1	B-T116
.	O
When	O
pericytes	B-T025
were	O
cocultured	B-T059
with	O
bEnd.3 cells	B-T025
,	O
Aβ42	B-T116
-induced	O
RhoA activation	B-T045
of	O
bEnd.3 cells	B-T025
was	O
inhibited	B-T080
by	O
the	O
secretion	B-T038
of	O
ANXA1	B-T116
from	O
pericytes	B-T025
.	O
Taken	O
together,	O
our	O
results	O
suggest	O
that	O
ANXA1	B-T116
restores	O
Aβ42	B-T116
-induced	O
BBB disruption	B-T061
through	O
inhibition	B-T044
of	O
RhoA-ROCK signaling pathway	B-T044
and	O
we	O
propose	O
ANXA1	B-T116
as	O
a	O
therapeutic reagent	B-T121
,	O
protecting	O
against	O
the	O
breakdown of the BBB	B-T061
in	O
AD	B-T047
.	O

Association	B-T080
of	O
kidney disease	B-T047
with	O
obstructive sleep apnea	B-T047
in	O
a	O
population study	B-T062
of	O
men	B-T098
To	O
determine	B-T059
the	O
relationship	B-T080
between	O
obstructive sleep apnea	B-T047
(	O
OSA	B-T047
)	O
and	O
chronic kidney disease	B-T047
(	O
CKD	B-T047
).	O
Previous	O
population studies	B-T062
of	O
the	O
association	B-T080
are	O
sparse	B-T079
,	O
conflicting	B-T033
and	O
confined	B-T169
largely	O
to	O
studies	B-T062
of	O
administrative	B-T033
data	B-T078
.	O
Cross-sectional analysis	B-T062
in	O
unselected	O
participants	B-T098
of	O
the	O
Men Androgens Inflammation Lifestyle Environment and Stress (MAILES) study	B-T081
,	O
aged	B-T032
>40	O
y.	O
Renal	B-T023
data	B-T078
were	O
available	O
on	O
812	O
men	B-T098
without	O
a	O
prior	B-T079
OSA	B-T047
diagnosis	B-T033
who	O
underwent	O
full	O
in-home	B-T082
polysomnography	B-T060
(	O
Embletta X100	B-T074
)	O
in	O
2010-2011.	O
CKD	B-T047
was	O
defined	O
as	O
an	O
estimated glomerular filtration rate	B-T059
(	O
eGFR	B-T059
)	O
<60	O
mL/min/1.73m2	O
or	O
eGFR	B-T059
≥60	O
and	O
albuminuria	B-T033
(	O
albumin creatinine ratio	B-T059
≥3.0	O
mg/mmol).	O
CKD	B-T047
[10.5%,	O
n=85	O
(	O
Stage	B-T079
1-3,	O
9.7%;	O
Stage	B-T079
4-5,	O
0.7%)]	O
of	O
predominantly	B-T080
mild severity	B-T033
showed	O
significant	B-T078
association	B-T080
s	O
with	O
OSA	B-T047
(AHI≥10):	O
odds ratio	B-T081
(	O
OR	B-T081
)=1.9,	O
95%	O
confidence interval	B-T081
(	O
CI	B-T081
):1.02-3.5,	O
severe	B-T080
OSA	B-T047
(AHI	O
≥30/h):	O
OR	B-T081
=2.6,	O
95%	O
CI:1.1-6.2,	O
and	O
respiratory	B-T169
related	O
arousal	B-T039
index	B-T170
:	O
≥7.6/h	O
OR	B-T081
=2.3,	O
95%CI:	O
1.1-4.7,	O
but	O
not	O
measures	B-T081
of	O
hypoxemia	B-T033
after	O
adjustment	B-T169
for	O
age	B-T032
,	O
hypertension	B-T047
,	O
diabetes	B-T047
,	O
smoking	B-T055
,	O
obesity	B-T047
,	O
and	O
NSAID	B-T121
use	B-T169
.	O
There	O
was	O
no	O
association	B-T080
of	O
CKD	B-T047
with	O
daytime sleepiness	B-T033
.	O
In	O
men	B-T098
with	O
CKD	B-T047
,	O
those	O
with	O
OSA	B-T047
were	O
not significantly	B-T033
more	B-T081
likely	B-T081
to	O
report	B-T058
symptoms	B-T184
(	O
sleepiness	B-T033
,	O
snoring	B-T184
,	O
apneas	B-T046
)	O
or	O
be	O
identified	B-T080
with	O
the	O
STOP OSA screening questionnaire	B-T062
,	O
compared	O
to	O
men	B-T098
without	O
OSA	B-T047
.	O
Predominantly	B-T080
mild	B-T080
CKD	B-T047
is	O
associated with	B-T080
severe	B-T080
OSA	B-T047
and	O
arousals	B-T041
.	O
Further	O
population studies	B-T062
examining	B-T033
the	O
longitudinal	B-T082
relationship	B-T080
between	O
CKD	B-T047
and	O
OSA	B-T047
are	O
warranted	B-T169
.	O
Better	O
methods	B-T170
are	O
needed	B-T080
to	O
identify	B-T041
OSA	B-T047
in	O
CKD	B-T047
which	O
may	O
have	O
few	B-T081
symptoms	B-T184
.	O

Evidence	O
that	O
vitronectin	B-T116
is	O
a	O
potent	O
migration-enhancing factor	B-T123
for	O
cancer cells	B-T025
chaperoned	B-T116
by	O
fibrinogen	B-T116
:	O
a	O
novel	O
view	O
of	O
the	O
metastasis	B-T046
of	O
cancer cells	B-T025
to	O
low-	O
fibrinogen	B-T116
lymphatics	B-T022
and	O
body cavities	B-T030
Diluted	B-T169
(1%)	O
plasma	B-T031
induces	O
migration	B-T043
of	O
malignant cell lines	B-T025
much	O
more	O
strongly	O
than	O
potent	O
pro-metastatic factors	B-T169
.	O
To	O
characterize	O
the	O
factor(s)	B-T169
present	O
in	O
diluted	B-T169
plasma	B-T031
responsible	O
for	O
this	O
phenomenon	B-T067
we	O
performed	O
i)	O
heat	B-T070
inactivation	B-T169
,	O
ii)	O
dialysis	B-T070
,	O
iii)	O
proteinase K	B-T116
treatment	B-T169
,	O
and	O
iv)	O
molecular size filtration studies	B-T068
.	O
We	O
found	O
that	O
this	O
remarkable	O
pro-migratory activity	B-T052
of	O
diluted	B-T169
normal	O
plasma	B-T031
is	O
associated	O
with	O
a	O
~50-100-kD	O
protein	B-T116
that	O
interacts	O
with	O
GαI protein-coupled receptors	B-T116
and	O
activates	O
p42/44 MAPK	B-T116
and	O
AKT signaling	B-T044
in	O
target	O
cells	B-T025
.	O
Since	O
this	O
pro-migratory activity	B-T052
of	O
1%	O
plasma	B-T031
decreases	O
at	O
higher	O
plasma concentrations	B-T081
(>	O
20%),	O
but	O
is	O
retained	O
in	O
serum	B-T031
,	O
we	O
hypothesized	O
that	O
fibrinogen	B-T116
may	O
be	O
involved	O
as	O
a	O
chaperone	B-T116
of	O
the	O
protein(s)	B-T116
.	O
To	O
identify	O
the	O
pro-migratory protein(s)	B-T116
present	O
in	O
diluted	B-T169
plasma	B-T031
and	O
fibrinogen	B-T116
-depleted	O
serum	B-T031
,	O
we	O
performed	O
gel filtration	B-T059
and	O
hydrophobic interaction chromatography	B-T059
followed	O
by	O
mass spectrometry analysis	B-T059
.	O
We	O
identified	O
several	O
putative	O
protein	B-T116
candidates	O
that	O
were	O
further	O
tested	O
in	O
in vitro	B-T080
experiments	B-T062
.	O
We	O
found	O
that	O
this	O
pro-migratory factor	B-T123
chaperoned	B-T116
by	O
fibrinogen	B-T116
is	O
vitronectin	B-T116
,	O
which	O
activates	O
uPAR,	O
and	O
that	O
this	O
effect	O
can	O
be	O
inhibited	O
by	O
fibrinogen	B-T116
.	O
These	O
results	O
provide	O
a	O
novel	O
mechanism	B-T044
for	O
the	O
metastasis	B-T046
of	O
cancer cells	B-T025
to	O
lymphatics	B-T022
and	O
body cavities	B-T030
,	O
in	O
which	O
the	O
concentration	B-T081
of	O
fibrinogen	B-T116
is	O
low,	O
and	O
thus	O
suggests	O
that	O
free	O
vitronectin	B-T116
stimulates	O
migration	B-T043
of	O
tumor cells	B-T025
.	O

Development	B-T169
and	O
initial	B-T079
validation	B-T062
of	O
the	O
Respirator	B-T074
Comfort	B-T041
,	O
Wearing Experience	B-T041
,	O
and	O
Function	B-T169
Instrument	B-T074
[	O
R-COMFI	B-T074
Filtering face-piece respirators	B-T074
(	O
FFRs	B-T074
)	O
are	O
worn	O
to	O
protect	B-T033
health care personnel	B-T097
from	O
airborne particles	B-T131
;	O
however,	O
clinical studies	B-T062
have	O
demonstrated	O
that	O
FFR	B-T074
adherence	B-T169
is	O
relatively	O
low	B-T080
in	O
some	O
settings,	O
in	O
part	B-T082
,	O
due	O
to	O
discomfort	B-T184
and	O
intolerance	B-T040
.	O
The	O
objective	B-T170
of	O
this	O
study	B-T062
was	O
to	O
develop	O
and	O
initially	B-T079
evaluate	B-T052
the	O
psychometric properties	B-T080
of	O
an	O
instrument	B-T074
designed	B-T057
to	O
measure	B-T081
the	O
comfort	B-T041
and	O
tolerability	B-T080
of	O
FFRs	B-T074
.	O
Instrument	B-T074
items	O
were	O
developed	O
through	O
literature reviews	B-T170
,	O
focus groups	B-T096
,	O
and	O
several	B-T081
iterations	B-T033
of	O
ranking	B-T170
and	O
refining	O
by	O
experts	B-T097
.	O
Psychometric evaluation	B-T060
of	O
the	O
instrument	B-T074
was	O
conducted	O
using	O
Rasch partial credit model	B-T170
(	O
PCM	B-T170
)	O
analysis	B-T062
.	O
Pivot anchoring	B-T170
was	O
used	O
to	O
specify	O
the	O
threshold	B-T080
defining	O
item	O
difficulty	B-T080
;	O
in	O
our	O
analyses	B-T062
,	O
this	O
was	O
the	O
point	B-T081
that	O
participants	B-T098
moved	O
from	O
possessing	B-T078
none	O
of	O
the	O
trait	B-T032
to	O
some	O
of	O
the	O
trait	B-T032
.	O
The	O
final	B-T079
instrument	B-T074
was	O
completed	B-T080
by	O
165	O
health care personnel	B-T097
from	O
3	O
Veterans	B-T098
Health Administration facilities	B-T058
,	O
and	O
data	B-T078
were	O
analyzed	B-T062
using	O
Rasch PCM	B-T170
.	O
Seven	O
items	O
were	O
removed	B-T080
because	O
they:	O
(1)	O
violated the assumption of independence	B-T080
;	O
(2)	O
were	O
mis-fitting	B-T080
;	O
and/or	O
(3)	O
were	O
deemed	O
not relevant	B-T080
.	O
Category	B-T170
function	B-T169
analysis	B-T062
demonstrated	O
that	O
all	O
categories	B-T170
progressed	B-T169
monotonically	B-T080
.	O
Principal components analysis	B-T081
demonstrated	O
the	O
existence	B-T081
of	O
three	O
subscales	B-T081
(	O
Discomfort	B-T184
,	O
General	O
Wearing Experience	B-T041
,	O
and	O
Function	B-T169
).	O
Final	B-T079
reliability	B-T081
analyses	B-T062
showed	O
that	O
the	O
scale	B-T081
had	O
moderate	B-T080
to	O
high person reliability	B-T081
and	O
high	O
item	O
reliability	B-T081
.	O
The	O
final	O
instrument	B-T074
contained	B-T169
21	O
items.	O
Until	O
now,	O
to	O
our	O
knowledge	B-T041
no	O
instrument	B-T074
with	O
evidence	B-T078
supporting	O
its	O
reliability and validity	B-T080
to	O
assess	B-T052
discomfort	B-T184
and	O
tolerance	B-T080
of	O
FFRs	B-T074
among	O
health care personnel	B-T097
has	O
been	O
published	B-T057
.	O
A	O
21-item	O
psychometrically sound measure	B-T081
of	O
comfort	B-T041
and	O
tolerability	B-T080
of	O
FFRs	B-T074
,	O
Respirator	B-T074
Comfort	B-T041
,	O
Wearing Experience	B-T041
,	O
and	O
Function	B-T169
Instrument	B-T074
(	O
R-COMFI	B-T074
),	O
was	O
developed.	O
The	O
significance	B-T078
of	O
developing	O
such	O
an	O
instrument	B-T074
is	O
that	O
it	O
will	O
help	O
identify	O
respirators	B-T074
that	O
are	O
likely	O
to	O
have	O
better	O
adherence	B-T169
in	O
practice	B-T041
settings.	O
The	O
R-COMFI	B-T074
may	O
be	O
used	O
within	B-T082
and	O
beyond	O
the	O
VA healthcare system	B-T093
as	O
a	O
psychometrically sound instrument	B-T074
to	O
evaluate	B-T052
the	O
comfort	B-T041
and	O
tolerability	B-T080
of	O
respirators	B-T074
,	O
including	O
developmental	B-T080
prototypes.	O

Kidney transplant recipients	B-T033
after	O
nonrenal solid organ transplantation	B-T061
show	O
low	O
alloreactivity	B-T039
but	O
an	O
increased	O
risk	B-T078
of	O
infection	B-T046
The	O
number	O
of	O
kidney transplant recipients	B-T033
(	O
KTRs	B-T033
)	O
after	O
nonrenal solid organ transplantation	B-T061
(	O
SOT	B-T061
)	O
has	O
increased	O
to	O
almost	O
5%.	O
Knowledge	O
on	O
patient	B-T101
and	O
allograft	B-T061
outcomes	B-T080
,	O
infections	B-T046
,	O
and	O
alloreactivity	B-T039
,	O
however,	O
remains	O
scarce.	O
We	O
studied	B-T062
40	O
KTRs	B-T033
after	O
nonrenal SOT	B-T061
.	O
Seven	O
hundred	O
and	O
twenty	O
primary	O
KTRs	B-T033
and	O
119	O
repeat	O
KTRs	B-T033
were	O
used	O
for	O
comparison.	O
Samples	B-T031
were	O
collected	O
pretransplantation	B-T079
,	O
at	O
+1,	O
+2,	O
and	O
+3	O
months	O
post-transplantation	B-T079
.	O
Alloreactive	B-T039
and	O
CMV-specific	B-T005
T cells	B-T025
were	O
measured	O
by	O
interferon-γ ELISPOT assay	B-T059
.	O
Patient	B-T101
survival	B-T052
in	O
KTRs	B-T033
after	O
SOT	B-T061
,	O
primary	O
and	O
repeat	O
KTRs	B-T033
was	O
comparable.	O
While	O
death	B-T040
-censored	O
allograft	B-T061
survival	B-T052
was	O
comparable	O
between	O
KTRs	B-T033
after	O
SOT	B-T061
and	O
primary	O
KTRs	B-T033
,	O
KTRs	B-T033
after	O
SOT	B-T061
showed	O
superior	O
5-year	B-T079
death	B-T040
-censored	O
allograft	B-T061
survival	B-T052
of	O
92.5%	O
compared	O
to	O
81.2%	O
in	O
repeat	O
KTRs	B-T033
.	O
Interestingly,	O
KTRs	B-T033
after	O
SOT	B-T061
show	O
less	O
preformed	O
panel-reactive antibodies	B-T059
,	O
frequencies	B-T079
of	O
alloreactive	B-T039
T cells	B-T025
,	O
and	O
acute rejections	B-T033
compared	O
to	O
repeat	O
KTRs	B-T033
.	O
KTRs	B-T033
after	O
SOT	B-T061
,	O
however,	O
show	O
higher	O
incidences	B-T081
of	O
EBV viremia	B-T047
and	O
PTLD	B-T191
,	O
sepsis	B-T047
,	O
and	O
death	B-T040
from	O
sepsis	B-T047
.	O
Impaired	O
CMV-specific	B-T005
cellular immunity	B-T040
was	O
associated with	B-T080
more	O
CMV	B-T005
replication	B-T043
compared	O
to	O
repeat	O
KTRs	B-T033
.	O
Our	O
results	O
suggest	O
comparable	O
patient	B-T101
and	O
allograft	B-T061
outcomes	B-T080
in	O
KTRs	B-T033
after	O
SOT	B-T061
and	O
primary	O
KTRs	B-T033
.	O
The	O
observed	O
low	O
alloreactivity	B-T039
may	O
contribute	O
to	O
excellent	O
allograft	B-T061
outcomes	B-T080
.	O
Caution	O
should	O
be	O
taken	O
in	O
KTRs	B-T033
after	O
SOT	B-T061
regarding	O
infectious complications	B-T047
due	O
to	O
overimmunosuppression	B-T047
.	O

Improved	B-T033
protocol	B-T170
for	O
the	O
isolation	B-T059
of	O
naïve	O
follicular dendritic cells	B-T025
Follicular dendritic cells	B-T025
(	O
FDCs	B-T025
)	O
in	O
lymphoid organs	B-T023
play	O
an	O
important	O
role	B-T077
in	O
the	O
humoral immune response	B-T043
.	O
However,	O
because	O
the	O
isolation	B-T061
of	O
FDCs	B-T025
is	O
difficult	B-T080
due	O
to	O
their	O
very	O
small	B-T081
population size	B-T081
and	O
fragility	B-T049
under	O
mechanical	B-T070
and	O
chemical stresses	B-T070
,	O
the	O
genetic	B-T169
and	O
biochemical	B-T169
characteristics	B-T080
of	O
FDCs	B-T025
remain	O
unclear	B-T033
.	O
Previously,	O
we	O
identified	O
FDCs	B-T025
as	O
ICAM-1(+)	B-T116
cells	B-T025
in	O
the	O
CD45	B-T116
(-)	B-T033
non-hematopoietic cell fraction	B-T026
from	O
naïve	O
mouse spleen	B-T024
after	O
cell separation	B-T059
by	O
means	O
of	O
digestion	O
with	O
a	O
combination	B-T080
of	O
enzymes	B-T116
.	O
In	O
the	O
present	O
study,	O
using	O
a	O
new	B-T080
combination	B-T080
of	O
enzymes	B-T116
,	O
we	O
found	O
that	O
FDCs	B-T025
are	O
highly	O
enriched	O
in	O
the	O
CD45	B-T116
(-)	B-T033
ICAM-1(+)	B-T116
CD21	B-T116
/	O
35(+)	B-T116
cell fraction	B-T026
.	O
CD45	B-T116
(-)	B-T033
ICAM-1(+)	B-T116
CD21	B-T116
/	O
35(+)	B-T116
cells	B-T025
in	O
the	O
mouse spleen	B-T024
retained	O
an	O
antigen	B-T129
administered	O
in vivo	B-T082
for	O
more	O
than	O
7	O
days	B-T079
.	O
Moreover,	O
CD45	B-T116
(-)	B-T033
ICAM-1(+)	B-T116
CD21	B-T116
/	O
35(+)	B-T116
cells	B-T025
isolated	B-T169
from	O
the	O
spleen of mice	B-T024
administered	O
with	O
a	O
cognate antigen	B-T129
enhanced	B-T052
the	O
survival	B-T043
and	O
proliferation	B-T169
of	O
antigen-specific B cells	B-T025
in vitro	B-T080
.	O
Our	O
improved	B-T033
protocol	B-T170
for	O
the	O
isolation	B-T059
of	O
naïve	O
FDCs	B-T025
will	O
be	O
useful	O
for	O
the	O
analysis	B-T062
of	O
FDCs	B-T025
in vitro	B-T080
and	O
in vivo	B-T082
.	O

Dental	B-T080
enamel defects	B-T033
in	O
German	B-T098
medieval	B-T079
and	O
early-modern-age	B-T079
populations	B-T098
Aim	B-T078
of	O
this	O
study	B-T062
was	O
to	O
investigate	B-T169
the	O
frequency	B-T079
and	O
type	B-T080
of	O
developmental defects of enamel	B-T033
(	O
DDE	B-T033
)	O
in	O
a	O
medieval	B-T079
and	O
an	O
early-modern-age	B-T079
population	B-T098
from	O
Thuringia, Germany	B-T083
.	O
Sixty-six	O
skeletons	B-T022
subdivided	B-T169
into	O
31	O
single	B-T081
burials	B-T052
(12(th)/13(th)	O
c.)	O
and	O
35	O
individuals	B-T098
buried	B-T052
in	O
groups	B-T078
(15(th)/16(th)	O
c.)	O
were	O
examined	B-T033
.	O
DDE	B-T033
were	O
classified	B-T185
on	O
1,246	O
teeth	B-T023
according	O
to	O
the	O
DDE	B-T033
index	B-T170
.	O
Molar-incisor-hypomineralisation	B-T047
(	O
MIH	B-T047
),	O
a	O
special	O
type	B-T080
of	O
DDE	B-T033
,	O
was	O
recorded	B-T170
according	O
to	O
the	O
European Academy of Paediatric Dentistry	B-T092
(	O
EAPD	B-T092
)	O
criteria	B-T078
.	O
DDE	B-T033
was	O
found	O
in	O
89.4%	O
of	O
the	O
individuals	B-T098
(	O
single	B-T081
burials	B-T052
90.3%	O
and	O
group	B-T078
burials	B-T052
88.6%).	O
Hypoplastic	B-T169
pits	B-T033
were	O
the	O
most	O
frequent	B-T079
defect	B-T169
in	O
primary teeth	B-T023
and	O
linear enamel hypoplasia	B-T047
(	O
LEH	B-T047
)	O
in	O
permanent teeth	B-T023
.	O
13	O
individuals	B-T098
(24.1%)	O
showed	O
at	O
least	O
one	O
hypomineralised	B-T047
permanent tooth	B-T023
,	O
12.2%	O
had	O
MIH	B-T047
on	O
at	O
least	O
one	O
first	O
permanent molar	B-T023
and	O
10.0%	O
in	O
permanent incisors	B-T023
.	O
Second primary molars	B-T023
were	O
affected	B-T169
in	O
8.0%	O
of	O
the	O
children	B-T100
and	O
juveniles	B-T100
.	O
No	O
individual	B-T098
suffered	O
from	O
affected	B-T169
molars	B-T023
and	O
incisors	B-T023
in	O
combination	B-T080
.	O
Endogenous	B-T169
factors	B-T169
like	O
nutritional deficiencies	B-T047
and	O
health problems	B-T033
in	O
early	B-T079
childhood	B-T079
could	O
have	O
been	O
aetiological	B-T169
reasons	B-T078
of	O
DDE	B-T033
and	O
MIH	B-T047
.	O
The	O
frequency	B-T079
of	O
DDE	B-T033
and	O
MIH	B-T047
might	O
have	O
been	O
masked	B-T062
by	O
extended	B-T082
carious lesions	B-T047
,	O
dental wear	B-T037
and	O
ante-mortem	B-T033
tooth loss	B-T020
.	O

Breast Cancer	B-T191
Detection Rate	B-T081
,	O
Incidence	B-T081
,	O
Prevalence	B-T081
and	O
Interval	B-T079
Cancer	B-T191
-related	O
Mammography Screening	B-T061
Times	B-T079
among	O
Thai	B-T098
Women	B-T098
A	O
recent	O
guideline	B-T170
by	O
the	O
American Cancer Society	B-T094
recommended	O
that	O
mammography	B-T060
(	O
MMG	B-T060
)	O
should	O
be	O
done	O
for	O
women	B-T098
starting	O
in	O
their	O
mid-40s.	O
In	O
Thailand	B-T083
,	O
information	O
on	O
opportunistic mammography screening	B-T058
is	O
limited	B-T169
and	O
data	B-T078
on	O
the	O
total	O
incidence	B-T081
of	O
breast cancer	B-T191
are	O
also	O
lacking.	O
The	O
purpose	O
of	O
this	O
study	B-T062
was	O
to	O
estimate	B-T081
the	O
breast cancer	B-T191
detection	B-T058
,	O
incident	B-T067
and	O
prevalence rates	B-T081
among	O
Thai	B-T098
women	B-T098
.	O
We	O
retrospectively	O
reviewed	O
the	O
opportunistic mammography screening	B-T058
of	O
normal	O
women	B-T098
between	O
30	O
and	O
80	O
years	B-T079
who	O
underwent	O
the	O
procedure	B-T058
between	O
2001	O
and	O
2010.	O
All	O
cases	O
were	O
followed	O
until	O
2012.	O
The	O
detection rate	B-T081
was	O
calculated	O
for	O
the	O
whole	O
period	O
of	O
observation	B-T062
using	O
'	O
number	B-T081
of	O
women	B-T098
with	O
positive findings	B-T033
'	O
divided	O
by	O
'	O
total number	B-T081
of	O
women	B-T098
screened	B-T060
'.	O
The	O
incidence rate	B-T081
was	O
calculated	B-T169
only	O
at	O
the	O
first	O
MMG	B-T060
while	O
the	O
subsequence	O
rate	O
was	O
calculated	O
based	O
on	O
all	O
new	O
cases	O
detected	B-T033
at	O
each	O
subsequent	O
MMG	B-T060
.	O
Among	O
the	O
47,430	O
women	B-T098
,	O
there	O
were	O
152,091	O
MMGs	B-T060
or	O
approximately	O
3.2	O
occasions	O
per	O
person	B-T098
(range,	O
1-10).	O
The	O
average	O
duration	B-T079
of	O
the	O
interval	B-T079
between	O
each	O
subsequence	O
visit	O
was	O
1.8	O
years	B-T079
.	O
Overall,	O
breast cancer	B-T191
was	O
detected	B-T033
in	O
543	O
women	B-T098
,	O
with	O
a	O
detection rate	B-T081
of	O
10.3	O
per	O
1,000	O
persons	B-T098
.	O
The	O
prevalence rate	B-T081
of	O
breast cancer	B-T191
at	O
the	O
first	O
visit	O
was	O
5.78	O
per	O
1,000	O
person	B-T098
s.	O
The	O
incidence	B-T081
or	O
new	O
cases	O
detected	B-T033
at	O
any	O
follow-up	O
visit	O
was	O
10.4	O
per	O
1,000	O
person	B-T098
s.	O
The	O
overall	O
interval	B-T079
cancer	O
was	O
0.91	O
per	O
1,000	O
women	B-T098
,	O
mainly	O
detected	B-T033
before	O
their	O
second	O
and	O
third	O
MMG	B-T060
,	O
with	O
a	O
rate	O
of	O
0.0.47	O
and	O
0.76	O
per	O
1,000	O
women	B-T098
.	O
Opportunistic mammography screening	B-T058
in	O
Thailand	B-T083
detected	B-T033
10	O
cases	O
of	O
breast cancer	B-T191
from	O
each	O
1,000	O
women	B-T098
.	O
This	O
paper	O
indicated	O
a	O
high	O
rate	O
of	O
cancer detection	B-T058
during	O
a	O
two	O
year	O
interval	B-T079
,	O
hence,	O
a	O
screening mammogram	B-T061
should	O
be	O
performed	O
more	O
often.	O

Assessment	O
of	O
groundwater	B-T082
vulnerability	B-T080
in	O
the	O
Daule aquifer	B-T070
,	O
Ecuador	B-T083
,	O
using	O
the	O
susceptibility index method	B-T059
The	O
Guayas region	B-T083
in	O
Ecuador	B-T083
is	O
economically	O
very	O
important,	O
producing	O
68%	O
of	O
the	O
national crops	B-T002
.	O
The	O
main	O
agricultural activities	B-T090
threaten	O
the	O
groundwater	B-T082
therein	O
with	O
nitrate	B-T197
contamination	B-T078
given	O
the	O
large	O
fertiliser	B-T073
and	O
water	B-T121
needs	B-T080
.	O
The	O
present	O
work	O
tests	O
the	O
applicability	O
of	O
the	O
susceptibility index assessment method	B-T059
in	O
evaluating	O
the	O
impact	O
of	O
agricultural activities	B-T090
on	O
groundwater	B-T082
quality	B-T080
,	O
using	O
as	O
a	O
case	O
study	O
an	O
aquifer	B-T070
of	O
the	O
Guayas	B-T083
river basin	B-T082
in	O
Ecuador	B-T083
.	O
The	O
index	O
adapts	O
four	O
parameters	O
of	O
the	O
DRASTIC method	B-T059
and	O
incorporated	O
a	O
new	O
land use	B-UnknownType
parameter.	O
Results	O
show	O
that	O
the	O
areas	B-T082
highly	B-T080
vulnerable	B-T080
to	O
contamination	B-T078
are	O
located	O
in	O
irrigation	B-T068
perimeters	B-T082
of	O
dominant	O
paddy fields	B-T082
associated	O
with	O
the	O
high	O
recharge	O
rates	O
in	O
the	O
alluvial deposits	B-T197
.	O
Respectively,	O
moderately	B-T080
vulnerable	B-T080
and	O
low	B-T080
-	O
vulnerability	B-T080
areas	B-T082
correspond	O
to	O
aquatic environments	B-T067
and	O
forests	B-T070
,	O
semi-natural zones	B-T082
and	O
water bodies	B-T067
.	O
One	O
of	O
the	O
main	O
contributions	O
of	O
the	O
Daule aquifer	B-T070
vulnerability	B-T080
is	O
likely	O
its	O
wide	B-T082
,	O
flat topography	B-T082
.	O
A	O
great	O
part	O
of	O
the	O
aquifer	B-T070
is	O
at	O
high risk of contamination	B-T033
by	O
nitrates	B-T197
if	O
a	O
code	O
of	O
good	B-T080
agricultural practices	B-T090
is	O
not	O
applied.	O
Therefore	O
the	O
implementation	O
of	O
a	O
monitoring network to control	B-T033
the	O
nitrates	B-T197
concentrations	B-T081
is	O
the	O
first	O
step	O
to	O
assure	O
groundwater	B-T082
quality	B-T080
for	O
drinking	B-T167
purposes	B-T169
.	O

Heterogeneous	B-T080
depression	B-T048
trajectories	B-T079
in	O
multiple sclerosis	B-T047
patients	B-T101
Trajectories	B-T079
of	O
depression	B-T048
over	O
time	O
may	O
be	O
heterogeneous	B-T080
in	O
Multiple Sclerosis	B-T047
(	O
MS	B-T047
)	O
patients	B-T101
.	O
Describing	O
these	O
trajectories	B-T079
will	O
help	O
clinicians	B-T097
understand	O
better	O
the	O
progression	B-T169
of	O
depression	B-T048
in	O
MS	B-T047
patients	B-T101
to	O
aid	O
in	O
patient	O
care	O
decisions.	O
Latent class growth analysis	B-T062
(	O
LCGA	B-T062
)	O
was	O
applied	O
to	O
3507	O
MS	B-T047
patients	B-T101
using	O
an	O
electronic health records (EHR) data base	B-T170
to	O
identify	O
subgroups	B-T098
of	O
MS	B-T047
patients	B-T101
based	O
on	O
self-reported	O
depression screening	B-T061
(	O
PHQ-9	B-T170
).	O
Latent	B-T080
trajectory	B-T079
classes	O
were	O
used	O
for	O
group	B-T098
comparisons	O
based	O
on	O
baseline	B-T081
clinical characteristics	B-T201
.	O
Three	O
subgroups	B-T098
were	O
found	O
characterized	O
by	O
high	B-T080
(10.0%	O
[of	O
participants	B-T098
]),	O
wavering	O
above	O
and	O
below	O
moderate	B-T080
(26.2%)	O
and	O
low	B-T080
and	O
variable	B-T080
(63.8%)	O
depression level	B-T033
trajectories	B-T079
.	O
The	O
subpopulation	B-T098
trajectories	B-T079
,	O
respectively,	O
were	O
also	O
characterized	O
by	O
high	B-T080
,	O
moderate	B-T080
and	O
low	B-T080
MS	B-T047
disability	B-T033
at	O
baseline	B-T081
.	O
In	O
contrast,	O
the	O
overall	O
average	O
trajectory	B-T079
was	O
slightly	O
declining	O
and	O
below	O
the	O
moderate	B-T080
depression	B-T048
threshold	B-T080
.	O
The	O
LCGA	B-T062
approach	O
described	O
in	O
this	O
paper	O
and	O
applied	O
to	O
MS	B-T047
patients	B-T101
provides	O
a	O
template	B-T078
for	O
improved	O
use	O
of	O
an	O
EHR data base	B-T170
for	O
understanding	O
heterogeneous	B-T080
depression screening	B-T061
trajectories	B-T079
.	O
Clinicians	B-T097
may	O
use	O
such	O
information	B-T078
to	O
more	O
closely	O
monitor patients	B-T058
that	O
are	O
expected	O
to	O
maintain	O
high	B-T080
or	O
unstable	B-T033
depression levels	B-T033
.	O

The	O
PLA2 gene	B-T028
mediates	O
the	O
humoral immune responses	B-T043
in	O
Bactrocera dorsalis (Hendel)	B-T204
The	O
phospholipase A2 (PLA2) gene	B-T028
encodes	B-T052
the	O
enzyme	B-T116
that	O
catalyzes	B-T169
the	O
hydrolysis	B-T070
of	O
phospholipids	B-T109
(	O
PLs	B-T109
)	O
from	O
the	O
sn-2 position	B-T082
.	O
However,	O
little	O
is	O
known	O
about	O
its	O
role	B-T170
in	O
humoral immune responses	B-T043
.	O
In	O
this	O
study	B-T062
,	O
we	O
investigated	B-T169
the	O
expression profile	B-T081
of	O
PLA2	B-T028
in	O
different	B-T080
tissues	B-T024
and	O
developmental stages	B-T079
in	O
Bactrocera dorsalis (Hendel)	B-T204
,	O
and	O
the	O
results	O
showed	O
that	O
the	O
transcriptional	B-T045
level	B-T080
of	O
PLA2	B-T028
was	O
high	B-T080
in	O
the	O
egg	B-T042
and	O
mature stage	B-T042
and	O
in	O
the	O
testis	B-T023
tissue	B-T024
.	O
Bacterial infection	B-T047
increased	O
the	O
expression	B-T045
of	O
PLA2	B-T028
,	O
and	O
the	O
highest	O
degree	O
of	O
up-regulation	B-T044
appeared	O
in	O
the	O
fat body	B-T023
.	O
Silencing	B-T045
PLA2	B-T028
influenced	B-T077
the	O
expression	B-T045
of	O
immune-related genes	B-T028
,	O
including	O
MyD88	B-T028
and	O
defensin	B-T116
in	O
the	O
Toll pathway	B-T044
and	O
relish	B-T116
and	O
diptericin	B-T116
in	O
the	O
Imd pathway	B-T077
.	O
Moreover,	O
the	O
expression	B-T045
of	O
MyD88	B-T028
and	O
defensin	B-T116
was	O
down-regulated	B-T044
significantly	O
in	O
the	O
ds-PLA2	B-T028
group	B-T078
compared	O
with	O
those	O
in	O
the	O
ds-egfp	B-T116
group	B-T078
when	O
B. dorsalis	B-T204
was	O
infected	B-T033
with	O
L. monocytogenes	B-T007
and	O
S. aureus	B-T007
,	O
indicating	O
that	O
PLA2	B-T028
was	O
involved	O
in	O
the	O
activation	B-T045
of	O
the	O
Toll pathway	B-T044
.	O
Meanwhile,	O
infection	B-T046
with	O
L. monocytogenes	B-T007
and	O
E. coli	B-T007
,	O
which	O
activate	B-T169
the	O
Imd pathway	B-T077
,	O
does	O
not	O
increase	B-T169
the	O
mRNA	B-T114
levels	B-T080
of	O
relish	B-T116
and	O
diptericin	B-T116
in	O
the	O
ds-PLA2	B-T028
group	B-T078
as	O
severely	O
as	O
it	O
increases	B-T169
those	O
in	O
the	O
ds-egfp	B-T116
group	B-T078
,	O
indicating	O
that	O
the	O
Imd pathway	B-T077
was	O
also	O
repressed	B-T169
after	O
silencing	B-T045
PLA2	B-T028
.	O
Notably,	O
the	O
development	B-T169
of	O
lipid droplets	B-T026
in	O
fat body	B-T023
cells	B-T025
was	O
influenced	B-T077
by	O
silencing	B-T045
PLA2	B-T028
,	O
implying	O
that	O
PLA2	B-T028
affects	O
the	O
function	B-T169
of	O
fat body	B-T023
tissue	B-T024
.	O
These	O
results	O
suggest	O
that	O
the	O
PLA2	B-T028
PLA2 gene	B-T028
may	O
mediate	O
humoral immune responses	B-T043
by	O
reducing	B-T080
lipid storage	B-T043
in	O
fat body	B-T023
cells	B-T025
in	O
B. dorsalis	B-T204
.	O

Gambling disorders	B-T048
,	O
gambling	B-T055
type	O
preferences,	O
and	O
psychiatric	B-T169
comorbidity	B-T078
among	O
the	O
Thai general population	B-T098
:	O
Results	O
of	O
the	O
2013	O
National Mental Health Survey	B-T170
Background	O
and	O
aims	O
To	O
estimate	O
the	O
prevalence	B-T081
of	O
problem	B-T048
and	O
pathological gambling	B-T048
,	O
gender	B-T032
and	O
age-group	B-T100
differences	O
in	O
gambling types	B-T055
,	O
and	O
comorbidities	B-T078
with	O
other	O
psychiatric disorders	B-T048
among	O
the	O
Thai general population	B-T098
.	O
Methods	O
Analysis	O
was	O
conducted	O
on	O
4,727	O
participants	B-T098
of	O
Thailand's	B-T083
2013	O
National Mental Health Survey	B-T170
,	O
a	O
multistage stratified cluster survey	B-T170
,	O
using	O
the	O
Composite International Diagnostic Interview	B-T170
.	O
Diagnoses	B-T033
of	O
problem	B-T048
and	O
pathological gambling	B-T048
and	O
other	O
psychiatric disorders	B-T048
were	O
based	O
on	O
the	O
DSM-IV-TR criteria	B-T170
with	O
the	O
following	O
additional	O
criteria	B-T078
for	O
gamblers	B-T055
:	O
more	O
than	O
10	O
lifetime	B-T079
gambling	O
episodes	O
and	O
a	O
single year loss	B-T081
of	O
at	O
least	O
365	O
USD	B-T081
from	O
gambling	B-T055
.	O
Results	O
The	O
estimated	O
lifetime	B-T079
prevalence rates	B-T081
of	O
pathological	B-T048
and	O
problem gambling	B-T048
were	O
0.90%	O
[95%	O
confidence interval	B-T081
(	O
CI	B-T081
):	O
0.51-1.29]	O
and	O
1.14%	O
(95%	O
CI	B-T081
:	O
0.58-1.70),	O
respectively.	O
The	O
most	O
popular	O
type	O
of	O
gambling	B-T055
was	O
playing lotteries	B-T055
[69.5%,	O
standard error	B-T081
(	O
SE	B-T081
)	O
=	O
1.9],	O
the	O
prevalence	B-T081
of	O
which	O
was	O
significantly	O
higher	O
among	O
females	B-T032
and	O
older age groups	B-T098
.	O
The	O
most	O
common	O
psychiatric disorders	B-T048
seen	O
among	O
pathological gamblers	B-T048
were	O
alcohol abuse	B-T048
(57.4%),	O
nicotine dependence	B-T048
(49.5%),	O
and	O
any	O
drug use disorder	B-T048
(16.2%).	O
Pathological gambling	B-T048
was	O
highly	O
prevalent	O
among	O
those	O
who	O
ever	O
experienced	O
major depressive episodes	B-T048
(5.5%),	O
any	O
drug dependence	B-T048
(5.1%),	O
and	O
intermittent explosive disorder	B-T048
(4.8%).	O
The	O
association	O
between	O
pathological gambling	B-T048
was	O
strongest	O
with	O
a	O
history	O
of	O
major depressive episode	B-T048
[	O
adjusted odds ratio	B-T081
(	O
AOR	B-T081
)	O
=	O
10.4,	O
95%	O
CI	B-T081
:	O
2.80-38.4].	O
Conclusion	O
The	O
study	O
confirms	O
the	O
recognition	B-T041
of	O
gambling disorders	B-T048
as	O
a	O
public health	B-T170
concern	O
in	O
Thailand	B-T083
and	O
suggests	O
a	O
need	O
for	O
culturally	B-T169
specific	O
preventive	B-T080
measures	O
for	O
pathological gamblers	B-T048
and	O
those	O
with	O
a	O
history	O
of	O
substance use disorders	B-T048
or	O
major depression	B-T048
.	O

Synovial sarcoma	B-T191
of	O
the	O
hypopharynx	B-T029
in	O
a	O
pediatric	B-T080
patient	B-T101
:	O
Case report	B-T170
Synovial sarcoma	B-T191
(	O
SS	B-T191
)	O
is	O
uncommon	O
high	O
grade	O
soft tissue	B-T024
sarcoma	B-T191
,	O
accounting	O
for	O
less	O
than	O
10%	O
of	O
all	O
head and neck sarcomas	B-T191
.	O
Also,	O
about	O
10%	O
of	O
SS	B-T191
occur	O
within	O
the	O
Head	B-T029
&	O
Neck	B-T029
.	O
In	O
the	O
pediatric	B-T080
population	B-T098
,	O
SS	B-T191
is	O
an	O
extremely	O
rare	B-T080
head & neck malignancy	B-T191
.	O
We	O
present	O
a	O
case	O
of	O
sixteen	O
years	O
old	O
boy	B-T100
diagnosed	B-T033
with	O
SS	B-T191
situated	O
of	O
the	O
hypopharynx	B-T029
treated by	B-T061
surgical excision	B-T061
and	O
post operative	B-T033
radio	B-T061
-	O
chemotherapy	B-T061
.	O
This	O
anatomical location	B-T029
brings	O
additional	O
functional	B-T169
challenges	B-T058
(	O
swallowing	B-T040
,	O
phonation	B-T042
,	O
respiration	B-T039
),	O
especially	O
in	O
the	O
pediatric	B-T080
population	B-T098
.	O
Pre-operative	B-T079
and	O
even	O
post-operative	B-T033
histopathological	B-T169
diagnosis	B-T033
of	O
SS	B-T191
remains	O
difficult.	O
Optimal	B-T080
treatment	B-T061
of	O
Head	B-T029
&	O
Neck	B-T029
SS	B-T191
has	O
to	O
balance	O
functional	B-T169
and	O
oncologic	B-T091
aspects	B-T080
.	O
SS	B-T191
is	O
an	O
extremely	O
rare	B-T080
head & neck malignancy	B-T191
in	O
pediatric	B-T080
population	B-T098
.	O
It	O
has	O
multifaceted	B-T082
challenges	B-T058
including	O
pre	O
and	O
post-operative	B-T033
histopathological	B-T169
diagnosis	B-T033
and	O
optimal	B-T080
modality	B-T078
of	O
treatment	B-T061
.	O
Clinical judgment	B-T170
,	O
especially	O
in	O
the	O
pediatric	B-T080
population	B-T098
,	O
needs	O
to	O
balance	O
tumor free margins	B-T034
and	O
organ preservation	B-T061
in	O
head	B-T029
and	O
neck	B-T029
region	B-T029
.	O

Ocular hypotensive	B-T047
effect	B-T080
of	O
the	O
novel	O
EP3	B-T116
/	O
FP	B-T116
agonist	B-T121
ONO-9054	B-T109
versus	O
Xalatan	B-T109
:	O
results	O
of	O
a	O
28-	O
day	B-T079
,	O
double-masked	B-T062
,	O
randomised	B-T080
study	B-T062
ONO-9054	B-T109
is	O
being	O
developed	O
for	O
the	O
reduction	B-T080
of	O
intraocular pressure	B-T042
(	O
IOP	B-T042
)	O
in	O
patients	B-T101
with	O
ocular hypertension	B-T047
(	O
OHT	B-T047
)	O
and	O
open-angle glaucoma	B-T047
(	O
OAG	B-T047
).	O
This	O
study	B-T062
compared	O
the	O
novel	O
dual	O
EP3	B-T116
/	O
FP	B-T116
agonist	B-T121
ONO-9054	B-T109
with	O
the	O
FP	B-T116
agonist	B-T121
Xalatan	B-T109
.	O
Adults	B-T100
(n=123)	O
with	O
bilateral	O
mild/moderate	O
OAG	B-T047
or	O
OHT	B-T047
,	O
with	O
unmedicated	O
IOP	B-T042
of	O
≥24	O
mm	O
Hg	O
at	O
8:00	O
hours,	O
≥21	O
mm	O
Hg	O
at	O
10:00	O
hours	O
and	O
≤36	O
mm	O
Hg,	O
were	O
randomised	O
1:1	O
to	O
receive	O
ONO-9054	B-T109
(0.003%,	O
30	O
μg/mL)	O
or	O
Xalatan	B-T109
(0.005%,	O
50	O
μg/mL)	O
once	O
daily	B-T079
for	O
28	O
days	B-T079
.	O
Day	B-T079
29	O
mean	O
diurnal	O
IOP	B-T042
was	O
-7.2	O
mm	O
Hg	O
for	O
ONO-9054	B-T109
vs	O
-6.6	O
mm	O
Hg	O
for	O
Xalatan	B-T109
.	O
At	O
08:00	O
hours,	O
the	O
IOPs	B-T042
were	O
comparable,	O
and	O
at	O
all	O
later	O
time	O
points	O
the	O
decrease	B-T081
in	O
IOP	B-T042
was	O
greater	O
for	O
ONO-9054	B-T109
.	O
On	O
day	B-T079
29,	O
the	O
odds	O
of	O
a	O
mean	O
IOP	B-T042
reduction	B-T080
of	O
≤-25%,	O
≤-30%	O
and	O
≤-35%	O
for	O
ONO-9054	B-T109
were	O
2.39,	O
2.37	O
and	O
4.85	O
times	O
more,	O
respectively,	O
than	O
the	O
odds	O
for	O
Xalatan	B-T109
(p<0.05,	O
post hoc analyses	B-T062
).	O
The	O
percentage	O
of	O
subjects	O
achieving	O
target	O
IOPs	B-T042
on	O
day	B-T079
29	O
(≤17,	O
≤16	O
and	O
≤15	O
mm	O
Hg)	O
was	O
greater	O
for	O
ONO-9054	B-T109
than	O
for	O
Xalatan	B-T109
;	O
the	O
odds	O
of	O
achieving	O
an	O
IOP	B-T042
≤15	O
mm	O
Hg	O
for	O
ONO-9054	B-T109
were	O
2.4	O
times	O
more	O
than	O
the	O
odds	O
for	O
Xalatan	B-T109
(p<0.01,	O
post hoc analysis	B-T062
).	O
Subjects	O
randomised	O
to	O
receive	O
ONO-9054	B-T109
were	O
more	O
likely	O
to	O
achieve	O
a	O
greater	O
per	O
cent	O
reduction	O
in	O
IOP	B-T042
and	O
were	O
more	O
likely	O
to	O
achieve	O
target	O
IOPs	B-T042
than	O
those	O
receiving	O
Xalatan	B-T109
.	O
The	O
effects	O
of	O
ONO-9054	B-T109
in	O
reducing	O
IOP	B-T042
appear	O
to	O
persist	O
longer	O
than	O
those	O
of	O
Xalatan	B-T109
.	O
NCT02083289,	O
Results.	O

Whole-body strength training	B-T061
with	O
Huber Motion Lab	B-T073
and	O
traditional strength training	B-T061
in	O
cardiac rehabilitation	B-T061
:	O
A	O
randomized controlled study	B-T062
Isometric strengthening	B-T061
has	O
been	O
rarely	O
studied	O
in	O
patients	B-T101
with	O
coronary heart disease	B-T047
(	O
CHD	B-T047
),	O
mainly	O
because	O
of	O
possible	O
potential side effects	B-T046
and	O
lack	B-T080
of	O
appropriate	B-T080
and	O
reliable	B-T170
devices	B-T073
.	O
We	O
aimed	O
to	O
compare	O
2	O
different	O
modes	B-T169
of	O
resistance training	B-T061
,	O
an	O
isometric	O
mode	B-T169
with	O
the	O
Huber Motion Lab	B-T073
(	O
HML	B-T073
)	O
and	O
traditional strength training	B-T061
(	O
TST	B-T061
),	O
in	O
CHD	B-T047
patients	B-T101
undergoing	O
a	O
cardiac rehabilitation	B-T061
program.	O
We	O
randomly	O
assigned	O
50	O
patients	B-T101
to	O
HML	B-T073
or	O
TST	B-T061
.	O
Patients	B-T101
underwent	O
complete	O
blinded	B-T062
evaluation	B-T058
before	O
and	O
after	O
the	O
rehabilitation program	B-T061
,	O
including	O
testing for cardiopulmonary exercise	B-T060
,	O
maximal isometric voluntary contraction	B-T060
,	O
endothelial	B-T024
function	B-T042
and	O
body composition	B-T032
.	O
After	O
4	O
weeks	B-T079
of	O
training	B-T065
(16	O
sessions),	O
the	O
groups	B-T078
did	O
not	O
differ	O
in	O
body composition	B-T032
,	O
anthropometric	B-T062
characteristics	B-T080
,	O
or	O
endothelial	B-T024
function	B-T042
.	O
With	O
HML	B-T073
,	O
peak	B-T080
power output	B-T070
(P=0.035),	O
maximal	B-T080
heart rate	B-T201
(P<0.01)	O
and	O
gain	B-T081
of	O
force	B-T067
measured	B-T080
in	O
the	O
chest	O
press	O
position	O
(P<0.02)	O
were	O
greater	B-T081
after	O
versus	O
before	O
training	B-T056
.	O
Both	O
protocols	B-T170
appeared	O
to	O
be	O
well	O
tolerated,	O
safe	O
and	O
feasible	O
for	O
these	O
CHD	B-T047
patients	B-T101
.	O
A	O
training protocol	B-T170
involving	O
6s	O
phases	O
of	O
isometric contractions	B-T042
with	O
10s	O
of	O
passive	B-T080
recovery	B-T040
on	O
an	O
HML	B-T073
device	O
could	O
be	O
safely	O
implemented	O
in	O
rehabilitation programs	B-T061
for	O
patients	B-T101
with	O
CHD	B-T047
and	O
improve	O
functional outcomes	B-T080
.	O

Percutaneous coronary intervention	B-T061
and	O
heart surgery	B-T061
learning	B-T041
needs of patients	B-T169
in	O
Jordan	B-T083
This	O
study	O
aimed	O
to	O
identify	O
and	O
prioritize	B-T079
the	O
perceived	B-T041
learning	B-T041
needs of patients	B-T169
who	O
underwent	O
percutaneous coronary intervention	B-T061
or	O
open-heart surgery	B-T061
.	O
Identifying	O
learning	B-T041
needs	O
for	O
post-cardiac intervention	B-T061
patients	B-T101
is	O
essential	O
to	O
establish	O
successful	O
health education programmes	B-T058
based	O
on	O
patient	B-T101
central care	B-T058
.	O
A	O
descriptive	O
comparative	O
design	B-T052
was	O
employed	O
on	O
a	O
convenience	B-T080
sample	B-T098
of	O
260	O
patients	B-T101
who	O
underwent	O
a	O
percutaneous coronary intervention	B-T061
and	O
105	O
patients	B-T101
who	O
underwent	O
open-heart surgery	B-T061
patients	B-T101
.	O
Participants	B-T098
had	O
completed	O
the	O
Patient	B-T101
Learning Needs Scale	B-T170
.	O
Data	B-T078
were	O
collected	O
between	O
1	O
October	O
2014	O
and	O
31	O
June	O
2015.	O
Patients	B-T101
from	O
the	O
two	O
groups	B-T078
highly	O
requesting	O
health and recovery related information	B-T058
.	O
They	O
scored	O
all	O
learning need	B-T041
topics	B-T170
as	O
important	O
or	O
highly	O
important	O
for	O
them.	O
The	O
top	O
priority	B-T079
learning	B-T041
need	O
for	O
both	O
patient groups	B-T101
was	O
'	O
information	B-T078
about	O
wound care	B-T061
',	O
and	O
the	O
lowest	O
priority	B-T079
learning	B-T041
need	O
topic	B-T170
was	O
'	O
physical activity	B-T056
'.	O
The	O
learning	B-T041
needs	B-T080
of	O
both	O
groups	B-T078
were	O
very	O
close,	O
which	O
indicated	O
that	O
educational secondary prevention programmes	B-T170
'	O
content	O
can	O
be	O
prepared	O
in	O
a	O
unified	O
structure	O
for	O
those	O
patients	B-T101
.	O
Although,	O
specific	O
headings	B-T170
can	O
be	O
used	O
to	O
address	O
the	O
unique	O
needs	B-T080
that	O
emerge	O
from	O
having	O
a	O
specific	O
cardiac	B-T023
interventional procedure	B-T061
.	O
The	O
fact	O
that	O
wound care	B-T061
and	O
medications	B-T058
are	O
areas	O
of	O
highest	O
learning	B-T041
needs	B-T080
for	O
patients	B-T101
requires	O
health policy	B-T089
decision makers	B-T097
to	O
address	O
these	O
topics	B-T170
at	O
the	O
time	B-T079
of	O
hospital discharge	B-T058
.	O
In	O
addition,	O
a	O
policy	B-T089
focus	O
on	O
considering	O
patients	B-T101
'	O
actual	O
learning	B-T041
needs	B-T080
requires	O
establishment	B-T073
and	O
managerial support	B-T054
.	O
As	O
patients	B-T101
'	O
learning	B-T041
needs	B-T080
might	O
change	O
later	O
after	O
discharge	B-T058
,	O
the	O
health services	B-T058
should	O
be	O
proactive	O
and	O
focus	O
on	O
continuous	O
support	B-T054
for	O
patients	B-T101
after	O
hospital discharge	B-T058
.	O
Secondary prevention programmes	B-T170
should	O
incorporate	O
health education	B-T065
topics	B-T170
based	O
on	O
patients	B-T101
'	O
own	O
views.	O
This	O
can	O
be	O
done	O
by	O
giving	O
higher	O
priority	B-T079
to	O
understand	O
patients' needs	B-T169
,	O
put	O
much	O
more	O
effort	O
into	O
how	O
to	O
meet	O
patients	B-T101
'	O
information	B-T078
needs	B-T080
and	O
to	O
create	O
a	O
more	O
engaging	O
learning	B-T041
environment	B-T082
for	O
patients	B-T101
and	O
their	O
families	B-T099
.	O

Complications	B-T046
and	O
Near-Miss	O
Events	B-T051
After	O
Hepatectomy	B-T061
for	O
Living-Related Liver Donation	B-T061
:	O
An	O
Italian	B-T083
Single Center	B-T073
Report	B-T170
of	O
One	O
Hundred	O
Cases	B-T169
BACKGROUND	O
In	O
healthy	B-T080
individuals	B-T098
,	O
such	O
as	O
liver living donors	B-T098
,	O
potential	O
complications	B-T046
may	O
occur	O
during	O
surgery	B-T061
.	O
Reporting	O
such	O
complications	B-T046
and	O
near-miss	O
events	O
is	O
mandatory	O
to	O
improve	O
living donor	B-T098
management	B-T057
and	O
safety	B-T068
.	O
MATERIAL	O
AND	O
METHODS	O
This	O
retrospective study	B-T062
was	O
performed	O
on	O
a	O
prospective	O
database	B-T170
with	O
the	O
aim	O
of	O
providing	O
a	O
brief	O
analysis	B-T062
of	O
the	O
perioperative	B-T079
,	O
medium-term	B-T079
,	O
and	O
long-term	B-T079
complications	B-T046
,	O
and	O
the	O
near-miss	O
events	B-T051
in	O
a	O
single center	B-T073
series	O
of	O
100	O
consecutive	O
liver resections	B-T061
for	O
adult	B-T100
-to-	O
adult	B-T100
living-donor	B-T098
liver transplantation	B-T061
.	O
RESULTS	O
Only	O
23.3%	O
of	O
potential	O
living donors	B-T098
underwent	O
surgery	B-T061
.	O
No	B-T033
living donor	B-T098
mortality	B-T081
was	O
reported;	O
29	O
patients	B-T101
(29%)	O
experienced	O
at	O
least	O
one	O
complication	B-T046
.	O
Five	O
patients	B-T101
developed	O
mild	B-T080
long-term	B-T079
dysfunction	B-T077
;	O
two	O
aborted	O
hepatectomies	B-T061
,	O
and	O
there	O
were	O
two	O
near-miss	O
events	B-T051
reported.	O
CONCLUSIONS	O
A	O
strategy	B-T041
for	O
an	O
accurate	O
assessment	B-T058
of	O
living donor	B-T098
complications	B-T046
and	O
strict	O
selection	B-T052
criterion	O
cannot	O
be	O
overemphasized,	O
as	O
well	O
as	O
the	O
need	O
to	O
continuously	O
update	O
center	B-T073
patient outcome	B-T078
reports	B-T170
.	O

Tooth wear	B-T037
as	O
a	O
means	O
to	O
quantify	B-T081
intra-specific	B-T080
variations	B-T080
in	O
diet	B-T168
and	O
chewing	B-T042
movements	B-T040
In	O
mammals	B-T015
,	O
tooth	B-T023
function	B-T169
,	O
and	O
its	O
efficiency	B-T081
,	O
depends	O
both	O
on	O
the	O
mechanical	B-T070
properties	B-T080
of	O
the	O
food	B-T168
and	O
on	O
chewing	B-T042
dynamics	B-T169
.	O
These	O
aspects	B-T080
have	O
rarely	O
been	O
studied	B-T062
in	O
combination	O
and/or	O
at	O
the	O
intra-specific	B-T080
level.	O
Here	O
we	O
applied	O
3D	B-T082
dental	B-T023
surface	B-T082
texture	B-T080
analysis	B-T062
to	O
a	O
sample	B-T077
of	O
field voles	B-T015
(	O
Microtus agrestis	B-T015
)	O
trapped	O
from	O
Finnish Lapland	B-T083
at	O
different	O
seasons	B-T079
and	O
localities	B-T083
to	O
test	B-T169
for	O
inter-population	B-T098
variations	B-T080
.	O
We	O
also	O
explored	O
intra-individual	B-T098
variation	B-T080
in	O
chewing	B-T042
dynamics	B-T169
by	O
analysing	B-T062
two	O
facets	B-T082
on	O
the	O
second upper molars	B-T023
.	O
Our	O
results	B-T033
confirm	O
that	O
the	O
two	O
localities	B-T083
have	O
similar	O
environments	B-T082
and	O
that	O
the	O
voles	B-T015
feed	B-T052
on	O
the	O
same	O
items	O
there.	O
On	O
the	O
other	O
hand,	O
the	O
texture	B-T080
data	B-T078
suggest	O
that	O
diets	B-T168
are	O
seasonally	O
variable	B-T080
,	O
probably	O
due	O
to	O
varying	O
concentrations	B-T081
of	O
abrasives	B-T120
.	O
Lastly,	O
the	O
textures	B-T080
on	O
the	O
buccal facets	B-T029
are	O
more	O
isotropic	B-T067
and	O
their	O
direction	B-T082
deviates	B-T082
more	O
from	O
the	O
mesial	B-T029
chewing	B-T042
direction	B-T082
than	O
the	O
lingual	B-T023
facets	B-T082
.	O
We	O
interpret	B-T169
these	O
results	B-T033
as	O
reflecting	O
food	B-T168
,	O
rather	O
than	O
chewing	B-T042
,	O
movements	B-T040
,	O
where	O
food particles	B-T168
are	O
more	O
guided	O
on	O
the	O
lingual	B-T023
side	O
of	O
the	O
molars	B-T023
.	O
This	O
has	O
implications	O
for	O
the	O
application	O
of	O
dental microwear	B-T037
analysis	B-T062
to	O
fossils	B-T167
:	O
only	O
homologous	B-T032
facets	B-T082
can	O
be	O
compared,	O
even	O
when	O
the	O
molar	B-T023
row	O
seems	O
to	O
constitute	O
a	O
functional unit	B-T169
.	O

Human cathelicidin LL-37	B-T116
enhance	O
the	O
antibiofilm effect	B-T033
of	O
EGCG	B-T109
on	O
Streptococcus mutans	B-T007
Streptococcus mutans	B-T007
forms	O
biofilms	B-T007
as	O
a	O
resistance	B-T169
mechanism	B-T169
against	O
antimicrobial agents	B-T121
in	O
the	O
human	B-T016
oral cavity	B-T030
.	O
We	O
recently	O
showed	O
that	O
human cathelicidin LL-37	B-T116
exhibits	O
inhibitory effects	B-T080
on	O
biofilm formation	B-T043
of	O
S. mutans	B-T007
through	O
interaction	B-T169
with	O
lipoteichoic acid	B-T109
(	O
LTA	B-T109
),	O
but	O
without	O
antibacterial	B-T033
or	O
biofilm	B-T007
dispersal abilities	B-T082
.	O
(-)-Epigallocatechin gallate	B-T109
(	O
EGCG	B-T109
)	O
is	O
the	O
most	O
abundant	O
constituent	O
of	O
tea	B-T168
catechins	B-T109
that	O
has	O
the	O
greatest	O
anti-infective potential	B-T033
to	O
inhibit the growth	B-T040
of	O
various	O
microorganisms	B-T001
and	O
biofilm formation	B-T043
.	O
Therefore,	O
in	O
this	O
study,	O
we	O
evaluated	B-T058
whether	O
LL-37	B-T116
interacts	O
with	O
EGCG	B-T109
to	O
enhance	O
the	O
antibiofilm effect	B-T033
of	O
EGCG	B-T109
on	O
S. mutans	B-T007
biofilm formation	B-T043
.	O
Clinical	O
S. mutans	B-T007
strains	B-T001
(n	O
=	O
10)	O
isolated	O
from	O
children's	B-T100
saliva	B-T031
were	O
tested	B-T169
in	O
a	O
biofilm formation	B-T043
assay	B-T059
.	O
The	O
antibiofilm effect	B-T033
of	O
EGCG	B-T109
with	O
and	O
without	O
LL-37	B-T116
was	O
analyzed	B-T062
by	O
the	O
minimum	O
biofilm	B-T007
eradication	B-T080
concentration	B-T081
assay	B-T059
and	O
confirmed	O
using	O
field	O
emission-scanning electron microscopy	B-T059
.	O
In	O
addition,	O
the	O
interaction	B-T169
among	O
EGCG	B-T109
,	O
LL-37	B-T116
,	O
and	O
LTA	B-T109
of	O
S. mutans	B-T007
was	O
determined	O
using	O
quartz crystal microbalance analysis	B-T062
.	O
EGCG	B-T109
killed	O
100	O
%	O
of	O
planktonic	B-T007
S. mutans	B-T007
within	O
5	O
h,	O
inhibited	O
biofilm formation	B-T043
within	O
24	O
h,	O
and	O
reduced	O
bacteria cells	B-T007
in	O
preformed	O
biofilms	B-T007
within	O
3	O
h	O
at	O
a	O
concentration	B-T081
of	O
0.2	O
mg/mL.	O
However,	O
EGCG	B-T109
did	O
not	O
appear	O
to	O
interact	O
with	O
LTA	B-T109
.	O
LL-37	B-T116
effectively	O
enhanced	O
the	O
bactericidal activity	B-T039
of	O
EGCG	B-T109
against	O
biofilm formation	B-T043
and	O
preformed	O
biofilms	B-T007
as	O
determined	O
by	O
quantitative	B-T081
crystal violet	B-T109
staining	B-T059
and	O
field	O
emission-scanning electron microscopy	B-T059
.	O
In	O
addition,	O
quartz crystal microbalance analysis	B-T062
revealed	O
that	O
LL-37	B-T116
interacted	B-T169
with	O
EGCG	B-T109
and	O
promoted	O
binding	B-T044
between	O
EGCG	B-T109
and	O
LTA	B-T109
of	O
S. mutans	B-T007
.	O
We	O
show	O
that	O
LL-37	B-T116
enhances	O
the	O
antibiofilm effect	B-T033
of	O
EGCG	B-T109
on	O
S. mutans	B-T007
.	O
This	O
finding	O
provides	O
new	O
knowledge	O
for	O
dental treatment	B-T061
by	O
using	O
LL-37	B-T116
as	O
a	O
potential	O
antibiofilm compound	B-T121
.	O

Discovery	B-T052
of	O
Orally	B-T030
Efficacious	B-T080
Phosphoinositide-3-Kinase delta	B-T116
Inhibitors	B-T121
with	O
Improved	B-T033
Metabolic	B-T169
Stability	B-T080
Aberrant signaling	B-T038
of	O
phosphoinositide-3-kinase delta	B-T116
(	O
PI3K-delta	B-T116
)	O
has	O
been	O
implicated	O
in	O
numerous	O
pathologies	B-T046
including	O
hematological malignancies	B-T191
and	O
rheumatoid arthritis	B-T047
.	O
Described	O
in	O
this	O
manuscript	O
is	O
the	O
discovery	B-T052
,	O
optimization	B-T052
and	O
in vivo	B-T082
evaluation	B-T058
of	O
a	O
novel	O
series	O
of	O
pyridine-containing	B-T109
PI3K-delta	B-T116
inhibitors	B-T121
.	O
This	O
work	O
led	O
to	O
the	O
discovery	B-T052
of	O
35	B-T121
,	O
a	O
highly	O
selective	O
inhibitor	B-T121
of	O
PI3K-delta	B-T116
which	O
displays	O
an	O
excellent	O
pharmacokinetic profile	B-T169
and	O
is	O
efficacious	B-T080
in	O
a	O
rodent model	B-T050
of	O
rheumatoid arthritis	B-T047
.	O

Mobile phone	B-T073
use	B-T169
,	O
behavioural problems	B-T048
and	O
concentration	B-T041
capacity	B-T081
in	O
adolescents	B-T100
:	O
A	O
prospective study	B-T062
The	O
aim	O
of	O
this	O
study	B-T062
is	O
to	O
prospectively	O
investigate	B-T169
whether	O
exposure to	B-T080
radiofrequency electromagnetic fields	B-T070
(	O
RF-EMF	B-T070
)	O
emitted	O
by	O
mobile phones	B-T073
and	O
other	O
wireless communication devices	B-T073
is	O
related	O
to	O
behavioural problems	B-T048
or	O
concentration	B-T041
capacity	B-T081
in	O
adolescents	B-T100
.	O
The	O
HERMES	B-T062
(	O
Health	B-T078
Effects	B-T080
Related	B-T080
to	O
Mobile phonE	B-T073
use	O
in	O
adolescentS	B-T100
)	O
study	O
sample	B-T096
consisted	O
of	O
439	O
Swiss	B-T098
adolescents	B-T100
aged	B-T032
12-17	O
years	B-T079
.	O
Behavioural problems	B-T048
were	O
assessed	B-T052
using	O
the	O
Strengths and Difficulties Questionnaire	B-T170
(	O
SDQ	B-T170
),	O
concentration	B-T041
capacity	B-T081
of	O
the	O
adolescents	B-T100
was	O
measured	B-T080
by	O
means	O
of	O
a	O
standardized computerized cognitive test	B-T170
named	O
FAKT	B-T170
.	O
Cross-sectional	B-T062
and	O
longitudinal	B-T062
(	O
1year	B-T079
of	O
follow-up	B-T033
)	O
analyses	B-T062
were	O
performed	B-T169
to	O
investigate	B-T169
possible	O
associations	B-T080
between	O
behavioural problems	B-T048
and	O
concentration	B-T041
capacity	B-T081
and	O
different	B-T080
exposure	B-T080
measures	B-T081
:	O
self-reported	B-T062
and	O
operator	B-T097
-recorded	O
wireless communication device	B-T073
use,	O
cumulative	B-T080
RF-EMF	B-T070
brain	B-T023
and	O
whole body	B-T017
dose	O
and	O
measured	B-T080
personal	O
RF-EMF	B-T070
exposure	B-T080
.	O
In	O
the	O
cross-sectional analyses	B-T062
behavioural problems	B-T048
were	O
associated with	B-T080
several	O
self-reported	B-T170
wireless device	B-T073
use	B-T169
measures	B-T081
but	O
not	O
operator	B-T097
-recorded	O
mobile phone	B-T073
use	B-T169
measures	B-T081
,	O
concentration	B-T041
capacity	B-T081
was	O
associated with	B-T080
several	O
self-reported	B-T062
and	O
operator	B-T097
-recorded	O
exposures	B-T080
.	O
The	O
longitudinal analyses	B-T062
point	O
towards	O
absence	B-T169
of	O
associations	B-T080
.	O
The	O
lack	B-T080
of	O
consistent	B-T078
exposure	B-T080
-response	O
patterns	B-T082
in	O
the	O
longitudinal analyses	B-T062
suggests	O
that	O
behavioural problems	B-T048
and	O
concentration	B-T041
capacity	B-T081
are	O
not	O
affected	B-T169
by	O
the	O
use	O
of	O
wireless communication devices	B-T073
or	O
RF-EMF	B-T070
exposure	B-T080
.	O
Information	B-T078
bias	B-T078
and	O
reverse	O
causality	O
are	O
likely	O
explanations	B-T170
for	O
the	O
observed	O
cross-sectional findings	B-T062
.	O

Twisting method	B-T169
for	O
reducing	B-T080
friction	B-T070
during	O
insertion	B-T061
of	O
a	O
sheath	B-T074
introducer	B-T074
and	O
a	O
sheathless guiding catheter	B-T074
A	O
sheathless system	B-T169
that	O
inserts	B-T058
a	O
catheter	B-T074
directly	B-T080
into	O
the	O
artery	B-T023
can	O
reduce	B-T080
puncture	B-T067
site	B-T082
-related	O
complications	B-T046
through	O
a	O
2-Fr reduction	B-T080
of	O
the	O
outer diameter	B-T082
.	O
However,	O
the	O
gap	B-T082
between	O
the	O
dilator	B-T074
and	O
the	O
guiding catheter	B-T074
of	O
the	O
sheathless system	B-T169
is	O
larger	B-T081
than	O
the	O
gap	B-T082
between	O
the	O
dilator	B-T074
and	O
sheath	B-T074
of	O
the	O
introducer system	B-T074
,	O
resulting	O
in	O
stronger	O
insertion	B-T061
resistance	B-T067
.	O
A	O
twisting method	B-T169
with	O
rapid	B-T080
alternating	B-T169
rotation	B-T169
of	O
a	O
device	B-T074
to	O
the	O
left	O
and	O
right	O
during	O
insertion	B-T061
insertion	B-T061
can	O
reduce	B-T080
the	O
insertion	B-T061
resistance	B-T067
.	O
This	O
method	O
can	O
be	O
effective	B-T080
with	O
the	O
sheathless system	B-T169
which	O
has	O
a	O
larger	B-T081
gap	B-T082
.	O
To	O
examine	O
the	O
effect of	B-T080
size	B-T082
reduction	B-T080
on	O
the	O
sheathless system	B-T169
and	O
the	O
effect of	B-T080
insertion	B-T061
resistance	B-T067
reduction	B-T080
using	O
the	O
twisting method	B-T169
,	O
we	O
developed	O
an	O
insertion	B-T061
simulator	B-T074
and	O
compared	B-T052
insertion	B-T061
resistance	B-T067
to	O
a	O
5-Fr sheath	B-T074
introducer	B-T074
and	O
a	O
5-Fr sheathless system	B-T169
,	O
with	O
and	O
without	O
the	O
twisting method	B-T169
.	O
The	O
insertion	B-T061
simulator	B-T074
pushed	O
a	O
sheath	B-T074
introducer	B-T074
or	O
a	O
sheathless system	B-T169
toward	O
a	O
mock	B-T033
artery	B-T023
consisted	O
with	O
a	O
5-mm urethane	B-T074
and	O
a	O
1-mm rubber sheet	B-T074
by	O
an	O
electrical motor	B-T073
with	O
or	O
without	O
twisting	B-T169
motion	B-T070
generated	O
by	O
a	O
crank shaft	B-T073
.	O
Insertion	B-T061
resistance	B-T067
during	O
the	O
penetration	B-T169
was	O
measured	B-T080
by	O
a	O
tension meter	B-T074
.	O
The	O
insertion	B-T061
resistance	B-T067
was	O
less	O
with	O
the	O
5-Fr sheathless system	B-T169
than	O
with	O
the	O
5-Fr sheath	B-T074
introducer	B-T074
.	O
The	O
resistance	B-T067
reduced	B-T080
further	O
with	O
use	O
of	O
twisting	B-T169
for	O
both	O
the	O
sheathed	B-T074
and	O
sheathless catheters	B-T074
.	O
In	O
conclusion	B-T078
,	O
the	O
experiment	O
suggests	O
the	O
benefits	B-T081
of	O
twisting	B-T169
insertion	B-T061
of	O
a	O
sheathless guiding catheter	B-T074
for	O
reduction	B-T080
of	O
puncture	B-T067
site	B-T082
-related	O
complications	B-T046
.	O

Unconventional	B-T080
Protein Secretion	B-T043
in	O
Plants	B-T002
Unconventional	B-T080
protein secretion	B-T043
(	O
UPS	B-T043
)	O
describes	B-T078
secretion pathways	B-T043
that	O
bypass	O
one	O
or	O
several	B-T081
of	O
the	O
canonical	B-T081
secretion	B-T038
pit-stops	O
on	O
the	O
way	O
to	O
the	O
plasma membrane	B-T026
,	O
and/or	O
involve	B-T169
the	O
secretion	B-T038
of	O
leaderless	O
proteins	B-T116
.	O
So	O
far,	O
alternatives	B-T077
to	O
conventional	B-T080
secretion	B-T038
were	O
primarily	B-T080
observed	B-T169
and	O
studied	B-T062
in	O
yeast	B-T004
and	O
animal cells	B-T025
.	O
The	O
sessile	B-T080
lifestyle	O
of	O
plants	B-T002
brings	O
with	O
it	O
unique	B-T080
restraints	O
on	O
how	O
they	O
adapt to adverse conditions	B-T040
and	O
environmental challenges	B-T082
.	O
Recently,	O
attention	B-T041
towards	O
unconventional	B-T080
secretion pathways	B-T043
in	O
plant cells	B-T025
has	O
substantially	O
increased,	O
with	O
the	O
large	O
number	O
of	O
leaderless	O
proteins	B-T116
identified	B-T080
through	O
proteomic studies	B-T091
.	O
While	O
UPS	B-T043
pathways	B-T077
in	O
plants	B-T002
are	O
certainly	O
not	O
yet	O
exhaustively	O
researched,	O
an	O
emerging	O
notion	O
is	O
that	O
induction	B-T169
of	O
UPS	B-T043
pathways	B-T077
is	O
correlated	B-T080
with	O
pathogenesis	B-T046
and	O
stress responses	B-T039
.	O
Given	O
the	O
multitude	O
UPS	B-T043
events	O
observed,	O
comprehensively	B-T080
organizing	B-T169
the	O
routes	O
proteins	B-T116
take	O
to	O
the	O
apoplast	B-T026
in	O
defined	O
UPS	B-T043
categories	O
is	O
challenging.	O
With	O
the	O
establishment	B-T080
of	O
a	O
larger	O
collection	B-T169
of	O
studied	O
plant proteins	B-T116
taking	O
these	O
UPS	B-T043
pathways	B-T077
,	O
a	O
clearer	O
picture	O
of	O
endomembrane	B-T026
trafficking	B-T043
as	O
a	O
whole	O
will	O
emerge.	O
There	O
are	O
several	B-T081
novel	B-T080
enabling	B-T041
technologies	B-T090
,	O
such	O
as	O
vesicle	B-T026
proteomics	B-T091
and	O
chemical	B-T103
genomics	B-T091
,	O
with	O
great	O
potential	B-T080
for	O
dissecting	B-T169
secretion pathways	B-T043
,	O
providing	B-T052
information	B-T078
about	O
the	O
cargo	O
that	O
travels	O
along	O
them	O
and	O
the	O
conditions	O
that	O
induce	B-T169
them.	O

Neospora caninum	B-T204
in	O
Axis Deer	B-T015
(	O
Axis axis	B-T015
)	O
and	O
Fallow Deer	B-T015
(	O
Dama dama	B-T015
)	O
in	O
Northern	B-T082
Mexico	B-T083
Serum samples	B-T031
from	O
18	O
axis deer	B-T015
(	O
Axis axis	B-T015
)	O
and	O
19	O
fallow deer	B-T015
(	O
Dama dama	B-T015
)	O
were	O
analyzed	O
with	O
an	O
enzyme-linked immunosorbent assay	B-T059
for	O
Neospora caninum antibodies	B-T116
.	O
Two	O
axis	B-T015
(11%)	O
and	O
two	O
fallow deer	B-T015
(11%)	O
were	O
positive	B-T033
for	O
N. caninum antibodies	B-T116
.	O

The	O
ABBA study	B-T062
-	O
approach	O
bias	O
modification	O
in	O
bulimia nervosa	B-T048
and	O
binge eating disorder	B-T048
:	O
study	O
protocol	O
for	O
a	O
randomised controlled trial	B-T062
The	O
core	O
symptoms	B-T184
of	O
bulimia nervosa	B-T048
(	O
BN	B-T048
)	O
and	O
binge eating disorder	B-T048
(	O
BED	B-T048
)	O
are	O
recurrent episodes of binge eating	B-T033
.	O
Despite	O
negative psychological	B-T048
and	O
physical consequences	B-T033
,	O
BN/BED	B-T048
patients	B-T101
show	O
uncontrollable	O
approach	O
tendencies towards food	B-T040
.	O
This	O
cognitive bias	B-T078
occurs	O
at	O
an	O
early	O
stage	O
of	O
information processing	B-T041
.	O
Cognitive bias modification	B-T061
(	O
CBM	B-T061
)	O
directly	O
targets	O
such	O
biases	B-T078
and	O
has	O
been	O
shown	O
to	O
be	O
effective	O
in	O
treating	B-T061
several	O
mental disorders	B-T048
.	O
In	O
alcohol addiction	B-T048
,	O
automatic	O
action	O
tendencies	O
towards	O
alcohol cues	B-UnknownType
and	O
relapse	B-T067
rates	B-T081
were	O
successfully	O
reduced	O
by	O
a	O
specific	O
form	O
of	O
CBM	B-T061
,	O
termed	O
approach	O
bias modification	B-T169
.	O
Based	O
on	O
these	O
findings	O
and	O
data	B-T078
from	O
a	O
proof-of-concept study	B-T062
in	O
people	B-T098
with	O
high	O
levels	O
of	O
food craving	B-T055
,	O
CBM	B-T169
is	O
considered	O
a	O
promising	O
new	O
treatment approach	B-UnknownType
for	O
BN/BED	B-T048
.	O
Given	O
the	O
similarities	O
between	O
BN/BED	B-T048
and	O
addictive disorders	B-T048
,	O
the	O
rationale	B-T078
for	O
using	O
approach	O
bias modification	B-T169
appears	O
to	O
be	O
particularly	O
strong.	O
The	O
aim	O
of	O
the	O
present	O
study	O
is	O
to	O
examine	O
whether,	O
compared	O
to	O
a	O
sham training	B-T062
,	O
computerised	O
approach	O
bias modification	B-T169
(10	O
sessions)	O
can	O
reduce	O
binge-eating episodes	B-T033
in	O
BN/BED	B-T048
patients	B-T101
from	O
pre-treatment	B-T079
to	O
follow-up.	O
Additionally,	O
we	O
will	O
investigate	O
whether	O
this	O
CBM	B-T061
programme	O
also	O
reduces	O
global	B-T080
eating disorder psychopathology	B-T048
,	O
trait	B-T032
and	O
cue-elicited food craving	B-T055
,	O
food intake	B-T040
as	O
well	O
as	O
approach	O
and	O
attentional bias	B-T041
towards	O
visual food cues	B-T078
.	O
Treatment acceptance	B-T061
will	O
be	O
determined	O
by	O
attrition rates	B-UnknownType
and	O
responses	B-T170
on	O
a	O
feedback	O
form.	O
This	O
is	O
a	O
double-blind	B-T062
,	O
randomised	B-T062
,	O
placebo-controlled	B-T062
,	O
parallel-group superiority trial	B-T078
with	O
two	O
parallel	O
arms.	O
A	O
total	O
of	O
54	O
BN/BED	B-T048
patients	B-T101
will	O
be	O
recruited.	O
Approach	O
bias towards food	B-T078
will	O
be	O
retrained	O
by	O
a	O
computer	O
task	O
adopting	O
an	O
implicit learning paradigm	B-T062
.	O
Patients	B-T101
in	O
the	O
control	O
condition	O
(	O
sham	B-T062
)	O
will	O
conduct	O
a	O
similar task	B-T057
but	O
will	O
not	O
be	O
trained	O
to	O
avoid	O
food cues	B-T078
.	O
Methods	O
against	O
bias	B-T078
include	O
public registration	B-T170
,	O
randomisation	B-T062
by	O
a	O
central study office	B-T097
,	O
standardisation of the treatments	B-T062
and	O
blinding of assessors	B-T062
.	O
Furthermore,	O
the	O
session	O
number	O
and	O
duration	O
will	O
be	O
equivalent	O
in	O
the	O
two	O
conditions.	O
This	O
is	O
the	O
first	O
registered	O
randomised controlled trial	B-T062
of	O
approach	O
bias modification	B-T169
in	O
a	O
clinical BN/BED sample	B-T062
.	O
Results	O
from	O
this	O
study	O
will	O
provide	O
an	O
indication	O
of	O
the	O
efficacy	O
of	O
approach	O
bias modification	B-T169
training	O
for	O
BN/BED	B-T048
and	O
the	O
potential	O
mechanisms	O
of	O
action	O
underlying	O
this	O
treatment	B-T061
.	O
DRKS00010231	O
(retrospectively	O
registered	O
on	O
24	O
March	O
2016;	O
first	O
version).	O

Protein	B-T116
Design	B-T052
for	O
Nanostructural Engineering	B-T059
:	O
Concluding	O
Remarks	B-T170
and	O
Future	O
Directions	O
This	O
final	O
chapter	B-T170
aims	O
to	O
summarize	O
the	O
main	O
conclusions	B-T170
of	O
the	O
book	B-T170
and	O
to	O
point	O
to	O
possible	O
directions	O
for	O
further	O
research	B-T062
in	O
the	O
field	B-UnknownType
of	O
protein	B-T116
design	B-T052
for	O
nanostructural engineering	B-T059
.	O
Even	O
though	O
this	O
research field	B-UnknownType
is	O
still	O
at	O
its	O
infancy,	O
multidisciplinary	B-T080
research efforts	B-T062
in	O
the	O
design	B-T052
of	O
synthetic protein	B-T116
-based	O
nanostructures	B-T073
and	O
functional	B-T169
materials	B-T167
have	O
resulted	O
in	O
significant	O
progress	B-T169
.	O
The	O
chapters	B-T170
in	O
this	O
book	B-T170
cover	O
several	O
selected	O
examples	B-T077
of	O
the	O
most	O
recent	O
advances	B-T079
concerning	O
the	O
use of	B-T169
proteins	B-T116
and	O
peptides	B-T116
as	O
building blocks	B-T077
for	O
the	O
fabrication	B-T067
of	O
architectures	B-T077
and	O
functional	B-T169
nanostructures	B-T073
,	O
assemblies	B-T052
,	O
and	O
materials	B-T167
.	O
Here,	O
we	O
provide	O
a	O
general	O
overview	O
of	O
the	O
strategies	B-T169
that	O
can	O
be	O
employed	O
to	O
prepare	B-T052
functional	B-T169
protein	B-T116
-based	O
nanostructures	B-T073
,	O
and	O
nanostructured materials	B-T073
and	O
devices	B-T073
.	O
Finally,	O
we	O
highlight	O
some	O
of	O
the	O
main	O
aspects	B-T080
to	O
be	O
considered	O
by	O
the	O
research	B-T062
community	B-T096
to	O
set	O
the	O
path	O
for	O
the	O
near	O
future	O
developments	B-T062
.	O

Synthesis	B-T052
,	O
characterization	B-T052
and	O
drug	B-T121
loading	B-T052
property	B-T080
of	O
Monomethoxy-Poly(ethylene glycol)-Poly(ε-caprolactone)-Poly(D,L-lactide) (MPEG-PCLA) copolymers	B-T104
Amphiphilic block copolymers	B-T104
have	O
attracted	O
a	O
great	O
deal	O
of	O
attention	O
in	O
drug delivery systems	B-T074
.	O
In	O
this	O
work,	O
a	O
series	O
of	O
monomethoxy-poly (ethylene glycol)-poly (ε-caprolactone-co-D,L-lactide) (MPEG-PCLA) copolymers	B-T104
with	O
variable	O
composition	B-T070
of	O
poly (ε-caprolactone)	B-T109
(	O
PCL	B-T109
)	O
and	O
poly (D,L-lactide)	B-T122
(	O
PDLLA	B-T122
)	O
were	O
prepared	O
via	O
ring-opening copolymerization	B-T044
of	O
ε-CL	B-T109
and	O
D,L-LA	B-T109
in	O
the	O
presence	O
of	O
MPEG	B-T109
and	O
stannous octoate	B-T109
.	O
The	O
structure	B-T082
and	O
molecular weight	B-T081
were	O
characterized	B-T052
by	O
nuclear magnetic resonance	B-T070
(	O
NMR	B-T070
)	O
and	O
gel permeation chromatography	B-T059
(	O
GPC	B-T059
).	O
The	O
crystallinity	B-T104
,	O
hydrophilicity	B-T080
,	O
thermal	B-T070
stability	B-T080
and	O
hydrolytic	B-T070
degradation behavior	B-T169
were	O
investigated	O
in	O
detail,	O
respectively.	O
The	O
results	O
showed	O
that	O
the	O
prepared	O
amphiphilic MPEG-PCLA copolymers	B-T104
have	O
adjustable	O
properties	B-T080
by	O
altering	O
the	O
composition	B-T070
of	O
PCLA	B-T109
,	O
which	O
make	O
it	O
convenient	O
for	O
clinical applications	B-T201
.	O
Besides,	O
the	O
drug	B-T121
loading	B-T052
properties	B-T080
were	O
also	O
studied.	O
Docetaxel	B-T109
(	O
DTX	B-T109
)	O
could	O
be	O
entrapped	O
in	O
MPEG-PCLA	B-T104
micelles	B-T109
with	O
high	B-T080
loading	B-T052
capacity	B-T081
and	O
encapsulation	B-T067
efficiency	B-T081
.	O
And	O
all	O
lyophilized	B-T080
DTX	B-T109
-loaded	O
MPEG-PCLA	B-T104
micelles	B-T109
except	O
MPEG-PCL	B-T104
micelles	B-T109
were	O
readily	O
re-dissolved	B-T169
in	O
normal saline	B-T121
at	O
25	O
°C.	O
In	O
addition,	O
DTX	B-T109
-loaded	O
MPEG-PCLA	B-T104
micelles	B-T109
showed	O
a	O
slightly	O
enhanced	B-T052
antitumor	B-T080
activity	B-T052
compared	O
with	O
free	O
DTX	B-T109
.	O
Furthermore,	O
DTX	B-T109
micelles	B-T109
exhibited	O
a	O
slower	B-T080
and	O
sustained	B-T169
release	B-T169
behavior	B-T080
in vitro	B-T080
,	O
and	O
higher	B-T080
DTX	B-T109
concentration	B-T081
and	O
longer	O
retention time	B-T081
in vivo	B-T082
.	O
The	O
results	O
suggested	O
that	O
the	O
MPEG-PCLA copolymer	B-T104
with	O
the	O
adjustable	O
ratio	B-T081
of	O
PCL	B-T109
to	O
PDLLA	B-T122
may	O
be	O
a	O
promising	O
drug delivery carrier	B-T122
for	O
DTX	B-T109
.	O

Thyroid cancer	B-T191
burden	B-T081
in	O
Central	B-T083
and	O
South America	B-T083
Incidence	B-T081
of	O
thyroid cancer	B-T191
(	O
TC	B-T191
)	O
is	O
rapidly	B-T080
increasing	B-T169
worldwide	B-T078
,	O
but	O
little	O
is	O
known	O
about	O
the	O
TC	B-T191
burden	B-T081
in	O
Central	B-T083
and	O
South America	B-T083
(	O
CSA	B-T083
).	O
We	O
describe	O
the	O
geographic patterns	B-T082
and	O
trends	B-T079
of	O
TC	B-T191
by	O
sex	B-T032
in	O
CSA	B-T083
.	O
We	O
obtained	O
regional	B-UnknownType
-	O
and	O
national-level	B-T082
incidence	B-T081
data	B-T078
from	O
48	O
population-based cancer registries	B-T170
in	O
13	O
countries	B-T083
and	O
nationwide	O
cancer deaths	B-T081
from	O
the	O
WHO	B-T093
mortality	B-T081
database	B-T170
for	O
18	O
countries	B-T083
.	O
We	O
estimated	O
world	B-T098
population	O
age-standardized incidence rates	B-T081
(	O
ASRs	B-T081
)	O
and	O
age-standardized mortality rates	B-T081
(	O
ASMRs	B-T081
)	O
per	O
100,000	O
person	B-T098
-	O
years	B-T079
.	O
We	O
calculated	O
ASRs	B-T081
by	O
histological subtype	B-T201
.	O
We	O
estimated the annual percentage change	B-T081
(	O
EAPC	B-T081
)	O
to	O
describe	O
time trends	B-T079
.	O
Between	O
CSA	B-T083
countries	B-T083
,	O
TC	B-T191
incidence	B-T081
and	O
mortality rates	B-T081
varied	O
from	O
8-fold	O
to	O
12-fold	O
and	O
from	O
2-fold	O
to	O
5-fold,	O
respectively.	O
In	O
2003-2007,	O
the	O
highest	B-T080
TC	B-T191
ASRs	B-T081
in	O
females	B-T032
and	O
males	B-T032
were	O
in	O
Ecuador	B-T083
(16.0	O
and	O
3.5,	O
respectively),	O
Brazil	B-T083
(14.4	O
and	O
3.4),	O
Costa Rica	B-T083
(12.6	O
and	O
2.1)	O
and	O
Colombia	B-T083
(10.7	O
and	O
2.5).	O
The	O
highest	B-T080
ASMRs	B-T081
were	O
in	O
Ecuador	B-T083
,	O
Colombia	B-T083
,	O
Mexico	B-T083
,	O
Peru	B-T083
and	O
Panama	B-T083
(0.68-0.91	O
in	O
females	B-T032
and	O
0.41-0.48	O
in	O
males	B-T032
).	O
Papillary TC	B-T191
was	O
the	O
most	O
commonly	O
diagnosed	B-T033
histological subtype	B-T201
,	O
following	O
the	O
same	O
incidence pattern	B-T081
as	O
overall	O
TC	B-T191
.	O
In	O
Argentinean	B-T098
,	O
Brazilian	B-T033
,	O
Chilean	B-T098
and	O
Costa Rican	B-T098
females	B-T032
TC	B-T191
incidence	B-T081
increased	B-T081
by	O
2.2-17.9%	O
annually	B-T079
,	O
and	O
papillary TC	B-T191
increased	B-T081
by	O
9.1-15.0%	O
annually	B-T079
,	O
while	O
mortality	B-T081
remained	O
stable	B-T080
between	O
1997	O
and	O
2008.	O
In	O
males	B-T032
,	O
trends	B-T079
in	O
TC	B-T191
were	O
stable	B-T080
.	O
TC	B-T191
occurred	B-T052
more	O
frequently	B-T079
in	O
females	B-T032
than	O
in	O
males	B-T032
.	O
The	O
overall	B-T080
high	B-T080
incidence	B-T081
and	O
low	B-T080
mortality	B-T081
of	O
TC	B-T191
suggest	B-T078
identification	O
of	O
subclinical disease	B-T047
due	O
to	O
improved	B-T080
detection methods	B-T170
.	O

Histopathological	B-T169
Evaluation	B-T058
of	O
the	O
Effectiveness	B-T080
of	O
Glycyrrhizic Acid	B-T109
as	O
a	O
Radioprotector	B-T061
Against	O
the	O
Development	B-T169
of	O
Radiation-Induced Lung Fibrosis	B-T047
Radiotherapy	B-T061
of	O
the	O
thorax	B-T029
often	O
causes	O
lung inflammation	B-T047
leading	O
to	O
fibrosis	B-T047
.	O
The	O
aim	B-T078
of	O
this	O
study	B-T062
was	O
to	O
investigate	B-T169
whether	O
the	O
use	O
of	O
glycyrrhizic acid	B-T109
(	O
GLA	B-T109
)	O
could	O
improve	O
the	O
development	B-T169
of	O
lung fibrosis	B-T047
in	O
irradiated	B-T061
animals	B-T008
.	O
Wistar rats	B-T015
were	O
divided	O
into	O
four	O
groups	B-T078
.	O
Group A	B-T078
rats	B-T015
received	O
thoracic irradiation	B-T061
.	O
Rats	B-T015
in	O
group B	B-T078
received	O
GLA	B-T109
and	O
irradiation	B-T061
.	O
Group C	B-T078
received	O
GLA	B-T109
and	O
no	O
irradiation	B-T061
.	O
Group D	B-T078
received	O
no	O
GLA	B-T109
and	O
irradiation	B-T061
.	O
GLA	B-T109
was	O
administered	B-T169
at	O
a	O
dose	B-T081
of	O
4	O
mg/kg	O
body weight	B-T032
using	O
an	O
intraperitoneal injection	B-T061
one	O
hour	O
before	O
thoracic irradiation	B-T061
.	O
Radiation therapy	B-T061
was	O
delivered	O
on	O
a	O
Cobalt-60	B-T130
unit	O
using	O
a	O
single	O
fraction	O
of	O
16	O
Gy.	O
The	O
animals	B-T008
were	O
sacrificed	O
at	O
32	O
weeks	O
following	O
thoracic irradiation	B-T061
.	O
The	O
lungs	B-T023
were	O
dissected	B-T169
and	O
blind	O
histopathological	B-T169
evaluation	B-T058
was	O
performed.	O
Histopathologically	B-T169
,	O
a	O
decrease	B-T081
(statistically	O
not	O
significant)	O
in	O
the	O
thickening	B-T033
of	O
alveolar	B-T023
or	O
bronchial wall	B-T023
,	O
formation	O
of	O
fibrous bands	B-T020
,	O
and	O
superimposed	O
collagen	B-T116
were	O
noted	O
in	O
the	O
animals	B-T008
in	O
group B	B-T078
as	O
compared	O
to	O
the	O
animals	B-T008
in	O
group A	B-T078
.	O
In	O
this	O
experimental study	B-T062
,	O
administration	B-T081
of	O
GLA	B-T109
one	O
hour	O
before	O
thoracic irradiation	B-T061
may	O
be	O
a	O
protective agent	B-T121
against	O
radiation-induced fibrosis	B-T047
in	O
animals	B-T008
and	O
this	O
model	B-T050
could	O
be	O
used	O
in	O
future	O
studies.	O

Avulsions	B-T037
of	O
Triceps Brachii	B-T023
:	O
associated	O
injuries	B-T037
and	O
surgical treatment	B-T061
;	O
a	O
case	O
series	O
This	O
study	B-T062
reports	O
the	O
clinical presentations	B-T170
,	O
intra -operative	B-T079
findings	B-T033
,	O
type	O
of	O
the	O
treatments	B-T061
,	O
outcome	B-T169
of	O
the	O
treatment	B-T061
and	O
specially	O
associated	O
injuries	B-T037
in	O
patients	B-T101
with	O
the	O
avulsion	B-T037
of	O
the	O
distal end	B-T082
of	O
the	O
triceps brachii (TB) tendon	B-T023
.	O
We	O
studied	O
6	O
patients	B-T101
with	O
rupture	B-T037
or	O
avulsion	B-T037
of	O
the	O
distal end	B-T082
of	O
the	O
TB tendon	B-T023
.	O
The	O
medical records	B-T170
,	O
imaging files	B-T170
,	O
clinical	B-T080
outcomes	B-T169
at	O
the	O
final	O
follow up visit	B-T058
were	O
reviewed.	O
The	O
clinical	B-T080
outcomes	B-T169
were	O
assessed	O
by	O
Mayo Elbow Score	B-T170
at	O
the	O
final	O
follow-up visit	B-T058
.	O
All	O
patients	B-T101
were	O
male	B-T032
,	O
4	O
of	O
them	O
having	O
injury	B-T037
in	O
the	O
left hand	B-T023
as	O
the	O
non-dominant	O
hand	B-T023
.	O
Mean	O
age	B-T032
of	O
them	O
was	O
34.5	O
years	B-T079
.	O
All	O
cases	O
had	O
small	O
bony	B-T169
fleck	B-T037
in	O
the	O
posterior	O
of	O
elbow	B-T029
in	O
lateral radiograph	B-T060
.	O
Three	O
patients	B-T101
had	O
associated	O
injuries	B-T037
-including	O
intra-articular	B-T082
fractures	B-T037
and	O
medial collateral ligament rupture	B-T037
.	O
In	O
one	O
case	O
V-Y plasty	B-T061
of	O
the	O
distal	B-T082
TB	B-T023
was	O
done.	O
In	O
4	O
patients	B-T101
the	O
results	O
of	O
surgery	B-T061
were	O
excellent,	O
one	O
was	O
good	O
and	O
one	O
was	O
fair.	O
Although	O
TB tendon	B-T023
rupture	B-T037
is	O
rare,	O
it	O
should	O
be	O
-considered	O
in	O
differential	O
diagnosis	B-T062
of	O
the	O
upper -extremity trauma	B-UnknownType
and	O
its	O
associated	O
injuries	B-T037
should	O
be	O
addressed	O
properly.	O

Prolyl-4-hydroxylase 2	B-T116
and	O
3	B-T116
coregulate	O
murine	B-T109
erythropoietin	B-T116
in	O
brain	B-T023
pericytes	B-T025
A	O
classic	O
response	B-T033
to	O
systemic	B-T169
hypoxia	B-T046
is	O
the	O
increased	B-T081
production of red blood cells	B-T042
due	O
to	O
hypoxia-inducible factor	B-T116
(	O
HIF	B-T116
)-mediated	O
induction	B-T169
of	O
erythropoietin	B-T116
(	O
EPO	B-T116
).	O
EPO	B-T116
is	O
a	O
glycoprotein hormone	B-T109
that	O
is	O
essential	O
for	O
normal erythropoiesis	B-T042
and	O
is	O
predominantly	O
synthesized	O
by	O
peritubular	B-T082
renal interstitial fibroblast-like cells	B-T025
,	O
which	O
express	O
cellular markers	B-T201
characteristic	O
of	O
neuronal cells	B-T025
and	O
pericytes	B-T025
.	O
To	O
investigate	B-T169
whether	O
the	O
ability	O
to	O
synthesize	O
EPO	B-T116
is	O
a	O
general	O
functional	B-T169
feature	B-T080
of	O
pericytes	B-T025
,	O
we	O
used	O
conditional	O
gene targeting	B-T063
to	O
examine	O
the	O
von Hippel-Lindau	B-T047
/	O
prolyl-4-hydroxylase domain (PHD)/HIF	B-T116
axis	O
in	O
cell	B-T025
-	O
expressing	B-T045
neural glial antigen 2	B-T116
,	O
a	O
known	O
molecular marker	B-T201
of	O
pericytes	B-T025
in	O
multiple organs	B-T023
.	O
We	O
found	O
that	O
pericytes	B-T025
in	O
the	O
brain	B-T023
synthesized	O
EPO	B-T116
in	O
mice	B-T015
with	O
genetic	B-T169
HIF	B-T116
activation	B-T052
and	O
were	O
capable	O
of	O
responding	O
to	O
systemic	B-T169
hypoxia	B-T046
with	O
the	O
induction	B-T169
of	O
Epo	B-T116
.	O
Using	O
high-resolution	B-T059
multiplex	O
in situ hybridization	B-T063
,	O
we	O
determined	O
that	O
brain	B-T023
pericytes	B-T025
represent	O
an	O
important	O
cellular source	B-T025
of	O
Epo	B-T116
in	O
the	O
hypoxic	B-T046
brain	B-T023
(up	O
to	O
70%	O
of	O
all	O
Epo	B-T116
-	O
expressing	B-T045
cells	B-T025
).	O
We	O
furthermore	O
determined	O
that	O
Epo	B-T116
transcription	B-T045
in	O
brain	B-T023
pericytes	B-T025
was	O
HIF-2	B-T116
dependent	O
and	O
cocontrolled	O
by	O
PHD2	B-T116
and	O
PHD3	B-T116
,	O
oxygen	B-T121
-	O
and	O
2-oxoglutarate	B-T109
-dependent	O
prolyl-4-hydroxylases	B-T116
that	O
regulate	O
HIF	B-T116
activity	B-T044
.	O
In	O
summary,	O
our	O
studies	O
provide	O
experimental	B-T080
evidence	B-T078
that	O
pericytes	B-T025
in	O
the	O
brain	B-T023
have	O
the	O
ability	O
to	O
function	O
as	O
oxygen sensors	B-T074
and	O
respond	O
to	O
hypoxia	B-T046
with	O
EPO	B-T116
synthesis.	O
Our	O
findings	B-T169
furthermore	O
suggest	O
that	O
the	O
ability	O
to	O
synthesize	O
EPO	B-T116
may	O
represent	O
a	O
functional	B-T169
feature	B-T080
of	O
pericytes	B-T025
in	O
the	O
brain	B-T023
and	O
kidney	B-T023
.	O

Patient Satisfaction	B-T080
with	O
Pharmacist	B-T097
-Led	O
Collaborative	B-T054
Follow-Up Care	B-T058
in	O
an	O
Ambulatory	B-T078
Rheumatology Clinic	B-T073
Patient satisfaction	B-T080
is	O
known	O
to	O
increase	O
with	O
pharmacist	B-T097
intervention	B-T061
in	O
general outpatient clinics	B-T073
and	O
with	O
nurse-led care	B-T058
in	O
rheumatology clinics	B-T073
.	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
describe	O
and	O
compare	O
patient satisfaction	B-T080
with	O
two	O
different	O
types	O
of	O
care	B-T058
:	O
a	O
pharmacist	B-T097
physician	B-T097
collaborative model	B-T170
and	O
a	O
traditional physician model	B-T170
in	O
a	O
rheumatology clinic	B-T073
setting.	O
A	O
cross-sectional survey	B-T062
of	O
inflammatory arthritis	B-T047
patients	B-T101
seen	O
during	O
a	O
follow-up visit	B-T058
in	O
Edmonton	B-UnknownType
,	O
Alberta	B-UnknownType
,	O
Canada	B-T083
,	O
was	O
conducted	O
over	O
a	O
ten-week period	B-T062
.	O
Patient satisfaction	B-T080
was	O
measured	O
using	O
a	O
modified	O
version	O
of	O
the	O
validated	O
Leeds Satisfaction Questionnaire	B-T058
,	O
which	O
uses	O
a	O
five-point	O
Likert scale	B-T170
to	O
measure	O
six dimensions	B-T082
of	O
satisfaction	B-T080
,	O
and	O
compared	O
between	O
the	O
collaborative care	B-T058
and	O
traditional physician models	B-T170
.	O
A	O
total	O
of	O
62	O
patients	B-T101
completed	O
the	O
questionnaire	B-T170
(21	O
collaborative care	B-T058
and	O
41	O
traditional physician model	B-T170
).	O
The	O
average	O
age	O
of	O
respondents	B-T098
was	O
52	O
years	O
and	O
the	O
majority	O
were	O
female	B-T032
.	O
The	O
mean score for satisfaction	B-T170
across	O
the	O
six dimensions	B-T082
was	O
4.56	O
in	O
the	O
collaborative care group	B-T093
and	O
4.30	O
in	O
the	O
traditional physician group	B-T097
(p	O
=	O
0.02).	O
Patient satisfaction	B-T080
in	O
the	O
collaborative care group	B-T093
was	O
consistently	O
higher	O
across	O
all	O
dimensions.	O
No difference	B-T033
was	O
noted	O
between	O
participants	B-T098
seen	O
for	O
the	O
first	O
time	O
compared	O
with	O
those	O
seen	O
two	O
or	O
more	O
times	O
by	O
the	O
pharmacist	B-T097
.	O
A	O
collaborative care model	B-T170
can	O
exceed	O
the	O
already	O
high expectations	B-T078
for	O
care of patients	B-T058
with	O
inflammatory arthritis	B-T047
.	O
Our	O
findings	O
support	O
the	O
role	O
of	O
pharmacists	B-T097
using	O
a	O
collaborative care	B-T058
approach	O
to	O
care for patients	B-T058
in	O
rheumatology clinics	B-T073
.	O

Ontology	B-T090
-Based	O
High	B-T080
-	O
Level	B-T080
Context	B-T078
Inference	B-T041
for	O
Human Behavior	B-T055
Identification	B-T080
Recent	O
years	O
have	O
witnessed	O
a	O
huge	O
progress	B-T169
in	O
the	O
automatic	B-T169
identification	B-T080
of	O
individual	B-T098
primitives	B-T170
of	O
human behavior	B-T055
,	O
such	O
as	O
activities	B-T056
or	O
locations	B-T082
.	O
However,	O
the	O
complex	B-T080
nature	B-T169
of	O
human behavior	B-T055
demands	O
more	O
abstract	O
contextual	B-T078
information	B-T078
for	O
its	O
analysis.	O
This	O
work	O
presents	O
an	O
ontology	B-T090
-based	O
method	B-T170
that	O
combines	O
low	B-T080
-	O
level	B-T080
primitives	B-T170
of	O
behavior	B-T053
,	O
namely	O
activity	B-T056
,	O
locations	B-T082
and	O
emotions	B-T041
,	O
unprecedented	B-T080
to	O
date	B-T079
,	O
to	O
intelligently	O
derive	O
more	O
meaningful	O
high	B-T080
-	O
level	B-T080
context	B-T078
information	B-T078
.	O
The	O
paper	O
contributes	B-T052
with	O
a	O
new	O
open	O
ontology	B-T090
describing	O
both	O
low	B-T080
-	O
level	B-T080
and	O
high	B-T080
-	O
level	B-T080
context	B-T078
information	B-T078
,	O
as	O
well	O
as	O
their	O
relationships	B-T080
.	O
Furthermore,	O
a	O
framework	B-T077
building	O
on	O
the	O
developed	O
ontology	B-T090
and	O
reasoning	O
models	B-T170
is	O
presented	O
and	O
evaluated.	O
The	O
proposed	O
method	O
proves	O
to	O
be	O
robust	O
while	O
identifying	O
high	B-T080
-	O
level	B-T080
contexts	B-T078
even	O
in	O
the	O
event	B-T051
of	O
erroneously	B-T080
-	O
detected	B-T033
low	B-T080
-l	O
evel	B-T080
context	B-T078
s.	O
Despite	O
reasonable	O
inference	B-T041
times	O
being	O
obtained	O
for	O
a	O
relevant	B-T080
set	B-T041
of	O
users	B-T098
and	O
instances	B-T078
,	O
additional	O
work	O
is	O
required	O
to	O
scale	O
to	O
long-term	O
scenarios	B-T169
with	O
a	O
large	O
number	O
of	O
users	B-T098
.	O

Characterization	B-T052
of	O
exposure	B-T037
in	O
epidemiological studies	B-T062
on	O
air pollution	B-T069
from	O
biodegradable	B-T080
wastes	B-T167
:	O
Misclassification	B-T185
and	O
comparison	B-T052
of	O
exposure	B-T037
assessment	B-T058
strategies	B-T062
The	O
assignment	O
of	O
exposure	B-T037
is	O
one	O
of	O
the	O
main	O
challenges	O
faced	O
by	O
environmental	B-T082
epidemiologists	B-T097
.	O
However,	O
misclassification	B-T185
of	O
exposures	B-T037
has	O
not	O
been	O
explored	O
in	O
population	B-T098
epidemiological studies	B-T062
on	O
air pollution	B-T069
from	O
biodegradable	B-T080
wastes	B-T167
.	O
The	O
objective	B-T078
of	O
this	O
study	B-T062
was	O
to	O
investigate	B-T169
the	O
use	O
of	O
different	O
approaches	O
for	O
assessing	O
exposure	B-T037
to	O
air pollution	B-T069
from	O
biodegradable	B-T080
wastes	B-T167
by	O
analyzing	B-T062
(1)	O
the	O
misclassification	B-T185
of	O
exposure	B-T037
that	O
is	O
committed	O
by	O
using	O
these	O
surrogates	B-T096
,	O
(2)	O
the	O
existence	O
of	O
differentia	B-T080
l	O
misclassification	B-T185
(3)	O
the	O
effects	B-T080
that	O
misclassification	B-T185
may	O
have	O
on	O
health	B-T078
effect	B-T080
estimates	B-T081
and	O
the	O
interpretation	B-T169
of	O
epidemiological	B-T062
results	B-T033
,	O
and	O
(4)	O
the	O
ability	O
of	O
the	O
exposure	B-T037
measures	O
to	O
predict	O
health outcomes	B-T170
using	O
10-fold	O
cross validation	B-T062
.	O
Four	O
different	O
exposure	B-T037
assessment	B-T058
approaches	O
were	O
studied	B-T062
:	O
ammonia	B-T121
concentrations	B-T081
at	O
the	O
residence	B-T082
(	O
Metric I	B-T081
),	O
distance	B-T081
to	O
the	O
closest	O
source	B-T033
(	O
Metric II	B-T081
),	O
number	O
of	O
sources	B-T033
within	O
certain	O
distances	B-T081
from	O
the	O
residence	B-T082
(	O
Metric IIIa	B-T081
,	O
b	B-T081
)	O
and	O
location	B-T082
in	O
a	O
specific	O
region	B-T083
(	O
Metric IV	B-T081
).	O
Exposure-response models	B-T170
based	O
on	O
Metric I	B-T081
provided	O
the	O
highest	O
predictive	O
ability	O
(72.3%)	O
and	O
goodness-of-fit	B-T080
,	O
followed	O
by	O
IV	B-T081
,	O
III	B-T081
and	O
II	B-T081
.	O
When	O
compared	O
to	O
Metric I	B-T081
,	O
Metric IV	B-T081
yielded	O
the	O
best	O
results	B-T033
for	O
exposure	B-T037
misclassification	B-T185
analysis	B-T062
and	O
interpretation	B-T169
of	O
health	B-T078
effect	B-T080
estimates	B-T081
,	O
followed	O
by	O
Metric IIIb	B-T081
,	O
IIIa	B-T081
and	O
II	B-T081
.	O
The	O
study	B-T062
showed	O
that	O
modelled	O
NH3	B-T121
concentrations	B-T081
provide	O
more	O
accurate	O
estimations	B-T081
of	O
true	O
exposure	B-T037
than	O
distances-based	O
surrogates	B-T096
,	O
and	O
that	O
distance-based	O
surrogates	B-T096
(especially	O
those	O
based	O
on	O
distance	B-T081
to	O
the	O
closest	O
point	O
source	B-T033
)	O
are	O
imprecise	O
methods	O
to	O
identify	O
exposed	O
populations	B-T098
,	O
although	O
they	O
may	O
be	O
useful	O
for	O
initial	O
studies	B-T062
.	O

De Ritis Ratio (AST/ALT)	B-T201
as	O
a	O
Significant Prognostic Factor	B-T201
in	O
Patients	B-T101
With	O
Upper Tract Urothelial Cancer	B-T191
Treated	B-T169
With	O
Surgery	B-T169
We	O
investigated	B-T169
the	O
clinical prognostic value	B-T170
of	O
preoperative	B-T079
De Ritis ratio (aspartate aminotransferase [AST]/alanine aminotransferase [ALT])	B-T201
on	O
postsurgical	B-T033
survival	B-T052
outcomes	B-T169
in	O
patients	B-T101
with	O
upper tract urothelial cancer	B-T191
(	O
UTUC	B-T191
).	O
We	O
retrospectively analyzed	B-T062
the	O
data	B-T078
of	O
623	O
patients	B-T101
who	O
underwent	O
radical nephrouretectomy	B-T061
for	O
UTUC	B-T191
.	O
Multivariate regression	B-T080
tests	B-T170
were	O
performed	O
to	O
identify	O
possible associations	B-T080
between	O
adverse pathologic events	B-T046
and	O
AST/ALT	B-T201
.	O
The	O
risk	O
of	O
postoperative	B-T079
progression	B-T169
and	O
survival	B-T052
were	O
tested	B-T169
using	O
Kaplan-Meier analyses	B-T081
and	O
Cox proportional hazards models	B-T081
.	O
According	O
to	O
the	O
receiver operator characteristic curve	B-T081
of	O
AST/ALT	B-T201
for	O
cancer-specific mortality	B-T081
,	O
patients	B-T101
with	O
AST/ALT	B-T201
value	O
≥1.5	O
were	O
regarded	O
as	O
the	O
high	O
AST/ALT	B-T201
group,	O
and	O
the	O
remaining	O
patients	B-T101
formed	O
the	O
low	O
AST/ALT	B-T201
group.	O
In	O
Kaplan-Meier analyses	B-T081
,	O
the	O
high	O
AST/ALT	B-T201
group	O
showed	O
worse	O
progression-free survival	B-T081
(	O
PFS	B-T081
),	O
cancer-specific survival	B-T081
(	O
CSS	B-T081
),	O
and	O
overall survival	B-T081
(all	O
P	O
<	O
.001).	O
Elevated	O
AST/ALT	B-T201
was	O
associated with	B-T080
higher	O
T stage	B-T185
(	O
hazard ratio	B-T081
[	O
HR	B-T081
],	O
1.577;	O
95%	O
confidence interval	B-T081
[	O
CI	B-T081
],	O
1.077-2.311;	O
P	O
=	O
.033)	O
and	O
higher cellular grade	B-T185
(	O
HR	B-T081
,	O
1.538;	O
95%	O
CI	B-T081
,	O
1.034-2.287;	O
P	O
=	O
.041)	O
in	O
multivariate regression	B-T080
tests	B-T170
.	O
In	O
multivariate Cox analyses	B-T081
,	O
high	O
AST/ALT	B-T201
was	O
revealed	O
as	O
an	O
independent predictor	B-T078
of	O
PFS	B-T081
(	O
HR	B-T081
,	O
2.335;	O
95%	O
CI	B-T081
,	O
1.633-3.340;	O
P	O
<	O
.001),	O
CSS	B-T081
(	O
HR	B-T081
,	O
2.550;	O
1.689-3.851;	O
P	O
<	O
.001),	O
and	O
overall survival	B-T081
(	O
HR	B-T081
,	O
2.069;	O
95%	O
CI	B-T081
,	O
1.409-3.038;	O
P	O
<	O
.001).	O
Elevated	O
preoperative	B-T079
AST/ALT	B-T201
was	O
a	O
significant predictor	B-T078
of	O
worse	B-T033
postoperative	B-T079
survival	B-T052
in	O
patients	B-T101
surgically treated	B-T061
for	O
UTUC	B-T191
.	O
Further	O
large	O
prospective studies	B-T062
are	O
needed	O
for	O
better	O
understanding	O
of	O
the	O
prognostic value	B-T170
of	O
preoperative	B-T079
AST/ALT	B-T201
.	O

Molecular simulation	B-T066
study	B-T062
on	O
concentration	B-T081
effects of	B-T080
rofecoxib	B-T109
with	O
POPC	B-T109
bilayer	B-T026
The	O
interactions	B-T044
between	O
rofecoxib	B-T109
and	O
POPC	B-T109
(1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine)	B-T109
bilayer	B-T026
were	O
studied	B-T062
using	B-T169
all-atom molecular dynamics simulation	B-T066
method	B-T170
.	O
Four	O
POPC	B-T109
bilayer	B-T026
systems	B-T169
with	O
different	B-T080
number	B-T081
of	O
rofecoxib	B-T109
molecules	B-T167
were	O
constructed	B-T169
to	O
simulate	B-T080
different	B-T080
drug	B-T121
concentration	B-T081
.	O
The	O
free energy	B-T070
of	O
rofecoxib	B-T109
passing	B-T077
across	O
pure	B-T080
POPC	B-T109
bilayer	B-T026
has	O
two	O
minima	B-T080
(at	O
z	O
∼1.2nm	O
or	O
1.6nm).	O
As	O
for	O
the	O
high	B-T080
concentration	B-T081
model	B-T170
,	O
the	O
minimum	B-T080
of	O
the	O
free energy	B-T070
profile	O
slightly	O
shifts	O
to	O
the	O
bilayer	B-T026
center	B-T082
.	O
Moreover,	O
the	O
energy change	B-UnknownType
from	O
bulk water	B-T121
to	O
POPC	B-T109
bilayer	B-T026
increases	B-T169
while	O
the	O
central	B-T082
barrier	B-T046
to	O
cross	B-T077
the	O
hydrophobic core	B-T120
of	O
bilayer	B-T026
slightly	B-T080
decreases	B-T081
,	O
suggesting	B-T078
that	O
increasing	B-T169
drug	B-T121
concentration	B-T081
makes	O
it	O
favorable	B-T033
for	O
rofecoxib	B-T109
to	O
partition	B-T169
into	O
the	O
bilayer	B-T026
and	O
easier	O
to	O
pass	B-T077
across	O
bialyer	B-T026
center	B-T082
.	O
Energy	B-T081
analysis	B-T062
show	O
that	O
the	O
stabilization	B-T080
between	O
the	O
selected	B-T052
rofecoxib	B-T109
and	O
other	O
pre-inserted	B-T169
rofecoxib	B-T109
molecule	B-T167
is	O
mainly	O
due	O
to	O
van der Waals interaction	B-T067
energy	B-T081
.	O
The	O
predicted	B-T078
permeability	B-T070
of	O
rofecoxib	B-T109
in	O
high	B-T080
concentration	B-T081
model	B-T170
slightly	O
weakens	B-T080
as	O
compared	B-T052
with	O
low	B-T080
concentration	B-T081
model	B-T170
.	O

Short-term Variability	B-T077
of	O
Vitamin D	B-T109
-Related	O
Biomarkers	B-T201
Quantifying	B-T081
the	O
variability	B-T077
of	O
biomarkers	B-T201
is	O
important	B-T080
,	O
as	O
high	O
within-person	O
variability	B-T077
can	O
lead	O
to	O
misclassification	B-T185
of	O
individuals	B-T098
.	O
Short-term	O
variability	B-T077
of	O
important	B-T080
markers	B-T201
of	O
vitamin D metabolism	B-T044
is	O
relatively	O
unknown.	O
A	O
repeatability study	B-T062
was	O
conducted	O
in	O
160	O
Atherosclerosis	B-T047
Risk	B-T078
in	O
Communities study participants	B-T098
(60%	O
female	B-T032
,	O
28%	O
black	B-T098
,	O
mean	O
age	B-T032
76	O
years).	O
Fasting	B-T033
serum	B-T031
was	O
drawn	O
at	O
2	O
time	O
points,	O
a	O
median	O
of	O
6	O
(range	O
3-13)	O
weeks	B-T079
apart.	O
Vitamin D binding protein	B-T116
(	O
VDBP	B-T116
)	O
and	O
25-hydroxyvitamin D	B-T109
[	O
25(OH)D	B-T109
]	O
were	O
measured	B-T080
by	O
LC-MS	B-T059
,	O
fibroblast growth factor	B-T116
(	O
FGF23	B-T116
)	O
and	O
parathyroid hormone	B-T116
(	O
PTH	B-T116
)	O
by	O
enzyme-linked immunoassay	B-T059
,	O
and	O
calcium	B-T121
and	O
phosphorus	B-T196
by	O
Roche Cobas 6000	B-T059
.	O
Free	B-T080
and	O
bioavailable	B-T080
25(OH)D	B-T109
were	O
calculated	B-T052
.	O
We	O
calculated	B-T052
the	O
within-person CV	B-T081
(	O
CVW	B-T081
),	O
intraclass correlation coefficient	B-T081
(	O
ICC	B-T081
),	O
Spearman rank correlation coefficient	B-T081
(	O
r	B-T081
),	O
and	O
percent	B-T081
reclassified	B-T080
.	O
The	O
CVW	B-T081
was	O
lowest	B-T080
for	O
calcium	B-T121
(2.0%),	O
albumin	B-T116
(3.6%),	O
25(OH)D	B-T109
(6.9%),	O
VDBP	B-T116
(7.0%)	O
and	O
phosphorus	B-T196
(7.6%);	O
intermediate	B-T034
for	O
free	B-T080
25(OH)D	B-T109
(9.0%)	O
and	O
bioavailable	B-T080
25(OH)D	B-T109
(9.9%);	O
and	O
highest	B-T080
for	O
PTH	B-T116
(16.7%)	O
and	O
FGF23	B-T116
(17.8%).	O
Reclassification	B-T185
was	O
highest	B-T080
for	O
PTH	B-T116
,	O
VDBP	B-T116
,	O
and	O
phosphorus	B-T196
(all	O
7.5%).	O
The	O
ICC	B-T081
and	O
r	B-T081
were	O
highest	B-T080
(≥0.80)	O
for	O
25(OH)D	B-T109
,	O
free	B-T080
25(OH)D	B-T109
,	O
bioavailable	B-T080
25(OH)D	B-T109
and	O
PTH	B-T116
,	O
but	O
somewhat	O
lower	B-T080
(	O
approximately	B-T080
0.60-0.75)	O
for	O
the	O
other	O
biomarkers	B-T201
.	O
Six-	O
week	B-T079
short-term variability	B-T077
,	O
as	O
assessed	B-T052
by	O
CVW	B-T081
,	O
was	O
quite low	B-T080
for	O
VDBP	B-T116
,	O
calcium	B-T121
and	O
phosphorus	B-T196
,	O
but	O
fairly high	B-T080
for	O
FGF23	B-T116
and	O
PTH	B-T116
.	O
As	O
such,	O
multiple measurements	B-T169
of	O
FGF23	B-T116
and	O
PTH	B-T116
may	O
be	O
needed	O
to	O
minimize	B-T080
misclassification	B-T185
.	O
These	O
results	B-T169
provide	O
insight	B-T041
into	O
the	O
extent	O
of	O
potential	B-T080
misclassification	B-T185
of	O
vitamin D	B-T109
markers	B-T201
in	O
research	B-T062
and	O
clinical settings	B-T169
.	O

Fabrication	B-T067
of	O
gelatin methacrylate	B-T109
/	O
nanohydroxyapatite	B-T197
microgel	B-T122
arrays	B-T082
for	O
periodontal tissue regeneration	B-T061
Periodontitis	B-T047
is	O
a	O
chronic infectious disease	B-T047
and	O
is	O
the	O
major cause	B-T033
of	O
tooth loss	B-T020
and	O
other	O
oral health	B-T058
issues	B-T033
around	O
the	O
world	B-T098
.	O
Periodontal tissue regeneration	B-T061
has	O
therefore	O
always	O
been	O
the	O
ultimate goal	B-T170
of	O
dentists	B-T097
and	O
researchers	B-T097
.	O
Existing	O
fabrication	B-T067
methods	B-T170
mainly	O
focused	B-T169
on	O
a	O
top-down tissue engineering	B-T061
strategy	B-T041
in	O
which	O
several	O
drawbacks	B-T080
remain	B-T033
,	O
including	O
low throughput	B-T080
and	O
limited	O
diffusion	B-T070
properties	B-T080
resulting	B-T169
from	O
a	O
large sample size	B-T081
.	O
Gelatin methacrylate	B-T109
(	O
GelMA	B-T109
)	O
is	O
a	O
kind	O
of	O
photocrosslinkable	B-T070
and	O
biocompatible	B-T122
hydrogel	B-T109
,	O
with	O
the	O
capacities	B-T081
of	O
enabling	B-T041
cell encapsulation	B-T059
and	O
regeneration of functional tissues	B-T042
.	O
Here,	O
we	O
developed	O
a	O
novel	B-T080
method	B-T169
to	O
fabricate	B-T067
GelMA	B-T109
/	O
nanohydroxylapatite	B-T197
(	O
nHA	B-T197
)	O
microgel	B-T122
arrays	B-T082
using	O
a	O
photocrosslinkable	B-T070
strategy	B-T041
.	O
The	O
viability	B-T043
,	O
proliferation	B-T043
,	O
and	O
osteogenic differentiation	B-T043
and	O
in vivo	B-T082
osteogenesis	B-T042
of	O
human	B-T016
periodontal ligament	B-T023
stem cells	B-T025
(	O
hPDLSCs	B-T025
)	O
encapsulated	B-T080
in	O
microgels	B-T122
were	O
evaluated	B-T058
.	O
The	O
results	B-T169
suggested	B-T078
that	O
such	O
microgels	B-T122
provide	B-T052
great	O
potential	B-T080
for	O
periodontal tissue repair and regeneration	B-T061
.	O
Microgel	B-T122
arrays	B-T082
were	O
fabricated	B-T067
by	O
blending	B-T068
different	B-T080
weight ratios	B-T081
of	O
GelMA	B-T109
and	O
nHA	B-T197
.	O
hPDLSCs	B-T025
were	O
encapsulated	B-T080
in	O
GelMA	B-T109
/	O
nHA	B-T197
microgels	B-T122
of	O
various	O
ratios	B-T081
for	O
a	O
systematic	B-T169
evaluation	B-T058
of	O
cell viability	B-T043
,	O
proliferation	B-T043
,	O
and	O
osteogenic differentiation	B-T043
.	O
In vivo	B-T082
osteogenesis	B-T042
in	O
nude mice	B-T015
was	O
also	O
studied.	O
The	O
GelMA	B-T109
/	O
nHA	B-T197
microgels	B-T122
exhibited	O
appropriate	B-T080
microarchitecture	B-T080
,	O
mechanical strength	B-T078
,	O
and	O
surface	B-T082
roughness	B-T080
,	O
thus	O
enabling	O
cell adhesion	B-T043
and	O
proliferation	B-T043
.	O
Additionally,	O
the	O
GelMA	B-T109
/	O
nHA	B-T197
microgels	B-T122
(10%/2%	O
w/v)	O
enhanced	B-T052
the	O
osteogenic differentiation	B-T043
of	O
hPDLSCs	B-T025
by	O
elevating	B-T080
the	O
expression levels	B-T081
of	O
osteogenic biomarker	B-T201
genes	B-T028
,	O
such	O
as	O
ALP	B-T028
,	O
BSP	B-T028
,	O
OCN	B-T028
,	O
and	O
RUNX2	B-T028
.	O
In vivo	B-T082
ectopic	B-T082
transplantation	B-T061
results	B-T169
showed	O
that	O
GelMA	B-T109
/	O
nHA	B-T197
microgels	B-T122
(10%/2%	O
w/v)	O
increased	B-T081
mineralized tissue	B-T024
formation	B-T169
with	O
abundant	B-T080
vascularization	B-T169
,	O
compared	B-T052
with	O
the	O
1%,	O
3%,	O
and	O
the	O
pure	O
GelMA group	B-T109
.	O
The	O
GelMA	B-T109
/	O
nHA	B-T197
microgels	B-T122
(10%/2%	O
w/v)	O
facilitated	O
hPDLSCs	B-T025
viability	B-T043
,	O
proliferation	B-T043
,	O
and	O
osteogenic differentiation	B-T043
in vitro	B-T080
and	O
further	B-T082
promoted	B-T052
new	B-T080
bone formation	B-T042
in vivo	B-T082
,	O
suggesting	O
that	O
the	O
GelMA	B-T109
/	O
nHA	B-T197
microgels	B-T122
(10%/2%	O
w/v)	O
provide	B-T052
great	O
potential	B-T080
for	O
periodontal tissue regeneration	B-T061
.	O

Esomeprazole	B-T109
-	O
or	O
rabeprazole	B-T109
-based	O
triple	B-T081
therapy	B-T061
eradicated	O
Helicobacter pylori	B-T007
comparably	O
regardless	B-T080
of	O
clarithromycin	B-T109
susceptibility	B-T169
and	O
CYP2C19	B-T028
genotypes	B-T032
The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
assess	B-T052
the	O
efficacy	B-T080
of	O
esomeprazole	B-T109
-based	O
triple	B-T081
therapy	B-T061
compared	B-T052
with	O
rabeprazole	B-T109
-based	O
triple	B-T081
therapy	B-T061
according	O
to	O
CYP2C19	B-T028
genotype	B-T032
and	O
clarithromycin	B-T109
susceptibility	B-T169
status	B-T080
for	O
first-line	O
eradication therapy of Helicobacter pylori	B-T061
(	O
H. pylori	B-T007
)	O
in	O
Japan	B-T083
.	O
We	O
enrolled	O
219	O
H. pylori	B-T007
-	O
infected patients	B-T101
,	O
and	O
randomly	B-T080
allocated	B-T052
patients	B-T101
to	O
the	O
EAC group	B-T101
(	O
esomeprazole	B-T109
20	O
mg,	O
clarithromycin	B-T109
200	O
mg,	O
amoxicillin	B-T109
750	O
mg	O
for	O
one	O
week	B-T079
,	O
with	O
all	O
drugs	B-T121
given	B-T169
twice daily	B-T079
)	O
or	O
RAC group	B-T101
(	O
rabeprazole	B-T109
10	O
mg,	O
clarithromycin	B-T109
200	O
mg,	O
amoxicillin	B-T109
750	O
mg	O
for	O
one	O
week	B-T079
,	O
with	O
all	O
drugs	B-T121
given	B-T169
twice daily	B-T079
).	O
The	O
H. pylori	B-T007
eradication rate	B-T081
according	O
to	O
the	O
PP analyses	B-T062
was	O
75.0%	O
(95%	O
CI	B-T081
:	O
65.2-82.8%)	O
in	O
the	O
EAC group	B-T101
and	O
71.4%	O
(95%	O
CI	B-T081
:	O
61.4-79.1%)	O
in	O
the	O
RAC group	B-T101
.	O
There	O
were	O
no	O
statistically	O
significant	O
differences	B-T080
.	O
The	O
eradication rates	B-T081
of	O
the	O
clarithromycin	B-T109
clarithromycin -resistant	B-T046
/-	O
sensitive	B-T169
strains	B-T007
were,	O
respectively,	O
45.0%	O
(95%	O
CI	B-T081
:	O
30.7-60.2%)/98.0%	O
(95%	O
CI	B-T081
:	O
88.7-100%)	O
in	O
the	O
EAC group	B-T101
and	O
39.5%	O
(95%	O
CI	B-T081
:	O
25.6-55.3%)/93.5%	O
(95%	O
CI	B-T081
:	O
81.9-98.4%)	O
in	O
the	O
RAC group	B-T101
.	O
The	O
eradication rate	B-T081
of	O
the	O
clarithromycin	B-T109
-	O
sensitive	B-T169
strains	B-T007
was	O
significantly	O
higher	B-T080
than	O
that	O
of	O
the	O
resistant strains	B-T046
in	O
both	B-T080
groups	B-T078
.	O
In	O
conclusion,	O
EAC	B-T101
and	O
RAC	B-T101
therapies	B-T061
show	O
a	O
comparable	O
efficacy	B-T080
regardless	B-T080
of	O
the	O
CYP2C19	B-T028
genotype	B-T032
and	O
clarithromycin	B-T109
susceptibility	B-T169
status	B-T080
in	O
Japan	B-T083
.	O

Optimization	O
of	O
Early	B-T079
Response Monitoring	B-T058
and	O
Prediction	O
of	O
Cancer	B-T191
Antiangiogenesis Therapy	B-T061
via	O
Noninvasive	B-T185
PET Molecular Imaging	B-T060
Strategies	O
of	O
Multifactorial	B-T033
Bioparameters	B-T077
Objective:	O
Antiangiogenesis therapy	B-T061
(	O
AAT	B-T061
)	O
has	O
provided	O
substantial	O
benefits	O
regarding	O
improved	O
outcomes	O
and	O
survival	B-T052
for	O
suitable	O
patients	B-T101
in	O
clinical settings	B-T082
.	O
Therefore,	O
the	O
early	B-T079
definition	O
of	O
therapeutic effects	B-T201
is	O
urgently	O
needed	O
to	O
guide	O
cancer	B-T191
AAT	B-T061
.	O
We	O
aimed	O
to	O
optimize	O
the	O
early	B-T079
response monitoring	B-T058
and	O
prediction	O
of	O
AAT	B-T061
efficacy	B-T080
,	O
as	O
indicated	O
by	O
the	O
multi-targeted	O
anti-angiogenic drug	B-T121
sunitinib	B-T109
in	O
U87MG tumors	B-T191
,	O
using	O
noninvasive	B-T185
positron emission computed tomography (PET) molecular imaging	B-T060
strategies	O
of	O
multifactorial	B-T033
bioparameters	B-T077
.	O
Methods:	O
U87MG tumor	B-T191
mice	B-T015
were	O
treated	O
via	O
intragastric	B-T082
injections	B-T061
of	O
sunitinib	B-T109
(80	O
mg/kg)	O
or	O
vehicle	B-T122
for	O
7	O
consecutive	O
days.	O
Longitudinal	B-T082
MicroPET/CT scans	B-T060
with	O
(18)F-FDG	B-T109
,	O
(18)F-FMISO,	B-T109
(18)F-ML-10	B-T109
and	O
(18)F-Alfatide II	B-T116
were	O
acquired	O
to	O
quantitatively	O
measure	O
metabolism	B-T040
,	O
hypoxia	B-T046
,	O
apoptosis	B-T043
and	O
angiogenesis	B-T191
on	O
days	O
0,	O
1,	O
3,	O
7	O
and	O
13	O
following	O
therapy	B-T061
initiation.	O
Tumor tissues	B-T024
from	O
a	O
dedicated	O
group	O
of	O
mice	B-T015
were	O
collected	O
for	O
immunohistochemical	B-T059
(	O
IHC	B-T059
)	O
analysis	O
of	O
key	O
biomarkers	B-T123
(	O
Glut-1	B-T116
,	O
CA-IX	B-T116
,	O
TUNEL	B-T063
,	O
ανβ3	B-T116
and	O
CD31	B-T116
)	O
at	O
the	O
time	O
points	O
of	O
PET imaging	B-T060
.	O
The	O
tumor sizes	B-T082
and	O
mouse	B-T015
weights	B-T032
were	O
measured	O
throughout	O
the	O
study.	O
The	O
tumor	B-T191
uptake	B-T039
(ID%/gmax),	O
the	O
ratios	O
of	O
the	O
tumor	B-T191
/	O
muscle	B-T024
(	O
T	B-T191
/	O
M	B-T024
)	O
for	O
each	O
probe,	O
and	O
the	O
tumor growth	B-T191
ratios	B-T081
(	O
TGR	B-T081
)	O
were	O
calculated	O
and	O
used	O
for	O
statistical analyses	B-T062
of	O
the	O
differences	O
and	O
correlations.	O
Results:	O
Sunitinib	B-T109
successfully	O
inhibited	O
U87MG tumor growth	B-T191
with	O
significant	O
differences	O
in	O
the	O
tumor size	B-T082
from	O
day	O
9	O
after	O
sunitinib	B-T109
treatment	B-T061
compared	O
with	O
the	O
control group	B-T096
(P	O
<	O
0.01).	O
The	O
uptakes	B-T039
of	O
(18)F-FMISO	B-T109
(reduced	O
hypoxia	B-T046
),	O
(18)F-ML-10	B-T109
(increased	O
apoptosis	B-T043
)	O
and	O
(18)F-Alfatide II	B-T116
(decreased	O
angiogenesis	B-T191
)	O
in	O
the	O
tumor	B-T191
lesions	B-T033
significantly	O
changed	O
during	O
the	O
early	B-T079
early stage	B-T079
(days	O
1	O
to	O
3)	O
of	O
sunitinib	B-T109
treatment	B-T061
;	O
however,	O
the	O
uptake	B-T039
of	O
(18)F-FDG	B-T109
(increased	O
glucose metabolism	B-T044
)	O
was	O
significantly	O
different	O
during	O
the	O
late stage	B-T079
.	O
The	O
PET imaging	B-T060
data	O
of	O
each	O
probe	O
were	O
all	O
confirmed	O
via	O
ex vivo	B-T169
IHC	B-T059
of	O
the	O
relevant	O
biomarkers	B-T123
.	O
Notably,	O
the	O
PET imaging	B-T060
of	O
(18)F-Alfatide II	B-T116
and	O
(18)F-FMISO	B-T109
was	O
significantly	O
correlated	O
(all	O
P	O
<	O
0.05)	O
with	O
TGR	B-T081
,	O
whereas	O
the	O
imaging	O
of	O
(18)F-FDG	B-T109
and	O
(18)F-ML-10	B-T109
was	O
not	O
significantly	O
correlated	O
with	O
TGR	B-T081
.	O
Conclusion:	O
Based	O
on	O
the	O
tumor	B-T191
uptake	B-T039
of	O
the	O
PET	B-T060
probes	O
and	O
their	O
correlations	O
with	O
MVD	B-T080
and	O
TGR	B-T081
,	O
(18)F-Alfatide II	B-T116
PET	B-T060
may	O
not	O
only	O
monitor	O
the	O
early	B-T079
response	B-T058
but	O
also	O
precisely	O
predict	O
the	O
therapeutic efficacy	B-T080
of	O
the	O
multi-targeted,	O
anti-angiogenic drug	B-T121
sunitinib	B-T109
in	O
U87MG tumors	B-T191
.	O
In	O
conclusion,	O
it	O
is	O
feasible	O
to	O
optimize	O
the	O
early	B-T079
response monitoring	B-T058
and	O
efficacy	B-T080
prediction	O
of	O
cancer	B-T191
AAT	B-T061
using	O
noninvasive	B-T185
PET molecular imaging	B-T060
strategies	O
of	O
multifactorial	B-T033
bioparameters	B-T077
,	O
such	O
as	O
angiogenesis	B-T191
imaging	B-T060
with	O
(18)F-Alfatide II	B-T116
,	O
which	O
represents	O
an	O
RGD	B-T116
-based	O
probe.	O

Identifying	O
research priorities	B-T062
with	O
nurses	B-T097
at	O
a	O
tertiary	O
children's	B-T100
hospital	B-T073
in	O
the	O
United Kingdom	B-T083
The	O
objective	O
of	O
this	O
study	B-T062
was	O
to	O
undertake	O
a	O
research priority	B-T062
setting	O
exercise	O
with	O
the	O
aim	O
of	O
maximizing	O
efficiency	B-T081
and	O
impact	B-T080
in	O
research activity	B-T062
undertaken	O
by	O
nurses	B-T097
at	O
one	O
children's	B-T100
tertiary	O
healthcare institution	B-T093
by	O
ensuring	O
the	O
clinical staff	B-T097
directly	O
shaped	O
a	O
coherent	B-T033
,	O
transparent	B-T080
and	O
consensus	B-T054
driven	O
nurse-led research agenda	B-T062
.	O
In	O
Round	O
1,	O
the	O
research topics	B-UnknownType
of	O
147	O
nurses	B-T097
were	O
elicited	O
using	O
a	O
modified nominal group technique	B-T062
as	O
the	O
consensus method	B-T170
.	O
The	O
number	O
of	O
participants	B-T098
in	O
the	O
24	O
separate	O
discussions	O
ranged	O
from	O
3	O
to	O
21,	O
generating	O
lists	O
of	O
between	O
6	O
and	O
23	O
topics.	O
In	O
Round	O
2,	O
nurses	B-T097
from	O
the	O
clinical areas	B-T078
ranked	B-T170
topics	O
of	O
importance	O
resulting	O
in	O
a	O
set	O
of	O
four	O
to	O
five	O
priorities	B-T062
.	O
In	O
Round	O
3,	O
the	O
divisional heads	B-T097
of	O
nursing	B-T091
consulted	O
with	O
staff	B-T097
in	O
all	O
of	O
their	O
clinical areas	B-T078
to	O
each	O
finalize	O
their	O
five	O
divisional priorities	B-T062
.	O
The	O
Nursing Research Working Group	B-T097
discussed	O
and	O
refined	O
the	O
divisions' priorities	B-T062
and	O
voted	B-T055
on	O
the	O
final	O
list	O
to	O
agree	O
the	O
top	O
five	O
research priorities	B-T062
for	O
the	O
organization	B-T093
.	O
A	O
total	O
of	O
269	O
research topics	B-UnknownType
were	O
initially	O
generated.	O
Following	O
three	O
rounds	O
of	O
ranking	B-T170
and	O
prioritizing,	O
five	O
priorities	B-T062
were	O
agreed	O
at	O
Divisional level	B-T092
,	O
and	O
from	O
these,	O
the	O
five	O
top	O
organizational priorities	B-T062
were	O
selected.	O
These	O
were	O
(i)	O
understanding	O
and	O
improving	O
all	O
aspects	O
of	O
the	O
patient	B-T101
journey	O
through	O
the	O
hospital system	B-T073
;	O
(ii)	O
play	B-T056
;	O
(iii)	O
staff wellbeing	B-T078
,	O
patient care	B-T058
and	O
productivity	B-T081
;	O
(iv)	O
team work	B-T057
-	O
linking	O
to	O
a	O
more	O
efficient	O
service	B-T057
;	O
and	O
(v)	O
supporting parents	B-T099
/	O
parent	B-T099
pathway.	O
Divisional	O
priorities	B-T062
have	O
been	O
disseminated	O
widely	O
to	O
clinical teams	B-T058
to	O
inform	O
a	O
patient-specific nurse-led research agenda	B-T062
.	O
Organizational priorities	B-T062
agreed	O
upon	O
have	O
been	O
disseminated	O
through	O
management structures	B-T090
and	O
processes	O
to	O
ensure	O
engagement	O
at	O
all	O
levels.	O
A	O
subgroup	B-T097
of	O
the	O
Nursing Research Working Group	B-T097
has	O
been	O
delegated	O
to	O
take	O
this	O
work	O
forward	O
so	O
that	O
the	O
agreed	O
priorities	B-T062
continue	O
to	O
contribute	O
towards	O
shaping	O
nurse-led research activity	B-T062
,	O
thereby	O
going	O
some	O
way	O
to	O
inform	O
and	O
embed	O
an	O
evidence-based	O
culture	O
of	O
inquiry	B-T052
.	O

Accurate	B-T080
Lungs	B-T023
Segmentation	B-T058
on	O
CT	B-T060
Chest	B-T029
Images	B-T170
by	O
Adaptive Appearance-Guided Shape Modeling	B-T062
To	O
accurately	B-T080
segment	B-T058
pathological	B-T169
and	O
healthy	B-T080
lungs	B-T023
for	O
reliable	B-T080
computer-aided disease diagnostics	B-T060
,	O
a	O
stack	B-T082
of	O
chest	B-T029
CT	B-T060
scans	B-T060
is	O
modeled	B-T062
as	O
a	O
sample	O
of	O
a	O
spatially inhomogeneous	B-T082
joint 3D Markov-Gibbs random field	B-T080
(	O
MGRF	B-T080
)	O
of	O
voxel-wise	B-T077
lung	B-T023
and	O
chest	B-T029
CT	B-T060
image	B-T170
signals	B-T067
(	O
intensities	B-T081
).	O
The	O
proposed	B-T080
learnable	O
MGRF	B-T080
integrates	B-T066
two	O
visual	B-T169
appearance	B-T080
sub-models	B-T075
with	O
an	O
adaptive	O
lung	B-T023
shape	O
submodel	B-T075
.	O
The	O
first-order	O
appearance	B-T080
submodel	B-T075
accounts	O
for	O
both	O
the	O
original	B-T078
CT	B-T060
image	B-T170
and	O
its	O
Gaussian scale space (GSS) filtered version	B-T080
to	O
specify	O
local	O
and	O
global	O
signal	B-T067
properties,	O
respectively.	O
Each	O
empirical	B-T080
marginal	B-T080
probability distribution	B-T081
of	O
signals	B-T067
is	O
closely	O
approximated	O
with	O
a	O
linear combination of discrete Gaussians	B-T080
(	O
LCDG	B-T080
),	O
containing	O
two	O
positive dominant and multiple sign-alternate subordinate DGs	B-T080
.	O
The	O
approximation	O
is	O
separated	O
into	O
two	O
LCDGs	B-T080
to	O
describe	O
individually	O
the	O
lungs	B-T023
and	O
their	O
background,	O
i.e.,	O
all	O
other	O
chest	B-T029
tissues	B-T024
.	O
The	O
second-order	O
appearance	B-T080
submodel	B-T075
quantifies	B-T081
conditional	B-T080
pairwise	B-T081
intensity	B-T081
dependencies	B-T170
in	O
the	O
nearest	O
voxel	O
26-neighborhood	O
in	O
both	O
the	O
original	B-T078
and	O
GSS-filtered	B-T080
images	B-T170
.	O
The	O
shape	O
submodel	B-T075
is	O
built	O
for	O
a	O
set	O
of	O
training data	B-T078
and	O
is	O
adapted	O
during	O
segmentation	B-T058
using	O
both	O
the	O
lung	B-T023
and	O
chest	B-T029
appearances	B-T080
.	O
The	O
accuracy	B-T080
of	O
the	O
proposed	B-T080
segmentation	B-T058
framework	O
is	O
quantitatively	B-T081
assessed	B-T052
using	O
two	O
public	O
databases	B-T170
(	O
ISBI VESSEL12 challenge	B-T170
and	O
MICCAI LOLA11 challenge	B-T170
)	O
and	O
our	O
own	O
database	B-T170
with,	O
respectively,	O
20,	O
55,	O
and	O
30	O
CT	B-T060
images	B-T170
of	O
various	O
lung	B-T023
pathologies	B-T169
acquired	O
with	O
different	O
scanners	B-T074
and	O
protocols	B-T061
.	O
Quantitative	B-T081
assessment	B-T052
of	O
our	O
framework	O
in	O
terms	O
of	O
Dice similarity coefficients	B-T081
,	O
95-percentile bidirectional Hausdorff distances	B-T081
,	O
and	O
percentage volume differences	B-T081
confirms	O
the	O
high	O
accuracy	B-T080
of	O
our	O
model	B-T075
on	O
both	O
our	O
database	B-T170
(98.4±1.0%,	O
2.2±1.0	O
mm,	O
0.42±0.10%)	O
and	O
the	O
VESSEL12 database	B-T170
(99.0±0.5%,	O
2.1±1.6	O
mm,	O
0.39±0.20%),	O
respectively.	O
Similarly,	O
the	O
accuracy	B-T080
accuracy	B-T080
of	O
our	O
approach	B-T078
is	O
further	O
verified	B-T169
via	O
a	O
blind	B-T170
evaluation	B-T170
by	O
the	O
organizers	O
of	O
the	O
LOLA11	B-T170
competition	B-T052
,	O
where	O
an	O
average	B-T081
overlap	O
of	O
98.0%	O
with	O
the	O
expert's	O
segmentation	B-T058
is	O
yielded	O
on	O
all	O
55	O
subjects	O
with	O
our	O
framework	O
being	O
ranked	O
first	O
among	O
all	O
the	O
state-of-the-art	B-T080
techniques	B-T169
compared	B-T052
.	O

Influence	B-T077
of	O
Different	B-T080
Levels	B-T079
of	O
Lipoic Acid Synthase	B-T028
Gene Expression	B-T045
on	O
Diabetic Nephropathy	B-T047
Oxidative stress	B-T049
is	O
implicated	O
in	O
the	O
pathogenesis	B-T046
of	O
diabetic nephropathy	B-T047
(	O
DN	B-T047
)	O
but	O
outcomes	B-T169
of	O
many	O
clinical trials	B-T062
are	O
controversial.	O
To	O
define	O
the	O
role	B-T077
of	O
antioxidants	B-T121
in	O
kidney	B-T023
protection	O
during	B-T079
the	O
development	B-T169
of	O
diabetic nephropathy	B-T047
,	O
we	O
have	O
generated	B-T052
a	O
novel	B-T080
genetic antioxidant mouse model	B-T050
with	O
over- or under-expression	B-T045
of	O
lipoic acid synthase gene	B-T028
(	O
Lias	B-T028
).	O
These	O
models	B-T050
have	O
been	O
mated	B-T040
with	O
Ins2Akita/+ mice	B-T015
,	O
a	O
type I diabetic	B-T047
mouse model	B-T050
.	O
We	O
compare	B-T052
the	O
major	B-T080
pathologic changes	B-T034
and	O
oxidative stress	B-T049
status	B-T080
in	O
two	O
new	O
strains	O
of	O
the	O
mice	B-T015
with	O
controls.	O
Our	O
results	B-T169
show	O
that	O
Ins2Akita/+ mice	B-T015
with	O
under-expressed	B-T045
Lias gene	B-T028
,	O
exhibit	O
higher	B-T080
oxidative stress	B-T049
and	O
more	B-T081
severe	B-T080
DN	B-T047
features	B-T080
(	O
albuminuria	B-T033
,	O
glomerular basement membrane thickening	B-T033
and	O
mesangial matrix expansion	B-T033
).	O
In	O
contrast,	O
Ins2Akita/+ mice	B-T015
with	O
highly	B-T080
-	O
expressed	B-T045
Lias gene	B-T028
display	B-T169
lower	B-T080
oxidative stress	B-T049
and	O
less	B-T080
DN	B-T047
pathologic changes	B-T034
.	O
Our	O
study	B-T062
demonstrates	B-T052
that	O
strengthening	O
endogenous	B-T169
antioxidant	B-T121
capacity	B-T081
could	O
be	O
an	O
effective strategy for prevention	B-UnknownType
and	O
treatment	B-T169
of	O
DN	B-T047
.	O

Assessment	B-T052
of	O
genetic	B-T169
relationship	B-T080
among	O
Rhododendron	B-T002
cultivars	B-T077
using	O
amplified fragment length polymorphism	B-T063
and	O
inter-simple sequence repeat	B-UnknownType
markers	B-T086
Genetic	B-T169
relationships	B-T080
of	O
17	O
Rhododendron	B-T002
cultivars	B-T077
,	O
China	B-T083
,	O
were	O
assessed	B-T052
using	O
inter-simple sequence repeat	B-UnknownType
(	O
ISSR	B-UnknownType
)	O
and	O
amplified fragment length polymorphism	B-T063
(	O
AFLP	B-T063
)	O
markers	B-T086
.	O
A	O
total	O
of	O
133	O
bands	O
were	O
obtained	O
using	O
nine	O
selected	O
ISSR	B-UnknownType
primers	B-T114
,	O
129	O
(96.99%)	O
of	O
which	O
were	O
polymorphic	B-T080
;	O
267	O
bands	O
were	O
amplified	O
by	O
four	O
AFLP	B-T063
primer pairs	B-T114
,	O
251	O
(94.01%)	O
of	O
which	O
exhibited	O
polymorphism	B-T080
.	O
Based	O
on	O
these	O
polymorphic	B-T080
products	B-T071
,	O
a	O
cluster analysis	B-T062
revealed	O
similarities	B-T080
between	O
the	O
results	B-T169
of	O
the	O
ISSR	B-UnknownType
and	O
AFLP	B-T063
.	O
All	O
of	O
the	O
cultivars	B-T077
were	O
clustered	B-T169
into	O
two	O
major	O
branches	B-T078
;	O
one	O
branch	B-T078
contained	O
the	O
same	O
four	O
cultivars	B-T077
,	O
and	O
the	O
other	O
cultivars	B-T077
were	O
separated	O
into	O
different	O
groups	B-T078
in	O
the	O
other	O
branch	B-T078
.	O
The	O
cluster	B-T081
results	B-T169
showed	O
that	O
the	O
genetic	B-T169
relationships	B-T080
of	O
the	O
17	O
cultivars	B-T077
were	O
partly	O
related	B-T080
to	O
their	O
morphological	B-T082
characteristics	B-T080
,	O
particularly	O
the	O
flowering	B-T040
phase	B-T079
.	O
Therefore,	O
the	O
results	B-T169
of	O
this	O
study	B-T062
support	O
the	O
classification	B-T185
of	O
Rhododendron	B-T002
cultivars	B-T077
according	O
to	O
flowering	B-T040
phase	B-T079
.	O
In	O
addition,	O
the	O
cluster	B-T081
results	B-T169
can	O
be	O
used	O
to	O
select	B-T052
suitable	O
parents	O
for	O
breeding	B-T040
.	O

Spontaneous activity	B-T039
is	O
correlated	B-T080
with	O
coding	B-T052
density	B-T081
in	O
primary auditory cortex	B-T029
Sensory neurons	B-T025
across	O
sensory modalities	B-T067
and	O
specific	O
processing	B-T052
areas	O
have	O
diverse	O
levels	O
of	O
spontaneous firing rates	B-T039
(	O
SFRs	B-T039
)	O
in	O
the	O
absence	O
of	O
sensory stimuli	B-UnknownType
.	O
However,	O
the	O
functional	B-T169
significance	B-T078
of	O
this	O
spontaneous activity	B-T039
is	O
not	O
well-understood.	O
Previous	O
studies	B-T062
in	O
the	O
auditory system	B-T022
have	O
demonstrated	O
that	O
different	O
levels	O
of	O
spontaneous activity	B-T039
are	O
correlated	B-T080
with	O
a	O
variety	O
of	O
physiological	B-T169
and	O
anatomic	B-T080
properties,	O
suggesting	O
that	O
neurons	B-T025
with	O
differing	O
SFRs	B-T039
make	O
unique	O
contributions	O
to	O
the	O
encoding	B-T052
of	O
auditory stimuli	B-T039
.	O
Additionally,	O
altered	O
SFRs	B-T039
are	O
a	O
correlate	O
of	O
tinnitus	B-T033
,	O
arising	O
in	O
several	O
auditory areas	B-T023
after	O
exposure	O
to	O
ototoxic	B-T037
substances	B-T167
and	O
noise	B-T067
trauma	B-T037
.	O
In	O
this	O
study	B-T062
,	O
we	O
recorded single-unit activity	B-T059
from	O
primary auditory cortex	B-T029
of	O
awake	O
marmoset	B-T015
monkeys	B-T015
while	O
delivering	O
wide-band random-spectrum stimuli	B-T067
and	O
white Gaussian noise	B-T170
(	O
WGN	B-T170
)	O
to	O
examine	O
any	O
divergences	B-T082
in	O
stimulus	B-T067
encoding	B-T052
properties	O
across	O
SFR	O
classes.	O
We	O
found	O
that	O
higher	O
levels	O
of	O
spontaneous activity	B-T039
were	O
associated	O
with	O
both	O
higher	O
levels	O
of	O
activation	B-T052
relative	O
to	O
suppression	B-T169
across	O
a	O
variety	O
of	O
wide-band stimuli	B-T067
and	O
higher	O
driven	O
rates	O
in	O
response	B-T032
to	O
WGN	B-T170
.	O
Moreover,	O
response latencies	B-T079
to	O
WGN	B-T170
were	O
negatively	O
correlated	B-T080
with	O
the	O
level	O
of	O
activation	B-T052
in	O
response	B-T032
to	O
both	O
stimulus	B-T067
types.	O
These	O
findings	O
are	O
consistent	O
with	O
a	O
novel	O
view	O
of	O
the	O
role	O
spontaneous spiking	B-T039
may	O
play	O
during	O
normal	O
stimulus	B-T067
processing	B-T052
in	O
primary auditory cortex	B-T029
and	O
how	O
it	O
may	O
malfunction	B-T169
in	O
cases	O
of	O
tinnitus	B-T033
.	O

Systematic mapping	B-T062
of	O
functional	B-T169
enhancer	B-T114
-	O
promoter	B-T114
connections	B-T169
with	O
CRISPR	B-T114
CRISPR interference	B-T059
Gene expression	B-T045
in	O
mammals	B-T015
is	O
regulated	B-T045
by	O
noncoding elements	B-T114
that	O
can	O
affect	O
physiology	B-T039
and	O
disease	B-T047
,	O
yet	O
the	O
functions	B-T169
and	O
target genes	B-T028
of	O
most	O
noncoding elements	B-T114
remain	O
unknown	B-T080
.	O
We	O
present	O
a	O
high-throughput approach	B-T170
that	O
uses	O
clustered regularly interspaced short palindromic repeats	B-T114
clustered regularly interspaced short palindromic repeats (CRISPR) interference	B-T059
CRISPR	B-T114
)	O
interference	O
(	O
CRISPRi	B-T059
)	O
to	O
discover	O
regulatory elements	B-T114
and	O
identify	O
their	O
target genes	B-T028
.	O
We	O
assess	B-T058
>1	O
megabase	B-T081
of	O
sequence	B-T086
in	O
the	O
vicinity	O
of	O
two	O
essential	O
transcription factors	B-T116
,	O
MYC	B-T116
and	O
GATA1	B-T116
,	O
and	O
identify	O
nine	O
distal	B-T082
enhancers	B-T114
that	O
control	B-T080
gene expression	B-T045
and	O
cellular proliferation	B-T043
.	O
Quantitative	B-T081
features	B-T080
of	O
chromatin	B-T116
state	B-T169
and	O
chromosome	B-T026
conformation	B-T033
distinguish	O
the	O
seven	O
enhancers	B-T114
that	O
regulate	O
MYC	B-T116
from	O
other	O
elements	B-T086
that	O
do	O
not,	O
suggesting	O
a	O
strategy	B-T169
for	O
predicting	O
enhancer	B-T114
-	O
promoter	B-T114
connectivity	B-T169
.	O
This	O
CRISPRi	B-T059
-based	O
approach	B-T169
can	O
be	O
applied	O
to	O
dissect	B-T169
transcriptional networks	B-T044
and	O
interpret	B-T169
the	O
contributions	B-T052
of	O
noncoding genetic variation	B-T070
to	O
human	B-T016
disease	B-T047
.	O

Proliferation	B-T043
-enhancing	O
effects of	B-T080
gastrodin	B-T109
on	O
RSC96 Schwann cells	B-T025
by	O
regulating	B-T038
ERK1	B-T116
/	O
2	B-T116
and	O
PI3K	B-T116
signaling pathways	B-T044
The	O
proliferation	B-T043
and	O
migration	B-T043
of	O
Schwann cells	B-T025
(	O
SCs	B-T025
)	O
are	O
essential	O
in	O
the	O
process	B-T067
of	O
peripheral nerve repair	B-T061
.	O
A	O
large	O
amount	O
of	O
studies	O
focused	O
on	O
the	O
promotion	B-T052
of	O
the	O
growth	B-T043
of	O
SCs	B-T025
for	O
cell based therapy	B-T061
.	O
Gastrodin	B-T109
(	O
GAS	B-T109
),	O
the	O
main	O
constituent	O
of	O
a	O
Chinese traditional	B-T091
herbal medicine	B-T121
named	O
Gastrodia elata Blume	B-T002
,	O
has	O
been	O
reported	B-T058
to	O
be	O
associated with	B-T080
neuroprotective properties	B-T043
.	O
Besides,	O
GAS	B-T109
activated	B-T052
MAPK	B-T116
and	O
PI3K	B-T116
signaling pathways	B-T044
which	O
are	O
often	O
involved	O
in	O
growth	B-T043
of	O
nerve cells	B-T025
were	O
also	O
reported	B-T058
.	O
Based	O
on	O
the	O
hypothesis	B-T078
that	O
GAS	B-T109
may	O
have	O
an	O
effect	O
on	O
SCs	B-T025
growth	B-T043
,	O
we	O
studied	O
the	O
effect of	B-T080
GAS	B-T109
on	O
rat	B-T015
RSC96 Schwann cells	B-T025
(	O
SCs	B-T025
)	O
and	O
further	O
explored	O
the	O
underlying	O
mechanism	B-T169
.	O
Various	O
concentration	B-T081
of	O
GAS	B-T109
(0μM,	O
50μM,	O
100μM,	O
and	O
200μM)	O
was	O
used	O
for	O
treatment	B-T061
of	O
RSC96 SCs	B-T025
,	O
with	O
the	O
cell proliferation	B-T043
and	O
gene expression	B-T045
of	O
several	O
neurotrophic factors	B-T116
to	O
be	O
detected.	O
Regulation of	B-T038
MAPK	B-T116
and	O
PI3K	B-T116
signaling pathways	B-T044
were	O
assayed	O
by	O
detecting	O
phosphorylation	B-T044
of	O
ERK1	B-T116
/	O
2	B-T116
and	O
Akt	B-T116
.	O
The	O
results	O
showed	O
that	O
GAS	B-T109
could	O
effectively	O
promote	B-T052
proliferation	B-T043
of	O
RSC96 SCs	B-T025
in	O
a	O
dose	B-T081
-	O
and	O
time	B-T079
-dependent	O
manner.	O
The	O
best	O
performance	O
was	O
obtained	O
at	O
the	O
concentration	B-T081
of	O
200μM.	O
Exploration	B-T061
of	O
the	O
underlying	O
mechanism	B-T169
showed	O
that	O
GAS	B-T109
probably	O
affects	O
SCs	B-T025
metabolism	B-T043
through	O
inhibiting	B-T052
ERK1	B-T116
/	O
2	B-T116
phosphorylation	B-T044
and	O
activating	B-T052
Akt	B-T116
phosphorylation	B-T044
in	O
RSC96 SCs	B-T025
.	O
This	O
study	O
may	O
provide	O
reference	O
for	O
its	O
application	O
in	O
treatment	B-T061
of	O
peripheral nerve injuries	B-T037
.	O

An	O
influenza A virus (H7N9)	B-T005
anti-neuraminidase	B-T033
monoclonal antibody	B-T116
with	O
prophylactic and therapeutic activity	B-T061
in vivo	B-T082
Zoonotic	B-T047
A(H7N9) avian influenza viruses	B-T005
emerged	O
in	O
China	B-T083
in	O
2013	O
and	O
continue	O
to	O
be	O
a	O
threat	B-T078
to	O
human	B-T016
public health	B-T058
,	O
having	O
infected	B-T033
over	O
800	O
individuals	B-T098
with	O
a	O
mortality rate	B-T081
approaching	O
40%.	O
Treatment options	B-T061
for	O
people	O
infected	B-T033
with	O
A(H7N9)	B-T005
include	O
the	O
use	O
of	O
neuraminidase (NA) inhibitors	B-T121
.	O
However,	O
like	O
other	O
influenza viruses	B-T005
,	O
A(H7N9)	B-T005
can	O
become	O
resistant	B-T169
to	O
these	O
drugs	B-T121
.	O
The	O
use	O
of	O
monoclonal antibodies	B-T116
is	O
a	O
rapidly	O
developing	O
strategy	B-T041
for	O
controlling	O
influenza virus	B-T005
infection	B-T046
.	O
Here	O
we	O
generated	O
a	O
murine	B-T015
monoclonal antibody	B-T116
(	O
3c10-3	B-T129
)	O
directed	O
against	O
the	O
NA	B-T116
of	O
A(H7N9)	B-T005
and	O
show	O
that	O
prophylactic	B-T169
systemic administration	B-UnknownType
of	O
3c10-3	B-T129
fully	O
protected	O
mice	O
from	O
lethal	O
challenge	O
with	O
wild-type	B-T028
A/Anhui/1/2013	B-T005
(	O
H7N9	B-T005
).	O
Further,	O
post-	O
infection	B-T046
treatment	B-T061
with	O
a	O
single	O
systemic	B-T169
dose	B-T081
of	O
3c10-3	B-T129
at	O
either	O
24,	O
48	O
or	O
72	O
h	O
post	O
A(H7N9)	B-T005
challenge	O
resulted	O
in	O
both	O
dose	B-T081
-	O
and	O
time	B-T079
-	O
dependent	B-T169
protection	B-T033
of	O
up	O
to	O
100%	O
of	O
mice	B-T015
,	O
demonstrating	O
therapeutic	B-T169
potential	B-T080
for	O
3c10-3	B-T129
.	O
Epitope mapping	B-T059
revealed	O
that	O
3c10-3	B-T129
binds	B-T044
near	O
the	O
enzyme	B-T116
active site	B-T169
of	O
NA	B-T116
,	O
and	O
functional	B-T169
characterization	O
showed	O
that	O
3c10-3	B-T129
inhibits	O
the	O
enzyme activity	B-T044
of	O
NA	B-T116
and	O
restricts	O
the	O
cell	O
-to-	O
cell	O
spread	B-T080
of	O
the	O
virus	B-T005
in	O
cultured cells	B-T025
.	O
Affinity	B-T070
analysis	B-T062
also	O
revealed	O
that	O
3c10-3	B-T129
binds	B-T044
equally	O
well	O
to	O
recombinant	B-T116
NA	B-T116
of	O
wild-type	B-T028
A/Anhui/1/2013	B-T005
and	O
to	O
a	O
variant	B-T080
NA	B-T116
carrying	O
a	O
R289K	O
mutation	B-T045
known	O
to	O
infer	O
NAI	B-T121
resistance	B-T169
.	O
These	O
results	O
suggest	O
that	O
3c10-3	B-T129
has	O
the	O
potential	B-T080
to	O
be	O
used	O
as	O
a	O
therapeutic	B-T169
to	O
treat	O
A(H7N9)	B-T005
infections	B-T046
either	O
as	O
an	O
alternative	B-T077
to,	O
or	O
in	O
combination	B-T080
with,	O
current	O
NA	B-T116
antiviral inhibitors	B-T121
.	O

Mechanisms	B-T169
of	O
ear	B-T023
trauma	B-T037
and	O
reconstructive	B-T061
techniques	B-T169
in	O
105	O
consecutive	B-T080
patients	B-T101
Acquired	B-T080
auricular	B-T023
deformities	B-T190
may	O
diminish	B-T081
facial esthetics	B-T032
and	O
cause	O
psychological distress	B-T048
.	O
The	O
aim	O
of	O
this	O
article	O
is	O
to	O
provide	O
an	O
overview	O
of	O
the	O
type	O
of	O
injuries	B-T037
and	O
applied reconstructive	B-T061
techniques	B-T169
in	O
a	O
large	O
academic hospital	B-T073
in	O
The	O
Netherlands	B-T083
.	O
A	O
retrospective	B-T080
chart review	B-UnknownType
was	O
conducted	O
for	O
the	O
last	O
105	O
patients	B-T101
who	O
underwent	O
auricular	B-T023
reconstruction	B-T061
for	O
an	O
acquired deformity	B-T020
.	O
Data	B-T078
concerning	O
gender	B-T032
,	O
affected side	B-T033
,	O
cause of injury	B-T033
,	O
anatomical region	B-T029
,	O
the	O
previous	O
and	O
further	O
surgeries	B-T061
,	O
type	O
of	O
cartilage	B-T024
,	O
and	O
skin cover used	B-T074
were	O
collected	O
and	O
analyzed	B-T062
.	O
105	O
patients	B-T101
were	O
included.	O
Acquired	B-T080
auricular	B-T023
deformities	B-T190
were	O
mainly	O
caused	O
by	O
bite injuries	B-T037
(22	O
%),	O
traffic accidents	B-T037
(17	O
%),	O
burns	B-T037
(9.5	O
%),	O
and	O
post-otoplasty	B-T061
complications	B-T046
(9.5	O
%).	O
The	O
upper third of the auricle	B-T023
was	O
most	O
often	O
injured	B-T169
(41	O
%),	O
followed	O
by	O
the	O
entire auricle	B-T023
(19	O
%).	O
70	O
%	O
of	O
cases	B-T169
required	O
reconstruction	B-T061
with	O
costal cartilage	B-T024
.	O
The	O
most	O
common	O
form	O
of	O
cutaneous cover	B-T082
was	O
a	O
postauricular skin flap	B-T061
(40	O
%	O
of	O
cases	B-T169
).	O
This	O
study	B-T062
gives	O
a	O
complete	O
overview	O
of	O
causes	O
and	O
treatment	B-T169
of	O
acquired	B-T080
auricular	B-T023
deformities	B-T190
.	O
The	O
results	O
are	O
comparable	O
with	O
the	O
results	B-T169
of	O
similar	O
studies	B-T062
found	O
in	O
literature	B-T170
.	O
Bite wounds	B-T037
are	O
the	O
leading	O
cause	O
of	O
acquired	B-T080
auricular	B-T023
injuries	B-T037
.	O
The	O
upper third	B-T023
is	O
most	O
commonly	O
affected.	O
In	O
the	O
largest	O
percentage	O
of	O
reconstructions	B-T061
,	O
costal cartilage	B-T024
and	O
a	O
postauricular flap	B-T023
were	O
used	O
to	O
correct	O
the	O
deformity	B-T190
.	O

Anatomic	B-T080
assessment	B-T058
of	O
the	O
left main bifurcation	B-T082
and	O
dynamic bifurcation angles	B-T082
using	O
computed tomography angiography	B-T060
An	O
understanding	O
of	O
the	O
left main coronary artery	B-T023
(	O
LMCA	B-T023
)	O
anatomy	B-T017
is	O
important	O
for	O
accurate	O
diagnosis	B-T080
and	O
therapeutic	B-T061
.	O
We	O
aimed	O
to	O
investigate	B-T169
LMCA	B-T023
anatomy	B-T017
via	O
128-multisliced coronary computed-tomography-angiography	B-T060
(	O
CCTA	B-T060
)	O
in	O
patients	B-T101
with	O
normal	O
LMCA	B-T023
.	O
A	O
total	O
of	O
201	O
CCTA	B-T060
studies	B-T062
were	O
included	O
in	O
this	O
study	B-T062
.	O
Anatomical features	B-T017
of	O
LMCA	B-T023
including	O
cross-sectional areas	B-T082
of	O
the	O
LMCA	B-T023
ostial	B-T030
,	O
LMCA	B-T023
distal	B-T082
,	O
LAD ostial	B-T023
and	O
LCX	B-T023
ostial	B-T030
,	O
and	O
degree	O
of	O
tapering	O
and	O
LMCA	B-T023
bifurcation angles	B-T082
(	O
BA	B-T082
)	O
in	O
the	O
form	O
of	O
LMCA	B-T023
-	O
LCX	B-T023
BA	B-T082
,	O
LMCA	B-T023
-	O
LAD	B-T023
BA	B-T082
,	O
LAD	B-T023
-	O
LCX	B-T023
BA	B-T082
at	O
end-diastole	B-T079
and	O
end-systole	B-T079
.	O
The	O
mean	O
age	B-T032
was	O
55	O
±	O
11	O
with	O
55.7%	O
males	B-T032
.	O
RCA	B-T023
was	O
dominant	B-T169
in	O
173	O
(86.1%)	O
patients	B-T101
.	O
Mean	O
LMCA	B-T023
length	B-T081
was	O
10.0±4.5	O
mm.	O
The	O
mean	O
values	O
of	O
LMCA	B-T023
ostial	B-T030
,	O
LMCA	B-T023
distal	B-T082
,	O
LAD ostial	B-T023
and	O
LCX	B-T023
ostial	B-T030
areas	B-T082
were	O
18.2±5.1	O
mm²,	O
13.2±4.0,	O
9.0±3.2	O
mm²	O
and	O
7.6±2.8	O
mm²,	O
respectively.	O
LMCA	B-T023
ostial	B-T030
-	O
distal	B-T082
area	B-T082
,	O
LMCA	B-T023
distal	B-T082
-	O
LAD ostial	B-T023
area	B-T082
and	O
LMCA	B-T023
distal	B-T082
-	O
LCX	B-T023
ostial	B-T030
area ratios	B-T081
were	O
≥1.44	O
-	O
<1.69	O
in	O
47	O
(23.4%),	O
53	O
(26.4%),	O
47	O
(23.4%)	O
patients	B-T101
,	O
respectively,	O
and	O
were	O
≥1.69-<1.96	O
in	O
19	O
(9.5%),	O
24(11.9%),	O
40(19.9%)	O
patients	B-T101
respectively.	O
Systolic motion	B-T070
modifies	O
LMCA	B-T023
BAs	B-T082
;	O
systolic motion	B-T070
begets	O
an	O
increment	O
of	O
LMCA	B-T023
-	O
LAD	B-T023
angle	O
in	O
72.6%	O
of	O
patients	B-T101
and	O
decrement	O
of	O
LAD	B-T023
-	O
LCX	B-T023
angle	O
in	O
75.6%	O
of	O
the	O
patients	B-T101
.	O
Patients	B-T101
with	O
T-shaped	O
LAD	B-T023
-	O
LCX	B-T023
BA	B-T082
was	O
shown	O
to	O
have	O
significantly	O
longer	O
LMCA	B-T023
,	O
larger	O
LAD ostial	B-T023
area	B-T082
,	O
larger	O
LCX	B-T023
ostial	B-T030
area	B-T082
and	O
higher	O
diastolic-to-systolic range	B-T081
(	O
DSR	B-T081
)	O
of	O
LAD	B-T023
-	O
LCX	B-T023
BA	B-T082
compared	O
to	O
patients	B-T101
with	O
Y-shaped	O
LAD	B-T023
-	O
LCX	B-T023
BA	B-T082
.	O
LMCA	B-T023
with	O
T-shaped distal	B-T082
BA	B-T082
was	O
found	O
to	O
have	O
significantly	O
longer	O
LMCA	B-T023
,	O
larger	O
LAD ostial	B-T023
area	B-T082
,	O
larger	O
LCX	B-T023
ostial	B-T030
area	B-T082
and	O
higher	O
DSR	B-T081
of	O
distal	B-T082
BA	B-T082
compared	O
to	O
patients	B-T101
with	O
Y-shaped distal	B-T082
BA	B-T082
.	O
These	O
findings	B-T033
may	O
provide	O
useful	O
information	O
for	O
LMCA	B-T023
bifurcation stenting	B-T061
or	O
designing	O
dedicated	O
stents	B-T074
for	O
LMCA	B-T023
.	O

A	O
three	B-T081
perspective study	B-T062
of	O
the	O
sense	O
of	O
home	B-T082
of	O
nursing home residents	B-T098
:	O
the	O
views	O
of	O
residents	B-T098
,	O
care professionals	B-T097
and	O
relatives	B-T099
The	O
sense	O
of	O
home	B-T082
of	O
nursing home residents	B-T098
is	O
a	O
multifactorial	B-T033
phenomenon	B-T067
which	O
is	O
important	B-T080
for	O
the	O
quality	B-T080
of	O
living	B-T078
.	O
The	O
purpose	B-T169
of	O
this	O
study	B-T062
is	O
to	O
investigate	B-T169
the	O
factors	B-T169
influencing	B-T077
the	O
sense	O
of	O
home	B-T082
of	O
older adults	B-T098
residing	B-T052
in	O
the	O
nursing home	B-T073
from	O
the	O
perspective	O
of	O
residents	B-T098
,	O
relatives	B-T099
and	O
care professionals	B-T097
.	O
A	O
total	O
of	O
78	O
participants	B-T098
(n	O
=	O
24	O
residents	B-T098
,	O
n	O
=	O
18	O
relatives	B-T099
and	O
n	O
=	O
26	O
care professionals	B-T097
)	O
from	O
4	O
nursing homes	B-T073
in	O
the	O
Netherlands	B-T083
engaged	O
in	O
a	O
qualitative study	B-T062
,	O
in	O
which	O
photography	O
was	O
as	O
a	O
supportive	O
tool	O
for	O
subsequent	B-T079
interviews	B-T052
and	O
focus groups	B-T096
.	O
The	O
data	B-T078
were	O
analyzed	O
based	O
on	O
open ended coding	B-T080
,	O
axial coding	B-T080
and	O
selective coding	B-T080
.	O
The	O
sense	O
of	O
home	B-T082
of	O
nursing home residents	B-T098
is	O
influenced	B-T077
by	O
a	O
number	O
of	O
jointly	O
identified	O
factors	B-T169
,	O
including	O
the	O
building	B-T073
and	O
interior design	B-T073
;	O
eating	B-T055
and	O
drinking	B-T055
;	O
autonomy	B-T078
and	O
control	B-T169
;	O
involvement	B-T169
of	O
relatives	B-T099
;	O
engagement	O
with	O
others	O
and	O
activities	B-T052
;	O
quality of care	B-T058
are	O
shared	O
themes.	O
Residents	B-T098
and	O
relatives	B-T099
stressed	O
the	O
importance	B-T080
of	O
having	O
a	O
connection	O
with	O
nature	B-T078
and	O
the	O
outdoors	B-T083
,	O
as	O
well	O
as	O
coping strategies	B-T055
.	O
Relatives	B-T099
and	O
care professionals	B-T097
emphasized	O
the	O
role	O
the	O
organization	B-T092
of	O
facilitation	B-T058
of	O
care	B-T052
played,	O
as	O
well	O
as	O
making	O
residents	B-T098
feel	O
like	O
they	O
still	O
matter.	O
The	O
sense	O
of	O
home	B-T082
of	O
nursing home residents	B-T098
is	O
influenced	B-T077
by	O
a	O
multitude	B-T081
of	O
factors	B-T169
related	O
to	O
the	O
psychology	B-T169
of	O
the	O
residents	B-T098
,	O
and	O
the	O
social and built environmental contexts	B-T078
.	O
A	O
holistic	B-T078
understanding	O
of	O
which	O
factors	B-T169
influence	B-T077
the	O
sense	O
of	O
home	B-T082
of	O
residents	B-T098
can	O
lead	O
to	O
strategies	O
to	O
optimize	B-T052
this	O
sense	O
of	O
home	B-T082
.	O
This	O
study	B-T062
also	O
indicated	O
that	O
the	O
nursing home	B-T073
has	O
a	O
dual	O
nature	B-T078
as	O
a	O
place	O
of	O
residence	B-T082
and	O
a	O
place	B-T082
where	O
people	B-T098
are	O
supported	O
through	O
numerous	B-T081
care	O
strategies.	O

Integrating	O
one health	B-T091
in	O
national health policies	B-T170
of	O
developing countries	B-T080
:	O
India's	B-T083
lost	O
opportunities	O
Globally	B-T080
,	O
the	O
threat	B-T078
of	O
infectious diseases	B-T047
,	O
particularly	O
emerging infectious diseases	B-T047
,	O
originating	B-T079
at	O
the	O
human	B-T016
-	O
animal	B-T008
-	O
environment	B-T082
interface	B-T169
,	O
has	O
caught	O
health systems	B-T064
off	O
guard.	O
With	O
forecasts	O
that	O
future	O
pathogen	B-T001
emergence	B-T047
will	O
be	O
centred	O
in	O
hotspots	O
in	O
Asia	B-T083
,	O
Africa	B-T083
,	O
and	O
Latin America	B-T083
,	O
the	O
need	O
to	O
prepare	O
policy frameworks	B-T170
that	O
can	O
combat	O
this	O
threat	B-T078
is	O
urgent	B-T079
.	O
Emergence of diseases	B-T047
such	O
as	O
avian influenza	B-T047
and	O
Ebola virus disease	B-T047
,	O
which	O
threatened	B-T078
social	B-T169
disruption	B-T169
,	O
have	O
established	B-T080
the	O
need	O
for	O
intersectoral coordination/collaboration	B-T058
.	O
These	O
events	B-T051
led	O
to	O
the	O
initiation	B-T169
of	O
establishing	B-T080
institutionalised	B-T033
collaborative frameworks	B-T054
in	O
India	B-T083
to	O
adopt	O
a	O
One Health approach	B-T091
to	O
disease prevention and control	B-T058
.	O
However,	O
the	O
gains	B-T081
made	O
in	O
influenza	B-T047
control	B-T067
could	O
not	O
be	O
adapted	O
to	O
other	O
infectious diseases	B-T047
.	O
Intersectoral coordination	B-T058
was	O
briefly	O
carried	O
out,	O
more	O
as	O
a	O
reactive	B-T080
response	O
to	O
threats	B-T078
.	O
The	O
systemic	B-T169
failure	B-T169
to	O
sustain	B-T169
such	O
efforts	O
have	O
therefore,	O
only	O
undermined	O
a	O
coordinated	B-T169
response	B-T169
.	O
The	O
recent	O
draft	B-T170
National Health Policy	B-T170
,	O
2015,	O
has	O
also	O
failed	B-T169
to	O
establish	B-T080
the	O
need	O
for	O
intersectoral coordination	B-T058
in	O
disease control approaches	B-T058
.	O
Neglecting	O
the	O
need	O
to	O
endorse	O
linkages	B-T185
between	O
human	B-T016
health	B-T078
,	O
animal	B-T008
health	B-T078
and	O
husbandry	B-T090
,	O
agriculture	B-T090
,	O
and	O
environmental	B-T082
sectors	B-T083
,	O
has	O
led	O
to	O
duplicative	B-T169
and	O
weak response systems	B-T033
.	O
The	O
absence	B-T169
of	O
health impact assessment	B-T058
with	O
respect	O
to	O
the	O
development	B-T169
agenda	B-T170
in	O
policies	B-T170
,	O
has	O
cast	O
negative	B-T033
effects	B-T080
on	O
the	O
health	B-T078
and	O
wellbeing of man	B-T170
,	O
animal	B-T008
,	O
and	O
the	O
environment	B-T082
.	O
Lack of attention	B-T033
to	O
building	O
core	O
capacity	B-T081
in	O
these	O
critical	B-T080
sectors	B-T083
has	O
further	O
raised	B-T080
challenges	B-T058
in	O
designing	O
and	O
deploying	B-T052
mitigation	B-T067
strategies	B-T041
.	O
With	O
developing countries	B-T080
like	O
India	B-T083
being	O
home	O
to	O
a	O
major	O
portion	B-T082
of	O
the	O
world's	B-T098
poorest	B-T080
livestock farmers	B-T097
,	O
the	O
absence	B-T169
of	O
a	O
policy	B-T170
discourse	B-T054
that	O
endorses	O
the	O
One Health approach	B-T091
in	O
development	B-T169
and	O
health policies	B-T089
is	O
a	O
major	O
hurdle	B-T046
in	O
eliminating	B-T052
poverty	B-T102
and	O
poverty	B-T102
-	O
related	B-T080
diseases	B-T047
.	O
The	O
adoption	B-T080
of	O
One Health approaches	B-T091
in	O
health	B-T078
and	O
related	O
sectoral	B-T082
policies	B-T170
is	O
a	O
critical	B-T080
policy	B-T170
requirement	O
for	O
India	B-T083
and	O
other	O
developing countries	B-T080
.	O
The	O
goal	O
should	O
be	O
to	O
not	O
just	O
establish	B-T080
preparedness	B-T033
plans	B-T041
,	O
but	O
also	O
to	O
encourage	B-T169
a	O
policy environment	B-T064
where	O
assessment	B-T058
and	O
mitigation	B-T067
of	O
downstream	B-T082
impacts	B-T080
of	O
different	O
agenda	B-T170
are	O
incorporated	B-T169
.	O

Assessment	B-T058
of	O
demographic	B-T078
and	O
pathoanatomic risk factors	B-T033
in	O
recurrent	B-T079
patellofemoral	B-T030
instability	B-T033
The	O
WARPS/STAID classification	B-T185
employs	O
clinical	B-T080
assessment	B-T058
of	O
presenting	O
features	B-T080
and	O
anatomic	B-T080
characteristics	B-T080
to	O
identify	O
two	O
distinct	O
subsets	B-T185
of	O
patients	B-T101
within	O
the	O
patellofemoral instability	B-T033
population	B-T101
.	O
The	O
purpose of this study	B-UnknownType
was	O
to	O
further	O
define	O
the	O
specific	O
demographics	B-T185
and	O
the	O
prevalence	B-T081
of	O
risky	B-T080
pathoanatomies	B-T080
in	O
patients	B-T101
classified	O
as	O
either	O
WARPS	B-T185
or	O
STAID	B-T185
presenting	O
with	O
recurrent	B-T079
patellofemoral	B-T030
instability	B-T033
.	O
A	O
secondary	O
purpose	O
was	O
to	O
further	O
validate	O
the	O
WARPS/STAID classification	B-T185
with	O
the	O
Banff Patella Instability Instrument	B-T170
(	O
BPII	B-T170
),	O
the	O
Marx activity scale	B-T170
and	O
the	O
Patellar	B-T023
Instability Severity Score	B-T170
(	O
ISS	B-T170
).	O
A	O
convenience	O
sample	O
of	O
50	O
patients	B-T101
with	O
recurrent	B-T079
patellofemoral	B-T030
instability	B-T033
,	O
including	O
25	O
WARPS	B-T185
and	O
25	O
STAID subtype	B-T185
patients	B-T101
,	O
were	O
assessed	B-T052
.	O
Clinical data	B-T170
were	O
collected	O
including	O
assessment	B-T058
of	O
demographic	B-T078
risk factors	B-T033
(	O
sex	B-T032
,	O
BMI	B-T201
,	O
bilaterality	B-T082
of	O
symptoms	B-T184
,	O
affected	B-T082
limb side	B-T023
and	O
age	B-T032
at	O
first	O
dislocation	B-T037
)	O
and	O
pathoanatomic risk factors	B-T033
(	O
TT-TG distance	B-T081
,	O
patella	B-T023
height	B-T032
,	O
patellar	O
tilt,	O
grade	B-T185
of	O
trochlear dysplasia	B-T047
,	O
Beighton score	B-T033
and	O
rotational abnormalities	B-T033
of	O
the	O
tibia	B-T023
or	O
femur	B-T023
).	O
Patients	B-T101
completed	O
the	O
BPII	B-T170
and	O
the	O
Marx activity scale	B-T170
.	O
The	O
ISS	B-T170
was	O
calculated	B-T059
from	O
the	O
clinical assessment data	B-T170
.	O
Patients	B-T101
were	O
stratified	O
into	O
the	O
WARPS	B-T185
or	O
STAID subtypes	B-T185
for	O
comparative analysis	B-T062
.	O
An	O
independent	O
t test	B-T170
was	O
used	O
to	O
compare	O
demographics	B-T185
,	O
the	O
pathoanatomic risk factors	B-T033
and	O
subjective	O
measures	O
between	O
the	O
groups	B-UnknownType
.	O
Convergent validity	B-T080
was	O
tested	O
with	O
a	O
Pearson r correlation coefficient	B-T081
between	O
the	O
WARPS/STAID	B-T081
and	O
ISS scores	B-T170
.	O
Demographic risk factors	B-T078
statistically	O
associated with	B-T080
a	O
WARPS subtype	B-T185
included	O
female sex	B-T032
,	O
age	B-T032
at	O
first	O
dislocation	B-T037
and	O
bilaterality	B-T082
.	O
Pathoanatomic risk factors	B-T033
statistically	O
associated with	B-T080
a	O
WARPS subtype	B-T185
included	O
trochlear dysplasia	B-T047
,	O
TT-TG distance	B-T081
,	O
generalized	O
ligamentous laxity	B-T046
,	O
patellar	O
tilt	O
and	O
rotational abnormalities	B-T033
.	O
The	O
independent	O
t test	B-T170
revealed	O
a	O
significant	O
difference	O
between	O
the	O
ISS	B-T170
scores:	O
WARPS subtype	B-T185
(M	O
=	O
4.4,	O
SD	O
=	O
1.1)	O
and	O
STAID subtype	B-T185
(M	O
=	O
2.5,	O
SD	O
=	O
1.5);	O
t(48)	O
=	O
5.2,	O
p	O
<	O
0.001.	O
The	O
relationship	B-T080
between	O
the	O
WARPS/STAID	B-T081
and	O
the	O
ISS scores	B-T170
,	O
measured	O
using	O
a	O
Pearson r correlation coefficient	B-T081
,	O
demonstrated	O
a	O
strong	O
relationship	B-T080
:	O
r	O
=	O
-0.61,	O
n	O
=	O
50,	O
p	O
<	O
0.001.	O
This	O
study	B-T062
has	O
demonstrated	O
statistically significant	B-T081
evidence	B-T078
that	O
certain	O
demographics	B-T185
and	O
pathoanatomies	B-T080
are	O
more	O
prevalent	O
in	O
each	O
of	O
the	O
WARPS	B-T185
and	O
STAID	B-T185
patellofemoral	B-T030
instability	B-T033
subtypes	B-T185
.	O
There	O
was	O
no	O
difference	O
in	O
quality-of-life	B-T078
or	O
activity level	B-T033
between	O
the	O
subtypes	B-T185
.	O
The	O
WARPS/STAID score	B-T081
demonstrated	O
convergent validity	B-T080
to	O
the	O
ISS	B-T170
and	O
divergent validity	B-T081
to	O
the	O
BPII score	B-T170
and	O
the	O
Marx activity scale	B-T170
.	O
This	O
study	B-T062
has	O
further	O
validated	O
both	O
the	O
WARPS/STAID classification	B-T185
and	O
the	O
ISS	B-T170
of	O
patients	B-T101
that	O
present	O
with	O
recurrent	B-T079
patellofemoral	B-T030
instability	B-T033
.	O
III.	O

Expression	B-T045
of	O
caspase 3	B-T116
in	O
ovarian follicle	B-T023
cells	B-T025
of	O
the	O
lizard	B-T014
Podarcis sicula	B-T014
In	O
this	O
study,	O
our	O
aim	O
was	O
to	O
determine	O
whether	O
caspase 3	B-T116
plays	O
a	O
role,	O
during	O
previtellogenesis	B-T042
,	O
in	O
the	O
ovarian	B-T023
follicular epithelium	B-T024
of	O
the	O
lizard	B-T014
Podarcis sicula	B-T014
.	O
We	O
investigated	O
the	O
presence	O
and	O
localization	B-T169
of	O
proform	O
and	O
active	O
caspase 3	B-T116
by	O
enzyme assay	B-T059
,	O
Western blotting	B-T059
and	O
immunocytochemistry	B-T059
.	O
In	O
parallel,	O
a	O
fragment	B-T080
of	O
caspase 3	B-T028
was	O
cloned	B-T059
for	O
the	O
first	O
time	O
in	O
this	O
species	B-T185
,	O
sequenced	B-T169
and	O
used	O
for	O
in situ hybridization	B-T063
to	O
localize	B-T082
messengers	B-UnknownType
and	O
analysed	O
by	O
a	O
phylogenetic survey	B-T062
to	O
shed	O
light	O
on	O
its	O
homology	B-T080
with	O
reptilian	B-T014
caspases	B-T116
.	O
Results	O
demonstrated	O
that:	O
(1)	O
the	O
follicle	B-T023
cells	B-T025
expressed	B-T045
a	O
caspase	B-T116
of	O
the	O
3/7	O
group	O
and	O
the	O
mRNA	B-T114
for	O
caspase 3	B-T116
was	O
transcribed	B-T045
in	O
the	O
stem phase	B-T079
and	O
was	O
completely	O
translated	B-T044
during	O
cell differentiation	B-T043
;	O
(2)	O
the	O
proform protein	B-T116
was	O
stored	O
during	O
the	O
differentiated (nurse) stage	B-T080
and	O
activated	B-T045
at	O
the	O
end	O
of	O
previtellogenesis	B-T042
provoking	O
the	O
degeneration of cells	B-T046
;	O
(3)	O
the	O
predicted	O
protein sequence	B-T087
,	O
although	O
partial,	O
had	O
a	O
strong	O
similarity	O
with	O
the	O
known	O
reptilian	B-T014
caspases 3	B-T116
.	O
The	O
epithelial cells	B-T025
of	O
the	O
ovarian follicle	B-T023
,	O
therefore,	O
do	O
not	O
employ	O
caspase 3	B-T116
during	O
the	O
nurse stage	B-T080
but,	O
instead,	O
prepare	O
for	O
apoptosis	B-T043
long	O
before	O
the	O
process	O
actually	O
begins.	O
The	O
relevance	O
of	O
this	O
strategy	O
is	O
discussed.	O

Increased	B-T081
acute	B-T079
mortality	B-T081
with	O
chemoradiotherapy	B-T061
for	O
locally advanced head and neck cancer	B-T191
in	O
patients	B-T101
≥70	O
years	B-T079
Concurrent chemoradiotherapy	B-T061
(	O
CRT	B-T061
)	O
is	O
the	O
standard of care	B-T061
for	O
many	O
sites	B-T082
of	O
locally advanced head and neck squamous cell carcinomas	B-T191
(	O
LAHNC	B-T191
).	O
However,	O
on	O
meta-analysis	B-T062
,	O
the	O
addition	O
of	O
chemotherapy	B-T061
did	O
not	O
improve	O
survival	B-T169
for	O
patients	B-T101
>70	O
years	B-T079
.	O
We	O
hypothesized	O
that	O
elderly	B-T098
patients	B-T101
treated	B-T169
with	O
CRT	B-T061
would	O
have	O
increased	B-T081
toxicity	B-T037
without	O
similar	O
improvements	B-T077
in	O
survival	B-T169
.	O
A	O
single-institution	B-T093
,	O
IRB-approved	B-T170
retrospective study	B-T062
took	O
place	O
from	O
2005	O
to	O
2012	O
including	O
369	O
patients	B-T101
treated	B-T169
with	O
CRT	B-T061
for	O
LAHNC	B-T191
.	O
Multivariate models	B-T081
for	O
death	B-T033
at	O
3	O
months	B-T079
and	O
death	B-T033
over	O
time	B-T079
were	O
developed	O
using	O
logistic regression	B-T062
and	O
Cox modeling	B-T062
,	O
respectively.	O
Patients	B-T101
≥70	O
years	B-T079
were	O
treated	B-T169
less	O
often	O
with	O
concurrent	B-T079
cisplatin	B-T121
dosed	O
every	O
3	O
weeks	B-T079
(25.5%	O
vs.	O
71.4%,	O
respectively)	O
and	O
more	O
often	O
with	O
weekly	B-T079
carboplatin	B-T109
(31.9%	O
vs.	O
3.4%)	O
than	O
patients	B-T101
<70	O
years	B-T079
(n=322;	O
p<0.001).	O
Patients	B-T101
≥70	O
years	B-T079
experienced	O
increased	B-T081
toxicity	B-T037
during	O
treatment	B-T061
with	O
more	O
frequently	O
hospitalizations	B-T058
(36.2%	O
vs.	O
21.1%;	O
p=0.02)	O
and	O
a	O
lower	O
rate	O
of	O
PEG removal	B-T061
at	O
last	O
follow-up	B-T058
or	O
death	B-T033
(77.1%	O
vs.	O
92.9%;	O
p=0.004).	O
A	O
higher	O
proportion	B-T081
of	O
patients	B-T101
≥70	O
years	B-T079
died	O
within	O
3	O
months	B-T079
(12.8%	O
vs.	O
2.8%;	O
p=0.001)	O
following	O
CRT	B-T061
.	O
Patients	B-T101
≥70	O
had	O
an	O
increased	B-T081
risk	B-T078
of	O
death	B-T033
at	O
3	O
months	B-T079
following	O
CRT	B-T061
(	O
odds ratio	B-T081
5.19,	O
95%	O
CI	B-T081
1.64-16.41;	O
p=0.005)	O
and	O
worse	O
survival	B-T169
over	O
time	B-T079
(	O
hazard ratio	B-T081
2.30,	O
95%	O
CI	B-T081
1.34-3.93;	O
p=0.002).	O
Patients	B-T101
≥70	O
years	B-T079
were	O
more	O
often	O
treated	B-T169
with	O
less	O
toxic	B-T080
chemotherapy	B-T061
,	O
yet	O
experienced	O
higher	O
rates	B-T081
of	O
hospitalization	B-T058
during	O
treatment	B-T061
and	O
increased	B-T081
rates	B-T081
of	O
acute	B-T079
mortality	B-T081
following	O
CRT	B-T061
.	O
The	O
efficacy	B-T080
of	O
chemoradiotherapy	B-T061
for	O
elderly	B-T098
patients	B-T101
should	O
be	O
evaluated	O
in	O
a	O
prospective setting	B-T080
.	O

Food security	B-T080
and	O
the	O
nutritional status	B-T033
of	O
children	B-T100
in	O
foster care	B-T073
:	O
new	O
horizons	O
in	O
the	O
protection	O
of	O
a	O
fragile	O
population	O
The	O
nutritional status	B-T033
of	O
foster children	B-T099
,	O
the	O
quality	B-T080
of	O
daily menus	B-T168
in	O
group homes	B-T073
and	O
the	O
Food Security	B-T080
inside	O
these	O
organizations	B-T092
have	O
been	O
poorly	O
studied	O
and	O
this	O
study	B-T062
means	O
to	O
investigate	O
them.	O
A	O
sample	O
of	O
125	O
children	B-T100
,	O
ranging	O
in	O
age	O
from	O
0-17	O
years,	O
among	O
seven	O
group homes	B-T073
(	O
group A	B-UnknownType
)	O
was	O
compared	O
with	O
121	O
children	B-T100
of	O
the	O
general population	B-T098
we	O
(	O
group B	B-UnknownType
).	O
To	O
evaluate	O
nutritional status	B-T033
,	O
BMI percentiles	B-T033
were	O
used.	O
Mean	B-T081
percentiles	B-T081
of	O
both	O
groups	B-UnknownType
were	O
compared	O
through	O
statistical analysis	B-T062
.	O
Both	O
nutritional	B-T033
and	O
caloric daily distributions	B-T033
in	O
each	O
organization	B-T092
were	O
obtained	O
using	O
the	O
24-hour	O
recall method	B-T170
.	O
A	O
specific	O
questionnaire	B-T170
was	O
administered	O
to	O
evaluate	O
Food Security	B-T080
.	O
From	O
the	O
analysis	B-T062
of	O
mean	B-T081
BMI	B-T201
-for-	O
age	B-T032
(or	O
height-for-length)	O
percentiles	B-T081
,	O
did	O
not	O
observe	O
statistically	O
significant	O
differences	B-T033
between	O
group A	B-UnknownType
and	O
group B	B-UnknownType
.	O
The	O
average	B-T081
daily	B-T079
nutrient	B-T033
and	O
calorie distribution	B-T033
in	O
group homes	B-T073
proves	O
to	O
be	O
nearly optimal	B-T033
with	O
the	O
exception	O
of	O
a	O
slight	O
excess	B-T080
in	O
proteins	B-T168
and	O
a	O
slight	O
deficiency	B-T169
in	O
PUFAs	B-T109
.	O
Moreover,	O
a	O
low intake	B-T033
of	O
iron	B-T033
and	O
calcium	B-T201
was	O
revealed.	O
All	O
organizations	B-T092
obtained	O
a	O
"	O
High Food Security	B-T080
"	O
profile.	O
Nutritional conditions	B-T033
of	O
foster children	B-T099
are	O
no	O
worse	O
than	O
that	O
of	O
children	B-T100
of	O
the	O
general population	B-T098
.	O
Foster care	B-T073
provides	O
the	O
necessary conditions	B-T080
to	O
support	O
their	O
growth	B-T040
.	O

Incontinence	B-T047
-associated	O
dermatitis	B-T047
:	O
reducing	B-T080
adverse events	B-T046
Incontinence	B-T047
-associated	O
dermatitis	B-T047
(	O
IAD	B-T047
)	O
is	O
a	O
common	O
problem	B-T033
in	O
patients	B-T101
with	O
faecal	B-T047
and/or	O
urinary incontinence	B-T046
.	O
Urine	B-T031
alters	O
the	O
normal	O
skin	B-T022
flora	B-T033
and	O
increases	O
permeability	B-T070
of	O
the	O
stratum corneum	B-T024
and	O
faecal	B-T031
enzymes	B-T116
on	O
the	O
skin	B-T022
contribute	O
to	O
skin damage	B-T184
.	O
Faecal	B-T031
bacteria	B-T007
can	O
then	O
penetrate	B-T169
the	O
skin	B-T022
,	O
increasing	O
the	O
risk	B-T078
of	O
secondary infection	B-T047
.	O
However,	O
IAD	B-T047
can	O
be	O
prevented	B-T061
and	O
healed	B-T169
with	O
timely	O
and	O
appropriate	B-T080
skin cleansing	B-T061
and	O
skin protection	B-T201
.	O
This	O
includes	O
appropriate	B-T080
use	O
of	O
containment devices	B-T074
.	O
This	O
article	O
also	O
looks	O
at	O
HARTMANN incontinence pads	B-T074
that	O
have	O
been	O
developed	O
to	O
absorb	O
the	O
fluids	B-T167
that	O
cause	O
IAD	B-T047
and	O
maintain	O
the	O
skin's	B-T022
acidic pH	B-T081
.	O
The	O
acidic pH	B-T081
of	O
the	O
skin	B-T022
contributes	O
to	O
its	O
barrier function	B-T042
and	O
defence	O
against	O
infection	B-T046
.	O
Therefore,	O
maintaining	O
an	O
acidic pH	B-T081
will	O
help	O
protect	O
the	O
skin	B-T022
from	O
damage	B-T169
.	O

Feasibility	B-T062
of	O
a	O
transition	B-T052
intervention	B-T061
aimed	B-T078
at	O
adolescents	B-T100
with	O
chronic illness	B-T047
International	B-T078
guidelines	B-T170
recommend	O
planned	O
and	O
structured	O
transition	B-T052
programmes	B-T058
for	O
adolescents	B-T100
with	O
chronic illness	B-T047
because	O
inadequate	B-T080
transition	B-T052
may	O
lead	O
to	O
poor disease control	B-T033
and	O
risk	B-T078
of	O
lacking	B-T080
outpatient follow-up	B-T058
.	O
To	O
investigate	B-T169
the	O
feasibility	B-T062
of	O
a	O
transition	B-T052
intervention	B-T061
aimed	B-T078
at	O
adolescents	B-T100
with	O
chronic illness	B-T047
focusing	B-T041
on	O
declines	B-T055
,	O
drop-outs	B-T098
,	O
no-shows	B-T081
and	O
advantages	B-T078
and	O
disadvantages	B-T078
of	O
participating	B-T169
.	O
We	O
invited	O
236	O
adolescents	B-T100
(12-20	O
years)	O
with	O
juvenile idiopathic arthritis	B-T047
(	O
JIA	B-T047
)	O
to	O
participate	B-T169
in	O
a	O
randomised controlled trial	B-T062
(	O
RCT	B-T062
)	O
transition	B-T052
intervention	B-T061
.	O
Reasons	B-T078
for	O
decline	B-T055
and	O
drop-outs	B-T098
were	O
calculated	B-T169
.	O
Adolescents	B-T100
'	O
experiences	B-T041
of	O
advantages	B-T078
and	O
disadvantages	B-T078
of	O
participating	B-T169
and	O
reasons	B-T078
for	O
no-shows	B-T081
were	O
investigated	B-T169
through	O
focus groups	B-T096
and	O
telephone interviews	B-T062
,	O
which	O
were	O
analysed	B-T062
using	O
thematic	B-T062
analysis	B-T062
.	O
One	O
hundred	O
and	O
twenty	O
of	O
the	O
236	O
eligible	O
patients	B-T101
declined to participate	B-T055
in	O
the	O
intervention	B-T061
and	O
20%	O
dropped out	B-T098
during	O
the	O
intervention	B-T061
.	O
Unspecified	B-T080
declines	B-T055
and	O
practical issues	B-T033
were	O
the	O
most	O
common	B-T081
reason	B-T078
to	O
decline	B-T055
,	O
and	O
'	O
do not wish to continue	B-T053
'	O
was	O
the	O
most	O
common	B-T081
reason	B-T078
to	O
drop-out	B-T098
.	O
Reasons	B-T078
for	O
no-shows	B-T081
were	O
forgetting	B-T048
and	O
being	O
too	O
busy.	O
Advantages	B-T078
of	O
participating	B-T169
were	O
stated	O
as	O
'	O
participating	B-T169
without	B-T080
parents	B-T099
',	O
'	O
trust	B-T054
and	O
confidentiality	B-T078
',	O
'being	O
able	O
to	O
set	O
the	O
agenda	B-T170
'	O
and	O
'	O
responsiveness	B-T169
'.	O
Disadvantages	B-T078
were	O
'	O
unclear	B-T033
aim	B-T078
of	O
the	O
study	B-T062
',	O
'meeting	O
others	O
with	O
JIA	B-T047
',	O
'too	O
few	O
conversations	B-T054
'	O
and	O
'	O
transport	B-T056
issues	B-T033
'.	O
Many	O
adolescents	B-T100
had	O
difficulties	B-T033
understanding	B-T041
the	O
aim	B-T078
of	O
the	O
intervention	B-T061
.	O
However,	O
most	O
participants	B-T100
appreciated	O
the	O
conversations	B-T054
about	O
identity	O
as	O
well	O
as	O
the	O
trust	B-T054
and	O
confidentiality	B-T078
in	O
the	O
communication	B-T054
.	O
In	O
the	O
future,	O
adolescents	B-T100
should	O
be	O
offered	O
more	O
individually	O
organised	O
programmes	B-T058
according	O
to	O
their	O
preferences	B-T078
and	O
needs	O
in	O
cooperation	B-T054
with	O
parents	B-T099
and	O
health care providers	B-T097
.	O

High-Throughput Analysis	B-T060
of	O
the	O
IgG N-Glycome	B-T116
by	O
UPLC	B-T059
-	O
FLR	B-T074
As	O
biological	B-T080
and	O
clinical	B-T080
relevance	B-T080
of	O
glycosylation	B-T070
is	O
becoming	O
more	O
apparent	B-T078
,	O
interest	O
in	O
large scale studies	B-T062
of	O
the	O
glycome	B-T109
is	O
growing.	O
Glycans	B-T109
attached	O
to	O
immunoglobulin G	B-T116
(	O
IgG	B-T116
)	O
were	O
shown	O
to	O
be	O
essential	B-T080
for	O
its	O
function	B-T039
and	O
IgG	B-T116
glycosylation	B-T070
was	O
shown	O
to	O
change	B-T169
with	O
various	O
processes	B-T067
,	O
making	O
IgG	B-T116
one	O
of	O
the	O
most	O
studied	O
glycoproteins	B-T116
.	O
Many	O
approaches	B-T082
including	O
liquid chromatography	B-T059
,	O
capillary gel electrophoresis	B-T059
,	O
and	O
mass spectrometry	B-T059
were	O
developed	O
to	O
study	B-T062
IgG	B-T116
glycosylation	B-T070
.	O
Generation	B-T052
of	O
high-quality	B-T080
glycomics	B-T090
data	B-T078
in	O
a	O
high-throughput	B-T170
fashion	O
requires	O
reproducible	B-T081
and	O
robust	B-T080
sample preparation	B-T059
and	O
accurate	B-T080
and	O
reliable	O
quantitative analysis	B-UnknownType
.	O
This	O
chapter	B-T078
presents	O
a	O
protocol	B-T170
for	O
an	O
optimized	O
and	O
high-throughput	B-T170
IgG N-glycan	B-T116
release	B-T169
,	O
fluorescent labeling	B-T059
and	O
cleanup	B-T169
,	O
and	O
analysis	B-T062
of	O
fluorescently labeled	B-T080
IgG N-glycans	B-T116
by	O
hydrophilic interaction liquid chromatography	B-T059
(	O
HILIC	B-T059
)	O
on	O
an	O
ultra performance liquid chromatography	B-T059
(	O
UPLC	B-T059
)	O
system	O
with	O
fluorescence	B-T070
(	O
FLR	B-T074
)	O
detection	B-T061
.	O

Biomimetic	B-T073
whitlockite	B-T122
inorganic	B-T077
nanoparticles	B-T073
-mediated	O
in situ	B-T082
remodeling	B-T042
and	O
rapid	O
bone regeneration	B-T042
Bone remodeling	B-T042
process	O
relies	O
on	O
complex	B-T080
signaling pathway	B-T044
between	O
osteoblasts	B-T025
and	O
osteoclasts	B-T025
and	O
control	O
mechanisms	B-T169
to	O
achieve	O
homeostasis	B-T038
of	O
their	O
growth	B-T043
and	O
differentiation	B-T043
.	O
Despite	O
previous	O
achievements	O
in	O
understanding	O
complicated	O
signaling pathways	B-T044
between	O
cells	B-T025
and	O
bone	B-T023
extracellular matrices	B-T024
during	O
bone remodeling	B-T042
process,	O
a	O
role	O
of	O
local	O
ionic	B-T196
concentration	B-T081
remains	O
to	O
be	O
elucidated	B-T052
.	O
Here,	O
we	O
demonstrate	O
that	O
synthetic	B-T052
whitlockite	B-T122
(	O
WH: Ca18Mg2(HPO4)2(PO4)12)	B-T122
nanoparticles	B-T073
can	O
recapitulate	B-T169
early-stage	O
of	O
bone regeneration	B-T042
through	O
stimulating	B-T070
osteogenic differentiation	B-T043
,	O
prohibiting	B-T169
osteoclastic	B-T025
activity	B-T052
,	O
and	O
transforming	B-T043
into	O
mechanically	O
enhanced	O
hydroxyapatite	B-T197
(	O
HAP	B-T197
)-	O
neo bone tissues	B-T024
by	O
continuous	O
supply	O
of	O
PO4(3-)	B-T121
and	O
Mg(2+)	B-T121
under	O
physiological	B-T169
conditions	B-T080
.	O
In	O
addition,	O
based	O
on	O
their	O
structural analysis	B-T062
,	O
the	O
dynamic	O
phase	B-T079
transformation	B-T043
from	O
WH	B-T122
into	O
HAP	B-T197
contributed	O
as	O
a	O
key	O
factor	B-T169
for	O
rapid	O
bone regeneration	B-T042
with	O
denser	B-T080
hierarchical	B-T169
neo-bone	B-T023
structure	B-T082
.	O
Our	O
findings	B-T033
suggest	O
a	O
groundbreaking	O
concept	O
of	O
'	O
living	B-T078
bone	B-T023
minerals	B-T197
'	O
that	O
actively	B-T169
communicate	B-T043
with	O
the	O
surrounding	O
system	O
to	O
induce	B-T169
self-healing	B-T042
,	O
while	O
previous	O
notions	O
about	O
bone	B-T023
minerals	B-T197
have	O
been	O
limited	O
to	O
passive	B-T080
products	O
of	O
cellular	B-T025
mineralization	B-T042
.	O

Is	O
the	O
inactivation	B-T169
of	O
dentin	B-T031
proteases	B-T116
by	O
crosslinkers	B-T130
reversible	B-T169
?	O
Inactivation	B-T169
of	O
dentin	B-T031
proteases	B-T116
by	O
crosslinkers	B-T130
has	O
been	O
suggested	B-T078
as	O
a	O
way	O
to	O
prevent	B-T080
the	O
degradation	B-T044
of	O
dentin	B-T031
collagen	B-T116
in	O
the	O
hybrid	B-T116
layer	B-T082
.	O
However,	O
it	O
is	O
not known	B-T080
if	O
the	O
inhibition	B-T052
is	O
reversible	B-T169
.	O
The	O
aim	B-T078
of	O
this	O
study	B-T062
was	O
to	O
evaluate	B-T052
the	O
inactivation	B-T169
effect	B-T080
of	O
various	O
crosslinkers	B-T130
on	O
dentin	B-T031
protease	B-T116
activity	B-T044
over	O
a	O
period	B-T079
of	O
6	O
months.	O
Demineralized dentin beams	B-T122
(1×2×6mm,	O
n=10/group)	O
were	O
treated with	B-T169
(1)	O
1%	O
glutaraldehyde	B-T109
(	O
GA1	B-T109
),	O
(2)	O
5%	O
glutaraldehyde	B-T109
(	O
GA5	B-T109
),	O
(3)	O
1%	O
grape seed extract	B-T109
(	O
GS1	B-T109
),	O
(4)	O
5%	O
grape seed extract	B-T109
(	O
GS5	B-T109
),	O
(5)	O
10%	O
sumac berry extract	B-T002
(	O
S	B-T002
),	O
(6)	O
20μM curcumin	B-T109
(	O
CR20	B-T109
),	O
and	O
(7)	O
200μM	O
curcumin	B-T109
(	O
CR200	B-T109
)	O
for	O
5min.	O
Untreated	B-T033
beams	B-T122
served	O
as	O
control	B-T096
.	O
The	O
beams	B-T122
were	O
incubated	B-T059
up	O
to	O
6	O
months	O
and	O
incubation media	B-T130
were	O
used	O
to	O
analyze	B-T062
solubilized	B-T080
telopeptide	B-T116
(	O
ICTP	B-T116
and	O
CTX	B-T116
)	O
fragments	B-T116
as	O
indicators	B-T169
of	O
MMP	B-T116
-	O
and	O
cathepsin K	B-T116
-mediated	O
degradation	B-T044
after	O
1,	O
3	O
and	O
6	O
months	O
of	O
incubation	B-T059
.	O
The	O
relative	B-T080
MMP	B-T116
activity	B-T044
of	O
dentin beams	B-T122
was	O
tested	O
using	O
a	O
generic	B-T077
MMP	B-T116
assay	B-T059
.	O
Data	B-T078
were	O
analyzed	B-T062
using	O
repeated-measures	B-T062
ANOVA	B-T081
,	O
α=0.05.	O
All	O
treated	B-T169
groups	B-T078
showed	O
significant	B-T078
decrease	B-T081
in	O
CTX	B-T116
release	O
(32.2-469.5pg/mg	O
dentin	B-T031
)	O
and	O
ICTP	B-T116
(1.8-47.6ng/mg	O
dentin	B-T031
)	O
fragments	B-T116
during	O
the	O
first	O
month	O
of	O
incubation	B-T059
compared	B-T052
to	O
control	B-T096
(1159pg/mg	O
and	O
72.9ng/mg	O
dentin	B-T031
,	O
respectively).	O
GA5	B-T109
,	O
GS5	B-T109
and	O
CR200	B-T109
maintained	B-T169
their	O
inhibitory	B-T052
effect	B-T080
during	O
6-month	O
incubation	B-T059
.	O
The	O
results	B-T034
were	O
confirmed	O
by	O
dry mass loss	B-T067
and	O
relative	B-T080
MMP	B-T116
activity	B-T044
following	O
6	O
months.	O
The	O
results	B-T033
of	O
this	O
study	B-T062
indicate	O
that	O
the	O
long-term effect	B-T067
is	O
both	O
crosslinker	B-T130
and	O
dose dependent	B-T081
.	O

Inhibition	B-T044
of	O
STEP61	B-T116
ameliorates	B-T080
deficits	B-T080
in	O
mouse	B-T015
and	O
hiPSC	B-T025
-based	O
schizophrenia	B-T048
models	B-T050
The	O
brain	B-T023
-	O
specific	B-T080
tyrosine phosphatase	B-T116
,	O
STEP	B-T116
(	O
STriatal-Enriched protein tyrosine Phosphatase	B-T116
)	O
is	O
an	O
important	O
regulator	B-T077
of	O
synaptic function	B-T043
.	O
STEP	B-T116
normally	O
opposes	O
synaptic	B-T030
strengthening	B-T080
by	O
increasing	B-T081
N-methyl D-aspartate glutamate receptor	B-T116
(	O
NMDAR	B-T116
)	O
internalization	B-T067
through	O
dephosphorylation	B-T044
of	O
GluN2B	B-T116
and	O
inactivation	B-T044
of	O
the	O
kinases	B-T116
extracellular signal-regulated kinase 1	B-T116
/	O
2	B-T116
and	O
Fyn	B-T116
.	O
Here	O
we	O
show	O
that	O
STEP61	B-T116
is	O
elevated	B-T080
in	O
the	O
cortex	B-T023
in	O
the	O
Nrg1(+/-)	B-T028
knockout	B-T050
mouse model	B-T050
of	O
schizophrenia	B-T048
(	O
SZ	B-T048
).	O
Genetic	B-T169
reduction	B-T061
or	O
pharmacological	B-T169
inhibition	B-T052
of	O
STEP	B-T116
prevents	B-T169
the	O
loss	O
of	O
NMDARs	B-T116
from	O
synaptic membranes	B-T026
and	O
reverses	O
behavioral deficits	B-T048
in	O
Nrg1(+/-)	B-T028
mice	B-T015
.	O
STEP61 protein	B-T116
is	O
also	O
increased	B-T081
in	O
cortical	B-T023
lysates	B-T072
from	O
the	O
central nervous system	B-T022
-	O
specific	B-T080
ErbB2	B-T116
/	O
4	B-T116
mouse model	B-T050
of	O
SZ	B-T048
,	O
as	O
well	O
as	O
in	O
human induced pluripotent stem cell	B-T025
(	O
hiPSC	B-T025
)-derived	O
forebrain	B-T023
neurons	B-T025
and	O
Ngn2	B-T028
-	O
induced	B-T169
excitatory neurons	B-T025
,	O
from	O
two	O
independent	B-T169
SZ	B-T048
patient	B-T101
cohorts	B-T098
.	O
In	O
these	O
selected	B-T052
SZ	B-T048
models	B-T050
,	O
increased	B-T081
STEP61	B-T116
protein levels	B-T059
likely	O
reflect	O
reduced	B-T080
ubiquitination	B-T044
and	O
degradation	B-T044
.	O
These	O
convergent	B-T080
findings	B-T033
from	O
mouse	B-T015
and	O
hiPSC	B-T025
SZ	B-T048
models	B-T050
provide	B-T052
evidence	B-T078
for	O
STEP61	B-T116
dysfunction	B-T077
in	O
SZ	B-T048
.Molecular	O
Psychiatry	O
advance	O
online	O
publication,	O
18	O
October	O
2016;	O
doi:10.1038/mp.2016.163.	O

Incident	B-T067
fracture	B-T037
associated with	B-T080
increased	B-T081
risk	B-T078
of	O
mortality	B-T081
even	O
after	O
adjusting	O
for	O
frailty	B-T033
status	B-T080
in	O
elderly	B-T098
Japanese	B-T098
men	B-T098
:	O
the	O
Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) Cohort Study	B-T081
Frail	B-T033
elderly	B-T098
individuals	B-T098
have	O
elevated	B-T080
risks	B-T078
of	O
both	O
fracture	B-T037
and	O
mortality	B-T081
.	O
We	O
found	O
that	O
incident	B-T067
fractures	B-T037
were	O
associated with	B-T080
an	O
increased	B-T081
risk	B-T078
of	O
death	B-T033
even	O
after	O
adjusting	O
for	O
pre-fracture	B-T037
frailty	B-T033
status	B-T080
as	O
represented	O
by	O
physical performance tests	B-T060
and	O
laboratory tests	B-T059
for	O
common	O
geriatric	B-T080
diseases	B-T047
in	O
community-dwelling	B-T056
elderly	B-T098
Japanese	B-T098
men	B-T098
.	O
While	O
fractures	B-T037
reportedly	O
increase	B-T169
the	O
risk	B-T078
of	O
mortality	B-T081
,	O
frailty	B-T033
may	O
complicate	B-T169
this	O
association	B-T080
,	O
generating	O
a	O
false-positive result	B-T033
.	O
We	O
evaluated	B-T058
this	O
association	B-T080
after	O
adjusting	O
for	O
pre-fracture	B-T037
levels	B-T080
of	O
frailty	B-T033
.	O
We	O
examined	B-T033
1998	O
community-dwelling	B-T056
ambulatory	B-T169
men	B-T098
aged	B-T032
≥65	O
years	B-T079
at	O
baseline	B-T081
in	O
the	O
Fujiwara-kyo Osteoporosis Risk in Men Study	B-T081
for	O
frailty	B-T033
status	B-T080
as	O
represented	O
by	O
activities of daily living	B-T056
(	O
ADL	B-T056
),	O
physical performance tests	B-T060
(	O
grip strength	B-T081
,	O
one-foot standing balance with eyes open	B-T033
,	O
timed 10-m walk	B-T060
),	O
and	O
laboratory sera tests	B-T059
sera	B-T031
tests.	O
Participants	B-T098
were	O
then	O
followed	O
for	O
5	O
years	B-T079
for	O
incident	B-T067
clinical	B-T080
fractures	B-T037
and	O
death	B-T033
.	O
Effects of	B-T080
incident	B-T067
fracture	B-T037
on	O
death	B-T033
were	O
determined	O
by	O
Cox proportional hazards model	B-T081
with	O
the	O
first	O
fracture	B-T037
during	O
follow-up	B-T058
as	O
a	O
time-dependent predictor	B-T078
and	O
with	O
frailty status indices	B-T170
as	O
covariates	B-T080
.	O
We	O
identified	B-T080
111	O
fractures	B-T037
in	O
99	O
men	B-T098
and	O
138	O
deaths	B-T033
during	O
the	O
follow-up	B-T058
period	B-T079
(	O
median	B-T082
follow-up	B-T058
,	O
4.5	O
years	B-T079
).	O
Participants	B-T098
with	O
incident	B-T067
fractures	B-T037
did	O
not have significantly worse	B-T033
frailty	B-T033
statuses	B-T080
,	O
but	O
did	O
show	O
a	O
significantly	B-T078
higher	B-T080
cumulative	B-T080
mortality rate	B-T081
than	O
those	O
without	O
fractures	B-T037
(p	O
=	O
0.0047).	O
Age-adjusted	B-T081
hazard ratio	B-T081
(	O
HR	B-T081
)	O
of	O
death	B-T033
for	O
incident	B-T067
fracture	B-T037
was	O
3.57	O
(95	O
%	O
confidence interval	B-T081
:	O
2.05,	O
6.24).	O
When	O
adjusted	O
for	O
physical performance	B-T032
,	O
this	O
decreased	B-T081
to	O
2.77	O
(1.51,	O
5.06),	O
but	O
remained	O
significant	B-T078
.	O
The	O
HR	B-T081
showed	O
no significant change	B-T033
when	O
adjusted	O
for	O
laboratory test results	B-T034
(3.96	O
(2.26,	O
6.94)).	O
Exclusion	B-T052
of	O
deaths	B-T033
within	O
the	O
first	O
24	O
months	B-T079
of	O
follow-up	B-T058
did	O
not alter	B-T033
these	O
results	B-T034
.	O
Incident	B-T067
clinical	B-T080
fracture	B-T037
was	O
associated with	B-T080
an	O
elevated	B-T080
risk	B-T078
of	O
death	B-T033
independently	B-T033
of	O
pre-fracture	B-T037
levels	B-T080
of	O
frailty	B-T033
in	O
community-dwelling	B-T056
elderly	B-T098
men	B-T098
.	O

Total Energy Expenditure	B-T033
in	O
Obese	B-T047
Kuwaiti Primary School	B-T073
Children	B-T100
Assessed	B-T052
by	O
the	O
Doubly-Labeled Water Technique	B-T169
The	O
aim	O
of	O
this	O
pilot study	B-T062
was	O
to	O
assess	B-T052
body	O
composition	O
and	O
total energy expenditure	B-T033
(	O
TEE	B-T033
)	O
in	O
35	O
obese	B-T047
7-9	O
years	B-T079
old	O
Kuwaiti	B-T098
children	B-T100
(18	O
girls	B-T100
and	O
17	O
boys	B-T100
).	O
Total body water	B-T033
(	O
TBW	B-T033
)	O
and	O
TEE	B-T033
were	O
assessed	B-T052
by	O
doubly-labeled water technique	B-T169
.	O
TBW	B-T033
was	O
derived	O
from	O
the	O
intercept	B-T081
of	O
the	O
elimination rate	B-T033
of	O
deuterium	B-T196
and	O
TEE	B-T033
from	O
the	O
difference	B-T081
in	O
elimination rates	B-T033
of	O
(18)O	B-T121
and	O
deuterium	B-T196
.	O
TBW	B-T033
was	O
used	O
to	O
estimate	B-T081
fat-free mass	B-T033
(	O
FFM	B-T033
),	O
using	O
hydration	B-T067
factors	B-T169
for	O
different	O
ages	B-T032
and	O
gender	B-T032
.	O
Fat mass	B-T032
(	O
FM	B-T032
)	O
was	O
calculated	B-T052
as	O
the	O
difference	B-T081
between	O
body weight	B-T032
and	O
FFM	B-T033
.	O
Body weight	B-T032
was	O
not	O
statistically different	B-T081
but	O
TBW	B-T033
was	O
significantly higher	B-T080
(p	O
=	O
0.018)	O
in	O
boys	B-T100
(44.9%	O
±	O
3.3%)	O
than	O
girls	B-T100
(42.4%	O
±	O
3.0%),	O
while	O
girls	B-T100
had	O
significantly higher	B-T080
estimated	B-T081
FM	B-T032
(45.2	O
±	O
3.9	O
weight	O
%	O
versus	O
41.6%	O
±	O
4.3%;	O
p	O
=	O
0.014).	O
TEE	B-T033
was	O
significantly higher	B-T080
in	O
boys	B-T100
(2395	O
±	O
349	O
kcal/day)	O
compared	O
with	O
girls	B-T100
(1978	O
±	O
169	O
kcal/day);	O
p	O
=	O
0.001.	O
Estimated	B-T081
physical activity level	B-T033
(	O
PAL	B-T033
)	O
was	O
significantly higher	B-T080
in	O
boys	B-T100
;	O
1.61	O
±	O
0.167	O
versus	O
1.51	O
±	O
0.870;	O
p	O
=	O
0.034.	O
Our	O
results	B-T169
provide	O
the	O
first	O
dataset	B-T170
of	O
TEE	B-T033
in	O
7-9	O
years	B-T079
old	O
obese	B-T047
Kuwaiti	B-T098
children	B-T100
and	O
highlight	O
important	O
gender differences	B-T032
to	O
be	O
considered	O
during	O
the	O
development	O
of	O
school based interventions	B-T058
targeted	O
to	O
combat	O
childhood obesity	B-T047
.	O

Mesenchymal stromal cells	B-T025
in	O
clinical	B-T080
kidney transplantation	B-T061
:	O
how	O
tolerant	B-T169
can	O
it	O
be?	O
Progress	B-T169
in	O
the	O
improvement	B-T077
of	O
short-term	B-T079
and	O
long-term	B-T079
outcomes	B-T080
of	O
kidney transplantation	B-T061
seems	O
to	O
have	O
reached	O
a	O
plateau	B-T081
,	O
partially	O
due	O
to	O
consequences of	B-T169
very	O
efficient	B-T080
,	O
but	O
nonspecific	B-T078
immunosuppressive drugs	B-T121
.	O
In	O
recent	O
years,	O
various	O
forms	O
of	O
cell therapy	B-T061
,	O
including	O
the	O
use	O
of	O
mesenchymal stromal cells	B-T025
,	O
have	O
been	O
put	O
forward	O
as	O
an	O
alternative	B-T077
strategy	B-T170
for	O
more	O
defined	O
therapy	B-T061
.	O
It	O
is	O
thought	O
that	O
these	O
therapies	B-T061
will	O
not	O
only	O
allow	O
controlled	B-T169
tapering	B-T058
of	O
immunosuppressive medication	B-T121
,	O
but	O
might	O
bring	O
us	O
also	O
closer	O
to	O
the	O
ambition	B-T041
of	O
generating	B-T052
donor	B-T098
-specific	O
immune regulation	B-T040
and	O
tolerance	B-T046
.	O
Different	O
forms	O
of	O
alloimmunity	B-T042
,	O
including	O
direct	B-T080
,	O
indirect	B-T080
and	O
semi-direct	B-T080
alloantigen	B-T129
presentation	O
have	O
to	O
be	O
controlled	O
before	O
donor	B-T098
-specific	O
immune regulation	B-T040
can	O
be	O
reached.	O
Several	O
mechanisms	B-T169
have	O
been	O
described	O
how	O
mesenchymal stromal cells	B-T025
can	O
affect	O
alloimmunity	B-T042
.	O
Especially,	O
the	O
interaction	B-T043
with	O
professional	O
antigen presenting cells	B-T025
,	O
like	O
dendritic cells	B-T025
,	O
is	O
of	O
critical	B-T080
importance	B-T080
.	O
This	O
review	O
will	O
discuss	O
the	O
current	B-T079
status	B-T080
of	O
ongoing	O
clinical trials	B-T062
with	O
mesenchymal stromal cells	B-T025
in	O
kidney transplantation	B-T061
and	O
specifically	O
concentrate	O
on	O
the	O
possibilities	O
and	O
impossibilities	O
of	O
how	O
these	O
therapeutic strategies	B-T061
can	O
contribute	B-T052
to	O
control	B-T080
of	O
the	O
different	O
forms	O
of	O
alloreactivity	B-T042
operation	O
in	O
organ transplantation	B-T061
.	O

Facilitating factors	B-T169
and	O
barriers	B-T080
to	O
malaria	B-T047
research	B-T062
utilization	B-T169
for	O
policy development	B-T064
in	O
Malawi	B-T083
Research	B-T062
on	O
various	O
determinants	B-T169
of	O
health	B-T078
is	O
key	O
in	O
providing	B-T052
evidence	B-T078
for	O
policy development	B-T064
,	O
thereby	O
leading	O
to	O
successful	B-T080
interventions.	O
Utilization	B-T169
of	O
research	B-T062
is	O
an	O
intricate	B-T080
process	B-T067
requiring	O
an	O
understanding	O
of	O
contextual factors	B-UnknownType
.	O
The	O
study	O
was	O
conducted	O
to	O
assess	O
enhancing	B-T052
factors	B-T169
and	O
barriers	B-T080
of	O
research	B-T062
utilization	B-T169
for	O
malaria	B-T047
policy development	B-T064
in	O
Malawi	B-T083
.	O
Qualitative	B-T080
research	B-T062
approach	O
was	O
used	O
through	O
in-depth	O
interviews	B-T052
with	O
39	O
key	O
informants	B-T098
that	O
included	O
malaria	B-T047
researchers	B-T097
,	O
policy makers	B-T097
,	O
programme	B-T057
managers	B-T097
,	O
and	O
key stakeholders	B-T098
.	O
Purposive sampling	B-T062
and	O
snowballing techniques	B-T062
were	O
used	O
in	O
identifying	B-T080
key	O
informants	B-T098
.	O
Interview	B-T052
transcripts	B-T170
were	O
entered	B-T080
in	O
QSR Nvivo 11 software	B-T073
for	O
coding	O
and	O
analysis	B-T062
.	O
Respondents	B-T098
identified	B-T080
global	B-T080
efforts	B-T052
as	O
key	O
in	O
advancing	O
knowledge translation	B-T062
,	O
while	O
local	B-T082
political will	B-T068
has	O
been	O
conducive	B-T080
for	O
research	B-T062
utilization	B-T169
.	O
Other	O
factors	B-T169
were	O
availability of	B-T169
research	B-T062
,	O
availability of	B-T169
diverse	O
local	B-T082
researchers	B-T097
and	O
stakeholders	B-T098
supporting	B-T077
knowledge translation	B-T062
.	O
While	O
barriers	B-T080
included:	O
lack	B-T080
of	O
platforms	O
for	O
researcher	B-T097
-	O
public	B-T092
engagement	B-T033
,	O
politics	B-T057
,	O
researchers'	B-T097
lack	B-T080
of	O
communication skills	B-T032
,	O
lack	B-T080
of	O
research	B-T062
collaborations	B-T054
,	O
funder driven research	B-T062
,	O
unknown	B-T080
World Health Organization	B-T093
policy	B-T170
position,	O
and	O
the	O
lack	B-T080
of	O
a	O
malaria	B-T047
research	B-T062
repository	B-T073
.	O
Overall,	O
the	O
study	O
identified	B-T080
facilitating factors	B-T169
to	O
malaria	B-T047
research	B-T062
utilization	B-T169
for	O
policy development	B-T064
in	O
Malawi	B-T083
.	O
These	O
factors	B-T169
need	O
to	O
be	O
systematically	B-T169
coordinated	B-T169
to	O
address	O
the	O
identified	B-T080
barriers	B-T080
and	O
improve	B-T033
on	O
malaria	B-T047
research	B-T062
utilization	B-T169
in	O
policy development	B-T064
.	O
Malaria	B-T047
research	B-T062
can	O
be	O
key	O
in	O
the	O
implementation	B-T052
of	O
evidence-based	B-T078
interventions	O
to	O
reduce	B-T080
the	O
malaria	B-T047
burden	B-T078
and	O
assist	O
in	O
the	O
paradigm shift	B-T062
from	O
malaria	B-T047
control	B-T169
to	O
elimination	B-T052
in	O
Malawi	B-T083
.	O

Altered	B-T169
interregional	B-T029
correlations	B-T080
between	O
serotonin transporter	B-T116
availability	B-T169
and	O
cerebral glucose	B-T109
glucose metabolism	B-T044
in	O
schizophrenia	B-T048
:	O
A	O
high-resolution PET	B-T060
study	O
using	O
[(11)C]DASB	B-T109
and	O
[(18)F]FDG	B-T109
The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
patterns	O
of	O
interregional	B-T029
correlations	B-T080
of	O
serotonin transporter	B-T116
(	O
SERT	B-T116
)	O
availability	B-T169
with	O
glucose metabolism	B-T044
using	O
7-Tesla magnetic resonance imaging	B-T060
(	O
MRI	B-T060
)	O
and	O
high-resolution positron emission tomography	B-T060
(	O
PET	B-T060
)	O
with	O
(11)C-3-amino-4-(2-dimethylaminomethylphenylthio)benzonitrile	B-T109
(	O
[(11)C]DASB	B-T109
)	O
and	O
[(18)F]fluorodeoxyglucose	B-T109
(	O
[(18)F]FDG	B-T109
)	O
in	O
antipsychotic-free patients	B-T101
with	O
schizophrenia	B-T048
in	O
order	O
to	O
shed	O
new	O
light	O
on	O
the	O
disrupted	B-T080
functional connectivity	B-T169
in	O
schizophrenia	B-T048
.	O
Nineteen	O
patients	B-T101
with	O
schizophrenia	B-T048
and	O
18	O
healthy controls	B-T080
underwent	O
high-resolution PET	B-T060
and	O
MRI	B-T060
.	O
The	O
binding potential	B-T067
(	O
BPND	B-T067
)	O
of	O
[(11)C]DASB	B-T109
and	O
standardized uptake value ratio	B-T081
(	O
SUVR	B-T081
)	O
of	O
[(18)F]FDG	B-T109
were	O
obtained.	O
In	O
SERT	B-T116
availability	B-T169
,	O
the	O
region of interest	B-T082
(	O
ROI	B-T082
)-based	O
analyses	B-T062
showed	O
no	O
significant	O
group	O
differences	O
in	O
any	O
region	B-T029
,	O
except	O
for	O
the	O
anterior	B-T082
hippocampus	B-T023
where	O
the	O
SERT	B-T116
availability	B-T169
was	O
lower	O
in	O
patients	B-T101
with	O
schizophrenia	B-T048
than	O
in	O
controls	B-T096
.	O
The	O
ROI	B-T082
-	O
and	O
voxel	B-T077
-based	O
analyses	B-T062
revealed	O
that	O
the	O
[(18)F]FDG	B-T109
SUVR values	B-T081
were	O
significantly	O
lower	O
in	O
patients	B-T101
than	O
in	O
controls	B-T096
in	O
the	O
right superior frontal gyrus	B-T023
and	O
medial part	B-T082
of	O
the	O
left superior frontal gyrus	B-T023
.	O
Regarding	O
the	O
interregional	B-T029
correlations	B-T080
of	O
[(11)C]DASB	B-T109
BPND	B-T067
with	O
[(18)F]FDG	B-T109
SUVR	B-T081
,	O
more	O
widespread	O
positive	B-T033
correlations	B-T080
across	O
the	O
brain regions	B-T029
were	O
observed	O
in	O
control subjects	B-T096
than	O
in	O
patients	B-T101
with	O
schizophrenia	B-T048
.	O
Notably,	O
the	O
patients	B-T101
and	O
control subjects	B-T096
showed	O
statistically	O
significant	O
differences	O
in	O
correlations	B-T080
between	O
the	O
SERT	B-T116
availability	B-T169
in	O
the	O
parietal	B-T023
and	O
temporal cortices	B-T023
and	O
the	O
glucose metabolism	B-T044
in	O
the	O
posterior cingulate cortex	B-T023
.	O
These	O
results	O
suggest	O
abnormal	B-T033
functional connectivity	B-T169
between	O
the	O
higher-order cortical regions	B-T029
in	O
schizophrenia	B-T048
and	O
a	O
possible	O
important	O
role	B-T077
of	O
the	O
posterior cingulate gyrus	B-T023
and	O
its	O
related	O
circuitry	B-UnknownType
in	O
the	O
pathophysiology	B-T169
of	O
schizophrenia	B-T048
.	O

Urticarial	B-T047
exanthema	B-T184
due	O
to	O
hepatitis B	B-T047
in	O
a	O
pregnant woman	B-T098
,	O
mimicking	O
a	O
polymorphic eruption	B-T047
of	O
pregnancy	B-T040
Hepatitis B virus (HBV) infection in pregnant women	B-T047
is	O
very	O
rare	O
in	O
western countries	B-T083
,	O
thus,	O
cutaneous	B-T082
manifestation of	B-T080
HBV infection	B-T047
may	O
be	O
confused	O
with	O
a	O
dermatosis	B-T047
specific	O
of	O
pregnancy	B-T040
.	O
We	O
report	O
a	O
39-year-old	O
woman	B-T098
who	O
presented	O
in	O
her	O
20th	O
week	O
of	O
pregnancy	B-T040
with	O
a	O
pruritic rash	B-T047
,	O
which	O
consisted	O
of	O
generalized	O
erythematous plaques	B-T033
,	O
some	O
of	O
them	O
with	O
a	O
purple centre	B-T033
.	O
Serology testing	B-T059
showed	O
acute HBV infection	B-T047
,	O
and	O
a	O
biopsy	B-T060
revealed	O
a	O
superficial	B-T082
and	O
interstitial perivascular inflammatory infiltrate	B-T033
of	O
lymphocytes	B-T025
and	O
eosinophils	B-T025
.	O
A	O
diagnosis	B-T033
of	O
exanthema	B-T184
due	O
to	O
acute hepatitis B infection	B-T047
was	O
established.	O
The	O
patient	B-T101
delivered	B-T033
a	O
clinically healthy boy	B-T033
,	O
who	O
was	O
given	O
the	O
first dose	B-T081
of	O
the	O
HBV vaccine	B-T061
and	O
intravenous specific immunoglobulin	B-T116
,	O
followed	O
by	O
the	O
second dose	B-T081
2	O
months	O
later,	O
and	O
did	O
not	O
get	O
infected	B-T033
with	O
HBV	B-T005
.	O
To	O
our	O
knowledge,	O
this	O
is	O
the	O
first	O
case	O
describing	O
HBV	B-T047
exanthema	B-T184
in	O
a	O
pregnant woman	B-T098
,	O
which	O
led	O
to	O
early	O
action	O
for	O
the	O
newborn	B-T100
,	O
avoiding	O
vertical transmission	B-T046
and	O
its	O
high	O
prevalence	O
of	O
cirrhosis	B-T047
and	O
hepatocellular carcinoma	B-T191
.	O

Determination	O
of	O
the	O
Mutant Prevention Concentration	B-T061
and	O
the	O
Mutant Selection Window	B-T081
of	O
Topical Antimicrobial Agents	B-T121
against	O
Propionibacterium acnes	B-T007
Determination	O
of	O
the	O
mutant prevention concentration	B-T061
(	O
MPC	B-T061
)	O
and	O
the	O
mutant selection window	B-T081
(	O
MSW	B-T081
)	O
of	O
antimicrobial agents	B-T121
used	O
to	O
treat	O
pathogenic	B-T001
bacteria	B-T007
is	O
important	O
in	O
order	O
to	O
apply	O
effective	O
antimicrobial	B-T121
therapies	B-T061
.	O
Here,	O
we	O
determined	O
the	O
MPCs	B-T061
of	O
the	O
major	O
topical antimicrobial agents	B-T121
against	O
Propionibacterium acnes	B-T007
and	O
Staphylococcus aureus	B-T007
which	O
cause	O
skin infections	B-T047
and	O
compared	O
their	O
MSWs	B-T081
.	O
Among	O
the	O
MPCs	B-T061
of	O
nadifloxacin	B-T109
and	O
clindamycin	B-T109
,	O
the	O
clindamycin	B-T109
MPC	B-T061
was	O
determined	O
to	O
be	O
the	O
lowest	B-T080
against	O
P. acnes	B-T007
.	O
In	O
contrast,	O
the	O
nadifloxacin	B-T109
MPC	B-T061
was	O
the	O
lowest	B-T080
against	O
S. aureus	B-T007
.	O
Calculations	B-T057
based	O
on	O
the	O
minimum inhibitory concentrations	B-T034
and	O
MPCs	B-T061
showed	O
that	O
clindamycin	B-T109
has	O
the	O
lowest	B-T080
MSW	B-T081
against	O
both	O
P. acnes	B-T007
and	O
S. aureus	B-T007
.	O
Nadifloxacin	B-T109
MSWs	B-T081
were	O
4-fold	O
higher	B-T080
against	O
P. acnes	B-T007
than	O
against	O
S. aureus	B-T007
.	O
It	O
is	O
more	O
likely	O
for	O
P. acnes	B-T007
to	O
acquire	O
resistance	B-T038
to	O
fluoroquinolones	B-T109
than	O
S. aureus	B-T007
.	O
Therefore,	O
topical application	B-T061
of	O
clindamycin	B-T109
contributes	O
very	O
little	O
to	O
the	O
emergence	O
of	O
resistant	B-T038
P. acnes	B-T007
and	O
S. aureus	B-T007
strains.	O

Total	O
colectomy	B-T061
for	O
colon perforation	B-T037
after	O
kayexalate	B-T109
administration	B-T061
:	O
a	O
case	O
report	O
and	O
literature review	B-T170
of	O
a	O
rare	B-T080
complication	B-T046
Kayexalate	B-T109
is	O
an	O
ion exchange resin	B-T121
that	O
is	O
commonly	O
used	O
to	O
acutely	O
treat	B-T061
patients	B-T101
with	O
hyperkalemia	B-T033
.	O
Bowel ulceration	B-T047
and	O
necrosis	B-T042
is	O
a	O
rare	B-T080
and	O
uncommonly	O
recognized	O
complication	B-T046
of	O
kayexalate	B-T109
administration	B-T061
.	O
More	O
often,	O
concomitant	B-T079
administration	B-T061
with	O
sorbitol	B-T109
is	O
reported	O
to	O
damage	B-T169
the	O
bowel	B-T023
;	O
however,	O
there	O
are	O
reports	O
of	O
kayexalate	B-T109
administration	B-T061
causing	O
bowel necrosis	B-T047
without	O
sorbitol	B-T109
.	O
We	O
present	O
a	O
case	O
of	O
a	O
critically ill	B-T047
patient	B-T101
who	O
underwent	O
total	O
colectomy	B-T061
for	O
colonic necrosis	B-T047
secondary	O
to	O
oral	B-T082
kayexalate	B-T109
administration	B-T061
that	O
was	O
not	O
recognized	O
until	O
late	O
in	O
the	O
pathologic process	B-T046
.	O
We	O
also	O
review the literature	B-T170
to	O
further	O
investigate	O
this	O
progression	B-T046
.	O

Total	B-T080
Arsenic	B-T121
,	O
Cadmium	B-T131
,	O
and	O
Lead	B-T131
Determination	B-T059
in	O
Brazilian Rice	B-T168
Samples	B-T167
Using	O
ICP-MS	B-T059
This	O
study	B-T062
is	O
aimed	O
at	O
investigating	B-T169
a	O
suitable	O
method	B-T170
for	O
rice	B-T168
sample	B-T167
preparation	B-T052
as	O
well	O
as	O
validating	B-T062
and	O
applying	B-T169
the	O
method	B-T170
for	O
monitoring	B-T169
the	O
concentration	B-T081
of	O
total	B-T080
arsenic	B-T121
,	O
cadmium	B-T131
,	O
and	O
lead	B-T131
in	O
rice	B-T168
by	O
using	O
Inductively Coupled Plasma Mass Spectrometry	B-T059
(	O
ICP-MS	B-T059
).	O
Various	O
rice	B-T168
sample	B-T167
preparation	B-T052
procedures	B-T169
were	O
evaluated.	O
The	O
analytical method	B-T170
was	O
validated	B-T062
by	O
measuring	B-T169
several	O
parameters	B-T033
including	O
limit of detection	B-T081
(	O
LOD	B-T081
),	O
limit of quantification	B-T081
(	O
LOQ	B-T081
),	O
linearity	B-T081
,	O
relative bias	B-T078
,	O
and	O
repeatability	B-T080
.	O
Regarding	O
the	O
sample	B-T167
preparation	B-T052
,	O
recoveries	B-T033
of	O
spiked samples	B-T167
were	O
within	O
the	O
acceptable range	B-T081
from	O
89.3	O
to	O
98.2%	O
for	O
muffle furnace	B-T073
,	O
94.2	O
to	O
103.3%	O
for	O
heating block	B-T074
,	O
81.0	O
to	O
115.0%	O
for	O
hot plate	B-T074
,	O
and	O
92.8	O
to	O
108.2%	O
for	O
microwave	B-T073
.	O
Validation	B-T062
parameters	B-T033
showed	O
that	O
the	O
method	B-T170
fits	O
for	O
its	O
purpose,	O
being	O
the	O
total	B-T080
arsenic	B-T121
,	O
cadmium	B-T131
,	O
and	O
lead	B-T131
within	O
the	O
Brazilian	O
Legislation	O
limits.	O
The	O
method	B-T170
was	O
applied	O
for	O
analyzing	B-T062
37	O
rice	B-T168
samples	B-T167
(including	O
polished	B-T168
,	O
brown	B-T168
,	O
and	O
parboiled	B-T168
),	O
consumed	O
by	O
the	O
Brazilian population	B-T081
.	O
The	O
total	B-T080
arsenic	B-T121
,	O
cadmium	B-T131
,	O
and	O
lead	B-T131
contents	B-T077
were	O
lower	O
than	O
the	O
established	O
legislative	B-T170
values	B-T080
,	O
except	O
for	O
total	B-T080
arsenic	B-T121
in	O
one	O
brown rice	B-T168
sample	B-T167
.	O
This	O
study	B-T062
indicated	O
the	O
need	O
to	O
establish	O
monitoring	B-T169
programs	B-T169
for	O
emphasizing	O
the	O
study	B-T062
on	O
this	O
type	B-T080
of	O
cereal	B-T168
,	O
aiming	O
at	O
promoting	O
the	O
Public Health	B-T170
.	O

Safety Precautions	B-T058
and	O
Operating Procedures	B-T170
in	O
an	O
(A)	O
BSL-4	B-T170
Laboratory	B-T073
:	O
1.	O
Biosafety Level 4	B-T170
Suit Laboratory	B-T073
Suite Entry and Exit Procedures	B-T170
Biosafety level 4	B-T170
(	O
BSL-4	B-T170
)	O
suit laboratories	B-T073
are	O
specifically	O
designed	B-T052
to	O
study	B-T062
high-consequence pathogens	B-T001
for	O
which	O
neither	O
infection	B-T046
prophylaxes	B-T061
nor	O
treatment	B-T061
options	O
exist.	O
The	O
hallmarks	O
of	O
these	O
laboratories	B-T073
are:	O
custom-designed	B-T052
airtight doors	B-T073
,	O
dedicated	O
supply	B-T169
and	O
exhaust airflow systems	B-T073
,	O
a	O
negative-pressure environment	B-T074
,	O
and	O
mandatory	O
use	O
of	O
positive-pressure ("space") suits	B-T073
.	O
The	O
risk	O
for	O
laboratory	B-T073
specialists	B-T097
working	O
with	O
highly	O
pathogenic agents	B-T001
is	O
minimized	O
through	O
rigorous	O
training	B-T065
and	O
adherence	O
to	O
stringent	O
safety protocols	B-T170
and	O
standard operating procedures	B-T170
.	O
Researchers	B-T097
perform	O
the	O
majority	B-T080
of	O
their	O
work	B-T057
in	O
BSL-2	B-T170
laboratories	B-T073
and	O
switch	O
to	O
BSL-4	B-T170
suit laboratories	B-T073
when	O
work	O
with	O
a	O
high-consequence pathogen	B-T001
is	O
required.	O
Collaborators	B-T094
and	O
scientists	B-T097
considering	O
BSL-4	B-T170
projects	B-T062
should	O
be	O
aware	O
of	O
the	O
challenges	B-T033
associated with	B-T080
BSL-4	B-T170
research	B-T062
both	O
in	O
terms	O
of	O
experimental	B-T080
technical	B-T169
limitations	B-T169
in	O
BSL-4	B-T170
laboratory	B-T073
space	B-T082
and	O
the	O
increased	B-T081
duration	B-T079
of	O
such	O
experiments	B-T062
.	O
Tasks	O
such	O
as	O
entering	B-T169
and	O
exiting	B-T169
the	O
BSL-4	B-T170
suit laboratories	B-T073
are	O
considerably	O
more	O
complex	B-T080
and	O
time-consuming	B-T080
compared	B-T052
to	O
BSL-2	B-T170
and	O
BSL-3	B-T170
laboratories	B-T073
.	O
The	O
focus	O
of	O
this	O
particular	O
article	B-T170
is	O
to	O
address	B-T170
basic	O
biosafety	B-T068
concerns	B-T078
and	O
describe	O
the	O
entrance and exit procedures	B-T170
for	O
the	O
BSL-4	B-T170
laboratory	B-T073
at	O
the	O
NIH	B-T093
/	O
NIAID	B-T093
Integrated Research Facility	B-T073
at	O
Fort	O
Detrick.	O
Such	O
procedures	B-T170
include	O
checking	O
external	O
systems	O
that	O
support	O
the	O
BSL-4	B-T170
laboratory	B-T073
,	O
and	O
inspecting	O
and	O
donning	O
positive-pressure suits	B-T073
,	O
entering	O
the	O
laboratory	B-T073
,	O
moving	O
through	O
air pressure	B-T070
-	O
resistant	B-T169
doors	B-T073
,	O
and	O
connecting	O
to	O
air-supply hoses	B-T074
.	O
We	O
will	O
also	O
discuss	O
moving	B-T040
within	O
and	O
exiting	B-T169
the	O
BSL-4	B-T170
suit laboratories	B-T073
,	O
including	O
using	O
the	O
chemical	B-T103
shower	B-T073
and	O
removing	B-T052
and	O
storing	B-T169
positive-pressure suits	B-T073
.	O

Masters Athletes	B-T097
:	O
Exemplars	O
of	O
Successful Aging	B-T040
?	O
Global population	B-T098
aging	B-T040
has	O
raised academic interest	B-T033
in	O
successful aging	B-T040
to	O
a	O
public policy	B-T064
priority.	O
Currently	O
there	O
is	O
no	O
consensus	B-T054
regarding	O
the	O
definition	O
of	O
successful aging	B-T040
.	O
However,	O
a	O
synthesis	O
of	O
research	O
shows	O
successful aging	B-T040
can	O
be	O
defined	O
as	O
a	O
late-life process of change	B-T048
characterized	O
by	O
high physical	B-T033
,	O
psychological	B-T041
,	O
cognitive	B-T041
,	O
and	O
social functioning	B-T054
.	O
Masters athletes	B-T097
systematically train	B-T080
for,	O
and	O
compete in	B-T054
,	O
organized forms of team	B-T096
and	O
individual sport	B-T056
specifically	O
designed	O
for	O
older adults	B-T098
.	O
Masters athletes	B-T097
are	O
often	O
proposed	O
as	O
exemplars	O
of	O
successful aging	B-T040
.	O
However,	O
their	O
aging status	B-T033
has	O
never	O
been	O
examined	O
using	O
a	O
comprehensive	B-T080
multidimensional	B-T082
successful aging	B-T040
definition.	O
Here,	O
we	O
examine	O
the	O
successful aging literature	B-T170
,	O
propose	O
a	O
successful aging	B-T040
definition	O
based	O
on	O
this	O
literature	B-T170
,	O
present	O
evidence	O
which	O
suggests	O
masters athletes	B-T097
could	O
be	O
considered	O
exemplars	O
of	O
successful aging	B-T040
according	O
to	O
the	O
proposed	O
definition,	O
and	O
list	O
future	O
experimental research	B-T062
directions.	O

Non-specific	O
transient	O
mutualism	B-T070
between	O
the	O
plant parasitic nematode	B-T204
,	O
Bursaphelenchus xylophilus	B-T204
,	O
and	O
the	O
opportunistic	O
bacterium	B-T007
Serratia quinivorans BXF1	B-T007
,	O
a	O
plant-growth	B-T040
promoting	O
pine	B-T002
endophyte	B-T004
with	O
antagonistic	B-T120
effects	B-T080
The	O
aim	O
of	O
this	O
study	B-T062
is	O
to	O
understand	O
the	O
biological	O
role	O
of	O
Serratia quinivorans BXF1	B-T007
,	O
a	O
bacterium	B-T007
commonly	O
found	O
associated	O
with	O
Bursaphelenchus xylophilus	B-T204
,	O
the	O
plant parasitic nematode	B-T204
responsible	O
for	O
pine	B-T002
wilt disease	B-T047
.	O
Therefore,	O
we	O
studied	O
strain BXF1	B-T007
effect	O
in	O
pine	B-T002
wilt disease	B-T047
.	O
We	O
found	O
that	O
strain BXF1	B-T007
promoted	O
in vitro	B-T080
nematode	B-T204
reproduction	B-T040
.	O
Moreover,	O
the	O
presence	O
of	O
bacteria	B-T007
led	O
to	O
the	O
absence	O
of	O
nematode	B-T204
chitinase gene (Bxcht-1)	B-T028
expression	B-T045
,	O
suggesting	O
an	O
effect	O
for	O
bacterial	B-T007
chitinase	B-T116
in	O
nematode	B-T204
reproduction	B-T040
.	O
Nevertheless,	O
strain BXF1	B-T007
was	O
unable	O
to	O
colonize	B-T033
the	O
nematode	B-T204
interior,	O
bind	O
to	O
its	O
cuticle	B-T023
with	O
high	O
affinity	O
or	O
protect	O
the	O
nematode	B-T204
from	O
xenobiotic	B-T123
stress	B-T046
.	O
Interestingly,	O
strain BXF1	B-T007
was	O
able	O
to	O
promote	O
tomato	B-T002
and	O
pine	B-T002
plant-growth	B-T040
,	O
as	O
well	O
as	O
to	O
colonize	B-T033
its	O
interior,	O
thus,	O
acting	O
like	O
a	O
plant-growth	B-T040
promoting	O
endophyte	B-T004
.	O
Consequently,	O
strain BXF1	B-T007
failed	O
to	O
induce	O
wilting symptoms	B-T184
when	O
inoculated	O
in	O
pine	B-T002
shoot	B-T002
artificial incisions	B-T169
.	O
This	O
bacterium	B-T007
also	O
presented	O
strong	O
antagonistic	B-T120
activities	B-T052
against	O
fungi	B-T004
and	O
bacteria	B-T007
isolated	O
from	O
Pinus pinaster	B-T002
.	O
Our	O
results	O
suggest	O
that	O
B. xylophilus	B-T204
does	O
not	O
possess	O
a	O
strict	O
symbiotic community	B-T001
capable	O
of	O
inducing	O
pine	B-T002
wilt disease	B-T047
symptoms	B-T184
as	O
previously	O
hypothesized.	O
We	O
show	O
that	O
bacteria	B-T007
like	O
BXF1	B-T007
,	O
which	O
possess	O
plant-growth	B-T040
promoting	O
and	O
antagonistic	B-T120
effects	B-T080
,	O
may	O
be	O
opportunistically	O
associated	O
with	O
B. xylophilus	B-T204
,	O
possibly	O
acquired	O
from	O
the	O
bacterial	B-T007
endophytic community	B-T004
of	O
the	O
host	B-T001
pine	B-T002
.	O

Habitual physical activity	B-UnknownType
is	O
associated with	B-T080
improved	O
anthropometric	B-T081
and	O
androgenic	B-T121
profile	B-T059
in	O
PCOS	B-T047
:	O
a	O
cross-sectional study	B-T062
To	O
examine	O
the	O
effect	B-T080
of	O
habitual physical activity	B-UnknownType
(	O
PA	B-T056
)	O
on	O
the	O
metabolic	B-T039
and	O
hormonal profiles	B-T060
of	O
women	B-T098
with	O
polycystic ovary syndrome	B-T047
.	O
Anthropometric	B-T081
,	O
metabolic	B-T059
and	O
hormonal assessment	B-T060
and	O
determination	O
of	O
habitual PA	B-UnknownType
levels	O
with	O
a	O
digital pedometer	B-T074
were	O
evaluated	O
in	O
84	O
women	B-T098
with	O
PCOS	B-T047
and	O
67	O
age-	O
and	O
body mass index	B-T201
(	O
BMI	B-T201
)-matched	O
controls	B-T096
.	O
PA	B-T056
status	O
was	O
defined	O
according	O
to	O
number of steps	B-T081
(≥7500	O
steps,	O
active,	O
or	O
<7500	O
steps,	O
sedentary	B-T080
).	O
BMI	B-T201
was	O
lower	O
in	O
active	O
women	B-T098
from	O
both	O
groups.	O
Active	O
PCOS	B-T047
women	B-T098
presented	O
lower	O
waist circumference	B-T201
(	O
WC	B-T201
)	O
and	O
lipid accumulation product	B-T081
(	O
LAP	B-T081
)	O
values	O
versus	O
sedentary	B-T080
PCOS	B-T047
women	B-T098
.	O
In	O
the	O
control group	B-T096
,	O
active	O
women	B-T098
also	O
had	O
lower	O
WC	B-T201
,	O
lower	O
values	O
for	O
fasting	O
and	O
120-min	O
insulin	B-T116
,	O
and	O
lower	O
LAP	B-T081
than	O
sedentary controls	B-T096
.	O
In	O
the	O
PCOS	B-T047
group,	O
androgen	B-T121
levels	O
were	O
lower	O
in	O
active	O
versus	O
sedentary women	B-T098
(p	O
=	O
0.001).	O
In	O
the	O
control group	B-T096
,	O
free androgen index	B-T034
(	O
FAI	B-T034
)	O
was	O
also	O
lower	O
in	O
active	O
versus	O
sedentary women	B-T098
(p	O
=	O
0.018).	O
Homeostasis model assessment	B-T058
of	O
insulin resistance	B-T046
and	O
2000	O
daily	O
step	O
increments	O
were	O
independent	O
predictors	B-T078
of	O
FAI	B-T034
.	O
Each	O
2000	O
daily	O
step	O
increment	O
was	O
associated with	B-T080
a	O
decrease	O
of	O
1.07	O
in	O
FAI	B-T034
.	O
Habitual PA	B-UnknownType
was	O
associated with	B-T080
a	O
better	O
anthropometric	B-T081
and	O
androgenic	B-T121
profile	B-T059
in	O
PCOS	B-T047
.	O

Geolocalization	B-T083
of	O
Influenza	B-T047
Outbreak	B-T067
Within	O
an	O
Acute Care	B-T058
Population	B-T098
:	O
A	O
Layered-Surveillance	B-T169
Approach	B-T082
We	O
seek	O
to	O
use	O
a	O
novel	O
layered-surveillance	B-T169
approach	B-T082
to	O
localize	B-T082
influenza	B-T047
clusters	B-T081
within	O
an	O
acute care	B-T058
population	B-T098
.	O
The	O
first	O
layer	O
of	O
this	O
system	B-T169
is	O
a	O
syndromic	B-T047
surveillance screen	B-T058
to	O
guide	O
rapid polymerase chain reaction testing	B-T059
.	O
The	O
second	B-T081
layer	O
is	O
geolocalization	B-T083
and	O
cluster analysis	B-T062
of	O
these	O
patients	B-T101
.	O
We	O
posit	O
that	O
any	O
identified	B-T080
clusters	B-T081
could	O
represent	O
at-risk populations	B-T098
who	O
could	O
serve	O
as	O
high-yield	B-T081
targets	B-T169
for	O
preventive medical interventions	B-T061
.	O
This	O
was	O
a	O
prospective observational surveillance study	B-T062
.	O
Patients	B-T101
were	O
screened	B-T058
with	O
a	O
previously	O
derived	O
clinical decision guideline	B-T170
that	O
has	O
a	O
90%	O
sensitivity	B-T081
and	O
30%	O
specificity	B-T081
for	O
influenza	B-T047
.	O
Patients	B-T101
received	O
points	B-T081
for	O
the	O
following	O
signs and symptoms	B-T184
within	O
the	O
past	B-T079
7	O
days	B-T079
:	O
cough	B-T184
(2	O
points),	O
headache	B-T184
(1	O
point),	O
subjective fever	B-UnknownType
(1	O
point),	O
and	O
documented fever	B-T184
at	O
triage	B-T061
(	O
temperature	B-T081
>38°C	O
[100.4°F])	O
(1	O
point).	O
Patients	B-T101
scoring	B-T081
3	O
points	O
or	O
higher	O
were	O
indicated	B-T033
for	O
influenza	B-T047
testing	B-T169
.	O
Patients	B-T101
were	O
tested	B-T169
with	O
Xpert Flu	B-T059
(	O
Cepheid	B-T073
,	O
Sunnyvale	B-T083
,	O
CA	B-T083
),	O
a	O
rapid polymerase chain reaction test	B-T059
.	O
Positive	B-T033
results	B-T169
were	O
mapped	B-T170
with	O
ArcGIS	B-T170
(	O
ESRI	B-T073
,	O
Redlands	B-T083
,	O
CA	B-T083
)	O
and	O
analyzed	B-T062
with	O
kernel density estimation	B-T062
to	O
create	O
heat maps	B-T073
.	O
There	O
were	O
1,360	O
patients	B-T101
tested	B-T169
with	O
Xpert Flu	B-T059
with	O
retrievable	B-T080
addresses	B-T170
within	O
the	O
greater	O
Phoenix metro area	B-UnknownType
.	O
One	O
hundred	O
sixty-seven	O
(12%)	O
of	O
them	O
tested	B-T169
positive for influenza A	B-T034
and	O
23	O
(2%)	O
tested	B-T169
positive for influenza B	B-T034
.	O
The	O
influenza A virus	B-T005
exhibited	O
a	O
clear cluster	B-T081
pattern	B-T082
within	O
this	O
patient	B-T101
population	B-T098
.	O
The	O
densest cluster	B-T081
was	O
located	B-T082
in	O
an	O
approximately	O
1-	O
square-mile	B-T081
region	B-T083
southeast	B-T082
of	O
our	O
hospital	B-T073
.	O
Our	O
layered-surveillance	B-T169
approach	B-T082
was	O
effective	B-T080
in	O
localizing	B-T082
a	O
cluster	B-T081
of	O
influenza A	B-T047
outbreak	B-T067
.	O
This	O
region	B-T083
may	O
house	B-T073
a	O
high-yield	B-T081
target	B-T169
population	B-T098
for	O
public health intervention	B-T058
.	O
Further	O
collaborative	B-T054
efforts	O
will	O
be	O
made	O
between	O
our	O
hospital	B-T073
and	O
the	O
Maricopa County	B-T083
Department of Public Health	B-T073
to	O
perform	B-T169
a	O
series	O
of	O
community	B-T096
vaccination	B-T061
events	B-T051
before	O
the	O
next	O
influenza	B-T047
season	B-T079
.	O
We	O
hope	O
these	O
efforts	O
will	O
ultimately	O
serve	O
to	O
reduce	B-T080
the	O
burden	B-T078
of	O
this	O
disease	B-T047
on	O
our	O
patient	B-T101
population	B-T098
,	O
and	O
that	O
this	O
system	B-T169
will	O
serve	O
as	O
a	O
framework	O
for	O
future	B-T079
investigations	B-T058
locating	O
at-risk populations	B-T098
.	O

Heart rate	B-T201
variability	B-T077
:	O
Pre-deployment	B-T079
predictor	B-T078
of	O
post-deployment	B-T079
PTSD	B-T048
symptoms	B-T184
Heart rate	B-T201
variability	B-T077
is	O
a	O
physiological	O
measure	O
associated	O
with	O
autonomic nervous system	B-T022
activity	B-T052
.	O
This	O
study	B-T062
hypothesized	O
that	O
lower	O
pre-deployment	B-T079
HRV	B-T039
would	O
be	O
associated	O
with	O
higher	O
post-deployment	B-T079
post-traumatic stress disorder	B-T048
(	O
PTSD	B-T048
)	O
symptoms	B-T184
.	O
Three-hundred-forty-three	O
Army National Guard soldiers	B-T097
enrolled	O
in	O
the	O
Warriors Achieving Resilience (WAR) study	B-T062
were	O
analyzed.	O
The	O
primary	O
outcome	B-T169
was	O
PTSD	B-T048
symptom	B-T184
severity	B-T080
using	O
the	O
PTSD	B-T048
Checklist	B-T170
-	O
Military	B-T097
version	B-T170
(	O
PCL	B-T170
)	O
measured	O
at	O
baseline	B-T081
,	O
3-	O
and	O
12-	O
month	B-T079
post-deployment	B-T079
.	O
Heart rate	B-T201
variability	B-T077
predictor	B-T078
variables	B-T080
included:	O
high frequency power	B-T081
(	O
HF	B-T081
)	O
and	O
standard deviation	B-T081
of	O
the	O
normal	O
cardiac inter-beat	B-T042
interval	B-T079
(	O
SDNN	B-T079
).	O
Generalized	O
linear mixed models	B-T170
revealed	O
that	O
the	O
pre-deployment	B-T079
PCL	B-T170
*	O
ln(HF) interaction	B-T081
term	O
was	O
significant	O
(p<0.0001).	O
Pre-deployment	B-T079
SDNN	B-T079
was	O
not	O
a	O
significant	O
predictor	B-T078
of	O
post-deployment	B-T079
PCL	B-T170
.	O
Covariates	B-T080
included	O
age	B-T032
,	O
pre-deployment	B-T079
PCL	B-T170
,	O
race	B-T098
/	O
ethnicity	B-T098
,	O
marital status	B-T102
,	O
tobacco use	B-T055
,	O
childhood abuse	B-T048
,	O
pre-deployment	B-T079
traumatic brain injury	B-T037
,	O
and	O
previous	O
combat zone	B-T082
deployment	B-T052
.	O
Pre-deployment	B-T079
heart rate	B-T201
variability	B-T077
predicts	O
post-deployment	B-T079
PTSD	B-T048
symptoms	B-T184
in	O
the	O
context	O
of	O
higher	O
pre-deployment	B-T079
PCL	B-T170
scores	B-T081
.	O

A	O
neuronal	B-T025
PI(3,4,5)P3	B-T109
-dependent	O
program	B-T169
of	O
oligodendrocyte	B-T025
precursor	B-T078
recruitment	B-T052
and	O
myelination	B-T043
The	O
molecular trigger	B-T044
of	O
CNS	B-T022
myelination	B-T043
is	O
unknown	B-T080
.	O
By	O
targeting	B-T169
Pten	B-T116
in	O
cerebellar granule cells	B-T025
and	O
activating	B-T052
the	O
AKT1	B-T116
-	O
mTOR	B-T116
pathway	B-T044
,	O
we	O
increased	B-T081
the	O
caliber	O
of	O
normally	B-T080
unmyelinated axons	B-T026
and	O
the	O
expression	B-T045
of	O
numerous	B-T081
genes	B-T028
encoding	B-T052
regulatory proteins	B-T116
.	O
This	O
led	O
to	O
the	O
expansion	B-T043
of	O
genetically wild-type	B-T028
oligodendrocyte	B-T025
progenitor cells	B-T025
,	O
oligodendrocyte	B-T025
differentiation	B-T043
and	O
de novo	B-T078
myelination	B-T043
of	O
parallel fibers	B-T026
.	O
Thus,	O
a	O
neuronal	B-T025
program	B-T169
dependent	O
on	O
the	O
phosphoinositide	B-T109
PI(3,4,5)P3	B-T109
is	O
sufficient	O
to	O
trigger	B-T044
all	O
steps	B-T077
of	O
myelination	B-T043
.	O

Atypical	O
microglial	B-T025
response	B-T032
to	O
biodiesel exhaust	B-T109
in	O
healthy	B-T080
and	O
hypertensive	B-T047
rats	B-T015
Accumulating	O
evidence	B-T078
suggests	B-T078
a	O
deleterious	B-T169
role	B-T077
for	O
urban	B-T083
air pollution	B-T069
in	O
central nervous system (CNS) diseases	B-T047
and	O
neurodevelopmental disorders	B-T048
.	O
Microglia	B-T025
,	O
the	O
resident	O
innate	B-T032
immune cells	B-T025
and	O
sentinels	B-T109
in	O
the	O
brain	B-T023
,	O
are	O
a	O
common	B-T081
source	B-T033
of	O
neuroinflammation	B-UnknownType
and	O
are	O
implicated	O
in	O
air pollution	B-T069
-	O
induced	B-T169
CNS effects	B-T047
.	O
While	O
renewable energy	B-T169
,	O
such	O
as	O
soy-based biofuel	B-T109
,	O
is	O
of	O
increasing	B-T169
public	B-T098
interest	B-T041
,	O
there	O
is	O
little	B-T081
information	B-T078
on	O
how	O
soy biofuel	B-T109
may	O
affect	B-T080
the	O
brain	B-T023
,	O
especially	O
in	O
people	B-T098
with	O
preexisting disease conditions	B-T033
.	O
To	O
address	O
this,	O
male	B-T032
spontaneously hypertensive rats	B-T015
(	O
SHR	B-T015
)	O
and	O
normotensive	B-T033
Wistar Kyoto (WKY) rats	B-T015
were	O
exposed to	B-T080
100% Soy-based Biodiesel Exhaust	B-T109
(	O
100SBDE	B-T109
;	O
0,	O
50,	O
150	O
and	O
500μg/m(3))	O
by	O
inhalation	B-T040
,	O
4h/	O
day	B-T079
for	O
4	O
weeks	B-T079
(5	O
days	B-T079
/	O
week	B-T079
).	O
Ionized calcium-binding adapter molecule-1	B-T116
(	O
IBA-1	B-T116
)	O
staining	B-T059
of	O
microglia	B-T025
in	O
the	O
substantia nigra	B-T023
revealed	B-T080
significant	B-T078
changes	B-T169
in	O
morphology	B-T080
with	O
100SBDE	B-T109
exposure	B-T080
in	O
rats	B-T015
from	O
both	B-T080
genotypes	B-T032
,	O
where	O
SHR	B-T015
were	O
less	B-T081
sensitive	B-T169
.	O
Aconitase activity	B-T044
was	O
inhibited	B-T080
in	O
the	O
frontal cortex	B-T023
and	O
cerebellum	B-T023
of	O
WKY rats	B-T015
exposed to	B-T080
100SBDE	B-T109
.	O
No	B-T169
consistent	B-T080
changes	B-T169
occurred	B-T079
in	O
pro-inflammatory	B-T169
cytokine	B-T116
expression	B-T045
,	O
nitrated protein	B-T116
,	O
or	O
arginase1	B-T116
expression	B-T045
in	O
brain regions	B-T029
from	O
either	O
rat strain	B-T015
exposed to	B-T080
100SBDE	B-T109
.	O
However,	O
while	O
IBA-1	B-T116
mRNA expression	B-T045
was	O
not	B-T169
modified	B-T169
,	O
CX3CR1	B-T116
mRNA expression	B-T045
was	O
lower	B-T080
in	O
the	O
striatum	B-T023
of	O
100SBDE	B-T109
exposed rats	B-T015
regardless	B-T080
of	O
genotype	B-T032
,	O
suggesting	B-T078
a	O
downregulation	B-T044
of	O
the	O
fractalkine receptor	B-T116
on	O
microglia	B-T025
in	O
this	O
brain region	B-T029
.	O
Together,	O
these	O
data	B-T078
indicate	B-T078
that	O
while	O
microglia	B-T025
are	O
detecting	B-T033
and	O
responding	B-T032
to	O
100SBDE	B-T109
exposure	B-T080
with	O
changes	B-T169
in	O
morphology	B-T080
,	O
there	O
is	O
reduced	B-T080
expression	B-T045
of	O
CX3CR1	B-T116
regardless	B-T080
of	O
genetic background	B-T032
and	O
the	O
activation	B-UnknownType
response	B-T032
is	O
atypical	B-T080
without	O
traditional	B-T169
inflammatory markers	B-T201
of	O
M1	B-T025
or	O
M2	B-T025
activation	B-UnknownType
in	O
the	O
brain	B-T023
.	O

Pre-Activation Negativity	B-T033
(	O
PrAN	B-T033
)	O
in	O
Brain	B-T023
Potentials	B-T080
to	O
Unfolding Words	B-T041
We	O
describe	O
an	O
event-related potential	B-T042
(	O
ERP	B-T042
)	O
effect	B-T080
termed	O
the	O
"	O
pre-activation negativity	B-T033
"	O
(	O
PrAN	B-T033
),	O
which	O
is	O
proposed	O
to	O
index	B-T170
the	O
degree of pre-activation	B-T081
of	O
upcoming	O
word	B-T078
-	O
internal	B-T082
morphemes	B-T170
in	O
speech	B-T040
processing	B-T052
.	O
Using	O
lexical competition	B-T067
measures	B-T081
based	O
on	O
word-initial speech fragments	B-T068
(	O
WIFs	B-T068
),	O
as	O
well	O
as	O
statistical analyses	B-T062
of	O
ERP	B-T042
data	B-T078
from	O
three	O
experiments	B-T062
,	O
it	O
is	O
shown	O
that	O
the	O
PrAN	B-T033
is	O
sensitive	O
to	O
lexical competition	B-T067
and	O
that	O
it	O
reflects	O
the	O
degree	B-T081
of	O
predictive	B-T080
certainty	B-T080
:	O
the	O
negativity	B-T033
is	O
larger	B-T081
when	O
there	O
are	O
fewer	B-T081
upcoming	O
lexical	B-T078
competitors	B-T098
.	O

Angiotensin-converting enzyme insertion/deletion polymorphism	B-T033
association with	B-T080
obesity	B-T047
and	O
some	O
related	O
disorders	B-T047
in	O
Egyptian	B-T098
females	B-T032
:	O
a	O
case-control observational study	B-T062
According	O
to	O
the	O
WHO	B-T093
report	B-T170
in	O
2015,	O
obesity	B-T047
is	O
the	O
fifth	O
leading	O
cause of death	B-T033
worldwide	B-T079
,	O
and	O
the	O
prevalence	B-T081
of	O
Egyptian	B-T098
female	B-T098
obesity	B-T047
is	O
37.5	O
%.	O
Since	O
obesity	B-T047
is	O
highly	O
influenced	B-T077
by	O
genetics	B-T169
,	O
and	O
adipose tissue	B-T024
renin-angiotensin system	B-T022
is	O
over-activated	B-T169
in	O
obesity	B-T047
,	O
the	O
effect of	B-T080
angiotensin-converting enzyme (ACE) insertion/deletion (I/D) polymorphism	B-T033
on	O
obesity	B-T047
and	O
related	O
disorders	B-T047
was	O
studied	O
in	O
several	O
populations	B-T098
,	O
because	O
of	O
its	O
effect	B-T080
on	O
ACE activity	B-T044
.	O
Our	O
objective	B-T170
was	O
to	O
study	B-T062
the	O
association	B-T080
of	O
ACE I/D polymorphism	B-T033
with	O
obesity	B-T047
and	O
certain	O
related	O
disorders	B-T047
,	O
namely	O
hypertension	B-T047
,	O
insulin resistance	B-T046
and	O
metabolic syndrome	B-T047
,	O
in	O
Egyptian	B-T098
females	B-T032
.	O
Eighty	B-T081
female	B-T098
volunteers	B-T098
were	O
recruited,	O
blood pressure	B-T058
and	O
body measurements	B-T060
were	O
recorded	B-T169
and	O
a	O
fasting	B-T033
blood sample	B-T031
was	O
obtained	O
for	O
the	O
quantitation	B-T081
of	O
glucose	B-T109
,	O
lipid profile	B-T059
,	O
insulin,	B-T116
leptin	B-T116
and	O
identification	B-T080
of	O
ACE I/D polymorphs	B-T033
.	O
Subjects	B-T098
were	O
grouped	O
based	O
on	O
hypertension	B-T047
and	O
obesity states	B-T033
.	O
Comparisons	B-T052
of	O
continuous	B-T078
parameters	B-T033
were	O
made	O
with	O
independent	B-T078
sample t-test	B-T170
between	O
two	O
groups	B-T078
.	O
The	O
frequencies	B-T081
of	O
ACE	B-T116
genotypes	B-T032
and	O
alleles	B-T028
,	O
and	O
the	O
association	B-T080
between	O
gene polymorphism	B-T045
and	O
metabolic	B-T169
parameters	B-T033
were	O
assessed	B-T052
using	O
chi-square	B-T170
or	O
Fisher's exact test	B-T170
.	O
Genotype	B-T032
frequencies	B-T081
were	O
in	O
Hardy-Weinberg equilibrium	B-T081
for	O
all	O
groups	B-T078
.	O
Genotype	B-T032
distribution	B-T169
did	O
not	O
differ	O
significantly	O
between	O
controls	B-T096
and	O
cases	B-T077
of	O
all	O
the	O
studied	O
disorders	B-T047
.	O
Although	O
DD carriers	B-T033
had	O
apparently	O
higher	B-T080
parameters	B-T033
of	O
blood pressure	B-T040
,	O
lipid profile	B-T059
and	O
insulin resistance	B-T046
,	O
only	O
diastolic blood pressure	B-T201
was	O
almost	O
significant	B-T078
(p	O
=	O
0.057).	O
I-carriers	B-T033
were	O
significantly	O
less	O
susceptible	B-T169
to	O
hypertension	B-T047
than	O
DD carriers	B-T033
having	O
normal	B-T080
waist/hip ratio	B-T032
(p	O
=	O
0.007,	O
OR	B-T081
=	O
17.29,	O
CI	B-T081
=	O
1.81-164.96)	O
and	O
normal	B-T080
conicity index	B-T034
(p	O
=	O
0.024,	O
OR	B-T081
=	O
7.00,	O
CI	B-T081
=	O
1.36-35.93).	O
In	O
DD genotype carriers	B-T033
,	O
a	O
significant	B-T078
association	B-T080
was	O
found	O
between	O
insulin resistance	B-T046
and	O
high body mass index	B-T033
(p	O
=	O
0.004,	O
OR	B-T081
=	O
8.89,	O
CI	B-T081
=	O
1.94-40.71),	O
waist circumference	B-T201
(p	O
=	O
0.003,	O
OR	B-T081
=	O
9.63,	O
CI	B-T081
=	O
2.14-43.36)	O
and	O
waist/height ratio	B-T033
(p	O
=	O
0.034,	O
OR	B-T081
=	O
6.86,	O
CI	B-T081
=	O
1.25-37.61),	O
although	O
the	O
variations	B-T070
in	O
percentages	B-T081
between	O
DD	B-T033
and	O
I-carriers	B-T033
were	O
not	O
high	O
enough	O
to	O
conclude	O
an	O
effect of	B-T080
ACE I/D	B-T033
on	O
such	O
an	O
association	B-T080
.	O
In	O
this	O
sample	B-T167
of	O
Egyptian	B-T098
females	B-T032
,	O
ACE I/D polymorphism	B-T033
was	O
not significantly	B-T033
associated with	B-T080
obesity	B-T047
nor	O
with	O
any	O
of	O
its	O
related	O
disorders	B-T047
studied.	O
The	O
I allele	B-T028
seemed	O
protective	O
against	O
hypertension	B-T047
in	O
subjects	B-T098
with	O
normal	B-T080
,	O
not	O
high,	O
waist/hip ratio	B-T032
and	O
conicity index	B-T034
compared	O
to	O
DD genotype carriers	B-T033
.	O

Expressed	B-T045
microRNA	B-T114
associated with	B-T080
high	B-T080
rate	B-T081
of	O
egg production	B-T042
in	O
chicken	B-T012
ovarian follicles	B-T023
MicroRNA	B-T114
(	O
miRNA	B-T114
)	O
is	O
a	O
highly	O
conserved	O
class	O
of	O
small	O
noncoding RNA	B-T114
about	O
19-24	O
nucleotides	B-T114
in	O
length	B-T081
that	O
function	B-T169
in	O
a	O
specific	O
manner	O
to	O
post-transcriptionally regulate	B-T045
gene expression	B-T045
in	O
organisms	B-T001
.	O
Tissue	B-T024
miRNA	B-T114
expression	B-T045
studies	B-T062
have	O
discovered	O
a	O
myriad	O
of	O
functions	B-T169
for	O
miRNAs	B-T114
in	O
various	O
aspects,	O
but	O
a	O
role	O
for	O
miRNAs	B-T114
in	O
chicken	B-T012
ovarian tissue	B-T024
at	O
300	O
days	B-T079
of	O
age	B-T032
has	O
not	O
hitherto	O
been	O
reported.	O
In	O
this	O
study,	O
we	O
performed	O
the	O
first	O
miRNA	B-T114
analysis	B-T062
of	O
ovarian tissues	B-T024
in	O
chickens	B-T012
with	O
low	B-T080
and	O
high	B-T080
rates	B-T081
of	O
egg production	B-T042
using	O
high-throughput sequencing	B-T063
.	O
By	O
comparing	O
low	B-T080
rate	B-T081
of	O
egg production	B-T042
chickens	B-T012
with	O
high	B-T080
rate	B-T081
of	O
egg production	B-T042
chickens	B-T012
,	O
17	O
significantly	O
differentially	O
expressed	B-T045
miRNAs	B-T114
were	O
found	O
(P	O
<	O
0.05),	O
including	O
11	O
known	O
and	O
six	O
novel	O
miRNAs	B-T114
.	O
We	O
found	O
that	O
all	O
11	O
known	O
miRNAs	B-T114
were	O
involved	O
mainly	O
in	O
pathways	B-T044
of	O
reproduction	B-T040
regulation	B-T045
,	O
such	O
as	O
steroid hormone biosynthesis	B-T044
and	O
dopaminergic synapse	B-T030
.	O
Additionally,	O
expression	B-T045
profiling	O
of	O
six	O
randomly	O
selected	O
differentially	O
regulated	B-T045
miRNAs	B-T114
were	O
validated	O
by	O
quantitative real-time polymerase chain reaction	B-T063
(	O
RT-qPCR	B-T063
).	O
Some	O
miRNAs	B-T114
,	O
such	O
as	O
gga-miR-34b	B-T028
,	O
gga-miR-34c	B-T028
and	O
gga-miR-216b	B-T028
,	O
were	O
reported	O
to	O
regulate	B-T045
processes	O
such	O
as	O
proliferation	B-T043
,	O
cell cycle	B-T043
,	O
apoptosis	B-T043
and	O
metastasis	B-T046
and	O
were	O
expressed	B-T045
differentially	O
in	O
ovaries	B-T023
of	O
chickens	B-T012
with	O
high	B-T080
rates	B-T081
of	O
egg production	B-T042
,	O
suggesting	O
that	O
these	O
miRNAs	B-T114
have	O
an	O
important	O
role	O
in	O
ovary	B-T023
development	B-T038
and	O
reproductive management	B-T040
of	O
chicken	B-T012
.	O
Furthermore,	O
we	O
uncovered	O
that	O
a	O
significantly	O
up-regulated	B-T044
miRNA	B-T114
-	O
gga-miR-200a-3p	B-T028
-is	O
ubiquitous	O
in	O
reproduction	B-T040
-	O
regulation	B-T045
-related	O
pathways	B-T044
.	O
This	O
miRNA	B-T114
may	O
play	O
a	O
special	O
central	O
role	O
in	O
the	O
reproductive management	B-T040
of	O
chicken	B-T012
,	O
and	O
needs	O
to	O
be	O
further	O
studied	O
for	O
confirmation.	O

Air pollution	B-T069
,	O
neighbourhood	B-T082
and	O
maternal	B-T033
-	O
level	B-T080
factors	B-T169
modify	B-T169
the	O
effect	B-T080
of	O
smoking	B-T055
on	O
birth weight	B-T032
:	O
a	O
multilevel analysis	B-T062
in	O
British Columbia	B-T083
,	O
Canada	B-T083
Maternal	B-T033
smoking	B-T055
during	O
pregnancy	B-T040
negatively	B-T033
impacts	B-T080
fetal growth	B-T039
,	O
but	O
the	O
effect	B-T080
is	O
not	O
homogenous	B-T082
across	O
the	O
population	B-T081
.	O
We	O
sought	O
to	O
determine	O
how	O
the	O
relationship	B-T080
between	O
cigarette use	B-T055
and	O
fetal growth	B-T039
is	O
modified	B-T033
by	O
the	O
social	B-T078
and	O
physical environment	B-T082
.	O
Birth records	B-T073
with	O
covariates	O
were	O
obtained	O
from	O
the	O
BC Perinatal Database Registry	B-T170
(N	O
=	O
232,291).	O
Maternal	B-T033
smoking status	B-T201
was	O
self-reported	B-T062
as	O
the	O
number	B-T081
of	O
cigarettes	B-T073
smoked	B-T055
per day	B-T079
usually	O
at	O
the	O
first prenatal care visit	B-T061
.	O
Census	B-T081
dissemination	B-T082
areas	B-T083
(	O
DAs	B-T083
)	O
were	O
used	O
as	O
neighbourhood	B-T082
-	O
level	B-T080
units	B-T081
and	O
linked	O
to	O
individual	B-T098
births	B-T040
using	O
residential postal codes	B-T078
to	O
assign	B-T169
exposure to	B-T080
particulate	B-T131
air pollution	B-T069
(PM2.5)	O
and	O
neighbourhood	B-T082
-	O
level	B-T080
attributes	B-T078
such	O
as	O
socioeconomic status	B-T080
(	O
SES	B-T080
),	O
proportion	B-T081
of	O
post-secondary education	B-T170
,	O
immigrant	B-T098
density	B-T081
and	O
living	B-UnknownType
in	O
a	O
rural place	B-T082
.	O
Random	B-T080
coefficient	B-T081
models	B-T170
were	O
used	O
with	O
cigarettes	B-T073
/day	B-T079
modeled	B-T170
with	O
a	O
random	B-T080
slope	B-T081
to	O
estimate	B-T081
its	O
between-	O
DA	B-T083
variability	B-T077
and	O
test	B-T169
cross-level	B-T080
interactions	B-T169
with	O
the	O
neighbourhood	B-T082
-	O
level	B-T080
variables	B-T080
on	O
continuous	B-T078
birth weight	B-T032
.	O
A	O
significant	B-T078
negative	B-T033
and	O
non-linear	O
association	B-T080
was	O
found	O
between	O
maternal	B-T033
smoking	B-T055
and	O
birth weight	B-T032
.	O
There	O
was	O
significant	B-T078
between-	O
DA	B-T083
intercept	B-T081
variability	B-T077
in	O
birth weight	B-T032
as	O
well	O
as	O
between-	O
DA	B-T083
slope	B-T081
variability	B-T077
of	O
maternal	B-T033
smoking	B-T055
on	O
birth weight	B-T032
of	O
which	O
68	O
and	O
30	O
%	O
respectively	O
was	O
explained	O
with	O
the	O
inclusion	B-T080
of	O
DA	B-T083
-	O
level	B-T080
variables	B-T080
and	O
their	O
cross-level	B-T080
interactions	B-T169
.	O
High	B-T080
DA	B-T083
-	O
level	B-T080
SES	B-T080
had	O
a	O
strong	B-T080
positive	B-T033
association	B-T080
with	O
birth weight	B-T032
but	O
the	O
effect	B-T080
was	O
moderated	B-T080
with	O
increased	B-T169
cigarettes	B-T073
/day	B-T079
.	O
Conversely,	O
heavy smokers	B-T033
showed	O
the	O
largest	B-T081
increases	B-T169
in	O
birth weight	B-T032
with	O
rising	B-T169
neighbourhood	B-T082
education levels	B-T033
.	O
Increased	B-T169
levels	B-T080
of	O
PM2.5	B-T131
and	O
immigrant	B-T098
density	B-T081
were	O
negatively	B-T033
associated with	B-T080
birth weight	B-T032
,	O
but	O
showed	O
positive	B-T033
interactions	B-T169
with	O
increased	B-T169
levels	B-T080
of	O
smoking	B-T055
.	O
Older	O
maternal age	B-T079
and	O
suspected	B-T078
drug	B-T048
or	O
alcohol use	B-T055
both	O
had	O
negative	B-T033
interactions	B-T169
with	O
increased	B-T169
levels	B-T080
of	O
maternal	B-T033
smoking	B-T055
.	O
Maternal	B-T033
smoking	B-T055
had	O
a	O
negative	B-T033
and	O
non-linear	O
dose-response association	B-T038
with	O
birth weight	B-T032
which	O
was	O
highly	B-T080
variable	B-T080
between	O
neighbourhood	B-T082
s	O
and	O
evidence	B-T078
of	O
effect	B-T080
modification	B-T033
with	O
neighbourhood	B-T082
-	O
level	B-T080
factors	B-T169
.	O
These	O
results	B-T169
suggest	B-T078
that	O
focusing	O
exclusively	O
on	O
individual	B-T098
behaviours	B-T053
may	O
have	O
limited	B-T169
success	B-T054
in	O
improving	B-T080
outcomes	B-T169
without	B-T080
addressing	O
the	O
contextual	B-T041
influences	B-T077
at	O
the	O
neighbourhood	B-T082
-	O
level	B-T080
.	O
Further	O
studies	B-T062
are	O
needed	O
to	O
corroborate	B-T080
our	O
findings	B-T033
and	O
to	O
understand	B-T041
how	O
neighbourhood	B-T082
-	O
level	B-T080
attributes	B-T078
interact	B-T169
with	O
smoking	B-T055
to	O
affect	B-T041
birth outcomes	B-T201
.	O

Individual	B-T098
Leg Muscle	B-T023
Contributions	B-T052
to	O
the	O
Cost	O
of	O
Walking	B-T056
:	O
Effects	B-T080
of	O
Age	B-T032
and	O
Walking Speed	B-T032
This	O
study	B-T062
examined	B-T033
the	O
contributions	B-T052
of	O
individual	B-T098
muscles	B-T024
to	O
changes	O
in	O
energetic	O
cost of transport	B-T169
(	O
COT	B-T169
)	O
over	O
seven	O
walking speeds	B-T032
,	O
and	O
compared	O
results	O
between	O
healthy young	B-T100
and	O
elderly subjects	B-T098
.	O
Twenty	O
six	O
participants	B-T098
(13	O
young aged	B-T100
18-30;	O
13	O
old aged	B-T098
70-80)	O
were	O
recruited.	O
COT	B-T169
(O2/kg	O
body	O
mass/km)	O
was	O
calculated	O
by	O
standardizing	O
the	O
mean oxygen consumption	B-T201
recorded	O
during	O
steady state walking	B-T056
.	O
Electromyography	B-T060
signals	B-T067
from	O
10	O
leg muscles	B-T023
were	O
used	O
to	O
calculate	O
the	O
cumulative activity required to traverse a unit of distance	B-T056
(	O
CMAPD	B-T056
)	O
for	O
each	O
muscle	B-T024
at	O
each	O
speed	B-T081
.	O
In	O
the	O
old group	B-T098
CMAPD	B-T056
was	O
correlated	B-T080
with	O
COT	B-T169
,	O
presented	O
higher	O
and	O
more	O
variable	O
values,	O
and	O
showed	O
greater	O
increases	O
around	O
optimal speed	B-T081
for	O
all	O
studied	O
muscles	B-T024
.	O
Soleus	B-T023
CMAPD	B-T056
was	O
independent	O
of	O
speed	B-T081
in	O
the	O
young group	B-T100
,	O
but	O
this	O
was	O
not	O
evident	O
with	O
aging	B-T040
.	O
Greater energy cost	B-T169
of	O
walking	B-T056
in	O
older	B-T098
individuals	B-T098
seems	O
to	O
be	O
attributable	O
to	O
increased	O
energy cost	B-T169
of	O
all	O
lower limb muscles	B-T023
.	O

Glycated Hemoglobin	B-T116
(	O
HbA1c	B-T116
)	O
Correlation	B-T080
with	O
Severity	B-T080
of	O
Coronary Artery Disease	B-T047
in	O
Non-diabetic	B-T033
Patients	B-T101
-	O
A	O
Hospital based	B-T073
Study	B-T062
from	O
North-Eastern India	B-T083
Glycated Hemoglobin (HbA1c) levels	B-T034
are	O
predictive	B-T080
of	O
cardiovascular disease	B-T047
and	O
mortality	B-T081
in	O
patients	B-T101
with	O
diabetes mellitus	B-T047
,	O
however,	O
association	O
of	O
HbA1c	B-T116
with	O
Coronary Artery Disease	B-T047
(	O
CAD	B-T047
)	O
in	O
non-diabetics	B-T033
is	O
inconsistent	B-T080
.	O
To	O
evaluate	B-T058
the	O
correlation	B-T080
between	O
HbA1c level	B-T034
and	O
severity	B-T080
of	O
CAD	B-T047
in	O
non-diabetic patients	B-T101
using	O
SYNTAX score	B-T081
in	O
a	O
cohort	B-T098
of	O
proven	O
CAD	B-T047
on	O
angiography	B-T060
at	O
Gauhati Medical College	B-T093
,	O
Guwahati, Assam	B-T083
,	O
India	B-T083
,	O
which	O
is	O
a	O
major	O
tertiary care hospital	B-T073
of	O
North-Eastern India	B-T083
.	O
We	O
prospectively	O
collected	O
data	B-T078
of	O
non-diabetic patients	B-T101
with	O
proven	O
CAD	B-T047
on	O
angiography	B-T060
from	O
June	O
2014	O
to	O
June	O
2015.	O
Patients	B-T101
were	O
divided	O
into	O
four	O
groups	B-T078
(	O
interquartiles	B-T080
)	O
according	O
to	O
HbA1c levels	B-T034
,	O
less	O
than	O
4.8%,	O
4.8%	O
to	O
5.1%,	O
5.1%	O
to	O
5.6%,	O
and	O
5.6%	O
to	O
6.5%.	O
Severity	B-T080
of	O
CAD	B-T047
was	O
assessed	B-T052
using	O
SYNTAX score	B-T081
and	O
the	O
number of coronary vessels diseased	B-T081
.	O
We	O
compared	O
different	O
quartiles	B-T080
of	O
HbA1c	B-T116
with	O
regard	O
to	O
SYNTAX score	B-T081
and	O
number	O
of	O
diseased vessels	B-T081
.	O
A	O
total	O
of	O
346	O
patients	B-T101
were	O
included	O
in	O
the	O
study	B-T062
.	O
Mean	O
age	B-T032
was	O
58.1±10.4	O
years.	O
Of	O
the	O
total	O
91.9%	O
(318)	O
were	O
males	B-T032
,	O
44.8%	O
(155)	O
were	O
hypertensives	B-T033
,	O
29.2%	O
(101)	O
were	O
smokers	B-T033
and	O
34.7%	O
(120)	O
were	O
dyslipidemic	B-T033
.	O
We	O
found	O
that	O
CAD	B-T047
severity	B-T080
by	O
SYNTAX score	B-T081
as	O
well	O
as	O
number	O
of	O
vessels	B-T023
involved	O
was	O
significantly	O
different	O
among	O
quartiles	B-T080
(	O
p-values	B-T081
<0.001	O
and	O
<0.001	O
respectively).	O
Increase	B-T169
in	O
HbA1c level	B-T034
was	O
strongly	O
correlated	B-T080
with	O
disease severity	B-T080
and	O
higher	O
SYNTAX score	B-T081
.	O
A	O
significant	O
increase	B-T169
was	O
noted	O
in	O
the	O
mean	O
number	O
of	O
diseased vessels	B-T081
(	O
p-value	B-T081
<0.001)	O
as	O
HbA1c level	B-T034
increases	B-T169
.	O
Age	B-T032
,	O
gender	B-T032
,	O
hypertension	B-T047
and	O
dyslipidemia	B-T047
did	O
not	O
show	O
significant	O
difference	O
among	O
quartiles	B-T080
however	O
smoking	B-T055
was	O
found	O
to	O
be	O
an	O
independent	O
predictor	B-T078
of	O
severity	B-T080
of	O
CAD	B-T047
by	O
SYNTAX score	B-T081
(p	O
<0.05).	O
From	O
this	O
clinical study	B-T062
,	O
we	O
can	O
conclude	O
that	O
a	O
significant	O
correlation	B-T080
exists	O
between	O
HbA1c	B-T116
and	O
severity	B-T080
of	O
CAD	B-T047
by	O
SYNTAX score	B-T081
as	O
well	O
as	O
number	O
of	O
vessels	B-T023
involved	O
in	O
non- diabetes	B-T033
.	O

On	O
the	O
Relation	B-T080
between	O
Face	B-T041
and	O
Object Recognition	B-T041
in	O
Developmental Prosopagnosia	B-T048
:	O
No	O
Dissociation	B-T048
but	O
a	O
Systematic	B-T169
Association	B-T080
There	O
is	O
an	O
ongoing	O
debate	B-T052
about	O
whether	O
face recognition	B-T041
and	O
object recognition	B-T041
constitute	O
separate	B-T080
domains	B-T169
.	O
Clarification	B-T052
of	O
this	O
issue	B-T033
can	O
have	O
important	B-T080
theoretical	B-T078
implications	B-T080
as	O
face recognition	B-T041
is	O
often	O
used	O
as	O
a	O
prime	O
example	B-T077
of	O
domain	B-T169
-	O
specificity	B-T081
in	O
mind	B-T078
and	O
brain	B-T023
.	O
An	O
important	B-T080
source	B-T033
of	O
input	B-T077
to	O
this	O
debate	B-T052
comes	O
from	O
studies	O
of	O
individuals	B-T098
with	O
developmental prosopagnosia	B-T048
,	O
suggesting	B-T078
that	O
face recognition	B-T041
can	O
be	O
selectively impaired	B-T169
.	O
We	O
put	O
the	O
selectivity	B-T080
hypothesis	B-T078
to	O
test	B-T169
by	O
assessing	O
the	O
performance	B-T052
of	O
10	O
individuals	B-T098
with	O
developmental prosopagnosia	B-T048
on	O
demanding	O
tests	O
of	O
visual object processing	B-T041
involving	B-T169
both	O
regular	B-T080
and	O
degraded	B-T033
drawings	B-T170
.	O
None	O
of	O
the	O
individuals	B-T098
exhibited	O
a	O
clear	O
dissociation	B-T048
between	O
face	B-T041
and	O
object recognition	B-T041
,	O
and	O
as	O
a	O
group	B-UnknownType
they	O
were	O
significantly	B-T078
more	O
affected	B-T169
by	O
degradation	B-T033
of	O
objects	B-T072
than	O
control	B-T096
participants	B-T098
.	O
Importantly,	O
we	O
also	O
find	O
positive	B-T033
correlations	B-T080
between	O
the	O
severity	B-T080
of	O
the	O
face recognition	B-T041
impairment	B-T169
and	O
the	O
degree	B-T081
of	O
impaired	B-T169
performance	B-T052
with	O
degraded	B-T033
objects	B-T072
.	O
This	O
suggests	O
that	O
the	O
face	B-T041
and	O
object	B-T041
deficits	B-T080
are	O
systematically	O
related	B-T080
rather	O
than	O
coincidental	B-T079
.	O
We	O
conclude	O
that	O
at	O
present,	O
there	O
is	O
no	O
strong	O
evidence	B-T078
in	O
the	O
literature	B-T170
on	O
developmental prosopagnosia	B-T048
supporting	O
domain	B-T169
-	O
specific	B-T080
accounts	O
of	O
face recognition	B-T041
.	O

Reduced Chest	B-T033
and	O
Abdominal Wall	B-T023
Mobility	B-T080
and	O
Their	O
Relationship	B-T080
to	O
Lung Function	B-T039
,	O
Respiratory	B-T169
Muscle Strength	B-T042
,	O
and	O
Exercise Tolerance	B-T201
in	O
Subjects	B-T096
With	O
COPD	B-T047
Advanced	O
air-flow	B-T039
limitation	B-T169
in	O
patients	B-T101
with	O
COPD	B-T047
leads	O
to	O
a	O
reduction	B-T080
in	O
vital capacity	B-T201
,	O
respiratory	B-T169
muscle strength	B-T042
,	O
and	O
exercise capacity	B-T201
.	O
However,	O
its	O
impact	O
on	O
chest	B-T029
and	O
abdominal wall	B-T023
mobility	B-T080
is	O
unknown	B-T080
.	O
This	O
study	O
aimed	O
to	O
ascertain	O
the	O
prevalence	B-T081
of	O
patients	B-T101
with	O
COPD	B-T047
with	O
reduced chest	B-T033
and	O
abdominal wall	B-T023
mobility	B-T080
and	O
to	O
investigate	B-T169
the	O
effect	B-T080
of	O
reduced chest	B-T033
and	O
abdominal wall	B-T023
mobility	B-T080
on	O
pulmonary function	B-T039
,	O
respiratory	B-T169
muscle strength	B-T042
,	O
and	O
exercise capacity	B-T201
.	O
In	O
51	O
elderly	B-T098
male	B-T032
subjects	B-T096
with	O
COPD	B-T047
,	O
chest	B-T029
and	O
abdominal wall	B-T023
mobility	B-T080
,	O
FVC	B-T034
,	O
FEV1	B-T060
,	O
FEV1/FVC	B-T059
,	O
maximal inspiratory pressure	B-T060
(	O
PImax	B-T060
),	O
maximal expiratory pressure	B-T060
(	O
PEmax	B-T060
),	O
and	O
the	O
6-min walk distance	B-T060
(	O
6MWD	B-T060
)	O
were	O
assessed	B-T052
.	O
Chest	B-T023
and	O
abdominal wall	B-T023
mobility	B-T080
were	O
measured	B-T080
using	O
the	O
breathing	B-T040
movement scale	B-T059
(0-8)	O
at	O
the	O
3	O
regions	B-T029
(	O
upper chest	B-T029
,	O
lower chest	B-T029
,	O
and	O
abdomen	B-T029
).	O
Reduced mobility	B-T033
was	O
defined	O
as	O
a	O
value	B-T081
lower	B-T052
than	O
the	O
lower limit of the normal scale	B-T081
.	O
The	O
unpaired t test	B-T170
,	O
Mann-Whitney test	B-T170
,	O
and	O
multiple regression analysis	B-T080
were	O
performed	B-T169
.	O
The	O
percentages	B-T081
of	O
subjects	B-T096
with	O
reduced mobility	B-T033
were	O
78%	O
for	O
the	O
upper chest	B-T029
,	O
76%	O
for	O
the	O
lower chest	B-T029
,	O
and	O
53%	O
for	O
the	O
abdomen	B-T029
.	O
The	O
subjects	B-T096
with	O
reduced mobility	B-T033
had	O
significantly low	B-T081
FVC	B-T034
,	O
FEV1	B-T060
,	O
and	O
6MWD	B-T060
in	O
each	O
region	B-T029
and	O
significantly low	B-T081
FEV1/FVC	B-T059
,	O
PImax	B-T060
,	O
and	O
PEmax	B-T060
in	O
the	O
abdominal region	B-T029
compared	B-T052
with	O
those	O
with	O
nonreduced	O
mobility	B-T080
.	O
FVC	B-T034
and	O
6MWD	B-T060
were	O
independently	O
associated with	B-T080
the	O
scale values	B-T080
in	O
each	O
region	B-T029
and	O
with	O
the	O
abdominal	B-T029
scale value	B-T080
,	O
respectively.	O
The	O
majority	O
of	O
subjects	B-T096
with	O
COPD	B-T047
had	O
reduced chest	B-T033
and	O
abdominal wall	B-T023
mobility	B-T080
,	O
which	O
was	O
independently	O
associated with	B-T080
FVC	B-T034
.	O
Even	O
though	O
abdominal wall	B-T023
mobility	B-T080
was	O
relatively	O
preserved	O
compared	B-T052
with	O
chest wall	B-T023
mobility	B-T080
,	O
it	O
was	O
also	O
independently	O
associated with	B-T080
6MWD	B-T060
.	O

FGF21	B-T116
is	O
a	O
biomarker	B-T201
for	O
mitochondrial translation	B-T045
and	O
mtDNA	B-T114
maintenance	B-T052
disorders	B-T047
To	O
validate	O
new	O
mitochondrial myopathy	B-T019
serum	B-T031
biomarkers	B-T201
for	O
diagnostic use	B-T060
.	O
We	O
analyzed	B-T062
serum	B-T031
FGF21	B-T116
(	O
S-FGF21	B-T116
)	O
and	O
GDF15	B-T116
from	O
patients	B-T101
with	O
(1)	O
mitochondrial diseases	B-T047
and	O
(2)	O
nonmitochondrial disorders	B-T047
partially	B-T081
overlapping	B-T079
with	O
mitochondrial disorder	B-T047
phenotypes	B-T032
.	O
We	O
(3)	O
did	O
a	O
meta-analysis	B-T062
of	O
S-FGF21	B-T116
in	O
mitochondrial disease	B-T047
and	O
(4)	O
analyzed	B-T062
S-Fgf21	B-T116
and	O
skeletal muscle	B-T024
Fgf21	B-T116
expression	B-T045
in	O
6	O
mouse	B-T015
models	B-T008
with	O
different	B-T080
muscle	B-T024
-	O
manifesting	B-T169
mitochondrial dysfunctions	B-T033
.	O
We	O
report	O
that	O
S-FGF21	B-T116
consistently	O
increases	B-T169
in	O
primary	B-T080
mitochondrial myopathy	B-T019
,	O
especially	O
in	O
patients	B-T101
with	O
mitochondrial translation	B-T045
defects	B-T019
or	O
mitochondrial DNA (mtDNA) deletions	B-T033
(675	O
and	O
347	O
pg/mL,	O
respectively;	O
controls	B-T096
:	O
66	O
pg/mL,	O
p	O
<	O
0.0001	O
for	O
both).	O
This	O
is	O
corroborated	O
in	O
mice	B-T015
(	O
mtDNA deletions	B-T033
1,163	O
vs	O
379	O
pg/mL,	O
p	O
<	O
0.0001).	O
However,	O
patients	B-T101
and	O
mice	B-T015
with	O
structural respiratory chain subunit or assembly factor defects	B-T019
showed	O
low	B-T080
induction	B-T169
(	O
human	B-T016
335	O
pg/mL,	O
p	O
<	O
0.05;	O
mice	B-T015
335	O
pg/mL,	O
not significant	B-T033
).	O
Overall	B-T080
specificities	B-T081
of	O
FGF21	B-T116
and	O
GDF15	B-T116
to	O
find	O
patients	B-T101
with	O
mitochondrial myopathy	B-T019
were	O
89.3%	O
vs	O
86.4%,	O
and	O
sensitivities	B-T081
67.3%	O
and	O
76.0%,	O
respectively.	O
However,	O
GDF15	B-T116
was	O
increased	B-T081
also	O
in	O
a	O
wide	O
range	O
of	O
nonmitochondrial conditions	B-T080
.	O
S-FGF21	B-T116
is	O
a	O
specific	B-T080
biomarker	B-T201
for	O
muscle	B-T024
-	O
manifesting	B-T169
defects	B-T019
of	O
mitochondrial translation	B-T045
,	O
including	O
mitochondrial	B-T026
transfer-RNA	B-T114
mutations	B-T045
and	O
primary	B-T080
and	O
secondary	B-T080
mtDNA deletions	B-T033
,	O
the	O
most	O
common	O
causes	B-T169
of	O
mitochondrial disease	B-T047
.	O
However,	O
normal	B-T080
S-FGF21	B-T116
does	O
not	B-T033
exclude	B-T169
structural respiratory chain complex or assembly factor defects	B-T019
,	O
important	O
to	O
acknowledge	O
in	O
diagnostics	B-T060
.	O
This	O
study	B-T062
provides	O
Class III	B-T170
evidence	B-T078
that	O
elevated	B-T080
S-FGF21	B-T116
accurately	O
distinguishes	O
patients	B-T101
with	O
mitochondrial myopathies	B-T019
from	O
patients	B-T101
with	O
other	O
conditions	B-T080
,	O
and	O
FGF21	B-T116
and	O
GDF15	B-T116
mitochondrial myopathy	B-T019
from	O
other	O
myopathies	B-T047
.	O

The	O
effects of	B-T080
captopril	B-T116
on	O
lipopolysaccharide	B-T109
induced	B-T169
learning	B-T048
and	O
memory impairments	B-T048
and	O
the	O
brain	B-T023
cytokine	B-T116
levels	B-T080
and	O
oxidative	B-T169
damage	B-T037
in	O
rats	B-T015
Renin-angiotensin system	B-T022
has	O
a	O
role	O
in	O
inflammation	B-T046
and	O
also	O
involves	O
in	O
learning	B-T041
and	O
memory	B-T041
.	O
In	O
the	O
present	O
study,	O
the	O
effects of	B-T080
captopril	B-T116
on	O
lipopolysaccharide	B-T109
(	O
LPS	B-T109
)	O
induced	B-T169
learning	B-T048
and	O
memory impairments	B-T048
,	O
hippocampal	B-T023
cytokine	B-T116
levels	B-T080
and	O
brain tissues	B-T023
oxidative	B-T169
damage	B-T037
was	O
investigated	B-T169
.	O
The	O
rats	B-T015
were	O
divided	O
and	O
treated:	O
[1]	O
saline	B-T167
(	O
Control	B-T096
),	O
[2]	O
LPS	B-T109
(1mg/kg),	O
[3-5]	O
10,	O
50	O
or	O
100mg/kg	O
captopril	B-T116
30min	O
before	O
LPS	B-T109
.	O
The	O
treatment	B-T061
was	O
started	O
since	O
six	O
days	B-T079
before	O
the	O
behavioral experiments	B-T060
and	O
continued	O
during	O
the	O
behavioral tests	B-T060
(	O
LPS	B-T109
injection	B-T061
two	O
h	O
before	O
each	O
behavioral experiment	B-T060
).	O
Administration	B-T061
of	O
LPS	B-T109
prolonged	B-T079
the	O
escape	O
latency	B-T080
and	O
traveled	O
path	O
to	O
find	O
the	O
platform	O
in	O
Morris water maze (MWM) test	B-T060
(P<0.01-P<0.001)	O
while,	O
shortened	O
the	O
latency	B-T080
to	O
enter	O
the	O
dark compartment	B-T058
in	O
passive avoidance	B-T041
(	O
PA	B-T041
)	O
test	B-T060
(P<0.001).	O
Pretreatment	B-T052
by	O
all	O
doses	B-T081
of	O
captopril	B-T116
improved	B-T080
performances	B-T052
of	O
the	O
rats	B-T015
in	O
MWM	B-T060
(P<0.05-P<0.001)	O
and	O
also	O
prolonged	B-T079
the	O
latency	B-T080
to	O
enter	O
the	O
dark	B-T058
in	O
PA	B-T041
test	B-T060
(P<0.001).	O
LPS	B-T109
also	O
increased	B-T081
IL-6	B-T116
,	O
TNF-α	B-T116
,	O
malondialdehyde	B-T109
(	O
MDA	B-T109
)	O
and	O
nitric oxide	B-T121
(	O
NO	B-T121
)	O
metabolites	B-T123
in	O
the	O
hippocampal	B-T023
tissues	B-T023
(P<0.05-P<0.001)	O
which	O
were	O
prevented	B-T061
by	O
captopril	B-T116
(P<0.05-P<0.001).	O
The	O
thiol	B-T123
,	O
superoxide dismutase	B-T116
(	O
SOD	B-T116
)	O
and	O
catalase	B-T116
(	O
CAT	B-T116
)	O
in	O
the	O
hippocampus	B-T023
of	O
LPS	B-T109
group	B-T078
were	O
lower	O
than	O
the	O
control	B-T096
(P<0.001)	O
while,	O
they	O
were	O
enhanced	B-T052
when	O
the	O
aniamls	B-T008
were	O
pretreated	B-T052
by	O
captopril	B-T116
(P<0.01-P<0.001).	O
The	O
results	O
of	O
present	O
study	O
showed	O
that	O
captopril	B-T116
improved	B-T080
the	O
LPS	B-T109
-	O
induced	B-T169
learning	B-T048
and	O
memory impairments	B-T048
in	O
rats	B-T015
which	O
were	O
accompanied	O
with	O
attenuating	B-T052
hippocampal	B-T023
cytokine	B-T116
levels	B-T080
and	O
improving	B-T080
the	O
brain tissues	B-T023
oxidative	B-T169
damage	B-T037
criteria	B-T078
.	O

Targeted therapy	B-T061
in	O
gastric cancer	B-T191
Gastric cancer	B-T191
is	O
the	O
fourth	O
most	O
common	O
cancer	B-T191
worldwide.	O
Surgery	B-T061
in	O
combination	O
with	O
multimodal therapy	B-T061
provides	O
the	O
only	O
curative therapy	B-T033
until	O
now.	O
The	O
importance	O
of	O
targeted therapy	B-T061
became	O
clear	O
over	O
the	O
last	O
few	O
years	B-T079
.	O
Due	O
to	O
the	O
implication	B-T169
of	O
HER2	B-T028
and	O
angiogenesis	B-T042
-directed	O
targeted therapies	B-T061
major	O
advances	O
in	O
the	O
treatment	B-T061
of	O
gastric cancer	B-T191
could	O
be	O
reached.	O
Nevertheless,	O
benefits	O
in	O
survival	O
remain	O
unsatisfactory	O
and	O
the	O
development	O
of	O
resistance	B-T169
to	O
monoclonal antibodies	B-T116
is	O
arising.	O
A	O
comprehensive	B-T080
and	O
comparative	B-T062
literature	B-T170
research	B-T062
was	O
performed	O
to	O
evaluate	B-T058
the	O
status	O
of	O
HER2	B-T028
and	O
angiogenesis	B-T042
-directed	O
targeted therapy	B-T061
in	O
gastric cancer	B-T191
.	O
Up	O
to	O
now,	O
trastuzumab	B-T116
and	O
ramucirumab	B-T116
are	O
the	O
only	O
agents	B-T109
showing	O
remarkable	O
benefits	O
in	O
the	O
therapy	B-T061
for	O
the	O
patients	B-T101
suffering	O
from	O
gastric cancer	B-T191
.	O
The	O
limitations	O
of	O
targeted therapies	B-T061
in	O
gastric cancer	B-T191
are	O
mainly	O
associated	O
with	O
the	O
development	O
of	O
secondary	O
resistance	B-T169
.	O
Addition	O
of	O
targeted therapy	B-T061
in	O
second-line treatment	B-T061
is	O
beneficial	O
when	O
compared	O
with	O
chemotherapy	B-T061
alone.	O
Nevertheless,	O
results	B-T033
in	O
first-line treatment	B-T061
remain	O
modest.	O
Therefore,	O
new	O
therapeutic agents	B-T121
and	O
combinations	B-T121
in	O
the	O
first-line treatment	B-T061
of	O
gastric cancer	B-T191
are	O
urgently	O
needed	O
and	O
remain	O
to	O
be	O
validated	O
in	O
clinical trials	B-T062
.	O

Serum C-Reactive Protein	B-T059
in	O
Children	B-T100
with	O
Liver Disease	B-T047
and	O
Ascites	B-T033
The	O
diagnosis	B-T062
of	O
peritonitis	B-T046
as	O
a	O
complication	B-T046
of	O
cirrhosis	B-T047
is	O
an	O
important	O
clinical	O
problem.	O
The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
evaluate	O
serum C-reactive protein levels	B-T059
as	O
a	O
diagnostic factor	B-T201
for	O
spontaneous bacterial peritonitis	B-T047
(	O
SBP	B-T047
)	O
in	O
child patients	B-T101
with	O
liver disease	B-T047
.	O
In	O
this	O
study	B-T062
,	O
150	O
children	B-T100
diagnosed	B-T062
with	O
liver disease	B-T047
and	O
ascites	B-T033
upon	O
admission	B-T058
to	O
Nemazee Teaching Hospital	B-T073
(	O
Shiraz	B-T083
,	O
Iran	B-T083
)	O
were	O
examined	B-T033
.	O
Patients	B-T101
were	O
divided	O
into	O
spontaneous bacterial peritonitis	B-T047
and	O
sterile ascetic fluid groups	B-T031
according	O
to	O
the	O
PMN count	B-T059
≥	O
250/mm(3)	O
in	O
the	O
ascetic fluids	B-T031
.	O
Routine laboratory tests	B-T059
were	O
conducted	O
and	O
quantitative	O
C-reactive protein (CRP) levels	B-T059
were	O
measured	O
for	O
all	O
of	O
the	O
patients	B-T101
.	O
Accuracy	B-T080
,	O
sensitivity, and specificity	B-T081
of	O
CRP	B-T059
was	O
evaluated	O
for	O
diagnosis	B-T062
of	O
SBP	B-T047
.	O
Of	O
150	O
cirrhotic	B-T047
patients	B-T101
,	O
109	O
patients	B-T101
presented	O
without	O
SBP	B-T047
(52.29%	O
male	B-T098
,	O
mean age	B-T032
:	O
5.02	O
±	O
4.49	O
years	B-T079
)	O
and	O
41	O
patients	B-T101
presented	O
with	O
SBP	B-T047
(51.21%	O
male	B-T098
,	O
mean age	B-T032
:	O
4.71	O
years	B-T079
).	O
Cell counts	B-T059
,	O
protein levels	B-T034
,	O
albumin levels	B-T034
,	O
and	O
lactate dehydrogenize (LDH) levels	B-T059
of	O
the	O
ascetic fluid	B-T031
and	O
serum samples	B-T031
in	O
the	O
SBP	B-T047
group	O
were	O
higher	O
than	O
the	O
rates	O
for	O
those	O
without	O
SBP	B-T047
(P	O
<	O
0.05(.	O
The	O
mean	O
±	O
SD	O
of	O
CRP	B-T059
in	O
the	O
SBP	B-T047
group	O
(36.89	O
±	O
23.43)	O
increased	O
significantly	O
compared	O
to	O
the	O
rate	O
among	O
those	O
without	O
SBP	B-T047
(21.59	O
±	O
15.43,	O
P	O
=	O
0.001).	O
The	O
percentages	O
for	O
sensitivity and specificity	B-T081
of	O
CRP	B-T059
,	O
the	O
diagnosis	B-T062
of	O
SBP	B-T047
based	O
on	O
the	O
PMN count	B-T059
≥	O
250/mm(3),	O
and	O
cultured ascites	B-T033
were	O
69.23%,	O
90.25%,	O
88.43%,	O
and	O
84.32%,	O
respectively.	O
The	O
areas	O
under	O
the	O
curve	O
of	O
CRP	B-T059
for	O
SBP	B-T047
based	O
on	O
the	O
PMN count	B-T059
≥	O
250/mm(3)	O
and	O
cultured ascites	B-T033
was	O
0.94	O
(CI	O
95%:	O
0.90	O
to	O
0.96)	O
and	O
0.85	O
(CI	O
95%:	O
0.84	O
to	O
0.92),	O
respectively	O
(P	O
<	O
0.001).	O
Our	O
study	B-T062
showed	O
that	O
CRP	B-T059
is	O
a	O
marker	O
with	O
high	O
sensitivity and specificity	B-T081
for	O
the	O
diagnosis	B-T062
of	O
SBP	B-T047
in	O
cirrhotic	B-T047
children	B-T100
.	O

Structure	O
of	O
the	O
bacterial	B-T080
plant	B-T002
-	O
ferredoxin	B-T116
receptor	B-T116
FusA	B-T116
Iron	B-T121
is	O
a	O
limiting	O
nutrient	B-T168
in	O
bacterial infection	B-T047
putting	O
it	O
at	O
the	O
centre	O
of	O
an	O
evolutionary	O
arms	O
race	O
between	O
host	B-T001
and	O
pathogen	B-T001
.	O
Gram-negative bacteria	B-T007
utilize	O
TonB	B-T116
-dependent	O
outer membrane	B-T026
receptors	B-T116
to	O
obtain	O
iron	B-T121
during	O
infection	B-T046
.	O
These	O
receptors	B-T116
acquire	O
iron	B-T121
either	O
in	O
concert	O
with	O
soluble	O
iron-scavenging siderophores	B-T109
or	O
through	O
direct interaction	B-T169
and	O
extraction	B-T061
from	O
host	B-T001
proteins	B-T116
.	O
Characterization	B-T052
of	O
these	O
receptors	B-T116
provides	O
invaluable	O
insight	O
into	O
pathogenesis	B-T046
.	O
However,	O
only	O
a	O
subset	O
of	O
virulence	B-T038
-related	O
TonB	B-T116
-dependent	O
receptors	B-T116
have	O
been	O
currently	O
described.	O
Here	O
we	O
report	O
the	O
discovery	B-T052
of	O
FusA	B-T116
,	O
a	O
new	O
class	O
of	O
TonB	B-T116
-dependent	O
receptor	B-T116
,	O
which	O
is	O
utilized	O
by	O
phytopathogenic Pectobacterium spp.	B-T007
to	O
obtain	O
iron	B-T121
from	O
plant	B-T002
ferredoxin	B-T116
.	O
Through	O
the	O
crystal structure	B-T104
of	O
FusA	B-T116
we	O
show	O
that	O
binding	B-T044
of	O
ferredoxin	B-T116
occurs	O
through	O
specialized	O
extracellular loops	B-T026
that	O
form	O
extensive	B-T080
interactions	B-T169
with	O
ferredoxin	B-T116
.	O
The	O
function	B-T169
of	O
FusA	B-T116
and	O
the	O
presence	O
of	O
homologues	B-T085
in	O
clinically important	B-T080
pathogens	B-T001
suggests	O
that	O
small	O
iron-containing proteins	B-T116
represent	O
an	O
iron	B-T121
source	B-T033
for	O
bacterial	B-T080
pathogens	B-T001
.	O

Antigen	B-T129
Masking	B-T070
During	O
Fixation	B-T059
and	O
Embedding	B-T059
,	O
Dissected	B-T169
Antigen	B-T129
masking	B-T070
in	O
routinely	O
processed	B-T067
tissue	B-T024
is	O
a	O
poorly	O
understood	O
process	O
caused	O
by	O
multiple	B-T081
factors	B-T169
.	O
We	O
sought	O
to	O
dissect	B-T169
the	O
effect	O
on	O
antigenicity	B-T038
of	O
each	O
step	B-T077
of	O
processing	B-T052
by	O
using	O
frozen sections	B-T024
as	O
proxies	B-T096
of	O
the	O
whole tissue	B-T024
.	O
An	O
equivalent	O
extent	O
of	O
antigen	B-T129
masking	B-T070
occurs	O
across	O
variable	O
fixation	B-T059
times	B-T079
at	O
room temperature	B-T080
.	O
Most	O
antigens	B-T129
benefit	O
from	O
longer	O
fixation	B-T059
times	B-T079
(>24	O
hr)	O
for	O
optimal	O
detection	B-T033
after	O
antigen	B-T129
retrieval	B-T058
(	O
AR	B-T058
;	O
for	O
example,	O
Ki-67	B-T116
,	O
bcl-2	B-T129
,	O
ER	B-T116
).	O
The	O
transfer	B-T169
to	O
a	O
graded alcohol	B-T109
series	B-T081
results	O
in	O
an	O
enhanced	O
staining effect	B-T033
,	O
reproduced	O
by	O
treating	B-T169
the	O
sections	B-T024
with	O
detergents	B-T120
,	O
possibly	O
because	O
of	O
a	O
better	O
access	O
of	O
the	O
polymeric	B-T104
immunohistochemical	B-T059
detection	B-T033
system	B-T169
to	O
tissue	B-T024
structures	B-T082
.	O
A	O
second	O
round	O
of	O
masking	B-T070
occurs	O
upon	O
entering	O
the	O
clearing agent	B-T120
,	O
mostly	O
at	O
the	O
paraffin	B-T109
embedding	B-T059
step	B-T077
.	O
This	O
may	O
depend	O
on	O
the	O
non-freezable	B-T080
water	B-T121
removal	B-T052
.	O
AR	B-T058
fully	O
reverses	O
the	O
masking	B-T070
due	O
both	O
to	O
the	O
fixation	B-T059
time	B-T079
and	O
the	O
paraffin	B-T109
embedding	B-T059
.	O
AR	B-T058
itself	O
destroys	B-T052
some	O
epitopes	B-T129
which	O
do	O
not	O
survive	O
routine	B-T080
processing	B-T052
.	O
Processed	B-T067
frozen sections	B-T024
are	O
a	O
tool	O
to	O
investigate	B-T169
fixation	B-T059
and	O
processing	B-T052
requirements	B-T169
for	O
antigens	B-T129
in	O
routine	B-T080
specimens	B-T167
.	O

Synthesis	B-T052
of	O
1,2-Dioxetanes	B-T109
as	O
Thermochemiluminescent Labels	B-T130
for	O
Ultrasensitive Bioassays	B-T059
:	O
Rational Prediction	B-T078
of	O
Olefin	B-T109
Photooxygenation	B-T067
Outcome	B-T169
by	O
Using	O
a	O
Chemometric Approach	B-T059
Great	O
interest	O
in	O
new	O
thermochemiluminescent (TCL) molecules	B-T167
,	O
for	O
example,	O
in	O
bioanalytical assays	B-T059
,	O
has	O
prompted	O
the	O
design	B-T052
and	O
synthesis	B-T052
of	O
a	O
small	O
library	B-T073
of	O
more	O
than	O
30	O
olefins	B-T109
to	O
be	O
subjected	O
to	O
photooxygenation	B-T067
,	O
with	O
the	O
aim	O
of	O
obtaining	O
new	O
1,2-dioxetane-based	B-T109
TCL labels	B-T130
with	O
optimized properties	B-T080
.	O
Fluorine	B-T123
atoms	O
on	O
the	O
acridan	B-T109
system	O
remarkably	O
stabilize	O
1,2-dioxetanes	B-T109
when	O
they	O
are	O
located	O
in	O
the	O
3- and/or 6-position	B-T082
(4	O
h	O
and	O
4	O
i).	O
On	O
the	O
other	O
hand,	O
2,7-difluorinated acridan dioxetane	B-T109
(4	O
j)	O
showed	O
a	O
significantly	O
enhanced	O
fluorescence quantum yield	B-T081
with	O
respect	O
to	O
the	O
unsubstituted dioxetane	B-T109
(4	O
a).	O
Some	O
of	O
the	O
synthesized	B-T052
olefins	B-T109
did	O
not	O
undergo	O
singlet oxygen addition	B-T067
and	O
a	O
rationale	B-T078
was	O
sought	O
to	O
ease	O
the	O
photooxygenation	B-T067
step,	O
leading	O
to	O
the	O
TCL dioxetanes	B-T109
.	O
A	O
chemometric approach	B-T059
has	O
been	O
adopted	O
to	O
exploit	O
principal component analysis	B-T062
and	O
linear discriminant analysis	B-T062
of	O
the	O
structural	B-T082
and	O
electronic molecular descriptors	B-T170
obtained	O
by	O
DFT optimizations	B-T052
of	O
olefins	B-T109
3.	O
This	O
approach	B-T082
allows	O
the	O
steric and electronic parameters	B-T077
that	O
govern	O
dioxetane	B-T109
formation	B-T169
to	O
be	O
revealed	B-T080
.	O

Prostate external beam radiotherapy	B-T061
combined	B-T080
with	O
high-dose-rate brachytherapy	B-T061
:	O
dose	B-T081
-	O
volume	B-T081
parameters	B-T033
from	O
deformably-registered plans	B-T170
correlate	B-T080
with	O
late	B-T079
gastrointestinal complications	B-T046
Derivation	B-T080
of	O
dose	B-T081
-	O
volume	B-T081
correlated	B-T080
with	O
toxicity	B-T080
for	O
multi-modal treatments	B-T061
can	O
be	O
difficult	B-T080
due	O
to	O
the	O
perceived	O
need	O
for	O
voxel-by-voxel dose accumulation	B-T059
.	O
With	O
data	B-T078
available	O
for	O
a	O
single	B-T081
-	O
institution	B-T073
cohort	B-T098
with	O
long	B-T080
follow-up	B-T058
,	O
an	O
investigation	B-T169
was	O
undertaken	O
into	O
rectal	B-T082
dose	B-T081
-	O
volume	B-T081
effects	B-T080
for	O
gastrointestinal toxicities	B-T033
after	O
deformably-registering	O
each	O
phase	B-T079
of	O
a	O
combined	B-T080
external beam radiotherapy	B-T061
(	O
EBRT	B-T061
)/	O
high-dose-rate (HDR) brachytherapy	B-T061
prostate treatment	B-T061
.	O
One	O
hundred	O
and	O
eighteen	O
patients	B-T101
received	O
EBRT	B-T061
in	O
23	O
fractions	B-T081
of	O
2	O
Gy	B-T081
and	O
HDR	B-T061
(	O
TG43 algorithm	B-T170
)	O
in	O
3	O
fractions	B-T081
of	O
6.5	O
Gy	B-T081
.	O
Results	B-T033
for	O
the	O
Late Effects of Normal Tissues - Subjective, Objective, Management and Analytic toxicity assessments	B-T170
were	O
available	O
with	O
a	O
median	B-T081
follow-up	B-T058
of	O
72	O
months	B-T079
.	O
The	O
HDR	B-T061
CT	B-T060
was	O
deformably-registered	O
to	O
the	O
EBRT	B-T061
CT	B-T060
.	O
Doses	B-T081
were	O
corrected	B-T080
for	O
dose fractionation	B-T061
.	O
Rectum	B-T023
dose-volume histogram	B-T170
(	O
DVH	B-T170
)	O
parameters	B-T033
were	O
calculated	B-T052
in	O
two	O
ways.	O
(1)	O
Distribution-adding	B-T170
:	O
parameters	B-T033
were	O
calculated	B-T052
after	O
the	O
EBRT	B-T061
dose	B-T081
distribution	B-T169
was	O
3D-summed	O
with	O
the	O
registered	O
HDR	B-T061
dose	B-T081
distribution	B-T169
.	O
(2)	O
Parameter-adding	B-T170
:	O
the	O
EBRT	B-T061
DVH	B-T170
parameters	B-T033
were	O
added	B-T169
to	O
HDR	B-T061
DVH	B-T170
parameters	B-T033
.	O
Logistic regressions	B-T062
and	O
Mann-Whitney U-tests	B-T081
were	O
used	O
to	O
correlate	B-T080
parameters	B-T033
with	O
late	B-T079
peak	B-T080
toxicity	B-T080
(	O
dichotomised	B-T169
at	O
grade	B-T185
1	O
or	O
2).	O
The	O
48-80,	O
40-63	O
and	O
49-55	O
Gy	B-T081
dose	B-T081
regions	B-T082
from	O
distribution-adding	B-T170
were	O
significantly	B-T078
correlated	B-T080
with	O
rectal bleeding	B-T046
,	O
urgency	B-T047
/	O
tenesmus	B-T184
and	O
stool frequency	B-T033
respectively.	O
Additionally	B-T169
,	O
urgency	B-T047
/	O
tenesmus	B-T184
and	O
anorectal pain	B-T184
were	O
associated with	B-T080
the	O
25-26	O
Gy	B-T081
and	O
44-48	O
Gy	B-T081
dose	B-T081
regions	B-T082
from	O
distribution-adding	B-T170
respectively.	O
Parameter-adding	B-T170
also	O
indicated	O
the	O
low	B-T080
-	O
mid	B-T082
dose	B-T081
region	B-T082
was	O
significantly	B-T078
correlated	B-T080
with	O
stool frequency	B-T033
and	O
proctitis	B-T047
.	O
This	O
study	B-T062
confirms	B-T033
significant	B-T078
dose-histogram	B-T170
effects	B-T080
for	O
gastrointestinal toxicities	B-T033
after	O
including	B-T169
deformable registration	B-T170
to	O
combine	B-T080
phases	B-T079
of	O
EBRT	B-T061
/	O
HDR	B-T061
prostate cancer	B-T191
treatment	B-T061
.	O
The	O
findings	B-T033
from	O
distribution-adding	B-T170
were	O
in	O
most	O
cases	B-T169
consistent with	B-T078
those	O
from	O
parameter-adding	B-T170
.	O
The	O
mid	B-T082
-	O
high	B-T080
dose	B-T081
range	B-T081
and	O
near	B-T080
maximum	B-T081
doses	B-T081
were	O
important	B-T080
for	O
rectal bleeding	B-T046
.	O
The	O
distribution-adding	B-T170
mid	B-T082
-	O
high	B-T080
dose	B-T081
range	B-T081
was	O
also	O
important	B-T080
for	O
stool frequency	B-T033
and	O
urgency	B-T047
/	O
tenesmus	B-T184
.	O
We	O
encourage	O
additional	B-T169
studies	B-T062
in	O
a	O
variety	B-T077
of	O
institutions	B-T078
using	O
a	O
variety	B-T077
of	O
dose accumulation methods	B-T059
with	O
appropriate	O
inter-fraction motion management	B-T058
.	O
NCT	O
NCT00193856.	O
Retrospectively	O
registered	O
12	O
September	O
2005.	O

Prescription	B-T170
of	O
opioids	B-T109
for	O
breathlessness	B-T184
in	O
end-stage	B-T080
COPD	B-T047
:	O
a	O
national	O
population-based study	B-T062
Low-dose	B-T081
opioids	B-T109
can	O
relieve	B-T169
breathlessness	B-T184
but	O
may	O
be	O
underused	O
in	O
late-stage	B-T079
COPD	B-T047
due	O
to	O
fear	B-T041
of	O
complications	B-T046
,	O
contributing	O
to	O
poor	O
symptom control	B-T061
.	O
We	O
aimed	O
to	O
study	B-T062
the	O
period	B-T079
prevalence	O
and	O
indications	B-T078
of	O
opioids	B-T109
actually	O
prescribed	B-T058
in	O
people	B-T098
with	O
end-stage	B-T080
COPD	B-T047
.	O
The	O
study	B-T062
was	O
a	O
longitudinal	B-T062
,	O
population-based study	B-T062
of	O
patients	B-T101
starting	O
long-term oxygen therapy	B-T061
(	O
LTOT	B-T061
)	O
for	O
COPD	B-T047
between	O
October	O
1,	O
2005	O
and	O
June	O
30,	O
2009	O
in	O
Sweden	B-T083
.	O
A	O
random	O
sample	O
(n=2,000)	O
of	O
their	O
dispensed	B-T058
opioid	B-T109
prescriptions	B-T170
was	O
obtained	O
from	O
the	O
national Prescribed Drugs Register	B-T170
from	O
91	O
days	B-T079
before	O
starting	O
LTOT	B-T061
until	O
the	O
first	O
of	O
LTOT	B-T061
withdrawal	B-T052
,	O
death	B-T040
,	O
or	O
study end	B-T079
(December	O
31,	O
2009).	O
We	O
analyzed	O
medication	O
type,	O
dispensed quantity	B-T081
,	O
date of dispensing	B-T033
,	O
and	O
indications	B-T078
categorized	O
as	O
pain	B-T184
,	O
breathlessness	B-T184
,	O
other,	O
or	O
unknown.	O
In	O
total,	O
2,249	O
COPD	B-T047
patients	B-T101
(59%	O
women	B-T098
)	O
were	O
included.	O
During	O
a	O
median	O
follow-up	B-T058
of	O
1.1	O
(	O
interquartile range	B-T081
0.6-2.0)	O
years	B-T079
,	O
1,034	O
patients	B-T101
(46%)	O
were	O
dispensed	B-T058
≥1	O
opioid	B-T109
prescription	B-T058
(N=13,722	O
prescriptions	B-T058
).	O
The	O
most	O
frequently	O
prescribed	B-T058
opioids	B-T109
were	O
tramadol	B-T109
(23%),	O
oxycodone	B-T109
(23%),	O
morphine	B-T109
(16%),	O
and	O
codeine	B-T109
(16%).	O
Average	O
dispensed quantity	B-T081
was	O
9.3	O
(	O
interquartile range	B-T081
3.7-16.7)	O
defined	O
daily doses	B-T081
per	O
prescription	B-T058
.	O
In	O
the	O
random	O
sample	B-T167
,	O
the	O
most	O
commonly	O
stated	O
indication	B-T078
was	O
pain	B-T184
(97%),	O
with	O
only	O
2%	O
for	O
breathlessness	B-T184
and	O
1%	O
for	O
other	O
reasons.	O
Despite	O
evidence	O
that	O
supported	O
the	O
use	O
of	O
opioids	B-T109
for	O
the	O
relief	B-T169
of	O
breathlessness	B-T184
predating	O
this	O
study	B-T062
,	O
opioids	B-T109
are	O
rarely	O
prescribed	B-T058
to	O
relieve	B-T169
breathlessness	B-T184
in	O
oxygen-dependent	B-T042
COPD	B-T047
,	O
potentially	O
contributing	O
to	O
less-than-optimal	O
symptom control	B-T061
.	O
This	O
study	B-T062
creates	O
a	O
baseline	B-T081
against	O
which	O
to	O
compare	O
future	O
changes	O
in	O
morphine	B-T109
prescribing	O
in	O
this	O
setting.	O

In Vivo	B-T082
3-Dimensional	B-T082
Strain Mapping	B-T052
Confirms	B-T080
Large	B-T081
Optic Nerve Head	B-T023
Deformations	B-T190
Following	B-T079
Horizontal Eye Movements	B-T039
To	O
measure	B-T081
lamina cribrosa	B-T023
(	O
LC	B-T023
)	O
strains	B-T190
(	O
deformations	B-T190
)	O
following	B-T079
abduction	B-T039
and	O
adduction	B-T169
in	O
healthy subjects	B-T098
and	O
to	O
compare	B-T052
them	O
with	O
those	O
resulting	B-T169
from	O
a	O
relatively	B-T080
high	B-T080
acute	B-T079
intraocular pressure	B-T042
(	O
IOP	B-T042
)	O
elevation	B-T082
.	O
A	O
total	B-T080
of	O
16	O
eyes	B-T023
from	O
8	O
healthy subjects	B-T098
were	O
included	B-T052
.	O
Among	O
the	O
16	O
eyes	B-T023
,	O
11	O
had	O
peripapillary atrophy	B-T033
(	O
PPA	B-T033
).	O
For	O
each	B-T081
subject	B-T096
,	O
both	O
optic nerve heads	B-T023
(	O
ONHs	B-T023
)	O
were	O
imaged	B-T170
using	O
optical coherence tomography	B-T060
(	O
OCT	B-T060
)	O
at	O
baseline	B-T081
(	O
twice	B-T081
),	O
in	O
different	B-T080
gaze	B-T074
positions	B-T082
(	O
adduction	B-T169
and	O
abduction	B-T039
of	O
20°)	O
and	O
following	B-T079
an	O
acute	B-T079
IOP	B-T042
elevation	B-T082
of	O
approximately	B-T080
20	O
mm	O
Hg	B-T131
from	O
baseline	B-T081
(via	O
ophthalmodynamometry	B-T060
).	O
Strains	B-T190
of	O
LC	B-T023
for	O
all	O
loading scenarios	B-T169
were	O
mapped	B-T170
using	O
a	O
three-dimensional	B-T082
tracking	B-T082
algorithm	B-T170
.	O
In	O
all	O
16	O
eyes	B-T023
,	O
LC	B-T023
strains	B-T190
induced	B-T169
by	O
adduction	B-T169
and	O
abduction	B-T039
were	O
5.83%	O
±	O
3.78%	O
and	O
3.93%	O
±	O
2.57%,	O
respectively,	O
and	O
both	O
significantly higher	B-T081
than	O
the	O
control	B-T096
strains	B-T190
measured	B-T080
from	O
the	O
repeated	B-T169
baseline	B-T081
acquisitions	B-T052
(P	O
<	O
0.01).	O
Strains	B-T190
of	O
LC	B-T023
in	O
adduction	B-T169
were	O
on	O
average	B-T081
higher	B-T080
than	O
those	O
in	O
abduction	B-T039
,	O
but	O
the	O
difference	B-T080
was	O
not	O
statistically significant	B-T081
(P	O
=	O
0.07).	O
Strains	B-T190
of	O
LC	B-T023
induced	B-T169
by	O
IOP	B-T042
elevations	B-T082
(on	O
average	B-T081
21.13	O
±	O
7.61	O
mm	O
Hg	B-T131
)	O
were	O
6.41%	O
±	O
3.21%	O
and	O
significantly higher	B-T081
than	O
the	O
control	B-T096
strains	B-T190
(P	O
<	O
0.0005).	O
Gaze	B-T074
-	O
induced	B-T169
LC	B-T023
strains	B-T190
in	O
the	O
PPA	B-T033
group	B-T101
were	O
on	O
average	B-T081
larger	B-T081
than	O
those	O
in	O
the	O
non-PPA group	B-T101
;	O
however,	O
the	O
relationship	B-T080
was	O
not	O
statistically significant	B-T081
.	O
Our	O
results	B-T033
confirm	B-T080
that	O
horizontal eye movements	B-T039
generate	B-T080
significant	B-T078
ONH	B-T023
strains	B-T190
,	O
which	O
is	O
consistent with	B-T078
our	O
previous	B-T079
estimations	B-T041
using	O
finite element analysis	B-T170
.	O
Further studies	B-T062
are	O
needed	O
to	O
explore	O
a	O
possible	B-T033
link	O
between	O
ONH	B-T023
strains	B-T190
induced	B-T169
by	O
eye movements	B-T039
and	O
axonal loss	B-T033
in	O
optic neuropathies	B-T047
.	O

Simultaneously	B-T079
Targeting	B-T169
Myofibroblast Contractility	B-T043
and	O
Extracellular Matrix	B-T024
Cross-Linking	B-T169
as	O
a	O
Therapeutic Concept	B-T169
in	O
Airway	B-T023
Fibrosis	B-T046
Fibrosis	B-T046
after	O
solid organ transplantation	B-T061
is	O
considered	O
an	O
irreversible	B-T079
process	B-T067
and	O
remains	O
the	O
major	B-T080
cause	O
of	O
graft dysfunction	B-T046
and	O
death	B-T040
with	O
limited	B-T169
therapies	B-T061
.	O
This	O
remodeling	B-UnknownType
is	O
characterized	B-T052
by	O
aberrant	B-T080
accumulation	B-T033
of	O
contractile myofibroblasts	B-T025
that	O
deposit	B-T169
excessive	B-T080
extracellular matrix	B-T024
(	O
ECM	B-T024
)	O
and	O
increase	B-T169
tissue stiffness	B-T184
.	O
Studies	B-T062
demonstrate,	O
however,	O
that	O
a	O
stiff	B-T184
ECM	B-T024
itself	O
promotes	B-T052
fibroblast	B-T025
-to-	O
myofibroblast	B-T025
differentiation	B-T043
,	O
stimulating	B-T052
further	O
ECM	B-T024
production	B-T052
.	O
This	O
creates	O
a	O
positive feedback loop	B-UnknownType
that	O
perpetuates	B-T080
fibrosis	B-T046
.	O
We	O
hypothesized	B-T078
that	O
simultaneously	B-T079
targeting	B-T169
myofibroblast contractility	B-T043
with	O
relaxin	B-T116
and	O
ECM	B-T024
stiffness	B-T184
with	O
lysyl oxidase	B-T116
inhibitors	B-T121
could	O
break	O
the	O
feedback loop	B-T039
,	O
reversing	B-T169
established	B-T080
fibrosis	B-T046
.	O
To	O
test	B-T169
this,	O
we	O
used	O
the	O
orthotopic tracheal transplantation	B-T061
(	O
OTT	B-T061
)	O
mouse model	B-T050
,	O
which	O
develops	O
robust	B-T080
fibrotic	B-T169
airway	B-T023
remodeling	B-UnknownType
.	O
Mice	B-T015
with	O
established	B-T080
fibrosis	B-T046
were	O
treated	B-T169
with	O
saline	B-T167
,	O
mono-	B-T061
,	O
or	O
combination therapies	B-T061
.	O
Although	O
monotherapies	B-T061
had	O
no effect	B-T080
,	O
combining these agents	B-T121
decreased	B-T081
collagen	B-T116
deposition	B-T169
and	O
promoted	B-T052
re-epithelialization	B-T042
of	O
remodeled airways	B-T033
.	O
Relaxin	B-T116
inhibited	B-T080
myofibroblast	B-T025
differentiation	B-T043
and	O
contraction	B-T046
in	O
a	O
matrix	B-T024
-	O
stiffness	B-T184
-	O
dependent	B-T169
manner	O
through	O
prostaglandin E2	B-T109
(	O
PGE2	B-T109
).	O
Furthermore,	O
the	O
effect	B-T080
of	O
combination therapy	B-T061
was	O
lost	O
in	O
PGE2 receptor	B-T116
knockout	B-T015
and	O
PGE2	B-T109
-	O
inhibited	B-T080
OTT	B-T061
mice	B-T015
.	O
This	O
study	B-T062
revealed	B-T080
the	O
important	O
synergistic	B-T080
roles	B-T077
of	O
cellular contractility	B-T046
and	O
tissue stiffness	B-T184
in	O
the	O
maintenance	B-T052
of	O
fibrotic	B-T169
tissue	B-T024
and	O
suggests	O
a	O
new	O
therapeutic	B-T169
principle	B-UnknownType
for	O
fibrosis	B-T046
.	O

Systemic matrix metalloproteinase-8	B-T116
response	B-T038
in	O
chronic tonsillitis	B-T047
The	O
development	B-T169
of	O
several	O
life-long	O
diseases	B-T047
,	O
such	O
as	O
coronary heart disease	B-T047
,	O
is	O
affected	O
by	O
low-grade	B-T080
systemic	B-T169
inflammation	B-T046
.	O
Data	B-T078
on	O
the	O
potential	B-T080
long-term	B-T079
health	B-T078
effects	B-T080
of	O
chronic tonsillitis	B-T047
are	O
limited.	O
Many	O
inflammatory	B-T046
conditions	B-T080
present	O
with	O
enhanced	O
systemic matrix metalloproteinase	B-T116
(MMP)-8	B-T116
response	B-T038
.	O
In	O
head and neck cancer	B-T191
,	O
high	B-T080
plasma	B-T031
level	B-T080
of	O
tissue inhibitor of metalloproteinase	B-T116
(TIMP)-1	B-T116
predicts	B-T078
poor prognosis	B-T033
.	O
We	O
analyzed	O
S-MMP-8	B-T116
with	O
immunofluorometric assay	B-T059
and	O
S-TIMP-1	B-T116
with	O
an	O
immunosorbent assay	B-T059
in	O
175	O
consecutive	B-T080
patients	B-T101
undergoing	O
tonsillectomy	B-T061
for	O
benign tonsillar disease	B-T191
,	O
and	O
in	O
33	O
control	B-T096
patients	B-T101
with	O
tonsillar squamous cell carcinoma	B-T191
.	O
Tonsillar	B-T023
human papillomavirus	B-T005
(	O
HPV	B-T005
)	O
status	O
was	O
determined	O
by	O
PCR	B-T063
.	O
In	O
patients	B-T101
with	O
benign tonsillar disease	B-T191
,	O
chronic tonsillitis	B-T047
without	O
hypertrophy	B-T046
was	O
associated with	B-T080
enhanced	O
systemic MMP-8	B-T116
response	B-T038
.	O
Compared	O
to	O
patients	B-T101
with	O
benign tonsillar disease	B-T191
,	O
patients	B-T101
with	O
tonsillar squamous cell carcinoma	B-T191
had	O
significantly higher	B-T081
concentrations	B-T081
of	O
S-MMP-8	B-T116
and	O
S-TIMP-1	B-T116
.	O
Neither	O
S-MMP-8	B-T116
nor	O
S-TIMP-1	B-T116
correlated	O
with	O
tonsillar	B-T023
HPV	B-T005
positivity	B-T033
.	O

Addressing	B-T170
holistic health	B-T078
and	O
work	B-T057
empowerment	B-T054
through	B-T169
a	O
body-mind-spirit intervention program	B-T058
among	O
helping	B-T054
professionals	B-T097
in	O
continuous	B-T078
education	B-T065
:	O
A	O
pilot study	B-T062
To	O
examine	O
the	O
effectiveness	B-T080
of	O
a	O
body-mind-spirit (BMS) intervention program	B-T058
in	O
improving	B-T080
the	O
holistic well-being	B-T078
and	O
work	B-T057
empowerment	B-T054
among	O
helping	B-T054
professionals	B-T097
in	O
continuous	B-T078
education	B-T065
.	O
Forty-four	O
helping	B-T054
professionals	B-T097
,	O
who	O
were	O
in	O
their	O
first-year	O
part-time	O
postgraduate study	B-T065
,	O
participated	O
in	O
the	O
present	O
study.	O
All	O
participants	B-T098
attended	B-T169
a	O
3-day	O
BMS intervention program	B-T058
which	O
emphasized	O
a	O
holistic approach	B-T078
to	O
health	B-T078
and	O
well-being	B-T078
.	O
Ratings	O
on	O
their	O
levels	B-T080
of	O
physical distress	B-T033
,	O
daily functioning	B-T054
,	O
affect	B-T041
,	O
spirituality	B-T078
,	O
and	O
psychologica	B-T169
l	O
empowerment	B-T054
at	O
work	B-T057
were	O
compared	O
before	O
and	O
immediately	O
after	O
the	O
intervention	B-T058
.	O
Participants	B-T098
reported	O
significantly	O
lower	O
levels	B-T080
of	O
negative affect	B-T033
and	O
physical distress	B-T033
,	O
and	O
were	O
less	O
spiritually disoriented	B-T033
after	O
the	O
intervention	B-T058
.	O
Enhanced	B-T052
levels	B-T080
of	O
daily functioning	B-T054
,	O
positive affect	B-T041
,	O
spiritual resilience	B-UnknownType
,	O
and	O
tranquility	B-T041
were	O
also	O
reported.	O
Results	O
also	O
suggested	O
that	O
participants	B-T098
were	O
empowered	B-T041
at	O
work	B-T057
,	O
and	O
specifically	O
felt	O
more	O
able	O
to	O
make	O
an	O
impact	O
on	O
work	B-T057
outcomes.	O
The	O
3-day	O
BMS intervention program	B-T058
produced	O
a	O
positive	B-T033
and	O
measurable	B-T169
effec	B-T080
t	O
on	O
participants	B-T098
'	O
holistic well-being	B-T078
and	O
empowerment	B-T054
at	O
work	B-T057
.	O
Educators	B-T097
in	O
related	O
fields	B-T077
could	O
incorporate	O
holistic	B-T078
practices	B-T041
into	O
the	O
curriculum	B-T170
to	O
better	O
prepare	O
the	O
future	O
practitioners	B-T097
,	O
leading	O
to	O
better	O
outcomes	O
both	O
to	O
the	O
professionals	B-T097
themselves	O
and	O
their	O
clients	B-T096
or	O
patients	B-T101
.	O

Successful Restoration	B-T061
of	O
Severely	O
Mutilated	B-T037
Primary Incisors	B-T023
Using	O
a	O
Novel	O
Method	O
to	O
Retain	O
Zirconia	B-T074
Crowns	B-T074
-	O
Two Year	B-T079
Results	B-T169
This	O
manuscript	B-T073
describes	O
a	O
simple	O
reliable technique	B-T169
for	O
restoring	B-T061
severely	O
mutilated	B-T037
primary anterior teeth	B-T023
.	O
A	O
rigid	O
glass ionomer post	B-T122
is	O
created	O
over	O
which	O
zirconia	B-T074
crowns	B-T074
can	O
be	O
fitted	O
to	O
achieve	O
a	O
long-term	B-T079
stable	O
esthetic	B-T061
restoration	B-T061
for	O
primary anterior teeth	B-T023
.	O
Children	B-T100
aged	O
2-5	O
years	B-T079
with	O
two	O
up	O
to	O
six	O
extensively	O
decayed	B-T047
upper primary incisors	B-T023
were	O
included.	O
Fuji IX	B-T122
was	O
condensed	O
into	O
an	O
intracanal space	B-T061
created	O
to	O
a	O
depth	B-T082
of	O
3mm,	O
to	O
provide	O
a	O
core	B-T082
which	O
also	O
extended	O
3mm	O
supragingivally	B-T061
.	O
Crown preparations	B-T061
were	O
completed	O
upon	O
these	O
cores	B-T082
.	O
Zirconia	B-T074
crowns	B-T074
(	O
Nusmile	B-T170
,	O
Houston Texas	B-T083
USA	B-T083
)	O
were	O
fitted	B-T067
and	O
cemented	B-T031
over	O
the	O
prepared	O
cores	B-T082
.	O
All	O
patients	B-T101
were	O
recalled	B-T061
at	O
regular intervals	B-T079
.	O
Twenty-three	O
healthy	O
children	B-T100
with	O
86	O
restorations	B-T061
participated	O
in	O
the	O
study	B-T062
.	O
The	O
overall survival	B-T081
of	O
the	O
restorations	B-T061
was	O
95.3%	O
after	O
12	O
months	B-T079
and	O
80.2%	O
after	O
24	O
months	B-T079
.	O
According	O
to	O
Kaplan-Meier survival analysis	B-T062
,	O
the	O
median survival time	B-T079
was	O
not	O
reached	O
while	O
the	O
estimated	O
mean survival time	B-T081
was	O
22.9	O
months	B-T079
.	O
This	O
newly	O
described	O
clinical technique	B-T058
is	O
simple	O
and	O
reliable	B-T170
to	O
use	O
for	O
restoration	B-T061
of	O
extensively	O
decayed	B-T047
primary incisors	B-T023
.	O
Use	O
of	O
zirconia	B-T074
crowns	B-T074
retained	O
using	O
this	O
technique	B-T169
offers	O
superior esthetic	B-T080
,	O
durable	O
restorations	B-T061
with	O
remarkable	O
gingival response	B-T033
up	O
to	O
24	O
months	B-T079
.	O

Reimbursement	B-T170
Based	O
on	O
Value	O
in	O
Knee Surgery	B-T061
:	O
What	O
You	O
Need	O
to	O
Know	O
about	O
the	O
Medicare Access and Children's Health Insurance Program Reauthorization Act of 2015	B-T089
Health care cost	B-T081
is	O
consuming	O
a	O
large	O
portion	O
of	O
the	O
nation's	B-T092
gross domestic product	B-T081
while	O
placing	O
added	O
economic burdens	B-T081
on	O
physicians	B-T097
and	O
their	O
patients	B-T101
.	O
With	O
total joint replacement	B-T061
being	O
one	O
of	O
the	O
early-targeted	O
procedures	B-T061
in	O
the	O
evolving	O
health care environment	B-T093
,	O
knee surgeons	B-T097
will	O
benefit	O
from	O
developing	O
a	O
critical	O
knowledge	O
on	O
health care reforms	B-T064
and	O
their	O
financial	O
implications.	O
The	O
Medicare Access and Children's Health Insurance Program Reauthorization Act	B-T089
represents	O
a	O
cohesive	O
movement	O
toward	O
value-based payment reform	B-T064
and	O
contains	O
several	O
unchartered	O
rulings	O
that	O
require	O
detailed	O
attention	O
by	O
knee surgeons	B-T097
.	O
In	O
this	O
article,	O
we	O
provide	O
a	O
contextual framework	B-T078
of	O
health care legislation	B-T089
that	O
has	O
led	O
to	O
the	O
formation	O
of	O
the	O
current	O
health policy	B-T089
,	O
and	O
present	O
a	O
comprehensive	B-T080
summary	B-T170
and	O
update	O
on	O
the	O
Merit-Based Incentive Payment Systems	B-T170
and	O
Alternative Payment Models reimbursement models	B-T170
.	O

Empty	B-T080
Capsids	B-T017
and	O
Macrophage	B-T025
Inhibition	B-T052
/	O
Depletion	B-T169
Increase	B-T169
rAAV	B-T121
Transgene	B-T028
Expression	B-T045
in	O
Joints	B-T030
of	O
Both	O
Healthy	B-T080
and	O
Arthritic	B-T047
Mice	B-T015
Gene therapy	B-T061
has	O
potential	B-T080
to	O
treat	B-T061
rheumatic diseases	B-T047
;	O
however,	O
the	O
presence	B-T033
of	O
macrophages	B-T025
in	O
the	O
joint	B-T030
might	O
hamper	O
adeno-associated viral	B-T005
vector	B-T121
-mediated	O
gene delivery	B-T077
.	O
Here	O
we	O
demonstrate	O
that	O
in	O
arthritic	B-T047
,	O
but	O
also	O
in	O
healthy	B-T080
,	O
mice	B-T015
administration of agents	B-T058
that	O
influence	B-T077
macrophage	B-T025
activity	B-T052
/	O
number	B-T081
and/or	O
addition	B-T169
of	O
empty	B-T080
decoy capsids	B-T017
substantially	O
improve	B-T033
the	O
efficacy	B-T080
of	O
recombinant	B-T001
adeno-associated viral	B-T005
vector	B-T121
5	O
transgene	B-T028
expression	B-T045
in	O
the	O
joint	B-T030
.	O
Pretreatment	B-T052
with	O
triamcinolone	B-T109
or	O
clodronate	B-T109
liposomes	B-T109
improved	B-T033
luciferase	B-T116
expression	B-T045
over	O
a	O
period	B-T079
of	O
4	O
weeks	B-T079
.	O
Similar	B-T080
results	B-T033
were	O
seen	O
when	O
empty	B-T080
decoy capsids	B-T017
were	O
added	B-T169
to	O
full	B-T080
genome	B-T028
containing	O
capsids	B-T017
in	O
a	O
5:1	O
ratio	B-T081
.	O
In	O
a	O
study	B-T062
to	O
assess	B-T052
the	O
duration	B-T079
of	O
expression	B-T045
as	O
well	O
as	O
to	O
investigate	B-T169
the	O
combination	B-T080
of	O
these	O
two	O
approaches	B-T169
,	O
we	O
observed	B-T169
a	O
synergistic	B-T080
enhancement	B-T052
of	O
gene expression	B-T045
,	O
sustained	B-T169
for	O
at	O
least	O
12	O
weeks	B-T079
.	O
The	O
enhancement	B-T052
of	O
gene expression	B-T045
was	O
independent	O
of	O
the	O
route of administration	B-T169
of	O
triamcinolone	B-T109
(	O
intra-articular	B-T082
or	O
intramuscular	B-T082
).	O
In	O
healthy	B-T080
mice	B-T015
it	O
was	O
demonstrated	O
that	O
the	O
combination	B-T080
improved	B-T033
expression	B-T045
of	O
the	O
transgene	B-T028
significantly,	O
in	O
a	O
serotype	B-T170
independent	O
manner.	O
These	O
data	B-T078
have	O
implications	O
for	O
future	O
applications	O
of	O
gene therapy	B-T061
to	O
the	O
joint	B-T030
and	O
for	O
other	O
tissues	B-T024
with	O
an	O
abundance	B-T080
of	O
macrophages	B-T025
.	O

An	O
Inhibitory	B-T052
Septum	B-UnknownType
to	O
Lateral Hypothalamus	B-T029
Circuit	B-UnknownType
That	O
Suppresses	B-T169
Feeding	B-T055
Feeding behavior	B-T055
is	O
orchestrated	B-T169
by	O
neural circuits	B-UnknownType
primarily	O
residing	O
in	O
the	O
hypothalamus	B-T023
and	O
hindbrain	B-T023
.	O
However,	O
the	O
relative	B-T080
influence	B-T077
of	O
cognitive	B-T169
and	O
emotional	B-T041
brain circuits	B-UnknownType
to	O
the	O
feeding	B-T055
circuitry	B-UnknownType
in	O
the	O
hypothalamus	B-T023
and	O
hindbrain	B-T023
remains	O
unclear	B-T033
.	O
Here,	O
using	B-T169
the	O
cell-type	B-T170
selectivity	O
of	O
genetic methods	B-T062
,	O
circuit mapping	B-T060
,	O
and	O
behavior	B-T053
assays	B-T059
,	O
we	O
sought	O
to	O
decipher	O
neural circuits	B-UnknownType
emanating	O
from	O
the	O
septal nucleus	B-T023
to	O
the	O
lateral hypothalamus	B-T029
(	O
LH	B-T029
)	O
that	O
contribute	O
to	O
neural regulation	B-T042
of	O
food intake	B-T040
in	O
mice	B-T015
.	O
We	O
found	O
that	O
chemogenetic	B-T169
and	O
optogenetic	B-T169
activation	B-T052
of	O
septal	B-T082
vesicular GABA transporter	B-T116
(	O
vGAT	B-T116
)-	O
containing	B-T169
neurons	B-T025
or	O
their	O
projections	O
in	O
the	O
LH	B-T029
reduced	B-T080
food intake	B-T040
in	O
mice	B-T015
.	O
Consistently,	O
chemogenetic	B-T169
inhibition	B-T052
of	O
septal	B-T082
vGAT	B-T116
neurons	B-T025
increased	B-T081
food intake	B-T040
.	O
Furthermore,	O
we	O
investigated	B-T169
a	O
previously	O
unknown	B-T080
neural circuit	B-UnknownType
originating	B-T079
from	O
septal	B-T082
vGAT	B-T116
neurons	B-T025
to	O
a	O
subset	B-T185
of	O
vGAT	B-T116
neurons	B-T025
in	O
the	O
LH	B-T029
,	O
an	O
area	B-T082
involved	B-T169
in	O
homeostatic	B-T038
and	O
hedonic	B-T038
control	B-T080
of	O
energy states	B-T033
.	O
Collectively,	O
our	O
data	B-T078
reveal	B-T080
an	O
inhibitory	B-T052
septohypothalamic	B-T029
feeding circuit	B-UnknownType
that	O
might	O
serve	O
as	O
a	O
therapeutic	B-T169
target	B-T169
for	O
the	O
treatment	B-T169
of	O
eating disorders	B-T048
such	O
as	O
anorexia nervosa	B-T048
.	O
Our	O
results	O
demonstrate	O
that	O
top-down	O
projections	O
from	O
the	O
septum	B-UnknownType
to	O
the	O
hypothalamus	B-T023
control	B-T080
food intake	B-T040
negatively	B-T033
.	O
Given	O
the	O
known	O
role	O
for	O
both	O
of	O
these	O
brain regions	B-T029
in	O
the	O
control	B-T080
of	O
feeding	B-T055
and	O
emotion	B-T041
-	O
related	B-T169
behaviors	B-T053
,	O
these	O
findings	B-T033
reveal	B-T080
previously	O
unknown	B-T080
neural circuitry	B-UnknownType
that	O
is	O
likely	O
implicated	O
in	O
emotional aspects	B-T078
of	O
food intake	B-T040
and	O
provide	B-T052
new	O
insights	B-T041
into	O
the	O
development	B-T169
of	O
therapeutic	B-T169
targets	B-T169
for	O
the	O
treatment	B-T169
of	O
eating disorders	B-T048
.	O

Human	B-T016
Umbilical Cord Blood	B-T031
-	O
Derived	B-T078
Neural Stem Cell Line	B-T025
as	O
a	O
Screening	B-T058
Model	B-T075
for	O
Toxicity	B-T037
The	O
aim	B-T078
was	O
to	O
investigate	B-T169
whether	O
a	O
human	B-T016
neural stem cell	B-T025
(	O
NSC	B-T025
)	O
line	B-T025
derived	B-T078
from	O
human	B-T016
umbilical cord blood	B-T031
(	O
hUCB	B-T031
)	O
can	O
be	O
used	O
for	O
toxicity	B-T037
study	B-T062
.	O
Toxicity	B-T037
of	O
both	O
neurotoxic	B-T131
environmental	B-T082
xenobiotics	B-T123
,	O
methyl mercury chloride	B-T109
(	O
CH3HgCl	B-T109
),	O
lead acetate	B-T121
(	O
CH3COOPb	B-T121
),	O
and	O
chlorpyrifos	B-T109
(	O
CP	B-T109
),	O
and	O
non-neurotoxic	B-T033
insecticide	B-T131
,	O
dichlorvos	B-T109
,	O
as	O
well	O
as	O
non-neurotoxic	B-T033
drugs	B-T121
,	O
theophylline	B-T109
and	O
acetaminophen	B-T109
were	O
assessed	B-T052
.	O
Additionally,	O
differentiation	B-T169
of	O
neuronal	B-T129
and	O
glial cell lines	B-T025
derived	B-T078
from	O
hUCB	B-T031
was	O
elucidated.	O
It	O
was	O
observed	B-T169
that	O
CH3HgCl	B-T109
was	O
more	O
toxic	B-T080
to	O
human	B-T016
NSCs	B-T025
in	O
comparison	B-T052
to	O
CH3COOPb	B-T121
and	O
CP	B-T109
.	O
The	O
minimum inhibitory concentration (MIC) value	B-T034
against	O
NSCs	B-T025
was	O
3,	O
10,	O
and	O
300	O
mg/L,	O
in	O
each	O
staining process	B-T059
,	O
acridine orange	B-T109
/	O
ethidium bromide	B-T109
(	O
AO	B-T109
/	O
EB	B-T109
)	O
staining	B-T059
,	O
3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl tetrazolium bromide	B-T109
(	O
MTT	B-T109
)	O
assay	B-T059
,	O
and	O
Hoechst staining	B-T059
,	O
for	O
CH3HgCl	B-T109
,	O
CP	B-T109
,	O
and	O
CH3COOPb	B-T121
,	O
respectively.	O
CH3HgCl	B-T109
had	O
the	O
LC25	B-T081
value	B-T080
as	O
10.0,	O
14.4,	O
and	O
12.7	O
mg/L,	O
by	O
staining method	B-T059
mentioned	O
in	O
succession.	O
CP	B-T109
had	O
the	O
LC25	B-T081
value	B-T080
as	O
21.9,	O
23.7,	O
and	O
18.4	O
mg/L;	O
similarly,	O
CH3COOPb	B-T121
had	O
LC25	B-T081
values	B-T080
,	O
successively	O
as	O
616.9,	O
719.2,	O
and	O
890.3	O
mg/L.	O
LC50	B-T081
values	B-T080
ranged	B-T081
from	O
18.2	O
to	O
21.7	O
mg/L	O
for	O
CH3HgCl	B-T109
,	O
56.4	O
to	O
60.2	O
mg/L	O
for	O
CP	B-T109
,	O
and	O
1000	O
to	O
1460.1	O
for	O
CH3COOPb	B-T121
.	O
Theophylline	B-T109
,	O
acetaminophen	B-T109
,	O
and	O
dichlorvos	B-T109
had	O
no	O
impact	B-T080
on	O
the	O
viability	B-T080
of	O
NSCs	B-T025
.	O
This	O
work	O
justified	O
that	O
hUCB	B-T031
-	O
NSC	B-T025
model	B-T075
can	O
be	O
used	O
for	O
toxicity	B-T037
study	B-T062
.	O

MiR 221	B-T028
/	O
222	B-T028
as	O
new	O
players	O
in	O
tamoxifen	B-T109
resistance	B-T038
Breast cancer	B-T191
is	O
the	O
most	O
frequent	O
cancer	B-T191
in	O
women	B-T098
.	O
Despite	O
advances	O
in	O
early detection	B-T060
and	O
treatment	B-T061
,	O
it	O
has	O
the	O
second	O
highest	O
mortality rate	B-T081
after	O
lung cancer	B-T191
.	O
Around	O
85%	O
of	O
breast carcinomas	B-T191
are	O
ER+	B-T033
;	O
thus,	O
antiestrogens	B-T121
like	O
tamoxifen	B-T109
are	O
beneficial.	O
Although,	O
tamoxifen	B-T109
is	O
useful	O
for	O
many	O
patients	B-T101
,	O
plenty	O
of	O
patients	B-T101
respond poorly	B-T033
to	O
initial	O
therapy	B-T061
or	O
recurrence	B-T067
occurs	O
in	O
about	O
30%	O
of	O
cases,	O
because	O
tamoxifen	B-T109
resistance	B-T038
happens.	O
Drug resistance	B-T038
remains	O
a	O
major	O
clinical	B-T080
obstacle	O
to	O
successful treatment	B-T201
of	O
breast cancer	B-T191
and	O
more	O
than	O
90%	O
of	O
unsuccessful treatments	B-T033
are	O
because	O
of	O
acquired	B-T080
resistance	B-T038
and	O
MultiDrug Resistance	B-T032
(MDR)	B-T032
is	O
a	O
major	O
contributor.	O
MicroRNAs	B-T114
are	O
members	O
of	O
a	O
novel	O
class	O
of	O
short	O
noncoding RNAs	B-T114
.	O
Besides	O
to	O
their	O
various	O
roles	O
in	O
gene expression	B-T045
,	O
miRNAs	B-T114
are	O
considered	O
as	O
important	O
cancer	B-T191
therapeutic targets	B-T104
and	O
biomarkers	B-T201
.	O
Since	O
2005,	O
when	O
miRNA	B-T114
deregulation	B-T052
was	O
first	O
reported	O
in	O
breast cancer	B-T191
,	O
more	O
than	O
1000	O
reports	B-T170
have	O
been	O
published	O
about	O
miRNAs	B-T114
.	O
Increasing	O
number	O
of	O
studies	B-T062
showed	O
the	O
importance	O
of	O
miRNAs	B-T114
in	O
antiestrogen therapy	B-T061
,	O
especially	O
on	O
tamoxifen	B-T109
;	O
thus,	O
it	O
is	O
not	O
surprising	O
that	O
these	O
tiny	O
molecules	B-T167
are	O
involved	O
in	O
drug resistance	B-T038
.	O
Due	O
to	O
the	O
pivotal	O
role	O
of	O
these	O
known	O
RNA molecules	B-T114
,	O
in	O
this	O
review,	O
we	O
tried	O
to	O
illustrate	O
the	O
importance	O
of	O
the	O
miRNAs	B-T114
as	O
a	O
new	O
player	O
in	O
breast cancer	B-T191
pathogenesis	B-T046
.	O
We	O
have	O
also	O
focused	O
on	O
cancer	B-T191
drug resistance	B-T038
mechanisms	B-T169
highlighting	O
the	O
role	O
of	O
important	O
oncomirs	B-T114
,	O
miR 221	B-T028
/	O
222	B-T028
,	O
involved	O
in	O
cell cycle deregulation	B-T049
in	O
breast cancer	B-T191
.	O
The	O
relationship	O
between	O
these	O
oncomiRs	B-T114
with	O
resistance	B-T038
to	O
tamoxifen	B-T109
is	O
also	O
emphasized	B-T080
.	O

Ultra-low activities	B-T052
of	O
a	O
common	O
radioisotope	B-T196
for	O
permission	B-T080
-free	O
tracking	B-T082
of	O
a	O
drosophilid fly	B-T204
in	O
its	O
natural habitat	B-T082
Knowledge	O
of	O
a	O
species	B-T185
'	O
ecology	B-T090
,	O
including	O
its	O
movement	B-T040
in	O
time	B-T079
and	O
space	B-T082
,	O
is	O
key	O
for	O
many	O
questions	O
in	O
biology	B-T091
and	O
conservation	B-T080
.	O
While	O
numerous	O
tools	B-T073
for	O
tracking	B-T082
larger	O
animals	B-T008
are	O
available,	O
millimetre-sized insects	B-T204
are	O
averse	O
to	O
standard	O
tracking	B-T082
and	O
labelling procedures	B-T062
.	O
Here,	O
we	O
evaluated	O
the	O
applicability	O
of	O
ultra-low	B-T052
,	O
permission	B-T080
-	O
exempt activities	B-T052
of	O
the	O
metastable isomer	B-T070
of	O
the	O
radionuclide	B-T196
Technetium-99	B-T130
for	O
labelling	B-T062
and	O
field detection	B-T033
of	O
the	O
mountain	B-T083
fly	B-T204
Drosophila nigrosparsa	B-T204
.	O
We	O
demonstrate	O
that	O
an	O
activity	B-T052
of	O
less	O
than	O
10	O
MBq	O
is	O
sufficient	O
to	O
label	B-T062
dozens	O
of	O
flies	B-T204
and	O
detect single individuals	B-T033
using	O
standard	O
radiation protection	B-T061
monitors	B-T059
.	O
The	O
methodology	B-T078
presented	O
here	O
is	O
applicable	O
to	O
many	O
small-sized	B-T033
,	O
low-mobility	B-T033
animals	B-T008
as	O
well	O
as	O
independent	O
from	O
light	B-T070
and	O
weather	B-T070
conditions	B-T080
and	O
visual contact	B-T033
with	O
the	O
target	B-T169
organism	B-T001
.	O

Injury surveillance	B-T057
of	O
female	B-T032
adult	B-T100
Zumba	B-T058
®	O
dancers	B-T097
We	O
sought	O
to	O
describe	O
the	O
patterns	B-T082
of	O
injury	B-T037
and	O
to	O
establish	O
the	O
injury	B-T037
incidence rates	B-T081
associated	B-T080
with	O
Zumba	B-T058
®.	O
Zumba	B-T058
®	O
dancers	B-T097
were	O
invited	O
to	O
complete	O
an	O
anonymous	O
web-based	B-T073
survey	B-T170
containing	O
13	O
demographic	B-T078
background	B-T077
and	O
14	O
(1	O
yr	B-T079
retrospective	B-T080
)	O
injury	B-T037
history	B-T169
questions	B-T170
.	O
Inclusion	B-T080
criteria	B-T078
stated	O
that	O
the	O
respondents	B-T098
had	O
to	O
be	O
aged	B-T032
18	O
-	O
64	O
yr	B-T079
and	O
currently	O
involved	O
in	O
group	B-T098
-based	O
classes	B-T170
of	O
Zumba	B-T058
®,	O
either	O
as	O
a	O
registered instructor	B-T097
or	O
class	B-T170
participant	B-T098
.	O
Binomial logistic regression analysis	B-UnknownType
was	O
used	O
to	O
predict	O
the	O
odds	B-T081
of	O
injury	B-T037
during	O
Zumba	B-T058
®	O
and	O
Mann-Whitney tests	B-T170
were	O
employed	O
to	O
ascertain	O
differences	O
between	O
groups	B-T098
.	O
The	O
survey	B-T170
response rate	B-T081
was	O
74%.	O
The	O
final	O
sample	O
of	O
respondents	B-T098
(N	O
=	O
138;	O
female	B-T032
=	O
100%)	O
included	O
19	O
registered instructors	B-T097
and	O
119	O
class	B-T170
participants	B-T098
,	O
of	O
which	O
58%	O
and	O
16%,	O
respectively,	O
sustained	B-T169
≥	O
1	O
injury	B-T037
during	O
Zumba	B-T058
®	O
in	O
the	O
past	O
year	B-T079
.	O
The	O
odds	B-T081
of	O
injury	B-T037
was	O
7	O
(95%	O
CI	B-T081
2	O
-	O
19)	O
times	O
greater	B-T081
(p	O
<	O
0.01)	O
for	O
registered instructors	B-T097
than	O
for	O
class	B-T170
participants	B-T098
.	O
Zumba	B-T058
®	O
dancers	B-T097
had	O
a	O
17	O
(95%	O
CI	B-T081
7	O
-	O
28)	O
%	O
greater	B-T081
(p	O
<	O
0.01)	O
odds	B-T081
of	O
injury	B-T037
for	O
every	O
1	O
h	B-T079
of	O
non-	O
Zumba	B-T058
®-	O
related	O
moderate to vigorous physical activity	B-T056
(	O
MVPA	B-T056
)	O
engagement	O
per	O
week	B-T079
.	O
The	O
injury	B-T037
incidence rate	B-T081
for	O
registered instructors	B-T097
and	O
class	B-T170
participants	B-T098
was	O
5.7	O
(95%	O
CI	B-T081
3.1	O
-	O
8.2)	O
and	O
3.9	O
(95%	O
CI	B-T081
2.5	O
-	O
5.3)	O
injuries	B-T037
per	O
1000	O
h	B-T079
of	O
exposure	B-T080
,	O
respectively.	O
Zumba	B-T058
®	O
presents	O
a	O
low risk	B-T081
of	O
injury	B-T037
;	O
for	O
registered instructors	B-T097
,	O
the	O
increased risk	B-T080
of	O
injury	B-T037
is	O
likely	O
due	O
to	O
the	O
high	O
total	O
volume	O
of	O
MVPA	B-T056
participated	B-T169
in	O
weekly	B-T079
.	O

Clinical	B-T080
Features	B-T080
of	O
Smokers	B-T033
With	O
Radiological	B-T060
Emphysema	B-T047
But	O
Without	O
Airway	B-T023
Limitation	B-T169
The	O
clinical characteristics	B-T201
of	O
patients	B-T101
with	O
emphysema	B-T047
but	O
without	O
airway	B-T023
limitations	B-T169
remain	O
unknown	B-T080
.	O
The	O
goal	B-T170
of	O
this	O
study	B-T062
was	O
to	O
compare	B-T052
the	O
clinical	B-T080
features	B-T080
of	O
current	B-T033
and	O
former smokers	B-T033
without	O
airflow	B-T039
limitation	B-T169
who	O
have	O
radiologic	B-T060
emphysema	B-T047
on	O
chest CT scans	B-T060
vs	O
a	O
control group	B-T096
of	O
current	B-T033
and	O
ex-smokers	B-T033
without	O
emphysema	B-T047
.	O
Subjects	B-T096
enrolled	O
had	O
anthropometric characteristics	B-T060
recorded,	O
provided	B-T052
a	O
medical history	B-T033
,	O
and	O
underwent	O
low-dose	B-T081
chest CT scanning	B-T060
.	O
The	O
following	O
parameters	B-T033
were	O
also	O
evaluated:	O
pulmonary function tests	B-T060
including	O
diffusion capacity for carbon monoxide	B-T060
(	O
Dlco	B-T060
),	O
the	O
modified	O
Medical Research Council dyspnea score	B-T170
,	O
COPD assessment test	B-T170
(	O
CAT	B-T170
),	O
and	O
6-min walk test	B-T060
(	O
6MWT	B-T060
).	O
A	O
comparison	B-T052
was	O
conducted	O
between	O
those	O
with	O
and	O
without	O
CT	B-T060
-	O
confirmed	B-T033
emphysema	B-T047
.	O
Of	O
the	O
203	O
subjects	B-T096
,	O
154	O
had	O
emphysema	B-T047
,	O
and	O
49	O
did	O
not.	O
Adjusted	O
group	B-T098
comparisons	B-T052
revealed	B-T080
that	O
a	O
higher	O
proportion	B-T081
of	O
patients	B-T101
with	O
emphysema	B-T047
according	O
to	O
low-dose	B-T081
chest CT scanning	B-T060
had	O
an	O
abnormal Dlco	B-T033
value	B-T081
(<	O
80%)	O
(46%	O
vs	O
19%;	O
P	O
=	O
.02),	O
a	O
decrease	B-T081
in	O
percentage	B-T081
of	O
oxygen saturation	B-T044
>	O
4%	O
during	O
the	O
6MWT	B-T060
(8.5%	O
vs	O
0;	O
P	O
=	O
.04),	O
and	O
an	O
altered	B-T169
quality of life	B-T078
(	O
CAT	B-T170
score	B-T081
≥	O
10)	O
(32%	O
vs	O
14%;	O
P	O
=	O
.01).	O
A	O
detailed	O
analysis	B-T062
of	O
the	O
CAT questionnaire	B-T170
items	O
revealed	B-T080
that	O
more	O
patients	B-T101
with	O
emphysema	B-T047
had	O
a	O
score	B-T081
≥	O
1	O
in	O
the	O
"	O
chest tightness	B-T184
"	O
(P	O
=	O
.05)	O
and	O
"	O
limitation	B-T169
when	O
doing	O
activities	B-T052
at	O
home	B-T082
"	O
(P	O
<	O
.01)	O
items	O
compared	B-T052
with	O
those	O
with	O
no emphysema	B-T033
.	O
They	O
also	O
experienced	O
significantly	O
more	O
exacerbations	B-T033
in	O
the	O
previous	O
year	B-T079
(0.19	O
vs	O
0.04;	O
P	O
=	O
.02).	O
A	O
significant	B-T078
proportion	B-T081
of	O
smokers	B-T033
with	O
emphysema	B-T047
according	O
to	O
low-dose	B-T081
chest CT scanning	B-T060
but	O
without	O
airway	B-T023
limitation	B-T169
had	O
alterations	B-T078
in	O
their	O
quality of life	B-T078
,	O
number	O
of	O
exacerbations	B-T033
,	O
Dlco	B-T060
values	B-T081
,	O
and	O
oxygen saturation	B-T044
during	O
the	O
6MWT test	B-T060
.	O

Anti-tumor activity	B-T042
of	O
SL4	B-T109
against	O
breast cancer cells	B-T025
:	O
induction	B-T169
of	O
G2/M arrest	B-T044
through	O
modulation	B-UnknownType
of	O
the	O
MAPK	B-T116
-dependent	O
p21	B-T116
signaling pathway	B-T043
SL4	B-T109
,	O
a	O
chalcone	B-T109
-based	O
compound	B-T103
,	O
has	O
been	O
shown	O
to	O
retard	B-T080
tumor invasion	B-T033
and	O
angiogenesis	B-T191
by	O
suppressing	B-T169
HIF1	B-T116
activity	B-T052
and	O
to	O
induce	B-T169
apoptosis	B-T043
by	O
promoting	B-T052
ROS	B-T123
release	B-T169
.	O
Here,	O
we	O
report	B-T170
that	O
SL4	B-T109
is	O
able	O
to	O
inhibit	B-T052
the	O
proliferation	B-T043
of	O
different	B-T080
types	B-T080
of	O
breast cancer cell	B-T025
in vitro	B-T080
and	O
in vivo	B-T082
by	O
inducing	B-T169
G2/M cell cycle arrest	B-T044
.	O
Our	O
results	B-T033
showed	O
that	O
SL4	B-T109
exhibited	B-T169
strong	B-T080
anti-proliferative	B-T109
activity	B-T052
in	O
several	O
human	B-T016
breast cancer	B-T191
cell lines	B-T025
,	O
with	O
IC50 values	B-T081
lower	B-T052
than	O
1.3	O
μM.	O
Further	O
studies	B-T062
indicated	B-T033
that	O
SL4	B-T109
induced	B-T169
G2/M arrest	B-T044
in	O
these	O
cell lines	B-T025
.	O
Mechanistically	B-T022
,	O
SL4	B-T109
reduces	B-T080
the	O
expression	B-T045
of	O
cyclin A2	B-T116
and	O
cdc25C	B-T116
and	O
decreases	B-T081
the	O
activity	B-T044
of	O
the	O
cdc2	B-T116
/	O
cyclin B1	B-T116
complex	B-T104
.	O
Notably,	O
SL4	B-T109
treatment	B-T061
resulted in	B-T169
an	O
obvious	O
increase	B-T169
in	O
p21	B-T028
mRNA	B-T114
and	O
protein	B-T116
levels	B-T080
through	O
activation	B-T043
of	O
MAPK signaling pathways	B-T043
,	O
but	O
not	O
the	O
TGF-β pathway	B-T044
.	O
SP600125	B-T109
and	O
PD98059	B-T109
,	O
specific	O
inhibitors	B-T120
of	O
JNK kinase	B-T116
and	O
ERK kinase	B-T116
,	O
significantly	B-T078
blocked	B-T169
the	O
SL4	B-T109
-	O
induced	B-T169
G2/M phase arrest	B-T044
and	O
upregulation	B-T044
of	O
p21	B-T116
.	O
Furthermore,	O
SL4	B-T109
suppressed	B-T169
the	O
growth	B-T043
of	O
established	B-T080
breast tumors	B-T191
in	O
nude mice	B-T015
through	O
upregulation	B-T044
of	O
p21	B-T116
and	O
downregulation	B-T044
of	O
cdc25C	B-T116
,	O
and	O
displayed	B-T169
a	O
good	O
safety	B-T068
profile	B-T169
.	O
Taken	O
together,	O
these	O
findings	B-T033
demonstrate	B-T080
the	O
potential	B-T080
value	B-T080
of	O
SL4	B-T109
as	O
a	O
novel	O
multi-target anti-tumor drug candidate	B-T109
.	O

Identification	B-T080
of	O
In-Chain-Functionalized Compounds	B-T103
and	O
Methyl-Branched Alkanes	B-T109
in	O
Cuticular	B-T002
Waxes	B-T122
of	O
Triticum aestivum cv. Bethlehem	B-T002
In	O
this	O
work,	O
cuticular	B-T002
waxes	B-T122
from	O
flag leaf	B-T002
blades	B-T002
and	O
peduncles	B-T002
of	O
Triticum aestivum cv. Bethlehem	B-T002
were	O
investigated	B-T169
in	O
search	O
for	O
novel	B-T080
wax compounds	B-T122
.	O
Seven	O
wax compound	B-T122
classes	B-T185
were	O
detected	B-T033
that	O
had	O
previously	O
not	O
been	O
reported,	O
and	O
their	O
structures	B-T170
were	O
elucidated	O
using	O
gas chromatography-mass spectrometry	B-T059
of	O
various	O
derivatives	B-T104
.	O
Six	O
of	O
the	O
classes	O
were	O
identified	O
as	O
series of homologs	B-T081
differing	B-T080
by	O
two methylene units	B-T104
,	O
while	O
the	O
seventh	O
was	O
a	O
homologous series	B-T081
with	O
homologs with single methylene unit	B-T104
differences.	O
In	O
the	O
waxes	B-T122
of	O
flag leaf	B-T002
blades	B-T002
,	O
secondary alcohols	B-UnknownType
(	O
predominantly	B-T080
C27	B-UnknownType
and	O
C33	B-UnknownType
),	O
primary	B-T109
/	O
secondary diols	B-T109
(	O
predominantly	B-T080
C28	B-T109
)	O
and	O
esters of primary	B-T109
/	O
secondary diols	B-T109
(	O
predominantly	B-T080
C50	B-T109
,	O
combining	O
C28 diol	B-T109
with	O
C22 acid	B-T109
)	O
were	O
found,	O
all	O
sharing	O
similar	O
secondary hydroxyl group positions	B-T104
at	O
and	O
around	O
C-12	O
or	O
ω-12.	O
7-	B-T109
and	O
8-hydroxy-2-alkanol esters	B-T109
(	O
predominantly	B-T080
C35	B-T109
),	O
7-	B-T109
and	O
8-oxo-2-alkanol esters	B-T109
(	O
predominantly	B-T080
C35	B-T109
),	O
and	O
4-alkylbutan-4-olides	B-T109
(	O
predominantly	B-T080
C28	B-T109
)	O
were	O
found	O
both	O
in	O
flag leaf	B-T002
and	O
peduncle	B-T002
wax	B-T122
mixtures.	O
Finally,	O
a	O
series	B-T081
of	O
even	B-T104
-	O
and	O
odd-numbered alkane homologs	B-T104
was	O
identified	O
in	O
both	O
leaf	B-T002
and	O
peduncle	B-T002
waxes	B-T122
,	O
with	O
an	O
internal methyl branch	B-T104
preferentially	O
on	O
C-11	B-T109
and	O
C-13 of homologs with even total carbon number	B-T109
and	O
on	O
C-12 of odd-numbered homologs	B-T109
.	O
Biosynthetic pathways	B-T044
are	O
suggested	O
for	O
all	O
compounds	B-T080
,	O
based	O
on	O
common	O
structural	B-T170
features	B-T080
and	O
matching	O
chain length	B-T081
profiles	B-T169
with	O
other	O
wheat	B-T002
wax compound	B-T122
classes.	O

Pupillary response	B-T040
abnormalities	B-T033
in	O
depressive disorders	B-T048
Depressive disorders	B-T048
lack	B-T080
objective	B-T080
physiological	B-T169
measurements	B-T169
to	O
characterize	B-T052
the	O
affected population	B-T201
and	O
facilitate	O
study	B-T062
of	O
relevant	B-T080
mechanisms	B-T169
.	O
The	O
melanopsin	B-T116
-	O
mediated	B-T041
light signaling pathway	B-T044
may	O
contribute	O
to	O
seasonal variation	B-T079
and	O
can	O
be	O
measured	B-T080
non-invasively	O
by	O
pupillometry	B-T060
.	O
We	O
prospectively studied	B-T062
changes	O
in	O
melanopsin	B-T116
-	O
mediated	B-T041
pupillary constriction	B-T042
in	O
19	O
participants	B-T101
with	O
major depressive disorder	B-T048
(	O
MDD	B-T048
)	O
and	O
10	O
control	B-T096
across	O
the	O
summer and winter solstices	B-T079
.	O
The	O
melanopsin	B-T116
-	O
mediated response	B-T041
,	O
as	O
measured	B-T080
by	O
the	O
pupil's sustained constriction	B-T033
six	O
s	O
after	O
a	O
high intensity	B-UnknownType
blue light	B-T070
stimulus	B-T067
,	O
was	O
marginally	O
attenuated	B-T052
in	O
those	O
with	O
MDD	B-T048
relative	O
to	O
controls	B-T096
(	O
p	B-T081
=0.071).	O
The	O
participants	B-T101
with	O
MDD	B-T048
unexpectedly	O
showed	O
a	O
significantly	B-T078
reduced	B-T080
transient	B-T079
pupillary response	B-T040
to	O
low intensity	B-UnknownType
red	B-T070
(	O
p	B-T081
=0.011)	O
and	O
blue light	B-T070
(	O
p	B-T081
=0.013),	O
but	O
not	O
high intensity	B-UnknownType
red	B-T070
and	O
blue light	B-T070
.	O
Sustained	O
pupillary constriction	B-T042
in	O
response	B-T040
to	O
high intensity	B-UnknownType
blue light	B-T070
was	O
more	O
pronounced	O
with	O
increasing	B-T169
daylight	B-T070
hours	B-T079
(	O
p	B-T081
=0.037)	O
and	O
was	O
more	O
strongly	O
related	O
to	O
objectively	B-T080
measured	B-T080
versus	O
estimated	B-T081
light exposure	B-T051
.	O
Melanopsin	B-T116
-	O
mediated	B-T041
impairments	B-T169
in	O
pupil response	B-T040
may	O
serve	O
as	O
a	O
biological marker	B-T201
for	O
vulnerability	B-T033
to	O
depression	B-T048
in	O
low light	B-UnknownType
conditions	B-T080
.	O
Assessment	B-T058
of	O
these	O
and	O
other	O
responses	B-T032
to	O
light	B-T070
stimuli	B-T067
,	O
such	O
as	O
response	B-T032
to	O
low intensity light	B-UnknownType
,	O
may	O
be	O
useful	O
for	O
the	O
study	B-T062
of	O
the	O
neurobiology	B-T091
of	O
MDD	B-T048
and	O
related	O
mood disorders	B-T048
.	O

Long Noncoding RNAs	B-T114
in	O
Cardiovascular Pathology	B-T047
,	O
Diagnosis	B-T062
,	O
and	O
Therapy	B-T061
Vast	O
parts	O
of	O
mammalian	B-T015
genomes	B-T028
encode	B-T052
for	O
transcripts	B-T114
that	O
are	O
not	O
further	O
translated into proteins	B-T045
.	O
The	O
purpose	B-T169
of	O
the	O
majority	B-T080
of	O
such	O
noncoding ribonucleic acids	B-T114
(RNAs)	B-T114
remained	O
paradoxical	B-T080
for	O
a	O
long	O
time.	O
However,	O
a	O
growing	B-T169
body	O
of	O
evidence	B-T078
demonstrates	B-T052
that	O
long noncoding RNAs	B-T114
are	O
dynamically	B-T169
expressed	B-T045
in	O
different	B-T080
cell types	B-T025
,	O
diseases	B-T047
,	O
or	O
developmental stages	B-T079
to	O
execute	B-T052
a	O
wide variety	B-T077
of	O
regulatory roles	B-T077
at	O
virtually	B-T080
every	O
step	B-T077
of	O
gene expression	B-T045
and	O
translation	B-T045
.	O
Indeed,	O
long noncoding RNAs	B-T114
influence	B-T077
gene expression	B-T045
via	O
epigenetic modulations	B-T045
,	O
through	O
regulating	B-T045
alternative splicing	B-T045
,	O
or	O
by	O
acting	O
as	O
molecular sponges	B-T080
.	O
The	O
abundance	B-T080
of	O
long noncoding RNAs	B-T114
in	O
the	O
cardiovascular system	B-T022
indicates	O
that	O
they	O
may	O
be	O
part	O
of	O
a	O
complex	B-T080
regulatory network	B-T044
governing	B-T067
physiology	B-T039
and	O
pathology	B-T046
of	O
the	O
heart	B-T023
.	O
In	O
this	O
review,	O
we	O
discuss	O
the	O
multifaceted	B-T082
functions	B-T169
of	O
long noncoding RNAs	B-T114
and	O
highlight	O
the	O
current literature	B-T170
with	O
an	O
emphasis	O
on	O
cardiac development	B-T039
and	O
disease	B-T047
.	O
Furthermore	B-T082
,	O
as	O
the	O
enormous	B-T080
spectrum	O
of	O
long noncoding RNAs	B-T114
potentially	B-T080
opens	O
up	O
new	O
avenues	B-T082
for	O
diagnosis	B-T062
and	O
prevention	B-T061
of	O
heart failure	B-T047
,	O
we	O
ultimately	O
evaluate	O
the	O
futuristic prospects	B-T079
of	O
long noncoding RNAs	B-T114
as	O
biomarkers	B-T201
,	O
and	O
therapeutic	B-T169
targets	B-T114
for	O
the	O
treatment	B-T061
of	O
cardiovascular disorders	B-T047
,	O
as	O
well.	O

Flexible	B-T080
Coordination	B-T169
of	O
Stationary	B-T080
and	O
Mobile	B-T169
Conversations	B-T054
with	O
Gaze	B-T033
:	O
Resource Allocation	B-T081
among	O
Multiple Joint Activities	B-T056
Gaze	B-T033
is	O
instrumental	O
in	O
coordinating	B-T169
face-to-face	B-T169
social interactions	B-T033
.	O
But	O
little	O
is	O
known	O
about	O
gaze	B-T033
use	O
when	O
social interactions	B-T033
co-occur	B-T052
with	O
other	O
joint activities	B-T056
.	O
We	O
investigated	B-T169
the	O
case	O
of	O
walking	B-T056
while	O
talking	B-T056
.	O
We	O
assessed	B-T052
how	O
gaze	B-T033
gets	O
allocated	B-T052
among	O
various	O
targets	B-T098
in	O
mobile	B-T169
conversations	B-T054
,	O
whether	O
allocation	B-T052
of	O
gaze	B-T033
to	O
other	O
targets	B-T098
affects	B-T041
conversational	B-T054
coordination	B-T169
,	O
and	O
whether	O
reduced	B-T080
availability of	B-T169
gaze	B-T033
for	O
conversational	B-T054
coordination	B-T169
affects	B-T041
conversational	B-T054
performance	B-T055
and	O
content	B-T077
.	O
In	O
an	O
experimental study	B-T062
,	O
pairs	O
were	O
videotaped	B-T073
in	O
four	O
conditions	B-T080
of	O
mobility	B-T033
(	O
standing still	B-T082
,	O
talking	B-T056
while	O
walking along a straight-line itinerary	B-T060
,	O
talking	B-T056
while	O
walking	B-T056
along	O
a	O
complex itinerary	B-T080
,	O
or	O
walking	B-T056
along	O
a	O
complex itinerary	B-T080
with	O
no conversational	B-T033
task	B-T057
).	O
Gaze	B-T033
to	O
partners	B-T098
was	O
substantially reduced	B-T080
in	O
mobile	B-T169
conversations	B-T054
,	O
but	O
gaze	B-T033
was	O
still	O
used	O
to	O
coordinate	B-T169
conversation	B-T054
via	O
displays	B-T169
of	O
mutual	B-T080
orientation	B-T082
,	O
and	O
conversational	B-T054
performance	B-T055
and	O
content	B-T077
was	O
not	O
different	B-T080
between	O
stationary	B-T080
and	O
mobile	B-T169
conditions	B-T080
.	O
Results	B-T034
expand	O
the	O
phenomena	B-T067
of	O
multitasking	O
to	O
joint activities	B-T056
.	O

Sepsis	B-T047
Clinical Criteria	B-T080
in	O
Emergency Department	B-T073
Patients	B-T101
Admitted	B-T058
to	O
an	O
Intensive Care Unit	B-T073
:	O
An	O
External Validation Study	B-T062
of	O
Quick Sequential Organ Failure Assessment	B-T033
Quick Sequential Organ Failure Assessment	B-T033
(	O
qSOFA	B-T033
)	O
is	O
a	O
prognostic score	B-T081
for	O
patients	B-T101
with	O
sepsis	B-T047
.	O
Our	O
aim	B-T078
was	O
to	O
compare	O
the	O
area under the receiver operating curve	B-T081
(	O
AUROC	B-T081
),	O
sensitivity	B-T081
,	O
specificity	B-T081
,	O
and	O
likelihood ratios	B-T081
of	O
qSOFA	B-T033
vs.	O
systemic inflammation response syndrome	B-T047
(	O
SIRS	B-T047
)	O
in	O
predicting	O
in-hospital mortality	B-T080
among	O
emergency department	B-T073
(	O
ED	B-T073
)	O
patients	B-T101
with	O
suspected infection	B-T046
admitted	B-T058
to	O
intensive care units	B-T073
(	O
ICUs	B-T073
).	O
We	O
conducted	O
a	O
retrospective cohort chart review study	B-T062
of	O
ED	B-T073
patients	B-T101
admitted	B-T058
to	O
an	O
ICU	B-T073
with	O
suspected infection	B-T046
from	O
August	B-T080
1,	O
2012	O
to	O
February	B-T080
28,	O
2015.	O
We	O
included	O
all	O
patients	B-T101
with	O
body fluid cultures sampled	B-T031
either	O
during	O
their	O
ED	B-T073
stay	O
without	O
antibiotic administration	B-T061
or	O
within	O
24	O
h	O
of	O
antibiotics administered	B-T061
in	O
the	O
ED	B-T073
.	O
Trained chart abstractors	B-T097
blinded	O
to	O
the	O
study	B-T062
hypothesis	O
double-entered data	B-T078
from	O
each	O
patient's	B-T101
electronic medical record	B-T170
including	O
demographic characteristics	B-T102
,	O
vital signs	B-T201
,	O
laboratory study results	B-T059
,	O
physical examination	B-T058
findings	B-T033
,	O
and	O
in-hospital mortality	B-T080
.	O
We	O
then	O
calculated	O
the	O
AUROC	B-T081
,	O
sensitivity	B-T081
,	O
specificity	B-T081
,	O
and	O
likelihood ratios	B-T081
for	O
qSOFA	B-T033
and	O
SIRS	B-T047
for	O
predicting	O
in-hospital mortality	B-T080
.	O
Of	O
214	O
patients	B-T101
admitted	B-T058
to	O
an	O
ICU	B-T073
with	O
presumed sepsis	B-T047
,	O
39	O
(18.2%)	O
died during hospitalization	B-T033
.	O
The	O
AUROC	B-T081
value	O
was	O
0.65	O
(95%	O
confidence interval	B-T081
[	O
CI	B-T081
]	O
0.56-0.74)	O
for	O
SIRS	B-T047
vs.	O
0.66	O
(95%	O
CI	B-T081
0.57-0.76)	O
for	O
qSOFA	B-T033
;	O
2+	O
qSOFA	B-T033
criteria	O
predicted	O
in-hospital mortality	B-T080
with	O
89.7%	O
sensitivity	B-T081
,	O
27.4%	O
specificity	B-T081
,	O
1.2	O
positive likelihood ratio	B-T081
,	O
and	O
0.4	O
negative likelihood ratio	B-T081
.	O
Among	O
ED	B-T073
patients	B-T101
admitted	B-T058
to	O
an	O
ICU	B-T073
,	O
the	O
SIRS	B-T047
and	O
qSOFA	B-T033
criteria	O
had	O
comparable	O
prognostic value	B-T081
for	O
predicting	O
in-hospital mortality	B-T080
.	O
These	O
prognostic values	B-T081
are	O
similar	O
to	O
those	O
reported	O
by	O
the	O
Sepsis-3 guidelines	B-T170
for	O
ICU	B-T073
encounters	B-T170
.	O

Repetitive transcranial magnetic stimulation	B-T061
improves	O
cognitive function	B-T041
of	O
Alzheimer's disease	B-T047
patients	B-T101
Repetitive transcranial magnetic stimulation	B-T061
(	O
rTMS	B-T061
)	O
acts	O
as	O
a	O
kind	O
of	O
widely-applied	O
and	O
non-invasive	O
method	O
in	O
the	O
intervention	B-T061
of	O
some	O
neurological disorders	B-T047
.	O
This	O
prospective	B-T062
,	O
randomized	B-T062
,	O
double-blind	B-T062
,	O
placebo-controlled trial	B-T062
investigates	B-T169
the	O
effect	O
of	O
rTMS	B-T061
on	O
30	O
cases	B-T169
of	O
Alzheimer's disease	B-T047
(	O
AD	B-T047
)	O
participants	B-T098
,	O
who	O
were	O
classified	O
into	O
mild	B-T080
and	O
moderate	B-T080
groups	B-T098
.	O
Neuropsychological tests	B-T060
were	O
carried	O
out	O
using	O
the	O
AD Assessment Scale	B-T170
-	O
cognitive subscale	B-T170
(	O
ADAS	B-T170
-	O
cog	B-T170
),	O
Mini-Mental State Examination	B-T060
(	O
MMSE	B-T060
),	O
Montreal Cognitive Assessment	B-T170
(	O
MoCA	B-T170
),	O
and	O
World Health Organization University of California-Los Angeles, Auditory Verbal Learning Test	B-T170
(	O
WHO-UCLA AVLT	B-T170
)	O
before,	O
immediately	O
after,	O
and	O
6	O
weeks	B-T079
after	O
the	O
intervention	B-T061
.	O
In	O
this	O
work,	O
data	B-T078
from	O
30	O
AD	B-T047
patients	B-T101
revealed	O
that	O
there	O
was	O
no	O
obvious	O
interaction effect	B-UnknownType
of	O
time-by-group.	O
The	O
ADAS	B-T170
-	O
cog	B-T170
,	O
MMSE	B-T060
and	O
WHO-UCLA AVLT	B-T170
score	B-T081
in	O
the	O
rTMS	B-T061
group	B-T098
was	O
significantly	O
improved	O
compared	B-T052
with	O
baselines	B-T081
at	O
6	O
weeks	B-T079
after	O
treatment	B-T061
(all	O
p<0.05).	O
Meanwhile,	O
MoCA	B-T170
scores	B-T081
were	O
also	O
obviously	O
ameliorated	B-T033
in	O
the	O
mild	B-T080
AD	B-T047
patients	B-T101
with	O
rTMS	B-T061
.	O
Besides,	O
subgroup analysis	B-T062
showed	O
that	O
the	O
effect	O
of	O
rTMS	B-T061
on	O
the	O
memory	B-T041
and	O
language	B-T171
of	O
mild	B-T080
AD	B-T047
patients	B-T101
was	O
superior	O
to	O
those	O
of	O
moderate	B-T080
AD	B-T047
patients	B-T101
.	O
In	O
conclusion,	O
our	O
findings	B-T033
suggested	O
that	O
repetitive transcranial magnetic stimulation	B-T061
improves	O
cognitive function	B-T041
,	O
memory	B-T041
and	O
language	B-T171
level	B-T080
of	O
AD	B-T047
patients	B-T101
,	O
especially	O
in	O
the	O
mild	B-T080
stage	B-T079
of	O
AD	B-T047
.	O
Thus,	O
rTMS	B-T061
can	O
be	O
recommended	O
as	O
a	O
promising	O
adjuvant therapy	B-T061
combined	O
with	O
cholinesterase inhibitors	B-T109
at	O
the	O
mild	B-T080
stage	B-T079
of	O
AD	B-T047
patients	B-T101
.	O

A	O
Novel	B-T080
Insulin/Glucose	B-T081
Model	B-T170
after	O
a	O
Mixed-Meal Test	B-T059
in	O
Patients	B-T101
with	O
Type 1 Diabetes	B-T047
on	O
Insulin Pump	B-T074
Therapy	B-T061
Current	B-T079
closed-loop insulin delivery methods	B-T074
stem	O
from	O
sophisticated	O
models	O
of	O
the	O
glucose-insulin (G/I) system	B-T081
,	O
mostly	B-T078
based	O
on	O
complex	B-T080
studies	B-T062
employing	B-T033
glucose tracer technology	B-T074
.	O
We	O
tested	B-T169
the	O
performance	B-T052
of	O
a	O
new	O
minimal model	B-T170
(	O
GLUKINSLOOP 2.0	B-T170
)	O
of	O
the	O
G/I system	B-T081
to	O
characterize	B-T052
the	O
glucose and insulin	B-T081
dynamics	B-T070
during	O
multiple	B-T081
mixed meal tests	B-T059
(	O
MMT	B-T059
)	O
of	O
different	B-T080
sizes	B-T082
in	O
patients	B-T101
with	O
type 1 diabetes	B-T047
(	O
T1D	B-T047
)	O
on	O
insulin pump	B-T074
therapy	B-T061
(	O
continuous subcutaneous insulin infusion	B-T061
,	O
CSII	B-T061
).	O
The	O
GLUKINSLOOP 2.0	B-T170
identified	B-T080
the	O
G/I system	B-T081
,	O
provided	B-T052
a	O
close	O
fit	O
of	O
the	O
G/I	B-T081
time-courses	B-T079
and	O
showed	O
acceptable	B-T080
reproducibility	B-T080
of	O
the	O
G/I system	B-T081
parameters	B-T033
in	O
repeated	B-T169
studies	B-T062
of	O
identical	B-T080
and	O
double-sized	B-T081
MMTs	B-T059
.	O
This	O
model	B-T170
can	O
provide	B-T052
a	O
fairly	O
good	O
and	O
reproducible	O
description	B-T170
of	O
the	O
G/I system	B-T081
in	O
T1D	B-T047
patients	B-T101
on	O
CSII	B-T061
,	O
and	O
it	O
may	O
be	O
applied	B-T169
to	O
create	O
a	O
bank	O
of	O
"virtual" patients	B-T058
.	O
Our	O
results	B-T034
might	O
be	O
relevant	B-T080
at	O
improving	B-T080
the	O
architecture	O
of	O
upcoming	O
closed-loop	B-T169
CSII	B-T061
systems.	O

Impact	B-T080
of	O
Strategically	O
Located	O
White Matter Hyperintensities	B-T046
on	O
Cognition	B-T041
in	O
Memory Clinic	B-T073
Patients	B-T101
with	O
Small Vessel Disease	B-T047
Studies	O
on	O
the	O
impact	B-T080
of	O
small vessel disease	B-T047
(	O
SVD	B-T047
)	O
on	O
cognition	B-T041
generally	O
focus	B-T082
on	O
white matter hyperintensity	B-T046
(	O
WMH	B-T046
)	O
volume	B-T081
.	O
The	O
extent	B-T082
to	O
which	O
WMH	B-T046
location	B-T029
relates	B-T080
to	O
cognitive performance	B-T041
has	O
received	B-T080
less	B-T081
attention	B-T041
,	O
but	O
is	O
likely	O
to	O
be	O
functionally	B-T169
important	B-T080
.	O
We	O
examined	O
the	O
relation	B-T080
between	O
WMH	B-T046
location	B-T029
and	O
cognition	B-T041
in	O
a	O
memory clinic	B-T073
cohort	B-T098
of	O
patients	B-T101
with	O
sporadic	B-T079
SVD	B-T047
.	O
A	O
total	O
of	O
167	O
patients	B-T101
with	O
SVD	B-T047
were	O
recruited	O
from	O
memory clinics	B-T073
.	O
Assumption-free region of interest-based analyses	B-T062
based	B-T169
on	O
major	O
white matter	B-T024
tracts	B-T023
and	O
voxel	B-T077
-	O
wise	B-T169
analyses	B-T062
were	O
used	B-T169
to	O
determine	O
the	O
association	B-T080
between	O
WMH	B-T046
location	B-T029
and	O
executive functioning	B-T041
,	O
visuomotor speed	B-T041
and	O
memory	B-T041
.	O
Region of interest-based analyses	B-T062
showed	O
that	O
WMHs	B-T046
located	B-T029
particularly	O
within	B-T082
the	O
anterior thalamic radiation	B-T023
and	O
forceps minor	B-T023
were	O
inversely	B-T080
associated with	B-T080
both	O
executive functioning	B-T041
and	O
visuomotor speed	B-T041
,	O
independent of	B-T169
total	B-T080
WMH	B-T046
volume	B-T081
.	O
Memory	B-T041
was	O
significantly	O
associated with	B-T080
WMH	B-T046
volume	B-T081
in	O
the	O
forceps minor	B-T023
,	O
independent of	B-T169
total	B-T080
WMH	B-T046
volume	B-T081
.	O
An	O
independent assumption-free voxel-wise analysis	B-T062
identified	B-T080
strategic	O
voxels	B-T077
in	O
these	O
same	B-T080
tracts	B-T023
.	O
Region of interest-based analyses	B-T062
showed	O
that	O
WMH	B-T046
volume	B-T081
within	B-T082
the	O
anterior thalamic radiation	B-T023
explained	O
6.8%	O
of	O
variance	B-T080
in	O
executive functioning	B-T041
,	O
compared	B-T052
to	O
3.9%	O
for	O
total	B-T080
WMH	B-T046
volume	B-T081
;	O
WMH	B-T046
volume	B-T081
within	B-T082
the	O
forceps minor	B-T023
explained	O
4.6%	O
of	O
variance	B-T080
in	O
visuomotor speed	B-T041
and	O
4.2%	O
of	O
variance	B-T080
in	O
memory	B-T041
,	O
compared	B-T052
to	O
1.8%	O
and	O
1.3%	O
respectively	O
for	O
total	B-T080
WMH	B-T046
volume	B-T081
.	O
Our	O
findings	B-T033
identify	B-T080
the	O
anterior thalamic radiation	B-T023
and	O
forceps minor	B-T023
as	O
strategic	O
white matter	B-T024
tracts	B-T023
in	O
which	O
WMHs	B-T046
are	O
most	O
strongly	O
associated with	B-T080
cognitive impairment	B-T048
in	O
memory clinic	B-T073
patients	B-T101
with	O
SVD	B-T047
.	O
WMH	B-T046
volumes	B-T081
in	O
individual	O
tracts	B-T023
explained	O
more	O
variance	B-T080
in	O
cognition	B-T041
than	O
total	B-T080
WMH	B-T046
burden,	O
emphasizing	O
the	O
importance	B-T080
of	O
lesion location	B-T033
when	O
addressing	O
the	O
functional	B-T169
consequences of	B-T169
WMHs	B-T046
.	O

Natural	B-T169
competence	B-T080
for	O
transformation	B-T045
While	O
most	O
molecular biologists	B-T097
are	O
familiar	O
with	O
the	O
artificial	B-T080
transformation of bacteria	B-T045
in	O
the	O
context	B-T078
of	O
laboratory	B-T073
cloning	B-T062
experiments	B-T062
,	O
natural	B-T169
competence	B-T080
for	O
transformation	B-T045
refers	O
to	O
a	O
specific	B-T080
physiological	B-T169
state	B-T169
in	O
which	O
prokaryotes	B-T001
are	O
able	O
to	O
take	O
up	O
genetic material	B-T028
from	O
their	O
surroundings	B-T082
.	O
Occasionally,	O
such	O
absorbed	B-T169
DNA	B-T114
is	O
recombined	B-T080
into	O
the	O
organism's	B-T001
own	O
genome	B-T028
,	O
resulting	O
in	O
natural	B-T169
transformation	B-T045
(Figure	O
1).	O
As	O
a	O
consequence	B-T169
,	O
natural	B-T169
competence	B-T080
for	O
transformation	B-T045
is	O
considered	O
a	O
primary	B-T080
mode	B-T169
of	O
horizontal gene transfer	B-T045
(	O
HGT	B-T045
)	O
in	O
prokaryotes	B-T001
,	O
together	O
with	O
conjugation	B-T045
(	O
direct	B-T080
cell	B-T025
to	O
cell	B-T025
transfer	B-T078
of	O
DNA	B-T114
via	O
a	O
specialized	B-T077
conjugal pilus	B-T026
)	O
and	O
phage	B-T005
transduction	B-T045
(	O
DNA	B-T114
transfer	B-T078
mediated	O
by	O
viruses	B-T005
).	O
HGT	B-T045
plays	O
a	O
major	O
role	O
in	O
bacterial	B-T080
evolution	B-T045
,	O
and	O
past	B-T079
research	B-T062
has	O
demonstrated	O
that	O
HGT	B-T045
,	O
including	O
natural	B-T169
competence	B-T080
for	O
transformation	B-T045
,	O
contributes	B-T052
to	O
the	O
emergence	O
of	O
pathogens	B-T001
and	O
the	O
spread	B-T080
of	O
virulence factors	B-T109
.	O
Indeed,	O
Frederick	O
Griffith	O
discovered	O
natural	B-T169
competence	B-T080
for	O
transformation	B-T045
in	O
1928	O
while	O
he	O
was	O
investigating	B-T169
the	O
exchange	B-T045
of	O
pathogenic	B-T033
traits	B-T032
in	O
pneumococci	B-T007
.	O
Due	O
to	O
the	O
increase	B-T169
in	O
the	O
abundance	B-T080
and	O
spread	B-T080
of	O
multidrug-resistant microbes	B-T007
,	O
research	B-T062
on	O
HGT	B-T045
is	O
even	O
more	O
important	O
today	O
than	O
ever	O
before.	O

Three-dimensional constructive interference in steady-state (3D-CISS) sequences	B-T169
and	O
Phase-contrast MRI	B-T060
of	O
arrested hydrocephalus	B-T047
to	O
evaluate	O
role	O
of	O
three-dimensional constructive interference in steady-state (3D-CISS) sequences	B-T169
and	O
phase-contrast magnetic resonance imaging	B-T060
(	O
PC-MRI	B-T060
)	O
in	O
patients	B-T101
with	O
arrested hydrocephalus	B-T047
.	O
Prospective study	B-T062
was	O
conducted	O
on	O
20	O
patients	B-T101
with	O
arrested hydrocephalus	B-T047
.	O
All	O
patients	B-T101
underwent	O
PC-MRI	B-T060
and	O
3D-CISS	B-T169
for	O
assessment	B-T058
of	O
the	O
aqueduct	B-T030
.	O
Axial	B-T082
(	O
through-plane	B-T082
),	O
sagittal	B-T082
(	O
in-plane	B-T082
)	O
PC-MRI	B-T060
and	O
sagittal	B-T082
3D-CISS	B-T169
were	O
applied	O
to	O
assess	B-T058
the	O
cerebral aqueduct	B-T030
and	O
the	O
spontaneous	B-T169
third ventriculostomy	B-T061
if	O
present.	O
Aqueductal	B-T030
patency	B-T082
was	O
graded	B-T185
using	O
3D-CISS	B-T169
and	O
PC-MRI	B-T060
.	O
Quantitative analysis	B-T059
of	O
flow	O
through	O
the	O
aqueduct	B-T030
was	O
done	O
using	O
PC-MRI	B-T060
.	O
The	O
causes	O
of	O
obstruction	B-T046
were	O
aqueductal	B-T030
obstruction	B-T046
in	O
75%	O
(n=15),	O
3rd	O
ventricular obstruction	B-T047
in	O
5%	O
(n=1)	O
and	O
4th	O
ventricular obstruction	B-T047
in	O
20	O
%	O
(n=4).	O
The	O
cause	O
of	O
arrest	B-T079
of	O
hydrocephalus	B-T047
was	O
spontaneous	B-T169
third ventriculostomy	B-T061
in	O
65%	O
(n=13),	O
endoscopic third ventriculostomy	B-T061
in	O
10%	O
(n=2),	O
ventriculo-peritoneal shunt	B-T074
in	O
5%	O
(n=1)	O
and	O
no	O
cause	O
could	O
be	O
detected	B-T033
in	O
20%	O
of	O
patients	B-T101
(n=4).	O
There	O
is	O
a	O
positive	B-T033
correlation	B-T080
(r=	O
0.80)	O
and	O
moderate	B-T080
agreement	B-T054
(κ=	O
0.509)	O
of	O
grading	B-T185
with	O
PC-MRI	B-T060
and	O
3D-CISS sequences	B-T169
.	O
The	O
mean peak systolic velocity	B-T081
of	O
CSF	B-T031
was	O
1.86	O
±	O
2.48	O
cm/sec,	O
the	O
stroke volume	B-T201
was	O
6.43	O
±	O
13.81μl/cycle,	O
and	O
the	O
mean flow	B-T081
was	O
0.21	O
±	O
0.32	O
ml/min.	O
We	O
concluded	O
that	O
3D-CISS	B-T169
and	O
PC-MRI	B-T060
are	O
non-invasive	B-T169
sequences	O
for	O
diagnosis	B-T033
of	O
the	O
level	O
and	O
cause	B-T169
of	O
arrested hydrocephalus	B-T047
.	O

Historical	B-T079
Environment	B-T082
Is	O
Reflected	O
in	O
Modern Population Genetics	B-T090
and	O
Biogeography	B-T090
of	O
an	O
Island	B-T083
Endemic	B-T169
Lizard	B-T014
(	O
Xantusia riversiana reticulata	B-T014
)	O
The	O
restricted distribution	B-T169
and	O
isolation	B-T169
of	O
island	B-T083
endemics	B-T169
often	O
produces	O
unique	O
genetic	B-T070
and	O
phenotypic	B-T032
diversity	B-T080
of	O
conservation	B-T080
interest	O
to	O
management	B-T090
agencies	B-T092
.	O
However,	O
these	O
isolated	B-T169
species	B-T185
,	O
especially	O
those	O
with	O
sensitive	B-T169
life history	B-T032
traits	B-T032
,	O
are	O
at	O
high risk	B-T033
for	O
the	O
adverse effects	B-T046
of	O
genetic drift	B-T045
and	O
habitat	B-T082
degradation	B-T169
by	O
non-native wildlife	B-T008
.	O
Here,	O
we	O
study	B-T062
the	O
population	B-T098
genetic diversity	B-T070
,	O
structure	B-T082
,	O
and	O
stability	B-T080
of	O
a	O
classic	O
"	O
island giant	B-T014
"	O
(	O
Xantusia riversiana	B-T014
,	O
the	O
Island Night Lizard	B-T014
)	O
on	O
San Clemente Island	B-T083
,	O
California	B-T083
following	O
the	O
removal	B-T052
of	O
feral goats	B-T015
.	O
Using	O
DNA	B-T114
microsatellites	B-T114
,	O
we	O
found	O
that	O
this	O
population	B-T098
is	O
reasonably	O
genetically	B-T169
robust	B-T080
despite	O
historical	B-T079
grazing	B-T040
,	O
with	O
similar	O
effective	O
population sizes	B-T081
and	O
genetic diversity	B-T070
metrics	O
across	O
all	O
sampling	B-T078
locations	B-T083
irrespective	O
of	O
habitat	B-T082
type	O
and	O
degree of degradation	B-T080
.	O
However,	O
we	O
also	O
found	O
strong	O
site-specific	B-T082
patterns	B-T082
of	O
genetic variation	B-T070
and	O
low	O
genetic diversity	B-T070
compared	O
to	O
mainland congeners	B-T014
,	O
warranting	O
continued	O
special	O
management	B-T090
as	O
an	O
island	B-T083
endemic	B-T169
.	O
We	O
identify	O
both	O
high	B-T080
and	O
low	B-T080
elevation areas	B-T082
that	O
remain	O
valuable	O
repositories	B-T073
of	O
genetic diversity	B-T070
and	O
provide	O
a	O
case study	B-T170
for	O
other	O
low-dispersal	B-T070
coastal	B-T082
organisms	B-T001
in	O
the	O
face	O
of	O
future	B-T079
climate change	B-T070
.	O

Cross-Species	O
Rhesus	B-T015
Cytomegalovirus Infection	B-T047
of	O
Cynomolgus Macaques	B-T015
Cytomegaloviruses	B-T005
(	O
CMV	B-T005
)	O
are	O
highly	O
species-specific	O
due	O
to	O
millennia	O
of	O
co-evolution	B-T045
and	O
adaptation	B-T038
to	O
their	O
host	B-T001
,	O
with	O
no	O
successful	O
experimental	O
cross-	O
species	B-T185
infection	B-T046
in	O
primates	B-T015
reported	O
to	O
date.	O
Accordingly,	O
full	O
genome	B-T028
phylogenetic analysis	B-T062
of	O
multiple	O
new	O
CMV	B-T005
field	O
isolates	B-T123
derived	O
from	O
two	O
closely	O
related	O
nonhuman primate	B-T015
species	B-T185
,	O
Indian-origin	B-T033
rhesus macaques	B-T015
(	O
RM	B-T015
)	O
and	O
Mauritian	B-T083
-origin	O
cynomolgus macaques	B-T015
(	O
MCM	B-T015
),	O
revealed	O
distinct	O
and	O
tight	O
lineage	B-T077
clustering	O
according	O
to	O
the	O
species of origin	B-T033
,	O
with	O
MCM	B-T015
CMV	B-T005
isolates	B-T123
mirroring	O
the	O
limited	O
genetic diversity	B-T070
of	O
their	O
primate	B-T015
host	B-T001
that	O
underwent	O
a	O
population	O
bottleneck	O
400	O
years	O
ago.	O
Despite	O
the	O
ability	B-T032
of	O
Rhesus	B-T015
CMV	B-T005
(	O
RhCMV	B-T005
)	O
laboratory strain	B-T025
68-1	O
to	O
replicate	B-T080
efficiently	O
in	O
MCM	B-T015
fibroblasts	B-T025
and	O
potently	O
inhibit antigen presentation	B-T039
to	O
MCM	B-T015
T cells	B-T025
in vitro	B-T080
,	O
RhCMV	B-T005
68-1	O
failed	O
to	O
productively	O
infect	B-T046
MCM	B-T015
in vivo	B-T082
,	O
even	O
in	O
the	O
absence	O
of	O
host	B-T001
CD8+ T	B-T025
and	O
NK cells	B-T025
.	O
In	O
contrast,	O
RhCMV	B-T005
clone	B-T024
68-1.2,	O
genetically	B-T169
repaired	B-T058
to	O
express	B-T045
the	O
homologues	B-T028
of	O
the	O
HCMV	B-T005
anti-apoptosis	B-T043
gene UL36	B-T116
and	O
epithelial cell tropism	B-T039
genes UL128	B-T116
and	O
UL130	B-T116
absent	O
in	O
68-1,	O
efficiently	O
infected	B-T046
MCM	B-T098
as	O
evidenced	O
by	O
the	O
induction	B-T045
of	O
transgene	B-T028
-specific	O
T cells	B-T025
and	O
virus shedding	B-T046
.	O
Recombinant variants	B-T116
of	O
RhCMV	B-T005
68-1	O
and	O
68-1.2	O
revealed	O
that	O
expression	B-T045
of	O
either	O
UL36	B-T116
or	O
UL128	B-T116
together	O
with	O
UL130	B-T116
enabled	O
productive	O
MCM	B-T098
infection	B-T046
,	O
indicating	O
that	O
multiple	O
layers	O
of	O
cross-	O
species	B-T185
restriction	B-T169
operate	O
even	O
between	O
closely	O
related	O
hosts	B-T001
.	O
Cumulatively,	O
these	O
results	O
implicate	O
cell tropism	B-T039
and	O
evasion	O
of	O
apoptosis	B-T043
as	O
critical	O
determinants	B-T169
of	O
CMV	B-T005
transmission	B-T043
across	O
primate	B-T015
species	B-T185
barriers,	O
and	O
extend	O
the	O
macaque	B-T015
model	B-T170
of	O
human	B-T016
CMV	B-T005
infection	B-T046
and	O
immunology	B-T091
to	O
MCM	B-T098
,	O
a	O
nonhuman primate	B-T015
species	B-T185
with	O
uniquely	O
simplified	O
host	B-T001
immunogenetics	B-T091
.	O

Mildly	B-T080
raised	B-T080
tricuspid regurgitant velocity	B-T033
2.5-3.0	O
m/s	O
in	O
pregnant women	B-T098
with	O
sickle cell disease	B-T047
is	O
not	O
associated with	B-T080
poor	B-T080
obstetric	B-T169
outcome	B-T169
-	O
An	O
observational cross-sectional study	B-T062
Pulmonary hypertension	B-T046
is	O
associated with	B-T080
36%	O
mortality	B-T081
in	O
pregnancy	B-T040
,	O
and	O
6-10%	O
of	O
patients	B-T101
with	O
sickle cell disease	B-T047
have	O
pulmonary hypertension	B-T046
.	O
Tricuspid regurgitant velocity	B-T033
≥2.5	O
m/s	O
on	O
echocardiography	B-T060
is	O
a	O
well	O
validated	O
means	O
of	O
screening	B-T058
for	O
pulmonary hypertension	B-T046
in	O
the	O
non-pregnant	B-T033
population	B-T098
.	O
This	O
is	O
a	O
pilot study	B-T062
to	O
determine	O
if	O
this	O
is	O
a	O
useful	O
non-invasive	B-T169
screening test	B-T058
for	O
pulmonary hypertension	B-T046
in	O
pregnancy	B-T040
,	O
and	O
whether	O
raised	O
tricuspid regurgitant velocity	B-T033
≥2.5	O
m/s	O
was	O
associated with	B-T080
poor	B-T080
outcomes	B-T169
.	O
This	O
is	O
a	O
cross-sectional study	B-T062
over	O
a	O
five-year	O
period	O
in	O
a	O
tertiary referral centre	B-T073
with	O
a	O
specialised	O
multidisciplinary clinic	B-T093
for	O
pregnant women	B-T098
with	O
sickle cell disease	B-T047
.	O
Women	B-T098
with	O
sickle cell disease	B-T047
,	O
no	O
prior	O
pulmonary hypertension	B-T046
and	O
singleton	B-T099
pregnancies	B-T040
who	O
had	O
echocardiography	B-T060
with	O
a	O
measurable	O
tricuspid regurgitant velocity	B-T033
in	O
pregnancy	B-T040
were	O
included.	O
There	O
were	O
34	O
pregnancies	B-T040
,	O
of	O
which	O
eight	O
had	O
tricuspid regurgitant velocity	B-T033
≥2.5	O
m/s.	O
There	O
were	O
no significant	B-T033
differences	O
in	O
their	O
characteristics	B-T080
,	O
sickle cell	B-T025
-related	O
complications	B-T046
or	O
medical	B-T169
co-morbidities	B-T081
.	O
The	O
women	B-T098
with	O
tricuspid regurgitant velocity	B-T033
≥2.5	O
m/s	O
had	O
similar	O
obstetric	B-T169
and	O
perinatal	B-T079
outcomes	B-T169
as	O
those	O
with	O
a	O
tricuspid regurgitant velocity	B-T033
<2.5	O
m/s.	O

A	O
randomized trial	B-T062
of	O
TLR-2	B-T116
agonist	B-T121
CADI-05	B-T109
targeting	B-T169
desmocollin-3	B-T116
for	O
advanced	B-T080
non-small-cell lung cancer	B-T191
Randomized controlled trial	B-T062
to	O
evaluate	B-T058
synergy	B-T044
between	O
taxane	B-T109
plus	O
platinum	B-T196
chemotherapy	B-T061
and	O
CADI-05	B-T109
,	O
a	O
Toll like receptor-2	B-T116
agonist	B-T121
targeting	B-T169
desmocollin-3	B-T116
as	O
a	O
first-line therapy	B-T061
in	O
advanced	B-T080
non-small-cell lung cancer	B-T191
(	O
NSCLC	B-T191
).	O
Patients	B-T101
with	O
advanced	B-T080
NSCLC	B-T191
(stage	O
IIIB	O
or	O
IV)	O
were	O
randomized	B-T033
to	O
cisplatin-paclitaxel	B-T061
(	O
chemotherapy	B-T061
group	B-T078
,	O
N	O
=	O
112)	O
or	O
cisplatin-paclitaxel	B-T061
plus	O
CADI-05	B-T109
(	O
chemoimmunotherapy	B-T061
group	B-T078
,	O
N	O
=	O
109).	O
CADI-05	B-T109
was	O
administered	B-T169
a	O
week	B-T079
before	O
chemotherapy	B-T061
and	O
on	O
days	B-T079
8	O
and	O
15	O
of	O
each	O
cycle	B-T061
and	O
every	O
month	B-T079
subsequently	O
for	O
12	O
months	B-T079
or	O
disease progression	B-T046
.	O
Overall survival	B-T081
was	O
compared	O
using	O
a	O
log-rank test	B-T170
.	O
Computed tomography	B-T060
was	O
carried	O
out	O
at	O
baseline	B-T081
,	O
end	O
of	O
two	O
cycles	B-T061
and	O
four	O
cycles	B-T061
.	O
Response rate	B-T079
was	O
evaluated	B-T058
using	O
Response Evaluation Criteria in Solid Tumors	B-T170
criteria	B-T078
by	O
an	O
independent radiologist	B-T097
.	O
As	O
per	O
intention-to-treat analysis	B-T062
,	O
no	O
survival	B-T052
benefit	B-T081
was	O
observed	O
between	O
two	O
groups	B-T078
[208	O
versus	O
196	O
days	B-T079
;	O
hazard ratio	B-T081
,	O
0.86;	O
95%	O
confidence interval	B-T081
(CI)	O
0.63-1.19;	O
P	O
=	O
0.3804].	O
In	O
a	O
subgroup analysis	B-T062
,	O
improvement	B-T077
in	O
median survival	B-T079
by	O
127	O
days	B-T079
was	O
observed	O
in	O
squamous NSCC	B-T191
with	O
chemoimmunotherapy	B-T061
(	O
hazard ratio	B-T081
,	O
0.55;	O
95%	O
CI	O
0.32-0.95;	O
P	O
=	O
0.046).	O
In	O
patients	B-T101
receiving	O
planned	O
four	O
cycles	B-T061
of	O
chemotherapy	B-T061
,	O
there	O
was	O
improved	B-T077
median	B-T081
overall survival	B-T081
by	O
66	O
days	B-T079
(299	O
versus	O
233	O
days	B-T079
;	O
hazard ratio	B-T081
,	O
0.64;	O
95%	O
CI	O
0.41	O
to	O
0.98;	O
P	O
=	O
0.04)	O
in	O
the	O
chemoimmunotherapy	B-T061
group	B-T078
compared	O
with	O
the	O
chemotherapy	B-T061
group	B-T078
.	O
This	O
was	O
associated with	B-T080
the	O
improved	B-T077
survival	B-T052
by	O
17.48%	O
at	O
the	O
end	O
of	O
1	O
year	B-T079
,	O
in	O
the	O
chemoimmunotherapy	B-T061
group	B-T078
.	O
Systemic adverse events	B-T046
were	O
identical	B-T080
in	O
both	O
the	O
group	B-T078
s.	O
There	O
was	O
no	O
survival	B-T052
benefit	B-T081
with	O
the	O
addition	B-T169
of	O
CADI-05	B-T109
to	O
the	O
combination	B-T080
of	O
cisplatin-paclitaxel	B-T061
in	O
patients	B-T101
with	O
advanced	B-T080
NSCLC	B-T191
;	O
however,	O
the	O
squamous cell subset	B-T025
did	O
demonstrate	O
a	O
survival	B-T052
advantage.	O

Sex Life	B-T078
and	O
Impact	B-T080
of	O
Operative	B-T169
Intervention	B-T061
on	O
Sex Life-related Pain	B-T184
in	O
Degenerative	B-T046
Spinal	B-T023
Conditions:	O
An	O
Analysis	B-T062
of	O
the	O
SPORT Study	B-T062
This	O
study	B-T062
is	O
a	O
therapeutic retrospective cohort study	B-T062
OBJECTIVES.:	O
This	O
study	B-T062
aims	O
to	O
determine	O
whether	O
sexual function	B-T040
is	O
relevant	O
for	O
patients	B-T101
with	O
spinal stenosis	B-T020
(	O
SPS	B-T020
)	O
and	O
degenerative spondylolisthesis	B-T047
(	O
DS	B-T047
)	O
and	O
to	O
determine	O
the	O
impact	B-T080
of	O
operative	B-T169
inter	O
vqAvention	O
on	O
sexual function	B-T040
for	O
these	O
patients	B-T101
.	O
The	O
benefits	O
of	O
nonoperative	B-T169
versus	O
operative	B-T169
treatment	B-T169
for	O
patients	B-T101
with	O
SPS	B-T020
and	O
DS	B-T047
with	O
regards	O
to	O
sexual function	B-T040
are	O
unknown.	O
Demographic	B-T090
,	O
treatment	B-T169
,	O
and	O
follow-up	B-T058
data	B-T078
,	O
including	O
the	O
Oswestry	O
Disability	O
Index	O
(ODI),	O
were	O
obtained	O
on	O
patients	B-T101
enrolled	O
in	O
the	O
SPORT study	B-T062
.	O
Based	O
on	O
the	O
response	O
to	O
question	O
#9	O
in	O
the	O
ODI,	O
patients	B-T101
were	O
classified	O
into	O
a	O
sexual life relevant	B-T078
(	O
SLR	B-T078
)	O
or	O
sexual life not relevant (NR) group	B-T078
.	O
Univariate	B-T062
and	O
multivariate analysis	B-T081
of	O
patient	B-T101
characteristics	B-T080
comparing	O
the	O
NR	B-T078
and	O
SLR group	B-T078
were	O
performed.	O
Operative	B-T169
treatment	B-T169
groups	B-T078
were	O
compared	O
to	O
the	O
nonoperative	B-T169
group	B-T078
with	O
regards	O
to	O
response	O
to	O
ODI	O
question	O
#9	O
to	O
determine	O
the	O
impact	B-T080
of	O
surgery	B-T061
on	O
sexual function	B-T040
.	O
A	O
total	O
of	O
1235	O
patients	B-T101
were	O
included	O
to	O
determine	O
relevance	O
of	O
sex life	B-T078
.	O
Three	O
hundred	O
sixty-six	O
patients	B-T101
(29%)	O
were	O
included	O
in	O
the	O
NR group	B-T078
.	O
Eight	O
hundred	O
sixty-nine	O
patients	B-T101
(71%)	O
were	O
included	O
in	O
the	O
SLR group	B-T078
.	O
Patients	B-T101
that	O
were	O
older	B-T098
,	O
female	B-T032
,	O
unmarried	B-T098
,	O
had	O
three	O
or	O
more	O
stenotic levels	B-T080
,	O
and	O
had	O
central stenosis	B-T169
were	O
more	O
likely	O
to	O
be	O
in	O
the	O
NR group	B-T078
.	O
Eight	O
hundred	O
twenty-five	O
patients	B-T101
were	O
included	O
in	O
the	O
analysis	B-T062
comparing	O
operative	B-T169
versus	O
nonoperative	B-T169
treatment	B-T169
.	O
At	O
all	O
follow-up	B-T058
time	O
points,	O
the	O
operative	B-T169
groups	B-T078
had	O
a	O
lower	O
percentage	B-T081
of	O
patients	B-T101
reporting	O
pain	B-T184
with	O
their	O
sex life	B-T078
compared	O
to	O
the	O
nonoperative	B-T169
group	B-T078
(P	O
<	O
0.05	O
at	O
all	O
time	O
points	O
except	O
between	O
more	O
than	O
one	O
level	O
fusion	O
and	O
nonoperative	B-T169
at	O
4	O
years	B-T079
'	O
follow-up	B-T058
).	O
Sex life	B-T078
is	O
a	O
relevant	O
consideration	O
for	O
the	O
majority	O
of	O
patients	B-T101
with	O
DS	B-T047
and	O
SPS	B-T020
;	O
operative	B-T169
treatment	B-T169
leads	O
to	O
improved	B-T033
sex life-related pain	B-T184
.	O
3.	O

Functional analyses	B-T062
of	O
OcRhS1	B-T116
and	O
OcUER1	B-T116
involved	O
in	O
UDP-L-rhamnose	B-T114
biosynthesis	B-T169
in	O
Ornithogalum caudatum	B-T002
UDP-L-rhamnose	B-T114
(	O
UDP-Rha	B-T114
)	O
is	O
an	O
important	O
sugar donor	B-T121
for	O
the	O
synthesis	B-T169
of	O
rhamnose	B-T109
-containing	O
compounds	B-T103
in	O
plants	B-T002
.	O
However,	O
only	O
a	O
few	O
enzymes	B-T116
and	O
their	O
encoding	B-T052
genes	B-T028
involved	O
in	O
UDP-Rha	B-T114
biosynthesis	B-T169
are	O
available	O
in	O
plants	B-T002
.	O
Here,	O
two	O
genes	B-T028
encoding	B-T052
rhamnose synthase	B-T116
(	O
RhS	B-T116
)	O
and	O
bi-functional	B-T116
UDP-4-keto-6-deoxy-D-glucose	B-T116
(	O
UDP-4K6DG	B-T116
)	O
3, 5-epimerase/UDP-4-keto-L-rhamnose	B-T116
(	O
UDP-4KR	B-T116
)	O
4-keto-reductase	B-T116
(	O
UER	B-T116
)	O
were	O
isolated	O
from	O
Ornithogalum caudatum	B-T002
based	O
on	O
the	O
RNA	B-T114
-	O
Seq data	B-T170
.	O
The	O
OcRhS1 gene	B-T028
has	O
an	O
ORF	B-T028
(	O
open reading frame	B-T028
)	O
of	O
2019	O
bp	O
encoding	B-T052
a	O
tri-functional RhS enzyme	B-T026
.	O
In vitro	B-T080
enzymatic assays	B-T059
revealed	B-T080
OcRhS1	B-T116
can	O
really	O
convert	O
UDP-D-glucose	B-T109
(	O
UDP-Glc	B-T109
)	O
into	O
UDP-Rha	B-T114
via	O
three	O
consecutive	B-T080
reactions	B-T169
.	O
Biochemical	B-T169
evidences	B-T169
indicated	O
that	O
the	O
recombinant OcRhS1	B-T116
was	O
active	O
in	O
the	O
pH	O
range	O
of	O
5-11	O
and	O
over	O
the	O
temperature range	B-T081
of	O
0-60	O
°C.	O
The	O
Km	B-T081
value	B-T081
of	O
OcRhS1	B-T116
for	O
UDP-Glc	B-T109
was	O
determined	O
to	O
be	O
1.52	O
×	O
10(-4)	O
M.	O
OcRhS1	B-T116
is	O
a	O
multi-domain protein	B-T116
with	O
two	O
sets	O
of	O
cofactor-binding motifs	B-T044
.	O
The	O
cofactors	B-T044
dependent	O
properties	O
of	O
OcRhS1	B-T116
were	O
thus	O
characterized	O
in	O
this	O
research	B-T062
.	O
Moreover,	O
the	O
N-terminal portion of OcRhS1	B-T116
(	O
OcRhS1-N	B-T116
)	O
was	O
observed	O
to	O
metabolize	B-T169
UDP-Glc	B-T109
to	O
form	O
intermediate	O
UDP-4K6DG	B-T114
.	O
OcUER1	B-T028
contains	O
an	O
ORF	B-T028
of	O
906	O
bp	O
encoding	B-T052
a	O
polypeptide	B-T116
of	O
301	O
aa	B-T116
.	O
OcUER1	B-T116
shared	O
high	O
similarity	O
with	O
the	O
carboxy-terminal domain of OcRhS1	B-T116
(	O
OcRhS1-C	B-T116
),	O
suggesting	O
its	O
intrinsic	O
ability	O
of	O
converting	O
UDP-4K6DG	B-T114
into	O
UDP-Rha	B-T114
.	O
It	O
was	O
thus	O
reasonably	O
inferred	O
that	O
UDP-Glc	B-T109
could	O
be	O
bio-transformed	B-T169
into	O
UDP-Rha	B-T114
under	O
the	O
collaborating	O
action	O
of	O
OcRhS1-N	B-T116
and	O
OcUER1	B-T116
.	O
The	O
subsequently	O
biochemical assay	B-T059
verified	O
this	O
notion.	O
Importantly,	O
expression profiles	B-T034
of	O
OcRhS1	B-T116
and	O
OcUER1	B-T116
revealed	B-T080
their	O
possible	O
involvement	O
in	O
the	O
biosynthesis	B-T169
of	O
rhamnose	B-T109
-containing	O
polysaccharides	B-T109
in	O
O. caudatum	B-T002
.	O

Differing	O
rates	O
of	O
antibody	B-T116
acquisition	B-T052
to	O
merozoite	B-T204
antigens	B-T129
in	O
malaria	B-T047
:	O
implications	O
for	O
immunity	B-T039
and	O
surveillance	B-T058
Antibodies	B-T116
play	O
a	O
key	O
role	O
in	O
acquired human immunity	B-T039
to	O
Plasmodium falciparum (Pf) malaria	B-T047
and	O
target	O
merozoites	B-T204
to	O
reduce	O
or	O
prevent	O
blood	B-T031
-stage	O
replication	B-T043
and	O
the	O
development	O
of	O
disease	B-T047
.	O
Merozoites	B-T204
present	O
a	O
complex	O
array	O
of	O
antigens	B-T129
to	O
the	O
immune system	B-T022
,	O
and	O
currently,	O
there	O
is	O
only	O
a	O
partial	O
understanding	O
of	O
the	O
targets	O
of	O
protective	O
antibodies	B-T116
and	O
how	O
responses	B-T039
to	O
different	O
antigens	B-T129
are	O
acquired	B-T080
and	O
boosted	B-T169
.	O
We	O
hypothesized	O
that	O
there	O
would	O
be	O
differences	O
in	O
the	O
rate	O
of	O
acquisition	B-T052
of	O
antibodies	B-T116
to	O
different	O
antigens	B-T129
and	O
how	O
well	O
they	O
are	O
boosted	O
by	O
infection	B-T046
,	O
which	O
impacts	O
the	O
acquisition	B-T052
of	O
immunity	B-T039
.	O
We	O
examined	O
responses	B-T039
to	O
a	O
range	O
of	O
merozoite	B-T204
antigens	B-T129
in	O
2	O
different	O
cohorts	O
of	O
children	B-T100
and	O
adults	B-T100
with	O
different	O
age	B-T032
structures	O
and	O
levels	O
of	O
malaria	B-T047
exposure.	O
Overall,	O
antibodies	B-T116
were	O
associated	O
with	O
age	B-T032
,	O
exposure,	O
and	O
active	O
infection	B-T046
,	O
and	O
the	O
repertoire	O
of	O
responses	B-T039
increased	O
with	O
age	B-T032
and	O
active	O
infection	B-T046
.	O
However,	O
rates	O
of	O
antibody	B-T116
acquisition	B-T052
varied	O
between	O
antigens	B-T129
and	O
different	O
regions	O
within	O
an	O
antigen	B-T129
following	O
exposure	O
to	O
malaria	B-T047
,	O
supporting	O
our	O
hypothesis	B-T078
.	O
Antigen	B-T129
-specific	O
responses	B-T039
could	O
be	O
broadly	O
classified	O
into	O
early	O
response	B-T039
types	O
in	O
which	O
antibodies	B-T116
were	O
acquired	B-T080
early	O
in	O
childhood	B-T079
exposure	O
and	O
late response	B-T079
response	B-T039
types	O
that	O
appear	O
to	O
require	O
substantially	O
more	O
exposure	O
for	O
the	O
development	O
of	O
substantial	O
levels.	O
We	O
identified	O
antigen	B-T129
-specific	O
responses	B-T039
that	O
were	O
effectively	O
boosted	O
after	O
recent	O
infection	B-T046
,	O
whereas	O
other	O
responses	B-T039
were	O
not.	O
These	O
findings	O
advance	O
our	O
understanding	O
of	O
the	O
acquisition	B-T052
of	O
human	B-T016
immunity	B-T039
to	O
malaria	B-T047
and	O
are	O
relevant	O
to	O
the	O
development	O
of	O
malaria vaccines	B-T121
targeting	O
merozoite	B-T204
antigens	B-T129
and	O
the	O
selection	O
of	O
antigens	B-T129
for	O
use	O
in	O
malaria	B-T047
surveillance	B-T058
.	O

Variety	B-T077
of	O
DNA Replication Activity	B-T045
Among	O
Cyanobacteria	B-T007
Correlates	B-T039
with	O
Distinct	O
Respiration Activity	B-T039
in	O
the	O
Dark	B-T070
Cyanobacteria	B-T007
exhibit	O
light	B-T070
-dependent	O
cell growth	B-T043
since	O
most	O
of	O
their	O
cellular	B-T025
energy	B-T081
is	O
obtained	O
by	O
photosynthesis	B-T070
.	O
In	O
Synechococcus elongatus PCC 7942	B-T007
,	O
one	O
of	O
the	O
model	O
cyanobacteria	B-T007
,	O
DNA replication	B-T045
depends	O
on	O
photosynthetic electron transport	B-T044
.	O
However,	O
the	O
critical signal	B-T067
for	O
the	O
regulatory	B-T038
mechanism	B-T169
of	O
DNA replication	B-T045
has	O
not	O
been	O
identified.	O
In	O
addition,	O
conservation	B-T080
of	O
this	O
regulatory mechanism	B-T169
has	O
not	O
been	O
investigated	B-T169
among	O
cyanobacteria	B-T007
.	O
To	O
understand	O
this	O
regulatory	B-T038
signal	B-T067
and	O
its	O
dependence	O
on	O
light	B-T070
,	O
we	O
examined	O
the	O
regulation	B-T038
of	O
DNA replication	B-T045
under	O
both	O
light	B-T070
and	O
dark	B-T070
conditions	O
among	O
three	O
model	B-T075
cyanobacteria	B-T007
,	O
S. elongatus PCC 7942	B-T007
,	O
Synechocystis sp. PCC 6803	B-T007
and	O
Anabaena sp. PCC 7120	B-T007
.	O
Interestingly,	O
DNA replication activity	B-T045
in	O
Synechocystis	B-T007
and	O
Anabaena	B-T007
was	O
retained	B-T169
when	O
cells	B-T025
were	O
transferred to	B-T033
the	O
dark	B-T070
,	O
although	O
it	O
was	O
drastically	O
decreased	B-T081
in	O
S. elongatus	B-T007
.	O
Glycogen metabolism	B-T044
and	O
respiration	B-T039
were	O
higher	O
in	O
Synechocystis	B-T007
and	O
Anabaena	B-T007
than	O
in	O
S. elongatus	B-T007
in	O
the	O
dark	B-T070
.	O
Moreover,	O
DNA replication activity	B-T045
in	O
Synechocystis	B-T007
and	O
Anabaena	B-T007
was	O
reduced	B-T081
to	O
the	O
same	O
level	O
as	O
that	O
in	O
S. elongatus	B-T007
by	O
inhibition	B-T052
of	O
respiratory	B-T169
electron transport	B-T044
after	O
transfer	O
to	O
the	O
dark	B-T070
.	O
These	O
results	O
demonstrate	O
that	O
there	O
is	O
disparity	B-T033
in	O
DNA replication	B-T045
occurring	O
in	O
the	O
dark	B-T070
among	O
cyanobacteria	B-T007
,	O
which	O
is	O
caused	O
by	O
the	O
difference	B-T080
in	O
activity	B-T169
of	O
respiratory	B-T169
electron transport	B-T044
.	O

Radiosensitization	B-T061
of	O
non-small-cell lung cancer	B-T191
cells	B-T025
and	O
xenografts	B-T061
by	O
the	O
interactive effects	B-T169
of	O
pemetrexed	B-T109
and	O
methoxyamine	B-T109
The	O
anti-folate	B-T121
pemetrexed	B-T109
is	O
a	O
radiosensitizer	B-T121
.	O
In	O
pre-clinical models	B-T170
,	O
pemetrexed	B-T109
is	O
more	O
effective	B-T080
along	O
with	O
the	O
base-excision-repair	B-T045
inhibitor	B-T080
methoxyamine	B-T109
.	O
We	O
tested	B-T169
whether	O
methoxyamine	B-T109
enhances	B-T052
pemetrexed	B-T109
-mediated	O
radiosensitization	B-T061
of	O
lung adenocarcinoma	B-T191
cells	O
and	O
xenografts	B-T061
.	O
A549	B-T025
and	O
H1299 cells	B-T025
were	O
evaluated	O
for	O
cell cycle	B-T043
distribution	B-T169
by	O
flow cytometry	B-T059
,	O
radiosensitization	B-T061
by	O
clonogenic assay	B-T059
,	O
and	O
DNA repair	B-T045
by	O
neutral comet assay	B-T063
and	O
repair protein	B-T044
activation	B-T045
.	O
H460 cells	B-T025
were	O
included	O
in	O
some	O
studies.	O
Xenografts	B-T061
in	O
nude mice	B-T015
received drug	B-T033
(s)	O
and/or	O
radiation	B-T070
,	O
and	O
tumor growth	B-T191
was	O
monitored	O
by	O
caliper	B-T074
and	O
in vivo	B-T062
toxicity	B-T037
by	O
animal weight	B-T032
.	O
Exposure to	B-T080
pemetrexed	B-T109
/	O
methoxyamine	B-T109
for	O
24	O
(	O
H1299	B-T025
,	O
H460	B-T025
)	O
or	O
48	O
(	O
A549	B-T025
)hours	O
before	O
irradiation	B-T070
resulted	O
in	O
accumulation	B-T033
of	O
cells	B-T025
near	O
the	O
radiosensitive G1/S border	B-T082
;	O
dose	B-T081
-	O
enhancement	B-T052
factors	B-T169
of	O
1.62±0.19,	O
1.97±0.25,	O
and	O
1.67±0.30,	O
respectively;	O
reduction	O
of	O
mean	O
inactivation	B-T169
dose	B-T081
by	O
32%,	O
30%,	O
and	O
46%,	O
respectively;	O
and	O
significant	O
reductions	O
of	O
SF2	O
and	O
SF4	O
(p<0.05).	O
Radiosensitization	B-T061
was	O
associated	O
with	O
rapid	O
DNA double-strand-break rejoining	B-T045
and	O
increased	O
levels	O
of	O
DNA-PKcs	B-T116
.	O
Both	O
tumor-growth	B-T191
rate	B-T079
and	O
tumor-growth	B-T191
delay	B-T079
were	O
significantly	O
improved	O
by	O
adding	O
methoxyamine	B-T109
to	O
pemetrexed	B-T109
pre-irradiation	B-T070
(p<0.0001);	O
no	O
mice	B-T015
lost	O
weight	O
during	O
treatment	B-T169
.	O
Addition	O
of	O
methoxyamine	B-T109
to	O
pemetrexed	B-T109
and	O
fractionated	O
radiotherapy	O
may	O
improve	O
outcome	O
for	O
patients	B-T101
with	O
locally	O
advanced	O
non-squamous non-small-cell lung cancer	B-T191
.	O

Using	O
language	B-T171
for	O
social interaction	B-T033
:	O
Communication	B-T054
mechanisms	O
promote	O
recovery	O
from	O
chronic	B-T079
non-fluent aphasia	B-T048
Clinical research	B-T062
highlights	O
the	O
importance	O
of	O
massed practice	B-T170
in	O
the	O
rehabilitation	B-T061
of	O
chronic	B-T079
post-stroke	B-T079
aphasia	B-T048
.	O
However,	O
while	O
necessary,	O
massed practice	B-T170
may	O
not	O
be	O
sufficient	O
for	O
ensuring	O
progress	B-T169
in	O
speech-language therapy	B-T058
.	O
Motivated	O
by	O
recent	O
advances	O
in	O
neuroscience	B-T091
,	O
it	O
has	O
been	O
claimed	O
that	O
using	O
language	B-T171
as	O
a	O
tool	O
for	O
communication	B-T054
and	O
social interaction	B-T033
leads	O
to	O
synergistic effects	B-T080
in	O
left perisylvian eloquent areas	B-T029
.	O
Here,	O
we	O
conducted	O
a	O
crossover	O
randomized	O
controlled	O
trial	O
to	O
determine	O
the	O
influence	O
of	O
communicative	B-T054
language function	B-T041
on	O
the	O
outcome	B-T169
of	O
intensive aphasia therapy	B-T061
.	O
Eighteen	O
individuals	B-T098
with	O
left-hemisphere lesions	B-T033
and	O
chronic	B-T079
non-fluent aphasia	B-T048
each	O
received	O
two	O
types	O
of	O
training	B-T065
in	O
counterbalanced order	B-T080
:	O
(i)	O
Intensive Language-Action Therapy	B-T061
(	O
ILAT	B-T061
,	O
an	O
extended	O
form	O
of	O
Constraint-Induced Aphasia Therapy	B-T061
)	O
embedding	O
verbal utterances	B-T061
in	O
the	O
context	O
of	O
communication	B-T054
and	O
social interaction	B-T033
,	O
and	O
(ii)	O
Naming Therapy	B-T073
focusing	O
on	O
speech production per se	B-T060
.	O
Both	O
types	O
of	O
training	B-T065
were	O
delivered	O
with	O
the	O
same	O
high	O
intensity	O
(3.5	O
h	O
per	O
session)	O
and	O
duration	B-T079
(six	O
consecutive	O
working	O
days	B-T079
),	O
with	O
therapy	B-T061
materials	B-T167
and	O
number of utterances	B-T033
matched	O
between	O
treatment groups	B-T061
.	O
A	O
standardized	O
aphasia	B-T048
test battery	B-T060
revealed	O
significantly	O
improved	O
language	B-T171
performance	B-T055
with	O
ILAT	B-T061
,	O
independent	O
of	O
when	O
this	O
method	B-T170
was	O
administered.	O
In	O
contrast,	O
Naming Therapy	B-T073
tended	O
to	O
benefit	O
language	B-T171
performance	O
only	O
when	O
given	O
at	O
the	O
onset	O
of	O
the	O
treatment	B-T061
,	O
but	O
not	O
when	O
applied	O
after	O
previous	O
intensive	O
training	B-T065
.	O
The	O
current	O
results	O
challenge	O
the	O
notion	O
that	O
massed practice	B-T170
alone	O
promotes	O
recovery	O
from	O
chronic	B-T079
post-stroke	B-T079
aphasia	B-T048
.	O
Instead,	O
our	O
results	O
demonstrate	O
that	O
using	O
language	B-T171
for	O
communication	B-T054
and	O
social interaction	B-T033
increases	O
the	O
efficacy	O
of	O
intensive aphasia therapy	B-T061
.	O

miR-27b	B-T028
inhibits	B-T052
gastric cancer	B-T191
metastasis	B-T191
by	O
targeting	B-T169
NR2F2	B-T116
Increasing	B-T169
attention	B-T041
is	O
focused	O
on	O
the	O
down-regulation	B-T044
of	O
miRNAs	B-T114
in	O
cancer process	B-T191
.	O
Nuclear receptor subfamily 2	B-T116
(	O
NR2F2	B-T116
,	O
also	O
known	O
as	O
COUP-TFII	B-T116
)	O
is	O
involved	B-T169
in	O
the	O
development	B-T169
of	O
many	O
types	B-T080
of	O
cancers	B-T191
,	O
but	O
its	O
role	B-T077
in	O
gastric cancer	B-T191
remains	O
elusive.	O
In	O
this	O
experiment	B-T062
,	O
oncomine	B-T170
and	O
Kaplan-meier database	B-T170
revealed	B-T080
that	O
NR2F2	B-T116
was	O
up-regulated	B-T044
in	O
gastric cancer	B-T191
and	O
that	O
the	O
high	B-T080
NR2F2	B-T116
expression	B-T045
contributed	B-T052
to	O
poor	B-T080
survival	B-T081
.	O
MicroRNA-27b	B-T028
was	O
targeted	B-T169
and	O
down-regulated	B-T044
by	O
NR2F2	B-T116
in	O
human	B-T016
gastric cancer	B-T191
tissues	B-T024
and	O
cells	B-T025
.	O
The	O
ectopic expression	B-T045
of	O
miR-27b	B-T028
inhibited	B-T080
gastric cancer	B-T191
cell proliferation	B-T043
and	O
tumor growth	B-T191
in vitro	B-T080
and	O
in vivo	B-T082
.	O
Assays	B-T059
suggested	B-T078
that	O
the	O
overexpression	B-T045
of	O
miR-27b	B-T028
could	O
promote	B-T052
MGC-803 cells	B-T025
'	O
migration	B-T043
and	O
invasion	B-T046
and	O
retard	B-T080
their	O
metastasis	B-T191
to	O
the	O
liver	B-T023
.	O
In	O
addition,	O
down-regulation	B-T044
of	O
miR-27b	B-T028
enhanced	O
GES-1 cells	B-T025
'	O
proliferation	B-T043
and	O
metastasis	B-T191
in vitro	B-T080
.	O
These	O
findings	B-T033
reveal	B-T080
that	O
miR-27b	B-T028
is	O
a	O
tumor suppressor	B-T028
in	O
gastric cancer	B-T191
and	O
a	O
biomarker	B-T201
for	O
improving	B-T080
patients	B-T101
'	O
survival	B-T081
.	O

Promoting	B-T052
Healthy	B-T080
Growth	B-T040
or	O
Feeding	B-T052
Obesity	B-T047
?	O
The	O
Need	B-T080
for	O
Evidence	B-T078
-Based	O
Oversight	O
of	O
Infant	B-T100
Nutritional Supplement	B-T168
Claims	O
The	O
Developmental Origins of Health and Disease	B-T170
(	O
DOHaD	B-T170
)	O
model	O
recognizes	O
growth	B-T040
in	O
infancy	B-T079
and	O
childhood	B-T079
as	O
a	O
fundamental	O
determinant	O
of	O
lifespan	B-T102
health	B-T078
.	O
Evidence of	B-T169
long-term	B-T079
health	B-T078
risks	B-T078
among	O
small	B-T081
neonates	B-T100
who	O
subsequently	O
grow	B-T067
rapidly	B-T080
poses	O
a	O
challenge	O
for	O
interventions	B-T058
aiming	O
to	O
support	O
healthy	B-T080
growth	B-T040
,	O
not	O
merely	O
drive	O
weight gain	B-T033
.	O
Defining	O
healthy	B-T080
growth	B-T040
beyond	O
"getting	O
bigger"	O
is	O
essential	B-T080
as	O
infant	B-T100
and	O
young	B-T079
child	B-T100
feeding	B-T052
industries	B-T057
expand.	O
Liquid	B-T167
-based	O
nutritional supplements	B-T168
,	O
originally	O
formulated	B-T168
for	O
undernourished	B-T047
children	B-T100
,	O
are	O
increasingly	B-T169
marketed	B-T057
for	O
and	O
consumed	B-T052
by	O
children	B-T100
generally.	O
Clarifying	B-T052
the	O
nature	O
of	O
the	O
evidentiary	O
base	O
on	O
which	O
structure/function	O
claims	O
promoting	B-T052
"	O
healthy	B-T080
growth	B-T040
"	O
are	O
constructed	O
is	O
important	B-T080
to	O
curb	O
invalid	O
generalizations.	O
Evidence	B-T078
points	O
to	O
changing	O
social	B-T169
beliefs	B-T078
and	O
cultural	B-T169
practices	B-T041
surrounding	O
supplementary feeding	B-T061
,	O
raising	O
specific	B-T080
concerns	B-T078
about	O
the	O
long-term	B-T079
health	B-T078
consequences of	B-T169
an	O
associated	B-T080
altered	B-T169
feeding	B-T052
culture	B-T169
,	O
including	O
reduced	B-T080
dietary	B-T168
variety	B-T077
and	O
weight gain	B-T033
.	O
Reassessing	B-T052
the	O
evidence for	B-T169
and	O
relevance	B-T080
of	O
dietary supplements'	B-T168
"	O
promoting	B-T052
healthy	B-T080
growth	B-T040
"	O
claims	O
for	O
otherwise	O
healthy	B-T080
children	B-T100
is	O
both	O
needed	B-T080
in	O
a	O
time	O
of	O
global	B-T080
obesity	B-T047
and	O
an	O
opportunity	B-T062
to	O
refine	O
intervention approaches	B-T061
among	O
small	B-T081
children	B-T100
for	O
whom	O
rapid	B-T080
subsequent	O
growth	B-T040
in	O
early	O
life	O
augments	O
risk	B-T078
for	O
chronic disease	B-T047
.	O
Scientific	B-T090
and	O
health care	B-T058
partnerships	B-T092
are	O
needed	B-T080
to	O
consider	O
current	O
governmental	B-UnknownType
oversight	O
shortfalls	O
in	O
protecting	O
vulnerable	O
populations	B-T098
from	O
overconsumption	B-T052
.	O
This	O
is	O
important	B-T080
because	O
we	O
may	O
be	O
doing	O
more	O
harm	O
than	O
good.	O

On-Site	B-T082
Fertility Preservation Services	B-T061
for	O
Adolescents	B-T100
and	O
Young Adults	B-T100
in	O
a	O
Comprehensive Cancer Center	B-T093
Adolescents	B-T100
and	O
young adults	B-T100
(	O
AYAs	B-T100
)	O
receiving	O
cancer treatments	B-T061
that	O
may	O
impair fertility	B-T046
should	O
receive	O
counseling	B-T058
about	O
risk of infertility	B-T033
and	O
options	O
for	O
fertility preservation	B-T061
(	O
FP	B-T061
)	O
before	O
treatment	B-T061
and/or	O
during	O
survivorship	B-T079
.	O
Our	O
objective	B-T170
was	O
to	O
define	O
the	O
AYA	B-T100
patient	B-T101
population	B-T098
referred	O
to	O
an	O
on-site fertility consultation service	B-T058
within	O
a	O
comprehensive cancer center	B-T093
and	O
determine	O
factors	B-T169
associated	O
with	O
patients	B-T101
proceeding	O
with	O
FP treatment	B-T061
.	O
We	O
conducted	O
a	O
retrospective chart review	B-T062
of	O
AYA	B-T100
women	B-T098
who	O
completed	O
a	O
consultation	B-T058
at	O
the	O
MD Anderson Fertility Preservation and Family Building Service	B-T058
during	O
the	O
first	O
year	O
of	O
service	B-T057
.	O
Records	B-T170
of	O
154	O
referred	O
AYA	B-T100
patients	B-T101
were	O
reviewed	B-T080
for	O
age	B-T032
,	O
ethnicity	B-T098
,	O
cancer type	B-T033
gravidity	B-T033
and	O
parity	B-T033
,	O
survivorship	B-T079
status	B-T080
,	O
and	O
decision	O
to	O
pursue	O
FP treatment	B-T061
.	O
Patients	B-T101
(mean	O
age	O
29.7)	O
were	O
Caucasian	B-T098
(55%),	O
Hispanic	B-T098
(23%),	O
and	O
African American	B-T098
(10%).	O
The	O
majority	O
of	O
women	B-T098
(67%)	O
were	O
seen	O
for	O
FP	B-T061
before	O
cancer treatment	B-T061
and	O
the	O
remaining	O
sought	O
options	B-T169
for	O
family building	B-T058
while	O
in	O
survivorship	B-T079
.	O
The	O
most	O
common	O
cancer types	B-T033
were	O
hematologic	B-T191
(29%),	O
breast	B-T191
(25%),	O
and	O
gynecologic	B-T191
(23%).	O
Patients	B-T101
referred	O
to	O
an	O
on-site fertility consultation service	B-T058
were	O
medically	O
and	O
ethnically	B-T080
diverse	B-T080
.	O
Interest	O
in	O
fertility counseling	B-T065
and	O
treatment	B-T061
was	O
apparent	O
in	O
both	O
survivorship	B-T079
pre- and postcancer treatment	B-T061
.	O
Although	O
the	O
referral	B-T058
group	B-T078
was	O
ethnically	B-T080
diverse	B-T080
,	O
Caucasian	B-T098
women	B-T098
were	O
most	O
likely	O
to	O
pursue	O
FP treatment	B-T061
compared	O
to	O
women	B-T098
of	O
other	O
ethnicities	B-T080
.	O

Results	B-T169
of	O
a	O
Multicenter	B-T062
,	O
Randomized	B-T062
,	O
Controlled Trial	B-T170
of	O
a	O
Hydrogen Peroxide	B-T121
-based	O
Kit	B-T074
versus	O
a	O
Benzoyl Peroxide	B-T109
-based	O
Kit	B-T074
in	O
Mild-to-moderate	B-T080
Acne	B-T047
Objective:To	O
evaluate	B-T058
the	O
efficacy	B-T080
and	O
tolerability	B-T062
of	O
a	O
novel	O
hydrogen peroxide	B-T121
-based	O
regimen	B-T061
versus	O
a	O
benzoyl peroxide	B-T109
-based	O
regimen	B-T061
in	O
mild-to-moderate	B-T080
acne	B-T047
.	O
Methods	B-T170
:	O
In	O
this	O
eight-	O
week	B-T079
multicenter study	B-T062
,	O
patients	B-T101
were	O
randomized	B-T062
to	O
either	O
a	O
hydrogen peroxide	B-T121
-based	O
or	O
a	O
benzoyl peroxide	B-T109
-based	O
regimen	B-T061
.The	O
primary outcome measure	B-T080
of	O
clinical response	B-T033
was	O
assessed	B-T052
using	O
the	O
Global Acne Grading System	B-T058
(	O
GAGS	B-T058
)	O
at	O
baseline	B-T081
,four	O
weeks	B-T079
,	O
and	O
eight	O
weeks	B-T079
.	O
At	O
Week	B-T079
8,	O
a	O
patient	B-T101
self-satisfaction questionnaire	B-T170
was	O
administered	B-T169
.	O
Investigators	B-T097
were	O
also	O
queried	B-T170
at	O
that	O
time	O
regarding	O
assessment	B-T058
of	O
tolerability	B-T062
and	O
cosmetic	B-T073
acceptability	B-T080
.	O
Tolerability	B-T062
was	O
also	O
measured	B-T080
at	O
each	O
visit	B-T058
.	O
Results:	O
Both	O
treatment regimens	B-T061
were	O
associated with	B-T080
improvement	B-T077
of	O
GAGS score	B-T081
at	O
Week	B-T079
8	O
compared	B-T052
to	O
baseline	B-T081
(p<0.0001).	O
GAGS score	B-T081
did	O
not	O
differ	O
significantly	O
between	O
the	O
two	O
regimens	B-T061
over	O
the	O
same	O
period	B-T079
(p=0.7765).	O
No significant adverse events	B-T033
were	O
reported	B-T058
or	O
observed	B-T169
in	O
either	O
treatment arm	B-T062
.	O
Both	O
patients	B-T101
and	O
investigators	B-T097
found	O
both	O
regimens	B-T061
to	O
be	O
similarly	O
effective	B-T080
and	O
cosmetically	B-T073
acceptable	B-T080
.	O
Conclusion:	O
A	O
novel	O
hydrogen peroxide	B-T121
-based	O
regimen	B-T061
was	O
shown	O
to	O
be	O
comparable	B-T052
in	O
efficacy	B-T080
,	O
safety	B-T068
,	O
and	O
cosmetic	B-T073
acceptability	B-T080
to	O
a	O
benzoyl peroxide	B-T109
-based	O
regimen	B-T061
in	O
the	O
treatment	B-T061
of	O
mild-to-moderate	B-T080
acne	B-T047
.	O

Multisensory Integration	B-T040
in	O
the	O
Virtual Hand Illusion	B-T048
with	O
Active Movement	B-T040
Improving	O
the	O
sense of	B-T041
sense of immersion	B-T033
is	O
one	O
of	O
the	O
core	O
issues	O
in	O
virtual reality	B-T066
.	O
Perceptual illusions	B-T048
of	O
ownership	O
can	O
be	O
perceived	B-T041
over	O
a	O
virtual body	B-T066
in	O
a	O
multisensory	B-T061
virtual reality	B-T066
environment.	O
Rubber Hand	B-T074
and	O
Virtual Hand Illusions	B-T048
showed	O
that	O
body	O
ownership	O
can	O
be	O
manipulated	O
by	O
applying	O
suitable	O
visual	B-T061
and	O
tactile stimulation	B-T061
.	O
In	O
this	O
study,	O
we	O
investigate	O
the	O
effects	O
of	O
multisensory integration	B-T040
in	O
the	O
Virtual Hand Illusion	B-T048
with	O
active movement	B-T040
.	O
A	O
virtual xylophone playing	B-T066
system	O
which	O
can	O
interactively	O
provide	O
synchronous	B-T079
visual	B-T061
,	O
tactile	B-T061
,	O
and	O
auditory stimulation	B-T061
was	O
constructed.	O
We	O
conducted	O
two	O
experiments	O
regarding	O
different	O
movement	O
conditions	O
and	O
different	O
sensory stimulations	B-T061
.	O
Our	O
results	O
demonstrate	O
that	O
multisensory integration	B-T040
with	O
free	O
active movement	B-T040
can	O
improve	O
the	O
sense of	B-T041
immersion in virtual reality	B-T066
.	O

Obstructive	B-T169
Acute Pancreatitis	B-T047
Secondary	O
to	O
PEG Tube	B-T074
Migration	B-T033
Percutaneous gastrostomy	B-T061
is	O
a	O
well-established	O
method	B-T169
of	O
providing	O
enteral nutrition	B-T061
to	O
patients	B-T101
incapable	B-T033
of	O
oral intake	B-T033
,	O
or	O
for	O
whom	O
oral intake	B-T033
is	O
insufficient	B-T080
to	O
meet	O
metabolic	B-T169
needs	B-T080
.	O
In	O
comparison	O
to	O
total parenteral nutrition	B-T061
,	O
enteral feeding	B-T058
is	O
advantageous	O
in	O
that	O
it	O
helps	O
maintain	O
gut	B-T023
mucosal	B-T024
integrity	B-T080
,	O
which	O
decreases	O
the	O
risk	B-T078
of	O
bacterial translocation	B-T043
through	O
the	O
gastrointestinal tract	B-T022
.	O
Complications	B-T046
include	O
bleeding	B-T046
,	O
aspiration	B-T046
,	O
internal organ injury	B-T037
,	O
perforation	B-T047
,	O
periostomal leaks	B-T047
,	O
tube dislodgement	B-T037
,	O
and	O
occlusion	B-T046
.	O
Acute pancreatitis	B-T047
secondary	O
to	O
percutaneous gastrostomy tube	B-T074
migration	B-T033
is	O
rare.	O
We	O
present	O
a	O
patient	B-T101
with	O
acute	B-T079
obstructive	B-T169
pancreatitis	B-T047
secondary	O
to	O
percutaneous gastrostomy tube	B-T074
migration	B-T033
.	O

A	O
Tractable	B-T080
Method	B-T170
for	O
Measuring	B-T080
Nanomaterial	B-T073
Risk	B-T078
Using	O
Bayesian Networks	B-T170
While	O
control	O
banding	B-T061
has	O
been	O
identified	O
as	O
a	O
suitable	O
framework	O
for	O
the	O
evaluation	B-T078
and	O
the	O
determination	O
of	O
potential	B-T080
human	B-T016
health risks	B-T061
associated	O
with	O
exposure to	B-T080
nanomaterials	B-T073
(	O
NMs	B-T073
),	O
the	O
approach	O
currently	O
lacks	O
any	O
implementation	B-T052
that	O
enjoys	O
widespread	O
support.	O
Large	O
inconsistencies	O
in	O
characterisation	O
data	B-T078
,	O
toxicological	B-T038
measurements	B-T169
and	O
exposure	O
scenarios	O
make	O
it	O
difficult	O
to	O
map	O
and	O
compare	O
the	O
risk	B-T078
associated	O
with	O
NMs	B-T073
based	O
on	O
physicochemical	B-T070
data	B-T078
,	O
concentration	B-T081
and	O
exposure route	B-UnknownType
.	O
Here	O
we	O
demonstrate	O
the	O
use	O
of	O
Bayesian networks	B-T170
as	O
a	O
reliable	O
tool	B-T169
for	O
NM	B-T073
risk	B-T078
estimation.	O
This	O
tool	B-T169
is	O
tractable	B-T080
,	O
accessible	B-T080
and	O
scalable	B-T081
.	O
Most	O
importantly,	O
it	O
captures	O
a	O
broad	O
span	O
of	O
data	B-T078
types,	O
from	O
complete,	O
high	O
quality	B-T080
data sets	B-T170
through	O
to	O
data sets	B-T170
with	O
missing	O
data	B-T078
and/or	O
values	B-T081
with	O
a	O
relatively	O
high	O
spread	O
of	O
probability distribution	B-T081
.	O
The	O
tool	B-T169
is	O
able	O
to	O
learn	O
iteratively	O
in	O
order	O
to	O
further	O
refine	O
forecasts	O
as	O
the	O
quality	B-T080
of	O
data	B-T078
available	O
improves.	O
We	O
demonstrate	O
how	O
this	O
risk	B-T078
measurement	B-T169
approach	O
works	O
on	O
NMs	B-T073
with	O
varying	O
degrees	O
of	O
risk	B-T078
potential	B-T080
,	O
namely,	O
carbon nanotubes	B-T104
,	O
silver	B-T196
and	O
titanium dioxide	B-T121
.	O
The	O
results	O
afford	O
even	O
non-experts	B-T098
an	O
accurate	O
picture	O
of	O
the	O
occupational	O
risk	B-T078
probabilities	O
associated	O
with	O
these	O
NMs	B-T073
and,	O
in	O
doing	O
so,	O
demonstrated	O
how	O
NM	B-T073
risk	B-T078
can	O
be	O
evaluated	B-T078
into	O
a	O
tractable	B-T080
,	O
quantitative	B-T081
risk	B-T078
comparator.	O

Gender	B-T032
and	O
Direction	B-T082
of	O
Effect	B-T080
of	O
Alcohol Problems	B-T048
and	O
Internalizing Symptoms	B-T041
in	O
a	O
Longitudinal Sample	B-T062
of	O
College Students	B-T098
Alcohol problems	B-T048
and	O
internalizing symptoms	B-T041
are	O
consistently	O
found	O
to	O
be	O
associated	B-T080
but	O
how	O
they	O
relate	B-T080
to	O
each	O
other	O
is	O
unclear	B-T033
.	O
The	O
present	O
study	B-T062
aimed	O
to	O
address	O
limitations	B-T169
in	O
the	O
literature	B-T170
of	O
comorbidity	B-T078
of	O
alcohol problems	B-T048
and	O
internalizing symptoms	B-T041
by	O
investigating	B-T169
the	O
direction	B-T082
of	O
effect	B-T080
between	O
the	O
phenotypes	B-T032
and	O
possible	O
gender differences	B-T032
in	O
college students	B-T098
.	O
We	O
utilized	O
data	B-T078
from	O
a	O
large	O
longitudinal study	B-T062
of	O
college students	B-T098
from	O
the	O
United States	B-T083
(N	O
=	O
2607).	O
Three	O
waves	O
of	O
questionnaire-based	B-T170
data	B-T078
were	O
collected	O
over	O
the	O
first	O
two	O
years	B-T079
of	O
college	B-T073
(in	O
2011-2013).	O
Cross-lagged models	B-T081
were	O
applied	O
to	O
examine	O
the	O
possible	O
direction	B-T082
of	O
effect	B-T080
of	O
internalizing symptoms	B-T041
and	O
alcohol problems	B-T048
.	O
Possible	O
effects	B-T080
of	O
gender	B-T032
were	O
investigated	B-T169
using	O
multigroup modeling	B-T081
.	O
There	O
were	O
significant	B-T078
correlations	B-T080
between	O
alcohol problems	B-T048
and	O
internalizing symptoms	B-T041
.	O
A	O
direction	B-T082
of	O
effect	B-T080
was	O
found	O
between	O
alcohol problems	B-T048
and	O
internalizing symptoms	B-T041
but	O
differed	O
between	O
genders	B-T032
.	O
A	O
unidirectional	O
relationship	B-T080
varying	O
with	O
age	B-T032
was	O
identified	O
for	O
males	B-T032
where	O
alcohol problems	B-T048
initially	O
predicted	B-T078
internalizing symptoms	B-T041
followed	O
by	O
internalizing symptoms	B-T041
predicting	O
alcohol problems	B-T048
.	O
For	O
females	B-T032
,	O
a	O
unidirectional	O
relationship	B-T080
existed	O
wherein	O
alcohol problems	B-T048
predicted	O
internalizing symptoms	B-T041
.	O
Conclusions/Importance:	O
We	O
conclude	O
that	O
the	O
relationship	B-T080
between	O
alcohol problems	B-T048
and	O
internalizing symptoms	B-T041
is	O
complex	B-T080
and	O
differ	O
between	O
genders	B-T032
.	O
In	O
males	B-T032
,	O
both	O
phenotypes	B-T032
are	O
predictive	B-T080
of	O
each	O
other,	O
while	O
in	O
females	B-T032
the	O
relationship	B-T080
is	O
driven	O
by	O
alcohol problems	B-T048
.	O
Importantly,	O
our	O
study	B-T062
examines	O
a	O
population-based sample	B-T081
,	O
revealing	O
that	O
the	O
observed	O
relationships	B-T080
between	O
alcohol problems	B-T048
and	O
internalizing symptoms	B-T041
are	O
not	O
limited	O
to	O
individuals	B-T098
with	O
clinically diagnosed	B-T060
mental health	B-T041
or	O
substance use problems	B-T048
.	O

Real-time	B-T079
monitoring	B-T058
of	O
vesicle	B-T026
pH	B-T081
in	O
an	O
endocytic	B-T043
pathway	B-T044
using	O
an	O
EGF	B-T116
-	O
conjugated two-photon probe	B-T120
Herein,	O
we	O
developed	O
a	O
ratiometric two-photon probe	B-T120
(	O
BHS3	B-T120
-	O
EGF	B-T116
),	O
derived	O
from	O
a	O
pH	B-T081
sensitive	B-T169
dye	O
and	O
epidermal growth factor	B-T116
(	O
EGF	B-T116
),	O
for	O
real-time	B-T079
monitoring	B-T058
and	O
quantitative	B-T081
analysis	B-T062
of	O
acidic luminal	B-T030
pH	B-T081
values	B-T080
during	O
endocytic	B-T043
pathway activity	B-T044
.	O
Two-photon microscopy imaging	B-T059
with	O
BHS3	B-T120
-	O
EGF	B-T116
allows	O
the	O
quantitative	B-T081
analysis	B-T062
of	O
pH	B-T081
distributions	B-T169
of	O
single	O
vesicles	B-T026
and	O
their	O
dynamics	B-T070
in	O
receptor-mediated endocytosis	B-T043
in	O
real-time	B-T079
.	O

Body burden	B-T081
of	O
heavy metals	B-T196
among	O
HIV	B-T033
high risk population	B-T098
in	O
USA	B-T083
HIV	B-T033
high risk population	B-T098
may	O
face	O
not	O
only	O
the	O
threat	B-T078
of	O
HIV infection	B-T047
but	O
also	O
a	O
higher	B-T080
chance	B-T080
of	O
exposure to environmental contaminants	B-T037
.	O
However,	O
no	O
previous	O
studies	B-T062
have	O
examined	B-T080
the	O
body burden	B-T081
of	O
environmental pollutants	B-T131
including	O
heavy metals	B-T196
among	O
HIV	B-T033
high risk populations	B-T098
.	O
The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
investigate	O
whether	O
adults aged	B-T100
20-59	O
years	O
old	O
at	O
high risk of	B-T033
HIV infection	B-T047
have	O
higher	B-T080
blood levels of heavy metals	B-T033
compared	B-T052
to	O
those	O
with	O
low risk	B-T081
of	O
HIV infection	B-T047
in	O
United States	B-T083
.	O
We	O
used	O
the	O
National Health and Nutrition Examination Survey	B-T062
(	O
NHANES	B-T062
)	O
1999-2010	O
to	O
compare	B-T052
exposures to	B-T080
heavy metals	B-T196
including	O
cadmium	B-T131
,	O
lead	B-T131
,	O
and	O
total	O
mercury	B-T131
by	O
HIV	B-T033
risk status	B-T033
.	O
The	O
results	B-T169
showed	O
that	O
people	B-T098
at	O
high risk of	B-T033
HIV	B-T033
had	O
higher	B-T080
blood concentrations	B-T034
of	O
all	O
heavy metals	B-T196
compared	B-T052
to	O
their	O
counterparts	O
with	O
lower	B-T080
HIV risks	B-T033
.	O
In	O
multivariate linear regression	B-T081
models	B-T075
,	O
HIV risk	B-T033
status	O
was	O
significantly	O
associated with	B-T080
increased	B-T081
blood cadmium	B-T059
,	O
lead	B-T059
,	O
and	O
total mercury	B-T059
after	O
adjusting	B-T169
for	O
age	B-T032
,	O
sex	B-T032
,	O
race	B-T098
,	O
education	B-UnknownType
,	O
and	O
poverty	B-T102
income	B-T081
ratio	B-T081
.	O
Our	O
study	B-T062
suggests	O
that	O
people	B-T098
at	O
high risk of	B-T033
HIV	B-T033
have	O
significantly	O
higher	B-T080
body burden	B-T081
of	O
heavy metals	B-T196
including	O
cadmium	B-T131
,	O
lead	B-T131
,	O
and	O
mercury	B-T131
compared	B-T052
to	O
those	O
with	O
low risk	B-T081
of	O
HIV	B-T033
.	O
Further	O
longitudinal study	B-T062
collecting	O
more	B-T081
pollutants	B-T131
are	O
warranted	B-T169
to	O
determine	O
the	O
potential	B-T080
health	B-T078
effects	B-T080
of	O
these	O
elevated	B-T080
pollutants	B-T131
on	O
both	O
HIV-infected	B-T047
and	O
HIV	B-T033
high-risk populations	B-T098
.	O

Fluorescence-	B-T059
and	O
magnetic-activated cell sorting	B-T059
strategies	B-T169
to	O
separate	B-T080
spermatozoa	B-T025
involving	O
plural	B-T081
contributors	B-T098
from	O
biological mixtures	B-T077
for	O
human identification	B-T060
No	O
effective	O
method	B-T169
has	O
been	O
developed	O
to	O
distinguish	B-T080
sperm cells	B-T025
originating	O
from	O
different	O
men	B-T098
in	O
multi-suspect	B-T078
sexual assault	B-T048
cases	B-T169
.	O
Here	O
we	O
combined	O
MACS	B-T059
and	O
FACS	B-T059
to	O
isolate	B-T059
single	B-T081
donor	B-T098
sperm cells	B-T025
from	O
forensic mixture samples	B-T167
including	O
female	B-T098
vaginal	B-T023
epithelial cells	B-T025
and	O
sperm cells	B-T025
from	O
multiple	B-T081
contributors	B-T098
.	O
Sperms	B-T025
from	O
vaginal swab	B-T167
were	O
isolated	B-T169
by	O
MACS	B-T059
using	O
FITC	B-T109
-conjugated	O
A kinase anchor protein 3	B-T116
(	O
AKAP3	B-T116
)	O
antibody	B-T116
;	O
target individual	B-T098
sperm cells	B-T025
involving	O
two	O
or	O
three	O
donors	B-T098
were	O
separated	B-T080
by	O
FACS	B-T059
using	O
FITC	B-T109
-labeled	O
blood group A/B antigen	B-T116
antibody	B-T116
.	O
This	O
procedure	B-T169
was	O
further	O
tested	B-T169
in	O
two	O
mock	B-T033
multi-suspect	B-T078
sexual assault	B-T048
samples	B-T167
and	O
one	O
practical casework	B-T074
sample	B-T167
.	O
Our	O
results	O
showed	O
that	O
complete	B-T080
single	B-T081
donor	B-T098
STR profiles	B-T114
could	O
be	O
successfully	O
obtained	O
from	O
sperm	B-T025
/	O
epithelial cell	B-T025
and	O
sperm	B-T025
mixtures	B-T167
from	O
two	O
contributors	B-T098
.	O
For	O
unbalanced	O
sperm	B-T025
/	O
epithelial cells	B-T025
and	O
sperm cells	B-T025
mixtures	B-T167
,	O
sensitivity	B-T081
results	O
revealed	O
that	O
target cells	B-T034
could	O
be	O
detected	B-T033
at	O
as	O
low	O
as	O
1:32	O
and	O
1:8	O
mixed	O
ratios,	O
respectively.	O
Although	O
highly	O
relies	O
on	O
cell number	B-T059
and	O
blood types	B-T201
or	O
secretor	O
status	O
of	O
the	O
individuals	B-T098
,	O
this	O
procedure	B-T169
would	O
still	O
be	O
useful	O
tools	O
for	O
forensic DNA analysis	B-T059
of	O
multi-suspect	B-T078
sexual assault	B-T048
cases	B-T169
by	O
the	O
combined	O
use of	B-T169
FACS	B-T059
and	O
MACS	B-T059
based	O
on	O
sperm	B-T025
-specific	O
AKAP3	B-T116
antigen	B-T129
and	O
human	B-T016
blood type antigen	B-T034
.	O

The	O
Role	O
of	O
the	O
Iron Stain	B-T059
in	O
Assessing	B-T052
Intracranial Hemorrhage	B-T047
The	O
timing	B-T079
of	O
the	O
breakdown	O
of	O
red blood cells	B-T025
and	O
organization	B-T169
of	O
hemorrhage	B-T046
has	O
significance	B-T081
in	O
the	O
catabolism	B-T040
of	O
heme	B-T109
and	O
the	O
processing	B-T052
of	O
iron	B-T121
,	O
but	O
also	O
has	O
a	O
practical	O
application	B-T169
in	O
terms	O
of	O
assigning	B-T169
,	O
or	O
attempting	B-T051
to	O
assign	B-T169
,	O
a	O
time course	B-T079
with	O
respect	O
to	O
traumatic	B-T037
events	B-T051
(e.g.	O
contusions	B-T037
and	O
hemorrhages	B-T046
).	O
Attempts	B-T051
to	O
date contusions	B-T037
,	O
however,	O
have	O
generally	O
been	O
unsuccessful	B-T080
by	O
macroscopic observation	B-T059
,	O
whereas	O
the	O
microscopic observations	B-T059
provide	O
broad	O
data	B-T078
but	O
are	O
also	O
anatomically	B-T080
imprecise	B-T080
as	O
a	O
function	B-T169
of	O
time	B-T079
.	O
Intracranial lesions	B-T033
are	O
of	O
particular	O
significance	B-T081
with	O
respect	O
to	O
the	O
timing	B-T079
of	O
organizing	B-T169
hemorrhage	B-T046
given	O
the	O
acute	B-T079
,	O
and	O
often	O
life-threatening	B-T033
nature	B-T078
of	O
the	O
hemorrhages	B-T046
,	O
and	O
the	O
medicolegal investigation	B-T060
into	O
potential	B-T080
crimes	B-T068
.	O
Of	O
concern	O
is	O
that	O
the	O
Prussian Blue reaction	B-T059
for	O
iron	B-T121
,	O
a	O
relatively	O
straightforward	O
histochemical	B-T059
reaction	B-T169
that	O
has	O
been	O
in	O
use	O
for	O
over	O
150	O
years	B-T079
,	O
is	O
sometimes	O
suggested	O
as	O
a	O
diagnostic test	B-T060
for	O
chronicity	B-T079
.	O
Therefore,	O
this	O
study	B-T062
examined	B-T033
the	O
utility	O
of	O
the	O
Prussian Blue iron stain	B-T121
in	O
living patients	B-T101
with	O
intracranial hemorrhages	B-T047
and	O
well-defined	O
symptom onset	B-T079
,	O
to	O
test	O
whether	O
the	O
presence	B-T033
of	O
Prussian Blue	B-T121
reactivity	B-UnknownType
could	O
be	O
correlated	B-T080
with	O
chronicity	B-T079
.	O
It	O
was	O
found	B-T033
that	O
out	O
of	O
12	O
cases	B-T169
with	O
intracranial hemorrhage	B-T047
,	O
eight	O
cases	B-T169
showed	O
at	O
least	O
focal iron	B-T121
reactivity	B-UnknownType
.	O
The	O
duration	B-T079
from	O
symptom onset	B-T079
to	O
surgery	B-T061
in	O
those	O
eight	O
cases	B-T169
ranged	B-T081
from	O
<	O
24	O
hours	B-T079
to	O
more	O
than	O
3	O
days	B-T079
.	O
Of	O
those	O
cases	B-T169
with	O
no iron reactivity	B-T033
,	O
the	O
duration	B-T079
from	O
symptom onset	B-T079
to	O
surgery	B-T061
ranged	O
from	O
<	O
24	O
hours	B-T079
to	O
six	O
days	B-T079
.	O
In	O
conclusion,	O
the	O
Prussian Blue reaction	B-T059
was	O
unreliable	B-T078
as	O
an	O
indicator	B-T130
of	O
timing	B-T079
in	O
intracranial hemorrhage	B-T047
.	O
The	O
use	O
of	O
the	O
Prussian blue reaction	B-T059
as	O
an	O
independent indicator	B-T130
of	O
chronicity	B-T079
is	O
therefore	O
not	O
valid	B-T080
and	O
can	O
be	O
misleading.	O
Caution	O
is	O
indicated	B-T033
when	O
employing	O
iron staining	B-T059
for	O
timing	B-T079
purposes,	O
as	O
its	O
only	O
use	O
is	O
to	O
highlight,	O
as	O
opposed	O
to	O
identify,	O
pre-existing	B-T080
lesions	B-T033
.	O
With	O
respect	O
to	O
brain lesions	B-T047
,	O
the	O
Prussian blue reaction	B-T059
should	O
not	O
be	O
used	O
in	O
place	O
of	O
the	O
clinical	B-T080
timing	B-T079
of	O
the	O
neurologic decline	B-T033
,	O
or	O
clinical data	B-T170
that	O
is	O
otherwise	O
more	O
accurate	B-T080
and	O
less	O
susceptible	B-T169
to	O
false positive results	B-T034
.	O

Successful	B-T080
Fetal Tele-Echo	B-T060
at	O
a	O
Small Regional Hospital	B-T073
Prenatal diagnosis	B-T060
of	O
complex	B-T080
congenital heart disease	B-T019
(	O
CHD	B-T019
)	O
has	O
been	O
shown	O
to	O
improve	B-T033
newborn	B-T033
outcomes	B-T169
.	O
The	O
rate	O
of	O
prenatal diagnosis	B-T060
and	O
access	B-T082
to	O
fetal echocardiography	B-T060
vary	O
widely	O
across	O
the	O
United States	B-T083
.	O
A	O
clinical fetal tele-echo	B-T060
service	O
was	O
established	O
at	O
King's Daughters Medical Center	B-T073
(	O
KDMC	B-T073
)	O
in	O
Ashland	B-T083
,	O
KY	B-T083
,	O
a	O
region	O
in	O
eastern Kentucky	B-T083
that	O
is	O
3	O
h	O
from	O
the	O
nearest	O
congenital heart surgeon	B-T097
.	O
The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
determine	O
if	O
fetal tele-echo	B-T060
utilizing	O
local sonographers	B-T097
at	O
a	O
small regional hospital	B-T073
can	O
accurately	B-T080
and	O
efficiently	B-T080
identify	O
fetuses	B-T018
with	O
complex	B-T080
CHD	B-T019
.	O
Medical records	B-T170
were	O
reviewed	B-T080
for	O
all	O
mother-infant pairs	B-T058
who	O
had	O
fetal tele-echoes	B-T060
performed	B-T169
at	O
KDMC	B-T073
and	O
interpreted	B-T169
by	O
University of Louisville pediatric cardiology	B-T073
between	O
March	O
2011	O
and	O
December	O
2013.	O
Findings	B-T033
on	O
fetal tele-echo	B-T060
were	O
compared	O
to	O
newborn	B-T100
newborn	B-T100
echo	B-T060
and	O
clinical course	B-T079
,	O
and	O
divided	O
into	O
four	O
groups:	O
(1)	O
Correct	B-T080
-	O
no difference	B-T033
between	O
fetal tele-echo	B-T060
and	O
newborn	B-T100
echo	B-T060
,	O
(2)	O
Likely	O
Correct-normal	O
fetal tele-echo	B-T060
and	O
benign	O
newborn	B-T100
course,	O
(3)	O
Major Difference	B-T081
-one	O
that	O
affected	B-T169
newborn	B-T100
newborn	B-T033
clinical course	B-T079
,	O
and	O
(4)	O
Minor Difference	B-T081
-did	O
not	O
affect	O
clinical course	B-T079
.	O
Seventy-five	O
mother-infant pairs	B-T058
were	O
analyzed	B-T062
.	O
Fetal tele-echoes	B-T060
were	O
Correct	B-T080
in	O
21%,	O
Likely	O
Correct	B-T080
in	O
56%,	O
showed	O
Major Differences	B-T081
in	O
0%,	O
and	O
showed	O
Minor Differences	B-T081
in	O
23%.	O
For	O
identifying	O
complex	B-T080
CHD	B-T019
,	O
fetal tele-echo	B-T060
had	O
a	O
sensitivity	B-T169
and	O
specificity	B-T081
of	O
100%.	O
The	O
average	O
number	O
of	O
fetal echocardiograms	B-T060
per	O
mother-infant pair	B-T058
was	O
1.1.	O
Fetal tele-echocardiography	B-T060
performed	B-T169
by	O
local sonographers	B-T097
at	O
a	O
small regional hospital	B-T073
can	O
accurately	B-T080
and	O
efficiently	B-T080
identify	O
fetuses	B-T018
with	O
complex	B-T080
CHD	B-T019
.	O

Identification	B-T080
of	O
mineral	B-T197
-	O
binding	B-T052
peptides	B-T116
that	O
discriminate	B-T080
between	O
chalcopyrite	B-T197
and	O
enargite	B-T197
Innovative	O
approaches	O
to	O
the	O
separation	B-T080
of	O
minerals	B-T197
and	O
subsequent	B-T079
extraction	B-T059
of	O
metals	B-T197
are	O
imperative	B-T080
owing	O
to	O
the	O
increasing	B-T169
mineralogical	B-T197
complexity	B-T080
of	O
ore deposits	B-T197
that	O
are	O
difficult	B-T080
or	O
even	O
impossible	B-T033
to	O
separate	B-T080
into	O
slurries	B-T167
or	O
solutions	B-T167
containing	B-T169
only	O
the	O
minerals	B-T197
or	O
metals	B-T197
of	O
interest.	O
Low	B-T080
recovery	B-T052
of	O
metal	B-T197
is	O
typical	B-T080
for	O
these	O
complex	B-T080
deposits	B-T197
leading	O
to	O
significant	B-T078
losses	B-T081
to	O
tailings	B-T069
.	O
In addition	B-T169
,	O
the	O
minerals	B-T197
often	O
contain	O
impurities	B-T167
,	O
some	O
toxic	B-T080
,	O
which	O
are	O
difficult	B-T080
and	O
costly	B-T169
to	O
control	B-T169
or	O
manage	O
during	O
the	O
processing	B-T052
of	O
a	O
concentrate	B-T080
or	O
other	O
mineral	B-T197
product	B-T071
.	O
One	O
example	B-T077
of	O
this	O
complex	B-T080
situation	O
is	O
the	O
significant	B-T078
economic	B-T169
and	O
environmental	B-T082
costs	B-T081
associated with	B-T080
diluting	B-T169
and	O
processing	B-T052
copper	B-T121
concentrates	B-T080
containing	B-T169
arsenic	B-T121
(in	O
the	O
form	O
of	O
the	O
mineral enargite	B-T197
,	O
Cu3 AsS4	B-T197
)	O
in	O
the	O
production	B-T057
of	O
pure	B-T081
copper	B-T121
.	O
To	O
overcome	O
these	O
separation	B-T080
problems	B-T033
,	O
we	O
have	O
utilized	O
phage display	B-T063
to	O
identify	B-T080
peptides	B-T116
that	O
demonstrate	O
selective	B-T080
recognition	B-T080
of	O
enargite	B-T197
and	O
the	O
arsenic	B-T121
-	O
free	B-T169
copper sulfide	B-T197
,	O
chalcopyrite	B-T197
.	O
Screening	O
of	O
two	O
random	B-T080
peptide phage display libraries	B-T116
resulted	O
in	O
the	O
identification	B-T080
of	O
an	O
enargite	B-T197
-	O
selective	B-T080
peptide	B-T116
with	O
the	O
sequence MHKPTVHIKGPT	B-T087
and	O
a	O
chalcopyrite	B-T197
-	O
selective	B-T080
peptide	B-T116
with	O
the	O
sequence RKKKCKGNCCYTPQ	B-T087
.	O
Mineral	B-T197
-	O
binding	B-T052
selectivity	B-T080
was	O
demonstrated	O
by	O
binding	B-T052
studies	B-T062
,	O
zeta potential	B-T067
determination	B-T059
and	O
immunochemistry	B-T091
.	O
Peptides	B-T116
that	O
have	O
the	O
ability	B-T033
to	O
discriminate	B-T080
between	O
enargite	B-T197
and	O
chalcopyrite	B-T197
provide	O
a	O
greener	O
option	B-T169
for	O
the	O
separation	B-T080
of	O
arsenic	B-T121
containing	B-T169
contaminants	B-T167
from	O
copper	B-T121
concentrates	B-T080
.	O
This	O
represents	O
the	O
first	O
step	O
towards	O
a	O
major	B-T080
advance	B-T079
in	O
the	O
replacement	B-T169
or	O
reduction	B-T080
of	O
toxic	B-T080
collectors	B-T169
as	O
well	O
as	O
reducing	B-T080
the	O
level	B-T080
of	O
arsenic	B-T121
-	O
bearing	B-T052
minerals	B-T197
in	O
the	O
early	B-T079
stages	B-T079
of	O
mineral	B-T197
processing	B-T052
.	O
Biotechnol.	O
Bioeng.	O
2016;9999:	O
1-8.	O
©	O
2016	O
Wiley	O
Periodicals,	O
Inc.	O

High-density lipoprotein	B-T116
-associated	O
sphingosine-1-phosphate	B-T109
activity	O
in	O
heterozygous familial hypercholesterolaemia	B-T047
Patients	B-T101
with	O
heterozygous familial hypercholesterolaemia	B-T047
(	O
FH	B-T047
)	O
suffer	B-T184
from	O
high plasma cholesterol	B-T033
and	O
an	O
environment	B-T082
of	O
increased	O
oxidative stress	B-T049
.	O
We	O
examined	O
its	O
potential	O
effects	O
on	O
high-density lipoprotein	B-T116
(	O
HDL	B-T116
)-associated	O
sphingosine-1-phosphate	B-T109
(	O
S1P	B-T109
)	O
content	O
(	O
HDL	B-T116
-	O
S1P	B-T109
)	O
and	O
HDL	B-T116
-mediated	O
protection against oxidative stress	B-T039
,	O
both	O
with	O
and	O
without	O
statin treatment	B-T058
.	O
In	O
a	O
case-control study	B-T062
,	O
HDL	B-T116
was	O
isolated	B-T169
from	O
12	O
FH	B-T047
patients	B-T101
with	O
and	O
without	O
statin treatment	B-T058
and	O
from	O
12	O
healthy controls	B-T080
.	O
The	O
HDL	B-T116
-	O
S1P	B-T109
content	O
and	O
the	O
capacity	O
of	O
HDL	B-T116
to	O
protect	B-T033
cardiomyocytes	B-T025
against	O
oxidative stress	B-T049
in vitro	B-T062
were	O
measured.	O
HDL	B-T116
-associated	O
S1P	B-T109
was	O
significantly	O
correlated	O
with	O
cell protection	B-T039
,	O
but	O
not	O
with	O
HDL-cholesterol	B-T109
or	O
apolipoprotein AI	B-T116
.	O
The	O
latter	O
did	O
not	O
correlate	O
with	O
HDL	B-T116
-mediated	O
cell protection	B-T039
.	O
Neither	O
the	O
HDL	B-T116
-	O
S1P	B-T109
content	O
nor	O
HDL	B-T116
protective	O
capacity	O
differed	O
between	O
nontreated	O
FH	B-T047
patients	B-T101
and	O
controls.	O
The	O
relative	O
amounts	O
of	O
apolipoprotein AI	B-T116
and	O
apolipoprotein M	B-T116
were	O
similar	O
between	O
controls	O
and	O
FH	B-T047
patients	B-T101
.	O
Statin treatment	B-T058
had	O
no	O
effect	O
on	O
any	O
of	O
these	O
measures.	O
The	O
FH	B-T047
environment	B-T082
is	O
not	O
detrimental	O
to	O
HDL	B-T116
-	O
S1P	B-T109
content	O
or	O
HDL	B-T116
-	O
S1P	B-T109
-mediated	O
cell protection	B-T039
.	O
Statin treatment	B-T058
does	O
not	O
modulate	O
HDL	B-T116
function	O
in	O
this	O
regard.	O

Moberg Picking-Up Test	B-T059
in	O
patients	B-T101
with	O
hand osteoarthritis	B-T047
Clinical measurement	B-T058
.	O
The	O
Moberg Pick-up Test	B-T059
(	O
MPUT	B-T059
)	O
was	O
previously	O
used	O
to	O
evaluate	O
functional performance	B-T033
in	O
patients	B-T101
with	O
hand	B-T023
inflammatory disease	B-T047
.	O
This	O
is	O
the	O
first	O
study	O
using	O
the	O
MPUT	B-T059
in	O
hand osteoarthritis	B-T047
(	O
OA	B-T047
).	O
Compare	O
the	O
functional performance	B-T033
(	O
MPUT	B-T059
)	O
in	O
hand OA	B-T047
patients	B-T101
and	O
healthy controls	B-T080
.	O
Fifty	O
hand OA	B-T047
patients	B-T101
and	O
50	O
controls	B-T096
were	O
assessed	O
using	O
the	O
MPUT	B-T059
,	O
AUSCAN	B-T170
and	O
Cochin questionnaires	B-T170
,	O
grip	B-T033
and	O
pinch strength	B-T060
,	O
pain	B-T184
using	O
a	O
visual analog scale	B-T060
and	O
a	O
Likert scale	B-T170
regarding	O
difficulty	O
to	O
perform	O
MPUT	B-T059
.	O
In	O
the	O
MPUT	B-T059
evaluation	B-T058
,	O
the	O
OA	B-T047
group	O
presented	O
a	O
statistically significant	B-T081
difference	O
from	O
the	O
control group	B-T096
.	O
The	O
OA	B-T047
group	O
spent	O
more	B-T081
time	B-T079
executing	O
test	B-T170
.	O
The	O
grip	B-T033
and	O
pinch strength measurements	B-T060
showed	O
higher	O
values	O
for	O
the	O
control group	B-T096
.	O
The	O
OA	B-T047
group	O
reported	O
a	O
greater	O
difficulty	B-T080
than	O
the	O
control group	B-T096
in	O
performing	O
the	O
test	B-T170
.	O
The	O
MPUT	B-T059
is	O
a	O
short	O
and	O
easy	O
to	O
apply	O
test	B-T170
,	O
which	O
can	O
be	O
safely	O
used	O
to	O
assess	O
the	O
functional performance	B-T033
of	O
the	O
hand OA	B-T047
.	O
II.	O

Soymilk	B-T168
residue	B-T077
(	O
okara	B-T116
)	O
as	O
a	O
natural	B-T169
immobilization carrier	B-T080
for	O
Lactobacillus plantarum	B-T007
cells	B-T025
enhances	B-T052
soymilk	B-T168
fermentation	B-T044
,	O
glucosidic isoflavone	B-T109
bioconversion	B-T169
,	O
and	O
cell survival	B-T043
under	O
simulated gastric	B-T080
and	O
intestinal	B-T023
conditions	B-T080
Cell immobilization	B-T025
is	O
an	O
alternative	B-T077
to	O
microencapsulation	B-T061
for	O
the	O
maintenance	O
of	O
cells	B-T025
in	O
a	O
liquid	B-T167
medium	B-T167
.	O
However,	O
artificial	B-T080
immobilization carriers	B-T080
are	O
expensive	O
and	O
pose	O
a	O
high	O
safety	B-T068
risk	B-T078
.	O
Okara	B-T116
,	O
a	O
food-grade	B-T168
byproduct	B-T167
from	O
soymilk	B-T168
production	B-T057
,	O
is	O
rich	O
in	O
prebiotics	B-T109
.	O
Lactobacilli	B-T007
could	O
provide	O
health	B-T078
enhancing	B-T052
effects	B-T080
to	O
the	O
host	B-T001
.	O
This	O
study	B-T062
aimed	O
to	O
evaluate	O
the	O
potential	O
of	O
okara	B-T116
as	O
a	O
natural	O
immobilizer	O
for	O
L. plantarum 70810 cells	B-T025
.	O
The	O
study	O
also	O
aimed	O
to	O
evaluate	O
the	O
effects	O
of	O
okara-immobilized	B-T116
L. plantarum 70810 cells	B-T025
(	O
IL	B-T025
)	O
on	O
soymilk	B-T168
fermentation	B-T044
,	O
glucosidic isoflavone	B-T109
bioconversion	B-T169
,	O
and	O
cell	B-T025
resistance	B-T169
to	O
simulated gastric	B-T080
and	O
intestinal	B-T023
stresses	B-T046
.	O
Scanning electron microscopy	B-T059
(	O
SEM	B-T059
)	O
was	O
used	O
to	O
show	O
cells	B-T025
adherence	B-T169
to	O
the	O
surface	B-T082
of	O
okara	B-T116
.	O
Lactic acid	B-T109
,	O
acetic acid	B-T109
and	O
isoflavone	B-T109
analyses	B-T062
in	O
unfermented	O
and	O
fermented	B-T168
soymilk	B-T168
were	O
performed	B-T169
by	O
HPLC with UV detection	B-T059
.	O
Viability	B-T080
and	O
growth	O
kinetics	O
of	O
immobilized	B-T025
and	O
free L. plantarum 70810 cells	B-T025
(	O
FL	B-T025
)	O
were	O
followed	O
during	O
soymilk	B-T168
fermentation	B-T044
.	O
Moreover,	O
changes	B-T169
in	O
pH	B-T034
,	O
titrable acidity	B-T034
and	O
viscosity	B-T070
were	O
measured	B-T080
by	O
conventional methods	B-T170
.	O
For	O
in vitro	B-T080
testing	B-T169
of	O
simulated	O
gastrointestinal	B-T082
resistance	B-T169
,	O
fermented	B-T168
soymilk	B-T168
was	O
inoculated	B-T061
with	O
FL	B-T025
or	O
IL	B-T025
and	O
an	O
aliquot	B-T081
incubated	B-T059
into	O
acidic MRS broth	B-T167
which	O
was	O
conveniently	O
prepared	O
to	O
simulate	O
gastric	B-T080
,	O
pancreatic juices	B-T031
and	O
bile salts	B-T109
.	O
Survival	O
to	O
simulated gastric	B-T080
and	O
intestinal	B-T023
stresses	B-T046
was	O
evaluated	O
by	O
plate count of colony forming units	B-T059
on	O
MRS agar	B-T130
.	O
SEM	B-T059
revealed	O
that	O
the	O
lactobacilli	B-T007
cells	B-T025
attached	B-T067
and	O
bound	O
to	O
the	O
surface	B-T082
of	O
okara	B-T116
.	O
Compared	B-T052
with	O
FL	B-T025
,	O
IL	B-T025
exhibited	O
a	O
significantly	O
higher	B-T080
specific	B-T080
growth rate	B-T079
,	O
shorter	B-T081
lag phase	B-T079
of	O
growth	B-T040
,	O
higher	O
productions	O
of	O
lactic	B-T109
and	O
acetic acids	B-T109
,	O
a	O
faster	B-T080
decrease	B-T081
in	O
pH	B-T034
and	O
increase	B-T169
in	O
titrable acidity	B-T034
,	O
and	O
a	O
higher	B-T080
soymilk	B-T168
viscosity	B-T070
.	O
Similarly,	O
IL	B-T025
in	O
soymilk	B-T168
showed	O
higher	O
productions	O
of	O
daizein	B-T109
and	O
genistein	B-T109
compared	B-T052
with	O
the	O
control	B-T167
.	O
Compared	B-T052
with	O
FL	B-T025
,	O
IL	B-T025
showed	O
reinforced	O
resistance	O
to	O
simulatedgastric	B-T080
and	O
intestinal	B-T023
stresses	B-T046
in vitro	B-T080
that	O
included	O
low pH	B-T033
,	O
low pH plus	B-T033
pepsin	B-T116
,	O
pancreatin	B-T116
,	O
and	O
bile salt	B-T109
.	O
Our	O
results	B-T169
indicate	O
that	O
okara	B-T116
is	O
a	O
new	O
potential	O
immobilization carrier	B-T080
to	O
enhance	B-T052
the	O
growth	B-T040
and	O
glucosidic isoflavone	B-T109
bioconversion	B-T169
activities	B-T052
of	O
L. plantarum	B-T007
in	O
soymilk	B-T168
and	O
improve	B-T033
cell survivability	B-T043
following	O
simulated gastric	B-T080
and	O
intestinal	B-T023
conditions	B-T080
.	O

Comparison	O
of	O
a	O
new	O
visual stylet (Discopo)-guided	B-T061
laryngeal mask airway placement	B-T061
vs	O
conventional blind technique	B-T061
:	O
a	O
prospective	O
randomized	B-T062
study	O
To	O
compare	O
the	O
ease	O
of	O
laryngeal mask airway (LMA) insertion	B-T061
and	O
fiberoptic view	B-T082
of	O
LMA	B-T074
after	O
placement	B-T080
using	O
the	O
Discopo visual stylet-guided insertion	B-T061
and	O
conventional blind technique	B-T061
.	O
Prospective,	O
randomized	B-T062
controlled study	B-T062
.	O
Operating room	B-T073
in	O
a	O
university hospital	B-T073
.	O
One	O
hundred	O
adult	B-T100
patients	B-T101
scheduled	O
for	O
elective surgery	B-T061
under	O
LMA	B-T074
general anesthesia	B-T061
were	O
enrolled.	O
Patients	B-T101
were	O
randomly	B-T062
allocated	O
to	O
2	O
groups	B-UnknownType
:	O
GLMA group	B-UnknownType
using	O
a	O
visual stylet-guided technique	B-T061
(n=50)	O
and	O
BLMA group	B-UnknownType
using	O
standard	O
blind technique	B-T061
(n=50).	O
Correct	O
placement	B-T080
of	O
the	O
LMA	B-T074
was	O
confirmed	O
using	O
clinical test	B-T201
along	O
with	O
fiberoptic	B-T073
assessment	B-T058
.	O
Unblinded data	B-T078
were	O
collected	O
about	O
the	O
insertion	B-T061
time,	O
the	O
first	O
attempt	O
success rate	B-T081
,	O
the	O
LMA	B-T074
position	B-T082
adjustment	O
rate,	O
fiberoptic view	B-T082
of	O
LMA	B-T074
anatomical position	B-T029
,	O
hemodynamic responses	B-T042
,	O
and	O
the	O
adverse	B-T169
insertion	B-T061
responses	B-T032
(	O
bucking	B-T037
,	O
breathholding	B-T033
,	O
and	O
laryngospasm	B-T037
).	O
Blinded data	B-T078
were	O
recorded	O
about	O
postoperative	B-T079
airway morbidity	B-T047
(visible	O
blood staining	B-T031
on	O
LMA	B-T074
at	O
removal,	O
sore throat	B-T184
,	O
and	O
hoarseness	B-T184
).	O
Insertion	B-T061
was	O
more	O
frequently	O
successful	O
at	O
the	O
first	O
attempt	O
in	O
GLMA	B-UnknownType
than	O
that	O
in	O
BLMA group	B-UnknownType
(100%	O
vs	O
92%;	O
P=.041).	O
The	O
time	O
taken	O
for	O
establishing	O
effective	O
airway	O
was	O
shorter	O
in	O
GLMA	B-UnknownType
than	O
that	O
in	O
BLMA	B-UnknownType
(54.8	O
vs	O
62.9	O
seconds;	O
P=.001).	O
The	O
patients	B-T101
in	O
BLMA group	B-UnknownType
required	O
more	O
readjustment	O
and	O
reinsertion	B-T061
than	O
those	O
in	O
GLMA group	B-UnknownType
(38%	O
vs	O
0%;	O
P=.000).	O
The	O
fiberoptic view	B-T082
was	O
significantly	O
better	O
in	O
GLMA group	B-UnknownType
(P<.001).	O
No	O
difference	O
between	O
the	O
2	O
groups	B-UnknownType
existed	O
regarding	O
hemodynamic stress responses	B-T039
,	O
incidences	B-T081
of	O
adverse	B-T169
insertion	B-T061
responses,	O
and	O
postoperative	B-T079
airway morbidity	B-T047
.	O
By	O
direct	O
visualizing	O
the	O
whole	O
process	O
of	O
LMA	B-T074
insertion	B-T061
,	O
the	O
Discopo visual stylet	B-T061
increases	O
the	O
success rate	B-T081
and	O
accuracy rate	B-T080
of	O
LMA	B-T074
placement	B-T080
without	O
increasing	O
hemodynamic stress response	B-T039
or	O
incidences	B-T081
of	O
adverse events	B-T046
.	O

Targeting	B-T169
brain	B-T023
and	O
peripheral plasticity	B-T042
of	O
the	O
lipidome	B-T109
in	O
acute	B-T079
kainic acid	B-T109
-	O
induced	B-T169
epileptic seizures	B-T047
in	O
mice	B-T015
via	O
quantitative mass spectrometry	B-T059
Epilepsy	B-T047
is	O
a	O
highly	O
common	O
chronic neurological disorder	B-T047
,	O
manifested	B-T169
in	O
many	O
different	O
types	B-T080
,	O
affecting	O
~1%	O
of	O
the	O
worldwide	O
human	B-T016
population	B-T098
.	O
The	O
molecular mechanisms	B-T044
of	O
epileptogenesis	B-T047
have	O
not	O
yet	O
been	O
clarified,	O
and	O
pharmacoresistance	B-T047
exhibited	O
by	O
30-40%	O
of	O
epilepsy	B-T047
patients	B-T101
remains	O
a	O
major	O
obstacle	O
in	O
medical	B-T169
care	B-T058
.	O
Growing	O
evidence	B-T078
indicates	O
a	O
role	O
of	O
lipid	B-T109
signalling pathways	B-T044
in	O
epileptogenesis	B-T047
,	O
thus	O
lipid	B-T109
signals	B-T044
emerge	O
as	O
potential	B-T080
biomarkers	B-T201
for	O
the	O
onset	O
and	O
evolving	O
course	O
of	O
the	O
epileptic disorder	B-T047
,	O
as	O
well	O
as	O
potential	B-T080
therapeutic agents	B-T121
and	O
targets	B-T169
.	O
For	O
this	O
purpose,	O
we	O
applied	O
a	O
lipidomic	B-T109
strategy	B-T062
to	O
unravel	O
lipid	B-T109
alterations	O
in	O
brain regions	B-T029
,	O
periphery tissues	B-T024
and	O
plasma	B-T031
that	O
are	O
specific	B-T080
for	O
acute	B-T079
epileptic seizures	B-T047
in	O
mice	B-T015
at	O
1h	O
after	O
seizure	B-T047
induction	B-T169
by	O
systemic	B-T062
kainic acid	B-T109
injection	B-T062
as	O
compared	B-T052
to	O
vehicle controls	B-T096
.	O
Specifically,	O
levels	B-T080
of	O
(i)	O
selected	O
phospholipids	B-T109
and	O
sphingomyelins	B-T109
,	O
(ii)	O
the	O
endocannabinoids	B-T109
anandamide	B-T109
(	O
AEA	B-T109
)	O
and	O
2-arachidonoyl glycerol	B-T109
(	O
2-AG	B-T109
),	O
and	O
the	O
endocannabinoid	B-T109
-related	O
compounds	B-T103
oleoylethanolamide	B-T109
(	O
OEA	B-T109
)	O
and	O
palmitoylethanolamide	B-T109
(	O
PEA	B-T109
),	O
(iii)	O
arachidonic acid	B-T109
(	O
AA	B-T109
),	O
(iv)	O
selected	O
eicosanoids	B-T109
,	O
and	O
(v)	O
fatty acyl	B-T123
content	O
of	O
lipidome	B-T109
were	O
determined	O
in	O
pulverized	B-T062
tissues	B-T023
from	O
six	O
brain regions	B-T029
of	O
kainic acid	B-T109
induced	B-T169
epileptic seizure	B-T047
models	B-T075
and	O
vehicle controls	B-T096
:	O
hypothalamus	B-T023
,	O
hippocampus	B-T023
,	O
thalamus	B-T023
,	O
striatum	B-T023
,	O
cerebellum	B-T023
and	O
cerebral cortex	B-T023
,	O
and	O
from	O
peripheral	B-T082
organs	B-T023
,	O
such	O
as	O
heart	B-T023
and	O
lungs	B-T023
,	O
and	O
in	O
plasma	B-T031
.	O
Alterations	O
in	O
lipid	B-T109
levels	O
after	O
acute	B-T079
epileptic seizures	B-T047
as	O
compared	B-T052
to	O
non-seizure controls	B-T096
were	O
found	O
to	O
be	O
brain region	B-T029
-	O
and	O
periphery tissue	B-T024
-	O
specific	B-T080
,	O
including	O
specific	B-T080
plasma	B-T031
lipid	B-T109
correlates,	O
highlighting	O
their	O
value	O
as	O
marker candidates	B-T201
in	O
translational	O
research studies	B-T062
,	O
and/or	O
drug discovery	B-T062
and	O
response monitoring	B-T058
.	O

Panitumumab	B-T116
-Associated	O
Encephalopathy	B-T047
after	O
Accidental	O
Intra-arterial	B-T169
Application	B-T058
through	O
Dislocated Central Venous Access Device	B-T074
Acute	B-T079
central nervous system	B-T022
(	O
CNS	B-T022
)	O
toxicity	B-T037
and	O
immune	B-T169
-related	O
side effects	B-T046
are	O
increasingly	O
recognized	O
with	O
the	O
use	O
of	O
monoclonal antibodies	B-T116
for	O
cancer therapy	B-T061
.	O
Here,	O
we	O
report	O
a	O
patient	B-T101
who	O
developed	O
of	O
acute-onset encephalopathy	B-T033
and	O
coma	B-T047
,	O
which	O
began	O
shortly	O
after	O
administration	B-T169
of	O
panitumumab	B-T116
for	O
the	O
treatment	B-T061
of	O
metastatic colorectal cancer	B-T191
.	O
Echocardiography	B-T060
revealed	O
that	O
the	O
drug	B-T121
had	O
been	O
infused	O
into	O
the	O
left cardiac ventricle	B-T023
via	O
a	O
dislocated central venous line	B-T074
.	O
Diffusion-weighted magnetic resonance imaging	B-T060
disclosed	O
multiple	O
cortical hyperintensities	B-T033
,	O
which	O
were	O
preferentially	O
located	O
in	O
the	O
frontal lobes	B-T023
.	O
While	O
the	O
neurological condition	B-T047
improved	O
within	O
a	O
few	O
days	B-T079
,	O
the	O
patient	B-T101
died	B-T040
4	O
weeks	B-T079
later.	O
It	O
seems	O
likely	O
that	O
the	O
administration	B-T169
of	O
the	O
antibody	B-T116
via	O
the	O
intra-arterial route	B-T169
contributed	O
to	O
the	O
development	O
of	O
this	O
condition	B-T047
.	O
Toxic encephalopathy	B-T037
may	O
be	O
a	O
hitherto	B-T079
unrecognized	O
complication	B-T046
of	O
panitumumab	B-T116
treatment	B-T061
and	O
should	O
be	O
taken	O
into	O
consideration	O
in	O
patients	B-T101
developing	O
CNS	B-T022
symptoms	B-T184
undergoing	O
this	O
therapy	B-T061
.	O

Abundance	B-T080
and	O
Characterization	B-T052
of	O
Perfect	O
Microsatellites	B-T114
on	O
the	O
Cattle	B-T015
Y Chromosome	B-T026
Microsatellites	B-T114
or	O
simple sequence repeats	B-T114
(	O
SSRs	B-T114
)	O
are	O
found	O
in	O
most	O
organisms	B-T001
and	O
play	O
an	O
important	O
role	O
in	O
genomic organization	B-T028
and	O
function	B-T045
.	O
To	O
characterize	B-T052
the	O
abundance	B-T080
of	O
SSRs	B-T114
(1-6	O
base-pairs	B-T044
[	O
bp	B-T044
])	O
on	O
the	O
cattle	B-T015
Y chromsome	B-T026
,	O
the	O
relative	O
frequency	B-T079
and	O
density	B-T081
of	O
perfect	O
or	O
uninterrupted	O
SSRs	B-T114
based	O
on	O
the	O
published	O
Y chromosome	B-T026
sequence	B-T086
were	O
examined	B-T033
.	O
A	O
total	O
of	O
17,273	O
perfect	O
SSRs	B-T114
were	O
found,	O
with	O
total	O
length	B-T081
of	O
324.78	O
kb,	O
indicating	O
that	O
approximately	O
0.75%	O
of	O
the	O
cattle	B-T015
Y chromosome	B-T026
sequence	B-T086
(43.30	O
Mb)	O
comprises	O
perfect	O
SSRs	B-T114
,	O
with	O
an	O
average	O
length	B-T086
of	O
18.80	O
bp	B-T044
.	O
The	O
relative	O
frequency	B-T079
and	O
density	B-T081
were	O
398.92	O
loci/Mb	O
and	O
7500.62	O
bp	B-T044
/Mb,	O
respectively.	O
The	O
proportions	O
of	O
the	O
six	O
classes	O
of	O
perfect	O
SSRs	B-T114
were	O
highly	O
variable	O
on	O
the	O
cattle	B-T015
Y chromosome	B-T026
.	O
Mononucleotide repeats	B-T114
had	O
a	O
total	O
number	O
of	O
8073	O
(46.74%)	O
and	O
an	O
average	O
length	B-T086
of	O
15.45	O
bp	B-T044
,	O
and	O
were	O
the	O
most	O
abundant	O
SSRs	B-T114
class,	O
while	O
the	O
percentages	O
of	O
di-	B-T114
,	O
tetra-	B-T114
,	O
tri-	B-T114
,	O
penta-	B-T114
,	O
and	O
hexa-nucleotide repeats	B-T114
were	O
22.86%,	O
11.98%,	O
11.58%,	O
6.65%,	O
and	O
0.19%,	O
respectively.	O
Different	O
classes	O
of	O
SSRs	B-T114
varied	O
in	O
their	O
repeat	O
number,	O
with	O
the	O
highest	O
being	O
42	O
for	O
dinucleotides	B-T114
.	O
Results	O
reveal	O
that	O
repeat	O
categories	O
A	B-T114
,	O
AC	B-T086
,	O
AT	B-T086
,	O
AAC	B-T086
,	O
AGC	B-T086
,	O
GTTT	B-T086
,	O
CTTT	B-T086
,	O
ATTT	B-T086
,	O
and	O
AACTG	B-T086
predominate	O
on	O
the	O
Y chromosome	B-T026
.	O
This	O
study	B-T062
provides	O
insight	O
into	O
the	O
organization	O
of	O
cattle	B-T015
Y chromosome	B-T026
repetitive	O
DNA	B-T114
,	O
as	O
well	O
as	O
information	O
useful	O
for	O
developing	O
more	O
polymorphic	B-T080
cattle	B-T015
Y-chromosome	B-T026
-specific	O
SSRs	B-T114
.	O

Antenatal	B-T079
Stressful Life Events	B-T051
and	O
Postpartum	B-T079
Depressive Symptoms	B-T184
in	O
the	O
United States	B-T083
:	O
The	O
Role	O
of	O
Women's	B-T098
Socioeconomic Status	B-T080
Indices	B-T170
at	O
the	O
State Level	B-T081
Approximately	O
10%-20%	O
of	O
women	B-T098
suffer	B-T048
from	O
postpartum depression	B-T048
(	O
PPD	B-T048
),	O
important	O
predictors	B-T078
of	O
which	O
are	O
antenatal	B-T079
stressful life event	B-T051
(	O
SLE	B-T051
)	O
experiences	B-T067
.	O
The	O
association	B-T080
between	O
women's	B-T098
state-level	B-T081
socioeconomic status	B-T080
(	O
SES	B-T080
)	O
and	O
PPD	B-T048
has	O
not	O
been	O
explored.	O
This	O
study	B-T062
aimed	O
to	O
examine	O
whether	O
the	O
association	B-T080
between	O
antenatal	B-T079
SLE	B-T051
and	O
PPD	B-T048
symptoms	B-T184
was	O
moderated	B-T080
by	O
women's	B-T098
state-level	B-T081
SES	B-T080
.	O
Data	B-T078
from	O
the	O
2009-2011	O
Pregnancy Risk Assessment Monitoring System	B-T170
(	O
PRAMS	B-T170
)	O
were	O
used.	O
State-level	B-T081
women's	B-T098
employment	B-T080
/	O
earnings	B-T081
and	O
social	B-T169
/	O
economic	B-T169
autonomy	B-T078
indices	B-T170
were	O
computed	O
from	O
indicators	B-T130
published	O
by	O
the	O
Institute of Women's Policy Research	B-T092
(	O
IWPR	B-T092
).	O
Multilevel multivariable logistic regression analyses	B-UnknownType
were	O
performed.	O
Among	O
91,253	O
women	B-T098
with	O
valid	B-T080
responses	B-T032
,	O
11.3%	O
had	O
PPD	B-T048
symptoms	B-T184
,	O
prevalence	B-T081
ranging	O
from	O
7.1%	O
in	O
Illinois	B-T083
to	O
17.1%	O
in	O
Arkansas	B-T083
.	O
Women	B-T098
who	O
experienced	O
all	O
four	O
stressor	B-T078
categories	B-T170
,	O
including	O
partner	B-T098
related	B-T033
,	O
traumatic	B-T169
,	O
emotional	B-T033
,	O
and	O
financial	B-T081
,	O
had	O
the	O
highest	O
odds	B-T081
(	O
adjusted odds ratio	B-T081
[	O
aOR	B-T081
]:	O
5.43;	O
95%	O
confidence interval	B-T081
[	O
CI	B-T081
]:	O
5.36-5.51)	O
of	O
PPD	B-T048
symptoms	B-T184
.	O
The	O
odds	B-T081
of	O
experiencing	O
PPD	B-T048
symptoms	B-T184
decreased	B-T081
with	O
an	O
increase	B-T169
in	O
the	O
state-level	B-T081
social	B-T169
/	O
economic	B-T169
autonomy	B-T078
index	B-T170
(	O
aOR	B-T081
:	O
0.75;	O
95%	O
CI	B-T081
:	O
0.64-0.88).	O
There	O
was	O
significant	O
cross-level interaction	B-T080
between	O
number	O
of	O
stressor	B-T078
categories	B-T170
experienced	O
and	O
state-level	B-T081
index	B-T170
.	O
Screening	B-T169
for	O
antenatal	B-T079
SLEs	B-T051
can	O
help	O
identify	O
women	B-T098
at risk	B-T080
for	O
PPD	B-T048
symptoms	B-T184
.	O
That	O
the	O
odds	B-T081
of	O
having	O
PPD	B-T048
symptoms	B-T184
decreased	B-T081
with	O
increasing	B-T169
state-level	B-T081
social	B-T169
/	O
economic	B-T169
autonomy	B-T078
and	O
women	B-T098
residing	O
in	O
states	B-T083
with	O
lower	O
indices	B-T170
were	O
more vulnerable	B-T169
to	O
the	O
impacts	O
of	O
antenatal	B-T079
stressors	B-T078
,	O
could	O
have	O
policy implications	B-UnknownType
related	O
to	O
improving	O
the	O
SES	B-T080
of	O
women	B-T098
in	O
these	O
states	B-T083
.	O

Multi-component model	B-T075
of	O
intramural hematoma	B-T046
A	O
novel	O
multi-component model	B-T075
is	O
introduced	O
for	O
studying	B-T062
interaction	B-T169
between	O
blood flow	B-T039
and	O
deforming	B-T033
aortic wall	B-T023
with	O
intramural hematoma	B-T046
(	O
IMH	B-T046
).	O
The	O
aortic wall	B-T023
is	O
simulated	B-T062
by	O
a	O
composite structure submodel	B-T075
representing	O
material properties	B-T080
of	O
the	O
three	O
main	O
wall layers	B-T023
.	O
The	O
IMH	B-T046
is	O
described	O
by	O
a	O
poroelasticity submodel	B-T075
which	O
takes	O
into	O
account	O
both	O
the	O
pressure	B-T070
inside	O
hematoma	B-T046
and	O
its	O
deformation	B-T033
.	O
The	O
submodel	B-T075
of	O
the	O
hematoma	B-T046
is	O
fully	O
coupled	O
with	O
the	O
aortic submodel	B-T075
as	O
well	O
as	O
with	O
the	O
submodel	B-T075
of	O
the	O
pulsatile blood flow	B-T067
.	O
Model simulations	B-T062
are	O
used	O
to	O
investigate	B-T169
the	O
relation	O
between	O
the	O
peak	O
wall	O
stress,	O
hematoma	B-T046
thickness	O
and	O
permeability	B-T070
in	O
patients	B-T101
of	O
different	O
age	B-T032
.	O
The	O
results	O
indicate	O
that	O
an	O
increase	O
in	O
hematoma	B-T046
thickness	O
leads	O
to	O
larger	O
wall stress	B-T033
,	O
which	O
is	O
in	O
agreement	O
with	O
clinical data	B-T170
.	O
Further	O
simulations	B-T062
demonstrate	O
that	O
a	O
hematoma	B-T046
with	O
smaller	O
permeability	B-T070
results	O
in	O
larger	O
wall stress	B-T033
,	O
suggesting	O
that	O
blood coagulation	B-T042
in	O
hematoma	B-T046
might	O
increase	O
its	O
mechanical stability	B-T033
.	O
This	O
is	O
in	O
agreement	O
with	O
previous	O
experimental	B-T080
observations	B-T062
of	O
coagulation	B-T042
having	O
a	O
beneficial effect	B-T080
on	O
the	O
condition	O
of	O
a	O
patient	B-T101
with	O
the	O
IMH	B-T046
.	O

The	O
Impact of	B-T080
Diabetes	B-T047
on	O
the	O
Risk	B-T078
of	O
Prostate Cancer	B-T191
Development	B-T169
according	O
to	O
Body Mass Index	B-T201
:	O
A	O
10-year	O
Nationwide	O
Cohort Study	B-T081
Purpose:	O
We	O
examined	O
the	O
association	O
between	O
obesity	B-T047
and	O
prostate cancer	B-T191
both	O
with	O
and	O
without	B-T080
diabetic	B-T047
patients	B-T101
included	O
in	O
the	O
analysis	O
using	O
nationally	O
representative	O
data	B-T078
of	O
the	O
Korean population	B-T098
from	O
the	O
National Health Insurance System	B-T058
(	O
NHIS	B-T058
).	O
Materials	O
and	O
Methods:	O
Of	O
the	O
424,712	O
participants	B-T098
who	O
underwent	O
health examinations	B-T061
in	O
2002-2008,	O
139,519	O
men ≥40 years old	B-T098
and	O
without	B-T080
prostate cancer	B-T191
were	O
followed	O
from	O
the	O
beginning	O
of	O
2002	O
to	O
the	O
end	O
of	O
2012.	O
Multivariate adjusted	B-T081
Cox regression analysis	B-T081
was	O
conducted	O
to	O
examine	O
the	O
hazard ratio	B-T081
(	O
HR	B-T081
)	O
and	O
95%	O
confidence interval	B-T081
(	O
CI	B-T081
)	O
for	O
the	O
association	O
between	O
prostate cancer	B-T191
and	O
body mass index	B-T201
(	O
BMI	B-T201
)	O
both	O
with	O
and	O
without	B-T080
diabetes	B-T047
.	O
Results:	O
The	O
HR	B-T081
for	O
prostate cancer	B-T191
according	O
to	O
the	O
existence	O
of	O
diabetes	B-T047
was	O
stratified	B-T080
by	O
BMI	B-T201
in	O
both	O
age	B-T032
-	O
and	O
multivariable-adjusted models	B-T081
.	O
In	O
the	O
population	B-T098
without	B-T080
diabetes	B-T047
,	O
the	O
HR	B-T081
for	O
prostate cancer	B-T191
significantly increased	B-T081
as	O
BMI	B-T201
increased	O
beyond	O
the	O
reference	O
range	O
in	O
a	O
model adjusted for age and multiple variables	B-T081
;	O
however,	O
the	O
increase	O
in	O
the	O
HR	B-T081
was	O
small.	O
In	O
the	O
population	B-T098
with	O
diabetes	B-T047
,	O
the	O
HR	B-T081
for	O
prostate cancer	B-T191
significantly increased	B-T081
as	O
BMI	B-T201
increased	O
from	O
<	O
18.5	O
kg/m(2)	O
to	O
within	O
the	O
reference	O
range	O
(18.5	O
to	O
22.9)	O
in	O
the	O
multivariable-adjusted model	B-T081
.	O
In	O
addition,	O
a	O
marked decrease	B-T081
in	O
HR	B-T081
in	O
the	O
population	B-T098
with	O
BMI	B-T201
of	O
<	O
18.5	O
kg/m(2)	O
was	O
seen	O
compared	O
to	O
the	O
reference	O
or	O
higher	O
BMI	B-T201
population	B-T098
.	O
Conclusion:	O
This	O
population	B-T098
-based	O
study	O
shows	O
the	O
evidence	O
of	O
association	O
between	O
obesity	B-T047
and	O
development	B-T169
of	O
prostate cancer	B-T191
,	O
and	O
the	O
risk increases	B-T033
vary	O
according	O
to	O
the	O
change	O
of	O
BMI	B-T201
category	O
and	O
the	O
existence	O
of	O
diabetes	B-T047
.	O

Bioinformatic	B-T091
Analysis	B-T062
of	O
Codon	B-T086
Usage	B-T169
and	O
Phylogenetic Relationships	B-T080
in	O
Different	O
Genotypes	B-T032
of	O
the	O
Hepatitis C Virus	B-T005
The	O
hepatitis C virus	B-T005
(	O
HCV	B-T005
)	O
has	O
six	O
major	O
genotypes	B-T032
.	O
The	O
purpose	O
of	O
this	O
study	B-T062
was	O
to	O
phylogenetically investigate	B-T062
the	O
differences	O
between	O
the	O
genotypes	B-T032
of	O
HCV	B-T005
,	O
and	O
to	O
determine	O
the	O
types	O
of	O
amino acid	B-T116
codon	B-T086
usage	B-T169
in	O
the	O
structure of the virus	B-T017
in	O
order	O
to	O
discover	O
new	O
methods	O
for	O
treatment regimes	B-T058
.	O
The	O
codon	B-T086
usage	B-T169
of	O
the	O
six	O
genotypes	B-T032
of	O
the	O
HCV	B-T005
nucleotide sequence	B-T086
was	O
investigated	B-T169
through	O
the	O
online	O
application	O
available	O
on	O
the	O
website Gene Infinity	B-T170
.	O
Also,	O
phylogenetic analysis	B-T062
and	O
the	O
evolutionary relationship	B-T080
of	O
HCV	B-T005
genotypes	B-T032
were	O
analyzed	B-T062
with	O
MEGA 7 software	B-T073
.	O
The	O
six	O
genotypes	B-T032
of	O
HCV	B-T005
were	O
divided	O
into	O
two	O
groups	B-T078
based	O
on	O
their	O
codon	B-T086
usage	B-T169
properties	B-T080
.	O
In	O
the	O
first	O
group	B-T078
,	O
genotypes 1 and 5	B-T032
(74.02%),	O
and	O
in	O
the	O
second	O
group	B-T078
,	O
genotypes 2 and 6	B-T032
(72.43%)	O
were	O
shown	O
to	O
have	O
the	O
most	O
similarity	B-T080
in	O
terms	O
of	O
codon	B-T086
usage	B-T169
.	O
Unlike	O
the	O
results	O
with	O
respect	O
to	O
determining	O
the	O
similarity	B-T080
of	O
codon	B-T086
usage	B-T169
,	O
the	O
phylogenetic analysis	B-T062
showed	O
the	O
closest	O
resemblance	B-T080
and	O
correlation	B-T080
between	O
genotypes 1 and 4	B-T032
.	O
The	O
results	O
also	O
showed	O
that	O
HCV	B-T005
has	O
a	O
GC	B-T114
(	O
guanine	B-T114
guanine - cytosine	B-T114
cytosine	B-T109
)	O
abundant	O
genome structure	B-T028
and	O
prefers	O
codons	B-T086
with	O
GC	O
for	O
translation	B-UnknownType
.	O
Genotypes 1 and 4	B-T032
demonstrated	O
remarkable	O
similarity	B-T080
in	O
terms	O
of	O
genome sequences	B-T085
and	O
proteins	B-T116
,	O
but	O
surprisingly,	O
in	O
terms	O
of	O
the	O
preferred	O
codons	B-T086
for	O
gene expression	B-T045
,	O
they	O
showed	O
the	O
greatest	O
difference.	O
More	O
studies	B-T062
are	O
therefore	O
needed	O
to	O
confirm	O
the	O
results	O
and	O
select	O
the	O
best	O
approach	B-T082
for	O
treatment	B-T169
of	O
these	O
genotypes	B-T032
based	O
on	O
their	O
codon	B-T086
usage	B-T169
properties	B-T080
.	O

Chronic	B-T079
adiponectin deficiency	B-T047
leads	O
to	O
Alzheimer's disease	B-T047
-like	O
cognitive impairments	B-T048
and	O
pathologies	B-T091
through	O
AMPK	B-T116
inactivation	O
and	O
cerebral	B-T023
insulin resistance	B-T046
in	O
aged	B-T032
mice	B-T015
Insulin resistance	B-T046
is	O
the	O
major	O
pathogenesis	B-T046
underlying	O
type 2 diabetes mellitus	B-T047
(	O
T2DM	B-T047
)	O
and	O
these	O
patients	B-T101
have	O
doubled	O
risk	B-T078
of	O
Alzheimer's disease	B-T047
(	O
AD	B-T047
).	O
Increasing	O
evidence	O
suggests	O
that	O
insulin resistance	B-T046
plays	O
an	O
important	O
role	O
in	O
AD	O
pathogenesis	B-T046
,	O
possibly	O
due	O
to	O
abnormal	O
GSK3β	B-T116
activation	B-T044
,	O
causing	O
intra-	B-T026
and	O
extracellular	B-T026
amyloid-beta	B-T116
(	O
Aβ	B-T116
)	O
accumulation.	O
Adiponectin	B-T116
(	O
APN	B-T116
)	O
is	O
an	O
adipokine	B-T116
with	O
insulin-sensitizing	O
and	O
anti-inflammatory effects	B-T080
.	O
Reduced	O
circulatory	O
APN	B-T116
level	O
is	O
associated	O
with	O
insulin resistance	B-T046
and	O
T2DM	B-T047
.	O
The	O
role	O
of	O
APN	B-T116
in	O
AD	B-T047
has	O
not	O
been	O
elucidated.	O
In	O
this	O
study	B-T062
,	O
we	O
aim	O
to	O
examine	O
if	O
adiponectin deficiency	B-T047
adiponectin deficiency	B-T047
would	O
lead	O
to	O
cerebral	B-T023
insulin resistance	B-T046
,	O
cognitive decline	B-T048
and	O
Alzheimer's-like pathology	B-T046
in	O
mice	B-T015
.	O
To	O
study	B-T062
the	O
role	O
of	O
adiponectin	B-T116
in	O
cognitive functions	B-T041
,	O
we	O
employed	O
adiponectin-knockout	B-T050
(APN-KO) mice	B-T015
and	O
demonstrated	O
chronic	B-T079
APN deficiency	B-T047
in	O
their	O
CNS	B-T022
.	O
Behavioral tests	B-T060
were	O
performed	O
to	O
study	B-T062
the	O
cognitions	B-T041
of	O
male	B-T032
APN-KO mice	B-T015
.	O
Brains	B-T023
and	O
tissue	B-T024
lysates	B-T072
were	O
collected	O
to	O
study	B-T062
the	O
pathophysiological	O
and	O
molecular changes	B-T044
in	O
the	O
brain	B-T023
of	O
APN-KO mice	B-T015
.	O
SH-SY5Y neuroblastoma cell line	B-T025
was	O
used	O
to	O
study	B-T062
the	O
molecular mechanism	B-T044
upon	O
APN	B-T116
and	O
insulin treatment	B-T061
.	O
Aged	B-T032
APN	B-T116
-deficient	O
mice	B-T015
displayed	O
spatial memory	B-T041
and	O
learning	B-T041
impairments	B-T046
,	O
fear-conditioned	B-T041
memory deficit	B-T048
as	O
well	O
as	O
anxiety	B-T033
.	O
These	O
mice	B-T015
also	O
developed	O
AD	B-T047
pathologies	B-T046
including	O
increased	O
cerebral	B-T023
Aβ42	B-T116
level,	O
Aβ	B-T116
deposition,	O
hyperphosphorylated Tau proteins	B-T116
,	O
microgliosis	B-T046
and	O
astrogliosis	B-T046
with	O
increased	O
cerebral	B-T023
IL-1β	B-T116
and	O
TNFα	B-T116
levels	O
that	O
associated	O
with	O
increased	O
neuronal apoptosis	B-T043
and	O
reduced	O
synaptic	B-T030
proteins levels	B-T034
,	O
suggesting	O
APN deficiency	B-T047
may	O
lead	O
to	O
neuronal	B-T129
and	O
synaptic	O
loss	O
in	O
the	O
brain	B-T023
.	O
AD	B-T047
pathologies	B-T169
-associated	O
APN	B-T116
-	O
KO mice	B-T015
displayed	O
attenuated	O
AMPK	B-T116
phosphorylation	B-T044
and	O
impaired	O
insulin signaling	B-T044
including	O
decreased	O
Akt	B-T116
induction	O
and	O
increased	O
GSK3β	B-T116
activation	B-T044
in	O
the	O
hippocampus	B-T023
and	O
frontal cortex	B-T023
.	O
Aged	B-T032
APN	B-T116
-KO	O
mice	B-T015
developed	O
hippocampal	B-T023
insulin resistance	B-T046
with	O
reduced	O
pAkt	B-T116
induction	O
upon	O
intracerebral	O
insulin injection	B-T061
.	O
Consistently,	O
APN	B-T116
treatment	B-T061
in	O
SH-SY5Y cells	B-UnknownType
with	O
insulin resistance	B-T046
and	O
overexpressing	B-T045
Aβ	B-T116
induce	O
higher	O
pAkt	B-T116
levels	O
through	O
AdipoR1	B-T116
upon	O
insulin treatment	B-T061
whereas	O
the	O
induction	O
was	O
blocked	B-T046
by	O
compound C	B-T103
,	O
indicating	O
APN	B-T116
can	O
enhance	O
neuronal	B-T129
insulin sensitivity	B-T046
through	O
AMPK	B-T116
activation.	O
Our	O
results	O
indicated	O
that	O
chronic	B-T079
APN deficiency	B-T047
inactivated	O
AMPK	B-T116
causing	O
insulin	O
desensitization	O
and	O
elicited	O
AD-like pathogenesis	B-T046
in	O
aged	B-T032
mice	B-T015
which	O
also	O
developed	O
significant	O
cognitive impairments	B-T048
and	O
psychiatric symptoms	B-T184
.	O

Can	O
inorganic phosphate	B-T121
explain	O
sag	B-T080
during	O
unfused	B-T080
tetanic contractions	B-T039
of	O
skeletal muscle	B-T024
?	O
We	O
test	O
the	O
hypothesis	B-T078
that	O
cytosolic	B-T026
inorganic phosphate	B-T121
(	O
Pi	B-T121
)	O
can	O
account	O
for	O
the	O
contraction	B-T039
-	O
induced	B-T169
reductions	B-T070
in	O
twitch	B-T033
duration	B-T079
which	O
impair	B-T169
summation	O
and	O
cause	O
force	B-T067
to	O
decline	B-T080
(	O
sag	B-T080
)	O
during	O
unfused	B-T080
tetanic contractions	B-T039
of	O
fast-twitch muscle	B-T025
.	O
A	O
five-state model	B-T075
of	O
crossbridge cycling	B-T042
was	O
used	O
to	O
simulate	B-T169
twitch	B-T033
and	O
unfused	B-T080
tetanic contractions	B-T039
.	O
As	O
Pi	B-T121
concentration	B-T081
([	O
Pi	B-T121
])	O
was	O
increased	B-T081
from	O
0	O
to	O
30	O
mmol·L(-1),	O
twitch	B-T033
duration	B-T079
decreased	B-T081
,	O
with	O
progressive	B-T169
reductions	B-T061
in	O
sensitivity	B-T169
to	O
Pi	B-T121
as	O
[	O
Pi	B-T121
]	O
was	O
increased	B-T081
.	O
When	O
unfused	B-T080
tetani	O
were	O
simulated	B-T062
with	O
rising	O
[	O
Pi	B-T121
],	O
sag	B-T080
was	O
most	O
pronounced	B-T080
when	O
initial	B-T079
[	O
Pi	B-T121
]	O
was	O
low	B-T080
,	O
and	O
when	O
the	O
magnitude	B-T081
of	O
[	O
Pi	B-T121
]	O
increase	B-T081
was	O
large	B-T081
.	O
Fast-twitch	B-T033
extensor digitorum longus (EDL) muscles	B-T023
(	O
sag-prone	B-T169
,	O
typically	O
low	O
basal	O
[	O
Pi	B-T121
])	O
and	O
slow-twitch	B-T033
soleus muscles	B-T023
(	O
sag	B-T080
-	O
resistant	B-T039
,	O
typically	O
high	O
basal	O
[	O
Pi	B-T121
])	O
were	O
isolated	B-T169
from	O
14	O
female	B-T032
C57BL/6 mice	B-T015
.	O
Muscles	B-T024
were	O
sequentially	O
incubated	B-T059
in	O
solutions	B-T167
containing	O
either	O
glucose	B-T109
or	O
pyruvate	B-T109
to	O
create	O
typical	B-T080
and	O
low	B-T080
Pi	B-T121
environments	B-T082
,	O
respectively.	O
Twitch	B-T033
duration	B-T079
was	O
greater	O
(P	O
<	O
0.05)	O
in	O
pyruvate	B-T109
than	O
glucose	B-T109
in	O
both	O
muscles	B-T024
.	O
Stimuli	B-T067
applied	B-T169
at	O
intervals	B-T079
approximately	O
three	O
times	O
the	O
time	O
to	O
peak	B-T080
twitch	B-T033
tension	B-T033
resulted	O
in	O
sag	B-T080
of	O
35.0	O
±	O
3.7%	O
in	O
glucose	B-T109
and	O
50.5	O
±	O
1.4%	O
in	O
pyruvate	B-T109
in	O
the	O
EDL	B-T023
(	O
pyruvate	B-T109
>	O
glucose	B-T109
;	O
P	O
<	O
0.05),	O
and	O
3.9	O
±	O
0.3%	O
in	O
glucose	B-T109
and	O
37.8	O
±	O
2.7%	O
in	O
pyruvate	B-T109
in	O
the	O
soleus	B-T023
(	O
pyruvate	B-T109
>	O
glucose	B-T109
;	O
P	O
<	O
0.05).	O
The	O
influence	O
of	O
Pi	B-T121
on	O
crossbridge cycling	B-T042
provides	O
a	O
tenable mechanism	B-T169
for	O
sag	B-T080
.	O
Moreover,	O
the	O
low basal	B-T033
[	O
Pi	B-T121
]	O
in	O
fast-twitch	B-T033
relative	O
to	O
slow-twitch muscle	B-T033
has	O
promise	O
as	O
an	O
explanation	B-T170
for	O
the	O
fiber-type	B-T025
dependency	O
of	O
sag	B-T080
.	O

Pancreatic Cancer	B-T191
:	O
A	O
Survival Analysis	B-T062
Study	B-T062
in	O
Oklahoma	B-T083
Pancreatic cancer	B-T191
is	O
among	O
the	O
most	O
deadly cancers	B-T191
.	O
Risk factors	B-T033
associated with	B-T080
the	O
disease	B-T047
include	O
age	B-T032
,	O
race	B-T098
,	O
sex	B-T032
,	O
smoking status	B-T201
,	O
and	O
diabetes status	B-T033
.	O
We	O
conducted	O
a	O
prospective analysis	B-T062
of	O
risk factors	B-T033
and	O
length of survival	B-T079
among	O
pancreatic cancer patients	B-T101
living	O
in	O
Oklahoma	B-T083
between	O
1997	O
and	O
2012	O
(n=6,291).	O
Kaplan-Meier survival curves	B-T081
were	O
created	B-T052
followed	O
by	O
the	O
log-rank test	B-T169
to	O
compare	O
difference	B-T080
in	O
the	O
survival time	B-T201
.	O
Cox proportional hazard regression models	B-T081
were	O
used	O
to	O
examine	O
the	O
strength of association	B-T080
through	O
the	O
estimated	B-T081
hazard ratios	B-T081
.	O
The	O
median survival time	B-T079
of	O
the	O
cohort	B-T098
was	O
three	O
months	B-T079
.	O
Significant	B-T078
risk factors	B-T033
for	O
reduced	B-T080
survival times	B-T201
included	O
age	B-T032
,	O
stage at diagnosis	B-T185
,	O
and	O
year of diagnosis	B-T201
.	O
Results	B-T034
are	O
in	O
agreement	O
with	O
previous	O
research findings	B-T033
.	O
There	O
have	O
been	O
small	O
but	O
noteworthy improvements	B-T077
in	O
survival times	B-T201
for	O
pancreatic cancer patients	B-T101
in	O
Oklahoma	B-T083
.	O
Length of survival	B-T079
during	O
the	O
study period	B-T062
was	O
significantly	B-T078
associated with	B-T080
known	O
risk factors	B-T033
such	O
as	O
age	B-T032
and	O
stage of diagnosis	B-T185
.	O

Biochemical	B-T169
and	O
proteomic	B-T091
analyses	B-T062
of	O
the	O
physiological response	B-T039
induced	O
by	O
individual	O
housing	B-T073
in	O
gilts	B-T015
provide	O
new	O
potential	B-T080
stress	B-T046
markers	B-T201
The	O
objective	B-T080
assessment	B-T058
of	O
animal	B-T008
stress	B-T046
and	O
welfare	O
requires	O
proper	O
laboratory	B-T073
biomarkers	B-T201
.	O
In	O
this	O
work,	O
we	O
have	O
analyzed	O
the	O
changes	O
in	O
serum	B-T031
composition	B-T201
in	O
gilts	B-T015
after	O
switching	O
their	O
housing	B-T073
,	O
from	O
pen	O
to	O
individual	O
stalls	B-T073
,	O
which	O
is	O
generally	O
accepted	O
to	O
cause	O
animal	B-T008
discomfort	B-T184
.	O
Blood	B-T031
and	O
saliva samples	B-T031
were	O
collected	O
a	O
day	O
before	O
and	O
up	O
to	O
four	O
days	O
after	O
changing	O
the	O
housing	B-T073
system.	O
Biochemical	B-T169
analyses	B-T062
showed	O
adaptive	B-T169
changes	O
in	O
lipid	B-T109
and	O
protein metabolism	B-T044
after	O
the	O
housing	B-T073
switch,	O
whereas	O
cortisol	B-T109
and	O
muscular	B-T024
markers	B-T201
showed	O
a	O
large	O
variability	B-T077
between	O
animals	B-T008
.	O
2D-DIGE	B-T059
and	O
iTRAQ	B-T170
proteomic	B-T091
approaches	B-T057
revealed	O
variations	O
in	O
serum protein	B-T116
composition	B-T201
after	O
changing	O
housing	B-T073
and	O
diet	O
of	O
gilts	B-T015
.	O
Both	O
techniques	B-T169
showed	O
alterations	B-T078
in	O
two	O
main	O
homeostatic mechanisms	B-T040
:	O
the	O
innate immune	B-T032
and	O
redox	B-T044
systems.	O
The	O
acute phase proteins	B-T116
haptoglobin	B-T116
,	O
apolipoprotein A-I	B-T116
and	O
α1-antichymotrypsin	O
3,	O
and	O
the	O
antioxidant	B-T121
enzyme	O
peroxiredoxin 2	B-T116
were	O
found	O
differentially	O
expressed	O
by	O
2D-DIGE	B-T059
.	O
Other	O
proteins	B-T116
related	O
to	O
the	O
innate immune system	B-T032
,	O
including	O
lactotransferrin	B-T116
,	O
protegrin 3	B-T116
and	O
galectin 1	B-T116
were	O
also	O
identified	O
by	O
iTRAQ	B-T170
,	O
as	O
well	O
as	O
oxidative stress	B-T049
enzymes	B-T116
such	O
as	O
peroxiredoxin 2	B-T116
and	O
glutathione peroxidase 3	B-T116
.	O
Proteomics	B-T091
also	O
revealed	O
the	O
decrease	B-T080
of	O
apolipoproteins	B-T116
,	O
and	O
the	O
presence	O
of	O
intracellular	B-T082
proteins	B-T116
in	O
serum	B-T031
,	O
which	O
may	O
indicate	O
physical injury	B-T037
to	O
tissues	B-T024
.	O
Housing	B-T073
of	O
gilts	B-T015
in	O
individual	O
stalls	B-T073
and	O
diet	O
change	O
increase	O
lipid	B-T109
and	O
protein catabolism	B-T044
,	O
oxidative stress	B-T049
,	O
activate	O
the	O
innate immune system	B-T032
and	O
cause	O
a	O
certain	O
degree	O
of	O
tissue damage	B-T037
.	O
We	O
propose	O
that	O
valuable	O
assays	O
for	O
stress assessment	B-T060
in	O
gilts	B-T015
may	O
be	O
based	O
on	O
a	O
score	B-T081
composed	O
by	O
a	O
combination	O
of	O
salivary	O
cortisol,	O
lipid	B-T109
metabolites	B-T123
,	O
innate immunity	B-T032
and	O
oxidative stress	B-T049
markers	B-T201
and	O
intracellular	B-T082
proteins	B-T116
.	O

Cultivation	B-T059
of	O
four	O
microalgae	B-T204
species	B-T185
in	O
the	O
effluent	B-T167
of	O
anaerobic digester	B-T075
for	O
biodiesel	B-T109
production	B-T057
This	O
study	B-T062
investigated	B-T169
if	O
an	O
effluent	B-T167
from	O
anaerobic digestion (AD) system	B-T075
can	O
be	O
used	B-T169
as	O
a	O
nutrients	B-T168
source	B-T033
for	O
the	O
microalgae	B-T204
cultivation	B-T059
,	O
and	O
in	O
so	O
doing,	O
if	O
the	O
effluent	B-T167
can	O
be	O
properly	O
treated	B-T169
.	O
Nitrogen	B-T123
and	O
phosphorus	B-T196
in	O
the	O
AD	B-T075
AD	B-T075
effluent	B-T167
well	O
supported	O
microalgal	B-T204
growth	B-T040
,	O
and	O
their	O
removal	B-T080
efficiency	B-T081
reached	O
>97.9%	O
and	O
99.2%,	O
respectively.	O
Among	O
four	O
different	B-T080
algal	B-T204
species	B-T185
tested	B-T169
,	O
Micractinium inermum	B-T002
particularly	O
stood out	B-T169
,	O
showing	O
the	O
highest	B-T080
biomass	B-T081
and	O
FAME	B-T109
productivity	B-T081
:	O
0.16gL(-1)d(-1)	O
with	O
3.23gL(-1)	O
of	O
dry	B-T080
cell	B-T025
weight	B-T032
,	O
and	O
0.04gL(-1)d(-1)	O
with	O
27.54%	O
(w/w)	O
of	O
FAME	B-T109
contents	B-T077
,	O
respectively.	O
As	O
the	O
concentrations	B-T081
of	O
the	O
nutrients	B-T168
decreased	B-T081
over	B-T079
time	B-T079
,	O
the	O
FAME	B-T109
contents	B-T077
were	O
increased	B-T081
and	O
its	O
quality	B-T080
as	O
well	B-T080
,	O
satisfying	O
several	B-T081
biodiesel	B-T109
quality	B-T080
standards	B-T080
.	O
This	O
study	B-T062
supports	O
that	O
the	O
AD	B-T075
effluent	B-T167
can	O
indeed	O
serve	O
as	O
a	O
cheap	B-T081
and	O
nutrient	B-T168
-	O
rich	B-T080
medium	B-T081
for	O
microalgae	B-T204
cultivation	B-T059
,	O
and	O
equally	B-T080
importantly	B-T080
,	O
microalgae	B-T204
can	O
be	O
a	O
workable	O
treatment	B-T169
option	B-T169
for	O
it.	O

Antiviral activities	B-T033
of	O
selected	O
antimalarials	B-T121
against	B-T080
dengue virus type 2	B-T005
and	O
Zika virus	B-T005
In	O
a	O
previous	B-T079
study,	B-T062
twelve	O
antimalarial compounds	B-T121
,	O
amodiaquine	B-T109
(	O
AQ	B-T109
)	O
and	O
derivatives	B-T104
,	O
were	O
shown	O
to	O
have	O
potent	B-T080
anti-dengue viral (DENV) activity	B-T033
by	O
using	O
the	O
stable	B-T080
DENV2	B-T005
Renilla luciferase	B-T116
reporter	B-T028
replicon	B-T114
expressing	B-T045
BHK-21 cells	B-T025
,	O
infectivity	B-T080
(	O
plaque	B-T059
),	O
and	O
the	O
qRT-PCR assays	B-T063
.	O
In	O
this	O
study	B-T062
,	O
we	O
performed	B-T169
molecular modeling	B-T062
on	O
these	O
compounds	B-T121
to	O
determine	O
their	O
stereo-electronic properties	B-T080
required	O
for	O
optimal	B-T080
antiviral activity	B-T033
.	O
Based	O
on	O
the	O
similarity	B-T080
of	O
calculated	O
stereo-electronic profiles	B-T080
,	O
specifically	O
the	O
electrostatic potential profiles	B-T081
of	O
the	O
compounds	B-T121
,	O
and	O
in silico screening	B-T062
of	O
related	O
compounds	B-T121
from	O
literature	B-T170
,	O
we	O
identified	B-T080
three	O
additional	B-T169
compounds	B-T121
,	O
Quinacrine	B-T109
(	O
QC	B-T109
),	O
Mefloquine	B-T109
(	O
MQ	B-T109
),	O
and	O
GSK369796	B-T109
.	O
Analysis	O
of	O
their	O
antiviral activities	B-T033
indicated	O
that	O
all	O
three compounds	B-T121
have	O
high	B-T080
anti-DENV activity	B-T033
in	O
the	O
DENV2	B-T005
replicon	B-T114
expressing	B-T045
cells	B-T025
with	O
EC50 values	B-T081
of	O
5.30	O
±	O
1.31	O
μM	O
(	O
QC	B-T109
),	O
3.22	O
±	O
0.37	O
μM	O
(	O
MQ	B-T109
),	O
and	O
5.06	O
±	O
0.86	O
μM	O
(	O
GSK369796	B-T109
).	O
The	O
infectivity assays	B-T059
revealed	B-T080
the	O
EC50 values	B-T081
of	O
7.09	O
±	O
1.67	O
μM	O
(	O
QC	B-T109
),	O
4.36	O
±	O
0.31	O
μM	O
(	O
MQ	B-T109
)	O
and	O
3.03	O
±	O
0.35	O
μM	O
(	O
GSK369796	B-T109
).	O
The	O
mode of action	B-T169
of	O
these	O
compounds	B-T121
is	O
through	B-T169
inhibition	B-T052
of	O
autophagy	B-T043
,	O
thereby	O
affecting	B-T169
DENV2	B-T005
replication	B-T043
.	O
Moreover,	O
these	O
compounds	B-T121
also	O
showed	O
antiviral activity	B-T033
against	B-T080
the	O
rapidly	O
emerging	O
Zika virus	B-T005
(	O
ZIKV	B-T005
)	O
with	O
EC50 values	B-T081
of	O
2.27	O
±	O
0.14	O
μM	O
(	O
QC	B-T109
),	O
3.95	O
±	O
0.21	O
μM	O
(	O
MQ	B-T109
),	O
and	O
2.57	O
±	O
0.09	O
μM	O
(	O
GSK369796	B-T109
).	O

1	O
in	O
100	O
babies	B-T100
:	O
the	O
fetal alcohol spectrum disorder	B-T019
pathway	B-T077
Alcohol	B-T168
consumed	B-T055
during	O
pregnancy	B-T040
is	O
the	O
nation's	B-UnknownType
leading	O
preventable	B-T080
cause	B-T169
of	O
developmental disabilities	B-T048
and	O
birth defects	B-T019
.	O
One	O
in	O
100	O
babies	B-T100
is	O
estimated	O
to	O
be	O
born	B-T040
with	O
alcohol-related damage	B-T047
,	O
according	O
to	O
the	O
World Health Organization	B-T093
.	O
Fetal alcohol spectrum disorders	B-T019
(	O
FASDs	B-T019
)	O
are	O
more	O
common	O
than	O
autism	B-T048
but	O
are	O
under-	O
diagnosed	B-T033
.	O

Genotyping	B-T059
of	O
German	B-T098
and	O
Austrian	B-T098
Taylorella equigenitalis	B-T007
isolates	B-T123
using	O
repetitive extragenic palindromic (REP) PCR	B-T063
and	O
pulsed-field gel electrophoresis	B-T059
(	O
PFGE	B-T059
)	O
A	O
total	B-T080
of	O
124	O
Taylorella (T.) equigenitalis	B-T007
and	O
five	O
T. asinigenitalis	B-T007
field	B-T077
isolates	B-T123
collected	B-T169
between	O
2002	O
and	O
2014	O
were	O
available	B-T169
for	O
genotyping	B-T059
using	O
REP- (repetitive extragenic palindromic) PCR	B-T063
and	O
PFGE	B-T059
(	O
pulsed-field gel electrophoresis	B-T059
).	O
The	O
study	B-T062
comprised	O
79	O
T. equigenitalis	B-T007
field	B-T077
isolates	B-T123
originating	O
from	O
ten	O
defined	O
breeds	B-T040
of	O
German horses	B-T015
and	O
revealed	B-T080
a	O
spectrum	B-T077
of	O
five	O
REP	B-T086
(	O
rep-E1-E4	B-T032
,	O
rep-E3a	B-T032
)	O
and	O
15	O
PFGE	B-T059
(	O
TE-A1-A9	B-T032
,	O
TE-B1-B3	B-T032
,	O
TE-C	B-T032
,	O
TE-E1	B-T032
,	O
and	O
TE-E2	B-T032
)	O
genotypes	B-T032
.	O
T. equigenitalis	B-T007
field	B-T077
isolates	B-T123
(n=40)	O
obtained	B-T169
from	O
Austrian Lipizzaner horses	B-T015
were	O
differentiated	B-T080
into	O
three	O
REP	B-T086
(	O
rep-E1	B-T032
,	O
rep-E3a	B-T032
,	O
and	O
rep-E4	B-T032
)	O
and	O
three	O
PFGE	B-T059
genotypes	B-T032
(	O
TE-A2	B-T032
,	O
TE-A5	B-T032
,	O
and	O
TE-D	B-T032
);	O
those	O
isolated	B-T169
from	O
four	O
Austrian Trotters	B-T015
belonged	O
to	O
the	O
REP	B-T086
/	O
PFGE	B-T059
genotype	B-T032
rep-E2/TE-A1	B-T032
.	O
Interestingly,	O
a	O
T. equigenitalis	B-T007
isolate	B-T123
recovered from	B-T080
a	O
Holsteiner stallion	B-T015
living	B-T078
in	O
South Africa	B-T083
revealed	B-T080
the	O
REP	B-T086
/	O
PFGE	B-T059
genotype	B-T032
rep-E1/TE-A5	B-T032
which	O
was	O
otherwise	O
exclusively	B-T078
present	B-T033
in	O
the	O
majority	B-T054
of	O
Austrian Lipizzaner horses	B-T015
in	O
our	O
study	B-T062
.	O
The	O
type	O
strain	B-T001
included	O
in	O
this	O
study	B-T062
revealed	B-T080
the	O
genotype	B-T032
REP	B-T086
/	O
PFGE	B-T059
rep-E1/TE-F	B-T032
.	O
Six	O
strains	B-T001
of	O
T. asinigenitalis	B-T007
including	O
the	O
type	O
strain	B-T001
were	O
separated	B-T080
into	O
three	O
REP	B-T086
(	O
rep-A1-A3	B-T032
)	O
and	O
six	O
PFGE	B-T059
genotypes	B-T032
(	O
TA-A1	B-T032
,	O
TA-A2	B-T032
,	O
TA-A3	B-T032
,	O
TA-B	B-T032
,	O
TA-C	B-T032
,	O
TA-D	B-T032
).	O
Overall,	B-T080
the	O
generated	B-T052
REP	B-T086
and	O
PFGE	B-T059
genotypes	B-T032
showed	O
a	O
good	B-T080
correlation	B-T080
,	O
whereas	O
REP-PCR	B-T063
proved	O
to	O
be	O
a	O
suitable method	B-T059
for	O
molecular epidemiological screening	B-T059
of	O
T. equigenitalis	B-T007
and	O
T. asinigenitalis	B-T007
isolates	B-T123
that	O
should	O
be	O
differentiated	B-T080
in	O
detail	B-T080
by	O
genotyping	B-T059
using	O
PFGE	B-T059
.	O

The	O
Urokinase	B-T116
/	O
Urokinase Receptor	B-T116
System	O
in	O
Mast Cells	B-T025
:	O
Effects	B-T080
of	O
its	O
Functional	B-T169
Interaction	B-T169
with	O
fMLF Receptors	B-T116
Mast cell	B-T025
and	O
basophils	B-T025
express	B-T045
the	O
high affinity receptor	B-T116
for	O
IgE	B-T116
(	O
FcɛRI	B-T116
)	O
and	O
are	O
primary effector cells	B-T025
of	O
allergic disorders	B-T046
.	O
The	O
urokinase	B-T116
(	O
uPA	B-T116
)-mediated	O
plasminogen activation system	B-T044
is	O
involved	O
in	O
physiological	B-T039
and	O
pathological events	B-T046
based	O
on	O
cell migration	B-T043
and	O
tissue remodelling	B-T042
,	O
such	O
as	O
inflammation	B-T046
,	O
wound healing	B-T040
,	O
angiogenesis	B-T042
and	O
metastasis	B-T046
.	O
uPA	B-T116
is	O
a	O
serine protease	B-T116
that	O
binds	O
uPAR	B-T116
,	O
a	O
high affinity glycosyl-phosphatidyl-inositol (GPI)-anchored	B-T109
receptor	B-T116
.	O
uPAR	B-T116
focuses	O
uPA	B-T116
activity	B-T044
at	O
the	O
cell surface	B-T026
and	O
activates intracellular signaling	B-T044
through	O
lateral	O
interactions	B-T169
with	O
integrins	B-T116
,	O
receptor tyrosine kinases	B-T116
and	O
the	O
G-protein-coupled family	B-T116
of	O
fMLF chemotaxis receptors	B-T116
(	O
FPRs	B-T116
).	O
We	O
investigated	B-T169
the	O
expression	B-T045
of	O
the	O
uPA	B-T116
-	O
uPAR	B-T116
system	O
and	O
its	O
functional	B-T169
interaction	B-T169
with	O
FPRs	B-T116
in	O
human	B-T016
mast cells	B-T025
(	O
MCs	B-T025
).	O
Differently	O
from	O
basophils	B-T025
,	O
MCs	B-T025
produced	O
uPA	B-T116
that	O
was	O
able	O
to	O
induce	O
their	O
chemotaxis	B-T043
.	O
Indeed,	O
MCs	B-T025
also	O
expressed	O
uPAR	B-T116
,	O
both	O
in	O
the	O
intact	O
and	O
in	O
a	O
cleaved	O
form	O
(	O
DII-DIII-uPAR	B-T116
)	O
that	O
can	O
expose,	O
at	O
the	O
N-terminus,	O
the	O
SRSRY sequence	B-T087
,	O
able	O
to	O
interact	O
with	O
FPRs	B-T116
and	O
to	O
mediate	O
cell chemotaxis	B-T043
.	O
MCs	B-T025
also	O
expressed	O
mRNAs	B-T114
for	O
FPRs	B-T116
that	O
were	O
functionally	O
active;	O
indeed,	O
uPA	B-T116
and	O
a	O
soluble peptide	B-T116
(	O
uPAR84-95	B-T116
),	O
containing	O
the	O
SRSRY chemotactic sequence	B-T087
of	O
uPAR	B-T116
and	O
able	O
to	O
interact	O
with	O
FPRs	B-T116
,	O
were	O
able	O
to	O
induce	O
MCs	B-T025
chemotaxis	B-T043
.	O
Thus,	O
uPA	B-T116
is	O
a	O
potent	O
chemoattractant	B-T123
for	O
MCs	B-T025
acting	O
through	O
the	O
exposure	B-T080
of	O
the	O
chemotactic	B-T043
epitope	B-T129
of	O
uPAR	B-T116
,	O
that	O
is	O
an	O
endogenous	B-T169
ligand	B-T103
for	O
FPRs	B-T116
.	O
The	O
same	O
mechanism	B-T169
could	O
be	O
involved	O
in	O
VEGF-A	B-T116
secretion	B-T038
by	O
human	B-T016
MCs	B-T025
,	O
also	O
induced	B-T169
by	O
uPA	B-T116
and	O
uPAR84-95	B-T116
stimulation.	B-T044

Psychogenic non-epileptic seizure	B-T048
in	O
patients	B-T101
with	O
intellectual disability	B-T048
with	O
special	O
focus	O
on	O
choice	B-T052
of	O
therapeutic intervention	B-T061
There	O
have	O
been	O
a	O
number	O
of	O
studies	B-T062
exploring	O
treatments	B-T061
for	O
psychogenic non-epileptic seizure	B-T048
(	O
PNES	B-T048
)	O
but	O
largely	O
neglecting	B-T033
the	O
sizable	O
subgroup	B-T185
of	O
patients	B-T101
with	O
intellectual disability	B-T048
(	O
ID	B-T048
).	O
In	O
the	O
present	B-T079
study	B-T062
,	O
we	O
attempted	B-T051
to	O
demonstrate	B-T169
effects	B-T080
and	O
preferred	B-T078
modes	O
of	O
therapeutic intervention	B-T061
in	O
PNES	B-T048
patients	B-T101
with	O
ID	B-T048
being	O
treated	B-T169
at	O
a	O
Japanese municipal center	B-T093
with	O
a	O
short	B-T081
referral chain	B-T058
.	O
We	O
examined	B-T033
46	O
PNES	B-T048
patients	B-T101
with	O
ID	B-T048
(	O
ID	B-T048
group	B-T078
)	O
and	O
106	O
PNES	B-T048
patients	B-T101
without	O
ID	B-T048
(	O
non-ID	B-T033
group	B-T078
)	O
retrospectively	B-T080
in	O
case charts	B-T170
.	O
In addition to	B-T169
examining	B-T033
basic	O
demographic	B-T090
and	O
clinical data	B-T170
,	O
effects of	B-T080
different	B-T080
therapeutic intervention	B-T061
were	O
examined	B-T033
as	O
a	O
function	B-T169
of	O
decrease	B-T081
or	O
disappearance	B-T079
of	O
PNES	B-T048
attacks	O
in	O
the	O
ID	B-T048
group	B-T078
.	O
Age	B-T032
at	O
the	O
first	O
visit	B-T058
as	O
well	O
as	O
PNES	B-T048
onset	B-T080
was	O
younger	B-T079
in	O
the	O
ID	B-T048
than	O
in	O
the	O
non-ID	B-T033
group	B-T078
(t=2.651,	O
p=0.009;	O
t=3.528,	O
p=0.001,	O
respectively).	O
PNES	B-T048
-free	O
ratio	B-T081
at	O
the	O
last	O
visit	B-T058
tended	O
to	O
be	O
higher	B-T080
in	O
the	O
non-ID	B-T033
group	B-T078
group	B-T078
(	O
chi square	B-T081
=3.455;	O
p=0.063).	O
Psychosis	B-T048
was	O
more	O
often	O
encountered	O
in	O
the	O
ID	B-T048
group	B-T078
(	O
chi square	B-T081
=13.443;	O
p=0.001).	O
Although	O
cognitive therapy	B-T061
and	O
pharmaco-therapeutic	B-T061
approaches	O
were	O
quite	O
similarly	B-T080
distributed	B-T169
in	O
both	O
groups	B-T078
,	O
environmental	B-T082
adjustment	B-T169
was	O
often	O
introduced	B-T169
in	O
the	O
ID	B-T048
group	B-T078
(44%)	O
as	O
compared	B-T052
to	O
the	O
non-ID	B-T033
group	B-T078
(15%)	O
(	O
chi square	B-T081
=14.299;	O
p=0.001).	O
Brief	B-T079
weekly	B-T079
visit service	B-T058
is	O
also	O
more	O
often	O
utilized	B-T169
by	O
the	O
patients	B-T101
with	O
ID	B-T048
(54%)	O
than	O
by	O
those	O
without	O
ID	B-T048
(35%)	O
(	O
chi square	B-T081
=5.021,	O
p=0.025).	O
Optimal	B-T080
treatment	B-T061
approaches	O
in	O
this	O
sizable	O
patient	B-T101
subgroup	B-T185
should	O
be	O
the	O
subject	B-T078
of	O
future	B-T079
prospective studies	B-T062
.	O

Effect of	B-T080
an	O
immunomodulatory regimen	B-T061
for	O
cancer prevention	B-T061
:	O
A	O
case report	B-T170
In	O
the	O
present	B-T033
case study	B-T170
,	O
an	O
immunomodulatory regimen	B-T061
for	O
cancer prevention	B-T061
is	O
reported	B-T058
.	O
A	O
patient	B-T101
with	O
an	O
abnormally high	B-T080
level	B-T080
of	O
the	O
tumor markers	B-T123
,	O
carbohydrate antigen-724	B-T109
(	O
CA724	B-T109
),	O
CA19-9	B-T109
and	O
carcinoembryonic antigen	B-T116
(	O
CEA	B-T116
),	O
although	O
without	B-T080
any	O
detectable	B-T201
tumor	B-T191
,	O
was	O
treated with	B-T061
an	O
immunomodulatory therapy	B-T061
featuring	O
an	O
infusion	B-T061
of	O
cytokine-induced autologous killer cells	B-T025
(	O
CIKs	B-T025
)	O
at	O
the	O
request	B-T052
of	O
the	O
patient	B-T101
.	O
Following	O
the	O
therapy	B-T061
,	O
the	O
three	O
tumor markers	B-T123
rapidly	B-T080
decreased	B-T081
to	O
below	O
the	O
normal reference level	B-T081
,	O
although	O
there	O
still	O
were	O
slight	B-T080
fluctuations	B-T079
within	O
a	O
narrow	B-T080
range	B-T081
frequently	B-T079
.	O
The	O
patient	B-T101
was	O
monitored	B-T058
for	O
21	O
months	B-T079
to	O
the	O
present	B-T033
day	B-T079
and	O
no abnormality	B-T033
was	O
observed	B-T169
.	O
The	O
results	B-T033
indicated	O
that	O
this	O
therapy	B-T061
may	O
be	O
applied	O
as	O
a	O
novel	B-T080
strategy	O
that	O
is	O
effective	B-T080
and	O
reliable	B-T080
for	O
cancer prevention	B-T061
.	O
As	O
there	O
is	O
no	O
promising	O
regimen	B-T061
for	O
the	O
prevention of malignancies	B-T061
to	O
date,	O
such	O
a	O
treatment	B-T061
may	O
become	O
a	O
major	B-T080
cancer	B-T191
prophylactic regimen	B-T061
,	O
particularly	O
for	O
patients	B-T101
who	O
are	O
at	O
a	O
high risk of	B-T033
cancer	B-T191
.	O

The	O
relationships	B-T080
between	O
rugby	B-T056
players'	B-T098
tackle	B-T053
training	B-T065
attitudes	B-T041
and	O
behaviour	B-T053
and	O
their	O
match tackle attitudes	B-T041
and	O
behaviour	B-T053
The	O
tackle	B-T053
event	O
in	O
rugby	B-T056
is	O
a	O
technical	B-T080
and	O
physical	B-T169
contest	B-T056
between	O
opposing	O
players	B-T098
.	O
A	O
player's	B-T098
ability	O
to	O
tolerate	B-T054
and	O
contest	B-T056
during	O
a	O
tackle	B-T053
is	O
a	O
prerequisite	B-T078
for	O
safe	B-UnknownType
participation	B-T169
and	O
success	B-T054
in	O
rugby	B-T056
.	O
Little	O
is	O
known	O
about	O
the	O
relationship	B-T080
between	O
tackle training	B-T065
and	O
tackling	B-T053
in	O
matches	B-T056
in	O
rugby union	B-T056
.	O
Therefore,	O
we	O
investigated	B-T169
the	O
relationships	B-T080
between	O
players'	B-T098
training attitudes	B-T041
and	O
behaviour	B-T053
and	O
their	O
match attitudes	B-T041
and	O
behaviour	B-T053
for	O
tackling	B-T053
in	O
rugby union	B-T056
.	O
A	O
questionnaire	B-T170
was	O
designed	O
to	O
assess	B-T058
attitude	B-T041
(importance)	O
and	O
behaviours	B-T053
(	O
frequency	B-T080
and	O
quantity	B-T081
)	O
among	O
junior	B-T078
(under	O
19)	O
players	B-T098
on	O
a	O
5-point Likert Scale	B-T170
.	O
Questionnaires	B-T170
were	O
handed	O
out	O
to	O
220	O
players	B-T098
(10	O
schools	B-T073
)	O
at	O
a	O
tournament	B-T056
and	O
75%	O
(9	O
schools	B-T073
,	O
n=164)	O
were	O
returned	O
for	O
analysis	B-T062
.	O
Associations	B-T041
between	O
training attitudes	B-T041
and	O
behaviours	B-T053
were	O
tested	B-T169
using	O
the	O
χ(2) test, Cramer's V and τ-b	B-T170
.	O
The	O
more	O
time	O
spent	O
on	O
emphasising	O
proper	O
technique	B-T169
to	O
prevent	B-T080
injuries	B-T037
in	O
training	B-T065
,	O
the	O
more	O
important	O
players	B-T098
rated	O
'own	O
safety'	O
(τ-b=0.21,	O
moderate	B-T080
,	O
z=3.1,	O
p<0.01),	O
'going	O
for	O
the	O
ball	B-T073
only'	O
(τ-b=0.27,	O
moderate	B-T080
,	O
z=4.6,	O
p<0.001)	O
and	O
'staying	O
on	O
feet'	O
(τ-b=0.23,	O
moderate	B-T080
,	O
z=3.6,	O
p<0.001)	O
in	O
match play	B-T056
.	O
The	O
more	O
time	O
spent	O
on	O
emphasising	O
proper	O
technique	B-T169
to	O
improve	B-T033
performance	B-T052
in	O
training	B-T065
,	O
the	O
more	O
important	O
players	B-T098
rated	O
actions	O
'going	O
for	O
ball	B-T073
only'	O
(τ-b=0.23,	O
moderate	B-T080
,	O
z=3.7,	O
p<0.001)	O
and	O
'	O
preventing	B-T080
the	O
ball	B-T073
carrier	O
from	O
retaining	B-T169
position	B-T082
'	O
(τ-b=0.20,	O
moderate	B-T080
,	O
z=3.1,	O
p<0.01)	O
in	O
match play	B-T056
.	O
This	O
is	O
the	O
first	O
study	B-T062
to	O
report	O
on	O
the	O
relationships	B-T080
between	O
players	B-T098
'	O
training attitudes	B-T041
and	O
behaviour	B-T053
and	O
their	O
match attitudes	B-T041
and	O
behaviour	B-T053
s	O
for	O
tackling	B-T053
in	O
rugby union	B-T056
.	O
The	O
importance	O
of	O
tackle	B-T053
training	B-T065
to	O
prevent	B-T080
injury	B-T037
,	O
and	O
the	O
amount	O
of	O
time	O
spent	O
on	O
technique	B-T169
to	O
prevent	B-T080
injuries	B-T037
,	O
was	O
associated with	B-T080
behaviours	B-T053
that	O
reduce	B-T080
the	O
risk of injury	B-T033
in	O
matches	B-T056
.	O

Role	B-T077
of	O
Oxidative Stress	B-T049
and	O
Inflammatory	B-T169
Factors	B-T169
in	O
Diabetic Kidney Disease	B-T047
Diabetic nephropathy	B-T047
(	O
DN	B-T047
)	O
is	O
a	O
serious	B-T080
complication	B-T046
of	O
diabetes mellitus	B-T047
,	O
and	O
its	O
prevalence	B-T081
has	O
been	O
increasing	B-T169
in	O
developed countries	B-T080
.	O
Diabetic nephropathy	B-T047
has	O
become	O
the	O
most	O
common	B-T081
single	B-T081
cause	O
of	O
end-stage renal disease	B-T047
worldwide	B-T098
.	O
Oxidative stress	B-T049
and	O
inflammation	B-T046
factors	B-T169
are	O
hypothesized	B-T078
to	O
play a role	B-T077
in	O
the	O
development	B-T169
of	O
late	B-T079
diabetes complications	B-T047
.	O
Chronic hyperglycemia	B-T046
increases	B-T169
oxidative stress	B-T049
,	O
significantly modifies	B-T169
the	O
structure	B-T082
and	O
function	B-T039
of	O
proteins	B-T116
and	O
lipids	B-T109
,	O
and	O
induces	B-T169
glycoxidation	B-UnknownType
and	O
peroxidation	B-T067
.	O
Therefore,	O
hyperglycemia	B-T047
causes	O
auto-oxidation	B-T070
of	O
glucose	B-T109
,	O
glycation	B-T067
of	O
proteins	B-T116
,	O
and	O
activation	B-T052
of	O
polyol mechanism	B-T169
.	O
Overproduction	B-T057
of	O
intracellular	B-T082
reactive oxygen species	B-T123
contributes	B-T052
to	O
several	B-T081
microvascular	B-T169
and	O
macrovascular	B-T169
complications	B-T046
of	O
DN	B-T047
.	O
On	O
the	O
other	O
hand,	O
reactive oxygen species	B-T123
modulates	B-T082
signaling cascade	B-T043
of	O
immune factors	B-T129
.	O
An	O
increase	B-T169
in	O
reactive oxygen species	B-T123
can	O
increase	B-T169
the	O
production	B-T057
of	O
inflammatory	B-T169
cytokines	B-T116
,	O
and	O
likewise,	O
an	O
increase	B-T169
in	O
inflammatory	B-T169
cytokines	B-T116
can	O
stimulate	B-T070
the	O
production	B-T057
of	O
free radicals	B-T104
.	O
Some	O
studies	B-T062
have	O
shown	O
that	O
kidney inflammation	B-T047
is	O
serious	B-T080
in	O
promoting	B-T052
the	O
development	B-T169
and	O
progression	B-T169
of	O
DN	B-T047
.	O
Inflammatory	B-T169
factors	B-T169
which	O
are	O
activated	B-T052
by	O
the	O
metabolic	B-T169
,	O
biochemical	B-T169
,	O
and	O
hemodynamic	B-T042
derangements	O
are	O
known	O
to	O
exist	B-T077
in	O
the	O
diabetic kidney	B-T047
.	O
This	O
review	B-T170
discusses	O
facts	O
for	O
oxidative stress	B-T049
and	O
inflammatory	B-T169
factors	B-T169
in	O
DN	B-T047
and	O
encompasses	O
the	O
role	B-T077
of	O
immune	B-T025
and	O
inflammatory cells	B-T025
,	O
inflammatory	B-T169
cytokines	B-T116
,	O
and	O
stress oxidative	B-T049
factors	B-T169
.	O

Cobalt-60 Machines	B-T074
and	O
Medical Linear Accelerators	B-T074
:	O
Competing Technologies	B-T090
for	O
External Beam Radiotherapy	B-T061
Medical linear accelerators	B-T074
(	O
linacs	B-T074
)	O
and	O
cobalt-60 machines	B-T074
are	O
both	O
mature	O
technologies	B-T090
for	O
external beam radiotherapy	B-T061
.	O
A	O
comparison	B-T052
is	O
made	O
between	O
these	O
two	O
technologies	B-T090
in	O
terms	O
of	O
infrastructure	B-T185
and	O
maintenance	B-T052
,	O
dosimetry	B-T059
,	O
shielding	B-T033
requirements	B-T169
,	O
staffing	B-T057
,	O
costs	B-T081
,	O
security	B-T077
,	O
patient	B-T101
throughput	B-T081
and	O
clinical use	B-T169
.	O
Infrastructure	B-T185
and	O
maintenance	B-T052
are	O
more	O
demanding	B-T078
for	O
linacs	B-T074
due	O
to	O
the	O
complex electric componentry	B-T073
.	O
In	O
dosimetry	B-T059
,	O
a	O
higher	B-T080
beam energy	B-T081
,	O
modulated	B-T082
dose rate	B-T081
and	O
smaller	B-T080
focal spot size	B-T080
mean	O
that	O
it	O
is	O
easier	B-T033
to	O
create	B-T052
an	O
optimised	B-T052
treatment	B-T061
with	O
a	O
linac	B-T074
for	O
conformal	O
dose	B-T081
coverage	B-T169
of	O
the	O
tumour	B-T191
while	O
sparing	O
healthy organs	B-T023
at	O
risk	B-T078
.	O
In	O
shielding	B-T033
,	O
the	O
requirements	B-T169
for	O
a	O
concrete bunker	B-T073
are	O
similar	O
for	O
cobalt-60 machines	B-T074
and	O
linacs	B-T074
but	O
extra	O
shielding	B-T033
and	O
protection	B-T033
from	O
neutrons	B-T167
are	O
required	O
for	O
linacs	B-T074
.	O
Staffing levels	B-T033
can	O
be	O
higher	B-T080
for	O
linacs	B-T074
and	O
more	O
staff training	B-T065
is	O
required	O
for	O
linacs	B-T074
.	O
Life cycle costs	B-T169
are	O
higher	B-T080
for	O
linacs	B-T074
,	O
especially	O
multi-energy linacs	B-T074
.	O
Security	B-T077
is	O
more	O
complex	B-T080
for	O
cobalt-60 machines	B-T074
because	O
of	O
the	O
high	B-T080
activity	B-T052
radioactive source	B-T122
.	O
Patient	B-T101
throughput	B-T081
can	O
be	O
affected	B-T169
by	O
source	B-T033
decay	B-T067
for	O
cobalt-60 machines	B-T074
but	O
poor	B-T080
maintenance	B-T052
and	O
breakdowns	B-T066
can	O
severely	O
affect	B-T169
patient	B-T101
throughput	B-T081
for	O
linacs	B-T074
.	O
In	O
clinical use	B-T169
,	O
more	O
complex	B-T080
treatment	B-T061
techniques	B-T169
are	O
easier	B-T033
to	O
achieve	O
with	O
linacs	B-T074
,	O
and	O
the	O
availability of	B-T169
electron beams	B-T073
on	O
high	B-T080
-	O
energy	B-T081
linacs	B-T074
can	O
be	O
useful	O
for	O
certain	O
treatments	B-T061
.	O
In	O
summary,	O
there	O
is	O
no	O
simple	O
answer	O
to	O
the	O
question	O
of	O
the	O
choice	O
of	O
either	O
cobalt-60 machines	B-T074
or	O
linacs	B-T074
for	O
radiotherapy	B-T061
in	O
low-	B-T033
and	O
middle-income	B-T080
countries	B-T083
.	O
In	O
fact	O
a	O
radiotherapy department	B-T093
with	O
a	O
combination	B-T080
of	O
technologies	B-T090
,	O
including	O
orthovoltage X-ray units	B-T092
,	O
may	O
be	O
an	O
option	B-T169
.	O
Local	B-T082
needs	B-T080
,	O
conditions	B-T080
and	O
resources	B-T078
will	O
have	O
to	O
be	O
factored	O
into	O
any	O
decision	B-T041
on	O
technology	B-T090
taking	O
into	O
account	O
the	O
characteristics	B-T080
of	O
both	O
forms	O
of	O
teletherapy	B-T061
,	O
with	O
the	O
primary	O
goal	B-T170
being	O
the	O
sustainability	B-T169
of	O
the	O
radiotherapy service	B-T093
over	O
the	O
useful	O
lifetime	B-T079
of	O
the	O
equipment	B-T073
.	O

Design	B-T052
,	O
synthesis	B-T052
,	O
molecular docking	B-T170
,	O
anti-Proteus mirabilis	B-T195
and	O
urease	B-T116
inhibition	B-T039
of	O
new	O
fluoroquinolone carboxylic acid derivatives	B-T121
New	O
hydroxamic acid	B-T109
,	O
hydrazide	B-T109
and	O
amide derivatives	B-T109
of	O
ciprofloxacin	B-T109
in	O
addition	O
to	O
their	O
analogues	B-T104
of	O
levofloxacin	B-T109
were	O
prepared	O
and	O
identified	O
by	O
different	O
spectroscopic techniques	B-T169
.	O
Some	O
of	O
the	O
prepared	O
compounds	B-T121
revealed	O
good	O
activity	B-T040
against	O
the	O
urease	B-T116
splitting	O
bacteria	B-T007
,	O
Proteus mirabilis	B-T007
.	O
The	O
urease	B-T116
inhibitory activity	B-T040
was	O
investigated	O
using	O
indophenol method	B-T059
.	O
Most	O
of	O
the	O
tested	B-T170
compounds	B-T121
showed	O
better	O
activity	B-T040
than	O
the	O
reference	O
acetohydroxamic acid	B-T109
(	O
AHA	B-T109
).	O
The	O
ciprofloxacin hydrazide derivative 3a	B-T121
and	O
levofloxacin hydroxamic acid 7	B-T121
experienced	O
the	O
highest	O
activity	B-T040
(	O
IC50	B-T081
=1.22μM	O
and	O
2.20μM,	O
respectively).	O
Molecular docking study	B-T170
revealed	O
high	O
spontaneous	O
binding ability	B-T044
of	O
the	O
tested	B-T170
compounds	B-T121
to	O
the	O
active site	B-T169
of	O
urease	B-T116
.	O

Interobserver	B-T170
and	O
Intraobserver	B-T096
Reliability	B-T081
of	O
Clinical Assessments	B-T033
in	O
Knee Osteoarthritis	B-T047
Clinical examination	B-T033
of	O
the	O
knee	B-T023
is	O
subject	O
to	O
measurement error	B-T081
.	O
The	O
aim	O
of	O
this	O
analysis	O
was	O
to	O
determine	O
interobserver	B-T170
and	O
intraobserver	B-T096
reliability	B-T081
of	O
commonly	O
used	O
clinical	O
tests	O
in	O
patients	B-T101
with	O
knee osteoarthritis	B-T047
(	O
OA	B-T047
).	O
We	O
studied	O
subjects	B-T096
with	O
symptomatic	B-T169
knee OA	B-T047
who	O
were	O
participants	B-T098
in	O
an	O
open-label clinical trial	B-T062
of	O
intraarticular steroid therapy	B-T061
.	O
Following	O
standardization	B-T062
of	O
the	O
clinical test procedures	B-T059
,	O
2	O
clinicians	B-T097
assessed	B-T058
25	O
subjects	B-T096
independently	O
at	O
the	O
same	O
visit	B-T058
,	O
and	O
the	O
same	O
clinician	B-T097
assessed	B-T058
88	O
subjects	B-T096
over	O
an	O
interval period	B-T079
of	O
2-10	O
weeks;	O
in	O
both	O
cases	O
prior	O
to	O
the	O
steroid	B-T061
intervention	B-T061
.	O
Clinical examination	B-T033
included	B-T169
assessment	B-T058
of	O
bony enlargement	B-UnknownType
,	O
crepitus	B-T046
,	O
quadriceps wasting	B-T033
,	O
knee effusion	B-T033
,	O
joint-line	B-T029
and	O
anserine	B-T023
tenderness	B-T184
,	O
and	O
knee range of movement	B-T033
(	O
ROM	B-T033
).	O
Intraclass correlation coefficients	B-T081
(	O
ICC	B-T081
),	O
estimated kappa	B-T081
(	O
κ	B-T081
),	O
weighted kappa	B-T081
(	O
κω	B-T081
),	O
and	O
Bland-Altman plots	B-T081
were	O
used	O
to	O
determine	O
interobserver	B-T170
and	O
intraobserver	B-T096
levels	B-T080
of	O
agreement	B-T054
.	O
Using	O
Landis and Koch criteria	B-T081
,	O
interobserver κ scores	B-T080
were	O
moderate	B-T080
for	O
patellofemoral joint	B-T030
(	O
κ	B-T081
=	O
0.53)	O
and	O
anserine	B-T023
tenderness	B-T184
(	O
κ	B-T081
=	O
0.48);	O
good	B-T080
for	O
bony enlargement	B-UnknownType
(	O
κ	B-T081
=	O
0.66),	O
quadriceps wasting	B-T033
(	O
κ	B-T081
=	O
0.78),	O
crepitus	B-T046
(	O
κ	B-T081
=	O
0.78),	O
medial	B-T082
tibiofemoral joint	B-T030
tenderness	B-T184
(	O
κ	B-T081
=	O
0.76),	O
and	O
effusion	B-T033
assessed	O
by	O
ballottement	B-T184
(	O
κ	B-T081
=	O
0.73)	O
and	O
bulge sign	B-T060
(	O
κω	B-T081
=	O
0.78);	O
and	O
excellent	B-T080
for	O
lateral	B-T082
tibiofemoral joint	B-T030
tenderness	B-T184
(	O
κ	B-T081
=	O
1.00),	O
flexion	B-T042
(	O
ICC	B-T081
=	O
0.97),	O
and	O
extension	B-T169
(	O
ICC	B-T081
=	O
0.87)	O
ROM	B-T033
.	O
Intraobserver κ scores	B-T080
were	O
moderate	B-T080
for	O
lateral	B-T082
tibiofemoral joint	B-T030
tenderness	B-T184
(	O
κ	B-T081
=	O
0.60);	O
good	O
for	O
crepitus	O
(	O
κ	B-T081
=	O
0.78),	O
effusion	B-T033
assessed	O
by	O
ballottement test	B-T184
(	O
κ	B-T081
=	O
0.77),	O
patellofemoral joint	B-T030
(	O
κ	B-T081
=	O
0.66),	O
medial	B-T082
tibiofemoral joint	B-T030
(	O
κ	B-T081
=	O
0.64),	O
and	O
anserine	B-T023
tenderness	B-T184
(	O
κ	B-T081
=	O
0.73);	O
and	O
excellent	B-T080
for	O
effusion	B-T033
assessed	O
by	O
bulge sign	B-T060
(	O
κω	B-T081
=	O
0.83),	O
bony enlargement	B-UnknownType
(	O
κ	B-T081
=	O
0.98),	O
quadriceps wasting	B-T033
(	O
κ	B-T081
=	O
0.83),	O
flexion	B-T042
(	O
ICC	B-T081
=	O
0.99),	O
and	O
extension	B-T169
(	O
ICC	B-T081
=	O
0.96)	O
ROM	B-T033
.	O
Among	O
individuals	B-T098
with	O
symptomatic	B-T169
knee OA	B-T047
,	O
the	O
reliability	B-T081
of	O
clinical examination	B-T033
of	O
the	O
knee	B-T023
was	O
at	O
least	O
good	O
for	O
the	O
majority	O
of	O
clinical signs	B-T033
of	O
knee OA	B-T047
.	O

Assessing	O
the	O
benefits	B-T081
of	O
targeted	B-T169
drug delivery	B-T074
by	O
nanocarriers	B-T073
:	O
A	O
partico/pharmacokinetic framework	B-T169
An	O
in vivo	B-T082
kinetic framework	B-T169
is	O
introduced	O
to	O
analyze	B-T062
and	O
predict	O
the	O
quantitative	B-T081
advantage	O
of	O
using	O
nanocarriers	B-T073
to	O
deliver drugs	B-T074
,	O
especially	O
anticancer agents	B-T109
,	O
compared	B-T052
to	O
administering	B-T061
the	O
same	O
drugs	B-T121
in	O
their	O
free	O
form.	O
This	O
framework	B-T078
recognizes	O
three	O
levels	B-T080
of	O
kinetics	B-T039
.	O
First	O
is	O
the	O
particokinetics	B-T070
associated with	B-T080
deposition	B-T169
of	O
nanocarriers	B-T073
into	O
tissues	B-T024
associated with	B-T080
drug effect	B-T169
and	O
toxicity	B-T037
,	O
their	O
residence	B-T082
inside	O
those	O
tissues	B-T024
,	O
and	O
elimination	B-T040
of	O
the	O
nanocarriers	B-T073
from	O
the	O
body	B-T016
.	O
Second	O
is	O
the	O
release pattern	B-T033
in	O
time	O
of	O
free drug	B-T081
from	O
the	O
nanocarriers	B-T073
.	O
Third	O
is	O
the	O
pharmacokinetics	B-T039
of	O
free drug	B-T081
,	O
as	O
it	O
relates	O
to	O
deposition	B-T169
and	O
elimination processes	B-T040
in	O
the	O
target	B-T169
and	O
toxicity	B-T037
associated	B-T080
tissues	B-T024
,	O
and	O
total body clearance	B-T034
.	O
A	O
figure	O
of	O
merit,	O
the	O
drug targeting index	B-T081
(	O
DTI	B-T081
),	O
is	O
used	O
to	O
quantitate	B-T081
the	O
benefit	O
of	O
nanocarrier	B-T073
based	O
drug delivery	B-T074
by	O
considering	O
the	O
effects	B-T080
of	O
preferential	O
deposition	B-T169
of	O
nanoparticles	B-T073
into	O
target	B-T169
tissues	B-T024
and	O
relative	O
avoidance	O
of	O
tissues	B-T024
associated with	B-T080
drug toxicity	B-T037
,	O
compared	B-T052
to	O
drug	B-T121
that	O
is	O
administered	B-T061
in	O
its	O
free	O
form.	O
General	O
methods	B-T170
are	O
derived	O
for	O
calculating	B-T052
DTI	B-T081
when	O
appropriate	O
particokinetic	B-T070
,	O
pharmacokinetic	B-T169
,	O
and	O
drug release rate	B-T081
information	O
is	O
available,	O
and	O
it	O
is	O
shown	O
that	O
relatively	O
simple	O
algebraic	O
forms	O
result	B-T169
when	O
some	O
common	O
assumptions	O
are	O
made.	O
This	O
approach	O
may	O
find	O
use	O
in	O
developing	B-T091
and	O
selecting	O
nanocarrier	B-T073
formulations	B-T077
,	O
either	O
for	O
populations	B-T098
or	O
for	O
individuals	B-T098
.	O

Recombinant	B-T001
MHC Tetramers	B-T028
for	O
Isolation	B-T061
of	O
Virus	B-T005
-	O
Specific	B-T080
CD8(+) Cells	B-T025
from	O
Healthy Donors	B-T080
:	O
Potential	B-T080
Approach	O
for	O
Cell Therapy	B-T061
of	O
Posttransplant Cytomegalovirus Infection	B-T047
Patients	B-T101
undergoing	O
allogeneic	B-T080
hematopoietic stem cell transplantation	B-T061
have	O
a	O
high	O
risk	O
of	O
cytomegalovirus reactivation	B-T047
,	O
which	O
in	O
the	O
absence	O
of	O
T-cell immunity	B-T040
can	O
result	O
in	O
the	O
development	O
of	O
an	O
acute inflammatory reaction	B-T033
and	O
damage of internal organs	B-T037
.	O
Transfusion	B-T061
of	O
the	O
virus-specific	B-T080
donor T-lymphocytes	B-T025
represents	O
an	O
alternative	O
to	O
a	O
highly toxic	B-T080
and	O
often	O
ineffective	B-T078
antiviral therapy	B-T061
.	O
Potentially	B-T080
promising	O
cell therapy	B-T061
approach	O
comprises	O
transfusion	B-T061
of	O
cytotoxic T-lymphocytes	B-T025
,	O
specific	B-T080
to	O
the	O
viral antigens	B-T129
,	O
immediately	O
after	O
their	O
isolation	B-T061
from	O
the	O
donor's blood circulation	B-T039
without	O
any	O
in vitro expansion	B-T080
.	O
Specific	B-T080
T-cells	B-T025
could	O
be	O
separated	O
from	O
potentially	B-T080
alloreactive lymphocytes	B-T025
using	O
recombinant	B-T001
major histocompatibility complex	B-T028
(	O
MHC	B-T028
)	O
multimers	B-T104
,	O
carrying	O
synthetic viral peptides	B-T116
.	O
Rapid	O
transfusion	B-T061
of	O
virus	B-T005
-	O
specific	B-T080
T-cells	B-T025
to	O
patients	B-T101
has	O
several	O
crucial	O
advantages	O
in	O
comparison	O
with	O
methods	O
based	O
on	O
the	O
in vitro expansion	B-T080
of	O
the	O
cells	B-T025
.	O
About	O
30%	O
of	O
hematopoietic	B-T169
stem cell donors	B-T080
and	O
46%	O
of	O
transplant recipients	B-T101
at	O
the	O
National Research Center for Hematology	B-T093
were	O
carriers	O
of	O
the	O
HLA-A*02 allele	B-T028
.	O
Moreover,	O
94%	O
of	O
Russian	B-T098
donors	B-T080
have	O
an	O
immune response	B-T042
against	O
the	O
cytomegalovirus	B-T005
(	O
CMV	B-T005
).	O
Using	O
recombinant	B-T001
HLA-A*02	B-T028
multimers	B-T104
carrying	O
an	O
immunodominant	B-T080
cytomegalovirus peptide	B-T116
(	O
NLV	B-T116
),	O
we	O
have	O
shown	O
that	O
the	O
majority	O
of	O
healthy donors	B-T080
have	O
pronounced	O
T-cell immunity	B-T040
against	O
this	O
antigen	B-T129
,	O
whereas	O
shortly	O
after	O
the	O
transplantation	B-T061
the	O
patients	B-T101
do	O
not	O
have	O
specific	B-T080
T-lymphocytes	B-T025
.	O
The	O
donor cells	B-T025
have	O
the	O
immune phenotype	B-T032
of	O
memory cells	B-T025
and	O
can	O
be	O
activated	B-T043
and	O
proliferate	B-T043
after	O
stimulation	O
with	O
the	O
specific	B-T080
antigen	B-T129
.	O
Donor lymphocytes	B-T033
can	O
be	O
substantially	O
enriched	B-UnknownType
to	O
significant	O
purity	B-T081
by	O
magnetic separation	B-T059
with	O
recombinant	B-T001
MHC	B-T028
multimers	B-T104
and	O
are	O
not	O
activated	B-UnknownType
upon	O
cocultivation	B-T059
with	O
the	O
antigen	B-T129
-presenting	O
cells	B-T025
from	O
HLA	B-T116
-	O
incompatible donors	B-T098
without	O
addition	O
of	O
the	O
specific	B-T080
antigen	B-T129
.	O
This	O
study	B-T062
demonstrated	O
that	O
strong	O
immune response	B-T042
to	O
CMV	B-T005
of	O
healthy donors	B-T080
and	O
prevalence	O
of	O
HLA-A*02 allele	B-T028
in	O
the	O
Russian population	B-T098
make	O
it	O
possible	O
to	O
isolate	O
a	O
significant	O
number	O
of	O
virus-specific	B-T080
cells	B-T025
using	O
HLA-A*02-NLV	B-T028
multimers	B-T104
.	O
After	O
the	O
transfusion	B-T061
,	O
these	O
cells	B-T025
should	O
protect	O
patients	B-T101
from	O
CMV	B-T005
without	O
development	O
of	O
allogeneic	B-T080
immune response	B-T042
.	O

Outcomes	B-T080
of	O
chest wall resections	B-T061
in	O
pediatric	B-T080
sarcoma	B-T191
patients	B-T101
Chest wall tumors	B-T191
in	O
pediatric	B-T080
patients	B-T101
are	O
rare.	O
This	O
study	B-T062
evaluates	O
outcomes	B-T080
in	O
pediatric	B-T080
patients	B-T101
who	O
have	O
undergone	O
chest wall resections	B-T061
secondary	O
to	O
sarcomas	B-T191
.	O
A	O
retrospective review	B-T062
was	O
performed	O
for	O
patients	B-T101
<19years	O
old	O
who	O
underwent	O
chest wall resections	B-T061
for	O
sarcoma	B-T191
1999-2014	O
at	O
the	O
University of Texas MD Anderson Cancer Center	B-T093
.	O
Of	O
44	O
patients	B-T101
,	O
Ewing's sarcoma	B-T191
(n=18)	O
and	O
osteosarcoma	B-T191
(n=16)	O
were	O
most	O
common.	O
Other	O
sarcomas	B-T191
included	O
synovial sarcoma	B-T191
,	O
chondrosarcoma	B-T191
,	O
and	O
rhabdomyosarcoma	B-T191
.	O
Gore-Tex	B-T109
®	O
or	O
a	O
Marlex™ mesh	B-T122
and	O
methyl methacrylate sandwich	B-T122
was	O
used	O
in	O
22	O
patients	B-T101
,	O
and	O
9	O
children	B-T100
did	O
not require reconstruction	B-T033
.	O
Twenty-four	O
(54.5%)	O
patients	B-T101
had	O
normal	B-T080
activity	B-T052
,	O
3	O
(6.8%)	O
had	O
occasional discomfort	B-T184
,	O
2	O
(4.5%)	O
had	O
pain impairing function	B-T046
,	O
7	O
(15.9%)	O
required	O
medication	B-T121
or	O
physical therapy	B-T061
for	O
impairment	B-T046
,	O
and	O
8	O
(18.2%)	O
needed	O
additional	O
surgery	B-T091
.	O
Five	O
children	B-T100
(11.4%)	O
developed	O
scoliosis	B-T190
,	O
and	O
all	O
of	O
these	O
patients	B-T101
had	O
posterior	B-T082
rib tumors	B-T191
.	O
Median overall survival	B-T081
for	O
the	O
entire cohort	B-T098
was	O
41.9±11.82	O
months	B-T079
.	O
Histology	B-T091
(p=0.003),	O
location	B-T082
of	O
tumor	B-T191
on	O
the	O
ribs	B-T023
(p=0.007),	O
and	O
surgical margins	B-T023
(p=0.011)	O
were	O
significantly associated with	B-T080
overall survival	B-T081
.	O
Tumors	B-T191
on	O
the	O
middle	O
and	O
posterior	B-T082
(p=0.003)	O
portions	O
of	O
the	O
ribs	B-T023
had	O
a	O
lower	O
chance	O
of	O
death	B-T040
.	O
Scoliosis	B-T190
is	O
more	O
common	O
in	O
posterior	B-T082
rib resections	B-T061
.	O
Histology	B-T091
,	O
location	B-T082
of	O
the	O
tumor	B-T191
,	O
and	O
surgical margins	B-T023
impact	O
survival	B-T052
,	O
but,	O
type	O
of	O
reconstruction	O
does	O
not.	O
III.	O
Treatment Study	B-T062
.	O

Tetrabromobisphenol A	B-T109
activates	B-T052
the	O
hepatic	B-T023
interferon pathway	B-T044
in	O
rats	B-T015
Tetrabromobisphenol A	B-T109
(	O
TBBPA	B-T109
)	O
is	O
a	O
widely	O
used	O
flame retardant	B-T120
in	O
printed circuit boards	B-T073
,	O
paper	B-T073
,	O
and	O
textiles	B-T073
.	O
In	O
a	O
two-year	B-T079
study	B-T062
,	O
TBBPA	B-T109
showed	O
evidence	O
of	O
uterine tumors	B-T191
in	O
female	B-T032
Wistar-Han rats	B-T015
and	O
liver	B-T191
and	O
colon tumors	B-T191
in	O
B6C3F1 mice	B-T015
.	O
In	O
order	O
to	O
gain	O
further	O
insight	O
into	O
early	O
gene	B-T028
and	O
pathway	B-T044
changes	O
leading	O
to	O
cancer	B-T191
,	O
we	O
exposed	O
female	B-T032
Wistar Han rats	B-T015
to	O
TBBPA	B-T109
at	O
0,	O
25,	O
250,	O
or	O
1000mg/kg	O
(	O
oral gavage	B-T169
in	O
corn oil	B-T109
,	O
5×/	O
week	B-T079
)	O
for	O
13	O
weeks	B-T079
.	O
Because	O
at	O
the	O
end	O
of	O
the	O
TBBPA	B-T109
exposure	B-T080
period,	O
there	O
were	O
no	O
treatment-related	O
effects	O
on	O
body weights	B-T032
,	O
liver	B-T033
or	O
uterus lesions	B-T033
,	O
and	O
liver	B-T023
and	O
uterine organ	B-T023
weights	B-T081
were	O
within	O
10%	O
of	O
controls	B-T096
,	O
only	O
the	O
high	O
dose	B-T081
animals	B-T008
were	O
analyzed	B-T062
.	O
Analysis	B-T062
of	O
the	O
hepatic	B-T023
and	O
uterine	B-T023
transcriptomes	B-T086
showed	O
TBBPA	B-T109
-induced	O
changes	O
primarily	O
in	O
the	O
liver	B-T023
(1000mg/kg),	O
with	O
159	O
transcripts	B-T114
corresponding	O
to	O
132	O
genes	B-T028
differentially	O
expressed	B-T045
compared	O
to	O
controls	B-T096
(FDR=0.05).	O
Pathway analysis	B-T170
showed	O
activation	B-T052
of	O
interferon	B-T116
(	O
IFN	B-T116
)	O
and	O
metabolic networks	B-T044
.	O
TBBPA	B-T109
induced	O
few	O
molecular	O
changes	O
in	O
the	O
uterus	B-T023
.	O
Activation	B-T052
of	O
the	O
interferon pathway	B-T044
in	O
the	O
liver	B-T023
occurred	O
after	O
13-weeks	B-T079
of	O
TBBPA	B-T109
exposure	B-T080
,	O
and	O
with	O
longer	O
term	O
TBBPA	B-T109
exposure	B-T080
this	O
may	O
lead	O
to	O
immunomodulatory	B-T061
changes	B-T169
that	O
contribute	O
to	O
carcinogenic processes	B-T191
.	O

Famous faces	B-T041
and	O
voices	B-T041
:	O
Differential	B-T080
profiles	B-T082
in	O
early	B-T079
right	B-T023
and	O
left	B-T023
semantic dementia	B-T048
and	O
in	O
Alzheimer's disease	B-T047
Famous face	B-T041
and	O
voice recognition	B-T041
is	O
reported	O
to	O
be	O
impaired	B-T169
both	O
in	O
semantic dementia	B-T048
(	O
SD	B-T048
)	O
and	O
in	O
Alzheimer's Disease	B-T047
(	O
AD	B-T047
),	O
although	O
more	O
severely	B-T080
in	O
the	O
former.	O
In	O
AD	B-T047
a	O
coexistence	O
of	O
perceptual	B-T041
impairment	B-T169
in	O
face	B-T041
and	O
voice	B-T041
processing	B-T041
has	O
also	O
been	O
reported	O
and	O
this	O
could	O
contribute	O
to	O
the	O
altered	O
performance	B-T052
in	O
complex	B-T080
semantic	B-T078
tasks	B-T052
.	O
On	O
the	O
other	O
hand,	O
in	O
SD	B-T048
both	O
face	B-T041
and	O
voice recognition	B-T041
disorders	B-T047
could	O
be	O
related	O
to	O
the	O
prevalence	B-T081
of	O
atrophy	B-T046
in	O
the	O
right temporal lobe	B-T023
(	O
RTL	B-T023
).	O
The	O
aim	O
of	O
the	O
present	O
study	B-T062
was	O
twofold:	O
(1)	O
to	O
investigate	B-T169
famous faces	B-T041
and	O
voices recognition	B-T041
in	O
SD	B-T048
and	O
AD	B-T047
to	O
verify	O
if	O
the	O
two	O
diseases	B-T047
show	O
a	O
differential	B-T080
pattern	B-T082
of	O
impairment	B-T169
,	O
resulting	O
from	O
disruption	B-T169
of	O
different	O
cognitive	B-T041
mechanisms	B-T169
;	O
(2)	O
to	O
check	O
if	O
face	B-T041
and	O
voice recognition	B-T041
disorders	B-T047
prevail	O
in	O
patients	B-T101
with	O
atrophy	B-T046
mainly	O
affecting	O
the	O
RTL	B-T023
.	O
To	O
avoid	O
the	O
potential	B-T080
influence	B-T077
of	O
primary	B-T080
perceptual	B-T041
problems	B-T033
in	O
face	B-T041
and	O
voice recognition	B-T041
,	O
a	O
pool	O
of	O
patients	B-T101
suffering	O
from	O
early	B-T079
SD	B-T048
and	O
AD	B-T047
were	O
administered	B-T169
a	O
detailed	O
set	O
of	O
tests	B-T058
exploring	O
face	B-T041
and	O
voice	B-T041
perception	B-T041
.	O
Thirteen	O
SD	B-T048
(8	O
with	O
prevalence	B-T081
of	O
right	B-T023
and	O
5	O
with	O
prevalence	B-T081
of	O
left temporal	B-T023
atrophy	B-T046
)	O
and	O
25	O
CE	O
patients	B-T101
,	O
who	O
did	O
not	O
show	O
visual	B-T169
and	O
auditory	B-T169
perceptual	B-T041
impairment	B-T169
,	O
were	O
finally	O
selected	O
and	O
were	O
administered	B-T169
an	O
experimental	B-T080
battery	B-T170
exploring	O
famous face	B-T041
and	O
voice recognition	B-T041
and	O
naming	B-T170
.	O
Twelve	O
SD	B-T048
patients	B-T101
underwent	O
cerebral	B-T023
PET imaging	B-T060
and	O
were	O
classified	O
in	O
right	B-T023
and	O
left	B-T023
SD	B-T048
according	O
to	O
the	O
onset	O
modality	B-T078
and	O
to	O
the	O
prevalent	O
decrease	B-T081
in	O
FDG uptake	B-T109
in	O
right	B-T023
or	O
left temporal lobe	B-T023
respectively.	O
Correlation	B-T080
of	O
PET imaging	B-T060
and	O
famous face	B-T041
and	O
voice recognition	B-T041
was	O
performed.	O
Results	B-T169
showed	O
a	O
differential	B-T080
performance	B-T052
profile	B-T082
in	O
the	O
two	O
diseases	B-T047
,	O
because	O
AD	B-T047
patients	B-T101
were	O
significantly	O
impaired	B-T169
in	O
the	O
naming tests	B-T170
,	O
but	O
showed	O
preserved	O
recognition	B-T041
,	O
whereas	O
SD	B-T048
patients	B-T101
were	O
profoundly	O
impaired	B-T169
both	O
in	O
naming	B-T170
and	O
in	O
recognition of famous faces	B-T041
and	O
voices	B-T041
.	O
Furthermore,	O
face	B-T041
and	O
voice recognition	B-T041
disorders	B-T047
prevailed	O
in	O
SD	B-T048
patients	B-T101
with	O
RTL	B-T023
atrophy	B-T046
,	O
who	O
also	O
showed	O
a	O
conceptual	B-T077
impairment	B-T169
on	O
the	O
Pyramids and Palm Trees test	B-T170
more	O
important	O
in	O
the	O
pictorial	O
than	O
in	O
the	O
verbal	B-T080
modality	B-T078
.	O
Finally,	O
in	O
12	O
SD	B-T048
patients	B-T101
in	O
whom	O
PET	B-T060
was	O
available,	O
a	O
strong	O
correlation	B-T080
between	O
FDG uptake	B-T109
and	O
face-to-name	B-T080
and	O
voice-to-name matching	B-T080
data	B-T078
was	O
found	O
in	O
the	O
right	B-T023
but	O
not	O
in	O
the	O
left temporal lobe	B-T023
.	O
The	O
data	B-T078
support	O
the	O
hypothesis	B-T078
of	O
a	O
different	O
cognitive	B-T041
basis	O
for	O
impairment	B-T169
of	O
face	B-T041
and	O
voice recognition	B-T041
in	O
the	O
two	O
dementias	B-T048
and	O
suggest	O
that	O
the	O
pattern	B-T082
of	O
impairment	B-T169
in	O
SD	B-T048
may	O
be	O
due	O
to	O
a	O
loss	O
of	O
semantic	B-T078
representations	B-T052
,	O
while	O
a	O
defect	O
of	O
semantic	B-T078
control	B-T169
,	O
with	O
impaired	B-T169
naming	B-T170
and	O
preserved recognition	B-T041
might	O
be	O
hypothesized	O
in	O
AD	B-T047
.	O
Furthermore,	O
the	O
correlation	B-T080
between	O
face	B-T041
and	O
voice recognition	B-T041
disorders	B-T047
and	O
RTL	B-T023
damage	B-T037
are	O
consistent	O
with	O
the	O
hypothesis	B-T078
assuming	O
that	O
in	O
the	O
RTL	B-T023
person	B-T098
-specific	O
knowledge	B-T170
may	O
be	O
mainly	O
based	O
upon	O
non-verbal representations	B-T041
.	O

Dry skin	B-T184
conditions	O
are	O
related	B-T080
to	O
the	O
recovery rate	B-T081
of	O
skin temperature	B-T032
after	O
cold	B-T070
stress	B-T046
rather	O
than	O
to	O
blood flow	B-T039
Cutaneous	B-T082
blood flow	B-T039
plays	O
an	O
important	B-T080
role	O
in	O
the	O
thermoregulation	B-T042
,	O
oxygen supply	B-T201
,	O
and	O
nutritional support	B-T061
necessary	O
to	O
maintain	B-T052
the	O
skin	B-T022
.	O
However,	O
there	O
is	O
little	O
evidence	B-T078
for	O
a	O
link	O
between	O
blood flow	B-T039
and	O
skin physiology	B-T042
.	O
Therefore,	O
we	O
conducted	O
surveys	B-T170
of	O
healthy volunteers	B-T098
to	O
determine	O
the	O
relationship	B-T080
(s)	O
between	O
dry skin	B-T184
properties	O
and	O
cutaneous	B-T082
vascular function	B-T201
.	O
Water	O
content	O
of	O
the	O
stratum corneum	B-T024
,	O
transepidermal water loss	B-T033
,	O
and	O
visual dryness score	B-T080
were	O
investigated	B-T169
as	O
dry skin	B-T184
parameters	B-T033
.	O
Cutaneous	B-T082
blood flow	B-T039
in	O
the	O
resting state	B-T033
,	O
the	O
recovery rate	B-T081
(	O
RR	B-T081
)	O
of	O
skin temperature	B-T032
on	O
the	O
hand	B-T023
after	O
a	O
cold-stress test	B-T059
,	O
and	O
the	O
responsiveness	B-T169
of	O
facial skin	B-T023
blood flow	B-T039
to	O
local cooling	B-T061
were	O
examined	B-T033
as	O
indices	B-T170
of	O
cutaneous	B-T082
vascular functions	B-T201
.	O
The	O
relationships	B-T080
between	O
dry skin	B-T184
parameters	B-T033
and	O
cutaneous	B-T082
vascular functions	B-T201
were	O
assessed	B-T052
.	O
The	O
RR	B-T081
correlated	B-T080
negatively	O
with	O
the	O
visual dryness score	B-T080
of	O
skin	B-T022
on	O
the	O
leg	B-T023
but	O
correlated	B-T080
positively	O
with	O
water	O
content	O
of	O
the	O
stratum corneum	B-T024
on	O
the	O
arm.	O
No	O
significant	O
correlation	B-T080
between	O
the	O
resting state	B-T033
of	O
blood flow	B-T039
and	O
dry skin	B-T184
parameters	B-T033
was	O
observed	B-T169
.	O
In	O
both	O
the	O
face	B-T029
and	O
the	O
body	B-T016
,	O
deterioration	B-T067
in	O
skin dryness	B-T184
from	O
summer	B-T079
to	O
winter	B-T079
was	O
significant	B-T078
in	O
subjects	O
with	O
low	O
RR	B-T081
.	O
The	O
RR	B-T081
correlated	B-T080
well	O
with	O
the	O
responsiveness	B-T169
of	O
facial skin	B-T023
blood flow	B-T039
to	O
local cooling	B-T061
,	O
indicating	B-T033
that	O
the	O
RR	B-T081
affects	O
systemic	O
dry skin	B-T184
conditions.	O
These	O
results	O
suggest	O
that	O
the	O
RR	B-T081
but	O
not	O
blood flow	B-T039
at	O
the	O
resting state	B-T033
is	O
associated	O
with	O
dry skin	B-T184
conditions	O
and	O
is	O
involved	O
in	O
skin	O
homeostasis	B-T038
during	O
seasonal	B-T079
environmental changes	B-T033
.	O

Molar loss	B-T020
and	O
powder diet	B-T061
leads	O
to	O
memory deficit	B-T048
and	O
modifies	O
the	O
mRNA expression	B-T045
of	O
brain-derived neurotrophic factor	B-T116
in	O
the	O
hippocampus	B-T023
of	O
adult	B-T100
mice	B-T015
It	O
is	O
known	O
that	O
tooth loss	B-T020
is	O
known	O
to	O
be	O
a	O
risk factor	B-T033
for	O
Alzheimer's disease	B-T047
and	O
soft diet	B-T061
feeding	B-T052
induces	O
memory impairment	B-T048
.	O
Recent	O
studies	O
have	O
shown	O
that	O
brain-derived neurotrophic factor	B-T116
(	O
BDNF	B-T116
)	O
is	O
associated with	B-T080
tooth loss	B-T020
or	O
soft diet	B-T061
in	O
young	O
animal model	B-T008
,	O
and	O
that	O
BDNF	B-T028
expression	B-T045
is	O
decreased	O
in	O
patients	B-T101
with	O
Alzheimer's disease	B-T047
.	O
However,	O
single	O
or	O
combined	O
effect of	B-T080
tooth loss	B-T020
and/or	O
soft diet	B-T061
on	O
brain function	B-T042
has	O
not	O
fully	O
understood.	O
Here	O
we	O
examined	O
the	O
effect of	B-T080
molar loss	B-T020
and	O
powder diet	B-T061
on	O
memory ability	B-T041
and	O
the	O
expression	B-T045
of	O
BDNF mRNA	B-T028
in	O
the	O
hippocampus	B-T023
of	O
adult	B-T100
C57BL/6J mice	B-T015
.	O
Twenty	O
eight-weeks-old	O
C57BL/6J mice	B-T015
were	O
divided	O
into	O
intact	O
molar	O
group	O
and	O
extracted	O
molar	O
group.	O
They	O
were	O
randomly	B-T062
divided	O
into	O
the	O
I/S	O
group	O
(Intact	O
upper molar teeth	B-T023
/	O
Solid diet	B-T168
feeding	B-T052
),	O
the	O
E/S	O
group	O
(	O
Extracted	B-T061
upper molar teeth	B-T023
/	O
Solid diet	B-T168
feeding	B-T052
),	O
the	O
I/P	O
group	O
(Intact	O
upper molar teeth	B-T023
/	O
Powder diet	B-T061
feeding	B-T052
),	O
and	O
the	O
E/P	O
group	O
(Extracted	O
upper molar teeth	B-T023
/	O
Powder diet	B-T061
feeding	B-T052
).	O
The	O
observation	O
periods	O
were	O
4	O
and	O
16-week.	O
To	O
analyze	B-T062
the	O
memory ability	B-T041
,	O
the	O
step-through	O
passive avoidance	B-T041
test	O
was	O
conducted.	O
BDNF-related mRNA	B-T028
in	O
the	O
hippocampus	B-T023
was	O
analyzed	B-T062
by	O
real-time polymerase chain reaction	B-T063
(	O
RT-PCR	B-T063
).	O
At	O
4	O
weeks	O
later,	O
we	O
performed	O
memory test	B-T059
and	O
isolated	O
brains	B-T023
to	O
analyze	B-T062
.	O
There	O
were	O
no differences	B-T033
in	O
memory function	B-T041
and	O
BDNF mRNA	B-T028
level	O
between	O
these	O
four	O
groups.	O
However,	O
at	O
16	O
weeks	O
later,	O
E/S	O
and	O
E/P	O
group	O
showed	O
memory impairment	B-T048
,	O
and	O
decreased	O
level	O
of	O
BDNF mRNA	B-T028
.	O
Whereas,	O
the	O
powder diet	B-T061
had	O
no effect	B-T080
on	O
memory function	B-T041
and	O
BDNF mRNA	B-T028
level	O
even	O
at	O
16	O
weeks	O
later.	O
These	O
results	O
suggest	O
that	O
the	O
effect of	B-T080
molar loss	B-T020
and	O
powder diet	B-T061
on	O
memory function	B-T041
and	O
BDNF mRNA	B-T028
levels	O
were	O
different,	O
molar loss	B-T020
may	O
have	O
a	O
greater	O
long-term effect	B-T067
on	O
memory ability	B-T041
than	O
powder diet	B-T061
does.	O

Description	O
of	O
the	O
first	O
species	B-T185
of	O
Fiorianteon Olmi	B-T204
(	O
Hymenoptera	B-T204
,	O
Dryinidae	B-T204
)	O
from	O
the	O
Afrotropical region	B-T083
Fiorianteon sulcatumsp	B-T204
.	O
n.	O
is	O
described	O
from	O
Fianarantsoa Province	B-T083
(	O
Madagascar	B-T083
).	O
It	O
is	O
the	O
first	O
species	B-T185
of	O
Fiorianteon	B-T204
found	O
in	O
the	O
Afrotropical region	B-T083
.	O
The	O
genus	B-T185
Fiorianteon	B-T204
can	O
be	O
distinguished	O
from	O
the	O
closely	O
related	O
genus	B-T185
Conganteon	B-T204
by	O
the	O
distal	B-T082
part	O
of	O
the	O
stigmal vein	B-T023
,	O
which	O
is	O
as	O
long	B-T080
as,	O
or	O
shorter	B-T033
than	O
the	O
proximal	B-T082
part	O
of	O
the	O
stigmal vein	B-T023
(longer	O
than	O
the	O
proximal	B-T082
part	O
of	O
the	O
vein	B-T023
in	O
Conganteon	B-T204
).	O

The Daniel K. Inouye College of Pharmacy Scripts	B-T170
:	O
Poha Berry	B-T168
(	O
Physalis peruviana	B-T002
)	O
with	O
Potential	B-T080
Anti-inflammatory	B-T080
and	O
Cancer Prevention	B-T061
Activities	B-T052
The Daniel K. Inouye College of Pharmacy	B-T073
,	O
during	O
a	O
historic event	B-T051
in	O
Spring	B-T079
2016,	O
graduated	B-T098
the	O
first	O
two	O
students	B-T098
in	O
the	O
Pacific region	B-T083
to	O
earn	O
a	O
PhD	B-T170
in	O
pharmaceutical sciences	B-T091
at	O
the	O
University of Hawai'i	B-T073
at	O
Hilo	B-T083
.	O
The	O
college	B-T073
offers	O
PhD	B-T170
programs	B-T169
in	O
these	O
five	O
disciplines	B-T090
:	O
Cancer Biology	B-T091
,	O
Medicinal Chemistry	B-T091
,	O
Pharmaceutics	B-T062
,	O
Pharmacognosy	B-T091
,	O
and	O
Pharmacology	B-T091
.	O
One	O
of	O
the	O
Pharmacognosy	B-T091
dissertations	B-T073
focused	O
on	O
plant-derived	B-T002
natural products	B-T123
with	O
potential	B-T080
anti-inflammatory	B-T080
and	O
cancer	B-T191
chemopreventive	B-T080
activities	B-T052
.	O
Physalis peruviana	B-T002
(	O
Pp	B-T002
)	O
L.	O
originated	O
in	O
tropical	O
South America	B-T083
.	O
It	O
has	O
become	O
naturalized	B-T169
and	O
is	O
found	O
readily	O
on	O
the	O
Island of Hawai'i	B-T083
.	O
The	O
edible	B-T168
fruits	B-T168
are	O
commonly	O
known	O
as	O
cape gooseberry	B-T002
or	O
poha	B-T002
in	O
Hawai'i	B-T083
.	O
In	O
part	O
of	O
our	O
study,	O
three	O
new	O
withanolides	B-T109
,	O
physaperuvin G	B-T121
(1),	O
physaperuvins I-J	B-T121
(2-3),	O
along	O
with	O
four	O
known	O
withanolides	B-T109
,	O
namely,	O
4β-hydroxywithanolide E	B-T121
(4),	O
withaperuvin C	B-T121
(5),	O
and	O
physalactone	B-T121
(6),	O
coagulin	B-T121
(7)	O
were	O
isolated	B-T169
from	O
the	O
aerial parts	B-T002
of	O
P. peruviana	B-T002
.	O
In	O
addition,	O
two	O
known	O
compounds	B-T103
,	O
phyperunolide F	B-T121
(8),	O
and	O
withanolide S	B-T121
(9),	O
were	O
isolated	B-T169
and	O
identified	O
from	O
the	O
poha berry fruits	B-T168
.	O
The	O
structures	B-T082
and	O
absolute stereochemistry	B-T082
of	O
new	O
compounds	O
from	O
poha	B-T002
were	O
elucidated	O
by	O
several	O
spectroscopy methods	B-T169
:	O
Nuclear Magnetic Resonance (NMR) spectroscopy	B-T060
,	O
X-ray diffraction	B-T059
,	O
and	O
mass spectrometry	B-T059
analyses	B-T062
.	O
All	O
isolated	B-T169
poha	B-T002
compounds	B-T103
(	O
aerial parts	B-T002
and	O
fruits	B-T168
)	O
were	O
evaluated	O
for	O
their	O
anti-inflammatory activity	B-T080
with	O
lipopolysaccharide	B-T109
(	O
LPS	B-T109
)-activated	O
murine	B-T015
macrophage RAW 264.7 cells	B-T025
,	O
and	O
tumor necrosis factor alpha	B-T116
(	O
TNF-α	B-T116
)-activated	O
nuclear factor-kappa B	B-T116
(	O
NF-κB	B-T116
)	O
with	O
transfected	O
human embryonic kidney cells 293	B-T025
.	O
Most	O
of	O
the	O
isolated	B-T169
natural compounds	B-T123
showed	O
activity	B-T169
with	O
these	O
assays	B-T059
.	O
Additional	O
studies	O
were	O
performed	O
with	O
models	B-T170
of	O
colon cancer	B-T191
.	O
Specifically,	O
4β-hydroxywithanolide E	B-T121
(	O
4HWE	B-T121
)	O
inhibited	B-T080
the	O
growth	B-T040
of	O
colon cancer	B-T191
monolayer	B-T059
and	O
spheroid	B-T025
cultures	B-T059
.	O
The	O
compound	B-T103
induced	B-T169
cell cycle arrest	B-T043
at	O
low concentrations	B-T081
and	O
apoptosis	B-T043
at	O
higher concentrations	B-T081
.	O
These	O
data	B-T078
suggest	O
the	O
ingestion	B-T038
of	O
poha berries	B-T168
may	O
have	O
some	O
effect	O
on	O
the	O
prevalence	O
of	O
colon cancer	B-T191
.	O
Additionally,	O
poha	B-T168
isolates compounds	B-T103
were	O
evaluated	O
for	O
their	O
growth inhibitory effects	B-T039
with	O
U251MG glioblastoma	B-T191
and	O
MDA-MB-231 breast cancer cells	B-T050
that	O
harbor	O
aberrantly-active	O
signal transducer and activation of transcription 3 (STAT3)	B-T116
,	O
compared	O
to	O
normal	O
NIH-3T3 mouse fibroblasts	B-T025
.	O
This	O
work	O
has	O
led	O
to	O
the	O
filing	O
of	O
three	O
provisional patents	B-T170
with	O
the	O
University of Hawai'i Office of Technology Transfer and Economic Development	B-T073
.	O

Air Pollutant	B-T131
Exposure	B-T080
Within	O
a	O
Few	O
Days	O
of	O
Delivery	B-T061
and	O
Placental Abruption	B-T046
in	O
Japan	B-T083
Placental abruption	B-T046
is	O
an	O
emergency obstetric complication	B-T046
.	O
Although	O
the	O
etiology	B-T169
of	O
abruption	B-T046
is	O
not	O
fully	O
understood,	O
acute	B-T079
stimuli	B-T067
,	O
such	O
as	O
ischemia	B-T046
and/or	O
inflammation	B-T046
,	O
are	O
associated with	B-T080
rupture of the decidual artery	B-T047
,	O
resulting	O
in	O
placental separation	B-T042
.	O
Ischemia	B-T046
and	O
inflammation	B-T046
are	O
acute	B-T079
biologic	B-T080
effects	B-T080
of	O
air pollution	B-T069
.	O
Using	O
a	O
case-crossover design	B-T062
,	O
we	O
tested	O
the	O
hypothesis	B-T078
that	O
a	O
short-term	B-T079
increase	B-T169
in	O
exposure	B-T080
to	O
air pollutants	B-T131
is	O
a	O
potential	B-T080
trigger	B-T201
of	O
placental abruption	B-T046
.	O
We	O
received	O
data	B-T078
for	O
western Japan	B-T083
(	O
Kyushu-Okinawa Districts	B-T083
)	O
from	O
the	O
Japan Perinatal Registry Network database	B-T170
.	O
From	O
2005	O
to	O
2010,	O
821	O
singleton	B-T099
pregnant women	B-T098
with	O
placental abruption	B-T046
were	O
identified.	O
We	O
assigned	O
daily	B-T079
concentrations	B-T081
of	O
air pollutants	B-T131
,	O
including	O
nitrogen dioxide	B-T131
(	O
NO2	B-T131
),	O
suspended particulate matter	B-T131
,	O
ozone	B-T103
,	O
and	O
sulfur dioxide	B-T131
(	O
SO2	B-T131
),	O
from	O
the	O
nearest	O
monitoring station	B-T073
to	O
the	O
respective	O
delivery	B-T061
hospital	B-T073
of	O
each	O
woman	B-T098
.	O
Because	O
information	B-T078
on	O
the	O
onset day	B-T079
of	O
abruption	B-T046
was	O
not	O
obtained,	O
we	O
assumed	O
the	O
case	B-T169
day	O
to	O
be	O
1	O
day	B-T079
before	O
the	O
day	B-T079
of	O
delivery	B-T061
.	O
Exposure	B-T080
to	O
NO2	B-T131
at	O
2	O
days'	O
lag	O
was	O
associated with	B-T080
placental abruption	B-T046
(	O
temperature	B-T081
adjusted	O
odds ratio	B-T081
per	O
10	O
ppb	O
increase	B-T169
=	O
1.4;	O
95%	O
confidence interval	B-T081
=	O
1.1,	O
1.8).	O
The	O
association	B-T080
patterns	O
were	O
similar,	O
when	O
we	O
restricted	O
to	O
participants	B-T098
who	O
delivered	B-T061
by	O
emergency cesarean	B-T061
(1.4,	O
1.1,	O
1.9),	O
or	O
who	O
delivered	B-T061
after	O
35 weeks of gestation	B-T079
(1.4,	O
1.0,	O
2.0).	O
There	O
was	O
no association	B-T033
with	O
suspended particulate matter	B-T131
,	O
ozone	B-T103
,	O
or	O
SO2	B-T131
.	O
We	O
observed	O
an	O
association	B-T080
between	O
NO2	B-T131
exposure	B-T080
at	O
2	O
days	B-T079
before	O
the	O
day	B-T079
of	O
delivery	B-T061
and	O
placental abruption	B-T046
in	O
pregnant Japanese women	B-T098
.	O

The	O
2016	O
Infusion Therapy	B-T061
Standards	B-T081
of	O
Practice	B-T041
Approximately	O
every	O
5	O
years,	O
the	O
Infusion Nurses Society	B-T093
publishes	B-T057
evidence-based practice	B-T169
standards	B-T081
.	O
This	O
article	B-T170
provides	O
an	O
overview	O
of	O
the	O
process	B-T067
used	B-T169
in	O
standards	B-T081
development	B-T169
,	O
describes	O
the	O
format	B-T170
of	O
the	O
standards	B-T081
,	O
and	O
provides	B-T052
a	O
short	O
summary	B-T170
of	O
selected	B-T052
standards	B-T081
as	O
applied	B-T169
to	O
home care	B-T058
.	O
The	O
Standards	B-T081
are	O
an	O
important	B-T080
document	B-T170
that	O
should	O
be	O
available	B-T169
to	O
every	B-T080
home care	B-T058
organization	B-T093
that	O
provides	B-T052
home infusion therapy	B-T061
.	O

Datasets	B-T170
for	O
the	O
validation	B-T062
of	O
the	O
"	O
in vivo	B-T082
"	O
siRNA	B-T114
-	O
silencing	B-T045
of	O
CD40	B-T028
and	O
for	O
the	O
detection	B-T061
of	O
new	O
markers	B-T045
of	O
atherosclerosis	B-T047
progression	B-T046
in	O
ApoE	B-T028
-	O
deficient	B-T169
mice	B-T015
Data	B-T078
presented	O
in	O
this	O
Data	B-T078
in	O
Brief	O
article	O
correspond	O
to	O
the	O
article	O
"	O
in vivo	B-T082
"	O
silencing	B-T045
of	O
CD40	B-T028
reduces	O
progression	B-T046
of	O
experimental	B-T062
atherogenesis	B-T046
through	O
a	O
NFκB	B-T116
/	O
miR-125b	B-T114
axis	O
and	O
reveals	O
new	O
potential	B-T080
mediators	B-T116
in	O
the	O
pathogenesis	B-T046
of	O
atherosclerosis	B-T047
"	O
(	O
M. Hueso	B-T170
,	O
L. De Ramon	B-T170
,	O
E. Navarro	B-T170
,	O
E. Ripoll	B-T170
,	O
J.M. Cruzado	B-T170
,	O
J.M. Grinyo	B-T170
,	O
J. Torras	B-T170
,	O
2016)	O
[1].	O
Here,	O
we	O
describe	O
the	O
validation	B-T062
of	O
the	O
silencing	B-T045
of	O
CD40	B-T028
expression	B-T045
with	O
a	O
specific	O
siRNA	B-T114
in	O
ApoE(-/-)	B-T028
mouse	B-T015
aortas	B-T023
,	O
and	O
its	O
systemic	O
effects	O
on	O
splenic	B-T023
lymphocytic subpopulations	B-T185
as	O
well	O
as	O
on	O
the	O
infiltration	B-T046
of	O
aortic intima	B-T023
by	O
F4/80(+)	B-T025
,	O
galectin-3(+) macrophages	B-T025
or	O
by	O
NF-κB(+) cells	B-T025
.	O
We	O
also	O
show	O
the	O
output	O
of	O
a	O
Gene Ontology	B-T170
and	O
TLDA analysis	B-T062
which	O
allowed	O
the	O
detection	B-T061
of	O
potential	B-T080
mediators	B-T116
of	O
atherosclerosis	B-T047
progression	B-T046
.	O
We	O
provide	O
the	O
scientific	O
community	O
with	O
a	O
set	O
of	O
genes	B-T028
whose	O
expression	B-T045
is	O
increased	B-T081
during	O
atherosclerosis	B-T047
progression	B-T046
but	O
downregulated	B-T044
upon	O
CD40	B-T028
silencing	B-T045
.	O

Investigation	B-T170
on	O
evaluation	B-T058
criteria	B-T078
of	O
backwashing	B-T067
effects	B-T080
for	O
a	O
pilot-scale	B-T062
BAF	B-T073
treating	B-T169
petrochemical	B-T103
wastewater	B-T069
Parameters	B-T077
for	O
evaluation	B-T058
criteria	B-T078
of	O
air	B-T167
-	O
water	B-T121
backwashing	B-T067
effect	B-T080
s	O
of	O
a	O
pilot-scale	B-T062
biological aerated filter	B-T073
(	O
BAF	B-T073
)	O
treating	B-T169
petrochemical	B-T103
wastewater	B-T069
were	O
investigated	B-T169
.	O
The	O
parameters	B-T077
included	O
the	O
suspended	B-T169
solids	B-T167
(	O
SS	B-T167
)	O
and	O
specific oxygen uptake rate	B-T033
(	O
SOUR	B-T033
)	O
of	O
the	O
backwashing	B-T067
effluent	B-T170
,	O
recovery	B-T052
of	O
the	O
BAF	B-T073
after	O
backwashing	B-T067
,	O
and	O
the	O
removal	B-T052
of	O
the	O
biomass	B-T081
/	O
bioactivity	B-T080
attached	B-T067
on	O
the	O
filter	B-T073
media	B-T167
after	O
backwashing	B-T067
.	O
Results	B-T169
showed	O
that	O
the	O
weight	B-T081
of	O
the	O
total	B-T080
sludge	B-T069
produced	O
in	O
the	O
backwashing	B-T067
effluent	B-T170
increased	B-T081
with	O
the	O
increase	B-T169
in	O
water	B-T121
-	O
backwashing	B-T067
intensity	B-T080
,	O
while	O
the	O
total	B-T080
SOUR	B-T033
of	O
backwashing	B-T067
effluent	B-T170
rose	O
notably	B-T080
with	O
the	O
increase	B-T169
of	O
air	B-T167
-	O
backwashing	B-T067
intensity	B-T080
.	O
The	O
optimal	B-T080
backwashing	B-T067
intensity	B-T080
of	O
14	O
L/(m(2)·s)	O
for	O
air	B-T167
and	O
4	O
L/(m(2)·s)	O
for	O
water	B-T121
were	O
obtained	B-T169
.	O
When	O
the	O
BAF	B-T073
was	O
backwashed	B-T067
on	O
this	O
condition,	O
the	O
BAF	B-T073
recovered	B-T080
with	O
high	B-T080
average	B-T081
removal	B-T052
of	O
chemical oxygen demand	B-T038
(	O
COD	B-T038
)	O
and	O
ammonia nitrogen	B-T197
[Formula:	O
see	O
text]	O
of	O
14.3%	O
and	O
50.3%,	O
respectively.	O
High	B-T080
amount	B-T081
of	O
biomass	B-T081
removal	B-T052
at	O
15.8%	O
and	O
low	B-T080
level	B-T080
of	O
bioactivity	B-T080
removal	B-T052
at	O
8.8%	O
attached	B-T067
on	O
the	O
filter	B-T073
media	B-T167
were	O
also	O
found.	O
Concentrations	B-T081
of	O
the	O
benzene	B-T109
,	O
toluene	B-T109
,	O
ethylbenzene	B-T109
and	O
(o-, m-, p-) xylenes	B-T109
(	O
BTEX	B-T109
)	O
and	O
phenol	B-T109
in	O
the	O
backwashed	B-T067
sludge	B-T069
were	O
analyzed	B-T062
,	O
showing	O
that	O
the	O
backwashing	B-T067
was	O
essential	B-T080
to	O
remove	B-T052
some	O
aromatic compounds	B-T109
adsorbed	B-T059
in	O
the	O
microorganisms	B-T001
.	O

Implementation	B-T052
of	O
infrared	B-T059
and	O
Raman	B-T059
modalities	B-T078
for	O
glycosaminoglycan	B-T109
characterization	B-T185
in	O
complex	B-T080
systems	B-T169
Glycosaminoglycans	B-T109
(	O
GAGs	B-T109
)	O
are	O
natural	B-T169
,	O
linear	B-T082
and	O
negatively charged	B-T196
heteropolysaccharides	B-T109
which	O
are	O
incident	B-T067
in	O
every	O
mammalian	B-T015
tissue	B-T024
.	O
They	O
consist	O
of	O
repeating	O
disaccharide	B-T109
units	B-T081
,	O
which	O
are	O
composed	O
of	O
either	O
sulfated	B-T109
or	O
non-sulfated monosaccharides	B-T109
.	O
Depending	O
on	O
tissue	B-T024
types	B-T080
,	O
GAGs	B-T109
exhibit	O
structural	B-T082
heterogeneity	B-T080
such	O
as	O
the	O
position	B-T082
and	O
degree	B-T081
of	O
sulfation	B-T067
or	O
within	O
their	O
disaccharide	B-T109
units	B-T081
composition	B-T080
being	O
heparin	B-T109
,	O
heparan sulfate	B-T109
,	O
chondroitine sulfate	B-T109
,	O
dermatan sulfate	B-T109
,	O
keratan sulfate	B-T109
,	O
and	O
hyaluronic acid	B-T109
.	O
They	O
are	O
covalently linked	B-T044
to	O
a	O
core	B-T082
protein	B-T116
(	O
proteoglycans	B-T116
)	O
or	O
as	O
free	B-T080
chains	B-T078
(	O
hyaluronan	B-T109
).	O
GAGs	B-T109
affect	O
cell	B-T025
properties	B-T080
and	O
functions	B-T043
either	O
by	O
direct	B-T080
interaction	B-T169
with	O
cell receptors	B-T116
or	O
by	O
sequestration	B-T169
of	O
growth factors	B-T116
.	O
These	O
evidences of	B-T169
divert	B-T080
biological	B-T080
roles	B-T077
of	O
GAGs	B-T109
make	O
their	O
characterization	B-T185
at	O
cell	B-T025
and	O
tissue	B-T024
levels	B-T080
of	O
importance.	O
Thus,	O
non-invasive	B-T169
techniques	B-T169
are	O
interesting	O
to	O
investigate	B-T169
,	O
to	O
qualitatively	B-T080
and	O
quantitatively	B-T081
characterize	O
GAGs	B-T109
in vitro	B-T080
in	O
order	O
to	O
use	O
them	O
as	O
diagnostic	B-T169
biomarkers	B-T201
and/or	O
as	O
therapeutic	B-T169
targets	B-T074
in	O
several	O
human	B-T016
diseases	B-T047
including	O
cancer	B-T191
.	O
Infrared	B-T059
and	O
Raman microspectroscopies	B-T059
and	O
imaging	B-T060
are	O
sensitive	B-T169
enough	O
to	O
differentiate	O
and	O
classify	B-T185
GAG	B-T109
types	B-T080
and	O
subtypes	B-T185
in	O
spite	O
of	O
their	O
close	O
molecular structures	B-T082
.	O
Spectroscopic	B-T059
markers	B-T080
characteristic	O
of	O
reference	O
GAG	B-T109
molecules	B-T167
were	O
identified	B-T080
.	O
Beyond	O
these	O
investigations	B-T058
of	O
the	O
standard	O
GAG	B-T109
spectral	O
signature,	O
infrared	B-T059
and	O
Raman	B-T059
spectral	O
signatures	O
of	O
GAG	B-T109
were	O
searched	O
in	O
complex	B-T080
biological	B-T080
systems	B-T169
like	O
cells	B-T025
.	O
The	O
aim	O
of	O
the	O
present	O
review	O
is	O
to	O
describe	O
the	O
implementation	B-T052
of	O
these	O
complementary	O
vibrational spectroscopy techniques	B-T059
,	O
and	O
to	O
discuss	O
their	O
potentials,	O
advantages	O
and	O
disadvantages	O
for	O
GAG	B-T109
analysis	B-T059
.	O
In	O
addition,	O
this	O
review	O
presents	O
new	O
data	O
as	O
we	O
show	O
for	O
the	O
first	O
time	O
GAG	B-T109
infrared	B-T059
and	O
Raman	B-T059
spectral	O
signatures	O
from	O
conditioned media	B-T130
and	O
live cells	B-T025
,	O
respectively.	O

Targeting	B-T169
HIF2	B-T116
in	O
Clear Cell Renal Cell Carcinoma	B-T191
Inactivation	O
of	O
the	O
von Hippel-Lindau tumor-suppressor protein	B-T116
(	O
pVHL	B-T116
)	O
is	O
the	O
signature "truncal" event	B-T033
in	O
clear cell renal cell carcinoma	B-T191
,	O
which	O
is	O
the	O
most	O
common	O
form	O
of	O
kidney cancer	B-T191
.	O
pVHL	B-T116
is	O
part	O
of	O
a	O
ubiquitin ligase	B-T116
the	O
targets	B-T169
the	O
α subunit	B-T116
of	O
the	O
hypoxia-inducible factor (HIF) transcription factor	B-T116
for	O
destruction	B-T052
when	O
oxygen	O
is	O
available.	O
Preclinical	B-T080
studies	B-T062
strongly	O
suggest	O
that	O
deregulation	B-T049
of	O
HIF	B-T116
,	O
and	O
particularly	O
HIF2	B-T116
,	O
drives	O
pVHL	B-T116
-defective	O
renal carcinogenesis	B-T191
.	O
Although	O
HIF2α	B-T116
was	O
classically	O
considered	O
undruggable	B-T080
,	O
structural	O
and	O
chemical	O
work	O
by	O
Rick Bruick	B-T170
and	O
Kevin Gardner	B-T170
at	O
University of Texas Southwestern	B-T073
laid	O
the	O
foundation	O
for	O
the	O
development	O
of	O
small molecule	B-T109
direct	O
HIF2α antagonists	B-T120
(	O
PT2385	B-T109
and	O
the	O
related	O
tool	O
compound	O
PT2399	B-T120
)	O
by	O
Peloton Therapeutics	B-T093
that	O
block	B-T169
the	O
dimerization	B-T044
of	O
HIF2α	B-T116
with	O
its	O
partner	O
protein ARNT1	B-T116
.	O
These	O
compounds	O
inhibit clear cell renal cell carcinoma growth	B-T043
in	O
preclinical models	B-T170
,	O
and	O
PT2385	B-T109
has	O
now	O
entered	O
the	O
clinic	B-T073
.	O
Nonetheless,	O
the	O
availability	O
of	O
such compounds	B-T121
,	O
together	O
with	O
clustered regularly interspaced short palindromic repeat	B-T114
(	O
CRISPR	B-T114
)-based	O
gene editing approaches	B-T063
,	O
has	O
revealed	O
a	O
previously	O
unappreciated heterogeneity	B-T080
among	O
clear cell renal carcinomas	B-T191
and	O
patient	B-T101
-derived	O
xenografts	B-T061
with	O
respect	O
to	O
HIF2	B-T116
dependence,	O
suggesting	O
that	O
predictive biomarkers	B-T123
will	O
be	O
needed	O
to	O
optimize	B-T052
the	O
use	O
of	O
such agents	B-T121
in	O
the	O
clinic	B-T073
.	O

Prevalence	B-T081
of	O
high-risk	B-T033
human papillomavirus infection	B-T047
among	O
women	B-T032
in	O
Shaanxi	B-T083
province	B-T083
of	O
China	B-T083
:	O
A	O
hospital	B-T073
-based	O
investigation	B-T058
This	O
study	O
aimed	O
to	O
investigate	B-T169
the	O
characteristics	B-T080
of	O
female	B-T032
high-risk human papillomavirus (HR-HPV) infection	B-T047
in	O
Shaanxi	B-T083
province	B-T083
of	O
China	B-T083
.	O
A	O
total	O
of	O
14	O
111	O
women	B-T032
were	O
enrolled	O
for	O
HPV	B-T005
genotyping test	B-T059
,	O
and	O
a	O
cytology	B-T059
,	O
and/or	O
cervix biopsy	B-T060
were	O
performed	O
in	O
partial	O
women	B-T032
.	O
Of	O
these	O
women	B-T032
,	O
the	O
HPV infection	B-T047
rate	B-T081
was	O
30.21%,	O
and	O
26.73%	O
were	O
caused	O
by	O
HR-HPV	B-T005
.	O
The	O
most	O
common	O
HR-HPV	B-T005
genotypes	B-T032
were	O
HPV-16	B-T005
,	O
HPV-58	B-T005
,	O
HPV-52	B-T005
,	O
HPV-18	B-T005
,	O
and	O
HPV-31	B-T005
.	O
The	O
prevalence	B-T081
of	O
HR-HPV	B-T005
among	O
women	B-T032
older	O
than	O
50	O
years	O
was	O
significantly	O
higher	O
than	O
the	O
other	O
groups	O
(P	O
<	O
0.05).	O
The	O
main	O
carcinogenic	B-T131
genotypes	B-T032
were	O
HPV-16	B-T005
,	O
HPV-18	B-T005
,	O
HPV-58	B-T005
,	O
HPV-52	B-T005
,	O
and	O
HPV-31	B-T005
.	O
HPV-16	B-T005
and	O
HPV-18	B-T005
combined	O
caused	O
80.79%	O
of	O
cervical cancer	B-T191
cases.	O
The	O
infection	B-T046
with	O
multiple	O
HR-HPVs	B-T005
was	O
not	B-T033
a	O
risk factor	B-T033
for	O
cervical lesions	B-T046
.	O
In	O
conclusion,	O
HPV infection	B-T047
was	O
common	O
among	O
women	B-T032
in	O
Shaanxi	B-T083
province	B-T083
.	O
Women	B-T032
older	O
than	O
50	O
years	O
were	O
a	O
high-risk group	B-T098
for	O
HR-HPV infection	B-T047
and	O
cervical cancer	B-T191
.	O
HPV-16	B-T005
and	O
HPV-18	B-T005
were	O
the	O
main	O
carcinogenic	B-T131
genotypes	B-T032
in	O
this	O
region	B-T083
.	O

Novel	B-T080
and	O
Lost	B-T169
Forests	B-T070
in	O
the	O
Upper Midwestern United States	B-T083
,	O
from	O
New	B-T080
Estimates	B-T081
of	O
Settlement-Era	B-T079
Composition,	O
Stem	B-T002
Density	B-T081
,	O
and	O
Biomass	B-T081
EuroAmerican	B-T098
land-use	B-UnknownType
and	O
its	O
legacies	B-T081
have	O
transformed	B-T081
forest structure	B-T070
and	O
composition	O
across	O
the	O
United States	B-T083
(	O
US	B-T083
).	O
More	B-T081
accurate	B-T080
reconstructions	B-T052
of	O
historical states	B-T083
are	O
critical	B-T080
to	O
understanding	O
the	O
processes	B-T067
governing	B-T080
past	B-T079
,	O
current	B-T079
,	O
and	O
future	B-T079
forest	B-T070
dynamics	B-T070
.	O
Here	O
we	O
present	O
new	O
gridded	O
(8x8km)	O
reconstructions	B-T052
of	O
pre-settlement	B-T079
(1800s)	O
forest	B-T070
composition	O
and	O
structure	O
from	O
the	O
upper Midwestern US	B-T083
(	O
Minnesota	B-T083
,	O
Wisconsin	B-T083
,	O
and	O
most	O
of	O
Michigan	B-T083
),	O
using	O
19th	O
Century Public Land Survey System	B-T170
(	O
PLSS	B-T170
),	O
with	O
estimates	B-T081
of	O
relative	B-T080
composition,	O
above-ground	B-T082
biomass	B-T081
,	O
stem	B-T002
density	B-T081
,	O
and	O
basal area	B-T082
for	O
28	O
tree	B-T002
types	B-T080
.	O
This	O
mapping	B-T052
is	O
more	O
robust	B-T080
than	O
past	B-T079
efforts	B-T051
,	O
using	O
spatially	O
varying	O
correction factors	B-T081
to	O
accommodate	O
sampling design	B-T170
,	O
azimuthal censoring	B-T080
,	O
and	O
biases	B-T078
in	O
tree	B-T002
selection	B-T052
.	O
We	O
compare	O
pre-settlement	B-T079
to	O
modern	B-T079
forests	B-T070
using	O
US	B-T083
Forest	B-T070
Service	B-T057
Forest Inventory and Analysis (FIA) data	B-T170
to	O
show	O
the	O
prevalence	B-T081
of	O
lost	B-T169
forests	B-T070
(	O
pre-settlement	B-T079
forests	B-T070
with	O
no	B-T169
current	B-T079
analog	B-T080
),	O
and	O
novel	B-T080
forests	B-T070
(	O
modern	B-T079
forests	B-T070
with	O
no	B-T169
past	B-T079
analogs	B-T080
).	O
Differences	O
between	O
pre-settlement	B-T079
and	O
modern	B-T079
forests	B-T070
are	O
spatially	O
structured	O
owing	O
to	O
differences	O
in	O
land-use	B-UnknownType
impacts	B-T080
and	O
accompanying	O
ecological responses	B-T055
.	O
Modern	B-T079
forests	B-T070
are	O
more	O
homogeneous	B-T080
,	O
and	O
ecotonal	B-T081
gradients	B-T081
are	O
more	O
diffuse	B-T082
today	O
than	O
in the past	B-T079
.	O
Novel	B-T080
forest	B-T070
assemblages	B-T169
represent	O
28%	O
of	O
all	O
FIA	B-T170
cells,	O
and	O
28%	O
of	O
pre-settlement	B-T079
forests	B-T070
no longer	B-T033
exist	B-T077
in	O
a	O
modern	B-T079
context	B-T078
.	O
Lost	B-T169
forests	B-T070
include	O
tamarack	B-T002
forests	B-T070
in	O
northeastern	B-T082
Minnesota	B-T083
,	O
hemlock	B-T002
and	O
cedar	B-T002
dominated	O
forests	B-T070
in	O
north-central Wisconsin	B-T083
and	O
along	O
the	O
Upper Peninsula of Michigan	B-T083
,	O
and	O
elm	B-T002
,	O
oak	B-T002
,	O
basswood	B-T002
and	O
ironwood	B-T002
forests	B-T070
along	O
the	O
forest	B-T070
-	O
prairie boundary	B-T082
in	O
south central Minnesota	B-T083
and	O
eastern	B-T082
Wisconsin	B-T083
.	O
Novel	B-T080
FIA	B-T170
forest	B-T070
assemblages	B-T169
are	O
distributed	O
evenly	O
across	O
the	O
region	B-T083
,	O
but	O
novelty	B-T080
shows	O
a	O
strong	B-T080
relationship	B-T080
to	O
spatial distance	B-T081
from	O
remnant	B-T080
forests	B-T070
in	O
the	O
upper Midwest	B-T083
,	O
with	O
novelty	B-T080
predicted	B-T078
at	O
between	O
20	O
to	O
60km	O
from	O
remnants	B-T080
,	O
depending	O
on	O
historical	B-T079
forest type	B-T070
.	O
The	O
spatial	B-T082
relationships	B-T080
between	O
remnant	B-T080
and	O
novel	B-T080
forests	B-T070
,	O
shifts	B-T169
in	O
ecotone structure	B-T082
and	O
the	O
loss	B-T081
of	O
historic	B-T079
forest types	B-T070
point	O
to	O
significant	B-T078
challenges	O
for	O
land	B-T073
managers	B-T097
if	O
landscape	B-T082
restoration	O
is	O
a	O
priority	B-T079
.	O
The	O
spatial	O
signals	O
of	O
novelty	B-T080
and	O
ecological	B-T070
change	B-T169
also	O
point	O
to	O
potential	B-T080
challenges	O
in	O
using	O
modern	B-T079
spatial distributions	B-T082
of	O
species	B-T002
and	O
communities	B-T070
and	O
their	O
relationship	B-T080
to	O
underlying	O
geophysical	B-T070
and	O
climatic attributes	B-T070
in	O
understanding	O
potential	B-T080
responses	O
to	O
changing	B-T169
climate	B-T070
.	O
The	O
signal	B-T067
of	O
human	B-T016
settlement	B-T052
on	O
modern	B-T079
forests	B-T070
is	O
broad	B-T082
,	O
spatially	O
varying	O
and	O
acts	O
to	O
homogenize	B-T080
modern	B-T079
forests	B-T070
relative	B-T080
to	O
their	O
historic	B-T079
counterparts,	O
with	O
significant	B-T078
implications	O
for	O
future	B-T079
management	B-T057
.	O

Prevalence	B-T081
of	O
Self-Reported	B-T062
Prescription Drug	B-T121
Use	B-T169
in	O
a	O
National	B-T082
Sample	B-T167
of	O
U.S	B-T083
.	O
Drivers	B-T098
Drug	B-T121
-involved	O
driving	B-T056
has	O
become	O
an	O
increasing	B-T169
concern	B-T078
.	O
Although	O
the	O
focus	O
has	O
been	O
on	O
illegal drugs	B-T131
,	O
there	O
is	O
evidence	B-T078
that	O
prescribed medications	B-T121
can	O
impair driving ability	B-T033
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	B-T059
the	O
self-reported	B-T062
prevalence	B-T081
of	O
prescription drug	B-T121
use	B-T169
,	O
including	O
medical	B-T169
and	O
nonmedical	B-T033
use	B-T169
,	O
among	O
a	O
nationally	B-T082
representative	B-T052
sample	B-T167
of	O
drivers	B-T098
and	O
to	O
report	O
related	O
driver	B-T098
characteristics	B-T080
.	O
As	O
part	O
of	O
the	O
2013-2014	O
National Roadside Survey	B-T062
,	O
drivers	B-T098
from	O
60	O
sites	O
were	O
randomly	B-T080
recruited	O
and	O
asked	O
to	O
complete	B-T080
a	O
survey	B-T062
on	O
prescription drug	B-T121
use	B-T169
.	O
Almost	O
20%	O
of	O
drivers	B-T098
reported	O
using	O
a	O
prescription drug	B-T121
within	O
the	O
past	B-T079
2	O
days	B-T079
,	O
with	O
the	O
most	O
common drug class	B-T121
being	O
sedatives	B-T121
(8.0%),	O
followed	O
by	O
antidepressants	B-T121
(7.7%),	O
narcotics	B-T121
(7.5%),	O
and	O
stimulants	B-T121
(3.9%).	O
Drivers	B-T098
who	O
reported	O
prescription drug	B-T121
use	B-T169
were	O
significantly	O
more	O
likely	O
to	O
be	O
female	B-T032
,	O
older	B-T098
,	O
non-Hispanic White	B-T098
,	O
and	O
report	O
disability	B-T033
.	O
Three	O
of	O
four	O
drivers	B-T098
who	O
reported	O
medication	B-T121
use	B-T169
(78.2%)	O
said	O
the	O
drug	B-T121
was	O
prescribed	B-T058
for	O
their	O
use	B-T169
;	O
the	O
odds	O
of	O
using	O
without	O
a	O
prescription	B-T170
were	O
significantly higher	B-T081
for	O
males	B-T032
,	O
Black/African American	B-T098
,	O
and	O
Hispanic	B-T098
drivers	B-T098
,	O
and	O
lower	O
for	O
older	B-T098
drivers	B-T098
.	O
Among	O
those	O
with	O
a	O
prescription	B-T170
,	O
taking	O
more	O
than	O
prescribed	B-T058
was	O
most	O
common	O
for	O
narcotics	B-T121
(6.8%),	O
followed	O
by	O
sedatives	B-T121
(4.8%),	O
stimulants	B-T121
(3.8%),	O
and	O
antidepressants	B-T121
(1.5%).	O
These	O
findings	B-T169
help	O
to	O
identify	O
drivers	B-T098
using	O
potentially impairing	B-T169
prescription drugs	B-T121
,	O
both	O
medically	B-T169
and	O
nonmedically	B-T033
,	O
and	O
may	O
inform	O
the	O
targeting	B-T169
of	O
interventions	B-T058
to	O
reduce	O
impaired driving	B-T033
related	O
to	O
medications	B-T170
.	O

Repetitive	B-T079
and	O
Prolonged	B-T079
Omega-3 Fatty Acid	B-T109
Treatment	B-T061
After	B-T079
Traumatic Brain Injury	B-T037
Enhances	B-T052
Long-Term	B-T079
Tissue	B-T024
Restoration	B-T061
and	O
Cognitive Recovery	B-T061
Traumatic brain injury	B-T037
(	O
TBI	B-T037
)	O
is	O
one	O
of	O
the	O
most	O
disabling clinical conditions	B-T033
that	O
could	O
lead	B-T169
to	O
neurocognitive disorders	B-T048
in	O
survivors	B-T101
.	O
Our	O
group	B-T098
and	O
others	B-T098
previously	O
reported	B-T170
that	O
prophylactic enrichment	B-T061
of	O
dietary	B-T169
omega-3 polyunsaturated fatty acids	B-T109
(	O
n-3 PUFAs	B-T109
)	O
markedly	O
ameliorate	B-T169
cognitive deficits	B-T048
after	B-T079
TBI	B-T037
.	O
However,	O
it	O
remains	O
unclear	B-T033
whether	O
a	O
clinically	B-T080
relevant	B-T080
therapeutic regimen	B-T061
with	O
n-3 PUFAs	B-T109
administered	B-T169
after	B-T079
TBI	B-T037
would	O
still	O
offer	O
significant	O
improvement	B-T077
of	O
long-term	B-T079
cognitive recovery	B-T061
.	O
In	O
the	O
present	O
study	B-T062
,	O
we	O
employed	O
the	O
decline	B-T080
of	O
spatial	O
cognitive function	B-T048
as	O
a	O
main	B-T080
outcome	B-T169
after	B-T079
TBI	B-T037
to	O
investigate	B-T169
the	O
therapeutic efficacy	B-T080
of	O
post	B-T079
-	O
TBI	B-T037
n-3 PUFA	B-T109
treatment	B-T061
and	O
the	O
underlying	O
mechanisms	B-T169
.	O
Mice	B-T015
were	O
subjected	O
to	O
sham operation	B-T061
or	O
controlled	B-T169
cortical	B-T023
impact	B-T080
,	O
followed	O
by	O
random assignment	B-UnknownType
to	O
receive	B-T080
the	O
following	O
four	B-T081
treatments	B-T061
:	O
(1)	O
vehicle	B-T122
control	B-T169
;	O
(2)	O
daily	B-T079
intraperitoneal injections	B-T061
of	O
n-3 PUFAs	B-T109
for	O
2	O
weeks	B-T079
,	O
beginning	B-T079
2	O
h	B-T079
after	B-T079
TBI	B-T037
;	O
(3)	O
fish oil dietary	B-T168
supplementation	B-T061
throughout	O
the	O
study	B-T062
,	O
beginning	B-T079
1	O
day	B-T079
after	B-T079
TBI	B-T037
;	O
or	O
(4)	O
combination	B-T080
of	O
treatments	B-T061
(2)	O
and	O
(3).	O
Spatial	O
cognitive	O
deficits	O
and	O
chronic	B-T079
brain tissue	B-T023
loss	B-T081
,	O
as	O
well	O
as	O
endogenous	B-T169
brain repair processes	B-T061
such	O
as	O
neurogenesis	B-T040
,	O
angiogenesis	B-T042
,	O
and	O
oligodendrogenesis	B-T038
,	O
were	O
evaluated	O
up	O
to	O
35	O
days	B-T079
after	B-T079
TBI	B-T037
.	O
The	O
results	B-T169
revealed	B-T080
prominent	O
spatial	O
cognitive deficits	B-T048
and	O
massive	B-T080
tissue	B-T023
loss	B-T081
caused	O
by	O
TBI	B-T037
.	O
Among	O
all	O
mice	B-T015
receiving	B-T080
post-TBI	B-T037
n-3 PUFA	B-T109
treatments	B-T061
,	O
the	O
combined	B-T080
treatment	B-T061
of	O
fish oil dietary	B-T168
supplement	B-T168
and	O
n-3 PUFA	B-T109
injections	B-T122
demonstrated	B-T052
a	O
reproducible beneficial effect	B-UnknownType
in	O
attenuating	O
cognitive deficits	B-T048
although	O
without	O
reducing	B-T080
gross	B-T080
tissue	B-T023
loss	B-T081
.	O
Mechanistically,	O
the	O
combined	O
treatment	B-T061
promoted	B-T052
post-TBI	B-T037
restorative processes	B-T061
in	O
the	O
brain	B-T023
,	O
including	B-T169
generation	O
of	O
immature neurons	B-T025
,	O
microvessels	B-T023
,	O
and	O
oligodendrocytes	B-T025
,	O
each	O
of	O
which	O
was	O
significantly	O
correlated	B-T080
with	O
the	O
improved	B-T033
cognitive recovery	B-T169
.	O
These	O
results	B-T169
indicated	B-T033
that	O
repetitive	B-T079
and	O
prolonged	B-T079
n-3 PUFA	B-T109
treatments	B-T061
after	B-T079
TBI	B-T037
are	O
capable	O
of	O
enhancing	B-T052
brain	B-T023
remodeling	B-UnknownType
and	O
could	O
be	O
developed	O
as	O
a	O
potential	B-T080
therapy	B-T061
to	O
treat	O
TBI	B-T037
victims	B-T098
in	O
the	O
clinic	B-T073
.	O

Influence	B-T077
of	O
yeast	B-T004
and	O
lactic acid bacterium	B-T007
on	O
the	O
constituent	B-T167
profile	B-T059
of	O
soy sauce	B-T168
during	B-T079
fermentation	B-T044
Soy sauce	B-T168
is	O
a	O
Japanese	B-T083
traditional	B-T169
seasoning	B-T168
composed	B-T081
of	O
various	B-T081
constituents	B-T167
that	O
are	O
produced	B-T057
by	O
various	O
microbes	B-T001
during	B-T079
a	O
long-term	B-T079
fermentation process	B-T044
.	O
Due to	B-T169
the	O
complexity	B-T169
of	O
the	O
process	B-T067
,	O
the	O
investigation	B-T062
of	O
the	O
constituent	B-T167
profile	B-T059
during	B-T079
fermentation	B-T044
is	O
difficult	B-T033
.	O
Metabolomics	B-T091
,	O
the	O
comprehensive	B-T080
study	B-T062
of	O
low	B-T080
molecular weight	B-T081
compounds	B-T080
in	O
biological	B-T080
samples	B-T167
,	O
is	O
thought	O
to	O
be	O
a	O
promising	O
strategy	O
for	O
deep	O
understanding	B-T041
of	O
the	O
constituent	B-T167
contribution	B-T052
to	O
food flavor	B-T080
characteristics	B-T080
.	O
Therefore,	O
metabolomics	B-T091
is	O
suitable	B-T080
for	O
the	O
analysis	B-T062
of	O
soy sauce	B-T168
fermentation	B-T044
.	O
Unfortunately,	O
only	O
few	O
and	O
unrefined	O
studies	B-T062
of	O
soy sauce	B-T168
fermentation	B-T044
using	B-T169
metabolomics	B-T091
approach	B-T082
have	O
been	O
reported	B-T170
.	O
Therefore,	O
we	O
investigated	B-T169
changes	B-T169
in	O
low	B-T080
molecular weight	B-T081
hydrophilic	B-T081
and	O
volatile compounds	B-T120
of	O
soy sauce	B-T168
using	O
gas chromatography/mass spectrometry	B-T059
(	O
GC/MS	B-T059
)-	O
based	B-T169
non-targeted	B-T169
metabolic profiling	B-T091
.	O
The	O
data	B-T078
were	O
analyzed	B-T062
by	O
statistical analysis	B-T062
to	O
evaluate	O
influences	B-T077
of	O
yeast	B-T004
and	O
lactic acid bacterium	B-T007
on	O
the	O
constituent	B-T167
profile	B-T059
.	O
Consequently,	O
our	O
results	B-T169
suggested	B-T078
a	O
novel	B-T080
finding	B-T033
that	O
lactic acid bacterium	B-T007
affected	B-T169
the	O
production	B-T057
of	O
several	B-T081
constituents	B-T167
such	O
as	O
cyclotene	B-T109
,	O
furfural	B-T109
,	O
furfuryl alcohol	B-T109
and	O
methional	B-T109
in	O
the	O
soy sauce	B-T168
fermentation process	B-T044
.	O

Low	B-T080
intensity	B-T080
sprint training	B-T061
with	O
blood flow restriction	B-T065
improves	O
100	O
m	O
dash	O
We	O
investigated	B-T169
the	O
effects of	B-T080
practical blood flow restriction	B-T065
(	O
pBFR	B-T065
)	O
of	O
leg muscles	B-T023
during	O
sprint training	B-T061
on	O
the	O
100	O
m	O
dash	O
time	B-T079
in	O
well-trained sport students	B-T098
.	O
Participants	B-T098
performed	O
6x100	O
m	O
sprints	B-T056
at	O
60-70%	O
of	O
their	O
maximal	O
100	O
m	O
sprinting speed	B-T081
twice a week	B-T079
for	O
6	O
weeks	B-T079
,	O
either	O
with	O
(	O
IG	B-T098
;	O
n=12)	O
or	O
without	O
pBFR	B-T065
(	O
CG	B-T096
;	O
n=12).	O
The	O
100	O
m	O
dash	O
time	B-T079
significantly	O
decreased	B-T081
more	O
in	O
the	O
IG	B-T098
(-0.38±0.24	O
s)	O
than	O
in	O
the	O
CG	B-T096
(-0.16±0.17	O
s).	O
The	O
muscle	B-T024
thickness	B-T080
of	O
the	O
rectus femoris	B-T023
increased	B-T081
only	O
in	O
the	O
IG	B-T098
,	O
while	O
no	O
group	B-T078
by	O
time	B-T079
interactions	B-T169
were	O
found	O
for	O
the	O
muscle	B-T024
thickness	B-T080
of	O
the	O
biceps femoris	B-T023
and	O
the	O
biceps brachii	B-T023
.	O
The	O
maximal isometric force	B-T081
,	O
measured	O
using	O
a	O
leg press	B-T056
,	O
did	O
not change	B-T033
in	O
either	O
group	B-T078
.	O
However,	O
the	O
rate of force development	B-T081
improved	O
in	O
the	O
IG	B-T098
.	O
Growth hormone	B-T116
,	O
testosterone	B-T109
,	O
insulin-like growth factor 1	B-T116
,	O
and	O
cortisol	B-T109
concentrations	B-T081
did	O
not significantly differ	B-T033
between	O
both	O
groups	B-T078
at	O
any	O
measurement	B-T169
time point	B-T079
(pre,	O
1	O
min,	O
20	O
min,	O
120	O
min,	O
and	O
24	O
h	O
after	O
the	O
six	O
all-out	O
sprints	B-T056
of	O
the	O
first	O
training	B-T065
session	B-T051
).	O
The	O
muscle damage	B-T020
marker	B-T201
h-FABP	B-T116
increased	B-T081
significantly	O
more	O
in	O
the	O
CG	B-T096
than	O
in	O
the	O
IG	B-T098
.	O
The	O
pBFR	B-T065
improved	O
the	O
100	O
m	O
dash	O
time	B-T079
significantly	O
more	O
than	O
low	B-T080
-	O
intensity	B-T080
sprint interval training	B-T061
alone.	O
Other	O
noted	O
benefits	B-T081
of	O
training	B-T065
with	O
pBFR	B-T065
were	O
a	O
decreased	B-T081
level	B-T080
of	O
muscle damage	B-T020
,	O
a	O
greater	O
increase	B-T169
of	O
the	O
rectus femoris muscle	B-T023
thickness	B-T080
,	O
and	O
a	O
higher	B-T080
rate of force development	B-T081
.	O
However,	O
the	O
tested	B-T169
hormones	B-T125
were	O
unable	O
to	O
explain	O
the	O
additional	O
beneficial effects	B-T080
.	O

Sedation	B-T061
of	O
Patients	B-T101
With	O
Disorders of Consciousness	B-T048
During	O
Neuroimaging	B-T060
:	O
Effects	O
on	O
Resting State Functional Brain Connectivity	B-T060
To	O
reduce	O
head movement	B-T040
during	O
resting state functional magnetic resonance imaging	B-T060
,	O
post-coma	B-UnknownType
patients	B-T101
with	O
disorders of consciousness	B-T048
(	O
DOC	B-T048
)	O
are	O
frequently	O
sedated	B-T061
with	O
propofol	B-T109
.	O
However,	O
little	O
is	O
known	O
about	O
the	O
effects	O
of	O
this	O
sedation	B-T061
on	O
the	O
brain connectivity patterns	B-T082
in	O
the	O
damaged brain	B-T037
essential	O
for	O
differential diagnosis	B-T060
.	O
In	O
this	O
study	B-T062
,	O
we	O
aimed	O
to	O
assess	B-T058
these	O
effects.	O
Using	O
resting state functional magnetic resonance imaging	B-T060
3T	O
data	O
obtained	O
over	O
several	O
years	O
of	O
scanning	B-T060
patients	B-T101
for	O
diagnostic	B-T169
and	O
research	B-T062
purposes	B-T169
,	O
we	O
employed	O
a	O
seed-based	O
approach	O
to	O
examine	O
resting state connectivity	B-T169
in	O
higher-order	O
(default	O
mode,	O
bilateral	B-T082
external control	B-UnknownType
,	O
and	O
salience)	O
and	O
lower-order	O
(	O
auditory	B-T169
,	O
sensorimotor	B-T040
,	O
and	O
visual	B-T169
)	O
resting state networks	B-T169
and	O
connectivity	B-T169
with	O
the	O
thalamus	B-T023
,	O
in	O
20	O
healthy	B-T080
unsedated	B-T033
controls	B-T096
,	O
8	O
unsedated	B-T033
patients	B-T101
with	O
DOC	B-T048
,	O
and	O
8	O
patients	B-T101
with	O
DOC	B-T048
sedated	B-T061
with	O
propofol	B-T109
.	O
The	O
DOC	B-T048
groups	O
were	O
matched	O
for	O
age at onset	B-T081
,	O
etiology	B-T169
,	O
time spent	B-T033
in	O
DOC	B-T048
,	O
diagnosis	B-T033
,	O
standardized behavioral assessment scores	B-T081
,	O
movement	B-T040
intensities	B-T080
,	O
and	O
pattern	O
of	O
structural brain injury	B-T037
(as	O
assessed	O
with	O
T1-based voxel-based morphometry	B-T059
).	O
DOC	B-T048
were	O
associated with	B-T080
severely	O
impaired	O
resting state network connectivity	B-T169
in	O
all	O
but	O
the	O
visual	B-T169
network	B-T169
.	O
Thalamic	B-T023
connectivity	B-T169
to	O
higher-order	O
network	O
regions	O
was	O
also	O
reduced	B-T080
.	O
Propofol	B-T109
administration	B-T061
to	O
patients	B-T101
was	O
associated with	B-T080
minor	O
further	O
decreases	B-T081
in	O
thalamic	B-T023
and	O
insular	B-T023
connectivity	B-T169
.	O
Our	O
findings	B-T169
indicate	O
that	O
connectivity	B-T169
decreases	B-T081
associated with	B-T080
propofol	B-T109
sedation	B-T061
,	O
involving	O
the	O
thalamus	B-T023
and	O
insula	B-T023
,	O
are	O
relatively	O
small	O
compared	O
with	O
those	O
already	O
caused	O
by	O
DOC	B-T048
-associated	O
structural brain injury	B-T037
.	O
Nonetheless,	O
given	O
the	O
known	O
importance	O
of	O
the	O
thalamus	B-T023
in	O
brain arousal	B-T041
,	O
its	O
disruption	B-T169
could	O
well	O
reflect	O
the	O
diminished	B-T081
movement	B-T040
obtained	O
in	O
these	O
patients	B-T101
.	O
However,	O
more	O
research	B-T062
is	O
needed	O
on	O
this	O
topic	O
to	O
fully	O
address	O
the	O
research question	B-T078
.	O

Potassium depletion	B-T047
stimulates	B-T070
Na-Cl cotransporter	B-T116
via	O
phosphorylation	B-T044
and	O
inactivation	B-T169
of	O
the	O
ubiquitin ligase	B-T116
Kelch-like 3	B-T116
Kelch-like 3	B-T116
(	O
KLHL3	B-T116
)	O
is	O
a	O
component	B-T116
of	O
an	O
E3 ubiquitin ligase complex	B-T116
that	O
regulates	B-T038
blood pressure	B-T040
by	O
targeting	B-T169
With-No-Lysine (WNK) kinases	B-T116
for	O
degradation	B-T169
.	O
Mutations	B-T045
in	O
KLHL3	B-T116
cause	O
constitutively	O
increased renal salt reabsorption	B-T033
and	O
impaired	B-T169
K(+)	B-T123
secretion	B-T038
,	O
resulting	O
in	O
hypertension	B-T047
and	O
hyperkalemia	B-T033
.	O
Although	O
clinical studies	B-T062
have	O
shown	O
that	O
dietary K(+)	B-T168
intake	B-T169
affects	B-T169
blood pressure	B-T040
,	O
the	O
mechanisms	B-T169
have	O
been	O
obscure	B-T033
.	O
In	O
this	O
study,	O
we	O
demonstrate	O
that	O
the	O
KLHL3	B-T116
ubiquitin ligase	B-T116
complex	B-T116
is	O
involved	O
in	O
the	O
low-	O
K(+)	B-T123
-mediated	O
activation	B-T045
of	O
Na-Cl cotransporter	B-T116
(	O
NCC	B-T116
)	O
in	O
the	O
kidney	B-T023
.	O
In	O
the	O
distal convoluted tubules	B-T023
of	O
mice	B-T015
eating	B-T040
a	O
low-K(+) diet	B-T061
,	O
we	O
found	O
increased	O
KLHL3	B-T116
phosphorylation	B-T044
at	O
S433	B-T082
(KLHL3(S433-P))	B-T116
,	O
a	O
modification	B-T033
that	O
impairs	B-T169
WNK	B-T116
binding	B-T052
,	O
and	O
also	O
reduced	O
total	O
KLHL3	B-T116
levels	B-T080
.	O
These	O
changes	O
are	O
accompanied	O
by	O
the	O
accumulation	B-T033
of	O
the	O
target	B-T169
substrate	B-T167
WNK4	B-T116
,	O
and	O
activation	B-T045
of	O
the	O
downstream	B-T082
kinases SPAK	B-T116
(	O
STE20	B-T116
/	O
SPS1	B-T116
-related	O
proline-alanine-rich protein kinase	B-T116
)	O
and	O
OSR1	B-T116
(	O
oxidative stress-responsive 1	B-T116
),	O
resulting	O
in	O
NCC	B-T116
phosphorylation	B-T044
and	O
its	O
accumulation	B-T033
at	O
the	O
plasma membrane	B-T026
.	O
Increased	O
phosphorylation	B-T044
of	O
S433	B-T082
was	O
explained	O
by	O
increased	O
levels	B-T080
of	O
active	B-T169
,	O
phosphorylated	O
protein kinase C	B-T116
(but	O
not	O
protein kinase A	B-T116
),	O
which	O
directly	O
phosphorylates	B-T044
S433	B-T082
.	O
Moreover,	O
in	O
HEK cells	B-T025
expressing	B-T045
KLHL3	B-T116
and	O
WNK4	B-T116
,	O
we	O
showed	O
that	O
the	O
activation	B-T045
of	O
protein kinase C	B-T116
by	O
phorbol 12-myristate 13-acetate	B-T109
induces	B-T169
KLHL3(S433-P)	B-T116
and	O
increases	O
WNK4	B-T116
levels	B-T080
by	O
abrogating	O
its	O
ubiquitination	B-T044
.	O
These	O
data	B-T078
demonstrate	O
the	O
role	B-T077
of	O
KLHL3	B-T116
in	O
low-	O
K(+)	B-T123
-mediated	O
induction	B-T169
of	O
NCC	B-T116
;	O
this	O
physiologic adaptation	B-T040
reduces	O
distal	B-T082
electrogenic	B-T042
Na(+) reabsorption	B-T039
,	O
preventing	B-T169
further	O
renal	B-T023
K(+)	B-T123
loss	B-T081
but	O
promoting	B-T052
increased	O
blood pressure	B-T040
.	O

The	O
relationship	B-T080
between	O
thoracic	B-T029
configuration	B-T029
and	O
changes	B-T169
in	O
volumes	B-T081
of	O
hemithoraces	B-T029
in	O
upright sitting	B-T033
[Purpose]	O
Some	O
patients	B-T101
with	O
respiratory disease	B-T047
exhibit	O
asymmetrical movement of the thorax	B-T033
.	O
The	O
purpose	O
of	O
this	O
study	B-T062
was	O
to	O
investigate	B-T169
the	O
relationship	B-T080
of	O
thoracic	B-T029
configuration	B-T029
with	O
changes	B-T169
in	O
thoracic volume	B-T201
in	O
13	O
sedentary	B-T080
healthy	B-T080
men	B-T098
.	O
[Subjects	O
and	O
Methods]	O
In	O
upright sitting	B-T033
,	O
84	O
reflective markers	B-T080
were	O
placed	O
on	O
the	O
anterior	B-T082
and	O
posterior	B-T082
aspects	B-T080
of	O
the	O
trunk	B-T029
to	O
record	O
thoracic volume	B-T201
during	O
quiet	B-T080
and	O
volitional	B-T041
deep breathing	B-T033
.	O
Using	O
a	O
three-dimensional motion analyzer	B-T074
,	O
the	O
difference	B-T081
in	O
volume	B-T081
within	O
the	O
upper	B-T082
and	O
lower	B-T082
hemithoraces	B-T029
was	O
measured	B-T080
.	O
For	O
calculation	B-T052
of	O
the	O
thoracic volume	B-T201
six	O
imaginary hexahedra	B-T082
were	O
visualized	O
for	O
the	O
upper	B-T082
and	O
lower	B-T082
thorax	B-T029
using	O
four	O
reflective markers	B-T080
for	O
each	O
on	O
the	O
anterior	B-T082
and	O
posterior	B-T082
aspects	B-T080
of	O
the	O
thorax	B-T029
.	O
Each	O
hexahedron	B-T082
was	O
then	O
divided	O
into	O
three	O
imaginary triangular pyramids	B-T082
to	O
calculate	B-T052
positional	B-T033
vectors	B-T082
.	O
Finally,	O
the	O
volume	B-T081
for	O
both	O
the	O
hexahedra	B-T082
and	O
triangular pyramids	B-T082
was	O
calculated	B-T052
.	O
Four	O
thoracic volumes	B-T201
were	O
obtained.	O
[Results]	O
The	O
findings	B-T169
showed	O
that	O
the	O
left	B-T082
upper	B-T082
and	O
right	B-T082
lower	B-T082
hemithorax	B-T029
yielded	O
significantly	O
larger	B-T081
thoracic volumes	B-T201
.	O
[Conclusion]	O
In	O
conclusion	B-T078
the	O
left	B-T082
upper	B-T082
and	O
right	B-T082
lower	B-T082
hemithoraces	B-T029
were	O
found	O
to	O
expand	B-T082
more	O
than	O
their	O
corresponding	O
sides	B-T082
.	O
Understanding	O
the	O
characteristics	B-T080
of	O
thoracic	B-T029
excursion	B-T184
during	O
quiet	B-T080
and	O
volitional	B-T041
deep breathing	B-T033
could	O
be	O
of	O
value	B-T080
in	O
assessment	B-T058
and	O
instruction	B-T170
of	O
breathing techniques	B-T065
to	O
patients	B-T101
.	O

Development	B-T169
of	O
the	O
four-item Letter and Shape Drawing test	B-UnknownType
(	O
LSD-4	B-UnknownType
):	O
A	O
brief	O
bedside test	B-T060
of	O
visuospatial function	B-T041
Conventional	B-T080
bedside tests	B-T060
of	O
visuospatial function	B-T041
such	O
as	O
the	O
Clock Drawing	B-UnknownType
(	O
CDT	B-UnknownType
)	O
and	O
Intersecting Pentagons	B-UnknownType
(	O
IPT	B-UnknownType
)	O
lack	B-T080
consistency	B-T080
in	O
delivery	O
and	O
interpretation	B-T033
.	O
We	O
compared	B-T052
performance	B-T052
on	O
a	O
novel	O
test	O
of	O
visuospatial ability	B-T041
-	O
the	O
LSD	B-UnknownType
-	O
with	O
the	O
IPT	B-UnknownType
,	O
CDT	B-UnknownType
and	O
MMSE	B-T060
in	O
180	O
acute	B-T079
elderly	B-T098
medical	B-T169
inpatients	B-T101
[	O
mean	B-T081
age	B-T032
79.7±7.1	O
(	O
range	B-T081
62-96);	O
91	O
females	B-T032
(50.6%)].	O
124	O
(69%)	O
scored	B-T081
≤23	O
on	O
the	O
MMSE	B-T060
;	O
60	O
with	O
mild	B-T080
(	O
score	B-T081
18-23)	O
and	O
64	O
with	O
severe	B-T080
(	O
score	B-T081
≤17)	O
impairment	B-T169
.	O
78	O
(43%)	O
scored	B-T081
≥6	O
on	O
the	O
CDT	B-UnknownType
,	O
while	O
for	O
the	O
IPT	B-UnknownType
,	O
87	O
(47%)	O
scored	B-T081
≥4.	O
The	O
CDT	B-UnknownType
and	O
IPT	B-UnknownType
agreed	B-T033
on	O
the	O
classification	B-T185
of	O
138	O
patients	B-T101
(77%)	O
with	O
modest-	O
strong	B-T080
agreement	O
with	O
the	O
MMSE	B-T060
categories	B-T170
.	O
Correlation	B-T080
between	O
the	O
LSD	B-UnknownType
and	O
visuospatial tests	B-UnknownType
was	O
high	B-T080
.	O
A	O
four-item version	B-T170
of	O
the	O
LSD	B-UnknownType
incorporating	O
items	B-T071
1,10,12,15	O
had	O
high	B-T080
correlation	B-T080
with	O
the	O
LSD-15	B-UnknownType
and	O
strong	B-T080
association with	B-T080
MMSE	B-T060
categories	B-T170
.	O
The	O
LSD-4	B-UnknownType
provides	O
a	O
brief	O
and	O
easily	B-T033
interpreted	B-T169
bedside test	B-T060
of	O
visuospatial function	B-T041
that	O
has	O
high	B-T080
coverage	B-T169
of	O
elderly	B-T098
patients	B-T101
with	O
neurocognitive impairment	B-T048
,	O
good	O
agreement	O
with	O
conventional	B-T080
tests	O
of	O
visuospatial ability	B-T041
and	O
favourable	O
ability	O
to	O
identify	B-T080
significant	B-T078
cognitive impairment	B-T048
.	O
[181	O
words].	O

Salvage Therapy	B-T061
with	O
Ceftolozane-Tazobactam	B-T121
for	O
Multidrug-Resistant Pseudomonas aeruginosa	B-T007
Infections	B-T047
Infections	B-T047
caused	O
by	O
multidrug-resistant Pseudomonas aeruginosa	B-T007
(	O
MDRPA	B-T007
)	O
present	O
a	O
major	O
problem	O
for	O
therapeutic management	B-T058
.	O
We	O
report	O
here	O
our	O
experience	O
with	O
12	O
patients	B-T101
with	O
a	O
severe	O
MDRPA	B-T007
infection	B-T047
(6	O
of	O
which	O
were	O
pneumonia	B-T047
)	O
who	O
received	O
salvage therapy	B-T061
with	O
ceftolozane-tazobactam	B-T121
after	O
inappropriate	O
empirical treatment	B-T061
and/or	O
suboptimal	B-T080
targeted	O
treatment	B-T061
.	O
Although	O
10	O
of	O
the	O
12	O
patients	B-T101
(83.3%)	O
experienced	O
septic shock	B-T046
,	O
only	O
3	O
patients	B-T101
(25%)	O
died	B-T040
during	O
the	O
follow-up	B-T058
period.	O
Microbiological	B-T059
cure	B-T077
in	O
7	O
patients	B-T101
(58.3%)	O
was	O
observed.	O

Ankaflavin	B-T109
and	O
Monascin	B-T109
Induce	B-T169
Apoptosis	B-T043
in	O
Activated	B-T052
Hepatic Stellate Cells	B-T025
through	O
Suppression	B-UnknownType
of	O
the	O
Akt	B-T116
/	O
NF-κB	B-T116
/	O
p38	B-T116
Signaling Pathway	B-T044
The	O
increased	B-T081
proliferation	B-T043
of	O
activated	B-T052
hepatic stellate cells	B-T025
(	O
HSCs	B-T025
)	O
is	O
associated with	B-T080
hepatic fibrosis	B-T047
and	O
excessive	B-T080
extracellular matrix	B-T024
(	O
ECM	B-T024
)-	O
protein	B-T116
production.	O
We	O
examined	O
the	O
inhibitory	B-T052
effects of	B-T080
the	O
Monascus purpureus	B-T004
-fermented	O
metabolites	B-T123
,	O
ankaflavin	B-T109
and	O
monascin	B-T109
(15	O
and	O
30	O
μM),	O
on	O
the	O
Akt	B-T116
/	O
nuclear factor (NF)-κB	B-T116
and	O
p38 mitogen-activated protein kinase	B-T116
(	O
MAPK	B-T116
)	O
signaling pathways	B-T044
in	O
HSC-T6	B-T025
(	O
activated hepatic stellate cell line	B-T025
).	O
Ankaflavin	B-T109
and	O
monascin	B-T109
(30	O
μM)	O
induced	B-T169
apoptosis	B-T043
and	O
significantly	B-T078
inhibited	B-T080
cell growth	B-T043
(	O
cell viabilities	B-T043
:	O
80.2	O
±	O
5.43%	O
and	O
62.8	O
±	O
8.20%,	O
respectively,	O
versus	O
control cells	B-T025
;	O
P	O
<	O
0.05).	O
Apoptosis	B-T043
and	O
G1 phase arrest	B-T043
(	O
G1 phase	B-T079
percentages	B-T081
:	O
76.1	O
±	O
2.85%	O
and	O
79.9	O
±	O
1.80%,	O
respectively,	O
versus	O
control cells	B-T025
65.9	O
±	O
4.94%;	O
P	O
<	O
0.05)	O
correlated	B-T080
with	O
increased	B-T081
p53	B-T116
and	O
p21	B-T116
levels	B-T034
and	O
caspase 3 activity	B-T044
and	O
decreased	B-T081
cyclin D1	B-T116
and	O
Bcl-2-family protein	B-T026
levels	B-T034
(P	O
<	O
0.05,	O
all	O
cases).	O
The	O
apoptotic	B-T080
effects of	B-T080
ankaflavin	B-T109
and	O
monascin	B-T109
were	O
HSC-T6	B-T025
-	O
specific	B-T080
,	O
suggesting	O
their	O
potential	B-T080
in	O
treating	B-T169
liver fibrosis	B-T047
.	O

Low-Volume	B-T073
vs	O
High-Volume Centers	B-T073
and	O
Management of Fournier's Gangrene	B-T058
Fournier's Gangrene	B-T047
in	O
Washington State	B-T083
Fournier's gangrene	B-T047
(	O
FG	B-T047
)	O
is	O
a	O
life-threatening infection	B-T033
affecting	B-T169
the	O
perineum	B-T029
and	O
genitals	B-T023
.	O
Complex	B-T080
patient management	B-T058
often	O
necessitates	O
transfer	O
to	O
tertiary centers	B-T073
.	O
We	O
aimed	O
to	O
characterize	O
hospital transfer	B-T058
patterns	B-T082
and	O
assess	O
morbidity	B-T081
among	O
patients	B-T101
with	O
FG	B-T047
in	O
Washington State	B-T083
.	O
The	O
Washington State	B-T083
Comprehensive	B-T080
Hospital	O
Abstract Reporting	B-T057
System	O
includes	O
claims	O
from	O
all	O
hospital discharges	B-UnknownType
in	O
Washington	B-T083
.	O
We	O
identified	O
patients	B-T101
with	O
FG	B-T047
between	O
2007	O
and	O
2013,	O
based	O
on	O
diagnosis and treatment codes	B-T170
.	O
Analyses	O
were	O
stratified	B-T080
by	O
center	O
volume	O
(	O
low-volume centers	B-T073
[	O
LVCs	B-T073
]	O
or	O
high-volume centers	B-T073
[	O
HVCs	B-T073
]),	O
and	O
transfer status	B-T033
.	O
Variables	O
of	O
interest	O
included	O
number	O
of	O
debridements	B-T061
,	O
septic shock	B-T046
,	O
acute renal failure	B-T047
,	O
acute respiratory failure	B-T047
,	O
length of hospitalization	B-T058
,	O
and	O
death	B-T033
.	O
We	O
identified	O
165	O
FG	B-T047
patients	B-T101
.	O
Only	O
1	O
HVC	B-T073
treated	B-T169
more	O
than	O
2	O
FG	B-T047
patients	B-T101
per	O
year.	O
Overall mortality	B-T081
was	O
6.7%.	O
Most	O
patients	B-T101
(57%)	O
were	O
treated	B-T169
entirely	O
at	O
LVCs	B-T073
;	O
87%	O
of	O
patients	B-T101
treated	B-T169
at	O
the	O
HVC	B-T073
were	O
transferred	O
from	O
an	O
LVC	B-T073
.	O
High-volume center	B-T073
-treated	O
patients	B-T101
had	O
similar	O
baseline	O
comorbidities	B-T078
(p	O
=	O
0.77)	O
and	O
similar	O
mortality	B-T081
(p	O
=	O
0.87),	O
despite	O
higher	O
rates	O
of	O
septic shock	B-T046
(p	O
<	O
0.01)	O
and	O
respiratory failure	B-T047
(p	O
=	O
0.01)	O
compared	O
with	O
LVC	B-T073
patients	B-T101
.	O
Among	O
HVC	B-T073
-	O
transferred patients	B-T058
,	O
immediate	B-T079
compared	O
with	O
delayed	B-T079
transfer	O
was	O
associated with	B-T080
fewer	O
debridements	B-T061
(p	O
<	O
0.01),	O
lower	O
rates	O
of	O
septic shock	B-T046
(p	O
=	O
0.05),	O
and	O
acute renal failure	B-T047
(p	O
=	O
0.04).	O
Patients	B-T101
treated	B-T169
at	O
the	O
HVC	B-T073
were	O
more	O
acutely ill	B-T033
,	O
yet	O
mortality	B-T081
was	O
similar	O
compared	O
with	O
patients	B-T101
treated	B-T169
solely	O
at	O
LVCs	B-T073
,	O
suggesting	O
a	O
benefit	O
to	O
transfer	O
of	O
high	O
acuity patients	B-T080
.	O
Immediate	B-T079
vs	O
delayed	B-T079
transfer	O
may	O
benefit	O
FG	B-T047
health outcomes	B-T170
;	O
however,	O
this	O
may	O
also	O
reflect	O
greater	O
disease	B-T047
acuity of patients	B-T080
with	O
delayed	O
transfer status	B-T033
.	O

Functional	O
Characterization	O
of	O
Pneumocystis carinii	B-T004
Inositol Transporter 1	B-T116
Fungi	B-T004
in	O
the	O
genus Pneumocystis	B-T004
live	O
in	O
the	O
lungs	B-T023
of	O
mammals	B-T015
,	O
where	O
they	O
can	O
cause	O
a	O
fatal	B-T080
pneumonia	B-T047
(	O
PCP	B-T047
[	O
Pneumocystis pneumonia	B-T047
])	O
in	O
hosts	B-T001
with	O
compromised	O
immune systems	B-T022
.	O
The	O
absence	O
of	O
a	O
continuous	O
in vitro	B-T080
culture system	B-T059
for	O
any	O
species	B-T185
of	O
Pneumocystis	B-T004
has	O
led	O
to	O
limited	O
understanding	O
of	O
these	O
fungi	B-T004
,	O
especially	O
for	O
the	O
discovery	B-T052
of	O
new	O
therapies	B-T061
.	O
We	O
recently	O
reported	O
that	O
Pneumocystis carinii	B-T004
,	O
Pneumocystis murina	B-T004
,	O
and	O
most	O
significantly,	O
Pneumocystis jirovecii	B-T004
lack	O
both	O
enzymes	B-T116
necessary	O
for	O
myo-inositol biosynthesis	B-T044
but	O
contain	O
genes with homologies	B-T028
to	O
fungal	B-T004
myo-inositol	B-T109
transporters	B-T116
.	O
Since	O
myo-inositol	B-T109
is	O
essential	O
for	O
eukaryotic	B-T025
viability	B-T043
,	O
the	O
primary	O
transporter	B-T116
,	O
ITR1	B-T116
,	O
was	O
functionally	B-T169
and	O
structurally	B-T082
characterized	O
in	O
P. carinii	B-T004
The	O
predicted	O
structure	B-T116
of	O
P. carinii	B-T004
ITR1	B-T116
(	O
PcITR1	B-T116
)	O
contained	O
12	O
transmembrane	B-T026
alpha-helices	B-T082
with	O
intracellular	B-T082
C	B-T087
and	O
N termini	B-T087
,	O
consistent	O
with	O
other	O
inositol	B-T109
transporters	B-T116
.	O
The	O
apparent	O
Km	O
was	O
0.94	O
±	O
0.08	O
(mean	O
±	O
standard	O
deviation),	O
suggesting	O
that	O
myo-inositol transport	B-T043
in	O
P. carinii	B-T004
is	O
likely	O
through	O
a	O
low-affinity,	O
highly	O
selective	O
transport system	B-T043
,	O
as	O
no	O
other	O
sugars	B-T109
or	O
inositol	B-T109
stereoisomers	B-T104
were	O
significant	O
competitive	B-T044
inhibitors	B-T120
.	O
Glucose transport	B-T043
was	O
shown	O
to	O
use	O
a	O
different	O
transport	B-T043
system.	O
The	O
myo-inositol transport	B-T043
was	O
distinct	O
from	O
mammalian	B-T015
transporters	B-T116
,	O
as	O
it	O
was	O
not	O
sodium dependent	B-T043
and	O
was	O
cytochalasin B	B-T121
resistant	B-T169
.	O
Inositol transport	B-T043
in	O
these	O
fungi	B-T004
offers	O
an	O
attractive	B-T080
new	O
drug	B-T121
target	B-T169
because	O
of	O
the	O
reliance	O
of	O
the	O
fungi	B-T004
on	O
its	O
transport	B-T043
,	O
clear	O
differences	O
between	O
the	O
mammalian	B-T015
and	O
fungal	B-T004
transporters	B-T116
,	O
and	O
the	O
ability	O
of	O
the	O
host	B-T001
to	O
both	O
synthesize	O
and	O
transport	B-T043
this	O
critical	B-T080
nutrient	B-T168
,	O
predicting	O
low	B-T080
toxicity	B-T037
of	O
potential	B-T080
inhibitors	B-T120
to	O
the	O
fungal	B-T004
transporter	B-T116
.	O
myo-Inositol	B-T109
is	O
a	O
sugarlike	B-T109
nutrient	B-T168
that	O
is	O
essential	B-T080
for	O
life	B-T078
in	O
most	O
organisms	B-T001
.	O
Humans	B-T016
and	O
microbes	B-T001
alike	O
can	O
obtain	O
it	O
by	O
making	O
it,	O
which	O
involves	O
only	O
2	O
enzymes	B-T116
,	O
by	O
taking	O
it	O
from	O
the	O
environment	B-T082
by	O
a	O
transport process	B-T044
,	O
or	O
by	O
recycling	O
it	O
from	O
other	O
cellular	B-T025
constituents	B-T167
.	O
Inspection	O
of	O
the	O
genomes	B-T028
of	O
the	O
pathogenic fungi	B-T004
of	O
the	O
genus Pneumocystis	B-T004
showed	O
that	O
these	O
pneumonia	B-T047
-	O
causing	B-T169
parasites	B-T204
could	O
not	O
make	O
myo-inositol	B-T109
,	O
as	O
they	O
lacked	O
the	O
2	O
enzymes	B-T116
.	O
Instead,	O
we	O
found	O
evidence	O
of	O
inositol	B-T109
transporters	B-T116
,	O
which	O
would	O
import	O
the	O
sugar	B-T109
from	O
the	O
lungs	B-T023
where	O
the	O
fungi	B-T004
reside.	O
In	O
the	O
present	O
report,	O
we	O
characterized	O
the	O
transport	B-T043
of	O
myo-inositol	B-T109
in	O
the	O
fungus	B-T004
and	O
found	O
that	O
the	O
transporter	B-T116
was	O
highly	O
selective	O
for	O
myo-inositol	B-T109
and	O
did	O
not	O
transport	B-T043
any	O
other	O
molecules	B-T167
.	O
The	O
transport	B-T043
was	O
distinct	O
from	O
that	O
in	O
mammalian cells	B-T025
,	O
and	O
since	O
mammals	B-T015
can	O
both	O
make	O
and	O
transport	B-T043
myo-inositol	B-T109
,	O
while	O
Pneumocystis fungi	B-T004
must	O
transport	B-T043
it,	O
this	O
process	O
offers	O
a	O
potential	B-T080
new	O
drug	B-T121
target	B-T169
.	O

Worldwide	B-T082
Occurrence	B-T079
of	O
Mycotoxins	B-T109
in	O
Cereals	B-T168
and	O
Cereal	B-T168
-	O
Derived	B-T080
Food Products	B-T168
:	O
Public	B-T092
Health	B-T078
Perspectives	B-T078
of	O
Their	O
Co-occurrence	O
Cereal grains	B-T168
and	O
their	O
processed	B-T067
food products	B-T168
are	O
frequently	O
contaminated	B-T169
with	O
mycotoxins	B-T109
.	O
Among	O
many,	O
five	B-T081
major	B-T080
mycotoxins	B-T109
of	O
aflatoxins	B-T109
,	O
ochratoxins	B-T109
,	O
fumonisins	B-T109
,	O
deoxynivalenol	B-T109
,	O
and	O
zearalenone	B-T109
are	O
of	O
significant	O
public	B-T092
health	B-T078
concern	B-T078
as	O
they	O
can	O
cause	B-T169
adverse effects	B-T046
in	O
humans	B-T016
.	O
Being	O
airborne	B-T169
or	O
soilborne	B-T169
,	O
the	O
cosmopolitan	O
nature	B-T080
of	O
mycotoxigenic fungi	B-T004
contribute	O
to	O
the	O
worldwide	B-T082
occurrence	B-T079
of	O
mycotoxins	B-T109
.	O
On	O
the	O
basis	B-T169
of	O
the	O
global	B-T080
occurrence	B-T079
data	B-T078
reported	B-T058
during	O
the	O
past	O
10	O
years,	O
the	O
incidences	B-T081
and	O
maximum	B-T081
levels	B-T080
in	O
raw	B-T080
cereal grains	B-T168
were	O
55%	O
and	O
1642	O
μg/kg	O
for	O
aflatoxins	B-T109
,	O
29%	O
and	O
1164	O
μg/kg	O
for	O
ochratoxin A	B-T109
,	O
61%	O
and	O
71,121	O
μg/kg	O
for	O
fumonisins	B-T109
,	O
58%	O
and	O
41,157	O
μg/kg,	O
for	O
deoxynivalenol	B-T109
,	O
and	O
46%	O
and	O
3049	O
μg/kg	O
for	O
zearalenone	B-T109
.	O
The	O
concentrations	B-T081
of	O
mycotoxins	B-T109
tend	O
to	O
be	O
lower	B-T080
in	O
processed	B-T067
food products	B-T168
;	O
the	O
incidences	B-T081
varied	O
depending	O
on	O
the	O
individual	O
mycotoxins	B-T109
,	O
possibly	O
due to	B-T169
the	O
varying	B-T169
stability	B-T080
during	B-T079
processing	B-T057
and	O
distribution	B-T169
of	O
mycotoxins	B-T109
.	O
It	O
should	O
be	O
noted	O
that	O
more	O
than	O
one	O
mycotoxin	B-T109
,	O
produced	B-T169
by	O
a	O
single	B-T081
or	O
several	B-T081
fungal	B-T004
species	B-T185
,	O
may	O
occur	O
in	O
various	B-T081
combinations	B-T080
in	O
a	O
given	O
sample	B-T167
or	O
food	B-T168
.	O
Most	O
studies	B-T062
reported	B-T058
additive	B-T080
or	O
synergistic	B-T080
effects	B-T080
,	O
suggesting	B-T078
that	O
these	O
mixtures	B-T167
may	O
pose	O
a	O
significant	B-T078
threat	B-T078
to	O
public	B-T092
health	B-T078
,	O
particularly	O
to	O
infants	B-T100
and	O
young children	B-T100
.	O
Therefore,	O
information	B-T078
on	O
the	O
co-occurrence	O
of	O
mycotoxins	B-T109
and	O
their	O
interactive	B-T169
toxicity	B-T037
is	O
summarized	B-T170
in	O
this	O
paper.	O

Locating	O
the	O
Seventh Cervical Spinous Process	B-T023
:	O
Development	O
and	O
Validation	O
of	O
a	O
Multivariate Model	B-T081
Using	O
Palpation	B-T060
and	O
Personal Information	B-T077
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
develop	O
and	O
validate	O
a	O
multivariate prediction model	B-T081
,	O
guided	O
by	O
palpation	B-T060
and	O
personal information	B-T077
,	O
for	O
locating	O
the	O
seventh cervical spinous process	B-T023
(	O
C7SP	B-T023
).	O
A	O
single-blinded, cross-sectional study	B-T062
at	O
a	O
primary to tertiary health care center	B-T073
was	O
conducted	O
for	O
model development	B-T170
and	O
temporal validation	B-T062
.	O
One-hundred	O
sixty	O
participants	B-T098
were	O
prospectively	O
included	O
for	O
model development	B-T170
(n	O
=	O
80)	O
and	O
time-split validation stages	B-T081
(n	O
=	O
80).	O
The	O
C7SP	B-T023
was	O
located	O
using	O
the	O
thorax-rib static method	B-T060
(	O
TRSM	B-T060
).	O
Participants	B-T098
underwent	O
chest radiography	B-T060
for	O
assessment	O
of	O
the	O
inner	B-T082
body structure	B-T017
located	O
with	O
TRSM	B-T060
and	O
using	O
radio-opaque markers	B-T074
placed	O
over	O
the	O
skin	B-T022
.	O
Age	B-T032
,	O
sex	B-T032
,	O
height	B-T032
,	O
body mass	B-T033
,	O
body mass index	B-T201
,	O
and	O
vertex-marker distanc	B-T081
e	O
(	O
DV-M	B-T081
)	O
were	O
used	O
to	O
predict	O
the	O
distance	B-T081
from	O
the	O
C7SP	B-T023
to	O
the	O
vertex	B-T029
(	O
DV-C7	B-T081
).	O
Multivariate linear regression modeling	B-T170
,	O
limits	O
of	O
agreement	O
plot,	O
histogram of residues	B-T170
,	O
receiver operating characteristic curves	B-T081
,	O
and	O
confusion tables	B-T170
were	O
analyzed.	O
The	O
multivariate linear prediction model	B-T081
for	O
DV-C7	B-T081
(in	O
centimeters)	O
was	O
DV-C7	B-T081
=	O
0.986DV-M	O
+	O
0.018(mass)	O
+	O
0.014(age)	O
-	O
1.008.	O
Receiver operating characteristic curves	B-T081
had	O
better	O
discrimination	O
of	O
DV-C7	B-T081
(area	O
under	O
the	O
curve	O
=	O
0.661;	O
95%	O
confidence interval	B-T081
=	O
0.541-0.782;	O
P	O
=	O
.015)	O
than	O
DV-M	B-T081
(area	O
under	O
the	O
curve	O
=	O
0.480;	O
95%	O
confidence interval	B-T081
=	O
0.345-0.614;	O
P	O
=	O
.761),	O
with	O
respective	O
cutoff	O
points	O
at	O
23.40	O
cm	O
(	O
sensitivity	B-T081
=	O
41%,	O
specificity	B-T081
=	O
63%)	O
and	O
24.75	O
cm	O
(	O
sensitivity	B-T081
=	O
69%,	O
specificity	B-T081
=	O
52%).	O
The	O
C7SP	B-T023
was	O
correctly	O
located	O
more	O
often	O
when	O
using	O
predicted	O
DV-C7	B-T081
in	O
the	O
validation	O
sample	O
than	O
when	O
using	O
the	O
TRSM	B-T060
in	O
the	O
development	O
sample:	O
n	O
=	O
53	O
(66%)	O
vs	O
n	O
=	O
32	O
(40%),	O
P	O
<	O
.001.	O
Better	O
accuracy	O
was	O
obtained	O
when	O
locating	O
the	O
C7SP	B-T023
by	O
use	O
of	O
a	O
multivariate model	B-T081
that	O
incorporates	O
palpation	B-T060
and	O
personal information	B-T077
.	O

Comparison	B-T052
of	O
Leishmania	B-T204
typing	B-T059
results	B-T034
obtained	B-T169
from	O
16	O
European	B-T083
clinical laboratories	B-T073
in	O
2014	O
Leishmaniasis	B-T047
is	O
endemic	B-UnknownType
in	O
southern Europe	B-T083
,	O
and	O
in	O
other	O
European	B-T083
countries	B-T083
cases	B-T081
are	O
diagnosed	B-T033
in	O
travellers	B-T097
who	O
have	O
visited	O
affected areas	B-T033
both	O
within	B-T082
the	O
continent	B-T083
and	O
beyond.	O
Prompt	B-T080
and	O
accurate	B-T080
diagnosis	B-T033
poses	O
a	O
challenge	O
in	O
clinical practice	B-T170
in	O
Europe	B-T083
.	O
Different	B-T080
methods	B-T170
exist	B-T077
for	O
identification	B-T080
of	O
the	O
infecting	B-T033
Leishmania	B-T204
species	B-T185
.	O
Sixteen	O
clinical laboratories	B-T073
in	O
10	O
European	B-T083
countries	B-T083
,	O
plus	O
Israel	B-T083
and	O
Turkey	B-T083
,	O
conducted	O
a	O
study	B-T062
to	O
assess	O
their	O
genotyping	B-T059
performance	B-T052
.	O
DNA	B-T114
from	O
21	O
promastigote cultures	B-T204
of	O
13	O
species	B-T185
was	O
analysed	B-T062
blindly	B-T080
by	O
the	O
routinely	B-T080
used	O
typing	B-T059
method	B-T170
.	O
Five	O
different	B-T080
molecular targets	B-T104
were	O
used,	O
which	O
were	O
analysed	B-T062
with	O
PCR-based	B-T063
methods	B-T170
.	O
Different	B-T080
levels	B-T080
of	O
identification	B-T080
were	O
achieved	B-T033
,	O
and	O
either	O
the	O
Leishmania	B-T204
subgenus	B-T077
,	O
species	B-T185
complex,	O
or	O
actual	O
species	B-T185
were	O
reported	B-T170
.	O
The	O
overall	B-T080
error	B-T080
rate	B-T081
of	O
strains	B-T001
placed	O
in	O
the	O
wrong	B-T080
complex	O
or	O
species	B-T185
was	O
8.5%.	O
Various	O
reasons	B-T078
for	O
incorrect	B-T080
typing	B-T059
were	O
identified	B-T080
.	O
The	O
study	B-T062
shows	O
there	O
is	O
considerable	B-T080
room	O
for	O
improvement	B-T077
and	O
standardisation	B-T062
of	O
Leishmania	B-T204
typing	B-T059
.	O
The	O
use	O
of	O
well	O
validated	B-T062
standard operating procedures	B-T077
is	O
recommended	B-T078
,	O
covering	O
testing	B-T169
,	O
interpretation	B-T170
,	O
and	O
reporting	B-T058
guidelines	B-T170
.	O
Application	O
of	O
the	O
internal	B-T082
transcribed	B-T080
spacer 1	B-T114
of	O
the	O
rDNA	B-T114
array	B-T075
should	O
be	O
restricted	B-T169
to	O
Old World	B-T080
samples	B-T077
,	O
while	O
the	O
heat-shock protein 70 gene	B-T028
and	O
the	O
mini-exon	B-T114
can	O
be	O
applied	B-T169
globally	B-T080
.	O

Scoparone	B-T109
Inhibits	O
LPS	B-T109
-	O
Simulated	B-T169
Inflammatory Response	B-T046
by	O
Suppressing	B-T169
IRF3	B-T116
and	O
ERK	B-T116
in	O
BV-2 Microglial Cells	B-T025
Microglia	B-T025
activation	B-T043
and	O
the	O
release	O
of	O
various	O
inflammatory	B-T169
cytokines	B-T116
are	O
largely	O
related	O
to	O
neurological diseases	B-T047
,	O
including	O
Parkinson's	B-T047
,	O
Alzheimer's	B-T047
,	O
and	O
other	B-T080
brain diseases	B-T047
.	O
The	O
suppression	O
of	O
microglial cells	B-T025
using	O
natural	B-T169
bioactive compounds	B-T123
has	O
become	O
increasingly	B-T169
important	B-T080
for	O
brain therapy	B-T061
owing	O
to	O
the	O
expected	O
beneficial effect	B-UnknownType
of	O
lower	B-T080
toxicity	B-T080
.	O
Scoparone	B-T109
(	O
6,7-dimethoxycoumarin	B-T109
),	O
a	O
major	O
bioactive compound	B-T123
found	B-T033
in	O
various	O
plant parts	B-T185
,	O
including	O
the	O
inner	O
shell	B-T080
of	O
chestnut	B-T168
(	O
Castanea crenata	B-T002
),	O
was	O
evaluated	O
on	O
lipopolysaccharide	B-T109
(	O
LPS	B-T109
)-	O
activated	B-T169
BV-2 microglia cells	B-T025
.	O
The	O
results	B-T169
indicated	B-T033
that	O
scoparone	B-T109
suppresses	B-T169
the	O
LPS	B-T109
-	O
stimulated	B-T169
increase	B-T169
of	O
neuroinflammatory responses	B-T046
and	O
inhibited	B-T080
the	O
pro-inflammatory	B-T169
cytokine	B-T116
production	O
in	O
the	O
BV-2 microglial cells	B-T025
.	O
A	O
mechanistic study	B-T169
showed	O
that	O
scoparone	B-T109
specifically	O
inhibited	B-T080
the	O
LPS	B-T109
-	O
stimulated	B-T169
activation	B-T043
via	O
a	O
major	O
regulation	B-T038
of	O
IRF-3	B-T116
and	O
a	O
regulation	B-T038
of	O
ERK	B-T116
,	O
whereby	O
the	O
phosphorylation	B-T044
in	O
the	O
BV-2 microglial cells	B-T025
is	O
blocked	B-T169
.	O
These	O
data	B-T078
suggest	B-T078
that	O
scoparone	B-T109
has	O
anti-neuroinflammatory effects	B-T080
in	O
LPS	B-T109
-	O
activated	B-T169
BV-2 microglial cells	B-T025
,	O
and	O
could	O
possibly	O
be	O
used	B-T169
in	O
the	O
development	B-T169
of	O
novel	B-T080
drugs	B-T121
for	O
the	O
prevention	B-T080
and	O
treatment	B-T169
of	O
neuroinflammatory diseases	B-T047
.	O

Efficient	O
genome editing	B-T063
of	O
differentiated	B-T080
renal	B-T023
epithelial cells	B-T025
Recent	O
advances	O
in	O
genome editing technologies	B-T063
have	O
enabled	O
the	O
rapid	O
and	O
precise	O
manipulation of genomes	B-T063
,	O
including	O
the	O
targeted introduction	B-T063
,	O
alteration	B-T063
,	O
and	O
removal of genomic sequences	B-T063
.	O
However,	O
respective	O
methods	B-T170
have	O
been	O
described	O
mainly	O
in	O
non-differentiated	B-T170
or	O
haploid	B-T025
cell types	B-T170
.	O
Genome editing	B-T063
of	O
well-differentiated	B-T080
renal	B-T023
epithelial cells	B-T025
has	O
been	O
hampered	O
by	O
a	O
range	O
of	O
technological issues	B-T033
,	O
including	O
optimal	B-T080
design	B-T052
,	O
efficient	B-T080
expression of multiple genome editing constructs	B-T063
,	O
attainable	B-T080
mutation rates	B-T080
,	O
and	O
best	O
screening strategies	B-T170
.	O
Here,	O
we	O
present	O
an	O
easily	O
implementable	O
workflow	B-T077
for	O
the	O
rapid	B-T080
generation of targeted heterozygous and homozygous genomic sequence alterations	B-T063
in	O
renal	B-T023
cells	B-T025
using	O
transcription activator-like effector nucleases	B-T116
(	O
TALENs	B-T116
)	O
and	O
the	O
clustered regularly interspaced short palindromic repeat (CRISPR) system	B-T114
.	O
We	O
demonstrate	O
the	O
versatility	O
of	O
established	O
protocols	B-T170
by	O
generating	B-T052
novel	B-T080
cellular models	B-T075
for	O
studying	B-T062
autosomal dominant polycystic kidney disease	B-T019
(	O
ADPKD	B-T019
).	O
Furthermore,	O
we	O
show	O
that	O
cell culture-validated genetic modifications	B-T063
can	O
be	O
readily	O
applied	O
to	O
mouse embryonic stem cells	B-T025
(	O
mESCs	B-T025
)	O
for	O
the	O
generation	B-T052
of	O
corresponding	O
mouse	B-T015
models	B-T008
.	O
The	O
described	O
procedure	B-T169
for	O
efficient	O
genome editing	B-T063
can	O
be	O
applied	O
to	O
any	O
cell type	B-T170
to	O
study	B-T062
physiological	B-T039
and	O
pathophysiological functions	B-T046
in	O
the	O
context	O
of	O
precisely	O
engineered genotypes	B-T028
.	O

Right Ventricular	B-T023
Response	B-T032
During	B-T079
Exercise	B-T056
in	O
Patients	B-T101
with	O
Chronic Obstructive Pulmonary Disease	B-T047
Right ventricular	B-T023
(	O
RV	B-T023
)	O
pump function	B-T042
is	O
of	O
essential	B-T080
clinical	B-T080
and	O
prognostic	B-T170
importance	B-T080
in	O
a	O
variety	B-T077
of	O
heart	B-T047
and	O
lung diseases	B-T047
.	O
While	O
the	O
evaluation	B-T058
of	O
RV	B-T023
performance	B-T052
at	O
rest	B-T056
has	O
been	O
implemented	O
in	O
the	O
clinical setting	B-T082
,	O
it	O
is	O
unknown	O
whether	O
this	O
assessment	B-T058
during	B-T079
exercise	B-T056
may	O
provide	O
additional	B-T169
benefit	B-T081
.	O
With	O
this	O
aim	B-T078
,	O
we	O
evaluated	B-T058
the	O
exercise	B-T056
-	O
induced	B-T169
pulmonary arterial systolic pressure	B-T060
(	O
PASP	B-T060
)	O
increase	B-T169
during	B-T079
exercise	B-T056
in	O
patients	B-T101
with	O
severe	B-T080
chronic obstructive pulmonary disease	B-T047
(	O
COPD	B-T047
)	O
as	O
an	O
expression	O
of	O
RV	B-T023
contractile reserve	B-T081
.	O
Cardiopulmonary exercise testing	B-T060
(	O
CPET	B-T060
)	O
with	O
synchronic echocardiography	B-T060
was	O
performed	B-T169
in	O
81	O
patients	B-T101
.	O
Patients	B-T101
were	O
classified	B-T185
into	O
two	O
groups	B-T078
according	O
to	O
an	O
exercise	B-T056
-	O
induced	B-T169
PASP	B-T060
increase	B-T169
above	O
30mmHg	O
(	O
High	B-T080
PSAP	B-T060
)	O
or	O
below	O
30mmHg	O
(	O
Low	B-T080
PSAP	B-T060
)	O
during	B-T079
maximal	B-T080
exercise	B-T056
.	O
Patients	B-T101
were	O
then	O
followed	B-T079
for	O
three	O
years	B-T079
.	O
Sixteen	O
patients	B-T101
(20%)	O
had	O
low	B-T080
PSAP	B-T060
and	O
65	O
(80%)	O
showed	O
high	B-T080
PSAP	B-T060
.	O
These	O
were	O
not significant	B-T033
clinical	B-T080
and	O
functional	B-T169
differences	B-T081
.	O
Low	B-T080
PSAP	B-T060
was	O
associated with	B-T080
a	O
significantly lower	B-T081
peak	B-T080
VO2	B-T033
(	O
mean	B-T081
(	O
SD	B-T081
),	O
35	O
(2)	O
%	O
predicted	B-T078
)	O
compared	B-T052
to	O
high	B-T080
PSAP	B-T060
response	B-T032
(	O
peak	B-T080
VO2	B-T033
45	O
(3)	O
%	O
predicted	B-T078
),	O
p=0.045.	O
Factors	B-T169
associated with	B-T080
mortality	B-T081
were	O
age	B-T032
and	O
exercise	B-T056
-	O
induced	B-T169
PASP	B-T060
.	O
Seventeen	O
patients	B-T101
died	O
during	B-T079
the	O
three	O
years	B-T079
of	O
follow-up	B-T058
(7	O
(39%)	O
in	O
the	O
low	B-T080
PSAP	B-T060
group	B-T078
and	O
only	O
10	O
(1%)	O
in	O
the	O
high	B-T080
PSAP	B-T060
group	B-T078
,	O
p=0.041).	O
Cardiopulmonary exercise testing	B-T060
with	O
a	O
synchronic echocardiography	B-T060
may	O
be	O
a	O
useful	O
tool	O
for	O
the	O
assessment	B-T058
of	O
RV	B-T023
contractile reserve	B-T081
in	O
severe	B-T080
COPD	B-T047
patients	B-T101
.	O
Exercise	B-T056
-	O
induced	B-T169
PSAP	B-T060
emerges	O
as	O
a	O
possible	O
prognostic factor	B-T201
in	O
these	O
patients	B-T101
.	O

Adverse outcomes	B-T169
in	O
older adults	B-T098
attending	B-T169
emergency departments	B-T073
:	O
a	O
systematic review	B-T170
and	O
meta-analysis	B-T062
of	O
the	O
Identification of Seniors At Risk (ISAR) screening tool	B-T170
older adults	B-T098
are	O
frequent	B-T079
users	O
of	O
emergency services	B-T058
and	O
demonstrate	O
high	B-T080
rates	B-T081
of	O
adverse outcomes	B-T169
following	O
emergency care	B-T061
.	O
to	O
perform	O
a	O
systematic review	B-T170
and	O
meta-analysis	B-T062
of	O
the	O
Identification of Seniors At Risk (ISAR) screening tool	B-T170
,	O
to	O
determine	O
its	O
predictive value	B-T080
in	O
identifying	O
adults	B-T100
≥65	O
years	B-T079
at	O
risk	B-T078
of	O
functional decline	B-T033
,	O
unplanned	O
emergency department (ED) readmission	B-T058
,	O
emergency	B-T067
hospitalisation	B-T058
or	O
death	B-T033
within	O
180	O
days	B-T079
after	O
index	O
ED visit	B-T058
/	O
hospitalisation	B-T058
.	O
a	O
systematic	B-T169
literature	B-T170
search	B-T052
was	O
conducted	O
in	O
PubMed	B-T170
,	O
EMBASE	B-T170
,	O
CINAHL	B-T170
,	O
EBSCO	B-T170
and	O
the	O
Cochrane Library	B-T170
to	O
identify	O
validation	B-T062
and	O
impact	B-T080
analysis	B-T062
studies	O
of	O
the	O
ISAR tool	B-T170
.	O
A	O
pre-specified	B-T080
ISAR	B-T170
score	B-T081
of	O
≥2	O
(maximum	O
score	B-T081
6	O
points)	O
was	O
used	O
to	O
identify	O
patients	B-T101
at	O
high risk of	B-T033
adverse outcomes	B-T169
.	O
A	O
bivariate random effects model	B-T170
generated	O
pooled	B-T169
estimates	B-T081
of	O
sensitivity and specificity	B-T081
.	O
Statistical heterogeneity	B-T080
was	O
explored	O
and	O
methodological quality	B-UnknownType
was	O
assessed	O
using	O
validated criteria	B-T078
.	O
thirty-two	O
validation studies	B-T062
(n	O
=	O
12,939)	O
are	O
included	B-T169
.	O
At	O
≥2,	O
the	O
pooled	B-T169
sensitivity	B-T081
of	O
the	O
ISAR	B-T170
for	O
predicting	O
ED	B-T073
return	B-T080
,	O
emergency	B-T067
hospitalisation	B-T058
and	O
mortality	B-T081
at	O
6	O
months	B-T079
is	O
0.80	O
(95%	O
confidence interval	B-T081
(	O
CI	B-T081
)	O
0.70-0.87),	O
0.82	O
(95%	O
CI	B-T081
0.74-0.88)	O
and	O
0.87	O
(95%	O
CI	B-T081
0.75-0.94),	O
respectively,	O
with	O
a	O
pooled	B-T169
specificity	B-T081
of	O
0.31	O
(95%	O
CI	B-T081
0.24-0.38),	O
0.32	O
(95%	O
CI	B-T081
0.24-0.41)	O
and	O
0.35	O
(95%	O
CI	B-T081
0.26-0.44).	O
Similar	O
values	B-T080
are	O
demonstrated	O
at	O
30	O
and	O
90	O
days	B-T079
.	O
Three	O
heterogeneous	B-T080
impact	B-T080
analysis	B-T062
studies	O
examined	B-T033
the	O
clinical	B-T080
implementation	B-T052
of	O
the	O
ISAR	B-T170
and	O
reported	O
mixed findings	B-T169
across	O
patient	B-T101
and	O
process	B-T067
outcomes	B-T169
.	O
the	O
ISAR	B-T170
has	O
modest	O
predictive	B-T080
accuracy	B-T080
and	O
may	O
serve	O
as	O
a	O
decision-making	B-T041
adjunct	B-T169
when	O
determining	O
which	O
older adults	B-T098
can	O
be	O
safely	O
discharged	B-T058
.	O

Ecohydrological modeling	B-T062
and	O
environmental	B-T082
flow	B-T070
regime	B-T080
in	O
the	O
Formoso River	B-T070
,	O
Minas Gerais State	B-T083
,	O
Brazil	B-T083
This	O
paper	B-T170
aimed	O
at	O
determining	B-T080
the	O
environmental	B-T082
flow	B-T070
regime	O
in	O
a	O
1 km	B-T081
stretch	B-T081
of	O
the	O
Formoso River	B-T070
,	O
MG	B-T083
,	O
using	O
River2D model	B-T062
.	O
To	O
carry	O
out	O
the	O
ecohydrological modeling	B-T062
,	O
the	O
following	B-T079
information	B-T078
was	O
used:	O
bathymetry	B-T081
,	O
physical	B-T169
and	O
hydraulic	B-T169
features	B-T080
,	O
and	O
the	O
Habitat	B-T082
Suitability Index	B-T080
for	O
species	B-T185
of	O
the	O
Hypostomus auroguttatus	B-T013
.	O
In	O
the	O
River2D	B-T062
,	O
the	O
Weighted	B-T081
Usable	B-T080
Areas	B-T082
were	O
determined	B-T080
from	O
the	O
average	B-T081
long-term	B-T079
streamflows	B-T070
with	O
percentage	B-T081
from	O
10%	O
to	O
100%.	O
Those	O
streamflows	B-T070
were	O
simulated	O
for	O
the	O
later	B-T079
construction	B-T169
of	O
optimization	B-T052
matrices	B-T082
that	O
maximize	B-T081
the	O
habitat	B-T082
area	B-T082
throughout	B-T169
the	O
year	B-T079
.	O
For	O
H. auroguttatus	B-T013
Juvenile	B-T100
,	O
higher	B-T080
values	B-T080
of	O
Weighted	B-T081
Usable	B-T080
Area	B-T082
were	O
associated with	B-T080
the	O
percentage	B-T081
of	O
60%	O
and	O
70%	O
of	O
the	O
average	B-T081
long-term	B-T079
streamflows	B-T070
in	O
October	B-T079
and	O
September	B-T079
,	O
respectively.	O
For	O
H. auroguttatus	B-T013
Adult	B-T100
,	O
the	O
highest	B-T080
value	B-T080
of	O
Weighted	B-T081
Usable	B-T080
Usable	B-T080
Area	B-T082
was	O
associated with	B-T080
the	O
percentage	B-T081
of	O
100%	O
of	O
the	O
average	B-T081
long-term	B-T079
streamflow	B-T070
in	O
September	B-T079
.	O
The	O
environmental	B-T082
flows	B-T070
found	B-T033
for	O
this	O
stretch	B-T081
of	O
the	O
Formoso River	B-T070
varied	B-T169
over	B-T079
the	O
year	B-T079
.	O
The	O
lowest	B-T080
environmental	B-T082
flow	B-T070
was	O
observed	B-T169
in	O
December	B-T080
(2.85	O
m3	O
s-1),	O
while	O
the	O
highest	B-T080
was	O
observed	B-T169
in	O
May	B-T079
(4.13	O
m3	O
s-1).	O
This	O
paper	B-T170
shows	O
the	O
importance	B-T080
of	O
ecohydrological studies	B-T062
in	O
forming	B-T169
a	O
basis	B-T169
for	O
water resources	B-T070
management	B-T080
actions	B-T052
.	O

Risk factors	B-T033
for	O
hepatitis C virus infection	B-T047
in	O
the	O
Colombian	B-T098
Caribbean coast	B-T083
:	O
A	O
case-control study	B-T062
An	O
estimated	O
6.8-8.9	O
million	B-T081
people	B-T098
are	O
infected	B-T033
with	O
hepatitis C virus	B-T005
in	O
Latin America	B-T083
,	O
of	O
which	O
less than	B-T081
1%	O
receives	O
antiviral treatment	B-T061
.	O
Studies	B-T062
so	O
far	O
in	O
Colombia	B-T083
have	O
attempted	B-T051
to	O
determine	O
the	O
prevalence	B-T081
of	O
the	O
disease	B-T047
in	O
some	O
risk	B-T078
groups	B-T098
,	O
thus	O
preventing	B-T169
the	O
identification	B-T080
of	O
other	O
factors	B-T169
potentially	B-T080
involved	O
in	O
the	O
spread	O
of	O
the	O
infection	B-T046
.	O
To	O
identify	B-T080
traditional	O
and	O
non-traditional	O
risk factors	B-T033
for	O
chronic hepatitis C	B-T047
in	O
the	O
Colombian	B-T098
Caribbean coast	B-T083
.	O
This	O
was	O
a	O
case-control study	B-T062
(1:3)	O
matched	O
by	O
health care provider	B-T097
and	O
age	B-T032
(±	O
10	O
years	B-T079
)	O
conducted	O
at	O
the	O
primary care level	B-T058
of	O
gastroenterology	B-T091
and	O
hepatology	B-T091
outpatient services	B-T058
.	O
All	O
patients	B-T101
with	O
a	O
positive	B-T033
ELISA	B-T059
underwent	O
a	O
confirmatory	B-UnknownType
viral load test	B-T059
.	O
A	O
multivariate logistic regression analysis	B-UnknownType
identified	B-T080
the	O
independent predictors	B-T078
of	O
infection	B-T046
.	O
Blood transfusion	B-T061
(	O
OR	B-T081
=159.2;	O
95%	O
CI	B-T081
:	O
35.4-715;	O
p<0.001)	O
and	O
history of hospitalization	B-T201
before	O
1994	O
(	O
OR	B-T081
=4.7;	O
95%	O
CI	B-T081
:	O
1.3-17.1;	O
p=0.018)	O
were	O
identified	B-T080
as	O
the	O
only	O
two	O
independent predictors	B-T078
of	O
infection	B-T046
.	O
It	O
is	O
necessary	O
to	O
check	O
the	O
reproducibility of these results	B-T081
and	O
to	O
conduct	O
cost-effectiveness	B-T081
studies	B-T062
before	O
recommending	B-T078
their	O
use	B-T169
in	O
the	O
design	B-T052
of	O
new screening strategies	B-T062
.	O

Quo	O
vadis	O
G protein-coupled receptor ligands	B-T044
?	O
A	O
tool	O
for	O
analysis	B-T062
of	O
the	O
emergence	B-T078
of	O
new	O
groups	B-T078
of	O
compounds	B-T103
over time	B-T079
Exponential	B-T081
growth	B-T067
in	O
the	O
number	B-T081
of	O
compounds	B-T103
with	O
experimentally	B-T080
verified	B-T169
activity	B-T052
towards	O
particular	O
target	B-T169
has	O
led	O
to	O
the	O
emergence	B-T078
of	O
various	O
databases	B-T170
gathering	O
data	B-T078
on	O
biological	B-T080
activity	B-T052
.	O
In	O
this	O
study	B-T062
,	O
the	O
ligands	B-T103
of	O
family A of the G Protein-Coupled Receptors	B-T116
that	O
are	O
collected	B-T078
in	O
the	O
ChEMBL database	B-T170
were	O
examined	B-T033
,	O
and	O
special	O
attention	O
was	O
given	O
to	O
serotonin receptors	B-T116
.	O
Sets	B-T077
of	O
compounds	B-T103
were	O
examined	B-T033
in	O
terms	O
of	O
their	O
appearance	B-T080
over time	B-T079
,	O
they	O
were	O
mapped	B-T052
to	O
the	O
chemical space	B-T104
of	O
drugs	B-T121
deposited	O
in	O
DrugBank	B-T170
,	O
and	O
the	O
emergence	B-T078
of	O
structurally new clusters of compounds	B-T104
was	O
indicated	B-T033
.	O
In	O
addition,	O
a	O
tool	O
for	O
detailed	O
analysis	B-T062
of	O
the	O
obtained	B-T169
visualizations	B-T170
was	O
prepared	B-T033
and	O
made	O
available	B-T169
online	B-UnknownType
at	O
http://chem.gmum.net/vischem	B-T170
,	O
which	O
enables	O
the	O
investigation	B-T080
of	O
chemical structures	B-T170
while	O
referring	B-T169
to	O
particular	O
data points	B-T033
depicted	O
in	O
the	O
figures	B-UnknownType
and	O
changes	B-T169
in	O
compounds	B-T103
datasets	B-T170
over time	B-T079
.	O

Diabetes	B-T047
and	O
breast cancer	B-T191
mortality	B-T081
in	O
Black women	B-T098
Breast cancer	B-T191
mortality	B-T081
is	O
higher	O
in	O
Black women	B-T098
than	O
in	O
White women	B-T098
.	O
The	O
prevalence	B-T081
of	O
type 2 diabetes mellitus	B-T047
is	O
also	O
higher,	O
yet	O
data	B-T078
on	O
whether	O
diabetes	B-T047
affects	B-T080
breast cancer	B-T191
mortality	B-T081
in	O
this	O
population	B-T098
are	O
lacking	B-T080
.	O
We	O
investigated	B-T169
the	O
relation	O
of	O
diabetes	B-T047
at	O
the	O
time	O
of	O
breast cancer	B-T191
diagnosis	B-T033
to	O
breast cancer	B-T191
mortality	B-T081
in	O
the	O
Black Women's	B-T098
Health	B-T058
Study	B-T062
,	O
a	O
prospective cohort study	B-T062
.	O
1,621	O
Black women	B-T098
with	O
invasive	B-T080
breast cancer	B-T191
diagnosed	B-T033
in	O
1995-2013	O
were	O
followed by	B-T079
mailed	O
questionnaires	B-T170
and	O
searches	O
of	O
the	O
National Death Index	B-T170
.	O
Multivariable Cox regression analysis	B-T170
was	O
used	O
to	O
compute	O
hazard ratios	B-T081
(	O
HRs	B-T081
)	O
for	O
diabetes	B-T047
in	O
relation	O
to	O
breast cancer	B-T191
mortality	B-T081
and	O
all-cause	O
mortality	B-T081
,	O
with	O
adjustment	O
for	O
age	B-T032
,	O
stage	B-T201
,	O
treatment modality	B-T061
,	O
estrogen receptor	B-T116
(	O
ER	B-T116
)	O
status	B-T080
,	O
and	O
body mass index	B-T201
.	O
There	O
were	O
368	O
deaths	B-T033
during	O
follow-up	B-T058
,	O
of	O
which	O
273	O
were	O
due	O
to	O
breast cancer	B-T191
.	O
Breast cancer	B-T191
mortality	B-T081
was	O
significantly increased	B-T081
in	O
women	B-T098
who	O
had	O
been	O
diagnosed	B-T033
with	O
diabetes	B-T047
at	O
least	O
5	O
years	O
before	O
breast cancer	B-T191
occurrence	B-T079
,	O
HR	B-T081
1.86	O
(95%	O
CI	O
1.20-2.89),	O
with	O
elevations	B-T082
observed	B-T169
for	O
both	O
ER+	B-T033
and	O
ER-	B-T033
breast cancer	B-T191
.	O
All-cause	O
mortality	B-T081
was	O
also	O
higher	O
in	O
diabetics	B-T033
,	O
with	O
HRs	B-T081
of	O
1.54	O
(95%	O
CI	O
1.12-2.07)	O
overall	B-T080
and	O
2.26	O
(95%	O
CI	O
1.62-3.15)	O
for	O
≥5-year	O
duration	O
of	O
diabetes	B-T047
relative	B-T080
to	O
non-diabetics	B-T033
.	O
Our	O
results	B-T034
present	B-T033
the	O
first	O
solid	O
evidence	B-T078
of	O
a	O
positive	B-T033
association	O
of	O
type 2 diabetes	B-T047
with	O
breast cancer	B-T191
mortality	B-T081
in	O
Black women	B-T098
.	O
Given	O
the	O
higher	O
prevalence	B-T081
and	O
earlier onset	B-T033
of	O
type 2 diabetes	B-T047
in	O
Black women	B-T098
,	O
it	O
is	O
likely	O
that	O
diabetes	B-T047
contributes	B-T052
to	O
racial	B-T098
disparities	B-T033
in	O
breast cancer	B-T191
mortality	B-T081
.	O

Neuro-Behcet disease	B-T047
presenting	B-T078
as	O
a	O
solitary	O
cerebellar hemorrhagic	B-T046
lesion	B-T033
:	O
a	O
case report	B-T170
and	O
review of the literature	B-T170
Behcet's disease	B-T047
is	O
a	O
heterogeneous	B-T033
,	O
multisystem	B-T047
,	O
inflammatory disorder	B-T047
of	O
unknown etiology	B-T033
.	O
The	O
classic	O
triad	O
of	O
oral	B-T047
and	O
genital ulcerations	B-T047
in	O
conjunction	B-T078
with	O
uveitis	B-T047
was	O
originally	O
described	B-T078
by	O
the	O
Turkish	B-T098
dermatologist	B-T097
Hulusi	O
Behcet	O
in	O
1937,	O
but	O
associated symptoms	B-T184
of	O
the	O
cardiovascular	B-T022
,	O
central nervous	B-T022
,	O
pulmonary	B-T022
,	O
and	O
gastrointestinal systems	B-T022
were	O
later	O
identified	B-T080
.	O
In	O
fact,	O
Behcet's disease	B-T047
with	O
neurological involvement	B-T047
(	O
neuro-Behcet's disease	B-T047
)	O
is	O
not	O
uncommon.	O
Patients	B-T101
with	O
neuro-Behcet's disease	B-T047
typically	O
exhibit	O
a	O
diverse	O
array	O
of	O
symptoms	B-T184
,	O
most	B-T081
commonly	B-T081
in	O
the	O
brainstem	B-T023
and	O
diencephalic	B-T023
regions	B-T082
.	O
Herein,	O
we	O
report	B-T170
an	O
unusual	B-T080
case	B-T169
of	O
neuro-Behcet's disease	B-T047
in	O
a	O
patient	B-T101
who	O
presented	B-T078
with	O
a	O
solitary	O
cerebellar hemorrhage	B-T046
.	O
A	O
39-year-old	B-T100
Asian	B-T098
woman	B-T098
was	O
admitted	B-T058
to	O
our	O
hospital	B-T073
with	O
complaints	B-T033
of	O
a	O
sudden	B-T080
speech difficulty	B-T033
that	O
had	O
manifested	B-T169
the	O
same	B-T080
morning	B-T079
,	O
and	O
dizziness	B-T184
and	O
mild	B-T080
vomiting	B-T184
experienced	O
over	B-T079
the	O
previous	B-T079
3	O
days	B-T079
.	O
Magnetic resonance images	B-T170
revealed	B-T080
target-like	O
hemorrhagic	B-T046
lesions	B-T033
in	O
the	O
right hemisphere of the cerebellum	B-T023
.	O
Risk factors	B-T033
that	O
may	O
result	B-T169
in	O
cerebellar hemorrhage	B-T046
,	O
such	O
as	O
high blood pressure	B-T047
or	O
bleeding diathesis	B-T046
,	O
were	O
ruled out	B-T033
,	O
and	O
subsequent	B-T079
brain	B-T023
angiograms	B-T060
were	O
normal	B-T080
.	O
These	O
findings	B-T033
suggest	B-T078
that	O
the	O
patient's	B-T101
cerebellar hemorrhage	B-T046
could	O
have	O
been	O
due to	B-T169
intracranial	B-T029
vasculitis	B-T047
in	O
a	O
rare	B-T080
,	O
if	O
not	O
unique,	O
complication	B-T046
of	O
neuro-Behcet's disease	B-T047
.	O

Intrinsic	B-T082
rifamycin	B-T109
resistance	B-T032
of	O
Mycobacterium abscessus	B-T007
is	O
mediated	O
by	O
ADP-ribosyltransferase	B-T116
MAB_0591	B-T028
Rifampicin	B-T109
,	O
a	O
potent	O
first-line	O
TB drug	B-T121
of	O
the	O
rifamycin group	B-T109
,	O
shows	O
only	O
little	O
activity	B-T169
against	O
the	O
emerging	O
pathogen	B-T001
Mycobacterium abscessus	B-T007
.	O
Reportedly,	O
bacterial resistance	B-T046
to	O
rifampicin	B-T109
is	O
associated	O
with	O
polymorphisms	B-T045
in	O
the	O
target	O
gene rpoB	B-T028
or	O
the	O
presence	O
of	O
enzymes	B-T116
that	O
modify	O
and	O
thereby	O
inactivate	O
rifampicin	B-T109
.	O
The	O
aim	B-T078
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
role	O
of	O
the	O
MAB_0591	B-T028
(	O
arrMab	B-T028
)-encoded	O
rifampicin	B-T109
ADP-ribosyltransferase	B-T116
(	O
Arr_Mab	B-T116
)	O
in	O
innate	O
high-level	O
rifampicin	B-T109
resistance	B-T032
in	O
M. abscessus	B-T007
.	O
Recombinant	B-T001
Escherichia coli	B-T007
and	O
Mycobacterium tuberculosis	B-T007
strains	B-T001
expressing	B-T045
MAB_0591	B-T028
were	O
generated,	O
as	O
was	O
an	O
M. abscessus	B-T007
deletion mutant	B-T045
deficient	B-T169
for	O
MAB_0591	B-T028
.	O
MIC assays	B-T059
were	O
used	O
to	O
study	O
susceptibility	B-T169
to	O
rifampicin	B-T109
and	O
C25 carbamate	B-T109
-modified	O
rifamycin derivatives	B-T109
.	O
Heterologous	B-T080
expression	B-T045
of	O
MAB_0591	B-T028
conferred	O
rifampicin	B-T109
resistance	B-T032
to	O
E. coli	B-T007
and	O
M. tuberculosis	B-T007
Rifamycin	B-T109
MIC values	B-T034
were	O
consistently	O
lower	O
for	O
the	O
M. abscessus	B-T007
ΔarrMab mutant	B-T028
as	O
compared	B-T052
with	O
the	O
M. abscessus ATCC 19977	B-T007
parental type strain	B-T001
.	O
The	O
rifamycin	B-T109
WT	B-T028
phenotype	B-T032
was	O
restored	O
after	O
complementation	B-T045
of	O
the	O
M. abscessus	B-T007
ΔarrMab mutant	B-T028
with	O
arrMab	B-T116
Further	O
MIC data	B-T034
demonstrated	O
that	O
a	O
C25	B-T109
modification	B-T033
increases	O
rifamycin	B-T109
activity	B-T169
in	O
WT	B-T028
M. abscessus	B-T007
However,	O
MIC studies	B-T062
in	O
the	O
M. abscessus	B-T007
ΔarrMab mutant	B-T028
suggest	O
that	O
C25	B-T109
modified	O
rifamycins	B-T109
are	O
still	O
subject	O
to	O
modification	B-T033
by	O
Arr_Mab	B-T116
CONCLUSIONS:	O
Our	O
findings	O
identify	O
Arr_Mab	B-T116
as	O
the	O
major	O
innate	O
rifamycin	B-T109
resistance	B-T032
determinant	O
of	O
M. abscessus	B-T007
.	O
Our	O
data	O
also	O
indicate	O
that	O
Arr_Mab	B-T116
-mediated	O
rifamycin	B-T109
resistance	B-T032
in	O
M. abscessus	B-T007
can	O
only	O
in	O
part	O
be	O
overcome	O
by	O
C25 carbamate	B-T109
modification	B-T033
.	O

The	O
Silorane-based Resin Composites	B-T122
:	O
A	O
Review	B-T170
This	O
article	B-T170
aims	O
to	O
review	B-T170
the	O
research	B-T062
done	O
on	O
the	O
silorane-based resin composites	B-T122
(	O
SBRC	B-T122
)	O
regarding	O
polymerization	B-T067
shrinkage	B-T169
and	O
contraction stresses	B-T070
and	O
their	O
ability	O
to	O
improve	O
the	O
shortcomings	O
of	O
the	O
methacrylate-based resin composites	B-T122
(	O
MRBC	B-T122
).	O
Special	O
attention	O
is	O
given	O
to	O
their	O
physical	B-T070
and	O
mechanical properties	B-T070
,	O
bond strength	B-T081
,	O
marginal adaptation	B-T061
,	O
and	O
cusp deflection	B-T070
.	O
The	O
clinical significance	B-T033
of	O
this	O
material	B-T167
is	O
critically	O
appraised	O
with	O
a	O
focus	O
on	O
the	O
ability	O
of	O
SBRC	B-T122
to	O
strengthen	O
the	O
tooth structure	B-T023
as	O
a	O
direct restorative material	B-T074
.	O
A	O
search	O
of	O
English	B-T171
peer-reviewed dental literature	B-T170
(2003-2015)	O
from	O
PubMed	B-T170
and	O
MEDLINE	B-T170
databases	B-T170
was	O
conducted	O
with	O
the	O
terms	O
"	O
low	B-T080
shrinkage	B-T169
"	O
and	O
"	O
silorane composites	B-T122
."	O
The	O
list	O
was	O
screened,	O
and	O
70	O
articles	B-T170
that	O
were	O
relevant	O
to	O
the	O
objectives	B-T170
of	O
this	O
work	O
were	O
included.	O

Endoscopic	B-T060
endonasal	B-T029
surgery	B-T061
for	O
remission	B-T033
of	O
Cushing's Disease	B-T047
caused	O
by	O
ectopic	B-T082
intracavernous	B-T169
macroadenoma	B-T191
:	O
case report	B-T170
and	O
literature review	B-T170
Complete	O
surgical resection	B-T061
of	O
an	O
ACTH-secreting pituitary adenoma	B-T191
is	O
the	O
gold standard	B-T080
of	O
treatment	B-T061
of	O
Cushing's Disease	B-T047
.	O
Ectopic	B-T082
location	B-T082
of	O
these	O
adenomas	B-T191
is	O
an	O
extremely	O
rare	B-T080
condition	O
that	O
may	O
compromise	O
the	O
diagnosis	B-T033
and	O
surgical	B-T061
success	B-T054
.	O
We	O
present	O
the	O
first	O
case	O
of	O
an	O
ectopic	B-T082
intracavernous	B-T169
ACTH-secreting macroadenoma	B-T191
totally	O
resected	O
with	O
endoscopic	B-T060
endonasal	B-T029
surgery	B-T061
(	O
EES	B-T061
).	O
A	O
36	O
year	O
old	O
female	B-T032
presented	O
with	O
Cushing syndrome	B-T047
.	O
Increased	B-T081
ACTH	B-T116
,	O
serum cortisol	B-T109
and	O
free urine cortisol	B-T109
levels	B-T080
were	O
identified,	O
however	O
the	O
pituitary MRI	B-T060
failed	O
to	O
reveal	O
a	O
pituitary tumor	B-T191
;	O
instead,	O
a	O
parasellar lesion	B-T033
in	O
the	O
left	O
cavernous sinus	B-T030
(	O
CS	B-T030
)	O
was	O
noticed.	O
Inferior petrosal sinus sampling	B-T060
demonstrated	O
a	O
significant	O
central	B-T082
-to-	O
peripheral	B-T082
and	O
lateralized	O
left-sided	O
ACTH	B-T116
gradient.	O
The	O
patient	B-T101
underwent	O
EES	B-T061
.	O
No tumor	B-T033
was	O
found	O
in	O
the	O
sella	B-T023
,	O
however,	O
the	O
left	O
CS	B-T030
was	O
widely	O
explored	O
and	O
a	O
tumor	B-T191
was	O
found	O
lateral	B-T082
to	O
the	O
paraclival	O
segment	O
of	O
the	O
carotid artery	B-T023
.	O
There	O
were	O
no	B-T033
complications	B-T046
following	O
EES	B-T061
.	O
Pathology	B-T091
confirmed	O
the	O
diagnosis	B-T033
of	O
an	O
ACTH-secreting adenoma	B-T191
.	O
During	O
the	O
immediately	O
postoperative	B-T079
course	O
serum cortisol	B-T109
levels	B-T080
dropped	O
below	O
5	O
mcg/dl.	O
Postoperative	B-T079
MRI	B-T060
demonstrated	O
complete	O
tumor resection	B-T061
.	O
At	O
20	O
months	O
follow-up	B-T058
,	O
the	O
patient	B-T101
remains	O
in	O
clinical	B-T080
and	O
biochemical	B-T169
remission	B-T033
of	O
Cushing's Disease	B-T047
.	O
Only	O
12	O
cases	O
of	O
ectopic	B-T082
intracavernous	B-T169
ACTH-secreting adenomas	B-T191
have	O
been	O
reported	O
to	O
date	O
and	O
all	O
were	O
microadenomas	B-T191
.	O
The	O
presence	O
of	O
an	O
ectopic	B-T082
ACTH-secreting macroadenoma	B-T191
in	O
the	O
CS	B-T030
represents	O
a	O
surgical	B-T061
challenge.	O
EES	B-T061
is	O
the	O
ideal	O
approach	O
for	O
complete	O
resection	B-T061
of	O
ectopic	B-T082
intracavernous	B-T169
adenomas	B-T191
allowing	O
for	O
a	O
wide	O
exploration	B-T061
of	O
the	O
CS	B-T030
with	O
no	B-T033
surgical	B-T061
complications	B-T046
.	O

Preliminary	O
Randomized Controlled Trial	B-T062
of	O
Habit Reversal Training	B-T061
for	O
Treatment	B-T061
of	O
Hair Pulling	B-T048
in	O
Youth	B-T100
This	O
study	B-T062
evaluated	B-T058
the	O
treatment	B-T061
efficacy	B-T080
of	O
habit reversal training	B-T061
(	O
HRT	B-T061
)	O
relative	O
to	O
treatment as usual	B-T077
(	O
TAU	B-T077
)	O
for	O
children	B-T100
and	O
adolescents	B-T100
aged	B-T032
7-17	O
years	B-T079
with	O
a	O
primary	O
diagnosis	B-T062
of	O
trichotillomania	B-T048
(	O
TTM	B-T048
).	O
An	O
initial	O
assessment	B-T058
consisting	O
of	O
semistructured	O
interviews	B-T052
and	O
rating scales	B-T081
was	O
conducted.	O
Participants	B-T098
(N	O
=	O
40,	O
85%	O
female	B-T032
)	O
meeting	O
diagnostic criteria	B-T170
for	O
TTM	B-T048
were	O
randomized	B-T062
to	O
either	O
8	O
weekly	B-T079
sessions	O
of	O
HRT	B-T061
by	O
trained	O
therapists	B-T097
or	O
8	O
weeks	B-T079
of	O
TAU	B-T077
.	O
One	O
week	B-T079
after	O
the	O
final	O
HRT	B-T061
session	O
or	O
final	O
TAU	B-T077
week	B-T079
,	O
patients	B-T101
completed	O
a	O
posttreatment assessment	B-T058
,	O
followed	O
by	O
1-	O
and	O
3-	O
month	B-T079
follow-up	B-T058
assessments	B-T058
.	O
All	O
assessments	B-T058
were	O
conducted	O
by	O
a	O
trained	O
rater	B-T097
who	O
was	O
blinded	B-T062
to	O
treatment	B-T061
condition	B-T080
.	O
The	O
group	O
by	O
time	O
analysis of variance	B-T081
yielded	O
a	O
significant	B-T078
interaction	O
on	O
the	O
National Institute of Mental Health	B-T093
-	O
Trichotillomania Severity Scale Total Score	B-T081
(F1,38	O
=	O
16.47,	O
p	O
<	O
0.001,	O
η(2)p	O
=	O
0.30).	O
The	O
mean score	B-T033
decreased	O
from	O
12.67	O
±	O
4.60	O
at	O
baseline	B-T081
to	O
5.62	O
±	O
4.38	O
at	O
posttreatment	B-T058
in	O
the	O
HRT	B-T061
group	B-T098
(t20	O
=	O
5.99,	O
p	O
<	O
0.001,	O
d	O
=	O
1.31),	O
whereas	O
the	O
TAU	B-T077
group	B-T098
changed	O
from	O
10.42	O
±	O
4.35	O
to	O
9.32	O
±	O
4.11	O
(t18	O
=	O
1.34,	O
p	O
=	O
0.20,	O
d	O
=	O
0.31).	O
The Massachusetts General Hospital-Hair Pulling Scale Total Score	B-T081
decreased	O
from	O
15.14	O
±	O
3.86	O
at	O
baseline	B-T081
to	O
7.14	O
±	O
5.54	O
at	O
posttreatment	B-T058
in	O
the	O
HRT	B-T061
group	B-T098
(t20	O
=	O
6.16,	O
p	O
<	O
0.001,	O
d	O
=	O
1.34);	O
the	O
TAU	B-T077
group	B-T098
changed	O
from	O
14.16	O
±	O
4.51	O
to	O
12.26	O
±	O
4.34	O
(t18	O
=	O
1.50,	O
p	O
=	O
0.15,	O
d	O
=	O
0.34).	O
On	O
the	O
Clinical Global Impressions-Improvement	B-T170
,	O
16/21	O
participants	B-T098
(76%)	O
were	O
rated	O
as	O
treatment	B-T061
responders	B-T098
in	O
the	O
HRT	B-T061
group	B-T098
versus	O
4/19	O
(21%)	O
in	O
the	O
TAU	B-T077
group	B-T098
(χ(2)	O
=	O
12.13,	O
p	O
<	O
0.001,	O
V	O
=	O
0.55).	O
At	O
1-	O
month	B-T079
follow-up	B-T058
,	O
10-12	O
treatment	B-T061
responders	B-T098
who	O
completed	O
the	O
assessment	B-T058
maintained	O
improvement	B-T077
.	O
At	O
3-	O
month	B-T079
follow-up	B-T058
,	O
six	O
of	O
eight	O
maintained	O
improvement	B-T077
.	O
HRT	B-T061
can	O
be	O
an	O
effective	O
treatment	B-T061
for	O
TTM	B-T048
in	O
youth	B-T100
.	O

Fully	B-T080
Endoscope	B-T074
-	O
Controlled	B-T169
Clipping	B-T061
Bilateral Middle Cerebral Artery Aneurysm	B-T047
Via	O
Unilateral Supraorbital Keyhole Approach	B-T061
Clipping	B-T061
bilateral middle cerebral artery (bMCA) aneurysms	B-T047
via	O
unilateral approach	B-T061
in	O
a	O
single-stage operation	B-T061
is	O
considered	O
as	O
a	O
challenge	O
procedure.	O
To	O
our	O
knowledge,	O
there	O
is	O
no	O
study	O
in	O
surgical management	B-T058
of	O
patients	B-T101
with	O
bMCA aneurysms	B-T047
by	O
fully	O
endoscope	B-T074
-	O
controlled	B-T169
techniques	B-T169
.	O
The	O
author	O
reported	O
a	O
patient	B-T101
with	O
bMCA aneurysms	B-T047
who	O
underwent	O
aneurysms clipping	B-T061
via	O
a	O
unilateral supraorbital keyhole approach	B-T061
by	O
endoscope	B-T074
-	O
controlled	B-T169
microneurosurgery	B-T061
,	O
and	O
the	O
patient	B-T101
had	O
an	O
uneventful	O
postoperative course	B-T079
without	B-T080
neurologic	B-T080
impairment	B-T046
and	O
complication	B-T046
.	O
Furthermore,	O
the	O
author	O
discussed	O
the	O
advantages	O
and	O
adaptation	B-T170
of	O
endoscope	B-T074
-	O
controlled	B-T169
clipping	B-T061
bMCA aneurysms	B-T047
via	O
unilateral supraorbital keyhole approach	B-T061
.	O

Novel	B-T080
Observations	B-T062
in	O
11	O
Heteroresistant	B-T039
Vancomycin-Intermediate	B-T116
Methicillin-Resistant Staphylococcus aureus Strains	B-T007
from	O
South India	B-T083
We	O
report	O
here	O
the	O
draft	O
genome sequences	B-T085
of	O
11	O
heteroresistant	B-T039
vancomycin-intermediate Staphylococcus aureus (hVISA) strains	B-T007
from	O
bloodstream infection	B-T046
.	O
All	O
strains	B-T001
harbor	O
mutations	B-T045
in	O
vraSR	B-T028
,	O
graSR	B-T028
,	O
walKR	B-T028
,	O
and/or	O
tcaRAB	B-T028
and	O
are	O
often	O
implicated	O
as	O
the	O
frequently	O
mutated	B-T045
candidate	O
genes	B-T028
in	O
hVISA	B-T007
phenotypes	B-T032
.	O

Endpoints	B-T080
for	O
screening	B-T060
thyroid cancer	B-T191
in	O
the	O
Republic of Korea	B-T083
:	O
thyroid	B-T023
specialists	B-T097
'	O
perspectives	B-T041
Cancer screening	B-T060
is	O
aimed	O
primarily	O
at	O
reducing	B-T080
deaths	B-T033
from	O
the	O
specific	O
cancer	B-T191
.	O
Thyroid-specific cancer	B-T191
mortality	B-T081
may	O
be	O
the	O
most	O
ambitious	O
endpoint	B-T080
for	O
obtaining	O
estimates	B-T081
of	O
screening	B-T058
effect	B-T080
.	O
Numerous	B-T081
observations	B-T060
have	O
accumulated	B-T033
over	O
the	O
years,	O
indicating	O
that	O
thyroid cancer	B-T191
mortality	B-T081
endpoint	B-T080
has	O
been	O
difficult	B-T080
to	O
study	O
and	O
is	O
confounded	O
by	O
population heterogeneity	B-T102
,	O
provision	B-T058
of	O
randomization	B-T062
,	O
and	O
requirement	B-T169
of	O
large	O
cohorts	B-T098
with	O
sufficiently	O
long follow-up	B-T058
due	O
to	O
the	O
excellent	B-T080
prognosis of the cancer	B-T201
.	O
Accordingly,	O
it	O
may	O
be	O
important	B-T080
to	O
reconsider	O
how	O
to	O
best	O
measure	O
thyroid cancer	B-T191
screening	B-T060
efficacy	B-T080
.	O
Recommendations	B-T078
against	O
thyroid cancer	B-T191
screening	B-T060
should	O
be	O
based	O
upon	O
trials	O
designed	O
to	O
evaluate	O
its	O
effectiveness	B-T080
not	O
only	O
in	O
significant reduction	B-T080
in	O
cancer	B-T191
mortality	B-T081
,	O
but	O
also	O
of	O
other	O
distinct	O
endpoint	B-T080
s.	O
It	O
is	O
desirable	O
to	O
evaluate	O
derivative	O
endpoints	B-T080
that	O
can	O
reliably	O
predict	O
reductions in mortality	B-T081
.	O
The	O
term	O
"derivative"	O
means	O
a	O
variable	O
that	O
is	O
related	O
to	O
the	O
true	O
endpoint	B-T080
and	O
is	O
likely	O
to	O
be	O
observable	O
before	O
the	O
primary	O
endpoint	B-T080
.	O
Derivative	O
endpoints	B-T080
may	O
include	O
thyroid cancer	B-T191
incidence	B-T081
,	O
the	O
proportion	B-T081
of	O
early-stage	B-T079
tumors	B-T191
detected	B-T033
,	O
more	O
treatable stage	B-T201
,	O
the	O
identification	B-T080
of	O
small tumors	B-T080
(to	O
maintain	O
in	O
observation),	O
decrease in the number of people	B-T058
who	O
develop	O
metastatic disease	B-T191
,	O
the	O
increased	B-T081
chance	O
of	O
lesser	O
extent	O
surgery	B-T061
,	O
and	O
the	O
application	O
of	O
minimally invasive approaches	B-T169
,	O
as	O
well	O
as	O
no	O
need	O
for	O
lifelong	B-T079
thyroid replacement therapy	B-T061
,	O
a	O
consistent	B-T078
follow-up	B-T058
,	O
low-dose	B-T081
or	O
no	O
RAI administration	B-T060
and	O
risk factor assessments	B-T170
where	O
case findings	B-T058
should	O
be	O
continuous	B-T078
.	O
The	O
Korean	B-T098
Korean guidelines	B-T170
for	O
thyroid cancer	B-T191
national-level	B-T082
screening	B-T058
were	O
published	O
by	O
a	O
relevant	O
group	O
of	O
multidisciplinary thyroid experts	B-T060
.	O
It	O
was	O
concluded	O
that	O
the	O
evidence is insufficient	B-T169
to	O
balance	O
the	O
benefits	B-T081
and	O
harms	O
of	O
thyroid cancer	B-T191
screening	B-T060
.	O
However,	O
the	O
paper	O
seems	O
to	O
raise	O
the	O
necessary	O
investments	O
in	O
future	O
research	B-T062
and	O
demand	O
a	O
complete	B-T080
analysis	B-T062
for	O
derivative	O
endpoints	B-T080
,	O
and	O
offer	O
screening	B-T058
participants	B-T098
with	O
complete	O
information	B-T078
necessary	O
to make decisions	B-T041
that	O
will	O
provide	O
them	O
with	O
the	O
most	O
value	O
when	O
a	O
small	O
thyroid cancer	B-T191
is	O
screen-	O
identified	B-T080
.	O

Zebrafish	B-T013
adult pigment stem cells	B-T025
are	O
multipotent	B-T025
and	O
form pigment cells	B-T025
by	O
a	O
progressive	B-T169
fate restriction process	B-T043
:	O
Clonal analysis	B-T060
identifies	B-T080
shared	O
origin	O
of	O
all	O
pigment cell types	B-T025
Skin pigment	B-T033
pattern formation	B-T040
is	O
a	O
paradigmatic	B-T061
example	O
of	O
pattern formation	B-T040
.	O
In	O
zebrafish	B-T013
,	O
the	O
adult	B-T100
body stripes	B-T023
are	O
generated	B-T052
by	O
coordinated	B-T169
rearrangement	B-T043
of	O
three	B-T081
distinct	O
pigment cell-types	B-T025
,	O
black	B-T080
melanocytes	B-T025
,	O
shiny	B-T080
iridophores	B-T025
and	O
yellow	B-T080
xanthophores	B-T025
.	O
A	O
stem cell origin	B-T025
of	O
melanocytes	B-T025
and	O
iridophores	B-T025
has	O
been	O
proposed	O
although	O
the	O
potency	B-T080
of	O
those	O
stem cells	B-T025
has	O
remained	B-T080
unclear	B-T033
.	O
Xanthophores	B-T025
,	O
however,	O
seemed	O
to	O
originate	O
predominantly	B-T080
from	O
proliferation	B-T043
of	O
embryonic	B-T018
xanthophores	B-T025
.	O
Now,	O
data	B-T078
from	O
Singh	O
et	O
al.	O
shows	O
that	O
all	O
three	B-T081
cell-types	B-T025
derive	B-T080
from	O
shared	O
stem cells	B-T025
,	O
and	O
that	O
these	O
cells	B-T025
generate	B-T052
peripheral	B-T082
neural cell-types	B-T025
too.	O
Furthermore,	O
clonal	B-T024
compositions	B-T080
are	O
best	O
explained	O
by	O
a	O
progressive	B-T169
fate restriction model	B-T043
generating	B-T052
the	O
individual	B-T080
cell-types	B-T025
.	O
The	O
numbers	B-T081
of	O
adult pigment stem cells	B-T025
associated with	B-T080
the	O
dorsal root ganglia	B-T023
remain	B-T033
low	B-T080
,	O
but	O
progenitor	B-T025
numbers	B-T081
increase	B-T169
significantly	O
during	B-T079
larval development	B-T040
up	O
to	O
metamorphosis	B-T040
,	O
likely	O
via	O
production	O
of	O
partially	B-T081
restricted	B-T169
progenitors	B-T025
on	O
the	O
spinal nerves	B-T023
.	O

Covalent Modulators	B-T121
of	O
the	O
Vacuolar ATPase	B-T116
The	O
vacuolar H(+) ATPase	B-T116
(	O
V-ATPase	B-T116
)	O
is	O
a	O
complex	B-T104
multisubunit	O
machine	B-T169
that	O
regulates	B-T038
important	O
cellular processes	B-T043
through	O
controlling	B-T169
acidity	B-T081
of	O
intracellular	B-T082
compartments	B-T017
in	O
eukaryotes	B-T204
.	O
Existing	O
small-molecule	B-T109
modulators	B-T121
of	O
V-ATPase	B-T116
either	O
are	O
restricted	B-T169
to	O
targeting	B-T043
one	O
membranous	B-T080
subunit	B-T081
of	O
V-ATPase	B-T116
or	O
have	O
poorly	O
understood	B-T041
mechanisms	B-T169
of	O
action.	O
Small molecules	B-T109
with	O
novel	B-T080
and	O
defined	B-T080
mechanisms	B-T169
of	O
inhibition	B-T044
are	O
thus	O
needed	B-T080
to	O
functionally	B-T169
characterize	B-T052
V-ATPase	B-T116
and	O
to	O
fully	O
evaluate	O
the	O
therapeutic	B-T169
relevance	B-T080
of	O
V-ATPase	B-T116
in	O
human	B-T016
diseases	B-T047
.	O
We	O
have	O
discovered	O
electrophilic	B-T080
quinazolines	B-T109
that	O
covalently modify	B-T044
a	O
soluble	B-T080
catalytic subunit	B-T087
of	O
V-ATPase	B-T116
with	O
high	B-T080
potency	B-T081
and	O
exquisite	O
proteomic selectivity	B-T080
as	O
revealed	B-T080
by	O
fluorescence imaging	B-T060
and	O
chemical proteomic activity-based profiling	B-T059
.	O
The	O
site	B-T082
of	O
covalent	O
modification	B-T169
was	O
mapped	B-T052
to	O
a	O
cysteine	B-T116
residue	B-T077
located in	B-T082
a	O
region	B-T087
of	O
V-ATPase	B-T116
subunit A	B-T116
that	O
is	O
thought	B-T041
to	O
regulate	B-T038
the	O
dissociation	B-T044
of	O
V-ATPase	B-T116
.	O
We	O
further	O
demonstrate	O
that	O
a	O
previously	O
reported	O
V-ATPase inhibitor	B-T121
,	O
3-bromopyruvate	B-T109
,	O
also	O
targets	B-T169
the	O
same	B-T080
cysteine	B-T116
residue	B-T077
and	O
that	O
our	O
electrophilic	B-T080
quinazolines	B-T109
modulate	B-T082
the	O
function	B-T169
of	O
V-ATPase	B-T116
in	O
cells	B-T025
.	O
With	O
their	O
well-defined	B-T080
mechanism	B-T169
of	O
action	B-T052
and	O
high	B-T080
proteomic specificity	B-T081
,	O
the	O
described	O
quinazolines	B-T109
offer	O
a	O
powerful	B-T081
set	B-T077
of	O
chemical probes	B-T120
to	O
investigate	B-T169
the	O
physiological	B-T169
and	O
pathological	B-T169
roles	B-T077
of	O
V-ATPase	B-T116
.	O

Association	B-T080
of	O
Radiomics	O
and	O
Metabolic	B-T169
Tumor Volumes	B-T081
in	O
Radiation Treatment	B-T061
of	O
Glioblastoma Multiforme	B-T191
To	O
build	O
a	O
framework	O
for	O
investigation	B-T058
of	O
the	O
associations	B-T080
between	O
imaging	B-T060
,	O
clinical target volumes	B-T081
(	O
CTVs	B-T081
),	O
and	O
metabolic	B-T169
tumor volumes	B-T081
(	O
MTVs	B-T081
)	O
features	B-T080
for	O
better	O
understanding	O
of	O
the	O
underlying	O
information	B-T078
in	O
the	O
CTVs	B-T081
and	O
dependencies	O
between	O
these	O
volumes	B-T081
.	O
High-throughput extraction	B-T170
of	O
imaging	B-T060
and	O
metabolomic	B-T091
quantitative	B-T081
features	B-T080
from	O
magnetic resonance imaging	B-T060
(	O
MRI	B-T060
)	O
and	O
magnetic resonance spectroscopic imaging	B-T060
of	O
glioblastoma multiforme	B-T191
(	O
GBM	B-T191
)	O
results	O
in	O
tens	O
of	O
variables	O
per	O
patient	B-T101
.	O
In	O
radiation therapy	B-T061
of	O
GBM	B-T191
the	O
relevant	B-T080
metabolic	B-T169
tumor volumes	B-T081
(	O
MTVs	B-T081
)	O
are	O
related	O
to	O
aberrant	B-T080
levels	B-T080
of	O
N-acetyl aspartate	B-T116
(	O
NAA	B-T116
)	O
and	O
choline	B-T109
(	O
Cho	B-T109
).	O
The	O
corresponding	O
clinical target volumes	B-T081
(	O
CTVs	B-T081
)	O
for	O
radiation therapy	B-T061
are	O
based	O
on	O
contrast-enhanced T1-weighted	B-T060
(	O
CE-T1w	B-T060
)	O
and	O
T2-weighted (T2w)/fluid-attenuated inversion recovery MRI	B-T060
.	O
Necrotic portions	B-T033
,	O
enhancing lesion	B-T033
,	O
and	O
edema	B-T184
were	O
manually	O
contoured	O
on	O
CE-T1w	B-T170
/	O
T2w images	B-T170
for	O
17	O
GBM	B-T191
patients	B-T101
.	O
Clinical target volumes	B-T081
and	O
MTVs	B-T081
for	O
NAA	B-T116
(	O
MTVNAA	B-T081
)	O
and	O
Cho	B-T109
(	O
MTVCho	B-T081
)	O
were	O
constructed.	O
Imaging	B-T060
and	O
metabolic features	B-T201
related	O
to	O
size	B-T082
,	O
shape	B-T082
,	O
and	O
signal intensities	B-T081
of	O
the	O
volumes	B-T081
were	O
extracted.	O
Tumors	B-T191
were	O
also	O
scored	O
categorically	O
for	O
10	O
semantic	B-T078
imaging traits	B-T080
by	O
a	O
neuroradiologist	B-T097
.	O
All	O
features	B-T080
were	O
investigated	B-T169
for	O
redundancy	B-T169
.	O
Two-way correlations	B-T080
between	O
imaging	B-T170
and	O
CTVs	B-T081
/	O
MTVs	B-T081
features	O
were	O
visualized	O
as	O
heatmaps	B-T073
.	O
Associations	B-T080
between	O
MTVNAA	B-T081
and	O
MTVCho	B-T081
and	O
imaging features	B-T080
were	O
studied	O
using	O
Spearman correlation	B-T170
.	O
Forty-eight	O
imaging features	B-T080
were	O
extracted	O
per	O
patient	B-T101
.	O
Half	B-T081
of	O
the	O
imaging traits	B-T080
were	O
replaced	B-T169
with	O
automatically	O
extracted	O
continuous variables	B-T080
.	O
Twenty	O
features	B-T080
were	O
extracted	O
from	O
CTVs	B-T081
and	O
MTVs	B-T081
.	O
A	O
series	O
of	O
semantic	B-T078
imaging traits	B-T080
were	O
replaced	B-T169
with	O
automatically	O
extracted	O
continuous variables	B-T080
.	O
There	O
were	O
multiple	O
(22)	O
significant	O
correlations	B-T080
of	O
imaging measures	B-T080
with	O
CTVs	B-T081
/	O
MTVNAA	B-T081
,	O
whereas	O
there	O
were	O
only	O
6	O
with	O
CTVs	B-T081
/	O
MTVCho	B-T081
.	O
A	O
framework	O
for	O
investigation	O
of	O
codependencies	O
between	O
MRI	B-T060
and	O
magnetic resonance spectroscopic imaging	B-T060
radiomic	O
features	B-T080
and	O
CTVs	B-T081
/	O
MTVs	B-T081
has	O
been	O
established.	O
The	O
MTV	B-T081
for	O
NAA	B-T116
was	O
found	O
to	O
be	O
closely	O
associated with	B-T080
MRI	B-T060
volumes	B-T081
,	O
whereas	O
very	O
few	O
imaging features	B-T080
were	O
related	O
to	O
MTVCho	B-T081
,	O
indicating	O
that	O
Cho	B-T109
provides	O
additional information	B-T079
to	O
imaging	B-T060
.	O

Measurement	B-T169
of	O
fidgeting	B-T033
in	O
patients	B-T101
with	O
anorexia nervosa	B-T048
using	O
a	O
novel	O
shoe	B-T073
-based	O
monitor	B-T074
To	O
objectively	O
assess	O
seated	B-T033
non-exercise physical activity	B-T056
in	O
patients	B-T101
with	O
anorexia nervosa	B-T048
(	O
AN	B-T048
)	O
relative	O
to	O
healthy controls	B-T080
(	O
HCs	B-T080
)	O
and	O
examine	O
the	O
associations	B-T080
between	O
this	O
physical activity	B-T056
,	O
eating disorder	B-T048
pathology	B-T046
,	O
and	O
levels	B-T080
of	O
anxiety	B-T033
and	O
depression	B-T048
.	O
Eleven	O
inpatients	B-T101
with	O
AN	B-T048
and	O
10	O
HCs	B-T080
wore	O
a	O
shoe	B-T073
-based	O
accelerometer	B-T074
(	O
SmartShoe	B-T074
)	O
at	O
three	O
time points	B-T079
:	O
a)	O
while eating lunch	B-T079
,	O
b)	O
filling out questionnaires	B-T079
,	O
and	O
c)	O
watching television for 1h	B-T079
.	O
Across	O
all	O
three	O
tasks	B-T057
,	O
patients	B-T101
with	O
AN	B-T048
were	O
significantly	O
more active	B-T169
than	O
HCs	B-T080
,	O
thereby	O
engaging	O
in	O
a	O
greater degree	B-T081
of	O
restless	B-T184
or	O
fidgeting	B-T033
behavior	B-T053
.	O
Degree	B-T081
of	O
physical activity	B-T056
was	O
positively correlated	B-T033
with	O
eating disorder	B-T048
psychopathology	B-T091
in	O
the	O
sample	O
with	O
AN	B-T048
,	O
and	O
a	O
trend	O
towards	O
a	O
positive association	B-T033
between	O
physical activity	B-T056
and	O
levels	B-T080
of	O
depression	B-T048
and	O
anxiety	B-T033
was	O
also	O
found	O
in	O
this	O
sample.	O
Among	O
individuals	B-T098
with	O
AN	B-T048
,	O
physical activity	B-T056
was	O
not	B-T033
significantly	O
correlated	B-T080
with	O
BMI	B-T201
,	O
duration of illness	B-T079
,	O
or	O
number of days	B-T081
since	O
hospital admission	B-T058
.	O
Use	O
of	O
a	O
minimally invasive	B-T169
,	O
shoe	B-T073
-based	O
monitor	B-T074
revealed	O
patients	B-T101
with	O
AN	B-T048
engaged	O
in	O
a	O
greater degree	B-T081
of	O
fidgeting	B-T033
relative	O
to	O
HCs	B-T080
during	O
quiet,	O
seated	B-T033
tasks	B-T057
and	O
this	O
heightened	O
activity	B-T056
was	O
related	O
to	O
measures	B-T081
of	O
pathology	B-T046
.	O
Non-exercise physical activity	B-T056
,	O
including	O
fidgeting	B-T033
,	O
may	O
warrant	O
further	O
clinical	B-T080
attention	O
in	O
this	O
patient population	B-T101
.	O

Hospital clowning	B-T073
:	O
a	O
paediatrician's	B-T097
view	B-T041
This	O
study	B-T062
investigates	B-T169
the	O
current	B-T079
position	O
of	O
hospital clowns	B-T097
from	O
the	O
perspective	B-T041
of	O
paediatricians	B-T097
and	O
paediatric residents	B-UnknownType
.	O
A	O
total	B-T080
of	O
14	O
attending paediatricians	B-T097
and	O
paediatric residents	B-UnknownType
participated	B-T169
in	O
two	O
focus group sessions	B-T077
.	O
Data	B-T078
were	O
analysed	B-T062
using	O
Atlas.ti 5.0	B-T073
.	O
In	O
general	B-T082
,	O
physicians	B-T097
reported	B-T170
positive	B-T033
experiences	B-T041
regarding	O
the	O
interaction	B-T033
between	O
hospital clowns	B-T097
and	O
paediatric patients	B-T101
on	O
the	O
ward	B-T073
.	O
Physicians	B-T097
were	O
more	O
interested	B-T041
in	O
research	B-T062
on	O
children's perception	B-T041
of	O
hospital clowns	B-T097
than	O
in	O
research	B-T062
on	O
the	O
clinical efficacy	B-T080
of	O
hospital clowning	B-T073
.	O
No direct	B-T080
collaboration	B-T054
between	O
physicians	B-T097
and	O
hospital clowns	B-T097
was	O
reported	B-T170
.	O
However,	O
physicians	B-T097
proposed	B-T080
conditions	B-T080
which	O
may	O
streamline	B-T080
their	O
encounters	B-T053
with	O
hospital clowns	B-T097
such	O
as	O
clear communication	B-T054
prior	B-T079
to	O
hospital clown	B-T097
visits	B-T058
,	O
and	O
the	O
condition	B-T080
that	O
visits	B-T053
do	O
not	O
impede	B-T080
medical interventions	B-T061
.	O
Overall	B-T080
,	O
paediatricians	B-T097
and	O
paediatric residents	B-UnknownType
view	B-T041
the	O
positive	B-T033
impact	B-T080
on	O
paediatric patients	B-T101
as	O
the	O
most	O
important	B-T080
aspect	B-T080
of	O
hospital clown	B-T097
visits	B-T058
,	O
rather	O
than	O
the	O
clinical efficacy	B-T080
of	O
hospital clowning	B-T073
.	O
In	O
light	O
of	O
the	O
growing	O
number	O
of	O
hospital clowns	B-T097
worldwide	B-T098
,	O
this	O
article	B-T170
provides	O
recommendations	B-T078
for	O
arranging	O
their	O
encounters	B-T053
with	O
paediatricians	B-T097
and	O
paediatric residents	B-UnknownType
to	O
maintain	B-T052
optimal	B-T080
health care	B-T058
.	O
What	O
is	O
known:	O
•	O
Previous	B-T079
studies	B-T062
show	O
a	O
clinically significant	B-T078
pain	B-T184
-	O
and	O
anxiety	B-T033
-	O
reducing effect	B-T080
of	O
hospital clowning	B-T073
in	O
paediatric patients	B-T101
admitted to hospitals	B-T058
or	O
undergoing	B-T080
(	O
invasive	B-T080
)	O
medical procedures	B-T058
.	O
•	O
In	O
general,	O
paediatricians	B-T097
have	O
positive	B-T033
ideas	B-T078
about	O
hospital clowns	B-T097
,	O
aside	O
from	O
personal prejudices	B-T055
.	O
What	O
is	O
new:	O
•	O
This	O
novel	B-T080
study	B-T062
gives	O
deeper	O
insight	B-T041
into	O
day-to-day	B-T079
interaction	B-T033
between	O
paediatricians	B-T097
and	O
hospital clowns	B-T097
on	O
the	O
ward	B-T073
.	O
•	O
This	O
study	B-T062
provides	O
recommendations	B-T078
for	O
clinical practice	B-T170
to	O
arrange	O
encounters	B-T053
between	O
physicians	B-T097
and	O
hospital clowns	B-T097
during	O
hospital clown	B-T097
visits	B-T058
.	O

Multiparametric estimation	B-T062
of	O
brain hemodynamics	B-T042
with	O
MR fingerprinting ASL	B-T060
Assessment	B-T058
of	O
brain hemodynamics	B-T042
without	O
exogenous	B-T169
contrast agents	B-T130
is	O
of	O
increasing	B-T169
importance	B-T080
in	O
clinical applications	B-UnknownType
.	O
This	O
study	O
aims	O
to	O
develop	O
an	O
MR perfusion technique	B-T060
that	O
can	O
provide	O
noncontrast	B-T033
and	O
multiparametric estimation	B-T062
of	O
hemodynamic	B-T042
markers	B-T074
.	O
We	O
devised	O
an	O
arterial spin labeling	B-T060
(	O
ASL	B-T060
)	O
method	O
based	O
on	O
the	O
principle	O
of	O
MR fingerprinting	B-T060
(	O
MRF	B-T060
),	O
referred	B-T169
to	O
as	O
MRF-ASL	B-T060
.	O
By	O
taking	O
advantage	O
of	O
the	O
rich	O
information	B-T078
contained	O
in	O
MRF sequence	B-T060
,	O
up	O
to	O
seven	O
hemodynamic	B-T042
parameters	B-T033
can	O
be	O
estimated	B-T081
concomitantly	B-T079
.	O
Feasibility demonstration	B-T062
,	O
flip angle	B-T080
optimization	B-T052
,	O
comparison	B-T052
with	O
Look-Locker ASL	B-T060
,	O
reproducibility test	B-T080
,	O
sensitivity	B-T169
to	O
hypercapnia challenge	B-T033
,	O
and	O
initial	O
clinical application	B-UnknownType
in	O
an	O
intracranial steno-occlusive process	B-T061
,	O
Moyamoya disease	B-T047
,	O
were	O
performed	B-T169
to	O
evaluate	O
this	O
technique	B-T169
.	O
Magnetic resonance fingerprinting ASL	B-T060
provided	B-T052
estimation	O
of	O
up	O
to	O
seven	O
parameters	B-T033
,	O
including	O
B1+	B-T081
,	O
tissue	B-T023
T1	B-T081
,	O
cerebral blood flow	B-T033
(	O
CBF	B-T033
),	O
tissue	B-T024
bolus arrival time	B-T033
(	O
BAT	B-T033
),	O
pass-through	O
arterial	B-T023
BAT	B-T033
,	O
pass-through	O
blood volume	B-T201
,	O
and	O
pass-through	O
blood travel time	B-T060
.	O
Coefficients	B-T081
of	O
variation	B-T080
of	O
the	O
estimated	B-T081
parameters	B-T033
ranged	O
from	O
0.2	O
to	O
9.6%.	O
Hypercapnia	B-T033
resulted	O
in	O
an	O
increase	B-T169
in	O
CBF	B-T033
by	O
57.7%,	O
and	O
a	O
decrease	B-T081
in	O
BAT	B-T033
by	O
13.7	O
and	O
24.8%	O
in	O
tissue	B-T024
and	O
vessels	B-T023
,	O
respectively.	O
Patients	B-T101
with	O
Moyamoya disease	B-T047
showed	O
diminished	B-T081
CBF	B-T033
and	O
lengthened	B-T169
BAT	B-T033
that	O
could not be detected	B-T033
with	O
regular	B-T080
ASL	B-T060
.	O
Magnetic resonance fingerprinting ASL	B-T060
is	O
a	O
promising	O
technique	B-T169
for	O
noncontrast	B-T033
,	O
multiparametric	B-T062
perfusion assessment	B-T058
.	O
Magn	O
Reson	O
Med,	O
2016.	O
©	O
2016	O
International Society for Magnetic Resonance in Medicine	B-T073
.	O

Acute	B-T079
sensitivity	B-T169
of	O
the	O
vernal pool fairy shrimp	B-T204
,	O
Branchinecta lynchi	B-T204
(	O
Anostraca	B-T204
;	O
Branchinectidae	B-T204
),	O
and	O
surrogate	B-T099
species	B-T185
to	O
10	O
chemicals	B-T103
Vernal pool fairy shrimp	B-T204
,	O
Branchinecta lynchi	B-T204
,	O
(	O
Branchiopoda	B-T204
;	O
Anostraca	B-T204
)	O
and	O
other	O
fairy shrimp	B-T204
species	B-T185
have	O
been	O
listed	O
as	O
threatened	B-T098
or	O
endangered	B-T098
under	O
the	O
US	O
Endangered	O
Species	O
Act.	O
Because	O
few	O
data	B-T078
exist	O
about	O
the	O
sensitivity	B-T169
of	O
Branchinecta	B-T204
spp.	B-T185
to	O
toxic effects	B-T037
of	O
contaminants	B-T167
,	O
it	O
is	O
difficult	O
to	O
determine	O
whether	O
they	O
are	O
adequately protected	B-T204
by	O
water quality	B-T080
criteria	B-T078
.	O
A	O
series	O
of	O
acute (24-h) lethality/immobilization tests	B-T059
was	O
conducted	O
with	O
3	O
species	B-T185
of	O
fairy shrimp	B-T204
(	O
B. lynchi	B-T204
,	O
Branchinecta lindahli	B-T204
,	O
and	O
Thamnocephalus platyurus	B-T204
)	O
and	O
10	O
chemicals	B-T103
with	O
varying	O
modes	O
of	O
toxic action	B-T131
:	O
ammonia	B-T121
,	O
potassium	B-T123
,	O
chloride	B-T197
,	O
sulfate	B-T197
,	O
chromium(VI)	B-T131
,	O
copper	B-T121
,	O
nickel	B-T123
,	O
zinc	B-T121
,	O
alachlor	B-T109
,	O
and	O
metolachlor	B-T109
.	O
The	O
same	O
chemicals	B-T103
were	O
tested	O
in	O
48-	O
h	B-T079
tests	B-T059
with	O
other	O
branchiopods	B-T204
(the	O
cladocerans	B-T204
Daphnia magna	B-T204
and	O
Ceriodaphnia dubia	B-T204
)	O
and	O
an	O
amphipod	B-T204
(	O
Hyalella azteca	B-T011
),	O
and	O
in	O
96-	O
h	B-T079
tests	B-T059
with	O
snails	B-T204
(	O
Physa gyrina	B-T204
and	O
Lymnaea stagnalis	B-T204
).	O
Median	O
effect concentrations	B-T081
(	O
EC50s	B-T081
)	O
for	O
B. lynchi	B-T204
were	O
strongly	O
correlated	B-T080
(r(2)	O
=	O
0.975)	O
with	O
EC50s	B-T081
for	O
the	O
commercially	O
available	O
fairy shrimp	B-T204
species	B-T185
T. platyurus	B-T204
for	O
most	O
chemicals	B-T103
tested.	O
Comparison	B-T052
of	O
EC50s	B-T081
for	O
fairy shrimp	B-T204
and	O
EC50s	B-T081
for	O
invertebrate taxa	B-T204
tested	O
concurrently	O
and	O
with	O
other	O
published	O
toxicity	B-T037
data	B-T078
indicated	O
that	O
fairy shrimp	B-T204
were	O
relatively	O
sensitive	B-T169
to	O
potassium	B-T123
and	O
several	O
trace metals	B-T121
compared	B-T052
with	O
other	O
invertebrate taxa	B-T204
,	O
although	O
cladocerans	B-T204
,	O
amphipods	B-T204
,	O
and	O
mussels	B-T204
had	O
similar	O
broad	O
toxicant	B-T131
sensitivity	B-T169
.	O
Interspecies correlation estimation models	B-T170
for	O
predicting	O
toxicity	B-T037
to	O
fairy shrimp	B-T204
from	O
surrogate	B-T099
species	B-T185
indicated	O
that	O
models	B-T170
with	O
cladocerans	B-T204
and	O
freshwater mussels	B-T204
as	O
surrogates	B-T099
produced	O
the	O
best	O
predictions	O
of	O
the	O
sensitivity	B-T169
of	O
fairy shrimp	B-T204
to	O
contaminants	B-T167
.	O
The	O
results	O
of	O
these	O
studies	B-T062
indicate	O
that	O
fairy shrimp	B-T204
are	O
relatively	O
sensitive	B-T169
to	O
a	O
range	O
of	O
toxicants	B-T131
,	O
but	O
Endangered	O
Species	O
Act	O
-listed	O
fairy shrimp	B-T204
of	O
the	O
genus Branchinecta	B-T204
were	O
not	O
consistently	O
more	O
sensitive	B-T169
than	O
other	O
fairy shrimp taxa	B-T204
.	O
Environ	O
Toxicol	O
Chem	O
2016;9999:1-10.	O
Published	O
2016	O
Wiley	O
Periodicals	O
Inc.	O
on	O
behalf	O
of	O
SETAC.	O
This	O
article	O
is	O
a	O
US	O
government	O
work	O
and,	O
as	O
such,	O
is	O
in	O
the	O
public	O
domain	O
in	O
the	O
United	O
States	O
of	O
America.	O

Bi-layered constructs	B-T122
of	O
poly(glycerol-sebacate)	B-T109
-	O
β-tricalcium phosphate	B-T122
for	O
bone-soft tissue	B-UnknownType
interface applications	B-T169
This	O
study	B-T062
aims	O
to	O
establish	O
a	O
facile	O
protocol	B-T170
for	O
the	O
preparation	B-T052
of	O
a	O
bi-layered	B-T080
poly(glycerol-sebacate)	B-T109
(	O
PGS	B-T109
)/	O
β-tricalcium phosphate	B-T122
(	O
β-TCP	B-T122
)	O
construct	B-T122
and	O
to	O
investigate	B-T169
its	O
potential	O
for	O
bone-soft tissue	B-UnknownType
engineering	B-T061
applications	B-T169
.	O
The	O
layered structure	B-T082
was	O
prepared	O
by	O
distributing	B-T169
the	O
ceramic	B-T073
particles	B-T104
within	O
a	O
prepolymer	B-T104
synthesized	B-T052
in	O
a	O
microwave reactor	B-T073
followed	O
by	O
a	O
cross-linking	B-T070
of	O
the	O
final	O
construct	B-T122
in	O
vacuum	B-T070
(<10mbar).	O
The	O
vacuum	B-T070
stage	B-T079
led	O
to	O
the	O
separation	B-UnknownType
of	O
cross-linked	B-T070
elastomer	B-T109
(	O
top	B-T082
)	O
and	O
ceramic	B-T073
(	O
bottom	B-T082
)	O
phases	B-T079
.	O
Results	O
showed	O
that	O
addition	O
of	O
β-TCP	B-T122
particles	B-T104
to	O
the	O
elastomer matrix	B-T109
after	O
the	O
polymerization	B-T067
led	O
to	O
an	O
increase	B-T169
in	O
compression strength	B-T081
(up	O
to	O
14±2.3MPa).	O
Tensile strength	B-T081
(σ),	O
Young's modulus	B-T081
(E),	O
and	O
elongation at break	B-T081
(%)	O
values	O
were	O
calculated	O
as	O
0.29±0.03MPa	O
and	O
0.21±0.03;	O
0.38±0.02	O
and	O
1.95±0.4;	O
and	O
240±50%	O
and	O
24±2%	O
for	O
PGS	B-T109
and	O
PGS	B-T109
/	O
β-TCP	B-T122
bi-layered constructs	B-T122
,	O
respectively.	O
Morphology	B-T082
was	O
characterized	O
by	O
using	O
Scanning Electron Microscopy	B-T059
(	O
SEM	B-T059
)	O
and	O
micro-computed tomography	B-T060
(	O
μ-CT	B-T060
).	O
Tomography	B-T060
data	B-T078
revealed	O
an	O
open porosity	B-T080
of	O
35%	O
for	O
the	O
construct	B-T122
,	O
mostly	O
contributed	O
from	O
the	O
ceramic phase	B-T079
since	O
the	O
elastomer	B-T109
side	B-T082
has	O
no	O
pore	B-T082
.	O
Homogeneous	B-T080
β-TCP	B-T122
distribution	B-T169
within	O
the	O
elastomeric structure	B-T082
was	O
observed.	O
Cell culture studies	B-UnknownType
confirmed	O
biocompatibility	B-T044
with	O
poor	O
elastomer	B-T109
-	O
side	B-T082
and	O
good	O
bone	B-T024
-	O
side	B-T082
cell attachment	B-T026
.	O
In	O
a	O
further	O
study	O
to	O
investigate	B-T169
the	O
osteogenic	B-T024
properties	B-T080
,	O
the	O
construct	B-T122
were	O
loaded	O
with	O
BMP-2	B-T116
and/or	O
TGF-β1	B-T116
.	O
The	O
PGS	B-T109
/	O
β-TCP	B-T122
bi-layered constructs	B-T122
with	O
improved	O
mechanical	B-T080
and	O
biological	B-T080
properties	B-T080
have	O
the	O
potential	O
to	O
be	O
used	O
in	O
bone-soft tissue	B-UnknownType
interface applications	B-T169
where	O
soft tissue	B-T024
penetration	B-T169
is	O
a	O
problem	B-T033
.	O

Effects of	B-T080
high-intensity training	B-T056
on	O
cardiovascular risk factors	B-T047
in	O
premenopausal	B-T033
and	O
postmenopausal	B-T033
women	B-T098
Menopause	B-T039
is	O
associated with	B-T080
increased	B-T081
risk	O
of	O
cardiovascular disease	B-T047
and	O
the	O
causal	O
factors	B-T169
have	O
been	O
proposed	O
to	O
be	O
the	O
loss	B-T081
of	O
estrogen	B-T109
and	O
the	O
subsequent	O
alterations	O
of	O
the	O
hormonal milieu	B-T125
.	O
However,	O
which	O
factors	B-T169
contribute	B-T052
to	O
the	O
deterioration	B-T067
of	O
cardiometabolic health	B-T042
in	O
postmenopausal	B-T033
women	B-T098
is	O
debated	O
as	O
the	O
menopausal	B-T039
transition	B-T052
is	O
also	O
associated with	B-T080
increased	B-T081
age	B-T032
and	O
fat mass	B-T032
.	O
Furthermore,	O
indications	B-T078
of	O
reduced	B-T080
cardiometabolic	B-T042
adaptations	B-T038
to	O
exercise	B-T056
in	O
postmenopausal	B-T033
women	B-T098
add	O
to	O
the	O
adverse	B-T046
health profile	B-T080
.	O
We	O
sought	O
to	O
evaluate	B-T058
risk factors	B-T033
for	O
type 2 diabetes	B-T047
and	O
cardiovascular disease	B-T047
in	O
late	B-T079
premenopausal	B-T033
and	O
early	B-T079
postmenopausal	B-T033
women	B-T098
,	O
matched	O
by	O
age	B-T032
and	O
body composition	B-T032
,	O
and	O
investigate	B-T169
the	O
effect	O
of	O
high-intensity training	B-T056
.	O
A	O
3-month	O
high-intensity aerobic training	B-T056
intervention	B-T061
,	O
involving	O
healthy	B-T080
,	O
nonobese	B-T033
,	O
late	B-T079
premenopausal	B-T033
(n	O
=	O
40)	O
and	O
early	B-T079
postmenopausal	B-T033
(n	O
=	O
39)	O
women	B-T098
was	O
conducted	O
and	O
anthropometrics	B-T201
,	O
body composition	B-T032
,	O
blood pressure	B-T040
,	O
lipid profile	B-T059
,	O
glucose tolerance	B-T039
,	O
and	O
maximal oxygen consumption	B-T201
were	O
determined	O
at	O
baseline	B-T081
and	O
after	O
the	O
intervention	B-T061
.	O
At	O
baseline	B-T081
,	O
the	O
groups	B-T098
matched	O
in	O
anthropometrics	B-T201
and	O
body composition	B-T032
,	O
and	O
only	O
differed	O
by	O
4.2	O
years	O
in	O
age	B-T032
(mean	O
[95%	O
confidence limits	B-T081
]	O
49.2	O
[48.5-49.9]	O
vs	O
53.4	O
[52.4-54.4]	O
years).	O
Time	O
since	O
last	O
menstrual period	B-T040
for	O
the	O
postmenopausal	B-T033
women	B-T098
was	O
(mean	O
[95%	O
confidecnce limits	B-T081
]	O
3.1	O
[2.6-3.7]	O
years).	O
Hormonal levels	B-T034
(	O
estrogen	B-T109
,	O
follicle stimulation hormone	B-T116
,	O
luteinizing hormone	B-T116
)	O
confirmed	O
menopausal status	B-T201
.	O
At	O
baseline	B-T081
the	O
postmenopausal	B-T033
women	B-T098
had	O
higher	O
total cholesterol	B-T109
(P	O
<	O
.001),	O
low-density lipoprotein-cholesterol	B-T109
(P	O
<	O
.05),	O
and	O
high-density lipoprotein-cholesterol	B-T109
(P	O
<	O
.001)	O
than	O
the	O
premenopausal	B-T033
women	B-T098
.	O
The	O
training	O
intervention	B-T061
reduced	B-T080
body weight	B-T032
(P	O
<	O
.01),	O
waist circumference	B-T201
(P	O
<	O
.01),	O
and	O
improved	B-T033
body composition	B-T032
by	O
increasing	B-T169
lean body mass	B-T201
(P	O
<	O
.001)	O
and	O
decreasing	B-T033
fat mass	B-T032
(P	O
<	O
.001)	O
similarly	O
in	O
both	O
groups	B-T098
.	O
Moreover,	O
training	O
resulted	O
in	O
lower diastolic blood pressure	B-T033
(P	O
<	O
.05),	O
resting heart rate	B-T033
(P	O
<	O
.001),	O
total cholesterol	B-T109
(P	O
<	O
.01),	O
low-density lipoprotein-cholesterol	B-T109
(P	O
<	O
.01),	O
total cholesterol	B-T109
/	O
high-density lipoprotein-cholesterol	B-T109
index	O
(P	O
<	O
.01),	O
and	O
improved	B-T033
plasma insulin concentration	B-T059
during	O
the	O
oral glucose tolerance test	B-T060
(P	O
<	O
.05)	O
in	O
both	O
groups	B-T098
.	O
Cardiovascular risk factors	B-T047
are	O
similar	O
in	O
late	B-T079
premenopausal	B-T033
and	O
early	B-T079
postmenopausal	B-T033
women	B-T098
,	O
matched	O
by	O
age	B-T032
and	O
body composition	B-T032
,	O
with	O
the	O
exception	O
that	O
postmenopausal	B-T033
women	B-T098
have	O
higher	O
high-	B-T059
and	O
low-density lipoprotein-cholesterol levels	B-T059
.	O
A	O
3-month	O
intervention	B-T061
of	O
high-intensity aerobic training	B-T056
reduces	O
risk factors	B-T033
for	O
type 2 .diabetes	B-T047
and	O
cardiovascular disease	B-T047
to	O
a	O
similar	O
extent	O
in	O
late	B-T079
premenopausal	B-T033
and	O
early	B-T079
postmenopausal	B-T033
women	B-T098
.	O

Correlation	B-T080
between	O
preoperative	B-T079
physical signs	B-T033
and	O
functional	B-T169
outcomes	B-T169
after	O
laminoplasty	B-T061
for	O
ossification of the posterior longitudinal ligament	B-T046
Ossification of the posterior longitudinal ligament	B-T046
(	O
OPLL	B-T046
)	O
can	O
cause	O
myelopathy	B-T047
that	O
is	O
often	B-T079
managed	B-T058
surgically	B-T061
.	O
Knowledge	B-T041
of	O
predictors	B-T078
of	O
surgical	B-T061
outcomes	B-T080
can	O
provide	B-T052
decision support	B-T170
to	O
surgeons	B-T097
.	O
The	O
aims	B-T078
of	O
this	O
study	B-T062
were	O
to	O
investigate	B-T169
the	O
relationships	B-T080
between	O
preoperative	B-T079
physical signs	B-T033
and	O
postoperative	B-T079
functional	B-T169
outcomes	B-T169
in	O
patients	B-T101
with	O
OPLL	B-T046
and	O
to	O
clarify	B-T052
whether	O
physical signs	B-T033
could	O
predict	B-T078
functional	B-T169
outcomes	B-T169
.	O
Fifty-five	O
patients	B-T101
with	O
OPLL	B-T046
who	O
had	O
undergone	O
cervical laminoplasty	B-T061
were	O
included	B-T169
in	O
this	O
study	B-T062
.	O
Six	O
physical signs	B-T033
including	O
hyperreflexia	B-T033
,	O
Babinski sign	B-T033
,	O
sensory disturbance	B-T047
,	O
grip strength	B-T081
,	O
10-s grip and release test	B-T060
,	O
and	O
bladder dysfunction	B-T046
,	O
and	O
four	O
other	O
factors	B-T169
including	O
age	B-T032
,	O
duration of symptoms	B-T079
,	O
history	O
of	O
minor trauma	B-T037
and	O
preoperative	B-T079
Japanese Orthopaedic Association (JOA) score	B-T081
were	O
investigated	B-T169
as	O
potential	B-T080
predictive	B-T080
prognostic factors	B-T201
using	O
both	O
univariate	B-T062
and	O
multivariate analyses	B-T081
.	O
The	O
mean	B-T081
recovery rate	B-T081
of	O
JOA score	B-T081
was	O
62.5	O
±	O
32.5%.	O
The	O
neurological	B-T080
recovery rate	B-T081
was	O
negatively	B-T033
associated with	B-T080
age	B-T032
(P	O
=	O
0.002),	O
the	O
duration of symptoms	B-T079
(P	O
=	O
0.002)	O
and	O
Babinski sign	B-T033
(P	O
=	O
0.007),	O
whereas	O
it	O
was	O
positively	B-T033
correlated	B-T080
with	O
grip strength	B-T081
(P	O
=	O
0.011).	O
Multiple logistic regression analyses	B-T170
revealed	B-T080
that	O
age	B-T032
(	O
Odds ratio	B-T081
:	O
0.89,	O
95%	O
CI	B-T081
:	O
0.81-0.99)	O
and	O
Babinski sign	B-T033
(	O
Odds ratio	B-T081
:	O
0.18,	O
95%	O
CI	B-T081
:	O
0.04-0.89)	O
were	O
factors	B-T169
associated with	B-T080
functional	B-T169
outcomes	B-T169
.	O
Satisfactory	B-T080
functional	B-T169
outcomes	B-T169
could	O
be	O
expected	B-T170
for	O
patients	B-T101
who	O
are	O
young	B-T079
and	O
do	O
not	O
exhibit	O
the	O
Babinski sign	B-T033
,	O
showing	O
that	O
the	O
Babinski sign	B-T033
could	O
be	O
useful	B-T080
as	O
an	O
indicator	B-T169
of	O
the	O
window of opportunity	B-T080
for	O
achieving	B-T080
satisfactory	B-T080
functional	B-T169
outcomes	B-T169
.	O

Bacteria	B-T007
and	O
Hoverflies	B-T204
(	O
Diptera	B-T204
:	O
Syrphidae	B-T204
)	O
in	O
Tree Hollows	B-T023
From	O
the	O
Iberian Mediterranean Forest	B-T070
Saproxylic insect communities	B-T204
inhabiting	B-T082
tree hollows	B-T023
in	O
Mediterranean forests	B-T070
depend	O
on	O
a	O
combination	O
of	O
physical characteristics	B-T080
and	O
interactions	B-T169
occurring	O
between	O
community member species	B-T185
.	O
Despite	O
the	O
need	O
to	O
preserve	O
these	O
organisms	B-T001
,	O
little	O
is	O
known	O
about	O
their	O
interrelationships	B-T080
,	O
in	O
particular	O
those	O
relationships	B-T080
between	O
saproxylic insects	B-T204
and	O
microbiota	B-T001
occurring	O
in	O
these	O
microhabitats	B-T082
.	O
In	O
tree hollows	B-T023
of	O
Quercus rotundifolia Lamark	B-T002
that	O
hold water	B-T169
and	O
contain	O
dead leaves	B-T002
,	O
abundant microbial populations	B-T001
can	O
be	O
found.	O
Developing	O
on	O
them	O
are	O
the	O
larvae	B-T204
of	O
Mallota dusmeti	B-T204
Andréu,	O
1926	O
(	O
Diptera	B-T204
:	O
Syrphidae	B-T204
),	O
a	O
vulnerable species	B-T185
(	O
IUCN category	B-T170
:	O
Marcos-García	B-T098
and	O
Quinto	B-T098
2011).	O
This	O
study	O
provides	O
the	O
first	O
data	O
on	O
the	O
microbiota	B-T001
living inside	B-T082
the	O
gut	B-T023
of	O
the	O
larvae	B-T204
of	O
M. dusmeti	B-T204
,	O
as	O
well	O
as	O
the	O
microbiota	B-T001
in	O
the	O
hollow	B-T082
where	O
these	O
larvae	B-T204
develop	B-T039
.	O
Bacteria	B-T007
were	O
identified	O
by	O
amplification and partial sequencing	B-T059
of	O
the	O
V1-V3 regions	B-T028
and	O
the	O
complete	O
nucleotide sequence	B-T086
of	O
16S rRNA genes	B-T114
.	O
We	O
found	O
eight	O
species of bacteria	B-T007
living in	B-T082
tree hollows	B-T023
and	O
three	O
species	B-T185
in the gut	B-T023
of	O
M. dusmeti	B-T204
larvae	B-T204
:	O
Bacillus cereus	B-T007
,	O
Bacillus toyonensis	B-T007
,	O
and	O
Lysinibacillus sphaericus	B-T007
The	O
filter-feeding mechanism characteristic	B-T033
of	O
M. dusmeti	B-T204
larvae	B-T204
is	O
selective	O
in	O
enabling	O
ingestion	B-T038
of	O
bacteria	B-T007
only	O
above	O
2.1	O
µm	O
in	O
diameter.	O

Impact sports	B-T056
and	O
bone fractures	B-T037
among	O
adolescents	B-T100
The	O
objective	O
of	O
the	O
present	O
study	B-T062
was	O
to	O
investigate	B-T169
the	O
effects of	B-T080
different	B-T080
sports	B-T056
on	O
stress fractures	B-T037
among	O
adolescents	B-T100
during	O
a	O
9-	O
month	B-T079
follow-up	B-T058
period	B-T079
.	O
The	O
sample	B-T098
was	O
composed	O
of	O
184	O
adolescents	B-T100
divided	O
into	O
three	O
groups	B-T098
(	O
impact sports	B-T056
[n	O
=	O
102];	O
swimming	B-T056
[n	O
=	O
35];	O
non-sports	B-T056
[n	O
=	O
47]).	O
The	O
occurrence	B-T079
of	O
stress fracture	B-T037
was	O
reported	O
by	O
participants	B-T098
and	O
coaches	B-T097
.	O
As	O
potential	O
confounders	B-T169
we	O
considered	O
age	B-T032
,	O
sex	B-T032
,	O
resistance training	B-T061
,	O
body composition	B-T032
variables	B-T080
and	O
age	B-T032
at	O
peak	B-T080
of	O
height velocity	B-T081
.	O
There	O
were	O
13	O
adolescents	B-T100
who	O
reported	O
fractures	B-T037
during	O
the	O
9-	O
month	B-T079
period	B-T079
.	O
Bone mineral density	B-T201
values	B-T080
were	O
higher	O
in	O
adolescents	B-T100
engaged	O
in	O
impact sports	B-T056
(	O
P-value	B-T081
=	O
0.002).	O
Independently	O
of	O
confounders	B-T169
,	O
the	O
risk	B-T078
of	O
stress fracture	B-T037
was	O
lower	O
in	O
adolescents	B-T100
engaged	O
in	O
impact sports	B-T056
than	O
in	O
non-active adolescents	B-T100
(	O
hazard ratio	B-T081
[	O
HR	B-T081
]	O
=	O
0.23	O
[95%	O
confidence interval	B-T081
(	O
CI	B-T081
)	O
=	O
0.05	O
to	O
0.98]),	O
while	O
swimming	B-T056
practice	B-T041
was	O
not	O
associated	O
to	O
lower	O
risk	B-T078
of	O
fracture	B-T037
(	O
HR	B-T081
=	O
0.49	O
[95%	O
CI	B-T081
=	O
0.09	O
to	O
2.55]).	O
In	O
conclusion,	O
the	O
findings	B-T033
from	O
this	O
study	B-T062
indicate	O
the	O
importance	O
of	O
sports	B-T056
participation	B-T169
among	O
adolescents	B-T100
in	O
the	O
reduction	B-T080
of	O
stress fracture	B-T037
risk	B-T078
,	O
especially	O
with	O
impact sports	B-T056
.	O
More	O
importantly,	O
these	O
results	B-T169
could	O
be	O
relevant	B-T080
for	O
recognising	O
adolescents	B-T100
in	O
danger	O
of	O
not	O
reaching	O
their	O
potential	O
for	O
peak	B-T080
bone mass	B-T201
and	O
later	O
an	O
increased	B-T081
risk	B-T078
of	O
fractures	B-T037
.	O

The	O
Business	B-UnknownType
of	O
Health Physics	B-T091
-	O
Jobs	B-T090
In	O
A	O
Changing Market	B-T057
The	O
health physics	B-T091
profession	B-T090
was	O
born	O
abruptly	O
when	O
once	O
rare	O
and	O
precious	O
radioactive materials	B-T122
became	O
commonplace	B-T081
.	O
The	O
technological advancements	B-UnknownType
that	O
triggered	O
an	O
industrial complex	B-T080
and	O
ended	O
World War II	B-T051
demanded	O
radiation safety	B-T067
on	O
an	O
unprecedented scale	B-T170
.	O
Until	O
then,	O
protective measures against radiation	B-T068
were	O
largely	O
absent	O
in	O
laboratories	B-T073
.	O
Over	O
the	O
subsequent	O
decades,	O
health physicists	B-T097
began	O
protecting people	B-T061
and	O
the	O
environment	B-T064
in	O
a	O
wide	O
range	O
of	O
settings	O
including	O
medical	B-T058
,	O
research	B-T062
,	O
and	O
industrial	B-T057
.	O
The	O
use of radioactive materials	B-T033
and	O
radiation-generating devices	B-T074
is	O
prevalent today	B-T082
.	O
Radiation doses	B-T081
occur	O
continuously	O
including	O
during	O
airline flights	B-T073
,	O
in	O
our	O
homes,	O
during	O
medical procedures	B-T058
,	O
and	O
in	O
energy	O
production.	O
Radiation	B-T070
is	O
integral to numerous applications	B-T169
including	O
those	O
in	O
medicine	B-T091
,	O
dentistry	B-T091
,	O
manufacturing	B-T090
,	O
construction,	O
scientific research	B-T062
,	O
nuclear electric power generation	B-T073
,	O
and	O
oil and gas exploration	B-T070
.	O
Activities	O
that	O
were	O
once	O
groundbreaking	O
have	O
now	O
become	O
routine	B-T080
and	O
scripted	B-T170
.	O
At	O
higher doses	B-T081
,	O
health effects	B-T033
are	O
understood and avoided	B-T169
.	O
Instruments for the detection and measurement of radiation	B-T074
are	O
at	O
times	O
smarter	O
than	O
their	O
users.	O
Ironically,	O
the	O
same	O
health physics	B-T091
community	O
that	O
has	O
been	O
successful	O
in	O
demonstrating	O
that	O
exposures to radiation	B-T037
and	O
to	O
radioactive materials	B-T122
can	O
be	O
effectively managed	B-T058
is	O
shrinking	O
at	O
an	O
increasingly	O
rapid rate	B-T081
.	O
This	O
paper	O
highlights	O
the	O
creation	B-T052
of	O
past	O
and	O
current	O
jobs	B-T090
,	O
predicts	O
the	O
future	O
opportunities in the profession	B-T078
,	O
and	O
makes	O
recommendations	B-T078
necessary	O
to	O
protect	O
the	O
disappearing specialties	B-T091
.	O

Permanence	B-T079
can	O
be	O
Defended	B-T054
In	O
donation	B-T055
after	O
the	O
circulatory-respiratory determination of death	B-T060
(	O
DCDD	B-T060
),	O
the	O
dead	B-T040
donor	B-T098
rule	B-T170
requires	B-T080
that	O
the	O
donor	B-T098
be	O
dead	B-T040
before	B-T079
organ procurement	B-T058
can	O
proceed.	O
Under	O
the	O
relevant limb	B-T080
of	O
the	O
Uniform Determination of Death Act 1981 (USA)	B-T170
,	O
a	O
person	B-T098
is	O
dead	B-T040
when	O
the	O
cessation	B-T052
of	O
circulatory-respiratory function	B-T169
is	O
'	O
irreversible	B-T033
'.	O
Critics	B-T097
of	O
current	B-T079
practice	B-T041
in	O
DCDD	B-T060
have	O
argued	B-T054
that	O
the	O
donor	B-T098
is	O
not	O
dead	B-T040
at	O
the	O
time	B-T079
organs	B-T023
are	O
procured	B-T058
,	O
and	O
so	O
the	O
procurement of organs	B-T058
from	O
these	O
donors	B-T098
violates	O
the	O
dead	B-T040
donor	B-T098
rule	B-T170
.	O
We	O
offer	B-T033
a	O
new	B-T080
argument	B-T054
here	O
in	O
defence	B-T054
of	O
current	B-T079
DCDD	B-T060
practice	B-T041
,	O
and,	O
in	O
particular,	O
of	O
the	O
interpretation	B-T170
of	O
the	O
requirement	B-T169
of	O
'	O
irreversibility	B-T033
'	O
as	O
permanence	B-T079
.	O

Untypeable	B-T080
hepatitis C virus	B-T005
subtypes	B-T185
in	O
Pakistan	B-T083
:	O
A	O
neglected	O
section	O
Diagnostically	B-T169
untypeable	B-T080
subtypes	B-T185
contribute	O
a	O
considerable	O
percent	O
of	O
hepatitis C virus	B-T005
(	O
HCV	B-T005
)	O
subtypes	B-T185
in	O
Pakistan	B-T083
.	O
In	O
the	O
present	O
study	B-T062
,	O
chronically infected	B-T047
HCV	B-T005
patients	B-T101
with	O
known	O
viremia	B-T047
were	O
subjected	O
to	O
HCV	B-T005
genotyping	B-T059
.	O
Among	O
the	O
total	O
retrieved	O
samples	B-T077
,	O
92.7%	O
(64/69)	O
were	O
found	O
typeable	B-T080
while	O
7.24%	O
(5/69)	O
were	O
diagnostically	B-T169
untypeable	B-T080
.	O
In	O
conclusion	B-T078
,	O
the	O
presence	O
of	O
large	O
number	O
of	O
untypeable	B-T080
HCV	B-T005
subtypes	B-T185
emphasizes	O
the	O
need	O
of	O
an	O
updated	O
type	B-T080
-	O
specific	B-T080
genotyping	B-T059
assay	B-T059
and	O
consideration	O
of	O
primers	B-T114
for	O
proportionally	O
rare	B-T080
subtypes	B-T185
to	O
minimize	B-T080
the	O
number	O
of	O
untypeable	B-T080
HCV	B-T005
subtypes	B-T185
.	O

ITPR3 gene	B-T028
haplotype	B-T032
is	O
associated	O
with	O
cervical squamous cell carcinoma	B-T191
risk	B-T078
in	O
Taiwanese	B-T098
women	B-T098
Host immunogenetic	B-T091
background	O
plays	O
an	O
important	O
role	O
in	O
human papillomavirus (HPV) infection	B-T047
and	O
cervical cancer development	B-T191
.	O
Inositol 1,4,5-triphosphate receptor type 3	B-T028
(	O
ITPR3	B-T028
)	O
is	O
essential	O
for	O
both	O
immune activation	B-T043
and	O
cancer	B-T191
pathogenesis	B-T046
.	O
We	O
aim	O
to	O
investigate	O
if	O
ITPR3	B-T028
genetic polymorphisms	B-T045
are	O
associated	O
with	O
the	O
risk of cervical cancer	B-T081
in	O
Taiwanese	B-T098
women	B-T098
.	O
ITPR3	B-T028
rs3748079 A/G	B-T086
and	O
rs2229634 C/T polymorphisms	B-T086
were	O
genotyped	B-T032
in	O
a	O
hospital-based study	B-T062
of	O
462	O
women	B-T098
with	O
cervical squamous cell carcinoma	B-T191
(	O
CSCC	B-T191
)	O
and	O
921	O
age-matched	O
healthy control	B-T080
women	B-T098
.	O
The	O
presence	O
and	O
genotypes	B-T032
of	O
HPV	B-T005
in	O
CSCC	B-T191
was	O
determined.	O
No	O
significant	O
association	O
of	O
individual	O
ITPR3	B-T028
variants	B-T028
were	O
found	O
among	O
controls,	O
CSCC	B-T191
,	O
and	O
HPV-16 positive	B-T034
CSCC	B-T191
.	O
However,	O
we	O
found	O
a	O
significant	O
association	O
of	O
haplotype AT	B-T032
between	O
CSCC	B-T191
and	O
controls	O
(	O
OR	B-T081
=	O
2.28,	O
95%	O
CI	B-T081
1.31-3.97,	O
P	O
=	O
2.83	O
×	O
10-3)	O
and	O
the	O
OR	B-T081
increased	O
further	O
in	O
CSCC	B-T191
patients infected	B-T101
with	O
HPV-16	B-T005
(	O
OR	B-T081
=	O
2.89,	O
95%	O
CI	B-T081
1.55-5.37,	O
P	O
=	O
4.54	O
×	O
10-4).	O
The	O
linkage disequilibrium analysis	B-T063
demonstrated	O
that	O
ITPR3	B-T028
association	B-T063
with	O
CSCC	B-T191
was	O
independent	O
of	O
HLA-DRB1	B-T028
alleles	B-T028
.	O
In	O
conclusion,	O
these	O
findings	O
suggest	O
that	O
AT haplotype	B-T032
in	O
the	O
ITPR3 gene	B-T028
may	O
serve	O
as	O
a	O
potential marker	B-T045
for	O
genetic susceptibility	B-T032
to	O
CSCC	B-T191
.	O

Defining	O
categories	B-T170
of	O
actionability	B-T052
for	O
secondary	B-T080
findings	B-T033
in	O
next-generation sequencing	B-T059
Next-generation sequencing	B-T059
is	O
increasingly	O
used	O
in	O
clinical practice	B-T057
for	O
the	O
diagnosis	B-T033
of	O
Mendelian diseases	B-T047
.	O
Because	O
of	O
the	O
high	O
likelihood	O
of	O
secondary	B-T080
findings	B-T033
associated	O
with	O
this	O
technique	B-T169
,	O
the	O
process	O
of	O
informing patients	B-T058
is	O
beset	O
with	O
new	O
challenges.	O
One	O
of	O
them	O
is	O
regarding	O
the	O
type	O
of	O
secondary	B-T080
findings	B-T033
that	O
ought	O
to	O
be	O
disclosed	O
to	O
patients	B-T101
.	O
The	O
aim	O
of	O
this	O
research	B-T062
is	O
to	O
propose	O
a	O
practical	O
implementation	B-T052
of	O
the	O
notion	O
of	O
actionability	B-T052
,	O
a	O
common	O
criteria	O
justifying	O
the	O
disclosure	B-T055
of	O
secondary	B-T080
findings	B-T033
but	O
whose	O
interpretation	B-T170
varies	O
greatly	O
among	O
professionals	B-T097
.	O
We	O
distinguish	O
three	O
types	O
of	O
actionability	B-T052
corresponding	O
to	O
(1)	O
well-established	O
medical	B-T169
actions	B-T052
,	O
(2)	O
patient	B-T101
-initiated	O
health-related actions	B-T055
and	O
(3)	O
life-plan decisions	B-T041
.	O
We	O
argue	O
that	O
actionability	B-T052
depends	O
on	O
the	O
characteristics	O
of	O
the	O
mutation	B-T045
or	O
gene	B-T028
and	O
on	O
the	O
values	O
of	O
patients	B-T101
.	O
In	O
discussing	O
the	O
return	O
of	O
secondary	B-T080
findings	B-T033
,	O
it	O
is	O
important	O
that	O
the	O
physician	B-T097
tries	O
to	O
get	O
an	O
impression	B-T080
of	O
the	O
specific	O
situation	O
and	O
values	O
of	O
patients	B-T101
.	O
Regarding	O
variants	B-T028
of	O
uncertain	O
clinical significance	B-T033
in	O
actionable	O
genes	B-T028
,	O
we	O
found	O
that	O
different	O
understandings	O
of	O
autonomy	B-T078
lead	O
to	O
different	O
conclusions	B-T078
and	O
that,	O
for	O
some	O
of	O
them,	O
it	O
may	O
be	O
legitimate	O
to	O
refrain	O
from	O
returning	O
uncertain	O
information	B-T078
.	O

Allergen	B-T129
Valency	B-T081
,	O
Dose	B-T081
,	O
and	O
FcεRI	B-T116
Occupancy	B-T080
Set	O
Thresholds	B-T080
for	O
Secretory Responses	B-T043
to	O
Pen a 1	B-T116
and	O
Motivate	O
Design	B-T052
of	O
Hypoallergens	B-T129
Ag	B-T196
-mediated	O
crosslinking	B-T070
of	O
IgE	B-T116
-	O
FcεRI	B-T116
complexes	B-T116
activates	O
mast cells	B-T025
and	O
basophils	B-T025
,	O
initiating	O
the	O
allergic response	B-T046
.	O
Of	O
34	O
donors	O
recruited	O
having	O
self-reported	B-T062
shrimp allergy	B-T046
,	O
only	O
35%	O
had	O
significant	O
levels	O
of	O
shrimp-specific IgE	B-T116
in	O
serum	B-T031
and	O
measurable	O
basophil	B-T025
secretory	B-T043
responses	B-T038
to	O
rPen a 1	B-T129
(	O
shrimp	B-T204
tropomyosin	B-T116
).	O
We	O
report	O
that	O
degranulation	O
is	O
linked	O
to	O
the	O
number	O
of	O
FcεRI	B-T116
occupied	O
with	O
allergen-specific IgE	B-T116
,	O
as	O
well	O
as	O
the	O
dose	B-T081
and	O
valency	B-T081
of	O
Pen a 1	B-T116
.	O
Using	O
clustered regularly interspaced palindromic repeat-based gene editing	B-T063
,	O
human	O
RBL(rαKO)	O
cells	O
were	O
created	O
that	O
exclusively	O
express	O
the	O
human	O
FcεRIα	B-T116
subunit.	O
Pen a 1	B-T116
-	O
specific IgE	B-T116
was	O
affinity	O
purified	O
from	O
shrimp	B-T204
-	O
positive	B-T033
plasma	B-T031
.	O
Cells	O
primed	O
with	O
a	O
range	O
of	O
Pen a 1	B-T116
-	O
specific IgE	B-T116
and	O
challenged	O
with	O
Pen a 1	B-T116
showed	O
a	O
bell-shaped	O
dose	B-T081
response for secretion	B-T043
,	O
with	O
optimal	O
Pen a 1	B-T116
doses	B-T081
of	O
0.1-10	O
ng/ml.	O
Mathematical modeling	B-T170
provided	O
estimates	O
of	O
receptor aggregation	B-T044
kinetics	B-T070
based	O
on	O
FcεRI	B-T116
occupancy	O
with	O
IgE	B-T116
and	O
allergen	B-T129
dose	B-T081
.	O
Maximal	O
degranulation	O
was	O
elicited	O
when	O
∼2700	O
I	O
gE	B-T116
-	O
FcεRI	B-T116
complexes	B-T116
were	O
occupied	O
with	O
specific IgE	B-T116
and	O
challenged	O
with	O
Pen a 1	B-T116
(	O
IgE	B-T116
epitope	B-T129
valency	B-T081
of	O
≥8),	O
although	O
measurable	O
responses	O
were	O
achieved	O
when	O
only	O
a	O
few	O
hundred	O
FcεRI	B-T116
were	O
occupied.	O
Prolonged	O
periods	O
of	O
pepsin	B-T116
-mediated	O
Pen a 1	B-T116
proteolysis	B-T044
,	O
which	O
simulates	O
gastric	B-T080
digestion	B-T040
,	O
were	O
required	O
to	O
diminish	O
secretory responses	B-T043
.	O
Recombinant fragments	B-T116
(60-79	O
aa),	O
which	O
together	O
span	O
the	O
entire	O
length	O
of	O
tropomyosin	B-T116
,	O
were	O
weak	O
secretagogues.	O
These	O
fragments	O
have	O
reduced	O
dimerization	B-T044
capacity	B-T081
,	O
compete	O
with	O
intact	O
Pen a 1	B-T116
for	O
binding	O
to	O
IgE	B-T116
-	O
FcεRI	B-T116
complexes	B-T116
,	O
and	O
represent	O
a	O
starting	O
point	O
for	O
the	O
design	O
of	O
promising	O
hypoallergens	B-T129
for	O
immunotherapy	B-T061
.	O

Selected	B-T052
flavonoid compounds	B-T109
as	O
promising	O
inhibitors	B-T120
of	O
protein kinase	B-T116
CK2α	B-T116
and	O
CK2α'	B-T116
,	O
the	O
catalytic subunits	B-T087
of	O
CK2	B-T116
CK2	B-T116
is	O
a	O
ubiquitous	O
protein kinase	B-T116
involved	O
in	O
many	O
cell functions	B-T043
.	O
During	O
the	O
last	O
years	B-T079
it	O
became	O
an	O
interesting	O
target	B-T169
in	O
cancer research	B-T062
.	O
A	O
series	O
of	O
flavonoid compounds	B-T109
was	O
tested	B-T169
as	O
inhibitors	B-T120
of	O
protein kinase	B-T116
CK2	B-T116
.	O
Several	O
substances	B-T167
were	O
found	O
to	O
be	O
highly	B-T080
active against	B-T078
both	O
catalytic subunits	B-T087
with	O
IC50	B-T081
values	B-T080
below	O
1	O
μM	O
in	O
case	O
of	O
CK2α'	B-T116
.	O
The	O
most	O
promising	O
inhibitor	B-T120
we	O
identified	B-T080
is	O
chrysoeriol	B-T109
with	O
IC50	B-T081
values	B-T080
of	O
250	O
and	O
34	O
nM	O
for	O
CK2α	B-T116
and	O
CK2α'	B-T116
,	O
respectively.	O

Fibrinogen	B-T116
:	O
A	O
Marker	B-T201
in	O
Predicting	O
Diabetic Foot Ulcer	B-T047
Severity	B-T080
Aims.	O
To	O
examine	B-T058
whether	O
fibrinogen levels	B-T034
are	O
a	O
valuable	O
biomarker	B-T201
for	O
assessing	B-T058
disease severity	B-T080
and	O
monitoring	B-T058
disease progression	B-T046
in	O
patients	B-T101
with	O
diabetic foot ulcer	B-T047
(	O
DFU	B-T047
).	O
Methods.	O
A	O
retrospective study	B-T062
was	O
designed	O
to	O
examine	O
the	O
utility	B-T169
of	O
fibrinogen	B-T116
in	O
estimating	O
disease severity	B-T080
in	O
patients	B-T101
with	O
DFU	B-T047
admitted	B-T058
to	O
our	O
hospital	B-T073
between	O
January	B-T080
2015	O
and	O
January	B-T080
2016.	O
In	O
total,	O
152	O
patients	B-T101
with	O
DFU	B-T047
were	O
enrolled	O
in	O
the	O
study group	B-UnknownType
,	O
and	O
52	O
age	O
and	O
gender	B-T032
matched	O
people	B-T101
with	O
diabetes	B-T047
but	O
no	O
DFU	B-T047
were	O
included	O
as	O
the	O
control group	B-T096
.	O
DFU	B-T047
severity	B-T080
was	O
assessed	O
using	O
Wagner	O
criteria.	O
Results.	O
Patients	B-T101
with	O
DFU	B-T047
were	O
divided	O
into	O
2	O
subgroups	B-T185
based	O
on	O
the	O
Wagner	O
criteria.	O
Mean	O
fibrinogen values	B-T034
were	O
significantly higher	B-T081
in	O
patients	B-T101
with	O
DFU	B-T047
grade	B-T185
≧	O
3	O
compared	O
to	O
those	O
with	O
DFU	B-T047
grades	B-T185
1-2	O
(5.23	O
±	O
1.37	O
g/L	O
versus	O
3.61	O
±	O
1.04	O
g/L).	O
Using	O
ROC statistic	B-T081
,	O
a	O
cut-off value	B-T081
of	O
5.13	O
g/L	O
indicated	O
the	O
possible	O
amputation	B-T061
with	O
a	O
sensitivity	B-T081
of	O
81.8%	O
and	O
a	O
specificity	B-T081
of	O
78.9%	O
(	O
positive predictive value	B-T081
[	O
PPV	B-T081
]	O
78.6%,	O
negative predictive value	B-T081
[89.0%]).	O
Fibrinogen values	B-T034
were	O
found	O
to	O
be	O
correlated	O
with	O
CRP levels	B-T034
,	O
neutrophil	B-T059
,	O
and	O
WBC count	B-T059
.	O
Conclusions.	O
Fibrinogen levels	B-T034
might	O
be	O
a	O
valuable	O
tool	O
for	O
assessing	B-T058
the	O
disease severity	B-T080
and	O
monitoring	B-T058
the	O
disease progression	B-T046
in	O
patients	B-T101
with	O
DFU	B-T047
.	O

Nitrogen utilization	B-T044
efficiency	B-T081
and	O
prediction	B-T078
of	O
nitrogen	B-T123
excretion	B-T039
in	O
sheep	B-T015
offered	B-T033
fresh perennial ryegrass	B-T002
()	O
Nitrogen	B-T123
excretion	B-T039
from	O
sheep	B-T015
production systems	B-T082
is	O
an	O
important	O
source	O
of	O
nitrate	B-T197
,	O
ammonia	B-T121
,	O
and	O
nitrous oxide	B-T121
responsible	O
for	O
groundwater	B-T082
pollution	B-T069
and	O
global warming	B-T069
.	O
The	O
present	O
study	B-T062
aimed	O
to	O
identify	B-T080
key parameters	B-T077
influencing	O
N utilization	B-T044
efficiency	B-T081
and	O
develop	O
prediction	B-T078
equations	B-T077
for	O
manure	B-T167
N	B-T123
,	O
feces	B-T031
N	B-T123
,	O
and	O
urine	B-T031
N	B-T123
outputs	B-T077
in	O
sheep	B-T015
.	O
Data	B-T078
used	O
were	O
collected	O
from	O
82	O
sheep	B-T015
offered	B-T033
fresh perennial ryegrass	B-T002
()	O
as	O
the	O
sole diet	B-T168
in	O
6	O
metabolism	B-T040
experiments	B-T062
(	O
data	B-T078
from	O
non-grass-only diets	B-T168
were	O
not used	B-T169
).	O
Sheep	B-T015
were	O
from	O
breeds	B-T185
of	O
Highlander	B-T098
,	O
Texel	B-T015
,	O
Scottish Blackface	B-T015
,	O
and	O
Swaledale	B-T015
at	O
the	O
age	B-T032
of	O
5	O
to	O
18	O
mo	B-T079
and	O
weighing	O
from	O
24.5	O
to	O
62.7	O
kg.	O
Herbage	B-T002
was	O
harvested	B-T067
daily	B-T079
from	O
6	O
swards	B-T002
of	O
contrasting	O
harvest	B-T067
dates	B-T079
(May	O
to	O
December),	O
offering	B-T033
wide	O
variation	B-T080
in	O
feed	O
value	O
to	O
cover	O
the	O
range	B-T081
that	O
would	O
be	O
offered	B-T033
in	O
most	O
practical	O
farm situations	B-T082
.	O
Before	O
the	O
commencement	O
of	O
each	O
study	B-T062
,	O
the	O
experimental	B-T080
sward	B-T002
was	O
harvested	B-T067
at	O
a	O
residual height	B-T032
of	O
4	O
cm	O
and	O
allowed	O
to	O
grow	B-T040
for	O
2	O
to	O
4	O
wk	B-T079
to	O
target	B-T169
an	O
average	O
pregrazing	O
sward	B-T002
height	B-T032
in	O
a	O
range	B-T081
of	O
8	O
to	O
15	O
cm	O
depending	B-T169
on	O
the	O
time of year	B-T081
.	O
Sheep	B-T015
were	O
housed	B-T082
in	O
individual	O
pens	O
for	O
14	O
d	B-T079
and	O
then	O
transferred to	B-T033
individual	O
metabolism	B-T040
crates	O
for	O
4	O
d	B-T079
with	O
feed	B-T052
intake	B-T169
and	O
feces	B-T031
and	O
urine	B-T031
outputs	B-T077
measured.	O
Data	B-T078
were	O
analyzed	B-T062
using	O
the	O
linear mixed model procedure	B-T081
to	O
develop	O
prediction	B-T078
equations	B-T077
for	O
feces	B-T031
N,	O
urine	B-T031
N,	O
and	O
manure	B-T167
N	B-T123
outputs	B-T077
using	O
N intake	B-T033
,	O
herbage	B-T002
chemical composition	B-T070
,	O
and	O
digestibility	B-T067
with	O
effects of	B-T080
sex	B-T032
,	O
breed	B-T185
,	O
and	O
experimental	O
periods	B-T079
removed	B-T080
.	O
Nitrogen	B-T123
intake	B-T169
was	O
the	O
best	B-T080
single predictor	B-T078
for	O
N	B-T123
output	B-T077
in	O
feces	B-T031
,	O
urine	B-T031
,	O
and	O
manure	B-T167
,	O
and	O
the	O
value	O
for	O
prediction	B-T078
of	O
manure	B-T167
N	B-T123
output	B-T077
was	O
greater	B-T081
than	O
those	O
for	O
feces	B-T031
N	B-T123
and	O
urine	B-T031
N	B-T123
(0.86	O
vs.	O
0.70	O
and	O
0.77,	O
respectively;	O
<	O
0.001).	O
Animal	B-T008
BW	B-T032
and	O
herbage	B-T002
DM	B-T167
,	O
ether extract	B-T081
,	O
NDF	B-T168
,	O
ADF	B-T168
,	O
water soluble carbohydrate	B-T059
,	O
and	O
DE	O
concentrations	O
and	O
N	B-T123
digestibility	B-T067
were	O
also	O
used	O
to	O
predict	B-T078
N	B-T123
outputs	B-T077
because	O
N	B-T123
intake	B-T169
may	O
not be available	B-T080
in	O
commercial practice	B-T078
.	O
The	O
prediction	B-T078
equations	B-T077
for	O
N utilizatio	B-T044
n	O
efficiency	B-T081
indicated	O
that	O
increasing	B-T169
feeding	B-T052
level	B-T080
and	O
ME	B-T081
concentration	B-T081
and	O
reducing	B-T080
N concentration	B-T033
could	O
improve	B-T033
N utilization	B-T044
efficiency	B-T081
and	O
shift	O
N	B-T123
excretion	B-T039
into	O
feces	B-T031
rather than	B-T033
urine	B-T031
(<	O
0.001).	O
The	O
equations	B-T077
developed	O
in	O
the	O
current	O
study	B-T062
provide	O
an	O
approach	B-T082
for	O
sheep	B-T015
producers	B-T098
to	O
quantify	B-T081
N	B-T123
excretion	B-T039
against	O
production	B-T057
and,	O
consequently,	O
to	O
develop	O
their	O
own	O
mitigation strategies	B-T062
to	O
reduce	B-T080
the	O
environmental impact	B-T067
of	O
sheep	B-T015
production systems	B-T082
.	O

Improving	B-T080
protein complex	B-T116
prediction	B-T078
by	O
reconstructing	B-T170
a	O
high-confidence	B-T080
protein-protein interaction network	B-T169
of	O
Escherichia coli	B-T007
from	O
different	O
physical interaction	B-T169
data sources	B-T081
Although	O
different	O
protein-protein physical interaction	B-T044
(	O
PPI	B-T044
)	O
datasets	B-T170
exist	O
for	O
Escherichia coli	B-T007
,	O
no	O
common	O
methodology	B-T078
exists	O
to	O
integrate	B-T066
these	O
datasets	B-T170
and	O
extract	O
reliable	O
modules	B-T077
reflecting	O
the	O
existing	O
biological process	B-T038
and	O
protein complexes	B-T116
.	O
Naïve Bayesian formula	B-T170
is	O
the	O
highly	O
accepted	O
method	O
to	O
integrate	B-T066
different	O
PPI	B-T044
datasets	B-T170
into	O
a	O
single	O
weighted	B-T081
PPI network	B-T169
,	O
but	O
detecting	O
proper	O
weights	B-T081
in	O
such	O
network	B-T169
is	O
still	O
a	O
major	O
problem.	O
In	O
this	O
paper,	O
we	O
proposed	O
a	O
new	O
methodology	B-T078
to	O
integrate	B-T066
various	O
physical PPI	B-T044
datasets	B-T170
into	O
a	O
single	O
weighted	B-T081
PPI network	B-T169
in	O
a	O
way	O
that	O
the	O
detected	B-T033
modules	B-T077
in	O
PPI network	B-T169
exhibit	O
the	O
highest	O
similarity	O
to	O
available	O
functional	B-T169
modules	B-T077
.	O
We	O
used	O
the	O
co-expression	B-T061
modules	B-T077
as	O
functional	B-T169
modules	B-T077
,	O
and	O
we	O
shown	O
that	O
direct	O
functional	B-T169
modules	B-T077
detected	B-T033
from	O
Gene Ontology	B-T170
terms	B-T078
could	O
be	O
used	O
as	O
an	O
alternative	O
dataset	B-T170
.	O
After	O
running	O
this	O
integrating	B-T066
methodology	B-T078
over	O
six	O
different	O
physical PPI	B-T044
datasets	B-T170
,	O
orthologous	B-T080
high-confidence	B-T080
interactions	B-T169
from	O
a	O
related	O
organism	B-T001
and	O
two	O
AP-MS	B-T059
PPI	B-T044
datasets	B-T170
gained high weights	B-T033
in	O
the	O
integrated	B-T066
networks	B-T169
,	O
while	O
the	O
weights	B-T081
for	O
one	O
AP-MS	B-T059
PPI	B-T044
dataset	B-T170
and	O
two	O
other	O
datasets	B-T170
derived	O
from	O
public databases	B-T170
have	O
converged	O
to	O
zero.	O
The	O
majority	O
of	O
detected	B-T033
modules	B-T077
shaped	O
around	O
one	O
or	O
few	O
hub protein(s)	B-T116
.	O
Still,	O
a	O
large	O
number	O
of	O
highly	O
interacting	O
protein	B-T116
modules	B-T077
were	O
detected	B-T033
which	O
are	O
functionally	B-T169
relevant	B-T080
and	O
are	O
likely	O
to	O
construct	B-T185
protein complexes	B-T116
.	O
We	O
provided	O
a	O
new	O
high confidence	B-T080
protein complex	B-T116
prediction	B-T078
method	O
supported	O
by	O
functional	B-T169
studies	O
and	O
literature	B-T170
mining.	O

AAV9	B-T005
-	O
NPC1	B-T028
significantly	B-T078
ameliorates	B-T033
Purkinje cell	B-T025
death	B-T043
and	O
behavioral abnormalities	B-T048
in	O
mouse	B-T015
NPC disease	B-T047
Niemann-Pick type C (NPC) disease	B-T047
is	O
a	O
fatal	B-T080
inherited	B-T169
neurodegenerative disorder	B-T047
caused	O
by	O
loss-of-function	B-T033
mutations	B-T045
in	O
the	O
NPC1	B-T028
or	O
NPC2 gene	B-T028
.	O
There	O
is	O
no	O
effective	O
way	O
to	O
treat	B-T169
NPC disease	B-T047
.	O
In	O
this	O
study,	O
we	O
used	O
adeno-associated virus	B-T005
(	O
AAV	B-T005
)	O
serotype 9	B-T170
(	O
AAV9	B-T005
)	O
to	O
deliver	O
a	O
functional	B-T169
NPC1 gene	B-T028
systemically	B-T169
into	O
NPC1(-/-)	B-T028
mice	B-T015
at	O
postnatal day 4	B-T061
.	O
One	O
single	B-T081
AAV9-NPC1 injection	B-T061
resulted	O
in	O
robust	B-T080
NPC1	B-T028
expression	B-T045
in	O
various	O
tissues	B-T024
,	O
including	O
brain	B-T023
,	O
heart	B-T023
,	O
and	O
lung	B-T023
.	O
Strikingly,	O
AAV9-mediated	B-T054
NPC1 delivery	B-T077
significantly	B-T078
promoted	B-T052
Purkinje cell	B-T025
survival	B-T052
,	O
restored	O
locomotor activity	B-T040
and	O
coordination	B-T042
,	O
and	O
increased	B-T081
the	O
lifespan	B-T079
of	O
NPC1(-/-)	B-T028
mice	B-T015
.	O
Our	O
work	O
suggests	O
that	O
AAV-based gene therapy	B-T061
is	O
a	O
promising	O
means	O
to	O
treat	B-T169
NPC disease	B-T047
.	O

Executive functions	B-T041
deficits	B-T080
impair	B-T169
extinction	B-T041
of	O
generalization	B-T041
of	O
fear	B-T041
of	O
movement-related pain	B-T033
Generalization	B-T041
of	O
fear	B-T041
of	O
movement-related pain	B-T033
across	O
novel	O
but	O
similar	O
movements	B-T040
can	O
lead	O
to	O
fear responses	B-T039
to	O
movements	B-T040
that	O
are	O
actually	O
not	O
associated with	B-T080
pain	B-T184
.	O
The	O
peak-shift effect	B-T080
describes	O
a	O
phenomenon	B-T067
whereby	O
particular	O
novel	O
movements	B-T040
elicit	B-T080
even	O
greater	O
fear responses	B-T039
than	O
the	O
original	O
pain-provoking	B-T184
movement	B-T040
(	O
CS+	B-T041
),	O
because	O
they	O
represent	O
a	O
more	O
extreme	O
version	O
of	O
the	O
CS+	B-T041
.	O
There	O
is	O
great	O
variance	B-T080
in	O
the	O
propensity	O
to	O
generalize	B-T041
as	O
well	O
as	O
the	O
speed	O
of	O
extinction learning	B-T041
when	O
these	O
novel	O
movements	B-T040
are	O
not	O
followed	O
by	O
pain	B-T184
.	O
It	O
can	O
be	O
argued	O
that	O
this	O
variance	B-T080
may	O
be	O
associated with	B-T080
executive function capacity	B-T041
,	O
as	O
individuals	B-T098
may	O
be	O
unable	O
to	O
intentionally	O
inhibit fear responses	B-T039
.	O
This	O
study	O
examined	B-T033
whether	O
executive function capacity	B-T041
contributes	O
to	O
generalization	B-T041
and	O
extinction	B-T041
of	O
generalization	B-T041
as	O
well	O
as	O
peak-shift	B-T169
of	O
conditioned fear	B-T041
of	O
movement-related pain	B-T033
and	O
expectancy	B-T078
.	O
Healthy participants	B-T098
performed	O
a	O
proprioceptive	B-T039
fear conditioning task	B-T041
.	O
Executive function tests	B-T041
assessing	O
updating	B-T079
,	O
switching,	O
and	O
inhibition	B-T041
were	O
used	O
to	O
predict	O
changes	O
in	O
(	O
extinction	B-T041
of)	O
fear	B-T041
of	O
movement-related pain	B-T033
and	O
pain	B-T184
expectancy	B-T078
generalization	B-T041
.	O
Low inhibitory capacity	B-T041
was	O
associated with	B-T080
slower	O
extinction	B-T041
of	O
generalized fear	B-T041
of	O
movement-related pain	B-T033
and	O
pain	B-T184
expectancy	B-T078
.	O
Evidence	O
was	O
found	O
in	O
favor	O
of	O
an	O
area-shift	B-T169
,	O
rather	O
than	O
a	O
peak-shift effect	B-T080
,	O
which	O
implies	O
that	O
the	O
peak	B-T080
conditioned fear response	B-T039
extended	O
to,	O
but	O
did	O
not	O
shift	O
to	O
a	O
novel	O
stimulus	B-T067
.	O
Participants	B-T098
with	O
low	O
inhibitory capacity	B-T041
may	O
have	O
difficulties	O
withholding	O
fear responses	B-T039
,	O
leading	O
to	O
a	O
slower	O
decrease	O
of	O
generalized fear	B-T041
over	O
time	B-T079
.	O
The	O
findings	B-T033
may	O
be	O
relevant	O
to	O
inform	O
treatments	B-T169
.	O
Low inhibitory capacity	B-T041
is	O
not	O
associated with	B-T080
slower	O
generalization	B-T041
,	O
but	O
extinction	B-T041
of	O
fear	B-T041
generalization	B-T041
.	O
Fear	B-T041
elicited by	B-T080
a	O
novel	O
safe	O
movement	B-T040
,	O
situated	O
outside	O
the	O
CS+/-	B-T041
continuum	O
on	O
the	O
CS+	B-T041
side,	O
can	O
be	O
as	O
strong	O
as	O
to	O
the	O
original	O
stimulus	B-T067
predicting	O
the	O
pain-onset	B-T033
.	O

Robust	B-T080
DLPP	B-T081
With	O
Nongreedy ℓ₁$-Norm Minimization	B-T080
and	O
Maximization	B-T080
Recently,	O
discriminant locality preserving projection based on L1-norm	B-T081
(	O
DLPP-L1	B-T081
)	O
was	O
developed	O
for	O
robust	B-T080
subspace learning	B-T041
and	O
image	B-T170
classification	B-T185
.	O
It	O
obtains	O
projection	B-T082
vectors	B-T082
by	O
greedy strategy	B-T062
,	O
i.e.,	O
all	O
projection	B-T082
vectors	B-T082
are	O
optimized	O
individually	O
through	O
maximizing	B-T080
the	O
objective	B-T080
function	B-T169
.	O
Thus,	O
the	O
obtained	O
solution	B-T170
does	O
not	O
necessarily	O
best	O
optimize	O
the	O
corresponding	O
trace ratio optimization algorithm	B-T170
,	O
which	O
is	O
the	O
essential	O
objective	B-T080
function	B-T169
for	O
general	O
dimensionality reduction	B-T170
.	O
It	O
results	O
in	O
insufficient	O
recognition	B-T041
accuracy	B-T080
.	O
To	O
tackle	O
this	O
problem,	O
we	O
propose	O
a	O
nongreedy algorithm	B-T170
to	O
solve	O
the	O
trace ratio formula	B-T170
of	O
DLPP-L1	B-T081
,	O
and	O
analyze	O
its	O
convergence	B-T052
.	O
Experimental	O
results	O
on	O
three	O
databases	B-T170
illustrate	O
the	O
effectiveness	O
of	O
our	O
proposed	O
algorithm	B-T170
.	O

A	O
Double-Blind	B-T062
Randomized Controlled Trial	B-T062
of	O
Maternal Postpartum	B-T047
Deworming	B-T061
to	O
Improve	O
Infant	B-T100
Weight Gain	B-T033
in	O
the	O
Peruvian	B-T098
Amazon	O
Nutritional interventions	B-T061
targeting	O
the	O
critical	B-T080
growth and development period	B-T033
before	O
two	O
years	O
of	O
age	B-T032
can	O
have	O
the	O
greatest	O
impact	O
on	O
health	B-T078
trajectories	B-T079
over	O
the	O
life course	B-T079
.	O
Compelling	O
evidence	B-T078
has	O
demonstrated	O
that	O
interventions	B-T061
investing	O
in	O
maternal health	B-T081
in	O
the	O
first	O
1000	O
days	B-T079
of	O
life	B-T078
are	O
beneficial	O
for	O
both	O
mothers	B-T099
and	O
their	O
children	B-T099
.	O
One	O
such	O
potential	O
intervention	B-T061
is	O
deworming	B-T061
integrated	O
into	O
maternal postpartum care	B-UnknownType
in	O
areas	B-T082
where	O
soil	B-T167
-	O
transmitted	B-T169
helminth	B-T204
(	O
STH	B-T204
)	O
infections	B-T047
are	O
endemic	B-T047
.	O
From	O
February	B-T080
to	O
August	B-T080
2014,	O
1010	O
mother	B-T099
-	O
infant	B-T100
pairs	O
were	O
recruited	O
into	O
a	O
trial	B-T062
aimed	O
at	O
assessing	B-T058
the	O
effectiveness	B-T080
of	O
maternal postpartum	B-T047
deworming	B-T061
on	O
infant	B-T100
and	O
maternal health	B-T081
outcomes	B-T080
.	O
Following	B-T079
delivery	B-T040
,	O
mothers	B-T099
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
single-	O
dose	B-T081
400	O
mg	O
albendazole	B-T109
or	O
placebo	B-T122
.	O
Participants	B-T098
were	O
followed-up	B-T058
at	O
1	B-T079
and	O
6 months	B-T079
postpartum	B-T079
.	O
There	O
was	O
no statistically significant	B-T033
difference	B-T081
in	O
mean	O
weight gain	B-T033
between	O
infants	B-T100
in	O
the	O
experimental	B-T101
and	O
control groups	B-T096
(	O
mean difference	B-T081
:	O
-0.02;	O
95%	O
CI	B-T081
:	O
-0.1,	O
0.08)	O
at	O
6 months	B-T079
of	O
age	B-T032
.	O
Further,	O
deworming	B-T061
had	O
no effect	B-T080
on	O
measured	O
infant morbidity	B-T046
indicators	B-T081
.	O
However,	O
ad hoc analyses	B-T081
restricted	O
to	O
mothers	B-T099
who	O
tested	O
positive	B-T033
for	O
STHs	B-T204
at	O
baseline	B-T081
suggest	O
that	O
infants	B-T100
of	O
mothers	B-T099
in	O
the	O
experimental	O
group	O
had	O
greater	O
mean	O
length	B-T032
gain	B-T081
in	O
cm	O
(	O
mean difference	B-T081
:	O
0.8;	O
95%	O
CI	B-T081
:	O
0.1,	O
1.4)	O
and	O
length-for-age z-score	B-T081
(	O
mean difference	B-T081
:	O
0.5;	O
95%	O
CI	B-T081
:	O
0.2,	O
0.8)	O
at	O
6 months	B-T079
of	O
age	B-T032
.	O
In	O
a	O
study population	B-T098
composed	O
of	O
both	O
STH-infected	B-T047
and	O
uninfected	B-T080
mothers	B-T099
,	O
maternal postpartum	B-T047
deworming	B-T061
was	O
insufficient	B-T080
to	O
impact	O
infant	B-T100
growth	B-T040
and	O
morbidity	B-T046
indicators	B-T081
up	O
to	O
6 months	B-T079
postpartum	B-T079
.	O
Among	O
STH-infected	B-T047
mothers	B-T099
,	O
however,	O
important	O
improvements	O
in	O
infant	B-T100
length	O
gain	O
and	O
length-for-age	B-T033
were	O
observed.	O
The	O
benefits	O
of	O
maternal postpartum	B-T047
deworming	B-T061
should	O
be	O
further	O
investigated	O
in	O
study populations	B-T098
having	O
higher	O
overall	O
prevalences	B-T081
and	O
intensities	B-T185
of	O
STH infections	B-T047
and,	O
in	O
particular,	O
where	O
whipworm	B-T047
and	O
hookworm infections	B-T047
are	O
of	O
public health concern	B-T058
.	O
ClinicalTrials.gov	O
(NCT01748929).	O

Technical	O
note:	O
A	O
preliminary	B-T079
comparative study	B-T062
between	O
classical	B-T169
and	O
interventional radiological approaches	B-T091
for	O
multi-phase	B-T079
post-mortem CT	B-T060
angiography	B-T060
Multi-phase	B-T079
post-mortem computed tomography angiography	B-T060
(	O
MPMCTA	B-T060
)	O
is	O
a	O
new	B-T080
diagnostic tool	B-T060
,	O
used	O
in	O
forensic pathology	B-T091
.	O
On	O
the	O
one	O
hand,	O
this	O
technique	B-T169
allows	O
a	O
better	O
and	O
direct visualization	B-T033
of	O
vascular	B-T047
and	O
solid organ	B-T023
lesions	B-T033
.	O
On	O
the	O
other	O
hand,	O
the	O
invasiveness	B-T080
of	O
the	O
procedure	B-T169
-which	O
requires	O
surgical denudation	B-T033
(	O
inguinal	B-T029
and/or	O
cervical	B-T082
)	O
and	O
the	O
insertion	B-T061
of	O
surgical cannulas	B-T074
-leads	O
to	O
many	O
relatives	B-T099
refusing	B-T052
scientific autopsies	B-T060
.	O
Our	O
hypothesis	B-T078
states	O
that	O
a	O
minimally-invasive procedure	B-T169
combining	O
interventional radiological techniques	B-T061
with	O
MPMCTA	B-T060
(	O
replacement	B-T169
of	O
surgical cannulas	B-T074
by	O
radiological catheters	B-T074
)	O
will	O
improve	B-T033
the	O
approval	B-T080
rate	B-T081
of	O
scientific autopsies	B-T060
by	O
families	B-T099
.	O
The	O
aim	B-T078
of	O
this	O
study	B-T062
was	O
to	O
evaluate	O
the	O
feasibility	B-T062
of	O
the	O
minimally-invasive	B-T169
MPMCTA	B-T060
approach	O
and	O
to	O
compare	B-T052
its	O
performance	B-T052
to	O
the	O
current	B-T079
reference-standard	B-T081
(the	O
conventional	O
approach).	O
We	O
included	O
consecutively	B-T080
16	O
corpses	B-T017
divided	O
in	O
two	O
groups	B-T078
according	O
to	O
the	O
contrast	B-T080
enhancement	B-T052
approach:	O
radiological catheters	B-T074
(n=8),	O
and	O
surgical cannulas	B-T074
(n=8).	O
Corpses	B-T017
were	O
chosen	O
and	O
assigned	O
randomly	O
from	O
our	O
local	O
data	B-T078
.	O
The	O
quality	B-T080
of	O
the	O
imaging procedure	B-T060
was	O
compared	B-T052
according	O
to	O
four	O
items:	O
global vascular	B-T023
opacification	B-T080
,	O
cerebral venous opacification	B-T080
,	O
and	O
lower limbs	B-T023
opacification	B-T080
(	O
arterial	B-T082
and	O
venous	B-T082
).	O
A	O
minimally-invasive approach	B-T169
for	O
scientific autopsies	B-T060
is	O
feasible	O
through	O
a	O
radiological catheter	B-T074
.	O
Vascular	B-T023
opacification	B-T080
was	O
optimal	B-T080
in	O
8	O
out	O
of	O
8	O
cases	O
and	O
was	O
no	O
less	O
effective	B-T080
than	O
the	O
control reference group	B-T096
using	O
surgical cannula	B-T074
incision	B-T061
associated with	B-T080
their	O
non-occlusive aspects	B-T080
.	O

Correlations	B-T080
between	O
physical activity	B-T056
and	O
neurocognitive domain functions	B-T041
in	O
patients	B-T101
with	O
schizophrenia	B-T048
:	O
a	O
cross-sectional study	B-T062
Neurocognitive dysfunction	B-T048
is	O
a	O
critical	O
target	O
symptom	B-T184
of	O
schizophrenia	B-T048
treatment	B-T061
.	O
A	O
positive	O
correlation	B-T080
between	O
physical activity	B-T056
level	O
and	O
neurocognitive function	B-T041
has	O
been	O
reported	O
in	O
healthy individuals	B-T098
,	O
but	O
it	O
is	O
unclear	O
whether	O
such	O
a	O
correlation	B-T080
exists	O
in	O
patients	B-T101
with	O
schizophrenia	B-T048
and	O
whether	O
the	O
relationship	B-T080
is	O
different	O
according	O
to	O
inpatients	B-T101
or	O
outpatients	B-T101
.	O
This	O
study	B-T062
aimed	O
to	O
examine	B-T058
the	O
differences	O
in	O
the	O
correlations	B-T080
between	O
physical activity	B-T056
and	O
multiple	O
neurocognitive domains	B-T041
in	O
inpatients	B-T101
and	O
outpatients	B-T101
with	O
schizophrenia	B-T048
and	O
obtain	O
suggestions	B-T078
for	O
further	O
study	B-T062
to	O
facilitate	O
this	O
field.	O
Twenty-nine	O
patients	B-T101
with	O
schizophrenia	B-T048
were	O
examined	B-T058
(16	O
inpatients	B-T101
and	O
13	O
outpatients	B-T101
,	O
56.0	O
±	O
11.4	O
years	B-T079
of	O
age	B-T032
).	O
Current	O
symptoms	B-T184
were	O
assessed	B-T052
using	O
the	O
Positive	B-T033
and	O
Negative	B-T033
Symptom Scale	B-T170
and	O
neurocognitive functions	B-T041
using	O
Cognitrax	B-T170
,	O
which	O
yields	O
a	O
composite	O
neurocognitive index	B-T060
(	O
NCI	B-T060
)	O
and	O
11	O
domain	O
scores	B-T081
.	O
After	O
testing,	O
participants	B-T098
wore	O
an	O
HJA-750C accelerometer	B-T074
for	O
one week	B-T079
to	O
measure	B-T081
physical activity	B-T056
levels	O
and	O
durations	B-T079
.	O
Partial correlation analyses	B-T062
were	O
performed	O
between	O
exercise	B-T056
and	O
cognitive	B-T041
parameters	B-T033
.	O
In	O
the	O
outpatient	B-T101
group,	O
higher	B-T080
physical activity	B-T056
was	O
associated	O
with	O
faster	O
Motor	B-T169
and	O
Psychomotor	B-T041
Speeds	B-T081
in	O
outpatients	B-T101
.	O
However,	O
higher	B-T080
physical activity	B-T056
was	O
associated with	B-T080
lower	B-T080
overall	O
NCI	B-T060
,	O
Attention	B-T041
score	B-T081
,	O
and	O
Memory	B-T041
scores	B-T081
in	O
inpatients	B-T101
.	O
Although	O
higher	B-T080
physical activity	B-T056
was	O
associated with	B-T080
better	O
neurocognitive functions	B-T041
of	O
outpatients	B-T101
,	O
in	O
inpatients	B-T101
with	O
non-remitted	O
schizophrenia	B-T048
,	O
higher	B-T080
physical activity	B-T056
was	O
associated with	B-T080
worsening	O
of	O
several	O
cognitive domains	B-T041
.	O
In	O
a	O
future	O
study	B-T062
examining	B-T058
the	O
relationship	B-T080
between	O
physical activity	B-T056
and	O
neurocognitive function	B-T041
for	O
facilitating	O
this	O
research	O
field,	O
separation	O
between	O
inpatients	B-T101
and	O
outpatients	B-T101
are	O
needed	O
because	O
the	O
relationship	B-T080
is	O
different	O
between	O
inpatients	B-T101
and	O
outpatients	B-T101
.	O

A	O
completely	B-T080
calcified	B-T080
prostate	B-T023
Prostatic calcification	B-T047
and	O
prostatic calculus	B-T047
formation	B-T169
is	O
commonly	O
seen	O
in	O
adult	B-T100
population	B-T098
with	O
chronic prostatitis	B-T047
,	O
however,	O
gross	O
prostatic calcification	B-T047
which	O
involves	O
more	O
than	O
3	O
cm(2)	O
of	O
the	O
gland	B-T023
is	O
quite	O
rare	B-T080
.	O
We	O
are	O
presenting	B-T078
here	O
one	O
such	O
case	B-T169
in	O
which	O
almost	O
whole	O
glandular prostate	B-T023
was	O
converted	B-T169
into	O
stone	B-T031
which	O
is	O
never	O
reported	O
so	O
far.	O

A	O
rare	B-T080
cause	B-T169
of	O
gastric obstruction	B-T047
:	O
Lighters	B-T073
swallowing	B-T040
The	O
majority	B-T080
of	O
swallowed foreign bodies	B-T033
are	O
thrown	B-T080
spontaneously	B-T169
without	B-T080
causing	B-T169
complications	B-T046
in	O
the	O
digestive system	B-T022
.	O
Multiple	B-T081
number	B-T081
of	O
foreign bodies	B-T037
may	O
be	O
swallowed	B-T040
by	O
psychiatric patients	B-T101
which	O
delay diagnosis	B-T080
and	O
increase	B-T169
the	O
complication	B-T046
rate	B-T081
.	O
Long	B-T080
and	O
hard	B-T080
objects	B-T037
cannot	O
pass	O
through	O
the	O
pylorus	B-T023
,	O
and	O
may	O
cause	B-T169
obstruction	B-T046
,	O
ulceration	B-T046
,	O
bleeding	B-T046
and	O
perforation	B-T033
.	O
Endoscopy	B-T060
is	O
used	B-T169
as	O
an	O
effective	B-T080
method	B-T169
in	O
such	O
cases	B-T169
.	O
An	O
exploratory laparatomy	B-T060
was	O
performed	B-T169
after	O
unsuccessful	B-T080
endoscopic	B-T082
foreign object	B-T037
removal	B-T061
in	O
a	O
28-year-old	O
schizophrenic	B-T048
patient	B-T101
with	O
gastric outlet obstruction	B-T047
due to	B-T169
multiple	B-T081
cigarette lighter	B-T073
swallowing	B-T040
.	O
Ten	O
lighters	B-T073
were	O
removed	B-T080
from	O
the	O
stomach	B-T023
through	B-T169
gastrotomy	B-T061
and	O
one	O
more	O
lighter	B-T073
was	O
removed	B-T080
from	O
the	O
descending colon	B-T023
by	O
milking	B-T061
through	B-T169
the	O
anus	B-T023
.	O
The	O
aim	O
of	O
this	O
paper	O
is	O
to	O
discuss	O
encountered	O
difficulties	B-T033
in	O
psychiatric patients	B-T101
who	O
underwent	O
surgery	B-T061
due to	B-T169
intake	B-T169
of	O
foreign bodies	B-T037
.	O

Ceftaroline fosamil	B-T109
for	O
community-acquired pneumonia	B-T047
and	O
skin	B-T022
and	O
skin structure infections	B-T046
:	O
a	O
systematic review	B-T170
Background	O
Ceftaroline	B-T109
is	O
a	O
parentally	O
administered	B-T169
cephalosporin	B-T109
that	O
has	O
an	O
in vitro	B-T080
expanded	B-T082
spectrum	O
of	O
activity	B-T044
compared	B-T052
with	O
other	O
cephalosporins	B-T109
yet	O
data	B-T078
is	O
conflicting	O
regarding	O
its	O
place	O
in	O
therapy	B-T061
.	O
Aim	O
of	O
the	O
Review	B-T170
To	O
compare	B-T052
the	O
efficacy	B-T080
and	O
safety	B-T068
of	O
ceftaroline	B-T109
against	O
standard	O
antibiotic	B-T195
regimens	B-T061
for	O
community-acquired pneumonia	B-T047
(	O
CAP	B-T047
)	O
and	O
complicated skin and skin structure infections	B-T046
(	O
cSSSIs	B-T046
).	O
Method	O
The	O
databases	B-T170
of	O
MEDLINE	B-T170
,	O
EBSCO	B-T170
,	O
and	O
Embase	B-T170
were	O
searched	O
up	O
to	O
June	O
2016.	O
Manual review of references was completed	B-T170
and	O
experts	B-T097
in	O
the	O
field	O
were	O
contacted	O
for	O
unpublished data	B-T170
.	O
Randomized controlled trials	B-T062
of	O
ceftaroline	B-T109
in	O
CAP	B-T047
or	O
cSSSI	B-T046
populations	B-T098
were	O
included.	O
Outcomes	B-T169
included	O
clinical cure	B-T033
,	O
mortality	B-T081
,	O
adverse events	B-T046
,	O
serious adverse events	B-T033
,	O
and	O
discontinuation	B-T061
due	O
to	O
adverse events	B-T046
.	O
Meta-analysis	B-T170
was	O
used	O
to	O
pool	O
results	O
for	O
these	O
outcomes	B-T169
.	O
We	O
performed	O
subgroup	B-T185
analyses	B-T062
for	O
gram positive infections	B-T047
in	O
CAP	B-T047
and	O
infections	B-T046
caused	O
by	O
methicillin-resistant Staphylococcus aureus	B-T007
in	O
cSSSIs	B-T046
.	O
Risk	B-T078
of	O
bias	B-T078
was	O
assessed	O
for	O
all	O
studies	B-T062
.	O
Results	O
Six	O
trials	B-T062
(three	O
for	O
each	O
indication)	O
were	O
included,	O
each	O
of	O
which	O
had	O
an	O
unclear	O
or	O
high	O
risk	B-T078
of	O
bias	B-T078
in	O
at	O
least	O
one	O
domain.	O
For	O
CAP	B-T047
,	O
ceftaroline	B-T109
was	O
significantly	O
more	O
efficacious	B-T080
in	O
achieving	O
clinical cure	B-T033
than	O
ceftriaxone	B-T109
[	O
risk ratio	B-T081
(	O
RR	B-T081
)	O
1.11,	O
95%	O
confidence interval	B-T081
(	O
CI	B-T081
)	O
1.04-1.19;	O
I(2)	O
=	O
47%].	O
For	O
cSSSIs	B-T046
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
clinical cure	B-T033
between	O
ceftaroline	B-T109
and	O
vancomycin	B-T116
plus	O
aztreonam	B-T109
(	O
RR	B-T081
1.01,	O
95%	O
CI	B-T081
0.97-1.05;	O
I(2)	O
=	O
0%).	O
No	O
differences	O
were	O
found	O
for	O
overall	O
mortality	B-T081
,	O
serious adverse events	B-T033
,	O
discontinuation	B-T061
due	O
to	O
adverse events	B-T046
,	O
and	O
overall	O
adverse events	B-T046
.	O
Conclusion	O
Ceftaroline	B-T109
is	O
a	O
viable	O
therapeutic alternative	B-T061
for	O
patients	B-T101
with	O
CAP	B-T047
and	O
cSSSIs	B-T046
,	O
yet	O
identified	O
risks	B-T078
of	O
bias	B-T078
and	O
poor external validity	B-T033
preclude	O
it	O
from	O
being	O
recommended	O
as	O
a	O
first-line agent	B-T195
.	O

Direct	O
effects of	B-T080
glucose	B-T109
,	O
insulin	B-T116
,	O
GLP-1	B-T116
,	O
and	O
GIP	B-T116
on	O
bulbospinal	B-T029
neurons	B-T025
in	O
the	O
rostral ventrolateral medulla	B-T023
in	O
neonatal	B-T100
wistar rats	B-T015
Although	O
patients	B-T101
with	O
diabetes mellitus	B-T047
(	O
DM	B-T047
)	O
often	O
exhibit	O
hypertension	B-T047
,	O
the	O
mechanisms	B-T169
responsible	O
for	O
this	O
correlation	B-T080
are	O
not	O
well	O
known.	O
We	O
hypothesized	O
that	O
the	O
bulbospinal	B-T029
neurons	B-T025
in	O
the	O
rostral ventrolateral medulla	B-T023
(	O
RVLM	B-T023
)	O
are	O
affected	B-T169
by	O
the	O
levels	B-T080
of	O
glucose	B-T109
,	O
insulin	B-T116
,	O
or	O
incretins	B-T116
(	O
glucagon like peptide-1	B-T116
[	O
GLP-1	B-T116
]	O
or	O
glucose-dependent insulinotropic peptide	B-T116
[	O
GIP	B-T116
])	O
in	O
patients	B-T101
with	O
DM	B-T047
.	O
To	O
investigate	B-T169
whether	O
RVLM	B-T023
neurons	B-T025
are	O
activated	B-T052
by	O
glucose	B-T109
,	O
insulin	B-T116
,	O
GLP-1	B-T116
,	O
or	O
GIP	B-T116
,	O
we	O
examined	O
changes	B-T169
in	O
the	O
membrane potentials	B-T043
of	O
bulbospinal	B-T029
RVLM	B-T023
neurons	B-T025
using	O
whole-cell	B-T025
patch-clamp technique	B-T062
during	O
superfusion	B-T067
with	O
various	O
levels	B-T080
of	O
glucose	B-T109
or	O
these	O
hormones	B-T125
in	O
neonatal	B-T100
Wistar rats	B-T015
.	O
A	O
brainstem	B-T023
-	O
spinal cord	B-T023
preparation	B-T052
was	O
used	O
for	O
the	O
experiments	B-T062
.	O
A	O
low	B-T080
level	B-T080
of	O
glucose	B-T109
stimulated	O
bulbospinal	B-T029
RVLM	B-T023
neurons	B-T025
.	O
During	O
insulin	B-T116
superfusion	B-T067
,	O
almost	O
all	O
the	O
RVLM	B-T023
neurons	B-T025
were	O
depolarized	B-T043
,	O
while	O
during	O
GLP-1	B-T116
or	O
GIP	B-T116
superfusion	B-T067
,	O
almost	O
all	O
the	O
RVLM	B-T023
neurons	B-T025
were	O
hyperpolarized	B-T043
.	O
Next,	O
histological examinations	B-T059
were	O
performed	O
to	O
examine	O
transporters for glucose	B-T116
and	O
receptors	B-T116
for	O
insulin	B-T116
,	O
GLP-1	B-T116
,	O
and	O
GIP	B-T116
on	O
RVLM	B-T023
neurons	B-T025
.	O
Low	B-T080
-	O
level	B-T080
glucose	B-T109
-	O
depolarized	B-T043
RVLM	B-T023
neurons	B-T025
exhibited	O
the	O
presence	B-T080
of	O
glucose transporter 3	B-T116
(	O
GLUT3	B-T116
).	O
Meanwhile,	O
insulin	B-T116
-	O
depolarized	B-T043
,	O
GLP-1	B-T116
-	O
hyperpolarized	B-T043
,	O
and	O
GIP	B-T116
-	O
hyperpolarized	B-T043
RVLM	B-T023
neurons	B-T025
showed	O
each	O
of	O
the	O
respective	O
specific	B-T080
receptor	B-T116
.	O
These	O
results	O
indicate	O
that	O
a	O
low	B-T080
level	B-T080
of	O
glucose	B-T109
stimulates	B-T070
bulbospinal	B-T029
RVLM	B-T023
neurons	B-T025
via	O
specific	B-T080
transporters	B-T116
on	O
these	O
neurons	B-T025
,	O
inducing	B-T169
hypertension	B-T047
.	O
Furthermore,	O
an	O
increase	B-T169
in	O
insulin	B-T116
or	O
a	O
reduction	B-T080
in	O
incretins	B-T116
may	O
also	O
activate	B-T052
the	O
sympathetic nervous system	B-T022
and	O
induce	B-T169
hypertension	B-T047
by	O
activating	B-T052
RVLM	B-T023
neurons	B-T025
via	O
their	O
own	O
receptors	B-T116
.	O

Mechanisms	B-T169
of	O
compensation	B-T058
in	O
the	O
gait	B-T033
of	O
patients	B-T101
with	O
drop foot	B-T047
Drop foot	B-T047
is	O
a	O
complex	O
syndrome	B-T047
,	O
with	O
multiple	B-T081
interactions	B-T169
between	O
joints	B-T030
and	O
muscles	B-T024
.	O
Abnormalities	B-T033
in	O
movement patterns	B-T033
can	O
be	O
measured	O
using	O
motion capture techniques	B-T058
,	O
but	O
identifying	O
compensation	B-T058
mechanisms	B-T169
mechanisms	B-T169
remains	O
challenging.	O
In	O
order	O
to	O
identify	O
compensatory	B-T169
mechanisms	B-T169
in	O
patients	B-T101
with	O
drop foot	B-T047
,	O
this	O
study	B-T062
evaluated	O
a	O
sample	O
of	O
15	O
such	O
patients	B-T101
using	O
a	O
computerized	B-T066
gait analysis system	B-T074
,	O
as	O
compared	O
to	O
a	O
group	O
of	O
15	O
healthy subjects	B-T098
.	O
Four	O
classes	O
of	O
parameters	O
were	O
distinguished,	O
falling	B-T033
in	O
differing	O
intervals	B-T079
of	O
percentage	B-T081
differences	B-T081
between	O
the	O
groups	B-T098
in	O
the	O
study	B-T062
.	O
The	O
first	O
class	O
comprised	O
two	O
kinematic parameters	B-T091
for	O
which	O
the	O
values	O
of	O
percentage	O
differences	O
in	O
the	O
control group	B-T096
were	O
more	O
than	O
100%	O
greater	O
than	O
for	O
the	O
patient group	B-T101
.	O
The	O
second	O
class	O
comprised	O
two	O
kinetic parameters	B-T070
falling	B-T033
in	O
the	O
interval	B-T079
of	O
100-49%.	O
In	O
the	O
third	O
class,	O
in	O
the	O
49-20%	O
interval	B-T079
the	O
main	O
differences	O
were	O
observed	O
for	O
spatiotemporal parameters	B-T062
,	O
whereas	O
in	O
the	O
20-4%	O
interval	B-T079
the	O
differences	O
were	O
distributed	O
similarly	O
for	O
kinematic	B-T091
,	O
kinetic	B-T070
and	O
spatiotemporal parameters	B-T062
.	O
These	O
differences	O
in	O
gait pattern	B-T033
between	O
the	O
groups	B-T098
may	O
be	O
related	O
to	O
both	O
primary	O
motor deficits	B-T033
and	O
secondary	O
compensatory	B-T169
mechanisms	B-T169
.	O
Generally,	O
we	O
conclude	O
that	O
drop foot	B-T047
affects	O
the	O
patients	B-T101
'	O
overall	O
kinematic	B-T091
and	O
kinetic	B-T070
gait	B-T033
parameters,	O
with	O
compensation	B-T058
seen	O
as	O
a	O
chain	O
originating	O
from	O
a	O
change	B-T169
of	O
movement	B-T040
within	O
the	O
ankle joint	B-T030
.	O

Inhibitory	B-T052
effects of	B-T080
Lactobacillus rhamnosus	B-T007
and	O
Lactobacillus casei	B-T007
on	O
Candida	B-T004
biofilm	B-T007
of	O
denture surface	B-T033
Candida albicans	B-T004
biofilm	B-T007
is	O
associated with	B-T080
denture-related stomatitis	B-T047
and	O
oral candidiasis	B-T047
of	O
elderly	B-T098
.	O
Probiotics	B-T007
are	O
beneficial	O
bacteria	B-T007
and	O
have	O
antibacterial activity	B-T033
against	O
pathogenic bacteria	B-T007
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	B-T169
the	O
antifungal activity	B-T033
of	O
various	O
probiotics	B-T007
against	O
C. albicans	B-T004
and	O
the	O
inhibitory	B-T052
effects of	B-T080
probiotics	B-T007
on	O
Candida	B-T004
biofilm	B-T007
on	O
the	O
denture surface	B-T033
.	O
The	O
spent culture media	B-T130
of	O
various	O
probiotics	B-T007
were	O
investigated	O
the	O
antifungal efficacy	B-T080
against	O
C. albicans	B-T004
.	O
Candida	B-T004
biofilm	B-T007
was	O
formed	O
on	O
a	O
denture base resin	B-T074
and	O
was	O
then	O
treated	B-T169
with	O
Lactobacillus rhamnosus	B-T007
and	O
Lactobacillus casei	B-T007
.	O
Also,	O
the	O
biofilm	B-T007
s	O
of	O
L. rhamnosus	B-T007
and	O
L. casei	B-T007
were	O
formed	O
and	O
were	O
sequentially	O
treated	B-T169
with	O
C. albicans	B-T004
.	O
Colony-forming units	B-T081
of	O
C. albicans	B-T004
on	O
the	O
denture surface	B-T033
were	O
counted	O
after	O
spreading	B-T080
on	O
agar	B-T109
plate	B-T074
.	O
The	O
denture base resin	B-T074
was	O
treated	B-T169
with	O
the	O
spent culture media	B-T130
for	O
30	O
days	B-T079
,	O
after	O
which	O
the	O
denture surface	B-T033
roughness	B-T033
was	O
analyzed	O
with	O
an	O
atomic force microscope	B-T059
.	O
L. rhamnosus	B-T007
and	O
L. casei	B-T007
exhibited	O
stronger	O
antifungal activity	B-T033
than	O
other	O
probiotics	B-T007
.	O
The	O
spent culture medium	B-T130
of	O
L. rhamnosus	B-T007
and	O
L. casei	B-T007
exhibited	O
the	O
antifungal activity	B-T033
against	O
blastoconidia	B-T004
and	O
biofilm	B-T007
of	O
C. albicans	B-T004
.	O
L. rhamnosus	B-T007
and	O
L. casei	B-T007
showed	O
the	O
antifungal activity	B-T033
against	O
Candida	B-T004
biofilm	B-T007
,	O
and	O
the	O
biofilm	B-T007
of	O
L. rhamnosus	B-T007
and	O
L. casei	B-T007
inhibited	B-T052
formation	B-T169
of	O
Candida	B-T004
biofilm	B-T007
on	O
denture surface	B-T033
.	O
Neither	O
of	O
the	O
probiotics	B-T007
affected	O
the	O
surface roughness	B-T033
of	O
the	O
denture base resin	B-T074
.	O
L. rhamnosus	B-T007
and	O
L. casei	B-T007
may	O
be	O
the	O
ideal	O
probiotics	B-T007
for	O
the	O
prevention	B-T080
and	O
treatment	B-T169
of	O
denture-related stomatitis	B-T047
.	O

Persistent Organic Pollutants	B-T131
(	O
POPs	B-T131
)	O
in	O
the	O
atmosphere	B-T070
of	O
three	O
Chilean	B-T098
cities	B-T083
using	O
passive	B-T080
air samplers	B-T074
In	O
this	O
study	B-T062
passive	B-T080
air samplers	B-T074
containing	O
polyurethane foam	B-T109
(	O
PUF	B-T109
)	O
disks	B-T074
were	O
deployed	B-T052
in	O
three	O
cities	B-T083
across	O
Chile	B-T083
;	O
Santiago	B-T083
(	O
STG	B-T083
)	O
(n=5,	O
sampling sites	B-T082
),	O
Concepciόn	B-T083
(	O
CON	B-T083
)	O
(n=6)	O
and	O
Temuco	B-T083
(	O
TEM	B-T083
)	O
(n=6)	O
from	O
2008	O
to	O
2009.	O
Polychlorinated biphenyls	B-T109
(	O
PCBs	B-T109
)	O
(7	O
indicator	B-T169
congeners	B-T104
),	O
chlorinated pesticides	B-T131
hexachlorocyclohexanes	B-T109
(	O
HCHs	B-T109
),	O
dichlorodiphenyl trichloroethanes	B-T109
(	O
DDTs	B-T109
)	O
and	O
flame retardants	B-T120
such	O
as	O
polybrominated diphenyl ethers	B-T109
(	O
PBDEs	B-T109
)	O
were	O
determined by	B-T080
gas chromatography coupled mass spectrometry	B-T059
(	O
GC/MS	B-T059
).	O
A	O
sampling	B-T078
rate	B-T081
(	O
R	B-T081
)	O
typical	O
of	O
urban sites	B-T082
(4m(3)/day)	O
was	O
used	O
to	O
estimate	B-T081
the	O
atmospheric	B-T070
concentrations	B-T081
of	O
individual	B-T081
compounds	B-T080
.	O
PCB	B-T109
concentrations	B-T081
in	O
the	O
air	B-T167
(pg/m(3))	O
ranged	B-T081
from	O
~1-10	O
(	O
TEM	B-T083
),	O
~1-40	O
(	O
STG	B-T083
)	O
and	O
4-30	O
(	O
CON	B-T083
).	O
Higher molecular weight	B-T080
PCBs	B-T109
(	O
PCB	B-T109
-153,	O
-180)	O
were	O
detected	B-T033
at	O
industrial sites	B-T082
(in	O
Concepción	B-T083
).	O
The	O
HCHs	B-T109
showed	O
a	O
prevalence	B-T081
of	O
γ-HCH	B-T109
across	O
all	O
sites	B-T082
,	O
indicative	B-T169
of	O
inputs	B-T077
from	O
the	O
use	O
of	O
lindane	B-T109
but	O
a	O
limited	B-T169
use	O
of	O
technical	B-T081
HCHs	B-T109
in	O
Chile	B-T083
.	O
DDTs	B-T109
were	O
detected	B-T033
with	O
a	O
prevalence	B-T081
of	O
p,p'-DDE	B-T109
accounting	B-UnknownType
for	O
~50%	O
of	O
the	O
total	O
DDTs	B-T109
.	O
PBDE	B-T109
concentrations	B-T081
in	O
air	B-T167
(pg/m(3))	O
ranged	B-T081
from	O
1	O
to	O
55	O
(	O
STG	B-T083
),	O
0.5	O
to	O
20	O
(	O
CON	B-T083
)	O
and	O
from	O
0.4	O
to	O
10	O
(	O
TEM	B-T083
),	O
and	O
were	O
generally	O
similar	B-T080
to	O
those	O
reported	B-T170
for	O
many	O
other	O
urban areas	B-T082
globally	B-T080
.	O
The	O
pattern	B-T082
of	O
PBDEs	B-T109
was	O
different	O
among	O
the	O
three	O
cities	B-T083
;	O
however,	O
PBDE	B-T109
-209	O
was	O
dominant	B-T169
at	O
most	O
of	O
the	O
sites	B-T082
.	O
These	O
results	B-T033
represent	O
one	O
of	O
the	O
few	O
assessments	B-T058
of	O
air	B-T167
concentrations	B-T081
of	O
POPs	B-T131
across	O
different	O
urban areas	B-T082
within	O
the	O
same	O
country	B-T083
.	O
These	O
data	B-T078
will	O
support	B-T077
Chilean	B-T098
commitments	B-T041
as	O
a	O
signatory	B-T169
to	O
the	O
Stockholm Convention	B-T064
on	O
POPs	B-T131
and	O
for	O
reporting	B-T062
as	O
a	O
member	B-T097
country	B-T083
of	O
the	O
Group of Latin America and Caribbean Countries (GRULAC) region	B-T083
.	O

Intraoperative	B-T079
ketamine	B-T109
reduces	B-T080
immediate	B-T079
postoperative	B-T079
opioid	B-T109
consumption	B-T169
after	O
spinal fusion surgery	B-T061
in	O
chronic pain	B-T184
patients	B-T101
with	O
opioid	B-T109
dependency	B-T080
:	O
a	O
randomized	B-T062
,	O
blinded trial	B-T062
Perioperative	B-T079
handling	B-T033
of	O
surgical patients	B-T101
with	O
opioid	B-T109
dependency	B-T080
represents	O
an	O
important	B-T080
clinical	B-T080
problem	B-T033
.	O
Animal studies	B-T008
suggest	O
that	O
ketamine	B-T109
attenuates	B-T052
central sensitization	B-T047
and	O
hyperalgesia	B-T184
and	O
thereby	O
reduces	B-T080
postoperative	B-T079
opioid	B-T109
opioid tolerance	B-UnknownType
.	O
We	O
hypothesized	B-T078
that	O
intraoperative	B-T079
ketamine	B-T109
would	O
reduce	B-T080
immediate	B-T079
postoperative	B-T079
opioid	B-T109
consumption	B-T169
compared	O
with	O
placebo	B-T122
in	O
chronic pain	B-T184
patients	B-T101
with	O
opioid	B-T109
dependency	B-T080
undergoing	O
lumbar spinal fusion surgery	B-T061
.	O
Primary outcome	B-T080
was	O
morphine	B-T109
consumption	B-T169
0 to 24 hours	B-T079
postoperatively	B-T079
.	O
Secondary outcomes	B-T080
were	O
acute pain at rest	B-T184
and	O
during	O
mobilization	B-T061
2 to 24 hours	B-T079
postoperatively	B-T079
(	O
visual analogue scale	B-T060
),	O
adverse events	B-T046
,	O
and	O
persistent	B-T079
pain	B-T184
6	O
months	O
postoperatively	B-T079
.	O
One	O
hundred	O
fifty	O
patients	B-T101
were	O
randomly assigned	B-T062
to	O
intraoperative	B-T079
S-ketamine	B-T109
bolus 0.5 mg/kg and infusion	B-T061
0.25	O
mg·kg·h	O
or	O
placebo	B-T122
.	O
Postoperatively	B-T079
,	O
patients	B-T101
received	O
their	O
usual	O
opioids	B-T109
,	O
paracetamol	B-T109
and	O
IV	O
patient-controlled analgesia	B-T061
with	O
morphine	B-T109
.	O
In	O
the	O
final analyses	B-T170
,	O
147	O
patients	B-T101
were	O
included.	O
Patient-controlled analgesia	B-T061
IV	O
morphine	B-T109
consumption	B-T169
0	O
to	O
24	O
hours	O
postoperatively	B-T079
was	O
significantly	B-T078
reduced	B-T080
in	O
the	O
ketamine	B-T109
group	O
compared	O
with	O
the	O
placebo	B-T122
group:	O
79	O
(47)	O
vs	O
121	O
(53)	O
mg	O
IV,	O
mean	B-T081
difference	B-T080
42	O
mg	O
(95%	O
confidence interval	B-T081
-59	O
to	O
-25),	O
P	O
<	O
0.001.	O
Sedation	B-T033
was	O
significantly	B-T078
reduced	B-T080
in	O
the	O
ketamine	B-T109
group	O
6	O
and	O
24	O
hours	O
postoperatively	B-T079
.	O
There	O
were	O
no significant differences	B-T033
regarding	O
acute pain	B-T184
,	O
nausea	B-T184
,	O
vomiting	B-T184
,	O
hallucinations	B-T048
,	O
or	O
nightmares	B-T184
.	O
Back pain	B-T184
at	O
6	O
months	O
postoperatively	B-T079
compared	O
with	O
preoperative	B-T079
pain	B-T184
was	O
significantly	B-T078
more	O
improved	B-T033
in	O
the	O
ketamine	B-T109
group	O
compared	O
with	O
the	O
placebo	B-T122
group,	O
P	O
=	O
0.005.	O
In	O
conclusion,	O
intraoperative	B-T079
ketamine	B-T109
significantly	B-T078
reduced	B-T080
morphine	B-T109
consumption	B-T169
0 to 24 hours	B-T079
after	O
lumbar fusion surgery	B-T061
in	O
opioid	B-T109
-	O
dependent	B-T080
patients	B-T101
.	O
The	O
trend	B-T079
regarding	O
less	O
persistent	B-T079
pain	B-T184
6	O
months	O
postoperatively	B-T079
needs	O
further	B-T082
investigation	B-T169
.	O

Effects of	B-T080
argan oil	B-T109
on	O
the	O
mitochondrial function	B-T043
,	O
antioxidant system	B-T022
and	O
the	O
activity	B-T044
of	O
NADPH	B-T114
-	O
generating	B-T052
enzymes	B-T116
in	O
acrylamide	B-T109
treated	B-T061
rat	B-T015
brain	B-T023
Argan oil	B-T109
(	O
AO	B-T109
)	O
is	O
rich	O
in	O
minor	O
compounds	B-T103
such	O
as	O
polyphenols	B-T109
and	O
tocopherols	B-T109
which	O
are	O
powerful	O
antioxidants	B-T121
.	O
Acrylamide	B-T109
(	O
ACR	B-T109
)	O
has	O
been	O
classified	B-T185
as	O
a	O
neurotoxic agent	B-T131
in	O
animals	B-T008
and	O
humans	B-T016
.	O
Mitochondrial	B-T026
oxidative stress	B-T049
and	O
dysfunction	B-T033
is	O
one	O
of	O
the	O
most	O
probable	B-T081
molecular mechanisms	B-T044
of	O
neurodegenerative diseases	B-T047
.	O
Female	B-T032
Sprague Dawley rats	B-T015
were	O
exposed to	B-T080
ACR	B-T109
(50mg/kg	O
i.p.	O
three	O
times	O
a	O
week),	O
AO	B-T109
(6ml/kg,o.p,	O
per	O
day)	O
or	O
together	O
for	O
30days.	O
The	O
activities	B-T052
of	O
cytosolic	B-T026
enzymes	B-T116
such	O
as	O
xanthine oxidase	B-T116
(	O
XO	B-T116
),	O
glucose 6-phosphate dehydrogenase	B-T116
(	O
G6PDH	B-T116
),	O
glutathione-S-transferase	B-T116
(	O
GST	B-T116
),	O
mitochondrial	B-T026
oxidative stress	B-T049
,	O
oxidative phosphorylation	B-T044
(	O
OXPHOS	B-T044
)	O
and	O
tricarboxylic acid cycle	B-T044
(	O
TCA	B-T044
)	O
enzymes	B-T116
,	O
mitochondrial	B-T026
metabolic function	B-T040
,	O
adenosine triphosphate	B-T114
(	O
ATP	B-T114
)	O
level	B-T080
and	O
acetylcholinesterase (AChE) activity	B-T044
were	O
assessed	B-T052
in	O
rat	B-T015
brain	B-T023
.	O
Cytosolic	B-T026
and	O
mitochondrial	B-T026
antioxidant enzymes	B-T116
were	O
significantly	B-T078
diminished	B-T081
in	O
the	O
brains	B-T023
of	O
rats	B-T015
treated with	B-T061
ACR	B-T109
compared	B-T052
to	O
those	O
in	O
control	B-T096
.	O
Besides,	O
ACR	B-T109
treatment	B-T061
resulted	B-T169
in	O
a	O
significant	B-T078
reduction	B-T080
in	O
brain	B-T023
ATP	B-T114
level	B-T080
,	O
mitochondrial	B-T026
metabolic function	B-T040
,	O
OXPHOS	B-T044
and	O
TCA	B-T044
enzymes	B-T116
.	O
Administration	B-T061
of	O
AO	B-T109
restored	O
both	O
the	O
cytosolic	B-T026
and	O
mitochondrial	B-T026
oxidative stress	B-T049
by	O
normalizing	B-T062
nicotinamide adenine dinucleotide phosphate	B-T114
(	O
NADPH	B-T114
)	O
generating	B-T052
enzymes	B-T116
.	O
In	O
addition,	O
improved	B-T033
mitochondrial function	B-T043
primarily	O
enhancing	B-T052
nicotinamide adenine dinucleotide	B-T114
(	O
NADH	B-T114
)	O
generated	B-T052
enzymes activities	B-T044
and	O
ATP	B-T114
level	B-T080
in	O
the	O
mitochondria	B-T026
.	O
The	O
reason	B-T078
for	O
AO's	B-T109
obvious	O
beneficial effects	B-UnknownType
in	O
this	O
study	B-T062
may	O
be	O
due	O
to	O
synergistic effects	B-UnknownType
of	O
its	O
different	B-T080
bioactive compounds	B-T167
which	O
is	O
especially	O
effective	B-T080
on	O
mitochondria	B-T026
.	O
Modulation	B-T082
of	O
the	O
brain	B-T023
mitochondrial functions	B-T043
and	O
antioxidant systems	B-T022
by	O
AO	B-T109
may	O
lead	O
to	O
the	O
development	B-T169
of	O
new	O
mitochondria	B-T026
-	O
targeted	B-T043
antioxidants	B-T121
in	O
the	O
future	B-T079
.	O

Encaged	B-T073
Chironomus riparius	B-T204
larvae	B-T204
in	O
assessment	B-T052
of	O
trace metal	B-T121
bioavailability	B-T169
and	O
transfer	B-T169
in	O
a	O
landfill leachate	B-T131
collection	B-T169
pond	B-T083
Household	B-T056
wastes	B-T073
may	O
constitute	B-T167
a	O
vector	B-T080
of	O
environmental contamination	B-T069
when	O
buried	B-T082
,	O
in	O
particular	O
through	O
degradation	B-T169
and	O
production	O
of	O
leachates	B-T131
containing	B-T169
significant	B-T078
trace metal	B-T121
(	O
TM	B-T121
)	O
concentrations	B-T081
that	O
may	O
constitute	B-T167
a	O
serious	O
risk	B-T078
to	O
biota	B-T070
.	O
The	O
objectives	B-T170
of	O
this	O
study	B-T062
were	O
to	O
assess	B-T052
the	O
bioavailability	B-T169
and	O
transfer	B-T169
potential	B-T080
of	O
various	O
TMs	B-T121
present	B-T033
in	O
water	B-T121
and	O
sediments	B-T070
in	O
a	O
reservoir	B-T083
receiving	B-T080
landfill leachates	B-T131
.	O
An	O
active	B-T169
biomonitoring	B-T057
approach	O
was	O
adopted	O
consisting	O
of	O
exposing	B-T080
naive	O
laboratory organisms	B-T001
in	O
cages	B-T073
deployed	B-T052
in the field	B-T082
.	O
Aquatic insects	B-T001
such	O
as	O
Chironomus riparius	B-T204
larvae	B-T204
are	O
good	O
candidates	O
since	O
they	O
represent	B-T052
key	O
organisms	B-T001
in	O
the	O
trophic	B-T070
functioning	B-T169
of	O
aquatic ecosystems	B-T067
.	O
The	O
results	B-T033
show	O
that	O
water	B-T121
,	O
suspended	B-T169
particles	B-T104
,	O
and	O
sediments	B-T070
were	O
significant	B-T078
ly	O
contaminated	B-T169
by	O
various	O
TMs	B-T121
(	O
As	B-T121
,	O
Cd	B-T131
,	O
Cu	B-T121
,	O
Ni	B-T123
,	O
Pb	B-T131
,	O
and	O
Zn	B-T121
).	O
Their	O
contribution	B-T052
to	O
the	O
transfer	B-T169
of	O
TMs	B-T121
depends,	O
however,	O
on	O
the	O
specific	B-T080
element	B-T196
considered	B-T078
,	O
e.g.,	O
Cd	B-T131
in	O
sediments	B-T070
or	O
Pb	B-T131
in	O
both	O
suspended	B-T169
particles	B-T104
and	O
sediments	B-T070
.	O
The	O
internal	O
fate	O
of	O
TMs	B-T121
was	O
investigated	B-T169
according	O
to	O
their	O
fractionation	B-T059
between	O
an	O
insoluble	B-T080
and	O
a	O
cytosolic	B-T026
fraction	B-T081
.	O
This	O
approach	O
revealed	B-T080
different	O
detoxification	B-T061
strategies	B-T041
capable	O
of	O
preventing	B-T169
the	O
induction	B-T169
of	O
deleterious effects	B-T046
at	O
the	O
individual	B-T098
scale	B-T077
.	O
However,	O
the	O
accumulation	B-T033
of	O
several	O
TMs	B-T121
in	O
C. riparius	B-T204
larvae	B-T204
tissues	B-T024
may	O
also	O
represent	B-T052
a	O
significant	B-T078
load	O
potentially	B-T080
transferable	B-T169
to	O
higher	B-T080
trophic	B-T070
levels	B-T080
.	O

Effects	O
of	O
Binge-Like	B-T055
Ethanol Exposure	B-UnknownType
During	O
Adolescence	B-T079
on	O
the	O
Febrile	B-T184
Response	B-T032
in	O
Rats	B-T015
Ethanol (EtOH) exposure	B-UnknownType
during	O
different	O
phases	B-T079
of	O
life	B-T078
may	O
increase	O
the	O
risk of infections	B-T033
and	O
cause	O
alterations	B-T078
in	O
the	O
central nervous system	B-T022
.	O
The	O
present	O
study	O
investigated	O
the	O
effects	O
of	O
binge-like	B-T055
EtOH exposure	B-UnknownType
in	O
adolescent	B-T079
rats	B-T015
on	O
the	O
febrile	B-T184
response	B-T032
that	O
was	O
induced	O
by	O
lipopolysaccharide	B-T109
(	O
LPS	B-T109
)	O
and	O
interleukin-1β	B-T116
(	O
IL-1β	B-T116
).	O
Male	O
rats	B-T015
were	O
exposed to EtOH	B-UnknownType
from	O
postnatal days	B-T079
25	O
to	O
38	O
in	O
a	O
binge-like	B-T055
pattern.	O
Fever	B-T184
was	O
induced	O
by	O
LPS	B-T109
(5	O
and	O
50	O
μg/kg,	O
intraperitoneally	B-T082
)	O
and	O
evaluated	O
on	O
postnatal days	B-T079
51	O
and	O
63,	O
or	O
by	O
IL-β	B-T116
(3	O
ng)	O
and	O
evaluated	O
on	O
postnatal day	B-T079
51.	O
Hematological	B-T091
parameters,	O
the	O
status	O
of	O
peritoneal macrophages	B-T025
,	O
and	O
plasma	B-T031
and	O
cerebrospinal	B-T169
IL-1β	B-T116
levels	B-T080
were	O
also	O
evaluated	O
on	O
postnatal day	B-T079
51.	O
EtOH exposure	B-UnknownType
during	O
adolescence	B-T079
did	O
not	O
alter	O
normal body temperature	B-T033
.	O
However,	O
a	O
significant	O
reduction	O
in	O
the	O
febrile	B-T184
response	B-T032
that	O
was	O
induced	O
by	O
LPS	B-T109
at	O
both	O
doses	O
was	O
observed	O
on	O
postnatal	B-T079
day	O
51.	O
However,	O
no	O
changes	O
in	O
the	O
febrile	B-T184
response	B-T032
were	O
observed	O
on	O
postnatal day	B-T079
63	O
in	O
EtOH-exposed	B-UnknownType
animals	B-T015
.	O
The	O
febrile	B-T184
response	B-T032
that	O
was	O
induced	O
by	O
intracerebroventricular	B-T082
IL-1β	B-T116
also	O
significantly	O
decreased	O
in	O
animals	B-T015
that	O
received	O
binge-like	B-T055
EtOH exposure	B-UnknownType
during	O
adolescence	B-T079
.	O
Acute oral treatment	B-T169
with	O
EtOH	B-T109
24	O
h	O
prior	O
to	O
LPS	B-T109
administration	B-T061
did	O
not	O
alter	O
the	O
febrile	B-T184
response	B-T032
that	O
was	O
induced	O
by	O
LPS	B-T109
.	O
Binge-like	B-T055
EtOH exposure	B-UnknownType
during	O
adolescence	B-T079
did	O
not	O
alter	O
hematological	B-T091
parameters	O
or	O
the	O
number	O
or	O
viability	B-T043
of	O
peritoneal macrophages	B-T025
.	O
Binge-like	B-T055
EtOH exposure	B-UnknownType
did	O
not	O
alter	O
plasma	B-T031
IL-1β	B-T116
levels	B-T080
but	O
reduced	O
the	O
cerebrospinal fluid	B-T031
levels	B-T080
of	O
this	O
cytokine	B-T116
.	O
These	O
results	O
suggest	O
that	O
binge-like	B-T055
EtOH exposure	B-UnknownType
during	O
adolescence	B-T079
causes	O
changes	O
in	O
the	O
central nervous system	B-T022
that	O
can	O
impair	O
the	O
febrile	B-T184
response	B-T032
that	O
can	O
be	O
observed	O
after	O
the	O
cessation	B-T052
of	O
EtOH exposure	B-UnknownType
.	O
These	O
changes	O
were	O
reversible	O
and	O
appeared	O
to	O
involve	O
the	O
LPS	B-T109
/	O
IL-1β	B-T116
system.	O

Genital	B-T047
and	O
Extragenital Gonorrhea	B-T047
and	O
Chlamydia	B-T047
in	O
Children	B-T100
and	O
Adolescents	B-T100
Evaluated	B-T058
for	O
Sexual Abuse	B-T037
The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
describe	O
the	O
use	O
of	O
a	O
nucleic acid amplification test	B-T059
in	O
detecting	B-T061
genital	B-T007
and	O
extragenital Neisseria gonorrhoeae	B-T007
(	O
NG	B-T007
)	O
and	O
Chlamydia trachomatis	B-T007
(	O
CT	B-T007
)	O
in	O
children	B-T100
and	O
adolescents	B-T100
assessed	B-T058
for	O
sexual abuse	B-T037
/	O
assault	B-T048
.	O
The	O
charts	O
of	O
children	B-T100
aged	B-T032
0	O
to	O
17	O
years	B-T079
,	O
consecutively	O
evaluated	B-T058
for	O
sexual victimization	B-T068
,	O
in	O
emergency department	B-T073
and	O
outpatient settings	B-T093
were	O
reviewed.	O
Data	B-T078
extracted	O
included	O
age	B-T032
,	O
sex	B-T032
,	O
type	O
of	O
sexual contact	B-T033
,	O
anogenital	B-T029
findings	B-T033
,	O
previous	B-T079
sexual contact	B-T033
,	O
toxicology results	B-T033
,	O
and	O
sites	B-T082
tested	B-T059
for	O
NG	B-T007
and	O
CT	B-T007
.	O
Of	O
the	O
1319	O
patients	B-T101
who	O
were	O
tested	B-T059
,	O
579	O
were	O
tested	B-T059
at	O
more	O
than	O
1	O
site	B-T082
,	O
and	O
120	O
had	O
at	O
least	O
1	O
infected	B-T033
site	B-T082
.	O
Chlamydia trachomatis	B-T007
was	O
identified	O
in	O
104	O
patients	B-T101
,	O
and	O
NG	B-T007
was	O
found	O
in	O
33.	O
In	O
bivariate analysis	B-UnknownType
,	O
a	O
positive	O
test	O
was	O
associated with	B-T080
female sex	B-T032
,	O
age	B-T032
older	O
than	O
11	O
years	B-T079
,	O
previous	B-T079
sexual contact	B-T033
,	O
acute	O
or	O
healed	B-T169
genital injury	B-T037
,	O
drug/alcohol intoxication	B-T033
,	O
and	O
examination	B-T058
within	O
72	O
hours	B-T079
of	O
sexual contact	B-T033
.	O
Fifty-one	O
patients	B-T101
had	O
positive	B-T033
anal	B-T023
tests	B-T059
,	O
and	O
24	O
had	O
positive	B-T033
oral	B-T082
tests	B-T059
.	O
More	O
than	O
75%	O
of	O
patients	B-T101
with	O
positive	B-T033
extragenital tests	B-T059
had	O
additional	O
positive	B-T033
tests	B-T059
or	O
anogenital	B-T029
injury	B-T037
.	O
Most	O
with	O
a	O
positive	B-T033
anal	B-T023
(59%)	O
or	O
oral	B-T082
(77%)	O
test	B-T059
did	O
not	O
report	O
that	O
the	O
assailant's	O
genitals	B-T023
came	O
into	O
contact	O
with	O
that	O
site	B-T082
.	O
Positive	B-T033
tests	B-T059
for	O
NG	B-T007
and	O
CT	B-T007
in	O
patients	B-T101
evaluated	B-T058
for	O
sexual victimization	B-T068
may	O
represent	O
infection	B-T046
from	O
sexual contact	B-T033
,	O
contiguous spread	B-T080
of	O
infection	B-T046
,	O
or	O
the	O
presence	O
of	O
infected assailant secretions	B-T031
.	O
Relying	O
on	O
patient	B-T101
reports	O
of	O
symptoms	B-T184
,	O
or	O
types	O
of	O
sexual contact	B-T033
,	O
to	O
determine	O
need	O
for	O
testing	O
may	O
miss	O
NG	B-T047
and	O
CT infections	B-T047
in	O
patients	B-T101
evaluated	B-T058
for	O
sexual victimization	B-T068
.	O

The	O
Longitudinal	B-T082
Effects of	B-T080
Parenting	B-T055
on	O
Adaptive Behavior	B-T055
in	O
Children	B-T100
with	O
Fragile X Syndrome	B-T047
Several	O
studies	B-T062
have	O
reported	O
declines	B-T080
in	O
adaptive behavior	B-T055
amongst	O
children	B-T100
with	O
fragile X syndrome	B-T047
(	O
FXS	B-T047
)	O
starting	O
in	O
middle	B-T079
childhood	B-T079
.	O
We	O
examined	B-T033
the	O
effects of	B-T080
maternal	B-T099
responsivity	B-T041
on	O
adaptive behavior	B-T055
in	O
55	O
children	B-T100
with	O
FXS	B-T047
visited	O
5-6	O
times	O
in	O
their	O
homes	B-T073
from	O
early	O
through	O
middle	B-T079
childhood	B-T079
.	O
Our	O
analyses	B-T062
indicated	O
that	O
sustained	B-T169
maternal	B-T099
responsivity	B-T041
had	O
a	O
significant	B-T078
positive impact	B-T080
on	O
the	O
trajectories	B-T082
of	O
communication	B-T054
and	O
to	O
a	O
lesser	O
extent	O
other	O
adaptive behavior	B-T055
domains	B-T077
through	O
middle	B-T079
childhood	B-T079
with	O
many	O
effects	B-T080
remaining	O
significant	B-T078
after	O
controlling	B-T067
for	O
autism symptoms	B-T033
and	O
developmental level	B-T040
.	O
For	O
children	B-T100
who	O
showed	O
declines	B-T080
in	O
adaptive behavior	B-T055
during	O
middle	B-T079
childhood	B-T079
,	O
sustained	B-T169
high levels	B-T080
of	O
maternal	B-T099
responsivity	B-T041
minimized	B-T080
the	O
amount	O
of	O
decline	B-T080
observed	B-T169
in	O
the	O
communication	B-T054
,	O
socialization	B-T065
,	O
and	O
daily living domains	B-UnknownType
.	O

Development	B-T169
and	O
Validation	B-T062
of	O
a	O
New	O
Reliable	O
Method	B-T059
for	O
the	O
Diagnosis	B-T033
of	O
Avian	B-T012
Botulism	B-T037
Liver	B-T023
is	O
a	O
reliable	O
matrix	B-T031
for	O
laboratory	B-T059
confirmation of	B-T080
avian	B-T012
botulism	B-T037
using	O
real-time PCR	B-T063
.	O
Here,	O
we	O
developed	B-T169
,	O
optimized	B-T052
,	O
and	O
validated	B-T062
the	O
analytical	B-T062
steps	B-T077
preceding	B-T079
PCR	B-T063
to	O
maximize	O
the	O
detection	B-T033
of	O
Clostridium botulinum group III	B-T007
in	O
avian	B-T012
liver	B-T023
.	O
These	O
pre	B-T079
-	O
PCR	B-T063
steps	B-T077
included	O
enrichment	B-T130
incubation	B-T059
of	O
the	O
whole	O
liver	B-T023
(maximum	O
25	O
g)	O
at	O
37°C	B-T059
for	O
at	O
least	O
24	O
h	B-T079
in	O
an	O
anaerobic chamber	B-T074
and	O
DNA extraction	B-T063
using	O
an	O
enzymatic digestion	B-T059
step	O
followed	O
by	O
a	O
DNA purification	B-T059
step.	O
Conditions	O
of	O
sample	B-T077
storage	B-T169
before	O
analysis	B-T062
appear	O
to	O
have	O
a	O
strong	O
effect	B-T080
on	O
the	O
detection	B-T033
of	O
group III C. botulinum strains	B-T007
and	O
our	O
results	B-T169
recommend	O
storage	B-T169
at	O
temperatures	B-T081
below	O
-18°C.	O
Short-term	B-T079
storage	B-T169
at	O
5°C	O
is	O
possible	O
for	O
up	O
to	O
24	O
h	B-T079
,	O
but	O
a	O
decrease	B-T081
in	O
sensitivity	B-T169
was	O
observed	O
at	O
48	O
h	B-T079
of	O
storage	B-T169
at	O
this	O
temperature	B-T081
.	O
Analysis	B-T062
of	O
whole	O
livers	B-T023
(maximum	O
25	O
g)	O
is	O
required	O
and	O
pooling	B-T169
samples	B-T077
before	O
enrichment culturing	B-T059
must	O
be	O
avoided.	O
Pooling	B-T169
is	O
however	O
possible	O
before	O
or	O
after	O
DNA extraction	B-T063
under	O
certain	O
conditions.	O
Whole	O
livers	B-T023
should	O
be	O
10-fold	O
diluted	O
in	O
enrichment medium	B-T130
and	O
homogenized	O
using	O
a	O
Pulsifier® blender	B-T074
(Microgen,	O
Surrey	B-T083
,	O
UK	B-T083
)	O
instead	O
of	O
a	O
conventional	O
paddle blender	B-T074
.	O
Spiked liver	B-T023
samples	B-T077
showed	O
a	O
limit	O
of	O
detection	B-T033
of	O
5	O
spores	B-T007
/g	O
liver	B-T023
for	O
types C	B-T007
and	O
D	B-T007
and	O
250	O
spores	B-T007
/g	O
for	O
type E	B-T007
.	O
Using	O
the	O
method	B-T059
developed	B-T169
here,	O
the	O
analysis	B-T062
of	O
268	O
samples	B-T077
from	O
73	O
suspected	O
outbreaks	B-T081
showed	O
100%	O
specificity	B-T081
and	O
95.35%	O
sensitivity	B-T169
compared	B-T052
with	O
other	O
PCR	B-T063
-based	O
methods	B-T059
considered	O
as	O
reference.	O
The	O
mosaic type C	B-T007
/	O
D	B-T007
was	O
the	O
most	O
common	O
neurotoxin	B-T131
type	O
found	O
in	O
examined	O
samples	B-T077
,	O
which	O
included	O
both	O
wild	B-T012
and	O
domestic birds	B-T012
.	O

Quality Improvement	B-T057
of	O
Liver	B-T023
Ultrasound	B-T060
Images	B-T170
Using	O
Fuzzy	B-T170
Techniques	B-T170
Liver	B-T023
ultrasound	B-T060
images	B-T170
are	O
so	O
common	O
and	O
are	O
applied	O
so	O
often	O
to	O
diagnose	B-T033
diffuse liver diseases	B-T047
like	O
fatty liver	B-T047
.	O
However,	O
the	O
low	B-T080
quality	B-T080
of	O
such	O
images	B-T170
makes	O
it	O
difficult	O
to	O
analyze	B-T062
them	O
and	O
diagnose	B-T033
diseases	B-T047
.	O
The	O
purpose	O
of	O
this	O
study	B-T062
,	O
therefore,	O
is	O
to	O
improve	O
the	O
contrast	B-T080
and	O
quality	B-T080
of	O
liver	B-T023
ultrasound	B-T060
images	B-T170
.	O
In	O
this	O
study	B-T062
,	O
a	O
number	O
of	O
image	B-T170
contrast	B-T080
enhancement algorithms	B-T170
which	O
are	O
based	O
on	O
fuzzy logic	B-T170
were	O
applied	O
to	O
liver	B-T023
ultrasound	B-T060
images	B-T170
-	O
in	O
which	O
the	O
view	O
of	O
kidney	B-T023
is	O
observable	O
-	O
using	O
Matlab2013b	B-T073
to	O
improve	O
the	O
image	B-T170
contrast	B-T080
and	O
quality	B-T080
which	O
has	O
a	O
fuzzy	B-T170
definition	B-T170
;	O
just	O
like	O
image	B-T170
contrast	B-T080
improvement	B-T077
algorithms	B-T170
using	O
a	O
fuzzy	B-T170
intensification operator	B-T074
,	O
contrast	B-T080
improvement	B-T077
algorithms	B-T170
applying	O
fuzzy	B-T170
image	B-T170
histogram hyperbolization	B-T170
,	O
and	O
contrast	B-T080
improvement	B-T077
algorithms	B-T170
by	O
fuzzy	B-T170
IF-THEN rules	B-T170
.	O
With	O
the	O
measurement	B-T169
of	O
Mean Squared Error	B-T080
and	O
Peak	B-T080
Signal to Noise Ratio	B-T081
obtained	O
from	O
different	O
images	B-T170
,	O
fuzzy	B-T170
methods	B-T170
provided	O
better	O
results	B-T169
,	O
and	O
their	O
implementation	B-T052
-	O
compared	B-T052
with	O
histogram equalization method	B-T170
-	O
led	O
both	O
to	O
the	O
improvement	B-T077
of	O
contrast	B-T080
and	O
visual quality	B-T033
of	O
images	B-T170
and	O
to	O
the	O
improvement	B-T077
of	O
liver	B-T023
segmentation algorithms	B-T170
results	O
in	O
images	B-T170
.	O
Comparison	B-T052
of	O
the	O
four	O
algorithms	B-T170
revealed	O
the	O
power	O
of	O
fuzzy logic	B-T170
in	O
improving	O
image	B-T170
contrast	B-T080
compared	B-T052
with	O
traditional	O
image processing	B-T066
algorithms	B-T170
.	O
Moreover,	O
contrast	B-T080
improvement	B-T077
algorithm	O
based	O
on	O
a	O
fuzzy	B-T170
intensification operator	B-T074
was	O
selected	O
as	O
the	O
strongest	O
algorithm	B-T170
considering	O
the	O
measured	O
indicators.	O
This	O
method	B-T170
can	O
also	O
be	O
used	O
in	O
future	O
studies	B-T062
on	O
other	O
ultrasound	B-T060
images	B-T170
for	O
quality improvement	B-T057
and	O
other	O
image processing	B-T066
and	O
analysis	B-T062
applications	B-T169
.	O

Development	B-T169
of	O
the	O
pediatric quality of life inventory	B-T170
neurofibromatosis type 1	B-T191
module	B-T170
items	B-T062
for	O
children	B-T100
,	O
adolescents	B-T100
and	O
young adults	B-T100
:	O
qualitative methods	B-T062
Health-related quality of life	B-T078
(	O
HRQOL	B-T078
)	O
is	O
arguably	O
one	O
of	O
the	O
most	O
important	B-T080
measures	B-T081
in	O
evaluating	B-T058
effectiveness	B-T080
of	O
clinical treatments	B-T061
.	O
At	O
present,	O
there	O
is	O
no	O
disease	B-T047
-	O
specific	B-T080
outcome measure	B-T081
to	O
assess	B-T058
the	O
HRQOL	B-T078
of	O
children	B-T100
,	O
adolescents	B-T100
and	O
young adults	B-T100
with	O
Neurofibromatosis Type 1	B-T191
(	O
NF1	B-T191
).	O
This	O
study	B-T062
aimed	O
to	O
develop	O
the	O
items	B-T062
and	O
support	O
the	O
content validity	B-T080
for	O
the	O
Pediatric Quality of Life Inventory™	B-T170
(	O
PedsQL™	B-T170
)	O
NF1	B-T191
Module	B-T170
for	O
children	B-T100
,	O
adolescents	B-T100
and	O
young adults	B-T100
.	O
The	O
iterative	B-T033
process	B-T067
included	O
multiphase qualitative methods	B-T062
including	O
a	O
literature review	B-T170
,	O
survey	B-T170
of	O
expert opinions	B-T077
,	O
semi-structured interviews	B-T052
,	O
cognitive	B-T169
interviews	B-T052
and	O
pilot testing	B-T062
.	O
Fifteen	O
domains	B-T169
were	O
derived	O
from	O
the	O
qualitative methods	B-T062
,	O
with	O
content	B-T077
saturation	O
achieved,	O
resulting	O
in	O
115	O
items	B-T062
.	O
The	O
domains	B-T169
include	O
skin	B-T022
,	O
pain	B-T184
,	O
pain	B-T184
impact	B-T080
,	O
pain management	B-T061
,	O
cognitive functioning	B-T041
,	O
speech	B-T040
,	O
fine motor	B-T042
,	O
balance	B-T169
,	O
vision	B-T040
,	O
perceived	B-T041
physical appearance	B-T184
,	O
communication	B-T054
,	O
worry	B-T033
,	O
treatment	B-T061
,	O
medicines	B-T121
and	O
gastrointestinal symptoms	B-T184
.	O
This	O
study	O
is	O
limited	B-T169
because	O
all	O
participants	B-T098
are	O
recruited	O
from	O
a	O
single	B-T081
-	O
site	B-T082
.	O
Qualitative methods	B-T062
support	O
the	O
content validity	B-T080
for	O
the	O
PedsQL™	B-T170
NF1	B-T191
Module	B-T170
for	O
children	B-T100
,	O
adolescents	B-T100
and	O
young adults	B-T100
.	O
The	O
PedsQL™	B-T170
NF1	B-T191
Module	B-T170
is	O
now	O
undergoing	O
national multisite field testing	B-T169
for	O
the	O
psychometric	B-T060
validation	B-T062
of	O
the	O
instrument	B-T170
development	B-T169
.	O

Mimiviruses	B-T005
and	O
the	O
Human	B-T016
Interferon	B-T116
System	B-T022
:	O
Viral Evasion	B-T043
of	O
Classical	B-T169
Antiviral Activities	B-T040
,	O
But	O
Inhibition	B-T052
By	O
a	O
Novel	O
Interferon-β	B-T116
Regulated	B-T038
Immunomodulatory	B-T061
Pathway	B-T077
In	O
this	O
review	B-T170
we	O
discuss	O
the	O
role	B-T077
of	O
mimiviruses	B-T005
as	O
potential	B-T080
human	B-T016
pathogens	B-T001
focusing	O
on	O
clinical	B-T080
and	O
evolutionary	B-T045
evidence	B-T078
.	O
We	O
also	O
propose	B-T080
a	O
novel	O
antiviral	B-T040
immunomodulatory	B-T121
pathway	B-T077
controlled	B-T169
by	O
interferon-β	B-T116
(	O
IFN-β	B-T116
)	O
and	O
mediated	O
by	O
immune-responsive gene 1	B-T116
(	O
IRG1	B-T116
)	O
and	O
itaconic acid	B-T109
,	O
its	O
product	B-T071
.	O
Acanthamoeba polyphaga Mimivirus	B-T005
(	O
APMV	B-T005
)	O
was	O
isolated	B-T169
from	O
amoebae	B-T204
in	O
a	O
hospital	B-T073
while	O
investigating	B-T169
a	O
pneumonia	B-T047
outbreak	B-T067
.	O
Mimivirus	B-T005
ubiquity	B-T080
and	O
role	B-T077
as	O
protist	B-T001
pathogens	B-T001
are	O
well	O
understood,	O
and	O
its	O
putative	B-T082
status	B-T169
as	O
a	O
human	B-T016
pathogen	B-T001
has	O
been	O
gaining	B-T081
strength	B-T078
as	O
more	O
evidence	B-T078
is	O
being	O
found.	O
The	O
study	B-T062
of	O
APMV	B-T005
and	O
human	B-T016
cells	B-T025
interaction	B-T040
revealed	O
that	O
the	O
virus	B-T005
is	O
able	O
to	O
evade	B-T040
the	O
IFN	B-T116
system	B-T022
by	O
inhibiting	B-T052
the	O
regulation	B-T045
of	O
interferon	B-T116
-stimulated	O
genes	B-T028
,	O
suggesting	O
that	O
the	O
virus	B-T005
and	O
humans	B-T016
have	O
had	O
host-pathogen interactions	B-T040
.	O
It	O
also	O
has	O
shown	O
that	O
the	O
virus	B-T005
is	O
capable	B-T080
of	O
growing	O
on	O
IFN-α2	B-T116
,	O
but	O
not	O
on	O
IFN-β	B-T116
-	O
treated	B-T169
cells	B-T025
,	O
hinting	O
at	O
an	O
exclusive	B-T078
IFN-β	B-T116
antiviral	B-T040
pathway	B-T077
.	O
Our	O
hypothesis	B-T078
based	B-T078
on	O
preliminary data	B-T078
and	O
published articles	B-T170
is	O
that	O
IFN-β	B-T116
preferentially	B-T078
upregulates	B-T044
IRG1 in human	B-T116
macrophagic cells	B-T025
,	O
which	O
in	O
turn	O
produces	O
itaconic acid	B-T109
.	O
This	O
metabolite	B-T123
links	O
metabolism	B-T040
to	O
antiviral activity	B-T040
by	O
inactivating	B-T169
the	O
virus	B-T005
,	O
in	O
a	O
novel	O
immunomodulatory	B-T061
pathway	B-T077
relevant	B-T080
for	O
APMV	B-T005
infections	B-T046
and	O
probably	O
to	O
other	O
infectious diseases	B-T047
as	O
well.	O

Heteroprotein	B-T116
Complex	B-T104
Formation	O
of	O
Bovine Lactoferrin	B-T116
and	O
Pea Protein	B-T116
Isolate	B-T121
:	O
A	O
Multiscale	O
Structural	O
Analysis	O
Associative	B-T080
electrostatic interactions	B-UnknownType
between	O
two	O
oppositely	B-T080
charged	B-T032
globular proteins	B-T116
,	O
lactoferrin	B-T116
(	O
LF	B-T116
)	O
and	O
pea protein	B-T116
isolate	B-T121
(	O
PPI	B-T116
),	O
the	O
latter	O
being	O
a	O
mixture	B-T167
of	O
vicilin	B-T116
,	O
legumin	B-T116
,	O
and	O
convicilin	B-T116
,	O
was	O
studied	B-T062
with	O
a	O
specific	B-T080
PPI	B-T116
/	O
LF	B-T116
molar ratio	B-T081
at	O
room temperature	B-T033
.	O
Structural	B-T082
aspects	B-T080
of	O
the	O
electrostatic	B-T070
complexes	B-T104
probed	O
at	O
different	B-T080
length	B-T081
scales	B-T081
were	O
investigated	B-T169
as	O
a	O
function	B-T169
of	O
pH	B-T081
by	O
means	O
of	O
different	B-T080
complementary techniques	B-T169
,	O
namely,	O
with	O
dynamic light scattering	B-T059
,	O
small-angle X-ray scattering	B-T059
(	O
SAXS	B-T059
),	O
turbidity measurements	B-T059
,	O
and	O
atomic force microscopy	B-T059
(	O
AFM	B-T059
).	O
Irrespective	O
of	O
the	O
applied	O
techniques	B-T169
,	O
the	O
results	B-T034
consistently	B-T078
displayed	B-T169
that	O
complexation	B-T104
between	O
LF	B-T116
and	O
PPI	B-T116
did	O
occur	B-T052
.	O
In	O
an	O
optimum	B-T080
narrow	B-T080
range	B-T081
of	O
pH	B-T081
5.0-5.8,	O
a	O
viscous	B-T080
liquid	B-T033
phase	B-T079
of	O
complex	B-T104
coacervate	B-T167
was	O
obtained	B-T169
upon	O
mild	O
centrifugation	B-T059
of	O
the	O
turbid	B-T080
LF	B-T116
-	O
PPI	B-T116
mixture	B-T167
with	O
a	O
maximum	B-T081
Rh,	O
turbidity	B-T080
and	O
the	O
ζ-potential	B-T067
being	O
close	O
to	O
zero	O
observed	B-T169
at	O
pH	B-T081
5.4.	O
In	O
particular,	O
the	O
SAXS	B-T059
data	B-T078
demonstrated	O
that	O
the	O
coacervates	B-T167
were	O
densely	B-T080
assembled	B-T052
with	O
a	O
roughly	B-T080
spherical	B-T082
size	B-T082
distribution	B-T082
exhibiting	O
a	O
maximum	B-T081
extension	B-T169
of	O
∼80	O
nm	O
at	O
pH	B-T081
5.4.	O
Equally,	O
AFM	B-T059
image analysis	B-T059
showed	O
size	B-T082
distributions	B-T082
containing	B-T169
most	O
frequent	B-T079
cluster	B-T081
sizes	B-T082
around	O
40-80	O
nm	O
with	O
spherical	B-T082
to	O
elliptical shapes	B-T082
(axis	O
aspect	O
ratio	O
≤	O
2)	O
as	O
well	O
as	O
less	O
frequent	B-T079
elongated	O
to	O
chainlike	B-T080
structures	B-T082
.	O
The	O
most	O
frequently	B-T079
observed	B-T169
compact	O
complexes	B-T104
,	O
we	O
identify	O
as	O
mainly	O
leading	O
to	O
LF	B-T116
-	O
PPI	B-T116
coacervation	B-T067
,	O
whereas	O
for	O
the	O
less	O
frequent	B-T079
chain-like aggregates	B-T080
,	O
we	O
hypothesize	O
that	O
additionally	O
PPI	B-T116
-	O
PPI	B-T116
facilitated	O
complexes	B-T104
exist.	O

Visual	B-T169
outcome	B-T169
,	O
endocrine function	B-T039
and	O
tumor	B-T191
control	B-T169
after	O
fractionated stereotactic radiation therapy	B-T061
of	O
craniopharyngiomas in adults	B-T191
:	O
findings	O
in	O
a	O
prospective cohort	B-T062
The	O
purpose	O
of	O
this	O
study	B-T062
was	O
to	O
examine	B-T058
visual	B-T169
outcome	B-T169
,	O
endocrine function	B-T039
and	O
tumor	B-T191
control	B-T169
in	O
a	O
prospective cohort	B-T062
of	O
craniopharyngioma	B-T191
patients	B-T101
,	O
treated with	B-T061
fractionated stereotactic radiation therapy	B-T061
(	O
FSRT	B-T061
).	O
Sixteen	O
adult	B-T100
patients	B-T101
with	O
craniopharyngiomas	B-T191
were	O
eligible	B-T080
for	O
analysis	B-T062
.	O
They	O
were	O
treated with	B-T061
linear accelerator-based	B-T074
FSRT	B-T061
during	O
1999-2015.	O
In	O
all	O
cases	B-T077
,	O
diagnosis	B-T062
was	O
confirmed	O
by	O
histological	B-T169
analysis	B-T062
.	O
The	O
prescription	B-T058
dose	B-T081
to	O
the	O
tumor	B-T191
was	O
54	O
Gy	B-T081
(	O
median	B-T081
,	O
range	B-T081
48-54)	O
in	O
1.8	O
or	O
2.0	O
Gy	B-T081
per	O
fraction	B-T081
,	O
and	O
the	O
maximum	O
radiation dose	B-T081
to	O
the	O
optic nerves	B-T023
and	O
chiasm	B-T023
was	O
54.2	O
Gy	B-T081
(	O
median	B-T081
,	O
range	B-T081
48.6-60.0)	O
for	O
the	O
cohort	B-T098
.	O
Serial	O
ophthalmological	B-T061
and	O
endocrine evaluations	B-T058
and	O
magnetic resonance imaging	B-T060
(	O
MRI	B-T060
)	O
scans	B-T060
were	O
performed	O
at	O
regular	O
intervals.	O
Median	B-T081
follow-up	B-T058
was	O
3.3	O
years	B-T079
(	O
range	B-T081
1.1-14.1),	O
3.7	O
years	B-T079
(	O
range	B-T081
0.8-15.2),	O
and	O
3.6	O
years	B-T079
(	O
range	B-T081
0.7-13.1)	O
for	O
visual	B-T169
outcome	B-T169
,	O
endocrine function	B-T039
,	O
and	O
tumor	B-T191
control	B-T169
,	O
respectively.	O
Visual acuity	B-T201
impairment	B-T169
was	O
present	O
in	O
10	O
patients	B-T101
(62.5%)	O
and	O
visual field defects	B-T033
were	O
present	O
in	O
12	O
patients	B-T101
(75%)	O
before	O
FSRT	B-T061
.	O
One	O
patient	B-T101
developed	O
radiation-induced optic neuropathy	B-T047
at	O
seven	O
years	B-T079
after	O
FSRT	B-T061
.	O
Thirteen	O
of	O
16	O
patients	B-T101
(81.3%)	O
had	O
pituitary deficiency	B-T047
before	O
FSRT	B-T061
,	O
and	O
did	O
not	O
develop	O
further	O
pituitary deficiency	B-T047
after	O
FSRT	B-T061
.	O
Mean	B-T081
tumor volume	B-T081
pre-	O
FSRT	B-T061
was	O
2.72	O
cm(3)	O
(	O
range	B-T081
0.20-9.90)	O
and	O
post-	O
FSRT	B-T061
1.2	O
cm(3)	O
(	O
range	B-T081
0.00-13.10).	O
Tumor	B-T191
control	B-T169
rate	B-T081
was	O
81.3%	O
at	O
two,	O
five,	O
and	O
10	O
years	B-T079
after	O
FSRT	B-T061
.	O
FSRT	B-T061
was	O
relatively	O
safe	O
in	O
this	O
prospective	O
cohort	B-T098
of	O
craniopharyngiomas	B-T191
,	O
with	O
only	O
one	O
case	B-T077
of	O
radiation-induced optic neuropathy	B-T047
and	O
no	O
case	B-T077
of	O
new	O
endocrinopathy	B-T047
.	O
Tumor	B-T191
control	B-T169
rate	B-T081
was	O
acceptable.	O

Scutellaria barbata D. Don extract	B-T123
inhibits	B-T052
the	O
tumor growth	B-T191
through	O
down-regulating	B-T044
of	O
Treg cells	B-T025
and	O
manipulating	B-T040
Th1	B-T043
/	O
Th17 immune response	B-T040
in	O
hepatoma H22	B-T025
-bearing	O
mice	B-T015
Previous	O
studies	O
showed	O
Scutellaria barbata D. Don extract	B-T123
(	O
SBE	B-T123
)	O
is	O
a	O
potent	O
inhibitor	B-T121
in	O
hepatoma	B-T191
and	O
could	O
improve	O
immune function	B-T042
of	O
hepatoma H22	B-T025
-bearing	O
mice	B-T015
.	O
However,	O
the	O
immunomodulatory function	B-T044
of	O
SBE	B-T123
on	O
the	O
tumor growth	B-T191
of	O
hepatoma	B-T191
remains	O
unclear	B-T033
.	O
This	O
study	B-T062
aimed	O
to	O
investigate	B-T169
the	O
anti-tumor	B-T080
effects	B-T080
of	O
SBE	B-T123
on	O
hepatoma H22	B-T025
-bearing	O
mice	B-T015
and	O
explore	O
the	O
underlying	O
immunomodulatory function	B-T044
.	O
The	O
hepatoma H22	B-T025
-bearing	O
mice	B-T015
were	O
treated	B-T169
by	O
SBE	B-T123
for	O
30	O
days	B-T079
.	O
The	O
effect of	B-T080
SBE	B-T123
on	O
the	O
proliferation	B-T043
of	O
HepG2 cells	B-T025
in vitro	B-T080
,	O
the	O
growth of transplanted tumor	B-T191
,	O
the	O
cytotoxicity of natural killer (NK) cells	B-T043
in	O
spleen	B-T023
,	O
the	O
amount	B-T081
of	O
CD4(+)CD25(+)Foxp3(+) Treg cells	B-T121
and	O
Th17 cells	B-T025
in	O
tumor tissue	B-T024
,	O
and	O
the	O
levels	B-T080
of	O
IL-10	B-T116
,	O
TGF-β	B-T116
,	O
IL-17A	B-T116
,	O
IL-2	B-T116
,	O
and	O
IFN-γ	B-T116
in	O
serum	B-T031
of	O
the	O
hepatoma H22	B-T025
-bearing	O
mice	B-T015
was	O
observered.	O
IL-17A	B-T116
was	O
injected	B-T169
to	O
the	O
SBE	B-T123
treated	B-T169
mice	B-T015
from	O
day	B-T079
9	O
post	B-T079
H22	B-T025
inoculation	B-T061
to	O
examine	O
its	O
effect	B-T080
on	O
tumor growth	B-T191
.	O
SBE	B-T123
treatment	B-T169
inhibited	B-T080
the	O
proliferation	B-T043
of	O
HepG2 cells	B-T025
in vitro	B-T080
with	O
a	O
dose-dependent manner	B-T169
and	O
significantly	O
suppressed	B-T169
the	O
tumor growth	B-T191
of	O
hepatoma H22	B-T025
-bearing	O
mice	B-T015
.	O
Meanwhile,	O
it	O
increased	B-T081
NK cells' cytotoxicity	B-T043
in	O
spleen	B-T023
,	O
down-regulated	B-T044
the	O
amount	B-T081
of	O
CD4(+)CD25(+)Foxp3(+) Treg cells	B-T121
and	O
Th17 cells	B-T025
in	O
tumor tissue	B-T024
,	O
and	O
decreased	B-T081
IL-10	B-T116
,	O
TGF-β	B-T116
,	O
and	O
IL-17A	B-T116
levels	B-T080
(P	O
<	O
0.01)	O
whereas	O
increased	B-T081
IL-2	B-T116
and	O
IFN-γ	B-T116
levels	B-T080
(P	O
<	O
0.01)	O
in	O
the	O
serum	B-T031
of	O
hepatoma H22	B-T025
-bearing	O
mice	B-T015
.	O
Moreover,	O
administration	B-T081
of	O
recombinant mouse	B-T015
IL-17A	B-T116
reversed	B-T169
the	O
anti-tumor	B-T080
effects	B-T080
of	O
SBE	B-T123
.	O
SBE	B-T123
could	O
inhibit	B-T052
the	O
proliferation	B-T043
of	O
HepG2 cells	B-T025
in vitro	B-T080
.	O
Meanwhile,	O
SBE	B-T123
also	O
could	O
inhibit	B-T052
the	O
growth	B-T043
of	O
H22	B-T025
implanted tumor	B-T191
in	O
hepatoma H22	B-T025
-bearing	O
mice	B-T015
,	O
and	O
this	O
function	B-T169
might	O
be	O
associated with	B-T080
immunomodulatory activity	B-T044
through	O
down-regulating	B-T044
of	O
Treg cells	B-T025
and	O
manipulating	B-T040
Th1	B-T043
/	O
Th17 immune response	B-T040
.	O

Clinical characteristics	B-T201
of	O
genital chlamydia infection	B-T047
in	O
pelvic inflammatory disease	B-T047
Chlamydia infection	B-T047
in	O
acute pelvic inflammatory disease	B-T047
(	O
PID	B-T047
)	O
is	O
associated	O
with	O
serious	O
complications	B-T046
including	O
ectopic pregnancy	B-T046
,	O
tubal infertility	B-T047
,	O
Fitz-Hugh-Curtis syndrome	B-T047
and	O
tubo-ovarian abscess	B-T047
(	O
TOA	B-T047
).	O
This	O
study	B-T062
compared	O
clinical	B-T170
and	O
laboratory data	B-T170
between	O
PID	B-T047
with	O
and	O
without	O
chlamydia infection	B-T047
.	O
The	O
medical records	B-T170
of	O
497	O
women	B-T098
who	O
were	O
admitted	O
with	O
PID	B-T047
between	O
2002	O
and	O
2011	O
were	O
reviewed.	O
The	O
patients	B-T101
were	O
divided	O
into	O
two	O
groups	B-T098
(	O
PID	B-T047
with	O
and	O
without	O
chlamydia infection	B-T047
),	O
which	O
were	O
compared	O
in	O
terms	O
of	O
the	O
patients' characteristics	B-T201
,	O
clinical presentation	B-T170
,	O
and	O
laboratory findings	B-T034
,	O
including	O
inflammatory	B-T169
markers	B-T201
.	O
The	O
chlamydia	B-T098
and	O
non-chlamydia groups	B-T098
comprised	O
175	O
and	O
322	O
women	B-T098
,	O
respectively.	O
The	O
patients	B-T101
in	O
the	O
chlamydia group	B-T098
were	O
younger	B-T079
and	O
had	O
a	O
higher	O
rate	O
of	O
TOA	B-T047
,	O
a	O
longer	O
mean	B-T081
hospital stay	B-T079
,	O
and	O
had	O
undergone	O
more	O
surgeries	B-T061
than	O
the	O
patients	B-T101
in	O
the	O
non- chlamydia group	B-T098
.	O
The	O
erythrocyte sedimentation rate	B-T034
(	O
ESR	B-T034
),	O
C-reactive protein	B-T116
(	O
CRP	B-T116
),	O
and	O
CA-125	B-T109
level	B-T080
were	O
higher	O
in	O
the	O
chlamydia group	B-T098
than	O
in	O
the	O
non-chlamydia group	B-T098
,	O
but	O
there	O
was	O
no	O
significant	B-T078
difference	O
in	O
the	O
white blood cell count	B-T033
between	O
the	O
two	O
groups	B-T098
.	O
The	O
CA-125	B-T109
level	B-T080
was	O
the	O
strongest	O
predictor	B-T078
of	O
chlamydia infection	B-T047
,	O
followed	O
by	O
the	O
ESR	B-T034
and	O
CRP	B-T116
level	B-T080
.	O
The	O
area	B-T082
under	O
the	O
receiving operating curve	B-T081
for	O
CA-125	B-T109
,	O
ESR	B-T034
,	O
and	O
CRP	B-T116
was	O
0.804,	O
0.755,	O
and	O
0.663,	O
respectively.	O
Chlamydia infection	B-T047
in	O
acute PID	B-T047
is	O
associated	O
with	O
increased	O
level	B-T080
of	O
inflammatory	B-T169
markers	B-T201
,	O
such	O
as	O
CA-125	B-T109
,	O
ESR	B-T034
and	O
CRP	B-T116
,	O
incidence	O
of	O
TOA	B-T047
,	O
operation	B-T061
risk	B-T078
,	O
and	O
longer	O
hospitalization	B-T058
.	O

Incidence	B-T081
and	O
effect of	B-T080
variant	B-T080
histology	B-T091
on	O
oncological outcomes	B-T080
in	O
patients	B-T101
with	O
bladder cancer	B-T191
treated	B-T169
with	O
radical cystectomy	B-T061
We	O
sought	O
to	O
describe	O
incidence	B-T081
of	O
histological	B-T169
variants	B-T080
after	O
radical cystectomy	B-T061
(	O
RC	B-T061
)	O
due	O
to	O
bladder cancer	B-T191
(	O
BCa	B-T191
).	O
Moreover,	O
we	O
investigated	O
survival	B-T169
outcomes	B-T080
accounting	O
for	O
this	O
parameter.	O
We	O
retrospectively	B-T080
evaluated	B-T058
data	B-T078
from	O
1,067	O
patients	B-T101
with	O
BCa	B-T191
treated	B-T169
with	O
RC	B-T061
between	O
1990	O
and	O
2013	O
at	O
a	O
single tertiary care referral center	B-T073
.	O
All	O
specimen	B-T167
were	O
evaluated	B-T058
by	O
dedicated	O
uropathologists	B-T097
.	O
Univariable and multivariable Cox regression analyses	B-T170
tested	O
the	O
effect of	B-T080
different	O
histopathological	B-T169
variant	B-T080
on	O
recurrence	B-T067
,	O
cancer-specific mortality	B-T081
(	O
CSM	B-T081
),	O
and	O
overall mortality	B-T081
(	O
OM	B-T081
)	O
after	O
accounting	O
for	O
all	O
available	O
confounders	B-T169
.	O
Of	O
1,067	O
patients	B-T101
,	O
729	O
(68.3%)	O
harbored	O
pure urothelial BCa	B-T191
while	O
338	O
(31.7%)	O
were	O
found	O
to	O
have	O
a	O
variant	B-T080
.	O
Considering	O
uncommon	O
variants	B-T080
,	O
21	O
(2.0%)	O
were	O
sarcomatoid	B-T191
,	O
10	O
(0.9%)	O
lymphoepitelial	B-T191
,	O
19	O
(1.8%)	O
small cell	B-T191
,	O
109	O
(10.2%)	O
squamous	B-T191
,	O
89	O
(8.3%)	O
micropapillary	B-T191
,	O
23	O
(2.2%)	O
glandular	B-T191
,	O
34	O
(3.2%)	O
mixed	O
variants	B-T080
,	O
and	O
33	O
(3.1%)	O
were	O
found	O
with	O
other	O
types	O
of	O
variants	B-T080
.	O
With	O
a	O
median	B-T081
follow-up	B-T058
of	O
6.2	O
years	B-T079
,	O
343	O
recurrence	B-T067
,	O
365	O
CSM	B-T081
,	O
and	O
451	O
OM	B-T081
were	O
recorded,	O
respectively.	O
At	O
multivariable Cox regression analyses	B-T170
,	O
the	O
presence	O
of	O
small cell variant	B-T191
was	O
associated with	B-T080
higher	O
recurrence	B-T067
(	O
hazard ratio	B-T081
[	O
HR	B-T081
]	O
=	O
3.47,	O
P<0.001),	O
CSM	B-T081
(	O
HR	B-T081
=	O
3.30,	O
P<0.04),	O
and	O
OM	B-T081
(	O
HR	B-T081
=	O
2.97,	O
P<0.003)	O
as	O
compared	O
with	O
pure	O
urothelial cancer	B-T191
.	O
Conversely,	O
no survival differences	B-T033
were	O
recorded	O
considering	O
other	O
histological	B-T169
variants	B-T080
(all	O
P>	O
0.1).	O
Our	O
study	B-T077
confirms	O
that	O
histological	B-T169
variant	B-T080
is	O
not	O
an	O
infrequent	O
event	O
at	O
RC	B-T061
specimen	B-T167
.	O
However,	O
in	O
our	O
single-center series	B-T093
,	O
only	O
patients	B-T101
found	O
with	O
small cell variant	B-T191
were	O
associated with	B-T080
a	O
negative	B-T033
effect	B-T080
on	O
survival	B-T169
after	O
RC	B-T061
.	O

Psychometric	B-T060
properties	B-T080
of	O
the	O
Japanese	B-T171
version	B-T170
of	O
short forms	B-T170
of	O
the	O
Pain Catastrophizing Scale	B-T170
in	O
participants	B-T098
with	O
musculoskeletal pain	B-T033
:	O
A	O
cross-sectional study	B-T062
The	O
Pain Catastrophizing Scale	B-T170
(	O
PCS	B-T170
)	O
is	O
a	O
commonly	O
used	O
as	O
measure	B-T081
of	O
pain catastrophizing	B-T041
.	O
The	O
scale	B-T170
comprises	O
13	O
items	B-T062
related	O
to	O
magnification	B-T060
,	O
rumination	B-T038
,	O
and	O
helplessness	B-T048
.	O
To	O
facilitate	O
quick	O
screening	B-T058
and	O
to	O
reduce	B-T080
participant's	B-T098
burden	B-T078
,	O
the	O
four-	O
item	B-T062
and	O
six-	O
item	B-T062
short forms	B-T170
of	O
the	O
English	B-T171
version	B-T170
of	O
the	O
PCS	B-T170
were	O
developed.	O
The	O
purpose	O
of	O
the	O
present	O
study	B-T062
was	O
to	O
evaluate	B-T058
the	O
psychometric	B-T060
properties	B-T080
of	O
a	O
Japanese	B-T171
version	B-T170
of	O
the	O
short forms	B-T170
of	O
PCS	B-T170
using	O
a	O
contemporary	O
approach	B-T169
called	O
Rasch analysis	B-T062
.	O
A	O
total	O
of	O
216	O
patients	B-T101
with	O
musculoskeletal disorders	B-T047
were	O
recruited	O
in	O
this	O
study	B-T062
.	O
Participants	B-T098
completed	O
study	B-T062
measures	B-T081
,	O
which	O
included	O
the	O
pain intensity	B-T201
,	O
the	O
Pain Catastrophizing Scale	B-T170
(	O
PCS	B-T170
),	O
and	O
the	O
Tampa Scale of Kinesiophobia	B-T170
(	O
TSK	B-T170
).	O
Furthermore,	O
the	O
four-	O
item	B-T062
(	O
items	B-T062
3,	O
6,	O
8,	O
and	O
11)	O
and	O
six-	O
item	B-T062
(	O
items	B-T062
4,	O
5,	O
6,	O
10,	O
11,	O
and	O
13)	O
short forms	B-T170
of	O
the	O
Japanese	B-T171
version	B-T170
of	O
PCS	B-T170
were	O
measured.	O
We	O
used	O
Rasch analysis	B-T062
to	O
analyze	B-T169
the	O
psychometric	B-T060
properties	B-T080
of	O
the	O
original,	O
four-	O
item	B-T062
,	O
and	O
six-	O
item	B-T062
short forms	B-T170
of	O
PCS	B-T170
.	O
Rasch analysis	B-T062
showed	O
that	O
both	O
short forms	B-T170
of	O
PCS	B-T170
had	O
acceptable	O
internal	O
consistency	B-T080
,	O
unidimensionality	B-T082
,	O
and	O
no	O
notable	O
DIF	O
and	O
were	O
functional	B-T169
on	O
the	O
category rating scale	B-T170
.	O
However,	O
four-	O
item	B-T062
short form	B-T170
of	O
PCS	B-T170
had	O
two	O
misfit	O
items	B-T062
.	O
Six-	O
item	B-T062
short form	B-T170
of	O
PCS	B-T170
has	O
acceptable	O
psychometric	B-T060
properties	B-T080
and	O
is	O
suitable	O
for	O
use	O
in	O
participants	B-T098
with	O
musculoskeletal pain	B-T033
.	O
Thus,	O
six-	O
item	B-T062
can	O
be	O
used	O
as	O
brief	O
instruments	B-T074
to	O
evaluate	B-T058
pain catastrophizing	B-T041
.	O

A	O
novel	O
quantitative PCR	B-T063
detects	O
Babesia	B-T204
infection	B-T046
in	O
patients	B-T101
not	O
identified	O
by	O
currently	O
available	O
non-nucleic acid amplification tests	B-T059
Ticks	B-T204
transmit	B-T169
Babesia microti	B-T204
,	O
the	O
causative agents	B-T033
of	O
babesiosis	B-T047
in	O
North America	B-T083
and	O
Europe	B-T083
.	O
Babesiosis	B-T047
is	O
now	O
endemic	B-T047
in	O
Northeastern	B-T083
USA	B-T083
and	O
affects	O
people	B-T098
of	O
all	O
ages	B-T032
.	O
Babesia species	B-T204
infect	O
erythrocytes	B-T025
and	O
can	O
be	O
transmitted	B-T046
through	O
blood transfusion	B-T061
.	O
Whole blood	B-T031
and	O
blood products	B-T121
,	O
which	O
are	O
not	O
tested	O
for	O
Babesia	B-T204
,	O
can	O
cause	O
transfusion	B-T061
-	O
transmitted	B-T046
babesiosis	B-T047
(	O
TTB	B-T047
)	O
resulting	O
in	O
severe	B-T080
consequences	B-T169
in	O
the	O
immuno-compromised	B-T033
patients	B-T101
.	O
The	O
purpose	O
of	O
this	O
study	B-T062
was	O
epidemiological evaluation	B-T062
of	O
babesiosis	B-T047
in	O
a	O
tick-infested state	B-T047
.	O
We	O
examined	B-T033
blood samples	B-T031
from	O
192	O
patients	B-T101
who	O
visited	O
clinics	B-T073
during	O
the	O
active	O
tick-borne diseases	B-T047
season	B-T079
,	O
using	O
a	O
newly	O
developed	O
qPCR assay	B-T063
that	O
uses	O
the	O
specific	O
molecular beacon probe	B-T114
.	O
Due	O
to	O
the	O
absence	B-T169
of	O
clear	O
symptomology	B-T184
,	O
clinical laboratories	B-T073
did	O
not	O
test	O
131	O
samples	B-T031
by	O
IFA	B-T059
,	O
FISH	B-T063
or	O
microscopic examination	B-T059
of	O
Giemsa-stained	B-T109
blood smears	B-T059
.	O
Babesia	B-T204
infection	B-T046
was	O
detected	O
in	O
all	O
age groups	B-T100
by	O
FISH	B-T063
and	O
microscopy	B-T059
;	O
notably	O
patients	B-T101
>40	O
years	B-T079
of	O
age	B-T032
represented	O
64%	O
of	O
tested	O
samples	B-T031
and	O
13%	O
were	O
younger	B-T079
patients	B-T101
.	O
We	O
tested	O
all	O
samples	B-T031
using	O
qPCR	B-T063
and	O
found	O
that	O
38%	O
were	O
positive	B-T033
for	O
Babesia	B-T204
.	O
Of	O
28	O
samples	B-T031
that	O
were	O
positive	B-T033
by	O
FISH	B-T063
,	O
27	O
(96%)	O
were	O
also	O
positive	B-T033
by	O
qPCR	B-T063
indicating	O
high	O
congruency	O
between	O
nucleic acid based tests	B-T059
.	O
Interestingly,	O
of	O
78	O
asymptomatic	B-T033
samples	B-T031
not	O
tested	O
by	O
FISH	B-T063
,	O
22	O
were	O
positive	B-T033
by	O
our	O
qPCR	B-T063
.	O
Direct	O
detection	B-T061
of	O
Babesia	B-T204
relies	O
upon	O
microscopic examination	B-T059
of	O
patient	B-T101
blood smears	B-T059
,	O
which	O
is	O
labor	O
intensive,	O
difficult	O
to	O
scale	O
up,	O
requires	O
specific	O
expertise	O
and	O
is	O
hence,	O
often	O
not	O
performed.	O
In	O
fact,	O
a	O
clinical laboratory	B-T073
examined	B-T033
only	O
23	O
of	O
86	O
blood samples	B-T031
obtained	O
from	O
two	O
different	O
counties	B-T083
by	O
microscopy	B-T059
.	O
By	O
considering	O
individuals	B-T098
positive	B-T033
for	O
Babesia	B-T204
infection	B-T046
when	O
results	O
from	O
currently	O
available	O
microscopy	B-T059
,	O
FISH	B-T063
or	O
serological tests	B-T059
were	O
positive	B-T033
,	O
we	O
found	O
that	O
our	O
qPCR	B-T063
is	O
highly	O
sensitive	B-T169
(96.2%)	O
and	O
showed	O
a	O
specificity	B-T081
of	O
70.5%	O
for	O
Babesia	B-T204
.	O
Robust	O
qPCR	B-T063
using	O
specific	O
probes	B-T130
can	O
be	O
highly	O
useful	O
for	O
efficient	O
and	O
appropriate	O
diagnosis	B-T062
of	O
babesiosis	B-T047
in	O
patients	B-T101
in	O
conjunction	O
with	O
conventional	O
diagnostics	B-T062
,	O
or	O
as	O
a	O
stand-alone	O
test,	O
especially	O
for	O
donated	O
blood screening	B-T059
.	O
The	O
use	O
of	O
a	O
nucleic acid amplification test	B-T059
based	O
screening of blood	B-T059
and	O
blood products	B-T121
could	O
prevent	O
TTB	B-T047
.	O

Historical relationships	B-T079
of	O
three	O
enigmatic	B-T080
phasianid genera	B-T012
(	O
Aves	B-T012
:	O
Galliformes	B-T012
)	O
inferred	O
using	O
phylogenomic and mitogenomic data	B-T170
The	O
phylogeny	B-T078
of	O
the	O
Phasianidae	B-T012
(	O
pheasants	B-T012
,	O
partridges	B-T012
,	O
and	O
allies	B-T012
)	O
has	O
been	O
studied	O
extensively.	O
However,	O
these	O
studies	O
have	O
largely	O
ignored	O
three	O
enigmatic genera	B-T080
because	O
of	O
scarce	B-T080
DNA	B-T114
source material	B-T033
and	O
limited	O
overlapping	O
phylogenetic data	B-T170
:	O
blood pheasants	B-T012
(	O
Ithaginis	B-T012
),	O
snow partridges	B-T012
(	O
Lerwa	B-T012
),	O
and	O
long-billed partridges	B-T012
(	O
Rhizothera	B-T012
).	O
Thus,	O
phylogenetic positions	B-T032
of	O
these	O
three	O
genera	O
remain	O
uncertain	O
in	O
what	O
is	O
otherwise	O
a	O
well-resolved	O
phylogeny	B-T078
.	O
Previous	O
studies	O
using	O
different	O
data	B-T078
types	O
place	O
Lerwa	B-T012
and	O
Ithaginis	B-T012
in	O
similar	O
positions,	O
but	O
the	O
absence	O
of	O
overlapping data	B-T079
means	O
the	O
relationship	B-T080
between	O
them	O
could	O
not	O
be	O
inferred.	O
Rhizothera	B-T012
was	O
originally	O
described	O
in	O
the	O
genus	O
Perdix	B-T012
(	O
true partridges	B-T012
),	O
although	O
a	O
partial	O
cytochrome b	B-T116
(	O
CYB	B-T116
)	O
sequence	O
suggests	O
it	O
is	O
sister	B-T077
to	O
Pucrasia	B-T012
(	O
koklass pheasant	B-T012
).	O
To	O
identify	O
robust	O
relationships	B-T080
among	O
Ithaginis	B-T012
,	O
Lerwa	B-T012
,	O
Rhizothera	B-T012
,	O
and	O
their	O
phasianid relatives	B-T012
,	O
we	O
used	O
3692	O
ultra-conserved element (UCE) loci	B-T028
and	O
complete	O
mitogenomes	B-T028
from	O
19	O
species	B-T185
including	O
previously	O
hypothesized	B-T078
relatives	B-T080
of	O
the	O
three	O
focal	O
genera	O
and	O
representatives	O
from	O
all	O
major	O
phasianid clades	B-T012
.	O
We	O
used	O
DNA extracted	B-T114
from	O
historical	O
specimen toepads	B-T033
for	O
species	O
that	O
lacked fresh tissue	B-T024
in	O
museum collections	B-T059
.	O
Maximum	O
likelihood	O
and	O
multispecies coalescent UCE analyses	B-T081
strongly	O
supported	O
Lerwa	B-T012
sister	B-T077
to	O
a	O
large clade	B-T012
which	O
included	O
Ithaginis	B-T012
at	O
its	O
base,	O
and	O
also	O
including	O
turkey	B-T012
,	O
grouse	B-T012
,	O
typical	O
pheasants	B-T012
,	O
tragopans	B-T012
,	O
Pucrasia	B-T012
,	O
and	O
Perdix	B-T012
.	O
Rhizothera	B-T012
was	O
also	O
in	O
this	O
clade	B-T012
,	O
sister	B-T077
to	O
a	O
diverse	O
group	O
comprising	O
Perdix	B-T012
,	O
typical	O
pheasants	B-T012
,	O
Pucrasia	B-T012
,	O
turkey	B-T012
and	O
grouse	B-T012
.	O
Mitogenomic genealogies	B-T170
differed	O
from	O
UCEs topologies	B-T169
,	O
supporting	O
a	O
sister relationship	B-T077
between	O
Ithaginis	B-T012
and	O
Lerwa	B-T012
rather	O
than	O
a	O
grade.	O
The	O
position	O
of	O
Rhizothera	B-T012
using	O
mitogenomes	B-T028
depended	O
on	O
analytical choices	B-T062
.	O
Unpartitioned	O
and	O
codon-based analyses	B-T059
placed	O
Rhizothera	B-T012
sister	B-T077
to	O
a	O
tragopan clade	B-T012
,	O
whereas	O
a	O
partitioned	O
DNA model	B-T170
of	O
the	O
mitogenome	B-T028
was	O
congruent	B-T080
with	O
UCE results	B-T033
.	O
In	O
all	O
mitogenome analyses	B-T059
,	O
Pucrasia	B-T012
was	O
sister	B-T077
to	O
a	O
clade	B-T012
including	O
Perdix	B-T012
and	O
the	O
typical	O
pheasants	B-T012
with	O
high	O
support,	O
in	O
contrast	O
to	O
UCEs	O
and	O
published nuclear intron data	B-T170
.	O
Due	O
to	O
the	O
strong	O
support	O
and	O
consistent	O
topology	B-T170
provided	O
by	O
all	O
UCE analyses	B-T170
,	O
we	O
have	O
identified	O
phylogenetic	B-T078
relationships	B-T080
of	O
these	O
three	O
enigmatic	B-T080
,	O
poorly-studied,	O
phasianid taxa	B-T012
.	O

A	O
novel	B-T080
combination	O
treatment	B-T169
to	O
stimulate	B-T061
bone healing	B-T033
and	O
regeneration	B-T042
under	O
hypoxic conditions	B-T046
:	O
photobiomodulation	B-T061
and	O
melatonin	B-T109
Melatonin	B-T109
has	O
anabolic effects	B-T039
on	O
the	O
bone	B-T024
,	O
even	O
under	O
hypoxia	B-T046
,	O
and	O
laser irradiation	B-T061
has	O
been	O
shown	O
to	O
improve	O
osteoblastic differentiation	B-T043
.	O
The	O
aim	B-T078
of	O
this	O
study	B-T062
was	O
to	O
investigate	B-T169
whether	O
laser irradiation	B-T061
and	O
melatonin	B-T109
would	O
have	O
synergistic	B-T080
effects	B-T080
on	O
osteoblastic differentiation	B-T043
and	O
mineralization	B-T042
under	O
hypoxic conditions	B-T046
.	O
MC3T3-E1 cells	B-T025
were	O
exposed	O
to	O
1%	O
oxygen tension	B-T033
for	O
the	O
hypoxia condition	B-T046
.	O
The	O
cells	B-T025
were	O
divided	O
into	O
four	O
groups	B-T078
:	O
G1	B-T078
-	O
osteoblast differentiation	B-T043
medium	B-T130
only	O
(as	O
the	O
hypoxic condition	B-T046
),	O
G2	B-T078
-	O
treatment	B-T169
with	O
50	O
μM	O
melatonin	B-T109
only,	O
G3	B-T078
-	O
laser irradiation	B-T061
(808	O
nm,	O
80	O
mW,	O
GaAlAs diode	B-T074
)	O
only,	O
and	O
G4	B-T078
-	O
treatment	B-T169
with	O
50	O
μM	O
melatonin	B-T109
and	O
laser irradiation	B-T061
(808	O
nm,	O
80	O
mW,	O
GaAlAs diode	B-T074
).	O
Immunoblotting	B-T059
showed	O
that	O
osterix	B-T116
expression	B-T045
was	O
markedly	O
increased	B-T081
in	O
the	O
melatonin	B-T109
-	O
treated	B-T169
and	O
laser-irradiated	B-T061
cells	B-T025
at	O
48	O
and	O
72	O
h.	O
In	O
addition,	O
alkaline phosphatase	B-T116
activity	B-T052
significantly	O
increased	B-T081
and	O
continued	B-T078
to	O
rise	O
throughout	O
the	O
experiment	B-T062
.	O
Alizarin Red staining	B-T059
showed	O
markedly	O
increased	B-T081
mineralized	B-T042
nodules	B-T046
as	O
compared	O
with	O
only	O
melatonin	B-T109
-	O
treated	B-T169
or	O
laser-irradiated	B-T061
cells	B-T025
at	O
day	O
7,	O
which	O
significantly	O
increased	B-T081
by	O
day	O
14.	O
Moreover,	O
when	O
melatonin	B-T109
-	O
treated	B-T169
cells	B-T025
were	O
laser-irradiated	B-T061
,	O
the	O
differentiation	B-T043
and	O
mineralization	B-T042
of	O
cells	B-T025
were	O
found	O
to	O
involve	O
p38 MAPK	B-T116
and	O
PRKD1	B-T116
signaling mechanisms	B-T043
.	O
However,	O
the	O
enhanced	B-T052
effects of	B-T080
laser irradiation	B-T061
with	O
melatonin	B-T109
were	O
markedly	O
inhibited	B-T080
when	O
the	O
cells	B-T025
were	O
treated	B-T169
with	O
luzindole	B-T109
,	O
a	O
selective	O
melatonin receptor antagonist	B-T121
.	O
Therefore,	O
we	O
concluded	O
that	O
laser irradiation	B-T061
could	O
promote	O
the	O
effect of	B-T080
melatonin	B-T109
on	O
the	O
differentiation	B-T043
and	O
mineralization	B-T042
of	O
MC3T3-E1 cells	B-T025
under	O
hypoxic conditions	B-T046
,	O
and	O
that	O
this	O
process	O
is	O
mediated	O
through	O
melatonin 1/2 receptors	B-T116
and	O
PKRD	B-T116
/	O
p38	B-T116
signaling pathways	B-T044
.	O

Aquaporin-2	B-T116
excretion	B-T042
in	O
hospitalized patients	B-T101
with	O
cirrhosis	B-T047
:	O
Relation	O
to	O
development	B-T169
of	O
renal insufficiency	B-T047
and	O
mortality	B-T081
Urinary	B-T080
aquaporin-2	B-T116
(	O
AQP2	B-T116
)	O
is	O
a	O
parameter	O
of	O
water transport	B-T043
in	O
the	O
principal cells	B-T025
in	O
the	O
distal part	B-T029
of	O
the	O
nephron	B-T023
and	O
involved	O
in	O
water retention	B-T040
in	O
cirrhosis	B-T047
and	O
may	O
be	O
a	O
marker	B-T201
of	O
renal function	B-T042
.	O
The	O
aim	B-T078
of	O
the	O
study	B-T062
was	O
to	O
evaluate	O
AQP2	B-T116
as	O
a	O
predictor	B-T170
of	O
renal insufficiency	B-T047
and	O
death	B-T040
in	O
patients	B-T101
with	O
cirrhosis	B-T047
.	O
Urine samples	B-T031
from	O
199	O
patients	B-T101
(90	O
patients	B-T101
without	O
organ failure	B-T184
[	O
Group 1	B-UnknownType
],	O
58	O
patients	B-T101
with	O
organ failure	B-T184
excluding	O
renal failure	B-T047
[	O
Group 2	B-UnknownType
],	O
and	O
51	O
patients	B-T101
with	O
organ failure	B-T184
including	O
renal failure	B-T047
[	O
Group 3	B-UnknownType
])	O
from	O
the	O
CANONIC study	B-T062
were	O
analyzed	O
for	O
urine	B-T031
AQP2	B-T116
and	O
urine osmolality	B-T201
.	O
There	O
was	O
no difference	B-T033
in	O
AQP2	B-T116
between	O
the	O
three	O
groups	B-UnknownType
.	O
Urine osmolality	B-T201
was	O
significantly lower	B-T081
in	O
patients	B-T101
in	O
Group 3	B-UnknownType
versus	O
Group 1	B-UnknownType
and	O
Group 2	B-UnknownType
(P	O
=	O
0.0004).	O
No relation	B-T033
was	O
found	O
between	O
AQP2	B-T116
and	O
glomerular filtration rate	B-T060
or	O
creatinine	B-T109
;	O
however,	O
AQP2	B-T116
was	O
a	O
significant	O
predictor	B-T170
of	O
the	O
development	B-T169
of	O
renal insufficiency	B-T047
(P	O
=	O
0.0485).	O
In	O
a	O
univariate analysis	B-T062
,	O
AQP2	B-T116
was	O
a	O
significant	O
predictor	B-T170
of	O
14	O
and	O
28-day	O
survival	B-T169
,	O
but	O
this	O
was	O
not	O
confirmed	O
in	O
multivariate analysis	B-T081
.	O
Aquaporin-2	B-T116
was	O
not	O
associated	O
with	O
disease severity	B-T080
or	O
markers	B-T080
of	O
renal function	B-T042
but	O
was	O
a	O
predictor	B-T170
for	O
the	O
development	B-T169
of	O
renal insufficiency	B-T047
and	O
death	B-T040
.	O
Therefore,	O
its	O
future	O
use	O
as	O
marker	B-T201
of	O
renal insufficiency	B-T047
could	O
be	O
promising,	O
but	O
further	O
research	B-T062
is	O
needed	O
before	O
it	O
can	O
be	O
considered	O
a	O
clinical	B-T080
useful	O
tool.	O

Decompression Surgery	B-T061
Alone	O
Versus	O
Decompression	B-T061
Plus	O
Fusion	B-T061
in	O
Symptomatic	B-T169
Lumbar Spinal Stenosis	B-T047
:	O
A	O
Swiss	B-T098
Prospective Multi-center Cohort Study	B-T062
with	O
3	O
Years	B-T079
of	O
Follow-up	B-T062
Retrospective analysis	B-T062
of	O
a	O
prospective, multicenter cohort study	B-T062
.	O
To	O
estimate	O
the	O
added	O
effect	B-T080
of	O
surgical fusion	B-T061
as	O
compared	O
to	O
decompression surgery	B-T061
alone	O
in	O
symptomatic	B-T169
lumbar spinal stenosis	B-T047
patients	B-T101
with	O
spondylolisthesis	B-T047
.	O
The	O
optimal surgical management	B-T058
of	O
lumbar spinal stenosis	B-T047
patients	B-T101
with	O
spondylolisthesis	B-T047
remains	O
controversial.	O
Patients	B-T101
of	O
the	O
LSOS	B-T062
with	O
confirmed	O
DLSS	B-T047
and	O
spondylolisthesis	B-T047
were	O
enrolled	O
in	O
this	O
study	B-T077
.	O
The	O
outcomes	B-T062
of	O
this	O
study	B-T077
were	O
Spinal Stenosis	B-T020
Spinal Stenosis Measure	B-T081
(	O
SSM	B-T081
)	O
symptoms	B-T184
(	O
score range	B-T081
1-5,	O
best-worst)	O
and	O
function	B-T169
(1-4)	O
over time	B-T079
,	O
measured	B-T080
at	O
baseline	B-T081
,	O
6,	O
12,	O
24	O
and	O
36	O
months	B-T079
follow-up	B-T062
.	O
In	O
order	O
to	O
quantify	B-T081
the	O
effect	B-T080
of	O
fusion surgery	B-T061
as	O
compared	O
to	O
decompression	B-T061
alone	O
and	O
number of decompressed levels	B-T033
,	O
we	O
used	O
mixed	O
effects	B-T080
models	B-T075
and	O
accounted	O
for	O
the	O
repeated observations	B-T062
in	O
main	O
outcomes	B-T062
(	O
SSM	B-T081
symptoms	B-T184
and	O
SSM	B-T081
function	B-T169
)	O
over time	B-T079
.	O
In	O
addition	O
to	O
individual	O
patients	B-T101
'	O
random effects	B-T080
,	O
we	O
also	O
fitted random slopes	B-T081
for	O
follow-up	B-T033
time points	B-T079
and	O
compared	O
these	O
two	O
approaches	B-T169
with	O
Akaike's Information Criterion	B-T170
(	O
AIC	B-T170
)	O
and	O
the	O
chi-squared test	B-T170
.	O
Confounders	B-T169
were	O
adjusted	O
with	O
fixed effects	B-T080
for	O
age	B-T032
,	O
gender	B-T032
,	O
BMI	B-T201
,	O
diabetes	B-T047
,	O
CIRS	B-T081
musculoskeletal disorders	B-T047
and	O
duration	B-T109
of	O
symptoms	B-T184
.	O
One	O
hundred	O
and	O
thirty-one	O
patients	B-T101
undergoing	O
decompression surgery	B-T061
alone	O
(n	O
=	O
85)	O
or	O
decompression	B-T061
plus	O
fusion surgery	B-T061
(n	O
=	O
46)	O
were	O
included	O
in	O
this	O
study	B-T077
.	O
In	O
the	O
multiple mixed effects	B-T080
model	B-T075
the	O
adjusted	O
effect	B-T080
of	O
fusion	B-T061
versus	O
decompression alone surgery	B-T061
on	O
SSM	B-T081
symptoms	B-T184
was	O
0.06	O
(95%	O
confidence interval	B-T081
,	O
CI	B-T081
:	O
-0.16	O
to	O
0.27)	O
and	O
-0.07	O
(95%	O
CI	B-T081
:	O
-0.25	O
to	O
0.10)	O
on	O
SSM	B-T081
function	B-T169
,	O
respectively.	O
Among	O
the	O
patients	B-T101
with	O
degenerative lumbar spinal stenosis	B-T047
and	O
spondylolisthesis	B-T047
our	O
study	B-T077
confirms	O
that	O
in	O
the	O
two	O
groups	B-T078
,	O
decompression	B-T061
alone	O
and	O
decompression	B-T061
plus	O
fusion	B-T061
,	O
patients	B-T101
distinctively	O
benefited	O
from	O
surgical treatment	B-T061
.	O
When	O
adjusted	O
for	O
confounders	B-T169
,	O
fusion surgery	B-T061
was	O
not	O
associated with	B-T080
a	O
more	O
favorable	O
outcome	B-T062
in	O
both	O
SSM scores	B-T081
as	O
compared	O
to	O
decompression alone surgery	B-T061
.	O
3.	O

Muscle	B-T024
synergies	B-T169
after	O
stroke	B-T047
are	O
correlated	O
with	O
perilesional	B-T082
high gamma	B-T081
Movements	B-T033
can	O
be	O
factored	O
into	O
modules	B-T077
termed	O
"	O
muscle	B-T024
synergies	B-T169
".	O
After	O
stroke	B-T047
,	O
abnormal	B-T033
synergies	B-T169
are	O
linked	O
to	O
impaired	B-T169
movements	B-T033
;	O
however,	O
their	O
neural	B-T025
basis	B-T169
is	O
not	O
understood.	O
In	O
a	O
single	O
subject,	O
we	O
examined	O
how	O
electrocorticography signals	B-T060
from	O
the	O
perilesional	B-T082
cortex	B-T023
were	O
associated	O
with	O
synergies	B-T169
.	O
The	O
measured	O
synergies	B-T169
contained	B-T169
a	O
mix	O
of	O
both	O
normal	B-T080
and	O
abnormal	B-T033
patterns	B-T082
and	O
were	O
remarkably	O
similar	O
to	O
those	O
described	O
in	O
past	O
work.	O
Interestingly,	O
we	O
found	O
that	O
both	O
normal	B-T080
and	O
abnormal	B-T033
synergies	B-T169
were	O
correlated	O
with	O
perilesional	B-T082
high gamma	B-T081
.	O
Given	O
the	O
link	O
between	O
high gamma	B-T081
and	O
cortical spiking	B-T033
,	O
our	O
results	O
suggest	O
that	O
perilesional spiking	B-T033
may	O
organize	O
synergies	B-T169
after	O
stroke	B-T047
.	O

Assessing	B-T058
nitrous oxide	B-T121
effect	B-T080
using	O
electroencephalographically	B-T060
-based	O
depth of anesthesia	B-T033
measures	B-T081
cortical	B-T023
state	B-T170
and	O
cortical	B-T023
input	B-T170
Existing	O
electroencephalography	B-T060
(	O
EEG	B-T060
)	O
based	O
depth of anesthesia	B-T033
monitors	B-T058
cannot	O
reliably	O
track	O
sedative	B-T121
or	O
anesthetic	B-T121
states	B-T080
during	O
n-methyl-D-aspartate (NMDA) receptor antagonist	B-T121
based	O
anesthesia	B-T061
with	O
ketamine	B-T109
or	O
nitrous oxide	B-T121
(	O
N2O	B-T121
).	O
Here,	O
a	O
physiologically	B-T169
-motivated	O
depth of anesthesia	B-T033
monitoring	B-T058
algorithm	B-T170
based	O
on	O
autoregressive-moving-average (ARMA) modeling	B-T170
and	O
derivative	O
measures	O
of	O
interest,	O
Cortical	B-T023
State	B-T170
(	O
CS	B-T170
)	O
and	O
Cortical	B-T023
Input	B-T170
(	O
CI	B-T170
),	O
is	O
retrospectively	B-T062
applied	O
in	O
an	O
exploratory	B-T169
manner	O
to	O
the	O
NMDA receptor antagonist	B-T121
N2O	B-T121
,	O
an	O
adjuvant anesthetic gas	B-T121
used	O
in	O
clinical practice	B-T169
.	O
Composite Cortical State	B-T170
(	O
CCS	B-T170
)	O
and	O
Composite Cortical State distance	B-T170
(	O
CCSd	B-T170
),	O
two	O
new	O
modifications	B-T033
of	O
CS	B-T170
,	O
along	O
with	O
CS	B-T170
and	O
CI	B-T170
were	O
evaluated	B-T058
on	O
electroencephalographic	B-T060
(	O
EEG	B-T060
)	O
data	B-T078
of	O
healthy control individuals	B-T080
undergoing	O
N2O	B-T121
inhalation	B-T040
up	O
to	O
equilibrated	B-T081
peak gas concentrations	B-T081
of	O
20,	O
40	O
or	O
60%	O
N2O	B-T121
/	O
O2	B-T121
.	O
In	O
particular,	O
CCSd	B-T170
has	O
been	O
devised	O
to	O
vary	O
consistently	O
for	O
increasing	B-T081
levels	B-T080
of	O
anesthetic concentration	B-T033
independent of	B-T169
the	O
anesthetic's	B-T121
microscopic	B-T080
mode of action	B-T169
for	O
both	O
N2O	B-T121
and	O
propofol	B-T109
.	O
The	O
strongest	O
effects	B-T080
were	O
observed	O
for	O
the	O
60%	O
peak gas concentration	B-T081
group	B-T098
.	O
For	O
the	O
50-60%	O
peak gas levels	B-T080
,	O
individuals	B-T098
showed	O
statistically significant	B-T081
reductions	B-T061
in	O
responsiveness	B-T033
compared	B-T052
to	O
rest	B-T056
,	O
and	O
across	O
the	O
group	B-T098
CS	B-T170
and	O
CCS	B-T170
increased	B-T081
by	O
39	O
and	O
42%,	O
respectively,	O
while	O
CCSd	B-T170
was	O
found	O
to	O
decrease	B-T081
by	O
398%.	O
On	O
the	O
other	O
hand	O
a	O
clear	O
conclusion	B-T078
regarding	O
the	O
changes	O
in	O
CI	B-T170
could	O
not	O
be	O
reached.	O
These	O
results	B-T169
indicate	O
that,	O
contrary	B-T082
to	O
previous	O
depth of anesthesia	B-T033
monitoring	B-T058
measures	B-T081
,	O
the	O
CS	B-T170
,	O
CCS	B-T170
,	O
and	O
especially	O
CCSd	B-T170
measures	B-T081
derived	B-T080
from	O
frontal	B-T082
EEG	B-T060
are	O
potentially	B-T080
useful	O
for	O
differentiating	O
gas concentration	B-T081
and	O
responsiveness levels	B-T033
in	O
people	B-T098
under	O
N2O	B-T121
.	O
On	O
the	O
other	O
hand,	O
determining	O
the	O
utility	B-T169
of	O
CI	B-T170
in	O
this	O
regard	O
will	O
require	O
larger	B-T081
sample sizes	B-T081
and	O
potentially	B-T080
higher	B-T080
gas concentrations	B-T081
.	O
Future	O
work	O
will	O
assess	B-T058
the	O
sensitivity	B-T081
of	O
CS	B-T170
-based	O
and	O
CI	B-T170
measures	B-T081
to	O
other	O
anesthetics	B-T121
and	O
their	O
utility	B-T169
in	O
a	O
clinical	B-T073
environment	B-T082
.	O

DT MRI	B-T060
microstructural	B-T080
cortical	B-T023
lesion	B-T047
damage	B-T169
does	O
not	O
explain	O
cognitive impairment	B-T048
in	O
MS	B-T047
We	O
combined	O
double inversion recovery	B-T060
(	O
DIR	B-T060
)	O
and	O
diffusion tensor (DT) magnetic resonance imaging (MRI)	B-T060
to	O
quantify	B-T081
the	O
severity	B-T080
of	O
cortical	B-T023
lesion	B-T047
(	O
CL	B-T047
)	O
microstructural	B-T080
tissue	B-T024
abnormalities	B-T020
in	O
a	O
large	B-T081
cohort	B-T098
of	O
relapse	B-T067
-	O
onset	B-T080
multiple sclerosis	B-T047
(	O
MS	B-T047
)	O
patients	B-T101
and	O
its	O
contribution	B-T052
to	O
cognitive dysfunction	B-T048
.	O
DIR	B-T060
,	O
DT	B-T060
,	O
dual-echo	B-T060
,	O
and	O
three-dimensional	B-T082
(	O
3D	B-T082
)	O
T1-weighted scans	B-T060
were	O
acquired	O
from	O
149	O
MS	B-T047
patients	B-T101
and	O
40	O
controls	B-T096
.	O
Cognitively impaired	B-T048
(	O
CI	B-T048
)	O
patients	B-T101
had	O
⩾2	O
abnormal	B-T033
neuropsychological tests	B-T060
.	O
Diffusivity values	B-T077
in	O
CLs	B-T047
,	O
cortex	B-T023
,	O
white matter (WM) lesions	B-T033
,	O
and	O
normal-appearing (NA) WM	B-T024
were	O
assessed	B-T052
.	O
Predictors	B-T078
of	O
cognitive impairment	B-T048
were	O
identified	B-T080
using	O
a	O
random forest analysis	B-T062
.	O
Compared	O
to	O
controls	B-T096
,	O
MS	B-T047
patients	B-T101
had	O
lower	B-T080
normalized brain volume	B-T081
(	O
NBV	B-T081
),	O
gray matter volume	B-T081
(	O
GMV	B-T081
),	O
WM volume	B-T033
,	O
lower	B-T080
fractional anisotropy	B-T081
(	O
FA	B-T081
),	O
and	O
higher	B-T080
mean diffusivity	B-T077
in	O
cortex	B-T023
and	O
normal-appearing white matter	B-T024
(	O
NAWM	B-T024
).	O
A	O
total	O
of	O
44	O
(29.5%)	O
patients	B-T101
were	O
CI	B-T048
.	O
Compared	O
to	O
cognitively preserved	B-T101
(	O
CP	B-T101
),	O
CI	B-T048
patients	B-T101
had	O
higher	B-T080
T2 WM lesion volume	B-T081
(	O
LV	B-T081
),	O
lower	B-T080
NBV	B-T081
and	O
GMV	B-T081
,	O
and	O
more	O
severe	B-T080
diffusivity	B-T077
abnormalities	B-T020
in	O
WM lesions	B-T033
,	O
cortex	B-T023
,	O
and	O
NAWM	B-T024
.	O
CL	B-T047
measures	B-T081
did	O
not differ	B-T033
between	O
CI	B-T101
and	O
CP patients	B-T101
.	O
Cortex	B-T023
FA	B-T081
,	O
age	B-T032
,	O
disease duration	B-T079
,	O
T2 WM LV	B-T081
,	O
and	O
GMV	B-T081
best	O
predicted	O
MS	B-T047
-related	O
cognitive impairment	B-T048
(C-statistic	O
=	O
0.88).	O
"	O
Diffuse	B-T082
"	O
GM	B-T024
and	O
NAWM	B-T024
damage	B-T169
and	O
WM lesions	B-T033
,	O
rather	O
than	O
intrinsic	B-T082
CL	B-T047
damage	B-T169
,	O
contribute	O
to	O
cognitive impairment	B-T048
in	O
MS	B-T047
.	O

Correlation	B-T080
between	O
the	O
histopathology	B-T169
of	O
chronic urticaria	B-T047
and	O
its	O
clinical picture	B-T201
Chronic urticaria	B-T047
is	O
characterized	O
by	O
transient	B-T079
,	O
pruritic lesions	B-UnknownType
of	O
varying	O
sizes	B-T082
,	O
with	O
central	B-T082
pallor	B-T033
and	O
well-defined	O
edges,	O
with	O
disease	B-T047
duration	O
longer	O
than	O
six	O
weeks	B-T079
.	O
Its	O
cellular infiltrate	B-T046
consists	O
of	O
neutrophils	B-T025
,	O
lymphocytes	B-T025
and	O
eosinophils	B-T025
.	O
There	O
is	O
a	O
subgroup	O
of	O
patients	B-T101
with	O
eosinophilic	B-T025
or	O
neutrophilic urticaria	B-T047
,	O
resistant	O
to	O
the	O
treatment	B-T061
with	O
antihistamines	B-T109
,	O
but	O
that	O
respond	O
to	O
a	O
combination	O
of	O
antihistamine	B-T109
with	O
other	O
drugs	B-T121
.	O
To	O
evaluate	O
the	O
present	O
infiltration	B-T046
in	O
chronic urticaria	B-T047
biopsies	B-T060
and	O
correlate	O
it	O
with	O
the	O
clinical disease activity	B-UnknownType
and	O
response to treatment	B-T201
.	O
Forty-one	O
patients	B-T101
with	O
chronic urticaria	B-T047
were	O
classified	O
according	O
to	O
the	O
score of severity	B-T081
of	O
the	O
disease	B-T047
,	O
response to treatment	B-T201
and	O
type	O
of	O
perivascular infiltrate	B-T046
.	O
Inflammatory infiltrates	B-T031
were	O
divided	O
in	O
eosinophilic	B-T025
(46.30%),	O
neutrophilic	B-T025
and	O
mixed.	O
An	O
association	B-T080
was	O
found	O
between	O
the	O
eosinophilic infiltrate	B-T031
and	O
clinical scores	B-T081
of	O
greater	O
severity	B-T080
(p	O
=	O
0.002).	O
This	O
association	B-T080
shows	O
that	O
the	O
eosinophilic inflammatory infiltrates	B-T031
denote	O
high	O
clinical activity	B-T184
,	O
which	O
means	O
more	O
severe	B-T080
and	O
exuberant	O
clinical pictures	B-T201
of	O
the	O
disease	B-T047
.	O

Barriers	B-T080
to	O
access and uptake	B-T080
of	O
antiretroviral therapy	B-T061
among	O
HIV-positive	B-T034
men who have sex with men	B-T098
in	O
Hanoi	B-UnknownType
,	O
Vietnam	B-T083
:	O
from	O
HIV testing	B-T059
to	O
treatment	B-T061
Little	O
is	O
known	O
about	O
the	O
experiences	B-T041
of	O
Vietnamese	B-T098
men who have sex with men	B-T098
in	O
accessing	B-T082
HIV testing	B-T059
and	O
treatment	B-T061
.	O
We	O
aimed	O
to	O
explore	O
barriers	B-T080
to	O
access and uptake	B-T080
of	O
antiretroviral therapy	B-T061
(	O
ART	B-T061
)	O
among	O
HIV-positive	B-T034
men who have sex with men	B-T098
in	O
Hanoi	B-UnknownType
.	O
During	O
2015,	O
we	O
conducted	O
qualitative	B-T080
interviews	B-T052
with	O
35	O
participants	B-T098
recruited	O
using	O
snowball sampling	B-T062
based	O
on	O
previous	O
research	B-T062
and	O
social networks	B-T098
.	O
Key	O
individual	O
impediments	O
to	O
ART	B-T061
uptake	O
included	O
inadequate	B-T080
preparation	B-T052
for	O
a	O
positive	B-T033
diagnosis	B-T033
and	O
the	O
dual	O
stigmatisation	B-T078
of	O
homosexuality	B-T054
and	O
HIV	B-T005
and	O
its	O
consequences	B-T062
,	O
leading	O
to	O
fear	B-T041
of	O
disclosure	B-T055
of	O
HIV status	B-T033
.	O
Health system	B-T093
barriers	B-T080
included	O
lack	O
of	O
clarity	O
and	O
consistency	B-T080
about	O
how	O
to	O
register	O
for	O
and	O
access	B-T080
ART	B-T061
,	O
failure	O
to	O
protect	O
patient	B-T101
confidentiality	B-T078
and	O
a	O
reticence	O
by	O
providers	B-T169
to	O
discuss	O
sexual identity	B-T041
and	O
same-sex issues	B-T054
.	O
Results	O
suggest	O
fundamental	O
problems	O
in	O
the	O
way	O
HIV testing	B-T059
is	O
currently	O
delivered	O
in	O
Hanoi	B-UnknownType
,	O
including	O
a	O
lack	O
of	O
client-centred	O
counselling	B-T058
,	O
peer support	B-T061
and	O
clear referral	B-T058
pathways.	O
Overcoming	O
these	O
barriers	B-T080
will	O
require	O
educating	O
men who have sex with men	B-T098
about	O
the	O
benefits	B-T081
of	O
routine testing	B-T060
,	O
improving	B-T080
access	B-T080
to	O
quality	O
diagnostic services	B-T058
and	O
building	O
a	O
safe,	O
confidential	B-T033
treatment	B-T061
environment	B-T082
for	O
HIV-positive	B-T034
men	B-T098
to	O
access	B-T080
,	O
receive and remain in care	B-T052
.	O

Cdc45	B-T116
-	O
induced	B-T169
loading	B-T052
of	O
human RPA	B-T116
onto	O
single-stranded DNA	B-T114
Cell division cycle protein 45	B-T116
(	O
Cdc45	B-T116
)	O
is	O
an	O
essential	O
component	O
of	O
the	O
eukaryotic	B-T204
replicative	B-T080
DNA helicase	B-T116
.	O
We	O
found	O
that	O
human Cdc45	B-T116
forms	O
a	O
complex	B-T104
with	O
the	O
single-stranded DNA (ssDNA) binding protein RPA	B-T116
.	O
Moreover,	O
it	O
actively	O
loads	B-T052
RPA	B-T116
onto	O
nascent	O
ssDNA	B-T114
.	O
Pull-down assays	B-T059
and	O
surface plasmon resonance studies	B-T063
revealed	O
that	O
Cdc45	B-T116
-	O
bound	B-T044
RPA	B-T116
complexed	B-T104
with	O
ssDNA	B-T114
in	O
the	O
8-10	O
nucleotide binding	B-T044
mode,	O
but	O
dissociated	B-T044
when	O
RPA	B-T116
covered	O
a	O
30-mer	B-T086
.	O
Real-time analysis	B-T059
of	O
RPA	B-T116
-	O
ssDNA	B-T114
binding	B-T044
demonstrated	O
that	O
Cdc45	B-T116
catalytically	O
loaded	B-T052
RPA	B-T116
onto	O
ssDNA	B-T114
.	O
This	O
placement	B-T080
reaction	B-T169
required	O
physical contacts	B-T067
of	O
Cdc45	B-T116
with	O
the	O
RPA70A subdomain	B-T087
.	O
Our	O
results	O
imply	O
that	O
Cdc45	B-T116
controlled	O
stabilization	B-T061
of	O
the	O
8-	O
nt	B-T114
RPA	B-T116
binding	B-T044
mode,	O
the	O
subsequent	O
RPA	B-T116
transition	O
into	O
30-mer	B-T086
mode	B-T169
and	O
facilitated	O
an	O
ordered	O
binding	B-T044
to	O
ssDNA	B-T114
.	O
We	O
propose	O
that	O
a	O
Cdc45	B-T116
-mediated	O
loading	B-T052
guarantees	O
a	O
seamless	O
deposition	B-T169
of	O
RPA	B-T116
on	O
newly	O
emerging	O
ssDNA	B-T114
at	O
the	O
nascent	O
replication fork	B-T026
.	O

The	O
antineoplastic drug	B-T109
,	O
trastuzumab	B-T116
,	O
dysregulates	B-T033
metabolism	B-T040
in	O
iPSC	B-T025
-derived	O
cardiomyocytes	B-T025
The	O
targeted ERBB2 therapy	B-T061
,	O
trastuzumab	B-T116
,	O
has	O
had	O
a	O
tremendous	O
impact	B-T080
on	O
management	B-T058
of	O
patients	B-T101
with	O
HER2+ breast cancer	B-T191
,	O
leading	O
to	O
development	B-T169
and	O
increased	B-T081
use	O
of	O
further	O
HER2	B-T116
targeted therapies	B-T061
.	O
The	O
major	O
clinical	B-T080
side effect	B-T046
is	O
cardiotoxicity	B-T037
but	O
the	O
mechanism	B-T169
is	O
largely	O
unknown.	O
On	O
the	O
basis	O
that	O
gene expression	B-T045
is	O
known	O
to	O
be	O
altered	B-T169
in	O
multiple	B-T081
models	B-T170
of	O
heart failure	B-T047
,	O
we	O
examined	O
differential gene expression	B-T045
of	O
iPSC	B-T025
-derived	O
cardiomyocytes	B-T025
treated	B-T169
at	O
day	B-T079
11	O
with	O
the	O
ERBB2	B-T116
targeted	O
monoclonal antibody	B-T116
,	O
trastuzumab	B-T116
for	O
48	O
h	O
and	O
the	O
small molecule tyrosine kinase inhibitor	B-T121
of	O
EGFR	B-T116
and	O
ERBB2	B-T116
.	O
Transcriptome sequencing	B-T059
was	O
performed	B-T169
on	O
four	O
replicates	B-T080
from	O
each	O
group	B-T078
(48	O
h	O
untreated,	O
48	O
h	O
trastuzumab	B-T116
and	O
48	O
h	O
lapatinib	B-T109
)	O
and	O
differential gene expression	B-T045
analyses	B-T062
were	O
performed	B-T169
on	O
each	O
treatment	B-T169
group	B-T078
relative	O
to	O
untreated	O
cardiomyocytes	B-T025
.	O
517	O
and	O
1358	O
genes	B-T028
were	O
differentially expressed	B-T045
,	O
p	O
<	O
0.05,	O
respectively	O
in	O
cardiomyocytes	B-T025
treated	B-T169
with	O
trastuzumab	B-T116
and	O
lapatinib	B-T109
.	O
Gene ontology	B-T170
analyses	B-T062
revealed	O
in	O
cardiomyocytes	B-T025
treated	B-T169
with	O
trastuzumab	B-T116
,	O
significant	B-T078
down-regulation	B-T044
of	O
genes	B-T028
involved	O
in	O
small molecule metabolism	B-T040
(p	O
=	O
3.22	O
�—	O
10(-9))	O
and	O
cholesterol	B-T109
(p	O
=	O
0.01)	O
and	O
sterol	B-T109
(p	O
=	O
0.03)	O
processing.	O
We	O
next	O
measured	B-T080
glucose uptake	B-T043
and	O
lactate	B-T109
production	B-T169
in	O
iPSC	B-T025
-derived	O
cardiomyocytes	B-T025
13	O
days	B-T079
post-plating,	O
treated	B-T169
with	O
trastuzumab	B-T116
up	O
to	O
96	O
h.	O
We	O
observed	B-T169
significantly	B-T081
decreased	B-T081
glucose uptake	B-T043
from	O
the	O
media	B-T130
of	O
iPSC	B-T025
-derived	O
cardiomyocytes	B-T025
treated	B-T169
with	O
trastuzumab	B-T116
as	O
early	O
as	O
24	O
h	O
(p	O
=	O
0.001)	O
and	O
consistently	B-T080
up	O
to	O
96	O
h	O
(p	O
=	O
0.03).	O
Our	O
study	B-T062
suggests	O
dysregulation	B-T033
of	O
cardiac	B-T023
gene expression	B-T045
and	O
metabolism	B-T040
as	O
key	O
elements	O
of	O
ERBB2	B-T028
signaling	B-T044
that	O
could	O
potentially	B-T080
be	O
early	O
biomarkers	B-T201
of	O
cardiotoxicity	B-T037
.	O

Simvastatin	B-T109
Promotes	O
Hematoma	B-T046
Absorption	B-T070
and	O
Reduces	O
Hydrocephalus	B-T047
Following	O
Intraventricular Hemorrhage	B-T046
in	O
Part	O
by	O
Upregulating	B-T044
CD36	B-T028
We	O
previously	O
found	O
that	O
hematoma	B-T046
worsens	B-T033
hydrocephalus	B-T047
after	O
intraventricular hemorrhage	B-T046
(	O
IVH	B-T046
)	O
via	O
increasing	B-T169
iron deposition	B-T046
and	O
aggravating	O
ependymal	B-T024
cilia	B-T026
injury	B-T037
;	O
therefore,	O
promoting	O
hematoma	B-T046
absorption	B-T070
may	O
be	O
a	O
promising	O
strategy	O
for	O
IVH	B-T046
.	O
Recently,	O
some	O
investigations	O
imply	O
that	O
simvastatin	B-T109
has	O
the	O
ability	O
of	O
accelerating	O
hematoma	B-T046
absorption	B-T070
.	O
Thus,	O
this	O
study	O
was	O
designed	O
to	O
examine	O
the	O
efficacy	B-T080
of	O
simvastatin	B-T109
for	O
IVH	B-T046
in	O
rats	B-T015
.	O
Intracerebral hemorrhage	B-T046
with	O
ventricular	O
extension	O
was	O
induced	O
in	O
adult male	B-T032
Sprague-Dawley rats	B-T015
after	O
autologous blood injection	B-T061
.	O
Simvastatin	B-T109
or	O
vehicle	B-T122
was	O
administered orally	B-T061
at	O
1	O
day	O
after	O
IVH	B-T046
and	O
then	O
daily	O
for	O
1	O
week.	O
MRI studies	B-T060
were	O
performed	O
to	O
measure	B-T169
the	O
volumes	B-T059
of	O
intracranial	B-T029
hematoma	B-T046
and	O
lateral ventricle	B-T030
at	O
days	O
1,	O
3,	O
7,	O
14,	O
and	O
28	O
after	O
IVH	B-T046
.	O
Motor	B-T038
and	O
neurocognitive functions	B-T038
were	O
assessed	B-T052
at	O
days	O
1	O
to	O
7	O
and	O
23	O
to	O
28,	O
respectively.	O
Iron deposition	B-T046
,	O
iron	B-T121
-related	O
protein expression	B-T045
,	O
ependymal damage	B-T033
,	O
and	O
histology	B-T169
were	O
detected	B-T033
at	O
day	O
28.	O
Expression	B-T045
of	O
CD36	B-T028
scavenger receptor	B-T116
(facilitating	O
phagocytosis	B-T043
)	O
was	O
examined	B-T033
at	O
day	O
3	O
after	O
IVH	B-T046
using	O
western blotting	B-T059
and	O
immunofluorescence	B-T059
.	O
Simvastatin	B-T109
significantly	O
increased	B-T081
hematoma	B-T046
absorption	B-T070
ratio	B-T081
,	O
reduced	B-T080
ventricular volume	B-T078
,	O
and	O
attenuated neurological dysfunction	B-T033
post-	O
IVH	B-T046
.	O
In	O
addition,	O
less iron accumulation	B-T033
and	O
more	O
cilia	B-T026
survival	B-T081
was	O
observed	O
in	O
the	O
simvastatin	B-T109
group	O
when	O
compared	O
with	O
the	O
control	B-T096
.	O
What's	O
more,	O
higher	B-T080
expression	B-T045
of	O
CD36	B-T028
was	O
detected	B-T033
around	O
the	O
hematoma	B-T046
after	O
simvastatin	B-T109
administration	B-T061
.	O
Simvastatin	B-T109
significantly	O
enhanced	O
brain	B-T023
hematoma	B-T046
absorption	B-T070
,	O
alleviated hydrocephalus	B-T047
,	O
and	O
improved	B-T033
neurological	B-T080
recovery	B-T040
after	O
experimental	B-T080
IVH	B-T046
,	O
which	O
may	O
in	O
part	O
by	O
upregulating	B-T044
CD36	B-T028
expression	B-T045
.	O
Our	O
data	B-T078
suggest	O
that	O
early	O
simvastatin	B-T109
use	O
may	O
be	O
a	O
novel	B-T080
therapy	B-T061
for	O
IVH	B-T046
patients	B-T101
.	O

AMPK	B-T116
-	O
autophagy	B-T043
inhibition	B-T052
sensitizes	O
icaritin	B-T109
-	O
induced	B-T169
anti-colorectal cancer	B-T033
cell activity	B-T043
The	O
current	B-T079
research	B-T062
studied	O
the	O
potential effect	B-T080
of	O
autophagy	B-T043
on	O
icaritin	B-T109
-	O
induced	B-T169
anti-colorectal cancer	B-T033
(	O
CRC	B-T191
)	O
cell activity	B-T043
.	O
Treatment	B-T169
of	O
icaritin	B-T109
in	O
both	O
primary	B-T080
and	O
established	B-T080
(	O
HT-29	B-T025
)	O
CRC	B-T191
cells	B-T025
induced	B-T169
feedback activation	B-T052
of	O
autophagy	B-T043
,	O
evidenced	O
by	O
p62	B-T028
degradation	B-T044
,	O
Beclin-1	B-T028
and	O
autophagy-related gene-5	B-T028
(	O
ATG-5	B-T028
)	O
upregulation	B-T044
,	O
as	O
well	O
as	O
light chain 3B	B-T116
(	O
LC3B	B-T116
)-	O
GFP	B-T116
puncta	O
formation	B-T169
.	O
Pharmacological	B-T169
inhibiting	B-T052
of	O
autophagy	B-T043
dramatically	O
potentiated	O
icaritin	B-T109
-	O
induced	B-T169
CRC	B-T191
cell death	B-T043
and	O
apoptosis	B-T043
.	O
Meanwhile,	O
shRNA	B-T114
-mediated	O
knockdown	B-T063
of	O
Beclin-1	B-T028
or	O
ATG-5	B-T028
also	O
sensitized	O
icaritin	B-T109
-	O
induced	B-T169
CRC	B-T191
cell death	B-T043
and	O
apoptosis	B-T043
.	O
Icaritin	B-T109
activated	B-T052
AMP-activated protein kinase	B-T116
(	O
AMPK	B-T116
)	O
signaling	B-T043
in	O
CRC	B-T191
cells	B-T025
,	O
functioning	B-T169
as	O
the	O
upstream	O
signaling	B-T043
for	O
autophagy	B-T043
activation	B-T052
.	O
shRNA	B-T114
/	O
siRNA	B-T114
-mediated	O
knockdown	B-T063
of	O
AMPKα1	B-T028
inhibited	B-T080
icaritin	B-T109
-	O
induced	B-T169
autophagy	B-T043
activation	B-T052
,	O
but	O
exacerbated	B-T080
CRC	B-T191
cell death	B-T043
.	O
On	O
the	O
other	O
hand,	O
the	O
AMPK	B-T116
activator	O
compound 13	B-T121
(	O
C13	B-T121
)	O
or	O
the	O
autophagy	B-T043
activator	O
MHY1485	B-T109
attenuated	B-T052
icaritin	B-T109
-	O
induced	B-T169
cytotoxicity	B-T049
.	O
In	O
nude mice	B-T015
,	O
icaritin	B-T109
(	O
oral administration	B-T061
)-	O
induced	B-T169
HT-29	B-T025
tumor growth	B-T191
inhibition	B-T052
was	O
potentiated	O
when	O
combined	O
with	O
AMPKα1	B-T028
shRNA	B-T114
knockdown	B-T063
in	O
tumors	B-T191
.	O
We	O
conclude	O
that	O
feedback activation	B-T052
of	O
AMPK	B-T116
-	O
autophagy	B-T043
pathway	B-T044
could	O
be	O
a	O
primary	O
resistance	B-T169
factor	B-T169
of	O
icaritin	B-T109
.	O

Classification	B-T185
of	O
Edible Oils	B-T168
Based	O
on	O
ATR-FTIR	B-T062
Spectral Information	B-T078
During	O
a	O
Long Heating Treatment	B-T067
Identification	B-T080
of	O
oil	B-T168
type	B-T080
and	O
its	O
QC	B-T169
are	O
important	O
concerns	O
in	O
food	B-T168
food control laboratories	B-T073
.	O
Classifying	B-T185
edible oils	B-T168
that	O
have	O
not	O
been	O
used	O
(i.e.,	O
unheated	B-T169
)	O
with	O
the	O
aid	O
of	O
vibrational spectroscopy	B-T059
has	O
previously	O
been	O
reported.	O
However,	O
the	O
classification	B-T185
of	O
used	O
(i.e.,	O
heat-treated	B-T169
)	O
oils	B-T168
needs	O
special	O
attention.	O
The	O
effect	B-T080
of	O
long heating times	B-T079
on	O
the	O
classification	B-T185
of	O
four	O
kinds	O
of	O
edible oils	B-T168
(	O
canola	B-T109
,	O
corn	B-T109
,	O
frying	B-T168
,	O
and	O
sunflower	B-T109
)	O
based	O
on	O
attenuated total reflectance (ATR)-FTIR spectra	B-T062
was	O
surveyed	B-T062
.	O
The	O
sampling	B-T078
was	O
done	O
on	O
the	O
oils	B-T168
during	O
a	O
36	O
h	O
heating process	B-T067
(at	O
170°C).	O
The	O
ATR-FTIR spectra	B-T062
of	O
the	O
samples	B-T167
were	O
collected	B-T169
in	O
the	O
range	O
of	O
4000-550	O
cm-1.	O
Interval extended canonical variates analysis	B-T081
(	O
ECVA	B-T081
),	O
as	O
a	O
variable selection	B-T080
and	O
classification	B-T185
tool,	O
was	O
used	O
to	O
determine	O
the	O
best	O
intervals	B-T079
during	O
the	O
heating procedure	B-T067
for	O
classification	B-T185
.	O
Principal component analysis	B-T081
discriminate analysis	B-T081
,	O
partial least-squares discriminate analysis	B-T081
,	O
and	O
ECVA	B-T081
were	O
performed	O
on	O
the	O
selected	O
intervals	B-T079
and	O
on	O
the	O
total heating time	B-T079
.	O
The	O
effect	O
of	O
autoscaling	B-T033
and	O
mean-centering	B-T033
,	O
as	O
data preprocessing methods	B-T170
,	O
was	O
also	O
investigated	B-T169
.	O
The	O
ECVA method	B-T081
resulted	O
in	O
the	O
best	O
performances	O
for	O
classification	B-T185
,	O
with	O
a	O
94%	O
cross-validated nonerror rate	B-T081
(one	O
misclassification)	O
for	O
the	O
heating process	B-T067
times	B-T079
of	O
24-27	O
and	O
33-36	O
h.	O

Intravitreal	B-T169
chemotherapy	B-T061
in	O
the	O
management	B-T058
of	O
vitreous disease	B-T047
in	O
retinoblastoma	B-T191
To	O
evaluate	O
the	O
therapeutic outcome	B-T080
of	O
intravitreal	B-T169
melphalan	B-T116
injection	B-T122
in	O
the	O
management	B-T058
of	O
vitreous disease	B-T047
in	O
patients	B-T101
with	O
retinoblastoma	B-T191
.	O
We	O
particularly	O
aimed	O
to	O
assess	O
whether	O
higher	B-T080
melphalan	B-T116
dose	B-T081
with	O
lower	B-T080
number	B-T081
of	O
injections	B-T122
was	O
more	O
effective	B-T080
and	O
associated with	B-T080
fewer	B-T081
side effects	B-T046
.	O
This	O
retrospective	B-T062
,	O
interventional	B-T062
,	O
noncomparative	B-T062
,	O
and	O
nonrandomized study	B-T062
included	O
39	O
eyes	B-T023
of	O
37	O
patients	B-T101
.	O
Vitreous seeds	B-T033
were	O
classified	B-T185
as	O
dust	B-T191
,	O
sphere	B-T191
,	O
and	O
cloud types	B-T191
.	O
Intravitreal	B-T169
injections	B-T122
were	O
performed	B-T169
through	B-T169
pars plana	B-T023
free	O
of	O
any	O
visible	B-T080
tumor	B-T191
using	B-T169
30-G needle	B-T074
.	O
Response of the seeds	B-T040
(	O
disappearance	B-T033
,	O
conversion	B-T169
into	O
inactive debris	B-T033
,	O
or	O
progression	B-T191
)	O
and	O
enucleation	B-T061
rate	B-T081
were	O
determined	O
as	O
outcome	B-T080
measures	B-T081
.	O
All	O
patients	B-T101
previously	O
received	B-T080
systemic	B-T061
or	O
intra-arterial chemotherapy	B-T061
.	O
Vitreous seeding	B-T033
was	O
primary	B-T080
in	O
54%	O
of	O
eyes	B-T023
and	O
secondary	B-T080
in	O
46%	O
of	O
eyes	B-T023
.	O
Vitreous seeds	B-T033
were	O
classified	B-T185
as	O
dust	B-T191
in	O
9	O
(23.1%)	O
eyes	B-T023
,	O
sphere	B-T191
in	O
24	O
(61.5%)	O
eyes	B-T023
,	O
and	O
cloud	B-T191
in	O
6	O
(15.4%)	O
eyes	B-T023
.	O
Melphalan	B-T116
dose	B-T081
varied	O
between	O
20	O
and	O
40	O
µg	O
and	O
20	O
(51.3%)	O
eyes	B-T023
received	B-T080
>30	O
µg.	O
The	O
total number	B-T081
of	O
injections	B-T122
was	O
70	O
(range	O
1-5,	O
mean	B-T081
1.8	O
per	O
eye	B-T023
).	O
Various	B-T081
types	B-T080
of	O
regression	B-T046
were	O
obtained	B-T169
in	O
27	O
(69.2%)	O
eyes	B-T023
.	O
Sphere-type seeds	B-T191
were	O
the	O
most	B-T081
responsive	B-T169
to	O
melphalan	B-T116
.	O
Nonresponse	B-T033
and	O
disease progression	B-T046
were	O
noted	B-T080
in	O
12	O
(30.8%)	O
eyes	B-T023
.	O
After	O
a	O
mean	B-T081
follow-up	B-T058
of	O
11.8	O
months	B-T079
,	O
17	O
(44%)	O
eyes	B-T023
were	O
enucleated	B-T037
.	O
Vitreous hemorrhage	B-T046
(18%)	O
and	O
retinal pigment epithelial	B-T023
alterations	B-T078
(8%)	O
were	O
the	O
most	B-T081
common	B-T081
side effects	B-T046
.	O
Intravitreal	B-T169
melphalan	B-T116
at	O
30-40	O
µg	O
in	O
1	O
or	O
2	O
injections	B-T122
proved	O
effective	B-T080
in	O
69.2%	O
of	O
eyes	B-T023
with	O
vitreous disease	B-T047
.	O

Fine structure	B-T082
of	O
the	O
anterior median eyes	B-T023
of	O
the	O
funnel	B-T082
-	O
web spider	B-T204
Agelena labyrinthica	B-T204
(	O
Araneae	B-T204
:	O
Agelenidae	B-T204
)	O
Only	O
few	O
electron microscopic studies	B-T059
exist	O
on	O
the	O
structure	B-T082
of	O
the	O
main	O
eyes	B-T023
(	O
anterior median eyes	B-T023
,	O
AME	B-T023
)	O
of	O
web spiders	B-T204
.	O
The	O
present	O
paper	O
provides	O
details	O
on	O
the	O
anatomy	B-T017
of	O
the	O
AME	B-T023
in	O
the	O
funnel-web	O
spider	B-T204
Agelena labyrinthica	B-T204
.	O
The	O
retina	B-T023
consists	O
of	O
two	O
separate	O
regions	B-T082
with	O
differently	O
arranged	O
photoreceptor cells	B-T025
.	O
Its	O
central part	B-T082
has	O
sensory cells	B-T026
with	O
rhabdomeres	B-T026
on	O
2,	O
3,	O
or	O
4	O
sides,	O
whereas	O
those	O
of	O
the	O
ventral	B-T082
retina	B-T023
have	O
only	O
two	O
rhabdomeres	B-T026
on	O
opposite	O
sides.	O
In	O
addition,	O
the	O
rhabdomeres	B-T026
of	O
the	O
ventral	B-T082
retina	B-T023
are	O
arranged	O
in	O
a	O
specific	O
way:	O
Whereas	O
in	O
the	O
most	O
ventral	B-T082
part	O
they	O
form	O
long tangential rows	B-T082
,	O
those	O
towards	O
the	O
center	B-T082
are	O
detached	O
and	O
are	O
arranged	O
radially.	O
All	O
sensory cells	B-T026
are	O
wrapped	O
by	O
unpigmented	B-T033
pigment cell	B-T025
processes	B-T043
.	O
In	O
agelenid	B-T204
spiders	B-T204
the	O
axons	B-T026
of	O
the	O
sensory cells	B-T026
exit	O
from	O
the	O
middle	O
of	O
the	O
cell body	B-T026
;	O
their	O
fine structure	B-T082
and	O
course	O
through	O
the	O
eye cup	B-T074
is	O
described	O
in	O
detail.	O
In	O
the	O
central part	B-T082
of	O
the	O
retina	B-T023
efferent	O
nerve fibres	B-T026
were	O
found	O
forming	O
synapses	B-T030
along	O
the	O
distal region	B-T082
of	O
the	O
receptor cells	B-T026
.	O
A	O
muscle	B-T024
is	O
attached	O
laterally	O
to	O
each	O
eye cup	B-T074
that	O
allows	O
mainly	O
rotational	B-T082
movements	B-T039
of	O
the	O
eyes	B-T023
.	O
The	O
optical performance	B-T070
(	O
image resolution	B-T077
)	O
of	O
these	O
main	O
eyes	B-T023
with	O
relatively	O
few	O
visual cells	B-T025
is	O
discussed.	O

Knocking down	B-T063
TCF8	B-T028
inhibits	O
high glucose	B-T033
-	O
and	O
angiotensin II	B-T116
-	O
induced	B-T169
epithelial to mesenchymal transition	B-T043
in	O
podocytes	B-T025
Epithelial to mesenchymal transition	B-T043
(	O
EMT	B-T043
)	O
is	O
a	O
physiological phenomenon	B-T039
in	O
mammalian	B-T015
embryogenesis	B-T042
by	O
which	O
epithelial cells	B-T025
become	O
mesenchymal stem cells	B-T025
.	O
Studies	O
have	O
indicated	O
that	O
an	O
inappropriate	O
EMT	B-T043
plays	O
a	O
key	O
role	O
in	O
a	O
variety	O
of	O
pathogenic	B-T033
processes	B-T067
such	O
as	O
embryonic development	B-T042
and	O
tumor metastasis	B-T191
.	O
Moreover,	O
recent	O
studies	O
have	O
indicated	O
EMT	B-T043
also	O
plays	O
an	O
important	O
role	O
in	O
renal fibrosis	B-T047
.	O
In	O
the	O
current	O
study,	O
glucose	B-T109
and	O
angiotensin II	B-T116
promoted	O
EMT	B-T043
in	O
podocytes	B-T025
as	O
well	O
as	O
changes	O
in	O
the	O
cellular morphology	B-T201
of	O
podocytes	B-T025
.	O
A	O
high	B-T080
concentration	B-T081
of	O
glucose	B-T109
and	O
angiotensin II	B-T116
also	O
promoted	O
podocyte	B-T025
movement	B-T040
and	O
migration	B-T043
.	O
Moreover,	O
a	O
high	B-T080
concentration	B-T081
of	O
glucose	B-T109
and	O
angiotensin II	B-T116
promoted	O
TCF8	B-T028
expression	B-T045
.	O
Inhibiting	B-T052
TCF8	B-T028
expression	B-T045
with	O
siRNA	B-T114
reversed	O
EMT	B-T043
in	O
podocytes	B-T025
in	O
the	O
presence	O
of	O
a	O
high	B-T080
concentration	B-T081
of	O
glucose	B-T109
and	O
angiotensin	B-T116
.	O
Inhibiting	B-T052
TCF8	B-T028
expression	B-T045
also	O
reversed	O
changes	O
in	O
cellular morphology	B-T201
and	O
podocyte	B-T025
movement	B-T040
and	O
migration	B-T043
.	O
Therefore,	O
glucose	B-T109
and	O
angiotensin II	B-T116
may	O
promote	O
EMT	B-T043
in	O
podocytes	B-T025
via	O
TCF8	B-T028
.	O

Temporal	O
upregulation	B-T044
of	O
host surface receptors	B-T116
provides	O
a	O
window	O
of	O
opportunity	O
for	O
bacterial adhesion	B-T040
and	O
disease	B-T047
Host surface receptors	B-T116
provide	O
bacteria	B-T007
with	O
a	O
foothold	O
from	O
which	O
to	O
attach	B-T067
,	O
colonize	O
and,	O
in	O
some	O
cases,	O
invade	O
tissue	B-T024
and	O
elicit	O
human	B-T016
disease	B-T047
.	O
In	O
this	O
review,	O
we	O
discuss	O
several	O
key	O
host receptors	B-T116
and	O
cognate adhesins	B-T026
that	O
function	O
in	O
bacterial	B-T007
pathogenesis	B-T046
.	O
In	O
particular,	O
we	O
examine	O
the	O
elevated	B-T080
expression	B-T045
of	O
host surface receptors	B-T116
such	O
as	O
CEACAM-1	B-T116
,	O
CEACAM-6	B-T116
,	O
ICAM-1	B-T116
and	O
PAFR	B-T116
in	O
response to specific stimuli	B-T039
.	O
We	O
explore	O
how	O
upregulated receptors	B-T044
,	O
in	O
turn,	O
expose	O
the	O
host	B-T001
to	O
a	O
range	O
of	O
bacterial infections	B-T047
in	O
the	O
respiratory tract	B-T022
.	O
It	O
is	O
apparent	O
that	O
exploitation	O
of	O
receptor	B-T116
induction	B-T169
for	O
bacterial adherence	B-T040
is	O
not	O
unique	O
to	O
one	O
body system	B-T022
,	O
but	O
is	O
also	O
observed	O
in	O
the	O
central nervous	B-T022
,	O
gastrointestinal	B-T022
and	O
urogenital systems	B-T022
.	O
Prokaryotic	B-T001
pathogens	B-T046
which	O
utilize	O
this	O
mechanism	O
for	O
their	O
infectivity	B-T046
include	O
Streptococcus pneumoniae	B-T007
,	O
Haemophilus influenzae	B-T007
,	O
Neisseria meningitidis	B-T007
and	O
Escherichia coli	B-T007
.	O
A	O
number	O
of	O
approaches	O
have	O
been	O
used,	O
in	O
both	O
in vitro	B-T062
and	O
in vivo experimental models	B-T062
,	O
to	O
inhibit	O
bacterial attachment	B-T040
to	O
temporally	O
expressed	B-T045
host receptors	B-T116
.	O
Some	O
of	O
these	O
novel	O
strategies	O
may	O
advance	O
future	O
targeted	B-T169
interventions	B-T058
for	O
the	O
prevention	B-T061
and	O
treatment	B-T061
of	O
bacterial disease	B-T047
.	O

Optogenetic	B-T063
Demonstration	B-T052
of	O
Functional	B-T169
Innervation	B-T042
of	O
Mouse	B-T015
Colon	B-T023
by	O
Neurons	B-T025
Derived	O
From	O
Transplanted	B-T169
Neural Cells	B-T025
Cell therapy	B-T061
offers	O
the	O
potential	O
to	O
treat	B-T169
gastrointestinal motility disorders	B-T047
caused	O
by	O
diseased	B-T025
or	O
absent	B-T169
enteric	B-T082
neurons	B-T025
.	O
We	O
examined	O
whether	O
neurons	B-T025
generated	O
from	O
transplanted	B-T169
enteric	B-T082
neural cells	B-T025
provide	O
a	O
functional	B-T169
innervation	B-T042
of	O
bowel	B-T023
smooth muscle	B-T024
in	O
mice	B-T015
.	O
Enteric	B-T082
neural cells	B-T025
expressing	O
the	O
light-sensitive ion channel	B-T116
,	O
channelrhodopsin	B-T116
,	O
were	O
isolated	B-T169
from	O
the	O
fetal	B-T169
or	O
postnatal	B-T079
mouse	B-T015
bowel	B-T023
and	O
transplanted	B-T169
into	O
the	O
distal colon	B-T024
of	O
3-	O
to	O
4-	O
week	B-T079
-old	O
wild-type	B-T028
recipient mice	B-T015
.	O
Intracellular	B-T082
electrophysiological recordings	B-T059
of	O
responses	B-T169
to	O
light stimulation	B-UnknownType
of	O
the	O
transplanted	B-T169
cells	B-T025
were	O
made	O
from	O
colonic	B-T023
smooth muscle cells	B-T025
in	O
recipient mice	B-T015
.	O
Electrical stimulation	B-T067
of	O
endogenous	B-T169
enteric	B-T082
neurons	B-T025
was	O
used	O
as	O
a	O
control	B-T096
.	O
The	O
axons	B-T026
of	O
graft	B-T024
-derived	O
neurons	B-T025
formed	O
a	O
plexus	B-T023
in	O
the	O
circular muscle layer	B-T023
.	O
Selective stimulation	B-T067
of	O
graft	B-T024
-derived	O
cells	B-T025
by	O
light	B-T070
resulted	O
in	O
excitatory	B-T042
and	O
inhibitory junction potentials	B-T042
,	O
the	O
electrical	B-T169
events	B-T051
underlying	O
contraction	B-T039
and	O
relaxation	B-T042
,	O
respectively,	O
in	O
colonic	B-T023
muscle cells	B-T025
.	O
Graft	B-T024
-derived	O
excitatory	B-T025
and	O
inhibitory motor neurons	B-T025
released	O
the	O
same	O
neurotransmitters	B-T123
as	O
endogenous	B-T169
motor neurons	B-T025
-	O
acetylcholine	B-T109
and	O
a	O
combination	O
of	O
adenosine triphosphate	B-T114
and	O
nitric oxide	B-T121
,	O
respectively.	O
Graft	B-T024
-derived	O
neurons	B-T025
also	O
included	O
interneurons	B-T025
that	O
provided	O
synaptic	O
inputs	O
to	O
motor	O
neurons	B-T025
,	O
but	O
the	O
pharmacologic properties	B-T080
of	O
interneurons	B-T025
varied	O
with	O
the	O
age	B-T032
of	O
the	O
donors	B-T098
from	O
which	O
enteric	B-T082
neural cells	B-T025
were	O
obtained.	O
Enteric	B-T082
neural cells	B-T025
transplanted	B-T169
into	O
the	O
bowel	B-T023
give	O
rise	O
to	O
multiple	B-T081
functional	B-T169
types	B-T080
of	O
neurons	B-T025
that	O
integrate	O
and	O
provide	O
a	O
functional	B-T169
innervation	B-T042
of	O
the	O
smooth muscle	B-T024
of	O
the	O
bowel wall	B-T023
.	O
Circuits	B-UnknownType
composed	O
of	O
both	O
motor neurons	B-T025
and	O
interneurons	B-T025
were	O
established,	O
but	O
the	O
age	B-T032
at	O
which	O
cells	B-T025
are	O
isolated	O
influences	O
the	O
neurotransmitter	B-T123
phenotype	B-T032
of	O
interneurons	B-T025
that	O
are	O
generated.	O

Assessment	B-T058
of	O
Vascular Stent	B-T074
Heating	B-T070
with	O
Repetitive Transcranial Magnetic Stimulation	B-T061
A	O
high	O
proportion	O
of	O
patients	B-T101
with	O
stroke	B-T047
do	O
not	O
qualify	O
for	O
repetitive transcranial magnetic stimulation	B-T061
(	O
rTMS	B-T061
)	O
clinical studies	B-T062
due	O
to	O
the	O
presence	O
of	O
metallic stents	B-T074
.	O
The	O
ultimate	O
concern	O
is	O
that	O
any	O
metal	B-T197
could	O
become	O
heated	B-T070
due	O
to	O
eddy currents	B-T070
.	O
However,	O
to	O
date,	O
no	O
clinical safety data	B-T170
are	O
available	O
regarding	O
the	O
risk	B-T078
of	O
metallic stents	B-T074
heating	B-T070
with	O
rTMS	B-T061
.	O
We	O
tested	B-T169
the	O
safety	B-T062
of	O
common	O
rTMS	B-T061
protocols	B-T170
(1	O
Hz	O
and	O
10	O
Hz)	O
with	O
stents	B-T074
used	O
commonly	O
in	O
stroke	B-T047
,	O
nitinol	B-T122
and	O
elgiloy	B-T122
.	O
In	O
our	O
method,	O
stents	B-T074
were	O
tested	B-T170
in	O
gelled	B-T167
saline	B-T167
at	O
2	O
different	O
locations	B-T082
:	O
at the center	B-T082
and	O
at	O
the	O
lobe	B-T023
of	O
the	O
coil	B-T074
.	O
In	O
addition,	O
at	O
each	O
location	B-T082
,	O
stent	B-T074
heating	B-T070
was	O
evaluated	B-T058
in	O
3	O
different	O
orientations	B-T082
:	O
parallel	B-T082
to	O
the	O
long axis	B-T082
of	O
coil	B-T074
,	O
parallel	B-T082
to	O
the	O
short axis	B-T082
of	O
the	O
coil	B-T074
,	O
and	O
perpendicular	B-T082
to	O
the	O
plane	O
of	O
the	O
coil	B-T074
.	O
We	O
found	O
that	O
stents	B-T074
did	O
not	O
heat	B-T070
to	O
more	O
than	O
1°C	O
with	O
either	O
1	O
Hz	O
rTMS	B-T061
or	O
10	O
Hz	O
rTMS	B-T061
in	O
any	O
configuration	O
or	O
orientation	B-T082
.	O
Heating	B-T070
in	O
general	O
was	O
greater	B-T081
at	O
the	O
lobe	B-T023
when	O
the	O
stent	B-T074
was	O
oriented	B-T082
perpendicularly	B-T082
.	O
Our	O
study	O
represents	O
a	O
new	O
method	O
for	O
ex vivo	B-T169
quantification	B-T081
of	O
stent	B-T074
heating	B-T070
.	O
We	O
have	O
found	O
that	O
heating	B-T070
of	O
stents	B-T074
was	O
well	O
below	O
the	O
Food and Drug Administration	B-T093
standards	B-T170
of	O
2°C.	O
Thus,	O
our	O
study	O
paves	O
the	O
way	O
for	O
in vivo	B-T082
testing	B-T169
of	O
rTMS	B-T061
(≤10	O
Hz)	O
in	O
the	O
presence	O
of	O
implanted	B-T074
magnetic resonance imaging	B-T060
-	O
compatible	B-T080
stents	B-T074
in	O
animal studies	B-T008
.	O
When	O
planning	O
human	B-T016
safety studies	B-T062
though,	O
geometry	B-T090
,	O
orientation	B-T082
,	O
and	O
location	B-T082
relative	O
to	O
the	O
coil	B-T074
would	O
be	O
important	O
to	O
consider	O
as	O
well.	O

Clinical Observation	B-T058
of	O
Treatment	B-T169
of	O
Chronic Subdural Hematoma	B-T046
With	O
Novel Double Needle Minimally Invasive Aspiration Technology	B-T074
The	O
aim	B-T078
of	O
the	O
present	O
study	B-T062
was	O
to	O
explore	O
the	O
clinical effects	B-T080
,	O
including	O
the	O
prevention	O
of	O
complications	B-T046
,	O
of	O
the	O
treatment	B-T169
of	O
chronic subdural hematoma	B-T046
with	O
double needle aspiration	B-T074
.	O
The	O
clinical data	B-T170
of	O
31	O
patients	B-T101
with	O
chronic subdural hematoma	B-T046
treated	B-T169
by	O
double YL-1 needle	B-T074
double	O
skull drilling	B-T061
and	O
31	O
controls	O
treated	B-T169
by	O
traditional	O
drilling	B-T061
and	O
drainage	B-T061
were	O
analyzed	O
retrospectively.	O
In	O
the	O
YL-1 needle	B-T074
group	B-T078
,	O
only	O
1	O
patient	B-T101
was	O
with	O
hematoma	B-T046
recurrence	B-T046
,	O
1	O
patient	B-T101
was	O
with	O
intracranial pneumocephalus	B-T047
,	O
and	O
the	O
remaining	O
patients	B-T101
who	O
were	O
followed	O
up	O
for	O
3	O
months	B-T079
achieved	O
a	O
clinical cure	B-T033
.	O
In	O
the	O
traditional drilling	B-T061
and	O
drainage	B-T061
group	B-T078
,	O
13	O
patients	B-T101
were	O
with	O
hematoma	B-T046
recurrence	B-T046
within	O
3	O
months	B-T079
after	O
the	O
operation	B-T061
and	O
7	O
patients	B-T101
were	O
with	O
postoperative	B-T079
intracranial pneumocephalus	B-T047
.	O
The	O
method	B-T170
of	O
double YL-1 needle	B-T074
is	O
better	O
than	O
the	O
traditional drilling	B-T061
and	O
drainage method	B-T061
for	O
the	O
treatment	B-T169
of	O
chronic subdural hematoma	B-T046
because	O
it	O
reduces	O
the	O
postoperative	B-T079
recurrence	B-T046
rate	O
and	O
complications	B-T046
.	O

The	O
impact	B-T080
of	O
adjunctive	B-T061
guanfacine	B-T109
extended release	B-T122
on	O
stimulant	B-T121
adherence	B-T169
in	O
children	B-T100
/	O
adolescents	B-T100
with	O
attention-deficit	B-T048
/	O
hyperactivity disorder	B-T048
To	O
assess	O
stimulant	B-T121
adherence	B-T169
among	O
children	B-T100
/	O
adolescents	B-T100
with	O
attention-deficit	B-T048
/	O
hyperactivity disorder	B-T048
(	O
ADHD	B-T048
)	O
augmenting stimulants	B-T120
stimulants	B-T121
with	O
guanfacine extended-release	B-T122
(	O
GXR	B-T122
).	O
Inclusion criteria	B-T078
:	O
6-17	O
years	B-T079
,	O
≥1	O
ADHD	B-T048
diagnosis	B-T033
,	O
≥1	O
long-acting	B-T121
and/or	O
short-acting stimulant	B-T121
with	O
GXR	B-T122
augmentation	B-T061
.	O
Modified medication possession ratio	B-T081
(	O
mMPR	B-T081
;	O
days	B-T079
medication	B-T058
available	B-T169
/	O
days	B-T079
in	O
period	B-T079
,	O
excluding	B-T169
medication	B-T058
holidays	B-T052
)	O
was	O
assessed;	O
mMPR	B-T081
<	O
0.80	O
nonadherent	B-T033
.	O
Regression	B-T170
models	B-T170
assessed	B-T058
change	B-T169
in	O
mMPR	B-T081
adjusting	B-T169
for	O
demographic	B-T102
and	O
clinical characteristics	B-T201
.	O
Among	O
patients	B-T101
nonadherent	B-T033
to	O
stimulants	B-T121
pre	B-T079
-	O
augmentation	B-T061
(n	O
=	O
165),	O
unadjusted	B-T169
mean	O
(	O
SD	B-T081
)	O
pre	B-T079
-	O
and	O
post	B-T079
-	O
stimulant	B-T121
mMPRs	B-T081
were	O
0.68	O
(0.11)	O
and	O
0.87	O
(0.16).	O
Adjusted	B-T169
mean	O
change	B-T169
in	O
mMPR	B-T081
was	O
0.20	O
for	O
long-acting	B-T121
versus	O
0.18	O
for	O
short-acting stimulants	B-T121
(p	O
=	O
0.34).	O
Among	O
patients	B-T101
nonadherent	B-T033
to	O
stimulants	B-T121
,	O
GXR	B-T122
augmentation	B-T061
was	O
associated with	B-T080
increased	B-T081
stimulant	B-T121
adherence	B-T169
.	O

Bxb1 phage	B-T005
recombinase	B-T116
assists	O
genome engineering	B-T063
in	O
Drosophila melanogaster	B-T204
Rapid	B-T080
and	O
reliable	B-T080
genome modifications	B-T063
provide	O
the	O
basis	O
for	O
detailed	O
in vivo	B-T082
functional analysis	B-T058
of	O
any	O
genomic entity	B-T169
(	O
gene	B-T028
,	O
regulatory DNA	B-T086
,	O
non-coding RNA	B-T114
,	O
etc).	O
With	O
the	O
advent	O
of	O
CRISPR	B-T114
/	O
Cas9 genome editing technology	B-T063
,	O
manipulation	B-T063
of	O
a	O
particular	O
genomic locus	B-T028
has	O
become	O
a	O
routine	O
undertaking	O
in	O
variety	O
of	O
model organisms	B-T001
,	O
including	O
the	O
fruit fly Drosophila melanogaster	B-T204
.	O
To	O
further	O
diversify	O
the	O
available	O
tools	O
for	O
genome engineering	B-T063
,	O
we	O
successfully	O
harnessed	O
the	O
phage	B-T005
recombinase Bxb1	B-T116
to	O
perform	O
recombinase-mediated	O
cassette	O
exchange	O
(RMCE)	O
in	O
D. melanogaster	B-T204
.	O
We	O
demonstrate	O
that	O
Bxb1	B-T005
possesses	O
highly	O
efficient	O
recombinase activity	B-T045
and	O
could	O
be	O
used	O
alone	O
or	O
in	O
conjunction	O
with	O
other	O
currently	O
available	O
recombinases	B-T116
for	O
creating	O
platforms	O
for	O
cassette	O
exchange	O
of	O
targeted loci	B-T028
.	O

Tailor-made drug carrier	B-T122
:	O
Comparison	B-T052
of	O
formation-dependent	O
physicochemical properties	B-T080
within	O
self-assembled	B-T044
aggregates	B-T080
for	O
an	O
optimal	B-T080
drug carrier	B-T122
Self-assembled	B-T044
surfactant	B-T122
aggregates	B-T080
,	O
such	O
as	O
micelles	B-T109
and	O
vesicles	B-T104
,	O
have	O
been	O
investigated	O
for	O
their	O
application	B-T169
as	O
drug carriers	B-T122
in	O
the	O
treatment	B-T061
of	O
various	O
diseases	B-T047
.	O
However,	O
the	O
characteristics	B-T080
that	O
decide	O
which	O
aggregate	B-T080
is	O
the	O
best	B-T080
drug carrier	B-T122
for	O
each	O
disease	B-T047
have	O
not	O
yet	O
been	O
clarified.	O
In	O
order	O
to	O
design	B-T052
an	O
optimal	B-T080
drug carrier	B-T122
for	O
each	O
disease	B-T047
,	O
various	O
kinds	O
of	O
self-assembled	B-T044
aggregates	B-T080
,	O
such	O
as	O
spherical micelles	B-T109
,	O
lens-like vesicles	B-T104
,	O
and	O
tube-like vesicles	B-T104
,	O
were	O
evaluated	O
by	O
"	O
multiple techniques	B-T169
"	O
including	O
dynamic light scattering	B-T059
,	O
differential scanning calorimetry	B-T059
,	O
nuclear magnetic resonance spectroscopy	B-T060
,	O
and	O
fluorescence measurement	B-T059
using	O
the	O
Laurdan	B-T109
probe	B-T074
.	O
These	O
studies	B-T062
led	O
to	O
the	O
compilation	O
of	O
a	O
database	B-T170
on	O
the	O
formation-dependent	O
properties	O
of	O
self-assembled	B-T044
aggregates	B-T080
.	O
As	O
the	O
relationship	B-T080
between	O
physicochemical properties	B-T080
of	O
self-assembled	B-T044
aggregates	B-T080
and	O
their	O
functions	B-T169
as	O
drug carriers	B-T122
have	O
been	O
extensively	O
reported,	O
this	O
database	B-T170
can	O
be	O
utilized	O
for	O
designing	O
an	O
optimal	B-T080
drug carrier	B-T122
,	O
i.e.,	O
a	O
tailor-made drug carrier	B-T122
.	O

Uridine	B-T114
stimulate	O
laxative	B-T121
effect	B-T080
in	O
the	O
loperamide	B-T109
-	O
induced	B-T169
constipation	B-T184
of	O
SD rats	B-T015
through	O
regulation	B-T044
of	O
the	O
mAChRs	B-T116
signaling pathway	B-T044
and	O
mucin	B-T116
secretion	B-T038
Uridine	B-T114
(	O
Urd	B-T114
),	O
which	O
has	O
been	O
reported	B-T058
as	O
a	O
major	B-T080
component	O
of	O
RNA	B-T114
,	O
plays	O
an	O
important	B-T080
role	B-T077
in	O
various	O
biological process	B-T038
including	O
neuroprotection	B-T043
,	O
biochemical modulation	B-UnknownType
and	O
glycolysis	B-T044
,	O
although	O
its	O
role	B-T077
in	O
constipation	B-T184
has	O
yet	O
to	O
be	O
established	B-T080
.	O
Therefore,	O
in	O
this	O
study	B-T062
,	O
we	O
investigated	B-T169
the	O
laxative	B-T121
effects	B-T080
of	O
Urd	B-T114
on	O
chronic	B-T079
constipation	B-T184
.	O
The	O
constipation	B-T184
phenotypes	B-T032
and	O
their	O
related	O
mechanisms	B-T169
were	O
investigated	B-T169
in	O
the	O
transverse colons	B-T023
of	O
SD rats	B-T015
with	O
loperamide	B-T109
(	O
Lop	B-T109
)-	O
induced	B-T169
constipation	B-T184
after	O
treatment	B-T061
with	O
100	O
mg/kg	O
of	O
Urd	B-T114
.	O
The	O
number	B-T081
,	O
weight	B-T081
and	O
water	B-T121
contents	B-T077
of	O
stools	B-T031
were	O
significantly	B-T078
higher	B-T080
in	O
the	O
Lop	B-T109
+	O
Urd	B-T114
treated	B-T033
group	B-T078
than	O
the	O
Lop	B-T109
+	O
Vehicle	B-T122
treated	B-T033
group	B-T078
,	O
while	O
food intake	B-T040
and	O
water consumption	B-T040
of	O
the	O
same	O
group	B-T078
were	O
maintained	O
at	O
a	O
constant	B-T080
level	B-T080
.	O
The	O
thickness	B-T080
of	O
the	O
mucosa layer	B-T024
,	O
muscle	B-T024
and	O
flat luminal surface	B-T029
,	O
as	O
well	O
as	O
the	O
number	B-T081
of	O
goblet cells	B-T025
,	O
paneth cells	B-T025
and	O
lipid droplets	B-T026
were	O
enhanced	B-T052
in	O
the	O
Lop	B-T109
+	O
Urd	B-T114
treated	B-T033
group	B-T078
.	O
Furthermore,	O
the	O
expression	B-T045
of	O
the	O
muscarinic acetylcholine receptors M2	B-T116
and	O
M3	B-T116
(	O
mAChR M2	B-T116
and	O
M3	B-T116
)	O
at	O
the	O
transcriptional	B-T045
and	O
translational	B-T045
level	B-T080
was	O
recovered	B-T080
in	O
the	O
Lop	B-T109
+	O
Urd	B-T114
treated	B-T033
group	B-T078
,	O
while	O
some	O
markers	B-T201
such	O
as	O
Gα	B-T116
and	O
inositol triphosphate	B-UnknownType
(	O
IP3	B-UnknownType
)	O
in	O
their	O
downstream	B-T082
signaling pathway	B-T044
were	O
completely	O
recovered	B-T080
by	O
Urd	B-T114
treatment	B-T061
.	O
Moreover,	O
the	O
ability	O
for	O
mucin	B-T116
secretion	B-T038
and	O
the	O
expression	B-T045
of	O
membrane water channel	B-T116
(	O
aquaporine 8	B-T116
,	O
AQP8	B-T116
)	O
were	O
increased	B-T081
significantly	B-T078
in	O
the	O
Lop	B-T109
+	O
Urd	B-T114
treated	B-T033
group	B-T078
compared	B-T052
with	O
Lop	B-T109
+	O
Vehicle	B-T122
treated	B-T033
group	B-T078
.	O
Finally,	O
the	O
activity	B-T052
of	O
Urd	B-T114
was	O
confirmed	O
in	O
primary smooth muscle	B-T024
of	O
rat	B-T015
intestine cells	B-T025
(	O
pRISMC	B-T025
)	O
based	O
on	O
Gα	B-T116
expression	B-T045
and	O
IP3	B-UnknownType
concentration	B-T081
.	O
The	O
results	B-T033
of	O
the	O
present	O
study	B-T062
provide	O
the	O
first	O
strong	B-T080
evidence	B-T078
that	O
Urd	B-T114
can	O
be	O
considered	O
an	O
important	B-T080
candidate	O
for	O
improving	B-T080
chronic	B-T079
constipation	B-T184
induced	B-T169
by	O
Lop	B-T109
treatment	B-T061
in	O
animal models	B-T008
.	O

Characterization	B-T052
of	O
Phytochrome Interacting Factors	B-T123
from	O
the	O
Moss	B-T002
Physcomitrella patens	B-T002
Illustrates	O
Conservation	B-T080
of	O
Phytochrome Signaling Modules	B-T123
in	O
Land Plants	B-T002
Across	O
the	O
plant kingdom	B-T002
,	O
phytochrome	B-T116
(	O
PHY	B-T116
)	O
photoreceptors	B-T025
play	O
an	O
important	O
role	O
during	O
adaptive	B-T169
and	O
developmental	O
responses to light	B-T040
.	O
In	O
Arabidopsis thaliana	B-T002
,	O
light-activated	O
PHYs	B-T116
accumulate	O
in	O
the	O
nucleus	B-T026
,	O
where	O
they	O
regulate	O
downstream signaling components	B-T123
,	O
such	O
as	O
phytochrome interacting factors	B-T123
(	O
PIFs	B-T123
).	O
PIFs	B-T123
are	O
transcription factors	B-T116
that	O
act	O
as	O
repressors	B-T116
of	O
photomorphogenesis	B-T039
;	O
their	O
inhibition	B-T040
by	O
PHYs	B-T116
leads	O
to	O
substantial	O
changes	O
in	O
gene expression	B-T045
.	O
The	O
nuclear function	B-T043
of	O
PHYs	B-T116
,	O
however,	O
has	O
so	O
far	O
been	O
investigated	O
in	O
only	O
a	O
few	O
non-seed plants	B-T002
.	O
Here,	O
we	O
identified	O
putative	O
target	O
genes	B-T028
of	O
PHY	B-T116
signaling	B-T038
in	O
the	O
moss	B-T002
Physcomitrella patens	B-T002
and	O
found	O
light-regulated genes	B-T028
that	O
are	O
putative	O
orthologs	B-T028
of	O
PIF-controlled genes	B-T028
in	O
Arabidopsis	B-T002
.	O
Phylogenetic analyses	B-T062
revealed	O
that	O
an	O
ancestral	O
PIF-like gene	B-T028
was	O
already	O
present	O
in	O
streptophyte algae	B-T204
,	O
i.e.,	O
before	O
the	O
water-to-land transition	B-T052
of	O
plants	B-T002
.	O
The	O
PIF homologs	B-T123
in	O
the	O
genome	B-T028
of	O
P. patens	B-T002
resemble	O
Arabidopsis	B-T002
PIFs	B-T123
in	O
their	O
protein domain structure	B-T116
,	O
molecular properties	B-T080
,	O
and	O
physiological effects	B-T039
,	O
albeit	O
with	O
notable	O
differences	O
in	O
the	O
motif-dependent	O
PHY	B-T116
interaction	B-T082
.	O
Our	O
results	O
suggest	O
that	O
P. patens	B-T002
PIFs	B-T123
are	O
involved	O
in	O
PHY	B-T116
signaling	B-T038
.	O
The	O
PHY-PIF signaling node	B-T044
that	O
relays	O
light signals	B-T067
to	O
target	O
genes	B-T028
has	O
been	O
largely	O
conserved	O
during	O
land plant	B-T002
evolution	B-T045
,	O
with	O
evidence	O
of	O
lineage-specific diversification	B-T077
.	O

Conditional reprogramming	B-T059
and	O
long-term	B-T079
expansion	B-T043
of	O
normal	B-T025
and	O
tumor cells	B-T025
from	O
human	B-T016
biospecimens	B-T077
Historically,	O
it	O
has	O
been	O
difficult	O
to	O
propagate	B-T052
cells	B-T025
in vitro	B-T080
that	O
are	O
derived	O
directly	O
from	O
human	B-T016
tumors	B-T191
or	O
healthy tissue	B-T024
.	O
However,	O
in vitro	B-T080
preclinical models	B-T170
are	O
essential	O
tools	O
for	O
both	O
the	O
study of basic cancer biology	B-T091
and	O
the	O
promotion	O
of	O
translational research	B-T062
,	O
including	O
drug discovery	B-T062
and	O
drug target identification	B-T074
.	O
This	O
protocol	B-T059
describes	O
conditional reprogramming	B-T043
(	O
CR	B-T043
),	O
which	O
involves	O
coculture	B-T059
of	O
irradiated	O
mouse	B-T015
fibroblast feeder cells	B-T025
with	O
normal	B-T025
and	O
tumor	B-T191
human	B-T016
epithelial cells	B-T025
in	O
the	O
presence	O
of	O
a	O
Rho kinase	B-T116
inhibitor	B-T121
(	O
Y-27632	B-T109
).	O
CR	B-T059
cells	B-T025
can	O
be	O
used	O
for	O
various	O
applications,	O
including	O
regenerative medicine	B-T091
,	O
drug sensitivity testing	B-T059
,	O
gene expression profiling	B-T059
and	O
xenograft studies	B-T061
.	O
The	O
method	B-T059
requires	O
a	O
pathologist	B-T097
to	O
differentiate	O
healthy tissue	B-T024
from	O
tumor tissue	B-T024
,	O
and	O
basic tissue culture	B-T059
skills.	O
The	O
protocol	B-T059
can	O
be	O
used	O
with	O
cells	B-T025
derived	O
from	O
both	O
fresh	B-T024
and	O
cryopreserved tissue samples	B-T024
.	O
As	O
approximately	O
1	O
million	O
cells	B-T025
can	O
be	O
generated	B-T052
in	O
7	O
d,	O
the	O
technique	B-T059
is	O
directly	O
applicable	O
to	O
diagnostic	B-T130
and	O
predictive	B-T080
medicine	B-T121
.	O
Moreover,	O
the	O
epithelial cells	B-T025
can	O
be	O
propagated	B-T052
indefinitely	O
in vitro	B-T080
,	O
yet	O
retain	O
the	O
capacity	B-T081
to	O
become	O
fully	O
differentiated	B-T043
when	O
placed	O
into	O
conditions	B-T082
that	O
mimic	O
their	O
natural environment	B-T082
.	O

Types	O
of	O
internal facilitation	B-T073
activities	B-T052
in	O
hospitals	B-T073
implementing evidence-based interventions	B-T058
Implementation	B-T052
models	B-T170
,	O
frameworks	B-T077
,	O
and	O
theories	B-T078
recognize	O
the	O
importance	O
of	O
activities	B-T052
that	O
facilitate	O
implementation	B-T052
success	B-T054
.	O
However,	O
little	O
is	O
known	O
about	O
internal facilitation	B-T073
activities	B-T052
that	O
hospital personnel	B-T097
engage	B-T169
in	O
during	O
implementation efforts	B-T052
.	O
The	O
aim	O
of	O
the	O
study	B-T062
was	O
to	O
examine	O
internal facilitation	B-T073
activities	B-T052
at	O
10	O
critical access hospitals	B-T073
in	O
rural Iowa	B-T083
during	O
their	O
implementation	B-T052
of	O
TeamSTEPPS	B-T093
,	O
a	O
patient safety	B-T058
intervention	B-T061
,	O
and	O
to	O
identify	O
characteristics	B-T080
that	O
distinguish	O
different	O
types	O
of	O
facilitation	B-T073
activities	B-T052
.	O
We	O
followed	O
10	O
critical access hospitals	B-T073
for	O
2	O
years	B-T079
after	O
the	O
onset of	B-T080
implementation	B-T052
,	O
conducting	O
quarterly	B-T079
interviews	B-T052
with	O
key informants	B-T098
.	O
On	O
the	O
basis	O
of	O
the	O
transcripts	B-T170
from	O
the	O
first	O
two	O
quarters	B-T081
,	O
a	O
coding template	B-T078
was	O
developed	O
using	O
inductive analyses	B-T062
.	O
The	O
template	B-T078
was	O
then	O
applied	O
deductively	B-T080
to	O
code	O
all	O
interview	B-T052
transcripts	B-T170
.	O
Using	O
comparative analysis	B-T062
,	O
we	O
examined	O
the	O
characteristics	B-T080
that	O
distinguish	O
between	O
the	O
facilitation	B-T073
types.	O
We	O
identified	O
four	O
types	O
of	O
facilitation	B-T073
activities	B-T052
-	O
Leadership	B-T054
,	O
Buy-in,	O
Customization	B-T052
,	O
and	O
Accountability	B-T078
.	O
Individuals	B-T098
and	O
teams	B-T096
engaged	B-T169
in	O
different	O
types	O
of	O
facilitation	B-T073
activities	B-T052
,	O
both	O
in	O
a	O
planned	O
and	O
an	O
ad hoc manner	B-T033
.	O
These	O
activities	B-T052
targeted	O
at	O
both	O
people	B-T098
and	O
practices	B-T041
and	O
exhibited	O
varying	O
temporal patterns	B-T079
(	O
start	B-T079
and	O
peak time	B-T079
).	O
There	O
are	O
four	O
types	O
of	O
facilitation	B-T073
activities	B-T052
that	O
hospitals	B-T073
engage	B-T169
in	O
while	O
implementing	B-T052
evidence-based practices	B-T091
,	O
offering	O
a	O
parsimonious	B-T080
way	O
to	O
characterize	O
facilitation	B-T073
activities	B-T052
.	O
New	O
theoretical	B-T078
and	O
empirical	B-T062
research opportunities	B-T062
are	O
discussed.	O
Understanding	O
the	O
types	O
of	O
facilitation	B-T073
activities	B-T052
and	O
their	O
distinguishing	O
characteristics	B-T080
can	O
assist	O
managers	B-T097
in	O
planning	B-T169
and	O
executing	B-T052
implementations	B-T052
of	O
evidence-based interventions	B-T091
.	O

Directing traffic on DNA	B-T045
-How	O
transcription factors	B-T116
relieve	B-T169
or	O
induce	B-T169
transcriptional interference	B-T045
Transcriptional interference	B-T045
(	O
TI	B-T045
)	O
is	O
increasingly	O
recognized	O
as	O
a	O
widespread	B-T082
mechanism	O
of	O
gene control	B-T045
,	O
particularly	O
given	O
the	O
pervasive nature	B-T081
of	O
transcription	B-T045
,	O
both	O
sense	B-T169
and	O
antisense	B-T114
,	O
across	O
all	O
kingdoms	B-T185
of	O
life.	O
Here,	O
we	O
discuss	O
how	O
transcription factor	B-T116
binding kinetics	B-T090
strongly	O
influence	B-T077
the	O
ability	B-T032
of	O
a	O
transcription factor	B-T116
to	O
relieve	B-T169
or	O
induce	B-T169
TI	B-T045
.	O

Acoustic startle response	B-T040
in	O
rats	B-T015
predicts	O
inter-individual	B-T098
variation	B-T080
in	O
fear	B-T041
extinction	B-T041
Although	O
a	O
large	O
portion	O
of	O
the	O
population	B-T098
is	O
exposed	O
to	O
a	O
traumatic	B-T169
event	B-T051
at	O
some	O
point,	O
only	O
a	O
small	O
percentage	B-T081
of	O
the	O
population	B-T098
develops	O
post-traumatic stress disorder	B-T048
(	O
PTSD	B-T048
),	O
suggesting	O
the	O
presence	O
of	O
predisposing factors	B-T079
.	O
Abnormal	B-T033
acoustic startle response	B-T040
(	O
ASR	B-T040
)	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
PTSD	B-T048
,	O
implicating	O
it	O
as	O
a	O
potential	B-T080
predictor	B-T078
of	O
the	O
development	B-T039
of	O
PTSD	B-T048
-like	O
behavior	B-T053
.	O
Since	O
poor	O
extinction	B-T041
and	O
retention	O
of	O
extinction learning	B-T041
are	O
characteristic	O
of	O
PTSD	B-T048
patients	B-T101
,	O
it	O
is	O
of	O
interest	O
to	O
determine	O
if	O
abnormal	B-T033
ASR	B-T040
is	O
predictive	O
of	O
development	B-T039
of	O
such	O
deficits	B-T080
.	O
To	O
determine	O
whether	O
baseline	B-T081
ASR	B-T040
has	O
utility	O
in	O
predicting	O
the	O
development	B-T039
of	O
PTSD	B-T048
-like	O
behavior	B-T053
,	O
the	O
relationship	O
between	O
baseline	B-T081
ASR	B-T040
and	O
freezing behavior	B-T053
following	O
Pavlovian fear conditioning	B-T062
was	O
examined	O
in	O
a	O
group	O
of	O
adult	B-T100
,	O
male	B-T032
Sprague-Dawley rats	B-T015
.	O
Baseline	B-T081
acoustic startle response	B-T040
(	O
ASR	B-T040
)	O
was	O
assessed	O
preceding	O
exposure	O
to	O
a	O
Pavlovian fear conditioning paradigm	B-T062
where	O
freezing behavior	B-T053
was	O
measured	O
during	O
fear conditioning	B-T062
,	O
extinction	B-T041
training	B-T065
,	O
and	O
extinction	B-T041
testing	B-T169
.	O
Although	O
there	O
was	O
no	O
relationship	O
between	O
baseline	B-T081
ASR	B-T040
and	O
fear	B-T041
memory	B-T041
following	O
conditioning	B-T062
,	O
rats	B-T015
with	O
low	O
baseline	B-T081
ASR	B-T040
had	O
significantly	O
lower	O
magnitude	O
of	O
retention	B-T041
of	O
the	O
extinction	B-T041
memory	B-T041
than	O
rats	B-T015
with	O
high	O
baseline	B-T081
ASR	B-T040
.	O
The	O
results	O
suggest	O
that	O
baseline	B-T081
ASR	B-T040
has	O
value	O
as	O
a	O
predictive	B-T080
index	B-T170
of	O
the	O
development	B-T039
of	O
a	O
PTSD	B-T048
-like	O
phenotype	B-T032
.	O

High	O
tacrolimus	B-T109
blood concentrations	B-T081
early	O
after	O
lung transplantation	B-T061
and	O
the	O
risk	B-T078
of	O
kidney injury	B-T037
Lung	B-T023
transplant recipients	B-T101
often	O
develop	O
acute kidney injury	B-T037
(	O
AKI	B-T037
)	O
evolving	O
into	O
chronic kidney disease	B-T047
(	O
CKD	B-T047
).	O
The	O
immunosuppressant	B-T121
tacrolimus	B-T109
might	O
be	O
associated with	B-T080
the	O
emergence	O
of	O
AKI	B-T037
.	O
We	O
analyzed	O
the	O
development	B-T169
and	O
recovery	B-T040
of	O
kidney injury	B-T037
after	O
lung transplantation	B-T061
and	O
related	O
AKI	B-T037
to	O
whole-blood	B-T031
tacrolimus	B-T109
trough concentrations	B-T081
and	O
other	O
factors	O
causing	O
kidney injury	B-T037
.	O
We	O
retrospectively studied	B-T062
kidney injury	B-T037
in	O
186	O
lung-transplantation	B-T061
patients	B-T101
at	O
the	O
UMC Utrecht	B-T093
between	O
2001	O
and	O
2011.	O
Kidney function	B-T042
and	O
whole-blood	B-T031
tacrolimus	B-T109
trough concentrations	B-T081
were	O
determined	O
from	O
day	B-T079
1	O
to	O
14	O
and	O
at	O
1,	O
3,	O
6,	O
and	O
12	O
months	B-T079
postoperative	B-T079
.	O
Systemic inflammatory response syndrome	B-T047
(	O
SIRS	B-T047
),	O
septic shock	B-T046
,	O
and	O
nephrotoxic	B-T080
medications	B-T170
were	O
evaluated	O
as	O
covariates	B-UnknownType
for	O
AKI	B-T037
.	O
We	O
analyzed	O
liver injury	B-T037
and	O
drug-drug interactions	B-T044
.	O
AKI	B-T037
was	O
present	B-T033
in	O
85	O
(46%)	O
patients	B-T101
.	O
Tacrolimus	B-T109
concentrations	B-T081
were	O
supra-therapeutic	B-T034
in	O
135	O
of	O
186	O
patients	B-T101
(73%).	O
AKI	B-T037
in	O
the	O
first	O
week	B-T079
after	O
transplantation	B-T061
was	O
related	O
to	O
supra-therapeutic	B-T034
tacrolimus	B-T109
concentrations	B-T081
(	O
OR	B-T081
1.55;	O
95%	O
CI	B-T081
1.06-2.27),	O
≥3	O
other	O
nephrotoxic drugs	B-T061
(	O
OR	B-T081
1.96;	O
95%	O
CI	B-T081
1.02-3.77),	O
infection	B-T046
(	O
OR	B-T081
2.48;	O
95%	O
CI	B-T081
1.31-4.70),	O
and	O
cystic fibrosis	B-T047
(	O
OR	B-T081
2.17;	O
95%	O
CI	B-T081
1.16-4.06).	O
Recovery rate	B-T081
of	O
AKI	B-T037
was	O
lower	O
than	O
expected	O
(19%),	O
and	O
the	O
cumulative	O
incidence	B-T169
of	O
severe	O
CKD	B-T047
at	O
1	O
year	B-T079
was	O
15%.	O
After	O
lung transplantation	B-T061
,	O
AKI	B-T037
is	O
common	O
and	O
often	O
evolves	O
into	O
severe	B-T080
CKD	B-T047
,	O
which	O
is	O
a	O
known	O
cause	O
of	O
morbidity	B-T081
and	O
mortality	B-T081
.	O
Supra-therapeutic	B-T034
whole-blood	B-T031
tacrolimus	B-T109
trough concentrations	B-T081
are	O
related	O
to	O
the	O
early	O
onset	O
of	O
AKI	B-T037
.	O
Conscientious	B-T033
targeting	B-T169
tacrolimus	B-T109
blood concentrations	B-T081
might	O
be	O
vital	B-T080
in	O
the	O
early phase	B-UnknownType
after	O
lung transplantation	B-T061
.	O
What	O
is	O
known	O
about	O
this	O
subject?	O
•	O
Lung	B-T023
transplant recipients	B-T101
often	O
develop	O
acute kidney injury	B-T037
evolving	O
into	O
chronic kidney disease	B-T047
increasing	O
both	O
morbidity	B-T081
and	O
mortality	B-T081
.	O
•	O
To	O
date,	O
the	O
pathophysiology	B-T169
of	O
kidney injury	B-T037
after	O
lung transplantation	B-T061
has	O
not	O
been	O
fully	O
elucidated.	O
•	O
The	O
immunosuppressant	B-T121
tacrolimus	B-T109
is	O
difficult	O
to	O
dose	B-T081
,	O
especially	O
in	O
the	O
unstable	B-T033
clinical setting	B-T082
,	O
and	O
is	O
nephrotoxic	B-T080
.	O
•	O
For	O
the	O
first	O
time,	O
supra-therapeutic	B-T034
whole-blood	B-T031
tacrolimus	B-T109
trough concentrations	B-T081
are	O
related	O
to	O
the	O
emergence	O
of	O
acute kidney injury	B-T037
in	O
the	O
first	O
days	B-T079
after	O
lung transplantation	B-T061
.	O
•	O
Supra-therapeutic	B-T034
whole-blood	B-T031
tacrolimus	B-T109
trough concentrations	B-T081
often	O
occur	O
early	O
after	O
lung transplantation	B-T061
.	O
•	O
AKI	B-T037
after	O
lung transplantation	B-T061
shows	O
low	B-T080
recovery	B-T040
rates	B-T081
.	O

Zebrafish	B-T013
akt2	B-T028
is	O
essential	B-T080
for	O
survival	B-T052
,	O
growth	B-T040
,	O
bone development	B-T042
,	O
and	O
glucose homeostasis	B-T039
As	O
one	O
of	O
three	O
akt	B-T116
isoforms	B-T116
,	O
akt2	B-T116
plays	O
a	O
key	O
role	B-T077
in	O
the	O
regulation	B-T038
of	O
widely	O
divergent	O
cellular processes	B-T043
in	O
mammals	B-T015
.	O
However,	O
its	O
role	B-T077
and	O
underlying	O
mechanisms	B-T169
in	O
zebrafish	B-T013
remain	O
largely	O
unknown	B-T080
.	O
To	O
elucidate	O
the	O
function	B-T169
of	O
akt2	B-T028
in	O
zebrafish	B-T013
,	O
we	O
generated	B-T080
zebrafish	B-T013
lacking	B-T080
akt2 gene	B-T028
via	O
CRISPR/Cas9	B-T044
technology	B-T090
.	O
Akt2	B-T028
-	O
null	B-T081
zebrafish	B-T013
exhibit	O
partial	O
lethality	B-T033
and	O
severe	B-T080
growth	B-T040
deficiency	B-T169
,	O
which	O
is	O
different	O
from	O
those	O
observed	O
in	O
akt2	B-T028
-	O
null	B-T081
mice	B-T015
.	O
Furthermore,	O
akt2	B-T028
-	O
null	B-T081
zebrafish	B-T013
display	B-T169
deficiency	B-T169
in	O
fin ray development	B-T040
,	O
but	O
their	O
cartilage	B-T024
is	O
not affected	B-T077
.	O
Similar	O
to	O
observations	B-T062
in	O
akt2	B-T028
-	O
null	B-T081
mice	B-T015
,	O
akt2	B-T028
-	O
null	B-T081
zebrafish	B-T013
display	B-T169
impaired	B-T169
glucose homeostasis	B-T039
.	O
However,	O
in	O
contrast	O
to	O
that	O
in	O
akt2	B-T028
-	O
null	B-T081
mice	B-T015
,	O
insulin level	B-T059
is	O
lower	B-T080
in	O
akt2	B-T028
-	O
null	B-T081
zebrafish	B-T013
,	O
implicating	O
the	O
symptoms	B-T184
of	O
type I diabetes	B-T047
exhibited	O
in	O
akt2	B-T028
-	O
null	B-T081
zebrafish	B-T013
.	O
In	O
addition,	O
transcriptome analysis	B-T059
reveals	B-T080
that	O
the	O
genes	B-T028
involved	O
in	O
metabolism	B-T040
and	O
osteogenesis	B-T042
are	O
disturbed	O
in	O
akt2	B-T028
-	O
null	B-T081
zebrafish	B-T013
.	O
Taken	O
together,	O
these	O
data	B-T078
not	O
only	O
support	O
an	O
important	O
role	B-T077
of	O
akt2	B-T028
in	O
zebrafish	B-T013
survival	B-T052
,	O
growth	B-T040
,	O
bone development	B-T042
and	O
glucose homeostasis	B-T039
,	O
but	O
also	O
suggest	O
that	O
akt2	B-T028
has	O
divergent	O
functions	B-T169
between	O
mice	B-T015
and	O
zebrafish	B-T013
,	O
even	O
though	O
they	O
are	O
evolutionarily	B-T045
conserved	B-T044
.	O

Physiological	B-T169
Properties	B-T080
and	O
Behavioral	B-T053
Correlates	B-T080
of	O
Hippocampal	B-T023
Granule Cells	B-T025
and	O
Mossy Cells	B-T025
The	O
hippocampal	B-T023
dentate gyrus	B-T023
is	O
often	O
viewed	O
as	O
a	O
segregator	B-T169
of	O
upstream information	B-T042
.	O
Physiological support	B-T039
for	O
such	O
function	B-T169
has	O
been	O
hampered	O
by	O
a	O
lack	B-T080
of	O
well-defined	B-T080
characteristics	B-T080
that	O
can	O
identify	O
granule cells	B-T025
and	O
mossy cells	B-T025
.	O
We	O
developed	O
an	O
electrophysiology	B-UnknownType
-based	O
classification	B-T185
of	O
dentate	B-T023
granule cells	B-T025
and	O
mossy cells	B-T025
in	O
mice	B-T015
that	O
we	O
validated	O
by	O
optogenetic tagging	B-T063
of	O
mossy cells	B-T025
.	O
Granule cells	B-T025
exhibited	O
sparse	O
firing	B-T043
,	O
had	O
a	O
single	B-T081
place field	B-T082
,	O
and	O
showed	O
only	O
modest	O
changes	B-T169
when	O
the	O
mouse	B-T015
was	O
tested	B-T169
in	O
different	O
mazes	B-T073
in	O
the	O
same	O
room	B-T082
.	O
In	O
contrast,	O
mossy cells	B-T025
were	O
more	O
active	B-T169
,	O
had	O
multiple	B-T081
place fields	B-T082
and	O
showed	O
stronger	O
remapping	O
of	O
place fields	B-T082
under	O
the	O
same	O
conditions	B-T080
.	O
Although	O
the	O
granule cell	B-T025
-	O
mossy cell	B-T025
synapse	B-T030
was	O
strong	O
and	O
facilitating,	O
mossy cells	B-T025
rarely	O
"inherited"	O
place fields	B-T082
from	O
single	B-T081
granule cells	B-T025
.	O
Our	O
findings	B-T169
suggest	O
that	O
the	O
granule cells	B-T025
and	O
mossy cells	B-T025
could	O
be	O
modulated	B-T082
separately	O
and	O
their	O
joint	O
action	B-T052
may	O
be	O
critical	O
for	O
pattern separation	B-T169
.	O

A	O
primer	O
on	O
intraosseous access	B-T169
:	O
History	B-T033
,	O
clinical considerations	B-T033
,	O
and	O
current devices	B-T074
Intraosseous (IO) access	B-T169
is	O
a	O
method	B-T170
recommended	O
by	O
the	O
American Heart Association	B-T093
and	O
the	O
European Resuscitation Council	B-T093
to	O
administer	B-T169
resuscitative drugs	B-T121
and	O
fluids	B-T167
when	O
intravenous (IV) access	B-T082
cannot	O
be	O
rapidly	O
or	O
easily	O
obtained.	O
Many	O
clinicians	B-T097
have	O
limited knowledge	B-T170
or	O
experience	B-T041
with	O
the	O
IO route	B-T169
.	O
The	O
purpose	O
of	O
this	O
review	B-T170
was	O
to	O
provide	O
the	O
reader	O
with	O
a	O
succinct review	B-T170
of	O
the	O
history	B-T033
,	O
clinical considerations	B-T033
,	O
and	O
devices	B-T074
associated with	B-T080
IO access	B-T169
.	O
Narrative	O
review.	O
University-based	O
academic	O
research	O
cell.	O
Not	O
applicable.	O
Not	O
applicable.	O
IO access	B-T169
IO access	B-T169
is	O
a	O
lifesaving bridge	B-T078
to	O
definitive vascular access	B-T074
that	O
may	O
be	O
considered	O
when	O
an	O
IV	B-T082
cannot	O
be	O
rapidly	O
attained	O
and	O
the	O
patient's outcome	B-T078
may	O
be	O
negatively affected	B-T033
without	O
prompt circulatory access	B-T082
.	O
The	O
IO route	B-T169
has	O
few	O
contraindications	B-T080
for	O
use	O
and	O
a	O
low	O
rate	O
of	O
serious complications	B-T046
.	O
Multiple	O
manual	B-T169
and	O
powered devices	B-T074
that	O
may	O
be	O
placed	O
in	O
several anatomic sites	B-T082
are	O
commercially	O
available.	O
All	O
clinicians	B-T097
who	O
provide	O
acute care	B-T058
or	O
respond	O
to	O
cardiovascular	B-T029
emergencies	B-T046
should	O
obtain	O
training	B-T065
and	O
maintain	O
proficiency	B-T080
in	O
placing	O
and	O
using	O
IO	B-T169
devices	B-T074
as	O
the	O
IO route	B-T169
is	O
recommended	O
by	O
the	O
major	O
resuscitation organizations	B-T093
as	O
the	O
preferred route of infusion	B-T169
when	O
rapid,	O
reliable	O
IV access	B-T082
is	O
unavailable.	O

C-5a-substituted validamine type	B-T109
glycosidase inhibitors	B-T116
A	O
series	O
of	O
N-alkyl derivatives	B-T121
of	O
the	O
D-galactosidase	B-T116
inhibitor	B-T121
1,4-di-epi-validamine	B-T121
featuring	O
lipophilic	B-T081
substituents at position C-5a	B-T104
was	O
prepared	O
and	O
screened	B-T059
for	O
their	O
glycosidase	B-T116
inhibitory properties	B-T039
.	O
Products	B-T071
turned	O
out	O
selective	O
for	O
β-galactosidases	B-T116
as	O
well	O
as	O
β-glucosidases	B-T116
.	O

Exposure to suicidal behaviors	B-T033
:	O
A	O
common	O
suicide	B-T033
risk factor	B-T033
or	O
a	O
personal	B-T032
negative life event	B-T033
?	O
Numerous	B-T081
suicide	B-T033
risk factors	B-T033
have	O
been	O
proposed	O
but	O
not	O
adequately	O
validated for epidemiology	B-T080
,	O
treatment	B-T061
and	O
prevention efforts	B-T080
.	O
Exposures to suicidal behaviors	B-T033
(	O
ESB	B-T033
),	O
from	O
family	B-T099
and	O
friend	B-T098
suicide attempts	B-T033
and	O
completions	B-T033
,	O
were	O
tested	O
for	O
validity	B-T080
as	O
a	O
suicidal	B-T033
risk factor	B-T033
and	O
also	O
for	O
measurement	B-T169
and	O
construct	O
adequacy	B-T080
.	O
An	O
anonymous	B-T080
online	B-T073
survey	B-T170
yielded	O
713	O
participants	B-T098
(	O
aged	B-T032
18-71),	O
who	O
reported	O
ESB	B-T033
,	O
completed	O
the	O
Suicidal Affect-Behavior-Cognition Scale	B-T170
(	O
SABCS	B-T170
),	O
and	O
comprised	O
a	O
broad	O
spectrum	O
on	O
those	O
variables	B-T080
.	O
Tests	B-T170
of	O
dimensionality	B-T082
and	O
internal consistency	B-T081
showed	O
the	O
four	O
ESB	B-T033
variables	B-T080
(	O
attempts	B-T033
/	O
completions	B-T033
through	O
family	B-T099
/	O
friends	B-T098
)	O
were	O
independent	B-T169
and	O
did	O
not	O
form	O
a	O
common	O
factor	O
or	O
an	O
identifiable	O
ESB	B-T033
latent	B-T080
trait	B-T032
.	O
ESB	B-T033
variables	B-T080
were,	O
however,	O
associated	O
with	O
demographic	B-T033
and	O
psychiatric histories	B-T033
.	O
A	O
battery	O
of	O
tests	B-T170
revealed	O
no	O
meaningful	O
associations	B-T080
between	O
ESB	B-T033
and	O
total	O
suicidality	B-T201
or	O
suicide	B-T033
risk factors	B-T033
(	O
social support	B-T054
,	O
depression	B-T048
,	O
anxiety	B-T033
,	O
stress	B-T033
,	O
satisfaction with life	B-T080
and	O
emotional stability	B-T041
).	O
In	O
addition,	O
in	O
contrast	O
to	O
previous	O
reports	B-T170
,	O
young adults	B-T100
(n	O
=	O
200;	O
aged	B-T032
18-20)	O
showed	O
no	O
increased	B-T081
suicidality	B-T201
due	O
to	O
ESB	B-T033
.	O
Results	B-T169
showed	O
no	O
validity	B-T080
for	O
ESB	B-T033
as	O
a	O
common	O
risk factor	B-T033
for	O
suicidality	B-T201
or	O
other	O
psychopathology	B-UnknownType
,	O
or	O
as	O
a	O
latent	B-T080
trait	B-T032
.	O
ESB	B-T033
showed	O
evidence	B-T078
as	O
a	O
personal	B-T032
negative life event	B-T033
with	O
individual	B-T098
effects	B-T080
and	O
interpretations	B-T170
.	O

Direct anterior approach	B-T082
for	O
total hip arthroplasty	B-T061
with	O
a	O
novel	O
mobile traction table	B-T074
-a	O
prospective cohort study	B-T062
The	O
purpose	O
of	O
this	O
prospective cohort study	B-T062
was	O
to	O
clarify	O
the	O
safety	O
and	O
efficacy	O
of	O
total hip arthroplasty	B-T061
via	O
the	O
direct anterior approach	B-T082
in	O
the	O
supine position	B-T082
with	O
a	O
novel	O
mobile traction table	B-T074
.	O
The	O
first	O
experience	O
of	O
consecutive surgeries	B-T061
by	O
a	O
single surgeon	B-T097
using	O
the	O
direct anterior approach	B-T082
with	O
a	O
traction table	B-T074
is	O
described	O
with	O
a	O
two-year	O
follow-up	B-T058
period.	O
Of	O
121	O
patients	B-T101
,	O
100	O
patients	B-T101
without	O
previous hip surgeries	B-T033
,	O
severe deformity	B-T190
,	O
or	O
cemented implants	B-T061
were	O
divided	O
into	O
two	O
groups	B-T078
comprising	O
the	O
first	O
50	O
patients	B-T101
and	O
the	O
second	O
50	O
patients	B-T101
.	O
The	O
implant survival rate	B-T081
was	O
99%	O
at	O
the	O
two-year	O
follow-up	B-T058
.	O
Revision surgery	B-T061
was	O
required	O
for	O
periprosthetic	B-T037
femoral fracture	B-T037
in	O
one	O
patient	B-T101
.	O
The	O
complication	B-T046
rate	B-T081
possibly	O
related	O
to	O
the	O
traction table	B-T074
was	O
5%	O
(5	O
patients	B-T101
):	O
three	O
anterior dislocations	B-T037
,	O
one	O
periprosthetic	B-T037
femoral fracture	B-T037
,	O
and	O
one	O
intraoperative perforation	B-T058
caused	O
by	O
femoral rasping	B-T037
.	O
The	O
complication	B-T046
rate	B-T081
tended	O
to	O
decrease	B-T081
in	O
the	O
second	O
group	B-T078
compared	O
to	O
the	O
first	O
group	O
(4%	O
versus	O
6%).	O
Mean surgical time	B-T079
(72.0	O
minutes	O
versus	O
82.5	O
min,	O
p	O
=	O
0.027),	O
rate	B-T081
of	O
allogeneic blood transfusion	B-T061
(2%	O
versus	O
24%,	O
p	O
=	O
0.001),	O
and	O
cup alignment	B-T033
in	O
the	O
safe zone	B-T082
(100%	O
versus	O
88%,	O
p	O
=	O
0.027)	O
were	O
significantly	O
improved	O
in	O
the	O
second	O
group	B-T078
compared	O
to	O
the	O
first	O
group	B-T078
.	O
The	O
direct anterior approach	B-T082
with	O
a	O
novel	O
mobile traction table	B-T074
showed	O
a	O
positive learning curve	B-T033
for	O
surgical time	B-T079
,	O
rate	B-T081
of	O
allogeneic blood transfusion	B-T061
,	O
and	O
cup alignment	B-T033
in	O
the	O
safe zone	B-T082
.	O

The	O
binding	B-T044
orientations	B-T082
of	O
structurally	B-T082
-related	O
ligands	B-T103
can	O
differ	B-T080
;	O
A	O
cautionary	O
note	O
Crystal structures	B-T104
can	O
identify	O
ligand-receptor interactions	B-T044
and	O
assist	O
the	O
development	O
of	O
novel	O
therapeutics	B-T061
,	O
but	O
experimental	B-T080
challenges	O
sometimes	O
necessitate	O
the	O
use	O
of	O
homologous proteins	B-T116
.	O
Tropisetron	B-T109
is	O
an	O
orthosteric ligand	B-T103
at	O
both	O
5-HT3	B-T116
and	O
α7 nACh receptors	B-T116
and	O
its	O
binding	B-T044
orientation	B-T082
has	O
been	O
determined	O
in	O
the	O
structural homologue	B-T087
AChBP	B-T116
(pdbid:	O
2WNC).	O
Co-crystallisation	B-T070
with	O
a	O
structurally	B-T082
-related	O
ligand	B-T103
,	O
granisetron	B-T109
,	O
reveals	O
an	O
almost	O
identical	B-T080
orientation	B-T082
(pdbid;	O
2YME).	O
However,	O
there	O
is	O
a	O
>1000-fold	O
difference	B-T080
in	O
the	O
affinity	B-T070
of	O
tropisetron	B-T109
at	O
5-HT3	B-T116
versus	O
α7 nACh receptors	B-T116
,	O
and	O
α7 nACh receptors	B-T116
do	O
not	B-T169
bind	B-T044
granisetron	B-T109
.	O
These	O
striking	O
pharmacological	B-T169
differences	B-T080
prompt	O
questions	O
about	O
which	O
receptor	B-T116
the	O
crystal structures	B-T104
most	O
closely	O
represent	O
and	O
whether	O
the	O
ligand	B-T103
orientations	B-T082
are	O
correct.	O
Here	O
we	O
probe	O
the	O
binding	B-T044
orientation	B-T082
of	O
tropisetron	B-T109
and	O
granisetron	B-T109
at	O
5-HT3 receptors	B-T116
by	O
in silico	B-T066
modelling	B-T090
and	O
docking	B-T044
,	O
radioligand binding	B-T044
on	O
cysteine	B-T116
-	O
substituted	B-T045
5-HT3 receptor	B-T116
mutants	B-T049
transiently	O
expressed	B-T045
in	O
HEK 293 cells	B-T025
,	O
and	O
synthetic modification	B-T091
of	O
the	O
ligands	B-T103
.	O
For	O
15	O
of	O
the	O
23	O
cysteine	B-T116
substitutions	B-T045
,	O
the	O
effects	B-T080
on	O
tropisetron	B-T109
and	O
granisetron	B-T109
were	O
different.	O
Structure-activity relationships	B-T080
on	O
synthesised	O
derivatives	O
of	O
both	O
ligands	B-T103
were	O
also	O
consistent	O
with	O
different	O
orientations	B-T082
,	O
revealing	B-T080
that	O
contrary	O
to	O
the	O
crystallographic	B-T059
evidence	B-T078
from	O
AChBP	B-T116
,	O
the	O
two	O
ligands	B-T103
adopt	O
different	B-T080
orientations	B-T082
in	O
the	O
5-HT3 receptor	B-T116
binding site	B-T192
.	O
Our	O
results	O
show	O
that	O
even	O
quite	O
structurally	B-T082
similar	O
molecules	B-T167
can	O
adopt	O
different	O
orientations	B-T082
in	O
the	O
same	O
binding site	B-T192
,	O
and	O
that	O
caution	O
may	O
be	O
needed	O
when	O
using	O
homologous proteins	B-T116
to	O
predict	O
ligand binding	B-T044
.	O

Pancreatic	B-T023
neuroendocrine cancer	B-T191
with	O
liver metastases	B-T191
and	O
multiple peritoneal metastases	B-T191
:	O
report	O
of	O
one	O
case	O
Pancreatic	B-T023
neuroendocrine tumor	B-T191
(	O
pNET	B-T191
)	O
is	O
a	O
rare	O
pancreatic tumor	B-T191
,	O
with	O
its	O
incidence	O
showing	O
a	O
rising	O
trend	O
in	O
recent	O
years.	O
Most	O
of	O
its	O
distant metastases	B-T201
are	O
found	B-T033
in	O
the	O
liver	B-T023
.	O
This	O
article	O
describes	O
a	O
59-year-old	O
male patient	B-T032
with	O
pNET	B-T191
with	O
liver metastasis	B-T191
and	O
multiple abdominal metastases	B-T191
,	O
focusing	O
on	O
the	O
management	B-T058
of	O
this	O
tumor	B-T191
in	O
its	O
advanced stage	B-T079
.	O

Lignans	B-T109
from	O
the	O
fruits	B-T168
of	O
Schisandra chinensis (Turcz.) Baill	B-T002
inhibit	B-T052
proprotein convertase subtilisin/kexin type 9	B-T028
expression	B-T045
Bioactivity-guided fractionation	B-T059
of	O
the	O
fruits	B-T168
of	O
Schisandra chinensis	B-T002
,	O
using	O
the	O
proprotein convertase subtilisin-kexin type 9	B-T028
(	O
PCSK9	B-T028
)	O
mRNA expression	B-T045
screening assay	B-T059
,	O
led	O
to	O
isolation	B-T169
of	O
two	B-T081
previously unknown	B-T080
lignans	B-T109
,	O
14-tigloylschinlignan D	B-T109
and	O
rel-(7R, 8R, 7'R, 8'R)-manglisin E	B-T109
,	O
along	O
with	O
28	O
known	O
compounds.	O
All	O
structures	B-T170
were	O
established	B-T080
by	O
NMR spectroscopic	B-T060
data	B-T078
as	O
well	O
as	O
CD	B-T059
and	O
MS	B-T059
analysis	B-T062
.	O
All	O
isolates	O
were	O
tested	B-T169
for	O
their	O
inhibitory	B-T052
activities	B-T052
on	O
the	O
mRNA expression	B-T045
of	O
PCSK9	B-T028
.	O
Of	O
the	O
tested	B-T169
compounds,	O
four	B-T081
of	O
the	O
compounds	O
rel-(7R, 8R, 7'R, 8'R)-manglisin E	B-T109
,	O
(-)-schisandrin C	B-T109
,	O
schinlignan D	B-T109
,	O
and	O
(+)-schisandrol B	B-T109
potently	O
inhibited	B-T080
PCSK9	B-T028
mRNA expression	B-T045
with	O
IC50	B-T081
values	O
of	O
3.15,	O
3.85,	O
0.36,	O
and	O
1.10	O
μM,	O
respectively.	O
Furthermore,	O
schinlignan	O
D	O
and	O
(+)-schisandrol B	B-T109
were	O
found	O
to	O
suppress	B-T169
PCSK9	B-T116
protein expressions	B-T045
and	O
schinlignan D	B-T109
deemed	O
to	O
increase	O
low density lipoprotein receptor	B-T116
expression	B-T045
.	O

A	O
comparison	O
of	O
outcomes	B-T080
in	O
morbidly obese	B-T047
,	O
obese	B-T047
and	O
non-obese	B-T032
patients	B-T101
undergoing	O
primary total knee	B-T061
and	O
total hip arthroplasty	B-T061
Obesity	B-T047
is	O
a	O
growing	O
public	B-T092
health issue	B-T033
with	O
the	O
prevalence	B-T081
of	O
morbid obesity, (Body Mass Index (BMI) ≥ 40 kg/m(2))	B-T033
increasing	B-T169
.	O
There	O
is	O
some	O
evidence	B-T078
these	O
patients	B-T101
have	O
more	O
peri- and post-operative complications	B-T047
and	O
poorer outcomes	B-T080
when	O
undergoing	O
arthroplasty procedures	B-T061
.	O
This	O
audit	O
aimed	O
to	O
determine	O
and	O
compare	O
the	O
outcomes	B-T080
of	O
non-obese	B-T032
,	O
obese	B-T047
and	O
morbidly obese	B-T047
patients	B-T101
undergoing	O
arthroplasty	B-T061
at	O
our	O
institution	B-T093
.	O
This	O
was	O
a	O
retrospective audit	B-T058
of	O
patients	B-T101
from	O
our	O
institution	B-T093
who	O
had	O
undergone	O
total knee	B-T061
(	O
TKA	B-T061
)	O
or	O
total hip arthroplasty	B-T061
(	O
THA	B-T061
)	O
in	O
2009.	O
Data	B-T078
collected	B-T078
were:	O
age	B-T032
,	O
gender	B-T032
,	O
BMI	B-T201
,	O
length of stay	B-T079
(	O
LOS	B-T079
),	O
Oxford knee	B-T201
or	O
hip score	B-T201
(	O
OKS	B-T201
/	O
OHS	B-T201
),	O
satisfaction	B-T033
and	O
complications	B-T046
up	O
to	O
two	O
years	B-T079
post operation	B-T061
.	O
Patients	B-T101
were	O
divided	O
into	O
three	O
groups	B-T078
:	O
BMI < 30	B-T033
,	O
BMI 30-40	B-T201
and	O
BMI > 40	B-T033
.	O
Outcomes	B-T080
for	O
each	O
BMI	B-T201
group	B-T078
were	O
compared.	O
1014	O
TKA	B-T061
and	O
906	O
THA	B-T061
operations	B-T061
were	O
included.	O
When	O
compared	O
to	O
obese	B-T047
and	O
non-obese	B-T032
patients	B-T101
,	O
morbidly obese	B-T047
patients	B-T101
undergoing	O
TKA	B-T061
had	O
a	O
mean	O
LOS	B-T079
one	O
day	B-T079
longer,	O
a	O
mean OKS	B-T201
four	O
points	O
lower	O
and	O
higher	O
rates	O
of	O
postoperative problems	B-T046
,	O
37%	O
vs.	O
21%.	O
For	O
THA	B-T061
patients	B-T101
there	O
was	O
no difference	B-T033
in	O
LOS	B-T079
,	O
OHS score	B-T201
was	O
two	O
points	O
lower	O
for	O
each	O
increasing	B-T169
BMI	B-T201
category	B-T170
and	O
postoperative problems	B-T046
increase	B-T169
from	O
25%	O
for	O
non-obese	B-T032
to	O
31%	O
for	O
obese	B-T047
and	O
38%	O
for	O
morbidly obese	B-T047
patients	B-T101
.	O
These	O
results	O
will	O
be	O
useful	O
in	O
informing	O
obese	B-T047
patients	B-T101
of	O
their	O
potential	O
outcomes	B-T080
following	O
TKA	B-T061
or	O
THA	B-T061
.	O
These	O
patients	B-T101
can	O
then	O
make	O
a	O
more	O
informed	O
choice	O
before	O
proceeding	O
with	O
arthroplasty	B-T061
.	O

Vitamin D Receptor Activator	B-T123
Use	O
and	O
Cause-specific Death	B-T081
among	O
dialysis	B-T061
Patients	B-T101
:	O
a	O
Nationwide Cohort Study	B-T081
using	O
Coarsened Exact Matching	B-T081
Vitamin D receptor activators	B-T123
(	O
VDRA	B-T123
)	O
may	O
exert	O
pleiotropic effects	B-T045
on	O
cardiovascular disease	B-T047
,	O
malignancy	B-T191
,	O
and	O
infections	B-T046
among	O
dialysis	B-T061
patients	B-T101
,	O
but	O
recent	O
studies	O
have	O
mainly	O
focused	O
on	O
cardiovascular outcomes	B-T033
.	O
Among	O
8,675	O
patients	B-T101
who	O
started	O
dialysis	B-T061
in	O
2007	O
and	O
who survived	B-T081
until	O
January	O
1,	O
2010,	O
listed	O
in	O
the	O
Renal Data Registry	B-T062
of	O
the	O
Japanese Society	B-T093
for	O
Dialysis Therapy	B-T061
,	O
5,365	O
VDRA	B-T123
users	O
were	O
matched	O
to	O
3,203	O
non-users	O
based	O
on	O
clinically relevant variables	B-T079
at	O
the	O
end	O
of	O
2009	O
using	O
the	O
coarsened exact matching procedure	B-T081
.	O
Until	O
December	O
31,	O
2011,	O
a	O
total	O
of	O
1,128	O
deaths	B-T081
occurred,	O
of	O
which	O
468	O
(42%)	O
were	O
cardiovascular deaths	B-T046
,	O
229	O
(20%)	O
were	O
infection-related deaths	B-T033
,	O
and	O
141	O
(12%)	O
were	O
malignancy-related deaths	B-T081
.	O
Multivariable survival analyses	B-T062
accounting	O
for	O
intra-region correlation	B-T080
revealed	O
that	O
VDRA	B-T123
use	O
was	O
significantly	O
associated	O
with	O
lower rates	B-T081
of	O
infection	B-T046
-	O
and	O
malignancy	B-T191
-related	O
deaths	B-T081
[	O
subhazard ratio	B-T081
0.62	O
(95%	O
CI	B-T081
,	O
0.52-0.73)	O
and	O
0.70	O
(95%	O
CI	B-T081
,	O
0.50-0.97),	O
respectively]	O
but	O
not	O
with	O
cardiovascular death	B-T046
[	O
subhazard ratio	B-T081
0.86	O
(95%	O
CI	B-T081
,	O
0.72-1.04)].	O
Future	O
randomized clinical trials	B-T062
with	O
a	O
sufficient	O
sample size	B-T081
and	O
an	O
adequate	O
follow-up	B-T058
period	O
are	O
warranted	O
to	O
test	O
the	O
clinical effectiveness	B-T080
of	O
VDRA	B-T123
on	O
infection	B-T046
and	O
malignancy	B-T191
,	O
rather	O
than	O
cardiovascular disease	B-T047
,	O
among	O
dialysis	B-T061
patients	B-T101
.	O

Burden	B-T078
of	O
cervical cancer	B-T191
and	O
role	O
of	O
screening	B-T058
in	O
India	B-T083
Cervical cancer	B-T191
is	O
a	O
major	O
cause	O
of	O
cancer mortality	B-T081
in	O
women	B-T098
and	O
more	O
than	O
a	O
quarter	B-T081
of	O
its	O
global	B-T080
burden	B-T078
is	O
contributed	B-T052
by	O
developing countries	B-T080
.	O
In	O
India	B-T083
,	O
in	O
spite	O
of	O
alarmingly	O
high	O
figures,	O
there	O
is	O
no	O
nationwide	O
government-sponsored screening program	B-T064
.	O
This	O
study	B-T062
was	O
conducted	B-T169
to	O
assess	B-T052
the	O
burden	B-T078
of	O
cervical cancer	B-T191
in	O
India	B-T083
and	O
review	B-T169
the	O
performance	B-T052
characteristics	B-T080
of	O
available	O
cervical cancer	B-T191
screening	B-T058
tools,	O
so	O
as	O
to	O
provide	B-T052
evidence	B-T078
-based	O
recommendations	B-T078
for	O
application	O
of	O
most	O
practically	O
suited	O
screening test	B-T060
to	O
be	O
used	O
in	O
resource	B-T078
-poor	O
field	O
settings.	O
MEDLINE	B-T170
and	O
Web of Science electronic database	B-T170
were	O
searched	B-T052
from	O
January	B-T080
1990	O
to	O
December	B-T080
2015,	O
using	O
the	O
keywords	B-T170
such	O
as	O
"	O
cervical cancer	B-T191
",	O
"	O
screening	B-T060
",	O
"	O
early detection	B-T060
",	O
"	O
cervical cytology	B-T059
"	O
and	O
"	O
visual inspection	B-T058
",	O
and	O
their	O
corresponding	O
MeSH terms	B-T170
in	O
combination	B-T080
with	O
Boolean operators	B-T169
"OR,	O
AND."	O
Two	O
authors	B-T097
independently	O
selected	B-T052
studies	B-T062
that	O
are	O
published	B-T170
in	O
English	B-T171
and	O
conducted	B-T169
in	O
India	B-T083
.	O
A	O
total	B-T080
of	O
11	O
studies	B-T062
were	O
found	B-T033
to	O
be	O
relevant	B-T080
and	O
eligible	B-T080
to	O
be	O
included	B-T169
in	O
the	O
present	B-T033
study	B-T062
.	O
In	O
India	B-T083
,	O
cervical cancer	B-T191
contributes	B-T052
to	O
approximately	B-T080
6-29%	O
of	O
all	O
cancers	B-T191
in	O
women	B-T098
.	O
The	O
age-adjusted incidence rate	B-T081
of	O
cervical cancer	B-T191
varies	O
widely	O
among	O
registries	B-T170
;	O
highest	B-T080
is	O
23.07/100,000	O
in	O
Mizoram state	B-UnknownType
and	O
the	O
lowest	B-T080
is	O
4.91/100,000	O
in	O
Dibrugarh district	B-UnknownType
.	O
The	O
pooled	O
estimates	B-T081
of	O
sensitivity	B-T081
and	O
specificity	B-T081
of	O
visual inspection with acetic acid	B-T060
(	O
VIA	B-T060
),	O
magnified VIA	B-T060
,	O
visual inspection with Lugol's iodine	B-T060
(	O
VILI	B-T060
),	O
cytology	B-T059
(	O
Pap smear	B-T060
),	O
and	O
human papillomavirus DNA	B-T059
were	O
found	O
to	O
be	O
67.65%	O
and	O
84.32%,	O
65.36%	O
and	O
85.76%,	O
78.27%	O
and	O
87.10%,	O
62.11%	O
and	O
93.51%,	O
and	O
77.81%	O
and	O
91.54%,	O
respectively.	O
In	O
developing countries	B-T080
because	O
of	O
lack	B-T080
of	O
necessary	O
infrastructure	B-T185
and	O
quality control	B-T169
,	O
high-quality	B-T080
cytology screening	B-T060
may	O
not	O
be	O
feasible	O
for	O
wide-scale	O
implementation	B-T052
.	O
Hence,	O
cervical cancer	B-T191
screening	B-T058
program	B-T169
based	O
on	O
visual screening test	B-T060
such	O
as	O
VIA	B-T060
/	O
VILI	B-T060
should	O
be	O
adopted	O
as	O
an	O
integral	O
part	O
of	O
primary	O
health-care setup	B-T058
in	O
resource	B-T078
-	O
poor	B-T080
countries	B-T083
like	O
India	B-T083
.	O

Structural and tribometric characterization	B-T052
of	O
biomimetically	O
inspired	O
synthetic	O
"	O
insect	B-T204
adhesives	B-T073
"	O
Background:	O
Based	O
on	O
previous	O
chemical analyses	B-T059
of	O
insect	B-T204
tarsal	B-T023
adhesives	B-T073
,	O
we	O
prepared	O
12	O
heterogeneous	B-T080
synthetic	B-T052
emulsions	B-T104
mimicking	O
the	O
polar/non-polar principle	B-T033
,	O
analysed	O
their	O
microscopical structure	B-T082
and	O
tested	O
their	O
adhesive	B-T080
,	O
frictional	B-T080
,	O
and	O
rheological properties	B-T080
.	O
Results:	O
The	O
prepared	B-T033
emulsions	B-T104
varied	O
in	O
their	O
consistency	B-T080
from	O
solid	B-T080
rubber-like	B-T109
,	O
over	O
soft	B-T080
elastic	B-T073
,	O
to	O
fluid	B-T167
(	O
watery	B-T080
or	O
oily	B-T080
).	O
With	O
droplet sizes	B-T082
>100	O
nm,	O
all	O
the	O
emulsions	B-T104
belonged	O
to	O
the	O
common	O
type	O
of	O
macroemulsions	B-T104
.	O
The	O
emulsions	B-T104
of	O
the	O
first generation	B-T079
generally	O
showed	O
broader	O
droplet-size	B-T082
ranges	O
compared	O
with	O
the	O
second generation	B-T079
,	O
especially	O
when	O
less	O
defined	O
components	B-T078
such	O
as	O
petrolatum	B-T109
or	O
waxes	B-T122
were	O
present	O
in	O
the	O
lipophilic	B-T081
fraction	B-T081
of	O
the	O
first generation	B-T079
of	O
emulsions	B-T104
.	O
Some	O
of	O
the	O
prepared	B-T033
emulsions	B-T104
showed	O
a	O
yield point	B-T033
and	O
were	O
Bingham fluids	B-T120
.	O
Tribometric adhesion	B-T059
was	O
tested	O
via	O
probe tack tests	B-T059
.	O
Compared	O
with	O
the	O
"	O
second generation	B-T079
"	O
(containing	O
less	O
viscous	B-T080
components	B-T167
),	O
the	O
"	O
first generation	B-T079
"	O
emulsions	B-T104
were	O
much	O
more adhesive	B-T033
(31-93	O
mN),	O
a	O
finding	O
attributable	O
to	O
their	O
highly	O
viscous	B-T080
components	B-T167
,	O
i.e.,	O
wax	B-T122
,	O
petrolatum	B-T109
,	O
gelatin	B-T116
and	O
poly(vinyl alcohol)	B-T109
.	O
In	O
the	O
second generation	B-T079
emulsions	B-T104
,	O
we	O
attained	O
much	O
lower	O
adhesivenesses	B-T070
,	O
ranging	O
between	O
1-18	O
mN.	O
The	O
adhesive	B-T073
performance	B-T052
was	O
drastically	O
reduced	B-T080
in	O
the	O
emulsions	B-T104
that	O
contained	O
albumin	B-T116
as	O
the	O
protein component	B-T116
or	O
that	O
lacked	O
protein	B-T116
.	O
Tribometric shear tests	B-T059
were	O
performed	O
at	O
moderate	O
normal loads	B-T080
.	O
Our	O
measured	O
friction forces	B-T070
(4-93	O
mN	O
in	O
the	O
first	O
and	O
0.1-5.8	O
mN	O
in	O
the	O
second generation	B-T079
emulsions	B-T104
)	O
were	O
comparatively	O
low.	O
Differences	B-T081
in	O
shear	B-T070
performance	B-T052
were	O
related	O
to	O
the	O
chemical composition	B-T070
and	O
emulsion	B-T104
structure	B-T082
.	O
Conclusion:	O
By	O
varying	O
their	O
chemical composition	B-T070
,	O
synthetic	O
heterogeneous	B-T080
adhesive	B-T073
emulsions	B-T104
can	O
be	O
adjusted	O
to	O
have	O
diverse	O
consistencies	B-T080
and	O
are	O
able	O
to	O
mimic	O
certain	O
rheological	B-T080
and	O
tribological properties	B-T080
of	O
natural	B-T169
tarsal	B-T023
insect	B-T204
adhesives	B-T073
.	O

Opioids	B-T109
for	O
chronic pain	B-T184
:	O
The	O
CDC's	B-T093
12	O
recommendations	B-T078
The	O
Centers for Disease Control and Prevention	B-T093
has	O
issued	O
12	O
recommendations	B-T078
to	O
help	O
clinicians	B-T097
prescribe	B-T058
an	O
optimal	B-T080
and	O
safe	O
course	O
of	O
treatment	B-T061
for	O
patients	B-T101
.	O

Three-Dimensional	B-T082
HyCoSy	B-T060
With	O
Perfluoropropane-Albumin Microspheres	B-T109
as	O
Contrast Agents	B-T130
and	O
Normal	O
Saline	B-T167
Injections	B-T061
Into	O
the	O
Pelvic Cavity	B-T030
for	O
Morphological	B-T080
Assessment	B-T058
of	O
the	O
Fallopian Tube	B-T023
in	O
Infertile	B-T046
Women	B-T098
To	O
apply	O
the	O
three-dimensional	B-T082
(	O
3D	B-T082
)	O
hysterosalpingo-contrast sonography	B-T060
(	O
HyCoSy	B-T060
)	O
with	O
perfluoropropane-albumin microspheres	B-T109
as	O
contrast agents	B-T130
and	O
normal	O
saline	B-T167
injections	B-T061
into	O
the	O
pelvic cavity	B-T030
for	O
assessment of the tubal patency	B-T060
and	O
adhesions of fimbrial parts	B-T047
.	O
Fifty-five	O
infertile	B-T046
female	B-T032
patients	B-T101
were	O
recruited	O
to	O
undergo	O
3D	B-T082
HyCoSy	B-T060
with	O
normal	O
saline	B-T167
injected	B-T061
into	O
the	O
pelvic cavity	B-T030
,	O
in	O
which	O
the	O
tubal	O
patency	O
was	O
observed	O
by	O
visualizing	O
the	O
spillage	O
of	O
contrast agents	B-T130
from	O
the	O
fimbriae	B-T023
,	O
and	O
the	O
fimbrial adhesion	B-T047
was	O
confirmed	O
by	O
the	O
finger-like projections	B-T082
of	O
the	O
fimbriae	B-T023
and	O
their	O
floating	B-T080
and	O
moving status	B-T078
.	O
Of	O
the	O
55	O
patients	B-T101
,	O
bilateral tubal patency	B-T033
was	O
observed	O
in	O
44	O
(80.0%),	O
unilateral tubal patency	B-T033
and	O
the	O
other	O
partial occlusion	B-T047
in	O
7	O
(12.7%),	O
unilateral	B-T082
partial occlusion	B-T047
and	O
the	O
other	O
complete occlusion	B-T046
in	O
3	O
(5.4%),	O
and	O
bilateral	B-T082
complete occlusion	B-T046
in	O
1	O
(1.8%).	O
The	O
fimbrial parts	B-T023
were	O
observed	O
in	O
105	O
fallopian tubes	B-T023
,	O
among	O
which	O
101	O
were	O
seen	O
with	O
the	O
finger-like	B-T082
fimbriae	B-T023
floated	B-T080
and	O
moved	B-T078
in	O
the	O
pelvic cavity	B-T030
,	O
whereas	O
4	O
tubes	O
were	O
not	O
because	O
of	O
adhesion	B-T047
to	O
the	O
pelvic cavity	B-T030
(n	O
=	O
3)	O
or	O
the	O
ovary	B-T023
and	O
intestine	B-T023
(n	O
=	O
1).	O
More	O
than	O
three	O
visible,	O
quite	O
long,	O
and	O
distributed	O
evenly	O
finger-like projection	B-T082
s	O
were	O
present	O
for	O
the	O
patent	B-T082
fimbrial parts	B-T023
;	O
however,	O
fewer	B-T081
,	O
flat	B-T082
,	O
and	O
not	O
evenly	O
distributed	O
finger-like projection	B-T082
s	O
were	O
present	O
for	O
the	O
adhesive tubes	B-T047
.	O
No	O
serious	O
complications	B-T046
occurred	O
during	O
or	O
after	O
this	O
procedure	B-T060
.	O
Combination	B-T080
of	O
3D	B-T082
HyCoSy	B-T060
with	O
normal	O
saline	B-T167
injected	B-T061
into	O
the	O
pelvic cavity	B-T030
may	O
be	O
a	O
feasible	O
and	O
safe	O
procedure	B-T060
to	O
assess	O
tubal	O
patency	O
and	O
adhesions of the fimbrial parts	B-T047
.	O

Challenging	B-T058
some	O
assumptions	O
about	O
empathy	B-T055
In	O
New Zealand	B-T083
little	O
nursing	B-T065
or	O
medical curricula	B-T065
time	B-T079
,	O
if	O
any,	O
is	O
specifically	O
devoted	O
to	O
the	O
enhancement	B-T052
of	O
empathy	B-T055
.	O
If	O
being	O
empathic	B-T033
is	O
important	B-T080
in	O
the	O
context	O
of	O
patient care	B-T058
,	O
it	O
is	O
a	O
quality	O
that	O
is	O
already	O
present	O
in	O
students	B-T098
or	O
is	O
learned	O
by	O
students	B-T098
during	O
their	O
practicum	B-T065
in	O
the	O
company	O
of	O
experienced	B-T041
clinicians	B-T097
.	O
This	O
study	B-T062
aimed	O
to	O
compare	B-T052
self-reported	B-T062
empathy	B-T055
ratings	O
between	O
different	O
groups	B-T098
of	O
medical students	B-T097
and	O
one	O
cohort	B-T098
of	O
nursing students	B-T097
who	O
were	O
either	O
exposed	O
or	O
not	O
exposed	O
to	O
explicit	O
empathy	B-T055
training	B-T065
or	O
learning	B-T041
in	O
clinical settings	B-T082
in	O
the	O
presence	O
of	O
patients	B-T101
.	O
The	O
Jefferson Scale of Physician Empathy	B-T080
(	O
JSPE	B-T080
)	O
was	O
completed	O
before	O
and	O
after	O
groups	O
of	O
medical	B-T097
and	O
nursing students	B-T097
had	O
been	O
exposed	O
to	O
various	O
extended	B-T079
periods	B-T079
of	O
practicum	B-T065
.	O
Some	O
medical student	B-T097
cohorts	B-T098
undertook	O
brief	B-T079
empathy	B-T055
training	B-T065
training	B-T065
,	O
whereas	O
others	O
had	O
no	O
exposure.	O
The	O
nursing student	B-T097
cohort	B-T098
had	O
no formal	B-T033
,	O
explicit	O
empathy	B-T055
training	B-T065
.	O
Irrespective	O
of	O
profession	B-T090
,	O
length	B-T079
of	O
practicum	B-T065
or	O
exposure	O
to	O
specific	O
empathy	B-T055
training	B-T065
,	O
there	O
were	O
no significant differences	B-T033
in	O
the	O
self-reported	B-T062
JSPE scores	B-T080
across	O
the	O
seven	O
different	O
cohorts	B-T098
of	O
students	B-T098
.	O
Empathy	B-T055
is	O
a	O
quality	B-T080
that	O
is	O
already	O
present	B-T033
in	O
students	B-T098
or	O
is	O
learned by	B-T041
students	B-T098
during	O
their	O
practicum	B-T065
DISCUSSION	B-T054
:	O
If	O
empathy	B-T055
is	O
caught	B-T055
rather	O
than	O
taught	B-T080
,	O
then	O
brief	O
efforts	O
to	O
enhance	B-T052
empathy	B-T055
may	O
be	O
futile	B-T033
.	O
To	O
optimise	O
the	O
inherent empathic qualities	B-T033
of	O
aspirant	O
health professionals	B-T097
,	O
explicit	O
consideration	B-T033
should	O
be	O
given	O
to	O
how	O
empathy	B-T055
is	O
influenced	B-T077
by	O
the	O
practicum	B-T065
experience	B-T041
.	O

Surface	B-T082
mediated	O
cooperative	O
interactions of drugs	B-T044
enhance	B-T052
mechanical forces	B-T067
for	O
antibiotic	B-T195
action	B-T052
The	O
alarming increase	B-T169
of	O
pathogenic bacteria	B-T001
that	O
are	O
resistant to multiple antibiotics	B-T046
is	O
now	O
recognized	O
as	O
a	O
major health issue	B-T033
fuelling	O
demand	B-T061
for	O
new	O
drugs	B-T121
.	O
Bacterial resistance	B-T046
is	O
often	O
caused	O
by	O
molecular changes	B-T033
at	O
the	O
bacterial surface	B-T034
,	O
which	O
alter	O
the	O
nature	O
of	O
specific	O
drug-target interactions	B-T044
.	O
Here,	O
we	O
identify	O
a	O
novel	O
mechanism	B-T169
by	O
which	O
drug-target interactions	B-T044
in	O
resistant bacteria	B-T007
can	O
be	O
enhanced	B-T052
.	O
We	O
examined	O
the	O
surface	B-T082
surface	B-T082
forces	B-T067
generated	O
by	O
four	O
antibiotics	B-T195
;	O
vancomycin	B-T116
,	O
ristomycin	B-T116
,	O
chloroeremomycin	B-T116
and	O
oritavancin	B-T116
against	O
drug-susceptible	B-T169
and	O
drug-resistant targets	B-T007
on	O
a	O
cantilever	O
and	O
demonstrated	O
significant	B-T078
differences	O
in	O
mechanical	B-T169
response	B-T032
when	O
drug-resistant targets	B-T007
are	O
challenged	O
with	O
different	O
antibiotics	B-T195
although	O
no	O
significant	O
differences	O
were	O
observed	B-T169
when	O
using	O
susceptible targets	B-T169
.	O
Remarkably,	O
the	O
binding affinity	B-T039
for	O
oritavancin	B-T116
against	O
drug-resistant targets	B-T007
(70	O
nM)	O
was	O
found	O
to	O
be	O
11,000	O
times	O
stronger	O
than	O
for	O
vancomycin	B-T116
(800	O
μM),	O
a	O
powerful	O
antibiotic	B-T195
used	O
as	O
the	O
last	O
resort treatment	B-T061
for	O
streptococcal	B-T007
and	O
staphylococcal bacteria	B-T007
including	O
methicillin-resistant Staphylococcus aureus	B-T007
(	O
MRSA	B-T007
).	O
Using	O
an	O
exactly solvable model	B-T170
,	O
which	O
takes	O
into	O
account	O
the	O
solvent	B-T130
and	O
membrane	B-T026
effects	B-T080
,	O
we	O
demonstrate	O
that	O
drug-target interactions	B-T044
are	O
strengthened	O
by	O
pronounced polyvalent interactions	B-T044
catalyzed	B-T070
by	O
the	O
surface	B-T082
itself.	O
These	O
findings	O
further	O
enhance	B-T052
our	O
understanding	B-T041
of	O
antibiotic mode of action	B-T169
and	O
will	O
enable	O
development	B-T169
of	O
more	O
effective	O
therapies	B-T061
.	O

Intra-articular	B-T082
corticosteroids	B-T121
versus	O
intra-articular	B-T082
corticosteroids	B-T121
plus	B-T169
methotrexate	B-T109
in	O
oligoarticular juvenile idiopathic arthritis	B-T047
:	O
a	O
multicentre	B-T062
,	O
prospective	B-T062
,	O
randomised	B-T062
,	O
open-label trial	B-T062
Little	O
evidence-based	O
information	O
is	O
available	O
to	O
guide	B-T170
the	O
treatment	B-T061
of	O
oligoarticular juvenile idiopathic arthritis	B-T047
.	O
We	O
aimed	O
to	O
investigate	B-T169
whether	O
oral methotrexate	B-T200
increases	B-T169
the	O
efficacy	B-T080
of	O
intra-articular corticosteroid therapy	B-T061
.	O
We	O
did	O
this	O
prospective	B-T062
,	O
open-label	B-T062
,	O
randomised trial	B-T062
at	O
ten	O
hospitals	B-T073
in	O
Italy	B-T083
.	O
Using	O
a	O
concealed	B-T080
computer-generated list	B-T170
,	O
children	B-T100
younger than	B-T033
18	O
years	B-T079
with	O
oligoarticular	B-T082
-	O
onset disease	B-T079
were	O
randomly	B-T080
assigned	B-T169
(1:1)	O
to	O
intra-articular	B-T082
corticosteroids	B-T121
alone	B-T081
or	O
in combination with	B-T080
oral methotrexate	B-T200
(15	O
mg/m(2);	O
maximum	B-T081
20	O
mg).	O
Corticosteroids	B-T121
used	O
were	O
triamcinolone hexacetonide	B-T109
(	O
shoulder	B-T030
,	O
elbow	B-T030
,	O
wrist	B-T030
,	O
knee	B-T030
,	O
and	O
tibiotalar joints	B-T030
)	O
or	O
methylprednisolone acetate	B-T109
(ie,	O
subtalar	B-T030
and	O
tarsal joints	B-T030
).	O
We	O
did	O
not	O
mask	O
patients	B-T101
or	O
investigators	B-T097
to	O
treatment	B-T061
assignments	B-T169
.	O
Our	O
primary outcome	B-T169
was	O
the	O
proportion	B-T081
of	O
patients	B-T101
in	O
the	O
intention-to-treat	B-T062
population	B-T098
who	O
had	O
remission	B-T033
of	O
arthritis	B-T047
in	O
all	O
injected	B-T061
joints	B-T030
at	O
12	O
months	B-T079
.	O
This	O
trial	B-T062
is	O
registered	B-T058
with	O
European Union Clinical Trials Register	B-T058
,	O
EudraCT number	B-T170
2008-006741-70.	O
Between	O
July	B-T080
7,	O
2009,	O
and	O
March	B-T079
31,	O
2013,	O
we	O
screened	B-T169
226	O
participants	B-T098
and	O
randomly	B-T080
assigned	B-T169
102	O
to	O
intra-articular	B-T082
corticosteroids	B-T121
alone	B-T081
and	O
105	O
to	O
intra-articular	B-T082
corticosteroids	B-T121
plus	B-T169
methotrexate	B-T109
.	O
33	O
(32%)	O
patients	B-T101
assigned	B-T169
to	O
intra-articular	B-T082
corticosteroids	B-T121
alone	B-T081
and	O
39	O
(37%)	O
assigned	B-T169
to	O
intra-articular	B-T082
corticosteroids	B-T121
and	O
methotrexate	B-T109
therapy	B-T061
had	O
remission	B-T033
of	O
arthritis	B-T047
in	O
all	O
injected	B-T061
joints	B-T030
(p=0·48).	O
Adverse events	B-T046
were	O
recorded	O
for	O
20	O
(17%)	O
patients	B-T101
who	O
received	O
methotrexate	B-T109
,	O
which	O
led	O
to	O
permanent	B-T079
treatment	B-T061
discontinuation	B-T033
in	O
two	O
patients	B-T101
(one	O
due	O
to	O
increased liver transaminases	B-T033
and	O
one	O
due	O
to	O
gastrointestinal discomfort	B-T184
).	O
No	B-T033
patient	B-T101
had	O
a	O
serious	B-T080
adverse event	B-T046
.	O
Concomitant administration	B-T169
of	O
methotrexate	B-T109
did	O
not	O
augment	B-T169
the	O
effectiveness	B-T080
of	O
intra-articular corticosteroid therapy	B-T061
.	O
Future studies	B-T062
are	O
needed	O
to	O
define	O
the	O
optimal	B-T080
therapeutic strategies	B-T061
for	O
oligoarticular juvenile idiopathic arthritis	B-T047
.	O
Italian Agency of Drug Evaluation	B-T092
.	O

Methylation Analysis	B-T063
of	O
BRCA1	B-T028
and	O
APC	B-T028
in	O
Breast Cancer	B-T191
and	O
It's	O
Relationship	B-T080
to	O
Clinicopathological	B-T169
Features	B-T080
Promoter methylation	B-T044
of	O
tumor suppressor genes	B-T028
is	O
an	O
important	O
epigenetic alteration	B-T045
that	O
occurs	O
in	O
the	O
primary	B-T080
stages	B-T079
of	O
human	B-T016
tumors	B-T191
,	O
including	O
breast cancer	B-T191
.	O
Identification	O
of	O
methylated genes	B-T028
and	O
their	O
relationship	B-T080
to	O
clinical	B-T080
features	B-T080
can	O
contribute	O
to	O
the	O
prognosis	B-T058
and	O
early detection	B-T060
of	O
tumors	B-T191
.	O
In	O
this	O
study	B-T062
,	O
we	O
explored	O
the	O
methylation	B-T044
status	B-T080
of	O
APC	B-T028
and	O
BRCA1 genes	B-T028
and	O
their	O
relationship	B-T080
to	O
clinical	B-T080
factors	B-T169
in	O
breast cancer	B-T191
patients	B-T101
.	O
BRCA1	B-T028
and	O
APC	B-T028
promoter methylation	B-T044
was	O
examined	O
by	O
methylation	B-T044
-	O
specific multiplex ligation-dependent probe amplification	B-T063
(	O
MS-MLPA	B-T063
)	O
assay	B-T059
in	O
formalin-fixed paraffin embedded (FFPE) breast tissue	B-T024
from	O
75	O
patients	B-T101
.	O
APC	B-T028
promoter methylation	B-T044
was	O
detected	B-T033
in	O
30.67%	O
breast cancer	B-T191
tissues	B-T024
and	O
BRCA1	B-T028
was	O
methylated	B-T044
in	O
9.33%	O
of	O
breast tumors	B-T191
.	O
Methylation	B-T044
of	O
APC	B-T028
was	O
associated with	B-T080
low	O
histological grade	B-T185
(p	O
=	O
0.006)	O
and	O
methylation	B-T044
of	O
BRCA1	B-T028
was	O
related	O
with	O
lymph node	B-T023
metastasis	B-T046
(p	O
=	O
0.017).	O
These	O
findings	B-T033
suggest	O
that	O
the	O
methylation	B-T044
status	B-T080
of	O
APC	B-T028
and	O
BRCA1	B-T028
can	O
be	O
a	O
predictive marker	B-T201
for	O
early detection	B-T060
and	O
better	O
management	B-T058
of	O
breast cancer	B-T191
patients	B-T101
.	O

Recombinant	B-T116
fibrinogen	B-T116
reveals	O
the	O
differential	B-T080
roles	O
of	O
α-	B-T116
and	O
γ-chain	B-T116
cross-linking	B-T044
and	O
molecular	B-T080
heterogeneity	B-T080
in	O
fibrin clot	B-T044
strain-stiffening	B-T070
Essentials	O
Fibrinogen	B-T116
circulates	B-T169
in	O
human	B-T016
plasma	B-T031
as	O
a	O
complex	B-T104
mixture	B-T167
of	O
heterogeneous	B-T080
molecular	B-T080
variants	B-T080
.	O
We	O
measured	B-T080
strain-stiffening	B-T070
of	O
recombinantly	B-T045
produced	O
fibrinogen	B-T116
upon	O
clotting	B-T042
.	O
Factor XIII	B-T116
and	O
molecular	B-T080
heterogeneity	B-T080
alter	O
clot	B-T044
elasticity	B-T070
at	O
the	O
protofibril	B-T116
and	O
fiber	B-T024
level.	O
This	O
highlights	O
the	O
hitherto	O
unknown	O
role	O
of	O
molecular	B-T080
composition	B-T080
in	O
fibrin clot	B-T044
mechanics	B-T070
.	O
Background	O
Fibrin	B-T116
plays	O
a	O
crucial	O
role	O
in	O
haemostasis	B-T042
and	O
wound healing	B-T040
by	O
forming	O
strain-stiffening	B-T070
fibrous networks	B-T026
that	O
reinforce	O
blood clots	B-T046
.	O
The	O
molecular	B-T080
origin	O
of	O
fibrin's	B-T116
strain-stiffening	B-T070
behavior	O
remains	O
poorly	O
understood,	O
primarily	O
because	O
plasma	B-T031
fibrinogen	B-T116
is	O
a	O
complex	B-T104
mixture	B-T167
of	O
heterogeneous	B-T080
molecular	B-T080
variants	B-T080
and	O
is	O
often	O
contaminated	O
by	O
plasma factors	B-T116
that	O
affect	O
clot	B-T044
properties	B-T080
.	O
Objectives	O
and	O
methods	O
To	O
facilitate	O
mechanistic dissection	B-T169
of	O
fibrin	B-T116
nonlinear elasticity	B-T070
,	O
we	O
produced	O
a	O
homogeneous	B-T080
recombinant	B-T116
fibrinogen	B-T116
corresponding	O
to	O
the	O
main	O
variant	B-T080
in	O
human	B-T016
plasma	B-T031
,	O
termed	O
rFib610	B-T116
.	O
We	O
characterized	O
the	O
structure	B-T082
of	O
rFib610	B-T116
clots	B-T044
using	O
turbidimetry	B-T059
,	O
microscopy	B-T059
and	O
X-ray scattering	B-T059
.	O
We	O
used	O
rheology	B-T059
to	O
measure	B-T081
the	O
strain-stiffening	B-T070
behavior	O
of	O
the	O
clots	B-T044
and	O
determined	O
the	O
fiber	B-T024
properties	B-T080
by	O
modeling	B-T062
the	O
clots	B-T044
as	O
semi-flexible polymer networks	B-T169
.	O
Results	O
We	O
show	O
that	O
addition	O
of	O
FXIII	B-T116
to	O
rFib610	B-T116
clots	B-T044
causes	O
a	O
dose-dependent stiffness	B-T080
increase	O
at	O
small	O
deformations	B-T169
and	O
renders	O
the	O
strain-stiffening	B-T070
response	O
reversible.	O
We	O
find	O
that	O
γ-chain	B-T116
cross-linking	B-T044
contributes	O
to	O
clot	B-T044
elasticity	B-T070
by	O
changing	O
the	O
force-extension behavior	B-T169
of	O
the	O
protofibrils	B-T116
,	O
whereas	O
α-chain	B-T116
cross-linking	B-T044
stiffens	O
the	O
fibers	B-T024
,	O
as	O
a	O
consequence	O
of	O
tighter coupling	B-T169
between	O
the	O
constituent	O
protofibrils	B-T116
.	O
Interestingly,	O
rFib610	B-T116
protofibrils	B-T116
have	O
a	O
25%	O
larger	O
bending rigidity	B-T080
than	O
plasma	B-T031
-purified	O
fibrin	B-T116
protofibrils	B-T116
and	O
a	O
delayed	O
strain-stiffening	B-T070
,	O
indicating	O
that	O
molecular	B-T080
heterogeneity	B-T080
influences	B-T077
clot	B-T044
mechanics	B-T070
at	O
the	O
protofibril scale	B-T116
.	O
Conclusions	O
Fibrinogen	B-T116
molecular	B-T080
heterogeneity	B-T080
and	O
FXIII	B-T116
affect	O
the	O
mechanical function	B-T169
of	O
fibrin clots	B-T044
by	O
altering	O
the	O
nonlinear viscoelastic properties	B-T080
at	O
the	O
protofibril	B-T026
and	O
fiber scale	B-T024
.	O
This	O
work	O
provides	O
a	O
starting	O
point	O
to	O
investigate	B-T169
the	O
role	O
of	O
molecular	B-T080
heterogeneity	B-T080
of	O
plasma	B-T031
fibrinogen	B-T116
in	O
fibrin clot	B-T044
mechanics	B-T070
and	O
haemostasis	B-T042
.	O

Effects	O
of	O
display	B-T169
curvature	B-T082
,	O
display	B-T169
zone	B-T082
,	O
and	O
task	B-UnknownType
duration	B-T079
on	O
legibility	B-T033
and	O
visual fatigue	B-T047
during	O
visual search task	B-UnknownType
This	O
study	O
examined	O
the	O
effects	O
of	O
display	B-T169
curvature	B-T082
(400,	O
600,	O
1200	O
mm,	O
and	O
flat	B-T082
),	O
display	B-T169
zone	B-T082
(5	O
zones	B-T082
),	O
and	O
task	B-UnknownType
duration	B-T079
(15	O
and	O
30	O
min)	O
on	O
legibility	B-T033
and	O
visual fatigue	B-T047
.	O
Each	O
participant	B-T098
completed	O
two	O
15-min	O
visual search task	B-UnknownType
sets	O
at	O
each	O
curvature	B-T082
setting	B-T082
.	O
The	O
600-mm	O
and	O
1200-mm	O
settings	B-T082
yielded	O
better	O
results	O
than	O
the	O
flat	B-T082
setting	B-T082
in	O
terms	O
of	O
legibility	B-T033
and	O
perceived	O
visual fatigue	B-T047
.	O
Relative	O
to	O
the	O
corresponding	O
centre	B-T082
zone	B-T082
,	O
the	O
outermost	O
zones	B-T082
of	O
the	O
1200-mm	O
and	O
flat	B-T082
settings	B-T082
showed	O
a	O
decrease	O
of	O
8%-37%	O
in	O
legibility	B-T033
,	O
whereas	O
those	O
of	O
the	O
flat	B-T082
setting	B-T082
showed	O
an	O
increase	B-T169
of	O
26%-45%	O
in	O
perceived	B-T041
visual fatigue	B-T047
.	O
Across	O
curvature	B-T082
s,	O
legibility	B-T033
decreased	B-T081
by	O
2%-8%,	O
whereas	O
perceived	B-T041
visual fatigue	B-T047
increased	B-T169
by	O
22%	O
during	O
the	O
second	O
task set	B-UnknownType
.	O
The	O
two	O
task sets	B-UnknownType
induced	O
an	O
increase	B-T169
of	O
102%	O
in	O
the	O
eye complaint score	B-T081
and	O
a	O
decrease	O
of	O
0.3	O
Hz	O
in	O
the	O
critical fusion frequency	B-T034
,	O
both	O
of	O
which	O
indicated	O
an	O
increase	B-T169
in	O
visual fatigue	B-T047
.	O
In	O
summary,	O
a	O
curvature	B-T082
of	O
around	O
600	O
mm,	O
central	B-T082
display	B-T169
zones	B-T082
,	O
and	O
frequent	O
breaks	B-T082
are	O
recommended	O
to	O
improve	B-T033
legibility	B-T033
and	O
reduce	O
visual fatigue	B-T047
.	O

Predicting	O
changes	O
in	O
adaptive	B-T169
functioning	B-T169
and	O
behavioral	B-T053
adjustment	B-T169
following	O
treatment	B-T061
for	O
a	O
pediatric brain tumor	B-T191
:	O
A	O
report	B-T201
from	O
the	O
Brain	B-T023
Radiation Investigative Study Consortium	B-T097
Children	B-T100
are	O
at	O
risk	B-T078
for	O
behavioral	B-T053
and	O
adaptive	B-T169
difficulties	B-T080
following	O
pediatric brain tumor	B-T191
.	O
This	O
study	B-T062
explored	O
whether	O
familial	B-T169
/	O
demographic	B-T090
,	O
developmental	B-T080
,	O
diagnostic	B-T169
,	O
or	O
treatment	B-T061
-related	O
variables	B-T080
best	O
predict	O
posttreatment	B-T079
behavioral	B-T053
and	O
adaptive	B-T169
functioning	B-T169
.	O
Participants	B-T098
included	O
40	O
children	B-T100
(	O
mean	B-T081
age	B-T032
=	O
12.76	O
years,	O
SD	B-T081
=	O
4.01)	O
posttreatment	B-T079
(	O
mean	B-T081
time	B-T079
since	O
diagnosis	B-T033
=	O
1.99	O
years,	O
SD	B-T081
=	O
0.21)	O
for	O
pediatric brain tumor	B-T191
.	O
Parents	B-T099
rated	O
children	B-T100
's	O
behavioral	B-T053
adjustment	B-T169
and	O
adaptive	B-T169
functioning	B-T169
and	O
provided	O
demographic	B-T090
and	O
developmental	B-T080
histories	B-T033
.	O
Diagnostic	B-T033
and	O
treatment	B-T061
-related	O
information	B-T078
was	O
abstracted	O
from	O
medical records	B-T170
.	O
Ratings	B-T052
of	O
adaptive	B-T169
and	O
behavioral	B-T053
functioning	B-T169
approximately	O
2	O
years	O
postdiagnosis	B-T033
were	O
within	O
the	O
average	B-T081
range	B-T081
,	O
although	O
the	O
percentage	B-T081
of	O
children	B-T100
exceeding	O
clinical	B-T080
cutoffs	B-T169
for	O
impairment	B-T169
in	O
adaptive	B-T169
skills	B-T055
exceeded	O
expectation	B-T078
,	O
particularly	O
practical	O
skills	B-T055
.	O
Premorbid behavior	B-T053
problems	B-T078
and	O
tumor size	B-T082
predicted	O
posttreatment	B-T079
adaptive	B-T169
functioning	B-T169
.	O
After	O
accounting	O
for	O
adaptive	B-T169
functioning	B-T169
near	O
diagnosis	B-T033
,	O
premorbid behavior	B-T053
problems	B-T078
predicted	O
declines	O
in	O
adaptive	B-T169
functioning	B-T169
2	O
years	O
postdiagnosis	B-T033
.	O
After	O
accounting	O
for	O
adjustment	B-T169
near	O
diagnosis	B-T033
,	O
no	O
variables	B-T080
predicted	O
declines	O
in	O
behavioral	B-T053
adjustment	B-T169
.	O
Children	B-T100
may	O
be	O
vulnerable	B-T169
to	O
reduced	O
adaptive	B-T169
functioning	B-T169
following	O
pediatric brain tumor	B-T191
treatment	B-T061
,	O
especially	O
in	O
practical	O
skills.	O
Assessing	O
prediagnosis	B-T033
functioning	B-T169
and	O
diagnostic	B-T033
and	O
treatment	B-T061
-related	O
variables	B-T080
may	O
improve	B-T033
our	O
ability	B-T032
to	O
predict	O
those	O
at	O
greatest	O
risk	B-T078
,	O
although	O
those	O
factors	B-T169
may	O
be	O
less	O
helpful	B-T080
in	O
identifying	B-T080
children	B-T100
likely	O
to	O
develop	O
behavioral	B-T053
difficulties	B-T080
.	O
Screening	B-T058
of	O
these	O
factors	B-T169
in	O
tertiary care	B-T058
and	O
long-term	B-T079
follow-up	B-T058
settings	O
may	O
improve	B-T033
identification	B-T080
of	O
those	O
at	O
greatest	O
need	B-T080
for	O
support services	B-UnknownType
.	O

Spine fracture	B-T037
prevalence	B-T081
in	O
a	O
nationally representative	B-T082
sample	O
of	O
US	B-T083
women	B-T098
and	O
men	B-T098
aged	B-T032
≥40	O
years:	O
results	O
from	O
the	O
National Health and Nutrition Examination Survey	B-T062
(	O
NHANES	B-T062
)	O
2013-2014	O
Spine fracture	B-T037
prevalence	B-T081
is	O
similar	O
in	O
men	B-T098
and	O
women	B-T098
,	O
increasing	O
from	O
<5	O
%	O
in	O
those	O
<60	O
to	O
11	O
%	O
in	O
those	O
70-79	O
and	O
18	O
%	O
in	O
those	O
≥80	O
years.	O
Prevalence	B-T081
was	O
higher	B-T080
with	O
age	B-T032
age	B-T032
,	O
lower	B-T080
bone mineral density	B-T201
(	O
BMD	B-T201
),	O
and	O
in	O
those	O
meeting	O
criteria	B-T080
for	O
spine imaging	B-T060
.	O
Most	O
subjects	B-T062
with	O
spine fractures	B-T037
were	O
unaware	B-T033
of	O
them.	O
Spine fractures	B-T037
have	O
substantial	O
medical	B-T169
significance	O
but	O
are	O
seldom	B-T080
recognized.	O
This	O
study	O
collected	O
contemporary	O
nationally representative	B-T082
spine fracture	B-T037
prevalence	B-T081
data.	O
Cross-sectional analysis	B-T062
of	O
3330	O
US	B-T083
adults	B-T100
aged	B-T032
≥40	O
years	O
participating	O
in	O
NHANES	B-T062
2013-2014	O
with	O
evaluable	O
Vertebral Fracture	B-T037
Assessment	O
(	O
VFA	B-T060
).	O
VFA	B-T060
was	O
graded	O
by	O
semiquantitative	O
measurement.	O
BMD	B-T201
and	O
an	O
osteoporosis	B-T047
questionnaire	B-T170
were	O
collected.	O
Overall	O
spine fracture	B-T037
prevalence	B-T081
was	O
5.4	O
%	O
and	O
similar	O
in	O
men	B-T098
and	O
women	B-T098
.	O
Prevalence	B-T081
increased	O
with	O
age	B-T032
from	O
<5	O
%	O
in	O
those	O
<60	O
to	O
11	O
%	O
in	O
those	O
70-79	O
and	O
18	O
%	O
in	O
those	O
≥80	O
years.	O
Fractures	B-T037
were	O
more	O
common	O
in	O
non-Hispanic whites	B-T098
and	O
in	O
people	O
with	O
lower	B-T080
body mass index	B-T201
and	O
BMD	B-T201
.	O
Among	O
subjects	B-T062
with	O
spine fracture	B-T037
,	O
26	O
%	O
met	O
BMD	B-T201
criteria	B-T080
for	O
osteoporosis	B-T047
.	O
Prevalence	B-T081
was	O
higher	B-T080
in	O
subjects	B-T062
who	O
met	O
National Osteoporosis Foundation	B-UnknownType
(	O
NOF	B-UnknownType
)	O
criteria	B-T080
for	O
spine imaging	B-T060
(14	O
vs	O
4.7	O
%,	O
P	O
<	O
0.001).	O
Only	O
8	O
%	O
of	O
people	O
with	O
a	O
spine fracture	B-T037
diagnosed	B-T033
by	O
VFA	B-T060
had	O
a	O
self-reported	B-T062
fracture	B-T037
,	O
and	O
among	O
those	O
who	O
self-reported	B-T062
a	O
spine fracture	B-T037
,	O
only	O
21	O
%	O
were	O
diagnosed	B-T033
with	O
fracture	B-T037
by	O
VFA	B-T060
.	O
Spine fracture	B-T037
prevalence	B-T081
is	O
similar	O
in	O
women	B-T098
and	O
men	B-T098
and	O
increases	O
with	O
age	B-T032
and	O
lower	B-T080
BMD	B-T201
,	O
although	O
most	O
subjects	B-T062
with	O
spine fracture	B-T037
do	O
not	O
meet	O
BMD	B-T201
criteria	O
for	O
osteoporosis	B-T047
.	O
Since	O
most	O
(>90	O
%)	O
individuals	B-T098
were	O
unaware	B-T033
of	O
their	O
spine fractures	B-T037
,	O
lateral	B-T082
spine imaging	B-T060
is	O
needed	O
to	O
identify	O
these	O
women	B-T098
and	O
men	B-T098
.	O
Spine fracture	B-T037
prevalence	B-T081
was	O
threefold	O
higher	B-T080
in	O
individuals	B-T098
meeting	O
NOF	B-UnknownType
criteria	B-T080
for	O
spine imaging	B-T060
(∼1	O
in	O
7	O
undergoing	O
VFA	B-T060
).	O
Identifying	O
spine fractures	B-T037
as	O
part	O
of	O
comprehensive	B-T080
risk assessment	B-T058
may	O
improve	B-T033
clinical decision making	B-T060
.	O

Renieramycin M	B-T109
Attenuates	O
Cancer Stem Cell	B-T025
-like	O
Phenotypes	B-T032
in	O
H460	B-T025
Lung	B-T023
Cancer Cells	B-T025
Cancer stem cells	B-T025
(	O
CSCs	B-T025
)	O
are	O
a	O
subpopulation	O
of	O
cancer cells	B-T025
that	O
possess	O
self-renewal	B-T043
and	O
differentiation	B-T043
capacities.	O
CSCs	B-T025
contribute	O
to	O
drug-resistance	B-T038
,	O
cancer recurrence	B-T191
and	O
metastasis	B-T046
,	O
thus	O
development	B-T169
of	O
CSC	B-T025
-targeted	O
therapeutic strategies	B-T061
has	O
recently	O
received	O
significant	O
attention	O
in	O
cancer research	B-T062
.	O
In	O
this	O
study	B-T062
,	O
the	O
potential	O
efficacy	B-T080
of	O
renieramycin M	B-T109
(	O
RM	B-T109
)	O
isolated	O
from	O
the	O
sponge	B-T204
Xestospongia species	B-T204
,	O
was	O
examined	B-T033
against	O
lung	B-T023
CSCs	B-T025
.	O
Colony and spheroid formation assays	B-T059
,	O
as	O
well	O
as	O
western blotting analysis	B-T059
of	O
lung	B-T023
CSC	B-T025
protein	B-T116
markers	B-T123
were	O
employed	O
to	O
determine	O
the	O
CSC	B-T025
-like	O
phenotypes	B-T032
of	O
H460	B-T025
lung	B-T023
cancer cells	B-T025
after	O
treatment	B-T061
with	O
RM	B-T109
at	O
non-toxic concentrations	B-UnknownType
.	O
RM	B-T109
treatment	B-T061
reduced	O
significantly	O
colony and spheroid formation	B-T059
of	O
H460 cells	B-T025
.	O
Moreover,	O
the	O
CSC	B-T025
markers	B-T123
CD133	B-T116
,	O
CD44	B-T116
and	O
ALDH1A1	B-T116
of	O
CSC	B-T025
-enriched	O
H460 cells	B-T025
were	O
reduced	O
significantly	O
following	O
RM	B-T109
treatment	B-T061
.	O
RM	B-T109
could	O
be	O
a	O
potent	O
anti-metastatic agent	B-T121
by	O
suppressing	O
lung	B-T023
CSC	B-T025
-like	O
phenotypes	B-T032
in	O
H460 cells	B-T025
.	O

Physicochemical	O
characterization	O
of	O
chitosan	B-T109
-	O
hyaluronan	B-T109
-coated	O
solid	O
lipid nanoparticles	B-T203
for	O
the	O
targeted	O
delivery	B-T061
of	O
paclitaxel	B-T109
:	O
a	O
proof-of-concept study	B-T062
in	O
breast cancer cells	B-T025
To	O
investigate	O
the	O
potential	O
of	O
modified	O
solid lipid nanoparticles	B-T203
(	O
SLN	B-T203
)	O
for	O
the	O
delivery	O
of	O
paclitaxel	B-T109
(	O
PAX	B-T109
).	O
SLN loaded with PAX	B-T109
were	O
prepared	O
via	O
modified	O
high-pressure hot homogenization	B-T059
.	O
Formulation parameters	B-T062
were	O
optimized	O
to	O
obtain	O
a	O
high-quality delivery system	B-T074
.	O
SLN	B-T203
cores	O
were	O
coated, layer-by-layer	B-T080
,	O
with	O
a	O
chitosan	B-T109
and	O
hyaluronan	B-T109
(	O
HA	B-T109
)	O
shell.	O
Selectivity	O
toward	O
HA	B-T109
receptors	B-T116
was	O
tested	O
in	O
a	O
breast cancer cell line	B-T025
,	O
MCF-7	B-T025
.	O
Stable and reproducible	B-T080
nano-sized	B-T080
and	O
negatively charged nanoparticles	B-T073
resulted.	O
Findings	O
reveal	O
that	O
chitosan	B-T109
-	O
HA	B-T109
-coated	O
SLN	B-T203
facilitated	O
the	O
targeting	B-T169
,	O
cellular uptake	B-T043
and	O
the	O
time-/dose-controlled delivery and release	B-T203
of	O
PAX	B-T109
,	O
enhancing	O
intrinsic chemotherapeutic activities	B-T061
.	O
SLN	B-T203
are	O
suitable	O
carrier candidates	B-T074
for	O
nano-oncology	B-T091
given	O
their	O
localized,	O
and	O
potent	O
cytotoxic potential	B-T121
overcoming	B-T033
multidrug-resistant cancer cells	B-T038
.	O

Epigenetic Editing	B-T063
of	O
Ascl1 Gene	B-T028
in	O
Neural Stem Cells	B-T025
by	O
Optogenetics	B-T063
Enzymes	B-T116
involved	O
in	O
epigenetic processes	B-T045
such	O
as	O
methyltransferases	B-T116
or	O
demethylases	B-T116
are	O
becoming	O
highly	B-T080
utilized	B-T169
for	O
their	O
persistent DNA	B-T114
or	O
histone modifying	B-T044
efficacy	B-T080
.	O
Herein,	O
we	O
have	O
developed	O
an	O
optogenetic	B-T063
toolbox	B-T170
fused	O
to	O
the	O
catalytic domain	B-T087
(	O
CD	B-T087
)	O
of	O
DNA-methyltransferase3A	B-T116
(	O
DNMT3A	B-T116
-	O
CD	B-T087
)	O
or	O
Ten-Eleven Dioxygenase-1	B-T116
(	O
TET1	B-T116
-	O
CD	B-T087
)	O
for	O
loci	B-T082
-	O
specific	B-T080
alteration	B-T045
of	O
the	O
methylation	B-T044
state	B-T169
at	O
the	O
promoter	B-T114
of	O
Ascl1	B-T028
(	O
Mash1	B-T028
),	O
a	O
candidate proneuron gene	B-T028
.	O
Optogenetical protein pairs	B-T116
,	O
CRY2	B-T116
linked	O
to	O
DNMT3A	B-T116
-	O
CD	B-T087
or	O
TET1	B-T116
-	O
CD	B-T087
and	O
CIB1	B-T116
fused	B-T169
to	O
a	O
Transcription Activator-Like Element	B-T116
(	O
TALE	B-T116
)	O
locating	O
an	O
Ascl1	B-T028
promoter region	B-T114
,	O
were	O
designed	O
for	O
site specific	B-T082
epigenetic editing	B-T063
.	O
A	O
differentially	B-T080
methylated region	B-T082
at	O
the	O
Ascl1	B-T028
promoter	B-T114
,	O
isolated	B-T169
from	O
murine	B-T015
dorsal root ganglion	B-T023
(	O
hypermethylated	B-T044
)	O
and	O
striated	B-T080
cells	B-T025
(	O
hypomethylated	B-T044
),	O
was	O
targeted	B-T169
with	O
these	O
optogenetic-epigenetic constructs	B-T116
.	O
Optimized	O
blue-light	B-T070
illumination	B-T059
triggered	B-T080
the	O
co-localization	B-T067
of	O
TALE constructs	B-T116
with	O
DNMT3A	B-T116
-	O
CD	B-T087
or	O
TET1	B-T116
-	O
CD	B-T087
fusion proteins	B-T116
at	O
the	O
targeted site	B-T082
of	O
the	O
Ascl1	B-T028
promoter	B-T114
.	O
We	O
found	O
that	O
this	O
spatiotemporal	B-T080
association	O
of	O
the	O
fusion proteins	B-T116
selectively	O
alters	B-T169
the	O
methylation	B-T044
state	B-T169
and	O
also	O
regulates	B-T045
gene activity	B-T045
.	O
This	O
proof	O
of	O
concept	B-T078
developed	O
herein	O
holds	O
immense	B-T081
promise	B-T078
for	O
the	O
ability	O
to	O
regulate	B-T044
gene activity	B-T045
via	O
epigenetic modulation	B-T063
with	O
spatiotemporal	B-T080
precision	B-T080
.	O

Vaginal Infections	B-T047
of	O
Albanian	B-T083
women	B-T098
Infected	B-T046
with	O
HPV	B-T005
and	O
their	O
impact	O
in	O
intraepithelial cervical lesions	B-T191
evidenced	O
by	O
Pap test	B-T059
Cervical cytology	B-T059
is	O
the	O
best	O
single	O
method	O
for	O
large	O
screening	B-T060
of	O
the	O
population	O
in	O
identifying	O
precancerous lesions	B-T191
of	O
the	O
uterine cervix	B-T023
.	O
To	O
estimate	O
the	O
frequency	O
of	O
human papillomavirus (HPV) positivity	B-T034
in	O
a	O
group	O
of	O
Albanian	B-T083
women	B-T098
,	O
the	O
prevalence	B-T081
of	O
vaginal coinfections	B-T047
,	O
and	O
the	O
relationship	O
of	O
coinfections	B-T047
with	O
HPV	B-T005
,	O
as	O
well	O
as	O
their	O
role	O
in	O
metaplasia	B-T049
or	O
cervical intraepithelial lesions	B-T191
(	O
CIN	B-T191
).	O
In	O
this	O
retrospective study	B-T062
,	O
2075	O
vaginal smears	B-T060
were	O
examined.	O
The	O
Papanicolaou stain	B-T060
was	O
used	O
for	O
all	O
slides.	O
The	O
New Bethesda System	B-T059
2001	O
was	O
used	O
for	O
the	O
interpretations of the smears	B-T059
.	O
Data	O
analysis	O
was	O
completed	O
using	O
the	O
Statistical Package for the Social Sciences version	B-T081
19.0.	O
Prevalence	B-T081
of	O
HPV positivity	B-T034
was	O
43.9%	O
with	O
an	O
average	O
age	O
of	O
35.48	O
±	O
9.27	O
years.	O
Candida coinfection	B-T047
resulted	O
in	O
57.8%	O
of	O
HPV positive	B-T034
women	B-T098
with	O
a	O
significant	O
relationship	O
between	O
them.	O
Gardnerella coinfection	B-T047
resulted	O
in	O
36	O
(23%),	O
mixed flora	B-T047
in	O
34	O
(8%),	O
and	O
Trichomonas vaginalis	B-T047
in	O
50%	O
of	O
HPV positive	B-T034
woman	B-T098
.	O
Among	O
the	O
women	B-T098
with	O
positive HPV	B-T034
,	O
19%	O
had	O
CIN	B-T191
,	O
8%	O
had	O
metaplasia	B-T049
,	O
and	O
1%	O
had	O
metaplasia	B-T049
and	O
CIN	B-T191
;	O
9%	O
of	O
the	O
women	B-T098
with	O
HPV	B-T005
had	O
CIN1	B-T191
and	O
one	O
of	O
the	O
coinfections	B-T047
.	O
There	O
is	O
a	O
strong	O
relationship	O
between	O
CIN1	B-T191
and	O
HPV positivity	B-T034
as	O
well	O
as	O
between	O
CIN1	B-T191
and	O
coinfections	B-T047
.	O
HPV infection	B-T047
is	O
a	O
major	O
factor	O
contributing	O
to	O
metaplasia	B-T049
,	O
and	O
bacterial coinfections	B-T047
in	O
HPV positive	B-T034
women	B-T098
have	O
a	O
statistically significant	B-T081
impact	O
in	O
the	O
development	O
of	O
metaplasia	B-T049
.	O

A	O
Case	O
of	O
Acute	B-T079
Hepatitis E Infection	B-T047
in	O
a	O
Patient	B-T101
with	O
Non-Hodgkin Lymphoma	B-T191
Treated	B-T061
Successfully	O
with	O
Ribavirin	B-T114
We	O
present	O
the	O
case	O
of	O
a	O
man	B-T098
who,	O
following	O
immunosuppressive treatment	B-T061
for	O
non-Hodgkin lymphoma	B-T191
,	O
became	O
infected	B-T033
with	O
viral hepatitis E	B-T047
.	O
Acute	B-T079
hepatitis E virus infection	B-T047
should	O
be	O
considered	O
in	O
patients	B-T101
with	O
deranged	B-T080
liver function	B-T042
on	O
a	O
background	O
of	O
haematological malignancies	B-T191
or	O
immunosuppression	B-T047
,	O
even	O
without	O
travel	O
to	O
endemic regions	B-T083
.	O
Whilst	O
clearance	O
is	O
usually	O
spontaneous	O
in	O
immune	B-T169
-	O
competent	B-T080
individuals	B-T098
,	O
these	O
at-risk groups	B-T098
may	O
develop	O
a	O
more	O
complicated	O
and	O
protracted disease course	B-T033
.	O
Thus	O
awareness	O
is	O
important	O
as	O
additional	O
treatment	B-T061
with	O
ribavirin	B-T114
or	O
pegylated interferon	B-T109
may	O
be	O
required,	O
as	O
in	O
this	O
case,	O
in	O
order	O
to	O
help	O
achieve	O
eradication	B-T058
.	O

Commissioning	B-T097
through	O
competition	B-T054
and	O
cooperation	B-T054
in	O
the	O
English	B-T098
NHS	B-T058
under	O
the	O
Health and Social Care Act 2012	B-T058
:	O
evidence	O
from	O
a	O
qualitative study	B-T062
of	O
four	O
clinical commissioning groups	B-T097
The	O
Health and Social Care Act 2012	B-T058
('	O
HSCA 2012	B-T058
')	O
introduced	O
a	O
new,	O
statutory,	O
form	O
of	O
regulation	B-T064
of	O
competition	B-T054
into	O
the	O
National Health Service	B-T058
(	O
NHS	B-T058
),	O
while	O
at	O
the	O
same	O
time	O
recognising	O
that	O
cooperation	B-T054
was	O
necessary.	O
NHS	B-T058
England's policy document	B-T170
,	O
The	O
Five Year Forward View	B-T170
('	O
5YFV	B-T170
')	O
of	O
2014	O
placed	O
less	O
emphasis	O
on	O
competition	B-T054
without	O
altering	O
the	O
legislation	B-T170
.	O
We	O
explored	O
how	O
commissioners	B-T062
and	O
providers	B-T169
understand	O
the	O
complex	B-T080
regulatory framework	B-T089
,	O
and	O
how	O
they	O
behave	O
in	O
relation	O
to	O
competition	B-T054
and	O
cooperation	B-T054
.	O
We	O
carried	O
out	O
detailed	O
case studies	B-T170
in	O
four	O
clinical commissioning groups	B-T097
,	O
using	O
interviews	B-T052
and	O
documentary analysis	B-T062
to	O
explore	O
the	O
commissioners	B-T062
'	O
and	O
providers	B-T169
'	O
understanding	O
and	O
experience	O
of	O
competition	B-T054
and	O
cooperation	B-T054
.	O
We	O
conducted	O
42	O
interviews	B-T052
with	O
senior managers	B-T097
in	O
commissioning	B-T097
organisations	B-T094
and	O
senior managers	B-T097
in	O
NHS	B-T058
and	O
independent provider organisations	B-T093
(	O
acute and community services	B-T095
).	O
Neither	O
commissioners	B-T062
nor	O
providers	B-T169
fully	O
understand	O
the	O
regulatory regime	B-T089
in	O
respect	O
of	O
competition	B-T054
in	O
the	O
NHS	B-T058
,	O
and	O
have	O
not	O
found	O
that	O
the	O
regulatory authorities	B-T089
have	O
provided	O
adequate	O
guidance	B-T065
.	O
Despite	O
the	O
HSCA 2012	B-T058
promoting	B-T052
competition	B-T054
,	O
commissioners	B-T062
chose	O
mainly	O
to	O
use	O
collaborative strategies	B-T062
to	O
effect	O
major	O
service	B-T057
reconfigurations,	O
which	O
is	O
endorsed	O
as	O
a	O
suitable	O
approach	O
by	O
providers	B-T169
.	O
Nevertheless,	O
commissioners	B-T062
are	O
using	O
competitive	B-T054
tendering	O
in	O
respect	O
of	O
more	O
peripheral services	B-T057
in	O
order	O
to	O
improve	O
quality of care	B-T058
and	O
value for money	B-T078
.	O
Commissioners	B-T062
regard	O
the	O
use	O
of	O
competition	B-T054
and	O
cooperation	B-T054
as	O
appropriate	O
in	O
the	O
NHS	B-T058
currently,	O
although	O
collaborative strategies	B-T062
appear	O
more	O
helpful	O
in	O
respect	O
of	O
large-scale changes	B-UnknownType
.	O
However,	O
the	O
current	O
regulatory framework	B-T089
contained	O
in	O
the	O
HSCA 2012	B-T058
,	O
particularly	O
since	O
the	O
publication	B-T073
of	O
the	O
5YFV	B-T170
,	O
is	O
not	O
clear.	O
Better	O
guidance	B-T065
should	O
be	O
issued	O
by	O
the	O
regulatory authorities	B-T089
.	O

Prevalence	B-T081
and	O
correlates	B-T080
of	O
antibiotic	B-T195
sharing	B-T054
in	O
the	O
Philippines	B-T083
:	O
antibiotic	B-T195
misconceptions	B-T041
and	O
community	B-T096
-	O
level	B-T080
access	O
to	O
non-medical	B-T056
sources	B-T033
of	O
antibiotics	B-T195
To	O
identify	O
sociodemographic	B-T078
,	O
knowledge	B-T170
and	O
attitudinal	B-T041
correlates	B-T080
to	O
antibiotic	B-T195
sharing	B-T054
among	O
a	O
community-based sample	B-T081
of	O
adults	B-T100
(age	O
18	O
and	O
older)	O
in	O
a	O
low-income setting	B-T033
of	O
the	O
Philippines	B-T083
and	O
to	O
explore	O
community	B-T096
-	O
level	B-T080
data	B-T078
on	O
informal	B-T033
antibiotic	B-T195
distribution	B-T057
in	O
roadside stands	B-T082
(i.e.,	O
sari-sari stands	B-T082
).	O
Participants	B-T098
(n	O
=	O
307)	O
completed	B-T080
self-administered	B-T169
surveys	B-T170
.	O
Correlates	B-T080
to	O
antibiotic	B-T195
sharing	B-T054
were	O
assessed	B-T052
using	O
logistic regression	B-T062
with	O
Firth's bias-adjusted estimate	B-T170
s.	O
Study	O
staff	B-T097
also	O
visited	O
106	O
roadside stands	B-T082
and	O
collected data	B-T033
on	O
availability	B-T169
and	O
characteristics	O
of	O
antibiotics	B-T195
in	O
the	O
stands	B-T082
.	O
78%	O
had	O
shared	B-T054
antibiotics	B-T195
in	O
their	O
lifetime	B-T079
,	O
most	O
often	B-T079
with	O
family members	B-T099
.	O
In	O
multivariable analysis	B-T081
,	O
agreement	B-T054
with	O
the	O
belief	B-T078
that	O
it	O
is	O
safe	O
to	O
prematurely	B-T079
stop	B-T052
an	O
antibiotic	B-T195
course	B-T079
(	O
OR	B-T081
:	O
2.8,	O
CI:	O
1.3-5.8)	O
and	O
concerns	B-T078
about	O
antibiotic side effects	B-T037
(	O
OR	B-T081
:	O
2.1,	O
CI:	O
1.1-4.4)	O
were	O
significantly	O
associated with	B-T080
increased	B-T081
odds	O
of	O
reported	O
antibiotic	B-T195
sharing	B-T054
.	O
Antibiotic	B-T195
sharing	B-T054
was	O
not	O
associated with	B-T080
sociodemographic characteristics	B-T102
or	O
antibiotic	B-T195
knowledge	B-T170
.	O
Antibiotics	B-T195
were	O
widely	O
available	B-T169
in	O
60%	O
of	O
sampled	O
sari-sari stands	B-T082
,	O
in	O
which	O
59%	O
of	O
antibiotics	B-T195
were	O
missing expiration dates	B-T033
.	O
Amoxicillin	B-T109
and	O
cephalexin	B-T109
were	O
the	O
most	O
commonly	B-T081
available	B-T169
antibiotics	B-T195
for	O
sale	O
at	O
the	O
stands	B-T082
(60%	O
and	O
21%,	O
respectively).	O
Antibiotic	B-T195
sharing	B-T054
was	O
common	B-T081
and	O
was	O
associated with	B-T080
misconceptions	B-T041
about	O
proper	O
antibiotic	B-T195
use.	O
Antibiotics	B-T195
were	O
widely	O
available	B-T169
in	O
sari-sari stands	B-T082
,	O
and	O
usually	O
without	B-T080
expiration information	B-T170
.	O
This	O
study	O
suggests	O
that	O
multipronged	O
and	O
locally	O
tailored	O
approaches	O
to	O
curbing	B-T169
informal	B-T033
antibiotic	B-T195
access	O
are	O
needed	O
in	O
the	O
Philippines	B-T083
and	O
similar	O
Southeast-Asian countries	B-T083
.	O

Automated	B-T169
characterization	B-T052
and	O
counting	B-T081
of	O
Ki-67 protein	B-T116
for	O
breast cancer	B-T191
prognosis	B-T058
:	O
A	O
quantitative	B-T081
immunohistochemistry	B-T060
approach	B-T082
Ki-67 protein	B-T116
expression	B-T045
plays	O
an	O
important	O
role	O
in	O
predicting	O
the	O
proliferative status	B-T081
of	O
tumour cell	B-T025
s	O
and	O
deciding	O
the	O
future	B-T079
course	B-T079
of	O
therapy	B-T061
in	O
breast cancer	B-T191
.	O
Immunohistochemical (IHC) determination	B-T060
of	O
Ki-67 score	B-T059
or	O
labelling index	B-T059
,	O
by	O
estimating	O
the	O
fraction of	B-T081
Ki67	B-T116
positively	B-T033
stained	B-T080
tumour cells	B-T025
,	O
is	O
the	O
most	O
widely	O
practiced	O
method	B-T060
to	O
assess	B-T058
tumour	B-T191
proliferation	B-T169
(Dowsett	O
et	O
al.	O
2011).	O
Accurate	B-T080
manual counting	B-T059
of	O
these	O
cells	B-T025
(	O
specifically	B-T080
nuclei	B-T026
)	O
due	O
to	O
complex	B-T080
and	O
dense	B-T080
distribution	B-T169
of	O
cells	B-T025
,	O
therefore,	O
becomes	O
critical	B-T080
and	O
presents	B-T078
a	O
major	B-T080
challenge	O
to	O
pathologists	B-T097
.	O
In	O
this	O
paper,	O
we	O
suggest	O
a	O
hybrid clustering algorithm	B-T170
to	O
quantify	B-T081
the	O
proliferative index	B-T081
of	O
breast cancer cells	B-T025
based	O
on	O
automated counting	B-T059
of	O
Ki-67	B-T116
nuclei	B-T026
.	O
The	O
proposed	O
methodology	B-T060
initially	B-T079
pre-processes	B-T067
the	O
IHC	B-T060
images	B-T170
of	O
Ki-67	B-T116
stained	B-T080
slides	B-T075
of	O
breast cancer	B-T191
.	O
The	O
RGB	O
images	O
are	O
converted	O
to	O
grey	B-T080
,	O
L*a*b*,	O
HSI,	O
YCbCr,	O
YIQ	O
and	O
XYZ	O
colour space	B-T170
.	O
All	O
the	O
stained	B-T080
cells	B-T025
are	O
then	O
characterized	B-T052
by	O
two stage segmentation process	B-T059
.	O
Fuzzy C-means	B-T170
quantifies	B-T081
all	O
the	O
stained	B-T080
cells	B-T025
as	O
one	O
cluster	B-T081
.	O
The	O
blue	B-T080
channel	B-T077
of	O
the	O
first stage	B-T185
output	B-T077
is	O
given	O
as	O
input	O
to	O
k-means algorithm	B-T062
,	O
which	O
provides	O
separate	B-T080
cluster	B-T081
for	O
Ki-67	B-T116
positive and negative	B-T033
cells	B-T025
.	O
The	O
count	B-T081
of	O
positive and negative	B-T033
nuclei	B-T026
is	O
used	O
to	O
calculate	B-T059
the	O
F-measure	B-T081
for	O
each	O
colour space	B-T170
.	O
A	O
comparative study	B-T062
of	O
our	O
work	O
with	O
the	O
expert opinion	B-T077
is	O
studied	O
to	O
evaluate	O
the	O
error	B-T080
rate	B-T081
.	O
The	O
positive and negative	B-T033
nuclei	B-T026
detection	B-T033
results	B-T169
for	O
all	O
colour space	B-T170
s	O
are	O
compared	B-T052
with	O
the	O
ground	O
truth	O
for	O
validation	O
and	O
F-measure	B-T081
is	O
calculated	B-T059
.	O
The	O
F-measure	B-T081
for	O
L*a*b*	O
colour space	B-T170
(0.8847)	O
provides	O
the	O
best	O
statistical	B-T081
result	B-T169
as	O
compared	B-T052
to	O
grey	B-T080
,	O
HSI,	O
YCbCr,	O
YIQ	O
and	O
XYZ	O
colour space	B-T170
.	O
Further,	O
a	O
study	B-T062
is	O
carried	O
out	O
to	O
count	B-T081
nuclei	B-T026
manually	B-T059
and	O
automatically	B-T059
from	O
the	O
proposed	O
algorithm	B-T170
with	O
an	O
average	B-T081
error	B-T080
rate	B-T081
of	O
6.84%	O
which	O
is	O
significant	B-T078
.	O
The	O
study	B-T062
provides	O
an	O
automated	B-T169
count	B-T081
of	O
positive and negative	B-T033
nuclei	B-T026
using	O
L*a*b*	O
colour space	B-T170
and	O
hybrid segmentation technique	B-T066
.	O
Computerized evaluation	B-T059
of	O
proliferation index	B-T081
can	O
aid	O
pathologist	B-T097
in	O
assessing	O
breast cancer	B-T191
severity	B-T080
.	O
The	O
proposed	O
methodology	B-T060
,	O
further,	O
has	O
the	O
potential	B-T080
advantage	O
of	O
saving	O
time	O
and	O
assisting	B-T058
in	O
decision	O
making	O
over	O
the	O
present	O
manual procedure	B-T059
and	O
could	O
evolve	O
as	O
an	O
assistive	O
pathological	B-T169
decision support system	B-T068
.	O

Multitarget	B-T169
sensing of glucose	B-T059
and	O
cholesterol	B-T059
based	O
on	O
Janus hydrogel microparticles	B-T109
A	O
visualized	B-T169
sensing method for glucose	B-T059
and	O
cholesterol	B-T059
was	O
developed	O
based	O
on	O
the	O
hemispheres	O
of	O
the	O
same	O
Janus hydrogel microparticles	B-T109
.	O
Single-phase	O
and	O
Janus hydrogel microparticles	B-T109
were	O
both	O
generated	O
using	O
a	O
centrifugal	B-T080
microfluidic chip	B-T075
.	O
For	O
glucose sensing	B-T059
,	O
concanavalin A	B-T116
and	O
fluorescein labeled dextran	B-T109
used	O
for	O
competitive binding assay	B-T059
were	O
encapsulated	B-T080
in	O
alginate	B-T109
microparticles	B-T104
,	O
and	O
the	O
fluorescence	B-T070
of	O
the	O
microparticles	B-T104
was	O
positively	B-T033
correlated	B-T080
with	O
glucose	B-T109
concentration	B-T081
.	O
For	O
cholesterol sensing	B-T059
,	O
the	O
microparticles	B-T104
embedded	O
with	O
γ-Fe2O3 nanoparticles	B-T130
were	O
used	O
as	O
catalyst	B-T067
for	O
the	O
oxidation	B-T044
of	O
3,3',5,5'-Tetramethylbenzidine	B-T109
by	O
H2O2	B-T121
,	O
an	O
enzymatic	B-T116
hydrolysis	B-T070
product	B-T071
of	O
cholesterol	B-T109
.	O
And	O
the	O
color	B-T080
transition	B-T052
was	O
more	O
sensitive	B-T169
in	O
the	O
microparticles	B-T104
than	O
in	O
solutions	B-T167
,	O
indicating	O
the	O
microparticles	B-T104
are	O
more	O
applicable	B-T080
for	O
visualized	B-T169
determination	B-T059
.	O
Furthermore,	O
Janus microparticles	B-T104
were	O
employed	B-T033
for	O
multitarget	B-T169
sensing	B-T080
in	O
the	O
two	O
hemespheres,	O
and	O
glucose	B-T109
and	O
cholesterol	B-T109
were	O
detected	B-T033
within	O
the	O
same	O
microparticles	B-T104
without	O
obvious	O
interference	B-T169
.	O
Besides,	O
the	O
particles	B-T104
could	O
be	O
manipulated	O
by	O
an	O
external	B-T082
magnetic field	B-T070
.	O
The	O
glucose	B-T034
and	O
cholesterol levels	B-T034
were	O
measured	B-T080
in	O
human	B-T016
serum	B-T031
utilizing	O
the	O
microparticles	B-T104
,	O
which	O
confirmed	B-T033
the	O
potential	B-T080
application	O
of	O
the	O
microparticles	B-T104
in	O
real	O
sample	B-T167
detection	B-T061
.	O

PI3K	B-T116
/	O
Akt	B-T116
pathway	B-T044
:	O
a	O
potential	O
therapeutic	B-T169
target	B-T169
for	O
chronic pain	B-T184
Chronic pain	B-T184
is	O
among	O
the	O
most	O
disabling	B-T047
and	O
costly	O
disorders	B-T047
,	O
with	O
prevalence	B-T081
ranging	B-T081
from	O
10%	O
to	O
55%.	O
However,	O
current	O
therapeutic	B-T169
strategies	O
for	O
chronic pain	B-T184
are	O
unsatisfactory	B-T080
due	O
to	O
our	O
poor	B-T080
understanding	B-T041
of	O
its	O
mechanisms	B-T169
.	O
Thus,	O
novel	O
therapeutic	B-T169
targets	B-T169
need	O
to	O
be	O
found	O
in	O
order	O
to	O
improve	B-T033
these	O
patients'	B-T101
quality of life	B-T078
.	O
PI3K	B-T116
and	O
its	O
downstream	B-T082
Akt	B-T116
are	O
widely	O
expressed	B-T045
in	O
the	O
spinal cord	B-T023
,	O
particularly	O
in	O
the	O
laminae I-IV	B-T023
of	O
the	O
dorsal horn	B-T023
,	O
where	O
nociceptive C	B-T026
and	O
Aδ fibers	B-T026
of	O
primary	B-T080
afferents	B-T023
principally	O
terminate	B-T079
.	O
Recent	O
studies	B-T062
have	O
demonstrated	O
their	O
critical	B-T080
roles	B-T077
in	O
the	O
development	B-T169
and	O
maintenance	B-T052
of	O
chronic pain	B-T184
.	O
In	O
this	O
review	B-T170
,	O
we	O
summarized	O
the	O
roles	B-T077
and	O
mechanisms	B-T169
of	O
PI3K	B-T116
/	O
Akt	B-T116
pathway	B-T044
in	O
the	O
progression	B-T046
of	O
chronic pain	B-T184
through	O
sciatic nerve injury	B-T037
,	O
diabetic neuropathy	B-T047
,	O
spinal cord injury	B-T037
,	O
bone cancer	B-T191
,	O
opioid tolerance	B-UnknownType
,	O
or	O
opioid	B-T109
-	O
induced	B-T169
hyperalgesia	B-T184
.	O

No	O
free bed	B-T073
with	O
ventilator	B-T074
:	O
experience	O
of	O
a	O
public health specialist	B-T097
While	O
the	O
author	B-T097
was	O
dealing	O
with	O
a	O
poor	B-T102
elderly father	B-T099
struggling	O
to	O
shift	O
his	O
gravely injured	B-T169
young	B-T079
son	B-T099
to	O
a	O
government hospital	B-T073
due	O
to	O
the	O
high	O
cost	O
of	O
intensive care	B-T058
,	O
her	O
friends	B-T098
across	O
the	O
globe	B-T082
were	O
discussing	O
euthanasia	B-T058
in	O
the	O
social media	B-T170
.	O
While	O
marginalised	B-T054
groups of people	B-T098
are	O
struggling	O
to	O
access	B-T078
care	B-T052
in	O
India	B-T083
,	O
friends	B-T098
who	O
have	O
moved	O
to	O
developed parts of the world	B-T080
were	O
discussing	O
one's	O
choice	B-T052
to	O
live	B-T080
or	O
die	B-T040
!	O
The	O
poor	B-T102
father	B-T099
,	O
after	O
battling	B-T048
to	O
save	B-T078
his	O
son	B-T099
and	O
reaching	O
out	O
to	O
many	O
people	B-T098
for	O
help	B-T080
,	O
could	O
not	O
save	B-T078
him.	O
Early treatment	B-UnknownType
might	O
have	O
helped	B-T080
the	O
young	B-T079
boy	B-T100
.	O
The	O
incident	B-T067
left	O
the	O
author	B-T097
thinking	O
about	O
how	O
the	O
poor	B-T102
are	O
denied	B-T052
care	B-T052
simply	O
because	O
they	O
cannot	O
afford	O
it.	O
Others	O
debate	B-T052
when	O
to	O
pull the plug	B-T078
on	O
the	O
patient	B-T101
.	O
…	O
How	O
many	O
families	B-T099
can	O
afford	O
such	O
care	B-T052
in	O
India	B-T083
?	O
When	O
nearly	O
71%	O
of	O
the	O
people	B-T098
are	O
paying out of pocket	B-T081
for	O
healthcare	B-T058
and	O
16%	O
are	O
pushed	O
below the poverty line	B-T102
every year	B-T079
,	O
can	O
we	O
even	O
think	B-T041
of	O
universal health coverage	B-T078
health	B-T078
coverage?	O
It	O
just	O
sounds	O
like	O
a	O
fancy term	B-T078
to	O
be	O
used	O
at	O
conferences and meetings	B-T058
because	O
the	O
ground reality	B-T078
is	O
completely different	B-T080
.	O

Quantitative	B-T081
determination	B-T059
of	O
five	O
metabolites	B-T123
of	O
aspirin	B-T109
by	O
UHPLC-MS	B-T059
/	O
MS	B-T059
coupled	B-T169
with	O
enzymatic reaction	B-T044
and	O
its	O
application	O
to	O
evaluate	O
the	O
effects	B-T080
of	O
aspirin	B-T109
dosage	B-T081
on	O
the	O
metabolic profile	B-T039
Acetylsalicylic acid	B-T109
(	O
Aspirin	B-T109
,	O
ASA	B-T109
)	O
is	O
a	O
famous	O
drug	B-T121
for	O
cardiovascular diseases	B-T047
in	O
recent	O
years	B-T079
.	O
Effects	O
of	O
ASA	B-T109
dosage	B-T081
on	O
the	O
metabolic profile	B-T039
have	O
not	O
been	O
fully	O
understood.	O
The	O
purpose	O
of	O
our	O
study	B-T062
is	O
to	O
establish	O
a	O
rapid	B-T080
and	O
reliable	B-T170
method	B-T059
to	O
quantify	B-T081
ASA	B-T109
metabolites	B-T123
in	O
biological matrices	B-T031
,	O
especially	O
for	O
glucuronide	B-T109
metabolites	B-T123
whose	O
standards	O
are	O
not	O
commercially	O
available.	O
Then	O
we	O
applied	O
this	O
method	B-T059
to	O
evaluate	O
the	O
effects	O
of	O
ASA	B-T109
dosage	B-T081
on	O
the	O
metabolic	B-T039
and	O
excretion	B-T039
profile	B-T081
of	O
ASA	B-T109
metabolites	B-T123
in	O
rat	B-T015
urine	B-T031
.	O
Salicylic acid	B-T109
(	O
SA	B-T109
),	O
gentisic acid	B-T109
(	O
GA	B-T109
)	O
and	O
salicyluric acid	B-T109
(	O
SUA	B-T109
)	O
were	O
determined	O
directly	O
by	O
UHPLC-MS	B-T059
/	O
MS	B-T059
,	O
while	O
salicyl phenolic glucuronide	B-T109
(	O
SAPG	B-T109
)	O
and	O
salicyluric acid phenolic glucuronide	B-T109
(	O
SUAPG	B-T109
)	O
were	O
quantified	B-T081
indirectly	O
by	O
measuring	O
the	O
released	O
SA	B-T109
and	O
SUA	B-T109
from	O
SAPG	B-T109
and	O
SUAPG	B-T109
after	O
β-glucuronidase	B-T116
digestion	B-T040
.	O
SUA	B-T109
and	O
SUAPG	B-T109
were	O
the	O
major	O
metabolites	B-T123
of	O
ASA	B-T109
in	O
rat	B-T015
urine	B-T031
24	O
h	B-T079
after	O
ASA	B-T109
administration	B-T081
,	O
which	O
accounted	O
for	O
50%	O
(	O
SUA	B-T109
)	O
and	O
26%	O
(	O
SUAPG	B-T109
).	O
When	O
ASA	B-T109
dosage	B-T081
was	O
increased	B-T081
,	O
the	O
contributions	O
dropped	O
to	O
32%	O
and	O
18%,	O
respectively.	O
The	O
excretion	B-T039
of	O
other	O
three	O
metabolites	B-T123
(	O
GA	B-T109
,	O
SA	B-T109
and	O
SAPG	B-T109
)	O
however	O
showed	O
remarkable	O
increases	O
by	O
16%,	O
6%	O
and	O
4%,	O
respectively.	O
In	O
addition,	O
SUA	B-T109
and	O
SUAPG	B-T109
were	O
mainly	O
excreted	B-T039
in	O
the	O
time period	B-T079
of	O
12-24	O
h	B-T079
,	O
while	O
GA	B-T109
was	O
excreted	B-T039
in	O
the	O
earlier	O
time periods	B-T079
(0-4	O
h	B-T079
and	O
4-8	O
h	B-T079
).	O
SA	B-T109
was	O
mainly	O
excreted	B-T039
in	O
the	O
time period	B-T079
of	O
0-4	O
h	B-T079
and	O
12-24	O
h	B-T079
.	O
And	O
the	O
excretion	B-T039
of	O
SAPG	B-T109
was	O
equally	O
distributed	O
in	O
the	O
four	O
time periods	B-T079
.	O
We	O
went	O
further	O
to	O
show	O
that	O
the	O
excretion	B-T039
of	O
five	O
metabolites	B-T123
in	O
rat	B-T015
urine	B-T031
was	O
delayed	O
when	O
ASA	B-T109
dosage	B-T081
was	O
increased	B-T081
.	O
In	O
conclusion,	O
we	O
have	O
developed	O
a	O
rapid	B-T080
and	O
sensitive	B-T169
method	B-T059
to	O
determine	O
the	O
five	O
ASA	B-T109
metabolites	B-T123
(	O
SA	B-T109
,	O
GA	B-T109
,	O
SUA	B-T109
,	O
SAPG	B-T109
and	O
SUAPG	B-T109
)	O
in	O
rat	B-T015
urine	B-T031
.	O
We	O
showed	O
that	O
ASA	B-T109
dosage	B-T081
could	O
significantly	O
influence	B-T077
the	O
metabolic	B-T039
and	O
excretion	B-T039
profile	B-T081
of	O
ASA	B-T109
metabolites	B-T123
in	O
rat	B-T015
urine	B-T031
.	O

Mismatch Repair	B-T045
Incompatibilities	B-T054
in	O
Diverse	B-T080
Yeast	B-T004
Populations	B-T090
An	O
elevated	B-T080
mutation rate	B-T080
can	O
provide	O
cells	B-T025
with	O
a	O
source	B-T033
of	O
mutations	B-T045
to	O
adapt	O
to	O
changing	B-T169
environments	B-T082
.	O
We	O
identified	B-T080
a	O
negative	B-T033
epistatic interaction	B-T045
involving	B-T169
naturally	O
occurring	O
variants	B-T080
in	O
the	O
MLH1	B-T028
and	O
PMS1	B-T028
mismatch repair	B-T045
(	O
MMR	B-T045
)	O
genes	B-T028
of	O
Saccharomyces cerevisiae	B-T004
We	O
hypothesized	O
that	O
this	O
MMR	B-T045
incompatibility	B-T054
,	O
created	O
through	O
mating	B-T040
between	O
divergent	O
S. cerevisiae	B-T004
,	O
yields	O
mutator	O
progeny	B-T099
that	O
can	O
rapidly	B-T080
but	O
transiently	O
adapt	O
to	O
an	O
environmental stress	B-T067
.	O
Here	O
we	O
analyzed	B-T062
the	O
MLH1	B-T028
and	O
PMS1 genes	B-T028
across	O
1010	O
S. cerevisiae	B-T004
natural	B-T169
isolates	B-T123
spanning	O
a	O
wide	O
range	B-T081
of	O
ecological	B-T070
sources	B-T033
(	O
tree	B-T002
exudates	B-T031
,	O
Drosophila	B-T204
,	O
fruits	B-T168
,	O
and	O
various	O
fermentation	B-T044
and	O
clinical	B-T080
isolates	B-T123
)	O
and	O
geographical	B-T082
sources	B-T033
(	O
Europe	B-T083
,	O
America	B-T083
,	O
Africa	B-T083
,	O
and	O
Asia	B-T083
).	O
We	O
identified	B-T080
one	O
homozygous	B-T032
clinical	B-T080
isolate	B-T123
and	O
18	O
heterozygous	B-T032
isolates	B-T123
containing	B-T169
the	O
incompatible	O
MMR	B-T045
genotype	B-T032
.	O
The	O
MLH1	B-T028
-	O
PMS1 gene	B-T028
combination	B-T080
isolated	B-T169
from	O
the	O
homozygous	B-T032
clinical	B-T080
isolate	B-T123
conferred	O
a	O
mutator	O
phenotype	B-T032
when	O
expressed	B-T045
in	O
the	O
S288c	O
laboratory	B-T073
background	B-T077
.	O
Using	O
a	O
novel	O
reporter	B-T130
to	O
measure	B-T081
mutation rates	B-T080
,	O
we	O
showed	O
that	O
the	O
overall	B-T080
mutation rate	B-T080
in	O
the	O
homozygous	B-T032
incompatible	O
background	B-T077
was	O
similar	O
to	O
that	O
seen	O
in	O
compatible	B-T080
strains	B-T001
,	O
indicating	O
the	O
presence	O
of	O
suppressor mutations	B-T049
in	O
the	O
clinical	B-T080
isolate	B-T123
that	O
lowered	O
its	O
mutation rate	B-T080
.	O
This	O
observation	B-T062
and	O
the	O
identification	B-T080
of	O
18	O
heterozygous	B-T032
isolates	B-T123
isolates	B-T123
,	O
which	O
can	O
lead	O
to	O
MMR	B-T045
incompatible	O
genotypes	B-T032
in	O
the	O
offspring	B-T099
,	O
are	O
consistent with	B-T078
an	O
elevated	B-T080
mutation rate	B-T080
rapidly	O
but	O
transiently	O
facilitating	O
adaptation	B-T038
.	O
To	O
avoid	O
long-term	B-T079
fitness	B-T045
costs	B-T081
,	O
the	O
incompatibility	B-T054
is	O
apparently	O
buffered	B-T121
by	O
mating	B-T040
or	O
by	O
acquiring	O
suppressors	B-T049
.	O
These	O
observations	B-T062
highlight	O
effective	B-T080
strategies	O
in	O
eukaryotes	B-T204
to	O
avoid	O
long-term	B-T079
fitness	B-T045
costs	B-T081
associated with	B-T080
elevated	B-T080
mutation rates	B-T080
.	O

Mapping	B-T052
circulating	B-T169
serum	B-T031
miRNAs	B-T114
to	O
their	O
immune	B-T169
-	O
related	B-T080
target	B-T169
mRNAs	B-T114
Evidence	B-T078
suggests	B-T078
that	O
circulating	B-T169
serum	B-T031
microRNAs	B-T114
(	O
miRNAs	B-T114
)	O
might	O
preferentially	O
target	B-T169
immune	B-T169
-	O
related	B-T080
mRNAs	B-T114
.	O
If	O
this	O
were	O
the	O
case,	O
we	O
hypothesized	O
that	O
immune	B-T169
-	O
related	B-T080
mRNAs	B-T114
would	O
have	O
more	O
predicted	B-T078
serum	B-T031
miRNA binding	B-T045
sites	B-T082
than	O
other	O
mRNAs	B-T114
and,	O
reciprocally	B-T080
,	O
that	O
serum	B-T031
miRNAs	B-T114
would	O
have	O
more	O
immune	B-T169
-	O
related	B-T080
mRNA	B-T114
targets	B-T169
than	O
non	B-T169
-	O
serum	B-T031
miRNAs	B-T114
.	O
We	O
developed	B-T169
a	O
consensus	O
target	B-T169
predictor	O
using	O
the	O
random forest framework	B-T169
and	O
calculated	B-T169
the	O
number	O
of	O
predicted	B-T078
miRNA	B-T114
-	O
mRNA	B-T114
interactions	B-T045
in	O
various	O
subsets	B-T185
of	O
miRNAs	B-T114
(	O
serum	B-T031
,	O
non	B-T169
-	O
serum	B-T031
)	O
and	O
mRNAs	B-T114
(	O
immune	B-T169
related	B-T080
,	O
nonimmune related	B-T080
).	O
Immune	B-T169
-	O
related	B-T080
mRNAs	B-T114
were	O
predicted	B-T078
to	O
be	O
targeted	B-T169
by	O
serum	B-T031
miRNA	B-T114
more	O
than	O
other	O
mRNAs	B-T114
.	O
Moreover,	O
serum	B-T031
miRNAs	B-T114
were	O
predicted	B-T078
to	O
target	B-T169
many	O
more	O
immune	B-T169
-	O
related	B-T080
mRNA	B-T114
targets	B-T169
than	O
non	B-T169
-	O
serum	B-T031
miRNAs	B-T114
;	O
however,	O
these	O
two	O
biases	B-T078
in	O
immune	B-T169
-	O
related	B-T080
mRNAs	B-T114
and	O
serum	B-T031
miRNAs	B-T114
appear	O
to	O
be	O
completely	B-T080
independent	B-T078
.	O
Immune	B-T169
-	O
related	B-T080
mRNAs	B-T114
have	O
more	O
miRNA binding	B-T045
sites	B-T082
in	O
general,	O
not	O
just	O
for	O
serum	B-T031
miRNAs	B-T114
;	O
likewise,	O
serum	B-T031
miRNAs	B-T114
target	B-T169
many	O
more	O
mRNAs	B-T114
than	O
non	B-T169
-	O
serum	B-T031
miRNAs	B-T114
overall,	O
regardless	B-T080
of	O
whether	O
they	O
are	O
immune	B-T169
related	B-T080
or	O
not.	O
Nevertheless,	O
these	O
two	O
independent	B-T078
phenomena	B-T067
result	B-T169
in	O
a	O
significantly	O
larger	O
number	O
of	O
predicted	B-T078
serum	B-T031
miRNA	B-T114
-	O
immune	B-T169
mRNA	B-T114
interactions	B-T045
than	O
would	O
be	O
expected	O
by	O
chance.	O

Oxidative stress	B-T049
and	O
immunosenescence	B-T039
in	O
spleen	B-T023
of	O
obese mice	B-T015
can	O
be	O
reversed	O
by	O
2-hydroxyoleic acid	B-T109
We	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
obesity	B-T047
on	O
oxidative stress	B-T049
and	O
leukocyte	B-T025
function	B-T043
in	O
spleen	B-T023
of	O
mice	B-T015
,	O
and	O
to	O
assess	O
whether	O
supplementation	B-T061
with	O
2-hydroxyoleic acid	B-T109
(	O
2-OHOA	B-T109
)	O
or	O
n-3 polyunsaturated fatty acids	B-T109
(	O
PUFA	B-T109
)	O
could	O
reverse	O
those	O
effects.	O
Female	B-T032
ICR/CD1 mice	B-T015
(8	O
weeks	B-T079
old,	O
n	O
=	O
24)	O
received	O
an	O
obesogenic diet	B-T168
(22%	O
fat	B-T109
for	O
4	O
weeks	B-T079
and	O
60%	O
fat	B-T109
for	O
14	O
weeks	B-T079
).	O
After	O
6	O
weeks	B-T079
,	O
mice	B-T015
were	O
split	O
in	O
three	O
groups	B-UnknownType
(n	O
=	O
8/	O
group	B-UnknownType
):	O
no supplementation	B-UnknownType
,	O
2-OHOA supplementation	B-UnknownType
(1500	O
mg	O
kg(-1))	O
and	O
n-3 PUFA supplementation	B-UnknownType
(	O
EPA	B-T109
+	O
DHA	B-T109
,	O
3000	O
mg	O
kg(-1)	O
diet).	O
Eight	O
mice	B-T015
were	O
fed	O
standard	O
diet	B-T168
for	O
the	O
whole	O
duration	B-T079
of	O
the	O
study	B-T062
(	O
control group	B-T096
).	O
At	O
the	O
end	O
of	O
the	O
experiment	B-T062
,	O
the	O
following	O
variables	B-T080
were	O
assessed	B-T052
in	O
spleens	B-T023
:	O
levels	B-T080
of	O
reduced	B-T116
(	O
GSH	B-T116
)	O
and	O
oxidized (GSSG) glutathione	B-T116
,	O
GSH	B-T116
/	O
GSSG	B-T116
,	O
xanthine oxidase (XO) activity	B-T044
,	O
lipid peroxidation	B-T044
,	O
lymphocyte chemotaxis	B-T043
,	O
natural killer (NK) activity	B-T043
and	O
mitogen	B-T121
(	O
ConA	B-T116
and	O
LPS	B-T109
)-induced	O
lymphocyte proliferation	B-T043
.	O
Obese	B-T032
animals	B-T008
presented	O
higher	B-T080
GSSG	B-T116
levels	B-T080
(P	O
=	O
0.003),	O
GSSG	B-T116
/	O
GSH	B-T116
ratio	B-T081
(P	O
=	O
0.013),	O
lipid peroxidation	B-T044
(P	O
=	O
0.004),	O
XO activity	B-T044
(P	O
=	O
0.015)	O
and	O
lymphocyte chemotaxis	B-T043
(P	O
<	O
0.001),	O
and	O
lower	O
NK activity	B-T043
(P	O
=	O
0.003)	O
and	O
proliferation	B-T169
in	O
response	O
to	O
ConA	B-T116
(P	O
<	O
0.001)	O
than	O
controls	B-T096
.	O
2-OHOA	B-T109
reversed	O
totally	O
or	O
partially	O
most	O
of	O
the	O
changes	B-T081
(	O
body weight	B-T032
,	O
fat	O
content,	O
GSSG	B-T116
levels	B-T080
,	O
GSH	B-T116
/	O
GSSG	B-T116
,	O
lipid peroxidation	B-T044
,	O
chemotaxis	B-T043
and	O
proliferation	B-T043
,	O
all	O
P	O
<	O
0.05),	O
while	O
n-3 PUFA	B-T109
reversed	O
the	O
increase	B-T169
in	O
XO activity	B-T044
(P	O
=	O
0.032).	O
In	O
conclusion,	O
2-OHOA	B-T109
,	O
and	O
to	O
a	O
lesser	O
extent	O
n-3 PUFA	B-T109
,	O
could	O
ameliorate	O
the	O
oxidative stress	B-T049
and	O
alteration	B-T078
of	O
leukocyte	B-T025
function	B-T043
in	O
spleen	B-T023
of	O
obese mice	B-T015
.	O
Our	O
findings	B-T033
support	O
a	O
link	O
between	O
obesity	B-T047
and	O
immunosenescence	B-T039
and	O
suggest	O
a	O
potential	O
therapeutic tool	B-T169
for	O
obesity	B-T047
-related	O
immune dysfunction	B-T047
.	O
This	O
article	O
is	O
protected	O
by	O
copyright.	O
All	O
rights	O
reserved.	O

Assembly of the outermost spore layer	B-T043
:	O
pieces	O
of	O
the	O
puzzle	O
are	O
coming	O
together	O
Certain	O
endospore-forming soil dwelling bacteria	B-T007
are	O
important	O
human	B-T016
,	O
animal	B-T008
or	O
insect	B-T204
pathogens	B-T001
.	O
These	O
organisms	B-T001
produce	O
spores	B-T001
containing	O
an	O
outer layer	B-T026
,	O
the	O
exosporium	B-T026
.	O
The	O
exosporium	B-T026
is	O
the	O
site of	B-T080
interactions	B-T169
between	O
the	O
spore	B-T001
and	O
the	O
soil	B-T167
environment	B-T082
and	O
between	O
the	O
spore	B-T001
and	O
the	O
infected	B-T033
host	B-T001
during	O
the	O
initial	B-T079
stages	B-T079
of	O
infection	B-T046
.	O
The	O
composition	B-T201
and	O
assembly process of the exosporium	B-T043
are	O
poorly	O
understood.	O
This	O
is	O
partly	O
due	O
to	O
the	O
extreme	O
stability	B-T080
of	O
the	O
exosporium	B-T026
that	O
has	O
proven	O
to	O
be	O
refractive	O
to	O
existing	O
methods	B-T169
to	O
deconstruct	O
the	O
intact	B-T080
structure	B-T082
into	O
its	O
component	B-T077
parts	B-T082
.	O
Although	O
more	O
than	O
20	O
proteins	B-T116
have	O
been	O
identified	B-T080
as	O
exosporium	B-T026
-	O
associated	B-T080
,	O
their	O
abundance	B-T080
,	O
relationship	B-T080
to	O
other	O
proteins	B-T116
and	O
the	O
processes	B-T067
by	O
which	O
they	O
are	O
assembled to create the exosporium	B-T043
are	O
largely	O
unknown.	O
In	O
this	O
issue	O
of	O
Molecular Microbiology	B-T091
,	O
Terry,	O
Jiang,	O
and	O
colleagues	O
in	O
Per	O
Bullough's	O
laboratory	B-T073
show	O
that	O
the	O
ExsY protein	B-T116
is	O
a	O
major	O
structural protein	B-T116
of	O
the	O
exosporium basal layer	B-T026
of	O
B. cereus family	B-T007
spores	B-T001
and	O
that	O
it	O
can	O
self-assemble	B-T052
into	O
complex	B-T080
structures	B-T082
that	O
possess	O
many	O
of	O
the	O
structural	B-T082
features	B-T080
characteristic	B-T080
of	O
the	O
exosporium basal layer	B-T026
.	O
The	O
authors	B-T097
refined	O
a	O
model	B-T170
for	O
exosporium assembly	B-T043
.	O
Their	O
findings	B-T033
may	O
have	O
implications	O
for	O
exosporium	B-T026
formation	B-T169
in	O
other	O
spore forming bacteria	B-T007
,	O
including	O
Clostridium species	B-T007
.	O

Skeletal muscle	B-T024
metabolic	O
adaptations	B-T038
to	O
endurance	B-T079
exercise training	B-T056
are	O
attainable	B-T052
in	O
mice	B-T015
with	O
simvastatin	B-T109
treatment	B-T061
We	O
tested	O
the	O
hypothesis	B-T078
that	O
a	O
6-week	O
regimen	B-T061
of	O
simvastatin	B-T109
would	O
attenuate	B-T052
skeletal muscle	B-T024
adaptation	B-T038
to	O
low-intensity exercise	B-T056
.	O
Male	B-T032
C57BL/6J wildtype mice	B-T015
were	O
subjected	O
to	O
6-weeks	O
of	O
voluntary wheel running	B-T056
or	O
normal	O
cage	B-T073
activities	B-T052
with	O
or	O
without	O
simvastatin	B-T109
treatment	B-T061
(20	O
mg/kg/d,	O
n	O
=	O
7-8	O
per	O
group).	O
Adaptations	B-T038
in	O
in vivo	B-T062
fatigue	B-T184
resistance	B-T169
were	O
determined	O
by	O
a	O
treadmill running test	B-T060
,	O
and	O
by	O
ankle plantarflexor	B-T023
contractile	B-T039
assessment.	O
The	O
tibialis anterior	B-T023
,	O
gastrocnemius	B-T023
,	O
and	O
plantaris muscles	B-T023
were	O
evaluated	B-T058
for	O
exercised	B-T056
-induced	O
mitochondrial	B-T026
adaptations	B-T038
(i.e.,	O
biogenesis	B-T070
,	O
function	B-T169
,	O
autophagy	B-T043
).	O
There	O
was	O
no difference	B-T033
in	O
weekly	O
wheel running distance	B-T052
between	O
control	O
and	O
simvastatin	B-T109
-	O
treated	B-T169
mice	B-T015
(P	O
=	O
0.51).	O
Trained	B-T065
mice	B-T015
had	O
greater	O
treadmill running	B-T056
distance	B-T081
(296%,	O
P<0.001),	O
and	O
ankle plantarflexor	B-T023
contractile	B-T039
fatigue	B-T184
resistance	B-T169
(9%,	O
P<0.05)	O
compared	O
to	O
sedentary	O
mice	B-T015
,	O
independent	O
of	O
simvastatin	B-T109
treatment	B-T061
.	O
At	O
the	O
cellular level	B-T025
,	O
trained	B-T065
mice	B-T015
had	O
greater	O
mitochondrial biogenesis	B-T043
(e.g.,	O
~2-fold	O
greater	O
PGC1α	B-T116
expression	B-T045
,	O
P<0.05)	O
and	O
mitochondrial	B-T026
content	O
(e.g.,	O
25%	O
greater	O
citrate synthase	B-T116
activity	B-T044
,	O
P<0.05),	O
independent	O
of	O
simvastatin	B-T109
treatment	B-T061
.	O
Mitochondrial	B-T026
autophagy	B-T043
-related	O
protein	B-T116
contents	O
were	O
greater	O
in	O
trained	B-T065
mice	B-T015
(e.g.,	O
40%	O
greater	O
Bnip3	B-T116
,	O
P<0.05),	O
independent	O
of	O
simvastatin	B-T109
treatment	B-T061
.	O
However,	O
Drp1	B-T116
,	O
a	O
marker	B-T201
of	O
mitochondrial fission	B-T043
,	O
was	O
less	O
in	O
simvastatin	B-T109
treated	B-T169
mice	B-T015
,	O
independent	O
of	O
exercise training	B-T056
,	O
and	O
there	O
was	O
a	O
significant	O
interaction	B-T169
between	O
training	B-T065
and	O
statin	O
treatment	B-T061
(P<0.022)	O
for	O
LC3-II protein	B-T116
content	B-T081
,	O
a	O
marker	B-T201
of	O
autophagy	B-T043
flux.	O
These	O
data	O
indicate	O
that	O
whole body	B-T017
and	O
skeletal muscle	B-T024
adaptations	B-T038
to	O
endurance	B-T079
exercise training	B-T056
are	O
attainable	B-T052
with	O
simvastatin	B-T109
treatment	B-T061
,	O
but	O
simvastatin	B-T109
may	O
have	O
side effects	B-T046
on	O
muscle	B-T024
mitochondrial	B-T026
maintenance	O
via	O
autophagy	B-T043
,	O
which	O
could	O
have	O
long-term	B-T079
implications	O
on	O
muscle	B-T024
health	B-T078
.	O

Evaluation	B-T058
and	O
Treatment	B-T169
of	O
Anemia	B-T047
in	O
Premature Infants	B-T047
Anemia	B-T047
in	O
preterm infants	B-T100
is	O
the	O
pathophysiological	B-T169
process	B-T067
with	O
greater	O
and	O
more	O
rapid	O
decline	B-T081
in	O
hemoglobin	B-T116
compared	B-T052
to	O
the	O
physiological	B-T169
anemia	B-T047
in	O
infants	B-T100
.	O
There	O
is	O
a	O
need	O
for	O
transfusions	B-T061
and	O
administration	B-T061
of	O
human recombinant erythropoietin	B-T116
.	O
To	O
determine	B-T078
the	O
frequency	B-T079
of	O
anemia	B-T047
in	O
premature infants	B-T047
at	O
the	O
Pediatric Clinic, University Clinical Center Sarajevo	B-T073
,	O
as	O
well	O
as	O
parameter values	B-T077
in	O
the	O
blood count	B-T059
of	O
premature infants	B-T047
and	O
to	O
explore	O
a	O
relationship	B-T080
between	O
blood transfusions	B-T061
with	O
the	O
advent	O
of	O
intraventricular hemorrhage	B-T046
(	O
determine	B-T078
treatment	B-T169
outcome	O
in	O
preterm infants	B-T100
).	O
Research	B-T062
is	O
retrospective study	B-T062
and	O
it	O
included	O
the	O
period	B-T079
of	O
six	O
months	B-T079
in	O
year	B-T079
2014.	O
Research	B-T062
included	O
100	O
patients	B-T101
,	O
gestational age	B-T032
<	O
37	O
weeks	B-T079
(	O
premature infants	B-T047
).	O
Data	B-T078
were	O
collected	B-T078
by	O
examining	B-T033
the	O
medical records	B-T170
of	O
patients	B-T101
at	O
the	O
Pediatric Clinic, UCCS	B-T073
.	O
The	O
first	B-T081
group	B-T078
of	O
patients	B-T101
were	O
premature infants	B-T047
of	O
gestational age	B-T032
≤	O
32	O
weeks	B-T079
(62/100)	O
and	O
the	O
second	B-T081
group	B-T078
were	O
premature infants	B-T047
of	O
gestational age	B-T032
33-37	O
weeks	B-T079
(38/100).	O
Among	O
the	O
patients	B-T101
,	O
5%	O
were	O
boys	B-T100
and	O
46%	O
girls	B-T100
.	O
There	O
was	O
significant difference	B-T081
in	O
birth weight	B-T032
and	O
APGAR score	B-T032
among	O
the	O
groups	B-T078
.	O
In	O
the	O
first	B-T081
group	B-T078
,	O
there	O
were	O
27.42%	O
of	O
deaths	B-T033
,	O
while	O
in	O
the	O
second	B-T081
group	B-T078
,	O
there	O
were	O
only	O
10.53%	O
of	O
deaths	B-T033
.	O
There	O
was	O
a	O
significant difference	B-T081
in	O
the	O
length	O
of	O
treatment	B-T169
.	O
There	O
was	O
a	O
statistically significant	B-T081
difference	B-T081
in	O
the	O
need	O
for	O
transfusion	B-T061
among	O
the	O
groups	B-T078
.	O
18	O
patients	B-T101
in	O
the	O
first	B-T081
group	B-T078
required	O
a	O
transfusion	B-T061
,	O
while	O
in	O
the	O
second	B-T081
group	B-T078
only	O
3	O
patients	B-T101
.	O
Preterm infants	B-T100
of	O
gestational age	B-T032
≤	O
32	O
weeks	B-T079
are	O
likely	O
candidates	B-T101
for	O
blood transfusion	B-T061
during	O
treatment	B-T169
.	O
Preterm infants	B-T100
of	O
gestational age	B-T032
≤	O
32	O
weeks	B-T079
have	O
the	O
risk	B-T078
of	O
intracranial bleeding	B-T047
associated with	B-T080
the	O
application	B-T058
of	O
blood transfusion	B-T061
in	O
the	O
first	O
week	B-T079
of	O
life	B-T078
.	O

Medial Patellofemoral Ligament	B-T023
Reconstruction	B-T061
Femoral	B-T023
Tunnel	B-T082
Accuracy	B-T080
:	O
Relationship	O
to	O
Disease	B-T047
-	O
Specific	B-T080
Quality of Life	B-T078
Medial patellofemoral ligament	B-T023
(	O
MPFL	B-T023
)	O
reconstruction	B-T061
is	O
a	O
procedure	O
aimed	O
to	O
reestablish	O
the	O
checkrein	O
to	O
lateral patellar translation	B-T037
in	O
patients	B-T101
with	O
symptomatic patellofemoral instability	B-T037
.	O
Correct	O
femoral	B-T023
tunnel	B-T082
position	B-T082
is	O
thought	O
to	O
be	O
crucial	O
to	O
successful	O
MPFL	B-T023
reconstruction	B-T061
,	O
but	O
the	O
accuracy	B-T080
of	O
this	O
statement	O
in	O
terms	O
of	O
patient outcomes	B-T058
has	O
not	O
been	O
tested.	O
To	O
assess	O
the	O
accuracy	B-T080
of	O
femoral	B-T023
tunnel	B-T082
placement	B-T058
in	O
an	O
MPFL	B-T023
reconstruction	B-T061
cohort	B-T098
and	O
to	O
determine	O
the	O
correlation	B-T080
between	O
tunnel	B-T082
accuracy	B-T080
and	O
a	O
validated	B-T062
disease	B-T047
-	O
specific	B-T080
,	O
patient	B-T101
-reported	O
quality-of-life	B-T078
outcome measure	B-T081
.	O
Case	O
series;	O
Level	O
of	O
evidence,	O
4.	O
Between	O
June	B-T079
2008	O
and	O
February	B-T080
2014,	O
a	O
total	O
of	O
206	O
subjects	B-T098
underwent	O
an	O
MPFL	B-T023
reconstruction	B-T061
.	O
Lateral	B-T082
radiographs	B-T060
were	O
measured	O
to	O
determine	O
the	O
accuracy	B-T080
of	O
the	O
femoral	B-T023
tunnel	B-T082
by	O
measuring	O
the	O
distance	O
from	O
the	O
center	O
of	O
the	O
femoral	B-T023
tunnel	B-T082
to	O
the	O
Schöttle point	B-T082
.	O
Banff Patella Instability Instrument (BPII) scores	B-T081
were	O
collected	O
a	O
mean	B-T081
24	O
months	B-T079
postoperatively	B-T079
.	O
A	O
total	O
of	O
155	O
(79.5%)	O
subjects	O
had	O
adequate	O
postoperative	B-T079
lateral	B-T082
radiographs	B-T060
and	O
complete	O
BPII scores	B-T081
.	O
The	O
mean	B-T081
duration	B-T079
of	O
follow-up	B-T058
(±	O
SD	B-T081
)	O
was	O
24.4	O
±	O
8.2	O
months	B-T079
(range,	O
12-74	O
months	B-T079
).	O
Measurement	B-T169
from	O
the	O
center	B-T082
of	O
the	O
femoral	B-T023
tunnel	B-T082
to	O
the	O
Schöttle point	B-T082
resulted	O
in	O
143	O
(92.3%)	O
tunnel	B-T082
s	O
being	O
categorized	O
as	O
"	O
good	B-T080
"	O
or	O
"	O
ideal	B-T080
."	O
There	O
were	O
8	O
failures	B-T046
in	O
the	O
cohort	B-T098
,	O
none	O
of	O
which	O
occurred	O
in	O
malpositioned	B-T082
tunnels	B-T082
.	O
The	O
mean	B-T081
distance	O
from	O
the	O
center	B-T082
of	O
the	O
MPFL	B-T023
tunnel	B-T082
to	O
the	O
center	B-T082
of	O
the	O
Schöttle point	B-T082
was	O
5.9	O
±	O
4.2	O
mm	O
(range,	O
0.5-25.9	O
mm).	O
The	O
mean	B-T081
postoperative	B-T079
BPII score	B-T081
was	O
65.2	O
±	O
22.5	O
(range,	O
9.2-100).	O
Pearson r correlation	B-T170
demonstrated	O
no statistically significant	B-T033
relationship	B-T080
between	O
accuracy	B-T080
of	O
femoral	B-T023
tunnel	B-T082
position	B-T082
and	O
BPII score	B-T081
(r	O
=	O
-0.08;	O
95%	O
CI,	O
-0.24	O
to	O
0.08).	O
There	O
was	O
no evidence of	B-T080
a	O
correlation	B-T080
between	O
the	O
accuracy	B-T080
of	O
MPFL	B-T023
reconstruction	B-T061
femoral	B-T023
tunnel	B-T082
in	O
relation	O
to	O
the	O
Schöttle point	B-T082
and	O
disease	B-T047
-	O
specific	B-T080
quality-of-life scores	B-T080
.	O
Graft failure	B-T046
was	O
not	O
related	O
to	O
femoral	B-T023
tunnel	B-T082
placement	B-T058
.	O
The	O
patellofemoral instability	B-T037
population	O
is	O
complex,	O
and	O
patients	B-T101
present	O
with	O
multiple	O
risk factors	B-T033
that,	O
in	O
addition	O
to	O
the	O
accuracy	B-T080
of	O
femoral	O
tunnel	B-T082
position	B-T082
,	O
contribute	O
to	O
quality of life	B-T078
and	O
warrant	O
further	O
investigation	B-T058
.	O

Evidence	O
for	O
instructions	B-T065
-based	O
updating	O
of	O
task-set representations	B-T061
:	O
the	O
informed	B-T080
fadeout effect	B-T041
The	O
cognitive system	B-T041
can	O
be	O
updated	O
rapidly	O
and	O
efficiently	O
to	O
maximize	O
performance	B-T061
in	O
cognitive tasks	B-T041
.	O
This	O
paper	O
used	O
a	O
task	B-T057
-	O
switching	B-T169
task	B-T057
to	O
explore	O
updating	O
at	O
the	O
level	B-T080
of	O
the	O
plausible	O
task	B-T057
-sets	O
held	O
for	O
future	O
performance	B-T061
.	O
Previous	O
research	B-T062
suggested	O
a	O
"	O
fadeout effect	B-T041
",	O
performance	B-T061
improvement	B-T061
when	O
moving	O
from	O
task	B-T057
-	O
switching	B-T169
context	O
to	O
single-task	B-T169
context,	O
yet	O
this	O
effect	O
could	O
reflect	O
passive	B-T080
learning	B-T041
rather	O
than	O
intentional	B-T080
control	B-T080
.	O
In	O
a	O
novel	O
"	O
informed	B-T080
fadeout	B-T078
paradigm	B-T062
",	O
one	O
of	O
two	O
tasks	B-T057
was	O
canceled	O
for	O
a	O
certain	O
number	O
of	O
trials	B-T062
and	O
participants	B-T098
were	O
informed	B-T080
or	O
uninformed	B-T033
regarding	O
task	B-T057
cancelation	B-T080
.	O
The	O
"	O
informed	B-T080
fadeout effect	B-T041
"	O
indicates	O
better	O
performance	B-T061
in	O
the	O
informed	B-T080
than	O
uninformed	B-T033
fadeout	B-T041
after	O
one	O
informed	B-T080
trial	B-T062
had	O
been	O
executed	B-T052
.	O
However,	O
the	O
results	O
regarding	O
the	O
first	O
trial	B-T062
were	O
inconclusive.	O
Possible	O
underlying	O
mechanisms	B-T169
are	O
discussed.	O

Metacarpophalangeal Joint Arthrodesis	B-T061
of	O
the	O
Thumb	B-T023
-	O
Minimum	O
of	O
Eight	O
Months	B-T079
Follow-up	B-T058
Disorders	B-T047
of	O
the	O
thumb metacarpophalangeal (MCP) joint	B-T030
can	O
lead	O
to	O
significant	O
loss	B-T081
of	O
function	B-T039
and	O
pain	B-T184
.	O
Thumb MCP	B-T030
arthrodesis	B-T061
following	O
traumatic injuries	B-T037
is	O
inadequately	O
described	B-T078
and	O
recent	O
studies	B-T062
have	O
questioned	O
the	O
outcome	B-T169
of	O
this	O
treatment	B-T061
.	O
The	O
purpose	O
of	O
this	O
study	B-T062
was	O
to	O
report	B-T058
outcome	B-T169
and	O
disability	B-T033
following	O
thumb MCP joint	B-T030
arthrodesis	B-T061
in	O
the	O
treatment	B-T061
of	O
chronic instability	B-T046
after	O
traumatic injuries	B-T037
.	O
A	O
retrospective	B-T080
review	B-T061
of	O
26	O
patients	B-T101
operated	B-T061
on	O
with	O
MCP joint	B-T030
arthrodesis	B-T061
,	O
median	O
follow-up	B-T058
42	O
months	B-T079
(8-104	O
months	B-T079
).	O
Subjective	O
outcome	B-T169
was	O
assessed	B-T052
using	O
the	O
disabilities of the Arm, Shoulder, and Hand-questionnaire	B-T170
(	O
DASH	B-T170
).	O
In	O
addition,	O
patient satisfaction	B-T080
,	O
pain	B-T184
,	O
stiffness	B-T184
,	O
and	O
impairment	B-T169
of	O
activities of daily living	B-T056
were	O
assessed	B-T052
on	O
a	O
Visual Analogue Scale	B-T060
(	O
VAS	B-T060
)	O
followed	O
by	O
a	O
question	O
stating	O
whether	O
they	O
would	O
undergo	O
the	O
same	O
procedure	B-T169
again.	O
Two	O
patients	B-T101
(7.7%)	O
needed	O
re-operation	B-T061
due	O
to	O
nonunion	B-T033
.	O
Four	O
patients	B-T101
(15.4%)	O
needed	O
hardware removal	B-T061
.	O
Median	B-T081
DASH	B-T170
-	O
score	B-T081
was	O
18	O
(25-75%	O
range	B-T081
6-47),	O
with	O
lower	O
DASH	B-T170
score s	B-T081
being	O
better.	O
Score s	B-T081
were	O
significantly	O
worse	O
in	O
gender	B-T032
and	O
age	B-T032
matched	O
individuals	B-T098
(p<0.05).	O
Median	B-T081
VAS	B-T060
for	O
pain	B-T184
was	O
3.7	O
(	O
range	B-T081
0-8).	O
More	O
than	O
50%	O
of	O
patients	B-T101
reported	O
mild	B-T033
,	O
moderate	B-T184
or	O
severe pain	B-T033
,	O
but	O
all	O
patients	B-T101
reported	O
that	O
they	O
were	O
willing	O
to	O
undergo	O
the	O
same	O
procedure	B-T169
again.	O
Our	O
data	B-T078
suggest,	O
that	O
patients	B-T101
with	O
post-traumatic	B-T079
thumb injuries	B-T037
managed	O
with	O
thumb MCP joint	B-T030
arthrodesis	B-T061
perform	O
worse	O
than	O
gender	B-T032
and	O
age	B-T032
matched	O
individuals	B-T098
.	O
Many	O
lived	O
with	O
pain	B-T184
,	O
but	O
all	O
reported	O
that	O
they	O
were	O
willing	O
to	O
undergo	O
the	O
same	O
procedure	B-T169
again.	O
We	O
suggest	O
that	O
the	O
disability scale	B-T170
by	O
the	O
National Board of Industrial Injuries	B-T092
should	O
be	O
reconsidered	O
for	O
patients	B-T101
operated	B-T061
on	O
with	O
thumb MCP	B-T030
arthrodesis	B-T061
.	O

Pyoderma gangrenosum	B-T047
:	O
A	O
clinician's	B-T097
nightmare	B-T184
Pyoderma gangrenosum	B-T047
(	O
PG	B-T047
)	O
is	O
a	O
rare disease	B-T047
and	O
that	O
affecting	O
specifically	O
the	O
sole of the foot	B-T029
,	O
is	O
even	O
rarer.	O
Here,	O
we	O
report	B-T170
the	O
case	O
of	O
a	O
54-year-	O
old	B-T079
female	B-T032
admitted	B-T058
with	O
a	O
painful	B-T184
ulcer	B-T047
on	O
the	O
sole of the right foot	B-T029
which	O
was	O
initially	O
treated with	B-T061
empirical	O
antibiotics	B-T195
and	O
debridement	B-T061
.	O
The	O
disease	B-T047
was	O
found	O
to	O
spread	O
rapidly	B-T080
after	O
each	O
debridement	B-T061
.	O
The	O
culture reports	B-T034
were	O
negative	B-T033
;	O
rheumatology	B-T091
workup	B-T060
and	O
Doppler study	B-T060
were	O
within	O
normal limits	B-T033
.	O
A	O
clinical	B-T080
suspicion	B-T078
of	O
PG	B-T047
was	O
made	O
and	O
was	O
confirmed	O
with	O
tissue biopsy	B-T060
.	O
She	O
was	O
started on oral steroids	B-T061
following	O
which	O
she	O
dramatically	O
improved	B-T033
.	O
Thus,	O
when	O
a	O
patient	B-T101
presents	O
with	O
a	O
rapidly	B-T080
expanding	O
painful	B-T184
ulcer	B-T047
in	O
a	O
vascular limb	B-T023
that	O
is	O
refractory	B-T169
to	O
antibiotic treatment	B-T061
and	O
exacerbating	B-T080
on	O
debridement	B-T061
,	O
it	O
is	O
imperative	O
to	O
consider	O
the	O
possibility	O
of	O
PG	B-T047
.	O

Visualization	B-T060
for	O
Understanding	O
Uncertainty	B-T033
in	O
Activation	B-T052
Volumes	B-T081
for	O
Deep Brain Stimulation	B-T061
We	O
have	O
created	O
the	O
Neurostimulation Uncertainty Viewer (nuView or νView) tool	B-T170
for	O
exploring	O
data	B-T078
arising	O
from	O
deep brain stimulation	B-T061
(	O
DBS	B-T061
).	O
Simulated	B-T062
volume of tissue activated	B-T081
(	O
VTA	B-T081
),	O
using	O
clinical electrode placements	B-T060
,	O
are	O
recorded	B-T052
along	O
with	O
patient	B-T101
outcomes	B-T080
in	O
the	O
Unified Parkinson's disease rating scale	B-T170
(	O
UPDRS	B-T170
).	O
The	O
data	B-T078
is	O
volumetric	B-T080
and	O
sparse	B-T080
,	O
with	O
multi-value	B-T080
patient	B-T101
results	B-T169
for	O
each	O
activated	B-T052
voxel	B-T077
in	O
the	O
simulation	B-T062
.	O
νView	B-T077
provides	O
a	O
collection	B-T169
of	O
visual methods	B-T170
to	O
explore	O
the	O
activated	B-T052
tissue	B-T024
to	O
enhance	O
understanding	O
of	O
electrode	B-T074
usage	B-T169
for	O
improved	O
therapy	B-T061
with	O
DBS	B-T061
.	O

Post-synthetic	O
conversion	B-T169
of	O
5-pivaloyloxymethyluridine	B-T114
present	B-T033
in	O
a	O
support-bound	O
RNA	B-T114
oligomer	B-T087
into	O
biologically	B-T080
relevant	B-T080
derivatives	B-T104
of	O
5-methyluridine	B-T114
A	O
post-synthetic	O
reaction	B-T169
of	O
5-pivaloyloxymethyluridine	B-T114
(	O
present	B-T033
in	O
a	O
support-bound	O
RNA	B-T114
oligomer	B-T087
)	O
with	O
various	O
nucleophilic reagents	B-T130
furnished	O
efficiently	O
the	O
corresponding	O
products	B-T071
bearing	O
one	O
aof	O
the	O
tRNA wobble	B-T045
5-methyluridines	B-T114
(	O
mnm(5)U	B-T114
,	O
cmnm(5)U	B-T114
,	O
τm(5)U	B-T114
,	O
nm(5)U	B-T114
,	O
inm(5)U	B-T114
or	O
cnm(5)U	B-T114
).	O
The	O
syntheses	B-T052
of	O
oligoribonucleotides	B-T114
modified	B-T169
with	O
inm(5)U	B-T114
and	O
cnm(5)U	B-T114
are	O
reported	O
for	O
the	O
first	O
time.	O

Non-pharmacological	B-T169
treatments	B-T061
for	O
pain relief	B-T061
:	O
TENS	B-T061
and	O
acupuncture	B-T061
Acupuncture	B-T061
and	O
transcutaneous electrical nerve stimulation	B-T061
(	O
TENS	B-T061
)	O
are	O
non-pharmacological	B-T169
methods	B-T169
that	O
have	O
been	O
used	O
for	O
millennia	B-T079
to	O
relieve pain	B-T061
.	O
As	O
with	O
all	O
complementary treatments	B-T061
,	O
efficacy	B-T080
evaluations	B-T058
face	O
two	O
hurdles:	O
the	O
non-feasibility	O
of	O
double-blinding	B-T062
and	O
the	O
difficulty	O
in	O
identifying	O
the	O
optimal control population	B-T081
or	O
treatment	B-T061
.	O
Nevertheless,	O
recent	O
studies	O
of	O
good	B-T080
methodological quality	B-UnknownType
have	O
demonstrated	O
benefits	B-T081
in	O
many	O
types	O
of	O
pain	B-T184
compared	O
to	O
conventional	B-T080
treatment	B-T061
.	O
The	O
mechanisms of action	B-T169
of	O
acupuncture	B-T061
and	O
TENS	B-T061
,	O
which	O
are	O
increasingly	B-T169
well	O
understood,	O
involve	O
endogenous	B-T169
pain control systems	B-T061
,	O
cerebral plasticity	B-T042
,	O
and	O
nonspecific	O
effects	B-T080
(e.g.,	O
expectations	B-T078
and	O
placebo effect	B-T078
).	O
No	O
serious	O
adverse effects	B-T046
have	O
been	O
reported.	O
These	O
data	B-T078
support	O
the	O
more	O
widespread	O
use	O
of	O
non-pharmacological	B-T169
pain management	B-T061
,	O
most	O
notably	O
in	O
patients	B-T101
with	O
chronic pain	B-T184
inadequately	O
relieved by	B-T169
medications	B-T121
alone.	O

Synaptic	B-T030
and	O
Neuronal	B-T025
Autoantibody	B-T116
-	O
Associated	B-T080
Psychiatric Syndromes	B-T048
:	O
Controversies	B-T054
and	O
Hypotheses	B-T078
Autoimmune encephalitis	B-T047
(	O
AE	B-T047
)	O
mediated	O
by	O
antibodies	B-T116
against	O
synaptic	B-T030
and	O
neuronal	B-T025
surface	B-T082
targets	B-T169
frequently	B-T079
presents	B-T033
with	O
a	O
psychiatric syndrome	B-T048
.	O
In	O
these	O
patients	B-T101
,	O
removal of	B-T061
autoantibodies	B-T116
treats	B-T169
the	O
disease	B-T047
and	O
outcomes	B-T080
are	O
closely	O
linked	O
to	O
early	O
intervention	B-T061
.	O
The	O
discovery	B-T052
of	O
these	O
autoantibodies	B-T116
in	O
isolated	B-T169
psychiatric syndromes	B-T048
has	O
raised	B-T080
the	O
possibility	O
that	O
these	O
patients	B-T101
may	O
derive	O
similar	O
benefits	B-T081
from	O
immunotherapy	B-T061
,	O
a	O
potentially	B-T080
transformational	O
approach	B-T082
to	O
the	O
treatment	B-T169
of	O
mental illness	B-T048
.	O
Although	O
open-label case series	B-T062
suggest	O
impressive	O
therapeutic outcomes	B-T080
,	O
the	O
pathological	B-T169
relevance	B-T080
of	O
these	O
autoantibodies	B-T116
outside	O
of	O
canonical presentations	B-T081
is	O
debated.	O
The	O
advent	O
of	O
diagnostic criteria	B-T170
for	O
AE	B-T047
attempts	B-T051
to	O
facilitate	O
its	O
prompt	O
identification	B-T080
but	O
risks	B-T078
prematurely	O
neglecting	O
the	O
potential	B-T080
scientific	B-T090
and	O
clinical significance	B-T033
of	O
isolated	B-T169
syndromes	B-T047
that	O
do	O
not	O
satisfy	O
these	O
criteria.	O
Here,	O
we	O
propose	O
using	O
a	O
syndrome	B-T047
-	O
level	B-T080
taxonomy	B-T090
that	O
has	O
occasional	B-T079
,	O
but	O
not	O
necessary,	O
overlap	B-T079
with	O
AE	B-T047
:	O
synaptic	B-T030
and	O
neuronal	B-T025
autoantibody	B-T116
-	O
associated	B-T080
psychiatric syndromes	B-T048
or	O
"	O
SNAps	B-T048
".	O
This	O
will	O
prevent	B-T169
confusion	O
with	O
AE	B-T047
and	O
act heuristically	B-T170
to	O
promote	B-T052
active	B-T169
investigation	B-T058
into	O
this	O
rare	B-T080
example	B-T077
of	O
psychopathology	B-T091
defined	B-T170
on	O
a	O
molecular level	B-T081
.	O
We	O
suggest	O
that	O
this	O
concept	B-T078
would	O
have	O
application	O
in	O
other	O
autoantibody	B-T116
-	O
associated	B-T080
syndromes	B-T047
including	B-T169
seizure	B-T184
,	O
cognitive	B-T169
,	O
and	O
movement disorders	B-T047
,	O
in	O
which	O
similar	B-T080
issues	B-T033
arise.	O
We	O
review	B-T169
putative	O
direct	B-T080
and	O
indirect	B-T080
mechanisms	B-T169
and	O
outline	O
experimentally	B-T080
testable	O
hypotheses	B-T078
that	O
would	O
help	O
to	O
determine	O
prospectively	B-T062
in	O
whom	O
autoantibody	B-T116
detection	B-T061
is	O
relevant	B-T080
,	O
and	O
as	O
important	B-T080
,	O
in	O
whom	O
it	O
is	O
not.	O
We	O
summarize	O
a	O
pragmatic	B-T054
approach	O
to	O
autoantibody	B-T116
testing	B-T169
and	O
management	B-T058
in	O
severe	B-T080
mental illness	B-T048
in	O
order	O
to	O
promptly	O
diagnose	B-T033
AE	B-T047
and	O
advocate	O
a	O
research	B-T062
-	O
orientated	B-T033
experimental	B-T080
medicine	B-T121
paradigm	B-T062
for	O
SNAps	B-T048
,	O
where	O
there	O
is	O
greater	B-T081
equipoise	B-T109
.	O
We	O
conclude	O
that	O
SNAps	B-T048
remains	O
a	O
nascent	O
area	O
of	O
clinical	B-T080
neuroscience	B-T091
with	O
great	O
potential	B-T080
and	O
in	O
ongoing	B-T078
need	B-T080
of	O
psychiatry	B-T091
-led	O
basic	O
and	O
clinical research	B-T062
.	O

NF-κB	B-T116
Links	O
TLR2	B-T116
and	O
PAR1	B-T116
to	O
Soluble	B-T080
Immunomodulator Factor	B-T121
Secretion	B-T038
in	O
Human	B-T016
Platelets	B-T025
The	O
primary	B-T080
toll-like receptor	B-T116
(	O
TLR	B-T116
)-mediated	O
immune cell response pathway	B-T043
common	O
for	O
all	O
TLRs	B-T116
is	O
MyD88	B-T116
-dependent	O
activation	B-T045
of	O
NF-κB	B-T116
,	O
a	O
seminal	B-T023
transcription factor	B-T116
for	O
many	O
chemokines	B-T116
and	O
cytokines	B-T116
.	O
Remarkably,	O
anucleate platelets	B-T025
express	O
the	O
NF-κB	B-T116
machinery,	O
whose	O
role	O
in	O
platelets	B-T025
remains	O
poorly	O
understood.	O
Here,	O
we	O
investigated	B-T169
the	O
contribution	B-T052
of	O
NF-κB	B-T116
in	O
the	O
release	B-T169
of	O
cytokines	B-T116
and	O
serotonin	B-T109
by	O
human	B-T016
platelets	B-T025
,	O
following	B-T079
selective	O
stimulation	O
of	O
TLR2	B-T116
and	O
protease activated receptor 1	B-T116
(	O
PAR1	B-T116
),	O
a	O
classical	O
and	O
non-classical	O
pattern-recognition receptor	B-T116
,	O
respectively,	O
able	O
to	O
participate	O
to	O
the	O
innate immune system	B-T032
.	O
We	O
discovered	O
that	O
platelet	B-T025
PAR1	B-T116
activation	B-T045
drives	O
the	O
process	O
of	O
NF-κB	B-T116
phosphorylation	B-T044
,	O
in	O
contrast	O
to	O
TLR2	B-T116
activation	B-T043
,	O
which	O
induces	B-T169
a	O
slower	O
phosphorylation process	B-T044
.	O
Conversely,	O
platelet	B-T025
PAR1	B-T116
and	O
TLR2	B-T116
activation	B-T052
induces	B-T169
similar	O
ERK1/2	B-T044
,	O
p38	B-T116
,	O
and	O
AKT	B-T116
phosphorylation	B-T044
.	O
Moreover,	O
we	O
found	O
that	O
engagement	O
of	O
platelet	B-T025
TLR2	B-T116
with	O
its	O
ligand	B-T103
,	O
Pam3CSK4	B-T116
,	O
significantly increases	B-T081
the	O
release	B-T169
of	O
sCD62P	B-T116
,	O
RANTES	B-T116
,	O
and	O
sCD40L	B-T116
;	O
this	O
effect	B-T080
was	O
attenuated by	B-T080
incubating	B-T059
platelets	B-T025
with	O
a	O
blocking	B-T169
anti-TLR2 antibody	B-T116
.	O
This	O
effect appeared	B-T080
selective	O
since	O
no	O
modulation	B-T082
of	O
serotonin secretion	B-T043
was	O
observed	B-T169
following	B-T079
platelet	B-T025
TLR2	B-T116
activation	B-T043
.	O
Platelet	B-T025
release	B-T169
of	O
sCD62P	B-T116
,	O
RANTES	B-T116
,	O
and	O
sCD40L	B-T116
following	B-T079
TLR2	B-T116
or	O
PAR1	B-T116
triggering	O
was	O
abolished	O
in	O
the	O
presence	B-T033
of	O
the	O
NF-κB	B-T116
inhibitor	B-T120
Bay11-7082	B-T109
,	O
while	O
serotonin release	B-T043
following	B-T079
PAR1	B-T116
activation	B-T043
was	O
significantly decreased	B-T081
.	O
These	O
new	B-T080
findings	B-T169
support	O
the	O
concept	O
that	O
NF-κB	B-T116
is	O
an	O
important	O
player	O
in	O
platelet	B-T025
immunoregulations	B-T040
and	O
functions	B-T042
.	O

Optical tweezers	B-T062
studies	B-T062
of	O
transcription	B-T045
by	O
eukaryotic	B-T025
RNA polymerases	B-T116
Transcription	B-T045
is	O
the	O
first step	B-T077
in	O
the	O
expression	B-T045
of	O
genetic	B-T169
information	B-T078
and	O
it	O
is	O
carried	B-T052
out	O
by	O
large	O
macromolecular	B-T104
enzymes	B-T116
called	O
RNA polymerases	B-T116
.	O
Transcription	B-T045
has	O
been	O
studied	B-T062
for	O
many	O
years	O
and	O
with	O
a	O
myriad	B-T170
of	O
experimental	B-T080
techniques	B-T169
,	O
ranging	B-T081
from	O
bulk	O
studies	B-T062
to	O
high-resolution transcript sequencing	B-T059
.	O
In	O
this	O
review	B-T170
,	O
we	O
emphasise	O
the	O
advantages	O
of	O
using	O
single-molecule	B-T167
techniques	B-T169
,	O
particularly	O
optical tweezers	B-T062
,	O
to	O
study	B-T062
transcription	B-T045
dynamics	B-T070
.	O
We	O
give	O
an	O
overview	B-T170
of	O
the	O
latest	O
results	B-T169
in	O
the	O
single-molecule	B-T167
transcription	B-T045
field	B-T077
,	O
focusing	O
on	O
transcription	B-T045
by	O
eukaryotic	B-T025
RNA polymerases	B-T116
.	O
Finally,	O
we	O
evaluate	O
recent	O
quantitative	B-T081
models	B-T075
that	O
describe	B-T078
the	O
biophysics	B-T091
of	O
RNA polymerase	B-T116
translocation	B-T043
and	O
backtracking	O
dynamics	B-T070
.	O

Decreased Frequencies	B-T080
of	O
Peripheral Blood	B-T031
CD4+CD25+CD127-Foxp3+	B-T025
in	O
Patients	B-T101
with	O
Graves' Disease	B-T047
and	O
Graves' Orbitopathy	B-T047
:	O
Enhancing Effect	B-T080
of	O
Insulin Growth Factor-1	B-T116
on	O
Treg Cells	B-T025
Graves' orbitopathy	B-T047
(	O
GO	B-T047
)	O
is	O
characterized	B-T052
by	O
orbital T cell	B-T025
infiltration	B-T046
.	O
We	O
evaluated	B-T058
the	O
regulatory T (Treg) cell	B-T025
fractions	B-T081
induced	B-T169
with	O
IGF-1	B-T116
in	O
Graves' disease	B-T047
(	O
GD	B-T047
)	O
with	O
and	O
without	O
GO	B-T047
.	O
Peripheral blood mononuclear cells	B-T025
(	O
PBMCs	B-T025
)	O
were	O
obtained	O
from	O
13	O
patients	B-T101
with	O
GD	B-T047
without	O
eye manifestations	B-T184
;	O
10	O
patients	B-T101
with	O
active	B-T169
GO	B-T047
;	O
and	O
12	O
patients	B-T101
with	O
nodular goiter	B-T047
(	O
NG	B-T047
).	O
All	O
the	O
patients	B-T101
from	O
GD	B-T047
,	O
GO	B-T047
,	O
and	O
NG	B-T047
were	O
subclinical hyperthyroid	B-UnknownType
.	O
We	O
analyzed	B-T062
the	O
expression of Treg cell markers	B-T059
(	O
CD4	B-T116
,	O
CD25	B-T116
,	O
CD127(-)	B-T116
,	O
Foxp3	B-T116
)	O
on	O
T cells	B-T025
and	O
their	O
ability	O
to	O
respond to	B-T170
IGF-1	B-T116
stimulation	B-T070
.	O
In	O
patients	B-T101
with	O
GD	B-T047
without	O
GO	B-T047
,	O
we	O
found	O
lowered percentages	B-T081
of	O
CD4(+) Foxp3(+) cells	B-T025
,	O
as	O
compared	O
to	O
nodular goiter	B-T047
1.77	O
vs.	O
5.42%	O
(p=0.0276).	O
Similarly,	O
significantly reduced frequencies	B-T080
of	O
CD4(+)CD25(+)CD127(-)Foxp3(+)	B-T025
and	O
CD4(+)CD25(+)CD127(-) cells	B-T025
were	O
observed	B-T169
in	O
GD	B-T047
patients	B-T101
as	O
compared	O
to	O
nodular goiter	B-T047
patients	B-T101
with	O
hyperthyreosis	B-T047
,	O
(0.7	O
vs.	O
1.48%)	O
(p=0.0071)	O
and	O
(14.5	O
vs.	O
37.2%)	O
(p=0.0051),	O
respectively.	O
In	O
GO	B-T047
with	O
active	B-T169
GO	B-T047
,	O
only	O
the	O
percentage	B-T081
of	O
CD4(+)CD25(+)CD127(-) cells	B-T025
was	O
found	O
to	O
be	O
decreased	B-T081
versus	O
nodular goiter	B-T047
(9.35	O
vs.	O
37.2)	O
(p=0.0275).	O
Stimulation	B-T070
of	O
PBMC	B-T025
derived	O
from	O
GO	B-T047
patients	B-T101
with	O
IGF-1	B-T116
resulted	O
in	O
significant increase of frequency	B-T080
of	O
both	O
CD4(+) Foxp3(+)	B-T025
and	O
CD4(+)CD25(+)CD127(-) Foxp3 cells	B-T025
.	O
Decreased frequencies	B-T080
of	O
peripheral blood	B-T031
CD4(+)CD25(+)CD127(-)Foxp3(+)	B-T025
in	O
patients	B-T101
with	O
GD	B-T047
and	O
GO	B-T047
could	O
be	O
an	O
useful marker	B-T201
of	O
autoimmune process	B-T046
and	O
perhaps	O
a	O
possible	O
target	O
for	O
future therapies	B-T169
.	O
This	O
is	O
the	O
first	O
study	B-T062
demonstrating	O
Treg	B-T025
-	O
enhancing effects	B-T080
of	O
IGF-1	B-T116
.	O
Thus	O
IGF-1	B-T116
can	O
be	O
accounted	O
for	O
modulating	B-T082
Treg cell	B-T025
-related	O
action	B-T052
in	O
GO	B-T047
.	O

γ-Butenolide	B-T123
and	O
furanone derivatives	B-T123
from	O
the	O
soil	B-T167
-derived	O
fungus	B-T004
Aspergillus sclerotiorum	B-T004
PSU-RSPG178	B-T004
Chromatographic separation	B-T059
of	O
the	O
broth	B-T130
extract	B-T167
of	O
the	O
soil	B-T167
-derived	O
fungus	B-T004
Aspergillus sclerotiorum	B-T004
PSU-RSPG178	B-T004
resulted	O
in	O
isolation	B-T169
of	O
four	O
γ-butenolide-furanone dimers	B-T123
,	O
aspersclerotiorones A-D	B-T123
,	O
a	O
furanone derivative	B-T123
,	O
aspersclerotiorone E	B-T123
,	O
and	O
two	O
γ-butenolide derivatives	B-T123
,	O
aspersclerotiorones F	B-T123
and	O
G	B-T123
,	O
together	O
with	O
six	O
known	O
compounds,	O
penicillic acid	B-T109
,	O
dihydropenicillic acid	B-T123
,	O
5,6-dihydro-6-hydroxypenicillic acid	B-T123
,	O
6-methoxy-5,6-dihydropenicillic acid	B-T123
,	O
coculnol	B-T123
and	O
(4R,5R)-4,5-dihydroxy-3-methoxy-5-methylcyclohex-2-en-1-one	B-T123
.	O
Their	O
structures	B-T170
were	O
determined	O
by	O
spectroscopic evidence	B-T059
.	O
For	O
aspersclerotiorones A	B-T123
and	O
B	B-T123
,	O
the	O
structures	B-T170
were	O
confirmed	O
by	O
single-crystal X-ray diffraction crystallography	B-T059
.	O
Penicillic	O
acid	O
displayed	O
weak	O
antibacterial activity	B-T034
against	O
Staphylococcus aureus	B-T007
and	O
Escherichia coli	B-T007
with	O
equal	O
MIC values	B-T034
of	O
128	O
μg/mL,	O
and	O
it	O
was	O
noncytotoxic	B-T080
towards	O
African green monkey	B-T015
kidney	B-T023
fibroblast cells	B-T025
.	O

E3 Ligase	B-T116
RNF126	B-T116
Directly	O
Ubiquitinates	B-T044
Frataxin	B-T116
,	O
Promoting	B-T052
Its	O
Degradation	B-T169
:	O
Identification	B-T080
of	O
a	O
Potential	O
Therapeutic	B-T169
Target	B-T169
for	O
Friedreich Ataxia	B-T047
Friedreich ataxia	B-T047
(	O
FRDA	B-T047
)	O
is	O
a	O
severe	O
genetic	B-T169
neurodegenerative disease	B-T047
caused	O
by	O
reduced	O
expression	B-T045
of	O
the	O
mitochondrial protein	B-T116
frataxin	B-T116
.	O
To	O
date,	O
there	O
is	O
no	O
therapy	B-T169
to	O
treat	B-T061
this	O
condition	B-T080
.	O
The	O
amount	O
of	O
residual	B-T080
frataxin	B-T116
critically	O
affects	O
the	O
severity	B-T080
of	O
the	O
disease	B-T047
;	O
thus,	O
attempts	O
to	O
restore	O
physiological	B-T169
frataxin	B-T116
levels	B-T080
are	O
considered	O
therapeutically	B-T169
relevant	B-T080
.	O
Frataxin	B-T116
levels	B-T080
are	O
controlled by	B-T169
the	O
ubiquitin-proteasome system	B-T044
;	O
therefore,	O
inhibition	B-T052
of	O
the	O
frataxin	B-T116
E3 ligase	B-T116
may	O
represent	O
a	O
strategy	B-T062
to	O
achieve	O
an	O
increase	O
in	O
frataxin	B-T116
levels	B-T080
.	O
Here,	O
we	O
report	O
the	O
identification	B-T080
of	O
the	O
RING E3 ligase	B-T116
RNF126	B-T116
as	O
the	O
enzyme	B-T116
that	O
specifically	O
mediates	O
frataxin	B-T116
ubiquitination	B-T044
and	O
targets	O
it	O
for	O
degradation	B-T169
.	O
RNF126	B-T116
interacts	B-T169
with	O
frataxin	B-T116
and	O
promotes	B-T052
its	O
ubiquitination	B-T044
in	O
a	O
catalytic activity	B-T169
-	O
dependent	B-T080
manner,	O
both	O
in vivo	B-T082
and	O
in vitro	B-T080
.	O
Most	O
importantly,	O
RNF126	B-T116
depletion	B-T169
results	O
in	O
frataxin	B-T116
accumulation	B-T033
in	O
cells	B-T025
derived	O
from	O
FRDA	B-T047
patients	B-T101
,	O
highlighting	O
the	O
relevance	B-T080
of	O
RNF126	B-T116
as	O
a	O
new	O
therapeutic	B-T169
target	B-T169
for	O
Friedreich ataxia	B-T047
.	O

Enhancing	O
Doctors'	B-T097
Competencies	B-T080
in	O
Communication	B-T054
With	O
and	O
Activation	B-T052
of	O
Older	B-T098
Patients	B-T101
:	O
The	O
Promoting	B-T052
Active	B-T169
Aging	B-T040
(	O
PRACTA	B-T058
)	O
Computer-Based Intervention Study	B-T058
Demographic	B-T090
changes	B-T169
over	O
the	O
past	O
decades	B-T081
call	O
for	O
the	O
promotion of health and disease prevention	B-UnknownType
for	O
older	B-T098
patients	B-T101
,	O
as	O
well	O
as	O
strategies	O
to	O
enhance	O
their	O
independence	B-T078
,	O
productivity	B-T081
,	O
and	O
quality of life	B-T078
.	O
Our	O
objective	O
was	O
to	O
examine	O
the	O
effects	O
of	O
a	O
computer-based educational intervention	B-T061
designed	O
for	O
general practitioners	B-T097
(	O
GPs	B-T097
)	O
to	O
promote	O
active	B-T169
aging	B-T040
.	O
The	O
Promoting	B-T052
Active	O
Aging	B-T040
(	O
PRACTA	B-T058
)	O
study	O
consisted	O
of	O
a	O
baseline questionnaire	B-T170
,	O
implementation	B-T052
of	O
an	O
intervention	B-T061
,	O
and	O
a	O
follow-up questionnaire	B-T170
that	O
was	O
administered	B-T169
1	O
month	O
after	O
the	O
intervention	B-T058
.	O
A	O
total	O
of	O
151	O
primary care facilities	B-T073
(	O
response rate	B-T079
151/767,	O
19.7%)	O
and	O
503	O
GPs	B-T097
(	O
response rate	B-T079
503/996,	O
50.5%)	O
agreed	O
to	O
participate	B-T169
in	O
the	O
baseline assessment	B-T062
.	O
At	O
the	O
follow-up	B-T062
,	O
393	O
GPs	B-T097
filled	O
in	O
the	O
questionnaires	B-T170
(	O
response rate	B-T079
,	O
393/503,	O
78.1%),	O
but	O
not	O
all	O
of	O
them	O
took	O
part	O
in	O
the	O
intervention	B-T061
.	O
The	O
final	O
study group	B-UnknownType
of	O
225	O
GPs	B-T097
participated	O
in	O
3	O
study	O
conditions:	O
e-learning	B-T065
(	O
knowledge	B-T041
plus	O
skills	B-T055
modelling	B-T170
,	O
n=42),	O
a	O
pdf article	B-T170
(	O
knowledge	B-T041
only,	O
n=89),	O
and	O
control	B-T096
(	O
no	B-T080
intervention	B-T058
,	O
n=94).	O
We	O
measured	O
the	O
outcome	O
as	O
scores	B-T081
on	O
the	O
Patients	B-T101
Expectations Scale	B-T170
,	O
Communication Scale	B-T170
,	O
Attitude Toward Treatment and Health Scale	B-T170
,	O
and	O
Self-Efficacy Scale	B-T170
.	O
GPs	B-T097
participating	O
in	O
e-learning	B-T065
demonstrated	O
a	O
significant	B-T078
rise	O
in	O
their	O
perception	B-T041
of	O
older	B-T098
patients	B-T101
'	O
expectations	B-T078
for	O
disease explanation	B-T170
(Wald	O
χ(2)=19.7,	O
P<.001)	O
and	O
in	O
perception	B-T041
of	O
motivational	B-T041
aspect	O
of	O
older	B-T098
patients	B-T101
'	O
attitude	O
toward	O
treatment	B-T169
and	O
health	B-T078
(Wald	O
χ(2)=8.9,	O
P=.03)	O
in	O
comparison	O
with	O
both	O
the	O
control	B-T096
and	O
pdf article groups	B-UnknownType
.	O
We	O
observed	O
additional	O
between-	O
group	B-UnknownType
differences	O
at	O
the	O
level	B-T080
of	O
statistical	B-T090
trend.	O
GPs	B-T097
participating	O
in	O
the	O
pdf article	B-T170
intervention	B-T061
demonstrated	O
a	O
decline	O
in	O
self-assessed	O
communication	B-T054
,	O
both	O
at	O
the	O
level	B-T080
of	O
global scoring	B-T081
(Wald	O
χ(2)=34.5,	O
P<.001)	O
and	O
at	O
the	O
level	B-T080
of	O
20	O
of	O
26	O
specific behaviors	B-UnknownType
(all	O
P<.05).	O
Factors	O
moderating	O
the	O
effects of	B-T080
the	O
intervention	B-T061
were	O
the	O
number	O
of	O
patients	B-T101
per	O
GP	B-T097
and	O
the	O
facility's	O
organizational structure	B-T170
.	O
Both	O
methods	O
were	O
suitable,	O
but	O
in	O
different	O
areas	B-T082
and	O
under	O
different	O
conditions	B-T080
.	O
The	O
key	O
benefit	O
of	O
the	O
pdf article	B-T170
intervention	B-T061
was	O
raising	O
doctors	B-T097
'	O
reflection	O
on	O
limitations	B-T169
in	O
their	O
communication skills	B-T032
,	O
whereas	O
e-learning	B-T065
was	O
more	O
effective	B-T080
in	O
changing	O
their	O
perception	O
of	O
older	B-T098
patients	B-T101
'	O
proactive	O
attitude,	O
especially	O
among	O
GPs	B-T097
working	O
in	O
privately owned facilities	B-T073
and	O
having	O
a	O
greater	O
number	O
of	O
assigned	B-T169
patients	B-T101
.	O
Although	O
we	O
did	O
not	O
achieve	O
all	O
expected	O
effects of	B-T080
the	O
PRACTA intervention	B-T058
,	O
both	O
its	O
forms	O
seem	O
promising	O
in	O
terms	O
of	O
enhancing	O
the	O
competencies	B-T080
of	O
doctors	B-T097
in	O
communication	B-T054
with	O
and	O
activation	O
of	O
older	B-T098
patients	B-T101
.	O

The	O
consummatory	B-T054
and	O
motivational	B-T041
behaviors	B-T053
for	O
natural	B-T169
rewards	B-T041
following	O
long-term	O
withdrawal	B-T061
from	O
morphine	B-T109
:	O
no	O
anhedonia	B-T048
but	O
persistent	O
maladaptive behaviors	B-T033
for	O
high-value	O
rewards	B-T041
The	O
negative	O
affective	O
state,	O
e.g.,	O
anhedonia	B-T048
,	O
emerges	O
after	O
abstinence	B-T061
from	O
abused drugs	B-T131
may	O
be	O
linked	O
to	O
the	O
motivational	B-T041
processes	B-T067
of	O
drug craving	B-T033
and	O
relapse	B-T067
.	O
Although	O
anhedonia	B-T048
diminishes	O
over	O
time	O
with	O
drug abstinence	B-T055
,	O
it	O
is	O
not	O
yet	O
rather	O
explicit	O
whether	O
anhedonia	B-T048
exists	O
or	O
not	O
following	O
protracted	O
withdrawal	B-T061
.	O
The	O
behavioral	B-T053
responses	B-T032
to	O
natural	B-T169
rewards	B-T041
were	O
examined	O
after	O
2	O
to	O
3	O
weeks	B-T079
withdrawal	B-T061
from	O
morphine	B-T109
.	O
Male	B-T032
rats	B-T015
were	O
pretreated	O
with	O
either	O
a	O
binge-like	O
morphine	B-T109
paradigm	B-T062
or	O
daily	B-T079
saline injection	B-T061
for	O
5	O
days	B-T079
.	O
The	O
consummatory	B-T054
and	O
motivational	B-T041
behaviors	B-T053
for	O
three	O
natural	B-T169
rewards	B-T041
(	O
sucrose solutions	B-T109
4,	O
15,	O
and	O
60%,	O
social	B-T169
stimulus	B-T067
:	O
male	B-T032
rat	B-T015
,	O
and	O
sexual	B-T054
stimulus	B-T067
:	O
estrous	B-T040
female	B-T032
rat	B-T015
)	O
were	O
examined	O
under	O
varied	O
testing conditions	B-T080
.	O
The	O
morphine	B-T109
-	O
withdrawn	B-T061
rats	B-T015
significantly	O
increased	O
their	O
intake	O
of	O
15%	O
sucrose solution	B-T109
during	O
the	O
1-h	O
consumption test	B-T060
and	O
their	O
operant responding	B-T041
for	O
15%	O
sucrose solution	B-T109
under	O
a	O
progressive ratio (PR) schedule of reinforcement	B-T062
.	O
When	O
obtaining	O
a	O
reinforcer	B-T078
was	O
associated	O
with	O
a	O
0.5	O
mA	O
foot	B-T023
shock	B-T061
under	O
a	O
PR-punishment schedule	B-T062
,	O
the	O
morphine	B-T109
-	O
withdrawn	B-T061
rats	B-T015
showed	O
a	O
higher	O
performance	O
for	O
60%	O
sucrose solution	B-T109
.	O
Meanwhile,	O
the	O
morphine	B-T109
-	O
withdrawn	B-T061
rats	B-T015
displayed	O
a	O
higher	O
motivation	B-T041
to	O
sexual	B-T054
stimulus	B-T067
during	O
the	O
free-approach test	B-T060
and	O
more	O
approaching	O
behaviors	B-T053
towards	O
sexual	B-T054
stimulus	B-T067
in	O
a	O
conflict-based approach test	B-T060
(concurrent	O
presence	O
of	O
reward	B-T041
and	O
aversive stimulus	B-T169
).	O
No	B-T033
anhedonia	B-T048
-like	O
behavior	B-T053
but	O
sensitized	B-T169
behaviors	B-T053
for	O
natural	B-T169
rewards	B-T041
were	O
found	O
after	O
long-term	O
morphine	B-T109
withdrawal	B-T061
.	O
Notably,	O
the	O
morphine	B-T109
-	O
withdrawn	B-T061
rats	B-T015
displayed	O
persistent	O
motivated	B-T041
behaviors	B-T053
for	O
high-value	O
rewards	B-T041
(60%	O
sucrose	B-T109
and	O
sexual	B-T054
stimulus	B-T067
)	O
in	O
the	O
conflict tests	B-T060
suggesting	O
impairments	O
in	O
inhibitory	O
control	O
in	O
morphine	B-T109
-	O
treated	B-T169
rats	B-T015
.	O

Extracellular	B-T026
Self-Assembly	B-T044
of	O
Functional	B-T169
and	O
Tunable Protein Conjugates	B-T116
from	O
Bacillus subtilis	B-T007
The	O
ability	O
to	O
stably	B-T080
and	O
specifically	O
conjugate	B-T043
recombinant proteins	B-T116
to	O
one	O
another	O
is	O
a	O
powerful	O
approach	O
for	O
engineering	B-T063
multifunctional	B-T169
enzymes	B-T116
,	O
protein therapeutics	B-T121
,	O
and	O
novel	B-T080
biological materials	B-T122
.	O
While	O
many	O
of	O
these	O
applications	B-UnknownType
have	O
been	O
illustrated	O
through	O
in vitro	B-T080
and	O
in vivo	B-T082
intracellular	B-T082
protein conjugation	B-T043
methods,	O
extracellular	B-T026
self-assembly	B-T044
of	O
protein conjugates	B-T116
offers	O
unique	O
advantages:	O
simplifying	O
purification	B-T059
,	O
reducing	B-T080
toxicity	B-T037
and	O
burden	B-T078
,	O
and	O
enabling	O
tunability	B-T080
.	O
Exploiting	O
the	O
recently	O
described	O
SpyTag-SpyCatcher system	B-T059
,	O
we	O
describe	O
here	O
how	O
enzymes	B-T116
and	O
structural proteins	B-T116
can	O
be	O
genetically encoded	B-T045
to	O
covalently	B-T044
conjugate	B-T043
in	O
culture media	B-T130
following	O
programmable secretion	B-T043
from	O
Bacillus subtilis	B-T007
.	O
Using	O
this	O
approach,	O
we	O
demonstrate	O
how	O
self-conjugation	B-T043
of	O
a	O
secreted	B-T043
industrial	O
enzyme	B-T116
,	O
XynA	B-T116
,	O
dramatically	O
increases	B-T081
its	O
resilience	B-T033
to	O
boiling	B-T069
,	O
and	O
we	O
show	O
that	O
cellular consortia	B-T025
can	O
be	O
engineered	B-T063
to	O
self-assemble	B-T044
functional	B-T169
protein-protein conjugates	B-T116
with	O
tunable	O
composition.	O
This	O
novel	B-T080
genetically encoded	B-T045
modular system	B-T169
provides	O
a	O
flexible strategy	B-T080
for	O
protein conjugation	B-T043
harnessing	O
the	O
substantial	O
advantages	O
of	O
extracellular	B-T026
self-assembly	B-T044
.	O

Vascular smooth muscle cell	B-T025
peroxisome proliferator-activated receptor γ	B-T116
protects	O
against	O
endothelin-1	B-T116
-	O
induced	B-T169
oxidative stress	B-T049
and	O
inflammation	B-T046
Peroxisome proliferator-activated receptor γ	B-T116
(	O
PPARγ	B-T116
)	O
agonists	B-T121
reduce	B-T080
blood pressure	B-T040
and	O
vascular injury	B-T037
in	O
hypertensive	B-T033
rodents	B-T015
.	O
Pparγ	B-T116
inactivation	B-T044
in	O
vascular smooth muscle cells	B-T025
(	O
VSMC	B-T025
)	O
enhances	B-T052
vascular injury	B-T037
.	O
Transgenic mice	B-T015
overexpressing	B-T045
endothelin (ET)-1	B-T116
selectively	O
in	O
the	O
endothelium	B-T024
(eET-1)	B-T116
exhibit	O
endothelial dysfunction	B-T047
,	O
increased	B-T081
oxidative stress	B-T049
and	O
inflammation	B-T046
.	O
We	O
hypothesized	B-T078
that	O
inactivation	B-T044
of	O
the	O
Pparγ gene	B-T028
in	O
VSMC	B-T025
(	O
smPparγ	B-T028
)	O
would	O
exaggerate	B-T080
ET-1	B-T116
-	O
induced	B-T169
vascular injury	B-T037
.	O
eET-1	B-T116
,	O
smPparγ	B-T116
and	O
eET-1	B-T116
/	O
smPparγ	B-T116
mice	B-T015
were	O
treated	B-T033
with	O
tamoxifen	B-T109
for	O
5	O
days	O
and	O
studied	B-T062
4	O
weeks	O
later.	O
SBP	B-T201
was	O
higher	B-T080
in	O
eET-1	B-T116
and	O
unaffected	B-T077
by	O
smPparγ	B-T116
inactivation	B-T044
.	O
Mesenteric artery	B-T023
vasodilatory	B-T042
responses	B-T032
to	O
acetylcholine	B-T109
were	O
impaired	B-T169
only	O
in	O
smPparγ	B-T116
.	O
N-Nitro-L-arginine methyl ester	B-T116
abrogated	B-T169
relaxation	B-T052
responses	B-T032
,	O
and	O
the	O
Ednra	B-T028
/	O
Ednrb	B-T028
mRNA	B-T114
ratio	B-T081
was	O
decreased	B-T081
in	O
eET-1	B-T116
/	O
smPparγ	B-T116
,	O
which	O
could	O
indicate	B-T078
that	O
nitric oxide	B-T121
production	B-T052
was	O
enhanced	B-T052
by	O
ET-1	B-T116
stimulation	B-T045
of	O
endothelin type B receptors	B-T116
.	O
Mesenteric artery	B-T023
media	B-T167
/	O
lumen	B-T080
was	O
greater	B-T081
only	O
in	O
eET-1	B-T116
/	O
smPparγ	B-T116
.	O
Mesenteric artery	B-T023
reactive oxygen species	B-T123
increased	B-T081
in	O
smPparγ	B-T116
and	O
were	O
further	O
enhanced	B-T052
in	O
eET-1	B-T116
/	O
smPparγ	B-T116
.	O
Perivascular	B-T082
fat monocyte	B-T025
/	O
macrophage	B-T025
infiltration	B-T046
was	O
higher	B-T080
in	O
eET-1	B-T116
and	O
smPparγ	B-T116
and	O
increased	B-T081
further	O
in	O
eET-1	B-T116
/	O
smPparγ	B-T116
.	O
Spleen	B-T023
CD11b cells	B-T025
were	O
increased	B-T081
in	O
smPparγ	B-T116
and	O
further	O
enhance	B-T052
d	O
in	O
eET-1	B-T116
/	O
smPparγ	B-T116
,	O
whereas	O
Ly-6C monocytes	B-T025
increased	B-T081
in	O
eET-1	B-T116
and	O
smPparγ	B-T116
but	O
not	O
in	O
eET-1	B-T116
/	O
smPparγ	B-T116
.	O
Spleen	B-T023
T regulatory lymphocytes	B-T025
increased	B-T081
in	O
smPparγ	B-T116
and	O
decreased	B-T081
in	O
eET-1	B-T116
,	O
and	O
decreased	B-T081
further	O
in	O
eET-1	B-T116
/	O
smPparγ	B-T116
.	O
VSMC	B-T025
Pparγ	B-T116
inactivation	B-T044
exaggerates	B-T080
ET-1	B-T116
-	O
induced	B-T169
vascular injury	B-T037
,	O
supporting	O
a	O
protective	O
role	B-T077
for	O
PPARγ	B-T116
in	O
hypertension	B-T047
through	O
modulation	B-T082
of	O
pro-oxidant	B-T123
and	O
proinflammatory	B-T169
pathways	B-T044
.	O
Paradoxically,	O
ET-1	B-T116
overexpression	B-T045
preserved	O
endothelial	B-T024
function	B-T169
in	O
smPparγ	B-T116
mice	B-T015
,	O
presumably	O
by	O
enhancing	B-T052
nitric oxide	B-T121
through	O
stimulation	B-T045
of	O
endothelin type B receptors	B-T116
.	O

Prospective	O
Evaluation	B-T058
of	O
Opioid Consumption	B-T048
After	O
Distal Radius Fracture	B-T037
Repair Surgery	B-T061
Pain management	B-T061
and	O
opioid consumption	B-T048
after	O
distal radius fracture	B-T037
(	O
DRF	B-T037
)	O
open reduction and internal fixation (ORIF)	B-T061
are	O
highly	O
variable	O
and	O
poorly	O
understood.	O
To	O
optimize	B-T061
postoperative	B-T079
opioid	B-T109
dosage	B-T081
and	O
better	O
understand	O
opioid consumption	B-T048
patterns	O
after	O
DRF	B-T037
-	O
ORIF	B-T061
,	O
we	O
conducted	O
a	O
prospective study	B-T062
with	O
the	O
hypothesis	B-T078
that	O
opioid consumption	B-T048
would	O
increase	B-T169
with	O
worsening	B-T080
fracture	B-T037
classification	B-T185
and	O
various	O
patient demographics	B-T078
.	O
All	O
patients	B-T101
who	O
underwent	O
DRF	B-T037
-	O
ORIF	B-T061
were	O
consecutively	O
enrolled	O
over	O
a	O
6-month period	B-T079
.	O
Information	O
collected	O
included	O
patient demographics	B-T078
,	O
fracture type	B-T080
,	O
anesthesia type	B-T185
,	O
amount	B-T081
and	O
type	B-T080
of	O
opioid	B-T109
prescribed	B-T058
,	O
number	B-T081
of	O
pills	B-T109
taken	B-T077
,	O
reason	B-T078
for	O
stopping	B-T061
,	O
and	O
adverse events	B-T046
.	O
Statistical analysis	B-T062
was	O
performed.	O
Ninety-eight	O
patients	B-T101
(79	O
female	B-T098
,	O
19	O
male	B-T098
)	O
were	O
eligible	O
for	O
the	O
study.	O
Mean	O
age	O
was	O
58	O
years.	O
Of	O
the	O
98	O
patients	B-T101
,	O
45	O
received	O
general anesthesia	B-T061
,	O
and	O
53	O
received	O
regional anesthesia	B-T061
with	O
a	O
single-shot	O
peripheral nerve block	B-T061
.	O
Mean	O
opioid consumption	B-T048
(	O
morphine	B-T109
equivalence	B-T080
)	O
over	O
a	O
mean	O
of	O
4.8	O
postoperative days	B-T079
(range,	O
0-16	O
days)	O
was	O
58.5	O
mg	O
(range,	O
0-280	O
mg).	O
There	O
were	O
no significant	B-T033
differences	O
in	O
opioid consumption	B-T048
between	O
the	O
general	B-T061
and	O
regional anesthesia	B-T061
groups.	O
Mean	O
opioid consumption	B-T048
for	O
the	O
3	O
fracture-type	B-T080
groups	O
(	O
AO/OTA [Arbeitsgemeinschaft für Osteosynthesefragen/Orthopaedic Trauma Association] classification	B-T170
)	O
was	O
57.7	O
mg	O
(	O
class A	B-T185
),	O
60.3	O
mg	O
(	O
class B	B-T185
),	O
and	O
62.0	O
mg	O
(	O
class C	B-T185
).	O
Demographic analysis	B-T062
revealed	O
an	O
inverse	B-T080
relationship	B-T080
between	O
age	B-T032
and	O
opioid use	B-T048
.	O
Similarly,	O
there	O
was	O
a	O
trend	O
toward	O
more	O
opioid consumption	B-T048
among	O
self-pay	B-T033
and	O
Medicaid	B-T064
patients	B-T101
.	O
Opioid consumption	B-T048
after	O
DRF	B-T037
-	O
ORIF	B-T061
was	O
equivalent	B-T080
for	O
general	B-T061
and	O
regional anesthesia	B-T061
.	O
A	O
significant	O
relationship	B-T080
was	O
found	O
between	O
increasing age	B-T033
and	O
decreasing	B-T033
opioid consumption	B-T048
.	O
Worsening	B-T080
fracture classification	B-T170
and	O
self-payment	B-T033
/	O
Medicaid payment	B-T064
trended	O
toward	O
increasing	B-T169
opioid consumption	B-T048
.	O
Mean	O
overall	O
opioid consumption	B-T048
(	O
morphine	B-T109
equivalence	B-T080
)	O
was	O
58.5	O
mg,	O
or	O
14.6	O
pills	B-T122
of	O
oxycodone/acetaminophen	B-T121
5/325	O
mg.	O
Surgeons	B-T097
should	O
take	O
these	O
findings	O
into	O
account	O
when	O
optimizing	B-T061
opioid	B-T109
prescribing	O
after	O
DRF	B-T037
repair	B-T061
.	O

Entrapment	B-T047
of	O
the	O
posterior femoral cutaneous nerve	B-T023
and	O
its	O
inferior cluneal branches	B-T023
:	O
anatomical basis	B-T029
of	O
surgery	B-T091
for	O
inferior cluneal neuralgia	B-T184
The	O
apparent	O
failure	O
of	O
pudendal nerve	B-T023
surgery	B-T091
in	O
some	O
patients	B-T101
has	O
led	O
us	O
to	O
suggest	O
the	O
possibility	O
of	O
entrapment	B-T047
of	O
other	O
adjacent nerve structures	B-T024
,	O
leading	O
to	O
the	O
concept	O
of	O
inferior cluneal neuralgia	B-T184
.	O
Via	O
its	O
numerous	O
collateral branches	B-T023
,	O
the	O
posterior femoral cutaneous nerve	B-T023
innervates	O
a	O
very	O
extensive	O
territory	O
including	O
the	O
posterior surface of the thigh	B-T029
,	O
the	O
infragluteal fold	B-T023
,	O
the	O
skin	B-T022
over	O
the	O
ischial tuberosity	B-T023
,	O
but	O
also	O
the	O
lateral anal region	B-T029
,	O
scrotum	B-T023
or	O
labium majus	B-T023
via	O
its	O
perineal branch	B-T023
.	O
We	O
described	O
the	O
pathophysiological	B-T169
features	B-T080
of	O
cluneal neuralgia	B-T184
,	O
the	O
surgical technique	B-T060
and	O
our	O
preliminary results	B-T078
.	O
We	O
performed	O
a	O
transmuscular approach	B-T061
leading	O
to	O
the	O
fat	B-T023
of	O
the	O
deep	O
gluteal region	B-T029
.	O
Exploration	B-T061
was	O
continued	O
cranially	O
underneath	O
the	O
piriformis	B-T023
,	O
looking	O
for	O
potential	O
entrapments	B-T047
affecting	O
the	O
posterior femoral cutaneous nerve	B-T023
and	O
the	O
sciatic nerve	B-T023
.	O
Nerve decompression	B-T061
on	O
the	O
lateral surface	B-T029
of	O
the	O
ischial tuberosity	B-T023
was	O
then	O
performed.	O
A	O
constant	O
anatomical finding	B-T029
must	O
be	O
highlighted:	O
the	O
presence	O
of	O
a	O
lateral fibrous	B-T024
expansion	B-T061
from	O
the	O
ischium	B-T023
passing	O
behind	O
the	O
nerves	B-T024
and	O
vessels	B-T023
,	O
especially	O
the	O
posterior femoral cutaneous nerve	B-T023
and	O
its	O
perineal branches	B-T023
.	O
In	O
our	O
patients	B-T101
,	O
release	O
of	O
this	O
expansion	B-T061
allowed	O
decompression	B-T061
of	O
the	O
nerve trapped	B-T047
by	O
this	O
expansion	B-T061
.	O
Cluneal neuralgia	B-T184
constitutes	O
a	O
distinct	O
entity	O
of	O
perineal pain	B-T184
,	O
which	O
must	O
be	O
identified	O
and	O
distinguished	O
from	O
pudendal neuralgia	B-T047
.	O
Surgery	B-T091
should	O
be	O
performed	O
via	O
a	O
transgluteal approach	B-T082
.	O
A	O
lateral ischial	B-T023
obstacle	O
must	O
be	O
investigated	B-T169
,	O
in	O
the	O
form	O
of	O
a	O
constant	O
fibrous	B-T024
expansion	B-T061
,	O
which,	O
like	O
a	O
retinaculum	B-T023
,	O
can	O
cause	O
nerve entrapment	B-T047
.	O

Methods	B-T170
to	O
Study	B-T062
Autophagy	B-T043
in	O
Zebrafish	B-T013
Autophagy	B-T043
(	O
cellular self-eating	B-T043
)	O
is	O
a	O
highly	O
regulated	O
degradation process	B-T044
of	O
the	O
eukaryotic cell	B-T025
during	O
which	O
parts	O
of	O
the	O
cytoplasm	B-T026
are	O
delivered	B-T169
into,	O
and	O
broken down	B-T080
within,	O
the	O
lysosomal compartment	B-T029
.	O
The	O
process	O
serves	O
as	O
a	O
main	O
route	O
for	O
the	O
elimination	B-T039
of	O
superfluous	O
and	O
damaged	O
cellular constituents	B-T026
,	O
thereby	O
mediating	O
macromolecular	B-T044
and	O
organellar turnover	B-T042
.	O
In	O
addition	O
to	O
maintaining	O
cellular homeostasis	B-T043
,	O
autophagy	B-T043
is	O
involved	O
in	O
various	O
other	O
cellular	B-T043
and	O
developmental processes	B-T040
by	O
degrading	B-T044
specific	O
regulatory proteins	B-T116
,	O
and	O
contributing	O
to	O
the	O
clearance	O
of	O
intracellular	B-T082
pathogens	B-T001
.	O
The	O
physiological roles	B-T169
and	O
pathological	B-T169
involvement	O
of	O
autophagy	B-T043
can	O
be	O
effectively	O
studied	O
in	O
divergent	O
eukaryotic	B-T204
model systems	B-T075
ranging	O
from	O
yeast	B-T004
to	O
mice	B-T015
.	O
Such	O
a	O
tractable	O
animal model	B-T008
applied	O
only	O
recently	O
for	O
autophagy	B-T043
researchis	O
the	O
zebrafish	B-T013
Danio rerio	B-T013
,	O
which	O
also	O
facilitates	O
the	O
analysis	B-T062
of	O
more	O
specific	O
biological processes	B-T038
such	O
as	O
tissue regeneration	B-T042
.	O
In	O
this	O
chapter,	O
we	O
overview	O
the	O
main	O
methods and tools	B-T169
that	O
are	O
used	O
to	O
monitor	O
autophagic structures	B-T026
and	O
to	O
assay	B-T059
autophagic responses	B-T043
in	O
this	O
vertebrate organism	B-T010
.	O
We	O
place	O
emphasis	O
on	O
genetic (functional) approaches	B-T062
applied	O
for	O
exploring	O
novel	O
cellular	B-T043
and	O
developmental roles	B-T040
of	O
the	O
autophagic process	B-T043
.	O

Healthcare	B-T058
usage	B-T169
and	O
economic impact	B-T081
of	O
non-treated	B-T033
obesity	B-T047
in	O
Italy	B-T083
:	O
findings	B-T169
from	O
a	O
retrospective	B-T080
administrative	B-T033
and	O
clinical database	B-T170
analysis	B-T062
Investigate	B-T169
the	O
prevalence	B-T081
of	O
obesity	B-T047
in	O
Italy	B-T083
and	O
examine	O
its	O
resource	B-T078
consumption	B-T033
and	O
economic impact	B-T081
on	O
the	O
Italian	B-T083
national healthcare system	B-T170
(	O
NHS	B-T170
).	O
Retrospective	B-T080
,	O
observational	B-T062
and	O
real-life study	B-T062
.	O
Data	B-T078
from	O
three	O
health units	B-T093
from	O
Northern	B-T082
(	O
Bergamo	B-T083
,	O
Lombardy	B-T083
),	O
Central	B-T082
(	O
Grosseto	B-T083
,	O
Tuscany	B-T083
)	O
and	O
Southern	B-T082
(	O
Naples	B-T083
,	O
Campania	B-T083
)	O
Italy	B-T083
.	O
All	O
patients	B-T101
aged	B-T032
≥18 years	B-T079
with	O
at	O
least	O
one	O
recorded	O
body mass index	B-T201
(	O
BMI	B-T201
)	O
measurement	B-T169
between	O
1	O
January	O
2009	O
and	O
31	O
December	O
2012	O
were	O
included.	O
Information	B-T078
retrieved	O
from	O
the	O
databases	B-T170
included	O
primary care data	B-T078
,	O
medical prescriptions	B-T170
,	O
specialist consultations	B-T058
and	O
hospital discharge records	B-T170
from	O
2009-2013.	O
Costs	B-T081
associated with	B-T080
these	O
data	B-T078
were	O
also	O
calculated	B-T052
.	O
Data	B-T078
are	O
presented	O
for	O
two	O
time periods	B-T079
(	O
1 year	B-T079
after	O
BMI	B-T201
measurement	B-T169
and	O
study	O
end).	O
Primary	B-T080
-to	O
estimate	B-T081
health resources	B-T078
consumption	B-T033
and	O
the	O
associated	O
economic impact	B-T081
on	O
the	O
Italian	B-T083
NHS	B-T170
.	O
Secondary	B-T081
-the	O
prevalence	B-T081
and	O
characteristics	B-T080
of	O
subjects	B-T098
by	O
BMI	B-T201
category	B-T170
.	O
20	O
159	O
adult	B-T100
subjects	B-T098
with	O
at	O
least	O
one	O
documented BMI	B-T033
measurement	B-T169
.	O
Subjects	B-T098
with	O
BMI	B-T201
≥30	O
kg/m(2)	O
were	O
defined	O
as	O
obese	B-T047
.	O
The	O
prevalence	B-T081
of	O
obesity	B-T047
was	O
22.2%	O
(N=4471)	O
and	O
increased	B-T081
with	O
age	B-T032
.	O
At	O
the	O
1-year	B-T079
observation	B-T062
period	B-T079
,	O
obese	B-T047
subjects	B-T098
who	O
did	O
not	O
receive	O
treatment	B-T061
for	O
their	O
obesity	B-T047
experienced	O
longer durations	B-T079
of	O
hospitalisation	B-T058
(median	O
length:	O
5 days	B-T079
vs	O
3 days	B-T079
),	O
used	O
more	O
prescription drugs	B-T121
(75.0%	O
vs	O
57.7%),	O
required	O
more	O
specialised	B-T077
outpatient	B-T101
healthcare	B-T058
(	O
mean number	B-T081
:	O
5.3	O
vs	O
4.4)	O
and	O
were	O
associated with	B-T080
greater costs	B-T081
,	O
primarily	O
owing	O
to	O
prescription drugs	B-T121
and	O
hospital admissions	B-T058
(	O
mean annual cost	B-T081
per	O
year	B-T079
per	O
patient	B-T101
:	O
€460.6	O
vs	O
€288.0	O
for	O
drug prescriptions	B-T170
,	O
€422.7	O
vs	O
€	O
279.2	O
for	O
hospitalisations	B-T058
and	O
€283.2	O
vs	O
€251.7	O
for	O
outpatient care	B-T058
),	O
compared	O
with	O
normal weight	B-T033
subjects	B-T098
.	O
Similar	O
findings	B-T169
were	O
observed	O
for	O
the	O
period	B-T079
up	O
to	O
data	B-T078
cut-off	O
(mean	O
follow-up	B-T058
of	O
2.7	O
years).	O
Untreated	B-T033
obesity	B-T047
has	O
a	O
significant	O
economic impact	B-T081
on	O
the	O
Italian	B-T083
healthcare system	B-T170
,	O
highlighting	O
the	O
need	O
to	O
raise	O
awareness	B-T041
and	O
proactively	O
treat	B-T061
obese	O
subjects	B-T098
.	O

Effects of	B-T080
heat	B-T070
treatment	B-T169
on	O
conformation	B-T082
and	O
cell growth	B-T043
activity	O
of	O
alpha- lactalbumin	B-T116
and	O
beta-lactoglobulin	B-T116
from	O
market	B-T083
milk	B-T168
Heat	B-T070
processes	B-T067
,	O
low	B-T080
temperature	B-T081
for	O
long	B-T080
time	B-T079
(	O
LTLT	B-T068
)	O
pasteurization	B-T068
and	O
ultra-heat treatment (UHT) sterilization	B-T061
,	O
are	O
essential	O
for	O
commercial	O
market	B-T083
milk	B-T168
to	O
improve	O
the	O
shelf life	B-T070
of	O
raw milk	B-T167
milk	B-T168
and	O
ensure	O
microbial	B-T001
safety	B-T068
.	O
We	O
evaluated	O
the	O
effects of	B-T080
heat	B-T070
experience	O
on	O
the	O
molecular	B-T080
properties	B-T080
of	O
α-lactalbumin	B-T116
(	O
α-LA	B-T116
)	O
and	O
β-lactoglobulin	B-T116
(	O
β-LG	B-T116
)	O
isolated	O
from	O
four	O
types	O
of	O
market	B-T083
milk	B-T168
such	O
as	O
LTLT-A	B-T068
(66°C	O
for	O
30	O
min),	O
LTLT-B	B-T068
(65°C	O
for	O
30	O
min),	O
UHT-I	B-T061
(130°C	O
for	O
2	O
s,	O
indirect	B-T080
heating	B-T070
)	O
and	O
UHT-D	B-T061
(135°C	O
for	O
2	O
s,	O
direct	B-T080
heating	B-T070
)	O
samples.	O
We	O
examined	O
molecular conformations	B-T082
using	O
circular dichroism spectrum measurement	B-T059
and	O
cell growth	B-T043
activity	O
using	O
the	O
WST-1 method	B-T062
for	O
the	O
proteins	B-T116
.	O
α-LA	B-T116
isolated	O
from	O
each	O
of	O
these	O
four	O
types	O
of	O
market	B-T083
milk	B-T168
displayed	O
no significant	B-T033
structural	B-T116
difference	B-T080
as	O
compared	O
to	O
raw milk	B-T167
α-LA	B-T116
,	O
while	O
α-LA	B-T116
of	O
UHT-I	B-T061
only	O
inhibited	B-T080
cell growth	B-T043
of	O
an	O
intestinal	B-T023
epithelial cell line	B-T025
more	O
potently	O
than	O
raw milk	B-T167
α-LA	B-T116
.	O
In	O
the	O
case	O
of	O
β-LG	B-T116
,	O
only	O
the	O
UHT-I	B-T061
sample	O
demonstrated	O
a	O
drastic	O
change	B-T169
in	O
structure	B-T116
,	O
while	O
it	O
did not exhibit	B-T033
any	O
cytotoxicity	B-T049
.	O
We	O
found	O
that	O
cell viability	B-T043
effects of	B-T080
α-LA	B-T116
and	O
β-LG	B-T116
are	O
attributable	O
to	O
the	O
type	O
of	O
UHT	B-T061
;	O
indirect	B-T080
and	O
direct	B-T080
.	O
These	O
findings	B-T033
indicate	O
that	O
the	O
effect of	B-T080
heat	B-T070
treatment	B-T169
on	O
whey proteins	B-T168
should	O
carefully	O
be	O
investigated	B-T169
further.	O

Comparison	B-T052
of	O
270	B-T200
Versus	O
320 mg I/mL of Iodixanol	B-T200
in	O
1	O
Image Assessment	B-T058
of	O
Both	O
Renal Arteries	B-T023
and	O
Veins	B-T023
With	O
Dual-Energy Spectral CT Imaging	B-T060
in	O
Late Arterial Phase	B-T079
and	O
Their	O
Influence	B-T077
on	O
Renal Function	B-T042
The	O
objective	O
of	O
this	O
study	B-T062
was	O
to	O
compare	B-T052
the	O
image quality	B-T080
of	O
renal arteries	B-T023
and	O
veins	B-T023
with	O
dual-energy spectral computed tomography (CT) imaging	B-T060
in	O
late arterial phase	B-T079
using	O
270	B-T200
and	O
320 mg I/mL of iodixanol	B-T200
and	O
their	O
influence	B-T077
on	O
renal function	B-T042
.	O
A	O
total	O
of	O
1062	O
patients	B-T101
underwent	O
renal CT angiography	B-T060
with	O
270	B-T200
or	O
320 mg I/mL of iodixanol	B-T200
with	O
dual-energy spectral CT imaging	B-T060
in	O
late arterial phase	B-T079
.	O
Image quality	B-T080
and	O
their	O
influence	B-T077
on	O
renal function	B-T042
were	O
compared	B-T052
.	O
There	O
were	O
no	O
significant	O
differences	O
of	O
CT value	B-T081
,	O
signal-to-noise ratio	B-T081
,	O
contrast-to-noise ratio	B-T081
,	O
and	O
subjective	O
score	B-T081
of	O
renal vessels	B-T023
between	O
2	O
groups	O
(all	O
P	O
>	O
0.05).	O
The	O
incidence	B-T081
of	O
contrast-induced nephropathy	B-T047
in	O
patients	B-T101
with	O
abnormal renal function	B-T046
using	O
320 mg I/mL of iodixanol	B-T200
was	O
significantly	O
higher	O
than	O
using	O
270 mg I/mL of iodixanol	B-T200
(P	O
=	O
0.043).	O
The	O
renal arteries	B-T023
and	O
veins	B-T023
can	O
be	O
fully	O
assessed	O
in	O
late arterial phase	B-T079
with	O
270 mg I/mL of iodixanol	B-T200
using	O
dual-energy spectral CT scan	B-T060
with	O
better	O
preserved	O
renal function	B-T042
.	O

Effect	O
of	O
magnesium supplementation	B-T061
on	O
depression	B-T048
status	B-T033
in	O
depressed	B-T048
patients	B-T101
with	O
magnesium deficiency	B-T047
:	O
A	O
randomized	B-T062
,	O
double-blind	B-T062
,	O
placebo-controlled trial	B-T062
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effect	B-T169
of	O
magnesium supplementation	B-T061
on	O
the	O
depression	B-T048
status	B-T033
of	O
depressed	B-T048
patients	B-T101
suffering	B-T033
from	O
magnesium deficiency	B-T047
.	O
Sixty depressed people	B-T033
suffering	B-T033
from	O
hypomagnesemia	B-T033
participated	O
in	O
this trial	B-T062
.	O
The	O
individuals	B-T098
were	O
randomly categorized	B-T062
into	O
two	O
groups	B-T078
of	O
30	O
members;	O
one	O
receiving	O
two	O
250-mg	O
tablets of magnesium oxide	B-T121
(	O
MG	B-T121
)	O
daily	O
and	O
the	O
other	O
receiving	O
placebo	B-T122
(	O
PG	B-T122
)	O
for	O
8	O
wk.	O
The	O
Beck Depression Inventory-II	B-T060
was	O
conducted	O
and	O
the	O
concentration	O
of	O
serum magnesium was measured	B-T059
.	O
At	O
the	O
end	O
of	O
intervention,	O
88.5%	O
of	O
the	O
MG	B-T121
and	O
48.1%	O
of	O
the	O
PG	B-T122
(P	O
=	O
0.002)	O
had	O
a	O
normal level of magnesium	B-T034
.	O
The	O
mean	O
changes of serum magnesium	B-T033
were	O
significantly	O
different	O
across	O
the	O
two	O
groups	B-T078
.	O
After	O
the	O
intervention,	O
the	O
mean Beck score	B-T201
significantly declined	B-T081
.	O
However,	O
in	O
the	O
MG	B-T121
,	O
this	O
reduction	O
was	O
more significant	B-T080
than	O
in	O
the	O
PG	B-T122
(P	O
=	O
0.02),	O
so	O
that	O
the	O
mean	O
changes	O
in	O
this	O
group	B-T078
experienced	O
15.65	O
±	O
8.9	O
reduction,	O
but	O
in	O
the	O
PG	B-T122
,	O
it	O
declined	O
by	O
10.40	O
±	O
7.9.	O
Daily consumption	B-UnknownType
of	O
500	O
mg	O
magnesium oxide tablets	B-T121
for	O
≥8	O
wk	O
by	O
depressed	B-T048
patients	B-T101
suffering	B-T033
from	O
magnesium deficiency	B-T047
leads	O
to	O
improvements	O
in	O
depression	B-T048
status	B-T033
and	O
magnesium levels	B-T034
.	O
Therefore,	O
assessment of the magnesium serum	B-T059
and	O
resolving	O
this	O
deficiency	B-T047
positively	O
influence	O
the	O
treatment	B-T061
of	O
depressed	B-T048
patients	B-T101
.	O

The	O
influence	B-T077
of	O
cognitive load	B-T081
on	O
metabolic	B-T040
cost	B-T081
of	O
transport	B-T078
during	O
overground walking	B-T056
in	O
healthy	B-T080
,	O
young adults	B-T100
Our	O
aim	O
was	O
to	O
examine	O
whether	O
cognitive processing	B-T041
during	O
walking	B-T056
increases	B-T169
the	O
metabolic	B-T040
cost	B-T081
of	O
transport	B-T078
in	O
healthy	B-T080
young adults	B-T100
.	O
Twenty	O
healthy	B-T080
,	O
young adults	B-T100
completed	O
five	O
conditions	B-T080
:	O
(1)	O
walking	B-T056
at	O
a	O
self	B-T078
-	O
selected	B-T052
speed	B-T081
(	O
spontaneous	B-T169
single-task	B-T052
),	O
(2)	O
seated	B-T033
resting	B-T056
(	O
baseline	B-T081
),	O
(3)	O
performing	O
cognitive	B-T041
task	B-T052
while	O
seated	B-T033
(	O
cognitive	B-T041
single-task	B-T052
),	O
(4)	O
walking	B-T056
while	O
simultaneously	B-T079
performing	B-T169
the	O
cognitive	B-T041
task	B-T052
(	O
dual-task	B-T052
),	O
and	O
(5)	O
single-task	B-T052
walking	B-T056
at	O
a	O
speed	B-T081
that	O
matched	B-T080
the	O
participant's	B-T098
dual-task	B-T052
gait speed	B-T032
(	O
matched	B-T080
single-task	B-T052
).	O
Rate of oxygen consumption	B-T081
(	O
V̇O2	B-T081
)	O
was	O
recorded	O
during	O
all	O
conditions	B-T080
.	O
Gait speed	B-T032
and	O
cost	B-T081
of	O
walking	B-T056
(	O
Cw	B-T081
;	O
oxygen consumed per distance traveled	B-T201
)	O
were	O
recorded	O
during	O
all	O
walking	B-T056
conditions	B-T080
.	O
Reaction time	B-T079
and	O
accuracy	B-T080
of	O
responses	B-T032
in	O
the	O
cognitive	B-T041
task	B-T052
were	O
recorded	O
during	O
all	O
cognitive	B-T041
task	B-T052
conditions	B-T080
.	O
Data	B-T078
from	O
the	O
fifth	O
minute	B-T079
of	O
each	O
5-	O
min	B-T079
condition	B-T080
were	O
analyzed	B-T062
.	O
There	O
was	O
no	O
difference	O
in	O
V̇O2	B-T081
between	O
the	O
dual-task	B-T052
and	O
matched	B-T080
single-task	B-T052
walking	B-T056
conditions	B-T080
.	O
V̇O2	B-T081
in	O
the	O
seated	B-T033
cognitive	B-T041
condition	B-T080
was	O
significantly	O
smaller	O
than	O
both	O
walking	B-T056
conditions	B-T080
,	O
but	O
was	O
not	O
significantly	O
different	O
than	O
zero.	O
Cw	B-T081
was	O
significantly	O
greater	O
during	O
the	O
matched	B-T080
single-task	B-T052
walking	B-T056
condition	B-T080
than	O
during	O
the	O
dual-task	B-T052
walking	B-T056
condition	B-T080
.	O
However,	O
the	O
difference	O
in	O
Cw	B-T081
was	O
so	O
small	O
that	O
it	O
is	O
unlikely	O
to	O
be	O
clinically	B-T080
significant	B-T078
(0.008	O
mLO2/kg/m,	O
95%	O
CI	O
0.002-0.014).	O
Cognitive processing	B-T041
while	O
walking	B-T056
may	O
not	O
increase	B-T169
energy	B-T081
demands	O
of	O
walking	B-T056
in	O
healthy	B-T080
young adults	B-T100
.	O
Maintaining	O
non-preferred	O
gait speed	B-T032
(	O
matched	B-T080
speed	B-T081
)	O
overground	O
continuously	O
for	O
5	O
min	B-T079
may	O
require	O
attentional	B-T041
resources	B-T078
,	O
and	O
thereby	O
increase	B-T169
metabolic	B-T040
costs	B-T081
relative	O
to	O
walking	B-T056
at	O
habitual	B-T079
speed	B-T081
.	O

Problem-based learning	B-T065
using	O
patient	B-T101
patient -simulated videos	B-T170
showing	O
daily	B-T079
life	B-T078
for	O
a	O
comprehensive	B-T080
clinical	B-T080
approach	B-T169
We	O
examined	O
whether	O
problem-based learning	B-T065
tutorials	B-T170
using	O
patient	B-T101
patient -simulated videos	B-T170
showing	O
daily	B-T079
life	B-T078
are	O
more	O
practical	O
for	O
clinical	B-T080
learning	B-T041
,	O
compared	O
with	O
traditional	O
paper-based problem-based learning	B-T065
,	O
for	O
the	O
consideration	O
rate of psychosocial issues	B-T033
and	O
the	O
recall rate	B-T033
for	O
experienced learning	B-T041
.	O
Twenty-two	O
groups	B-T078
with	O
120	O
fifth-	O
year	B-T079
students	B-T098
were	O
each	O
assigned	O
paper-based problem-based learning	B-T065
and	O
video	B-T170
video -based problem-based learning	B-T065
using	O
patient	B-T101
patient -simulated videos	B-T170
.	O
We	O
compared	O
target	B-T169
achievement rates	B-T033
in	O
questionnaires	B-T170
using	O
the	O
Wilcoxon signed-rank test	B-T170
and	O
discussion	B-T054
contents	B-T077
diversity	B-T080
using	O
the	O
Mann-Whitney U test	B-T081
.	O
A	O
follow-up	B-T062
survey	B-T170
used	O
a	O
chi-square test	B-T170
to	O
measure	O
students	B-T098
'	O
recall	O
of	O
cases	O
in	O
three	O
categories	B-T170
:	O
video	B-T170
,	O
paper	B-T073
,	O
and	O
non-experienced	B-T078
.	O
Video	B-T170
Video -based problem-based learning	B-T065
displayed	O
significantly	O
higher	O
achievement rates	B-T033
for	O
imagining	O
authentic patients	B-T101
(p=0.001),	O
incorporating	O
a	O
comprehensive	B-T080
approach	B-T169
including	O
psychosocial aspects	B-T078
(p<0.001),	O
and	O
satisfaction	O
with	O
sessions	B-T077
(p=0.001).	O
No significant differences	B-T033
existed	O
in	O
the	O
discussion	B-T054
contents	B-T077
diversity	B-T080
regarding	O
the	O
International Classification of Primary Care Second Edition codes and chapter types	B-T170
or	O
in	O
the	O
rate of psychological codes	B-T033
.	O
In	O
a	O
follow-up	B-T062
survey	B-T170
comparing	O
video	B-T170
and	O
paper	B-T073
groups	B-T078
to	O
non-experienced groups	B-T078
,	O
the	O
rates	B-T081
were	O
higher	O
for	O
video	B-T170
(χ(2)=24.319,	O
p<0.001)	O
and	O
paper	B-T073
(χ(2)=11.134,	O
p=0.001).	O
Although	O
the	O
video	B-T170
rate	B-T081
tended	O
to	O
be	O
higher	O
than	O
the	O
paper	B-T073
rate	B-T081
,	O
no significant difference	B-T033
was	O
found	O
between	O
the	O
two.	O
Patient	B-T101
Patient -simulated videos	B-T170
showing	O
daily	B-T079
life	B-T078
facilitate	O
imagining	O
true	O
patients	B-T101
and	O
support	O
a	O
comprehensive	B-T080
approach	B-T169
that	O
fosters	B-T056
better	O
memory	B-T041
.	O
The	O
clinical	B-T080
patient	B-T101
patient -simulated video	B-T170
method	B-T169
is	O
more	O
practical	O
and	O
clinical	B-T080
problem-based tutorials	B-T170
can	O
be	O
implemented	O
if	O
we	O
create	O
patient	B-T101
patient -simulated videos	B-T170
for	O
each	O
symptom	B-T184
as	O
teaching materials	B-T073
.	O

Forensic characteristics	B-UnknownType
and	O
phylogenetic analyses	B-T062
of	O
the	O
Chinese	B-T098
Yi population	B-T098
via	O
19	O
X-chromosomal	B-T026
STR	B-T086
loci	B-T028
The	O
demographic characteristics	B-T102
and	O
genetic polymorphism	B-T045
data	B-T078
of	O
56	O
Chinese	B-T098
nationalities	B-T102
or	O
31	O
administrative divisions	B-T092
in	O
Chinese mainland	B-T083
have	O
repeatedly	O
been	O
the	O
genetic research	B-T062
hotspots	B-T082
.	O
While	O
most	O
genetic studies	B-T062
focused	O
on	O
some	O
particular	O
Chinese	B-T098
populations	B-T098
based	O
on	O
autosomal	B-T026
or	O
Y-chromosomal	B-T026
genetic markers	B-T045
,	O
the	O
forensic characteristics	B-UnknownType
and	O
phylogenetic analyses	B-T062
of	O
the	O
seventh	O
largest	O
Chinese	B-T098
population	B-T098
(	O
Yi ethnicity	B-T098
)	O
on	O
the	O
X-chromosomal	B-T026
genetic markers	B-T045
are	O
scarce.	O
Here,	O
allele frequencies	B-T081
and	O
forensic statistical parameters	B-T033
for	O
19	O
X-chromosomal	B-T026
short tandem repeat	B-T086
loci	B-T028
(	O
DXS7424-DXS101	B-T028
,	O
DXS6789-DXS6809	B-T028
,	O
DXS7423-DXS10134	B-T028
,	O
DXS10103-HPRTB-DXS10101	B-T028
,	O
DXS10159-DXS10162-DXS10164	B-T028
,	O
DXS10148-DXS10135-DXS8378	B-T028
,	O
and	O
DXS7132-DXS10079-DXS10074-DXS10075	B-T028
)	O
of	O
331	O
Chinese	B-T098
Yi individuals	B-T098
were	O
obtained.	O
All	O
19	O
X-chromosomal	B-T026
short tandem repeat	B-T086
(	O
STR	B-T086
)	O
loci	B-T028
in	O
females	B-T098
were	O
consistent	O
with	O
the	O
Hardy-Weinberg	O
equilibrium	O
test.	O
A	O
total	O
of	O
214	O
alleles	B-T028
were	O
identified	B-T080
with	O
the	O
corresponding	O
allele frequencies	B-T081
spanned	O
from	O
0.0019	O
to	O
0.6106.	O
The	O
combined	O
PE	B-T081
,	O
PDF	B-T081
,	O
and	O
PDM	B-T081
were	O
0.9999999214,	O
0.9999999999999999999993,	O
and	O
0.9999999999998,	O
respectively.	O
The	O
high	O
combined	O
MECKrüger	B-T081
,	O
MECKishida	B-T081
,	O
MECDesmarais	B-T081
,	O
and	O
MECDesmarais Duo	B-T081
were	O
achieved	O
as	O
0.9999999617638,	O
0.9999999999971,	O
0.9999999999971,	O
and	O
0.9999999931538,	O
respectively.	O
The	O
findings	B-T033
suggested	O
that	O
the	O
panel	B-T078
of	O
19	O
X-STR	B-T086
loci	B-T028
is	O
highly	O
polymorphic	B-T080
and	O
informative	B-T080
in	O
the	O
Yi ethnic population	B-T098
and	O
can	O
be	O
considered	O
to	O
be	O
a	O
powerful	O
tool	B-T073
in	O
forensic complex kinship identification	B-T078
.	O
Population differentiation analyses	B-T062
among	O
12	O
populations	B-T098
indicated	O
that	O
significant	O
differences	B-T080
in	O
genetic structure	B-T028
were	O
observed	O
in	O
between	O
the	O
Yi ethnicity	B-T098
and	O
the	O
Chinese	B-T098
Uyghur	B-T098
as	O
well	O
as	O
Kazakh	B-T098
,	O
and	O
genetic homogeneity	B-T080
existed	O
in	O
similar	O
ethno-origin	B-T098
or	O
geographic origin populations	B-T081
.	O

Loss	B-T081
of	O
Snf5	B-T028
Induces	B-T169
Formation	B-T169
of	O
an	O
Aberrant	B-T080
SWI/SNF Complex	B-T026
The	O
SWI/SNF	B-T026
chromatin remodeling complex	B-T026
is	O
highly	O
conserved	O
from	O
yeast	B-T004
to	O
human	B-T016
,	O
and	O
aberrant	B-T080
SWI/SNF complexes	B-T026
contribute	O
to	O
human	B-T016
disease	B-T047
.	O
The	O
Snf5/SMARCB1/INI1	B-T028
subunit	B-T081
of	O
SWI/SNF	B-T026
is	O
a	O
tumor suppressor	B-T028
frequently	O
lost	B-T169
in	O
pediatric	B-T080
rhabdoid cancers	B-T191
.	O
We	O
examined	O
the	O
effects of	B-T080
Snf5	B-T028
loss	B-T081
on	O
the	O
composition	B-T033
,	O
nucleosome binding	B-T045
,	O
recruitment,	O
and	O
remodeling	O
activities	O
of	O
yeast	B-T004
SWI/SNF	B-T026
.	O
The	O
Snf5	B-T028
subunit	B-T081
is	O
shown	O
by	O
crosslinking-mass spectrometry	B-T059
(	O
CX-MS	B-T059
)	O
and	O
subunit	B-T081
deletion analysis	B-T059
to	O
interact	O
with	O
the	O
ATPase domain	B-T087
of	O
Snf2	B-T116
and	O
to	O
form	O
a	O
submodule	B-T044
consisting	O
of	O
Snf5	B-T028
,	O
Swp82	B-T028
,	O
and	O
Taf14	B-T028
.	O
Snf5	B-T028
promotes	O
binding	B-T045
of	O
the	O
Snf2	B-T116
ATPase domain	B-T087
to	O
nucleosomal DNA	B-T045
and	O
enhances	O
the	O
catalytic	O
and	O
nucleosome	O
remodeling	O
activities	O
of	O
SWI/SNF	B-T026
.	O
Snf5	B-T028
is	O
also	O
required	O
for	O
SWI/SNF	B-T026
recruitment	O
by	O
acidic transcription factors	B-T116
.	O
RNA-seq analysis	B-T059
suggests	O
that	O
both	O
the	O
recruitment	O
and	O
remodeling	O
functions	O
of	O
Snf5	B-T028
are	O
required	O
in vivo	B-T082
for	O
SWI/SNF	B-T026
regulation of gene expression	B-T045
.	O
Thus,	O
loss	B-T081
of	O
SNF5	B-T028
alters	O
the	O
structure	B-T082
and	O
function	B-T169
of	O
SWI/SNF	B-T026
.	O

Identifying	O
the	O
presence	B-T033
of	O
Parkinson's disease	B-T047
using	O
low-frequency	B-T079
fluctuations	B-T184
in	O
BOLD signals	B-T060
Parkinson's disease	B-T047
(	O
PD	B-T047
)	O
is	O
a	O
chronic	B-T079
,	O
progressive	B-T169
,	O
and	O
degenerative	B-T169
neurological disorder	B-T047
that	O
is	O
characterized	B-T052
by	O
the	O
degeneration	B-T169
of	O
dopamine neurons	B-T025
in	O
the	O
substantia nigra	B-T023
and	O
the	O
formation	B-T169
of	O
intracellular	B-T082
Lewy inclusion bodies	B-T026
.	O
Resting-state functional magnetic resonance imaging	B-T060
(	O
RS-fMRI	B-T060
)	O
has	O
demonstrated	O
evidence	B-T078
of	O
changes	O
in	O
metabolic	B-T169
patterns	B-T082
in	O
individuals	B-T098
with	O
PD	B-T047
.	O
The	O
purpose	B-T169
of	O
this	O
study	B-T062
was	O
to	O
determine	O
whether	O
the	O
presence	B-T033
of	O
PD	B-T047
could	O
be	O
"	O
predicted	B-T078
"	O
based	O
on	O
resting	O
fluctuations	B-T184
in	O
the	O
blood oxygenation level dependent signal	B-T042
.	O
We	O
utilized	O
RS-fMRI	B-T060
to	O
measure	O
the	O
amplitude	B-T082
of	O
low-frequency	B-T079
fluctuation	B-T184
(	O
ALFF	B-T184
)	O
and	O
the	O
fractional	O
ALFF	B-T184
(	O
fALFF	B-T184
)	O
in	O
51	O
patients	B-T101
with	O
PD	B-T047
and	O
50	O
age	B-T032
-	O
and	O
sex	B-T032
-matched	O
healthy controls	B-T080
.	O
Compared	O
with	O
the	O
healthy controls	B-T080
,	O
the	O
individuals	B-T098
with	O
PD	B-T047
exhibited	O
altered	O
ALFFs	B-T184
in	O
the	O
bilateral	B-T082
lingual gyrus	B-T023
and	O
left putamen	B-T023
and	O
an	O
altered	O
fALFF	B-T184
in	O
the	O
right cerebellum posterior lobe	B-T029
.	O
Support vector machines	B-T081
(	O
SVMs	B-T081
),	O
which	O
comprise	O
a	O
supervised	O
pattern recognition	B-T041
method	B-T170
that	O
enables	O
predictions	B-T078
at	O
the	O
individual	B-T098
level	B-T080
,	O
were	O
trained	O
to	O
separate	O
individuals	B-T098
with	O
PD	B-T047
from	O
healthy controls	B-T080
based	O
on	O
the	O
ALFF	B-T184
and	O
fALFF	B-T184
.	O
Using	O
the	O
leave-one-out	O
cross-validation method	B-T062
to	O
analyze	B-T062
our	O
sample	B-T167
,	O
we	O
reliably	O
distinguished	O
the	O
participants	B-T098
with	O
PD	B-T047
from	O
the	O
controls	B-T096
with	O
92%	O
sensitivity	B-T080
and	O
87%	O
specificity	B-T081
.	O
Overall,	O
these	O
findings	B-T169
suggest	O
that	O
the	O
SVM	B-T081
-	O
neuroimaging	B-T060
approach	O
may	O
be	O
of	O
particular	O
clinical	B-T080
value	O
because	O
it	O
enables	O
the	O
accurate	O
identification	O
of	O
PD	B-T047
at	O
the	O
individual	B-T098
level	B-T080
.	O
RS-fMRI	B-T060
should	O
be	O
considered	O
for	O
development	B-T169
as	O
a	O
biomarker	B-T201
and	O
an	O
analytical	O
tool	O
for	O
the	O
evaluation	B-T058
of	O
PD	B-T047
.	O

Methylation	B-T044
dynamics	B-T070
during	O
folliculogenesis	B-T042
and	O
early	B-T079
embryo development	B-T042
in	O
sheep	B-T015
Genome	B-T028
-wide	O
DNA methylation	B-T044
reprogramming	O
occurs	O
during	O
mammalian	B-T015
gametogenesis	B-T042
and	O
early	B-T079
embryogenesis	B-T042
.	O
Post	B-T079
-	O
fertilization	B-T040
demethylation	B-T045
of	O
paternal	B-T080
and	O
maternal	B-T033
genomes	B-T028
is	O
considered	O
to	O
occur	O
by	O
an	O
active	O
and	O
passive	O
mechanism	O
respectively,	O
in	O
most	O
mammals	B-T015
but	O
sheep	B-T015
;	O
in	O
this	O
species	O
no	O
loss	O
of	O
methylation	B-T044
was	O
observed	O
in	O
either	O
pronucleus	B-T026
.	O
Post	B-T079
-	O
fertilization	B-T040
reprogramming	O
relies	O
on	O
methylating	B-T116
and	O
demethylating enzymes	B-T116
and	O
co-factors	O
that	O
are	O
stored	O
during	O
oocyte growth	B-T043
,	O
concurrently	O
with	O
the	O
re-methylation	B-T044
of	O
the	O
oocyte	B-T025
itself.	O
The	O
crucial	O
remodelling	O
of	O
the	O
oocyte	B-T025
epigenetic	O
baggage	O
often	O
overlaps	O
with	O
potential	O
interfering	O
events	O
such	O
as	O
exposure	O
to	O
assisted	O
reproduction technologies	B-T061
or	O
environmental changes	B-T033
.	O
Here,	O
we	O
report	O
a	O
temporal	O
analysis	O
of	O
methylation	B-T044
dynamics	B-T070
during	O
folliculogenesis	B-T042
and	O
early	B-T079
embryo development	B-T042
in	O
sheep	B-T015
.	O
We	O
characterized	O
global	O
DNA methylation	B-T044
and	O
hydroxymethylation	B-T045
by	O
immunofluorescence	B-T059
and	O
relatively	O
quantified	O
the	O
expression	B-T045
of	O
the	O
enzymes	B-T116
and	O
co-factors	O
mainly	O
responsible	O
for	O
their	O
remodelling	O
(	O
DNA methyltransferases	B-T116
(	O
DNMTs	B-T116
),	O
ten-eleven translocation (TET) proteins	B-T116
and	O
methyl-CpG-binding domain	B-T087
(	O
MBD	B-T087
)	O
proteins	B-T116
).	O
Our	O
results	O
illustrate	O
for	O
the	O
first	O
time	O
the	O
patterns	O
of	O
hydroxymethylation	B-T045
during	O
oocyte growth	B-T043
.	O
We	O
observed	O
different	O
patterns	O
of	O
methylation	B-T044
and	O
hydroxymethylation	B-T045
between	O
the	O
two	O
parental pronuclei	B-T026
,	O
suggesting	O
that	O
male pronucleus	B-T026
undergoes	O
active	O
demethylation	B-T045
also	O
in	O
sheep	B-T015
.	O
Finally,	O
we	O
describe	O
gene	B-T028
-specific	O
accumulation	O
dynamics	B-T070
for	O
methylating	B-T116
and	O
demethylating enzymes	B-T116
during	O
oocyte growth	B-T043
and	O
observe	O
patterns	O
of	O
expression	B-T045
associated	O
with	O
developmental	B-T080
competence	B-T080
in	O
a	O
differential	O
model	O
of	O
oocyte	B-T025
potential.	O
Our	O
work	O
contributes	O
to	O
the	O
understanding	O
of	O
the	O
methylation	B-T044
dynamics	B-T070
during	O
folliculogenesis	B-T042
and	O
early	B-T079
embryo development	B-T042
and	O
improves	O
the	O
overall	O
picture	O
of	O
early	B-T079
rearrangements	O
that	O
will	O
originate	O
the	O
embryo	B-T018
epigenome	B-T028
.	O

Network	B-T169
analysis	B-T062
reveals	B-T080
why	O
Xylella fastidiosa	B-T007
will	O
persist	O
in	O
Europe	B-T083
The	O
insect vector	B-T204
borne	O
bacterium	B-T007
Xylella fastidiosa	B-T007
was	O
first	O
detected	O
in	O
olive trees	B-T002
in	O
Southern Italy	B-T083
in	O
2013,	O
and	O
identified	O
as	O
the	O
main	O
culprit	O
behind	O
the	O
'	O
olive quick decline syndrome	B-T047
'.	O
Since	O
then,	O
the	O
disease	B-T047
has	O
spread	O
rapidly	O
through	O
Italy's	B-T083
main	O
olive oil	B-T109
producing	O
region	B-T083
.	O
The	O
epidemiology	B-T062
of	O
the	O
outbreak	B-T067
is	O
largely	O
unstudied,	O
with	O
the	O
list	O
of	O
X. fastidiosa	B-T007
hosts	B-T001
and	O
vectors	B-T204
in	O
Europe	B-T083
likely	O
incomplete,	O
and	O
the	O
role	O
humans	B-T016
play	O
in	O
dispersal	B-T080
unknown	B-T080
.	O
These	O
knowledge	B-T170
gaps	B-T082
have	O
led	O
to	O
management strategies	B-T057
based	O
on	O
general	O
assumptions	O
that	O
require,	O
among	O
others,	O
local	O
vector control	B-T057
and,	O
in	O
certain	O
areas	B-UnknownType
,	O
the	O
destruction	B-T052
of	O
infected plants	B-T002
and	O
healthy	B-T080
ones	O
around	O
them	O
in	O
an	O
attempt	O
to	O
eradicate	B-T052
or	O
halt	B-T079
the	O
spreading	B-T080
pest	B-T047
.	O
Here	O
we	O
show	O
that,	O
regardless	O
of	O
epidemiological	B-T169
uncertainties	B-T033
,	O
the	O
mere	O
distribution	O
of	O
olive	B-T002
olive orchards	B-UnknownType
in	O
Southern Italy	B-T083
makes	O
the	O
chances	O
of	O
eradicating	B-T052
X. fastidiosa	B-T007
from	O
the	O
region	B-T083
extremely	O
slim.	O
Our	O
results	B-T169
imply	O
that	O
Southern Italy	B-T083
is	O
becoming	O
a	O
reservoir	B-T083
for	O
X. fastidiosa	B-T007
.	O
As	O
a	O
consequence,	O
management strategies	B-T057
should	O
keep	O
the	O
prevalence	B-T081
of	O
X. fastidiosa	B-T007
in	O
the	O
region	B-T083
as	O
low	O
as	O
possible,	O
primarily	O
through	O
vector control	B-T057
,	O
lest	B-T169
the	O
pathogen	B-T001
,	O
that	O
has	O
also	O
been	O
detected	O
in	O
southern France	B-T083
and	O
the	O
island of Mallorca	B-T083
(	O
Spain	B-T083
),	O
continues	O
spreading	B-T080
through	O
Italy	B-T083
and	O
Europe	B-T083
.	O

Novel	O
biomarkers	B-T201
for	O
patients	B-T101
with	O
idiopathic	B-T169
acute anterior uveitis	B-T047
:	O
neutrophil	B-T025
to	O
lymphocyte	B-T025
ratio	B-T081
and	O
platelet	B-T025
to	O
lymphocyte	B-T025
ratio	B-T081
To	O
assess	B-T052
the	O
levels	B-T080
of	O
the	O
neutrophil	B-T025
to	O
lymphocyte	B-T025
ratio	B-T081
(	O
N	B-T025
/	O
L	B-T025
)	O
and	O
the	O
platelet	B-T025
to	O
lymphocyte	B-T025
ratio	B-T081
(	O
P	B-T025
/	O
L	B-T025
)	O
in	O
patients	B-T101
with	O
idiopathic	B-T169
acute anterior uveitis	B-T047
(	O
AAU	B-T047
)	O
and	O
to	O
compare	B-T052
with	O
healthy controls	B-T080
.	O
Thirty-six	O
male	B-T098
patients	B-T101
with	O
idiopathic	B-T169
AAU	B-T047
and	O
36	O
male	B-T098
healthy	B-T080
subjects	B-T098
were	O
enrolled	O
in	O
this	O
retrospective study	B-T062
.	O
Complete	B-T080
ophthalmological examination	B-T061
and	O
complete	O
blood count measurements	B-T059
results	B-T033
of	O
all	O
subjects	B-T098
were	O
evaluated	B-T058
.	O
There	O
was	O
a	O
significant	B-T078
difference	O
in	O
N	B-T025
/	O
L	B-T025
and	O
P	B-T025
/	O
L	B-T025
between	O
idiopathic	B-T169
AAU	B-T047
and	O
control groups	B-T096
(P=0.006,	O
P=0.022).	O
Also,	O
correlation analysis	B-T062
revealed	O
a	O
significant	B-T078
correlation	B-T080
between	O
C-reactive protein	B-T116
(	O
CRP	B-T116
)	O
and	O
N	B-T025
/	O
L	B-T025
(P=0.002;	O
r=0.461).	O
Our	O
study	B-T062
for	O
the	O
first	O
time	O
provides	O
evidence of	B-T169
N	B-T025
/	O
L	B-T025
and	O
P	B-T025
/	O
L	B-T025
may	O
be	O
useful	B-T080
biomarkers	B-T201
in	O
patients	B-T101
with	O
idiopathic	B-T169
AAU	B-T047
.	O
N	B-T025
/	O
L	B-T025
is	O
correlated	B-T080
with	O
CRP	B-T116
,	O
so	O
it	O
can	O
be	O
a	O
useful	B-T080
biomarker	B-T201
to	O
predict	O
the	O
prognosis	B-T058
in	O
idiopathic	B-T169
AAU	B-T047
.	O

Comparison	B-T052
between	O
magnetic resonance imaging	B-T060
and	O
B-mode ultrasound	B-T060
in	O
detecting	B-T033
and	O
estimating	B-T081
the	O
extent	B-T082
of	O
human	B-T016
carotid atherosclerosis	B-T047
In	O
MRI studies	B-T060
of	O
carotid plaques	B-T020
,	O
ultrasound	B-T060
is	O
used	O
to	O
find	B-T033
plaques	B-T033
,	O
which	O
are	O
later	O
imaged	B-T170
using	O
MRI	B-T060
.	O
The	O
performance	B-T052
in	O
plaque	B-T033
detection	B-T033
has	O
not	O
been	O
compared	B-T052
between	O
the	O
modalities	B-T169
.	O
The	O
aim	O
of	O
the	O
current	O
study	B-T062
was	O
to	O
compare	B-T052
the	O
performance	B-T052
of	O
MRI	B-T060
and	O
ultrasound	B-T060
in	O
detecting	B-T033
carotid artery plaques	B-T020
and	O
measuring	B-T080
extent	B-T082
of	O
atherosclerosis	B-T047
.	O
Subjects	B-T096
with	O
at	O
least	O
one	O
plaque	B-T033
(	O
height	B-T081
≥2·5	O
mm)	O
on	O
ultrasound	B-T060
were	O
imaged	B-T170
using	O
MRI	B-T060
.	O
The	O
number	B-T081
of	O
plaques	B-T033
and	O
their	O
height	B-T081
was	O
measured	B-T080
in	O
both	O
modalities	B-T169
;	O
plaque	B-T033
area	B-T082
and	O
volume	B-T081
were	O
analysed	B-T062
on	O
ultrasound	B-T060
and	O
MRI	B-T060
,	O
respectively.	O
Thirty-eight	B-T081
subjects	B-T096
were	O
included	B-T169
.	O
MRI	B-T060
detected	B-T033
plaques	B-T033
in	O
95%	O
of	O
carotid arteries	B-T023
with	O
a	O
plaque	B-T033
height	B-T081
of	O
≥2·5	O
mm	O
on	O
ultrasound	B-T060
and	O
in	O
all	O
carotid arteries	B-T023
with	O
a	O
plaque	B-T033
exceeding	O
2·5	O
mm.	O
MRI	B-T060
detected	B-T033
53%	O
of	O
the	O
plaques	B-T033
with	O
a	O
height	B-T081
below	O
2·5	O
mm.	O
The	O
plaque	B-T033
height	B-T081
measured	B-T080
with	O
both	O
techniques	B-T169
correlated	B-T080
significantly,	O
0·59,	O
P<0·0001.	O
Ultrasound	B-T060
-derived	O
plaque	B-T033
height	B-T081
and	O
plaque	B-T033
area	B-T082
correlated	B-T080
similarly	B-T080
to	O
MRI	B-T060
-derived	O
plaque	B-T033
volume	B-T081
,	O
r	O
=	O
0·52;	O
P<0·0001	O
and	O
r	O
=	O
0·47;	O
P	O
=	O
0·001,	O
respectively.	O
We	O
conclude	O
that	O
MRI	B-T060
has	O
a	O
similar	B-T080
sensitivity	B-T081
to	O
ultrasound	B-T060
in	O
finding	B-T033
carotid artery plaques	B-T020
that	O
are	O
2·5	O
mm	O
or	O
higher	B-T080
.	O
In	O
smaller	B-T080
plaques	B-T033
,	O
MRI	B-T060
detects	B-T033
fewer	B-T081
plaques	B-T033
.	O
Multiple carotid plaques	B-T020
seen	O
on	O
ultrasound	B-T060
most	O
often	O
are	O
a	O
misinterpretation	O
of	O
the	O
anatomy	B-T080
and	O
correspond	O
to	O
a	O
single plaque	B-T033
.	O
Plaque	B-T033
height	B-T081
on	O
ultrasound	B-T060
is	O
comparable	O
to	O
plaque	B-T033
height	B-T081
on	O
MRI	B-T060
and	O
correlates	B-T080
fairly	O
well	O
with	O
plaque	B-T033
volume	B-T081
on	O
MRI	B-T060
making	O
it	O
an	O
interesting	O
proxy	O
for	O
plaque	B-T033
burden	B-T078
.	O

Lightweight	O
Open-Cell Scaffolds	B-T026
from	O
Sea Urchin	B-T204
Spines	B-T122
with	O
Superior	O
Material	B-T167
Properties	B-T080
for	O
Bone Defect Repair	B-T061
Sea urchin	B-T204
spines	B-T122
(	O
Heterocentrotus mammillatus	B-T204
),	O
with	O
a	O
hierarchical	O
open-cell structure	B-T026
similar	O
to	O
that	O
of	O
human	B-T016
trabecular bone	B-T024
and	O
superior	O
mechanical property	B-T080
(	O
compressive strength	B-T081
∼43.4	O
MPa)	O
suitable	B-T080
for	O
machining	B-T052
to	O
shape	B-T080
,	O
were	O
explored	O
for	O
potential	B-T080
applications	B-T169
of	O
bone defect repair	B-T061
.	O
Finite element analyses	B-T170
reveal	O
that	O
the	O
compressive	O
stress	B-T033
concentrates	B-T052
along	O
the	O
dense	B-T080
growth rings	B-T042
and	O
dissipates	B-T082
through	O
strut	O
structures of the stereoms	B-T017
,	O
indicating	O
that	O
the	O
exquisite	O
mesostructures	B-T082
play	O
an	O
important	B-T080
role	O
in	O
high	O
strength	B-T080
-to-	O
weight	B-T081
ratios	B-T081
.	O
The	O
fracture	B-T037
strength	B-T080
of	O
magnesium	B-T123
-	O
substituted tricalcium phosphate	B-T122
(β-TCMP) scaffolds	B-T122
produced	O
by	O
hydrothermal	B-T067
conversion	B-T169
of	O
urchin	B-T204
spines	B-T122
is	O
about	O
9.3	O
MPa,	O
comparable	B-T052
to	O
that	O
of	O
human	B-T016
trabecular bone	B-T024
.	O
New	O
bone	B-T023
forms	B-T169
along	O
outer	O
surfaces	B-T082
of	O
β-TCMP scaffolds	B-T122
after	O
implantation	B-T061
in	O
rabbit	B-T015
femoral defects	B-T037
for	O
one	O
month	B-T079
and	O
grows	B-T042
into	O
the	O
majority	O
of	O
the	O
inner	O
open-cell spaces	B-T030
postoperation	B-T079
in	O
three	O
month	B-T079
s,	O
showing	O
tight interface	B-T044
between	O
the	O
scaffold	B-T122
and	O
regenerative bone tissue	B-T042
.	O
Fusion	B-T061
of	O
beagle	B-T015
lumbar facet joints	B-T030
using	O
a	O
Ti-6Al-4V cage	B-T197
and	O
β-TCMP scaffold	B-T122
can	O
be	O
completed	B-T080
within	O
seven	O
months	B-T079
with	O
obvious	O
biodegradation	B-T070
of	O
the	O
β-TCMP scaffold	B-T122
,	O
which	O
is	O
nearly	O
completely	B-T080
degraded	B-T070
and	O
replaced by	B-T169
newly	O
formed	B-T169
bone	B-T023
ten	O
months	B-T079
after	O
implantation	B-T061
.	O
Thus,	O
sea urchin	B-T204
spines	B-T122
suitable	O
for	O
machining	B-T052
to	O
shape	B-T080
have	O
advantages	O
for	O
production	O
of	O
biodegradable	B-T070
artificial grafts	B-T122
for	O
bone defect repair	B-T061
.	O

Melatonin	B-T109
and	O
nitric oxide	B-T121
regulate	B-T040
sunflower	B-T002
seedling growth	B-T040
under	O
salt stress	B-T043
accompanying	O
differential	O
expression	B-T045
of	O
Cu/Zn SOD	B-T116
and	O
Mn SOD	B-T116
Salinity results	B-T043
in	O
significant reduction	B-T080
in	O
sunflower	B-T002
(	O
Helianthus annuus L.	B-T002
)	O
seedling growth	B-T040
and	O
excessive	O
generation	O
of	O
reactive oxygen species	B-T123
(	O
ROS	B-T123
).	O
Present	O
work	O
highlights	O
the	O
possible	O
role	O
of	O
melatonin	B-T109
as	O
an	O
antioxidant	B-T121
through	O
its	O
interaction	O
with	O
nitric oxide	B-T121
(	O
NO	B-T121
),	O
and	O
as	O
an	O
early	O
and	O
long	O
distance	O
NaCl-stress	B-T043
sensing	O
signaling molecule	B-T123
in	O
seedling	B-T002
cotyledons	B-T002
.	O
Exogenous	B-T169
melatonin	B-T109
(15µM)±	O
NaCl	B-T121
(120mM)	O
inhibit	B-T052
seedling growth	B-T040
,	O
which	O
is	O
also	O
correlated	O
with	O
NO	B-T121
availability,	O
accumulation	O
of	O
potential superoxide anion	B-T196
(	O
O2(•-)	B-T196
)	O
and	O
peroxynitrite anion	B-T123
(	O
ONOO(-)	B-T123
),	O
extent	O
of	O
tyrosine-nitration	B-T044
of	O
proteins	B-T116
,	O
spatial localization	B-T169
and	O
activity of superoxide dismutase	B-T044
(	O
SOD	B-T116
)	O
isoforms	B-T116
.	O
NO	B-T121
acts	O
as	O
a	O
positive	O
modulator	O
of	O
melatonin	B-T109
accumulation	O
in	O
seedling	B-T002
cotyledons	B-T002
as	O
a	O
long-distance signaling response	B-T044
.	O
Modulation of superoxide anion	B-T040
and	O
peroxynitrite anion	B-T123
content	O
by	O
melatonin	B-T109
highlights	O
its	O
crucial	O
role	O
in	O
combating	O
deleterious	O
effects	O
of	O
ROS	B-T123
and	O
reactive nitrogen species	B-T104
(RNS).	O
Present	O
findings	O
provide	O
evidence	O
for	O
an	O
interaction	O
between	O
melatonin	B-T109
and	O
NO	B-T121
in	O
their	O
effect	O
on	O
seedling growth	B-T040
under	O
salt stress accompanying	B-T043
differential	O
modulation	O
of	O
two	O
SOD	B-T116
isoforms	B-T116
,	O
i.e.	O
Cu/Zn SOD	B-T116
and	O
Mn SOD	B-T116
.	O

The	O
Physiological	B-T169
Role	O
and	O
Regulation	B-T038
of	O
Aquaporins	B-T116
in	O
Teleost	B-T013
Germ Cells	B-T025
The	O
unicellular	O
germ cells	B-T025
and	O
gametes	B-T025
of	O
oviparous	B-T042
teleosts	B-T013
lack	O
the	O
osmoregulatory	B-T043
organs	B-T023
present	O
in	O
juveniles	B-T100
and	O
adults	B-T100
,	O
yet	O
during	O
development	B-T039
and	O
particularly	O
at	O
spawning	B-T032
,	O
they	O
face	O
tremendous	O
osmotic	B-T169
challenges	B-T033
when	O
released	O
into	O
the	O
external	B-T082
aquatic environment	B-T067
.	O
Increasing	O
evidence	O
suggests	O
that	O
transmembrane water channels	B-T116
(	O
aquaporins	B-T116
)	O
evolved	O
to	O
play	O
vital	O
adaptive	O
roles	O
that	O
mitigate	B-T067
the	O
osmotic	B-T070
and	O
oxidative stress	B-T049
problems	B-T033
of	O
the	O
developing	B-T039
oocytes	B-T025
,	O
embryos	B-T018
and	O
spermatozoa	B-T025
.	O
In	O
this	O
chapter,	O
we	O
provide	O
a	O
short	O
overview	O
of	O
the	O
diversity	B-T080
of	O
the	O
aquaporin	B-T116
superfamily	O
in	O
teleosts	B-T013
,	O
and	O
summarize	O
the	O
findings	O
that	O
uncovered	O
a	O
highly	O
specific	O
molecular regulation	B-T044
of	O
aquaporins	B-T116
during	O
oogenesis	B-T042
and	O
spermatogenesis	B-T043
.	O
We	O
further	O
review	O
the	O
multiple	O
functions	O
that	O
these	O
channels	B-T116
play	O
during	O
the	O
establishment	O
of	O
egg	B-T025
buoyancy	B-T039
and	O
the	O
activation	B-T052
and	O
detoxification	B-T061
of	O
spermatozoa	B-T025
in	O
the	O
marine	B-T083
environment	B-T082
.	O

Caribbean	B-T083
massive corals	B-T204
not recovering from	B-T080
repeated	O
thermal stress	B-T067
events	B-T051
during	O
2005-2013	O
Massive coral	B-T204
bleaching	B-T070
events	B-T051
associated	O
with	O
high	O
sea	B-T083
surface	B-T082
temperatures	B-T081
are	O
forecast	O
to	O
become	O
more	O
frequent	B-T079
and	O
severe	B-T080
in	O
the	O
future	O
due	O
to	O
climate change	B-T070
.	O
Monitoring	B-T062
colony	B-T096
recovery	B-T052
from	O
bleaching	B-T070
disturbances	O
over	O
multiyear time frames	B-T079
is	O
important	O
for	O
improving	O
predictions	O
of	O
future	O
coral	B-T204
community	B-T096
changes	B-T169
.	O
However,	O
there	O
are	O
currently	O
few	O
multiyear studies	B-T062
describing	O
long-term	B-T079
outcomes	B-T169
for	O
coral	B-T204
colonies	B-T096
following	O
acute bleaching	B-T070
events	B-T051
.	O
We	O
recorded	O
colony	B-T096
pigmentation	B-T032
and	O
size	B-T082
for	O
bleached	B-T078
and	O
unbleached groups	B-T078
of	O
co-located	O
conspecifics	O
of	O
three	O
major	O
reef-building scleractinian	B-T204
corals	B-T204
(	O
Orbicella franksi	B-T204
,	O
Siderastrea siderea	B-T204
,	O
and	O
Stephanocoenia michelini	B-T204
;	O
n	O
=	O
198	O
total)	O
in	O
Bocas del Toro	B-UnknownType
,	O
Panama	B-T083
,	O
during	O
the	O
major	O
2005	O
bleaching	B-T070
event	B-T051
and	O
then	O
monitored	B-T062
pigmentation	B-T032
status	B-T080
and	O
changes	O
live tissue	B-T024
colony	B-T096
size	B-T082
for	O
8	O
years	B-T079
(2005-2013).	O
Corals	B-T204
that	O
were	O
bleached	B-T070
in	O
2005	O
demonstrated	O
markedly	O
different	O
response	O
trajectories	O
compared	O
to	O
unbleached	O
colony	B-T096
groups	B-T078
,	O
with	O
extensive	O
live tissue	B-T024
loss	B-T081
for	O
bleached	B-T070
corals	B-T204
of	O
all	O
species	B-T185
following	O
bleaching	B-T070
,	O
with	O
mean	O
live tissue	B-T024
losses	B-T081
per	O
colony	B-T096
9	O
months	B-T079
postbleaching	B-T079
of	O
26.2%	O
(±5.4	O
SE)	O
for	O
O. franksi	B-T204
,	O
35.7%	O
(±4.7	O
SE)	O
for	O
S. michelini	B-T204
,	O
and	O
11.2%	O
(±3.9	O
SE)	O
for	O
S. siderea	B-T204
.	O
Two	O
species	B-T185
,	O
O. franksi	B-T204
and	O
S. michelini	B-T204
,	O
later	O
recovered	O
to	O
net	O
positive	B-T033
growth	B-T040
,	O
which	O
continued	O
until	O
a	O
second	O
thermal stress	B-T067
event	B-T051
in	O
2010.	O
Following	O
this	O
event	B-T051
,	O
all	O
species	B-T185
again	O
lost	B-T169
tissue	B-T024
,	O
with	O
previously	O
unbleached	O
colony	B-T096
species	B-T185
groups	B-T078
experiencing	O
greater	O
declines	O
than	O
conspecific	O
sample	O
groups	B-T078
,	O
which	O
were	O
previously	O
bleached	B-T070
,	O
indicating	O
a	O
possible	O
positive	O
acclimative response	B-T040
.	O
However,	O
despite	O
this	O
beneficial	O
effect	O
for	O
previously	O
bleached	B-T070
corals	B-T204
,	O
all	O
groups	B-T078
experienced	O
substantial	O
net	O
tissue	B-T024
loss	B-T081
between	O
2005	O
and	O
2013,	O
indicating	O
that	O
many	O
important	O
Caribbean	B-T083
reef-building corals	B-T204
will	O
likely	O
suffer	O
continued	O
tissue	B-T024
loss	B-T081
and	O
may	O
be	O
unable	O
to	O
maintain	O
current	O
benthic coverage	B-T082
when	O
faced	O
with	O
future	O
thermal stress	B-T067
forecast	O
for	O
the	O
region	B-T083
,	O
even	O
with	O
potential	O
benefits	O
from	O
bleaching	B-T070
-related	O
acclimation	B-T040
.	O

Preparation	B-T052
and	O
characterization	B-T052
of	O
gastrointestinal	B-T082
wafer	B-T122
formulations	B-T073
Many	O
active pharmaceutical ingredients	B-T121
(	O
API	B-T121
)	O
have	O
a	O
very	O
poor	O
or	O
highly	O
variable	B-T080
bioavailability	B-T081
after	O
oral administration	B-T061
.	O
One	O
possibility	O
to	O
overcome	B-T052
this	O
problem	O
might	O
be	O
found	O
in	O
the	O
application	O
of	O
mucoadhesive dosage forms	B-T122
like	O
gastrointestinal	B-T082
wafers	B-T122
.	O
However,	O
a	O
currently	B-T079
unsolved	B-T077
challenge	O
is	O
the	O
control	B-T080
of	O
the	O
adhesion	B-T070
of	O
the	O
wafer	B-T122
to	O
the	O
intestinal mucus	B-T031
.	O
One	O
suggested	O
solution	O
might	O
be	O
the	O
combination	B-T080
of	O
gastrointestinal	B-T082
wafers	B-T122
and	O
expanding systems	B-T169
.	O
Such	O
a	O
combination	B-T080
requires	O
thin and elastic wafers	B-T122
which	O
are	O
further	O
characterized	B-T052
by	O
an	O
unidirectional drug release	B-T070
.	O
In	O
this	O
study	B-T062
gastrointestinal	B-T082
,	O
twolayered wafers	B-T122
containing	O
a	O
water-insoluble backing layer	B-T080
and	O
a	O
drug-loaded	B-T081
,	O
mucoadhesive layer	B-T080
were	O
fabricated	O
by	O
casting solvent technique	B-T169
.	O
The	O
backing layer	B-T080
consists	O
of	O
Ethocel™ Standard 10 Premium	B-T121
and	O
the	O
mucoadhesive layer	B-T080
was	O
prepared	O
using	O
a	O
mixture	B-T167
of	O
Methocel™ E15 Premium LV	B-T109
,	O
polyvinyl alcohol	B-T122
and	O
Macrogol 400	B-T109
.	O
The	O
wafers	B-T122
were	O
characterized	B-T052
regarding	O
their	O
appearance	B-T080
,	O
mechanical properties	B-T080
and	O
dissolution profiles	B-T070
as	O
well	O
as	O
the	O
influence	B-T077
of	O
backing layer	B-T080
thickness	B-T080
on	O
drug transfer	B-T052
and	O
their	O
ability	O
of	O
unidirectional drug release	B-T070
.	O
The	O
wafers	B-T122
with	O
backing layer	B-T080
thickness	B-T080
of	O
500μg Ethocel	B-T109
™/cm(2)	O
presented	O
adequate	B-T080
mechanical properties	B-T080
,	O
a	O
drug transfer	B-T052
about	O
73%	O
and	O
unidirectional drug release	B-T070
.	O

Discovery	B-T052
of	O
<i>Neopanorpa chillcotti</i> Byers	B-T204
(	O
Mecoptera	B-T204
:	O
Panorpidae	B-T204
)	O
from	O
Tibet	B-T083
,	O
China	B-T083
,	O
with	O
discussion	O
of	O
its	O
generic status	B-T078
Neopanorpa chillcotti Byers	B-T204
,	O
1971	O
was	O
originally	O
described	O
from	O
Kathmandu	B-UnknownType
in	O
Nepal	B-T083
and	O
is	O
now	O
found	O
to	O
be	O
distributed	O
in	O
Gyirong	B-UnknownType
,	O
Tibet	B-T083
in	O
China	B-T083
.	O
The	O
species	O
is	O
redescribed	O
and	O
illustrated	O
based	O
on	O
new material	B-T167
from	O
China	B-T083
and	O
Nepal	B-T083
.	O
The	O
generic status	B-T078
of	O
this	O
species	B-T185
is	O
briefly	O
discussed	B-T054
.	O

Passive case detection	B-T062
of	O
malaria	B-T047
in	O
Ratanakiri Province	B-UnknownType
(	O
Cambodia	B-UnknownType
)	O
to	O
detect	B-T033
villages	B-T083
at higher risk	B-T033
for	O
malaria	B-T047
Cambodia	B-UnknownType
reduced	B-T080
malaria	B-T047
incidence	B-T081
by	O
more	O
than	O
75%	O
between	O
2000	O
and	O
2015,	O
a	O
target	B-T169
of	O
the	O
Millennium Development Goal 6	B-T170
.	O
The	O
Cambodian	B-UnknownType
Government	B-T092
aims	B-T078
to	O
eliminate	B-T080
all	O
forms	O
of	O
malaria	B-T047
by	O
2025.	O
The	O
country's	B-T083
malaria	B-T047
incidence	B-T081
is	O
highly	B-T080
variable	B-T080
at	O
provincial	B-UnknownType
level	B-T080
,	O
but	O
less	O
is	O
known	O
at	O
village	B-T083
level	B-T080
.	O
This	O
study	B-T062
used	O
passive case detection	B-T062
(	O
PCD	B-T062
)	O
data	O
at	O
village	B-T083
level	B-T080
in	O
Ratanakiri Province	B-UnknownType
from	O
2010	O
to	O
2014	O
to	O
describe	O
incidence	B-T081
trends	B-T079
and	O
identify	B-T080
high-risk areas of	B-T033
malaria	B-T047
to	O
be	O
primarily	B-T080
targeted	B-T169
towards	O
malaria	B-T047
elimination	B-T080
.	O
In	O
2010,	O
the	O
Cambodian	B-UnknownType
malaria	B-T047
programme	B-T170
created	O
a	O
Malaria Information System	B-T170
(	O
MIS	B-T170
)	O
to	O
capture	O
malaria	B-T047
information	B-T078
at	O
village	B-T083
level	B-T080
through	O
PCD	B-T062
by	O
village	B-T083
malaria workers	B-T097
and	O
health facilities	B-T073
.	O
The	O
MIS	B-T170
data	B-T078
of	O
Ratanakiri Province	B-UnknownType
2010-2014	O
were	O
used	O
to	O
calculate	B-T052
annual	B-T079
incidence rates	B-T081
by	O
Plasmodium species	B-T204
at	O
province	B-UnknownType
and	O
commune	B-T098
levels	B-T080
.	O
For	O
estimating	B-T081
the	O
trend	B-T079
at	O
provincial	B-UnknownType
level	B-T080
only	O
villages	B-T083
reporting	B-T058
each	O
year	B-T079
were	O
selected.	O
The	O
communal	B-T096
incidences	B-T081
and	O
the	O
number	O
of	O
cases	B-T169
per	B-T080
village	B-T083
were	O
visualized	O
on	O
a	O
map	B-T073
per	O
Plasmodium species	B-T204
and	O
per year	B-T079
.	O
Analysis of spatial clustering	B-UnknownType
of	O
village	B-T083
malaria	B-T047
cases	B-T169
by	O
Plasmodium species	B-T204
was	O
performed	B-T169
by	O
year	B-T079
.	O
Overall,	O
malaria	B-T047
annual	B-T079
incidence rates	B-T081
per	O
1000	O
inhabitants	B-T101
decreased	B-T080
from	O
86	O
(2010)	O
to	O
30	O
(2014).	O
Falciparum	B-T204
incidence	B-T081
decreased	B-T080
(by	O
79%	O
in	O
2014	O
compared	B-T052
to	O
2010;	O
CI	B-T081
95%	O
76-82%)	O
more	O
rapidly	B-T080
than	O
vivax	B-T204
incidence	B-T081
(by	O
19%	O
in	O
2014	O
compared	B-T052
to	O
2010;	O
CI	B-T081
95%	O
5-32%).	O
There	O
were	O
ten	O
to	O
16	O
significant	B-T078
spatial clusters	B-T081
each	O
year	B-T079
.	O
Big clusters	B-T081
tended	O
to	O
extend	B-T082
along	O
the	O
Cambodian-Vietnamese border	B-UnknownType
and	O
along	O
the	O
Sesan River	B-T070
.	O
Three	O
clusters	B-T081
appeared	O
throughout	O
all	O
years	B-T079
(2010-2014):	O
one	O
with	O
21	O
villages	B-T083
appeared	O
each	O
year	B-T079
,	O
the	O
second	O
shrunk	B-T081
progressively	B-T169
from	O
2012	O
to	O
2014	O
and	O
the	O
third	O
was	O
split	B-T169
into	O
two	O
smaller	O
clusters	B-T081
in	O
2013	O
and	O
2014.	O
The	O
decline	B-T067
of	O
malaria	B-T047
burden	B-T078
can	O
be	O
attributed	O
to	O
intensive	B-T169
malaria control activities	B-T052
implemented	B-T052
in	O
the	O
areas	B-T082
:	O
distribution	B-T078
of	O
a	O
long-lasting	B-T078
insecticidal net	B-T074
per	O
person	B-T098
and	O
early diagnosis	B-T060
and	O
prompt	B-T169
treatment	B-T169
.	O
Dihydro-artemisinin	B-T109
piperaquine	B-T109
was	O
the	O
only	O
first-line treatment	B-T061
for	O
all	O
malaria	B-T047
cases	B-T169
.	O
No	O
radical	B-T080
treatment	B-T169
with	O
primaquine	B-T109
was	O
provided	O
for	O
Plasmodium vivax	B-T204
cases	B-T169
,	O
which	O
could	O
explain	O
the	O
slow	B-T080
decrease	B-T081
of	O
P. vivax	B-T204
due	O
to	O
relapses	B-T067
.	O
To	O
achieve	B-T080
malaria	B-T047
elimination	B-T080
by	O
2025,	O
priority	B-T079
should	O
be	O
given	O
to	O
the	O
control	O
of	O
stable	B-T080
malaria clusters	B-T081
appearing	O
over	O
time.	O

Interaction of lifestyle	B-T054
,	O
behaviour	B-T053
or	O
systemic diseases	B-T047
with	O
dental caries	B-T047
and	O
periodontal diseases	B-T047
:	O
consensus report of group 2 of the joint EFP/ORCA workshop	B-T097
on	O
the	O
boundaries	O
between	O
caries	B-T047
and	O
periodontal diseases	B-T047
Periodontal diseases	B-T047
and	O
dental caries	B-T047
are	O
the	O
most	O
common diseases	B-T047
of	O
humans	O
and	O
the	O
main	O
cause	O
of	O
tooth loss	B-T020
.	O
Both	O
diseases	B-T047
can	O
lead	O
to	O
nutritional compromise	B-T169
and	O
negative	O
impacts	O
upon	O
self-esteem	B-T041
and	O
quality of life	B-T078
.	O
As	O
complex chronic diseases	B-T047
,	O
they	O
share	O
common risk factors	B-T033
,	O
such	O
as	O
a	O
requirement	O
for	O
a	O
pathogenic plaque biofilm	B-T001
,	O
yet	O
they	O
exhibit	O
distinct pathophysiologies	B-T046
.	O
Multiple exposures	B-T080
contribute	O
to	O
their	O
causal	O
pathways,	O
and	O
susceptibility involves	B-T201
risk factors	B-T033
that	O
are	O
inherited	B-T169
(e.g.	O
genetic variants	B-T070
),	O
and	O
those	O
that	O
are	O
acquired	O
(e.g.	O
socio-economic factors	B-T080
,	O
biofilm	B-T007
load	O
or	O
composition,	O
smoking	B-T055
,	O
carbohydrate intake	B-T201
).	O
Identification	O
of	O
these	O
factors	O
is	O
crucial	O
in	O
the	O
prevention of both diseases	B-T061
as	O
well	O
as	O
in	O
their management	B-T058
.	O
To	O
systematically	O
appraise	O
the	O
scientific literature	B-T170
to	O
identify	O
potential risk factors	B-T033
for	O
caries	B-T047
and	O
periodontal diseases	B-T047
.	O
One	O
systematic review	B-T170
(	O
genetic risk factors	B-T080
),	O
one	O
narrative review	B-UnknownType
(	O
role of diet and nutrition	B-T062
)	O
and	O
reference documentation	B-T170
for	O
modifiable acquired risk factors	B-T033
common	O
to	O
both	O
disease	O
groups,	O
formed	O
the	O
basis	O
of	O
the	O
report.	O
There	O
is	O
moderately	O
strong	O
evidence	O
for	O
a	O
genetic contribution	B-T033
to	O
periodontal diseases	B-T047
and	O
caries susceptibility	B-T032
,	O
with	O
an	O
attributable risk	B-T080
estimated	O
to	O
be	O
up	O
to	O
50%.	O
The	O
genetics literature	B-T169
for	O
periodontal disease	B-T047
is	O
more	O
substantial	O
than	O
for	O
caries	B-T047
and	O
genes	B-T028
associated with	B-T080
chronic periodontitis	B-T047
are	O
the	O
vitamin D receptor	B-T028
(	O
VDR	B-T028
),	O
Fc gamma receptor IIA	B-T028
(	O
Fc-γRIIA	B-T028
)	O
and	O
Interleukin 10 (IL10) genes	B-T028
IL10	B-T028
)	O
genes.	O
For	O
caries	B-T047
,	O
genes	B-T028
involved	O
in	O
enamel formation	B-T033
(	O
AMELX	B-T028
,	O
AMBN	B-T028
,	O
ENAM	B-T028
,	O
TUFT	B-T116
,	O
MMP20	B-T028
,	O
and	O
KLK4	B-T028
),	O
salivary characteristics	B-T033
(	O
AQP5	B-T028
),	O
immune regulation	B-T040
and	O
dietary preferences	B-T080
had	O
the	O
largest impact	B-T080
.	O
No	O
common	O
genetic	O
variants	O
were	O
found.	O
Fermentable carbohydrates	B-T109
(	O
sugars and starches	B-UnknownType
)	O
were	O
the	O
most	O
relevant	O
common	O
dietary	O
risk factor for both diseases	B-T033
,	O
but	O
associated	O
mechanisms	O
differed.	O
In	O
caries	B-T047
,	O
the	O
fermentation process	B-T044
leads	O
to	O
acid	O
production	O
and	O
the	O
generation of biofilm	B-T043
components	O
such	O
as	O
Glucans	B-T109
.	O
In	O
periodontitis	B-T047
,	O
glycaemia drives	B-T033
oxidative stress	B-T049
and	O
advanced glycation	B-T067
end-products	O
may	O
also	O
trigger	O
a	O
hyper inflammatory	B-T046
state.	O
Micronutrient deficiencies	B-T046
,	O
such	O
as	O
for	O
vitamin C	B-T109
,	O
vitamin D	B-T109
or	O
vitamin B12	B-T109
,	O
may	O
be	O
related	O
to	O
the	O
onset	B-T079
and	O
progression of both diseases	B-T046
.	O
Functional foods	B-T168
or	O
probiotics	B-T007
could	O
be	O
helpful	O
in	O
caries prevention	B-T058
and	O
periodontal disease	B-T047
management	B-T058
,	O
although	O
evidence	O
is	O
limited	O
and	O
biological mechanisms	B-T044
not	O
fully	O
elucidated.	O
Hyposalivation	B-T033
,	O
rheumatoid arthritis	B-T047
,	O
smoking/tobacco use	B-T033
,	O
undiagnosed	B-T033
or	O
sub-optimally controlled	B-T033
diabetes	B-T047
and	O
obesity	B-T047
are	O
common	O
acquired	O
risk factors	B-T033
for	O
both	O
caries	B-T047
and	O
periodontal diseases	B-T047
.	O

Intestinal	B-T023
micropatches	B-T074
for	O
oral	B-T082
insulin delivery	B-T061
Diabetes mellitus	B-T047
has	O
become	O
a	O
major	O
public health issue	B-T078
that	O
has	O
almost	O
reached	O
epidemic proportions	B-T169
worldwide.	O
Injectable insulin	B-UnknownType
has	O
been	O
typically	O
utilized	O
for	O
the	O
management	B-T058
of	O
this	O
chronic disease	B-T047
.	O
However,	O
lack of patient compliance	B-T033
with	O
injectable	B-T121
formulations	B-T077
has	O
spurred	O
the	O
development	O
of	O
oral	B-T082
insulin	B-T116
formulations	B-T077
,	O
which	O
although	O
appealing,	O
face	O
several	O
delivery	B-T061
challenges	B-T058
.	O
We	O
have	O
developed	O
novel	O
mucoadhesive	B-T073
intestinal	B-T023
patches	B-T074
,	O
several	O
hundred	O
micrometers	B-T081
in	O
dimension	B-T081
(	O
micropatches	B-T074
)	O
that	O
address	O
the	O
challenges	B-T058
of	O
oral	B-T082
insulin delivery	B-T061
.	O
The	O
micropatches	B-T074
adhere	B-T067
to	O
the	O
intestinal mucosa	B-T024
,	O
release	O
their	O
drug	B-T121
load	O
rapidly	B-T080
within	O
30	O
min	O
and	O
are	O
effective	B-T080
in	O
lowering blood glucose levels	B-T033
in vivo	B-T082
.	O
When	O
insulin	B-T116
-loaded	O
micropatches	B-T074
were	O
administered	B-T061
with	O
a	O
permeation enhancer	B-T121
and	O
protease inhibitor	B-T121
,	O
a	O
peak	B-T080
efficacy	B-T080
of	O
34%	O
drop in blood glucose levels	B-T033
was	O
observed	O
within	O
3	O
h.	O
Efficacy	B-T080
further	O
improved	O
to	O
41%	O
when	O
micropatches	B-T074
were	O
administered	B-T061
in	O
multiple doses	B-T201
.	O
Here,	O
we	O
describe	O
the	O
design	O
of	O
micropatches	B-T074
as	O
an	O
oral	B-T082
insulin	B-T116
formulation	B-T077
and	O
report	O
their	O
in vivo	B-T082
efficacy	B-T080
.	O

Hybrid automata models	B-T075
of	O
cardiac ventricular	B-T023
electrophysiology	B-T060
for	O
real-time	B-T079
computational applications	B-T169
Virtual	O
heart models	B-T075
have	O
been	O
proposed	O
for	O
closed loop	B-T169
validation	B-T062
of	O
safety	B-T068
-	O
critical	B-T080
embedded	O
medical devices	B-T074
,	O
such	O
as	O
pacemakers	B-T074
.	O
These	O
models	B-T075
must	O
react	O
in	O
real-time	B-T079
to	O
off-the-shelf	O
medical devices	B-T074
.	O
Real-time	B-T079
performance	B-T052
can	O
be	O
obtained	B-T169
by	O
implementing	O
models	B-T075
in	O
computer hardware	B-T073
,	O
and	O
methods	B-T169
of	O
compiling	O
classes	O
of	O
Hybrid Automata	B-T075
(	O
HA	B-T075
)	O
onto	O
FPGA	B-T074
have	O
been	O
developed.	O
Models	B-T075
of	O
ventricular cardiac cell	B-T025
electrophysiology	B-T060
have	O
been	O
described	B-T078
using	O
HA	B-T075
which	O
capture	B-T067
the	O
complex	O
nonlinear	O
behavior	B-T080
of	O
biological systems	B-T169
.	O
However,	O
many	O
models	B-T075
that	O
have	O
been	O
used	O
for	O
closed-loop	B-T169
validation	B-T062
of	O
pacemakers	B-T074
are	O
highly	O
abstract	B-T078
and	O
do	O
not	O
capture	B-T067
important	B-T080
characteristics	B-T080
of	O
the	O
dynamic	B-T169
rate response	B-T079
.	O
We	O
developed	O
a	O
new	O
HA model	B-T075
of	O
cardiac cells	B-T025
which	O
captures	B-T067
dynamic	B-T169
behavior	B-T080
and	O
we	O
implemented	O
the	O
model	B-T075
in	O
hardware	B-T073
.	O
This	O
potentially	B-T080
enables	O
modeling	B-T062
the	O
heart	B-T023
with	O
over	O
1	O
million	B-T081
dynamic	B-T169
cells	B-T025
,	O
making	O
the	O
approach	O
ideal	B-T080
for	O
closed loop	B-T169
testing	B-T169
of	O
medical devices	B-T074
.	O

Comparison	B-T052
of	O
pulse wave velocity	B-T081
derived	O
from	O
accelerometer	B-T074
and	O
reflective photo-plethysmography signals	B-T060
placed	O
at	O
the	O
carotid	B-T023
and	O
femoral artery	B-T023
Carotid	B-T023
-	O
femoral	B-T023
pulse wave velocity	B-T081
is	O
an	O
established measure	B-T081
to	O
assess	B-T058
cardiovascular risk	B-T033
and	O
an	O
interesting	O
surrogate parameter	B-T077
towards	O
non-invasive continuous blood pressure inference	B-T201
.	O
Due	O
to	O
progress	B-T169
in	O
sensing	O
technologies	O
for	O
wearable wrist worn sensors	B-T073
,	O
there	O
are	O
low	O
cost	O
sensor	O
combinations	O
of	O
photo-plethysmography	B-T060
and	O
high fidelity accelerometer s	B-T074
available	O
offering	O
access	O
to	O
pulse information	B-T058
from	O
larger arteries	B-T023
complemented	O
by	O
blood volume	B-T201
changes	O
in	O
the	O
superficial tissue	B-T024
.	O
In	O
this	O
work	O
we	O
compare	O
pulse wave velocities	B-T081
derived	O
from	O
accelerometer	B-T074
and	O
reflective photo-plethysmography signals	B-T060
placed	O
at	O
the	O
carotid	B-T023
and	O
femoral artery	B-T023
.	O
We	O
discuss	O
the	O
different	O
underlying	O
physiological processes	B-T039
for	O
the	O
two	O
sensing principles	B-T078
and	O
present	O
experimental results	B-T033
obtained	O
in	O
a	O
study	B-T062
with	O
healthy subjects	B-T098
.	O

Constructive and Unproductive Processing	B-T033
of	O
Traumatic Experiences	B-T048
in	O
Trauma-Focused Cognitive-Behavioral Therapy	B-T061
for	O
Youth	B-T100
Although	O
there	O
is	O
substantial	O
evidence	B-T078
to	O
support	O
the	O
efficacy	B-T080
of	O
cognitive-behavioral treatments	B-T061
(	O
CBT	B-T061
)	O
for	O
posttraumatic stress disorder	B-T048
(	O
PTSD	B-T048
),	O
there	O
is	O
some	O
debate	O
about	O
how	O
these	O
treatments	B-T061
have	O
their	O
effects.	O
Modern	O
learning theory	B-T170
and	O
cognitive and emotional processing theories	B-T170
highlight	O
the	O
importance	O
of	O
reducing	O
avoidance	B-T041
,	O
facilitating	O
the	O
constructive processing of feared experiences	B-T033
,	O
and	O
strengthening	O
new	O
inhibitory learning	B-T041
.	O
We	O
examined	O
variables	O
thought	O
to	O
be	O
associated	O
with	O
unproductive and constructive processing	B-T033
of	O
traumatic experiences	B-T048
in	O
a	O
sample	O
of	O
81	O
youth	O
with	O
elevated	O
PTSD	B-T048
symptoms	B-T184
,	O
who	O
received	O
Trauma-Focused Cognitive Behavioral Therapy	B-T061
(	O
TF-CBT	B-T061
)	O
for	O
abuse	B-T033
or	O
traumatic	B-T048
interpersonal loss	B-UnknownType
.	O
Sessions	B-T077
during	O
the	O
trauma narrative phase	B-T061
of	O
TF-CBT	B-T061
were	O
coded	O
for	O
indicators	O
of	O
unproductive processing	B-T033
(	O
overgeneralization	B-T033
,	O
rumination	B-T048
,	O
avoidance	B-T041
)	O
and	O
constructive processing	B-T033
(	O
decentering	B-T033
,	O
accommodation of corrective information	B-T033
),	O
as	O
well	O
as	O
levels of negative emotion	B-T058
.	O
In	O
previous	B-T079
analyses	O
of	O
this	O
trial	O
(Ready	O
et	O
al.,	O
2015),	O
more	O
overgeneralization	B-T033
during	O
the	O
narrative phase	B-T061
predicted	O
less	O
improvement	O
in	O
internalizing symptoms	B-T184
at	O
posttreatment	B-UnknownType
and	O
a	O
worsening	B-T080
of	O
externalizing symptoms	B-T184
over	O
the	O
12-month	O
follow-up	B-T058
.	O
In	O
contrast,	O
more	O
accommodation predicted improvement	B-T033
in	O
internalizing symptoms	B-T184
and	O
also	O
moderated	B-T080
the	O
negative	B-T033
effects of	B-T080
overgeneralization	B-T033
on	O
internalizing and externalizing symptoms	B-T184
.	O
The	O
current	O
study	O
examined	O
correlates	O
of	O
overgeneralization	B-T033
and	O
accommodation	B-T033
.	O
Overgeneralization	B-T033
was	O
associated with	B-T080
more	O
rumination	B-T048
,	O
less	O
decentering,	O
and	O
more	O
negative emotion	B-T058
,	O
suggesting	B-T078
immersion	B-T058
in	O
trauma	B-T048
-related	O
material.	O
Accommodation	B-T033
was	O
associated with	B-T080
less	O
avoidance	B-T041
and	O
more	O
decentering	B-T033
,	O
suggesting	O
a	O
healthy	B-T080
distance	O
from	O
trauma	B-T048
-related	O
material	O
that	O
might	O
allow	O
for	O
processing	O
and	O
cognitive change	B-T048
.	O
Decentering	O
also	O
predicted	B-T078
improvement	B-T077
in	O
externalizing symptoms	B-T184
at	O
posttreatment	B-UnknownType
.	O
Rumination	B-T048
and	O
avoidance	B-T041
showed	O
important	O
associations	O
with	O
overgeneralization	B-T033
and	O
accommodation	B-T033
,	O
respectively,	O
but	O
did	O
not	O
predict	O
treatment outcomes	B-T080
.	O
This	O
study	O
identifies	O
correlates	O
of	O
overgeneralization	B-T033
and	O
accommodation	B-T033
that	O
might	O
shed	O
light	O
on	O
how	O
these	O
variables	O
relate	O
to	O
unproductive and constructive processing	B-T033
of	O
traumatic experiences	B-T048
.	O

Giant	B-T025
Antrochoanal Polyp	B-T191
-A	O
Rare	B-T080
Presentation	B-T078
Antrochoanal polyp	B-T191
(	O
ACP	B-T191
),	O
also	O
called	O
as	O
Killian polyp	B-T191
,	O
is	O
an	O
infrequent,	O
benign lesion	B-T033
of	O
maxillary	B-T023
origin	O
in	O
non-atopic	O
patients	B-T101
.	O
The	O
antrochoanal polyp	B-T191
is	O
shaped	O
according	O
to	O
the	O
anatomical	B-T080
constraints	O
of	O
the	O
lateral nasal wall	B-T029
,	O
particularly	O
the	O
middle meatus	B-T023
and	O
antrum	B-T023
,	O
resembling	O
typically	O
a	O
dumbbell	B-T082
.	O
Here	O
presenting	O
a	O
common	O
problem	B-T033
with	O
unusual	B-T080
presentation	B-T078
.	O

Effects	B-T080
of	O
obesity	B-T047
on	O
IL-33	B-T116
/	O
ST2	B-T116
system	B-T169
in	O
heart	B-T023
,	O
adipose tissue	B-T024
and	O
liver	B-T023
:	O
study	B-T062
in	O
the	O
experimental model	B-T170
of	O
Zucker rats	B-T015
Suppression of tumorigenicity 2	B-T116
(	O
ST2	B-T116
)	O
mediates	O
the	O
effect	B-T080
of	O
Interleukin-33	B-T116
(	O
IL-33	B-T116
).	O
Few	O
data	O
are	O
reported	O
on	O
the	O
relationship	B-T080
between	O
IL-33	B-T116
/	O
ST2	B-T116
and	O
obesity	B-T047
.	O
We	O
aimed	O
to	O
investigate	O
effects	B-T080
of	O
obesity	B-T047
on	O
IL-33	B-T116
/	O
ST2	B-T116
system	B-T169
in	O
heart	B-T023
,	O
adipose tissue	B-T024
and	O
liver	B-T023
in	O
a	O
rodent model	B-T050
of	O
obesity	B-T047
.	O
The	O
relationship	B-T080
of	O
cardiac	B-T024
expression	B-T045
of	O
IL-33	B-T116
/	O
ST2	B-T116
system	B-T169
with	O
natriuretic peptides	B-T116
(	O
NPs	B-T116
)	O
system	B-T169
and	O
inflammatory mediators	B-T038
was	O
also	O
studied.	O
mRNA expression	B-T045
of	O
IL-33	B-T028
/	O
ST2	B-T028
system	B-T169
was	O
evaluated	O
in	O
cardiac	B-T060
,	O
adipose	B-T024
and	O
hepatic biopsies	B-T060
from	O
obese Zucker rats	B-T015
(	O
O	B-T015
)	O
and	O
controls	B-T096
(	O
CO	B-T096
).	O
Expression	B-T045
levels	O
of	O
sST2	B-T116
was	O
significantly	O
lower	O
in	O
O rats	B-T015
compared	O
with	O
CO	B-T096
(p<0.05)	O
in	O
all	O
tissues	B-T024
.	O
Besides,	O
the	O
mRNA	B-T114
levels	O
of	O
IL-33	B-T028
decreased	O
significant	O
in	O
fat	O
of	O
O	B-T015
respect	O
to	O
CO	B-T096
,	O
while,	O
expression	B-T045
levels	O
of	O
ST2L	B-T028
was	O
significantly	O
higher	O
in	O
liver	B-T023
of	O
CO	B-T096
than	O
in	O
O	B-T015
.	O
A	O
strong	O
relationship	B-T080
of	O
IL-33	B-T116
/	O
ST2	B-T116
with	O
NPs	B-T116
and	O
classical	O
inflammatory mediators	B-T038
was	O
observed	O
in	O
cardiac tissue	B-T024
.	O
Expression	B-T045
of	O
sST2	B-T116
in	O
cardiac	B-T024
,	O
adipose	B-T024
and	O
liver tissue	B-T023
decreased	O
in	O
O	B-T015
compared	O
with	O
controls	B-T096
,	O
suggesting	O
an	O
involvement	O
for	O
IL-33	B-T116
/	O
ST2	B-T116
system	B-T169
in	O
molecular mechanisms	B-T044
of	O
obesity	B-T047
.	O
The	O
strong	O
relationships	B-T080
with	O
NP	B-T116
systems	B-T169
and	O
inflammatory mediators	B-T038
could	O
suggest	O
an	O
involvement	O
for	O
IL-33	B-T116
/	O
ST2	B-T116
in	O
molecular pathways	B-T044
leading	O
to	O
cardiac dysfunction	B-T033
and	O
inflammation	B-T046
associated	O
with	O
obesity	B-T047
.	O

CXCL14	B-T116
-	O
CXCR4	B-T116
and	O
CXCL12	B-T116
-	O
CXCR4	B-T116
Axes	O
May	O
Play	O
Important	O
Roles	O
in	O
the	O
Unique	O
Invasion	B-T033
Process	B-T067
of	O
Endometrioid Carcinoma	B-T191
With	O
MELF-Pattern	B-T082
Myoinvasion	B-T033
The	O
term	O
"	O
MELF-pattern	B-T082
myometrial	B-T029
invasion	B-T033
"	O
(	O
MELF pattern	B-T082
)	O
denotes	O
an	O
unusual	B-T080
morphology	B-T080
of	O
myometrial	B-T029
invasion	B-T033
in	O
endometrioid carcinomas	B-T191
,	O
and	O
is	O
associated with	B-T080
frequent	O
lymphovascular invasion	B-T033
and	O
lymph node metastasis	B-T191
.	O
In	O
this	O
study,	O
tumor cells	B-T025
were	O
directly	O
collected	B-T078
from	O
a	O
MELF pattern	B-T082
site,	O
using	O
laser microdissection	B-T059
.	O
Comprehensive	B-T080
microarray analysis	B-T059
of	O
the	O
genes	B-T028
was	O
conducted,	O
and	O
based	O
on	O
the	O
results,	O
expression	B-T045
of	O
a	O
metastasis progression gene, CXCR4	B-T116
,	O
and	O
its	O
ligands	B-T044
CXCL14	B-T116
and	O
CXCL12	B-T116
,	O
was	O
further	O
investigated	B-T169
.	O
In vitro studies	B-T062
of	O
endometrioid carcinoma	B-T191
cell lines	B-T025
revealed	O
elevated	B-T080
invasion	B-T033
activity	B-T052
in	O
a	O
manner	O
dependent	O
on	O
the	O
CXCL14	B-T116
-	O
CXCR4	B-T116
or	O
CXCL12	B-T116
-	O
CXCR4	B-T116
axis.	O
Immunohistochemical analysis	B-T059
of	O
93	O
(	O
MELF group	B-T078
,	O
46;	O
non-MELF group	B-T078
,	O
47)	O
cases	O
illustrated	O
CXCR4	B-T116
was	O
expressed	B-T045
in	O
all	O
endometrioid carcinomas	B-T191
,	O
while	O
based	O
on	O
CXCL14	B-T116
and	O
CXCL12	B-T116
expression	B-T045
score	B-T081
,	O
high proportions	B-T081
of	O
cells	B-T025
were	O
positive	B-T033
at	O
the	O
sites	B-T082
of	O
the	O
MELF pattern	B-T082
(P<0.01).	O
There	O
was	O
no significant difference	B-T033
in	O
progression-free survival	B-T081
or	O
overall survival	B-T081
between	O
MELF group	B-T078
and	O
non-MELF group	B-T078
by	O
Kaplan-Meier analysis	B-T081
.	O
These	O
findings	O
suggest	O
a	O
possibility	O
that	O
cells	B-T025
at	O
the	O
sites	B-T082
of	O
MELF pattern	B-T082
had	O
acquired	O
increased	B-T081
invasiveness	B-T046
through	O
the	O
function	B-T039
of	O
the	O
CXCL14	B-T116
-	O
CXCR4	B-T116
and	O
CXCL12	B-T116
-	O
CXCR4	B-T116
axes.	O

Crude	B-T080
4-methylcyclohexanemethanol	B-T109
(	O
MCHM	B-T109
)	O
did	O
not	O
cause	B-T169
skin irritation	B-T033
in	O
humans	B-T016
in	O
48-h	B-T079
patch test	B-T060
Crude	B-T080
4-methylcyclohexanemethanol	B-T109
(	O
MCHM	B-T109
)	O
is	O
an	O
industrial	B-T057
chemical	B-T103
used	O
to	O
wash	B-T052
and	O
clean	B-T052
coal	B-T109
.	O
On	O
January	O
9th,	O
2014	O
approximately	O
10,000 gallons	B-T081
of	O
a	O
mixture	B-T167
containing	O
crude	B-T080
MCHM	B-T109
were	O
released	O
into	O
the	O
Elk River	B-T070
near	O
Charleston	B-T083
,	O
West Virginia	B-T083
,	O
contaminating	B-T169
the	O
local	B-T082
water supply	B-T081
.	O
Following	O
the	O
spill	B-T069
,	O
residents	B-T098
reported	B-T058
numerous	B-T081
health complaints	B-T184
,	O
and	O
sought	O
medical attention	B-T033
for	O
ailments	B-T184
including	O
rashes	B-T184
and	O
itching	B-T184
.	O
The	O
relationship	B-T080
between	O
the	O
complaints	B-T184
and	O
the	O
spill	B-T069
were	O
unknown,	O
as	O
such	O
symptoms	B-T184
are	O
reported	B-T058
frequently	B-T079
in	O
the	O
background.	O
In	O
this	O
study	B-T062
,	O
the	O
primary	B-T080
irritation	B-T033
potential	B-T080
of	O
crude	B-T080
MCHM	B-T109
was	O
evaluated	B-T169
in	O
206	O
individuals	B-T098
who	O
underwent	O
48 hour	B-T079
semi-occluded	B-T169
patch testing	B-T060
.	O
MCHM	B-T109
concentrations	B-T081
assessed	O
in	O
this	O
study	B-T062
were	O
1,	O
5,	O
15,	O
and	O
100	O
ppm.	O
No	O
appreciable	O
skin reactions	B-T201
were	O
observed	O
in	O
individuals	B-T098
at	O
any	O
concentration	B-T081
.	O
Three	O
of	O
the	O
five	O
concentrations	B-T081
evaluated	B-T169
were	O
above	O
the	O
highest	O
measured concentration	B-T081
of	O
MCHM	B-T109
in	O
the	O
tap water	B-T121
of	O
residents	B-T098
in	O
West Virginia	B-T083
(3.7	O
ppm).	O
The	O
results	B-T169
of	O
this	O
study	B-T062
suggest	O
that	O
crude	B-T080
MCHM	B-T109
would	O
not	O
be	O
a	O
dermal	B-T080
irritant	B-T131
for	O
the	O
vast	O
majority,	O
if	O
not	O
all,	O
potentially	O
exposed	O
persons	B-T098
at	O
the	O
concentrations	B-T081
in	O
the	O
water	B-T121
reported	B-T058
after	O
the	O
spill	B-T069
.	O

New	B-T080
metabolites	B-T123
from	O
the	O
sponge	B-T204
-derived	O
fungus	B-T004
Aspergillus sydowii J05B-7F-4	B-T004
Two	O
new	B-T080
metabolites	B-T123
,	O
diorcinolic acid	B-T123
(1)	O
and	O
β-d-glucopyranosyl aspergillusene A	B-T109
(8),	O
together	O
with	O
six	O
diphenylethers	B-T123
(2-7),	O
a	O
diketopiperazine	B-T109
(9),	O
a	O
chromone	B-T109
(10)	O
and	O
a	O
xanthone	B-T109
(11)	O
were	O
isolated	B-T169
from	O
the	O
fungus	B-T004
Aspergillus sydowii	B-T004
derived	O
from	O
the	O
marine sponge	B-T204
Stelletta sp	B-T204
.	O
The	O
planar	O
structures	O
and	O
their	O
relative	O
configurations	B-T082
were	O
elucidated	O
by	O
analysing	O
1D, 2D NMR	B-T070
and	O
HRESIMS	B-T059
data	B-T078
.	O
Compound	B-T103
8	O
is	O
the	O
first	O
glycoside	B-T109
of	O
phenolic	B-T109
bisabolane sesquiterpenes	B-T109
.	O
Compounds 1 and 8	B-T121
exhibited	O
mild	B-T080
cytotoxicity	B-T049
against	O
KB	B-T025
(	O
human nasopharyngeal carcinoma cells	B-T025
),	O
HepG2	B-T025
(	O
human liver cancer cells	B-T025
)	O
and	O
HCT 116	B-T025
(	O
human colon cancer cells	B-T025
).	O
All	O
compounds	B-T121
were	O
evaluated	B-T058
for	O
antibacterial activity	B-T052
and	O
their	O
abilities	O
to	O
suppress	B-T169
LPS	B-T109
-induced	O
nitric oxide	B-T121
(	O
NO	B-T121
)	O
production.	O
Compounds 2 and 4-7	B-T121
showed	O
mild	B-T080
antibacterial activity	B-T033
against	O
human	B-T016
pathogen	B-T001
Staphylococcus aureus	B-T007
and	O
fish	B-T013
pathogens	B-T001
Streptococcus iniae	B-T007
and	O
Vibrio ichthyoenteri	B-T007
,	O
and	O
compounds 4 and 7	B-T103
weakly	O
suppressed	B-T169
NO	B-T121
production.	O

The	O
neural	B-T169
legacy	B-T081
of	O
a	O
single	O
concussion	B-T037
It	O
has	O
been	O
hypothesized	B-T078
that	O
concussions	B-T037
impart	B-T080
lasting	B-T079
brain damage	B-T037
,	O
even	O
after	O
a	O
patient	B-T101
has	O
ostensibly	O
recovered	B-T080
.	O
This	O
hypothesis	B-T078
is	O
based	O
largely	B-T081
upon	O
neuropathological	B-T169
studies	B-T062
in	O
deceased	B-T040
athletes	B-T097
,	O
however,	O
leaving	O
open	O
the	O
question	O
of	O
whether	O
it	O
can	O
be	O
detected	B-T061
in vivo	B-T062
.	O
We	O
measured	B-T080
neural	B-T169
responses	B-T032
to	O
speech	B-T040
in	O
collegiate student	B-T098
-	O
athletes	B-T097
with	O
a	O
history	B-T033
of	O
a	O
single	O
concussion	B-T037
from	O
which	O
they	O
had	O
recovered	B-T080
.	O
These	O
student	B-T098
-	O
athletes	B-T097
had	O
weaker	B-T080
responses	B-T032
to	O
speech	B-T040
than	O
age	B-T032
-	O
and	O
position	B-T082
-	O
matched	B-T080
peers	B-T098
.	O
This	O
group	B-UnknownType
difference	B-T080
suggests	B-T078
that	O
concussions	B-T037
engender	B-T169
small	B-T081
,	O
but	O
detectable	B-T201
,	O
changes	B-T169
in	O
brain function	B-T042
prior	B-T079
to	O
the	O
emergence	B-T079
of	O
frank	B-T080
behavioral indications	B-T184
.	O

Enhanced	O
Performance	B-T052
of	O
Colorimetric	B-T059
Biosensing	B-T059
on	O
Paper	B-T073
Microfluidic Platforms	B-T059
Through	O
Chemical Modification	B-T169
and	O
Incorporation	B-T169
of	O
Nanoparticles	B-T073
This	O
chapter	O
describes	O
two	O
different	O
methodologies	B-T062
used	O
to	O
improve	O
the	O
analytical performance	B-T052
of	O
colorimetric	B-T059
paper	B-T073
-based	O
biosensors	B-T075
.	O
Microfluidic paper-based analytical devices	B-T075
(	O
μPADs	B-T075
)	O
have	O
been	O
produced	O
by	O
a	O
stamping process	B-T067
and	O
CO2	B-T123
laser ablation	B-T061
and	O
modified	B-T080
,	O
respectively,	O
through	O
an	O
oxidation	B-T067
step	B-T077
and	O
incorporation	O
of	O
silica	B-T122
nanoparticles	B-T073
on	O
the	O
paper structure	B-T073
.	O
Both	O
methods	B-T170
are	O
employed	O
in	O
order	O
to	O
overcome	O
the	O
largest	O
problem	B-T033
associated with	B-T080
colorimetric detection	B-T059
,	O
the	O
heterogeneity	B-T080
of	O
the	O
color	B-T080
distribution	B-T169
in	O
the	O
detection zones	B-T082
.	O
The	O
modification	B-T169
steps	B-T077
are	O
necessary	O
to	O
improve	O
the	O
interaction	B-T169
between	O
the	O
paper	B-T073
surface	B-T082
and	O
the	O
selected	O
enzymes	B-T116
.	O
The	O
enhanced	O
performance	B-T052
has	O
ensured	O
reliability	B-T081
for	O
quantitative	B-T081
analysis	B-T062
of	O
clinically	B-T080
relevant	O
compounds	B-T103
.	O

CXCR4	B-T116
(	O
CD184	B-T116
)	O
expression	B-T045
on	O
stem cell harvest	B-T061
and	O
CD34(+)	B-T116
cells	B-T025
post-transplant	B-T079
CXCR4	B-T116
is	O
a	O
receptor	B-T116
for	O
stromal-derived factor-1	B-T116
(	O
SDF-1	B-T116
),	O
a	O
molecule	B-T167
that	O
has	O
a	O
chemotactic	B-T043
activity	B-T052
for	O
lymphocytes	B-T025
and	O
is	O
important	O
in	O
homing	B-T043
of	O
hematopoietic stem cells	B-T025
to	O
their	O
adult marrow	B-T024
.	O
We	O
evaluated	B-T058
the	O
CXCR4	B-T116
(	O
CD184	B-T116
)	O
expression	B-T045
in	O
the	O
harvest cells	B-T025
and	O
in	O
the	O
post-transplant	B-T079
bone marrow	B-T024
(	O
BM	B-T024
)	O
and	O
its	O
relation	B-T080
to	O
engraftment	B-T039
,	O
as	O
determined	O
by	O
the	O
consensus criteria	B-T170
and	O
chimerism	B-T032
.	O
This	O
is	O
a	O
prospective study	B-T062
which	O
included	O
30	O
patients	B-T101
undergoing	O
hematopoietic stem cell transplantation	B-T061
;	O
15	O
patients	B-T101
received	B-T080
autograft	B-T061
and	O
15	O
patients	B-T101
received	B-T080
allograft	B-T061
on	O
dates	O
between	O
January	O
2012	O
and	O
May	O
2014.	O
We	O
assessed	B-T052
CD184	B-T116
(	O
CXCR4	B-T116
)	O
using	O
flow cytometry	B-T059
in	O
the	O
harvest cells	B-T025
together	O
with	O
post-transplant	B-T079
BM	B-T024
assessment	B-T058
on	O
Day	O
28	O
and	O
Day	O
90	O
for	O
complete	B-T080
morphologic	B-T082
,	O
molecular studies	B-T059
,	O
and	O
detection	B-T061
of	O
CD184	B-T116
expression	B-T045
on	O
CD34(+)	B-T116
cells	B-T025
with	O
chimerism	B-T032
studies	O
on	O
total	B-T080
peripheral blood mononuclear cells	B-T025
.	O
Diagnoses	B-T033
of	O
the	O
enrolled	O
patients	B-T101
were	O
as	O
follows:	O
seven	O
(24.1%)	O
with	O
acute myeloid leukemia	B-T191
,	O
eight	O
(27.6%)	O
with	O
multiple myeloma	B-T191
,	O
four	O
(13.8%)	O
with	O
acute lymphoblastic leukemia	B-T191
,	O
three	O
(10.3%)	O
with	O
non-Hodgkin lymphoma	B-T191
,	O
two	O
(6.9%)	O
with	O
myelodysplastic syndromes	B-T191
,	O
two	O
(6.9%)	O
with	O
aplastic anemia	B-T047
,	O
two	O
(6.9%)	O
with	O
chronic myeloid leukemia	B-T191
,	O
one	O
(3.4%)	O
with	O
Hodgkin lymphoma	B-T191
,	O
and	O
one	O
(3.4%)	O
with	O
plasmacytomas	B-T191
.	O
One	O
patient	B-T101
died	B-T033
and	O
was	O
excluded	B-T052
from	O
the	O
study	B-T062
because	O
there	O
were	O
not	O
enough	O
data	O
about	O
engraftment	B-T039
.	O
There	O
was	O
no	B-T033
statistical significance	B-T081
between	O
the	O
level	B-T034
of	O
CD184	B-T116
in	O
stem cell harvest	B-T061
and	O
the	O
prediction	B-T078
of	O
successful	B-T080
engraftment	B-T039
(p>0.05)	O
as	O
well	O
as	O
in	O
Day	O
28	O
BM sample	B-T031
(p>0.05),	O
whereas	O
there	O
was	O
a	O
statistical significance	B-T081
between	O
the	O
level	B-T034
of	O
CD184	B-T116
in	O
Day	O
90	O
BM sample	B-T031
and	O
the	O
occurrence	B-T079
of	O
successful	B-T080
engraftment	B-T039
(p=0.002).	O
SDF-1	B-T116
/	O
CXCR4	B-T116
axis	O
plays	O
a	O
crucial	O
role	O
in	O
engraftment	B-T039
;	O
however,	O
more	O
studies	O
are	O
warranted	O
to	O
assess	B-T052
their	O
expression	B-T045
post-transplant	B-T079
.	O
Evaluating	O
the	O
ligand	O
(	O
chemokine	B-T116
,	O
SDF-1	B-T116
)	O
or	O
its	O
receptor	B-T116
(	O
CXCR4	B-T116
)	O
may	O
serve	O
as	O
potential	B-T080
surrogate markers	B-T080
for	O
assessment	B-T058
of	O
engraftment	B-T039
.	O

Genetic diversity	B-T070
of	O
Taenia saginata	B-T204
(	O
Cestoda	B-T204
:	O
Cyclophyllidea	B-T204
)	O
from	O
Lao People's Democratic Republic	B-T083
and	O
northeastern	B-T083
Thailand	B-T083
based	O
on	O
mitochondrial DNA	B-T114
Taenia saginata	B-T204
is	O
a	O
tapeworm	B-T204
found	O
in	O
cattle	B-T015
worldwide.	O
Analysis	B-T062
of	O
genetic diversity	B-T070
in	O
different	O
geographical populations	B-T081
of	O
T. saginata	B-T204
not	O
only	O
helps	O
to	O
understand	O
the	O
origin	B-T079
,	O
transmission	B-T070
and	O
spread	B-T080
of	O
this	O
organism	B-T001
,	O
but	O
also	O
to	O
evaluate	O
the	O
selection	O
pressures	O
acting	O
on	O
T. saginata	B-T204
and	O
how	O
it	O
is	O
responding	O
to	O
them.	O
However,	O
there	O
are	O
few	O
reports	O
of	O
the	O
genetic variability	B-T070
of	O
T. saginata populations	B-T204
in	O
different	O
regions	B-T083
of	O
the	O
world	B-T098
,	O
including	O
Lao PDR	B-T083
and	O
Thailand	B-T083
.	O
We	O
report	O
the	O
genetic diversity	B-T114
of	O
T. saginata populations	B-T204
in	O
Lao PDR	B-T083
and	O
northeastern	B-T083
Thailand	B-T083
together	O
with	O
sequences	B-T086
of	O
T. saginata	B-T204
from	O
other	O
countries	B-T083
deposited	O
in	O
GenBank	B-T170
.	O
Mitochondrial cox1	B-T028
sequence analysis	B-T059
revealed	O
that	O
15	O
and	O
8	O
haplotypes	B-T032
were	O
identified	O
in	O
30	O
and	O
21	O
T. saginata	B-T204
isolates	O
from	O
Lao PDR	B-T083
and	O
northeastern	B-T083
Thailand	B-T083
,	O
respectively.	O
Fifty-three	O
haplotypes	B-T032
were	O
identified	O
from	O
98	O
sequences	B-T086
.	O
Phylogenetic tree	B-T062
and	O
haplotype network analyses	B-T062
revealed	O
that	O
global	B-T080
isolates	O
of	O
T. saginata	B-T204
were	O
genetically	O
divided	O
into	O
five	O
groups	B-T078
(	O
A	B-T078
,	O
B	B-T078
,	O
C1	B-T078
,	O
C2	B-T078
and	O
D	B-T078
).	O
Taenia saginata	B-T204
isolates	O
from	O
Lao PDR	B-T083
and	O
northeastern	B-T083
Thailand	B-T083
belonged	O
to	O
either	O
Group A	B-T078
or	O
B	B-T078
.	O
Taenia saginata	B-T204
from	O
western	B-T083
Thailand	B-T083
clustered	O
in	O
groups C1	B-T078
,	O
C2	B-T078
and	O
D	B-T078
,	O
and	O
populations	B-T204
from	O
the	O
northeast	B-T083
and	O
western	B-T083
Thailand	B-T083
were	O
found	O
to	O
be	O
genetically	O
distinct.	O
Taenia saginata	B-T204
isolates	O
in	O
Lao PDR	B-T083
and	O
Thailand	B-T083
were	O
also	O
found	O
to	O
be	O
genetically diverse	B-T070
but	O
the	O
degree	O
of	O
genetic differentiation	B-T045
was	O
low.	O
Taenia saginata populations	B-T204
from	O
Lao PDR	B-T083
and	O
northeastern	B-T083
Thailand	B-T083
are	O
genetically	O
distinct	O
from	O
the	O
population	B-T204
in	O
western	B-T083
Thailand	B-T083
and	O
it	O
is	O
proposed	O
that	O
T. saginata	B-T204
has	O
been	O
dispersed	O
by	O
different	O
transmission routes	B-T070
in	O
Southeast Asia	B-T083
.	O

Development	O
of	O
a	O
novel	B-T080
near-infrared	B-T070
fluorescent	B-T070
theranostic	B-T091
combretastain A-4	B-T109
analogue	B-T104
,	O
YK-5-252	B-T121
,	O
to	O
target	O
triple negative breast cancer	B-T191
The	O
treatment	B-T061
of	O
triple negative breast cancer	B-T191
(	O
TNBC	B-T191
)	O
is	O
a	O
significant	O
challenge	O
to	O
cancer research	B-T062
.	O
The	O
lack	O
of	O
hormone receptors	B-T116
limits	O
the	O
treatment	B-T061
options	O
available	O
to	O
patients	B-T101
with	O
this	O
diagnosis	B-T033
,	O
forcing	O
them	O
to	O
endure	O
prolonged	O
radiation	B-T061
and	O
chemotherapy	B-T061
.	O
Anti-angiogenesis	B-T061
is	O
a	O
chemotherapeutic	O
strategy	O
that	O
targets	O
the	O
vasculature	B-T017
of	O
tumors	B-T191
.	O
Combretastatin A-4	B-T109
(	O
CA-4	B-T109
)	O
is	O
a	O
well-known	O
vasculature	B-T017
-	O
disrupting	O
agent,	O
which	O
has	O
been	O
shown	O
to	O
effectively	O
kill	O
a	O
variety	O
of	O
cancers	B-T191
through	O
inhibition	B-T052
of	O
tubulin	B-T116
polymerization	B-T067
.	O
Due	O
to	O
its	O
toxicity	B-T037
,	O
small	O
molecule	O
analogues	B-T104
of	O
CA-4	B-T109
have	O
been	O
sought	O
out.	O
We	O
have	O
designed	O
a	O
novel	B-T080
dual	O
action	O
CA-4	B-T109
prodrug	B-T120
,	O
YK-5-252	B-T121
,	O
which	O
releases	O
the	O
drug	B-T121
through	O
a	O
disulfide bond	B-T044
cleavage	B-T067
mechanism	B-T169
and	O
contains	O
a	O
near-infrared	B-T070
(	O
NIR	B-T070
)	O
fluorophore	B-T121
,	O
which	O
allows	O
fluorescence	B-T070
monitoring	O
of	O
cleavage	B-T067
.	O
This	O
disulfide linkage	B-T044
causes	O
CA-4	B-T109
to	O
become	O
effective	O
only	O
when	O
released	O
by	O
glutathione	B-T116
(	O
GSH	B-T116
)	O
reducing	O
the	O
toxicity	B-T037
of	O
the	O
drug	B-T121
while	O
simultaneously	O
releasing	O
the	O
NIR	B-T070
fluorophore	B-T121
.	O
Therefore	O
the	O
prodrug	B-T120
,	O
YK-5-252	B-T121
,	O
represents	O
a	O
novel	B-T080
CA-4	B-T109
analogue	B-T104
which	O
has	O
reduced	O
toxicity	B-T037
and	O
can	O
be	O
used	O
for	O
theranostics	B-T091
imaging	B-T060
.	O

Epidemiological	B-T169
patterns	B-T082
of	O
bovine	B-T015
besnoitiosis	B-T047
in	O
an	O
endemic	B-T169
beef cattle	B-T015
herd	B-T054
reared	B-T082
under	O
extensive	O
conditions	O
Bovine	B-T015
besnoitiosis	B-T047
is	O
a	O
parasitic disease	B-T047
caused	O
by	O
the	O
protozoan	B-T204
Besnoitia besnoiti	B-T204
.	O
Described	O
many	O
decades	O
ago,	O
recent	O
epidemiological studies	B-T062
reveal	O
its	O
important	O
spread	O
within	O
Europe	B-T083
in	O
the	O
last	O
years	B-T079
.	O
To	O
date,	O
many	O
epidemiological	B-T169
aspects	B-T080
related	O
to	O
life	O
cycle,	O
routes	O
of	O
transmission	B-T046
,	O
incidence rates	B-T081
and	O
associated	O
risk factors	B-T033
are	O
lacking	B-T080
;	O
hence,	O
the	O
establishment	O
of	O
appropriate disease control	B-T058
programmes	B-T170
poses	O
an	O
important	O
challenge.	O
Thus,	O
the	O
aim	O
of	O
the	O
present	O
study	B-T062
was	O
to	O
determine	O
the	O
epidemiological	B-T169
pattern	B-T082
of	O
the	O
disease	B-T047
in	O
an	O
endemic	B-T169
herd	B-T054
reared	B-T082
under	O
extensive	O
conditions	O
(	O
Spanish	B-T083
Pyrenees	B-T083
)	O
by	O
identifying	O
main	O
factors	O
associated with	B-T080
infection	B-T046
and	O
clinical disease	B-T047
dynamics	B-T070
.	O
The	O
study population	B-T062
consisted	O
of	O
276	O
Brown Swiss	B-T015
and	O
Pirenaica	B-T015
adult animals	B-T008
and	O
145	O
calves	B-T015
born	B-T040
and	O
weaned	B-T033
at	O
the	O
farm	B-T082
during	O
the	O
study	B-T062
.	O
Three	O
sampling	B-T078
time frames	B-T079
were	O
used:	O
January	O
2010,	O
September	O
2010	O
and	O
February	O
2011,	O
which	O
allowed	O
us	O
to	O
differentiate	O
two	O
periods	B-T079
designated	O
as	O
mountain	B-T083
and	O
valley	B-T082
periods	B-T079
.	O
The	O
data	B-T078
related	O
to	O
animals	B-T008
(	O
breed	B-T185
,	O
sex	B-T032
and	O
age	B-T032
)	O
and	O
herd	B-T054
management	B-T057
(	O
animal grouping	B-T096
and	O
time	B-T079
in	O
housing	B-T073
)	O
were	O
recorded.	O
The	O
data collection	B-T062
methodology	B-T078
was	O
mainly	O
based	O
on	O
clinical examinations	B-T033
and	O
defining	O
the	O
serological	B-T169
status	B-T080
against	O
bovine	B-T015
besnoitiosis	B-T047
by	O
the	O
immunofluorescent antibody testing	B-T059
of	O
blood samples	B-T031
.	O
The	O
total	O
prevalence	B-T081
among	O
adult animals	B-T008
was	O
38.34%	O
(	O
CI	B-T081
95%:	O
34.53-42.07),	O
with	O
18.54%	O
of	O
seropositive	B-T080
animals	B-T008
showing	O
clinical	O
signs.	O
In	O
regard	O
to	O
the	O
cumulative incidence	B-T081
,	O
34.57%	O
of	O
new	B-T080
infections	B-T046
were	O
detected	B-T033
during	O
the	O
mountain	B-T083
period	B-T079
,	O
in	O
contrast	O
to	O
the	O
24.59%	O
observed	O
in	O
the	O
valley	B-T082
period	B-T079
.	O
The	O
incidence density	B-T081
was	O
0.058	O
and	O
0.061	O
new	B-T080
infections	B-T046
per	O
animal	B-T008
-	O
month	B-T079
for	O
the	O
mountain	B-T083
and	O
valley	B-T082
periods	B-T079
,	O
respectively.	O
According	O
to	O
the	O
seroepidemiological study	B-T062
,	O
the	O
seroconversion	B-T070
probability	B-T081
of	O
B. besnoiti	B-T204
infection	B-T046
was	O
directly	O
associated with	B-T080
the	O
number	B-T081
of	O
seropositive	B-T080
cows	B-T015
with	O
whom	O
an	O
animal	B-T008
had	O
been	O
stabled	O
as	O
well	O
as	O
the	O
housing	B-T073
period	B-T079
duration	B-T079
,	O
supporting	O
horizontal transmission	B-T046
by	O
close	O
contact	O
as	O
one	O
of	O
the	O
most	O
important	O
methods	O
of	O
disease	B-T047
spread	B-T080
.	O
In	O
addition,	O
the	O
risk	B-T078
of	O
developing	O
the	O
clinical course	B-T079
increased	B-T081
with	O
age	B-T032
,	O
and	O
the	O
presence	B-T033
of	O
clinical signs	B-T033
was	O
related	O
to	O
higher	B-T080
antibody responses	B-T038
.	O
Among	O
calves	B-T015
(from	O
3.1	O
to	O
7.1	O
months	B-T079
old	B-T079
)	O
sampled	O
once	O
at	O
weaning	B-T033
,	O
the	O
total	O
seroprevalence	B-T062
was	O
15.17%	O
(	O
CI	B-T081
95%:	O
9.36-21.04),	O
and	O
the	O
chronic	B-T079
stage	B-T079
was	O
observed	O
in	O
three	O
animals	B-T008
,	O
supporting	O
the	O
ability	O
of	O
B. besnoiti	B-T204
to	O
infect	B-T046
and	O
even	O
cause	B-T169
disease	B-T047
in	O
animals	B-T008
less	O
than	O
6	O
months	B-T079
old	B-T079
.	O
Finally,	O
the	O
risk	B-T078
of	O
calf	B-T015
seroconversion	B-T070
was	O
positively	O
related	O
to	O
the	O
serological	B-T169
status	B-T080
of	O
the	O
cows	B-T015
,	O
suggesting	O
postnatal	B-T079
transmission	B-T046
between	O
dams	B-T015
and	O
offspring	B-T015
by	O
contact	O
during	O
the	O
suckling	B-T015
period	B-T079
.	O

A	O
fast small-sample kernel independence test	B-T170
for	O
microbiome	B-T001
community	B-T096
-	O
level association analysis	B-T062
To	O
fully	O
understand	O
the	O
role	B-T077
of	O
microbiome	B-T001
in	O
human	B-T016
health	B-T078
and	O
diseases	B-T047
,	O
researchers	B-T097
are	O
increasingly	O
interested	O
in	O
assessing	B-T052
the	O
relationship	B-T080
between	O
microbiome composition	B-T001
and	O
host	B-T001
genomic	B-T028
data	B-T078
.	O
The	O
dimensionality	B-T082
of	O
the	O
data	B-T078
as	O
well	O
as	O
complex	B-T080
relationships	B-T080
between	O
microbiota	B-T001
and	O
host	B-T001
genomics	B-T028
pose	O
considerable	O
challenges	B-T058
for	O
analysis	B-T062
.	O
In	O
this	O
article,	O
we	O
apply	O
a	O
kernel RV coefficient (KRV) test	B-T170
to	O
evaluate	O
the	O
overall	B-T080
association	B-T080
between	O
host	B-T001
gene expression	B-T045
and	O
microbiome composition	B-T001
.	O
The	O
KRV statistic	B-T170
can	O
capture	O
nonlinear correlations	B-T080
and	O
complex	B-T080
relationships	B-T080
among	O
the	O
individual	O
data types	B-T078
and	O
between	O
gene expression	B-T045
and	O
microbiome composition	B-T001
through	O
measuring	O
general	O
dependency	B-T078
.	O
Testing	B-T169
proceeds	O
via	O
a	O
similar	O
route	O
as	O
existing	O
tests	B-T170
of	O
the	O
generalized	O
RV coefficients	B-T081
and	O
allows	O
for	O
rapid	O
p-value	B-T081
calculation	B-T052
.	O
Strategies	B-T169
to	O
allow	O
adjustment	O
for	O
confounding effects	B-T169
,	O
which	O
is	O
crucial	O
for	O
avoiding	O
misleading	O
results	B-T169
,	O
and	O
to	O
alleviate	O
the	O
problem	B-T033
of	O
selecting	O
the	O
most	O
favorable	O
kernel	B-T170
are	O
considered.	O
Simulation studies	B-T062
show	O
that	O
KRV	B-T081
is	O
useful	O
in	O
testing	B-T169
statistical independence	B-T078
with	O
finite	O
samples	O
given	O
the	O
kernels	B-T170
are	O
appropriately	O
chosen,	O
and	O
can	O
powerfully	O
identify	O
existing	O
associations	B-T080
between	O
microbiome composition	B-T001
and	O
host	B-T001
genomic	B-T028
data	B-T078
while	O
protecting	O
type I	B-T185
error	B-T080
.	O
We	O
apply	O
the	O
KRV	B-T081
to	O
a	O
microbiome	B-T001
study	B-T062
examining	O
the	O
relationship	B-T080
between	O
host	B-T001
transcriptome	B-T086
and	O
microbiome composition	B-T001
within	O
the	O
context	B-T078
of	O
inflammatory bowel disease	B-T047
and	O
are	O
able	O
to	O
derive	O
new	O
biological	O
insights	O
and	O
provide	O
formal	O
inference	O
on	O
prior	O
qualitative observations	B-T080
.	O

An	O
Analysis	B-T062
of	O
Systematic	B-T169
Elemental	B-T196
Changes	B-T081
in	O
Decomposing Bone	B-T023
The	O
aim	B-T078
of	O
this	O
pilot study	B-T062
was	O
to	O
investigate	B-T169
compositional	B-T201
changes	B-T081
in	O
bone	B-T023
during	O
decomposition	B-T067
.	O
Elemental	B-T196
concentrations	B-T081
of	O
barium	B-T196
,	O
calcium	B-T121
,	O
iron	B-T121
,	O
potassium	B-T123
,	O
magnesium	B-T123
,	O
zinc	B-T121
and	O
phosphorus	B-T196
in	O
porcine	B-T015
bone	B-T023
(as	O
an	O
experimental	B-T080
analog	B-T104
for	O
human	B-T016
bone	B-T023
)	O
were	O
analyzed	B-T062
by	O
inductively coupled plasma optical emission spectroscopy	B-T059
(	O
ICP-OES	B-T059
).	O
The	O
samples	B-UnknownType
were	O
taken	O
from	O
porcine	B-T015
bone	B-T023
subjected	B-T169
to	O
shallow burial	B-T052
and	O
surface	B-T029
depositions	B-T169
at	O
28-	O
day	B-T079
intervals	B-T079
for	O
a	O
period	B-T079
of	O
140	O
days	B-T079
.	O
Results	B-T033
indicated	B-T033
that	O
ICP-OES	B-T059
elemental	B-T196
profiling	B-T169
has	O
potential	B-T080
to	O
be	O
developed	B-T080
as	O
a	O
forensic test	B-T059
for	O
determining	B-T080
whether	O
a	O
bone sample	B-UnknownType
originates	O
from	O
the	O
early	B-T079
stages	B-T079
of	O
soft tissue	B-T024
putrefaction	B-T046
.	O
Significant changes	B-T081
in	O
iron	B-T121
,	O
sodium	B-T123
and	O
potassium	B-T123
concentrations	B-T081
were	O
found	B-T033
over	B-T079
140	O
days	B-T079
.	O
These	O
elements	B-T196
are	O
known	B-T080
to	O
be	O
primarily	B-T080
associated with	B-T080
proteins	B-T116
and/or	O
tissue fluids	B-T031
within	O
the	O
bone	B-T023
.	O
Changes	B-T081
in	O
their	O
respective	O
concentrations	B-T081
may	O
therefore	O
be	O
linked	O
to	O
dehydration	B-T033
over	O
time	B-T079
and	O
in	O
turn	O
may	O
be	O
indicative	O
of	O
time	B-T079
since	B-T079
deposition	B-T169
.	O

Chasing	O
ghosts:	O
allopolyploid	O
origin	O
of	O
Oxyria sinensis	B-T002
(	O
Polygonaceae	B-T002
)	O
from	O
its	O
only	O
diploid	B-T032
congener	B-T104
and	O
an	O
unknown	O
ancestor	B-T099
Reconstructing	O
the	O
origin	B-T070
of	O
a	O
polyploid	B-T049
species	B-T185
is	O
particularly	O
challenging	O
when	O
an	O
ancestor	B-T099
has	O
become	O
extinct	B-T070
.	O
Under	O
such	O
circumstances,	O
the	O
extinct	B-T070
donor	O
of	O
a	O
genome	B-T028
found	O
in	O
the	O
polyploid	B-T049
may	O
be	O
treated	O
as	O
a	O
'ghost'	O
species	B-T185
in	O
that	O
its	O
prior	O
existence	B-T081
is	O
recognized	O
through	O
the	O
presence	B-T080
of	O
its	O
genome	B-T028
in	O
the	O
polyploid	B-T049
.	O
In	O
this	O
study,	O
we	O
aimed	O
to	O
determine	O
the	O
polyploid	B-T049
origin	B-T070
of	O
Oxyria sinensis	B-T002
(2n	O
=	O
40)	O
for	O
which	O
only	O
one	O
congeneric	B-T104
species	B-T185
is	O
known,	O
that	O
is	O
diploid	B-T032
O. digyna	B-T002
(2n	O
=	O
14).	O
Genomic in situ hybridization	B-T063
(	O
GISH	B-T063
),	O
transcriptome	B-T059
,	O
phylogenetic	B-T062
and	O
demographic analyses	B-T062
,	O
and	O
ecological niche modelling	B-T170
were	O
conducted	O
for	O
this	O
purpose.	O
GISH	B-T063
revealed	O
that	O
O. sinensis	B-T002
comprised	O
14	O
chromosomes	B-T026
from	O
O. digyna	B-T002
and	O
26	O
chromosomes	B-T026
from	O
an	O
unknown	O
ancestor	B-T099
.	O
Transcriptome analysis	B-T059
indicated	O
that	O
following	O
divergence	B-T082
from	O
O. digyna	B-T002
,	O
involving	O
genome duplication	B-T045
around	O
12	O
million	O
years	O
ago	O
(Ma),	O
a	O
second	O
genome duplication	B-T045
occurred	O
approximately	O
6	O
Ma	O
to	O
give	O
rise	O
to	O
O. sinensis	B-T002
.	O
Oxyria sinensis	B-T002
was	O
shown	O
to	O
contain	O
homologous gene sequences	B-T085
divergent	B-T082
from	O
those	O
present	O
in	O
O. digyna	B-T002
in	O
addition	O
to	O
a	O
set	O
that	O
clustered	B-T028
with	O
those	O
in	O
O. digyna	B-T002
.	O
Coalescent simulations	B-T170
indicated	O
that	O
O. sinensis	B-T002
expanded	O
its	O
distribution	B-T067
approximately	O
6-7	O
Ma,	O
possibly	O
following	O
the	O
second	O
polyploidization event	B-T049
,	O
whereas	O
O. digyna	B-T002
expanded	O
its	O
range	O
much	O
later.	O
It	O
was	O
also	O
indicated	O
that	O
the	O
distributions	B-T067
of	O
both	O
species	B-T185
contracted and re-expanded	B-T169
during	O
the	O
Pleistocene climatic oscillations	B-T070
.	O
Ecological niche modelling	B-T170
similarly	O
suggested	O
that	O
both	O
species	B-T185
experienced	O
changes	O
in	O
their	O
distributional	B-T067
ranges	O
in	O
response	O
to	O
Quaternary climatic changes	B-T070
.	O
The	O
extinction	B-T070
of	O
the	O
unknown	O
'ghost'	O
tetraploid	B-T049
species	B-T185
implicated	O
in	O
the	O
origin	B-T070
of	O
O. sinensis	B-T002
could	O
have	O
resulted	O
from	O
superior	O
adaptation	B-T040
of	O
O. sinensis	B-T002
to	O
repeated climatic changes	B-T070
in	O
the	O
region	O
where	O
it	O
now	O
occurs.	O

Primitive Neuroectodermal Tumors	B-T191
of	O
the	O
Female Genital Tract	B-T023
:	O
A	O
Morphologic	B-T080
,	O
Immunohistochemical	B-T059
,	O
and	O
Molecular	B-T080
Study	B-T062
of	O
19	O
Cases	B-T077
Primary primitive neuroectodermal tumor	B-T191
(	O
PNET	B-T191
)	O
of	O
the	O
female genital tract	B-T023
is	O
rare,	O
and	O
its	O
proper	O
classification	B-T185
remains	O
unclear.	O
The	O
clinical	B-T080
,	O
histologic	B-T169
,	O
and	O
immunophenotypic	B-T059
features	B-T080
as	O
well	O
as	O
EWSR1	B-T028
rearrangement	B-T045
status	O
of	O
19	O
gynecologic	B-T082
PNETs	B-T191
,	O
including	O
10	O
ovarian	B-T023
,	O
8	O
uterine	B-T023
,	O
and	O
1	O
vulvar	B-T023
tumors	B-T191
,	O
are	O
herein	O
reported	B-T170
.	O
Patient	B-T101
age	B-T032
ranged	B-T081
from	O
12	O
to	O
68	O
years	B-T079
,	O
with	O
a	O
median	O
age	B-T032
of	O
20	O
and	O
51	O
years	B-T079
among	O
those	O
with	O
ovarian	B-T023
and	O
uterine	B-T023
PNETs	B-T191
,	O
respectively.	O
Morphologic	B-T080
features	B-T080
of	O
central nervous system	B-T022
(	O
CNS	B-T022
)	O
tumors	B-T191
were	O
seen	O
in	O
15	O
PNETs	B-T191
,	O
including	O
9	O
medulloblastomas	B-T191
,	O
3	O
ependymomas	B-T191
,	O
2	O
medulloepitheliomas	B-T191
,	O
and	O
1	O
glioblastoma	B-T191
,	O
consistent	O
with	O
central PNET	B-T191
.	O
The	O
remaining	O
4	O
PNETs	B-T191
were	O
composed	O
entirely	O
of	O
undifferentiated	B-T080
small round blue cells	B-T025
and	O
were	O
classified	O
as	O
Ewing sarcoma/peripheral PNET	B-T191
.	O
Eight	O
PNETs	B-T191
were	O
associated	O
with	O
another	O
tumor	B-T191
type,	O
including	O
5	O
ovarian	B-T023
mature cystic teratomas	B-T191
,	O
2	O
endometrial low-grade	B-T080
endometrioid carcinomas	B-T191
,	O
and	O
a	O
uterine carcinosarcoma	B-T191
.	O
By	O
immunohistochemistry	B-T060
,	O
17	O
PNETs	B-T191
expressed	O
at	O
least	O
1	O
marker	B-T123
of	O
neuronal differentiation	B-T033
,	O
including	O
synaptophysin	B-T116
,	O
NSE	B-T116
,	O
CD56	B-T116
,	O
S100	B-T116
,	O
and	O
chromogranin	B-T116
in	O
10,	O
8,	O
14,	O
8,	O
and	O
1	O
tumors	B-T191
,	O
respectively.	O
GFAP	B-T116
was	O
positive	O
in	O
4	O
PNETs	B-T191
,	O
all	O
of	O
which	O
were	O
of	O
central	O
type.	O
Membranous	B-T024
CD99	B-T116
and	O
nuclear	B-T082
Fli-1	B-T116
staining	B-T059
was	O
seen	O
in	O
10	O
and	O
16	O
tumors	B-T191
,	O
respectively,	O
and	O
concurrent	O
expression	B-T045
of	O
both	O
markers	B-T123
was	O
seen	O
in	O
both	O
central	B-T191
and	O
Ewing sarcoma/peripheral PNET	B-T191
s.	O
All	O
tumors	B-T191
expressed	B-T045
vimentin	B-T116
,	O
whereas	O
keratin	B-T116
cocktail	O
(	O
CAM5.2	B-T116
,	O
AE1/AE3	B-T116
)	O
staining	B-T059
was	O
only	O
focally	O
present	O
in	O
4	O
PNETs	B-T191
.	O
Fluorescence in situ hybridization	B-T063
was	O
successful	O
in	O
all	O
cases	B-T077
and	O
confirmed	O
EWSR1	B-T028
rearrangement	B-T045
in	O
2	O
of	O
4	O
tumors	B-T191
demonstrating	O
morphologic	B-T080
features	B-T080
of	O
Ewing sarcoma/peripheral PNET	B-T191
and	O
concurrent	O
CD99	B-T116
and	O
Fli-1	B-T116
expression	B-T045
.	O
In	O
conclusion,	O
central	B-T191
and	O
Ewing sarcoma/peripheral PNETs	B-T191
may	O
be	O
encountered	O
in	O
the	O
female genital tract	B-T023
with	O
central PNETs	B-T191
being	O
more	O
common.	O
Central PNETs	B-T191
show	O
a	O
spectrum	B-T077
of	O
morphologic	B-T080
features	B-T080
that	O
overlaps	O
with	O
CNS	B-T022
tumors	B-T191
but	O
lack	O
EWSR1	B-T028
rearrangement	B-T045
s.	O
GFAP	B-T116
expression	B-T045
supports	O
a	O
morphologic	B-T080
impression	O
of	O
central PNET	B-T191
and	O
is	O
absent	O
in	O
Ewing	O
sarcoma/peripheral PNET	B-T191
.	O
Ewing sarcoma/peripheral PNETs	B-T191
lack	O
morphologic	B-T080
features	B-T080
of	O
CNS	B-T022
tumors	B-T191
.	O

Surgical Excision	B-T061
of	O
Heterotopic Ossification	B-T046
Leads	O
to	O
Re-Emergence	B-T079
of	O
Mesenchymal Stem Cell Populations	B-T025
Responsible	O
for	O
Recurrence	B-T067
Trauma-induced	O
heterotopic ossification	B-T046
(	O
HO	B-T046
)	O
occurs	O
after	O
severe	B-T080
musculoskeletal injuries	B-T037
and	O
burns	B-T037
,	O
and	O
presents	O
a	O
significant	B-T078
barrier	O
to	O
patient	B-T101
rehabilitation	B-T061
.	O
Interestingly,	O
the	O
incidence	B-T081
of	O
HO	B-T046
significantly	O
increases	B-T081
with	O
repeated operations	B-T061
and	O
after	O
resection	B-T061
of	O
previous	O
HO	B-T046
.	O
Treatment	B-T061
of	O
established	O
heterotopic ossification	B-T046
is	O
challenging	O
because	O
surgical excision	B-T061
is	O
often	O
incomplete	B-T080
,	O
with	O
evidence of	B-T169
persistent	B-T079
heterotopic bone	B-T033
.	O
As	O
a	O
result,	O
patients	B-T101
may	O
continue	B-T078
to	O
report	O
the	O
signs or symptoms	B-T033
of	O
HO	B-T046
,	O
including	O
chronic pain	B-T184
,	O
nonhealing	B-T033
wounds	B-T037
,	O
and	O
joint restriction	B-T033
.	O
In	O
this	O
study	B-T062
,	O
we	O
designed	O
a	O
model	B-T050
of	O
recurrent	B-T079
HO	B-T046
that	O
occurs	O
after	O
surgical excision	B-T061
of	O
mature	B-T079
HO	B-T046
in	O
a	O
mouse model	B-T050
of	O
hind-limb Achilles' tendon	B-T023
transection	B-T061
with	O
dorsal	B-T082
burn injury	B-T037
.	O
We	O
first	O
demonstrated	O
that	O
key	B-T080
signaling	B-T044
mediators	B-T116
of	O
HO	B-T046
,	O
including	O
bone morphogenetic protein signaling	B-T044
,	O
are	O
diminished	O
in	O
mature bone	B-T024
.	O
However,	O
upon	O
surgical excision	B-T061
,	O
we	O
have	O
noted	O
upregulation	B-T044
of	O
downstream	B-T082
mediators	B-T116
of	O
osteogenic	B-T116
differentiation	B-T169
,	O
including	O
pSMAD 1	B-T116
/	O
5	B-T116
.	O
Additionally,	O
surgical excision	B-T061
resulted	O
in	O
re-emergence	B-T079
of	O
a	O
mesenchymal cell population	B-T025
marked	O
by	O
expression	B-T045
of	O
platelet-derived growth factor receptor-α	B-T116
(	O
PDGFRα	B-T116
)	O
and	O
present	B-T033
in	O
the	O
initial	B-T079
developing	O
HO	B-T046
lesion	B-T033
but	O
absent	B-T169
in	O
mature	B-T079
HO	B-T046
.	O
In	O
the	O
recurrent	B-T079
lesion	B-T033
,	O
these	O
PDGFRα	B-T116
+	O
mesenchymal cells	B-T025
are	O
also	O
highly	O
proliferative	B-T046
,	O
similar	O
to	O
the	O
initial	B-T079
developing	O
HO	B-T046
lesion	B-T033
.	O
These	O
findings	O
indicate	O
that	O
surgical excision	B-T061
of	O
HO	B-T046
results	B-T033
in	O
recurrence	B-T067
through	O
similar	O
mesenchymal cell populations	B-T025
and	O
signaling	B-T044
mechanisms	B-T169
that	O
are	O
present	B-T033
in	O
the	O
initial	B-T079
developing	O
HO	B-T046
lesion	B-T033
.	O
These	O
results	B-T033
are	O
consistent with	B-T078
findings	B-T033
in	O
patients	B-T101
that	O
new	O
foci	B-T082
of	O
ectopic bone	B-T024
can	O
develop	O
in	O
excision	B-T061
sites	B-T029
and	O
are	O
likely	O
related	O
to	O
de novo	B-T078
formation	B-T169
rather	O
than	O
extension	B-T169
of	O
unresected	B-T185
bone	B-T024
.	O
Stem	O
Cells	O
Translational	O
Medicine	O
2017;6:799-806.	O

Extended release	B-T079
of	O
flurbiprofen	B-T109
from	O
tromethamine	B-T109
-	O
buffered	B-T121
HPMC	B-T109
hydrophilic	B-T080
matrix tablets	B-T122
The	O
pH	B-T081
-	O
dependent	B-T169
solubility	B-T080
of	O
a	O
drug	B-T121
can	O
lead	O
to	O
pH	B-T081
-	O
dependent	B-T169
drug release	B-T070
from	O
hydrophilic	B-T080
matrix tablets	B-T122
.	O
Adding	O
buffer salts	B-T121
to	O
the	O
formulation	B-T122
to	O
attempt	B-T051
to	O
mitigate	B-T067
this	O
can	O
impair	B-T169
matrix hydration	B-T067
and	O
negatively	B-T033
impact	B-T080
drug release	B-T070
.	O
An	O
evaluation	B-T058
of	O
the	O
buffering	B-T121
of	O
hydrophilic	B-T080
matrix tablets	B-T122
containing	O
a	O
pH	B-T081
-	O
dependent	B-T169
solubility	B-T080
weak acid drug	B-T121
(	O
flurbiprofen	B-T109
),	O
identified	B-T080
as	O
possessing	B-T078
a	O
deleterious effect	B-T080
on	O
hydroxypropyl methylcellulose	B-T109
(	O
HPMC	B-T109
)	O
solubility	B-T080
,	O
swelling	B-T067
and	O
gelation	B-T067
,	O
with	O
respect	O
to	O
drug dissolution	B-T070
and	O
the	O
characteristics	B-T080
of	O
the	O
hydrophilic	B-T080
matrix gel layer	B-T122
in	O
the	O
presence	B-UnknownType
of	O
tromethamine	B-T109
as	O
a	O
buffer	B-T121
was	O
undertaken.	O
The	O
inclusion	B-T080
of	O
tromethamine	B-T109
as	O
an	O
alkalizing agent	B-T121
afforded	O
pH	B-T081
-	O
independent	B-T169
flurbiprofen	B-T109
release	B-T079
from	O
matrices	B-T167
based	O
on	O
both	O
HPMC 2910 (E series)	B-T109
and	O
2208 (K series)	B-T109
,	O
while	O
concomitantly	B-T079
decreasing	B-T033
the	O
apparent	O
critical effect	B-T080
on	O
dissolution	B-T070
mediated	B-T054
by	O
this	O
drug	B-T121
with	O
respect	O
to	O
the	O
early	O
pseudo-gel layer formation	B-T169
and	O
functionality	B-T169
.	O
Drug release profiles	B-T073
were	O
unaffected	B-T077
by	O
matrix	B-T167
pH-changes	B-T033
resulting	O
from	O
loss	B-T081
of	O
tromethamine	B-T109
over time	B-T079
,	O
suggesting	O
that	O
HPMC	B-T109
inhibited	B-T080
precipitation	B-T070
of	O
drug	B-T121
from	O
supersaturated solution	B-T167
in	O
the	O
hydrated matrix	B-T067
.	O
We	O
propose	O
that	O
facilitation	B-T042
of	O
diffusion-based	B-T070
release	B-T079
of	O
potentially	O
deleterious drugs	B-T121
in	O
hydrophilic	B-T080
matrices	B-T167
may	O
be	O
achieved	O
through	O
judicious	O
selection	O
of	O
a	O
buffering species	B-T121
.	O

The	O
influence	B-T077
of	O
slope	B-T082
on	O
Spartium junceum	B-T002
root system	B-T002
:	O
morphological	B-T080
,	O
anatomical	B-T080
and	O
biomechanical	B-T080
adaptation	B-T038
Root systems	B-T002
have	O
a	O
pivotal	O
role	B-T077
in	O
plant	B-T002
anchorage	B-T052
and	O
their	O
mechanical interactions	B-T169
with	O
the	O
soil	B-T167
may	O
contribute	O
to	O
soil	B-T167
reinforcement	B-T169
and	O
stabilization	B-T080
of	O
slide-prone slopes	B-T082
.	O
In	O
order	O
to	O
understand	O
the	O
responses	B-T032
of	O
root system	B-T002
to	O
mechanical stress	B-T070
induced	B-T169
by	O
slope	B-T082
,	O
samples	B-T167
of	O
Spartium junceum L.	B-T002
,	O
growing	B-T169
in	O
slope	B-T082
and	O
in	O
plane	B-T082
natural conditions	B-T169
,	O
were	O
compared	O
in	O
their	O
morphology	B-T080
,	O
biomechanical properties	B-T080
and	O
anatomical features	B-T082
.	O
Soils	B-T167
sampled	B-T078
in	O
slope	B-T082
and	O
plane	B-T082
revealed	O
similar	O
characteristics	B-T080
,	O
with	O
the	O
exception	B-T077
of	O
organic matter	B-T167
content	B-T077
and	O
penetrometer resistance	B-T169
,	O
both	O
higher	O
in	O
slope	B-T082
.	O
Slope	B-T082
significantly	O
influenced	B-T077
root	B-T002
morphology	B-T080
and	O
in	O
particular	O
the	O
distribution	B-T169
of	O
lateral	B-T082
roots	B-T002
along	O
the	O
soil	B-T167
depth	B-T082
.	O
Indeed,	O
first-order	B-T169
lateral	B-T082
roots	B-T002
of	O
plants	B-T002
growing	B-T169
on	O
slope	B-T082
condition	B-T080
showed	O
an	O
asymmetric	B-T082
distribution	B-T169
between	O
up-	B-T082
and	O
down-slope	B-T082
.	O
Contrarily,	O
this	O
asymmetric	B-T082
distribution	B-T169
was	O
not	O
observed	O
in	O
plants	B-T002
growing	B-T169
in	O
plane	B-T082
.	O
The	O
tensile strength	B-T081
was	O
higher	O
in	O
lateral	B-T082
roots	B-T002
growing	B-T169
up-slope	B-T082
and	O
in	O
plane	B-T082
conditions	B-T080
than	O
in	O
those	O
growing	B-T169
down-slope	B-T082
.	O
Anatomical investigations	B-T062
revealed	O
that,	O
while	O
roots	B-T002
grown	O
up-slope	B-T082
had	O
higher	O
area	B-T082
covered	O
by	O
xylem fibers	B-T002
,	O
the	O
ratio	B-T081
of	O
xylem	B-T002
and	O
phloem fibers	B-T002
to	O
root	B-T002
diameter	B-T081
did	O
not	O
differ	O
among	O
the	O
three	O
conditions	B-T080
,	O
as	O
also,	O
no differences	B-T033
were	O
found	O
for	O
xylem fiber	B-T002
cell wall	B-T026
thickness	B-T080
.	O
Roots	B-T002
growing	B-T169
up-slope	B-T082
were	O
the	O
main	O
contributors	O
to	O
anchorage	B-T052
properties	B-T080
,	O
which	O
included	O
higher	O
strength	B-T081
and	O
higher	O
number	O
of	O
fibers	B-T002
in	O
the	O
xylematic	B-T002
tissues	B-T025
.	O
Results	O
suggested	O
that	O
a	O
combination	O
of	O
root	B-T002
-	O
specific	B-T080
morphological	B-T080
,	O
anatomical	B-T080
and	O
biomechanical	B-T080
traits	B-T032
,	O
determines	O
anchorage	B-T052
functions	B-T169
in	O
slope	B-T082
conditions	B-T080
.	O

Altered	O
expression	B-T045
of	O
the	O
Olr59	B-T028
,	O
Ethe1	B-T028
,	O
and	O
Slc10a2 genes	B-T028
in	O
the	O
liver	B-T023
of	O
F344 rats	B-T015
by	O
neonatal	B-T100
thyroid hormone disruption	B-T037
Many	O
concerns	O
have	O
been	O
expressed	O
regarding	O
the	O
possible	O
adverse	O
effects	O
of	O
thyroid hormone-disrupting	B-T037
chemicals	B-T131
in	O
the	O
environment	B-T082
.	O
The	O
disruption of thyroid hormones	B-T037
in	O
the	O
neonatal period	B-T079
may	O
lead	O
to	O
permanent effects	B-T080
on	O
thyroid hormone	B-T116
homeostasis	B-T038
as	O
well	O
as	O
related	O
developmental disorders	B-T048
,	O
as	O
thyroid hormones	B-T116
are	O
essential	O
for	O
regulating the growth	B-T040
and	O
differentiation of many tissues	B-T033
.	O
To	O
understand	O
the	O
long-term	O
alteration	O
in	O
gene expressions	B-T045
by	O
neonatal	B-T100
administration of thyroid hormone	B-T061
-like	O
chemicals	O
in	O
general,	O
we	O
identified	O
genes whose expression	B-T045
was	O
altered	B-T169
in	O
the	O
liver	B-T023
,	O
an	O
important	O
component	O
of	O
the	O
thyroid hormone	B-T116
axis,	O
by	O
neonatal	B-T100
exposure to	B-T080
triiodothyronine	B-T116
(	O
T3	B-T116
).	O
T3	B-T116
was	O
administered	B-T061
to	O
male F344 rats	B-T015
on	O
postnatal days	B-T079
1,	O
3,	O
and	O
5	O
(week	O
0).	O
At	O
8	O
weeks	O
of	O
age,	O
cDNA microarray analysis	B-T062
was	O
used	O
to	O
identify	O
hepatic	B-T029
genes	B-T028
whose	O
expression	B-T045
was	O
altered	O
by	O
neonatal	B-T100
exposure to	B-T080
T3	B-T116
.	O
Among	O
the	O
up-regulated genes	B-T044
that	O
were	O
identified,	O
the	O
expression	B-T045
of	O
Olr59	B-T028
,	O
Ethe1	B-T028
,	O
and	O
Slc10a2	B-T028
increased	O
specifically	O
in	O
rats	B-T015
neonatally	B-T100
exposed to	B-T080
T3	B-T116
.	O
Interestingly,	O
altered	O
hepatic	B-T029
expression of these genes	B-T045
indeed	O
increased	O
when	O
a	O
hydroxylated polybrominated diphenyl ether	B-T109
(	O
PBDE	B-T109
),	O
OH-BDE42	B-T109
,	O
which	O
is	O
capable	O
of	O
binding to the TR	B-T044
,	O
was	O
given	O
neonatally	B-T100
.	O
Our	O
data	O
demonstrated	O
that	O
neonatal	B-T100
exposure	O
to	O
thyroid hormones	B-T116
could	O
affect	O
the	O
long-term	O
expression of the genes	B-T045
,	O
which	O
could	O
be	O
useful	O
markers	O
for	O
neonatal effects	B-T047
by	O
thyroid hormone	B-T116
-	O
disrupting chemicals	B-T131
.	O
Copyright	O
©	O
2017	O
John	O
Wiley	O
&	O
Sons,	O
Ltd.	O

The	O
Psychometric Costs	B-T060
of	O
Applicants	B-T098
'	O
Faking	B-T055
:	O
Examining	O
Measurement	B-T169
Invariance	O
and	O
Retest Correlations	B-T062
Across	O
Response Conditions	B-T041
This	O
study	O
examines the stability	B-T080
of	O
the	O
response process	B-T041
and	O
the	O
rank-order	B-T062
of	O
respondents	B-T098
responding	B-T041
to	O
3	O
personality scales	B-T170
in	O
4	O
different	O
response conditions	B-T041
.	O
Applicants	B-T098
to	O
the	O
University College of Teacher Education	B-T073
Styria	B-T083
(N	O
=	O
243)	O
completed	O
personality scales	B-T170
as	O
part	O
of	O
their	O
college admission process	B-T170
.	O
Half	O
a	O
year	O
later,	O
they	O
retook	O
the	O
same	O
personality scales	B-T170
in	O
1	O
of	O
3	O
randomly assigned	B-UnknownType
experimental	O
response conditions	B-T041
:	O
honest	B-T055
,	O
faking-good	B-T055
,	O
or	O
reproduce.	O
Longitudinal means	B-T062
and	O
covariance structure analyses	B-T081
showed	O
that	O
applicants	B-T098
'	O
response processes	B-T041
could	O
be	O
partially	O
reproduced	O
after	O
half	O
a	O
year,	O
and	O
respondents	B-T098
seemed	O
to	O
rely	O
on	O
an	O
honest	B-T055
response behavior	B-T041
as	O
a	O
frame of reference	B-T077
.	O
Additionally,	O
applicants	B-T098
'	O
faking behavior	B-T055
and	O
instructed	O
faking	B-T055
(	O
faking-good	B-T055
)	O
caused	O
differences	O
in	O
the	O
latent	B-T080
retest correlations	B-T062
and	O
consistently	O
affected	O
measurement	B-T169
properties.	O
The	O
varying	O
latent	B-T080
retest correlations	B-T062
indicated	B-T033
that	O
faking	B-T055
can	O
distort	B-T169
respondents	B-T098
'	O
rank-order	B-T062
and	O
thus	O
the	O
fairness	B-T080
of	O
subsequent	O
selection decisions	B-T041
,	O
depending	O
on	O
the	O
kind	O
of	O
faking behavior	B-T055
.	O
Instructed	O
faking	B-T055
(	O
faking-good	B-T055
)	O
even	O
affected	O
weak	O
measurement	B-T169
invariance,	O
whereas	O
applicants	B-T098
'	O
faking behavior	B-T055
did	O
not.	O
Consequently,	O
correlations	B-T080
with	O
personality scales	B-T170
-which	O
can	O
be	O
utilized	O
for	O
predictive validity	B-T080
-may	O
be	O
readily	O
interpreted	B-T169
for	O
applicants	B-T098
.	O
Faking behavior	B-T055
also	O
introduced	O
a	O
uniform bias	B-T078
,	O
implying	O
that	O
the	O
classically	O
observed	O
mean raw score	B-T081
differences	O
may	O
not	O
be	O
readily	O
interpreted	B-T169
.	O

Intraspinal meningioma	B-T191
with	O
malignant transformation	B-T191
and	O
distant metastasis	B-T185
Meningioma	B-T191
is	O
typically	O
considered	O
to	O
be	O
a	O
benign tumor	B-T191
.	O
Malignant transformation	B-T191
and	O
metastasis	B-T191
of	O
meningiomas	B-T191
are	O
rare	B-T080
.	O
Moreover,	O
most	O
meningiomas	B-T191
are	O
intracranial	B-T029
,	O
and	O
there	O
are	O
few	O
reports	B-T170
on	O
intraspinal meningiomas	B-T191
.	O
This	O
report	B-T170
aimed	O
to	O
describe	O
the	O
clinical features	B-T201
and	O
pathological	B-T169
findings	B-T033
of	O
a	O
case	B-T077
of	O
malignant transformation	B-T191
and	O
distant metastasis	B-T185
of	O
intraspinal meningioma	B-T191
,	O
with	O
a	O
review of	B-T169
the	O
literature	B-T170
.	O
A	O
44-year-old	O
man	B-T098
with	O
a	O
bilateral	B-T082
lower limb paresis	B-T184
was	O
diagnosed	B-T033
with	O
an	O
intradural extramedullary tumor of the thoracic spine	B-T191
.	O
Primary	B-T080
tumor resection	B-T061
was	O
performed	B-T169
,	O
and	O
the	O
histological findings	B-T033
revealed	O
atypical meningioma	B-T191
.	O
The	O
meningioma	B-T191
recurred	B-T067
2	O
years	B-T079
after	O
the	O
primary	B-T080
surgery	B-T061
,	O
and	O
a	O
second	B-T081
resection	B-T061
was	O
performed	B-T169
,	O
but	O
only	O
partial	B-T081
resection	B-T061
was	O
possible	O
because	O
of	O
decreased	B-T081
motor evoked potential	B-T042
.	O
At	O
age	B-T032
48,	O
the	O
patient's	B-T101
lower limb weakness	B-T184
returned	B-T067
,	O
and	O
a	O
third	B-T081
resection	B-T061
was	O
performed	B-T169
,	O
and	O
the	O
histological finding	B-T033
remained	O
atypical meningioma	B-T191
.	O
At	O
age	B-T032
54,	O
the	O
tumor	B-T191
increased	B-T081
and	O
stereotactic irradiation	B-T061
was	O
performed	B-T169
.	O
At	O
age	B-T032
60,	O
the	O
patient	B-T101
was	O
diagnosed	B-T033
with	O
metastatic tumors	B-T191
of	O
the	O
rib	B-T023
,	O
lumbar vertebra	B-T023
,	O
cervical spine	B-T023
,	O
and	O
sacrum	B-T023
.	O
Biopsy	B-T060
of	O
the	O
rib	B-T023
metastatic tumor	B-T191
was	O
performed	B-T169
,	O
and	O
the	O
histological findings	B-T033
revealed	O
anaplastic meningioma	B-T191
.	O
This	O
case	B-T077
is	O
the	O
first	O
report	B-T170
of	O
an	O
intraspinal meningioma	B-T191
that	O
transformed	B-T191
from	O
atypical	B-T191
to	O
anaplastic meningioma	B-T191
with	O
distant hematogenous metastasis	B-T185
hematogenous	B-T033
metastasis.	O

Epidemiology	B-T091
and	O
risk factors	B-T033
associated with	B-T080
surgical site infection	B-T046
after	O
different	O
types	B-T080
of	O
hepatobiliary and pancreatic surgery	B-T091
Surgical site infection	B-T046
(	O
SSI	B-T046
)	O
is	O
one	O
of	O
the	O
most	O
common	O
healthcare-associated infections	B-T046
(	O
HAIs	B-T046
);	O
however,	O
SSI	B-T046
after	O
hepatobiliary and pancreatic surgery	B-T091
(	O
HBPS	B-T091
)	O
has	O
not	O
been	O
well	O
investigated	B-T169
in	O
a	O
large	B-T081
cohort	B-T098
of	O
patients	B-T101
.	O
This	O
study	O
analyzed	O
the	O
factors	B-T169
associated with	B-T080
SSI	B-T046
following	O
HBPS	B-T091
in	O
Japan	B-T083
,	O
using	O
a	O
Japanese national database	B-T170
.	O
Data	B-T078
on	O
HBPS	B-T091
performed	B-T169
between	O
2012	O
and	O
2014	O
were	O
extracted	B-T062
from	O
a	O
national monitoring system	B-T170
for	O
HAI	B-T046
:	O
The	O
Japan Nosocomial Infections Surveillance	B-T061
.	O
Using	O
multivariate logistic regression	B-T062
,	O
I	O
assessed	B-T052
the	O
factors	B-T169
associated with	B-T080
SSI	B-T046
.	O
The	O
cumulative	B-T080
incidence	B-T081
of	O
SSI	B-T046
following	O
HBPS	B-T091
was	O
15.6%	O
(2873/18,398).	O
The	O
incidence	B-T081
of	O
SSI	B-T046
after	O
pancreatoduodenectomy	B-T061
was	O
28.0%,	O
which	O
was	O
significantly higher	B-T081
than	O
that	O
after	O
liver resection	B-T061
and	O
other	O
types	B-T080
of	O
HBPS	B-T091
(8.8	O
and	O
15.5%,	O
respectively).	O
Among	O
the	O
four	O
traditional	B-T169
risk factors	B-T033
,	O
the	O
American Society of Anesthesiologists	B-T094
score	B-T081
was	O
ineffective	B-T078
for	O
predicting	B-T078
SSI	B-T046
in	O
the	O
final	O
model	B-T170
of	O
all	O
three	O
types	B-T080
of	O
surgery	B-T061
.	O
Additional	O
risk factors	B-T033
were	O
identified	B-T080
,	O
including	O
age	B-T032
and	O
male gender	B-T032
.	O
The	O
incidence	B-T081
of	O
and	O
factors	B-T169
associated with	B-T080
SSI	B-T046
after	O
the	O
three	O
types	B-T080
of	O
HBPS	B-T091
analyzed	O
differed	O
significantly.	O
To	O
accurately	B-T080
compare	B-T052
hospital	B-T073
performance	B-T080
in	O
relation	B-T080
to	O
SSI	B-T046
following	O
HBPS	B-T091
,	O
the	O
operative procedure	B-T061
category	B-T170
in	O
the	O
surveillance system	B-T058
must	O
be	O
divided	B-T169
into	O
three	O
types	B-T080
.	O

Signature	B-T087
of	O
an	O
aggregation	B-T169
-	O
prone	B-T082
conformation	O
of	O
tau	B-T116
The	O
self-assembly	B-T044
of	O
the	O
microtubule	B-T026
associated	B-T080
tau protein	B-T116
into	O
fibrillar cell inclusions	B-T026
is	O
linked	B-T082
to	O
a	O
number	B-T081
of	O
devastating	O
neurodegenerative disorders	B-T047
collectively	O
known	O
as	O
tauopathies	B-T047
.	O
The	O
mechanism	B-T169
by	O
which	O
tau	B-T116
self-assembles	B-T044
into	O
pathological	B-T169
entities	B-T071
is	O
a	O
matter	O
of	O
much	O
debate	B-T052
,	O
largely	B-T081
due to	B-T169
the	O
lack	O
of	O
direct	B-T080
experimental	B-T080
insights	B-T041
into	O
the	O
earliest stages	B-T079
of	O
aggregation	B-T169
.	O
We	O
present	O
pulsed double electron-electron resonance	B-T059
measurements	B-T169
of	O
two	O
key	O
fibril	B-T026
-	O
forming	B-T169
regions	B-T082
of	O
tau	B-T116
,	O
PHF6	B-T116
and	O
PHF6*	B-T116
,	O
in	O
transient	B-T079
as	O
aggregation	B-T169
happens.	O
By	O
monitoring	O
the	O
end-to-end distance	B-T081
distribution	B-T169
of	O
these	O
segments	O
as	O
a	O
function	B-T169
of	O
aggregation	B-T169
time	B-T079
,	O
we	O
show	O
that	O
the	O
PHF6((*))	B-T116
regions	B-T082
dramatically	O
extend	B-T169
to	O
distances	B-T081
commensurate	B-T080
with	O
extended	B-T082
β-strand structures	B-T082
within	O
the	O
earliest stages	B-T079
of	O
aggregation	B-T169
,	O
well	O
before	O
fibril	B-T026
formation	B-T169
.	O
Combined	B-T080
with	O
simulations	B-T062
,	O
our	O
experiments	B-T062
show	O
that	O
the	O
extended	B-T082
β-strand conformational	B-T082
state	B-T169
of	O
PHF6((*))	B-T116
is	O
readily	O
populated	O
under	O
aggregating	B-T169
conditions	B-T080
,	O
constituting	O
a	O
defining	O
signature	B-T087
of	O
aggregation	B-T169
-	O
prone	B-T082
tau	B-T116
,	O
and	O
as	O
such,	O
a	O
possible	O
target	B-T169
for	O
therapeutic interventions	B-T061
.	O

Design	B-T052
,	O
Synthesis	B-T070
,	O
and	O
Cytotoxic	B-T049
Evaluation	B-T058
of	O
Certain	O
7-Chloro-4-(piperazin-1-yl)quinoline	B-T109
Derivatives	B-T104
as	O
VEGFR-II	B-T116
Inhibitors	B-T120
Signaling pathway	B-T044
inhibition	B-T052
of	O
VEGFR-II	B-T116
is	O
visualized	O
as	O
valuable	O
tool	O
in	O
cancer	B-T191
management	B-T058
.	O
In	O
the	O
current study	B-T062
,	O
the	O
synthesis	B-T070
of	O
novel	B-T080
1-4-(7-chloroquinolin-4-yl)piperazin-1-yl)-2-(N-substituted-amino)-ethanone	B-T109
derivatives	B-T104
(	O
4a-t	B-T109
)	O
was	O
achieved	O
through	O
the	O
amination	B-T070
of	O
2-chloro-1-(4-(7-chloroquinolin-4-yl)piperazin-1-yl)ethanone (3)	B-T109
with	O
different	O
secondary amines.	B-T109
The	O
structures	B-T085
of	O
the	O
target	B-T169
compounds	B-T103
were	O
confirmed by	B-T080
IR	B-T059
,	O
(1) H-NMR	B-T060
,	O
(13) C-NMR	B-T060
,	O
HRMS	B-T059
,	O
and	O
microanalysis	B-T059
.	O
Compounds	B-T103
4a-t	B-T109
were	O
subjected	O
to	O
in vitro	B-T080
anticancer	B-T061
screening	B-T058
against	O
human breast cancer	B-T191
(	O
MCF-7	B-T025
)	O
and	O
prostate cancer	B-T191
(	O
PC3	B-T025
)	O
cell lines	B-T025
.	O
The	O
highest	O
cytotoxicty	B-T049
against	O
both	O
cell lines	B-T025
was	O
displayed	O
by	O
2-(4-(4-bromobenzyl)piperazin-1-yl)-1-(4-(7-chloroquinolin-4-yl)piperazin-1-yl)ethanone (4q)	B-T109
,	O
with	O
IC50 values	B-T081
of	O
6.502	O
and	O
11.751	O
μM	O
against	O
MCF-7	B-T025
and	O
PC3 cells	B-T025
,	O
respectively,	O
compared	B-T052
with	O
the	O
standard drug	B-T170
doxorubicin	B-T109
(	O
MCF-7	B-T025
:	O
6.774	O
μM,	O
PC3	B-T025
:	O
7.7316	O
μM).	O
Due	O
to	O
its	O
notable	O
activity	B-T052
toward	O
MCF-7 cells	B-T025
,	O
4q	B-T109
was	O
further	O
evaluated	O
as	O
VEGFR-II	B-T116
inhibitor	B-T120
,	O
showing	O
an	O
IC50	B-T081
of	O
1.38	O
μM	O
compared	O
to	O
sorafenib	B-T109
(0.33	O
μM).	O
The	O
docking	B-T044
study	O
proved	O
that	O
4q	B-T109
has	O
a	O
binding mode	B-T044
akin	O
to	O
that	O
of	O
VEGFR-II	B-T116
inhibitors	B-T120
.	O

The	O
ErbB3 receptor tyrosine kinase	B-T116
negatively	O
regulates	B-T038
Paneth cells	B-T025
by	O
PI3K	B-T116
-	O
dependent	B-T169
suppression	B-T045
of	O
Atoh1	B-T028
Paneth cells	B-T025
(	O
PCs	B-T025
),	O
a	O
secretory population	B-T025
located	O
at	O
the	O
base	O
of	O
the	O
intestinal crypt	B-T023
,	O
support	O
the	O
intestinal	B-T023
stem cells	B-T025
(	O
ISC	B-T025
)	O
with	O
growth factors	B-T116
and	O
participate	O
in	O
innate immunity	B-T032
by	O
releasing	O
antimicrobial peptides	B-T116
,	O
including	O
lysozyme	B-T116
and	O
defensins	B-T116
.	O
PC	B-T025
dysfunction	B-T077
is	O
associated	O
with	O
disorders	B-T047
such	O
as	O
Crohn's disease	B-T047
and	O
necrotizing enterocolitis	B-T047
,	O
but	O
the	O
specific	O
pathways	B-T044
regulating	B-T038
PC	B-T025
development	B-T043
and	O
function	B-T043
are	O
not	O
fully	O
understood.	O
Here	O
we	O
tested	O
the	O
role	O
of	O
the	O
neuregulin receptor ErbB3	B-T116
in	O
control	O
of	O
PC	B-T025
differentiation	B-T043
and	O
the	O
ISC niche	B-T022
.	O
Intestinal	B-T023
epithelial	B-T080
ErbB3	B-T028
knockout	B-T063
caused	O
precocious	B-T079
appearance	B-T080
of	O
PCs	B-T025
as	O
early	O
as	O
postnatal	B-T079
day 7	B-T033
,	O
and	O
substantially	O
increased	B-T081
the	O
number	O
of	O
mature	B-T079
PCs	B-T025
in	O
adult mouse	B-T015
ileum	B-T023
.	O
ErbB3	B-T116
loss	O
had	O
no	O
effect	O
on	O
other	O
secretory lineages	B-T078
,	O
but	O
increased	B-T081
expression	B-T045
of	O
the	O
ISC	B-T025
marker	O
Lgr5	B-T116
.	O
ErbB3	B-T116
-null	O
intestines	B-T023
had	O
elevated	O
levels	O
of	O
the	O
Atoh1	B-T028
transcription factor	B-T116
,	O
which	O
is	O
required	O
for	O
secretory	O
fate	O
determination,	O
while	O
Atoh1(+)	B-T116
cells	B-T025
had	O
reduced	O
ErbB3	B-T028
,	O
suggesting	O
reciprocal	B-T080
negative	B-T033
regulation	B-T038
.	O
ErbB3	B-T116
-null	O
intestinal progenitor cells	B-T025
showed	O
reduced	B-T080
activation	B-T052
of	O
the	O
PI3K-Akt	B-T169
and	O
ERK MAPK pathways	B-T044
.	O
Inhibiting	O
these	O
pathways	B-T044
in	O
HT29 cells	B-T025
increased	B-T081
levels	O
of	O
ATOH1	B-T028
and	O
the	O
PC	B-T025
marker	O
LYZ	B-T028
.	O
Conversely,	O
ErbB3	B-T116
activation	O
suppressed	B-T045
LYZ	B-T028
and	O
ATOH1	B-T028
in	O
a	O
PI3K	B-T116
-	O
dependent	B-T169
manner.	O
Expansion	O
of	O
the	O
PC	B-T025
compartment	O
in	O
ErbB3	B-T116
-null	O
intestines	B-T023
was	O
accompanied	O
with	O
elevated	O
ER stress	B-T049
and	O
inflammation	B-T046
markers	B-T201
,	O
raising	O
the	O
possibility	O
that	O
negative	B-T033
regulation	B-T038
of	O
PCs	B-T025
by	O
ErbB3	B-T116
is	O
necessary	O
to	O
maintain	O
homeostasis	B-T038
.	O
Taken	O
together,	O
our	O
data	B-T078
suggest	O
that	O
ErbB3	B-T116
restricts	O
PC	B-T025
numbers	O
through	O
PI3K	B-T116
-mediated	O
suppression	B-T045
of	O
Atoh1	B-T028
levels	O
leading	O
to	O
inhibition	O
of	O
PC	B-T025
differentiation	B-T043
,	O
with	O
important	O
implications	O
for	O
regulation	B-T043
of	O
the	O
ISC niche	B-T022
.	O

CDF	B-T081
-	O
quantile	B-T081
distributions	B-T081
for	O
modelling	B-T170
random variables	B-T081
on	O
the	O
unit interval	B-T170
This	O
paper	O
introduces	O
a	O
two-parameter	B-T077
family	O
of	O
distributions	B-T081
for	O
modelling	B-T170
random variables	B-T081
on	O
the	O
(0,1)	O
interval	B-T170
by	O
applying	O
the	O
cumulative distribution function	B-T081
of	O
one	O
'	O
parent' distribution	B-T081
to	O
the	O
quantile	B-T081
function	B-T170
of	O
another.	O
Family	O
members	O
have	O
explicit	O
probability density	B-T081
functions	B-T170
,	O
cumulative distribution functions	B-T081
and	O
quantile	B-T081
s	O
in	O
a	O
location	B-T082
parameter	B-T077
and	O
a	O
dispersion	B-T082
parameter	B-T077
.	O
They	O
capture	O
a	O
wide	O
variety	B-T077
of	O
shapes	B-T082
that	O
the	O
beta	B-T081
and	O
Kumaraswamy distributions	B-T081
cannot	B-T033
.	O
They	O
are	O
amenable	B-T080
to	O
likelihood inference	B-T081
,	O
and	O
enable	O
a	O
wide	O
variety	B-T077
of	O
quantile	B-T081
regression models	B-T170
,	O
with	O
predictors	B-T078
for	O
both	O
the	O
location	B-T082
and	O
dispersion	B-T082
parameters	B-T077
.	O
We	O
demonstrate	O
their	O
applicability	O
to	O
psychological	B-T091
research problems	B-T062
and	O
their	O
utility	B-T169
in	O
modelling	B-T170
real data	B-T170
.	O

First	B-T081
and	O
second	B-T081
generation	B-T079
DESs	B-T074
reduce	B-T080
diabetes	B-T047
adverse effect	B-T046
on	O
mortality	B-T081
and	O
re-intervention	B-T061
in	O
multivessel	B-T023
coronary disease	B-T047
:	O
9-	O
Year	B-T079
analysis	B-T062
Diabetes	B-T047
portends	B-T169
an	O
increased	B-T081
risk	B-T078
of	O
adverse	B-T046
early	B-T079
and	O
late	B-T079
outcomes	B-T169
in	O
patients	B-T101
undergoing	O
PCI	B-T061
.	O
In	O
this	O
study	B-T062
,	O
we	O
aimed	O
to	O
investigate	B-T169
if	O
the	O
adverse effect	B-T046
of	O
diabetes mellitus	B-T047
(	O
DM	B-T047
)	O
on	O
early	B-T079
and	O
late	B-T079
PCI	B-T061
outcomes	B-T169
is	O
reduced	B-T080
with	O
drug-eluting	B-T074
(	O
DES	B-T074
)	O
compared	O
to	O
bare-metal (BMS) stents	B-T074
.	O
We	O
reviewed	B-T078
the	O
Mount Sinai Beth Israel Hospital	B-T073
first	B-T081
PCI	B-T061
experience	O
for	O
multivessel	B-T023
coronary artery disease	B-T047
(	O
CAD	B-T047
,	O
1998-2009).	O
Patients	B-T101
were	O
excluded	B-T052
if	O
they	O
had	O
single-vessel CAD	B-T047
,	O
emergency	B-T078
,	O
no	B-T033
stent	B-T074
,	O
prior	B-T079
bypass graft	B-T061
or	O
myocardial infarction	B-T047
<24h.	O
Diabetes	B-T047
-	O
effect	B-T080
was	O
derived	O
from	O
9-	O
year	B-T079
all-cause	O
mortality	B-T081
and	O
re-intervention	B-T061
risk-adjusted hazard ratios	B-T081
[	O
AHR	B-T081
(95%	O
confidence intervals	B-T081
)]	O
for	O
DES	B-T074
(N=2679;	O
48%	O
three-vessel	B-T047
;	O
39%	O
DM	B-T047
)	O
and	O
BMS	B-T074
(N=2651;	O
40%	O
three-vessel	B-T047
;	O
33%	O
DM	B-T047
)	O
and	O
then	O
stratified	O
based	O
on	O
stent	B-T074
(	O
DES	B-T074
/	O
BMS	B-T074
)	O
and	O
vessel disease	B-T047
(	O
two	B-T047
/	O
three	B-T047
).	O
Diabetes	B-T047
-	O
effect	B-T080
on	O
mortality	B-T081
was	O
lower	B-T080
for	O
DES	B-T074
(	O
AHRDM/NoDM	B-T081
=1.41	O
[1.14-1.74])	O
versus	O
BMS	B-T074
(	O
AHRDM/NoDM	B-T081
=1.71	O
[1.50-2.01]),	O
but	O
this	O
was	O
predominantly	B-T080
driven	O
by	O
two-vessel	B-T047
patients	B-T101
.	O
This	O
diabetes	B-T047
effect	B-T080
was	O
similar	O
for	O
first	B-T081
(	O
DES1	B-T074
:	O
AHRDM/NoDM	B-T081
=1.43	O
[1.14-1.79])	O
and	O
second	B-T081
(	O
DES2	B-T074
:	O
AHRDM/NoDM	B-T081
=1.53	O
[0.77-3.07])	O
generation	B-T079
DES	B-T074
.	O
Re-intervention	B-T061
comparisons	B-T052
were	O
similarly	O
increased	B-T081
by	O
diabetes	B-T047
in	O
all	O
sub-cohorts	B-T098
.	O
Our	O
analysis	B-T062
of	O
a	O
large	O
real-world	O
PCI	B-T061
series	O
indicates	O
that	O
diabetes	B-T047
is	O
associated with	B-T080
worse	B-T033
9-	O
year	B-T079
mortality	B-T081
irrespective	B-T077
of	O
stent	B-T074
type	B-T080
,	O
albeit	O
this	O
is	O
mitigated	O
to	O
varying	O
degrees	O
with	O
DES	B-T074
,	O
particularly	O
in	O
DES2	B-T074
and	O
in	O
case	O
of	O
2-vessel disease	B-T047
.	O
A	O
complementary	B-T077
stent	B-T074
-	O
effect	B-T080
analysis	B-T062
confirmed	B-T033
DES	B-T074
-to-	O
BMS	B-T074
and	O
DES2	B-T074
-to-	O
DES1	B-T074
superiority	B-T080
in	O
both	O
diabetics	B-T033
and	O
non-diabetics	B-T033
.	O

Lycopene	B-T109
and	O
risk	B-T078
of	O
cardiovascular diseases	B-T047
:	O
A	O
meta-analysis	B-T062
of	O
observational studies	B-T033
The	O
aim	O
of	O
current	O
meta-analysis	B-T062
was	O
to	O
investigate	B-T169
the	O
relation	O
between	O
lycopene	B-T109
and	O
risk	B-T078
of	O
cardiovascular diseases	B-T047
(	O
CVD	B-T047
).	O
Studies	B-T062
concerning	O
about	O
the	O
association	O
between	O
lycopene	B-T109
and	O
risk	B-T078
of	O
CVD	B-T047
were	O
searched	O
on	O
Pubmed	B-T170
,	O
Embase	B-T170
,	O
and	O
Web of Science	B-T170
from	O
inception	O
to	O
October	O
2016.	O
A	O
total	O
of	O
14	O
eligible studies	B-T062
were	O
identified	B-T080
.	O
A	O
significantly	O
inverse association	B-T077
with	O
a	O
pooled	O
risk ratio	B-T081
(	O
RR	B-T081
)	O
of	O
0.83	O
(95%	O
CI	B-T081
:	O
0.76-0.90)	O
was	O
shown	O
between	O
lycopene	B-T109
exposure	B-T080
and	O
risk	B-T078
of	O
CVD	B-T047
.	O
Findings	B-T033
were	O
similar	O
restricting	O
to	O
dietary	B-T168
studies	B-T062
(	O
RR	B-T081
=	O
0.87,	O
95%	O
CI	B-T081
=	O
0.79-0.96)	O
and	O
biomarker	B-T201
studies	B-T062
(	O
RR	B-T081
=	O
0.74,	O
95%	O
CI	B-T081
=	O
0.	O
62-0.87).	O
Dietary	B-T168
lycopene	B-T109
intake	B-T169
was	O
statistically significant	B-T081
for	O
coronary heart disease	B-T047
(	O
CHD	B-T047
)	O
(	O
RR	B-T081
:	O
0.87;	O
95%	O
CI	B-T081
:	O
0.76-0.98)	O
and	O
stroke	B-T047
(	O
RR	B-T081
:	O
0.83;	O
95%	O
CI	B-T081
:	O
0.69-0.96).The	O
pooled	O
risk estimate	B-T081
was	O
generally	O
similar	O
for	O
lycopene	B-T109
biomarker	B-T201
concentrations,	O
but	O
the	O
association	O
was	O
only	O
statistically significant	B-T081
for	O
stroke	B-T047
(	O
RR	B-T081
:	O
0.65;	O
95%	O
CI	B-T081
:	O
0.42-0.87).	O
Subgroup	B-T185
analyses	B-T062
showed	O
that	O
retrospective	B-T062
and	O
low	O
quality	O
studies	B-T062
were	O
statistically significant	B-T081
sources	O
of	O
heterogeneity	B-T080
.	O
Higher	O
lycopene	B-T109
exposure	B-T080
is	O
inversely associated	B-T077
with	O
a	O
lower	O
risk	B-T078
of	O
CVD	B-T047
.	O
Further	O
well-designed	O
randomized clinical trials	B-T062
are	O
required	O
to	O
assess	O
the	O
role	O
of	O
lycopene	B-T109
on	O
CVD	B-T047
.	O

Bacteria	B-T007
from	O
Wheat	B-T002
and	O
Cucurbit	B-T002
Plant Roots	B-T002
Metabolize	B-T040
PAHs	B-T109
and	O
Aromatic	B-T109
Root	B-T002
Exudates	B-T167
:	O
Implications	B-T078
for	O
Rhizodegradation	B-T069
The	O
chemical interaction	B-T070
between	O
plants	B-T002
and	O
bacteria	B-T007
in	O
the	O
root	B-T002
zone	B-T082
can	O
lead	O
to	O
soil	B-T167
decontamination	B-T169
.	O
Bacteria	B-T007
which	O
degrade	B-T169
PAHs	B-T109
have	O
been	O
isolated	B-T169
from	O
the	O
rhizospheres	B-T070
of	O
plant	B-T002
species	B-T185
with	O
varied	O
biological	B-T080
traits	B-T032
,	O
however,	O
it	O
is	O
not	O
known	O
what	O
phytochemicals	B-T109
promote	O
contaminant	B-T167
degradation	B-T169
.	O
One	O
monocot	B-T002
and	O
two	O
dicotyledon plants	B-T002
were	O
grown	B-T040
in	O
PAH	B-T109
-	O
contaminated	B-T169
soil	B-T167
from	O
a	O
manufactured gas plant	B-T073
(	O
MGP	B-T073
)	O
site	B-T082
.	O
A	O
phytotoxicity assay	B-T059
confirmed	O
greater	O
soil	B-T167
decontamination	B-T169
in	O
rhizospheres	B-T070
when	O
compared	B-T052
to	O
bulk	O
soil	B-T167
controls	B-T169
.	O
Bacteria	B-T007
were	O
isolated	B-T169
from	O
plant roots	B-T002
(	O
rhizobacteria	B-T007
)	O
and	O
selected	B-T052
for	O
growth	B-T040
on	O
anthracene	B-T109
and	O
chrysene	B-T109
on	O
PAH	B-T109
-	O
amended	B-T080
plates	B-T074
.	O
Rhizosphere	B-T070
isolates	B-T123
metabolized	B-T040
3-	O
and	O
4-ring	O
PAHs	B-T109
and	O
PAH	B-T109
catabolic	B-T169
intermediates	O
in	O
liquid incubations	B-T059
.	O
Aromatic	B-T109
root	B-T002
exudate compounds	B-T167
,	O
namely	O
flavonoids	B-T109
and	O
simple phenols	B-T109
,	O
were	O
also	O
substrates	B-T167
for	O
isolated	B-T169
rhizobacteria	B-T007
.	O
In	O
particular,	O
the	O
phenolic compounds	B-T109
-	O
morin	B-T109
,	O
caffeic acid	B-T109
,	O
and	O
protocatechuic acid	B-T109
-	O
appear	O
to	O
be	O
linked	O
to	O
bacterial	B-T007
degradation	B-T169
of	O
3-	O
and	O
4-	O
ring	O
PAHs	B-T109
in	O
the	O
rhizosphere	B-T070
.	O

Joint model imputation	B-T081
to	O
estimate	B-T081
the	O
treatment effect	B-T033
on	O
long-term	B-T079
survival	B-T052
using	O
auxiliary events	B-T051
Clinical trial	B-T062
duration	B-T079
may	O
be	O
a	O
concern	O
in	O
clinical research	B-T062
,	O
especially	O
in	O
cancer trials	B-T062
where	O
the	O
endpoint	B-T201
is	O
overall survival	B-T081
.	O
A	O
surrogate endpoint	B-T080
can	O
be	O
used	O
as	O
an	O
auxiliary variable	B-T080
to	O
analyze	B-T062
the	O
treatment effect	B-T033
earlier.	O
At	O
an	O
early	O
time	O
point,	O
the	O
high	O
number	O
of	O
censored	B-T052
observations	B-T062
can	O
be	O
compensated	B-T080
by	O
the	O
imputation	B-T081
of	O
the	O
unobserved	B-T033
deaths	B-T033
times.	O
We	O
propose	O
to	O
use	O
predictions	B-T078
of	O
the	O
risk	B-T078
of	O
death	B-T040
from	O
a	O
joint model	B-T081
for	O
a	O
recurrent	B-T079
event	B-T051
and	O
a	O
terminal	B-T080
event	B-T051
,	O
which	O
account	O
for	O
disease relapse	B-T047
information	B-T078
.	O
Two	O
imputation methods	B-T081
were	O
compared	B-T052
:	O
sampling	B-T062
from	O
the	O
estimated parametric distribution	B-T081
of	O
the	O
survival time	B-T201
and	O
sampling	B-T062
using	O
its	O
nonparametric estimation	B-T081
.	O
The	O
treatment effect	B-T033
and	O
its	O
standard error	B-T081
were	O
estimated	B-T081
via	O
multiple imputations	B-T081
.	O
The	O
performances	B-T052
of	O
the	O
two	O
methods	B-T170
were	O
compared	B-T052
in	O
terms	O
of	O
bias	B-T078
in	O
the	O
estimates	B-T081
,	O
standard errors	B-T081
,	O
and	O
coverage	B-T052
probability	B-T081
.	O
Both	O
methods	B-T170
were	O
then	O
retrospectively	B-T080
applied	B-T169
to	O
two	O
randomized clinical trials	B-T062
studying	O
the	O
effect	B-T080
of	O
adjuvant	B-T169
chemotherapy	B-T061
in	O
breast cancer	B-T191
patients	B-T101
.	O

The	O
Corneal Epithelial	B-T025
Barrier	B-T033
and	O
Its	O
Developmental	B-T080
Role	O
in	O
Isolating	B-T169
Corneal Epithelial	B-T025
and	O
Conjunctival Cells	B-T025
From	O
One	O
Another	O
During	O
development	B-T169
,	O
the	O
corneal epithelium	B-T024
(	O
CE	B-T024
)	O
and	O
the	O
conjunctiva	B-T023
are	O
derived	O
from	O
the	O
surface ectoderm	B-T018
.	O
Here	O
we	O
have	O
examined	B-T033
how,	O
during	O
development	B-T169
,	O
the	O
cells	B-T025
of	O
these	O
two	O
issues	O
become	O
isolated	B-T169
from	O
each	O
other.	O
Epithelia	B-T024
from	O
the	O
anterior eyes	B-T023
of	O
chicken embryos	B-T018
were	O
labeled	B-T130
with	O
the	O
fluorescent	B-T130
,	O
lipophilic dye	B-T130
,	O
1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate	B-T109
(	O
DiI	B-T109
).	O
DiI	B-T109
was	O
placed	O
on	O
the	O
epithelial surface	B-T026
of	O
the	O
developing	O
anterior eye	B-T023
and	O
its	O
diffusion	B-T070
was	O
monitored	O
by	O
fluorescence microscopy	B-T059
.	O
Concomitant	O
morphologic	B-T080
changes	B-T169
in	O
the	O
surface cells of these epithelial	B-T026
were	O
examined	B-T033
by	O
scanning electron microscopy	B-T059
.	O
Immunofluorescence	B-T059
was	O
used	O
to	O
analyze	O
the	O
expression	B-T045
of	O
cytokeratin K3	B-T116
,	O
ZO-1	B-T116
,	O
N-cadherin	B-T116
and	O
Connexin-43	B-T116
and	O
the	O
function	B-T039
of	O
gap junctions	B-T030
was	O
analyzed	B-T062
using	O
a	O
cut-loading	B-T081
with	O
the	O
fluorescent dye	B-T130
rhodamine-dextran	B-T109
.	O
Prior	O
to	O
embryonic	B-T042
day	B-T079
8	O
(	O
E	B-T042
8),	O
DiI	B-T109
placed	O
on	O
the	O
surface	B-T082
of	O
the	O
CE	B-T024
spreads	B-T080
throughout	O
all	O
the	O
epithelial cells	B-T025
of	O
the	O
anterior eye	B-T023
.	O
When	O
older eyes	B-T023
were	O
similarly	O
labeled	B-T130
,	O
dye	B-T130
diffusion	B-T070
was	O
restricted	B-T169
to	O
the	O
CE	B-T024
.	O
Similarly,	O
diffusion	B-T070
of	O
DiI	B-T109
placed	O
on	O
the	O
conjunctival	B-T023
surface	B-T082
after	O
E	B-T042
8	O
was	O
restricted	B-T169
to	O
the	O
conjunctiva	B-T023
.	O
Scanning electron microscopy	B-T059
showed	O
that	O
developmentally	B-T169
(1)	O
physical separations	B-T033
progressively	B-T169
form	O
between	O
the	O
cells	B-T025
of	O
the	O
CE	B-T024
and	O
those	O
of	O
the	O
conjunctiva	B-T023
,	O
and	O
(2)	O
by	O
E	B-T042
8	O
these	O
separations	B-T169
form	O
a	O
ring	B-T023
that	O
completely	O
encompasses	O
the	O
cornea	B-T023
.	O
The	O
functional	B-T169
restriction	B-T169
of	O
gap junctions	B-T030
between	O
these	O
tissues	B-T024
did	O
not	O
occur	B-T052
until	O
E	B-T042
14.	O
During	O
ocular development	B-T042
,	O
a	O
barrier	B-T033
to	O
the	O
diffusion	B-T070
of	O
DiI	B-T109
forms	O
between	O
the	O
contiguous	B-T082
CE	B-T024
and	O
conjunctiva	B-T023
prior	O
to	O
the	O
differential	B-T080
expression	B-T045
of	O
gap junctions	B-T030
within	O
these	O
tissues	B-T024
.	O

Longitudinal study	B-T062
of	O
bovine	B-T015
rotavirus group A	B-T005
in	O
newborn	B-T008
calves	B-T015
from	O
vaccinated	B-T033
and	O
unvaccinated	B-T033
dairy herds	B-T015
Reports	O
of	O
rotavirus	B-T005
excretion	B-T031
in	O
calves	B-T015
usually	O
result	O
from	O
cross-sectional studies	B-T062
,	O
and	O
in	O
face	O
of	O
the	O
conflicting	O
results	O
regarding	O
protection	B-T061
of	O
calves	B-T015
born	B-T040
to	O
vaccinated	B-T033
dams	B-T015
against	O
diarrhea	B-T184
,	O
the	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
rotavirus	B-T005
excretion	B-T031
in	O
dairy calves	B-T015
born	O
to	O
vaccinated	B-T033
or	O
unvaccinated	B-T033
dams	B-T015
,	O
to	O
identify	O
the	O
genotypes	B-T032
of	O
bovine	B-T015
rotavirus group A	B-T005
(	O
RVA	B-T005
)	O
strains	B-T001
isolated	O
from	O
these	O
animals	B-T015
as	O
well	O
as	O
to	O
investigate	O
characteristics	O
of	O
the	O
disease	B-T047
in	O
naturally	B-T169
occurring	B-T052
circumstances	O
throughout	O
the	O
first month of life	B-T033
.	O
Five	O
hundred	O
fifty-two	O
fecal samples	B-T031
were	O
taken	O
from	O
56	O
calves	B-T015
,	O
28	O
from	O
each	O
farm	B-T082
and,	O
in	O
the	O
vaccinated	B-T033
herd	B-T015
,	O
11/281	O
samples	B-T031
(3.91%)	O
taken	O
from	O
six	O
different	O
calves	B-T015
tested positive	B-T033
for	O
RVA	B-T005
while	O
in	O
the	O
unvaccinated	B-T033
herd,	O
3/271	O
samples	B-T031
(1.11%)	O
taken	O
from	O
3	O
different	O
calves	B-T015
tested positive	B-T033
.	O
The	O
genotyping	B-T059
of	O
the	O
VP7 genes	B-T028
showed	O
91.2%	O
nucleotide sequence	B-T086
identity	O
to	O
G6 genotype	B-T032
(	O
NCDV strain	B-T001
),	O
and	O
for	O
the	O
VP4 gene	B-T028
,	O
strains	B-T001
from	O
the	O
vaccinated	B-T033
herd	O
were	O
96.6%	O
related	O
to	O
B223 strain	B-T001
,	O
while	O
strains	B-T001
from	O
the	O
unvaccinated	B-T033
herd	B-T015
were	O
88%	O
related	O
to	O
P[5] genotype	B-T032
(	O
UK strain	B-T001
).	O
Genotypes	B-T032
found	O
in	O
this	O
study	O
were	O
G6P[11]	B-T032
in	O
the	O
vaccinated	B-T033
herd	B-T015
and	O
G6P[5]	B-T032
in	O
the	O
unvaccinated	B-T033
herd	B-T015
.	O
All	O
calves	B-T015
infected	B-T033
with	O
rotavirus	B-T005
presented	O
an	O
episode	O
of	O
diarrhea	B-T184
in	O
the	O
first	O
month	O
of	O
life,	O
and	O
the	O
discrepancy	O
between	O
the	O
genotypes	B-T032
found	O
in	O
the	O
commercial vaccine	B-T121
(	O
G6P[1]	B-T032
and	O
G10P[11]	B-T032
)	O
and	O
the	O
rotavirus	B-T005
strains	B-T001
circulating	O
in	O
both	O
vaccinated	B-T033
and	O
unvaccinated	B-T033
herds	B-T015
show	O
the	O
importance	O
of	O
keeping	O
constant	B-T080
surveillance	B-T061
in	O
order	O
to	O
avoid	O
potential	B-T080
causes	B-T169
of	O
vaccination	B-T061
failure	B-T033
.	O

Gene	B-T028
-based	O
genome-wide association study	B-T063
identified	B-T080
19p13.3	B-T026
for	O
lean body mass	B-T201
Lean body mass	B-T201
(	O
LBM	B-T201
)	O
is	O
a	O
complex	O
trait	B-T032
for	O
human	B-T016
health	B-T078
.	O
To	O
identify	O
genomic loci	B-T028
underlying	O
LBM	B-T201
,	O
we	O
performed	O
a	O
gene	B-T028
-based	O
genome-wide association study	B-T063
of	O
lean mass index	B-T081
(	O
LMI	B-T081
)	O
in	O
1000	O
unrelated	B-T033
Caucasian	B-T098
subjects	B-T098
,	O
and	O
replicated	B-T169
in	O
2283	O
unrelated	B-T033
Caucasians	B-T098
subjects	B-T098
.	O
Gene	B-T028
-based	O
association analyses	B-T063
highlighted	O
the	O
significant	O
associations	B-T080
of	O
three	O
genes	B-T028
UQCR	B-T028
,	O
TCF3	B-T028
and	O
MBD3	B-T028
in	O
one	O
single	B-T081
locus	B-T028
19p13.3	B-T026
(	O
discovery	B-T080
p	O
=	O
6.10	O
×	O
10(-5),	O
1.65	O
×	O
10(-4)	O
and	O
1.10	O
×	O
10(-4);	O
replication	B-T080
p	O
=	O
2.21	O
×	O
10(-3),	O
1.84	O
×	O
10(-3)	O
and	O
6.95	O
×	O
10(-3);	O
combined	O
p	O
=	O
2.26	O
×	O
10(-6),	O
4.86	O
×	O
10(-6)	O
and	O
1.15	O
×	O
10(-5),	O
respectively).	O
These	O
results,	O
together	O
with	O
the	O
known	O
functional	B-T169
relevance	B-T080
of	O
the	O
three	O
genes	B-T028
to	O
LMI	B-T081
,	O
suggested	O
that	O
the	O
19p13.3	B-T026
region	B-T082
containing	O
UQCR	B-T028
,	O
TCF3	B-T028
and	O
MBD3 genes	B-T028
was	O
a	O
novel	O
locus	B-T028
underlying	O
lean mass	B-T201
variation	B-T070
.	O

Basal	B-T082
ryanodine receptor activity	B-T044
suppresses	B-T169
autophagic	B-T026
flux	B-T070
The	O
inositol 1,4,5-trisphosphate receptors	B-T116
(	O
IP3Rs	B-T116
)	O
and	O
intracellular Ca(2+) signaling	B-T043
are	O
critically	B-T080
involved	B-T169
in	O
regulating	B-T038
different	B-T080
steps	B-T077
of	O
autophagy	B-T043
,	O
a	O
lysosomal	B-T026
degradation pathway	B-T077
.	O
The	O
ryanodine receptors	B-T116
(	O
RyR	B-T116
),	O
intracellular Ca(2+)-release channels	B-T044
mainly	O
expressed	B-T045
in	O
excitable	B-T033
cell types	B-T170
including	B-T169
muscle	B-T024
and	O
neurons	B-T025
,	O
have	O
however	O
not	O
yet	O
been	O
extensively	B-T080
studied	B-T062
in	O
relation	O
to	O
autophagy	B-T043
.	O
Yet,	O
aberrant	B-T080
expression	B-T045
and	O
excessive	B-T080
activity	B-T044
of	O
RyRs	B-T116
in	O
these	O
tissues	B-T024
has	O
been	O
implicated	B-T033
in	O
the	O
onset of	B-T080
several	B-T081
diseases	B-T047
including	B-T169
Alzheimer's disease	B-T047
,	O
where	O
impaired	B-T169
autophagy	B-T043
regulation	B-T038
contributes	B-T052
to	O
the	O
pathology	B-T169
.	O
In	O
this	O
study	B-T062
,	O
we	O
determined	B-T059
whether	O
pharmacological	B-T038
RyR	B-T116
inhibition	B-T052
could	O
modulate	B-T082
autophagic	B-T026
flux	B-T070
in	O
ectopic	B-T082
RyR	B-T116
-	O
expressing	B-T045
models	B-T170
,	O
like	O
HEK293 cells	B-T025
and	O
in	O
cell types	B-T170
that	O
endogenously	B-T169
express	B-T045
RyR	B-T116
s,	O
like	O
C2C12 myoblasts	B-T025
and	O
primary	B-T080
hippocampal	B-T023
neurons	B-T025
.	O
Importantly	B-T080
,	O
RyR3	B-T116
overexpression	B-T045
in	O
HEK293 cells	B-T025
impaired	B-T169
the	O
autophagic	B-T026
flux	B-T070
.	O
Conversely,	O
in	O
all	O
cell	B-T025
models	B-T170
tested	B-T169
,	O
pharmacological	B-T038
inhibition	B-T052
of	O
endogenous	B-T169
or	O
ectopically	B-T082
expressed	B-T045
RyRs	B-T116
,	O
using	O
dantrolene	B-T109
or	O
ryanodine	B-T109
,	O
augmented	B-T081
autophagic	B-T026
flux	B-T070
by	O
increasing	B-T169
lysosomal	B-T026
turn-over	B-T044
(	O
number	B-T081
of	O
autophagosomes	B-T026
and	O
autolysosomes	B-T026
measured	B-T080
as	O
mCherry	B-T116
-	O
LC3 punctae	B-T116
/	O
cell	B-T025
increased	B-T081
from	O
70.37±7.81	O
in	O
control	B-T096
HEK RyR3 cells	B-T025
to	O
111.18±7.72	O
and	O
98.14±7.31	O
after	O
dantrolene	B-T109
and	O
ryanodine	B-T109
treatments	B-T061
,	O
respectively).	O
Moreover,	O
in	O
differentiated	B-T043
C2C12 cells	B-T025
,	O
transmission electron microscopy	B-T059
demonstrated	B-T080
that	O
dantrolene	B-T109
treatment	B-T061
decreased	B-T081
the	O
number	B-T081
of	O
early	O
autophagic	B-T026
vacuoles	B-T026
from	O
5.9±2.97	O
to	O
1.8±1.03	O
per	O
cellular	B-T025
cross section	B-T082
.	O
The	O
modulation	B-UnknownType
of	O
the	O
autophagic	B-T026
flux	B-T070
could	O
be	O
linked	O
to	O
the	O
functional	B-T169
inhibition	B-T052
of	O
RyR channels	B-T116
as	O
both	O
RyR	B-T116
inhibitors	B-T120
efficiently	B-T080
diminished	O
the	O
number	B-T081
of	O
cells	B-T025
showing	O
spontaneous	B-T169
RyR3	B-T116
activity	B-T044
in	O
the	O
HEK293 cell	B-T025
model	B-T170
(from	O
41.14%±2.12	O
in	O
control	B-T096
cells	B-T025
to	O
18.70%±2.25	O
and	O
9.74%±2.67	O
after	O
dantrolene	B-T109
and	O
ryanodine	B-T109
treatments	B-T061
,	O
respectively).	O
In	O
conclusion	B-T078
,	O
basal	B-T082
RyR	B-T116
-mediated	O
Ca(2+)-release events	B-T044
suppress	B-T169
autophagic	B-T026
flux	B-T070
at	O
the	O
level	B-T080
of	O
the	O
lysosomes	B-T026
.	O

Fluoride	B-T121
concentration	B-T081
in	O
saliva	B-T031
and	O
biofilm fluid	B-T007
following	O
the	O
application	B-T058
of	O
three	O
fluoride varnishes	B-T122
Most	O
of	O
the	O
commercially	O
available	O
fluoride varnishes	B-T122
(	O
FV	B-T122
)	O
have	O
not	O
been	O
evaluated	B-T058
for	O
their	O
cariostatic properties	B-T039
.	O
Consequently	B-T033
,	O
the	O
aim	B-T078
of	O
this	O
in vivo	B-T082
study	B-T062
was	O
to	O
investigate	B-T058
intra	B-T082
-	O
oral	B-T082
fluoride	B-T121
retention	B-T169
and	O
clearance patterns	B-T033
from	O
three	O
different	O
FV	B-T122
.	O
Eighteen	O
subjects	B-T098
(7-11	O
years	B-T079
)	O
participated	O
in	O
a	O
laboratory	B-T073
analyst	B-T097
-	O
blinded	B-T062
,	O
randomized	B-T062
,	O
crossover study	B-T062
comparing	B-T052
the	O
ability	B-T032
of	O
5%	O
sodium fluoride varnishes	B-T122
(	O
CavityShield-CS	B-T122
,	O
Enamel Pro-EP	B-T122
,	O
Vanish-V	B-T122
)	O
to	O
enhance	B-T052
fluoride	B-T121
concentrations	B-T081
in	O
biofilm fluid	B-T007
,	O
centrifuged	B-T031
and	O
whole	B-T081
saliva	B-T031
over	O
a	O
period	B-T079
of	O
48h	O
after	O
a	O
single	O
FV	B-T122
application.	O
Similar	O
fluoride	B-T121
concentration	B-T081
×	O
time patterns	B-T079
were	O
noted	B-T170
for	O
all	O
investigated	B-T080
FV	B-T122
and	O
studied	B-T062
variables	B-T080
,	O
with	O
the	O
highest	B-T080
fluoride	B-T121
concentrations	B-T081
observed	B-T169
for	O
the	O
first	O
biological sample	B-T077
collected	B-T169
after	O
FV	B-T122
application	O
(30min).	O
Mean±SE	B-T081
(	O
area under fluoride clearance curve	B-T081
)	O
values	B-T080
were	O
(μg	O
F/g	O
or	O
ml×min):	O
biofilm fluid	B-T007
-	O
CS	B-T122
(472±191),	O
EP	B-T122
(423±75),	O
V	B-T122
(1264±279);	O
centrifuged	B-T031
saliva	B-T031
-	O
CS	B-T122
(42±7),	O
EP	B-T122
(19±3),	O
V	B-T122
(41±8);	O
whole	B-T081
saliva	B-T031
-	O
CS	B-T122
(68±11),	O
EP	B-T122
(64±10),	O
V	B-T122
(60±7).	O
V	B-T122
delivered	O
more	O
fluoride	B-T121
to	O
biofilm fluid	B-T007
than	O
CS	B-T122
(p=0.0116)	O
and	O
EP	B-T122
(p=0.0065),	O
which	O
did	O
not	O
differ	O
(p=0.27).	O
For	O
centrifuged	B-T031
saliva	B-T031
,	O
CS	B-T122
and	O
V	B-T122
were	O
not	O
significantly	B-T078
different	O
(p=0.86),	O
but	O
resulted	B-T169
in	O
higher	B-T080
fluoride	B-T121
retention	B-T169
than	O
EP	B-T122
(p<0.0008).	O
No	O
significant	B-T078
differences	O
among	O
FV	B-T122
were	O
observed	B-T169
for	O
whole	B-T081
saliva	B-T031
(p=0.79).	O
The	O
present	B-T033
study	B-T062
has	O
shown	O
that	O
FV	B-T122
vary	O
in	O
their	O
ability	B-T032
to	O
deliver	O
fluoride	B-T121
intra	B-T082
-	O
orally	B-T082
potentially	B-T080
related	B-T080
to	O
formulation	O
differences	B-T080
.	O
To	O
what	O
extent	B-T082
the	O
present	B-T033
findings	B-T033
relate	B-T080
to	O
clinical efficacy	B-T080
remains,	O
however,	O
to	O
be	O
determined	B-T059
.	O
Clinical research	B-T062
that	O
investigates	B-T058
fluoride	B-T121
release	B-T080
patterns	B-T082
into	O
saliva	B-T031
and	O
biofilm fluid	B-T007
from	O
different	O
FV products	B-T122
is	O
insufficient	B-T080
.	O
More	O
research	B-T062
is	O
needed	O
to	O
investigate	B-T058
different	O
FV formulations	B-T122
for	O
their	O
efficacy	B-T080
in	O
order	O
to	O
help	O
clinicians	B-T097
make	O
better	B-T080
evidence	B-T078
based	O
treatment	B-T169
choices.	O

The	O
prognostic value	B-T201
of	O
extranodal extension	B-T033
in	O
human papillomavirus	B-T005
-associated	O
oropharyngeal squamous cell carcinoma	B-T191
Extranodal (or extracapsular) extension	B-T033
(	O
ENE	B-T033
)	O
is	O
an	O
adverse prognostic factor	B-T201
in	O
patients	B-T101
with	O
head and neck cancers	B-T191
who	O
undergo	O
primary surgery	B-T058
.	O
However,	O
the	O
significance	O
of	O
ENE	B-T033
in	O
human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC)	B-T191
is	O
not	O
well	O
established,	O
and	O
single-institution	B-T093
studies	B-T062
have	O
not established	B-T080
that	O
ENE	B-T033
predicts	B-T078
inferior	B-T082
outcome	B-T169
.	O
The	O
authors	O
investigated	O
the	O
prognostic value	B-T201
of	O
ENE	B-T033
in	O
HPV	B-T005
-	O
positive	B-T033
patients	B-T101
who	O
underwent	O
primary surgery	B-T058
and	O
whether	O
adjuvant chemoradiation	B-T061
improved	O
overall survival	B-T081
(	O
OS	B-T081
)	O
compared	B-T052
with	O
radiation alone	B-T070
in	O
ENE	B-T033
-	O
positive	B-T033
patients	B-T101
.	O
Patients	B-T101
who	O
underwent	O
primary surgery	B-T058
for	O
pathologic T1	B-T169
(	O
pT1	B-T169
)	O
through	O
pT4 tumors	B-T191
,	O
pathologic N1	B-T169
(	O
pN1	B-T169
)	O
through	O
pN3 lymph node	B-T023
status	B-T080
,	O
HPV-positive OPSCC	B-T191
were	O
identified	B-T080
in	O
the	O
National Cancer Data Base	B-T170
from	O
2010	O
through	O
2012.	O
Features	B-T080
associated with	B-T080
ENE	B-T033
were	O
analyzed	B-T062
.	O
Univariable and multivariable Cox regression analyses	B-T170
identified	B-T080
predictors	B-T078
of	O
OS	B-T081
.	O
The	O
effect	B-T080
of	O
adjuvant treatment	B-T061
on	O
OS	B-T081
in	O
ENE	B-T033
-	O
positive	B-T033
cohort	B-T081
was	O
also	O
evaluated	B-T058
.	O
In	O
total,	O
1043	O
patients	B-T101
met	O
inclusion criteria	B-T080
,	O
among	O
whom	O
43.5%	O
were	O
ENE	B-T033
-	O
positive	B-T033
.	O
Of	O
the	O
ENE	B-T033
-	O
positive	B-T033
patients	B-T101
who	O
had	O
treatment	B-T061
details	O
available,	O
72%	O
received	B-T080
concurrent chemoradiotherapy	B-T061
,	O
16%	O
received	B-T080
radiotherapy	B-T061
,	O
and	O
12%	O
received	B-T080
no	B-T080
adjuvant treatment	B-T061
.	O
After	O
a	O
median	B-T081
follow-up	B-T058
of	O
28.4	O
months	B-T079
,	O
ENE	B-T033
was	O
associated with	B-T080
worse	B-T033
3-	O
year	B-T079
OS	B-T081
(89.3%	O
vs	O
93.6%;	O
P	O
=	O
.01).	O
On	O
multivariable analysis	B-T170
that	O
included	B-T169
involved	O
lymph nodes	B-T023
,	O
only	O
ENE	B-T033
,	O
lymphovascular invasion	B-T033
,	O
pT3/pT4 tumors	B-T191
,	O
and	O
Charlson-Deyo score	B-T081
were	O
associated with	B-T080
worse	B-T033
OS	B-T081
.	O
Among	O
ENE	B-T033
-	O
positive	B-T033
patients	B-T101
,	O
there	O
was	O
no difference	B-T033
in	O
3-	O
year	B-T079
OS	B-T081
between	O
those	O
who	O
received	B-T080
adjuvant concurrent chemoradiotherapy	B-T061
versus	O
radiotherapy alone	B-T061
(89.6%	O
vs	O
89.3%,	O
respectively;	O
P	O
=	O
.55).	O
Propensity score	B-T081
-	O
matched comparison	B-T081
revealed	B-T080
similar	O
results	B-T169
.	O
ENE	B-T033
is	O
associated with	B-T080
inferior	B-T082
OS	B-T081
in	O
patients	B-T101
with	O
HPV-positive OPSCC	B-T191
.	O
However,	O
OS	B-T081
was	O
not better	B-T033
with	O
adjuvant chemoradiotherapy	B-T061
compared	B-T052
with	O
radiotherapy alone	B-T061
in	O
ENE	B-T033
-	O
positive	B-T033
patients	B-T101
.	O
The	O
current findings support	B-T081
the	O
need	O
for	O
prospective studies	B-T062
of	O
adjuvant chemoradiation	B-T061
in	O
HPV	B-T005
-	O
positive	B-T033
patients	B-T101
with	O
ENE	B-T033
.	O
Cancer	O
2017.	O
©	O
2017	O
American	O
Cancer	O
Society.	O

Psychological Distress	B-T048
Is	O
More	O
Prevalent	O
in	O
Fertile	B-T040
Age	B-T032
and	O
Premenopausal	B-T039
Women	B-T098
with	O
PCOS	B-T047
Symptoms	B-T184
-15-yr	O
Follow-up	B-T058
Polycystic ovary syndrome	B-T047
(	O
PCOS	B-T047
)	O
is	O
associated	O
with	O
increased	O
psychological distress	B-T048
;	O
obesity	B-T047
and	O
hyperandrogenism	B-T047
being	O
suggested	O
as	O
key	O
promoters	B-T052
.	O
To	O
investigate	B-T169
the	O
prevalence	B-T081
of	O
anxiety	B-T048
/	O
depression	B-T048
and	O
their	O
coexistence	O
in	O
women	B-T098
with	O
PCOS	B-T047
/	O
PCOS	B-T047
symptoms	B-T184
at	O
age	B-T032
s	O
31	O
and	O
46.	O
The	O
roles	O
of	O
obesity	B-T047
,	O
hyperandrogenism	B-T047
and	O
awareness	B-T041
of	O
PCOS	B-T047
on	O
psychological distress	B-T048
were	O
also	O
assessed	B-T052
.	O
Population based follow-up	B-T062
.	O
Northern Finland	B-T083
Birth Cohort	B-T081
1966	O
with	O
15-	O
year	B-T079
follow-up	B-T058
.	O
At	O
age	B-T032
31	O
a	O
questionnaire-based screening	B-T062
for	O
oligoamenorrhea	B-T046
(	O
OA	B-T046
)	O
and	O
hirsutism	B-T047
(	O
H	B-T047
):	O
2188	O
asymptomatic	B-T033
(	O
controls	B-T096
),	O
331	O
OA	B-T046
,	O
323	O
H	B-T047
,	O
125	O
OA	B-T046
+	O
H	B-T047
(	O
PCOS	B-T047
).	O
46	O
year	B-T079
old	O
follow-up	B-T058
:	O
1576	O
controls	B-T096
,	O
239	O
OA	B-T046
,	O
231	O
H	B-T047
and	O
85	O
PCOS	B-T047
.	O
Questionnaire-based screening	B-T062
for	O
anxiety	B-T048
and	O
depression symptoms	B-T184
(	O
Hopkins Symptom Checklist-25	B-T170
)	O
and	O
previously	O
diagnosed	B-T033
/	O
treated	B-T033
depression	B-T048
at	O
age	B-T032
31	O
and	O
46.	O
BMI	B-T201
,	O
serum testosterone	B-T059
/	O
free androgen index	B-T059
(	O
FAI	B-T059
)	O
and	O
awareness	B-T041
of	O
polycystic ovaries	B-T047
/	O
PCOS	B-T047
on	O
psychological distress	B-T048
were	O
also	O
assessed	B-T052
.	O
Population-based prevalence	B-T081
of	O
anxiety	B-T048
and/or	O
depression	B-T048
in	O
women	B-T098
with	O
PCOS	B-T047
/	O
PCOS	B-T047
symptoms	B-T184
at	O
age	B-T032
s	O
31	O
and	O
46.	O
Anxiety	B-T048
and/or	O
depression symptoms	B-T184
,	O
their	O
coexistence	O
and	O
rate	O
of	O
depression	B-T048
were	O
increased	O
at	O
age	B-T032
31	O
and	O
46	O
in	O
women	B-T098
with	O
PCOS	B-T047
or	O
isolated	O
H	B-T047
compared	O
with	O
controls	B-T096
.	O
High	O
BMI	B-T201
or	O
hyperandrogenism	B-T047
did	O
not	O
associate	O
with	O
increased	O
anxiety	B-T048
or	O
depression symptoms	B-T184
.	O
The	O
awareness	B-T041
of	O
PCOS	B-T047
was	O
associated	O
with	O
increased	O
anxiety	B-T048
.	O
Women	B-T098
with	O
PCOS	B-T047
or	O
isolated	O
H	B-T047
present	O
more	O
often	O
with	O
anxiety	B-T048
and/or	O
depression symptoms	B-T184
and	O
their	O
coexistence	O
compared	O
with	O
controls	B-T096
.	O
High	O
BMI	B-T201
or	O
hyperandrogenism	B-T047
did	O
not	O
provoke	O
psychological distress	B-T048
in	O
PCOS	B-T047
.	O
The	O
awareness	B-T041
of	O
PCOS	B-T047
increased	O
anxiety	B-T048
but	O
did	O
not	O
associate	O
with	O
severe	O
anxiety	B-T048
or	O
depression	B-T048
.	O

The	O
use of	B-T169
Oxford Nanopore	B-T092
native	B-T169
barcoding	B-T062
for	O
complete	B-T080
genome assembly	B-T085
The	O
Oxford Nanopore Technologies	B-T092
MinION(TM)	B-T074
is	O
a	O
mobile	B-T169
DNA	O
sequencer	O
that	O
can	O
produce	O
long read sequences	B-T086
with	O
a	O
short	O
turn-around time	B-T079
.	O
Here	O
we	O
report	B-T170
the	O
first	O
demonstration	O
of	O
single contig genome assembly	B-T085
using	B-T169
Oxford Nanopore	B-T092
native	B-T169
barcoding	B-T062
when	O
applied	B-T169
to	O
a	O
multiplexed library	B-T028
of	O
12	O
samples	B-T077
and	O
combined	B-T080
with	O
existing	B-T077
Illumina	O
short-read data	B-T170
.	O
This	O
paves	O
the	O
way	O
for	O
the	O
closure	B-T062
of	O
multiple	B-T081
bacterial genomes	B-T028
from	O
a	O
single	B-T081
MinION(TM)	B-T074
sequencing	B-T063
run	B-T169
,	O
given	O
the	O
availability of	B-T169
existing	B-T077
short-read data	B-T170
.	O
The	O
strain	B-T001
we	O
used	B-T169
,	O
MHO_001	B-T001
,	O
represents	O
the	O
important	O
community-acquired	O
methicillin resistant	B-T032
Staphylococcus aureus	B-T007
lineage	O
USA300	B-T001
.	O
Using	B-T169
a	O
hybrid	O
assembly	B-T085
of	O
existing	B-T077
short read	B-T080
and	O
barcoded long read sequences	B-T086
from	O
multiplexed data	B-T078
,	O
we	O
completed	O
a	O
genome	B-T028
of	O
the	O
S. aureus	B-T007
USA300 strain MHO_001	B-T001
.	O
The	O
long-read data	B-T170
represented	O
only	O
~5-10%	O
of	O
an	O
average	B-T081
MinION(TM)	B-T074
run	B-T169
(~7x	O
genomic	B-T028
coverage	B-T169
),	O
but,	O
using	B-T169
standard	B-T081
tools	B-T170
,	O
this	O
was	O
sufficient	B-T080
to	O
complete	B-T080
the	O
circular chromosome	B-T026
of	O
S. aureus	B-T007
strain MHO_001	B-T001
(2.86	O
Mb)	O
and	O
two	O
complete	B-T080
plasmids	B-T114
(27	O
Kb	O
and	O
3	O
Kb).	O
Minor	B-T080
differences	B-T080
were	O
noted	B-T080
when	O
compared	B-T052
to	O
USA300	B-T001
reference	O
genome	B-T028
,	O
USA300_FPR3757	B-T028
,	O
including	B-T169
the	O
translocation	B-T043
,	O
loss	B-T081
and	O
gain	B-T081
of	O
mobile genetic elements	B-T114
.	O
Here	O
we	O
demonstrate	O
that	O
MinION(TM)	B-T074
reads	B-T169
,	O
multiplexed	B-T169
using	B-T169
native	B-T169
barcoding	B-T062
,	O
can	O
be	O
used	B-T169
in	O
combination	B-T080
with	O
short-read data	B-T170
,	O
to	O
fully	O
complete	B-T080
a	O
bacterial genome	B-T028
.	O
The	O
ability	O
to	O
complete	B-T080
multiple	B-T081
genomes	B-T028
,	O
for	O
which	O
short-read data	B-T170
is	O
already	O
available	B-T033
,	O
from	O
a	O
single	B-T081
MinION(TM)	B-T074
run	B-T169
is	O
set	O
to	O
impact	B-T080
on	O
our	O
understanding	B-T041
of	O
accessory	B-T081
genome content	B-T028
,	O
plasmid	B-T114
diversity	B-T080
and	O
genome	B-T028
rearrangements	B-T045
.	O

Doxorubicin	B-T109
Has	O
Dose-Dependent	B-T081
Toxicity	B-T037
on	O
Mouse	B-T015
Ovarian Follicle	B-T023
Development	B-T039
,	O
Hormone Secretion	B-T042
,	O
and	O
Oocyte Maturation	B-T043
Doxorubicin	B-T109
(	O
DOX	B-T109
),	O
one	O
of	O
the	O
most	O
commonly	B-T081
used	O
anticancer medications	B-T109
,	O
has	O
been	O
reported	O
to	O
affect	O
fertility	B-T040
by	O
damaging	B-T169
ovarian follicles	B-T023
;	O
however,	O
the	O
dose-dependent	B-T081
toxicity	B-T037
of	O
DOX	B-T109
on	O
the	O
dynamic	B-T169
follicle	B-T023
development	B-T039
and	O
oocyte maturation	B-T043
has	O
not	O
been	O
well-defined.	O
Our	O
objective	B-T170
is	O
to	O
determine	O
the	O
effects of	B-T080
human	B-T016
-	O
relevant	B-T080
exposure	B-T080
levels	B-T080
of	O
DOX	B-T109
on	O
follicular	B-T023
functions	B-T169
across	O
developmental	B-T039
time	B-T079
.	O
In vitro	B-T080
cultured	B-T059
multilayered secondary mouse follicles	B-T023
were	O
treated	B-T169
with	O
DOX	B-T109
at	O
0,	O
2,	O
20,	O
100,	O
and	O
200	O
nM	O
for	O
24	O
h,	O
and	O
follicle	B-T023
development	B-T039
,	O
hormone secretion	B-T042
,	O
and	O
oocyte maturation	B-T043
were	O
analyzed.	O
DOX	B-T109
caused	O
dose-dependent	B-T081
toxicity	B-T037
on	O
follicle growth	B-T042
,	O
survival	B-T169
,	O
and	O
secretion	B-T042
of	O
17β-estradiol	B-T109
(	O
E2	B-T109
).	O
At	O
200	O
nM,	O
DOX	B-T109
induced	B-T169
DNA damage	B-T049
and	O
apoptosis	B-T043
in	O
follicle	B-T023
somatic cells	B-T025
first	O
and	O
then	O
in	O
oocytes	B-T025
,	O
which	O
was	O
correlated	O
with	O
the	O
uptake	B-T039
of	O
DOX	B-T109
first	O
to	O
the	O
somatic cells	B-T025
followed	O
by	O
germ cells	B-T025
.	O
Follicles	B-T023
treated	B-T169
with	O
DOX	B-T109
at	O
0,	O
2,	O
and	O
20	O
nM	O
showed	O
similar	O
oocyte	B-T025
metaphase II	B-T043
(	O
MII	B-T043
)	O
percentages	B-T081
after	O
in vitro	B-T080
oocyte maturation	B-T043
;	O
however,	O
20	O
nM	O
DOX	B-T109
significantly	O
increased	B-T081
the	O
number	O
of	O
MII	B-T043
oocytes	B-T025
with	O
abnormal	B-T033
spindle	B-T026
morphology	B-T080
and	O
chromosome	B-T026
misalignment	B-T080
.	O
In	O
an	O
effort	O
to	O
harmonize	O
the	O
in vitro study	B-T062
to	O
in vivo	B-T082
treatment	B-T169
,	O
dose-dependent	B-T081
toxicity	B-T037
on	O
oocyte meiotic maturation	B-T043
was	O
found	O
in	O
16-day-old	O
CD-1 mice	B-T015
treated	B-T169
with	O
DOX	B-T109
at	O
0,	O
0.4,	O
2,	O
and	O
10	O
mg/kg,	O
consistent with	B-T078
the	O
in vitro	B-T080
oocyte maturation	B-T043
outcomes	B-T169
.	O
Our	O
study	B-T062
demonstrates	O
that	O
DOX	B-T109
has	O
dose-dependent	B-T081
toxicity	B-T037
on	O
ovarian follicle	B-T023
development	B-T039
,	O
hormone secretion	B-T042
,	O
and	O
oocyte maturation	B-T043
,	O
which	O
are	O
three	O
key	O
factors	B-T169
to	O
support	O
the	O
female reproductive	B-T040
and	O
endocrine functions	B-T039
.	O

Involvement	O
of	O
apoptotic pathways	B-T043
in	O
docosahexaenoic acid	B-T109
-induced	O
benefit	O
in	O
prostate cancer	B-T191
:	O
Pathway-focused	O
gene expression analysis	B-T063
using	O
RT(2) Profile PCR Array System	B-T063
Present	O
study	O
aimed	O
to	O
better	O
understand	O
the	O
potential	O
apoptotic pathways	B-T043
that	O
involved	O
in	O
docosahexaenoic acid	B-T109
(	O
DHA	B-T109
)-induced	O
apoptosis	B-T043
of	O
prostate cancer	B-T191
cells	B-T025
.	O
Human	B-T016
prostate cancer	B-T191
DU145 cells	B-T025
were	O
treated	O
with	O
different	O
concentrations	O
of	O
fish oil	B-T109
,	O
omega-3 PUFA	B-T109
(	O
DHA	B-T109
,	O
and	O
Eicosapentaenoic acid	B-T109
,	O
EPA	B-T109
),	O
or	O
omega-6 PUFA	B-T109
(	O
Arachidonic acid	B-T109
,	O
AA	B-T109
).	O
Cell viability	B-T043
and	O
apoptosis	B-T043
were	O
evaluated	O
by	O
MTT assay	B-T062
and	O
Hoechst staining	B-T059
.	O
Pathway-focused	O
gene expression profiling	B-T059
of	O
DU145 cells	B-T025
was	O
analyzed	O
with	O
the	O
RT(2)	O
Profile	O
PCR	O
Array	O
System.	O
The	O
results	O
were	O
verified	O
by	O
real time quantitative polymerase chain reaction	B-T063
(	O
RT-qPCR	B-T063
).	O
AA	B-T109
exposure	O
showed	O
no	O
obvious	O
effect	O
on	O
viability	B-T043
of	O
DU145 cells	B-T025
.	O
However,	O
exposure	O
with	O
fish oil	B-T109
,	O
EPA	B-T109
,	O
or	O
DHA	B-T109
for	O
24	O
h	O
significantly	O
affected	O
cell viability	B-T043
.	O
The	O
growth inhibition	B-T043
of	O
DHA	B-T109
was	O
more	O
pronounced	O
than	O
that	O
of	O
EPA	B-T109
and	O
showed	O
a	O
time-dependent	O
increase.	O
DHA	B-T109
exposure	O
caused	O
typical	O
apoptotic	B-T080
characteristics.	O
Ten	O
genes	B-T028
were	O
more	O
expressed,	O
while	O
5	O
genes	B-T028
were	O
less	O
expressed	O
following	O
DHA	B-T109
exposure.	O
RT-qPCR	B-T063
confirmed	O
the	O
time	O
dependent	O
effect	O
of	O
DHA	B-T109
on	O
the	O
expression	O
of	O
these	O
differentially	O
expressed	O
genes	B-T028
.	O
KEGG	O
pathway	O
analysis	O
showed	O
that	O
DHA	B-T109
may	O
induce	O
the	O
apoptosis	B-T043
of	O
cancer cells	B-T025
preferentially	O
through	O
mediating	O
P53	B-T044
,	O
MAPK	B-T044
,	O
TNF	B-T039
,	O
PI3K/AKT	B-T169
,	O
and	O
NF-κB signaling pathways	B-T045
.	O
Our	O
study	O
demonstrated	O
the	O
beneficial	O
action	O
of	O
DHA	B-T109
on	O
human	B-T016
prostate carcinoma	B-T191
cell line DU145	B-T025
.	O
The	O
pro-apoptotic	O
effect	O
of	O
DHA	B-T109
on	O
DU145 cells	B-T025
may	O
involve	O
mediation	O
various	O
pathways	B-T044
,	O
especially	O
P53	B-T044
,	O
MAPK	B-T044
,	O
TNF	B-T039
,	O
PI3K/AKT	B-T169
,	O
and	O
NF-κB signaling pathways	B-T045
.	O
Molecular mechanisms	B-T044
of	O
DHA	B-T109
on	O
apoptosis	B-T043
of	O
cancer cells	B-T025
still	O
need	O
to	O
be	O
further	O
clarified.	O

Medication Reconciliation	B-T058
During	O
Hospitalization	B-T058
and	O
in	O
Hospital-Home Interface	B-T058
:	O
An	O
Observational Retrospective Study	B-T062
Medication errors	B-T080
are	O
one	O
of	O
the	O
leading	O
causes	O
of	O
patient harms	B-T080
.	O
Medication reconciliation	B-T058
is	O
a	O
fundamental	O
process	O
that	O
to	O
be	O
effective,	O
it	O
should	O
be	O
embraced	O
during	O
each	O
single	O
care transition	B-T058
.	O
Our	O
objectives	O
were	O
to	O
investigate	B-T169
current	O
medication reconciliation	B-T058
practices	O
in	O
the	O
2	O
Fondazione Toscana Gabriele Monasterio hospitals	B-T073
and	O
comprehensively	O
assess the quality	B-T080
of	O
medication reconciliation	B-T058
practices	O
between	O
inpatient	B-T101
and	O
outpatient	B-T101
care	B-T052
by	O
analyzing	B-T062
the	O
medication patterns	B-T058
6	O
months	B-T079
before	O
admission	B-T058
,	O
during	O
hospitalization	B-T058
,	O
and	O
9	O
months	B-T079
after	O
discharge	B-T058
for	O
a	O
selected	O
group	O
of	O
patients	B-T101
with	O
cardiovascular diseases	B-T047
.	O
A	O
retrospective observational study	B-T062
was	O
conducted	O
in	O
the	O
Cardiothoracic Department	B-T093
of	O
the	O
Fondazione Toscana Gabriele Monasterio hospitals	B-T073
.	O
Medication history	B-T170
was	O
reviewed	B-T080
for	O
all	O
the	O
patients	B-T101
admitted	B-T058
from	O
and	O
discharged	B-T058
to	O
the	O
community	B-T096
,	O
from	O
January	O
to	O
March	O
2013.	O
Patients	B-T101
were	O
excluded	O
if	O
they	O
had	O
less	O
than	O
4	O
drugs	B-T061
or	O
less	O
than	O
2	O
drugs	B-T061
for	O
cardiovascular system	B-T022
in	O
their	O
prescription list	B-T170
at	O
admission	B-T058
or	O
if	O
they	O
died	B-T033
during	O
follow-up	B-T058
.	O
We	O
selected	O
714	O
patients	B-T101
,	O
and	O
we	O
obtained	O
the	O
clinical charts	B-T170
and	O
all	O
drug prescriptions	B-T170
collected	O
during	O
patients	B-T101
'	O
hospitalization	B-T058
by	O
the	O
electronic clinical recording system	B-T170
.	O
We	O
also	O
analyzed	B-T062
the	O
list of prescriptions	B-T170
of	O
this	O
sample	O
of	O
patients	B-T101
,	O
from	O
6	O
months	B-T079
before	O
admission	B-T058
to	O
9	O
months	B-T079
after	O
discharge	B-T058
,	O
extracted	O
from	O
the	O
regional prescription registry	B-T170
.	O
In	O
the	O
resulting	O
sample,	O
prescriptions	B-T170
were	O
analyzed	B-T062
to	O
assess	O
unintentional	B-T169
discrepancies	B-T033
.	O
The	O
study	B-T062
included	O
298	O
patients	B-T101
(mean	O
age	B-T032
,	O
71.2	O
years	B-T079
),	O
according	O
to	O
the	O
inclusion and exclusion criteria	B-T078
.	O
Among	O
14,573	O
prescriptions	B-T170
analyzed	B-T062
,	O
we	O
found	O
4363	O
discrepancies	B-T033
(14.6	O
discrepancies	B-T033
per	O
patient	B-T101
).	O
Among	O
these	O
discrepancies	B-T033
,	O
1310	O
were	O
classified	O
as	O
unintentional	B-T169
(4.4	O
discrepancies	B-T033
per	O
patient	B-T101
).	O
Among	O
unintentional	B-T169
discrepancies	B-T033
,	O
only	O
63	O
(4.8%)	O
took	O
place	O
during	O
hospitalization	B-T058
.	O
Although	O
at	O
the	O
hospital-home interface	B-T058
,	O
33.1%	O
of	O
unintentional	B-T169
discrepancies	B-T033
were	O
detected	O
through	O
the	O
comparison	B-T052
between	O
the	O
patients	B-T101
'	O
declared	O
therapy	B-T169
and	O
the	O
previous	O
medication consumption	B-T058
and	O
62.1%	O
were	O
identified	O
in	O
the	O
comparison	B-T052
between	O
the	O
prescription	B-T170
at	O
the	O
discharge	B-T058
and	O
the	O
following	O
medication pattern	B-T058
at	O
home	B-T082
.	O
Medication errors	B-T080
have	O
important	O
implications	O
for	O
patient safety	B-T058
,	O
and	O
their	O
identification	O
is	O
a	O
main	O
target	O
for	O
improving	O
clinical practice	B-T058
.	O
The	O
comparison	B-T052
between	O
the	O
medication patterns	B-T058
acquired	O
through	O
the	O
regional prescription registry	B-T170
before	O
and	O
after	O
hospitalization	B-T058
outlined	O
critical	O
touchpoint	O
in	O
the	O
current	O
medication reconciliation	B-T058
process,	O
calling	O
for	O
the	O
definition	O
of	O
shared	O
medication reconciliation	B-T058
standards	O
between	O
hospitals	B-T073
and	O
primary care services	B-T058
to	O
minimize	O
medication discrepancies	B-T080
and	O
enhance	O
patient safety	B-T058
.	O

Autologous	B-T122
vs	O
Irradiated Homologous Costal Cartilage	B-T122
as	O
Graft Material	B-T122
in	O
Rhinoplasty	B-T061
Studies	O
comparing	O
surgical	O
results	O
of	O
rhinoplasty	B-T061
using	O
autologous costal cartilage	B-T122
(	O
ACC	B-T122
)	O
and	O
irradiated homologous costal cartilage	B-T122
(	O
IHCC	B-T122
)	O
are	O
rare.	O
To	O
compare	O
the	O
clinical results	B-T034
of	O
major	O
augmentation rhinoplasty	B-T061
using	O
ACC	B-T122
vs	O
IHCC	B-T122
and	O
analyze	O
the	O
histologic properties	B-T169
of	O
both	O
types	O
of	O
cartilage	B-T024
.	O
A	O
retrospective clinical study	B-T062
was	O
conducted	O
among	O
patients	B-T101
who	O
had	O
undergone	O
rhinoseptoplasty	B-T061
using	O
ACC	B-T122
or	O
IHCC	B-T122
from	O
January	O
1,	O
2009,	O
to	O
December	O
31,	O
2014.	O
Patients	B-T101
were	O
followed up	B-T058
for	O
more	O
than	O
1	O
year	O
after	O
surgery	B-T061
and	O
the	O
histologic characteristics	B-T169
of	O
ACC	B-T122
and	O
IHCC	B-T122
were	O
compared	B-T052
.	O
The	O
details	O
of	O
the	O
surgical procedures	B-T061
and	O
complications	B-T033
,	O
including	O
warping	B-T033
,	O
infection	B-T046
,	O
resorption	B-T040
,	O
and/or	O
donor-site	B-T029
morbidity	B-T081
,	O
were	O
evaluated	B-T058
by	O
reviewing	O
medical records	B-T170
and	O
facial photographs	B-T073
.	O
Patients	B-T101
'	O
subjective	B-T080
satisfaction	B-T041
with	O
aesthetic	B-T055
and	O
functional	B-T169
results	B-T169
was	O
evaluated	B-T058
using	O
a	O
questionnaire	B-T170
.	O
The	O
details	O
of	O
the	O
surgical procedures	B-T061
and	O
complications	B-T033
,	O
including	O
warping	B-T033
,	O
infection	B-T046
,	O
resorption	B-T040
,	O
and/or	O
donor-site	B-T029
morbidity	B-T081
;	O
patients	B-T101
'	O
subjective	B-T080
satisfaction	B-T041
with	O
aesthetic	B-T055
and	O
functional	B-T169
results	B-T169
'	O
objective	B-T080
evaluation	B-T058
of	O
surgical	B-T061
outcomes	B-T169
,	O
including	O
symmetry	B-T067
,	O
dorsal	B-T082
height	B-T032
,	O
dorsal	B-T082
length	B-T081
,	O
dorsal	B-T082
width	B-T081
,	O
tip projection	B-T033
,	O
tip rotation	B-T033
,	O
tip width	B-T033
,	O
and	O
overall	B-T080
result	B-T169
;	O
and	O
histologic	B-T169
structures	B-T082
.	O
Objective	B-T080
evaluation	B-T058
of	O
surgical	B-T061
outcomes	B-T169
was	O
graded	O
using	O
the	O
Objective	B-T080
Rhinoplasty	B-T061
Outcome Score	B-T033
,	O
which	O
assessed	O
symmetry	B-T067
,	O
dorsal	B-T082
height	B-T032
,	O
dorsal	B-T082
length	B-T081
,	O
dorsal	B-T082
width	B-T081
,	O
tip projection	B-T033
,	O
tip rotation	B-T033
,	O
tip width	B-T033
,	O
and	O
overall	B-T080
result	B-T169
.	O
Histologic structures	B-T169
were	O
evaluated	B-T058
using	O
hematoxylin and eosin	B-T059
,	O
Masson trichrome	B-T059
,	O
Alcian blue	B-T059
,	O
and	O
Verhoeff elastic stains	B-T059
.	O
A	O
total	O
of	O
63	O
patients	B-T101
(27	O
males	B-T032
and	O
36	O
females	B-T032
;	O
mean	O
[SD]	O
age,	O
30.6	O
[9.5]	O
years)	O
had	O
rhinoseptoplasty	B-T061
using	O
ACC	B-T122
and	O
20	O
(9	O
males	B-T032
and	O
11	O
females	B-T032
;	O
mean	O
[SD]	O
age,	O
35.4	O
[15.4]	O
years)	O
had	O
rhinoseptoplasty	B-T061
using	O
IHCC	B-T122
.	O
Among	O
observed	B-T169
complications	B-T033
,	O
only	O
notable	B-T080
resorption	B-T040
occurred	B-T052
more	O
frequently	B-T079
in	O
patients	B-T101
using	O
IHCC	B-T122
(6	O
[30%])	O
than	O
with	O
ACC	B-T122
(2	O
[3%])	O
(P	O
=	O
.002).	O
In	O
subjective	B-T080
evaluations	B-T058
of	O
aesthetic	B-T055
satisfaction	B-T041
,	O
patients	B-T101
who	O
received	B-T080
ACC	B-T122
showed	O
significantly	B-T078
greater	B-T081
satisfaction	B-T041
(37	O
of	O
51	O
patients	B-T101
[73%]	O
were	O
very satisfied	B-T033
)	O
than	O
did	O
those	O
who	O
received	B-T080
IHCC	B-T122
(6	O
of	O
20	O
[30%])	O
(P	O
=	O
.001).	O
However,	O
there	O
was	O
no	O
between-group	O
difference	O
in	O
subjective	B-T080
functional	B-T169
outcomes	B-T169
:	O
4	O
of	O
51	O
patients	B-T101
receiving	B-T080
ACC	B-T122
(8%)	O
and	O
5	O
of	O
20	O
receiving	B-T080
IHCC	B-T122
(25%)	O
were	O
satisfied	B-T041
(P	O
=	O
.50)	O
and	O
45	O
of	O
51	O
receiving	B-T080
ACC	B-T122
(88%)	O
and	O
15	O
of	O
20	O
receiving	B-T080
IHCC	B-T122
(75%)	O
were	O
very satisfied	B-T033
(P	O
=	O
.15).	O
Regarding	O
objective	B-T080
aesthetic	B-T055
outcomes	B-T169
,	O
all	O
scores	B-T081
for	O
both	O
ACC	B-T122
and	O
IHCC	B-T122
were	O
more	O
than	O
3.1	O
(between	O
good	B-T080
and	O
excellent	B-T080
).	O
Histologic analyses	B-T059
showed	O
larger	B-T081
,	O
more	O
evenly	O
distributed,	O
uniform	B-T080
chondrocytes	B-T025
and	O
more	O
collagens	B-T116
and	O
proteoglycan	B-T116
contents	B-T078
in	O
ACC	B-T122
than	O
in	O
IHCC	B-T122
.	O
Compared	B-T052
with	O
patients	B-T101
receiving	B-T080
IHCC	B-T122
,	O
those	O
receiving	B-T080
ACC	B-T122
for	O
rhinoseptoplasty	B-T061
showed	O
superior	B-T080
aesthetic	B-T055
satisfaction	B-T041
;	O
ACC	B-T122
also	O
had	O
less	B-T080
frequent	B-T079
notable	B-T080
resorption	B-T040
.	O
Autologous costal cartilage	B-T122
also	O
had	O
better	B-T080
histologic properties	B-T169
than	O
IHCC	B-T122
did,	O
suggesting	O
it	O
as	O
an	O
ideal	B-T080
graft material	B-T122
with	O
less	B-T080
chance	B-T080
of	O
long-term	B-T079
resorption	B-T040
.	O
3.	O

Testing	O
the	O
Ret	B-T028
and	O
Sema3d	B-T028
genetic interaction	B-T045
in	O
mouse	B-T015
enteric nervous system development	B-T042
For	O
most	O
multigenic disorders	B-T047
,	O
clinical manifestation	B-T080
(	O
penetrance	B-T081
)	O
and	O
presentation	B-T078
(	O
expressivity	B-T078
)	O
are	O
likely	O
to	O
be	O
an	O
outcome	B-T169
of	O
genetic interaction	B-T045
between	O
multiple	O
susceptibility genes	B-T028
.	O
Here,	O
using	O
gene knockouts	B-UnknownType
in	O
mice	B-T015
we	O
evaluated	O
genetic interaction	B-T045
between	O
loss	O
of	O
Ret	B-T028
and	O
loss	O
of	O
Sema3d	B-T028
,	O
two	O
Hirschsprung disease	B-T019
susceptibility genes	B-T028
.	O
We	O
intercrossed	O
Ret	B-T028
and	O
Sema3d	B-T028
double	O
null	O
heterozygotes	O
to	O
generate mice	B-T169
with	O
the	O
nine	O
possible	O
genotypes	B-T032
and	O
assessed survival	B-T052
by	O
counting various genotypes	B-T059
,	O
myenteric plexus	B-T023
presence	O
by	O
acetylcholinesterase staining	B-T059
and	O
embryonic day 12.5	B-UnknownType
(	O
E12.5	B-UnknownType
)	O
intestine transcriptome	B-T086
by	O
RNA-sequencing	B-T086
.	O
Survival rates	B-T081
of	O
Ret	B-T028
wildtype	B-T028
,	O
null	O
heterozygote	O
and	O
null	O
homozygote	O
mice	B-T015
at	O
E12.5	B-UnknownType
,	O
birth	B-T040
and	O
weaning	B-T033
were	O
not	O
influenced	O
by	O
the	O
genotypes	B-T032
at	O
Sema3d	B-T028
locus	B-T082
and	O
vice-versa.	O
Loss	O
of	O
myenteric plexus	B-T023
was	O
observed	O
only	O
in	O
all	O
Ret	B-T028
null	O
homozygotes,	O
irrespective	O
of	O
the	O
genotypes	B-T032
at	O
Sema3d	B-T028
locus	B-T082
,	O
and	O
Sema3d	B-T028
null	O
heterozygote	B-T032
and	O
homozygote mice	B-T032
had	O
normal	O
intestinal innervation	B-T080
.	O
As	O
compared	O
to	O
wildtype mice intestinal	B-T028
gene expression	B-T045
,	O
loss	O
of	O
Ret	B-T028
in	O
null	O
homozygotes	O
led	O
to	O
differential	O
expression of ∼300 genes,	B-T045
whereas	O
loss	O
of	O
Sema3d	B-T028
in	O
null	O
homozygotes	O
had	O
no	O
major	O
consequence	O
and	O
there	O
was	O
no evidence	B-T080
supporting	O
major	O
interaction between the two genes	B-T045
influencing	O
intestine transcriptome	B-T086
.	O
Overall,	O
given	O
the	O
null alleles	B-T049
and	O
phenotypic assays	B-T059
used,	O
we	O
did	O
not find evidence	B-T080
for	O
genetic interaction	B-T045
between	O
Ret	B-T028
and	O
Sema3d	B-T028
affecting	O
survival,	O
presence	O
of	O
myenteric plexus	B-T023
or	O
intestine transcriptome	B-T086
.	O

Pembrolizumab	B-T116
for	O
the	O
treatment	B-T061
of	O
non-small cell lung cancer	B-T191
In	O
the	O
last	O
years,	O
a	O
spectacular	O
development	B-T169
of	O
immunotherapeutic agents	B-T121
aimed	O
at	O
the	O
PD-1	B-T116
/	O
PD-L1	B-T129
axis	O
has	O
taken	O
place.	O
This	O
development	B-T169
of	O
these	O
checkpoint inhibitors	B-T120
has	O
greatly	O
influenced	O
our	O
approach	O
to	O
the	O
treatment	B-T061
of	O
lung cancer	B-T191
in	O
first	B-T061
and	O
second line	B-T061
.	O
The	O
limited	B-T169
toxicity	B-T037
profile	O
and	O
the	O
ability	O
to	O
treat	B-T061
for	O
prolonged	B-T079
periods	B-T079
,	O
even	O
in	O
smokers	B-T033
,	O
is	O
a	O
welcome	O
expansion	O
of	O
the	O
therapeutic	O
arsenal	O
of	O
the	O
oncologist	B-T097
.	O
Areas	O
covered:	O
This	O
review	B-T170
highlights	O
the	O
results	B-T169
of	O
recent	O
clinical trials	B-T062
on	O
pembrolizumab	B-T116
for	O
the	O
treatment	B-T061
of	O
non-small cell lung cancer	B-T191
.	O
The	O
authors	B-T097
discuss	O
both	O
first	B-T061
and	O
second line treatment	B-T061
with	O
pembrolizumab	B-T116
as	O
monotherapy	B-T061
and	O
in	O
combination therapies	B-T061
.	O
Additionally,	O
implications	O
of	O
the	O
PD-L1	B-T129
immunohistochemistry assay	B-T059
with	O
the	O
22C3 antibody	B-T116
and	O
its	O
use	B-T169
in	O
clinical practice	B-T062
and	O
trials	B-T062
is	O
discussed.	O
Expert	O
commentary:	O
A	O
higher	B-T080
overall response	B-T033
,	O
overall survival	B-T081
and	O
a	O
moderate	B-T080
toxicity	B-T037
profile	O
is	O
observed	O
with	O
the	O
use	B-T169
of	O
pembrolizumab	B-T116
,	O
compared	O
to	O
chemotherapy	B-T061
,	O
in	O
both	O
first	B-T061
and	O
second line	B-T061
.	O
These	O
promising	O
results	B-T169
have	O
already	O
translated	O
into	O
the	O
registration	B-T058
of	O
pembrolizumab	B-T116
in	O
first	B-T061
and	O
second line	B-T061
in	O
patients	B-T101
with	O
a	O
high	B-T080
expression	B-T045
of	O
PD-L1	B-T129
.	O
However,	O
as	O
PD-L1	B-T129
staining	B-T059
does	O
not	O
sufficiently	O
discriminate	O
responders	B-T033
from	O
non-responders	B-T033
for	O
all	O
checkpoint inhibitors	B-T120
,	O
there	O
still	O
is	O
a	O
need	O
for	O
a	O
better	O
predictive	B-T080
biomarker	B-T201
.	O

Synchronisms	B-T079
between	O
bud	B-T002
and	O
cambium	B-T023
phenology	B-T080
in	O
black spruce	B-T002
:	O
early	B-T079
-	O
flushing	B-T052
provenances	B-T077
exhibit	O
early	B-T079
xylem	B-T002
formation	B-T169
Bud	B-T002
and	O
cambial	B-T023
phenology	B-T080
represent	B-T052
the	O
adaptation	B-T038
of	O
species	B-T185
to	O
the	O
local	B-T082
environment	B-T082
that	O
allows	O
the	O
growing season	B-T079
to	O
be	O
maximized	B-T169
while	O
minimizing	B-T080
the	O
risk	B-T078
of	O
frost	B-T197
for	O
the	O
developing	B-T169
tissues	B-T025
.	O
The	O
temporal	B-T079
relationship	B-T080
between	O
the	O
apical	B-T082
and	O
radial	B-T077
meristems	B-T002
can	O
help	O
in	O
the	O
understanding	O
of	O
tree	B-T002
growth	B-T040
growth	B-T040
as	O
a	O
whole	B-T081
process	B-T067
.	O
The	O
aim	B-T078
of	O
this	O
study	B-T062
was	O
to	O
compare	B-T052
cambial	B-T023
phenology	B-T080
in	O
black spruce	B-T002
(	O
Picea mariana	B-T002
(Mill.)	O
B.S.P.)	O
provenances	B-T077
classified	B-T185
as	O
early	B-T079
and	O
late	B-T079
bud	B-T002
flushing	B-T052
.	O
The	O
different	B-T080
phases	B-T079
of	O
cambial	B-T023
phenology	B-T080
were	O
assessed	B-T052
on	O
wood	B-T167
microcores	B-T082
sampled	B-T078
weekly	B-T079
from	O
April	O
to	O
October	O
in	O
2014	O
and	O
2015	O
from	O
61	O
trees	B-T002
growing	B-T040
in	O
a	O
provenance trial	B-T062
in	O
Quebec	B-T083
,	O
Canada	B-T083
.	O
Trees	B-T002
showing	O
an	O
early	B-T079
bud	B-T002
flush	B-T052
also	O
exhibited	O
early	B-T079
reactivation	B-T052
of	O
xylem	B-T002
differentiation	B-T043
,	O
although	O
an	O
average	B-T081
difference	B-T081
of	O
12	O
days	B-T079
for	O
buds	B-T002
corresponded	O
to	O
small	B-T081
although	O
significant	B-T081
differences	B-T081
of	O
4	O
days	B-T079
for	O
xylem	B-T002
.	O
Provenances	B-T077
with	O
early	B-T079
bud	B-T002
flush	B-T052
had	O
an	O
early	B-T079
bud	B-T002
set	O
and	O
completed	B-T080
xylem	B-T002
formation	B-T169
earlier	B-T079
than	O
late	B-T079
bud	B-T002
flush	B-T052
provenances	B-T077
.	O
No significant	B-T033
difference	B-T081
in	O
the	O
period	B-T079
of	O
xylem	B-T002
formation	B-T169
and	O
total	B-T080
growth	B-T040
growth	B-T040
was	O
observed	B-T169
between	O
the	O
flushing	B-T052
classes.	O
Our	O
results	B-T033
demonstrate	O
that	O
the	O
ecotype	B-T032
differentiation	B-T043
of	O
black spruce	B-T002
provenances	B-T077
represented	O
by	O
the	O
phenological	B-T080
adaptation	B-T038
of	O
buds	B-T002
to	O
the	O
local	B-T082
climate	B-T070
corresponds	O
to	O
specific	B-T080
growth	B-T040
dynamics	B-T070
of	O
the	O
xylem	B-T002
.	O

An	O
approach	O
for	O
liposome	B-T109
immobilization	B-T061
using	O
sterically stabilized	B-T080
micelles	B-T109
(	O
SSMs	B-T109
)	O
as	O
a	O
precursor	B-T078
for	O
bio-layer interferometry	B-T059
-	O
based	B-T169
interaction	B-T169
studies	B-T062
Non-fluidic	B-T080
bio-layer interferometry	B-T059
(	O
BLI	B-T059
)	O
has	O
rapidly	B-T080
become	O
a	O
standard	B-T080
tool	O
for	O
monitoring	B-T057
almost	O
all	O
biomolecular	B-T080
interactions	B-T169
in	O
a	O
label-free	B-T080
,	O
real-time	B-T079
and	O
high-throughput	B-T080
manner.	O
High	B-T080
-	O
efficiency	B-T081
screening methods	B-T059
which	O
measure	B-T081
the	O
kinetics	B-T070
of	O
liposomes	B-T109
with	O
a	O
variety	B-T077
of	O
compounds	B-T103
require	O
the	O
immobilization	B-T061
of	O
liposomes	B-T109
.	O
In	O
this	O
work,	O
a	O
method	B-T169
is	O
described	B-T078
for	O
immobilizing	B-T061
liposomes	B-T109
for	O
interaction	B-T169
studies	B-T062
,	O
based	B-T169
on	O
the	O
biophysical principles	B-T070
of	O
this	O
biosensor	B-T075
platform	B-T075
.	O
The	O
immobilization	B-T061
approach	O
includes	B-T169
the	O
loading	B-T052
of	O
DSPE-PEG(2000)	B-T109
-	O
biotin	B-T109
containing	O
sterically stabilized	B-T080
micelles	B-T109
(	O
SSMs	B-T109
)	O
which	O
are	O
restructured	B-T080
in	O
a	O
buffer change	B-T080
step,	O
resulting in	B-T169
an	O
accessible	O
substrate	B-T167
for	O
liposome	B-T109
immobilization	B-T061
.	O
Liposomes	B-T109
in	O
a	O
concentration	B-T081
of	O
5mM	O
of	O
varying	O
composition	B-T201
and	O
fluidity	B-T081
were	O
immobilized	B-T061
on	O
the	O
sensor	B-T075
surface	B-T082
by	O
inserting	O
the	O
hydrophobic	B-T080
residues	B-T077
of	O
the	O
former	B-T079
loaded	O
SSMs	B-T109
.	O
This	O
proof	O
of	O
principle	O
was	O
carried	O
out	O
using	O
Cytochrome C	B-T116
as	O
a	O
membrane-interacting	B-T080
model	O
protein	B-T116
.	O
The	O
binding	B-T044
of	O
Cytochrome C	B-T116
to	O
the	O
immobilized	B-T061
liposomes	B-T109
was	O
demonstrated,	O
and	O
the	O
derived	O
kinetic	B-T070
and	O
affinity	B-T070
constants	B-T081
were	O
similar	B-T080
to	O
values	B-T080
given	O
in	O
the	O
literature	B-T170
.	O
In	O
order	O
to	O
obtain	O
a	O
detailed	B-T080
understanding	B-T041
of	O
this	O
surface	B-T082
,	O
and	O
to	O
show	O
the	O
integrity	B-T080
of	O
the	O
liposomes	B-T109
,	O
confocal fluorescence microscopy	B-T059
was	O
used.	O
Images	O
of	O
immobilized	B-T061
liposomes	B-T109
containing	B-T169
calcein	B-T109
in	O
the	O
aqueous	B-T080
core	B-T082
indicated	B-T033
intact	B-T080
vesicles	B-T026
.	O
A	O
combination	B-T080
of	O
this	O
simple	O
liposome	B-T109
immobilization	B-T061
approach,	O
the	O
possibility	O
of	O
automation	B-T066
on	O
BLI	B-T059
systems	B-T169
with	O
high throughput	B-T080
within	O
an	O
acceptable	B-T080
timescale	O
and	O
excellent	B-T080
reproducibility	B-T080
makes	O
this	O
assay	B-T059
suitable	B-T080
for	O
basic	O
research	B-T062
as	O
well	O
as	O
for	O
industrial	B-T169
and	O
regulatory applications	B-T170
.	O

Exercise	B-T056
increases	B-T081
lactoferrin	B-T116
,	O
but	O
decreases	B-T081
lysozyme	B-T116
in	O
salivary	B-T082
granulocytes	B-T025
Intracellular lactoferrin	B-T116
(	O
Lac	B-T116
)	O
and	O
lysozyme	B-T116
(	O
Lys	B-T116
)	O
content	O
play	O
an	O
important	O
role	O
in	O
regulating	O
inflammation	B-T046
and	O
promoting	B-T052
host protection	B-T039
.	O
While	O
exercise	B-T056
has	O
demonstrated	O
an	O
increase	B-T081
in	O
Lac	B-T116
and	O
Lys	B-T116
concentration	B-T081
in	O
exocrine solutions	B-T031
,	O
little	O
is	O
known	O
regarding	O
intracellular concentration changes	B-T081
in	O
response	O
to	O
exercise	B-T056
.	O
To	O
quantify	B-T081
intracellular	O
Lac	B-T116
and	O
Lys	B-T116
concentration	B-T081
before	O
and	O
after	O
exercise	B-T056
in	O
salivary	B-T082
CD45(+)CD15(+) cells	B-T025
.	O
11	O
males	B-T032
(20.3	O
±	O
0.8	O
years	B-T079
,	O
57.2	O
±	O
7.6	O
mL/kg/min	O
V̇O2pk	B-T081
,	O
11.1	O
±	O
3.9%	O
body fat	B-T201
)	O
ran	B-T056
for	O
45	O
min	B-T079
at	O
75%	O
of	O
VO2pk	B-T081
.	O
12	O
mL	O
of	O
stimulated saliva	B-T031
were	O
collected	B-T169
pre	B-T079
and	O
immediately	O
post exercise	B-T079
.	O
Saliva	B-T031
was	O
filtered	O
through	O
a	O
30-µm	O
filter	O
before	O
analysis	O
of	O
leukocytes	B-T025
(	O
CD45(+)	B-T025
)	O
and	O
granulocytes	B-T025
(	O
CD45(+)CD15(+)	B-T025
)	O
using	O
flow cytometry	B-T059
.	O
Median fluorescent intensity	B-T081
(	O
MFI	B-T081
)	O
of	O
Lac	B-T116
increased	B-T081
from	O
pre	B-T079
(64,268	O
±	O
46,036	O
MFI	B-T081
)	O
to	O
post	B-T079
(117,134	O
±	O
88,115	O
MFI	B-T081
)	O
exercise	B-T056
(p	O
<0.05).	O
Lys	B-T116
MFI	B-T081
decreased	B-T081
with	O
exercise	B-T056
(	O
pre	B-T079
:	O
16,933	O
±	O
8249;	O
post	B-T079
:	O
11,616	O
±	O
6875)	O
(p	O
<0.05).	O
Acute running	B-T056
resulted	O
in	O
an	O
increased	B-T081
Lac	B-T116
concentration	B-T081
which	O
could	O
lead	O
to	O
a	O
decrease	B-T081
in	O
inflammation	B-T046
,	O
adding	O
further	O
evidence	O
of	O
the	O
anti-inflammatory effects	B-T080
of	O
exercise	B-T056
.	O
Conversely,	O
the	O
exercise	B-T056
-associated	O
decrease	B-T081
of	O
intracellular Lys	B-T116
content	O
could	O
be	O
the	O
cause	B-T169
of	O
increased	B-T081
Lys	B-T116
in	O
exocrine solutions	B-T031
.	O

Chronic Enzyme Replacement	B-T061
to	O
the	O
Brain	B-T023
of	O
a	O
Late Infantile Neuronal Ceroid Lipofuscinosis	B-T047
Mouse	B-T015
Has	O
Differential	O
Effects	B-T080
on	O
Phenotypes	B-T032
of	O
Disease	B-T047
Late infantile neuronal ceroid lipofuscinosis	B-T047
(	O
LINCL	B-T047
)	O
is	O
a	O
fatal	B-T080
inherited	O
neurodegenerative disease	B-T047
caused	O
by	O
loss	O
of	O
lysosomal protease tripeptidyl peptidase 1	B-T116
(	O
TPP1	B-T116
).	O
We	O
have	O
investigated	O
the	O
effects	B-T080
of	O
chronic intrathecal (IT) administration	B-T169
using	O
enzyme replacement therapy	B-T061
(	O
ERT	B-T061
)	O
to	O
the	O
brain	B-T023
of	O
an	O
LINCL	B-T047
mouse model	B-T050
,	O
in	O
which	O
locomotor function	B-T038
declines	O
dramatically	O
prior	O
to	O
early death	B-T033
.	O
Median	O
lifespan	B-T102
was	O
significantly	O
extended	O
from	O
126	O
days	B-T079
to	O
>259	O
days	B-T079
when	O
chronic IT treatment	B-T061
was	O
initiated	O
before	O
the	O
onset	B-T079
of	O
disease	B-T047
.	O
While	O
treated	O
animals	B-T008
lived	O
longer	O
and	O
showed	O
little	O
sign	O
of	O
locomotor dysfunction	B-T033
as	O
measured	O
by	O
stride	O
length,	O
some	O
or	O
all	O
(depending	O
on	O
regimen)	O
still	O
died	B-T040
prematurely.	O
One	O
explanation	O
is	O
that	O
cerebrospinal fluid	B-T031
(	O
CSF	B-T031
)-mediated	O
delivery	B-T169
may	O
not	O
deliver	B-T169
TPP1	B-T116
to	O
all	O
brain regions	B-T029
.	O
Morphological	B-T082
studies	B-T062
support	O
this,	O
showing	O
delivery	B-T169
of	O
TPP1	B-T116
to	O
ventral	B-T029
,	O
but	O
not	O
deeper	O
and	O
dorsal regions	B-T029
.	O
When	O
IT treatment	B-T061
is	O
initiated	O
in	O
severely	B-T080
affected	B-T169
LINCL	B-T047
mice	B-T015
,	O
lifespan	B-T102
was	O
extended	O
modestly	O
in	O
most	O
but	O
dramatically	O
extended	O
in	O
approximately	O
one-third	O
of	O
the	O
cohort	B-T098
.	O
Treatment	B-T169
improved	O
locomotor function	B-T038
in	O
these	O
severely	O
compromised	O
animals	B-T008
after	O
it	O
had	O
declined	O
to	O
the	O
point	O
at	O
which	O
animals	B-T008
normally	O
die	B-T040
.	O
This	O
indicates	O
that	O
some	O
pathology	B-T046
in	O
LINCL	B-T047
is	O
reversible	B-T169
and	O
does	O
not	O
simply	O
reflect	O
neuronal death	B-T043
.	O

5-Bromo-2-aryl benzimidazole derivatives	B-T109
as	O
non-cytotoxic	B-T121
potential	B-T080
dual	O
inhibitors	B-T121
of	O
α-glucosidase	B-T116
and	O
urease enzymes	B-T116
On	O
the	O
basis	O
of	O
previous	O
report	B-T170
on	O
promising	O
α-glucosidase	B-T116
inhibitory activity	B-T044
of	O
5-bromo-2-aryl benzimidazole derivatives	B-T109
,	O
these	O
derivatives	O
were	O
further	O
screened	B-T059
for	O
urease	B-T116
inhibitory	B-T044
and	O
cytotoxicity activity	B-T059
in	O
order	O
to	O
get	O
more potent	B-T080
and	O
non-cytotoxic	B-T121
potential	B-T080
dual	O
inhibitor	B-T121
for	O
the	O
patients	B-T101
suffering	O
from	O
diabetes	B-T047
as	O
well	O
as	O
peptic ulcer	B-T047
.	O
In	O
this	O
study	B-T062
,	O
all	O
compounds	B-T121
showed	O
varying	O
degree of potency	B-T038
in	O
the	O
range	O
of	O
(	O
IC50	B-T081
=8.15±0.03-354.67±0.19μM)	O
as	O
compared	O
to	O
standard	B-T081
thiourea	B-T109
(	O
IC50	B-T081
=21.25±0.15μM).	O
It	O
is	O
worth	O
mentioning	O
that	O
derivatives 7	B-T121
(	O
IC50	B-T081
=12.07±0.05μM),	O
8	B-T121
(	O
IC50	B-T081
=10.57±0.12μM),	O
11	B-T121
(	O
IC50	B-T081
=13.76±0.02μM),	O
14	B-T121
(	O
IC50	B-T081
=15.70±0.12μM)	O
and	O
22	B-T121
(	O
IC50	B-T081
=8.15±0.03μM)	O
were	O
found	O
to	O
be	O
more	O
potent inhibitors	B-T121
than	O
standard	B-T081
.	O
All	O
compounds	B-T121
were	O
also	O
evaluated	O
for	O
cytotoxicity	B-T059
towards	O
3T3	B-T025
mouse fibroblast cell line	B-T025
and	O
found	O
to	O
be	O
completely	O
non-toxic	B-T033
.	O
Previously	O
benzimidazole 1-25	B-T109
were	O
also	O
showed	O
α-glucosidase	B-T116
inhibitory potential	B-T044
.	O
In silico	B-T066
studies	B-T062
were	O
performed	O
on	O
the	O
lead molecules	B-T121
i.e.	O
2	B-T121
,	O
7	B-T121
,	O
8	B-T121
,	O
11	B-T121
,	O
14	B-T121
,	O
and	O
22	B-T121
,	O
in	O
order	O
to	O
rationalize	O
the	O
binding interaction	B-T044
of	O
compounds	B-T121
with	O
the	O
active site	B-T169
of	O
urease enzyme	B-T116
.	O

Intra-articular	B-T082
implantation	B-T061
of	O
collagen	B-T116
scaffold	B-T073
carriers	B-T074
is	O
safe	B-T082
in	O
both	O
native	B-T169
and	O
arthrofibrotic	B-T047
rabbit	B-T015
knee joints	B-T030
Sustained	B-T169
intra-articular	B-T082
delivery of pharmacological agents	B-T070
is	O
an	O
attractive	B-T080
modality	B-T078
but	O
requires	O
use	B-T169
of	O
a	O
safe	B-T082
carrier	B-T074
that	O
would	O
not	O
induce	B-T169
cartilage damage	B-T037
or	O
fibrosis	B-T046
.	O
Collagen	B-T116
scaffolds	B-T073
are	O
widely	O
available	B-T169
and	O
could	O
be	O
used	O
intra-articularly	B-T082
,	O
but	O
no	O
investigation	B-T058
has	O
looked	O
at	O
the	O
safety	B-T068
of	O
collagen	B-T116
scaffolds	B-T073
within	O
synovial joints	B-T030
.	O
The	O
aim	B-T078
of	O
this	O
study	B-T062
was	O
to	O
determine	B-T078
the	O
safety	B-T068
of	O
collagen	B-T116
scaffold	B-T073
implantation	B-T061
in	O
a	O
validated	B-T062
in vivo	B-T082
animal	B-T008
model	O
of	O
knee arthrofibrosis	B-T047
.	O
A	O
total	O
of	O
96	O
rabbits	B-T015
were	O
randomly	B-T080
and	O
equally	B-T080
assigned	B-T169
to	O
four	O
different	B-T080
groups	B-T078
:	O
arthrotomy	B-T061
alone;	O
arthrotomy	B-T061
and	O
collagen	B-T116
scaffold	B-T073
placement	B-T058
;	O
contracture	B-T190
surgery	B-T061
;	O
and	O
contracture	B-T190
surgery	B-T061
and	O
collagen	B-T116
scaffold	B-T073
placement	B-T058
.	O
Animals	B-T008
were	O
killed	B-T054
in	O
equal	B-T080
numbers	O
at	O
72	O
hours	B-T079
,	O
two	O
weeks	B-T079
,	O
eight	O
weeks	B-T079
,	O
and	O
24	O
weeks	B-T079
.	O
Joint contracture	B-T190
was	O
measured	B-T080
,	O
and	O
cartilage	B-T024
and	O
synovial	B-T023
samples	B-T167
underwent	O
histological analysis	B-T059
.	O
Animals	B-T008
that	O
underwent	O
arthrotomy	B-T061
had	O
equivalent	B-T080
joint contractures	B-T190
regardless	O
of	O
scaffold	B-T073
implantation	B-T061
(-13.9°	O
versus	O
-10.9°,	O
equivalence	O
limit	O
15°).	O
Animals	B-T008
that	O
underwent	O
surgery	B-T061
to	O
induce	B-T169
contracture	B-T190
did	O
not	O
demonstrate	O
equivalent	B-T080
joint contracture	B-T190
joint contracture s	B-T190
with	O
(41.8°)	O
or	O
without	O
(53.9°)	O
collagen	B-T116
scaffold	B-T073
implantation	B-T061
.	O
Chondral	B-T082
damage	B-T169
damage	B-T169
occurred	B-T052
in	O
similar	O
rates	B-T081
with	O
(11	O
of	O
48)	O
and	O
without	O
(nine	O
of	O
48)	O
scaffold	B-T073
implantation	B-T061
.	O
No	O
significant difference	B-T081
in	O
synovitis	B-T047
was	O
noted	O
between	O
groups	B-T078
.	O
Absorption	B-T070
of	O
the	O
collagen	B-T116
scaffold	B-T073
occurred	B-T052
within	O
eight	O
weeks	B-T079
in	O
all	O
animals	B-T008
CONCLUSION:	O
Our	O
data	B-T078
suggest	O
that	O
intra-articular	B-T082
implantation	B-T061
of	O
a	O
collagen	B-T116
sponge	B-T073
does	O
not	O
induce	B-T169
synovitis	B-T047
or	O
cartilage damage	B-T037
.	O
Implantation	B-T061
in	O
a	O
native	B-T169
joint	B-T030
does	O
not	O
seem	O
to	O
induce	B-T169
contracture	B-T190
.	O
Implantation	B-T061
of	O
the	O
collagen	B-T116
sponge	B-T073
in	O
a	O
rabbit	B-T015
knee	O
model	O
of	O
contracture	B-T190
may	O
decrease	B-T081
the	O
severity	B-T080
of	O
the	O
contracture	B-T190
.Cite	O
this	O
article:	O
J.	O
A.	O
Walker,	O
T.	O
J.	O
Ewald,	O
E.	O
Lewallen,	O
A.	O
Van	O
Wijnen,	O
A.	O
D.	O
Hanssen,	O
B.	O
F.	O
Morrey,	O
M.	O
E.	O
Morrey,	O
M.	O
P.	O
Abdel,	O
J.	O
Sanchez-Sotelo.	O
Intra-articular	O
implantation	O
of	O
collagen	O
scaffold	O
carriers	O
is	O
safe	O
in	O
both	O
native	O
and	O
arthrofibrotic	O
rabbit	O
knee	O
joints.	O
Bone	O
Joint	O
Res	O
2016;6:162-171.	O
DOI:	O
10.1302/2046-3758.63.BJR-2016-0193.	O

HOST	B-T001
IMMUNE RECOGNITION	B-T042
OF	O
THE	O
EPIDEMIC	B-T067
CYSTIC FIBROSIS	B-T047
PATHOGEN	B-T001
BURKHOLDERIA DOLOSA	B-T007
Burkholderia dolosa	B-T007
caused	O
an	O
outbreak	O
in	O
the	O
cystic fibrosis	B-T047
(	O
CF	B-T047
)	O
clinic	O
at	O
Boston Children's Hospital	B-T093
from	O
1998	O
to	O
2005	O
and	O
led	O
to	O
the	O
infection	B-T046
of	O
over	O
40	O
patients	B-T101
,	O
many	O
of	O
whom	O
died	B-T040
due	O
to	O
complications	B-T046
from	O
infection	B-T046
by	O
this	O
organism	B-T007
.	O
To	O
assess	O
whether	O
B. dolosa	B-T007
significantly	O
contributes	O
to	O
disease	B-T047
or	O
is	O
recognized	O
by	O
the	O
host	B-T001
immune response	B-T042
,	O
mice	B-T015
were	O
infected	B-T033
with	O
a	O
sequenced	O
outbreak	O
B. dolosa strain	B-T007
,	O
AU0158	B-T007
,	O
and	O
responses	B-T032
compared	O
to	O
the	O
well-studied	O
CF	B-T047
pathogen	B-T001
,	O
Pseudomonas aeruginosa	B-T007
In	O
parallel,	O
mice	B-T015
were	O
also	O
infected	B-T033
with	O
a	O
polar	O
flagellin	B-T026
mutant	B-T049
of	O
B. dolosa	B-T007
to	O
examine	O
the	O
role	O
of	O
flagella	B-T026
in	O
B. dolosa	B-T007
lung	B-T023
colonization	B-T033
.	O
The	O
results	O
showed	O
a	O
higher	B-T080
persistence	B-T041
in	O
the	O
host	B-T001
by	O
B. dolosa strains	B-T007
and	O
yet	O
neutrophil	B-T025
recruitment	O
and	O
cytokine	B-T116
production	B-T169
were	O
lower	O
compared	O
to	O
P. aeruginosa	B-T007
The	O
ability	O
of	O
host	B-T001
immune cells	B-T025
to	O
recognize	O
B. dolosa	B-T007
was	O
then	O
assessed	O
and	O
B. dolosa	B-T007
induced	O
a	O
robust	O
cytokine	B-T116
response	O
in	O
cultured cells	B-T025
and	O
this	O
effect	O
was	O
dependent	O
on	O
the	O
flagella	B-T026
only	O
when	O
bacteria	B-T007
were	O
dead	B-T040
.	O
Together,	O
these	O
results	O
suggest	O
that	O
B. dolosa	B-T007
can	O
be	O
recognized	O
by	O
host cells	B-T026
in vitro	B-T080
but	O
may	O
avoid	O
or	O
suppress	B-T169
the	O
host	B-T001
immune response	B-T042
in vivo	B-T082
through	O
unknown	O
mechanisms.	O
B. dolosa	B-T007
was	O
then	O
compared	O
to	O
other	O
Burkholderia species	B-T007
and	O
found	O
to	O
induce	O
similar	O
levels	O
of	O
cytokine	B-T116
production	B-T169
despite	O
being	O
internalized	O
by	O
macrophages	B-T025
more	O
than	O
B. cenocepacia strains	B-T007
.	O
These	O
data	B-T078
suggest	O
that	O
B. dolosa AU0158	B-T007
may	O
act	O
differently	O
with	O
host cells	B-T026
and	O
is	O
it	O
recognized	O
differently	O
by	O
immune systems	B-T022
compared	O
other	O
Burkholderia strains	B-T007
or	O
species	B-T185
.	O

Visualization	B-T033
and	O
targeting	B-T169
of	O
LGR5(+)	B-T028
human	B-T016
colon	B-T023
cancer stem cells	B-T025
The	O
cancer stem cell	B-T025
(	O
CSC	B-T025
)	O
theory	B-T078
highlights	O
a	O
self-renewing	B-T043
subpopulation	B-T185
of	O
cancer cells	B-T025
that	O
fuels	O
tumour growth.	B-T191
The	O
existence	B-T081
of	O
human	B-T016
CSCs	B-T025
is	O
mainly	O
supported	O
by	O
xenotransplantation	B-T061
of	O
prospectively	O
isolated cells	B-T033
,	O
but	O
their	O
clonal	B-T024
dynamics	B-T070
and	O
plasticity	B-T070
remain	O
unclear.	O
Here,	O
we	O
show	O
that	O
human	B-T016
LGR5(+)	B-T028
colorectal cancer cells	B-T025
serve	O
as	O
CSCs	B-T025
in	O
growing	O
cancer	B-T191
tissues	B-T024
.	O
Lineage	B-T077
-	O
tracing experiments	B-T059
with	O
a	O
tamoxifen	B-T109
-inducible	O
Cre	B-T116
knock-in	B-T063
allele	B-T028
of	O
LGR5	B-T116
reveal	O
the	O
self-renewal	B-T043
and	O
differentiation	B-T043
capacity	B-T081
of	O
LGR5(+)	B-T028
tumour cells	B-T025
.	O
Selective	O
ablation	B-T061
of	O
LGR5(+)	B-T028
CSCs	B-T025
in	O
LGR5	B-T028
-i	O
Caspase9	B-T028
knock-in	B-T063
organoids	B-T024
leads	O
to	O
tumour regression	B-T201
,	O
followed	O
by	O
tumour regrowth	B-T191
driven	O
by	O
re-emerging	O
LGR5(+)	B-T028
CSCs	B-T025
.	O
KRT20	B-T028
knock-in	B-T063
reporter	B-T028
marks	O
differentiated	B-T043
cancer cells	B-T025
that	O
constantly	O
diminish	O
in	O
tumour tissues	B-T024
,	O
while	O
reverting	O
to	O
LGR5(+)	B-T028
CSCs	B-T025
and	O
contributing	O
to	O
tumour regrowth	B-T191
after	O
LGR5(+)	B-T028
CSC	B-T025
ablation	B-T061
.	O
We	O
also	O
show	O
that	O
combined	O
chemotherapy	B-T061
potentiates	O
targeting	B-T169
of	O
LGR5(+)	B-T028
CSCs	B-T025
.	O
These	O
data	B-T078
provide	O
insights	O
into	O
the	O
plasticity	B-T070
of	O
CSCs	B-T025
and	O
their	O
potential	B-T080
as	O
a	O
therapeutic	B-T169
target	B-T169
in	O
human	B-T016
colorectal cancer	B-T191
.	O

The	O
Use	O
of	O
a	O
Software	B-T073
-	O
Assisted	B-T080
Method	B-T170
to	O
Estimate	B-T081
Fetal Weight	B-T032
at	O
and	O
Near	O
Term	B-T040
Using	O
Magnetic Resonance Imaging	B-T060
The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
apply	O
a	O
semi-automated	B-T169
calculation	B-T052
method	B-T170
of	O
fetal	B-T018
body volume	B-T032
and,	O
thus,	O
of	O
magnetic resonance-estimated fetal weight	B-T032
(	O
MR-EFW	B-T032
)	O
prior	O
to	O
planned	B-T169
delivery	B-T040
and	O
to	O
evaluate	B-T058
whether	O
the	O
technique	B-T169
of	O
measurement	B-T169
could	O
be	O
simplified	B-T080
while	O
remaining	B-T080
accurate	B-T080
.	O
MR-EFW	B-T032
was	O
calculated	B-T169
using	O
a	O
semi-automated	B-T169
method	B-T170
at	O
38.6	O
weeks	B-T079
of	O
gestation	B-T040
in	O
36	O
patients	B-T101
and	O
compared	O
to	O
the	O
picture archiving and communication system	B-T074
(	O
PACS	B-T074
).	O
Per	O
patient	B-T101
,	O
8	O
sequences	B-T169
were	O
acquired	B-T080
with	O
a	O
slice thickness	B-T081
of	O
4-8	O
mm	O
and	O
an	O
intersection gap	B-T082
of	O
0,	O
4,	O
8,	O
12,	O
16,	O
or	O
20	O
mm.	O
The	O
median	B-T082
absolute	B-T080
relative errors	B-T080
for	O
MR-EFW	B-T032
and	O
the	O
time	B-T079
of	O
planimetric measurements	B-T169
were	O
calculated	B-T169
for	O
all	O
8	O
sequences	B-T169
and	O
for	O
each	O
method	B-T170
(	O
assisted	B-T170
vs.	O
PACS	B-T074
),	O
and	O
the	O
difference	O
between	O
the	O
methods	B-T170
was	O
calculated	B-T169
.	O
The	O
median	B-T082
delivery	O
weight	O
was	O
3,280	O
g.	O
The	O
overall	O
median	B-T082
relative error	B-T080
for	O
all	O
288	O
MR-EFW	B-T032
calculations	B-T052
was	O
2.4%	O
using	O
the	O
semi-automated	B-T169
method	B-T170
and	O
2.2%	O
for	O
the	O
PACS	B-T074
method	B-T170
.	O
Measurements	B-T169
did	O
not	O
differ	O
between	O
the	O
8	O
sequences	B-T169
using	O
the	O
assisted	B-T170
method	B-T170
(p	O
=	O
0.313)	O
or	O
the	O
PACS	B-T074
(p	O
=	O
0.118),	O
while	O
the	O
time	B-T079
of	O
planimetric measurement	B-T169
decreased	B-T081
significantly	O
with	O
a	O
larger	O
gap	B-T082
(p	O
<	O
0.001)	O
and	O
in	O
the	O
assisted	B-T170
method	B-T170
compared	O
to	O
the	O
PACS	B-T074
method	B-T170
(p	O
<	O
0.01).	O
Our	O
simplified	B-T080
MR-EFW	B-T032
measurement	B-T169
showed	O
a	O
dramatic decrease	B-T081
in	O
time	B-T079
of	O
planimetric measurement	B-T169
without	O
a	O
decrease	B-T081
in	O
the	O
accuracy	B-T080
of	O
weight	B-T032
estimates	B-T081
.	O

Abiraterone	B-T109
-	O
induced	B-T169
rhabdomyolysis	B-T046
resulting	O
in	O
acute kidney injury	B-T037
:	O
A	O
case report	B-T170
and	O
review of the literature	B-T170
Abiraterone	B-T109
,	O
a	O
CYP17 inhibitor	B-T121
,	O
blocks	O
androgen biosynthesis	B-T044
in	O
multiple	O
tissue	B-T024
types.	O
In	O
combination	O
with	O
prednisone	B-T109
,	O
it	O
is	O
approved	O
as	O
a	O
first-line treatment	B-T061
for	O
metastatic	B-T191
castration-resistant prostate cancer	B-T191
.	O
We	O
present	O
a	O
case	B-T077
of	O
rhabdomyolysis	B-T046
associated	O
with	O
abiraterone	B-T109
therapy	B-T061
resulting	O
in	O
acute	B-T037
on	O
chronic	B-T079
kidney injury	B-T037
in	O
a	O
patient	B-T101
with	O
metastatic	B-T191
castration-resistant prostate cancer	B-T191
.	O
Strict	O
monitoring	B-T062
should	O
be	O
employed	O
in	O
patients	B-T101
started	O
on	O
abiraterone	B-T109
who	O
have	O
additional	O
risk factors	B-T033
for	O
developing	O
rhabdomyolysis	B-T046
.	O

Association	B-T080
between	O
XRCC1	B-T028
and	O
ERCC1	B-T028
single-nucleotide polymorphisms	B-T086
and	O
the	O
efficacy	B-T080
of	O
concurrent radiochemotherapy	B-T061
in	O
patients	B-T101
with	O
esophageal squamous cell carcinoma	B-T191
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	B-T169
the	O
association	B-T080
between	O
single-nucleotide polymorphisms	B-T086
(	O
SNPs	B-T086
)	O
in	O
X-ray repair cross-complementing 1-399	B-T028
(	O
XRCC1-399	B-T028
)	O
or	O
excision repair cross-complementation group 1-118	B-T028
(	O
ERCC1-118	B-T028
)	O
and	O
the	O
short-term	B-T079
efficacy	B-T080
of	O
radiochemotherapy	B-T061
,	O
tumor metastasis	B-T191
and	O
relapse	B-T067
,	O
as	O
well	O
as	O
the	O
survival time	B-T201
in	O
patients	B-T101
with	O
esophageal squamous cell carcinoma	B-T191
(	O
ESCC	B-T191
).	O
TaqMan probe-based quantitative polymerase chain reaction	B-T063
(	O
qPCR	B-T063
)	O
was	O
conducted	O
to	O
examine	B-T033
the	O
levels	B-T080
of	O
XRCC1-399	B-T028
and	O
ERCC1-118	B-T028
SNPs	B-T086
in	O
the	O
peripheral blood	B-T031
of	O
50	O
patients	B-T101
with	O
pathologically	B-T169
confirmed	B-T033
ESCC	B-T191
.	O
In	O
addition,	O
the	O
associations	B-T080
between	O
different	B-T080
genotypes	B-T032
and	O
short-term	B-T079
therapeutic efficacy	B-T080
[the	O
complete remission	B-T033
(	O
CR	B-T033
)	O
rate	B-T081
],	O
tumor metastasis	B-T191
and	O
relapse	B-T067
,	O
as	O
well	O
as	O
the	O
survival time	B-T201
following	O
concurrent radiochemotherapy	B-T061
,	O
were	O
determined	B-T080
.	O
A	O
total	O
of	O
50	O
ESCC	B-T191
patients	B-T101
who	O
received	O
concurrent radiochemotherapy	B-T061
were	O
enrolled.	O
It	O
was	O
found	O
that	O
the	O
short-term	B-T079
therapeutic efficacy	B-T080
(	O
CR	B-T033
rate	B-T081
)	O
was	O
higher	O
in	O
the	O
group	B-T078
of	O
patients	B-T101
carrying	O
the	O
homozygous mutation	B-T045
of	O
XRCC1-399	B-T028
(	O
A	B-T114
/	O
A	B-T114
genotype	B-T032
)	O
than	O
in	O
the	O
group	B-T078
of	O
patients	B-T101
without	O
the	O
XRCC1-399	B-T028
mutation	B-T045
(	O
G	B-T114
/	O
G	B-T114
genotype	B-T032
).	O
In	O
addition,	O
the	O
CR	B-T033
rate	B-T081
was	O
significantly increased	B-T081
in	O
patients	B-T101
carrying	O
one	O
or	O
two	O
ERCC1-118	B-T028
C	O
alleles	B-T028
(	O
C	B-T114
/	O
C	B-T114
or	O
C	B-T114
/	O
T	B-T114
genotype	B-T032
)	O
compared	B-T052
with	O
patients	B-T101
lacking	O
the	O
C	B-T114
allele	B-T028
(	O
T	B-T114
/	O
T	B-T114
genotype	B-T032
).	O
The	O
differences	O
were	O
statistically significant	B-T081
(	O
A	B-T114
/	O
A	B-T114
vs.	O
G	B-T114
/	O
G	B-T114
,	O
P=0.014;	O
T	B-T114
T	B-T114
vs.	O
C	B-T114
/	O
T	B-T114
+	O
C	B-T114
/	O
C	B-T114
,	O
P=0.040).	O
During	O
the	O
follow-up period	B-T033
,	O
the	O
group	B-T078
of	O
patients	B-T101
carrying	O
the	O
homozygous mutation	B-T045
of	O
XRCC1-399	B-T028
(	O
A	B-T114
/	O
A	B-T114
genotype	B-T032
)	O
exhibited	O
a	O
markedly reduced	B-T080
risk	B-T078
of	O
metastasis	B-T046
and	O
relapse	B-T067
compared	B-T052
with	O
the	O
group	B-T078
of	O
patients	B-T101
carrying	O
non-mutated	O
XRCC1-399	B-T028
(	O
G	B-T114
/	O
G	B-T114
genotype	B-T032
;	O
P=0.031).	O
By	O
contrast,	O
ERCC1-118	B-T028
SNP	B-T086
was	O
not	O
associated with	B-T080
the	O
risk	B-T078
of	O
metastasis	B-T046
and	O
recurrence	B-T067
(P>0.05).	O
The	O
combined	O
results	O
of	O
univariate	B-T062
and	O
multivariate Cox regression analysis	B-T170
showed	O
that	O
the	O
SNP	B-T086
in	O
ERCC1-118	B-T028
was	O
closely	O
associated with	B-T080
survival time	B-T201
.	O
The	O
mean survival time	B-T081
was	O
significantly	B-T078
prolonged	B-T079
in	O
patients	B-T101
carrying	O
1	O
or	O
2	O
C	B-T114
alleles	B-T028
(	O
C	B-T114
/	O
C	B-T114
or	O
C	B-T114
/	O
T	B-T114
genotype	B-T032
)	O
compared	B-T052
with	O
patients	B-T101
lacking	O
the	O
C	B-T114
allele	B-T028
(	O
T	B-T114
/	O
T	B-T114
genotype	B-T032
)	O
[	O
T	B-T114
/	O
T	B-T114
vs.	O
C	B-T114
/	O
C	B-T114
,	O
HR	B-T081
=12.96,	O
95%	O
confidence interval	B-T081
(	O
CI	B-T081
)=3.08-54.61,	O
P<0.001;	O
T	B-T114
T	B-T114
vs.	O
C	B-T114
/	O
T	B-T114
+	O
C	B-T114
/	O
C	B-T114
,	O
HR	B-T081
=11.71,	O
95%	O
CI	B-T081
=3.06-44.83,	O
P<0.001].	O
However,	O
XRCC1-399	B-T028
SNP	B-T086
had	O
no effect	B-T080
on	O
survival time	B-T201
(P>0.05).	O
XRCCl-399	B-T028
SNP	B-T086
was	O
associated with	B-T080
the	O
short-term	B-T079
therapeutic efficacy	B-T080
(the	O
CR	B-T033
rate	B-T081
)	O
and	O
tumor metastasis	B-T191
/	O
relapse	B-T067
in	O
ESCC	B-T191
patients	B-T101
who	O
received	O
the	O
docetaxel plus cisplatin (TP) regimen	B-T061
-based	O
concurrent radiochemotherapy	B-T061
.	O
By	O
contrast,	O
ERCC1-118	B-T028
SNP	B-T086
was	O
significantly	B-T078
associated with	B-T080
the	O
short-term	B-T079
therapeutic efficacy	B-T080
(the	O
CR	B-T033
rate	B-T081
)	O
and	O
survival time	B-T201
in	O
ESCC	B-T191
patients	B-T101
who	O
received	O
TP regimen	B-T061
-based	O
concurrent radiochemotherapy	B-T061
.	O

Ventricular pacing	B-T061
site separation	B-T082
by	O
cardiac	B-T082
computed tomography	B-T060
:	O
validation	B-T062
for	O
the	O
prediction	B-T078
of	O
clinical response	B-T033
to	O
cardiac resynchronization therapy	B-T061
Cardiac Resynchronization Therapy	B-T061
(	O
CRT	B-T061
)	O
fails	O
to	O
provide	B-T052
benefit	B-T081
in	O
up	O
to	O
one-third	O
of	O
patients	B-T101
.	O
Maximizing	O
the	O
geographic separation	B-T082
of	O
right	B-T082
and	O
left	B-T082
ventricular pacing	B-T061
lead sites	B-T029
has	O
been	O
suggested	B-T078
as	O
one	O
way	O
to	O
improve	B-T033
response	B-T032
.	O
Cardiac CT	B-T060
provides	B-T052
an	O
opportunity	B-T062
to	O
explore	O
3-dimensional	B-T082
inter-lead distance	B-T082
(	O
ILD	B-T082
)	O
measures	B-T081
for	O
the	O
prediction	B-T078
of	O
CRT	B-T061
response	B-T032
.	O
The	O
objective	B-T170
of	O
this	O
study	B-T062
was	O
to	O
investigate	B-T169
associations	B-T080
between	O
standardized	B-T080
measures	B-T081
of	O
ILD	B-T082
by	O
cardiac CT	B-T060
and	O
echocardiographic	B-T060
response	B-T032
to	O
CRT	B-T061
.	O
Forty-two	O
consecutive	B-T080
patients	B-T101
undergoing	O
CRT	B-T061
had	O
serial	O
clinical	B-T058
and	O
echocardiographic	B-T060
evaluations	B-T058
performed	B-T169
in addition to	B-T169
a	O
post-procedural	B-T079
cardiac	B-T082
-gated	O
CT	B-T060
with	O
blinded	B-T062
measurement	B-T169
of	O
direct	B-T080
and	O
circumferential	B-T082
(via	O
the	O
myocardium	B-T024
)	O
ILD	B-T082
measures	B-T081
.	O
Clinical response	B-T033
to	O
CRT	B-T061
,	O
the	O
primary clinical outcome	B-T034
,	O
was	O
defined	O
as	O
a	O
≥15%	O
reduction	B-T080
in	O
LVESV	B-T033
using	O
echocardiography	B-T060
at	O
6-months.	O
The	O
mean age	B-T032
and	O
ejection fraction	B-T033
was	O
63.6	O
±	O
8.9	O
years	O
and	O
25.2	O
±	O
7.8%,	O
respectively.	O
The	O
primary outcome	B-T080
occurred	B-T052
in	O
35	O
of	O
42	O
patients	B-T101
(83%).	O
Both	O
direct	B-T080
and	O
circumferential	B-T082
CT	B-T060
-based	O
ILD	B-T082
measures	B-T081
were	O
associated with	B-T080
the	O
primary outcome	B-T080
by	O
univariate analysis	B-T062
.	O
Receiver Operator Characteristic	B-T081
analysis	B-T062
identified	O
Circumferential	B-T082
ILD	B-T082
to	O
have	O
the	O
strongest	O
predictive	B-T080
accuracy	B-T080
(AUC	O
0.78).	O
Inter-	B-T081
and	O
intra-observer	B-T081
reproducibility	B-T080
of	O
CT	B-T060
-derived	O
ILD	B-T082
measures	B-T081
was	O
excellent	B-T080
.	O
Circumferential	B-T082
ILD	B-T082
measures	B-T081
on	O
cardiac CT	B-T060
are	O
predictive	B-T080
of	O
clinical response	B-T033
to	O
CRT	B-T061
.	O
Incorporation	B-T169
of	O
these	O
measures	B-T081
into	O
the	O
selection	B-T052
of	O
optimal	B-T080
pacing	B-T061
targets	B-T169
,	O
particularly	O
from	O
pre-procedural	B-T079
CT	B-T060
coronary vein	B-T023
imaging	B-T060
may	O
be	O
of	O
therapeutic	B-T169
benefit	B-T081
and	O
warrants	O
further	O
investigation	B-T058
.	O

Iodine Storage	B-T196
and	O
Metabolism	B-T040
of	O
Mild to Moderate	B-T080
Iodine-Deficient	B-T046
Pregnant	B-T040
Rats	B-T015
Severe iodine deficiency	B-T046
during pregnancy results	B-T079
in	O
neurodevelopmental disorders	B-T048
in	O
children	B-T100
,	O
while	O
the	O
consequences of	B-T169
mild to moderate iodine deficiency	B-T046
(	O
MMID	B-T046
)	O
are	O
uncertain	B-T033
.	O
The	O
concentration of iodine	B-T059
in	O
the	O
thyroid	B-T023
is	O
the	O
most	O
accurate	O
indicator	O
of	O
iodine nutrition	B-T196
.	O
This	O
study	O
aimed	O
to	O
evaluate	O
whether	O
the	O
iodine stores	B-T196
in	O
the	O
thyroid cover	B-T023
the	O
needs	O
of	O
the	O
mother and the fetus	B-T029
in	O
iodine	B-T121
-	O
sufficient	B-T080
and	O
MMID	B-T046
conditions	O
by	O
inductively coupled plasma-mass spectrometry	B-T059
.	O
One	O
hundred	O
four-week-old	O
female Wistar rats	B-T015
were	O
randomly	O
divided	O
into	O
MMID	B-T046
(	O
low iodine intake	B-T033
[L])	O
and	O
normal	B-T033
(	O
normal iodine intake	B-T033
[N])	O
groups	B-T078
.	O
The	O
rats	B-T015
were	O
fed for the next three months	B-T052
,	O
and	O
after pregnancy	B-T079
they	O
were	O
further	O
divided into two subgroups	B-T185
,	O
respectively:	O
low iodine	B-T033
pregnancy	B-T040
(	O
LP	B-T033
)	O
and	O
low iodine	B-T033
pregnancy	B-T040
with	O
iodine supplement	B-T168
(	O
LP+	B-T168
),	O
and	O
normal iodine intake	B-T033
pregnancy	B-T040
(	O
NP	B-T040
)	O
and	O
normal iodine intake	B-T033
pregnancy	B-T040
with	O
iodine supplement	B-T168
(	O
NP+	B-T168
).	O
The	O
iodine intake	B-T033
of	O
pregnant	B-T040
rats	B-T015
in	O
the	O
NP+	B-T168
and	O
LP+ groups	B-T168
was	O
twice	O
as	O
much	O
as	O
in	O
the	O
NP	B-T033
and	O
LP groups	B-T033
.	O
The	O
rats	B-T015
were	O
sacrificed	O
on	O
gestational day	B-T079
15	O
and	O
postnatal day	B-T079
7.	O
The	O
iodine concentration	B-T059
in	O
the	O
thyroid	B-T023
of	O
the	O
maternal	B-T033
and	O
newborn	B-T033
rats	B-T015
,	O
maternal serum	B-T059
,	O
placenta	B-T018
,	O
and	O
amniotic fluid	B-T031
were	O
determined	O
by	O
inductively coupled plasma-mass spectrometry	B-T059
.	O
The	O
concentration of iodine	B-T059
in	O
the	O
thyroid	B-T023
of	O
the	O
N group	B-T033
was	O
significantly higher	B-T081
than	O
that	O
in	O
the	O
L group	B-T033
before pregnancy	B-T033
.	O
The	O
concentration of iodine	B-T059
in	O
the	O
maternal thyroids	B-T058
of	O
the	O
LP group	B-T033
decreased	O
during pregnancy	B-T079
,	O
whereas	O
that	O
of	O
the	O
NP group	B-T033
did	O
not	O
change	O
significantly.	O
There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
iodine concentration	B-T059
in	O
the	O
thyroid	B-T023
of	O
mothers	B-T099
and	O
offspring	B-T099
between	O
the	O
NP	B-T033
and	O
NP+ groups	B-T168
,	O
but	O
it	O
was	O
significant	O
between	O
LP	B-T040
and	O
LP+ groups	B-T168
.	O
The	O
concentration of iodine	B-T059
in	O
amniotic fluid	B-T031
was	O
significantly	O
different	O
between	O
the	O
four	O
groups	B-T078
.	O
There	O
is	O
sufficient	O
iodine storage	B-T196
in	O
the	O
thyroid	B-T023
of	O
maternal	B-T033
rats	B-T015
with	O
normal iodine intake	B-T033
during pregnancy	B-T079
,	O
and	O
there	O
is	O
no	O
need	O
for	O
iodine supplementation	B-T058
.	O
However,	O
iodine stores	B-T196
are	O
insufficient	O
in	O
rats	B-T015
with	O
MMID	B-T046
.	O
Iodine supplementation	B-T058
can	O
increase	O
the	O
iodine concentration	B-T059
in	O
the	O
thyroid	B-T023
of	O
maternal	B-T033
rats	B-T015
with	O
MMID	B-T046
and	O
their	O
offspring	B-T099
,	O
as	O
well	O
as	O
in	O
the	O
amniotic fluid	B-T031
during pregnancy	B-T079
.	O

Omega 3 Fatty Acids	B-T109
Reduce	B-T080
Bone Resorption	B-T042
While	O
Promoting Bone Generation	B-T042
in	O
Rat	B-T015
Apical Periodontitis	B-T047
This	O
study	O
evaluated	B-T058
the	O
effects of	B-T080
the	O
dietary supplement	B-T168
omega 3 polyunsaturated fatty acids	B-T109
(	O
ω-3 PUFAs	B-T109
)	O
on	O
pulp exposure	B-T047
-induced	O
apical periodontitis	B-T047
(	O
AP	B-T047
)	O
in	O
rats	B-T015
.	O
Twenty-eight	O
male	B-T032
rats	B-T015
were	O
divided	O
into	O
groups	B-T098
:	O
control	O
untreated	B-T033
rats	B-T015
(C),	O
control	O
rats	B-T015
treated with	B-T169
ω-3 PUFAs	B-T109
alone	O
(C-O),	O
rats	B-T015
with	O
pulp exposure	B-T047
-induced	O
AP	B-T047
,	O
and	O
rats	B-T015
with	O
pulp exposure	B-T047
-induced	O
AP	B-T047
treated with	B-T169
ω-3 PUFAs	B-T109
(	O
AP	B-T047
-O).	O
The	O
ω-3 PUFAs	B-T109
were	O
administered orally	B-T061
,	O
once	O
a	O
day,	O
for	O
15	O
days	O
before	O
pulp exposure	B-T047
and,	O
subsequently,	O
30	O
days	O
after	O
pulp exposure	B-T047
.	O
Rats	B-T015
were	O
killed	B-T054
30	O
days	O
after	O
pulp exposure	B-T047
,	O
and	O
jaws	B-T023
were	O
subjected	O
to	O
histologic	B-UnknownType
and	O
immunohistochemical	B-T059
analyses	B-T062
.	O
Immunohistochemical	B-T059
analyses	B-T062
were	O
performed	O
to	O
detect	O
tartrate-resistant acid phosphatase	B-T116
-	O
positive	B-T033
osteoclasts	B-T025
and	O
osteocalcin	B-T116
-	O
positive	B-T033
osteoblasts	B-T025
on	O
the	O
bone surface	B-T029
of	O
periapical area	B-T082
.	O
Results	O
were	O
statistically	O
evaluated	B-T058
by	O
using	O
analysis of variance	B-T081
and	O
Tukey honestly significant difference	B-T081
,	O
and	O
P	O
<	O
.05	O
was	O
considered	O
statistically significant	B-T081
.	O
The	O
bone resorption	B-T042
lesion	B-T033
was	O
significantly larger	B-T081
in	O
the	O
AP	B-T047
group	O
compared	O
with	O
AP	B-T047
-O,	O
C,	O
and	O
C-O	O
groups	B-T098
(P	O
<	O
.05).	O
The	O
level	B-T080
of	O
inflammatory cell infiltration	B-T046
was	O
significantly	O
elevated,	O
and	O
the	O
number	O
of	O
tartrate-resistant acid phosphatase	B-T116
-	O
positive	B-T033
osteoclasts	B-T025
was	O
significantly higher	B-T081
in	O
the	O
periapical	B-T082
lesions	B-T033
of	O
the	O
AP	B-T047
group	O
compared	O
with	O
AP	B-T047
-O,	O
C,	O
and	O
C-O	O
groups	B-T098
(P	O
<	O
.05).	O
The	O
number	O
of	O
osteocalcin	B-T116
-	O
positive	B-T033
osteoblasts	B-T025
was	O
significantly	O
increased	B-T081
in	O
the	O
AP	B-T047
-O	O
group	O
compared	O
with	O
the	O
AP	B-T047
group	O
(P	O
>	O
.05).	O
Supplementation	B-T061
with	O
ω-3 PUFAs	B-T109
not	O
only	O
suppresses	B-T169
bone resorption	B-T042
but	O
also	O
promotes new bone formation	B-T042
in	O
the	O
periapical area	B-T082
of	O
rats	B-T015
with	O
AP	B-T047
in	O
conjunction	B-T078
with	O
downregulation	B-T044
of	O
inflammatory cell infiltration	B-T046
into	O
the	O
lesion	B-T033
.	O

MagR	B-T116
Alone	O
Is	O
Insufficient	B-T080
to	O
Confer	O
Cellular Calcium Responses	B-T043
to	O
Magnetic	B-T070
Stimulation	B-T061
Magnetic	B-T070
manipulation	B-T061
of	O
cell activity	B-T043
offers	O
advantages	B-T081
over	O
optical manipulation	B-T061
but	O
an	O
ideal	O
tool	O
remains	O
elusive.	O
The	O
MagR protein	B-T116
was	O
found	O
through	O
its	O
interaction	B-T044
with	O
cryptochrome	B-T116
(	O
Cry	B-T116
)	O
and	O
the	O
protein	B-T116
in	O
solution	B-T167
appeared	O
to	O
respond	B-T032
to	O
magnetic	B-T070
stimulation	B-T061
(	O
MS	B-T061
).	O
After	O
we	O
initiated	O
an	O
investigation	B-T058
on	O
the	O
specific	O
role	B-T077
of	O
MagR	B-T116
in	O
cellular response	B-T043
to	O
MS	B-T061
,	O
a	O
subsequent	O
study	B-T062
claimed	O
that	O
MagR	B-T116
expression	B-T045
alone	O
could	O
achieve	O
cellular activation	B-T043
by	O
MS	B-T061
.	O
Here	O
we	O
report	O
that	O
despite	O
systematically	B-T169
testing	B-T169
different	O
ways	O
of	O
measuring	B-T080
intracellular	B-T082
calcium	B-T121
and	O
different	O
MS	B-T061
protocols	B-T170
,	O
it	O
was	O
not	O
possible	O
to	O
detect	B-T033
any	O
cellular	B-T025
or	O
neuronal	B-T025
responses	B-T032
to	O
MS	B-T061
in	O
MagR	B-T116
-	O
expressing	B-T045
HEK cells	B-T025
or	O
primary	B-T080
neurons	B-T025
from	O
the	O
dorsal	B-T082
root ganglion	B-T023
and	O
the	O
hippocampus	B-T023
.	O
By	O
contrast,	O
in	O
neurons	B-T025
co-expressing	B-T045
MagR	B-T116
and	O
channelrhodopin	B-T116
,	O
optical	B-T061
but	O
not	O
MS	B-T061
increased	B-T081
calcium influx	B-T043
in	O
hippocampal	B-T023
neurons	B-T025
.	O
Our	O
results	O
indicate	O
that	O
MagR	B-T116
alone	O
is	O
not sufficient	B-T080
to	O
confer	O
cellular	B-T025
magnetic responses	B-T040
.	O

Acute kidney injury	B-T037
and	O
fluid overload	B-T047
in	O
infants	B-T100
and	O
children	B-T100
after	O
cardiac surgery	B-T061
Acute kidney injury	B-T037
is	O
a	O
common	O
and	O
serious	B-T080
complication	B-T046
after	O
congenital heart surgery	B-T061
,	O
particularly	O
among	O
infants	B-T100
.	O
This	O
comorbidity	B-T078
has	O
been	O
independently	O
associated with	B-T080
adverse outcomes	B-T046
including	O
an	O
increase	B-T169
in	O
mortality	B-T081
.	O
Postoperative	B-T079
acute kidney injury	B-T037
has	O
a	O
complex	O
pathophysiology	B-T169
with	O
many	O
risk factors	B-T033
,	O
and	O
therefore	O
no single medication	B-T033
or	O
therapy	B-T033
has	O
been	O
demonstrated	O
to	O
be	O
effective	B-T080
for	O
treatment	B-T061
or	O
prevention	B-T080
.	O
However,	O
it	O
has	O
been	O
established	O
that	O
the	O
associated	O
fluid overload	B-T047
is	O
one	O
of	O
the	O
major	O
determinants	B-T169
of	O
morbidity	B-T081
,	O
particularly	O
in	O
infants	B-T100
after	O
cardiac surgery	B-T061
.	O
Therefore,	O
in	O
the	O
absence	B-T169
of	O
an	O
intervention	B-T061
to	O
prevent	O
acute kidney injury	B-T037
,	O
much	O
of	O
the	O
effort	O
to	O
improve	B-T080
outcomes	B-T080
has	O
focused	O
on	O
treating	B-T169
and	O
preventing	B-T080
fluid overload	B-T047
.	O
Early	B-T079
renal replacement therapy	B-T061
,	O
often	O
in	O
the	O
form	O
of	O
peritoneal dialysis	B-T061
,	O
has	O
been	O
shown	O
to	O
be	O
safe	B-T068
and	O
beneficial	B-T081
in	O
infants	B-T100
with	O
oliguria	B-T047
after	O
heart surgery	B-T061
.	O
As	O
understanding	O
of	O
the	O
pathophysiology	B-T169
of	O
acute kidney injury	B-T037
and	O
the	O
ability	O
to	O
confidently	O
diagnose	B-T033
it	O
earlier	O
continues	O
to	O
evolve,	O
it	O
is	O
likely	O
that	O
novel	O
preventative	B-T080
and	O
therapeutic interventions	B-T061
will	O
be	O
available	O
in	O
the	O
future.	O

Systems	B-T169
Toxicology	B-T091
:	O
Real	O
World	B-T098
Applications	B-T169
and	O
Opportunities	B-T078
Systems	B-T169
Toxicology	B-T091
aims	O
to	O
change	O
the	O
basis	O
of	O
how	O
adverse biological effects	B-T169
of	O
xenobiotics	B-T123
are	O
characterized	B-T052
from	O
empirical	B-T080
end points	B-T080
to	O
describing	O
modes	B-T169
of	O
action	B-T052
as	O
adverse	B-T169
outcome	B-T169
pathways	B-T077
and	O
perturbed networks	B-T169
.	O
Toward	O
this	O
aim,	O
Systems	B-T169
Toxicology	B-T091
entails	O
the	O
integration	B-T066
of	O
in vitro	B-T080
and	O
in vivo	B-T082
toxicity	B-T037
data	B-T078
with	O
computational modeling	B-T066
.	O
This	O
evolving	O
approach	B-T169
depends	O
critically	O
on	O
data	B-T078
reliability	B-T081
and	O
relevance	B-T080
,	O
which	O
in	O
turn	O
depends	O
on	O
the	O
quality	B-T080
of	O
experimental models	B-T170
and	O
bioanalysis techniques	B-T062
used	O
to	O
generate	O
toxicological	B-T169
data	B-T078
.	O
Systems	B-T169
Toxicology	B-T091
involves	O
the	O
use	O
of	O
large-scale	O
data streams	B-T170
("big	O
data	B-T078
"),	O
such	O
as	O
those	O
derived	O
from	O
omics measurements	B-T062
that	O
require	O
computational	B-T052
means	O
for	O
obtaining	O
informative	B-T080
results	B-T169
.	O
Thus,	O
integrative analysis	B-T062
of	O
multiple	B-T081
molecular measurements	B-T169
,	O
particularly	O
acquired	O
by	O
omics strategies	B-T059
,	O
is	O
a	O
key	O
approach	B-T169
in	O
Systems	B-T169
Toxicology	B-T091
.	O
In	O
recent	O
years,	O
there	O
have	O
been	O
significant	O
advances	O
centered	O
on	O
in vitro	B-T080
test	O
systems	O
and	O
bioanalytical strategies	B-T059
,	O
yet	O
a	O
frontier	O
challenge	O
concerns	O
linking	B-T169
observed	O
network	B-T169
perturbations	B-T169
to	O
phenotypes	B-T032
,	O
which	O
will	O
require	O
understanding	O
pathways	B-T077
and	O
networks	B-T169
that	O
give	O
rise	O
to	O
adverse responses	B-T169
.	O
This	O
summary	B-T170
perspective	O
from	O
a	O
2016	O
Systems	B-T169
Toxicology	B-T091
meeting	B-T052
,	O
an	O
international conference	B-T068
held	O
in	O
the	O
Alps	B-T083
of	O
Switzerland	B-T083
,	O
describes	O
the	O
limitations	B-T169
and	O
opportunities	B-T078
of	O
selected	O
emerging	O
applications	B-T169
in	O
this	O
rapidly	O
advancing	O
field.	O
Systems	B-T169
Toxicology	B-T091
aims	O
to	O
change	O
the	O
basis	O
of	O
how	O
adverse biological effects	B-T169
of	O
xenobiotics	B-T123
are	O
characterized	B-T052
,	O
from	O
empirical	B-T080
end points	B-T080
to	O
pathways	B-T077
of	O
toxicity	B-T037
.	O
This	O
requires	O
the	O
integration	B-T066
of	O
in vitro	B-T080
and	O
in vivo	B-T082
data	B-T078
with	O
computational modeling	B-T066
.	O
Test	O
systems	O
and	O
bioanalytical technologies	B-T059
have	O
made	O
significant	O
advances,	O
but	O
ensuring	O
data	B-T078
reliability	B-T081
and	O
relevance	B-T080
is	O
an	O
ongoing	O
concern.	O
The	O
major	O
challenge	O
facing	O
the	O
new	O
pathway	B-T077
approach	B-T169
is	O
determining	O
how	O
to	O
link	B-T169
observed	O
network	B-T169
perturbations	B-T169
to	O
phenotypic	B-T032
toxicity	B-T037
.	O

Validating	B-T062
Signs and Symptoms	B-T184
From	O
An	O
Actual	O
Mass Casualty Incident	B-T051
to	O
Characterize	B-T052
An	O
Irritant Gas Syndrome Agent	B-T131
(	O
IGSA	B-T131
)	O
Exposure:	O
A	O
First	O
Step	O
in	O
The	O
Development	B-T169
of	O
a	O
Novel	B-T080
IGSA	B-T131
Triage	B-T061
Algorithm	B-T170
Chemical exposures	B-T033
can	O
pose	O
a	O
significant	B-T078
threat	B-T078
to	O
life	B-T078
.	O
Rapid	O
assessment	B-T058
by	O
first responders	B-T097
/	O
emergency nurses	B-T097
is	O
required	B-T169
to	O
reduce	B-T080
death	B-T040
and	O
disability	B-T033
.	O
Currently,	O
no	B-T169
informatics tools	B-T170
for	O
irritant gas syndrome agent	B-T131
s	O
(	O
IGSA	B-T131
)	O
exposures	B-T080
exist	B-T077
to	O
process	B-T067
victims	B-T098
efficiently	B-T080
,	O
continuously	B-T078
monitor	B-T058
for	O
latent	B-T080
signs/symptoms	B-T184
,	O
or	O
make	O
triage	B-T061
recommendations	B-T078
.	O
This	O
study	B-T062
describes	O
the	O
first	O
step	O
in	O
developing	O
ED	B-T073
informatics tools	B-T170
for	O
chemical incidents	B-T068
:	O
validation	B-T062
of	O
signs/symptoms	B-T184
that	O
characterize	B-T052
an	O
IGSA	B-T131
syndrome	B-T047
.	O
Data abstracted	B-T079
from	O
146	O
patients	B-T101
treated	B-T061
for	O
chlorine exposure	B-T033
in	O
one	O
emergency department	B-T073
during	B-T079
a	O
2005	O
train derailment	B-T067
and	O
152	O
patients	B-T101
not	B-T169
exposed to chlorine	B-T033
(a	O
comparison group	B-T096
)	O
were	O
mapped	B-T170
to	O
93	O
possible	O
signs/symptoms	B-T184
within	O
2	O
tools	B-T170
(	O
WISER	B-T170
and	O
CHEMM-IST	B-T170
)	O
designed	B-T052
to	O
assist	B-T080
emergency responders	B-T097
/	O
emergency nurses	B-T097
with	O
managing	O
hazardous material	B-T131
exposures	B-T080
.	O
Inferential statistics	B-T081
(χ(2)/	O
Fisher's exact test	B-T170
)	O
and	O
diagnostics tests	B-T060
were	O
used	B-T169
to	O
examine	O
mapped	B-T170
signs/symptoms	B-T184
of	O
persons	B-T098
who	O
were	O
and	O
were	O
not	O
exposed to chlorine	B-T033
.	O
Three	O
clusters	B-T081
of	O
signs/symptoms	B-T184
are	O
statistically	B-T081
associated with	B-T080
an	O
IGSA	B-T131
syndrome	B-T047
(P	O
<	O
.01):	O
respiratory	B-T169
(	O
shortness of breath	B-T184
,	O
wheezing	B-T184
,	O
coughing	B-T184
,	O
and	O
choking	B-T046
);	O
chest discomfort	B-T184
(	O
tightness	B-T184
,	O
pain	B-T184
,	O
and	O
burning	B-T184
),	O
and	O
eye	B-T023
,	O
nose	B-T023
and/or	O
throat	B-T023
(	O
pain	B-T184
,	O
irritation	B-T067
,	O
and	O
burning	B-T184
).	O
The	O
syndrome	B-T047
requires	O
the	O
presence	B-T033
of	O
signs/symptoms	B-T184
from	O
at	O
least	O
2	O
of	O
these	O
clusters	B-T081
.	O
The	O
latency period	B-T079
must	O
also	O
be	O
considered	B-T078
for	O
exposed	B-T098
/	O
potentially	B-T080
exposed persons	B-T098
.	O
This	O
study	B-T062
uses	B-T169
actual	O
patient data	B-T170
from	O
a	O
chemical incident	B-T068
to	O
characterize	B-T052
and	O
validate	B-T062
signs/symptoms	B-T184
of	O
an	O
IGSA	B-T131
syndrome	B-T047
.	O
Validating	B-T062
signs/symptoms	B-T184
is	O
the	O
first	O
step	O
in	O
developing	O
new	B-T080
ED	B-T073
informatics tools	B-T170
with	O
the	O
potential	B-T080
to	O
revolutionize	O
the	O
process	B-T067
by	O
which	O
emergency nurses	B-T097
manage	O
triage	B-T061
victims	B-T098
of	O
chemical incidents	B-T068
.	O

Fyn	B-T116
regulates	O
multipolar	B-T082
-	O
bipolar	B-T082
transition	B-T052
and	O
neurite morphogenesis	B-T043
of	O
migrating neurons	B-T043
in	O
the	O
developing neocortex	B-T042
Fyn	B-T116
is	O
a	O
non-receptor	B-T033
protein tyrosine kinase	B-T116
that	O
belongs	O
to	O
Src family kinases	B-T116
.	O
Fyn	B-T116
plays	O
a	O
critical	O
role	O
in	O
neuronal migration	B-T043
,	O
but	O
the	O
mechanism	B-T169
remains	O
unclear	B-T033
.	O
Here,	O
we	O
reported	O
that	O
suppression	B-T045
of	O
Fyn	B-T116
expression	B-T045
in	O
mouse cerebral cortex	B-T024
led	O
to	O
migration defects	B-T033
of	O
both	O
early-born	B-T079
and	O
late-born	B-T079
neurons	B-T025
.	O
Morphological	B-T082
analysis	B-T062
showed	O
that	O
loss	O
of	O
Fyn	B-T116
function	O
impaired	O
multipolar	B-T082
-	O
bipolar	B-T082
transition	B-T052
of	O
newly	O
generated	B-T052
neurons	B-T025
and	O
neurite formation	B-T043
in	O
the	O
early	O
phase	B-T079
of	O
migration	B-T043
.	O
Moreover,	O
Fyn	B-T116
inhibition	B-T045
increased	O
the	O
length	O
of	O
leading process	B-T043
and	O
decreased	O
the	O
branching	B-T082
number	O
of	O
the	O
migrating cortical neurons	B-T043
.	O
Together,	O
these	O
results	O
indicate	O
that	O
Fyn	B-T116
controls	B-T169
neuronal migration	B-T043
by	O
regulating	B-T038
the	O
cytoskeletal	B-T026
dynamics	B-T070
and	O
multipolar	B-T082
-	O
bipolar	B-T082
transition	B-T052
of	O
newly	B-T078
generated	B-T052
neurons	B-T025
during	O
cortical development	B-T042
.	O

Closing the Loop	B-T169
in	O
Adults	B-T100
,	O
Children	B-T100
and	O
Adolescents	B-T100
With	O
Suboptimally Controlled Type 1 Diabetes	B-T033
Under	O
Free	B-T078
Living Conditions	B-T080
:	O
A	O
Psychosocial	B-T169
Substudy	B-T062
The	O
objective	O
was	O
to	O
explore	O
psychosocial experiences	B-T033
of	O
closed loop technology	B-T074
for	O
adults	B-T100
,	O
children	B-T100
,	O
and	O
adolescents	B-T100
with	O
type 1 diabetes	B-T047
and	O
their	O
parents	B-T099
taking	O
part	O
in	O
two	O
multicenter	B-T062
,	O
free	B-T078
-	O
living	B-T080
,	O
randomized	B-T062
crossover home studies	B-T062
.	O
Participants	B-T098
using	O
insulin pump	B-T074
therapy	B-T061
were	O
randomized	B-T062
to	O
either	O
12	O
weeks	B-T079
of	O
automated	B-T169
closed-loop	B-T169
glucose control	B-T130
,	O
then	O
12	O
weeks	B-T079
of	O
sensor	B-T073
augmented	B-T081
insulin pump	B-T074
therapy	B-T061
(	O
open loop	B-T169
),	O
or	O
vice	O
versa.	O
Closed loop	B-T169
was	O
used	O
for	O
24	O
hours	B-T079
by	O
adults	B-T100
and	O
overnight	B-T079
only	O
by	O
children	B-T100
and	O
adolescents	B-T100
.	O
Participants	B-T098
completed	O
the	O
Diabetes Technology Questionnaire	B-T170
(	O
DTQ	B-T170
)	O
periodically	B-T079
and	O
shared	O
their	O
views	B-T082
in	O
semistructured interviews	B-UnknownType
.	O
This	O
analysis	B-T062
characterizes	B-T078
the	O
impact	B-T080
of	O
the	O
technology	B-T090
,	O
positive	B-T033
and	O
negative	B-T080
aspects	O
of	O
living	B-T080
with	O
the	O
device	B-T074
,	O
alongside	O
participants	B-T098
'	O
expectations	B-T078
,	O
hopes	B-T041
,	O
and	O
anxieties	B-T033
.	O
Participants	B-T098
were	O
32	O
adults	B-T100
,	O
age	O
38.6	O
±	O
9.6	O
years	B-T079
,	O
55%	O
male	B-T032
,	O
and	O
26	O
children	B-T100
,	O
mean	O
age	B-T032
12	O
years	B-T079
(range	O
6-18	O
years	B-T079
),	O
54%	O
male	B-T032
.	O
DTQ	B-T170
results	B-T169
indicated	O
moderately favorable impact	B-T080
of,	O
and	O
satisfaction	O
with,	O
both	O
open	B-T169
and	O
closed loop	B-T169
interventions	B-T061
,	O
but	O
little	O
evidence	B-T078
of	O
a	O
comparative advantage	B-UnknownType
of	O
either.	O
Key	O
positive themes	B-T033
included	O
perceived	O
improved blood glucose control	B-T130
,	O
improved general well-being	B-T033
,	O
particularly	O
on	O
waking	B-T039
,	O
improved sleep	B-T040
,	O
reduced	B-T080
burden	B-T078
of	O
diabetes	B-T047
,	O
and	O
visibility	B-T080
of	O
data	B-T078
.	O
Key	O
negative themes	B-T080
included	O
having	O
to	O
carry	O
around	O
the	O
equipment	B-T073
and	O
dislike	B-T041
of	O
the	O
pump	B-T074
and	O
second	O
cannula	B-T074
(ie,	O
sensor	B-T073
)	O
inserted.	O
Overall,	O
participants	B-T098
reported	O
a	O
positive	B-T033
experience	B-T055
of	O
the	O
closed loop technology	B-T074
.	O
Results	B-T169
are	O
consistent with	B-T078
previous	O
research	O
with	O
size	B-T082
of	O
equipment	B-T073
continuing	O
to	O
be	O
a	O
problem	B-T033
.	O
Progress	O
is	O
being	O
made	O
in	O
the	O
usability	B-T169
of	O
the	O
closed-loop system	B-T074
.	O

Serum	B-T031
levels	B-T080
of	O
genomic DNA	B-T114
of	O
α1(I) collagen	B-T028
are	O
elevated	B-T080
in	O
scleroderma	B-T047
patients	B-T101
Recent	O
studies	O
have	O
indicated	O
that	O
various	O
nucleic acids	B-T114
are	O
present	O
in	O
human	B-T016
sera	B-T031
,	O
and	O
attracted	O
attention	O
for	O
their	O
potential	O
as	O
novel	O
disease markers	B-T078
in	O
many	O
human	B-T016
diseases	B-T047
.	O
In	O
this	O
study,	O
we	O
tried	O
to	O
evaluate	O
the	O
possibility	O
that	O
DNA	B-T114
and	O
RNA	B-T114
of	O
collagens	B-T028
exist	O
in	O
human	B-T016
sera	B-T031
,	O
and	O
determined	O
whether	O
their	O
serum	B-T031
levels	B-T080
can	O
be	O
useful	O
biomarkers	B-T201
in	O
scleroderma	B-T047
patients	B-T101
.	O
The	O
RNA	B-T114
or	O
DNA	B-T114
of	O
collagens	B-T028
were	O
purified	B-T169
from	O
sera	B-T031
,	O
and	O
detected	B-T033
by	O
polymerase chain reaction	B-T063
or	O
quantitated	B-T081
by	O
real-time polymerase chain reaction	B-T063
.	O
Among	O
approximately	O
18	O
360 bases of full-length α1(I) collagen	B-T028
DNA	B-T114
,	O
various	O
regions	B-T028
were	O
detected	B-T033
by	O
polymerase chain reaction	B-T063
in	O
human	B-T016
sera	B-T031
.	O
However,	O
α2(I) collagen	B-T028
DNA	B-T114
,	O
α1(I) collagen	B-T028
RNA	B-T114
or	O
α2(I) collagen	B-T028
RNA	B-T114
were	O
not detectable	B-T033
.	O
α1(I) Collagen	B-T028
DNA	B-T114
in	O
sera	B-T031
was	O
quantitative	B-T081
using	O
our	O
method.	O
The	O
levels	B-T080
of	O
serum	B-T031
α1(I) collagen	B-T028
DNA	B-T114
were	O
significantly	O
increased	B-T081
in	O
scleroderma	B-T047
patients	B-T101
compared	O
with	O
healthy control	B-T080
subjects	B-T098
or	O
systemic lupus erythematosus	B-T047
patients	B-T101
.	O
According	O
to	O
the	O
receiver-operator curve analysis	B-T081
,	O
serum	B-T031
α1(I) collagen	B-T028
DNA	B-T114
levels	B-T080
were	O
shown	O
to	O
be	O
effective	O
as	O
a	O
diagnostic marker	B-T201
of	O
scleroderma	B-T047
.	O
Furthermore,	O
when	O
we	O
determined	O
the	O
association	B-T080
of	O
serum	B-T031
α1(I) collagen	B-T028
DNA	B-T114
levels	B-T080
with	O
clinical	B-T080
/	O
laboratory	B-T073
features	B-T080
in	O
scleroderma	B-T047
patients	B-T101
,	O
those	O
with	O
elevated	B-T080
α1(I) collagen	B-T028
DNA	B-T114
levels	B-T080
showed	O
significantly	O
higher	O
prevalence	B-T081
of	O
pitting scars	B-T047
/	O
ulcers	B-T047
.	O
In	O
summary,	O
elevation	B-T080
of	O
serum	B-T031
α1(I) collagen	B-T028
DNA	B-T114
levels	B-T080
in	O
scleroderma	B-T047
patients	B-T101
may	O
be	O
useful	O
as	O
the	O
diagnostic marker	B-T201
,	O
reflecting	O
the	O
presence	O
of	O
vasculopathy	B-T047
.	O
Jou	O
rna	B-T114

Metabolite	B-T123
mapping	B-T052
by	O
consecutive	O
nanostructure	B-T073
and	O
silver-assisted mass spectrometry imaging	B-T059
on	O
tissue sections	B-T024
Nanostructure-based mass spectrometry imaging	B-T059
(	O
MSI	B-T059
)	O
is	O
a	O
promising	O
technology	O
for	O
molecular imaging	B-T060
of	O
small molecules	B-T109
,	O
without	O
the	O
complex	O
chemical	O
background	O
typically	O
encountered	O
in	O
matrix-assisted molecular imaging	B-T060
approaches.	O
Here,	O
we	O
have	O
enhanced	O
these	O
surfaces	B-T082
with	O
silver	B-T196
(	O
Ag	B-T196
)	O
to	O
provide	O
a	O
second	O
tier	O
of	O
MSI data	B-T170
from	O
a	O
single	O
sample.	O
MSI data	B-T170
was	O
acquired	O
through	O
the	O
application	B-T169
of	O
laser desorption/ionization mass spectrometry	B-T059
to	O
biological samples	B-UnknownType
imprinted	O
onto	O
desorption/ionization on silicon	B-T067
(	O
DIOS	B-T067
)	O
substrates	B-T167
.	O
Following	O
initial	O
analysis	B-T062
,	O
ultra-thin Ag layers	B-T080
were	O
overlaid	O
onto	O
the	O
followed	O
by	O
MSI analysis	B-T059
(	O
Ag-DIOS MSI	B-T059
).	O
This	O
approach	O
was	O
first	O
demonstrated	O
for	O
fingermark	O
small molecules	B-T109
including	O
environmental	B-T082
contaminants	B-T167
and	O
sebum	B-T031
components.	O
Subsequently,	O
this	O
bimodal	O
method	O
was	O
translated	O
to	O
lipids	B-T109
and	O
metabolites	B-T123
in	O
fore-stomach sections	B-T024
from	O
a	O
6-bromoisatin	B-T109
chemopreventative	B-T080
murine mouse model	B-T050
.	O
DIOS MSI	B-T059
allowed	O
mapping	B-T052
of	O
common	O
ions	B-T196
in	O
fingermarks	O
as	O
well	O
as	O
6-bromoisatin	B-T109
metabolites	B-T123
and	O
lipids	B-T109
in	O
murine fore-stomach	B-T024
.	O
Furthermore,	O
DIOS MSI	B-T059
was	O
complemented	O
by	O
the	O
Ag-DIOS MSI	B-T059
of	O
Ag-adductable lipids	B-T109
such	O
as	O
wax esters	B-T109
in	O
fingermarks	O
and	O
cholesterol	B-T109
in	O
murine fore-stomach	B-T024
.	O
Gastrointestinal acid	B-T031
condensation	B-T067
products	B-T123
of	O
6-bromoisatin	B-T109
,	O
such	O
as	O
the	O
6,6'-dibromoindirubin	B-T123
mapped	O
herein,	O
are	O
very	O
challenging	O
to	O
isolate	B-T059
and	O
characterize	B-T052
.	O
By	O
re-analyzing	O
the	O
same	O
tissue	B-T024
imprints,	O
this	O
metabolite	B-T123
was	O
readily	O
detected	O
by	O
DIOS	B-T067
,	O
placed	O
in	O
a	O
tissue-specific spatial context	B-T024
,	O
and	O
subsequently	O
overlaid	O
with	O
additional	O
lipid distributions	B-T043
acquired	O
using	O
Ag-DIOS MSI	B-T059
.	O
The	O
ability	O
to	O
place	O
metabolite	B-T123
and	O
lipid	B-T109
classes	O
in	O
a	O
tissue-specific	B-T024
context	O
makes	O
this	O
novel	O
method	O
suited	O
to	O
MSI analyses	B-T059
where	O
the	O
collection	O
of	O
additional	O
information	O
from	O
the	O
same	O
sample	O
maximises	O
resource	O
use,	O
and	O
also	O
maximises	O
the	O
number	O
of	O
annotated	O
small molecules	B-T109
,	O
in	O
particular	O
for	O
metabolites	B-T123
that	O
are	O
typically	O
undetectable	B-T201
with	O
traditional	O
platforms.	O
Copyright	O
©	O
2017	O
John	O
Wiley	O
&	O
Sons,	O
Ltd.	O

Towards	O
culturally competent paediatric oncology care	B-T058
.	O
A	O
qualitative study	B-T062
from	O
the	O
perspective	B-T077
of	O
care providers	B-T097
In	O
order	O
to	O
gain	O
more	O
insight	O
on	O
the	O
influence	B-T077
of	O
ethnic	B-T033
diversity	B-T080
in	O
paediatric	B-T091
cancer care	B-T061
,	O
the	O
perspectives	B-T077
of	O
care providers	B-T097
were	O
explored.	O
Semi-structured interviews	B-T058
were	O
conducted	O
among	O
12	O
paediatric oncologists	B-T097
and	O
13	O
nurses	B-T097
of	O
two	O
different	O
paediatric oncology wards	B-T093
and	O
were	O
analysed	B-T062
using	O
a	O
framework method	B-T170
.	O
We	O
found	O
that	O
care providers	B-T097
described	O
the	O
contact	O
with	O
Turkish	B-T098
and	O
Moroccan	B-T098
parents	B-T099
as	O
more	O
difficult.	O
They	O
offered	O
two	O
reasons	O
for	O
this:	O
(1)	O
language barriers	B-T033
between	O
care provider	B-T097
and	O
parents	B-T099
hindered	B-T169
the	O
exchange of information	B-T170
;	O
(2)	O
cultural barriers	B-T058
between	O
care provider	B-T097
and	O
parents	B-T099
about	O
sharing	O
the	O
diagnosis	B-T033
and	O
palliative	B-T080
perspective	B-T077
hindered	B-T169
communication	B-T054
.	O
Care providers	B-T097
reported	O
different	O
solutions	B-T077
to	O
deal	O
with	O
these	O
barriers	B-T078
,	O
such	O
as	O
using	O
an	O
interpreter	B-T097
and	O
improving	O
their	O
cultural knowledge	B-T170
about	O
their	O
patients	B-T101
.	O
They,	O
however,	O
were	O
not	O
using	O
interpreters	B-T097
sufficiently	O
and	O
were	O
unaware	O
of	O
the	O
importance	O
of	O
eliciting	B-T048
parents	B-T099
'	O
perspectives	B-T077
.	O
Communication	B-T054
techniques	B-T169
to	O
overcome	O
dilemmas	B-T068
between	O
parents	B-T099
and	O
care providers	B-T097
were	O
not	O
used	O
and	O
care providers	B-T097
were	O
unaware	O
of	O
stereotypes	B-T041
and	O
prejudice	B-T055
.	O
Care providers	B-T097
should	O
be	O
offered	O
insight	O
in	O
cultural barriers	B-T058
they	O
are	O
unaware	O
of.	O
Training	B-T065
in	O
cultural competence	B-T054
might	O
be	O
a	O
possibility	O
to	O
overcome	O
manifest	B-T169
barriers	B-T078
.	O

Obesogenic	B-T047
eating behaviors	B-T055
mediate	O
the	O
relationships	B-T080
between	O
psychological problems	B-T033
and	O
BMI	B-T201
in	O
children	B-T100
To	O
examine	O
the	O
association	B-T080
between	O
psychological problems	B-T033
and	O
weight	B-T032
status	B-T080
in	O
children	B-T100
aged	B-T032
3.5	O
to	O
4	O
years	B-T079
and	O
test	O
whether	O
obesogenic	B-T047
eating behaviors	B-T055
mediate	O
this	O
relationship	B-T080
.	O
This	O
study	O
is	O
a	O
cross-sectional secondary analysis	B-T062
of	O
data	B-T078
from	O
first-time mothers	B-T099
(N	O
=	O
194)	O
in	O
the	O
control	O
arm	O
of	O
the	O
NOURISH randomized controlled trial	B-T062
.	O
At	O
child	B-T100
child	B-T100
age	O
3.5	O
to	O
4	O
years,	O
maternal	B-T099
-reported	O
child	B-T100
eating behaviors	B-T055
and	O
psychological problems	B-T033
were	O
collected	O
via	O
valid	O
tools,	O
and	O
child	B-T100
weight	B-T032
and	O
height	B-T032
data were collected	B-T062
by	O
trained	O
study	O
staff	B-T080
.	O
Pearson's correlations	B-T170
and	O
linear regressions	B-T081
examined	O
associations	B-T080
between	O
eating behaviors	B-T055
,	O
psychological problems	B-T033
,	O
and	O
BMI	B-T201
z score	B-T081
.	O
Multiple mediation models	B-UnknownType
were	O
tested	B-T169
by	O
assessing	O
indirect	B-T080
effects	B-T080
of	O
psychological problems	B-T033
on	O
BMI	B-T201
z score	B-T081
via	O
obesogenic	B-T047
eating behaviors	B-T055
.	O
Peer	B-T098
problems	B-T033
were	O
associated with	B-T080
both	O
higher	B-T080
food	B-T168
responsiveness	B-T169
and	O
emotional overeating	B-T048
and	O
directly	B-T080
with	O
higher	B-T080
BMI	B-T201
z score	B-T081
.	O
This	O
relationship	B-T080
was	O
partially	O
mediated	O
by	O
emotional overeating	B-T048
.	O
Both	O
emotional overeating	B-T048
and	O
food	B-T168
responsiveness	B-T169
fully	O
mediated	O
the	O
association	B-T080
between	O
emotional problems	B-T048
and	O
BMI	B-T201
z score	B-T081
,	O
and	O
food	B-T168
responsiveness	B-T169
fully	O
mediated	O
the	O
association	B-T080
between	O
conduct problems	B-T048
and	O
BMI	B-T201
z score	B-T081
.	O
The	O
findings	O
suggest	O
that	O
children	B-T100
with	O
psychological problems	B-T033
may	O
also	O
display	O
obesogenic	B-T047
eating behaviors	B-T055
,	O
which	O
may	O
result	O
in	O
higher	B-T080
BMI	B-T201
.	O
This	O
needs	O
to	O
be	O
considered	O
in	O
the	O
clinical management	B-T058
of	O
both	O
pediatric	B-T080
overweight	B-T184
/	O
obesity	B-T047
and	O
psychological problems	B-T033
.	O

Homocysteine	B-T116
as	O
a	O
peripheral	B-T082
biomarker	B-T201
in	O
bipolar disorder	B-T048
:	O
A	O
meta-analysis	B-T062
Bipolar disorder	B-T048
(	O
BD	B-T048
)	O
is	O
a	O
psychiatric disorder	B-T048
with	O
an	O
uncertain	B-T033
aetiology	B-T169
.	O
Recently,	O
special	O
attention	O
has	O
been	O
given	O
to	O
homocysteine	B-T116
(	O
Hcy	B-T116
),	O
as	O
it	O
has	O
been	O
suggested	O
that	O
alterations	B-T078
in	O
1-carbon metabolism	B-T044
might	O
be	O
implicated	O
in	O
diverse	O
psychiatric disorders	B-T048
.	O
However,	O
there	O
is	O
uncertainty	B-T033
regarding	O
possible	O
alterations	B-T078
in	O
peripheral	B-T082
Hcy	B-T116
levels	O
in	O
BD	B-T048
.	O
This	O
study	O
comprises	O
a	O
meta-analysis	B-T062
comparing	O
serum	B-T059
and	O
plasma Hcy levels	B-T059
in	O
persons	B-T098
with	O
BD	B-T048
and	O
healthy controls	B-T080
.	O
We	O
conducted	O
a	O
systematic	B-T169
search	B-T052
for	O
all	O
eligible	B-T080
English	O
and	O
non-English	O
peer-reviewed articles	B-T170
.	O
Nine	O
cross-sectional studies	B-T062
were	O
included	B-T169
in	O
the	O
meta-analyses	B-T062
,	O
providing	B-T052
data	B-T078
on	O
1547	O
participants	B-T098
.	O
Random-effects	B-T080
meta-analysis	B-T062
showed	O
that	O
serum	B-T059
and	O
plasma levels of Hcy	B-T059
were	O
increased	B-T081
in	O
subjects	B-T096
with	O
BD	B-T048
in	O
either	O
mania	B-T048
or	O
euthymia	B-T048
when	O
compared	B-T052
to	O
healthy controls	B-T080
,	O
with	O
a	O
large	O
effect size	B-T081
in	O
the	O
mania	B-T048
group	B-T098
(g=0.98,	O
95%	O
CI	B-T081
:	O
0.8-1.17,	O
P<0.001,	O
n=495)	O
and	O
a	O
small	O
effect	B-T080
in	O
the	O
euthymia	B-T048
group	B-T098
(g=0.3,	O
95%	O
CI	B-T081
:	O
0.11-0.48,	O
P=0.002,	O
n=1052).	O
Our	O
meta-analysis	B-T062
provides	O
evidence	O
that	O
Hcy levels are elevated	B-T033
in	O
persons	B-T098
with	O
BD	B-T048
during	O
mania	B-T048
and	O
euthymia	B-T048
.	O
Peripheral	B-T082
Hcy	B-T116
could	O
be	O
considered	B-T078
as	O
a	O
potential	B-T080
biomarker	B-T201
in	O
BD	B-T048
,	O
both	O
of	O
trait	B-T032
(since	O
it	O
is	O
increased	B-T081
in	O
euthymia	B-T048
),	O
and	O
also	O
of	O
state	B-T169
(since	O
its	O
increase	B-T169
is	O
more	O
accentuated	B-T080
in	O
mania	B-T048
).	O
Longitudinal studies	B-T062
are	O
needed	O
to	O
clarify	O
the	O
relationship	B-T080
between	O
bipolar disorder	B-T048
and	O
Hcy	B-T116
,	O
as	O
well	O
as	O
the	O
usefulness	B-T080
of	O
peripheral	B-T082
Hcy	B-T116
as	O
both	O
a	O
trait	B-T032
and	O
state	B-T169
biomarker	B-T201
in	O
BD	B-T048
.	O

Structural Modification	B-T061
of	O
Lipopolysaccharide	B-T109
Conferred	O
by	O
mcr-1	B-T028
in	O
Gram-Negative ESKAPE	B-T007
Pathogens	B-T001
mcr-1	B-T028
was	O
initially	O
reported	O
as	O
the	O
first	O
plasmid	B-T114
-mediated	O
colistin	B-T116
resistance gene	B-T028
in	O
clinical isolates	B-T123
of	O
Escherichia coli	B-T007
and	O
Klebsiella pneumoniae	B-T007
in	O
China	B-T083
and	O
has	O
subsequently	O
been	O
identified	O
worldwide	O
in	O
various	O
species	B-T185
of	O
the	O
family Enterobacteriaceae	B-T007
mcr-1	B-T028
encodes	O
a	O
phosphoethanolamine transferase	B-T044
,	O
and	O
its	O
expression	B-T045
has	O
been	O
shown	O
to	O
generate	O
phosphoethanolamine	B-T109
-modified	O
bis-phosphorylated hexa-acylated lipid A	B-T109
in	O
E. coli	B-T007
Here,	O
we	O
investigated	O
the	O
effects of	B-T080
mcr-1	B-T028
on	O
colistin	B-T116
susceptibility	B-T033
and	O
on	O
lipopolysaccharide	B-T109
structures	B-T082
in	O
laboratory	B-T073
and	O
clinical	B-T080
strains	B-T080
of	O
the	O
Gram-negative ESKAPE	B-T007
(	O
Enterococcus faecium	B-T007
,	O
Staphylococcus aureus	B-T007
,	O
K. pneumoniae	B-T007
K. pneumoniae	B-T007
,	O
Acinetobacter baumannii	B-T007
,	O
Pseudomonas aeruginosa	B-T007
,	O
and	O
Enterobacter species	B-T007
)	O
pathogens	B-T001
,	O
which	O
are	O
often	O
treated	B-T169
clinically	B-T080
by	O
colistin	B-T116
.	O
The	O
effects of	B-T080
mcr-1	B-T028
on	O
colistin	B-T116
resistance	B-T032
were	O
determined	O
using	O
MIC assays	B-T059
of	O
laboratory	B-T073
and	O
clinical	B-T080
strains	B-T080
of	O
E. coli	B-T007
,	O
K. pneumoniae	B-T007
,	O
A. baumannii	B-T007
,	O
and	O
P. aeruginosa	B-T007
Lipid A	B-T109
structural	B-T082
changes	O
resulting	O
from	O
MCR-1	B-T116
were	O
analyzed	O
by	O
mass spectrometry	B-T059
.	O
The	O
introduction	O
of	O
mcr-1	B-T028
led	O
to	O
colistin	B-T116
resistance	B-T032
in	O
E. coli	B-T007
,	O
K. pneumoniae	B-T007
,	O
and	O
A. baumannii	B-T007
but	O
only	O
moderately	O
reduced	B-T080
susceptibility	B-T033
in	O
P. aeruginosa	B-T007
Phosphoethanolamine	B-T109
modification	B-T033
of	O
lipid A	B-T109
was	O
observed	O
consistently	O
for	O
all	O
four	O
species	B-T185
.	O
These	O
findings	B-T169
highlight	O
the	O
risk	B-T078
of	O
colistin	B-T116
resistance	B-T032
as	O
a	O
consequence of	B-T169
mcr-1	B-T028
expression	B-T045
among	O
ESKAPE	B-T007
pathogens	B-T001
,	O
especially	O
in	O
K. pneumoniae	B-T007
and	O
A. baumannii	B-T007
Furthermore,	O
the	O
observation	O
that	O
lipid A	B-T109
structures	B-T082
were	O
modified	O
despite	O
only	O
modest	O
increases	B-T169
in	O
colistin	B-T116
MICs	B-T059
in	O
some	O
instances	O
suggests	O
more	O
sophisticated	O
surveillance methods	B-T062
may	O
need	O
to	O
be	O
developed	O
to	O
track	O
the	O
dissemination	B-T082
of	O
mcr-1	B-T028
or	O
plasmid	B-T114
plasmid	B-T114
-mediated	O
phosphoethanolamine transferases	B-T044
in	O
general.	O

Effects	B-T080
of	O
Transplanted	B-T061
Human	B-T016
Cord Blood	B-T031
-	O
Mononuclear Cells	B-T025
on	O
Pulmonary Hypertension	B-T046
in	O
Immunodeficient Mice	B-T015
and	O
Their	O
Distribution	B-T169
To	O
investigate	B-T058
the	O
effects	B-T080
of	O
human	B-T016
umbilical cord blood	B-T031
-derived	O
mononuclear cell	B-T025
(	O
hUCB	B-T031
-	O
MNC	B-T025
)	O
transplantation	B-T061
on	O
pulmonary hypertension	B-T046
(	O
PH	B-T046
)	O
induced	B-T169
by	O
monocrotaline	B-T109
(	O
MCT	B-T109
)	O
in	O
immunodeficient mice	B-T015
and	O
their	O
distribution	B-T169
.	O
MCT	B-T109
was	O
administered	B-T169
to	O
BALB/c Slc-nu/nu mice	B-T015
,	O
and	O
PH	B-T046
was	O
induced	B-T169
in	O
mice	B-T015
4	O
weeks	O
later.	O
Fresh	B-T080
hUCB	B-T031
-	O
MNCs	B-T025
harvested	B-T061
from	O
a	O
human	B-T016
donor	B-T098
after	O
her	O
delivery	B-T169
were	O
injected intravenously	B-T169
into	O
those	O
PH	B-T046
mice	B-T015
.	O
The	O
medial	B-T082
thickness	B-T080
of	O
pulmonary arterioles	B-T023
,	O
ratio	B-T081
of	O
right ventricular	B-T023
to	O
septum	B-T023
plus	B-T169
left ventricular	B-T023
weight	B-T081
(	O
RV	B-T023
/	O
S	B-T023
+	O
LV	B-T023
),	O
and	O
ratio	B-T081
of	O
acceleration time	B-T081
to	O
ejection time	B-T201
of	O
pulmonary blood flow	B-T201
waveform	B-T070
(	O
AT	B-T081
/	O
ET	B-T201
)	O
were	O
determined	B-T080
4	O
weeks	O
after	O
hUCB	B-T031
-	O
MNC	B-T025
transplantation	B-T061
.	O
To	O
reveal	B-T080
the	O
incorporation	B-T169
into	O
the	O
lung	B-T023
,	O
CMTMR	B-T109
-	O
labeled	B-T130
hUCB	B-T031
-	O
MNCs	B-T025
were	O
observed	B-T169
in	O
the	O
lung	B-T023
by	O
fluorescent microscopy	B-T059
.	O
DiR-labeled	B-T130
hUCB	B-T031
-	O
MNCs	B-T025
were	O
detected	B-T033
in	O
the	O
lung	B-T023
and	O
other	O
organs	B-T023
by	O
bioluminescence images	B-T074
.	O
Medial	B-T082
thickness	B-T080
,	O
RV	B-T023
/	O
S	B-T023
+	O
LV	B-T023
and	O
AT	B-T081
/	O
ET	B-T201
were	O
significantly	B-T078
improved	B-T033
4	O
weeks	O
after	O
hUCB	B-T031
-	O
MNC	B-T025
transplantation	B-T061
compared	B-T052
with	O
those	O
in	O
mice	B-T015
without	O
hUCB	B-T031
-	O
MNC	B-T025
transplantation	B-T061
.	O
CMTMR	B-T109
-	O
positive	B-T033
hUCB	B-T031
-	O
MNCs	B-T025
were	O
observed	B-T169
in	O
the	O
lung	B-T023
3	O
hours	O
after	O
transplantation	B-T061
.	O
Bioluminescence	B-T038
signals	B-T067
were	O
detected	B-T033
more	O
strongly	B-T080
in	O
the	O
lung	B-T023
than	O
in	O
other	O
organs	B-T023
for	O
24	O
hours	O
after	O
transplantation	B-T061
.	O
The	O
results	B-T033
indicate	B-T033
that	O
hUCB	B-T031
-	O
MNCs	B-T025
are	O
incorporated	B-T169
into	O
the	O
lung	B-T023
early	B-T079
after	O
hUCB	B-T031
-	O
MNC	B-T025
transplantation	B-T061
and	O
improve	B-T033
MCT	B-T109
-	O
induced	B-T169
PH	B-T046
.	O
J.	O
Med.	O
Invest.	O
64:	O
43-49,	O
February,	O
2017.	O

Interprofessional Barriers	B-T033
:	O
A	O
Study	O
of	O
Quality Improvement Work	B-T057
Among	O
Nurses	B-T097
and	O
Physicians	B-T097
This	O
article	O
studies	O
interprofessional barriers	B-T033
between	O
nurses	B-T097
and	O
physicians	B-T097
in	O
the	O
context	B-T078
of	O
quality improvement work	B-T057
.	O
A	O
total	O
of	O
17	O
nurses	B-T097
and	O
10	O
physicians	B-T097
were	O
interviewed	B-T062
at	O
2	O
hospitals	B-T073
in	O
Sweden	B-T083
.	O
The	O
study uncovered	B-T169
a	O
number of barriers	B-T033
relating	O
to	O
both	O
the	O
relative	O
status	O
of	O
each group	B-T078
and	O
their	O
defined	O
areas of responsibility	B-T055
.	O

Recovery	B-T052
from	O
alcohol dependence	B-T048
:	O
Do	O
smoking	B-T055
indicators	B-T169
predict	O
abstinence	B-T061
?	O
There	O
is	O
inconsistent	B-T080
evidence	B-T078
about	O
the	O
potential	B-T080
influence	B-T077
of	O
smoking	B-T055
on	O
recovery	B-T052
from	O
alcohol dependence	B-T048
.	O
Our	O
study	B-T059
aimed	O
at	O
assessing	B-T058
the	O
impact	B-T080
of	O
smoking-behavior	B-T055
on	O
relapse	B-T067
during	O
a	O
12	O
months	B-T079
follow-up	B-T058
period	B-T079
following	O
a	O
detoxification	B-T061
in	O
patients	B-T101
with	O
Alcohol Use Disorder	B-T048
(	O
AUD	B-T048
).	O
Three	O
hundred	O
Patients	B-T101
with	O
AUD	B-T048
(74.9%	O
smoking	B-T055
)	O
were	O
recruited	O
from	O
two	O
inpatient	B-T101
detoxification units	B-T093
in	O
psychiatric hospitals	B-T073
in	O
Germany	B-T083
and	O
their	O
alcohol consumption	B-T055
was	O
prospectively	O
followed	O
for	O
1	O
year	B-T079
.	O
Data	B-T078
on	O
different	O
indicators	B-T169
of	O
smoking behavior	B-T055
was	O
gathered.	O
Cox regression model	B-T081
was	O
used	O
to	O
evaluate	B-T058
potential	B-T080
risk factors	B-T033
on	O
time	O
to	O
relapse	B-T067
of	O
alcohol consumption	B-T055
.	O
Two	O
hundred	O
seventy-nine	O
participants	B-T098
(n	O
=	O
279)	O
were	O
included	O
in	O
the	O
final	B-T079
analysis	B-T062
.	O
Smoking	B-T055
increased	B-T081
the	O
risk	B-T078
for	O
alcohol relapse	B-T067
(	O
hazard ratio	B-T081
=	O
3.962,	O
95%	O
CI	B-T081
1.582-9.921).	O
However,	O
this	O
increased	B-T081
risk	B-T078
is	O
slightly	O
reduced	B-T080
with	O
higher	O
numbers	O
of	O
daily	B-T079
consumed cigarettes	B-T033
(	O
hazard ratio	B-T081
per	B-T080
cigarette	B-T033
=	O
.986,	O
95%	O
CI	B-T081
.976-.995).	O
Smoking reduced	B-T033
the	O
probability	B-T081
of	O
maintaining	B-T052
alcohol abstinence	B-T061
significantly	B-T078
,	O
whereas	O
higher	B-T080
number	O
of	O
cigarettes smoked	B-T033
daily	B-T079
diminished	B-T081
the	O
increased	B-T081
risk	B-T078
of	O
alcohol relapse	B-T067
in	O
alcohol-dependent	B-T048
patients	B-T101
.	O
Coordinated	B-T169
psychiatric	B-T169
and	O
substance abuse	B-T048
interventions	B-T061
for	O
different	O
subgroups	B-T185
of	O
patients	B-T101
with	O
AUD	B-T048
in	O
the	O
post-acute treatment phase	B-UnknownType
are	O
necessary.	O
Individualized	B-T080
treatment	B-T169
planning	O
is	O
especially	O
important	O
in	O
smoking	B-T055
patients	B-T101
with	O
AUD	B-T048
who	O
are	O
vulnerable	O
for	O
a	O
relapse to alcohol drinking	B-T067
and	O
for	O
somatic	B-T080
complications	B-T046
.	O
Our	O
findings	B-T033
might	O
support	O
individualized	B-T080
treatment plans	B-T170
.(Am	O
J	O
Addict	O
2017;XX:1-8).	O

Similar	O
patterns	B-T082
of	O
neural activity	B-T042
predict	O
memory function	B-T041
during	O
encoding	B-T041
and	O
retrieval	B-T041
Neural networks	B-T023
that	O
span	B-T081
the	O
medial temporal lobe	B-T023
(	O
MTL	B-T023
),	O
prefrontal cortex	B-T023
,	O
and	O
posterior cortical regions	B-T023
are	O
essential	O
to	O
episodic memory function	B-T041
in	O
humans	B-T016
.	O
Encoding	B-T041
and	O
retrieval	B-T041
are	O
supported	O
by	O
the	O
engagement	O
of	O
both	O
distinct	O
neural pathways	B-T023
across	O
the	O
cortex	B-T023
and	O
common	O
structures	B-T082
within	O
the	O
medial temporal lobes	B-T023
.	O
However,	O
the	O
degree	O
to	O
which	O
memory performance	B-T041
can	O
be	O
determined	O
by	O
neural processing	B-T040
that	O
is	O
common	O
to	O
encoding	B-T041
and	O
retrieval	B-T041
remains	O
to	O
be	O
determined.	O
To	O
identify	O
neural signatures	B-T169
of	O
successful	O
memory function	B-T041
,	O
we	O
administered	O
a	O
delayed	O
free-recall task	B-T057
to	O
187	O
neurosurgical	B-T061
patients	B-T101
implanted	B-T061
with	O
subdural	B-T030
or	O
intraparenchymal	B-T023
depth electrodes	B-T074
.	O
We	O
developed	O
multivariate classifiers	B-T170
to	O
identify	O
patterns	B-T082
of	O
spectral	O
power	O
across	O
the	O
brain	B-T023
that	O
independently	O
predicted	O
successful	O
episodic encoding	B-T041
and	O
retrieval	B-T041
.	O
During	O
encoding	B-T041
and	O
retrieval	B-T041
,	O
patterns	B-T082
of	O
increased	O
high frequency	B-T079
activity	B-T042
in	O
prefrontal	B-T023
,	O
MTL	B-T023
,	O
and	O
inferior parietal cortices	B-T023
,	O
accompanied	O
by	O
widespread	O
decreases	O
in	O
low frequency	B-T079
power	O
across	O
the	O
brain	B-T023
predicted	O
successful	O
memory function	B-T041
.	O
Using	O
a	O
cross-decoding approach	B-T081
,	O
we	O
demonstrate	O
the	O
ability	O
to	O
predict	O
memory function	B-T041
across	O
distinct	O
phases	O
of	O
the	O
free-recall task	B-T057
.	O
Furthermore,	O
we	O
demonstrate	O
that	O
classifiers	B-T170
that	O
combine	O
information	O
from	O
both	O
encoding	B-T041
and	O
retrieval states	B-T041
can	O
outperform	O
task-independent models	B-T170
.	O
These	O
findings	O
suggest	O
that	O
the	O
engagement	O
of	O
a	O
core	O
memory network	B-T041
during	O
either	O
encoding	B-T041
or	O
retrieval	B-T041
shapes	B-T082
the	O
ability to remember the past	B-T033
,	O
despite	O
distinct	O
neural interactions	B-T042
that	O
facilitate	O
encoding	B-T041
and	O
retrieval	B-T041
.	O

Trump's	B-T016
got	O
the	O
right idea	B-T078
I	O
am	O
a	O
US	B-T083
nursing student	B-T097
and	O
feel	B-T041
that	O
Obamacare	B-T089
is	O
a	O
bad idea	B-T078
.	O
I'm	O
disappointed	B-T041
that	O
President	B-T090
Trump	B-T016
was	O
not able to get rid of	B-T033
it	O
last month	B-T079
.	O

Bilirubin	B-T109
and	O
atherosclerotic	B-T047
diseases	B-T047
Bilirubin	B-T109
is	O
the	O
final	O
product	B-T071
of	O
heme catabolism	B-T044
in	O
the	O
systemic circulation	B-UnknownType
.	O
For	O
decades	B-T081
,	O
increased	B-T081
serum	B-T031
/	O
plasma	B-T031
bilirubin	B-T109
levels	B-T080
were	O
considered	O
an	O
ominous	O
sign	B-T033
of	O
an	O
underlying	O
liver disease	B-T047
.	O
However,	O
data	B-T078
from	O
recent	O
years	B-T079
convincingly	O
suggest	O
that	O
mildly	O
elevated	B-T080
bilirubin	B-T109
concentrations	B-T081
are	O
associated	B-T080
with	O
protection	B-T033
against	O
various	O
oxidative stress	B-T049
-mediated	O
diseases	B-T047
diseases	B-T047
,	O
atherosclerotic	B-T047
conditions	O
being	O
the	O
most	O
clinically	B-T080
relevant	B-T080
.	O
Although	O
scarce	O
data	B-T078
on	O
beneficial	B-T081
effects	B-T080
of	O
bilirubin	B-T109
had	O
been	O
published	B-T057
also	O
in	O
the	O
past,	O
it	O
took	O
until	O
1994	O
when	O
the	O
first	O
clinical study	B-T062
demonstrated	O
an	O
increased	B-T081
risk	B-T078
of	O
coronary heart disease	B-T047
in	O
subjects	O
with	O
low	B-T080
serum	B-T031
bilirubin	B-T109
levels	B-T080
,	O
and	O
bilirubin	B-T109
was	O
found	O
to	O
be	O
a	O
risk factor	B-T033
for	O
atherosclerotic	B-T047
diseases	B-T047
independent	O
of	O
standard	O
risk factors	B-T033
.	O
Consistent	O
with	O
these	O
results	B-T169
,	O
we	O
proved	O
in	O
our	O
own	O
studies	B-T062
,	O
that	O
subjects	O
with	O
mild elevation of serum levels of unconjugated bilirubin	B-UnknownType
(	O
benign	B-T080
hyperbilirubinemia	B-T047
,	O
Gilbert syndrome	B-T047
)	O
have	O
much	O
lower	O
prevalence	B-T081
/	O
incidence	B-T081
of	O
coronary heart	B-T047
as	O
well	O
as	O
peripheral vascular disease	B-T047
.	O
We	O
have	O
also	O
demonstrated	O
that	O
this	O
association	B-T080
is	O
even	O
more	O
general,	O
with	O
serum	B-T031
bilirubin	B-T109
being	O
a	O
biomarker	B-T201
of	O
numerous	O
other	O
diseases	B-T047
diseases	B-T047
,	O
often	O
associated	B-T080
with	O
increased	B-T081
risk	B-T078
of	O
atherosclerosis	B-T047
.	O
In	O
addition,	O
very	O
recent	O
data	B-T078
have	O
demonstrated	O
biological pathways	B-T044
modulated	O
by	O
bilirubin	B-T109
,	O
which	O
are	O
responsible	O
for	O
observed	O
strong	O
clinical	B-T080
associations	B-T080
.	O

An	O
Automated	B-T169
,	O
Pharmacist	B-T097
-Driven	O
Initiative	B-T041
Improves	B-T033
Quality of Care	B-T058
for	O
Staphylococcus aureus Bacteremia	B-T047
Infectious diseases	B-T047
(	O
ID	B-T047
)	O
consultation	B-T058
and	O
antimicrobial stewardship intervention	B-T058
have	O
been	O
shown	O
to	O
improve	B-T033
the	O
management	B-T058
of	O
Staphylococcus aureus bacteremia	B-T047
(	O
SAB	B-T047
).	O
As	O
the	O
workload	B-T081
of	O
antimicrobial stewardship programs	B-T058
(	O
ASPs	B-T058
)	O
continues	O
to	O
increase,	O
ASPs	B-T058
must	O
find	O
a	O
way	O
to	O
maximize	O
the	O
efficiency of the program	B-T078
while	O
optimizing	O
patient	B-T101
outcomes	B-T169
.	O
The	O
objective	O
of	O
this	O
study	B-T062
was	O
to	O
evaluate	B-T058
the	O
impact	B-T080
of	O
incorporating	O
health informatics	B-T091
into	O
the	O
management	B-T058
of	O
SAB	B-T047
via	O
a	O
pharmacist	B-T097
-driven	O
initiative	B-T041
.	O
Retrospective	B-T080
,	O
single-center	O
quasi-experimental	B-T062
study	B-T062
of	O
hospitalized patients	B-T101
with	O
SAB	B-T047
.	O
During	O
the	O
intervention	B-T061
period	B-T079
,	O
pharmacists	B-T097
were	O
alerted	O
to	O
patients	B-T101
with	O
SAB	B-T047
via	O
a	O
patient	B-T101
scoring tool	B-T074
integrated	O
into	O
the	O
electronic medical record	B-T170
.	O
Pharmacists	B-T097
utilized	O
the	O
scoring tool	B-T074
and	O
the	O
institution's	B-T093
evidence-based practice	B-T169
guideline	B-T170
to	O
make	O
standardized recommendations	B-T078
to	O
promote	O
adherence	B-T169
to	O
SAB	B-T047
quality-of-care	B-T058
measures	B-T081
and	O
encourage	O
ID	B-T047
consultation	B-T058
.	O
The	O
primary	B-T080
outcome	B-T169
was	O
overall	O
compliance	B-T033
along	O
with	O
adherence	B-T169
to	O
individual	B-T098
quality-of-care	B-T058
components	B-T077
.	O
Secondary	B-T080
clinical	O
outcomes	B-T169
were	O
also	O
analyzed	B-T062
.	O
84	O
patients	B-T101
were	O
identified	O
for	O
study	B-T062
inclusion	B-T080
,	O
45	O
in	O
the	O
pre-	O
intervention	B-T061
and	O
39	O
in	O
the	O
intervention	B-T061
group	B-T078
.	O
As	O
a	O
whole,	O
all	O
four	O
quality-of-care	B-T058
components	B-T077
for	O
the	O
management	B-T058
of	O
SAB	B-T047
were	O
significantly	B-T078
more	O
frequently	O
adhered	O
to	O
in	O
the	O
intervention	B-T061
group	B-T078
(68.9%	O
vs.	O
92.3%;	O
P=0.008).	O
The	O
incidence	B-T081
of	O
ID	B-T047
consult	B-T058
improved	B-T033
significantly	B-T078
by	O
almost	O
20%	O
in	O
the	O
intervention	B-T061
group	B-T078
(75.6%	O
vs.	O
94.9%,	O
P=0.015).	O
No	O
statistically significant	B-T081
differences	B-T080
in	O
duration	O
of	O
bacteremia	B-T047
,	O
length-of-stay	B-T079
,	O
infection	B-T046
-related	O
length-of-stay	B-T079
,	O
or	O
readmission	B-T058
were	O
observed	O
between	O
the	O
groups	B-T078
.	O
The	O
incidence	B-T081
of	O
all-cause	O
mortality	B-T081
was	O
6-fold	O
higher	O
in	O
the	O
pre-	O
intervention	B-T061
group	B-T078
compared	O
to	O
the	O
intervention	B-T061
group	B-T078
(15.6%	O
vs.	O
2.6%,	O
P=0.063).	O
An	O
automated	B-T169
,	O
pharmacist	B-T097
-driven	O
intervention	B-T061
for	O
the	O
management	B-T058
of	O
patients	B-T101
with	O
SAB	B-T047
demonstrated	O
a	O
significant	B-T078
improvement	B-T077
in	O
patients	B-T101
receiving	O
an	O
ID	B-T047
consult	B-T058
,	O
targeted	B-T169
antimicrobial therapy	B-T121
,	O
and	O
adherence	B-T169
to	O
all	O
SAB	B-T047
quality-of-care	B-T058
measures	B-T081
.	O
As	O
antimicrobial stewardship	B-T058
becomes	O
a	O
mandatory	B-T169
aspect	O
of	O
healthcare	B-T058
in	O
all	O
hospitals	B-T073
in	O
the	O
U.S.	B-T083
,	O
ASPs	B-T058
will	O
be	O
forced	B-T169
to	O
find	B-T033
ways	O
to	O
provide	O
more	O
efficient	B-T080
,	O
impactful	B-T080
,	O
disease	B-T047
state-based	O
patient care	B-T058
.	O
Our	O
study	B-T062
provides	O
the	O
framework	O
for	O
and	O
data	B-T078
to	O
support	O
this	O
intervention	B-T061
in	O
one	O
of	O
the	O
most	O
clinically important	B-T080
infectious diseases	B-T047
.	O

Involvement	O
of	O
intracellular	B-T026
Zn(2+)	B-T121
signaling	B-T043
in	O
LTP	B-T042
at	O
perforant pathway	B-T023
-	O
CA1 pyramidal cell synapse	B-T023
Physiological	B-T169
significance	O
of	O
synaptic Zn(2+) signaling	B-T043
was	O
examined	O
at	O
perforant pathway	B-T023
-	O
CA1 pyramidal cell synapses	B-T023
.	O
In vivo	B-T082
long-term potentiation	B-T042
(	O
LTP	B-T042
)	O
at	O
perforant pathway	B-T023
-	O
CA1 pyramidal cell synapses	B-T023
was	O
induced	O
using	O
a	O
recording	O
electrode	B-T074
attached	O
to	O
a	O
microdialysis	B-T058
probe	B-T074
and	O
the	O
recording	O
region	O
was	O
locally	O
perfused	B-T061
with	O
artificial cerebrospinal fluid	B-T103
(	O
ACSF	B-T103
)	O
via	O
the	O
microdialysis	B-T058
probe	B-T074
.	O
Perforant pathway	B-T023
LTP	B-T042
was	O
not	O
attenuated	O
under	O
perfusion	B-T061
with	O
CaEDTA	B-T130
(10	O
mM),	O
an	O
extracellular	B-T026
Zn(2+)	B-T121
chelator,	O
but	O
attenuated	O
under	O
perfusion	B-T061
with	O
ZnAF-2DA	B-T130
(50	O
μM),	O
an	O
intracellular	B-T026
Zn(2+)	B-T121
chelator,	O
suggesting	O
that	O
intracellular	B-T026
Zn(2+)	B-T121
signaling	B-T043
is	O
required	O
for	O
perforant pathway	B-T023
LTP	B-T042
.	O
Even	O
in	O
rat brain slices	B-T023
bathed	O
in	O
CaEDTA	B-T130
in	O
ACSF	B-T103
,	O
intracellular	B-T026
Zn(2+)	B-T121
level,	O
which	O
was	O
measured	O
with	O
intracellular	B-T026
ZnAF-2	B-T130
,	O
was	O
increased	O
in	O
the	O
stratum lacunosum-moleculare	B-T023
where	O
perforant pathway	B-T023
-	O
CA1 pyramidal cell synapses	B-T023
were	O
contained	O
after	O
tetanic stimulation	B-T061
.	O
These	O
results	O
suggest	O
that	O
intracellular	B-T026
Zn(2+)	B-T121
signaling	B-T043
,	O
which	O
originates	O
in	O
internal	O
stores/	O
proteins	B-T116
,	O
is	O
involved	O
in	O
LTP	B-T042
at	O
perforant pathway	B-T023
-	O
CA1 pyramidal cell synapses	B-T023
.	O
Because	O
the	O
influx	B-T043
of	O
extracellular	B-T026
Zn(2+)	B-T121
,	O
which	O
originates	O
in	O
presynaptic Zn(2+) release	B-T043
,	O
is	O
involved	O
in	O
LTP	B-T042
at	O
Schaffer collateral	B-T026
-	O
CA1 pyramidal cell synapses	B-T023
,	O
synapse	B-T030
-dependent	O
Zn(2+)	B-T121
dynamics	O
may	O
be	O
involved	O
in	O
plasticity	B-T043
of	O
postsynaptic	B-UnknownType
CA1 pyramidal cells	B-T025
.	O

20S immunoproteasomes	B-T116
remove	O
formaldehyde	B-T109
-	O
damaged	B-T169
cytoplasmic proteins	B-T116
suppressing	B-T169
caspase-independent cell death	B-T043
Immunoproteasomes	B-T116
are	O
known	O
for	O
their	O
involvement	B-T169
in	O
antigen presentation	B-T043
.	O
However,	O
their	O
broad	B-T082
tissue	B-T024
presence	B-T033
and	O
other	O
evidence	B-T169
are	O
indicative of	B-T078
nonimmune functions	B-T039
.	O
We	O
examined	O
a	O
role	O
for	O
immunoproteasomes	B-T116
in	O
cellular responses	B-T043
to	O
the	O
endogenous	B-T169
and	O
environmental carcinogen	B-T131
formaldehyde	B-T109
(	O
FA	B-T109
)	O
that	O
binds	O
to	O
cytosolic	B-T026
and	O
nuclear proteins	B-T116
producing	O
proteotoxic stress	B-T046
and	O
genotoxic	B-T049
DNA	B-T114
-	O
histone	B-T116
crosslinks	B-T070
.	O
We	O
found	O
that	O
immunoproteasomes	B-T116
were	O
important	B-T080
for	O
suppression	B-T169
of	O
a	O
caspase-independent cell death	B-T043
and	O
the	O
long-term	B-T079
survival	B-T169
of	O
FA-treated cells	B-T025
.	O
All	O
major	O
genotoxic	B-T049
responses	B-T032
to	O
FA	B-T109
,	O
including	O
replication inhibition	B-T045
and	O
activation	B-T052
of	O
the	O
transcription factor p53	B-T116
and	O
the	O
apical	B-T082
ATM	B-T116
and	O
ATR kinases	B-T116
,	O
were	O
unaffected	B-T077
by	O
immunoproteasome	B-T116
inactivity	B-T080
.	O
Immunoproteasome	O
inhibition	B-T052
enhanced	B-T052
activation	B-T052
of	O
the	O
cytosolic	B-T026
protein	B-T116
damage	B-T169
sensor HSF1	B-T116
,	O
elevated levels	B-T080
of	O
K48-polyubiquitinated	B-T044
cytoplasmic proteins	B-T116
and	O
increased	B-T081
depletion	B-T169
of	O
unconjugated	B-T080
ubiquitin	B-T116
.	O
We	O
further	O
found	O
that	O
FA	B-T109
induced	B-T169
the	O
disassembly	B-T052
of	O
26S immunoproteasomes	B-T116
,	O
but	O
not	O
standard	O
26S proteasomes	B-T116
,	O
releasing	O
the	O
20S catalytic immunoproteasome	B-T116
.	O
FA-treated cells	B-T025
also	O
had	O
higher amounts	B-T081
of	O
small	O
activators PA28αβ	B-T116
and	O
PA28γ	B-T116
bound	O
to	O
20S particles	B-T116
.	O
Our	O
findings	O
highlight	O
the	O
significance	B-T078
of	O
nonnuclear damage	B-T169
in	O
FA	B-T109
injury	O
and	O
reveal	O
a	O
major	O
role	O
for	O
immunoproteasomes	B-T116
in	O
elimination	O
of	O
FA-damaged	B-T169
cytoplasmic proteins	B-T116
through	O
ubiquitin	B-T116
-	O
independent	B-T078
proteolysis	B-T044
.	O

Musculoskeletal pain	B-T033
profile	B-T170
of	O
obese	B-T047
individuals	B-T098
attending	B-T169
a	O
multidisciplinary weight management service	B-T093
Obesity	B-T047
is	O
associated with	B-T080
numerous	B-T081
chronic diseases	B-T047
,	O
including	B-T169
musculoskeletal (MSK) pain	B-T033
,	O
which	O
impacts	B-T080
on	O
quality of life	B-T078
(	O
QoL	B-T078
).	O
There	O
is,	O
however,	O
limited	O
research	O
providing	O
a	O
comprehensive	B-T080
MSK pain	B-T033
profile	B-T170
of	O
an	O
obese	B-T047
cohort	B-T098
.	O
This	O
retrospective study	B-T062
utilized	O
a	O
patient	B-T101
database	B-T170
at	O
a	O
national weight management service	B-T093
(	O
WMS	B-T093
).	O
Following	O
ethical	B-T078
approval	B-T170
,	O
anonymized	B-T170
patient data	B-T170
were	O
statistically analyzed	B-T062
to	O
develop	O
a	O
pain	B-T184
profile	B-T170
,	O
investigate	B-T169
relationships	B-T080
between	O
pain	B-T184
,	O
sleep	B-T040
,	O
and	O
function	B-T033
,	O
and	O
explore	O
variables	B-T080
associated with	B-T080
having	O
low back pain	B-T184
(	O
LBP	B-T184
)	O
and	O
knee pain	B-T033
.	O
Overall,	O
915	O
individuals	B-T098
attended	O
the	O
WMS	B-T093
from	O
January	O
2011	O
to	O
September	O
2015	O
[	O
male	B-T098
,	O
35%	O
(n=318;	O
CI	B-T081
=32-38);	O
female	B-T098
,	O
65%	O
(n=597;	O
CI	B-T081
=62-68);	O
mean	B-T081
age	B-T032
44.6].	O
Mean	B-T081
BMI	B-T201
was	O
50.7	O
kg/m2	O
[Class	O
III	O
obese	B-T047
(	O
BMI	B-T201
≥40	O
kg/m2),	O
92%	O
(n=835;	O
CI	B-T081
=91-94)].	O
Approximately	B-T080
91%	O
reported	O
MSK pain	B-T033
:	O
LBP	B-T184
,	O
69%	O
(n=539;	O
CI	B-T081
=65-	O
72)	O
[	O
mean	B-T081
NRS	O
7.4];	O
knee pain	B-T033
,	O
58%	O
(n=447;	O
CI	B-T081
=55-61)	O
[	O
mean	B-T081
NRS	O
6.8].	O
Class	O
III	O
obese	B-T047
and	O
multi-site	B-T082
pain	B-T184
patients	B-T101
had	O
lower	B-T052
QoL	B-T078
and	O
physical activity	B-T056
levels	B-T080
,	O
reduced	B-T080
sleep	B-T040
,	O
and	O
poorer	B-T080
physical function	B-T033
than	O
less	B-T080
obese	B-T047
patients	B-T101
and	O
those	O
without	B-T080
pain	B-T184
(p<0.05).	O
Relationships	B-T080
were	O
found	O
between	O
demographic	B-T090
,	O
pain	B-T184
,	O
self-report	B-T062
,	O
psychological	B-T169
,	O
and	O
functional	B-T169
measures	B-T081
(p<0.05).	O
Patients	B-T101
who	O
slept fewer hours	B-T033
and	O
had	O
poorer	B-T080
functional outcomes	B-T033
were	O
more	O
likely	O
to	O
have	O
LBP	B-T184
;	O
patients	B-T101
who	O
were	O
divorced	B-T033
,	O
had	O
lower	B-T052
QoL	B-T078
,	O
and	O
more	O
frequent	B-T079
nocturia	B-T047
were	O
more	O
likely	O
to	O
have	O
knee pain	B-T033
(p<0.05).	O
Multi-site	B-T082
MSK pain	B-T033
is	O
prevalent	B-T081
and	O
severe	B-T080
in	O
obese	B-T047
patients	B-T101
and	O
is	O
negatively	B-T033
associated with	B-T080
most	O
self-report	O
and	O
functional outcomes	B-T033
.	O
This	O
high	O
prevalence	B-T081
suggests	O
pain management	B-T061
strategies	O
must	O
be	O
considered	O
when	O
treating	B-T061
obesity	B-T047
.	O

Primary	B-T080
Management	B-T058
and	O
Outcome	B-T169
-	O
Open Laryngotracheal Trauma	B-T037
Acute	B-T079
external injury	B-T080
to	O
the	O
larynx	B-T023
is	O
both	O
life threatening	B-T033
and	O
a	O
potential	O
long term	B-T079
management	B-T170
challenge.	O
As	O
Otorhinolaryngologist	B-T097
we	O
must	O
be	O
prepared	O
and	O
well	O
versed	O
to	O
manage	O
these	O
patients	B-T101
.	O
In	O
our	O
study	O
seven	O
patients	B-T101
of	O
open laryngeal traumas	B-T037
were	O
managed	O
by	O
primary closure	B-T061
.	O
In	O
five	O
patients	B-T101
nature of injury	B-T037
was	O
known	O
in	O
other	O
two	O
patients	B-T101
exact	O
nature of injury	B-T037
was	O
not	O
known.	O
After	O
primary closure	B-T061
five	O
patients	B-T101
with	O
known	O
injury	B-T037
survived	B-T052
and	O
two	O
patients	B-T101
with	O
unknown	O
injury	B-T037
died	B-T040
.	O
As	O
per	O
our	O
experience	B-T033
,	O
we	O
recommend	O
primary closure	B-T061
,	O
if	O
the	O
exact	O
nature of injury	B-T037
is	O
known	O
as	O
the	O
outcome	B-T169
is	O
definitely	O
favourable	B-T033
.	O

Comparative	O
kinematic gait analysis	B-T060
in	O
young	B-T079
and	O
old	B-T079
Beagle dogs	B-T015
Age-related	B-T079
involution	B-T040
in	O
dogs	B-T015
involves	O
loss of muscle mass	B-T033
and	O
changes	O
in	O
connective tissue	B-T024
and	O
articular cartilage	B-T024
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	B-T033
whether	O
an	O
age-related	B-T079
influence	O
on	O
joint mobility	B-T033
can	O
be	O
detected	B-T033
in	O
the	O
absence	B-T169
of	O
diseases	B-T047
.	O
Five	O
young	B-T079
(Ø	O
2.0	O
years	B-T079
)	O
and	O
five	O
old	B-T079
(Ø	O
10.4	O
years	B-T079
)	O
healthy	B-T080
and	O
sound Beagle dogs	B-T015
were	O
measured	B-T080
during	O
locomotion	B-T040
on	O
a	O
treadmill	B-T073
by	O
computer-assisted	B-T059
gait analysis	B-T060
.	O
Angles	B-T082
of	O
the	O
shoulder	B-T030
,	O
elbow	B-T030
,	O
carpal	B-T030
,	O
hip	B-T030
,	O
stifle	B-T030
and	O
tarsal joints	B-T030
were	O
analyzed	B-T062
,	O
including	O
joint angle progression curves	B-T081
,	O
minimum	B-T080
and	O
maximum	B-T081
joint	B-T030
angles	B-T082
and	O
range of motion	B-T201
(	O
ROM	B-T201
).	O
The	O
old	B-T079
group	B-T096
showed	O
a	O
smaller	O
maximum	O
joint	B-T030
angle	B-T082
(p	O
=	O
0.037)	O
and	O
ROM	B-T201
(p	O
=	O
0.037)	O
of	O
the	O
carpal joint	B-T030
and	O
similar	O
tendencies	O
in	O
the	O
shoulder	B-T030
,	O
elbow	B-T030
and	O
carpal joint	B-T030
.	O
The	O
descriptive analysis	B-T170
of	O
the	O
progression curves	B-T081
revealed	O
less flexion	B-T033
and	O
extension	B-T169
of	O
the	O
joints	B-T030
of	O
the	O
forelimb	B-T029
.	O
This	O
indicates	O
restricted	B-T169
joint mobility	B-T033
of	O
the	O
forelimb	B-T029
but	O
primarily	O
of	O
the	O
carpal joint	B-T030
.	O
Findings	B-T169
in	O
the	O
joints	B-T030
of	O
the	O
hindlimb	B-T023
were	O
not	O
consistent	B-T078
;	O
contrasting	O
alterations	B-T078
may	O
be	O
due	O
to	O
a	O
compensatory	B-T169
mechanism	B-T169
.	O
As	O
most	O
alterations	B-T078
were	O
found	B-T033
in	O
the	O
distal joints	B-T030
,	O
these	O
should	O
receive	O
particular attention	B-T041
when	O
examining	O
elderly dogs	B-T015
.	O

Propensity Score	B-T081
Matched	O
Comparison	B-T052
of	O
Partial	B-T081
to	O
Whole	B-T081
Gland	B-T023
Cryotherapy	B-T061
for	O
Intermediate-Risk	B-T033
Prostate Cancer	B-T191
:	O
An	O
analysis	B-T062
of	O
the	O
COLD registry data	B-T170
To	O
compare	O
the	O
oncological	B-T191
and	O
functional	B-T169
outcomes	B-T080
of	O
partial	B-T081
versus	O
whole	B-T081
-	O
gland	B-T023
cryotherapy	B-T061
for	O
men	B-T098
with	O
intermediate-risk	B-T033
prostate cancer	B-T191
.	O
Men	B-T098
with	O
intermediate-risk	B-T033
prostate cancer	B-T191
treated with	B-T061
primary	B-T080
prostate cryotherapy	B-T061
from	O
1993-2013	O
were	O
selected	O
from	O
the	O
Cryo On-Line Data Registry	B-T170
for	O
a	O
1:1	O
matched	B-T062
comparison	B-T052
between	O
those	O
undergoing	O
whole	B-T081
-	O
gland	B-T023
and	O
partial	B-T081
prostate cryotherapy	B-T061
(	O
targeted-ablation	B-T061
,	O
unilateral/bilateral nerve-sparing ablations	B-T061
).	O
A	O
propensity score	B-T081
was	O
developed	O
based	O
on	O
age	B-T032
,	O
pre-biopsy serum	B-T031
PSA	B-T116
,	O
biopsy Gleason score	B-T033
,	O
clinical stage	B-T079
,	O
prostate volume	B-T081
,	O
neoadjuvant androgen deprivation	B-T061
status	B-T080
,	O
year	B-T079
of	O
surgery	B-T061
and	O
pre-treatment	B-T079
potency.	O
Outcomes	B-T080
were	O
biochemical	B-T170
progression-free survival	B-T081
(	O
BPFS	B-T081
)	O
using	O
ASTRO	B-T170
and	O
Phoenix criteria	B-T170
,	O
12-month	O
continence	B-T040
(strictly	O
pad-free)	O
and	O
sexual function	B-T040
(potency	O
sufficient	B-T080
for	O
sexual intercourse	B-T040
).	O
After	O
propensity score	B-T081
-	O
matching	B-T062
,	O
BPFS	B-T081
was	O
compared	B-T052
using	O
Kaplan-Meier analysis	B-T081
and	O
functional	B-T169
outcomes	B-T080
using	O
chi-square tests	B-T170
.	O
In	O
all,	O
897	O
men	B-T098
were	O
identified	B-T080
(731	O
whole	B-T081
-	O
gland	B-T023
and	O
166	O
partial	B-T081
).	O
Post-matching	B-T079
,	O
166	O
pairs	O
of	O
men	B-T098
were	O
analysed	B-T062
(mean	O
follow-up	B-T058
31	O
months).	O
The	O
2/5	O
year	O
BPFS	B-T081
rate	B-T081
was	O
87.2%/76.4%	O
for	O
whole	B-T081
-	O
gland	B-T023
vs.	O
80.7%/70.0%	O
for	O
partial	B-T081
ablation	B-T061
using	O
Phoenix	B-T170
(p=0.26)	O
and	O
72.3%/69.6%	O
for	O
whole	B-T081
gland	B-T023
vs.	O
82.1%/75.0%	O
for	O
partial	B-T081
ablation	B-T061
using	O
ASTRO	B-T170
criteria	O
(p=0.10).	O
Of	O
164	O
pairs,	O
the	O
12-month	O
continence	B-T040
rate	B-T081
was	O
similar	B-T080
94.1%	O
vs.	O
95.1%	O
(p=0.803).	O
Of	O
139	O
pairs,	O
the	O
12-month	O
rate	O
of	O
successful	B-T080
intercourse	B-T040
was	O
29.5%	O
for	O
whole	B-T081
-	O
gland	B-T023
and	O
46.8%	O
for	O
partial	B-T081
ablation	B-T061
(OR	O
2.1,	O
p=0.003).	O
The	O
incidence	B-T081
of	O
post-treatment	B-T079
urinary retention	B-T033
was	O
6.0%	O
and	O
6.6%	O
(p=0.88)	O
following	O
whole	B-T081
-	O
gland	B-T023
and	O
partial	B-T081
ablation	B-T061
respectively	O
and	O
that	O
of	O
rectourethral fistula	B-T047
was	O
1.2%	O
and	O
0%	O
(p=0.50)	O
Conclusion:	O
Partial	B-T081
ablation	B-T061
results	B-T033
in	O
better	B-T080
post-treatment	B-T079
sexual function	B-T040
compared	B-T052
to	O
whole	B-T081
-	O
gland	B-T023
ablation	B-T061
in	O
men	B-T098
with	O
intermediate-risk	B-T033
prostate cancer	B-T191
.	O
We	O
did	O
not	O
observe	O
a	O
difference	O
in	O
early	B-T079
BPFS	B-T081
between	O
the	O
two	O
groups	B-T078
.	O

Abnormal	B-T033
metabolic	B-T169
brain	B-T023
network	B-T040
associated	O
with	O
Parkinson's disease	B-T047
:	O
replication	B-T080
on	O
a	O
new	O
European	B-T098
sample	B-T077
The	O
purpose	O
of	O
this	O
study	B-T062
was	O
to	O
identify	B-T080
the	O
specific	O
metabolic	B-T169
brain	B-T023
pattern	B-T082
characteristic	B-T080
for	O
Parkinson's disease	B-T047
(	O
PD	B-T047
):	O
Parkinson's disease-related pattern	B-T081
(	O
PDRP	B-T081
),	O
using	O
network	B-T040
analysis	O
of	O
[18F]-fluorodeoxyglucose positron emission tomography	B-T060
(	O
FDG-PET	B-T060
)	O
brain	B-T023
images	B-T170
in	O
a	O
cohort	B-T098
of	O
Slovenian	B-T083
PD	B-T047
patients	B-T101
.	O
Twenty	O
PD	B-T047
patients	B-T101
(	O
age	B-T032
70.1	O
±	O
7.8	O
years	B-T079
,	O
Movement Disorder Society Unified Parkinson's Disease Motor Rating Scale	B-T170
(	O
MDS-UPDRS-III	B-T170
)	O
38.3	O
±	O
12.2;	O
disease duration	B-T079
4.3	O
±	O
4.1	O
years	B-T079
)	O
and	O
20	O
age	B-T032
-	O
matched	B-T080
normal controls	B-T096
(	O
NCs	B-T096
)	O
underwent	O
FDG-PET	B-T060
brain imaging	B-T060
.	O
An	O
automatic voxel-based scaled subprofile model	B-T075
/	O
principal component analysis	B-T081
(	O
SSM	B-T075
/	O
PCA	B-T081
)	O
was	O
applied	O
to	O
these	O
scans	B-T060
for	O
PDRP	B-T081
-	O
Slovenia	B-T083
identification	B-T080
.	O
The	O
pattern	B-T081
was	O
characterized	B-T052
by	O
relative	O
hypermetabolism	B-T033
in	O
pallidum	B-T023
,	O
putamen	B-T023
,	O
thalamus	B-T023
,	O
brain stem	B-T023
,	O
and	O
cerebellum	B-T023
associated	O
with	O
hypometabolism	B-T033
in	O
sensorimotor cortex	B-T023
,	O
posterior parietal	B-T023
,	O
occipital	B-T029
,	O
and	O
frontal cortices	B-T023
.	O
The	O
expression	B-T078
of	O
PDRP	B-T081
-	O
Slovenia	B-T083
discriminated	O
PD	B-T047
patients	B-T101
from	O
NCs	B-T096
(p	O
<	O
0.0001)	O
and	O
correlated	B-T080
positively	O
with	O
patients	B-T101
'	O
clinical	B-T080
score	B-T081
(	O
MDS-UPDRS-III	B-T170
,	O
p	O
=	O
0.03).	O
Additionally,	O
its	O
topography	B-T185
agrees	O
well	O
with	O
the	O
original	O
PDRP	B-T081
(p	O
<	O
0.001)	O
identified	B-T080
in	O
American	B-T098
cohort	B-T098
of	O
PD	B-T047
patients	B-T101
.	O
We	O
validated	O
the	O
PDRP	B-T081
-	O
Slovenia	B-T083
expression	B-T078
on	O
additional	O
FDG-PET	B-T060
scans	B-T060
of	O
20	O
PD	B-T047
patients	B-T101
,	O
20	O
NCs	B-T096
,	O
and	O
25	O
patients	B-T101
with	O
atypical parkinsonism	B-T047
(	O
AP	B-T047
).	O
We	O
confirmed	O
that	O
the	O
expression	B-T078
of	O
PDRP	B-T081
-	O
Slovenia	B-T083
manifests	O
good	O
diagnostic accuracy	B-T080
with	O
specificity	B-T081
and	O
sensitivity	B-T081
of	O
85-90%	O
at	O
optimal	O
pattern	B-T081
expression	B-T078
cutoff	O
for	O
discrimination	O
of	O
PD	B-T047
patients	B-T101
and	O
NCs	B-T096
and	O
is	O
not	O
expressed	O
in	O
AP	B-T047
.	O
PDRP	B-T081
-	O
Slovenia	B-T083
proves	O
to	O
be	O
a	O
robust	O
and	O
reproducible	O
functional imaging	B-T060
biomarker	B-T201
independent	O
of	O
patient	B-T101
population	B-T098
.	O
It	O
accurately	O
differentiates	O
PD	B-T047
patients	B-T101
from	O
NCs	B-T096
and	O
AP	B-T047
and	O
correlates	O
well	O
with	O
the	O
clinical	B-T080
measure	B-T081
of	O
PD	B-T047
progression	B-T046
.	O

The	O
effects of	B-T080
gestational	B-T079
use of	B-T169
antidepressants	B-T121
and	O
antipsychotics	B-T121
on	O
neonatal	B-T100
outcomes	B-T169
for	O
women	B-T098
with	O
severe	B-T080
mental illness	B-T048
Psychotropic medication	B-T121
use	B-T169
occurs	B-T079
in	O
8%	O
of	O
pregnancies	B-T040
,	O
with	O
rates	B-T033
increasing	B-T169
,	O
and	O
often	B-T079
multiple	B-T081
medications	B-T121
prescribed	B-T058
.	O
This	O
study	B-T062
aims	O
to	O
determine	O
if	O
the	O
use of	B-T169
psychotropic medication	B-T121
,	O
in	O
a	O
cohort	B-T098
of	O
women	B-T098
with	O
severe	B-T080
mental illness	B-T048
,	O
increases	B-T169
rates	B-T081
of	O
special care nursery	B-T061
admission	B-T058
and	O
reports	B-T170
differences	B-T080
between	O
antidepressant	B-T121
and	O
antipsychotic medication	B-T121
use	B-T169
either	O
alone	B-T081
or	O
in	O
combination	B-T121
.	O
A	O
retrospective database analysis from a cohort	B-T062
with	O
severe	B-T080
mental illness	B-T048
in	O
pregnancy	B-T040
identified	B-T080
268	O
pregnant women	B-T098
who	O
were	O
grouped	B-T185
according	O
to	O
medication	B-T121
type	B-T080
.	O
Demographic	B-T080
,	O
obstetric	B-T169
and	O
neonatal	B-T100
variables	B-T080
were	O
analysed	B-T062
using	B-T169
t-tests	B-T170
,	O
χ(2),	O
analysis	B-T062
of	O
variance	B-T080
and	O
logistic regression analysis	B-UnknownType
for	O
special care nursery	B-T061
admission	B-T058
.	O
The	O
medication groups	B-T101
consisted	O
of:	O
women	B-T098
taking no psychotropic medications	B-T101
(n	O
=	O
67);	O
those taking antipsychotics	B-T101
(n	O
=	O
87);	O
those taking antidepressants	B-T101
(n	O
=	O
55);	O
those taking and a combination of antidepressants/antipsychotics	B-T101
(n	O
=	O
59).	O
Rates	B-T033
of	O
special care nursery	B-T061
admission	B-T058
in	O
women	B-T098
who	O
took	O
psychotropic medication	B-T121
(41.3%)	O
were	O
elevated	O
compared	B-T052
to	O
those who did not	B-T101
(26.9%)	O
(P	O
=	O
0.035),	O
and	O
were	O
significantly	B-T078
raised	B-T080
when	O
compared	B-T052
to	O
the	O
general population	B-T098
(P	O
<	O
0.000).	O
No significant difference	B-T033
occurred	O
between	O
the	O
medication groups	B-T101
.	O
A	O
significant	B-T078
adjusted	O
odds ratio	B-T081
of	O
2.79	O
(95%	O
CI	O
1.286-6.049)	O
was	O
found	B-T033
for	O
special care nursery	B-T061
and	O
psychiatric admission	B-T058
during	B-T079
pregnancy	B-T040
but	O
not	O
for	O
psychotropic medication	B-T121
.	O
Rates	B-T081
of	O
special care nursery	B-T061
admission	B-T058
are	O
elevated	O
in	O
neonates	B-T100
of	O
women	B-T098
with	O
severe	B-T080
mental illness	B-T048
taking	O
psychotropic medication	B-T121
,	O
but	O
were	O
not	O
different	O
for	O
monotherapy	B-T061
or	O
polytherapy	B-T061
when	O
prescribing	B-T058
antidepressants	B-T121
or	O
antipsychotic medication	B-T121
.	O
Additional	O
vulnerability	B-T033
occurs	B-T079
in	O
the	O
neonates	B-T100
of	O
women	B-T098
with	O
a	O
mental illness	B-T048
and	O
paediatric	B-T097
presence	O
at	O
delivery	B-T040
is	O
recommended	B-T078
.	O

Does	O
Intrawound Vancomycin	B-T116
Application	B-T169
During	O
Spine Surgery	B-T061
Create	O
Vancomycin-Resistant	B-T032
Organism	B-T001
?	O
Surgical site infection	B-T046
(	O
SSI	B-T046
)	O
following	O
spine surgery	B-T061
is	O
a	O
morbid	B-T080
and	O
expensive complication	B-T169
.	O
The	O
use	O
of	O
intrawound vancomycin	B-T116
is	O
emerging	O
as	O
a	O
solution	O
to	O
reduce	O
SSI	B-T046
.	O
The	O
development	O
of	O
vancomycin-resistant	B-T032
pathogens	B-T001
is	O
an	O
understandable	O
concern.	O
To	O
determine	O
the	O
occurrence	B-T079
of	O
vancomycin-resistant	B-T032
SSI	B-T046
in	O
patients	B-T101
with	O
and	O
without	O
use	O
of	O
intrawound vancomycin	B-T116
.	O
Patients	B-T101
Patients	B-T101
undergoing	O
elective	O
spine surgery	B-T061
were	O
dichotomized	B-T080
based	O
on	O
whether	O
intrawound vancomycin	B-T116
was	O
applied.	O
Outcome	O
was	O
occurrence	B-T079
of	O
SSI	B-T046
requiring	O
return	O
to	O
the	O
operating room	B-T073
within	O
postoperative 90 days	B-T079
.	O
The	O
intrawound culture	B-T059
and	O
vancomycin	B-T116
minimal inhibitory concentrations	B-T059
(	O
MIC	B-T059
)	O
were	O
reviewed.	O
Analyses	O
were	O
conducted	O
to	O
compare	O
the	O
pathogen profile	B-T001
and	O
MIC	B-T059
for	O
vancomycin	B-T116
in	O
patients	B-T101
who	O
received	O
vancomycin	B-T116
and	O
those	O
who	O
did	O
not.	O
Of	O
the	O
total	O
2802	O
patients	B-T101
,	O
43%	O
(n	O
=	O
1215)	O
had	O
intrawound vancomycin	B-T116
application	O
during the index surgery	B-T079
.	O
The	O
use	O
of	O
vancomycin	B-T116
was	O
associated	O
with	O
significantly lower	B-T081
deep	O
SSI	B-T046
rates	B-T023
(1.6%	O
[n	O
=	O
20]	O
vs	O
2.5%	O
[n	O
=	O
40],	O
P	O
=	O
.02).	O
The	O
occurrence	B-T079
of	O
Staphylococcus aureus	B-T007
SSI	B-T046
was	O
significantly lower	B-T081
in	O
the	O
patients	B-T101
who	O
had	O
application	B-T169
of	O
intrawound vancomycin	B-T116
(32%	O
vs	O
65%,	O
P	O
=	O
.003).	O
None	O
of	O
the	O
patients	B-T101
who	O
had	O
application	B-T169
of	O
intrawound vancomycin powder	B-T116
,	O
and	O
subsequently	O
developed	O
an	O
S aureus	B-T007
SSI	B-T046
,	O
demonstrated	O
pathogens	B-T001
with	O
resistance to vancomycin	B-T033
.	O
All	O
patients	B-T101
had	O
MIC	B-T059
<	O
2	O
μg/mL,	O
the	O
vancomycin	B-T116
susceptibility	O
threshold.	O
The	O
occurrence	B-T079
of	O
gram-negative	B-T047
SSI	B-T046
(28%	O
vs	O
7%)	O
and	O
culture negative fluid collection	B-T033
(16%	O
vs	O
5%)	O
was	O
higher	B-T080
in	O
the	O
vancomycin	B-T116
cohort	B-T098
.	O
The	O
use	O
of	O
intrawound vancomycin	B-T116
during	O
the	O
index	O
spine surgery	B-T061
was	O
protective	O
against	O
SSI	B-T046
following	O
spine surgery	B-T061
.	O
The	O
application	B-T169
of	O
intrawound vancomycin	B-T116
during index surgery	B-T079
does	O
not	O
appear	O
to	O
create	O
vancomycin-resistant	B-T032
organisms	B-T001
in	O
the	O
event	O
of	O
an	O
SSI	B-T046
.	O

Adequacy	B-T170
criteria	B-T078
for	O
thyroid FNA	B-T060
evaluated	B-T058
by	O
ThinPrep slides	B-T060
only	O
Adequacy	B-T170
criteria	B-T078
for	O
thyroid fine-needle aspiration	B-T060
(	O
FNA	B-T060
)	O
recommended	B-T078
by	O
The	O
Bethesda System for Reporting Thyroid Cytopathology	B-T059
(	O
TBS	B-T059
)	O
were	O
developed	O
with	O
smears	B-T060
,	O
but	O
they	O
are	O
commonly	O
applied	B-T169
to	O
ThinPreps	B-T060
(	O
TPs	B-T060
).	O
This	O
study	O
evaluated	B-T058
adequacy	B-T170
in	O
TPs	B-T060
at	O
different	O
diagnostic	B-T169
thresholds	B-T080
.	O
All	O
FNA procedures	B-T060
performed	B-T169
between	O
2010	O
and	O
2015	O
with	O
matched	B-T080
surgical specimens	B-T167
were	O
analyzed	B-T062
.	O
Cell counts	B-T059
and	O
cytological	B-T169
features	B-T080
were	O
evaluated	B-T058
in	O
all	O
initially	O
nondiagnostic	B-T033
(	O
ND	B-T033
)	O
cases	B-T096
.	O
ND	B-T033
cases	B-T096
were	O
reclassified	B-T080
into	O
TBS	B-T059
categories	B-T170
by	O
2	O
pathologists	B-T097
,	O
and	O
the	O
results	B-T169
were	O
compared	B-T052
with	O
surgical outcomes	B-T169
.	O
One	O
hundred forty-six	B-T081
of	O
the	O
151	O
cases	B-T096
initially	O
classified	B-T185
as	O
ND	B-T033
were	O
available	B-T169
for	O
review	B-T169
,	O
and	O
they	O
had	O
a	O
mean	B-T081
cell count	B-T059
of	O
60.5	O
(	O
standard deviation	B-T081
,	O
71.4).	O
Interobserver agreement	B-T054
on	O
the	O
reclassification	B-T185
of	O
ND	B-T033
cases	B-T096
was	O
moderate	B-T080
(k	O
=	O
0.57),	O
and	O
consensus	B-T054
yielded	B-T081
48	O
ND	B-T033
cases	B-T096
(33%),	O
72	O
benign	B-T080
cases	B-T096
(49%),	O
24	O
cases	B-T096
of	O
atypia	B-T033
of	O
undetermined significance	B-T033
(16%),	O
and	O
2	O
cases	B-T096
suspicious for malignancy	B-T033
(1%).	O
Lowering	B-T052
the	O
diagnostic	B-T169
threshold	B-T080
to	O
any	O
follicular	B-T023
cells	B-T025
yielded	B-T081
a	O
sensitivity	B-T081
of	O
92%,	O
a	O
specificity	B-T081
of	O
60%,	O
a	O
positive predictive value	B-T081
of	O
59%,	O
a	O
negative predictive value	B-T081
of	O
92%,	O
and	O
a	O
false-negative	B-T034
rate	B-T081
of	O
7.7%,	O
whereas	O
the	O
values	O
for	O
the	O
initially	O
diagnostic	B-T169
cases	B-T096
were	O
93%,	O
58%,	O
59%,	O
93%,	O
and	O
7.7%,	O
respectively.	O
Including	O
cases	B-T096
with	O
>60	O
cells	B-T025
but	O
lacking	B-T080
6	O
groups	B-UnknownType
containing	B-T052
at	O
least	O
10	O
cells	B-T025
did	O
not	O
affect	O
test performance	B-T060
.	O
Nuclear enlargement	B-T049
,	O
pallor	B-T033
,	O
grooves	B-T030
,	O
and	O
the	O
presence	B-T033
of	O
histiocytoid cells	B-T025
in	O
initially	O
ND	B-T033
FNA	B-T060
correlated	B-T080
with	O
malignancy	B-T191
.	O
In	O
thyroid FNA	B-T060
examined	B-T033
with	O
TP	B-T060
only,	O
lowering	B-T052
the	O
adequacy	B-T170
threshold	B-T080
and	O
eliminating	O
the	O
requirement	B-T169
of	O
6	O
groups	B-UnknownType
of	O
at	O
least	O
10	O
cells	B-T025
did	O
not	O
significantly	B-T078
affect	O
test performance	B-T060
if	O
cytological	B-T169
features	B-T080
associated with	B-T080
malignancy	B-T191
were	O
absent	B-T169
.	O
Cancer	O
Cytopathol	O
2017.	O
©	O
2017	O
American	O
Cancer	O
Society.	O

Silk I	B-T116
and	O
Silk II	B-T116
studied	B-T062
by	O
fast scanning calorimetry	B-T059
Using	O
fast scanning calorimetry	B-T059
(	O
FSC	B-T059
),	O
we	O
investigated	B-T169
the	O
glass transition	B-T052
and	O
crystal	B-T104
melting	B-T070
of	O
samples	B-T167
of	O
B. mori	B-T204
silk fibroin	B-T116
containing	O
Silk I	B-T116
and/or	O
Silk II	B-T116
crystal	B-T104
s.	O
Due	O
to	O
the	O
very	O
short	B-T081
residence	B-T082
times	B-T079
at	O
high	B-T080
temperatures	B-T081
during	O
such	O
measurements	B-T169
,	O
thermal	B-T070
decomposition	B-T067
of	O
silk protein	B-T116
can	O
be	O
significantly	B-T078
suppressed	B-T080
.	O
FSC	B-T059
was	O
performed	B-T169
at	O
2000K/s	O
using	O
the	O
Mettler Flash DSC1	B-T059
on	O
fibroin	B-T116
films	B-T167
with	O
masses	B-T081
around	O
130-270ng.	O
Films	B-T167
were	O
prepared	O
with	O
different	B-T080
crystalline	B-T104
fractions	B-T081
(ranging	O
from	O
0.26	O
to	O
0.50)	O
and	O
with	O
different	B-T080
crystal structures	B-T104
(	O
Silk I	B-T116
,	O
Silk II	B-T116
,	O
or	O
mixed)	O
by	O
varying	O
the	O
processing	B-T052
conditions	B-T080
.	O
These	O
included	O
water	B-T121
annealing	B-T061
at	O
different	B-T080
temperatures	B-T081
,	O
exposure to	B-T080
50%	O
MeOH	B-T109
in	O
water	B-T121
,	O
or	O
autoclaving	B-T074
.	O
The	O
resulting	B-T169
crystal structure	B-T104
was	O
examined	O
using	O
wide angle	B-T082
X-ray scattering	B-T060
.	O
Degree	B-T081
of	O
crystallinity	B-T104
was	O
evaluated	B-T033
from	O
Fourier transform infrared (FTIR) spectroscopy	B-T062
and	O
from	O
analysis	B-T062
of	O
the	O
heat capacity	B-T081
increment	B-T081
at	O
the	O
glass transition temperature	B-T080
.	O
Silk fibroin	B-T116
films	B-T167
prepared	O
by	O
water	B-T121
annealing	B-T061
at	O
25°C	O
were	O
the	O
least	O
crystalline	B-T104
and	O
had	O
Silk I	B-T116
structure	B-T116
.	O
FTIR	B-T062
and	O
FSC	B-T059
studies	B-T062
showed	O
that	O
films	B-T167
prepared	O
by	O
autoclaving	B-T074
or	O
50%	O
MeOH	B-T109
exposure	B-T080
were	O
the	O
most	O
crystalline	B-T104
and	O
had	O
Silk II	B-T116
structure	B-T116
.	O
Intermediate	B-T082
crystalline	B-T104
fraction	B-T081
and	O
mixed	O
Silk I	B-T116
/	O
Silk II	B-T116
structure	B-T116
s	O
were	O
found	O
in	O
films	B-T167
prepared	O
by	O
water	B-T121
annealing	B-T061
at	O
37°C.	O
FSC	B-T059
results	B-T033
indicate	O
that	O
Silk I	B-T116
Silk I I	B-T116
crystals	B-T104
exhibit	O
endotherms	B-T080
of	O
narrower width	B-T080
and	O
have	O
higher	B-T080
mean	B-T081
melting temperature	B-T081
Tm(II)=351±2.6°C,	O
compared	B-T052
to	O
Silk I	B-T116
crystals	B-T104
which	O
melt	B-T070
at	O
Tm(I)=292±3.8°C.	O
Films	B-T167
containing	O
mixed	O
Silk I	B-T116
/	O
Silk II	B-T116
structure	B-T116
showed	O
two	O
clearly	B-T080
separated	B-T080
endothermic	B-T080
peaks	B-T080
.	O
Evidence	B-T078
suggests	O
that	O
the	O
two	O
types	O
of	O
crystal	B-T104
s	O
melt	B-T070
separately	B-T080
and	O
do	O
not	O
thermal	B-T070
ly	O
interconvert	B-T169
on	O
the	O
extremely	B-T080
short	B-T081
time scale	B-T079
(0.065s	O
between	O
onset	O
and	O
end	O
of	O
melting	B-T070
)	O
of	O
the	O
FSC experiment	B-T059
.	O
Silkworm	B-T204
silk	B-T116
is	O
a	O
naturally	B-T169
occurring	O
biomaterial	B-T169
.	O
The	O
fibroin component	B-T116
of	O
silk forms	B-T116
two	O
types	O
of	O
crystals	B-T104
.	O
Silk	B-T116
properties	B-T080
depend	O
upon	O
the	O
amount	B-T081
and	O
type	O
of	O
crystals	B-T104
,	O
and	O
their	O
stability	B-T080
.	O
One	O
measure	B-T081
of	O
stability	B-T080
is	O
crystal	B-T104
melting temperature	B-T081
.	O
Crystal	B-T104
s	O
which	O
are	O
more	O
stable	B-T080
have	O
a	O
higher	B-T080
melting temperature	B-T081
.	O
Until	O
now,	O
it	O
has	O
been	O
challenging	O
to	O
study	B-T062
thermal	B-T070
behavior	B-T053
of	O
silk	B-T116
crystal	B-T104
s	O
because	O
they	O
degrade	B-T169
at	O
high	B-T080
temperature	B-T081
.	O
To	O
avoid	O
degradation	B-T169
,	O
and	O
study	B-T062
the	O
melting	B-T070
properties	B-T080
of	O
silk	B-T116
biomaterial	B-T169
,	O
we	O
heated	B-T067
silk	B-T116
at	O
a	O
very	O
fast	O
rate	O
of	O
2000K/s	O
using	O
a	O
special calorimeter	B-UnknownType
.	O
We	O
have	O
shown	O
that	O
the	O
two	O
crystal	B-T104
types	O
have	O
very	O
different	B-T080
melting temperature	B-T081
s,	O
indicating	O
that	O
one	O
crystal	B-T104
type	B-T080
is	O
much	O
more	O
stable	B-T080
than	O
the	O
other.	O

Leonurine	B-T109
Attenuates	B-T052
Hyperalgesia	B-T184
in	O
Mice	B-T015
with	O
Induced	B-T169
Adenomyosis	B-T047
BACKGROUND	O
Adenomyosis	B-T047
,	O
defined	O
as	O
the	O
invasion	B-T046
of	O
endometrial glands	B-T023
and	O
stroma	B-T023
into	O
the	O
myometrium	B-T023
,	O
is	O
a	O
common	B-T081
gynecological disorder	B-T047
.	O
In	O
the	O
present	O
study	O
we	O
report	B-T170
on	O
the	O
effect	B-T080
of	O
leonurine	B-T109
on	O
ICR mice	B-T015
with	O
adenomyosis	B-T047
induced	B-T169
by	O
neonatal	B-T079
tamoxifen	B-T109
.	O
MATERIAL	O
AND	O
METHODS	O
After	O
being	O
treated	B-T169
with	O
tamoxifen	B-T109
for	O
4,	O
8,	O
and	O
12	O
weeks,	O
we	O
assessed	B-T052
body weight	B-T032
and	O
pain	B-T184
modulation	O
in	O
mice	B-T015
in	O
hotplate	B-T074
tests	B-T059
.	O
The	O
mice	B-T015
were	O
divided	B-T169
into	O
5	O
groups	B-T078
:	O
a	O
low-dose	B-T081
leonurine	B-T109
treatment	B-T061
group	B-T078
,	O
a	O
high-dose	B-T081
leonurine	B-T109
treatment	B-T061
group	B-T078
,	O
a	O
valproic acid	B-T109
(	O
VPA	B-T109
)	O
treatment	B-T061
group	B-T078
,	O
a	O
vehicle	B-T122
only	B-T081
treatment	B-T061
group	B-T078
,	O
and	O
a	O
blank	B-T033
control group	B-T096
.	O
We	O
evaluated	B-T058
body weight	B-T032
,	O
pain	O
modulation	O
in	O
hotplate	B-T074
tests	B-T059
,	O
and	O
the	O
depth	B-T082
of	O
myometrial	B-T029
infiltration	B-T046
.	O
Immunoreactivity	B-T044
staining	B-T059
of	O
progesterone receptor	B-T116
(	O
PR	B-T116
),	O
nuclear factor-κB phosphorylated-p65	B-T116
(	O
p-p65	B-T116
),	O
cyclooxygenase-2	B-T116
(	O
COX-2	B-T116
),	O
and	O
oxytocin receptor	B-T116
(	O
OTR	B-T116
)	O
was	O
evaluated	B-T058
by	O
immunohistochemistry	B-T060
.	O
RESULTS	O
The	O
measurement	B-T169
of	O
the	O
body weight	B-T032
,	O
myometrial	B-T029
infiltration	B-T046
,	O
and	O
pain	O
modulation	O
showed	O
that	O
neonatal	B-T079
tamoxifen	B-T109
treatment	B-T061
led	O
to	O
adenomyosis	B-T047
.	O
Leonurine	B-T109
treatment	B-T061
appeared	O
to	O
decrease	B-T081
hyperalgesia	B-T184
and	O
myometrial	B-T029
infiltration	B-T046
.	O
Immunoreactivity	B-T044
staining	B-T059
showed	O
decreased	B-T081
p-p65	B-T116
,	O
COX-2	B-T116
,	O
and	O
OTR	B-T116
protein expressions	B-T045
.	O
CONCLUSIONS	O
Our	O
results	O
indicate	O
that	O
leonurine	B-T109
attenuates	B-T052
hyperalgesia	B-T184
in	O
mice	B-T015
with	O
induced	B-T169
adenomyosis	B-T047
via	O
down-regulating	B-T044
expressions	B-T045
of	O
p-P65	B-T116
,	O
COX-2	B-T116
,	O
and	O
OTR	B-T116
,	O
and	O
could	O
be	O
beneficial	O
for	O
treating	B-T169
adenomyosis	B-T047
.	O

A	O
Randomized	B-T062
,	O
Head-to-Head	B-T080
Study	B-T062
of	O
Virtual Reality Exposure Therapy	B-T061
for	O
Posttraumatic Stress Disorder	B-T048
Virtual reality exposure therapy	B-T061
(	O
VRET	B-T061
)	O
is	O
one	O
of	O
the	O
few	O
interventions	B-T058
supported	B-T077
by	O
randomized controlled trials	B-T062
for	O
the	O
treatment	B-T061
of	O
combat-related posttraumatic stress disorder	B-T048
(	O
PTSD	B-T048
)	O
in	O
active duty service	B-T033
members	B-T098
.	O
A	O
comparative effectiveness study	B-T062
was	O
conducted	O
to	O
determine	O
if	O
virtual reality	B-T066
technology	B-T090
itself	O
improved	B-T033
outcomes	B-T080
,	O
or	O
if	O
similar	B-T080
results	B-T169
could	O
be	O
achieved	B-T053
with	O
a	O
control exposure therapy	B-T061
(	O
CET	B-T061
)	O
condition	B-T080
.	O
Service	B-T057
members	B-T098
with	O
combat-related PTSD	B-T048
were	O
randomly	B-T080
selected	B-T052
to	O
receive	B-T080
nine	O
weeks	B-T079
of	O
VRET	B-T061
or	O
CET	B-T061
.	O
Assessors	B-T097
,	O
but	O
not	O
therapists	B-T097
,	O
were	O
blinded	B-T062
.	O
PTSD	B-T048
symptom	B-T184
improvement	B-T077
was	O
assessed	B-T052
one	O
week	B-T079
and	O
3	O
months	B-T079
after	O
the	O
conclusion	B-T078
of	O
treatment	B-T061
using	O
the	O
clinician-administered PTSD scale	B-T170
(	O
CAPS	B-T170
).	O
A	O
small	B-T081
crossover	O
component	O
was	O
included	B-T169
.	O
Results	B-T169
demonstrated	O
that	O
PTSD	B-T048
symptoms	B-T184
improved	B-T033
with	O
both	O
treatments	B-T061
,	O
but	O
there	O
were	O
no	O
statistically significant	B-T081
differences	B-T033
between	O
groups	B-T078
.	O
Dropout	B-T098
rates	B-T081
were	O
higher	B-T080
in	O
VRET	B-T061
.	O
Of	O
those	O
who	O
received	B-T080
VRET	B-T061
,	O
13/42	O
(31%)	O
showed	O
>30%	O
improvement	B-T077
on	O
the	O
CAPS	B-T170
,	O
versus	O
16/43	O
(37%)	O
who	O
received	B-T080
CET	B-T061
.	O
Three	O
months	B-T079
after	O
treatment	B-T061
,	O
>30%	O
improvement	B-T077
was	O
seen	O
in	O
10/33	O
(30%)	O
of	O
VRET	B-T061
participants	B-T098
and	O
12/33	O
(36%)	O
in	O
CET	B-T061
.	O
Participants	B-T098
who	O
crossed over	B-T033
(n	O
=	O
11)	O
showed	O
no	O
statistically significant	B-T081
improvements	B-T077
in	O
a	O
second	B-T081
round	O
of	O
treatment	B-T061
,	O
regardless	B-T080
of	O
condition	B-T080
.	O
This	O
study	B-T062
supported	B-T077
the	O
utility	B-T169
of	O
exposure therapy	B-T061
for	O
PTSD	B-T048
,	O
but	O
did	O
not	O
support	B-T077
additional	B-T169
benefit	B-T081
by	O
the	O
inclusion	B-T080
of	O
virtual reality	B-T066
.	O

Accounting	B-UnknownType
for	O
linkage disequilibrium	B-T081
in	O
genome scans	B-T061
for	O
selection	B-T045
without	B-T080
individual	B-T080
genotypes	B-T032
:	O
The	O
local score approach	B-T062
Detecting genomic footprints	B-T063
of	O
selection	B-T045
is	O
an	O
important	O
step	O
in	O
the	O
understanding	O
of	O
evolution	B-T045
.	O
Accounting	O
for	O
linkage disequilibrium	B-T081
in	O
genome scans	B-T061
increases	O
detection	B-T061
power	B-T081
,	O
but	O
haplotype	B-T032
-based	O
methods	O
require	O
individual	B-T080
genotypes	B-T032
and	O
are	O
not	O
applicable	O
on	O
pool-sequenced samples	B-T201
.	O
We	O
propose	O
to	O
take	O
advantage	O
of	O
the	O
local score approach	B-T062
to	O
account	O
for	O
linkage disequilibrium	B-T081
in	O
genome scans	B-T061
for	O
selection	B-T045
,	O
cumulating	B-T169
(possibly	O
small)	O
signals	B-T044
from	O
single	O
markers	B-T045
over	O
a	O
genomic segment	B-T077
,	O
to	O
clearly	O
pinpoint	O
a	O
selection	B-T045
signal	B-T044
.	O
Using	O
computer simulations	B-T066
,	O
we	O
demonstrate	O
that	O
this	O
approach	O
detects	B-T033
selection	B-T045
with	O
higher	O
power	O
than	O
several	O
state-of-the-art	B-UnknownType
single-marker	B-T045
,	O
windowing	O
or	O
haplotype	B-T032
-based	O
approaches.	O
We	O
illustrate	O
this	O
on	O
two	O
benchmark	B-T081
data sets	B-T170
including	O
individual	B-T080
genotypes	B-T032
,	O
for	O
which	O
we	O
obtain	O
similar	O
results	O
with	O
the	O
local score	B-T062
and	O
one	O
haplotype	B-T032
-based	O
approach.	O
Finally,	O
we	O
apply	O
the	O
local score approach	B-T062
to	O
Pool-Seq data	B-T170
obtained	O
from	O
a	O
divergent	B-T080
selection	B-T045
experiment	B-T062
on	O
behaviour	B-T053
in	O
quail	B-T012
and	O
obtain	O
precise	O
and	O
biologically	B-T080
coherent	B-T033
selection	B-T045
signals	B-T044
:	O
while	O
competing	O
methods	O
fail	O
to	O
highlight	O
any	O
clear	O
selection	B-T045
signature,	O
our	O
method	O
detects	B-T033
several	O
regions	O
involving	O
genes	B-T028
known	O
to	O
act	O
on	O
social	B-T169
responsiveness	B-T169
or	O
autistic traits	B-T033
.	O
Although	O
we	O
focus	O
here	O
on	O
the	O
detection	B-T033
of	O
positive	B-T033
selection	B-T045
from	O
multiple population data	B-T170
,	O
the	O
local score approach	B-T062
is	O
general	O
and	O
can	O
be	O
applied	O
to	O
other	O
genome scans	B-T061
for	O
selection	B-T045
or	O
other	O
genomewide analyses	B-T063
such	O
as	O
GWAS	B-T063
.	O

Is	O
UV	B-T070
-	O
Induced	B-T169
Electron-Driven Proton Transfer	B-T070
Active	B-T169
in	O
a	O
Chemically Modified	B-T080
A	B-T114
·	O
T	B-T114
DNA	B-T114
Base Pair	B-T044
?	O
Transient electronic and vibrational absorption spectroscopies	B-T059
have	O
been	O
used	O
to	O
investigate	B-T169
whether	O
UV	B-T070
-	O
induced	B-T169
electron-driven proton transfer	B-T070
(	O
EDPT	B-T070
)	O
mechanisms	B-T169
are	O
active	B-T169
in	O
a	O
chemically modified	B-T080
adenine	B-T114
-	O
thymine	B-T114
(	O
A	B-T114
·	O
T	B-T114
)	O
DNA	B-T114
base pair	B-T044
.	O
To	O
enhance	O
the	O
fraction of	B-T081
biologically relevant	B-T080
Watson-Crick (WC) hydrogen-bonding	B-T070
motifs	B-T086
and	O
eliminate	O
undesired	O
Hoogsteen structures	B-T104
,	O
a	O
chemically modified	B-T080
derivative of A	B-T169
A	B-T114
was	O
synthesized	B-T052
,	O
8-(tert-butyl)-9-ethyladenine	B-T109
(	O
8tBA	B-T109
).	O
Equimolar solutions	B-T167
of	O
8tBA	B-T109
and	O
silyl-protected T	B-T114
nucleosides	B-T114
in	O
chloroform	B-T109
yield	B-T081
a	O
mixture	B-T167
of	O
WC pairs	B-T044
,	O
reverse WC pairs	B-T044
,	O
and	O
residual monomers	B-T104
.	O
Unlike	O
previous	O
transient absorption studies	B-T059
of	O
WC	O
guanine	B-T114
-	O
cytosin	B-T109
e	O
(	O
G	B-T114
·	O
C	B-T109
)	O
pairs	B-T044
,	O
no	O
clear	O
spectroscopic or kinetic evidence	B-T078
was	O
identified	B-T080
for	O
the	O
participation	B-T169
of	O
EDPT	B-T070
in	O
the	O
excited-state relaxation dynamics	B-T070
of	O
8tBA	B-T109
·	O
T	B-T114
pairs	B-T044
,	O
although	O
ultrafast	B-T080
(sub-100	O
fs)	O
EDPT	B-T070
cannot	O
be	O
discounted.	O
Monomer-like dynamics	B-T070
are	O
proposed	O
to	O
dominate	O
in	O
8tBA	B-T109
·	O
T	B-T114
.	O

Monitoring	B-T058
proteolytic processing	B-T044
events	B-T051
by	O
quantitative mass spectrometry	B-T059
Protease activity	B-T044
plays	O
a	O
key	O
role	B-T170
in	O
a	O
wide	O
variety	O
of	O
biological processes	B-T038
including	B-T169
gene expression	B-T045
,	O
protein turnover	B-T044
and	O
development	B-T040
.	O
misregulation	B-T033
of	O
these	O
proteins	B-T116
has	O
been	O
associated with	B-T080
many	O
cancer types	B-T033
such	O
as	O
prostate	B-T191
,	O
breast	B-T191
,	O
and	O
skin cancer	B-T191
.	O
thus,	O
the	O
identification	B-T080
of	O
protease	B-T116
substrates	B-T167
will	O
provide	B-T052
key	O
information	B-T078
to	O
understand	B-T041
proteolysis	B-T044
-related	O
pathologies	B-T091
.	O
Areas	O
covered	B-T169
:	O
Proteomics	B-T091
-based	O
methods	B-T170
to	O
investigate	B-T169
proteolysis activity,	B-T044
focusing	O
on	O
substrate	B-T167
identification	B-T080
,	O
protease	B-T116
specificity	B-UnknownType
and	O
their	O
applications	B-T061
in	O
systems biology	B-T091
are	O
reviewed	B-T080
.	O
Their	O
quantification	B-T081
strategies,	O
challenges	B-T058
and	O
pitfalls	B-T080
are	O
underlined	O
and	O
the	O
biological	B-T080
implications	O
of	O
protease	B-T116
malfunction	B-T169
are	O
highlighted.	O
Expert commentary	B-T077
:	O
Dysregulated	B-T033
protease activity	B-T044
is	O
a	O
hallmark	B-T080
for	O
some	O
disease	B-T047
pathologies	B-T091
such	O
as	O
cancer	B-T191
.	O
Current	B-T079
biochemical	B-T169
approaches	B-T169
are	O
low	B-T080
throughput	B-T081
and	O
some	O
are	O
limited	B-T169
by	O
the	O
amount	B-T081
of	O
sample	B-T077
required	B-T169
to	O
obtain	B-T169
reliable	O
results	B-T034
.	O
Mass spectrometry	B-T059
based	O
proteomics	B-T091
provides	B-T052
a	O
suitable	B-T080
platform	B-T075
to	O
investigate	B-T169
protease activity	B-T044
,	O
providing	B-T052
information	B-T078
about	O
substrate specificity	B-T081
and	O
mapping	B-T059
cleavage sites	B-T087
.	O

Diabetic nephropathy	B-T047
as	O
the	O
cause	B-T169
of	O
end-stage kidney disease	B-T047
reported	O
on	O
the	O
medical evidence form	B-T170
CMS2728	B-T170
at	O
a	O
single	O
center	B-T073
Background:	O
End-stage renal disease	B-T047
(	O
ESRD	B-T047
)	O
incidence	B-T081
due	O
to	O
Type 2	B-T185
diabetic nephropathy	B-T047
(	O
DN	B-T047
)	O
is	O
35-50%,	O
according	O
to	O
the	O
United States Renal Data System	B-T073
.	O
Methods:	O
A	O
single-	O
center	B-T073
,	O
retrospective cohort study	B-T062
to	O
determine	O
incidence	B-T081
and	O
diagnostic accuracy	B-T080
for	O
Type 2	B-T185
DN	B-T047
as	O
the	O
primary	B-T080
cause	B-T169
of	O
ESRD	B-T047
(Code	O
250.40)	O
on	O
the	O
Center for Medicare & Medicaid	B-T093
(	O
CMS	B-T093
)	O
Medical Evidence Report form	B-T170
(	O
CMS2728	B-T170
)	O
submitted	B-T169
at	O
renal replacement therapy	B-T061
initiation.	O
All	O
patients	B-T101
≥18	O
years	B-T079
of	O
age	B-T032
with	O
a	O
CMS2728	B-T170
submitted	B-T169
between	O
1	O
March	O
2006	O
and	O
31	O
March	O
2015	O
at	O
a	O
single	O
academic military medical center	B-T073
(	O
ESRD	B-T047
Network	O
5)	O
were	O
included.	O
Medical records	B-T170
of	O
those	O
with	O
a	O
Code	O
250.40	O
diagnosis	B-T033
were	O
reviewed	B-T080
to	O
determine	O
whether	O
they	O
met	O
the	O
Kidney Disease Outcomes Quality Initiative	B-T093
(	O
KDOQI	B-T093
)	O
2007	O
criteria	B-T170
for	O
DN	B-T047
.	O
Results:	O
ESRD	B-T047
incidence	B-T081
secondary	O
to	O
Type 2	B-T185
DN	B-T047
was	O
18.7%	O
(56/299	O
individual	B-T098
CMS2728	B-T170
submissions	B-T169
over	O
9.09	O
years).	O
In	O
all,	O
12/56	O
(21.4%)	O
did	O
not	O
meet	O
KDOQI criteria	B-T170
for	O
Type 2	B-T185
DN	B-T047
.	O
Although	O
all	O
had	O
diabetes	B-T047
,	O
those	O
not meeting criteria	B-T077
had	O
shorter	O
disease duration	B-T079
(P	O
=	O
0.007),	O
were	O
more	O
likely	O
to	O
have	O
active	B-T169
urine sediment	B-T031
(P	O
=	O
0.006),	O
and	O
were	O
less	O
likely	O
to	O
have	O
macroalbuminuria	B-T033
(P	O
=	O
0.037)	O
or	O
retinopathy	B-T047
(P	O
=	O
0.002)	O
prior	O
to	O
ESRD	B-T047
.	O
On	O
exact	O
logistic regression	B-T062
,	O
retinopathy	B-T047
was	O
significantly	O
associated with	B-T080
KDOQI	B-T093
-predicted	O
DN	B-T047
[	O
odds ratio	B-T081
=	O
19.16	O
(	O
confidence interval	B-T081
2.76-223.7),	O
P	O
=	O
0.0009].	O
Conclusions	B-T078
:	O
In	O
this	O
single-	O
center	B-T073
cohort	B-T062
,	O
21.4%	O
identified	B-T080
as	O
having	O
Type 2	B-T185
DN	B-T047
as	O
the	O
primary	B-T080
cause	B-T169
of	O
ESRD	B-T047
were	O
incorrectly	O
assigned	B-T169
per	O
KDOQI	B-T093
2007	O
clinical	B-T080
criteria	B-T170
.	O
If	O
replicated	B-T169
in	O
larger	B-T081
populations	B-T098
,	O
this	O
could	O
have	O
substantial	O
implications	O
regarding	O
the	O
epidemiology	B-T091
of	O
ESRD	B-T047
in	O
the	O
USA	B-T083
.	O

Socioeconomic	B-T077
Predictors	B-T078
of	O
Adherence Behavior	B-T033
Among	O
HIV-Positive	B-T034
Patients	B-T101
Receiving	B-T080
Antiretroviral Therapy	B-T061
in	O
Selangor	B-T083
,	O
Malaysia	B-T083
Medication adherence	B-T033
remains	O
a	O
critical	B-T080
link	O
between	O
the	O
prescribed	B-T058
ART	B-T061
regimen	B-T061
and	O
treatment outcome	B-T080
.	O
Several	B-T081
factors	B-T169
may	O
influence	B-T077
adherence behavior	B-T033
.	O
This	O
cross-sectional study	B-T062
aimed	B-T078
to	O
highlight	O
socioeconomic	B-T077
predictors	B-T078
of	O
adherence behavior	B-T033
among	O
a	O
cohort	B-T098
of	O
242	O
adult	B-T100
Malaysian	B-T098
patients	B-T101
receiving	B-T080
antiretroviral therapy	B-T061
in	O
Hospital Sungai Buloh	B-T073
,	O
Malaysia	B-T083
,	O
where	O
they	O
were	O
enrolled	O
in	O
a	O
parent	O
study	O
(	O
single-blinded	B-T062
randomized controlled trial	B-T062
)	O
between	O
January	B-T080
and	O
December	B-T080
2014.	O
Statistical analysis	B-T062
of	O
secondary data	B-UnknownType
on	O
adherence behavior	B-T033
and	O
sociodemographic characteristics	B-T102
of	O
the	O
patients	B-T101
revealed	B-T080
mean age	B-T033
of	O
33.4	O
years	B-T079
and	O
ranged	B-T081
from	O
18	O
to	O
64	O
years	B-T079
;	O
88.8%	O
were	O
males	B-T032
.	O
A	O
total	O
of	O
224	O
(93%)	O
patients	B-T101
who	O
completed	O
6	O
months'	O
adherence assessment	B-T058
were	O
included	B-T169
in	O
the	O
model.	O
Of	O
these,	O
135	O
(60.3%)	O
achieved	B-T033
optimal	B-T080
adherence	B-T169
.	O
Multivariate binary logistic regression analysis	B-T170
revealed	B-T080
that	O
patient's	B-T101
income	B-T081
and	O
ethnicity	B-T080
were	O
significant	B-T078
predictors	B-T078
of	O
adherence behavior	B-T033
.	O
This	O
may	O
be	O
valuable	O
for	O
targeted	B-T169
programmatic interventions	B-T061
to	O
further	O
enhance	B-T052
successful treatment	B-T201
outcomes	B-T169
among	O
the	O
target population	B-T098
.	O

A	O
Tobramycin Vector	B-T109
Enhances	B-T052
Synergy	B-T034
and	O
Efficacy	B-T080
of	O
Efflux Pump Inhibitors	B-T121
against	B-T080
Multidrug-Resistant	B-T032
Gram-Negative Bacteria	B-T007
Drug efflux	B-T044
mechanisms	B-T169
interact	B-T044
synergistically	B-T080
with	O
the	O
outer membrane	B-T026
permeability	B-T043
barrier	B-T046
of	O
Gram-negative bacteria	B-T007
,	O
leading	B-T169
to	O
intrinsic	B-T082
resistance	B-T169
that	O
presents	O
a	O
major	B-T080
challenge	B-T058
for	O
antibiotic	B-T195
drug development	B-T062
.	O
Efflux pump inhibitors	B-T121
(	O
EPIs	B-T121
)	O
which	O
block	B-T169
the	O
efflux	B-T044
of	O
antibiotics	B-T195
synergize	B-T080
antibiotics	B-T195
,	O
but	O
the	O
clinical development	B-T062
of	O
EPI	B-T121
/	O
antibiotic	B-T195
combination therapy	B-T061
to	O
treat	B-T061
multidrug-resistant	B-T032
(	O
MDR	B-T032
)	O
Gram-negative infections	B-T047
has	O
been	O
challenging	B-T058
.	O
This	O
is	O
in	O
part	O
caused	B-T169
by	O
the	O
inefficiency	B-T033
of	O
current	B-T079
EPIs	B-T121
to	O
penetrate	B-T169
the	O
outer membrane	B-T026
and	O
resist	B-T169
efflux	B-T044
.	O
We	O
demonstrate	O
that	O
conjugation	B-T043
of	O
a	O
tobramycin	B-T109
(	O
TOB	B-T109
)	O
vector	O
to	O
EPIs	B-T121
like	O
NMP	B-T109
,	O
paroxetine	B-T109
,	O
or	O
DBP	B-T201
enhances	B-T052
synergy	B-T034
and	O
efficacy	B-T080
of	O
EPIs	B-T121
in	O
combination	B-T080
with	O
tetracycline antibiotics	B-T109
against	O
MDR	B-T032
Gram-negative bacteria	B-T007
including	O
Pseudomonas aeruginosa	B-T007
.	O
Besides	O
potentiating	B-T044
tetracycline antibiotics	B-T109
,	O
TOB	B-T109
-	O
EPI	B-T121
conjugates	B-T104
can	O
also	O
suppress	B-T169
resistance	B-T169
development	B-T169
to	O
the	O
tetracycline antibiotic	B-T109
minocycline	B-T109
,	O
thereby	O
providing	B-T052
a	O
strategy	B-T041
to	O
develop	B-T169
more	O
effective	B-T080
adjuvants	B-T120
to	O
rescue	O
tetracycline antibiotics	B-T109
from	O
resistance	B-T169
in	O
MDR	B-T032
Gram-negative bacteria	B-T007
.	O

Detection	B-T061
of	O
AMA-M2	B-T116
in	O
human	B-T016
saliva	B-T031
:	O
Potentials	B-T080
in	O
diagnosis	B-T033
and	O
monitoring	B-T058
of	O
primary biliary cholangitis	B-T047
Serum	B-T031
anti-mitochondrial antibody type 2	B-T116
(	O
AMA-M2	B-T116
)	O
is	O
considered	O
as	O
a	O
pivotal	O
biomarker	B-T201
for	O
the	O
diagnosis	B-T033
of	O
primary biliary cholangitis	B-T047
(	O
PBC	B-T047
).	O
However,	O
serological tests	B-T059
have	O
many	O
limitations	B-T169
,	O
including	O
inconvenience	B-T033
,	O
invasiveness	B-T080
,	O
and	O
infection risks	B-T033
.	O
Thus,	O
a	O
less	B-T080
invasive	B-T080
approach	B-T082
to	O
detect	B-T033
AMA-M2 titer	B-T059
is	O
desirable.	O
We	O
examined	O
salivary	B-T031
AMA-M2	B-T116
of	O
potential	B-T080
PBC	B-T047
patients	B-T101
and	O
found	O
that	O
AMA-M2	B-T116
could	O
be	O
detected	B-T033
only	O
in	O
saliva	B-T031
of	O
serum	B-T031
AMA-M2-positive	B-T033
PBC	B-T047
patients	B-T101
,	O
but	O
not	O
in	O
saliva	B-T031
of	O
serum	B-T031
AMA-M2-negative	B-T033
PBC	B-T047
patients	B-T101
,	O
oral lichen planus	B-T047
patients	B-T101
(	O
OLP	B-T047
)	O
patients	B-T101
,	O
or	O
healthy controls	B-T080
.	O
Furthermore,	O
the	O
concentration	B-T081
of	O
salivary	B-T031
AMA-M2	B-T116
was	O
positively correlated	B-T080
with	O
the	O
amount	B-T081
of	O
serum	B-T031
AMA-M2	B-T116
in	O
patients	B-T101
.	O
The	O
salivary	B-T031
inflammatory cytokines	B-T116
were	O
increased	B-T081
in	O
the	O
PBC	B-T047
,	O
consistent with	B-T078
the	O
results	B-T169
of	O
serum	B-T031
test	B-T059
.	O
These	O
findings	O
indicated	O
that	O
saliva	B-T031
might	O
be	O
a	O
less	B-T080
invasive	B-T080
and	O
cost-effective	B-T057
medium	B-T167
to	O
accurately	O
test	B-T169
for	O
AMA-M2 levels	B-T059
and	O
this	O
is	O
a	O
promising	O
development	B-T169
for	O
the	O
diagnosis	B-T033
and	O
monitoring	B-T058
of	O
PBC	B-T047
.	O

Mental health	B-T041
and	O
associated	B-T080
factors	B-T169
among	O
young	B-T079
offenders	B-T098
in	O
Chile	B-T083
:	O
a	O
cross-sectional study	B-T062
Few	O
studies	O
in	O
Latin America	B-T083
have	O
explored	O
mental disorder	B-T048
among	O
young	B-T079
offenders	B-T098
,	O
or	O
variables	B-T080
associated with	B-T080
it.	O
Our	O
aim	O
was	O
to	O
test	O
for	O
associations	B-T080
between	O
childhood	B-T079
adversity	B-T077
or	O
substance misuse	B-T033
and	O
psychiatric disorders	B-T048
among	O
young	B-T079
offenders	B-T098
.	O
Sentenced	B-T064
adolescent	B-T100
offenders	B-T098
were	O
recruited	B-T052
from	O
young	B-T079
offenders'	B-T098
institutions	B-T073
or	O
community centres	B-T058
provided	O
by	O
the	O
Chilean National Service for Minors	B-UnknownType
.	O
Psychiatric disorders	B-T048
were	O
assessed	B-T052
using	O
the	O
Mini International Neuropsychiatric Interview	B-T060
,	O
conducted	O
by	O
trained psychologists	B-T097
.	O
A	O
trained sociologist	B-T097
used	O
an	O
ad hoc interview	B-T052
to	O
collect	O
information	B-T078
about	O
childhood experiences	B-T201
,	O
including	O
parenting	B-T033
,	O
trauma	B-T037
,	O
education	B-T185
and	O
substance misuse	B-T033
.	O
Multivariable logistic regressions	B-T062
were	O
used	O
to	O
analyse data	B-T081
.	O
The	O
most	O
prevalent	O
psychiatric disorders	B-T048
among	O
the	O
935	O
participants	B-T098
were	O
marijuana dependence disorder	B-T048
,	O
major depressive disorder	B-T048
,	O
and	O
anxiety disorders	B-T048
.	O
Substance use disorders	B-T048
were	O
less	O
frequent	O
among	O
young	B-T079
offenders	B-T098
who	O
were	O
serving	O
their	O
sentence	B-T033
in	O
young	B-T079
offenders'	B-T098
institutions	B-T073
than	O
among	O
those	O
serving	O
in	O
community centres	B-T058
and	O
more	O
frequent	B-T079
among	O
those	O
who	O
started	B-T080
to	O
use marijuana	B-T048
at	O
an	O
earlier age	B-T032
.	O
Among	O
other	O
variables	B-T081
,	O
childhood maltreatment	B-T048
was	O
related	O
to	O
major depressive disorder	B-T048
,	O
and	O
maternal death	B-T040
to	O
anxiety disorders	B-T048
.	O
Higher	O
educational status	B-T033
was	O
related	O
to	O
a	O
lower frequency	B-T079
of	O
depressive	B-T048
and	O
anxiety disorders	B-T048
.	O
Our	O
findings	B-T033
suggest	B-T078
that	O
greater	O
efforts	O
must	O
be	O
made	O
to	O
identify	B-T080
vulnerable	B-T169
young	B-T079
people	B-T098
much	O
earlier	B-T079
.	O
Few	B-T081
of	O
these	O
young	B-T079
offenders	B-T098
with	O
mental health	B-T041
problems	B-T033
had	O
been	O
well	O
adjusted	B-T169
in	O
health	B-T078
,	O
education	B-T185
or	O
socially	B-T054
before	O
this	O
period	B-T079
of	O
detention	B-T064
.	O
©	O
2017	O
The	O
Authors.	O
Criminal	O
Behaviour	O
and	O
Mental	O
Health	O
Published	O
by	O
John	O
Wiley	O
&	O
Sons	O
Ltd.	O

Effects of	B-T080
regular	B-T080
water	B-T056
-	O
and	O
land-based exercise	B-T056
on	O
physical function	B-T033
after	O
5	O
years	B-T079
:	O
A	O
long-term study	B-T062
on	O
the	O
well-being	O
of	O
older Japanese	B-T098
adults	B-T098
To	O
investigate	B-T169
the	O
effects	B-T080
of	O
5	O
years	B-T079
of	O
physical exercise	B-T056
on	O
functional	B-T169
parameters	B-T077
among	O
older Japanese	B-T098
adults	B-T098
who	O
carried	O
out	O
water	B-T056
-	O
or	O
land-based exercise	B-T056
.	O
We	O
retrospectively	B-T080
investigated	B-T169
data	B-T078
from	O
5707	O
medical examinations	B-T058
and	O
enrolled	B-T058
77	O
older adults	B-T098
into	O
the	O
study	B-T062
.	O
Eligible	O
participants	B-T098
had	O
to	O
be	O
aged	B-T032
≥60	O
years	B-T079
,	O
and	O
engaged	O
in	O
water-based exercise	B-T056
(n	O
=	O
38)	O
or	O
a	O
combination	B-T080
of	O
water	B-T056
-	O
and	O
land-based exercise	B-T056
(n	O
=	O
39)	O
for	O
at	O
least	O
80%	O
of	O
their	O
total exercise time	B-T079
for	O
over	O
5	O
years	B-T079
at	O
our	O
fitness center	B-T073
.	O
In	O
statistical analysis	B-T062
,	O
a	O
two-way repeated-measures analysis of variance	B-T081
was	O
carried	O
out	O
to	O
examine	B-T033
the	O
effects	B-T080
over	O
time	B-T079
and	O
by	O
exercise type	B-T033
,	O
and	O
the	O
changes	B-T169
in	O
each	O
parameter	B-T077
over	O
5	O
years	B-T079
were	O
also	O
compared	B-T052
between	O
the	O
two	O
groups	B-T078
.	O
We	O
found	B-T033
significant	B-T078
main	B-T080
effects	B-T080
and	O
an	O
interaction	B-T169
between	O
time	B-T079
and	O
exercise type	B-T033
for	O
gait speed	B-T032
,	O
with	O
an	O
early decline	B-T081
in	O
the	O
combined	B-T080
exercise group	B-T078
,	O
as	O
well	O
as	O
significant	B-T078
main	B-T080
effects of	B-T080
time	B-T079
,	O
showing	O
a	O
functional decline	B-T033
in	O
grip strength	B-T081
,	O
one-leg standing	B-T082
time	B-T079
and	O
step/height	B-T033
ratio	B-T081
in	O
both	O
exercise types	B-T033
at	O
the	O
5-	O
year	B-T079
follow up	B-T058
.	O
The	O
5-	O
year	B-T079
changes	B-T169
in	O
each	O
parameter	B-T077
did	O
not	O
differ	O
between	O
the	O
two	O
groups	B-T078
despite	O
the	O
frequency of exercise	B-T033
,	O
even	O
though	O
we	O
found	B-T033
a	O
negative	B-T033
correlation	B-T080
between	O
changes	B-T169
in	O
one-leg standing	B-T082
time	B-T079
and	O
total	B-T080
amount	B-T081
of	O
water-based exercise	B-T056
.	O
Contrary	O
to	O
expectations	B-T078
,	O
these	O
results	B-T169
suggest	B-T078
that	O
regular	B-T080
engagement	O
in	O
water-based exercise	B-T056
,	O
even	O
combined	B-T080
with	O
land-based exercise	B-T056
,	O
might	O
have	O
poor	O
long-term	B-T079
benefits	B-T081
for	O
maintaining	B-T169
physical performance	B-T032
in	O
older adults	B-T098
.	O
Geriatr	O
Gerontol	O
Int	O
2017;	O
••:	O
••-••.	O

Combined	B-T080
exposures	B-T037
of	O
whole-body vibration	B-T033
and	O
awkward posture	B-T033
:	O
a	O
cross sectional investigation	B-T062
among	O
occupational	B-T090
drivers	B-T098
by	O
means	O
of	O
simultaneous	B-T079
field measurements	B-T169
Multifactorial	B-T033
workloads	B-T081
such	O
as	O
whole-body vibration	B-T033
(	O
WBV	B-T033
),	O
awkward posture	B-T033
and	O
heavy	O
lifting	B-T052
are	O
potential	B-T080
predictors	B-T033
for	O
low back pain	B-T184
(	O
LBP	B-T184
).	O
In	O
this	O
study	B-T062
,	O
we	O
investigate	B-T169
the	O
association	B-T080
between	O
LBP	B-T184
and	O
these	O
exposures	B-T037
among	O
102	O
professional	B-T090
drivers	B-T098
.	O
The	O
combined	B-T080
exposures	B-T037
of	O
WBV	B-T033
and	O
posture	O
are	O
measured	B-T080
at	O
different	B-T080
workplaces	B-T082
.	O
Health	B-T078
and	O
personal	O
data	B-T078
as	O
well	O
as	O
information	B-T078
about	O
lifting	B-T052
tasks	B-T057
are	O
collected	B-T169
by	O
a	O
questionnaire	B-T170
.	O
The	O
daily	B-T079
vibration exposure	B-T037
value	B-T081
(	O
odds ratio	B-T081
1.69)	O
and	O
an	O
index	B-T081
for	O
awkward posture	B-T033
(	O
odds ratio	B-T081
1.63)	O
show	O
significant	B-T078
association	B-T080
with	O
the	O
occurence	B-T079
of	O
LBP	B-T184
.	O
Awkward posture	B-T033
and	O
heavy	O
lifting	B-T052
appear	B-T080
to	O
be	O
more	O
strongly	O
associated with	B-T080
sick leave	B-T078
than	O
WBV	B-T033
exposure	B-T037
.	O
Furthermore,	O
a	O
combination	B-T080
of	O
the	O
measurement	B-T169
results	B-T169
of	O
WBV	B-T033
and	O
awkward posture	B-T033
into	O
one	O
quantity	B-T081
also	O
shows	O
significant	B-T078
correlation	B-T080
to	O
LBP	B-T184
.	O
The	O
combined	B-T080
exposure	B-T037
of	O
WBV	B-T033
and	O
awkward posture	B-T033
can	O
be	O
described	B-T078
in	O
terms	O
of	O
the	O
daily	B-T079
vibration exposure	B-T037
and	O
the	O
index	B-T081
for	O
awkward posture	B-T033
.	O
This	O
facilitates	O
work place	B-T082
assessments	B-T052
and	O
future	B-T079
research	B-T062
in	O
this	O
area	B-T082
.	O
Practitioner	O
Summary:	O
For	O
the	O
first	O
time,	O
quantitative	B-T081
measures	B-T081
combining	O
whole-body vibration	B-T033
and	O
awkward posture	B-T033
exposures	B-T037
have	O
shown	O
to	O
correlate	B-T080
with	O
the	O
occurrence	B-T079
of	O
low back pain	B-T184
significantly.	O
This	O
validates	O
the	O
proposed	O
quantities	B-T081
and	O
measurement	B-T169
methods	B-T169
,	O
which	O
facilitate	O
workplace	B-T082
assessments	B-T052
and	O
assist	B-T080
in	O
the	O
design	B-T052
of	O
further	B-T079
studies	B-T062
which	O
are	O
necessary	O
to	O
establish	B-T080
a	O
causal exposure	B-T037
-	O
response	B-T032
relationship	B-T080
.	O

Association	B-T080
of	O
CKIP-1 P21A	B-T028
polymorphism	B-T086
with	O
risk	B-T078
of	O
chronic heart failure	B-T047
in	O
a	O
Chinese population	B-T098
Pathological	B-T169
cardiac hypertrophy	B-T046
is	O
an	O
independent	O
risk factor	B-T033
for	O
chronic heart failure	B-T047
.	O
Casein kinase-2 interacting protein-1	B-T116
(	O
CKIP-1	B-T116
)	O
can	O
inhibit	O
pathological	B-T169
cardiac hypertrophy	B-T046
.	O
Therefore,	O
we	O
investigated	B-T169
whether	O
CKIP-1	B-T028
nonsynonymous polymorphism rs2306235	B-T086
(	O
Pro21Ala	B-T045
)	O
contributes	O
to	O
risk	B-T078
and	O
prognosis	B-T058
of	O
chronic heart failure	B-T047
in	O
a	O
Chinese population	B-T098
.	O
A	O
total	O
of	O
923	O
adult	B-T100
patients	B-T101
with	O
chronic heart failure	B-T047
and	O
1020	O
age	B-T032
-	O
and	O
gender	B-T032
-matched	O
healthy controls	B-T080
were	O
recruited.	O
CKIP-1 rs2306235	B-T028
polymorphism	B-T086
was	O
genotyped	B-T059
using	O
PCR	B-T063
-	O
restriction fragment length polymorphism	B-T059
.	O
Additional	O
follow-up	B-T058
data	B-T078
for	O
140	O
chronic heart failure	B-T047
patients	B-T101
was	O
evaluated	B-T058
.	O
The	O
rs2306235	B-T028
G allele	B-T028
was	O
associated	O
with	O
an	O
increased	B-T081
risk	B-T078
of	O
chronic heart failure	B-T047
(	O
OR	B-T081
=	O
1.38,	O
95%	O
CI	B-T081
=	O
1.09-1.75,	O
p	B-T081
=	O
0.007),	O
especially	O
in	O
patients	B-T101
with	O
hypertension	B-T047
(	O
OR	B-T081
=	O
1.45,	O
95%	O
CI	B-T081
=	O
1.09-1.75,	O
p	O
=	O
0.006)	O
and	O
coronary heart disease	B-T047
(	O
OR	B-T081
=	O
1.41,	O
95%	O
CI	B-T081
=	O
1.09-1.83,	O
p	B-T081
=	O
0.010)	O
after	O
adjustment	O
for	O
multiple cardiovascular	B-T033
risk factors	B-T033
.	O
However,	O
rs2306235	B-T028
polymorphism	B-T086
was	O
not	O
associated	O
with	O
cardiovascular mortality	B-T081
in	O
chronic heart failure	B-T047
(p	O
=	O
0.875).	O
CKIP-1 rs2306235	B-T028
polymorphism	B-T086
may	O
be	O
a	O
risk factor	B-T033
for	O
chronic heart failure	B-T047
in	O
a	O
Chinese Han population	B-UnknownType
.	O

Linking	O
phenological events	B-T079
in	O
migratory passerines	B-T012
with	O
a	O
changing climate	B-T070
:	O
50	O
years	B-T079
in	O
the	O
Laurel Highlands of Pennsylvania	B-T083
Advanced timing	B-T079
of	O
both	O
seasonal	B-T079
migration	O
and	O
reproduction	B-T039
in	O
birds	B-T012
has	O
been	O
strongly	O
associated with	B-T080
a	O
warming climate	B-T070
for	O
many	O
bird	B-T012
species	B-T185
.	O
Phenological responses	B-T079
to	O
climate	B-T070
linking	O
these	O
stages	B-T079
may	O
ultimately	O
impact	B-T080
fitness	B-T052
.	O
We	O
analyzed	B-T062
five	O
decades	B-T081
of	O
banding data	B-T078
from	O
17	O
migratory bird	B-T012
species	B-T185
to	O
investigate	O
1)	O
how	O
spring	B-T079
arrival	B-T052
related	O
to	O
timing	B-T079
of	O
breeding	B-T040
,	O
2)	O
if	O
the	O
interval	B-T079
between	O
arrival	B-T052
and	O
breeding	B-T040
has	O
changed	O
with	O
increasing	B-T169
spring	B-T079
temperatures	B-T081
,	O
and	O
3)	O
whether	O
arrival	B-T052
timing	B-T079
or	O
breeding	B-T040
timing	B-T079
best	O
predicted	O
local productivity	B-T033
.	O
Four	O
of	O
17	O
species	B-T185
,	O
all	O
mid- to long-distance migrants	B-T012
,	O
hatched	B-T040
young	O
earlier	O
in	O
years	B-T079
when	O
migrants	B-T098
arrived	B-T052
earlier	B-T079
to	O
the	O
breeding grounds	B-T082
(~1:1	O
day advancement	B-T079
).	O
The	O
interval	B-T079
between	O
arrival	B-T052
on	O
breeding grounds	B-T082
and	O
appearance	B-T080
of	O
juveniles	B-T100
shortened	B-T080
with	O
warmer	O
spring	B-T079
temperatures	B-T081
for	O
12	O
species	B-T185
(1-6	O
days	B-T079
for	O
every	O
1°C	O
increase	B-T169
)	O
and	O
over	O
time	O
for	O
seven	O
species	B-T185
(1-8	O
days	O
per	O
decade	B-T081
),	O
suggesting	O
that	O
some	O
migratory passerines	B-T012
adapt	O
to	O
climate change	B-T070
by	O
laying	B-T040
more quickly	B-T033
after	O
arrival	B-T033
or	O
reducing	B-T080
the	O
time	B-T079
from	O
laying	B-T040
to	O
fledging.	O
We	O
found	O
more	O
support	O
for	O
the	O
former	B-T078
,	O
that	O
the	O
rate	B-T081
of	O
reproductive advancement	B-T040
was	O
higher	B-T080
than	O
that	O
for	O
arrival	B-T033
in	O
warm years	B-T070
.	O
Timing	B-T079
of	O
spring	B-T079
arrival	B-T052
and	O
breeding	B-T040
were	O
both	O
poor	B-T080
predictors	B-T078
of	O
avian	B-T012
productivity	B-T081
for	O
most	O
migrants	B-T012
analyzed	B-T062
.	O
Nevertheless,	O
we	O
found	O
evidence	B-T078
that	O
fitness	B-T045
benefits	O
may	O
occur	O
from	O
shifts	B-T067
to	O
earlier	O
spring	B-T079
arrival	B-T052
for	O
the	O
multi-brooded Song Sparrow	B-T012
.	O
Our	O
results	B-T169
uniquely	O
demonstrate	O
that	O
co-occurring	O
avian	B-T012
species	B-T185
are	O
phenologically plastic	B-T079
in	O
their	O
response	B-T032
to	O
climate change	B-T070
on	O
their	O
breeding grounds	B-T082
.	O
If	O
migrants	B-T098
continue	O
to	O
show	O
a	O
weaker	B-T080
response	B-T032
to	O
temperatures	B-T081
during	O
migration	O
than	O
breeding	B-T040
,	O
and	O
the	O
window	B-T079
between	O
arrival	B-T052
and	O
optimal breeding	B-T040
shortens	B-T080
further,	O
biological	O
constraints	O
to	O
plasticity	B-T070
may	O
limit	O
the	O
ability	B-T032
of	O
species	B-T185
to	O
adapt	O
successfully	O
to	O
future warming	B-T070
.	O

Mucosal	B-T024
IgM Antibody	B-T116
with	O
d-Mannose	B-T109
Affinity	B-T070
in	O
Fugu Takifugu rubripes	B-T013
Is	O
Utilized	O
by	O
a	O
Monogenean	B-T204
Parasite	B-T204
Heterobothrium okamotoi	B-T204
for	O
Host Recognition	B-T040
How	O
parasites	B-T204
recognize	B-T041
their	O
definitive	B-T079
hosts	B-T001
is	O
a	O
mystery;	O
however,	O
parasitism	B-T070
is	O
reportedly	O
initiated	O
by	O
recognition	B-T041
of	O
certain	O
molecules	B-T167
on	O
host surfaces	B-T026
.	O
Fish	B-T013
ectoparasites	B-T204
make	O
initial contact	B-T033
with	O
their	O
hosts	B-T001
at	O
body surfaces	B-T032
,	O
such	O
as	O
skin	B-T022
and	O
gills	B-T023
,	O
which	O
are	O
covered	B-T169
with	O
mucosa	B-T024
that	O
are	O
similar	O
to	O
those	O
of	O
mammalian guts	B-T023
.	O
Fish	B-T013
are	O
among	O
the	O
most	O
primitive vertebrates	B-T010
with	O
immune systems	B-T022
that	O
are	O
equivalent	O
to	O
those	O
in	O
mammals	B-T015
,	O
and	O
they	O
produce	O
and	O
secrete	B-T038
IgM	B-T116
into	O
mucus	B-T031
.	O
In	O
this	O
study,	O
we	O
showed	O
that	O
the	O
monogenean	B-T204
parasite	B-T204
Heterobothrium okamotoi	B-T204
utilizes	O
IgM	B-T116
to	O
recognize	B-UnknownType
its	O
host	B-T001
,	O
fugu Takifugu rubripes Oncomiracidia	B-T013
are	O
infective larvae	B-T204
of	O
H. okamotoi	B-T204
that	O
shed	O
their	O
cilia	B-T026
and	O
metamorphose	B-T040
into	O
juveniles	B-T100
when	O
exposed	O
to	O
purified	B-T169
d-mannose	B-T109
-	O
binding	B-T052
fractions	B-T081
from	O
fugu	B-T013
fugu	B-T013
mucus	B-T031
.	O
Using	O
liquid chromatography-tandem mass spectrometry analysis	B-T059
,	O
proteins	B-T116
contained	O
in	O
the	O
fraction	B-T081
were	O
identified	B-T080
as	O
d-mannose	B-T109
-specific	O
IgM	B-T116
with	O
two	O
d-mannose	B-T109
d-mannose -binding	B-T052
lectins	B-T116
.	O
However,	O
although	O
deciliation	B-T039
was	O
significantly	O
induced	B-T169
by	O
IgM	B-T116
and	O
was	O
inhibited	B-T080
by	O
d-mannose	B-T109
or	O
a	O
specific	O
Ab	B-T116
against	O
fugu	B-T013
IgM	B-T116
,	O
other	O
lectins	B-T116
had	O
no effect	B-T080
,	O
and	O
IgM	B-T116
without	O
d-mannose	B-T109
affinity	B-T070
induced	B-T169
deciliation	B-T039
to	O
a	O
limited	O
degree.	O
Subsequent	O
immunofluorescent staining experiments	B-T059
showed	O
that	O
fugu	B-T013
d-mannose	B-T109
-specific	O
IgM	B-T116
binds	B-T052
ciliated epidermal cells	B-T025
of	O
oncomiracidium	B-T013
.	O
These	O
observations	B-T078
suggest	O
that	O
deciliation	B-T039
is	O
triggered by	B-T080
binding	B-T052
of	O
fugu	B-T013
IgM	B-T116
to	O
cell surface Ags	B-T129
via	O
Ag binding sites	B-T129
.	O
Moreover,	O
concentrations	B-T081
of	O
d-mannose	B-T109
-	O
binding	B-T052
IgM	B-T116
in	O
gill mucus	B-T031
were	O
sufficient	O
to	O
induce	B-T169
deciliation	B-T039
in vitro	B-T080
,	O
indicating	B-T078
that	O
H. okamotoi parasites	B-T204
initially	O
use	B-T169
host	B-T001
Abs	B-T116
to	O
colonize	B-T033
host	B-T001
gills	B-T023
.	O

BALB/c mice	B-T015
immunized	B-T061
with	O
a	O
combination	O
of	O
virus-like particles	B-T026
incorporating	O
Kaposi sarcoma-associated herpesvirus	B-T005
(	O
KSHV	B-T005
)	O
envelope	O
glycoproteins gpK8.1	B-T116
,	O
gB	B-T116
,	O
and	O
gH	B-T116
/	O
gL	B-T116
induced	O
comparable	O
serum	B-T031
neutralizing antibody	B-T116
activity	B-T044
to	O
UV	B-T070
-	O
inactivated	B-T169
KSHV	B-T005
Infection	O
with	O
Kaposi sarcoma-associated herpesvirus	B-T005
(	O
KSHV	B-T005
)	O
is	O
estimated	O
to	O
account	O
for	O
over	O
44,000	O
new	O
cases	O
of	O
Kaposi sarcoma	B-T191
annually,	O
with	O
84%	O
occurring	O
in	O
Africa	B-T083
,	O
where	O
the	O
virus	B-T005
is	O
endemic.	O
To	O
date,	O
there	O
is	O
no	O
prophylactic vaccine	B-T121
against	O
KSHV	B-T005
.	O
KSHV	B-T005
gpK8.1	B-T116
,	O
gB	B-T116
,	O
and	O
gH	B-T116
/	O
gL glycoproteins	B-T116
,	O
implicated	O
in	O
the	O
virus	B-T005
entry	O
into	O
host cells	B-T026
,	O
are	O
attractive	O
vaccine	B-T121
targets	B-T169
for	O
eliciting	O
potent	O
neutralizing antibodies	B-T116
(	O
nAbs	B-T116
)	O
against	O
virus infection	B-T047
.	O
We	O
incorporated	O
gpK8.1	B-T116
,	O
gB	B-T116
gB	B-T116
,	O
or	O
gH	B-T116
/	O
gL	B-T116
on	O
the	O
surface	O
of	O
virus-like particles	B-T026
(	O
VLPs	B-T026
)	O
and	O
characterized	O
these	O
VLPs	B-T026
for	O
their	O
composition,	O
size,	O
and	O
functionality.	O
To	O
determine	O
which	O
viral glycoprotein(s)	B-T026
elicit	O
the	O
most	O
effective	O
serum	B-T031
-	O
nAbs	B-T116
,	O
we	O
immunized	B-T061
BALB/c mice	B-T015
with	O
gpK8.1	B-T116
,	O
gB	B-T116
,	O
or	O
gH	B-T116
/	O
gL	B-T116
VLPs	B-T026
individually	O
or	O
in	O
combination.	O
Neutralizing antibody	B-T116
assay	O
revealed	O
that	O
sera	O
from	O
mice	B-T015
immunized	B-T061
with	O
the	O
VLPs	B-T026
inhibited	O
KSHV	B-T005
infection	B-T047
of	O
HEK-293 cells	B-T025
in	O
a	O
dose-dependent	B-T081
manner.	O
As	O
a	O
single	O
immunogen	B-T129
,	O
gpK8.1	B-T116
VLPs	B-T026
stimulated	O
comparable	O
nAb	B-T116
activity	O
to	O
that	O
of	O
UV	B-T070
-	O
inactivated	B-T169
KSHV	B-T005
(	O
UV-KSHV	B-T005
).	O
In	O
contrast,	O
UV-KSHV	B-T005
stimulated	O
higher	O
titers	O
of	O
nAb	O
compared	O
to	O
gB	B-T116
(p	O
=	O
0.0316)	O
or	O
gH	B-T116
/	O
gL	B-T116
(p	O
=	O
0.0486).	O
Mice	B-T015
immunized	B-T061
with	O
the	O
combination	O
of	O
gB	B-T116
and	O
gH	B-T116
/	O
gL	B-T116
VLPs	B-T026
had	O
a	O
better	O
nAb	O
response	O
than	O
those	O
immunized	B-T061
with	O
either	O
gB	B-T116
(p	O
=	O
0.0268),	O
or	O
gH	B-T116
/gL	O
(p	O
=	O
0.0397)	O
as	O
single	O
VLP	B-T026
immunogens	B-T129
.	O
Immunization	B-T061
with	O
any	O
VLP	B-T026
combination	O
stimulated	O
comparable	O
nAb	B-T116
activity	O
to	O
UV-KSHV	B-T005
serum	B-T031
.	O
Our	O
data	O
provide	O
the	O
first	O
evidence	O
that	O
KSHV	B-T005
gpK8.1	B-T116
,	O
gB	B-T116
,	O
and	O
gH	B-T116
/	O
gL glycoproteins	B-T116
can	O
be	O
incorporated	O
onto	O
the	O
surface	O
of	O
VLPs	B-T026
and	O
used	O
as	O
prophylactic vaccine	B-T121
candidates,	O
with	O
potential	O
to	O
prevent	O
KSHV	B-T005
infection	B-T047
.	O

A	O
missense	B-T045
variant	B-T080
,	O
rs373863828-A (p.Arg457Gln), of CREBRF	B-T028
and	O
body mass index	B-T201
in	O
Oceanic populations	B-UnknownType
It	O
has	O
been	O
suggested	O
that	O
a	O
'thrifty'	O
genotype	B-T032
hypothesis	B-T078
can	O
account	O
for	O
high prevalence	B-T081
of	O
obesity	B-T047
in	O
the	O
island	B-T083
populations	B-T098
of	O
Oceania	B-T083
.	O
A	O
recent	O
genome-wide association study	B-T063
revealed	O
that	O
a	O
missense	B-T045
variant	B-T080
,	O
rs373863828-A (p.Arg457Gln), of the CREBRF gene	B-T028
(encoding	O
CREB3 regulatory factor	B-T116
)	O
was	O
associated with	B-T080
an	O
excessive	B-T080
increase	B-T169
in	O
body mass index	B-T201
(	O
BMI	B-T201
)	O
in	O
Samoans	B-T098
.	O
In	O
the	O
present	O
study,	O
the	O
association	O
of	O
rs373863828-A	B-T028
with	O
an	O
increase	B-T169
in	O
BMI	B-T201
was	O
examined	B-T033
in	O
four	O
Austronesian	B-UnknownType
(	O
AN	B-UnknownType
)-	O
speaking	B-T056
populations	B-T098
in	O
Oceania	B-T083
.	O
We	O
found	O
that	O
rs373863828-A	B-T028
was	O
frequently	O
observed	O
(frequency	O
of	O
0.15)	O
in	O
Tongans	B-T098
(	O
Polynesians	B-T098
),	O
and	O
was	O
strongly	O
associated with	B-T080
higher	O
BMI	B-T201
(P=6.1	O
×	O
10(-4)).	O
A	O
single	O
copy	O
of	O
the	O
rs373863828-A	B-T028
allele	B-T028
increased	B-T081
BMI	B-T201
by	O
3.09	O
kg	O
m(-2)	O
after	O
adjustment	O
of	O
age	B-T032
and	O
sex	B-T032
.	O
No significant	B-T033
association	B-T080
was	O
detected	B-T061
in	O
the	O
other	O
three	O
AN	B-UnknownType
-	O
speaking	B-T056
populations	B-T098
(	O
Melanesians	B-T098
and	O
Micronesians	B-T098
)	O
living	B-T078
in	O
Solomon Islands	B-T083
.	O
This	O
was	O
probably	O
due	O
to	O
the	O
low	B-T080
allele frequency	B-T081
(0.02-0.06)	O
of	O
rs373863828-A	B-T028
as	O
well	O
as	O
small	O
sample size	B-T081
.	O
The	O
rs373863828-A	B-T028
allele	B-T028
was	O
not	O
found	O
in	O
both	O
AN	B-UnknownType
-	O
speaking	B-T056
and	O
non-	O
AN	B-UnknownType
-	O
speaking	B-T056
Melanesians	B-T098
living	O
in	O
Papua New Guinea	B-T083
.	O
Our	O
results	O
suggest	O
that	O
rs373863828-A of CREBRF	B-T028
,	O
a	O
promising	O
thrifty	O
variant	B-T080
,	O
arose	O
in	O
recent	O
ancestors	B-T099
of	O
AN	B-UnknownType
-	O
speaking	B-T056
Polynesians	B-T098
.Journal	O
of	O
Human	O
Genetics	O
advance	O
online	O
publication,	O
13	O
April	O
2017;	O
doi:10.1038/jhg.2017.44.	O

Vaccination	B-T061
of	O
piglets	B-T015
at	O
2	O
and	O
3	O
weeks	O
of	O
age	O
with	O
Ingelvac PRRSFLEX® EU	B-T121
provides	O
protection	B-T033
against	O
heterologous	B-T080
field	O
challenge	O
in	O
the	O
face	O
of	O
homologous	B-T032
maternally derived antibodies	B-T116
Due	O
to	O
difficulties	O
in	O
eradicating	B-T058
porcine reproductive and respiratory syndrome	B-T047
(	O
PRRS	B-T047
)	O
linked	O
to	O
biosecurity	O
challenges,	O
transmission of the virus	B-T043
and	O
the	O
lack	O
of	O
efficient	B-T080
DIVA vaccines	B-T121
,	O
successful	B-T080
control	B-T080
of	O
PRRS	B-T047
requires	O
a	O
combination	O
of	O
strict	O
management measures	B-T058
and	O
vaccination	B-T061
of	O
both	O
sows	B-T015
and	O
piglets	B-T015
.	O
The	O
present	O
study	B-T062
aimed	O
to	O
assess	B-T058
the	O
efficacy	B-T080
of	O
a	O
recently	O
developed	O
MLV vaccine	B-T121
(	O
Ingelvac PRRSFLEX® EU	B-T121
)	O
in	O
piglets	B-T015
at	O
2	O
and	O
3-weeks	O
of	O
age	O
in	O
the	O
presence	B-T033
of	O
homologous	B-T032
maternally derived antibodies	B-T116
as	O
the	O
dams	O
were	O
vaccinated	B-T061
with	O
the	O
same	O
vaccine strain	B-T121
(	O
ReproCyc® PRRS EU	B-T121
).	O
The	O
study	B-T062
was	O
carried	O
out	O
on	O
a	O
Hungarian farrow	B-T015
to	O
finish	O
farm	B-T082
naturally infected	B-T033
with	O
PRRSv	B-T005
.	O
The	O
study	B-T062
was	O
designed	O
as	O
a	O
blind	B-T062
,	O
placebo controlled	B-T062
side	O
by	O
side	O
trial.	O
ORF5	B-T116
sequence similarity	B-T081
of	O
the	O
vaccine strain	B-T121
and	O
the	O
resident field strain	B-T098
was	O
87.8	O
%.	O
PRRS	B-T047
specific	O
real-time quantitative PCR	B-T063
was	O
performed	O
from	O
serum samples	B-T031
to	O
measure	B-T081
both	O
the	O
viral load	B-T059
and	O
the	O
frequency	O
of	O
virus positive	B-T034
animals	B-T008
.	O
At	O
the	O
time	O
of	O
the	O
natural infection	B-T046
observed	B-T169
in	O
the	O
control group	B-T096
at	O
10-12	O
weeks	O
of	O
age,	O
the	O
number	O
of	O
viraemic	B-T033
animals	B-T008
did	O
not	O
increase	O
significantly	O
in	O
the	O
vaccinated	B-T061
group.	O
To	O
understand	O
the	O
infection	B-T046
dynamics	B-T070
,	O
positive	B-T033
PCR	B-T063
samples	B-T167
with	O
low	O
Ct	O
values	O
were	O
sequenced	O
(	O
ORF5	B-T116
)	O
and	O
the	O
data analysis	B-T057
indicated	B-T033
the	O
circulation	B-T033
of	O
wild	O
type	O
virus	O
in	O
both	O
groups,	O
however	O
wild	O
type	O
virus	B-T005
was	O
only	O
found	O
in	O
non-vaccinated	O
animals.	O
Our	O
data	B-T078
indicate	O
that	O
piglets	B-T015
vaccinated	B-T061
at	O
as	O
early	O
as	O
2	O
weeks	O
of	O
age	O
with	O
Ingelvac PRRSFLEX® EU	B-T121
were	O
protected	O
both	O
in	O
terms	O
of	O
proportion	B-T081
of	O
viraemic	B-T033
animals	B-T008
and	O
viraemia	B-T047
levels.	O
It	O
has	O
to	O
be	O
highlighted	O
that	O
these	O
results	O
were	O
achieved	O
in	O
piglets	B-T015
with	O
high	O
levels	O
of	O
homologous	B-T032
maternally derived antibodies	B-T116
(	O
MDA	B-T116
)	O
at	O
the	O
time	O
of	O
vaccination	B-T061
.	O

Lung nodule	B-T033
in	O
French Guiana	B-T083
in	O
a	O
immunocompetent	B-T201
patient	B-T101
We	O
report	O
the	O
case	B-T077
of	O
an	O
immunocompetent	B-T201
French	B-T098
soldier	B-T097
stationed	O
in	O
French Guiana	B-T083
,	O
who	O
developed	O
symptomatic	B-T169
pulmonary histoplasmosis	B-T047
.	O

Comparison	B-T052
of	O
Occlusive	B-T169
and	O
Open	B-T082
Application	B-T169
in	O
a	O
Psoriasis Plaque Test Design	B-T062
,	O
Exemplarily	O
Using	O
Investigations	B-T169
of	O
Mapracorat	B-T109
0.1%	O
Ointment	B-T122
versus	O
Vehicle	B-T122
and	O
Reference	B-T077
Drugs	B-T121
Psoriasis plaque tests	B-T062
(	O
PPTs	B-T062
)	O
are	O
important	O
tools	O
in	O
the	O
early	O
phases	O
of	O
antipsoriatic	B-T121
drug development	B-T091
.	O
Two	O
distinct	O
PPT design	B-T062
variants	O
(	O
open	B-T169
vs.	O
occluded drug application	B-T169
)	O
are	O
commonly	O
used,	O
but	O
no	O
previous	O
work	O
has	O
aimed	O
to	O
directly	O
compare	O
and	O
contrast	O
their	O
performance.	O
We	O
compared	O
the	O
antipsoriatic	B-T121
efficacy	O
of	O
mapracorat	B-T109
0.1%	O
ointment	B-T122
and	O
reference	B-T077
drugs	B-T121
reported	O
in	O
2	O
separate	O
studies	B-T062
,	O
representing	O
open	B-T062
and	O
occluded PPT designs	B-T062
.	O
The	O
drug effect	B-T169
size	O
was	O
measured	O
by	O
sonography	B-T060
(mean	O
change	O
in	O
echo-poor	O
band	O
thickness	B-T080
),	O
chromametry	B-T059
,	O
and	O
standardized	O
clinical assessment	B-T033
.	O
Antipsoriatic	B-T121
effects	B-T169
were	O
detectable	O
for	O
the	O
study	B-T062
drugs	B-T121
in	O
both	O
occluded	B-T062
and	O
open PPTs	B-T062
.	O
Differences	O
between	O
the	O
potency	B-T038
of	O
antipsoriatic drugs	B-T121
and	O
vehicle	B-T122
were	O
observable.	O
The	O
total	O
antipsoriatic	B-T121
effect	B-T169
size	O
appeared	O
to	O
be	O
higher	O
in	O
the	O
occluded PPT	B-T062
than	O
the	O
open PPT	B-T062
,	O
despite	O
the	O
shorter	O
treatment duration	B-T079
(2	O
vs.	O
4	O
weeks	B-T079
).	O
Effect	B-T169
dynamics	B-T070
over	O
time	B-T079
revealed	O
greater	O
differences	O
between	O
some	O
study	B-T062
drugs	B-T121
in	O
the	O
open PPT	B-T062
compared	O
to	O
the	O
occluded PPT	B-T062
.	O
Taking	O
the	O
higher	O
technical challenges	B-T067
for	O
the	O
open PPT	B-T062
into	O
account,	O
we	O
recommend	O
the	O
occluded PPT	B-T062
as	O
a	O
standard	O
screening	B-T062
setting	O
in	O
early	B-T079
drug development	B-T091
.	O
In	O
special	O
cases,	O
considering	O
certain	O
drug	B-T121
aspects	B-T080
or	O
study	B-T062
objectives	O
that	O
would	O
require	O
procedural	O
adaptations,	O
an	O
open PPT	B-T062
could	O
be	O
the	O
better-suited	O
design.	O
Finally,	O
both	O
PPT	B-T062
models	O
show	O
clear	O
advantages:	O
classification	B-T185
as	O
phase I studies	B-T062
,	O
small	O
number	O
of	O
psoriatic	O
subjects,	O
relatively	O
short	O
study	B-T062
duration	B-T079
,	O
excellent	O
discrimination	O
between	O
compounds	B-T103
and	O
concentrations	B-T081
,	O
parallel	O
measurement	B-T169
of	O
treatment response	B-T201
,	O
and	O
go/no	O
go	O
decisions	O
very	O
early	B-T079
in	O
clinical development	B-T062
.	O

Insurance Coverage	B-T078
and	O
Utilization	B-T169
at	O
a	O
Sexually Transmitted Disease Clinic	B-T073
in	O
a	O
Medicaid	B-T064
Expansion	O
State	B-T083
In	O
Rhode Island	B-T083
,	O
the	O
Patient Protection and Affordable Care Act	B-T089
has	O
led	O
to	O
over	O
95%	O
of	O
the	O
state's	B-T083
population	B-T081
being	O
insured	B-T170
.	O
We	O
evaluated	B-T058
insurance coverage	B-T078
and	O
barriers	B-T033
to	O
insurance	B-T058
use	O
among	O
patients	B-T101
presenting	O
for	O
services	B-T058
at	O
the	O
Rhode Island	B-T083
sexually transmitted disease (STD) clinic	B-T073
.	O
We	O
analyzed	B-T062
factors	B-T169
associated with	B-T080
insurance coverage	B-T078
and	O
utilization	B-T169
among	O
patients	B-T101
presenting	O
for	O
STD	B-T047
services	B-T058
between	O
July	B-T080
and	O
December	B-T080
2015.	O
A	O
total	O
of	O
692	O
patients	B-T101
had	O
insurance information	B-T078
available	B-T077
;	O
of	O
those,	O
40%	O
were	O
uninsured	B-T098
.	O
Patients	B-T101
without insurance	B-T098
were	O
more	O
likely	O
than	O
those	O
with	O
insurance	B-T058
to	O
be	O
nonwhite	O
(50%	O
among	O
uninsured	B-T098
,	O
compared	O
with	O
40%	O
among	O
insured	B-T170
;	O
P	O
=	O
0.014)	O
and	O
Hispanic	B-T098
or	O
Latino/a	B-T098
(25%,	O
compared	O
with	O
16%;	O
P	O
=	O
0.006),	O
and	O
less	O
likely	O
to	O
be	O
men	B-T098
who	O
have	O
sex	B-T040
with	O
men	B-T098
(27%,	O
compared	O
with	O
39%;	O
P	O
=	O
0.001).	O
Of	O
those	O
with	O
health insurance	B-T058
,	O
26%	O
obtained	O
coverage	B-T078
as	O
a	O
result	B-T169
of	O
the	O
Affordable Care Act	B-T089
,	O
and	O
56%	O
of	O
those	O
were	O
previously	O
uninsured	B-T098
.	O
Among	O
uninsured individuals	B-T098
,	O
barriers	B-T033
to	O
obtaining	O
health insurance	B-T058
included	O
cost	B-T081
and	O
unemployment	B-T033
.	O
Among	O
those	O
with insurance	B-T170
,	O
43%	O
reported	O
willingness	B-T033
to	O
use	O
insurance	B-T058
for	O
STD	B-T047
services	B-T058
.	O
Barriers	B-T033
to	O
insurance	B-T058
use	O
included	O
concerns	O
about	O
anonymity	B-T078
and	O
out-of-pocket costs	B-T081
.	O
Despite	O
expanded	O
insurance	B-T058
access	B-T078
,	O
many	O
individuals	B-T098
presenting	O
to	O
the	O
Rhode Island	B-T083
STD Clinic	B-T073
were	O
uninsured	B-T098
.	O
Among	O
those	O
who	O
were	O
insured	B-T170
,	O
significant	O
barriers	B-T033
still	O
existed	O
to	O
using	O
insurance	B-T058
.	O
STD clinics	B-T073
continue	O
to	O
play	O
an	O
important	O
role	O
in	O
providing	O
safety-net	B-T058
STD	B-T047
services	B-T058
in	O
states	B-T083
with	O
low	O
uninsured	B-T098
rates	B-T081
.	O
Both	O
public	B-T092
and	O
private	B-T092
insurers	B-T092
are	O
needed	O
to	O
address	O
financial barriers	B-T033
and	O
optimize	B-T052
payment	B-T081
structures	B-T082
for	O
services	B-T058
.	O

Molecular subtyping	B-T059
of	O
Treponema pallidum	B-T007
and	O
associated factors	B-T169
of	O
serofast	B-T033
status	B-T080
in	O
early syphilis	B-T047
patients	B-T101
:	O
Identified	B-T080
novel	O
genotype	B-T032
and	O
cytokine	B-T116
marker	B-T201
Serofast	B-T033
,	O
a	O
persistent	B-T079
nontreponemal serological	B-T169
response	B-T201
observed	B-T169
in	O
early syphilis	B-T047
patients	B-T101
after	O
conventional treatment	B-T061
,	O
remains	O
a	O
concern	B-T078
of	O
clinicians	B-T097
and	O
syphilis	B-T047
patients	B-T101
.	O
No	O
consensus	O
has	O
been	O
established,	O
however,	O
that	O
defines	O
an	O
effective	B-T080
treatment strategy	B-T061
and	O
clarifies	B-T052
the	O
pathogenesis	B-T046
.	O
In	O
this	O
study	B-T062
,	O
517	O
patients	B-T101
with	O
early syphilis	B-T047
were	O
enrolled	B-T058
and	O
treated	B-T169
.	O
Twelve	O
months	B-T079
after	O
treatment	B-T061
,	O
79.3%	O
(410/517)	O
of	O
patients	B-T101
achieved	O
serological	B-T169
cure	B-T077
,	O
20.1%	O
(104/517)	O
were	O
serofast	B-T033
,	O
and	O
0.6%	O
(3/517)	O
were	O
serological	B-T169
failures	B-T169
.	O
Multivariate analysis	B-T081
demonstrated	O
that	O
older age	B-T098
(>40	O
years	B-T079
)	O
and	O
lower	O
baseline	B-T081
RPR titer	B-T059
(≤	O
1:8)	O
were	O
associated with	B-T080
serofast	B-T033
status	B-T080
.	O
We	O
also	O
identified	O
21	O
T. pallidum	B-T007
molecular subtypes	B-T185
among	O
early syphilis	B-T047
patients	B-T101
and	O
detected	O
a	O
new	O
subtype, 14i/a	B-T185
.	O
We	O
found	O
that	O
the	O
proportion	O
of	O
14i/a type	B-T185
in	O
serofast	B-T033
patients	B-T101
was	O
significantly	O
higher	O
than	O
that	O
in	O
patients	B-T101
with	O
serological	B-T169
cure	B-T077
,	O
predicting	O
an	O
increasing	B-T169
risk	B-T078
of	O
serofast	B-T033
status	B-T080
status	B-T080
.	O
Levels	B-T080
of	O
chemerin	B-T116
were	O
higher	B-T080
in	O
the	O
serum	B-T031
of	O
serofast	B-T033
cases	O
than	O
serological	B-T169
cure	B-T077
cases,	O
potentially	O
indicating	O
a	O
novel	O
cytokine	B-T116
marker	B-T201
for	O
serofast	B-T033
in	O
early syphilis	B-T047
patients	B-T101
after	O
therapy	B-T061
.	O
We	O
hope	O
that	O
these	O
results	B-T169
contribute	B-T052
to	O
improve	B-T033
guidelines	B-T170
for	O
the	O
management	B-T058
of	O
syphilis	B-T047
patients	B-T101
who	O
experience	O
serofast	B-T033
.	O

Total	O
Fluorescence	B-T070
Fingerprinting	B-T073
of	O
Pesticides	B-T131
:	O
A	O
Reliable	O
Approach	O
for	O
Continuous	B-T078
Monitoring of Soils and Waters	B-T057
The	O
present	O
work	O
relates	O
to	O
the	O
creation	B-T052
/	O
extension	B-T169
of	O
a	O
database	B-T170
of	O
Total Excitation-Emission and Total Synchronous Fluorescence Matrices	B-T059
(	O
TEEMs and TSFMs	B-T059
)	O
along	O
with	O
optimal Synchronous Fluorescence Spectra	B-T059
(	O
SFS	B-T059
)	O
to	O
fingerprint	B-T073
pesticides	B-T131
widely	O
used	O
in	O
Morocco	B-T083
.	O
This	O
spectrometric multi-component fingerprinting	B-T059
may	O
permit	O
the	O
direct	O
detection of pesticides	B-T059
persisting in soil	B-T131
or	O
water	B-T131
.	O
The	O
objective	O
of	O
the	O
current	O
investigation	O
is	O
to	O
detect four pesticide	B-T059
remains	O
in	O
agricultural soils	B-T082
by	O
applying	O
the	O
spectrometric fingerprinting	B-T059
results.	O
They	O
are	O
the	O
commercial:	O
i)	O
insecticide Axlera 5G	B-T131
(	O
carbamate	B-T131
),	O
ii)	O
fungicide Orsalis 5% SC	B-T131
(	O
triazole	B-T131
),	O
iii)	O
insecticide Force 0,5 G	B-T109
(	O
pyrethrinoid	B-T109
)	O
and	O
iv)	O
insecticide Proclaim 05 SG	B-T131
(non-assigned).	O
The	O
agricultural plantations monitored	B-T090
are	O
located	O
in	O
the	O
great agricultural Doukkala region	B-T083
at	O
the	O
western Atlantic side	B-T083
of	O
Morocco	B-T083
,	O
where	O
these	O
chemicals	B-T103
are	O
in	O
large	O
sale	O
and	O
use.	O

Engagement	O
of	O
cellular prion protein	B-T116
with	O
the	O
co-chaperone	B-T116
Hsp70	B-T116
Hsp70 / 90 organizing protein	B-T116
90	B-T116
organizing	O
protein	O
regulates	O
the	O
proliferation	B-T043
of	O
glioblastoma	B-T191
glioblastoma stem-like cells	B-T025
Glioblastoma	B-T191
(	O
GBM	B-T191
),	O
a	O
highly	O
aggressive	O
brain tumor	B-T191
,	O
contains	O
a	O
subpopulation	O
of	O
glioblastoma	B-T191
glioblastoma stem-like cells	B-T025
(	O
GSCs	B-T025
)	O
that	O
play	O
roles	O
in	O
tumor	B-T191
maintenance	B-T052
,	O
invasion	B-T046
,	O
and	O
therapeutic resistance	B-T038
.	O
GSCs	B-T025
are	O
therefore	O
a	O
promising	O
target	B-T169
for	O
GBM	B-T191
treatment	B-T169
.	O
Our	O
group	O
identified	O
the	O
cellular prion protein	B-T116
(	O
PrP(C)	B-T116
)	O
and	O
its	O
partner,	O
the	O
co-chaperone	B-T116
Hsp70	B-T116
Hsp70 / 90 organizing protein	B-T116
90	B-T116
organizing	O
protein	O
(	O
HOP	B-T116
),	O
as	O
potential	O
target	B-T169
candidates	O
due	O
to	O
their	O
role	O
in	O
GBM	B-T191
tumorigenesis	B-T191
and	O
in	O
neural stem cell	B-T025
maintenance.	O
GSCs	B-T025
expressing	O
different	O
levels	O
of	O
PrP(C)	B-T116
were	O
cultured	B-T059
as	O
neurospheres	B-T025
with	O
growth factors	B-T116
,	O
and	O
characterized	O
with	O
stem cells	B-T025
markers	B-T086
and	O
adhesion molecules markers	B-T086
through	O
immunofluorescence	B-T059
and	O
flow cytometry	B-T059
.	O
We	O
than	O
evaluated	O
GSC	B-T025
self-renewal	B-T043
and	O
proliferation	B-T043
by	O
clonal density assays	B-T059
and	O
BrdU	B-T114
BrdU incorporation	B-T059
,	O
respectively,	O
in	O
front	O
of	O
recombinant	O
HOP	B-T116
treatment	B-T169
,	O
combined	O
or	O
not	O
with	O
a	O
HOP	B-T116
peptide	B-T116
which	O
mimics	O
the	O
PrP(C)	B-T116
binding site	B-T192
.	O
Stable	O
silencing	B-T045
of	O
HOP	B-T116
was	O
also	O
performed	O
in	O
parental	O
and/or	O
PrP(C)	B-T116
-depleted	O
cell populations	B-T025
,	O
and	O
proliferation	B-T043
in vitro	B-T080
and	O
tumor growth	B-T191
in vivo	B-T082
were	O
evaluated.	O
Migration assays	B-T059
were	O
performed	O
on	O
laminin-1	B-T116
laminin-1 pre-coated glass	B-T073
.	O
We	O
observed	O
that,	O
when	O
GBM	B-T191
cells	B-T025
are	O
cultured	B-T059
as	O
neurospheres	B-T025
,	O
they	O
express	O
specific	O
stemness markers	B-T086
such	O
as	O
CD133	B-T116
,	O
CD15	B-T109
,	O
Oct4	B-T116
,	O
and	O
SOX2	B-T116
;	O
PrP(C)	B-T116
is	O
upregulated	O
compared	O
to	O
monolayer culture	B-T059
and	O
co-localizes	O
with	O
CD133	B-T116
.	O
PrP(C)	B-T116
silencing	B-T045
downregulates	O
the	O
expression of molecules	B-T045
associated	O
with	O
cancer stem cells	B-T025
,	O
upregulates	O
markers	B-T086
of	O
cell differentiation	B-T043
and	O
affects	O
GSC	B-T025
self-renewal	B-T043
,	O
pointing	O
to	O
a	O
pivotal	O
role	O
for	O
PrP(C)	B-T116
in	O
the	O
maintenance	O
of	O
GSCs	B-T025
.	O
Exogenous	O
HOP	B-T116
treatment	B-T169
increases	O
proliferation	B-T043
and	O
self-renewal	B-T043
of	O
GSCs	B-T025
in	O
a	O
PrP(C)	B-T116
-dependent	O
manner	O
while	O
HOP	B-T116
knockdown	O
disturbs	O
the	O
proliferation process	B-T043
.	O
In vivo	B-T082
,	O
PrP(C)	B-T116
and/or	O
HOP	B-T116
knockdown	O
potently	O
inhibits	B-T052
the	O
growth	B-T043
of	O
subcutaneously	O
implanted	O
glioblastoma	B-T191
cells	B-T025
.	O
In	O
addition,	O
disruption	O
of	O
the	O
PrP(C)	B-T116
PrP(C) - HOP complex	B-T116
HOP	B-T116
complex	O
by	O
a	O
HOP	B-T116
peptide	B-T116
,	O
which	O
mimics	O
the	O
PrP(C)	B-T116
binding site	B-T192
,	O
affects	O
GSC	B-T025
self-renewal	B-T043
and	O
proliferation	B-T043
indicating	O
that	O
the	O
HOP	B-T116
HOP - PrP(C) complex	B-T116
PrP(C)	B-T116
complex	O
is	O
required	O
for	O
GSC	B-T025
stemness	B-T080
.	O
Furthermore,	O
PrP(C)	B-T116
-depleted	O
GSCs	B-T025
downregulate	O
cell	B-T025
adhesion-related proteins	B-T116
and	O
impair	O
cell migration	B-T043
indicating	O
a	O
putative	O
role	O
for	O
PrP(C)	B-T116
in	O
the	O
cell surface stability	B-T033
of	O
cell adhesion molecules	B-T116
and	O
GBM	B-T191
cell	O
invasiveness	B-T046
,	O
respectively.	O
In	O
conclusion,	O
our	O
results	O
show	O
that	O
the	O
modulation	O
of	O
HOP	B-T116
-	O
PrP(C)	B-T116
engagement	O
or	O
the	O
decrease	O
of	O
PrP(C)	B-T116
and	O
HOP	B-T116
expression	B-T045
may	O
represent	O
a	O
potential	O
therapeutic intervention	B-T061
in	O
GBM	B-T191
,	O
regulating	O
glioblastoma	B-T191
glioblastoma stem-like cell	B-T025
self-renewal	B-T043
,	O
proliferation	B-T043
,	O
and	O
migration	B-T043
.	O

Cyclic thrombocytopenia	B-T047
synchronizing	B-T079
with	O
the	O
menstrual cycle	B-T040
showing	O
periodic	B-T079
phases	B-T079
of	O
thrombocytopenia	B-T047
and	O
rebound	B-T067
thrombocytosis	B-T047
A	O
37-	O
year	B-T079
-old	O
woman	B-T098
was	O
admitted	B-T058
to	O
our	O
hospital	B-T073
for	O
purpura	B-T047
involving	O
the	O
extremities	B-T023
and	O
thrombocytopenia	B-T047
.	O
Prednisolone	B-T109
(	O
PSL	B-T109
)	O
was	O
administered	B-T169
based	O
on	O
a	O
diagnosis	B-T033
of	O
idiopathic thrombocytopenic purpura	B-T047
(	O
ITP	B-T047
),	O
but	O
was	O
not effective	B-T080
for	O
maintaining	B-T052
her	O
platelet count	B-T059
within	O
the	O
normal range	B-T081
,	O
which	O
showed	O
cyclic fluctuation	B-UnknownType
corresponding	O
to	O
the	O
menstrual cycle	B-T040
.	O
Therefore,	O
we	O
discontinued	B-T033
PSL	B-T109
,	O
and	O
cyclic thrombocytopenia	B-T047
(	O
CTP	B-T047
)	O
was	O
diagnosed	B-T033
.	O
CTP	B-T047
is	O
a	O
rare disease	B-T047
which	O
is	O
usually	O
treated	B-T169
as	O
ITP	B-T047
but	O
with	O
no response	B-T033
.	O
Although	O
the	O
exact	O
cause	B-T078
of	O
CTP	B-T047
is	O
uncertain	B-T033
,	O
in	O
our	O
case	B-T077
,	O
a	O
hormonal mechanism	B-T040
may	O
be	O
responsible	O
for	O
fluctuating	B-T079
platelet count	B-T059
.	O

Comparative evaluation	B-T058
of	O
iodine-131 metaiodobenzylguanidine	B-T109
and	O
18-fluorodeoxyglucose	B-T109
positron emission tomography	B-T060
in	O
assessing	O
neural crest tumors	B-T047
:	O
Will	O
they	O
play	O
a	O
complementary	O
role?	O
18-Fluorodeoxyglucose	B-T109
positron emission tomography	B-T060
(	O
FDG-PET	B-T060
)	O
has	O
established	O
a	O
role	O
in	O
the	O
evaluation	O
of	O
several	O
malignancies	B-T191
.	O
However,	O
its	O
precise	O
clinical role	B-T078
in	O
the	O
neural crest cell tumors	B-T047
continues	O
to	O
evolve.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
iodine-131 metaiodobenzylguanidine	B-T109
(	O
(131)I-MIBG	B-T109
)	O
and	O
FDG-PET	B-T060
of	O
head	O
to	O
head	O
in	O
patients	B-T101
with	O
neural crest tumors	B-T047
both	O
qualitatively	B-T080
and	O
semiquantitatively	B-T057
and	O
to	O
determine	O
their	O
clinical utility	B-T033
in	O
disease status evaluation	B-T033
and	O
further management	B-T058
.	O
A	O
total	O
of	O
32	O
patients	B-T101
who	O
had	O
undergone	O
(131)I-MIBG	B-T109
and	O
FDG-PET	B-T060
prospectively	O
were	O
evaluated	O
and	O
clinicopathologically	B-T169
grouped	O
into	O
three	O
categories:	O
neuroblastoma	B-T191
,	O
pheochromocytoma	B-T191
,	O
and	O
medullary carcinoma thyroid	B-T191
.	O
In	O
18	O
patients	B-T101
of	O
neuroblastoma	B-T191
,	O
FDG PET	B-T060
and	O
(131)I-MIBG	B-T109
showed	O
patient-specific sensitivity	B-T033
of	O
84%	O
and	O
72%,	O
respectively.	O
The	O
mean	O
maximum standardized uptake value	B-T081
(	O
SUVmax	B-T081
)	O
of	O
primary lesions	B-T047
in	O
patients	B-T101
with	O
unfavorable histology	B-T169
was	O
found	O
to	O
be	O
relatively	O
higher	O
than	O
those	O
with	O
favorable histology	B-T169
(5.18	O
±	O
2.38	O
vs.	O
3.21	O
±	O
1.69).	O
The	O
mean	O
SUVmax	B-T081
of	O
two	O
common	O
sites	O
(	O
posterior superior iliac spine	B-T023
[	O
PSIS	B-T023
]	O
and	O
greater trochanter	B-T023
)	O
was	O
higher	O
in	O
patients	B-T101
with	O
involved	O
marrow	B-T023
than	O
those	O
with	O
uninvolved	O
one	O
(2.36	O
and	O
2.75	O
vs.	O
1.26	O
and	O
1.34,	O
respectively).	O
The	O
ratio	O
of	O
SUVmax	B-T081
of	O
the	O
involved/	O
contralateral normal sites	B-T082
was	O
2.16	O
±	O
1.9.	O
In	O
equivocal	B-T080
bone marrow results	B-T034
,	O
the	O
uptake	O
pattern	O
with	O
SUV	B-T081
estimation	O
can	O
depict	O
metastatic involvement	B-T169
and	O
help	O
in	O
redirecting	O
the	O
biopsy site	B-T201
.	O
Among	O
seven	O
patients	B-T101
of	O
pheochromocytoma	B-T191
,	O
FDG-PET	B-T060
revealed	O
100%	O
patient-specific sensitivity	B-T033
.	O
FDG-PET	B-T060
detected	O
more	O
metastatic foci	B-T082
than	O
(131)I-MIBG	B-T109
(18	O
vs.	O
13	O
sites).	O
In	O
seven	O
patients	B-T101
of	O
medullary carcinoma thyroid	B-T191
,	O
FDG-PET	B-T060
localized	O
residual,	O
recurrent	B-T047
,	O
or	O
metastatic disease	B-T191
with	O
much	O
higher	O
sensitivity	O
(32	O
metastatic foci	B-T082
with	O
72%	O
patient specific sensitivity	B-T033
)	O
than	O
(131)I-MIBG	B-T109
,	O
trending	O
along	O
the	O
higher serum calcitonin levels	B-T059
.	O
FDG-PET	B-T060
is	O
not	O
only	O
a	O
good	O
complementary modality	B-T078
in	O
the	O
management	O
of	O
neural crest cell tumors	B-T047
but	O
also	O
it	O
can	O
even	O
be	O
superior,	O
especially	O
in	O
cases	O
of	O
(131)I-MIBG	B-T109
nonavid tumors	B-T191
.	O

Progressive Occlusion	B-T169
and	O
Recanalization	B-T061
after	O
Endovascular Treatment	B-T061
for	O
287	O
Unruptured Small Aneurysms	B-T047
(<5mm):	O
A	O
Single-Center	B-T093
6-Year	B-T079
Experience	B-T041
We	O
aimed	O
to	O
investigate	O
the	O
effect	B-T080
of	O
coiling	B-T082
for	O
small	O
unruptured intracranial aneurysms	B-T047
(	O
UIAs	B-T047
)﹤5mm)	O
on	O
progressive occlusio	B-T169
n	O
and	O
recanalization	B-T061
,	O
and	O
the	O
dubious	O
factors	O
related	O
to	O
progressive occlusion	B-T169
and	O
recanalization	B-T061
among	O
UIAs	B-T047
without	O
complete	O
occlusion	B-T169
.	O
A	O
total	O
of	O
264	O
patients	B-T101
with	O
287	O
small	O
UIAs	B-T047
were	O
coiled	O
in	O
our	O
institute	B-T092
between	O
June	O
2009	O
and	O
December	O
2014.	O
All	O
UIAs	B-T047
enrolled	O
were	O
divided	O
into	O
small	O
(3-5mm)	O
and	O
very	O
small	O
(<3mm)	O
group	B-T078
s,	O
and	O
UIAs	B-T047
without	O
initial	O
complete	O
occlusion	B-T169
were	O
divided	O
into	O
progressive	B-T169
,	O
stable	B-T080
and	O
recanalization	B-T061
groups	B-T078
.	O
Baseline	B-T081
characteristics	B-T080
,	O
procedure	B-T061
-related	O
complications	B-T046
,	O
angiographic	B-T060
follow-up results	B-T058
,	O
and	O
clinical outcomes	B-T080
were	O
statistically analyzed	B-T062
.	O
Among	O
287	O
aneurysms	B-T047
,	O
211	O
aneurysms	B-T047
(73.5%)	O
were	O
completely	O
coiled,	O
three	O
(1.2%)	O
intraoperative	B-T079
ruptures	B-T037
and	O
12	O
(4.2%)	O
perioperative	B-T079
thromboembolic events	B-T046
occurred.	O
Angiographic	B-T060
follow-up	B-T058
was	O
available	O
for	O
174	O
patients	B-T101
(65.9%),	O
the	O
incidence	B-T081
of	O
recanalization	B-T061
was	O
5.7%.	O
Among	O
56	O
aneurysms	B-T047
without	O
complete	O
occlusion	B-T169
,	O
43	O
(76.8%)	O
had	O
progressive occlusion	B-T169
and	O
6(10.7%)	O
had	O
recanalization	B-T061
.	O
Anatomic results	B-T033
of	O
initial	O
and	O
follow-up	B-T058
between	O
small	O
and	O
very	O
small	O
groups	B-T078
were	O
similar	O
in	O
both	O
groups	B-T078
.	O
On	O
logistic regression analysis	B-UnknownType
,	O
smaller	O
size	B-T082
(<3mm)	O
without	O
complete	O
occlusion	B-T169
related	O
to	O
recanalization	B-T061
(OR,	O
8.0,	O
95%	O
CI,	O
1.3-50.0,	O
P=0.026).	O
Our	O
study	B-T062
suggested	O
that	O
coil embolization	B-T061
of	O
small	O
UIAs	B-T047
can	O
achieve	O
a	O
high	O
rate	O
of	O
progressive occlusion	B-T169
and	O
low	O
rate	O
of	O
recanalization	B-T061
during	O
follow-up	B-T058
.	O
Anatomic results	B-T033
of	O
initial	O
and	O
follow-up	B-T058
between	O
small	O
(3-5mm)	O
and	O
very	O
small	O
(<3mm)	O
groups	B-T078
were	O
similar	O
in	O
both	O
groups	B-T078
.	O
What's	O
more,	O
smaller	O
size	O
(<3mm)	O
without	O
complete	O
occlusion	B-T169
may	O
relate	O
to	O
recanalization	B-T061
.	O

Selection	B-T052
of	O
an	O
Artificial	B-T080
Diet	B-T168
for	O
Laboratory	B-T073
Rearing	B-T059
of	O
Opogona sacchari	B-T204
(	O
Lepidoptera	B-T204
:	O
Tineidae	B-T204
)	O
(Bojer,	O
1856)	O
The	O
banana moth Opogona sacchari	B-T204
(	O
Bojer	B-T204
)	O
(	O
Lepidoptera	B-T204
:	O
Tineidae	B-T204
)	O
is	O
a	O
polyphagous pest	B-T204
that	O
can	O
cause	O
serious	B-T080
damage	B-T169
,	O
in	O
particular	O
to	O
banana	B-T168
crops	B-T002
in	O
southern	B-T082
Brazil	B-T083
.	O
The	O
insect	B-T204
is	O
a	O
quarantine	O
pest	B-T204
in	O
several	O
countries	B-T083
,	O
including	O
Argentina	B-T083
,	O
the	O
main	O
consumer	B-T098
market	B-T083
for	O
bananas	B-T168
from	O
southern	B-T082
Brazil	B-T083
.	O
Little	O
information	B-T078
is	O
available	O
about	O
the	O
biology	B-T091
and	O
ecology	B-T090
of	O
this	O
moth	B-T204
,	O
such	O
as	O
a	O
suitable	O
diet	B-T168
for	O
laboratory	B-T073
rearing	B-T059
.	O
In	O
order	O
to	O
provide	O
support	O
for	O
integrated	O
pest management	B-T057
of	O
the	O
pest	B-T204
,	O
this	O
study	B-T062
furnished	O
data	B-T078
for	O
selecting	O
two	O
diets	B-T168
suitable	O
for	O
continuous	O
laboratory	B-T073
rearing	B-T059
of	O
O. sacchari	B-T204
,	O
one	O
based	O
on	O
dried	B-T080
beans	B-T168
,	O
wheat germ	B-T168
,	O
soy bran	B-T168
,	O
brewer's yeast	B-T004
,	O
and	O
casein	B-T116
and	O
another	O
diet	B-T168
with	O
wheat germ	B-T168
and	O
casein	B-T116
as	O
protein	B-T116
sources	B-T033
.	O
With	O
both	O
diets	B-T168
,	O
the	O
viability	B-T080
of	O
the	O
egg	B-T025
-	O
adult	B-T100
period	B-T079
exceeded	O
68%,	O
with	O
fertility	B-T040
over	O
338	O
eggs	B-T025
per	O
female	B-T098
.	O
A	O
corrected	O
biotic	B-T070
potential	B-T080
analysis	B-T062
gave	O
similar	O
values	B-T080
for	O
the	O
two	O
diets	B-T168
.	O

The	O
impact	B-T080
on	O
productivity	B-T081
of	O
a	O
hypothetical tax	B-T081
on	O
sugar-sweetened beverages	B-T168
To	O
quantify	O
the	O
potential	B-T080
impact	B-T080
of	O
an	O
additional	B-T169
20%	O
tax	B-T081
on	O
sugar-sweetened beverages	B-T168
(	O
SSBs	B-T168
)	O
on	O
productivity	B-T081
in	O
Australia	B-T083
.	O
We	O
used	O
a	O
multi-state lifetable Markov model	B-T081
to	O
examine	B-T033
the	O
potential	B-T080
impact	B-T080
of	O
an	O
additional	B-T169
20%	O
tax	B-T081
on	O
SSBs	B-T168
on	O
total lifetime	B-T079
productivity	B-T081
in	O
the	O
paid and unpaid sectors	B-T078
of	O
the	O
economy	B-T081
.	O
The	O
study population	B-T098
consisted	O
of	O
Australians	B-T098
aged	B-T032
20	O
years	B-T079
or	O
older	B-T098
in	O
2010,	O
whose	O
health	B-T170
and	O
other	O
relevant	B-T080
outcomes	B-T169
were	O
modelled	B-T062
over	O
their	O
remaining	B-T080
lifetime	B-T079
.	O
The	O
SSBs	B-T168
tax	B-T081
was	O
estimated	B-T081
to	O
reduce	B-T080
the	O
number	B-T081
of	O
people	B-T098
with	O
obesity	B-T047
by	O
1.96%	O
of	O
the	O
entire	O
population	B-T098
(437,000	O
fewer	O
persons	B-T098
with	O
obesity	B-T047
),	O
and	O
reduce	B-T080
the	O
number	B-T081
of	O
employees	B-T097
with	O
obesity	B-T047
by	O
317,000	O
persons	B-T098
.	O
These	O
effects	B-T080
translated	O
into	O
productivity	B-T081
gains	B-T081
in	O
the	O
paid sector	B-T078
of	O
AU$751	O
million	B-T081
for	O
the	O
working	B-T057
-	O
age	B-T032
population	B-T098
(95%	O
confidence interval	B-T081
:	O
AU$565	O
million	B-T081
to	O
AU$954	O
million	B-T081
),	O
using	O
the	O
human capital	B-T081
approach	B-T082
.	O
In	O
the	O
unpaid sector	B-T078
,	O
the	O
potential	B-T080
productivity	B-T081
gains	B-T081
amounted	B-T081
to	O
AU$1172	O
million	B-T081
(AU$929	O
million	B-T081
to	O
AU$1435	O
million	B-T081
)	O
using	O
the	O
replacement cost method	B-T170
.	O
These	O
productivity	B-T081
benefits	B-T081
are	O
in	O
addition	O
to	O
the	O
health benefits	B-T081
of	O
35,000	O
life years	B-T079
gained	B-T081
and	O
a	O
reduction	B-T080
in	O
healthcare costs	B-T081
of	O
AU$425	O
million	B-T081
.	O
An	O
additional	B-T169
20%	O
tax	B-T081
on	O
SSBs	B-T168
not	O
only	O
improves	B-T033
health outcomes	B-T170
and	O
reduces	B-T080
healthcare costs	B-T081
,	O
but	O
provides	O
productivity	B-T081
gains	B-T081
in	O
both	O
the	O
paid and unpaid sectors	B-T078
of	O
the	O
economy	B-T081
.	O

Keeping	O
the	O
Spirits	O
Up:	O
The	O
Effect	B-T080
of	O
Teachers'	B-T097
and	O
Parents'	B-T099
Emotional Support	B-T058
on	O
Children's	B-T100
Working Memory	B-T041
Performance	B-T041
Working memory	B-T041
,	O
used	O
to	O
temporarily store	B-T041
and	O
mentally	O
manipulate	O
information	B-T078
,	O
is	O
important	O
for	O
children's	B-T100
learning	B-T041
.	O
It	O
is	O
therefore	O
valuable	O
to	O
understand	O
which	O
(contextual)	O
factors	B-T169
promote	B-T052
or	O
hinder	B-T052
working memory	B-T041
performance	B-T041
.	O
Recent	O
research	B-T062
shows	O
positive	B-T033
associations	B-T080
between	O
positive	B-T033
parent-child	B-T054
and	O
teacher-student interactions	B-T054
and	O
working memory	B-T041
performance	B-T041
and	O
development	B-T169
.	O
However,	O
no	O
study	B-T062
has	O
yet	O
experimentally investigated	B-T169
how	O
parents	B-T099
and	O
teachers	B-T097
affect	O
working memory	B-T041
performance	B-T041
.	O
Based	O
on	O
attachment theory	B-T078
,	O
the	O
current	O
study	B-T062
investigated	B-T169
the	O
role	O
of	O
parent	B-T099
and	O
teacher	B-T097
emotional support	B-T058
in	O
promoting	B-T052
working memory	B-T041
performance	B-T041
by	O
buffering	O
the	O
negative	B-T033
effect	B-T080
of	O
social stress	B-T048
.	O
Questionnaires	B-T170
and	O
an	O
experimental session	B-T062
were	O
completed	O
by	O
170	O
children	B-T100
from	O
grade	O
1	O
to	O
2	O
(Mage	O
=	O
7	O
years	B-T079
6	O
months	B-T079
,	O
SD	O
=	O
7	O
months	B-T079
).	O
Questionnaires	B-T170
were	O
used	O
to	O
assess	O
children's	B-T100
perceptions	B-T041
of	O
the	O
teacher-student	B-T054
and	O
parent-child relationship	B-T054
.	O
During	O
an	O
experimental session	B-T062
,	O
working memory	B-T041
was	O
measured	O
with	O
the	O
Corsi task backward	B-UnknownType
(Milner,	O
1971)	O
in	O
a	O
pre-	B-T052
and	O
post-test design	B-T052
.	O
In-between	O
the	O
tests	B-T170
stress	B-T033
was	O
induced	B-T169
in	O
the	O
children	B-T100
using	O
the	O
Cyberball paradigm	B-T062
(Williams	O
et	O
al.,	O
2000).	O
Emotional support	B-T058
was	O
manipulated	B-T053
(between-subjects)	O
through	O
an	O
audio	B-T073
message	B-T170
(either	O
a	O
weather	B-T070
report	B-T170
,	O
a	O
supportive	B-T058
message	B-T170
of	O
a	O
stranger	B-T098
,	O
a	O
supportive	B-T058
message	B-T170
of	O
a	O
parent	B-T099
,	O
or	O
a	O
supportive	B-T058
message	B-T170
of	O
a	O
teacher	B-T097
).	O
Results	B-T169
of	O
repeated measures	B-T062
ANOVA	B-T081
showed	O
no	O
clear	O
effect	B-T080
of	O
the	O
stress	B-T033
induction	B-T169
.	O
Nevertheless,	O
an	O
effect	B-T080
of	O
parent	B-T099
and	O
teacher	B-T097
support	B-T058
was	O
found	O
and	O
depended	O
on	O
the	O
quality	B-T080
of	O
the	O
parent-child relationship	B-T054
.	O
When	O
children	B-T100
had	O
a	O
positive	B-T033
relationship	B-T080
with	O
their	O
parent	B-T099
,	O
support	B-T058
of	O
parents	B-T099
and	O
teachers	B-T097
had	O
little	O
effect	B-T080
on	O
working memory	B-T041
performance	B-T041
.	O
When	O
children	B-T100
had	O
a	O
negative	B-T033
relationship	B-T080
with	O
their	O
parent	B-T099
,	O
a	O
supportive	B-T058
message	B-T170
of	O
that	O
parent	B-T099
decreased	O
working memory	B-T041
performance	B-T041
,	O
while	O
a	O
supportive	B-T058
message	B-T170
from	O
the	O
teacher	B-T097
increased	O
performance	B-T041
.	O
In	O
sum,	O
the	O
current	O
study	B-T062
suggests	O
that	O
parents	B-T099
and	O
teachers	B-T097
can	O
support	B-T058
working memory	B-T041
performance	B-T041
by	O
being	O
supportive	B-T058
for	O
the	O
child	B-T100
.	O
Teacher	B-T097
support	B-T058
is	O
most	O
effective	B-T080
when	O
the	O
child	B-T100
has	O
a	O
negative	B-T033
relationship	B-T080
with	O
the	O
parent	B-T099
.	O
These	O
insights	O
can	O
give	O
direction	O
to	O
specific	O
measures	O
aimed	O
at	O
preventing	B-T169
and	O
resolving	B-T033
working memory	B-T041
problems	B-T033
and	O
related	O
issues	B-T033
.	O

Management	B-T057
of	O
tachyarrhythmia	B-T033
during	O
pregnancy	B-T040
Maternal	B-T033
tachyarrhythmia	B-T033
is	O
a	O
common	B-T081
complication	B-T046
during	O
pregnancy	B-T040
due	O
to	O
hormonal changes	B-T033
that	O
enhance	B-T052
pre-existing	B-T080
arrhythmias	B-T033
or	O
induce	B-T169
new	O
arrhythmias	B-T033
in	O
the	O
presence	B-T033
of	O
congenital heart defects	B-T019
in	O
pregnant females	B-T098
.	O
Presence	B-T033
of	O
tachyarrhythmia	B-T033
during	O
pregnancy	B-T040
poses	O
risk	B-T078
to	O
the	O
mother	B-T099
and	O
fetus	B-T018
,	O
calling	B-T041
for	O
proper treatment	B-T061
with	O
medications	B-T121
.	O
Use	O
of	O
antiarrhythmic drugs	B-T121
in	O
cases	O
of	O
maternal	B-T033
tachyarrhythmia	B-T033
must	O
give	O
due	O
consideration	B-T078
of	O
potential	B-T080
teratogenic side effects	B-T046
.	O
Utilization	B-T169
of	O
antiarrhythmic drugs	B-T121
during	O
pregnancy	B-T040
has	O
been	O
well	O
studied	B-T062
;	O
some	O
result	B-T169
in	O
minimal	B-T080
fetal	B-T018
harm	B-T037
or	O
none	O
at	O
all.	O
New	O
techniques	B-T169
,	O
such	O
as	O
cardiac ablation	B-T061
,	O
have	O
also	O
been	O
implemented	B-T052
with	O
minimal	B-T080
or	O
no	O
radiation exposure	B-T037
to	O
the	O
fetus	B-T018
or	O
mother	B-T099
.	O
Pregnant women	B-T098
with	O
tachyarrhythmia	B-T033
have	O
been	O
successfully	B-T080
treated	B-T033
with	O
little	B-T081
to	O
no	O
impact	B-T080
on	O
the	O
developing fetus	B-T039
as	O
result	B-T169
of	O
increasing	B-T169
experience	B-T041
with	O
antiarrhythmic drugs	B-T121
and	O
progress	B-T169
of	O
new	O
procedural	B-T169
techniques	B-T169
.	O

Hif-1α	B-T116
Overexpression	B-T045
Improves	B-T033
Transplanted Bone Mesenchymal Stem Cells	B-T061
Survival	B-T043
in	O
Rat MCAO Stroke Model	B-T050
Bone mesenchymal stem cells	B-T025
(	O
BMSCs	B-T025
)	O
death	B-T043
after	O
transplantation	B-T061
is	O
a	O
serious	O
obstacle	O
impacting	O
on	O
the	O
outcome	O
of	O
cell therapy	B-T061
for	O
cerebral infarction	B-T047
.	O
This	O
study	B-T062
was	O
aimed	B-T078
to	O
investigate	B-T169
whether	O
modification	B-T169
of	O
BMSCs	B-T025
with	O
hypoxia-inducible factor 1α	B-T116
(	O
Hif-1α	B-T116
)	O
could	O
enhance	B-T052
the	O
survival	B-T043
of	O
the	O
implanted BMSCs	B-T061
.	O
BMSCs	B-T025
were	O
isolated	B-T059
from	O
Wistar rats	B-T015
,	O
and	O
were	O
infected	B-T046
with	O
Hif-1α-GFP lentiviral vector	B-T121
or	O
Hif-1α siRNA	B-T114
.	O
The	O
modified	B-T169
BMSCs	B-T025
were	O
exposed	O
to	O
oxygen-glucose deprivation (OGD) condition	B-T039
,	O
cellular viability	B-T043
and	O
apoptosis	B-T043
were	O
then	O
assessed	B-T052
.	O
An	O
inhibitor	B-T121
of	O
AMPK	B-T116
(	O
compound C	B-T121
)	O
was	O
used	O
to	O
detect	B-T061
whether	O
AMPK	B-T116
and	O
mTOR	B-T116
were	O
implicated	O
in	O
the	O
functions	O
of	O
Hif-1α	B-T116
on	O
BMSCs survival	B-T043
.	O
Besides,	O
ultrastructure	O
of	O
BMSCs	B-T025
was	O
observed	O
and	O
the	O
expression of autophagy markers	B-T045
was	O
measured.	O
The	O
modified	B-T169
BMSCs	B-T025
were	O
transplanted	B-T061
into	O
middle cerebral artery occlusion	B-T020
(	O
MCAO	B-T020
)	O
model of rats	B-T050
,	O
and	O
the	O
cerebral infarction	B-T047
volume	B-T081
and	O
neurological function	B-T042
was	O
assessed	B-T052
.	O
The	O
results	O
indicated	O
that	O
Hif-1α overexpression	B-T045
protected	O
OGD	B-T039
induced	B-T169
injury	B-T037
by	O
promoting	O
cellular viability	B-T043
and	O
inhibiting	B-T044
apoptosis	B-T043
.	O
AMPK	B-T116
was	O
activated	O
while	O
mTOR	B-T116
was	O
inactivated	B-T169
by	O
Hif-1α overexpression	B-T045
,	O
and	O
that	O
might	O
be	O
through	O
which	O
Hif-1α	B-T116
functioned	O
BMSCs survival	B-T043
.	O
Hif-1α overexpression	B-T045
promoted	O
autophagy	B-T043
;	O
more	O
important,	O
compound C	B-T121
abolished	O
the	O
induction of Hif-1α	B-T045
on	O
autophagy	B-T043
.	O
Transplantation of the overexpressed Hif-1α of BMSCs	B-T061
into	O
the	O
MCAO rats	B-T050
reduced	O
brain infarct	B-T047
volume	B-T081
and	O
improved	B-T033
neurobehavioral outcome	B-T080
;	O
besides,	O
it	O
inhibited	O
pro-inflammatory cytokines	B-T116
generation	O
while	O
promoted	O
neurotrophin	B-T116
secretion	B-T043
.	O
In	O
conclusion,	O
Hif-1α	B-T116
might	O
be	O
contributed	O
in	O
the	O
survival of BMSCs	B-T043
by	O
regulating	O
the	O
activation of AMPK and mTOR	B-T044
,	O
as	O
well	O
as	O
by	O
promoting	O
autophagy	B-T043
.	O

Associations	B-T080
between	O
major life events	B-T032
and	O
adherence	B-T169
,	O
glycemic control,	B-T061
and	O
psychosocial characteristics	B-T080
in	O
teens	B-T098
with	O
type 1 diabetes	B-T047
This	O
cross-sectional study	B-T062
assessed	B-T052
the	O
type	O
of	O
major life events	B-T032
occurring	O
in	O
a	O
contemporary	O
sample	O
of	O
teens	B-T098
with	O
type 1 diabetes	B-T047
and	O
the	O
association	B-T080
between	O
event frequency	B-T051
and	O
demographic	B-T078
,	O
diabetes management	B-T061
,	O
and	O
psychosocial characteristics	B-T080
.	O
Parents	B-T099
of	O
178	O
teens	B-T098
completed	O
the	O
Life Events	B-T032
Checklist	B-T170
to	O
report	O
major	O
events	B-T051
teens	B-T098
had	O
experienced	B-T067
in	O
the	O
last	O
year	B-T079
:	O
42%	O
experienced	B-T067
0	O
to	O
1	O
event	B-T051
(n	O
=	O
75),	O
32%	O
experienced	B-T067
2	O
to	O
3	O
events	B-T051
(n	O
=	O
57),	O
and	O
26%	O
experienced	B-T067
4+	O
events	B-T051
(n	O
=	O
46).	O
Teens	B-T098
and	O
parents	B-T099
completed	O
validated	O
measures	B-T081
of	O
treatment adherence	B-T033
,	O
diabetes	B-T047
-specific	O
self-efficacy	B-T041
,	O
quality of life	B-T078
,	O
and	O
diabetes	B-T047
-specific	O
family conflict	B-T033
.	O
Parent-youth interview	B-T052
and	O
chart review	B-T058
provided	O
demographics	B-T062
and	O
diabetes management	B-T061
data.	O
Mean	O
number	O
of	O
events	B-T051
/	O
teen	B-T098
was	O
2.6	O
±	O
2.7	O
(range	O
=	O
0-15).	O
The	O
most	O
common	O
events	B-T051
were	O
"	O
Hospitalization	B-T058
of	O
a	O
family member	B-T099
"	O
(24%),	O
"	O
Getting a bad report card	B-T033
"	O
(20%),	O
"Serious	O
arguments	B-T054
between	O
parents	B-T099
"	O
(19%),	O
and	O
"	O
Serious illness	B-T184
/	O
injury	B-T037
in	O
a	O
family member	B-T099
"	O
(19%).	O
Compared	O
with	O
teens	B-T098
experiencing	O
0	O
to	O
1	O
event	B-T051
,	O
teens	B-T098
experiencing	O
4+	O
events	B-T051
were	O
less	O
likely	O
to	O
have	O
married	O
parents	B-T099
(P	O
=	O
.01)	O
and	O
a	O
parent	B-T099
with	O
a	O
college degree	B-T170
(P	O
=	O
.006).	O
Teen	B-T098
s	O
with	O
4+	O
events	B-T051
had	O
significantly	O
poorer	O
adherence	B-T169
(P	O
=	O
.002	O
teen	B-T098
,	O
P	O
=	O
.02	O
parent	B-T099
),	O
lower	O
self-efficacy	B-T041
(P	O
=	O
.03	O
teen	B-T098
,	O
P	O
<	O
.0001	O
parent	B-T099
),	O
poorer	O
quality of life	B-T078
(P	O
<	O
.0001	O
teen	B-T098
,	O
P	O
<	O
.0001	O
parent	B-T099
),	O
and	O
more	O
conflict	B-T033
(P	O
=	O
.006	O
teen	B-T098
,	O
P	O
=	O
.02	O
parent	B-T099
)	O
than	O
teens	B-T098
with	O
fewer	O
events	B-T051
.	O
In	O
a	O
multivariate model	B-T170
(R	O
(2)	O
=	O
0.21,	O
P	O
<	O
.0001)	O
controlling	O
for	O
demographic	B-T078
and	O
diabetes management	B-T061
characteristics,	O
fewer	O
events	B-T051
was	O
associated	O
with	O
lower	O
A1c	B-T116
(P	O
=	O
.0009).	O
Occurrence	O
of	O
more	O
major life events	B-T032
was	O
associated with	B-T080
poorer	O
diabetes care	B-T061
and	O
A1c	B-T116
and	O
more	O
negative	O
psychosocial qualities	B-T078
in	O
teens	B-T098
with	O
type 1 diabetes	B-T047
.	O

Metabolomics	B-T091
,	O
Nutrition	B-T033
,	O
and	O
Potential	B-T080
Biomarkers	B-T201
of	O
Food Quality	B-T080
,	O
Intake	B-T169
,	O
and	O
Health Status	B-T080
Diet	B-T168
,	O
dietary patterns	B-T062
,	O
and	O
other	O
environmental factors	B-T080
such	O
as	O
exposure to	B-T080
toxins	B-T123
are	O
playing	O
an	O
important	O
role	B-T077
in	O
the	O
prevention	B-T080
/	O
development	B-T169
of	O
many	O
diseases	B-T047
,	O
like	O
obesity	B-T047
,	O
type 2 diabetes	B-T047
,	O
and	O
consequently	O
on	O
the	O
health status	B-T080
of	O
individuals	B-T098
.	O
A	O
major	O
challenge	O
nowadays	O
is	O
to	O
identify	B-T080
novel	B-T080
biomarkers	B-T201
to	O
detect	B-T033
as	O
early	B-T079
as	O
possible	O
metabolic	B-T169
dysfunction	B-T077
and	O
to	O
predict	B-T078
evolution	B-T169
of	O
health status	B-T080
in	O
order	O
to	O
refine	O
nutritional advices	B-T061
to	O
specific	O
population groups	B-T098
.	O
Omics technologies	B-T090
such	O
as	O
genomics	B-T091
,	O
transcriptomics,	O
proteomics	B-T091
,	O
and	O
metabolomics	B-T091
coupled	B-T169
with	O
statistical	B-T170
and	O
bioinformatics tools	B-T170
have	O
already	O
shown	O
great	O
potential	B-T080
in	O
this	O
research field	B-UnknownType
even	O
if	O
so	O
far	O
only	O
few	O
biomarkers	B-T201
have	O
been	O
validated.	O
For	O
the	O
past	O
two	O
decades	B-T081
,	O
important	O
analytical techniques	B-T059
have	O
been	O
developed	B-T169
to	O
detect	B-T033
as	O
many	O
metabolites	B-T123
as	O
possible	O
in	O
human	B-T016
biofluids	B-T031
such	O
as	O
urine	B-T031
,	O
blood	B-T031
,	O
and	O
saliva	B-T031
.	O
In	O
the	O
field	O
of	O
food science	B-T090
and	O
nutrition	B-T091
,	O
many	O
studies	B-T062
have	O
been	O
carried	O
out	O
for	O
food	B-T168
authenticity	B-T080
,	O
quality	B-T080
,	O
and	O
safety	B-T068
,	O
as	O
well	O
as	O
for	O
food processing	B-T057
.	O
Furthermore,	O
metabolomic	B-T091
investigations	B-T169
have	O
been	O
carried	O
out	O
to	O
discover	B-T052
new	O
early	B-T079
biomarkers	B-T201
of	O
metabolic	B-T169
dysfunction	B-T077
and	O
predictive	B-T080
biomarkers	B-T201
of	O
developing	O
pathologies	B-T091
(	O
obesity	B-T047
,	O
metabolic syndrome	B-T047
,	O
type-2 diabetes	B-T047
,	O
etc.).	O
Great	O
emphasis	O
is	O
also	O
placed	O
in	O
the	O
development	B-T169
of	O
methodologies	B-T062
to	O
identify	B-T080
and	O
validate	O
biomarkers	B-T201
of	O
nutrients	B-T168
exposure	B-T080
.	O

Draft Genome Sequence	B-T086
of	O
Bacillus cereus LA2007	B-T007
,	O
a	O
Human-Pathogenic Isolate	B-T123
Harboring	O
Anthrax	B-T204
Anthrax -Like Plasmids	B-T114
We	O
present	O
the	O
genome sequence	B-T086
of	O
Bacillus cereus LA2007	B-T007
,	O
a	O
strain	B-T001
isolated	B-T169
in	O
2007	O
from	O
a	O
fatal pneumonia	B-T047
case	B-T170
in	O
Louisiana	B-T083
.	O
Sequence-based genome analysis	B-T059
revealed	B-T080
that	O
LA2007	B-T007
carries	B-T033
a	O
plasmid	B-T114
highly	O
similar	O
to	O
Bacillus anthracis pXO1	B-T007
,	O
including	O
the	O
genes	B-T028
responsible	O
for	O
the	O
production	B-T131
and	O
regulation	B-T038
of	O
anthrax toxin	B-T116
.	O

Developing	O
elite	B-T080
Neurospora crassa	B-T004
strains	B-T001
for	O
cellulosic	B-T109
ethanol production	B-T040
using	O
fungal	B-T169
breeding	B-T040
The	O
demand	O
for	O
renewable	B-T169
and	O
sustainable energy	B-T169
has	O
generated	B-T052
considerable	O
interest	B-T041
in	O
the	O
conversion	B-T169
of	O
cellulosic	B-T109
biomass	B-T081
into	O
liquid	B-T167
fuels	B-T073
such	O
as	O
ethanol	B-T109
using	O
a	O
filamentous fungus	B-T004
.	O
While	O
attempts	B-T051
have	O
been	O
made	O
to	O
study	B-T062
cellulose metabolism	B-T044
through	O
the	O
use of	B-T169
knock-out	B-T050
mutants	B-T049
,	O
there	O
have	O
been	O
no	O
systematic	B-T169
effort	O
to	O
characterize	B-T052
natural	B-T169
variation	B-T070
for	O
cellulose metabolism	B-T044
in	O
ecotypes	B-T032
adapted	B-T070
to	O
different	B-T080
habitats	B-T082
.	O
Here,	O
we	O
characterized	B-T052
natural	B-T169
variation	B-T070
in	O
saccharification	B-T067
of	O
cellulose	B-T109
and	O
fermentation	B-T044
in	O
73	O
ecotypes	B-T032
and	O
89	O
laboratory	B-T073
strains	B-T001
of	O
the	O
model	B-T170
fungus	B-T004
Neurospora crassa	B-T004
.	O
We	O
observed	B-T169
significant	B-T078
variation	B-T070
in	O
both	O
traits	B-T032
among	O
natural	B-T169
and	O
laboratory generated	B-T080
populations	B-T004
,	O
with	O
some	O
elite	B-T080
strains	B-T001
performing	B-T169
better	B-T080
than	O
the	O
reference	B-T081
strain	B-T001
.	O
In	O
the	O
F1 population N345	B-T099
,	O
15%	O
of	O
the	O
population	B-T004
outperformed	O
both	O
parents	B-T004
with	O
the	O
top	O
performing	B-T169
strain	B-T001
having	O
10%	O
improvement	B-T077
in	O
ethanol production	B-T040
.	O
These	O
results	B-T034
suggest	O
that	O
natural	B-T169
alleles	B-T028
can	O
be	O
exploited	O
through	O
fungal	B-T169
breeding	B-T040
for	O
developing	O
elite	B-T080
industrial	B-T057
strains	B-T001
for	O
bioethanol production	B-T040
.	O

The	O
role	O
of	O
the	O
hippocampus	B-T023
and	O
the	O
function	O
of	O
calcitonin gene-related peptide	B-T116
in	O
the	O
mechanism	O
of	O
traumatic brain injury	B-T037
accelerating	O
fracture-healing	B-T042
This	O
research	O
attempts	O
to	O
identify	O
the	O
part	O
the	O
hippocampus	B-T023
plays	O
in	O
accelerated	O
fracture-healing	B-T042
after	O
traumatic brain injury	B-T037
as	O
well	O
as	O
to	O
test	O
functions	O
of	O
calcitonin gene-related peptide	B-T116
(	O
CGRP	B-T116
)	O
during	O
this	O
process.	O
Experiments	O
were	O
carried	O
out	O
on	O
Male	O
Sprague-Dawley rats	B-T015
that	O
were	O
split	O
into	O
four	O
groups	B-T078
at	O
random:	O
TBI	B-T037
-	O
fracture	B-T037
group	B-T078
,	O
fracture	B-T037
-	O
only	B-T081
group	B-T078
,	O
TBI	B-T037
-	O
only	B-T081
group	B-T078
,	O
and	O
control group	B-T096
.	O
In	O
the	O
first	O
week,	O
blood specimen	B-T031
would	O
be	O
drawn	O
from	O
rats	B-T015
among	O
the	O
groups	B-T078
except	O
those	O
of	O
the	O
control group	B-T096
at	O
three-time	O
points	O
(24,	O
72	O
and	O
168	O
hours)	O
post	B-T079
-	O
damage	B-T037
.	O
These	O
rats	B-T015
would	O
be	O
assessed	O
from	O
the	O
neurological	B-T080
perspective	O
based	O
on	O
their	O
grades	O
of	O
performance	O
in	O
a	O
sequence	O
of	O
tests	O
24	O
hours	O
before	O
and	O
12	O
hours	O
after	O
brain injury	B-T037
.	O
Blood samples	B-T059
were	O
also	O
taken	O
from	O
the	O
control group	B-T096
24	O
hours	O
before	O
the	O
injury	B-T037
,	O
and	O
whole	O
brain tissues	B-T023
in	O
the	O
injured	B-T169
groups	B-T078
were	O
harvested	B-T061
at	O
72	O
and	O
168	O
hours	O
post	B-T079
-	O
injury	B-T037
.	O
We	O
compared	O
the	O
serum	B-T031
CGRP	B-T116
concentration	B-T081
,	O
the	O
distribution	O
of	O
CGRP	B-T116
,	O
the	O
CGRP	B-T116
expression	B-T045
,	O
and	O
the	O
expression	B-T045
of	O
CGRP	B-T116
in	O
the	O
hippocampus	B-T023
,	O
the	O
expression	B-T045
of	O
CGRP	B-T116
in	O
the	O
hippocampus	B-T023
,	O
the	O
expression	B-T045
of	O
CGRP	B-T116
in	O
the	O
hippocampus	B-T023
,	O
and	O
the	O
expression	B-T045
of	O
CGRP	B-T116
in	O
the	O
brain	B-T023
by	O
immunohistochemistry	B-T060
,	O
Western blotting	B-T059
,	O
RT	B-T045
-	O
Of	O
CGRP	B-T028
RNA expression	B-T045
levels.	O
Neurological examinations	B-T060
suggested	O
that	O
the	O
functions	O
of	O
the	O
cerebral cortex	B-T023
,	O
cerebellum	B-T023
,	O
and	O
brain stem	B-T023
showed	O
significant	O
differences	O
pre	B-T079
-	O
and	O
post	B-T079
-	O
injury	B-T037
(p	O
<	O
0.001).	O
ELISA analysis	B-T059
indicated	O
a	O
great	O
density	O
of	O
CGRP	B-T116
in	O
TBI	B-T037
-	O
fracture	B-T037
group	B-T078
at	O
different	O
time	O
points.	O
Furthermore,	O
in	O
the	O
TBI	B-T037
-	O
fracture	B-T037
group	B-T078
,	O
CGRP	B-T116
in	O
both	O
hippocampus	B-T023
and	O
the	O
whole brain	B-T023
showed	O
a	O
noticeable	O
augment	O
in	O
RT-PCR	B-T063
and	O
western blot analysis	B-T059
at	O
72	O
and	O
168	O
h	O
post	B-T079
-	O
injury	B-T037
,	O
and	O
only	B-T081
in	O
this	O
group,	O
immunohistochemistry analysis	B-T060
indicated	O
that	O
CGRP	B-T116
was	O
present	O
in	O
the	O
hippocampus	B-T023
at	O
168	O
hours	O
post	B-T079
-	O
injury	B-T037
.	O
We	O
observed	O
that	O
the	O
hippocampus	B-T023
and	O
CGRP	B-T116
were	O
responsible	O
for	O
quick	O
bone-healing	B-T047
mechanisms.	O
We	O
suggest	O
a	O
role	O
for	O
the	O
hippocampus	B-T023
in	O
accelerated	O
fracture healing	B-T042
.	O
CGRP	B-T116
expression	B-T045
,	O
as	O
determined	O
by	O
IHC	B-T060
,	O
cannot	O
be	O
observed	O
in	O
other	O
groups	B-T078
,	O
indicating	O
that	O
the	O
hippocampus	B-T023
may	O
be	O
the	O
specific	O
component	O
of	O
the	O
brain	B-T023
that	O
responds	O
to	O
"	O
big stress	B-T046
".	O

Bone	B-T024
extracellular matrix	B-T024
hydrogel	B-T122
enhances	O
osteogenic differentiation	B-T043
of	O
C2C12 myoblasts	B-T025
and	O
mouse	B-T015
primary	O
calvarial	B-T023
cells	B-T025
Hydrogel scaffolds	B-T122
derived	O
from	O
the	O
extracellular matrix	B-T024
(	O
ECM	B-T024
)	O
of	O
mammalian tissues	B-T024
have	O
been	O
successfully	O
used	O
to	O
promote	O
tissue repair	B-T040
in vitro	B-T080
and	O
in vivo	B-T082
.	O
The	O
objective	O
of	O
this	O
study	B-T062
was	O
to	O
evaluate	O
the	O
osteogenic potential	B-T042
of	O
ECM	B-T024
hydrogels	B-T122
prepared	O
from	O
demineralized	B-T122
and	O
decellularized bovine bone	B-T122
in	O
the	O
presence	O
and	O
absence	O
of	O
osteogenic medium	B-T130
.	O
Culture	B-T059
of	O
C2C12	B-T025
and	O
mouse	B-T015
primary	O
calvarial	B-T023
cells	B-T025
(	O
mPCs	B-T025
)	O
on	O
decellularized bone ECM	B-T122
(	O
bECM	B-T122
)	O
and	O
demineralized bone matrix	B-T122
(	O
DBM	B-T122
)	O
gels	B-T122
resulted	O
in	O
increased	O
expression	B-T059
of	O
osteogenic gene markers	B-T045
,	O
including	O
a	O
3.6-	O
and	O
13.4-fold	O
increase	O
in	O
osteopontin	B-T116
and	O
15.7-	O
and	O
27.1-fold	O
increase	O
in	O
osteocalcin	B-T116
when	O
mPCs	B-T025
were	O
cultured	B-T059
upon	O
bECM	B-T122
with	O
basal	B-T130
and	O
osteogenic media	B-T130
,	O
respectively.	O
bECM	B-T122
hydrogels	B-T122
stimulated	O
the	O
osteogenic differentiation	B-T043
of	O
C2C12	B-T025
and	O
mPCs	B-T025
even	O
in	O
the	O
absence	O
of	O
osteogenic medium	B-T130
.	O
These	O
results	O
suggest	O
that	O
bECM	B-T122
hydrogel scaffolds	B-T122
may	O
have	O
great	O
utility	O
in	O
future	O
clinical	B-T080
applications	B-T169
for	O
bone	B-T024
tissue engineering	B-T061
.	O
©	O
2017	O
Wiley	O
Periodicals,	O
Inc.	O
J	O
Biomed	O
Mater	O
Res	O
Part	O
B:	O
Appl	O
Biomater,	O
2017.	O

Prostate-specific antigen	B-T116
increase	B-T169
during	O
dutasteride	B-T109
to	O
indicate	O
the	O
need	O
for	O
prostate biopsy	B-T060
:	O
influence	O
of	O
prostatic inflammation	B-T047
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyze	B-T062
the	O
significance	O
of	O
an	O
increase	B-T169
in	O
total prostate-specific antigen (PSA) serum levels	B-T059
despite	O
dutasteride	B-T109
treatment	B-T061
as	O
a	O
predictor	B-T078
of	O
prostate cancer	B-T191
(	O
PC	B-T191
)	O
at	O
biopsy	B-T060
.	O
We	O
focused	O
our	O
attention	O
on	O
the	O
rate	B-T081
of	O
the	O
first	O
PSA	B-T116
PSA	B-T116
increase	B-T169
and	O
on	O
the	O
influence	O
of	O
prostatic inflammation	B-T047
.	O
From	O
2011	O
to	O
2016,	O
365	O
men	B-T098
with	O
a	O
previous	O
negative	O
prostate biopsy	B-T060
and	O
persistent	O
elevated	B-T080
PSA	B-T116
PSA levels	B-T059
received	O
dutasteride	B-T109
treatment	B-T061
.	O
The	O
population	B-T098
was	O
followed	O
for	O
a	O
range	O
of	O
12-48	O
months.	O
One	O
hundred	O
twelve	O
cases	O
with	O
a	O
confirmed	O
PSA	B-T116
increase	B-T169
>0.5	O
ng/ml	O
over	O
the	O
nadir	O
value	O
during	O
the	O
follow-up	B-T058
were	O
included	O
in	O
Group	O
A	O
and	O
underwent	O
a	O
new	O
prostate biopsy	B-T060
.	O
In	O
Group	O
A,	O
the	O
PSA	B-T116
increase	B-T169
was	O
associated with	B-T080
PC	B-T191
at	O
the	O
re-biopsy	B-T060
in	O
66%	O
of	O
cases.	O
The	O
percentage	O
of	O
PSA reduction	B-T033
after	O
6	O
months	O
of	O
treatment	B-T061
was	O
not	O
a	O
significant	O
indicator	B-T201
of	O
the	O
risk	O
for	O
PC	B-T191
.	O
The	O
distribution	O
of	O
inflammatory infiltrates	B-T033
significantly	O
(p<00.01)	O
varied	O
from	O
positive	O
to	O
negative	O
prostate biopsies	B-T060
.	O
The	O
relative	O
risk	O
for	O
PC	B-T191
at	O
biopsy	B-T060
significantly	O
increase	B-T169
d	O
according	O
to	O
PSA	B-T116
PSA level	B-T059
during	O
dutasteride	B-T109
.	O
Treatment	B-T061
with	O
dutasteride	B-T109
can	O
help	O
to	O
analyze	B-T062
PSA	B-T116
kinetic	B-T070
.	O
A	O
persistent	O
prostatic inflammation	B-T047
is	O
a	O
factor	O
able	O
to	O
reduce	O
the	O
performance	O
of	O
PSA	B-T116
kinetic	B-T070
during	O
dutasteride	B-T109
treatment	B-T061
.	O

Neurological Decline	B-T033
in	O
an	O
Elderly	B-T098
with	O
Repaired	B-T169
Myelomeningocele	B-T019
Complicated	B-T169
with	O
Lumbar Canal Stenosis	B-T047
:	O
a	O
case report	B-T170
Tethered cord syndrome	B-T047
is	O
a	O
well-known	O
complication	B-T046
after	O
myelomeningocele	B-T019
(	O
MMC	B-T019
)	O
repair	B-T058
in	O
childhood	B-T079
.	O
However,	O
late	O
complications	B-T046
in	O
adults	B-T100
with	O
a	O
repaired	B-T169
MMC	B-T019
are	O
not	O
well	O
understood.	O
In	O
particular,	O
the	O
influence	B-T077
of	O
a	O
degenerative spinal deformity	B-T190
on	O
a	O
sustained	B-T169
tethered cord	B-T033
is	O
still	O
unclear.	O
A	O
63-year-old	B-T100
man	B-T032
with	O
a	O
repaired	B-T169
MMC	B-T019
presented	O
with	O
a	O
progressive gait disturbance	B-T033
and	O
numbness	B-T184
in	O
both	O
lower limbs	B-T023
.	O
Magnetic resonance images	B-T170
demonstrated	O
that	O
the	O
tethered spinal cord	B-T033
was	O
compressed	B-T169
by	O
severe	B-T080
canal stenosis	B-T047
along	O
the	O
entire lumbar spine	B-T029
.	O
After	O
a	O
multi-level lumbar decompression	B-T061
surgery	B-T061
,	O
the	O
patient recovered	B-T032
to	O
baseline	B-T081
neurological	B-T080
status.	O
In	O
adults	B-T100
with	O
a	O
repaired	B-T169
MMC	B-T019
,	O
lumbar canal stenosis	B-T047
should	O
be	O
investigated	B-T169
as	O
a	O
possible	O
cause	O
of	O
late	O
neurological decline	B-T033
.	O
Clinical	O
manifestations	O
may	O
be	O
complicated	B-T169
by	O
the	O
coexistence	O
of	O
both	O
the	O
original	O
and	O
subsequent	O
neurological disorders	B-T047
.	O
Because	O
these	O
additional	O
disorders	B-T047
result	O
from	O
compressive myelopathy	B-T047
,	O
early	O
surgical decompression	B-T061
is	O
indicated	O
to	O
avoid	O
irreversible	O
spinal cord dysfunction	B-T047
.	O

Epidemiology	B-T091
of	O
polyomavirus BK	B-T005
(	O
BKV	B-T005
)	O
and	O
the	O
emergent	B-T078
African	B-T083
variant	B-T080
in	O
kidney	B-T023
and	O
bone marrow	B-T024
transplant recipients	B-T101
in	O
the	O
Fundacion Valle del Lili in Cali	B-T093
,	O
Colombia	B-T083
To	O
describe	O
the	O
epidemiology	B-T091
of	O
BKV	B-T005
and	O
to	O
assess	B-T052
the	O
presence	B-T033
of	O
the	O
African	B-T083
variant	B-T080
in	O
bone marrow	B-T024
and	O
kidney transplant patients	B-T033
who	O
have	O
suspected	B-T080
BKV	B-T005
reactivation	B-T052
.	O
A	O
descriptive study	B-T062
was	O
conducted	B-T033
,	O
using	O
institutional records	B-T170
,	O
at	O
the	O
Fundación Valle del Lili, Cali	B-T093
-	O
Colombia	B-T083
.	O
The	O
overall prevalence	B-T081
of	O
BKV	B-T005
during	O
the	O
study	O
period	O
was	O
51%.	O
The	O
African	B-T083
variant	B-T080
was	O
identified	B-T080
in	O
49.4%	O
of	O
samples	B-T167
that	O
were	O
positive	B-T033
for	O
BKV	B-T005
.	O
50.6%	O
of	O
the	O
samples	B-T167
were	O
found	O
to	O
have	O
the	O
wild	B-T028
strain	B-T080
of	O
BKV	B-T005
.	O
Among	O
BKV	B-T005
positive	B-T033
patients	B-T101
,	O
57%	O
were	O
kidney transplant recipients	B-T033
and	O
43%	O
were	O
bone marrow	B-T024
transplant recipients	B-T101
.	O
This	O
is	O
the	O
first	O
epidemiological study	B-T062
describing	O
the	O
African	B-T083
variant	B-T080
of	O
BKV	B-T005
in	O
Colombia	B-T083
.	O

Thaw	B-T059
-and-use	O
target cells	B-T025
pre-labeled	B-T080
with	O
calcein AM	B-T130
for	O
antibody-dependent cell-mediated cytotoxicity assays	B-T059
In vitro	B-T080
antibody-dependent cell-mediated cytotoxicity (ADCC) assays	B-T059
are	O
routinely	O
performed	O
to	O
support	O
the	O
research	O
and	O
development	O
of	O
therapeutic antibodies	B-T116
.	O
In	O
ADCC assays	B-T059
,	O
target cells	B-T025
bound	O
by	O
the	O
antibodies	B-T116
are	O
lysed	B-T046
by	O
activated	B-T052
effector cells	B-T025
following	O
interactions	O
between	O
the	O
Fc region	B-T116
of	O
the	O
bound	O
antibody	B-T116
and	O
Fcγ receptors	B-T116
on	O
effector cells	B-T025
.	O
Target cell	B-T025
lysis	B-T046
is	O
typically	O
measured	O
by	O
quantification	B-T081
of	O
released	O
endogenous	B-T169
enzymes	B-T116
,	O
e.g.,	O
lactate dehydrogenase	B-T116
,	O
or	O
measurement	O
of	O
released	O
exogenous	B-T169
labels	B-T130
,	O
e.g.,	O
(51)Cr	B-T121
,	O
europium	B-T196
or	O
calcein	B-T109
.	O
ADCC assays	B-T059
based	O
on	O
the	O
detection	O
of	O
exogenous	B-T169
labels	B-T130
released	O
from	O
lysed	B-T046
target cells	B-T025
generally	O
show	O
higher	O
sensitivity	O
and	O
require	O
shorter	O
incubation times	B-T033
.	O
However,	O
target cells	B-T025
are	O
usually	O
labeled	B-T080
immediately	O
prior	O
to	O
assay	B-T059
,	O
which	O
inadvertently	O
introduces	O
additional	O
assay	B-T059
variations	B-T080
due	O
to	O
differences	O
in	O
target cell	B-T025
conditions	O
and	O
labeling	B-T059
/	O
handling processes	B-T059
.	O
In	O
this	O
report,	O
we	O
describe	O
the	O
use	O
of	O
thaw	B-T059
-and-use	O
pre-labeled	B-T080
target cells	B-T025
for	O
ADCC assays	B-T059
.	O
Thaw	B-T059
-and-use	O
target cells	B-T025
in	O
our	O
experiments	O
were	O
pre-labeled	B-T080
with	O
the	O
fluorescent dye calcein AM	B-T130
,	O
cryopreserved	B-T059
in	O
single-use	O
aliquots	O
and	O
used	O
directly	O
in	O
assays	B-T059
after	O
thawing	B-T059
.	O
Upon	O
thaw	B-T059
,	O
the	O
pre-labeled	B-T080
cells	B-T025
displayed	O
viability	B-T043
and	O
label	B-T130
retention	B-T169
comparable	O
to	O
freshly	O
labeled	B-T080
cells	B-T025
,	O
responded	O
to	O
ADCC	B-T043
mediated	O
by	O
both	O
peripheral blood mononuclear cells	B-T025
and	O
engineered natural killer cells	B-T025
,	O
performed	O
stably	O
for	O
at	O
least	O
3	O
years	O
and	O
provided	O
favorable	O
precision	O
and	O
accuracy	O
to	O
ADCC assays	B-T059
.	O
Implementation	O
of	O
thaw	B-T059
-and-use	O
pre-labeled	B-T080
target cells	B-T025
in	O
ADCC assays	B-T059
can	O
help	O
to	O
alleviate	O
both	O
cell culture	B-T059
and	O
dye labeling	B-T059
derived	O
variability,	O
increase	O
the	O
flexibility	O
of	O
assay	B-T059
scheduling	O
and	O
improve	O
assay consistency	B-T080
and	O
robustness	B-T080
.	O

Pathways	B-T044
and	O
Genes	B-T028
Associated with	B-T080
Immune	B-T022
Dysfunction	B-T046
in	O
Sheep	B-T015
Paratuberculosis	B-T047
Multibacillary	B-T033
and	O
paucibacillary	B-T033
paratuberculosis	B-T047
are	O
both	O
caused	O
by	O
Mycobacterium avium subspecies paratuberculosis	B-T007
.	O
Multibacillary	B-T033
lesions	B-T033
are	O
composed	O
largely	O
of	O
infected	B-T033
epithelioid macrophages	B-T025
and	O
paucibacillary	B-T033
lesions	B-T033
contain	O
T cells	B-T025
but	O
few	O
bacteria	B-T007
.	O
Multibacillary	B-T033
disease	B-T047
is	O
similar	O
to	O
human	O
lepromatous leprosy	B-T047
,	O
with	O
variable/high	O
levels	O
of	O
antibody	B-T116
and	O
a	O
dysfunctional	B-T169
immune response	B-T042
.	O
Animals	B-T008
with	O
paucibacillary	B-T033
disease	B-T047
have	O
high	O
cell-mediated immunity	B-T040
and	O
variable levels	B-T080
of	O
antibody	B-T116
.	O
This	O
study	O
aims	O
to	O
characterize	O
the	O
immunological dysfunction	B-T047
using	O
TruSeq	B-T170
analysis	B-T062
of	O
the	O
ileocaecal	B-T082
lymph node	B-T023
that	O
drains	O
disease	B-T047
lesions	B-T033
.	O
Immune	B-T022
dysfunction	B-T046
is	O
highlighted	O
by	O
repression	B-T045
of	O
TCR	B-T028
/	O
CD3 genes	B-T028
,	O
T cell co-receptors	B-T116
/	O
co-stimulators	B-T116
,	O
T cell activation	B-T043
and	O
signal-transduction	B-T043
genes	B-T028
.	O
Inflammation	B-T046
was	O
an	O
acute phase response	B-T046
and	O
chronic inflammation	B-T046
,	O
with	O
little	O
evidence	O
of	O
acute inflammation	B-T033
.	O
The	O
high	O
levels	O
of	O
immunoglobulin	B-T116
and	O
plasma cell	B-T025
transcripts	B-T114
is	O
consistent	O
with	O
the	O
anti-MAP antibody responses	B-T038
in	O
paratuberculosis	B-T047
sheep	B-T015
.	O
Also	O
notable	O
was	O
the	O
overwhelming	O
reduction	B-T080
in	O
mast cell	B-T025
transcripts	B-T114
,	O
potentially	O
affecting	B-T169
DC activation of the immune response	B-T043
.	O
This	O
study	O
also	O
shows	O
that	O
there	O
were	O
no	O
fundamental	O
differences	O
in	O
the	O
gene expression	B-T045
patterns	O
in	O
multibacillary	B-T033
and	O
paucibacillary	B-T033
disease	B-T047
,	O
no	O
shift	O
in	O
T cell	B-T025
genes	B-T028
from	O
Th1	B-T025
to	O
Th2	B-T025
pattern	O
but	O
rather	O
an	O
incremental	B-T081
decline	O
into	O
immune	B-T022
dysfunction	B-T046
leading	O
to	O
multibacillary	B-T033
pathology	B-T047
.	O

Modified	B-T169
frailty index	B-T170
predicts	B-T078
postoperative	B-T033
outcomes	B-T081
in	O
older	B-T098
gastrointestinal cancer	B-T191
patients	B-T101
Frailty	B-T033
disproportionately	B-T080
impacts	B-T080
older	B-T098
patients	B-T101
with	O
gastrointestinal cancer	B-T191
,	O
rendering	B-T169
them	O
at	O
increased risk for poor outcomes	B-T033
.	O
A	O
frailty index	B-T170
may	O
aid	O
in	O
preoperative	B-T079
risk	B-T078
stratification	B-T062
.	O
We	O
hypothesized	B-T078
that	O
high	O
modified frailty index (mFI) scores	B-T033
are	O
associated with	B-T080
adverse outcomes	B-T033
after	O
tumor	B-T191
resection	B-T061
in	O
older	B-T098
,	O
gastrointestinal cancer	B-T191
patients	B-T101
.	O
Patients	B-T101
(	O
60-90 years old	B-T098
)	O
who	O
underwent	B-T169
gastrointestinal tumor resection	B-UnknownType
were	O
identified	B-T080
in	O
the	O
2005-2012	O
NSQIP	B-T033
Participant	B-T098
Use	O
File.	O
mFI	B-T033
was	O
defined	O
by	O
11	O
previously	B-T079
described	B-T078
,	O
preoperative	B-T079
variables	B-T080
.	O
Frailty	B-T033
was	O
defined	O
by	O
an	O
mFI score	B-T033
>0.27.	O
The	O
postoperative course	B-T058
was	O
evaluated	B-T058
using	O
univariate	B-T062
and	O
multivariate analysis	B-T081
.	O
41	O
455	O
patients	B-T101
(mean	O
age	O
72.4	O
years,	O
47.4%	O
female	B-T032
)	O
were	O
identified	B-T080
.	O
The	O
most	O
prevalent form	B-T082
of	O
cancer	B-T191
was	O
colorectal	B-T191
(69.3%,	O
n	O
=	O
28	O
708)	O
and	O
2.8%	O
of	O
patients	B-T101
were	O
frail	B-T033
(n	O
=	O
1,164).	O
Frail	B-T033
patients	B-T101
were	O
significantly	B-T078
more likely	B-T078
to	O
have	O
increased length of stay	B-T079
(11.7	O
vs	O
9.0	O
days),	O
major	B-T080
complications	B-T046
(29.1%	O
vs	O
17.9%),	O
and	O
30-day	O
mortality	B-T081
(5.6%	O
vs	O
2.5%),	O
(all	O
P	O
<	O
0.001).	O
Multivariate analysis	B-T081
identified	B-T080
mFI	B-T033
as	O
an	O
independent	B-T078
predictor	B-T078
of	O
major	B-T080
complications	B-T046
(OR	O
1.52,	O
95%CI	O
1.39-1.65,	O
P	O
<	O
0.001)	O
and	O
30-day	O
mortality	B-T081
(OR	O
1.48,	O
95%CI	O
1.24-1.75,	O
P	O
<	O
0.001).	O
mFI	B-T033
was	O
associated with	B-T080
the	O
incidence	B-T081
of	O
postoperative	B-T033
complications	B-T046
and	O
mortality	B-T081
in	O
older	B-T098
surgical patients	B-T101
with	O
gastrointestinal cancer	B-T191
.	O

Spermatocytic Tumor	B-T191
With	O
Sarcoma	B-T191
:	O
A	O
Rare	B-T080
Testicular Neoplasm	B-T191
Spermatocytic tumor	B-T191
,	O
formerly	O
known	O
as	O
spermatocytic seminoma	B-T191
,	O
is	O
an	O
uncommon	B-T080
testicular neoplasm	B-T191
which	O
is	O
a	O
distinct	O
clinicopathologic entity	B-T169
from	O
classic	O
seminoma	B-T191
.	O
These	O
tumors	B-T191
are	O
not	O
associated	O
with	O
germ cell neoplasia	B-T191
in	O
situ,	O
other	O
germ cell tumors	B-T191
,	O
or	O
isochromosome 12p	B-T049
.	O
Although	O
typically,	O
these	O
tumors	B-T191
have	O
an	O
excellent	B-T080
prognosis	B-T058
occasional cases	B-T169
are	O
associated with	B-T080
sarcoma	B-T191
and	O
have	O
a	O
very poor prognosis	B-T033
.	O
We	O
present	O
a	O
case	B-T077
of	O
spermatocytic tumor	B-T191
with	O
sarcoma	B-T191
showing	O
a	O
chondrosarcomatous component	B-T191
,	O
discuss	O
the	O
pathologic findings	B-T033
and	O
differential diagnosis	B-T060
and	O
provide	O
follow-up	B-T058
information	B-T078
.	O

Remote	B-T082
Ischemic Conditioning	B-T061
and	O
Renal	B-T023
Protection	B-T033
Over	O
the	O
course	O
of	O
the	O
last	O
2	O
decades,	O
the	O
concept	O
of	O
remote	B-T082
ischemic conditioning	B-T061
(	O
RIC	B-T061
)	O
has	O
attracted	O
considerable	O
research	B-T062
interest	B-T041
,	O
because	O
RIC	B-T061
,	O
in	O
most	O
of	O
its	O
embodiments	O
offers	O
an	O
inexpensive	O
way	O
of	O
protecting	B-T033
tissues	B-T024
against	O
ischemic	B-T169
damage	B-T037
inflicted	O
by	O
a	O
number	O
of	O
medical	B-T169
conditions	B-T080
or	O
procedures	B-T058
.	O
Acute kidney injury	B-T037
(	O
AKI	B-T037
)	O
is	O
a	O
common	O
side effect	B-T169
in	O
the	O
context	O
of	O
various	O
medical procedures	B-T058
,	O
and	O
RIC	B-T061
has	O
been	O
suggested	O
as	O
a	O
means	O
of	O
reducing	O
its	O
incidence.	O
Outcomes	B-T169
regarding	O
kidney function	B-T042
have	O
been	O
reported	O
in	O
numerous	O
studies	B-T062
that	O
evaluated	O
the	O
effects of	B-T080
RIC	B-T061
in	O
a	O
variety	O
of	O
settings	O
(eg,	O
cardiac surgery	B-T061
,	O
interventions	B-T061
requiring	O
intravenous administration	B-T082
of	O
contrast media	B-T130
).	O
Although	O
several	O
individual	O
studies	B-T062
have	O
implied	O
a	O
beneficial	O
effect of	B-T080
RIC	B-T061
in	O
preserving	O
kidney function	B-T042
,	O
3	O
recently	O
published	O
randomized controlled trials	B-T062
evaluating	O
more	O
than	O
1000	O
patients	B-T101
each	O
(	O
Effect of	B-T080
Remote Ischemic Preconditioning	B-T061
in	O
the	O
Cardiac Surgery	B-T061
,	O
Remote Ischaemic Preconditioning	B-T061
for	O
Heart Surgery	B-T061
,	O
and	O
E RIC CA	B-T061
RIC	B-T061
CA)	O
were	O
negative	B-T033
.	O
However,	O
AKI	B-T037
or	O
any	O
other	O
index	O
of	O
renal function	B-T042
was	O
not	O
a	O
stand-alone	O
primary	O
end	O
point	O
in	O
any	O
of	O
these	O
trials	B-T062
.	O
On	O
the	O
other	O
hand,	O
a	O
range	O
of	O
meta-analyses	B-T062
(each	O
including	O
thousands	O
of	O
participants	B-T098
)	O
have	O
reported	O
mixed	O
results	B-T169
,	O
with	O
the	O
most	O
recent	O
among	O
them	O
showing	O
benefit	O
from	O
RIC	B-T061
,	O
pinpointing	O
at	O
the	O
same	O
time	O
a	O
number	O
of	O
shortcomings	O
in	O
published	B-T170
studies	B-T062
,	O
adversely affecting	B-T169
the	O
quality	B-T080
of	O
available data	B-T170
.	O
The	O
present	O
review	B-T170
provides	O
a	O
critical	O
appraisal	O
of	O
the	O
current	O
state	O
of	O
this	O
field	O
of	O
research	B-T062
.	O
It	O
is	O
the	O
opinion	O
of	O
the	O
authors	B-T097
of	O
this	O
review	B-T170
that	O
there	O
is	O
a	O
clear	O
need	O
for	O
a	O
common	O
clinical trial	B-T062
framework	O
for	O
ischemic conditioning	B-T061
studies	B-T062
.	O
If	O
the	O
current	O
babel	O
of	O
definitions	B-T170
,	O
procedures	B-T169
,	O
outcomes	B-T169
,	O
and	O
goals persists	B-T170
,	O
it	O
is	O
most	O
likely	O
that	O
soon	O
ischemic conditioning	B-T061
will	O
be	O
"yesterday's	O
news"	O
with	O
no	O
definitive	O
conclusions	O
having	O
been	O
reached	O
in	O
terms	O
of	O
its	O
real	O
clinical utility	B-T061
.	O

Temporal	B-T079
and	O
Spatial	B-T082
Variability	B-T077
of	O
Fungal Structures	B-T017
and	O
Host Responses	B-T042
in	O
an	O
Incompatible Rust-Wheat Interaction	B-T040
Information	B-T078
about	O
temporal	B-T079
and	O
spatial	B-T082
variability	B-T077
of	O
fungal structures	B-T017
and	O
host responses	B-T042
is	O
scarce	B-T080
in	O
comparison	B-T052
to	O
the	O
vast	O
amount	B-T081
of	O
genetic	B-T169
,	O
biochemical	B-T169
,	O
and	O
physiological	B-T169
studies	B-T062
of	O
host-pathogen interactions	B-T040
.	O
In	O
this	O
study	B-T062
,	O
we	O
used	B-T169
avirulent	B-T080
wild type	B-T028
and	O
virulent	B-T080
mutant	B-T028
isolates	B-T123
of	O
Puccinia striiformis	B-T004
to	O
characterize	B-T052
the	O
interactions	B-T169
in	O
wheat	B-T168
carrying	B-T052
yellow rust	B-T004
Yr2	B-T004
resistance	B-T046
.	O
Both	O
conventional	B-T080
and	O
advanced	B-T080
microscopic	B-T080
techniques	B-T169
were	O
used	B-T169
for	O
a	O
detailed	B-T080
study	B-T062
of	O
morphology	B-T080
and	O
growth	B-T040
of	O
fungal	B-T169
colonies	B-T025
and	O
associated	B-T080
host cell responses	B-T042
.	O
The	O
growth	B-T040
of	O
the	O
wild type	B-T028
isolates	B-T123
was	O
highly	B-T080
restricted	B-T169
due	O
to	O
hypersensitive response	B-T046
(	O
HR	B-T046
,	O
plant	B-T002
cell death	B-T043
)	O
indicated	B-T033
by	O
autofluorescence	B-T059
and	O
change	B-T169
in	O
the	O
shape	B-T082
of	O
the	O
affected	B-T169
plant cells	B-T025
.	O
The	O
host response	B-T042
appeared	B-T080
post	B-T079
-	O
haustorial	B-T017
,	O
but	O
large	B-T081
variation	B-T080
in	O
the	O
time	B-T079
and	O
stage	B-T079
of	O
arrest	B-T046
was	O
observed	B-T169
for	O
individual	B-T098
fungal	B-T169
colonies	B-T025
,	O
probably	B-T078
due	O
to	O
a	O
delay	B-T079
between	B-T082
detection	B-T061
and	O
response	B-T032
.	O
Some	O
colonies	B-T025
were	O
stopped	B-T079
right after	B-T079
the	O
formation	B-T169
of	O
the	O
primary infection	B-T047
hyphae	B-T004
whereas	O
others	O
formed	B-T169
highly	B-T080
branched	B-T082
mycelia	B-T004
.	O
HR	B-T046
was	O
first	O
observed	B-T169
in	O
host cells	B-T026
in	O
direct	B-T080
contact	B-T067
with	O
fungal structures	B-T017
,	O
after	O
which	O
the	O
defense responses	B-T040
spread	B-T080
to	O
adjacent	B-T082
host cells	B-T026
,	O
and	O
eventually	O
led	O
to	O
encasement	B-T082
of	O
the	O
fungal	B-T169
colony	B-T025
.	O
Several	B-T081
cells	B-T025
with	O
HR	B-T046
contained	B-T052
haustoria	B-T017
,	O
which	O
were	O
small	B-T081
and	O
underdeveloped	B-T080
,	O
but	O
some	B-T081
cells	B-T025
contained	B-T052
normal	B-T080
sized	B-T082
haustoria	B-T017
without	O
signs	B-T184
of	O
hypersensitivity	B-T046
.	O
The	O
growth	B-T040
of	O
the	O
virulent	B-T080
mutants	B-T028
in	O
the	O
resistant	B-T169
plants	B-T002
was	O
similar	B-T080
to	O
the	O
growth	B-T040
in	O
plants	B-T002
without	O
Yr2	B-T004
resistance	B-T046
,	O
which	O
is	O
a	O
strong	B-T080
indication	B-T078
that	O
the	O
incompatible	B-T080
phenotype	B-T032
was	O
associated	B-T080
with	O
Yr2	B-T004
.	O
The	O
interaction	B-T169
between	B-T082
P. striiformis	B-T004
and	O
wheat	B-T168
with	O
Yr2	B-T004
resistance	B-T046
was	O
highly	B-T080
variable	B-T080
in	O
time	B-T079
and	O
space	B-T082
,	O
which	O
demonstrate	B-T080
that	O
histological	B-T091
studies	B-T062
are	O
important	B-T080
for	O
a	O
deeper understanding	B-T041
of	O
host-pathogen interactions	B-T040
and	O
plant	B-T002
defense	B-T042
mechanisms	B-T169
in	O
general	B-T082
.	O

The	O
Effects of	B-T080
Messages	B-T170
about	O
the	O
Causes	B-T169
of	O
Obesity	B-T047
on	O
Disciplinary Action	B-T057
Decisions	B-T041
for	O
Overweight	B-T047
Employees	B-T097
We	O
investigated	B-T169
the	O
impact	B-T080
of	O
messages	B-T170
about	O
the	O
causes	B-T169
of	O
obesity	B-T047
(	O
controllable	B-T033
or	O
uncontrollable	B-T080
)	O
on	O
the	O
disciplinary action	B-T057
consequences	B-T169
selected	O
for	O
obese	B-T047
employees	B-T097
in	O
response	B-T032
to	O
a	O
work-related	B-T033
mistake	B-T080
.	O
Participants	B-T098
read	O
about	O
either	O
the	O
controllable	B-T033
or	O
uncontrollable	B-T080
causes	B-T169
of	O
obesity	B-T047
before	O
reviewing	B-T080
an	O
ostensible	B-T078
employee	B-T097
file	B-T057
that	O
included	O
a	O
description	O
of	O
an	O
employee	B-T097
mistake	B-T080
.	O
Depending	O
on	O
condition,	O
the	O
file	B-T057
contained	O
a	O
photo	B-T073
of	O
the	O
employee	B-T097
that	O
either	O
depicted	O
them	O
as	O
obese	B-T047
or	O
average	B-T081
weight	B-T032
.	O
Participants	B-T098
were	O
more	O
willing	O
to	O
withhold	B-T052
a	O
raise	O
or	O
promotion	B-T057
from	O
an	O
obese	B-T047
employee	B-T097
than	O
from	O
an	O
average	B-T081
-	O
weight	B-T032
employee	B-T097
.	O
Further,	O
there	O
was	O
little	O
evidence	B-T078
that	O
the	O
messages	B-T170
about	O
the	O
causes	B-T169
of	O
obesity	B-T047
affected	B-T169
participants	B-T098
'	O
perceived control	B-T033
and	O
self-efficacy	B-T041
for	O
healthy	B-T080
behaviors	B-T053
.	O

Experience	B-T041
is	O
Instrumental	B-T081
in	O
Tuning	B-T081
a	O
Link	B-T052
Between	O
Language	B-T171
and	O
Cognition	B-T041
:	O
Evidence	B-T078
from	O
6- to 7- Month-Old	B-T032
Infants	B-T100
'	O
Object	O
Categorization	B-T185
At birth	B-T080
,	O
infants	B-T100
not	O
only	O
prefer	O
listening	B-T041
to	O
human	B-T016
vocalizations	B-T054
,	O
but	O
also	O
have	O
begun	B-T079
to	O
link	B-T052
these	O
vocalizations	B-T054
to	O
cognition	B-T041
:	O
For	O
infants	B-T100
as	O
young	B-T079
as	O
three months	B-T079
of	O
age	B-T032
,	O
listening	B-T041
to	O
human	B-T016
language	B-T171
supports	O
object	O
categorization	B-T185
,	O
a	O
core	B-T082
cognitive	B-T169
capacity	B-T081
.	O
This	O
precocious	B-T079
link	B-T082
is	O
initially	B-T079
broad	B-T082
:	O
At	O
3	O
and	O
4	O
months,	O
vocalizations	B-T054
of	O
both	B-T080
humans	B-T016
and	O
nonhuman primates	B-T015
support	O
categorization	B-T185
.	O
But	O
by	O
6 months	B-T079
,	O
infants	B-T100
have	O
narrowed	B-T080
the	O
link	B-T052
:	O
Only	O
human	B-T016
vocalizations	B-T054
support	O
object	O
categorization	B-T185
.	O
Here	O
we	O
ask	O
what	O
guides	O
infants	B-T100
as	O
they	O
tune	B-T081
their	O
initially	B-T079
broad	B-T082
link	B-T052
to	O
a	O
more	O
precise	B-T080
one,	O
engaged	O
only	O
by	O
the	O
vocalizations	B-T054
of	O
our	O
species	B-T185
.	O
Across	O
three	O
studies	B-T062
,	O
we	O
use	O
a	O
novel	B-T080
exposure	B-T080
paradigm	B-T062
to	O
examine	O
the	O
effects	B-T080
of	O
experience	B-T041
.	O
We	O
document	O
that	O
merely	O
exposing	B-T080
infants	B-T100
to	O
nonhuman primate	B-T015
vocalizations	B-T054
enables	B-T041
infants	B-T100
to	O
preserve	O
the	O
early	B-T079
-	O
established	B-T080
link	B-T052
between	O
this	O
signal	B-T067
and	O
categorization	B-T185
.	O
In	O
contrast,	O
exposing	B-T080
infants	B-T100
to	O
backward	B-T169
speech	B-T040
-	O
a	O
signal	B-T067
that	O
fails	B-T169
to	O
support	B-T077
categorization	B-T185
at	O
any	O
age	B-T032
-	O
offers	O
no	O
such	O
advantage.	O
Our	O
findings	B-T033
reveal	B-T080
the	O
power	B-T081
of	O
early	B-T079
experience	B-T041
as	O
infants	B-T100
specify	O
which	O
signals	B-T067
,	O
from	O
an	O
initially	B-T079
broad	B-T082
set,	O
they	O
will	O
continue	B-T078
to	O
link	B-T052
to	O
cognition	B-T041
.	O

Bone Degeneration	B-T047
and	O
Its	O
Recovery	O
in	O
SMP30/GNL	B-T028
-	O
Knockout Mice	B-T015
Senescence marker protein-30	B-T116
(	O
SMP30	B-T116
)	O
decreases	O
androgen	B-T121
-independently	O
with	O
aging	B-T040
and	O
is	O
a	O
lactone	B-T109
-	O
hydrolyzing enzyme	B-T116
gluconolactonase	B-T116
(	O
GNL	B-T116
)	O
that	O
is	O
involved	O
in	O
vitamin C	B-T109
biosynthesis	B-T169
.	O
In	O
the	O
present	O
study	B-T062
,	O
bone	B-T023
properties	O
of	O
SMP30/GNL	B-T028
knockout (KO) mice	B-T015
with	O
deficiency	B-T169
in	O
vitamin C	B-T109
synthesis	B-T169
were	O
investigated	O
to	O
reveal	O
the	O
effects	O
of	O
SMP30/GNL	B-T116
and	O
exogenous	B-T169
vitamin C	B-T109
supplementation	B-T121
on	O
bone formation	B-T042
.	O
Mineral content	B-T081
(	O
BMC	B-T081
)	O
and	O
mineral density	B-T201
(	O
BMD	B-T201
)	O
of	O
the	O
mandible	B-T023
and	O
femur	B-T023
of	O
SMP30/GNL	B-T028
KO	B-T015
and	O
wild-type mice	B-T015
at	O
2	O
and	O
3	O
months	B-T079
of	O
age	B-T032
with	O
or	O
without	O
vitamin C	B-T109
supplementation	B-T121
were	O
measured	O
by	O
dual-energy X-ray absorptiometry	B-T060
.	O
Body	B-T032
and	O
bone	B-T023
weight	B-T081
of	O
both	O
age groups	B-T100
decreased	O
and	O
became	O
significantly	O
lower	O
than	O
those	O
of	O
wild-type mice	B-T015
.	O
The	O
bones	B-T023
of	O
SMP30/GNL	B-T028
KO mice	B-T015
were	O
rough	O
and	O
porous,	O
with	O
BMC	B-T081
and	O
BMD	B-T201
significantly	O
below	O
wild-type	B-T015
.	O
Oral	B-T030
supplementation	B-T121
with	O
vitamin C	B-T109
eliminated	O
differences	O
in	O
body weight	B-T032
,	O
bone	B-T023
weight,	O
BMC	B-T081
,	O
and	O
BMD	B-T201
between	O
SMP30/GNL	B-T028
KO	B-T015
and	O
wild-type mice	B-T015
at	O
each	O
age	B-T032
.	O
These	O
results	O
indicate	O
that	O
bone degeneration	B-T047
in	O
SMP30/GNL	B-T028
KO mice	B-T015
was	O
caused	O
by	O
lack	O
of	O
vitamin C	B-T109
,	O
and	O
that	O
this	O
mouse strain	B-T015
is	O
an	O
appropriate	O
model	B-T008
for	O
bone metabolism	B-T042
in	O
humans	B-T016
,	O
which	O
have	O
no	O
ability	O
to	O
synthesize	B-T169
vitamin C	B-T109
.	O

Utility	O
of	O
Post-Mortem	B-T060
Genetic Testing	B-T062
in	O
Cases	O
of	O
Sudden Arrhythmic Death Syndrome	B-T047
Sudden arrhythmic death syndrome	B-T047
(	O
SADS	B-T047
)	O
describes	O
a	O
sudden death	B-T046
with	O
negative	O
autopsy	B-T060
and	O
toxicological	B-T169
analysis	B-T062
.	O
Cardiac genetic disease	B-T047
is	O
a	O
likely	O
etiology	B-T169
.	O
This	O
study	B-T062
investigated	B-T169
the	O
clinical utility	B-T080
and	O
combined	O
yield	O
of	O
post-mortem	B-T060
genetic testing	B-T062
(	O
molecular autopsy	B-T060
)	O
in	O
cases	O
of	O
SADS	B-T047
and	O
comprehensive	B-T080
clinical evaluation	B-T058
of	O
surviving	B-T052
relatives	B-T099
.	O
We	O
evaluated	B-T058
302	O
expertly	O
validated	O
SADS	B-T047
cases	O
with	O
suitable	O
DNA	B-T114
(median	O
age	B-T032
:	O
24	O
years;	O
65%	O
males	B-T032
)	O
who	O
underwent	O
next-generation	B-T090
sequencing	B-T059
using	O
an	O
extended	O
panel	B-T078
of	O
77	O
primary electrical disorder	B-T028
and	O
cardiomyopathy genes	B-T028
.	O
Pathogenic	B-T033
and	O
likely	O
pathogenic variants	B-T080
were	O
classified	O
using	O
American College of Medical Genetics	B-T093
(	O
ACMG	B-T093
)	O
consensus guidelines	B-T170
.	O
The	O
yield	O
of	O
combined	O
molecular autopsy	B-T060
and	O
clinical evaluation	B-T058
in	O
82	O
surviving families	B-T099
was	O
evaluated	B-T058
.	O
A	O
gene-level rare variant association analysis	B-T063
was	O
conducted	O
in	O
SADS	B-T047
cases	O
versus	O
controls	B-T096
.	O
A	O
clinically actionable	B-T080
pathogenic	B-T033
or	O
likely	O
pathogenic variant	B-T080
was	O
identified	O
in	O
40	O
of	O
302	O
cases	O
(13%).	O
The	O
main	O
etiologies	B-T169
established	O
were	O
catecholaminergic polymorphic ventricular tachycardia	B-T047
and	O
long QT syndrome	B-T047
(17	O
[6%]	O
and	O
11	O
[4%],	O
respectively).	O
Gene-based rare variants association analysis	B-T063
showed	O
enrichment	O
of	O
rare	O
predicted	O
deleterious variants	B-T080
in	O
RYR2	B-T028
(p	O
=	O
5	O
×	O
10(-5)).	O
Combining	O
molecular autopsy	B-T060
with	O
clinical evaluation	B-T058
in	O
surviving families	B-T099
increased	O
diagnostic yield	B-T080
from	O
26%	O
to	O
39%.	O
Molecular autopsy	B-T060
for	O
electrical disorder	B-T028
and	O
cardiomyopathy genes	B-T028
,	O
using	O
ACMG	B-T093
guidelines	B-T170
for	O
variant classification	B-T185
,	O
identified	O
a	O
modest	O
but	O
realistic	O
yield	O
in	O
SADS	B-T047
.	O
Our	O
data	O
highlighted	O
the	O
predominant	O
role	O
of	O
catecholaminergic polymorphic ventricular tachycardia	B-T047
and	O
long QT syndrome	B-T047
,	O
especially	O
the	O
RYR2 gene	B-T028
,	O
as	O
well	O
as	O
the	O
minimal	O
yield	O
from	O
other	O
genes	B-T028
.	O
Furthermore,	O
we	O
showed	O
the	O
enhanced	O
utility	O
of	O
combined	O
clinical	B-T058
and	O
genetic evaluation	B-T058
.	O

Binding	B-T052
of	O
DEAD-box helicase	B-T116
Dhh1	B-T116
to	O
the	O
5'UTR	B-T114
of	O
ASH1	B-T028
mRNA	B-T114
represses	B-T045
localized	O
translation	B-T045
of	O
ASH1	B-T028
in	O
yeast	B-T004
cells	B-T025
Local translation	B-T045
of	O
specific	B-T080
mRNAs	B-T114
is	O
regulated	B-T043
by	O
dynamic	O
changes	O
in	O
their	O
subcellular	B-T026
localization	B-T169
,	O
and	O
these	O
changes	B-T169
are	O
due	O
to	O
complex	B-T080
mechanisms	B-T169
controlling	B-T067
cytoplasmic	B-T026
mRNA transport	B-T043
.	O
The	O
budding yeast	B-T004
Saccharomyces cerevisiae	B-T004
is	O
well	O
suited	O
to	O
studying	O
these	O
mechanisms	B-T169
because	O
many	O
of	O
its	O
transcripts	B-T114
are	O
transported	B-T044
from	O
the	O
mother cell	B-T025
to	O
the	O
budding	B-T043
daughter cell	B-T025
.	O
Here,	O
we	O
investigated	B-T169
the	O
translational control	B-T043
of	O
ASH1	B-T028
mRNA	B-T114
after	O
transport	B-T044
and	O
localization	B-T169
.	O
We	O
show	O
that	O
although	O
ASH1	B-T028
ASH1	B-T028
transcripts	B-T114
were	O
translated	B-T045
after	O
they	O
reached	O
the	O
bud-tip	B-T026
,	O
some	O
mRNAs	B-T114
were	O
bound	O
by	O
the	O
RNA-binding protein	B-T116
Puf6	B-T116
and	O
were	O
non-polysomal	B-T033
.	O
We	O
also	O
found	O
that	O
the	O
DEAD-box helicase	B-T116
Dhh1	B-T116
complexed	B-T080
with	O
the	O
untranslated	B-T114
ASH1	B-T028
mRNA	B-T114
and	O
Puf6	B-T116
.	O
Loss	O
of	O
Dhh1	B-T116
affected	O
local translation	B-T045
of	O
ASH1	B-T028
mRNA	B-T114
and	O
resulted	O
in	O
delocalization	B-T169
of	O
ASH1	B-T028
transcript	B-T114
in	O
the	O
bud	B-T002
.	O
Forcibly	O
shifting	O
the	O
non-polysomal	B-T033
ASH1	B-T028
mRNA	B-T114
into	O
polysomes	B-T026
was	O
associated	O
with	O
Dhh1	B-T116
dissociation	B-T048
.	O
We	O
further	O
demonstrated	O
that	O
Dhh1	B-T116
is	O
not	O
recruited	O
to	O
ASH1	B-T028
mRNA	B-T114
co-transcriptionally	B-T045
,	O
suggesting	B-T078
that	O
it	O
could	O
bind	O
to	O
ASH1	B-T028
mRNA	B-T114
within	O
the	O
cytoplasm	B-T026
.	O
Of	O
note,	O
Dhh1	B-T116
bound	O
to	O
the	O
5 UTR	B-T114
of	O
ASH1	B-T028
mRNA	B-T114
and	O
inhibited	B-T080
its	O
translation	B-T045
in vitro	B-T080
.	O
These	O
results	O
suggest	B-T078
that	O
after	O
localization	B-T169
to	O
the	O
bud tip,	B-T026
a	O
portion	B-T082
of	O
the	O
localized	B-T082
ASH1	B-T028
mRNA	B-T114
becomes	O
translationally	B-T045
inactive	B-T080
,	O
because	O
of	O
binding	B-T052
of	O
Dhh1	B-T116
and	O
Puf6	B-T116
to	O
the	O
5' and 3' UTRs	B-T114
of	O
ASH1	B-T028
mRNA	B-T114
.	O

The	O
Abundance	B-T080
of	O
Endofungal Bacterium	B-T007
Rhizobium radiobacter	B-T007
(syn.	O
Agrobacterium tumefaciens	B-T007
)	O
Increases	B-T169
in	O
Its	O
Fungal	B-T169
Host	B-T001
Piriformospora indica	B-T004
during	O
the	O
Tripartite	O
Sebacinalean	B-T004
Symbiosis	B-T070
with	O
Higher Plants	B-T002
Rhizobium radiobacter	B-T007
(syn.	O
Agrobacterium tumefaciens	B-T007
,	O
syn.	O
"	O
Agrobacterium fabrum	B-T007
")	O
is	O
an	O
endofungal bacterium	B-T007
of	O
the	O
fungal	B-T169
mutualist	B-T070
Piriformospora	B-T004
(syn.	O
Serendipita	B-T004
)	O
indica	B-T004
(	O
Basidiomycota	B-T004
),	O
which	O
together	O
form	O
a	O
tripartite	O
Sebacinalean	B-T004
symbiosis	B-T070
with	O
a	O
broad	O
range	O
of	O
plants	B-T002
.	O
R. radiobacter	B-T007
strain F4	B-T001
(	O
RrF4	B-T001
),	O
isolated	O
from	O
P. indica DSM 11827	B-T004
,	O
induces	B-T169
growth	B-T040
promotion	B-T052
and	O
systemic resistance	B-T043
in	O
cereal	B-T168
crops	B-T002
,	O
including	O
barley	B-T002
and	O
wheat	B-T002
,	O
suggesting	O
that	O
R. radiobacter	B-T007
contributes	O
to	O
a	O
successful	O
symbiosis	B-T070
.	O
Here,	O
we	O
studied	O
the	O
impact	B-T080
of	O
endobacteria	B-T007
on	O
the	O
morphology	B-T080
and	O
the	O
beneficial	O
activity	O
of	O
P. indica	B-T004
during	O
interactions	B-T169
with	O
plants	B-T002
.	O
Low	O
numbers	O
of	O
endobacteria	B-T007
were	O
detected	B-T033
in	O
the	O
axenically grown	B-T059
P. indica	B-T004
(	O
long term	B-T079
lab-cultured	B-T059
,	O
lcPiri	B-T004
)	O
whereas	O
mycelia	B-T004
colonizing	B-T033
the	O
plant root	B-T002
contained	O
increased	B-T081
numbers	O
of	O
bacteria	B-T007
.	O
Higher	O
numbers	O
of	O
endobacteria	B-T007
were	O
also	O
found	O
in	O
axenic cultures	B-T059
of	O
P. indica	B-T004
that	O
was	O
freshly	O
re-isolated	B-T169
(	O
riPiri	B-T004
)	O
from	O
plant roots	B-T002
,	O
though	O
numbers	O
dropped	O
during	O
repeated	O
axenic re-cultivation	B-T059
.	O
Prolonged	B-T079
treatments	B-T061
of	O
P. indica	B-T004
cultures	B-T059
with	O
various	O
antibiotics	B-T195
could	O
not	O
completely	O
eliminate	O
the	O
bacterium	B-T007
,	O
though	O
the	O
number	O
of	O
detectable	B-T201
endobacteria	B-T007
decreased	B-T081
significantly	B-T078
,	O
resulting	O
in	O
partial-cured	B-T033
P. indica	B-T004
(	O
pcPiri	B-T004
).	O
pcPiri	B-T004
showed	O
reduced	B-T080
growth	B-T040
in	O
axenic cultures	B-T059
and	O
poor	B-T080
sporulation	B-T043
.	O
Consistent with	B-T078
this,	O
pcPiri	B-T004
also	O
showed	O
reduced	B-T080
plant growth	B-T040
promotion	B-T052
and	O
reduced	B-T080
systemic resistanc	B-T043
e	O
against	O
powdery mildew	B-T004
infection	B-T046
as	O
compared	O
with	O
riPiri	B-T004
and	O
lcPiri	B-T004
.	O
These	O
results	B-T169
are	O
consistent with	B-T078
the	O
assumption	O
that	O
the	O
endobacterium	B-T007
R. radiobacter	B-T007
improves	B-T033
P. indica's	B-T004
fitness	B-T032
and	O
thus	O
contributes	O
to	O
the	O
success	O
of	O
the	O
tripartite	O
Sebacinalean	B-T004
symbiosis	B-T070
.	O

Stem cell	B-T025
registry	B-T170
programme	B-T169
for	O
patients	B-T101
with	O
ischemic cardiomyopathy	B-T047
undergoing	O
coronary artery bypass grafting	B-T061
:	O
what	O
benefits	B-T081
does	O
it	O
derive?	O
Standardization	B-T062
of	O
stem cell therapy	B-T061
requires	O
application	O
of	O
appropriate	O
methods	B-T062
to	O
evaluate	B-T058
safety and efficac	B-T058
y,	O
including	O
long-term	B-T079
pharmacovigilance	B-T062
.	O
To	O
accomplish	O
this	O
objective	B-T170
,	O
a	O
long-term	B-T079
registry programme	B-T073
was	O
installed.	O
We	O
analysed	O
150	O
patients	B-T101
with	O
ischemic cardiomyopathy	B-T047
,	O
who	O
received	B-T080
intramyocardial	B-T024
CD133+ bone marrow mononuclear stem cell	B-T025
treatment	B-T061
combined	B-T080
with	O
coronary artery bypass grafting	B-T061
(	O
CABG	B-T061
)	O
or	O
CABG	B-T061
alone	B-T081
.	O
The	O
mortality rate	B-T081
,	O
major	B-T080
adverse cerebral	B-T033
and	O
cardiac events	B-T033
,	O
and	O
functional	O
outcome	O
parameters	O
were	O
evaluated	B-T058
for	O
the	O
time period	B-T079
up	O
to	O
14	O
years	O
follow-up	B-T058
.	O
As	O
a	O
result,	O
we	O
have	O
stratified	B-T080
the	O
patient	B-T101
population	B-T098
(96	O
patients	B-T101
)	O
into	O
responders	B-T033
and	O
non-responders	B-T033
.	O
Furthermore,	O
the	O
analysis	B-T062
of	O
relevant	B-T080
predictors	B-T078
of	O
good response	B-T033
to	O
CD133+ bone marrow mononuclear stem cell	B-T025
treatment	B-T061
was	O
performed	B-T169
.	O
Several	B-T081
positive	O
tendencies	O
related	O
to	O
stem cells transplantation	B-T061
were	O
demonstrated.	O
First,	O
no significant	B-T033
difference	B-T080
in	O
major	B-T080
adverse cardiovascular	B-T033
and	O
cerebral events	B-T033
was	O
observed	B-T169
between	O
stem cell	B-T025
and	O
control group	B-T096
up	O
to	O
14	O
years	O
follow-up	B-T058
.	O
Second,	O
an	O
improvement	B-T077
of	O
left ventricle ejection fraction	B-T201
(	O
LVEF	B-T201
)	O
in	O
stem cell	B-T025
group	B-T078
retained	B-T169
for	O
5	O
years	O
in	O
contrast	B-T080
with	O
CABG	B-T061
-	O
only	B-T081
group	B-T078
,	O
where	O
no	O
significant	O
changes	O
in	O
LVEF	B-T201
after	O
2	O
years	O
were	O
observed.	O
In	O
addition,	O
LVEF	B-T201
under	O
30%	O
and	O
left ventricle end diastolic diameter	B-T060
above	O
60	O
mm	O
were	O
independent	O
predictors	B-T078
of	O
functional	B-T169
response	O
to	O
CD133+ cell	B-T025
therapy	B-T061
.	O
Participants	B-T098
with	O
overt heart failure	B-T047
benefit	B-T081
most	B-T081
from	O
CABG	B-T061
combined	B-T080
with	O
intramyocardial	B-T024
injection	B-T061
of	O
CD133+ bone marrow mononuclear cell	B-T025
within	O
the	O
group	B-T078
.	O
An	O
improvement	B-T077
LVEF	B-T201
in	O
stem cell	B-T025
group	B-T078
remained	O
for	O
5	O
years	O
in	O
contrast	B-T080
with	O
the	O
CABG	B-T061
-	O
only	B-T081
group	B-T078
.	O
The	O
patients	B-T101
,	O
in	O
whom	O
the	O
improvement	B-T077
of	O
both	O
LVEF	B-T201
and	O
LVED	B-T060
was	O
observed	B-T169
,	O
have	O
benefited	O
by	O
increased	B-T081
life expectancy	B-T102
.	O

Effects	B-T080
of	O
Environmental	B-T082
Factors	B-T169
and	O
Metallic	B-T197
Electrodes	B-T074
on	O
AC	B-T070
Electrical Conduction	B-T081
Through	O
DNA Molecule	B-T114
Deoxyribonucleic acid (DNA)	B-T114
is	O
one	O
of	O
the	O
best	O
candidate	O
materials	O
for	O
various	O
device	B-T073
applications	B-T169
such	O
as	O
in	O
electrodes	B-T074
for	O
rechargeable batteries	B-T073
,	O
biosensors	B-T075
,	O
molecular electronics	B-T074
,	O
medical	B-T074
-	O
and	O
biomedical	B-T074
-	O
applications	B-T169
etc.	O
Hence,	O
it	O
is	O
worthwhile	O
to	O
examine	O
the	O
mechanism	O
of	O
charge transport	B-T070
in	O
the	O
DNA molecule	B-T114
,	O
however,	O
still	O
a	O
question	O
without	O
a	O
clear	O
answer	O
is	O
DNA	B-T114
a	O
molecular	B-T080
conducting	B-T070
material	B-T167
(	O
wire	B-T073
),	O
semiconductor	B-T073
,	O
or	O
insulator	B-T073
?	O
The	O
answer,	O
after	O
the	O
published	O
data,	O
is	O
still	O
ambiguous	O
without	O
any	O
confirmed	O
and	O
clear	O
scientific	O
answer.	O
DNA	B-T114
is	O
found	O
to	O
be	O
always	O
surrounded	O
with	O
different	O
electric charges	B-T070
,	O
ions	B-T196
,	O
and	O
dipoles	B-UnknownType
.	O
These	O
surrounding	O
charges	B-T070
and	O
electric barrier(s)	B-T073
due	O
to	O
metallic	B-T197
electrodes	B-T074
(as	O
environmental	B-T082
factors	B-T169
(	O
EFs	B-T169
))	O
play	O
a	O
substantial	O
role	O
when	O
measuring	B-T080
measuring	B-T080
the	O
electrical conductivity	B-T081
through	O
λ-double helix (DNA) molecule	B-T114
suspended	O
between	O
metallic	B-T197
electrodes	B-T074
.	O
We	O
found	O
that	O
strong	B-T080
frequency	B-T079
dependence	O
of	O
AC	B-T070
-	O
complex	B-T080
conductivity	B-T081
comes	O
from	O
the	O
electrical conduction	B-T067
of	O
EFs	B-T169
.	O
This	O
leads	O
to	O
superimposing	O
serious	O
incorrect	O
experimental	B-T062
data	O
to	O
measured	B-T080
ones.	O
At	O
1	O
MHz,	O
we	O
carried	O
out	O
a	O
first	O
control	O
experiment	B-T062
on	O
electrical conductivity	B-T081
with	O
and	O
without	O
the	O
presence	O
of	O
DNA molecule	B-T114
.	O
If	O
there	O
are	O
possible	O
electrical conduction	B-T081
due	O
to	O
stray	O
ions	B-T196
and	O
contribution	O
of	O
substrate,	O
we	O
will	O
detected	O
them.	O
This	O
control	O
experiment	B-T062
revealed	O
that	O
there	O
is	O
an	O
important	O
role	O
played	O
by	O
the	O
environmental	B-T082
-	O
charges	B-T070
around	O
DNA molecule	B-T114
and	O
any	O
experiment	B-T062
should	O
consider	O
this	O
role.	O
We	O
have	O
succeeded	O
to	O
measure	B-T081
both	O
electrical conductivity	B-T081
due	O
to	O
EFs	B-T169
(σ	O
ENV)	O
and	O
electrical conductivity	B-T081
due	O
to	O
DNA molecule	B-T114
(	O
σ DNA	B-T114
)	O
independently	O
by	O
carrying	O
the	O
measurements	B-T169
at	O
different	O
DNA	B-T114
-	O
lengths	B-T081
and	O
subtracting	O
the	O
data.	O
We	O
carried	O
out	O
measurements	B-T169
as	O
a	O
function	O
of	O
frequency (f)	B-T079
and	O
temperature (T)	B-T081
in	O
the	O
ranges	O
0.1	O
Hz	O
<	O
f	O
<	O
1	O
MHz	O
and	O
288	O
K	O
<	O
T	O
<	O
343	O
K.	O
The	O
measured	B-T080
conductivity	B-T081
(σ	O
MES)	O
portrays	O
a	O
metal	B-T197
-like	O
behavior	O
at	O
high frequencies	B-T079
near	O
1	O
MHz.	O
However,	O
we	O
found	O
that	O
σ DNA	B-T114
was	O
far	O
from	O
this	O
behavior	O
because	O
the	O
conduction	B-T070
due	O
to	O
EFs	B-T169
superimposes	O
σ DNA	B-T114
,	O
in	O
particular	O
at	O
low frequencies	B-T079
.	O
By	O
measuring	B-T080
the	O
electrical conductivity	B-T081
at	O
different	O
lengths	B-T081
:	O
40,	O
60,	O
80,	O
and	O
100	O
nm,	O
we	O
have	O
succeeded	O
not	O
only	O
to	O
separate	O
the	O
electrical conduction	B-T067
of	O
the	O
DNA molecule	B-T114
from	O
all	O
EFs	B-T169
effects	O
that	O
surround	O
the	O
molecule	B-T114
,	O
but	O
also	O
to	O
present	O
accurate	O
values	O
of	O
σ DNA	B-T114
and	O
the	O
dielectric constant	B-UnknownType
of	O
the	O
molecule	O
ε'DNA	B-T114
as	O
a	O
function	O
of	O
temperature	O
and	O
frequency.	O
Furthermore,	O
in	O
order	O
to	O
explain	O
these	O
data,	O
we	O
present	O
a	O
model	O
describing	O
the	O
electrical conduction	B-T067
through	O
DNA molecule	B-T114
:	O
DNA	B-T114
is	O
a	O
classical	O
semiconductor	B-T073
with	O
charges	B-T070
,	O
dipoles	B-UnknownType
and	O
ions	B-T196
that	O
result	O
in	O
creation	O
of	O
localized	B-T169
energy	B-T081
-	O
states	B-T169
(LESs)	O
in	O
the	O
extended	O
bands	O
and	O
in	O
the	O
energy gap	B-T070
of	O
the	O
DNA molecule	B-T114
.	O
This	O
model	O
explains	O
clearly	O
the	O
mechanism	O
of	O
charge transfer mechanism	B-T070
in	O
the	O
DNA	B-T114
,	O
and	O
it	O
sheds	O
light	O
on	O
why	O
the	O
charge transfer	B-T070
through	O
the	O
DNA	B-T114
can	O
lead	O
to	O
insulating	B-T070
,	O
semiconducting	B-T070
,	O
or	O
metallic	B-T197
behavior	O
on	O
the	O
same	O
time.	O
The	O
model	O
considers	O
charges	B-T070
on	O
DNA	B-T114
,	O
in	O
the	O
extended	O
bands,	O
either	O
could	O
be	O
free	O
to	O
move	O
under	O
electric field	B-T070
or	O
localized	O
in	O
potential wells/hills	B-T082
.	O
Localization	B-T169
of	O
charges	B-T070
in	O
DNA	B-T114
is	O
an	O
intrinsic	B-T169
structural	B-T082
-	O
property	B-T080
of	O
this	O
solitaire	O
molecule.	O
At	O
all	O
temperatures,	O
the	O
expected	O
increase	O
in	O
thermal	B-T070
-	O
induced	B-T169
charge	B-T070
is	O
attributed	O
to	O
the	O
delocalization of holes	B-T070
(or/and	O
electrons	B-T196
)	O
in	O
potential hills	B-T082
(or/and	O
potential wells)	B-T082
which	O
accurately	O
accounts	O
for	O
the	O
total	O
electric	B-T081
and	O
dielectric behavior	B-T081
through	O
DNA molecule	B-T114
.	O
We	O
succeeded	O
to	O
fit	O
the	O
experiment	B-T062
al	O
data	O
to	O
the	O
proposed	O
model	O
with	O
reasonable	O
magnitudes	O
of	O
potential hills/wells	B-T082
that	O
are	O
in	O
the	O
energy	B-T081
range	O
from	O
0.068	O
eV.	O

Next-Generation Sequencing	B-T063
Approaches	B-T169
to	O
Define	O
the	O
Role	B-T077
of	O
the	O
Autophagy Lysosomal Pathway	B-T043
in	O
Human	B-T016
Disease	B-T047
:	O
The	O
Example	B-T077
of	O
LysoPlex	B-T170
Next-Generation Sequencing (NGS) technologies	B-T063
have	O
deeply	O
changed	O
the	O
throughput	B-T081
of	O
genetic testing	B-T059
allowing	O
analyzing	O
millions	O
of	O
DNA fragments	B-UnknownType
in	O
parallel	B-T080
.	O
One	O
key	O
application	B-T169
is	O
the	O
understanding	O
of	O
genetically	B-T169
heterogeneous	B-T033
and	O
complex diseases	B-T047
where	O
50-100	O
different	O
genes	B-T028
may	O
converge	O
to	O
control	B-T080
the	O
same	O
pathways	B-T044
.	O
These	O
disorders	B-T047
cannot	O
be	O
studied	O
using	O
traditional	B-T169
approaches	B-T169
,	O
based	O
on	O
gene-by-gene Sanger sequencing	B-T063
.	O
We	O
have	O
set	O
up	O
an	O
NGS	B-T063
protocol	B-T170
based	O
on	O
a	O
specific	O
selection	B-T052
of	O
DNA regions	B-T114
belonging	O
to	O
about	O
900	O
genes	B-T028
of	O
the	O
autophagy-lysosomal (ALP) pathway	B-T043
.	O
We	O
here	O
specify	O
all	O
the	O
technical steps	B-T077
and	O
challenges	B-T058
of	O
our	O
protocol	B-T170
,	O
named	O
LysoPlex	B-T170
.	O
This	O
is	O
based	O
on	O
the	O
Haloplex	O
technology	O
and	O
together	O
with	O
high-coverage sequencing	B-UnknownType
empowers	O
a	O
high	O
and	O
uniform	O
coverage	O
of	O
ALP genes	B-T028
.	O
LysoPlex	B-T170
outplays	O
other	O
NGS	B-T063
applications	B-T169
in	O
sensitivity and specificity	B-T081
,	O
providing	O
an	O
accurate	O
picture	O
of	O
all	O
variations	B-T070
in	O
ALP genes	B-T028
.	O

Typical	O
Skin Injuries	B-T037
in	O
Children	B-T100
With	O
Autism Spectrum Disorder	B-T048
Pediatric	B-T080
skin injuries	B-T037
have	O
primarily	O
been	O
described	O
in	O
typically	O
developing children	B-T100
.	O
Our	O
objectives	B-T170
were	O
to	O
describe	O
the	O
prevalence	B-T081
and	O
pattern	B-T082
of	O
skin injuries	B-T037
of	O
children	B-T100
with	O
autism spectrum disorder	B-T048
(	O
ASD	B-T048
),	O
to	O
describe	O
how	O
this	O
compared	O
with	O
previously	O
demonstrated	O
skin injury	B-T037
locations	B-T033
in	O
typically	O
developing children	B-T100
,	O
and	O
to	O
identify	O
differences	B-T080
in	O
skin injury	B-T037
frequency	B-T079
and	O
locations	B-T033
between	O
autistic children	B-T101
with	O
and	O
without	O
self-injurious behaviors	B-T055
(	O
SIBs	B-T055
).	O
Children	B-T100
with	O
ASD	B-T048
were	O
recruited	O
between	O
September	B-T079
of	O
2011	O
and	O
September	B-T079
of	O
2014.	O
Demographic information	B-T078
was	O
obtained	O
from	O
the	O
caregiver	B-T097
.	O
All	O
skin injuries	B-T037
and	O
their	O
locations	B-T033
were	O
documented	B-T058
.	O
Of	O
the	O
41	O
children	B-T100
enrolled,	O
half	O
were	O
reported	O
to	O
have	O
SIBs	B-T055
.	O
The	O
most	O
identified	O
skin injury	B-T037
locations	B-T033
were	O
the	O
legs	B-T023
,	O
knees	B-T023
,	O
and	O
back	B-T029
.	O
Children	B-T100
with	O
autism	B-T048
(1)	O
obtain	O
skin injuries	B-T037
frequently	O
and	O
in	O
similar	O
locations	B-T033
as	O
typically	O
developing children	B-T100
and	O
(2)	O
rarely	O
obtain	O
skin injuries	B-T037
to	O
locations	B-T033
that	O
are	O
considered	O
uncommon	O
for	O
accidental injuries	B-T037
despite	O
reports	O
of	O
SIBs	B-T055
.	O

Is	O
Total Elbow Arthroplasty	B-T061
Safe	B-T068
as	O
an	O
Outpatient Procedure	B-T061
?	O
Ambulatory surgery centers	B-T073
are	O
the	O
preferred setting	B-T073
for	O
many	O
procedures	B-T169
formerly	O
performed	B-T169
in	O
a	O
hospital	B-T073
setting	B-T073
.	O
This	O
study	B-T062
sought	O
to	O
determine	O
whether	O
outpatient	B-T101
total elbow arthroplasty	B-T061
(	O
TEA	B-T061
)	O
is	O
as	O
safe	B-T068
as	O
inpatient	B-T101
TEA	B-T061
.	O
A	O
retrospective analysis	B-T062
was	O
performed	B-T169
of	O
inpatient	B-T101
(	O
IP	B-T101
)	O
versus	O
outpatient	B-T101
(	O
OP	B-T101
)	O
TEA	B-T061
by	O
a	O
single	B-T081
surgeon	B-T097
over	O
a	O
period	O
of	O
18	O
years	B-T079
.	O
Demographic	B-T062
,	O
social	B-T080
,	O
and	O
comorbidity measures	B-T081
as	O
well	O
as	O
complication	B-T046
rates	B-T081
were	O
analyzed	B-T062
and	O
stratified	B-T080
by	O
IP	B-T101
or	O
OP	B-T101
status	B-T080
.	O
Bivariate comparison	B-UnknownType
showed	O
increased	B-T081
prevalence	B-T081
of	O
coronary artery disease	B-T047
in	O
the	O
OP	B-T101
group	B-T098
(32%	O
vs.	O
7%)	O
and	O
increased	B-T081
age	B-T032
in	O
the	O
IP	B-T101
group	B-T098
(68	O
years	B-T079
vs.	O
58	O
years	B-T079
).	O
All	O
other	O
demographic	B-T062
,	O
social	B-T080
,	O
and	O
comorbidity factors	B-T081
were	O
comparable	B-T052
between	O
the	O
IP	B-T101
and	O
OP	B-T101
groups	B-T098
,	O
although	O
more	B-T081
infections	B-T046
were	O
seen	B-T080
in	O
the	O
IP	B-T101
group	B-T098
.	O
The	O
surgeons'	B-T097
initial learning curve	B-T041
occurred	B-T052
mostly	O
within	O
the	O
IP	B-T101
group	B-T098
.	O
Most	O
important,	O
no difference	B-T033
in	O
complication	B-T046
rate	B-T081
was	O
observed	B-T169
between	O
the	O
IP	B-T101
and	O
OP	B-T101
groups	B-T098
.	O

Developmental	B-T080
Hypoxia	B-T046
Has	O
Negligible	B-T080
Effects	B-T080
on	O
Long-Term	B-T079
Hypoxia	B-T046
Tolerance	B-T080
and	O
Aerobic Metabolism	B-T043
of	O
Atlantic Salmon	B-T013
(	O
Salmo salar	B-T013
)	O
Exposure to	B-T080
developmental	B-T080
hypoxia	B-T046
can	O
have	O
long-term	B-T079
impacts	B-T080
on	O
the	O
physiological	B-T039
performance	B-T052
of	O
fish	B-T013
because	O
of	O
irreversible	B-T169
plasticity	B-T070
.	O
Wild	B-T170
and	O
captive-reared	B-T033
Atlantic salmon	B-T013
(	O
Salmo salar	B-T013
)	O
can	O
be	O
exposed to	B-T080
hypoxic	B-T046
conditions	B-T080
during	O
development	B-T169
and	O
continue	B-T078
to	O
experience	O
fluctuating	B-T079
oxygen	B-T121
levels	B-T080
as	O
juveniles	B-T100
and	O
adults	B-T100
.	O
Here,	O
we	O
examine	B-T033
whether	O
developmental	B-T080
hypoxia	B-T046
impacts	B-T080
subsequent	B-T079
hypoxia	B-T046
tolerance	B-T080
and	O
aerobic	B-T080
performance	B-T052
of	O
Atlantic salmon	B-T013
.	O
Individuals	B-T013
at	O
8°C	O
were	O
exposed to	B-T080
50%	O
(	O
hypoxia	B-T046
)	O
or	O
100%	O
(	O
normoxia	B-T070
)	O
dissolved oxygen (DO) saturation	B-T044
(as	O
percent	O
of	O
air saturation	B-T070
)	O
from	O
fertilization	B-T040
for	O
∼100	O
d	O
(800	O
degree	O
days)	O
and	O
then	O
raised	B-T080
in	O
normoxic	B-T070
conditions	B-T080
for	O
a	O
further	O
15	O
mo.	O
At	O
18	O
mo	O
after	O
fertilization	B-T040
,	O
aerobic	B-T080
scope	B-T077
was	O
calculated	B-T052
in	O
normoxia	B-T070
(100%	O
DO	B-T121
)	O
and	O
acute	B-T079
(18	O
h)	O
hypoxia	B-T046
(50%	O
DO	B-T121
)	O
from	O
the	O
difference	B-T080
between	O
the	O
minimum	B-T080
and	O
maximum	B-T081
oxygen consumption	B-T201
rates	B-T081
([Formula:	O
see	O
text]	O
and	O
[Formula:	O
see	O
text],	O
respectively)	O
at	O
10°C.	O
Hypoxia	B-T046
tolerance	B-T080
was	O
determined	B-T080
as	O
the	O
DO	B-T121
at	O
which	O
loss of equilibrium	B-T184
(	O
LOE	B-T184
)	O
occurred	B-T052
in	O
a	O
constantly	O
decreasing	B-T033
DO	B-T121
environment.	O
There	O
was	O
no difference	B-T033
in	O
[Formula:	O
see	O
text],	O
[Formula:	O
see	O
text],	O
or	O
aerobic	B-T080
scope	B-T077
between	O
fish	B-T013
raised	B-T080
in	O
hypoxia	B-T046
or	O
normoxia	B-T070
.	O
There	O
was	O
some	O
evidence	B-T078
that	O
hypoxia	B-T046
tolerance	B-T080
was	O
lower	B-T052
(higher	O
DO	B-T121
at	O
LOE	B-T184
)	O
in	O
hypoxia	B-T046
-	O
raised	B-T080
fish	B-T013
compared	O
with	O
those	O
raised	B-T080
in	O
normoxia	B-T070
,	O
but	O
the	O
magnitude	B-T081
of	O
the	O
effect	B-T080
was	O
small	B-T081
(12.52%	O
DO	B-T121
vs.	O
11.73%	O
DO	B-T121
at	O
LOE	B-T184
).	O
Acute	B-T079
hypoxia	B-T046
significantly	O
reduced	B-T080
aerobic	B-T080
scope	B-T077
by	O
reducing	B-T080
[Formula:	O
see	O
text],	O
while	O
[Formula:	O
see	O
text]	O
remained	O
unchanged	B-T033
.	O
Interestingly,	O
acute	B-T079
hypoxia	B-T046
uncovered	O
individual	B-T013
-level	O
relationships	B-T080
between	O
DO	B-T121
at	O
LOE	B-T184
and	O
[Formula:	O
see	O
text],	O
[Formula:	O
see	O
text],	O
and	O
aerobic	B-T080
scope	B-T077
.	O
We	O
discuss	O
our	O
findings	B-T169
in	O
the	O
context	O
of	O
developmental	B-T080
trajectories	O
and	O
the	O
role	O
of	O
aerobic	B-T080
performance	B-T052
in	O
hypoxia	B-T046
tolerance	B-T080
.	O

LDL	B-T109
particle number	B-T081
and	O
size	B-T081
and	O
cardiovascular	B-T029
risk	B-T078
:	O
anything	O
new	O
under	O
the	O
sun?	O
We	O
provide	O
here	O
an	O
up-to-date	O
perspective	O
on	O
the	O
potential	B-T080
use	B-T169
of	O
LDL	B-T109
particle number	B-T081
and	O
size	B-T081
as	O
complementary	O
risk factors	B-T033
to	O
predict	O
and	O
manage	O
cardiovascular disease	B-T047
(	O
CVD	B-T047
)	O
risk	B-T078
in	O
the	O
clinical	B-T080
realm.	O
Studies	B-T062
show	O
that	O
a	O
significant	B-T078
proportion	B-T081
of	O
the	O
population	B-T098
has	O
discordant	B-T077
LDL	B-T109
particle number	B-T081
and	O
cholesterol	B-T109
indices	B-T170
[	O
non-HDL cholesterol	B-T109
(	O
HDL-C	B-T109
)].	O
Data	O
also	O
show	O
that	O
risk	O
prediction	O
may	O
be	O
improved	O
when	O
using	O
information	B-T078
on	O
LDL	B-T109
particle number	B-T081
in	O
patients	B-T101
with	O
discordant	B-T077
particle number	B-T081
and	O
cholesterol	B-T109
data.	O
Yet,	O
most	O
of	O
the	O
current	O
CVD	B-T047
guidelines	B-T170
conclude	O
that	O
LDL	B-T109
particle number	B-T081
is	O
not	O
superior	O
to	O
cholesterol	B-T109
indices	B-T170
,	O
including	O
non-HDL-C	B-T109
concentrations	B-T081
,	O
in	O
predicting	O
CVD	B-T047
risk	B-T078
.	O
LDL	B-T109
particle size	B-T081
,	O
on	O
the	O
other	O
hand,	O
has	O
not	O
been	O
independently	O
associated with	B-T080
CVD	B-T047
risk	B-T078
after	O
adjustment	B-T169
for	O
other	O
risk factors	B-T033
such	O
as	O
LDL cholesterol	B-T109
,	O
triglycerides	B-T109
,	O
and	O
HDL-C	B-T109
and	O
that	O
routine	O
use	O
of	O
information	B-T078
pertaining	O
to	O
particle size	B-T081
to	O
determine	O
and	O
manage	O
patients'	B-T101
risk	B-T078
is	O
not	O
yet	O
justified.	O
Additional	B-T169
studies	B-T062
are	O
required	O
to	O
settle	O
the	O
debate	B-T052
on	O
which	O
of	O
cholesterol	B-T109
indices	B-T170
and	O
LDL	B-T109
particle number	B-T081
is	O
the	O
best	O
predictor	O
of	O
CVD	B-T047
risk	B-T078
,	O
and	O
if	O
such	O
measures	B-T081
should	O
be	O
integrated	O
in	O
clinical practice	B-T061
.	O

The	O
emerging contribution	B-T052
of	O
social wasps	B-T204
to	O
grape rot disease	B-T047
ecology	B-T090
Grape sour (bunch) rot	B-T047
is	O
a	O
polymicrobial disease	B-T047
of	O
vineyards	B-T083
that	O
causes	O
millions	B-T081
of	O
dollars	B-T081
in	O
lost revenue	B-T081
per year	B-T079
due	O
to	O
decreased	B-T081
quality	B-T080
of	O
grapes	B-T168
and	O
resultant wine	B-T168
.	O
The	O
disease	B-T047
is	O
associated with	B-T080
damaged	B-T169
berries	B-T168
infected	B-T033
with	O
a	O
community	B-T096
of	O
acetic acid bacteria	B-T007
,	O
yeasts	B-T004
,	O
and	O
filamentous fungi	B-T004
that	O
results	O
in	O
rotting	B-T067
berries	B-T168
with	O
high	B-T080
amounts	B-T081
of	O
undesirable	O
volatile	B-T080
acidity	B-T103
.	O
Many	O
insect	B-T204
species	B-T185
cause	O
the	O
initial	B-T079
grape	B-T168
berry	B-T168
damage	B-T169
that	O
can	O
lead	O
to	O
this	O
disease	B-T047
,	O
but	O
most	O
studies	B-T062
have	O
focused	B-T169
on	O
the	O
role	B-T077
of	O
fruit flies	B-T204
in	O
facilitating	O
symptoms	B-T184
and	O
vectoring	B-T204
the	O
microorganisms	B-T001
of	O
this	O
disease	B-T047
complex	B-T080
.	O
Like	O
fruit flies	B-T204
,	O
social wasps	B-T204
are	O
abundant	B-T080
in	O
vineyards	B-T083
where	O
they	O
feed	O
on	O
ripe berries	B-T168
and	O
cause	O
significant	B-T078
damage	B-T169
,	O
while	O
also	O
dispersing	B-T082
yeasts	B-T004
involved	B-T169
in	O
wine	B-T168
fermentation	B-T044
.	O
Despite	O
this,	O
their	O
possible	O
role	B-T077
in	O
disease	B-T047
facilitation	O
and	O
dispersal of grape rots	B-T047
has	O
not	O
been	O
explored.	O
We	O
tested	B-T169
the	O
hypothesis	B-T078
that	O
the	O
paper wasp	B-T204
Polistes dominulus	B-T129
could	O
facilitate	O
grape sour rot	B-T047
in	O
the	O
absence	B-T169
of	O
other	O
insect vectors	B-T204
.	O
Using	O
marker gene sequencing	B-T059
we	O
characterized	B-T052
the	O
bacterial	B-T007
and	O
fungal	B-T004
community	B-T096
of	O
wild-caught adults	B-T100
.	O
We	O
used	O
a	O
sterilized	O
foraging arena	B-T082
to	O
determine	O
if	O
these	O
wasps	B-T204
transfer	O
viable	B-T080
microorganisms	B-T001
when	O
foraging	B-T055
.	O
We	O
then	O
tested	B-T169
if	O
wasps	B-T204
harboring	O
their	O
native	B-T098
microbial	B-T001
community	B-T096
,	O
or	O
those	O
inoculated	B-T061
with	O
sour rot	B-T047
,	O
had	O
an	O
effect	B-T080
on	O
grape sour rot	B-T047
incidence	B-T081
and	O
severity	B-T080
using	O
a	O
laboratory foraging arena	B-T083
.	O
We	O
found	O
that	O
all	O
wasps	B-T204
harbor	O
some	O
portion	O
of	O
the	O
sour rot	B-T047
microbial	B-T001
community	B-T096
and	O
that	O
they	O
have	O
the	O
ability	B-T032
to	O
transfer	O
viable	B-T080
microorganisms	B-T001
when	O
foraging	B-T055
.	O
Foraging	B-T055
by	O
inoculated	B-T061
and	O
uninoculated wasps	B-T204
led	O
to	O
an	O
increase	B-T169
in	O
berry rot disease	B-T047
symptom	B-T184
severity	B-T080
and	O
incidence	B-T081
.	O
Our	O
results	B-T033
indicate	O
that	O
paper wasps	B-T204
can	O
facilitate	O
sour rot diseases	B-T047
in	O
the	O
absence	B-T169
of	O
other vectors	B-T204
and	O
that	O
the	O
mechanism	B-T169
of	O
this	O
facilitation	O
may	O
include	O
both	O
increasing	B-T169
host	B-T001
susceptibility	B-T201
and	O
transmitting	B-T169
these	O
microbial	B-T001
communities	B-T096
to	O
the	O
grapes	B-T168
.	O
Social wasps	B-T204
are	O
understudied	O
but	O
relevant players	B-T080
in	O
the	O
sour rot	B-T047
ecology	B-T090
of	O
vineyards	B-T083
.	O

Low-intensity pulsed ultrasound	B-T070
reduces	O
periodontal atrophy	B-T047
in	O
occlusal	B-T042
hypofunctional	B-T046
teeth	B-T023
To	O
clarify	O
whether	O
low-intensity pulsed ultrasound	B-T070
(	O
LIPUS	B-T070
)	O
exposure	O
has	O
recovery	O
effects	O
on	O
the	O
hypofunctional	B-T046
periodontal ligament	B-T023
(	O
PDL	B-T023
)	O
and	O
interradicular alveolar bone	B-T023
(	O
IRAB	B-T023
).	O
Twelve-	O
week	B-T079
-old	O
male	B-T032
Sprague-Dawley rats	B-T015
were	O
divided	O
into	O
three	O
groups	B-T098
(n	O
=	O
5	O
each):	O
a	O
normal occlusion	B-T042
(C)	O
group	B-T098
,	O
an	O
occlusal	B-T042
hypofunction	B-T046
(H)	O
group	B-T098
,	O
and	O
an	O
occlusal hypofunction group	B-T098
subjected	O
to	O
LIPUS	B-T070
(HL)	O
treatment	B-T061
.	O
Hypofunctional	B-T046
occlusion	B-T042
of	O
the	O
maxillary first molar	B-T023
(	O
M1	B-T023
)	O
of	O
the	O
H	B-T098
and	O
HL groups	B-T098
was	O
induced	O
by	O
the	O
bite-raising technique	B-T058
.	O
Only	O
the	O
HL group	B-T098
was	O
irradiated	O
with	O
LIPUS	B-T070
for	O
5	O
days	B-T079
.	O
The	O
IRAB	B-T023
and	O
PDL	B-T023
of	O
M1	B-T023
were	O
examined	O
by	O
microcomputed tomography	B-T060
(	O
micro-CT	B-T060
)	O
analysis	B-T062
.	O
To	O
quantify	O
mRNA	B-T114
expression	B-T045
of	O
cytokines	B-T116
involved	O
in	O
PDL	B-T023
proliferation	B-T169
and	O
development	B-T169
,	O
real-time reverse transcription quantitative PCR	B-T063
(	O
qRT-PCR	B-T063
)	O
was	O
performed	O
for	O
twist family bHLH transcription factor 1	B-T028
(	O
Twist1	B-T028
),	O
periostin	B-T028
,	O
and	O
connective tissue growth factor	B-T028
(	O
CTGF	B-T028
)	O
in	O
the	O
PDL	B-T023
samples	B-T167
.	O
Micro-CT	B-T060
analysis	B-T062
showed	O
that	O
the	O
PDL	B-T023
volume	B-T081
was	O
decreased	O
in	O
the	O
H group	B-T098
compared	O
with	O
that	O
of	O
the	O
C	B-T098
and	O
HL groups	B-T098
.	O
Both	O
bone volume	B-T032
per	O
tissue volume	B-T081
(	O
BV	B-T032
/	O
TV	B-T081
)	O
of	O
IRAB	B-T023
was	O
decreased	O
in	O
the	O
H group	B-T098
compared	O
with	O
that	O
in	O
the	O
C group	B-T098
.	O
LIPUS	B-T070
exposure	O
restored	O
BV	B-T032
/	O
TV	B-T081
in	O
the	O
IRAB	B-T023
of	O
the	O
HL group	B-T098
.	O
qRT-PCR	B-T063
analysis	B-T062
showed	O
that	O
Twist1	B-T028
,	O
periostin	B-T028
,	O
and	O
CTGF	B-T028
mRNA	B-T114
levels	B-T080
were	O
decreased	O
in	O
the	O
H group	B-T098
and	O
increased	O
in	O
the	O
HL group	B-T098
.	O
LIPUS	B-T070
exposure	O
reduced	O
the	O
atrophic	B-T046
changes	B-T169
of	O
alveolar bone	B-T023
by	O
inducing	B-T169
the	O
upregulation	B-T044
of	O
periostin	B-T028
and	O
CTGF	B-T028
expression	B-T045
to	O
promote	O
PDL	B-T023
healing	B-T040
after	O
induction	B-T061
of	O
occlusal	B-T042
hypofunction	B-T046
.	O

Radiologic assessment	B-T060
of	O
quality	O
of	O
root canal fillings	B-T061
and	O
periapical status	B-T082
in	O
an	O
Austrian	B-T098
subpopulation	B-T098
-	O
An	O
observational study	B-T062
Progress	B-T169
in	O
endodontic techniques	B-T061
and	O
methodological	O
advances	O
have	O
altered	O
root canal therapy	B-T061
over	O
the	O
last	O
decades.	O
These	O
techniques	O
and	O
methods	O
need	O
periodical	B-T170
documentation	B-T170
.	O
This	O
observational study	B-T062
determined	O
the	O
current	O
prevalence	B-T081
of	O
endodontic treatments,	B-T061
and	O
investigated	B-T169
the	O
relationship	O
of	O
various	O
factors	O
with	O
the	O
periapical status	B-T082
in	O
a	O
Lower	O
Austrian	B-T098
subpopulation	B-T098
.	O
One	O
thousand	O
orthopantomograms	B-T060
of	O
first-time	O
university	B-T073
adult	O
patients	B-T101
radiographed	B-T060
at	O
an	O
outpatient clinic	B-T073
were	O
evaluated	B-T058
.	O
For	O
each	O
tooth	B-T023
,	O
the	O
presence	B-T033
of	O
periradicular pathosis	B-T047
and/or	O
endodontic treatment	B-T061
was	O
recorded,	O
as	O
was	O
the	O
quality	O
of	O
(post-)	O
endodontic treatment	B-T061
(	O
homogeneity	B-T080
and	O
length	O
of	O
root canal fillings	B-T061
;	O
preparation failures	B-T033
;	O
posts	B-T074
/	O
screws	B-T074
;	O
apicoectomies	B-T061
;	O
coronal restorations	B-T061
).	O
Two	O
evaluators	B-T097
,	O
blinded	B-T062
to	O
each	O
other,	O
scored	B-T081
all	O
teeth	B-T023
.	O
In	O
cases	O
of	O
disagreement,	O
they	O
joined	O
for	O
a	O
consensus	O
score	B-T081
.	O
In	O
all,	O
22,586	O
teeth were counted	B-T081
.	O
Of	O
these,	O
2,907	O
teeth	B-T023
(12.9%)	O
had	O
periapical pathosis	B-T047
,	O
while	O
2,504	O
teeth	B-T023
had	O
undergone	O
root canal treatment	B-T061
.	O
Of	O
the	O
endodontically treated teeth	B-T047
,	O
52%	O
showed	O
no	O
radiographic	B-T070
signs	O
of	O
apical periodontitis	B-T047
,	O
while	O
44.9%	O
had	O
overt	O
apical lesions	B-T047
,	O
and	O
3,1%	O
revealed	O
widened periodontal ligament space	B-T047
.	O
The	O
majority	O
of	O
the	O
root canal fillings	B-T061
was	O
inhomogeneous	O
(70.4%);	O
75.4%	O
were	O
rated	O
too	O
short,	O
and	O
3.8%	O
too	O
long.	O
The	O
presence	B-T033
of	O
apical	B-T023
pathosis	B-T047
was	O
significantly correlated	B-T080
(	O
odds ratio	B-T081
(	O
OR	B-T081
)	O
2.556	O
[	O
confidence interval	B-T081
(	O
CI	B-T081
)	O
2.076-3.146];	O
P<0.0001)	O
with	O
poor	O
root canal fillings	B-T061
(length	O
and	O
homogeneity	B-T080
).	O
Posts	B-T074
or	O
screws	B-T074
positively	O
affected	O
periapical status	B-T082
(	O
OR	B-T081
1.853	O
[CI	O
1.219-2.819];	O
P	O
=	O
0.004),	O
but	O
endodontically treated posterior teeth	B-T047
were	O
infrequently	O
restored	B-T061
(	O
posts	B-T074
,	O
7.5%;	O
screws	B-T074
,	O
2.7%).	O
Best	O
results	O
were	O
found	O
for	O
teeth	B-T023
with	O
both	O
appropriate	O
endodontic treatment	B-T061
and	O
adequate	O
coronal restoration	B-T061
.	O
A	O
high prevalence	B-T081
of	O
periradicular radiolucencies	B-T033
was	O
observed	O
with	O
root canal filled teeth	B-T023
,	O
along	O
with	O
high	O
numbers	O
of	O
unmet	O
treatment	B-T061
needs.	O
Periapical	B-T082
health	B-T078
was	O
associated with	B-T080
adequate	O
root canal obturation	B-T061
and	O
high-grade	O
postendodontic restorations	B-T061
,	O
and	O
quality	O
regarding	O
these	O
latter	O
aspects	O
is	O
considered	O
mandatory	O
to	O
promote	O
periapical	B-T082
health	B-T078
.	O

Chemical composition	B-T070
and	O
amino acid	B-T116
digestibility	B-T081
of	O
soybean meal	B-T168
produced	O
in	O
the	O
United States	B-T083
,	O
China	B-T083
,	O
Argentina	B-T083
,	O
Brazil	B-T083
,	O
or	O
India	B-T083
An	O
experiment	O
was	O
conducted	O
to	O
compare	O
nutritional	B-T080
composition	B-T070
of	O
soybean meal	B-T168
(	O
SBM	B-T168
)	O
produced	O
in	O
China	B-T083
,	O
Argentina	B-T083
,	O
Brazil	B-T083
,	O
the	O
U.S	B-T083
.,	O
or	O
India	B-T083
and	O
the	O
apparent ileal digestibility	B-T081
(	O
AID	B-T081
)	O
and	O
the	O
standardized ileal digestibility	B-T081
(	O
SID	B-T081
)	O
of	O
CP	B-T116
and	O
AA	B-T116
in	O
these	O
SBM	B-T168
when	O
fed	O
to	O
growing	O
pigs	B-T015
.	O
Five	O
sources	O
of	O
SBM	B-T168
from	O
China	B-T083
,	O
Argentina	B-T083
,	O
Brazil	B-T083
,	O
and	O
the	O
U.S	B-T083
.,	O
and	O
4	O
sources	O
from	O
India	B-T083
were	O
collected	O
for	O
a	O
total	O
of	O
24	O
sources	O
of	O
SBM	B-T168
.	O
All	O
samples	O
were	O
analyzed	O
for	O
energy	B-T081
,	O
DM	B-T167
,	O
and	O
nutrients	B-T168
,	O
and	O
each	O
source	O
was	O
included	O
in	O
a	O
cornstarch based diet	B-T109
in	O
which	O
SBM	B-T168
was	O
the	O
only	O
AA	B-T116
contributing	O
ingredient	B-T120
.	O
An	O
N-free diet	B-T168
was	O
also	O
formulated.	O
Twenty-five	O
barrows	O
(initial	O
BW:	O
30.53	O
±	O
1.73	O
kg)	O
were	O
equipped	O
with	O
a	O
T-cannula	O
in	O
the	O
distal ileum	B-T029
and	O
randomly	O
allotted	O
to	O
a	O
25	O
×	O
8	O
Youden square design	B-T062
with	O
25	O
diets	B-T168
and	O
8	O
periods	B-T079
.	O
Results	O
indicate	O
that	O
the	O
concentration	B-T081
of	O
CP	B-T116
was	O
greater	O
(<	O
0.05)	O
in	O
SBM	B-T168
from	O
Brazil	B-T083
and	O
India	B-T083
(49.3	O
and	O
49.5%,	O
respectively)	O
than	O
in	O
SBM	B-T168
from	O
China	B-T083
,	O
Argentina	B-T083
,	O
or	O
the	O
U.S	B-T083
.	O
(45.1,	O
46.7,	O
and	O
47.3%,	O
respectively,	O
as-fed	O
basis).	O
The	O
concentration	B-T081
of	O
most	O
indispensable	O
AA	B-T116
followed	O
the	O
same	O
pattern	O
as	O
CP	B-T116
with	O
the	O
exception	O
that	O
SBM	B-T168
from	O
the	O
U.S	B-T083
.	O
contained	O
more	O
(<	O
0.05)	O
indispensable	O
AA	B-T116
than	O
SBM	B-T168
from	O
China	B-T083
or	O
Argentina	B-T083
.	O
However,	O
SBM	B-T168
from	O
India	B-T083
contained	O
more	O
(<	O
0.05)	O
trypsin inhibitors	B-T116
than	O
SBM	B-T168
from	O
the	O
other	O
countries	B-T083
.	O
A	O
greater	O
(<	O
0.05)	O
AID	B-T081
and	O
SID	B-T081
of	O
CP	B-T116
and	O
most	O
AA	B-T116
was	O
observed	O
in	O
SBM	B-T168
from	O
the	O
U.S	B-T083
.	O
compared	O
with	O
SBM	B-T168
from	O
Brazil	B-T083
,	O
Argentina	B-T083
,	O
and	O
India	B-T083
,	O
but	O
there	O
were	O
no	O
differences	O
between	O
SBM	B-T168
from	O
the	O
U.S	B-T083
.	O
and	O
SBM	B-T168
from	O
China	B-T083
.	O
However,	O
because	O
of	O
the	O
lower	O
concentration	B-T081
of	O
AA	B-T116
in	O
SBM	B-T168
from	O
China	B-T083
,	O
the	O
concentration	B-T081
of	O
standardized ileal digestible	B-T081
AA	B-T116
in	O
SBM	B-T168
from	O
China	B-T083
was	O
less	O
(<	O
0.05)	O
than	O
in	O
SBM	B-T168
from	O
the	O
U.S	B-T083
.	O
Soybean	O
meal	O
from	O
the	O
U.S	B-T083
.	O
or	O
Brazil	B-T083
had	O
less	O
(<	O
0.05)	O
variability	O
in	O
SID	B-T081
values	O
than	O
SBM	B-T168
from	O
Argentina	B-T083
,	O
China	B-T083
,	O
or	O
India	B-T083
.	O
In	O
conclusion,	O
the	O
SID	B-T081
of	O
CP	B-T116
and	O
AA	B-T116
is	O
dependent	O
on	O
the	O
country	B-T083
where	O
the	O
SBM	B-T168
is	O
produced.	O
This	O
difference	O
and	O
the	O
variability	O
within	O
each	O
country	B-T083
should	O
be	O
evaluated	O
when	O
formulating diets	B-T061
for	O
pigs	B-T015
.	O

Developing	B-T169
understanding	B-T041
of	O
object	B-T072
fall	B-T033
:	O
Going	O
beyond	O
inhibitory	B-T052
processes	B-T067
A	O
study	B-T062
is	O
reported	B-T170
where	O
118	O
participants	B-T098
aged	B-T032
between	O
10	O
years	O
and	O
early	B-T079
20s	O
drew	O
the	O
trajectories	B-T079
they	O
expected	B-T170
objects	B-T072
to	O
follow	B-T169
as	O
they	O
fell	B-T033
.	O
The	O
younger	B-T079
participants	B-T098
typically	B-T080
anticipated	B-T033
backward	B-T082
trajectories	B-T079
during	O
fall	B-T033
from	O
moving	B-T040
carriers	B-T073
while	O
forward	B-T082
but	O
non-parabolic trajectories	B-T079
were	O
relatively	B-T080
more	B-T081
frequent	B-T079
amongst	O
the	O
older participants	B-T098
.	O
Both	O
patterns	B-T082
suggest	B-T078
strong	B-T080
sociocultural	B-UnknownType
influences	B-T077
,	O
with	O
implications	B-T078
for	O
models	B-T170
that	O
regard	O
development	B-T169
in	O
this	O
area	B-T078
as	O
purely	B-T080
the	O
inhibition	B-T052
of	O
principles	B-UnknownType
established	B-T080
in	O
infancy	B-T079
.	O
Statement	B-T078
of	O
contribution	B-T052
What	O
is	O
already	O
known	B-T080
on	O
this	O
subject	B-T096
?	O
Research	B-T062
with	O
infants	B-T100
demonstrates	B-T080
an	O
early	B-T079
-	O
established	B-T080
belief	B-T078
that	O
dropped	B-T052
objects	B-T072
fall	B-T033
straight	B-T082
down	B-T082
.	O
The	O
erroneous	B-T078
expectations	B-T078
that	O
pre-schoolers	B-T100
hold	B-T052
about	O
object	B-T072
fall	B-T033
are	O
consistent with	B-T078
failure	B-T055
to	O
inhibit	B-T052
the	O
presumption	B-T078
of	O
straight	B-T082
-	O
down	B-T082
fall	B-T033
,	O
in	O
contexts	B-T078
where	O
it	O
is	O
inappropriate	B-T080
.	O
What	O
does	O
this	O
study	B-T062
add?	O
The	O
research	B-T062
replicates	B-T169
and	O
extends	B-T169
research	B-T062
with	O
older participants	B-T098
,	O
which	O
indicates	B-T078
errors	B-T080
that	O
cannot	O
be	O
explained	B-T058
via	O
failed	B-T169
inhibition	B-T052
of	O
straight	B-T082
-	O
down	B-T082
fall	B-T033
.	O
It	O
is	O
the	O
first	O
study	B-T062
to	O
trace	O
patterns	B-T082
of	O
errors	B-T080
across	O
late	B-T079
childhood	B-T079
,	O
adolescence	B-T079
and	O
early	B-T079
adulthood	B-T079
.	O
A	O
consequence of	B-T169
the	O
findings	B-T033
is	O
that	O
adequate	B-T080
modelling	B-T077
in	O
developmental psychology	B-T091
must	O
consider	B-T078
multilayered	B-T077
interactions	B-T169
between	O
prior	B-T079
representations	B-T052
and	O
sociocultural	B-UnknownType
experiences	B-T041
.	O

Attenuation	B-T052
of	O
High Glucose	B-T109
-	O
Induced	B-T169
Rat	B-T015
Cardiomyocyte	B-T025
Apoptosis	B-T043
by	O
Exendin-4	B-T116
via	O
Intervention	B-T061
of	O
HO-1	B-T116
/	O
Nrf-2	B-T116
and	O
the	O
PI3K/AKT Signaling Pathway	B-T169
Exendin-4	B-T116
,	O
a	O
glucagon-like peptide-1 receptor agonist	B-T121
,	O
demonstrated	O
cytoprotective actions	B-T039
beyond	O
glycemic control	B-T033
in	O
recent	O
studies.	O
The	O
aims	B-T078
of	O
the	O
present	O
study	B-T062
were	O
to	O
investigate	B-T169
the	O
effects of	B-T080
exendin-4	B-T116
on	O
high glucose	B-T109
(	O
HG	B-T109
)-	O
induced	B-T169
cardiomyocyte	B-T025
apoptosis	B-T043
and	O
the	O
possible	O
mechanisms	B-T169
.	O
Rat	B-T015
cardiomyocytes	B-T025
were	O
divided	O
into	O
3	O
groups	B-UnknownType
:	O
normal glucose	B-T109
group	B-UnknownType
(	O
NG	B-T109
group	B-UnknownType
),	O
HG	B-T109
group	B-UnknownType
and	O
HG	B-T109
+	O
exendin-4	B-T116
group	B-UnknownType
(	O
HG	B-T109
+	O
Ex	B-T116
Group	B-UnknownType
).	O
Cardiomyocyte	B-T025
apoptosis	B-T043
was	O
evaluated	O
by	O
double-staining	B-T059
with	O
annexin V-fluorescein isothiocyanate	B-T109
(	O
FITC	B-T109
)/	O
propidium iodide	B-T109
(	O
PI	B-T109
)	O
and	O
flow cytometry	B-T059
.	O
Intracellular	B-T082
reactive oxygen species (ROS)	B-T123
production	B-T169
was	O
detected	B-T033
by	O
2’,7’-dichlorodihydrofluorescein diacetate	B-T109
(	O
DCHF-DA	B-T109
)	O
incubation	B-T059
and	O
fluorescence microscopy	B-T059
.	O
LY294002	B-T109
(	O
LY	B-T109
),	O
a	O
phosphoinositide 3-kinase	B-T116
(	O
PI3K	B-T116
)	O
pathway	B-T044
inhibitor	B-T080
,	O
was	O
added	O
to	O
the	O
medium	B-T130
of	O
the	O
HG	B-T109
+	O
Ex	B-T116
+	O
LY	B-T109
Group	B-UnknownType
for	O
further	O
western blot analysis	B-T059
.	O
The	O
proteins	B-T116
analyzed	B-T062
involved	O
oxidative stress	B-T049
-	O
associated proteins	B-T116
,	O
heme oxygenase-1	B-T116
(	O
HO-1	B-T116
)	O
and	O
nuclear factor E2-related factor 2	B-T116
(	O
Nrf-2	B-T116
),	O
and	O
apoptosis	B-T043
-	O
associated proteins	B-T116
,	O
caspase-3	B-T116
,	O
Bax/B-cell lymphoma 2	B-T116
(	O
Bcl-2	B-T116
)	O
and	O
p-AKT	B-T116
/	O
AKT	B-T116
.	O
HG	B-T109
treatment	B-T169
induced	B-T169
cardiomyocyte	B-T025
apoptosis	B-T043
(P	O
=	O
0.00)	O
and	O
clearly	O
upregulated	B-T044
ROS	B-T123
production	B-T169
(P	O
=	O
0.00);	O
exendin-4	B-T116
co-incubation	B-T059
also	O
ameliorated	O
cardiomyocyte	B-T025
apoptosis	B-T043
(P	O
=	O
0.004)	O
and	O
decreased	B-T081
ROS	B-T123
(P	O
=	O
0.00)	O
level	B-T080
significantly	B-T078
.	O
HO-1	B-T116
and	O
Nrf-2	B-T116
protein expression	B-T045
levels	B-T080
decreased	B-T081
significantly	B-T078
in	O
the	O
HG	B-T109
group	B-UnknownType
(P	O
<	O
0.05),	O
but	O
the	O
levels	B-T080
were	O
elevated	B-T080
by	O
exendin-4	B-T116
intervention	B-T061
(P	O
<	O
0.05).	O
Furthermore,	O
exendin-4	B-T116
attenuated	B-T052
HG	B-T109
-	O
induced	B-T169
higher	O
protein expression	B-T045
,	O
including	O
cleaved	O
caspase-3	B-T116
and	O
Bax	B-T116
,	O
increased	B-T081
the	O
expression	B-T045
of	O
Bcl-2 protein	B-T116
(P	O
<	O
0.05).	O
However,	O
these	O
impacts	B-T080
of	O
exendin-4	B-T116
were	O
counteracted	O
significantly	B-T078
by	O
co-incubation	B-T059
with	O
LY294002	B-T109
.	O
In	O
addition,	O
exendin-4	B-T116
ameliorated	O
HG	B-T109
-	O
induced	B-T169
p-AKT	B-T116
/	O
AKT	B-T116
lower expression	B-T045
,	O
and	O
this	O
impact	B-T080
was	O
also	O
suppressed	B-T169
by	O
LY294002	B-T109
.	O
Exendin-4	B-T116
ameliorates	O
HG	B-T109
-	O
induced	B-T169
cardiomyocyte	B-T025
apoptosis	B-T043
,	O
and	O
the	O
mechanisms	B-T169
may	O
involve	O
anti-oxidative stress	B-T044
via	O
the	O
HO-1	B-T116
/	O
Nrf-2	B-T116
system,	O
as	O
well	O
as	O
intervention	B-T061
of	O
the	O
PI3K/AKT signaling pathway	B-T169
.	O

KMAP-O framework	B-T058
for	O
care management	B-T058
research	B-T062
of	O
patients	B-T101
with	O
type 2 diabetes	B-T047
To	O
review	B-T080
impacts	B-T080
of	O
interventions	B-T058
involving	O
self-management education	B-T058
,	O
health coaching	B-T065
,	O
and	O
motivational interviewing	B-T061
for	O
type 2 diabetes	B-T047
.	O
A	O
thorough	O
review	B-T078
of	O
the	O
scientific literature	B-T170
on	O
diabetes	B-T047
care and management	B-T058
was	O
executed	O
by	O
a	O
research	B-T062
team	B-T096
.	O
This	O
article	B-T170
summarizes	O
important	O
findings	B-T169
in	O
regard	O
to	O
the	O
validity	B-T081
of	O
developing	B-T169
a	O
comprehensive	B-T080
behavioral system	B-T078
as	O
a	O
framework	B-T058
for	O
empirical	B-T080
investigation	B-T058
.	O
The	O
behavioral system	B-T078
framework	B-T058
consists	O
of	O
patients	B-T101
'	O
knowledge	B-T033
(	O
K	B-T033
),	O
motivation	B-T041
(	O
M	B-T041
),	O
attitude	B-T041
(	O
A	B-T041
),	O
and	O
practice	B-T041
(	O
P	B-T041
)	O
as	O
predictor	B-T078
variables	B-T080
for	O
diabetes	B-T047
care outcomes	B-T170
(	O
O	B-T170
).	O
Care management	B-T058
strategies	O
or	O
health education programs	B-T058
serve	O
as	O
the	O
intervention	B-T058
variable	B-T080
that	O
directly	O
influences	B-T077
K	B-T033
,	O
M	B-T041
,	O
A	B-T041
,	O
and	O
P	B-T041
and	O
then	O
indirectly	O
affects	O
the	O
variability	B-T077
in	O
patient	B-T101
care outcomes	B-T170
of	O
patients	B-T101
with	O
type 2 diabetes	B-T047
.	O
This	O
review	B-T170
contributes	O
to	O
the	O
understanding	O
of	O
the	O
KMAP-O framework	B-T058
and	O
how	O
it	O
can	O
guide	B-T170
the	O
care management	B-T058
of	O
patients	B-T101
with	O
type 2 diabetes	B-T047
.	O
It	O
will	O
allow	O
the	O
tailoring	O
of	O
interventions	B-T058
to	O
be	O
more	O
effective	O
through	O
knowledge	B-T033
enhancement	B-T052
,	O
increased motivation	B-T041
,	O
attitudinal	B-T041
changes	B-T169
,	O
and	O
improved	B-T033
preventive practice	B-T058
to	O
reduce	B-T080
the	O
progression	B-T046
of	O
type 2 diabetes	B-T047
and	O
comorbidities	B-T078
.	O
Furthermore,	O
the	O
use of	B-T169
health information technology	B-T066
for	O
enhancing	B-T052
changes	B-T169
in	O
KMAP	B-T058
and	O
communications	B-T054
is	O
advocated	O
in	O
health promotion	B-T058
and	O
development	B-T169
.	O

Bayesian	B-T081
and	O
Phylogenic Approaches	B-T062
for	O
Studying	O
Relationships	B-T080
among	O
Table Olive Cultivars	B-T002
To	O
enhance	O
table olive tree	B-T002
authentication	B-T080
,	O
relationship	B-T080
,	O
and	O
productivity	B-T081
,	O
we	O
consider	O
the	O
analysis	B-T062
of	O
18	O
worldwide	O
table olive cultivars	B-T002
(	O
Olea europaea L.	B-T002
)	O
based	O
on	O
morphological	B-T080
,	O
biological	B-T080
,	O
and	O
physicochemical markers	B-T045
analyzed	O
by	O
bioinformatic	B-T170
and	O
biostatistic tools	B-T170
.	O
Accordingly,	O
we	O
assess	O
the	O
relationships	B-T080
between	O
the	O
studied	O
varieties	B-T080
,	O
on	O
the	O
one	O
hand,	O
and	O
the	O
potential	O
productivity	B-T081
-	O
quantitative	B-T081
parameter	B-T077
links	O
on	O
the	O
other	O
hand.	O
The	O
bioinformatic	B-T170
analysis	B-T062
based	O
on	O
the	O
graphical representation	B-T170
of	O
the	O
matrix of Euclidean distances	B-T062
,	O
the	O
principal components analysis	B-T081
,	O
unweighted pair group method	B-T062
with	O
arithmetic mean	B-T081
,	O
and	O
principal coordinate analysis	B-T062
(	O
PCoA	B-T062
)	O
revealed	O
three	O
major	O
clusters	B-T081
which	O
were	O
not	O
correlated	O
with	O
the	O
geographic	B-T082
origin	B-T033
.	O
The	O
statistical analysis	B-T062
based	O
on	O
Kendall's	O
and	O
Spearman correlation coefficients	B-T081
suggests	O
two	O
highly	O
significant	O
associations	B-T080
with	O
both	O
fruit	B-T168
color	B-T080
and	O
pollinization	B-T040
and	O
the	O
productivity	B-T081
character.	O
These	O
results	B-T169
are	O
confirmed	O
by	O
the	O
multiple linear regression prediction models	B-T081
.	O
In	O
fact,	O
based	O
on	O
the	O
coefficient of determination	B-T081
(	O
R (2)	B-T081
)	O
value,	O
the	O
best	O
model	B-T170
demonstrated	O
the	O
power	B-T081
of	O
the	O
pollinization	B-T040
on	O
the	O
tree	O
productivity	B-T081
(	O
R (2)	B-T081
=	O
0.846).	O
Moreover,	O
the	O
derived	O
directed acyclic graph	B-T170
showed	O
that	O
only	O
two	O
direct	O
influences	B-T077
are	O
detected	B-T033
:	O
effect	B-T080
of	O
tolerance	B-T080
on	O
fruit	B-T168
and	O
stone symmetry	B-T080
on	O
side	O
and	O
effect	B-T080
of	O
tolerance	B-T080
on	O
stone form	B-T080
and	O
oil	B-T109
content	B-T077
on	O
the	O
other	O
side.	O
This	O
work	O
provides	O
better	O
understanding	O
of	O
the	O
diversity	B-T080
available	O
in	O
worldwide	O
table olive cultivars	B-T002
and	O
supplies	O
an	O
important	O
contribution	O
for	O
olive	B-T002
breeding	B-T040
and	O
authenticity	B-T080
.	O

Wiedemann-Rautenstrauch Syndrome	B-T047
With	O
Bilateral	B-T082
Tarsal Kink	B-T019
:	O
Three	O
Sutures	B-T061
for	O
Correction	B-T169
The	O
authors	O
describe	O
a	O
5-	O
month-old	B-T079
male	B-T032
infant	B-T100
with	O
Wiedemann-Rautenstrauch syndrome	B-T047
,	O
which	O
is	O
an	O
extremely	O
rare	B-T080
condition	B-T047
.	O
He	O
had	O
tarsal kink	B-T019
in	O
upper eyelids	B-T023
in	O
both eyes	B-T023
.	O
The	O
authors	O
treated	B-T169
bilateral	B-T082
tarsal kink	B-T019
with	O
an	O
everting	B-T058
suture	B-T061
via	O
a	O
transconjunctival approach	B-T082
under	O
local anesthesia	B-T061
.	O

The	O
Indications	B-T078
for	O
Laparoscopic Pancreatectomy	B-T061
Laparoscopic pancreatectomy	B-T061
is	O
not	O
yet	O
established	O
as	O
a	O
routine procedure	B-T061
everywhere	O
in	O
Germany	B-T083
or	O
in	O
other	O
countries	B-T083
.	O
Few	O
data	B-T078
are	O
available	O
on	O
its	O
short- and long-term outcomes	B-T080
.	O
From	O
2008	O
onward,	O
a	O
working group	B-T098
initiated	O
by	O
10	O
centers	B-T073
and	O
currently	O
comprising	O
34	O
centers	B-T073
has	O
gathered	O
data	B-T078
on	O
all	O
cases	B-T169
of	O
laparoscopic pancreatectomy	B-T061
.	O
Procedures	B-T061
in	O
which	O
laparoscopy	B-T061
was	O
converted	O
to	O
open surgery	B-T061
are	O
also	O
included.	O
The	O
registry	B-T170
now	O
contains	O
550	O
data	B-T078
sets	O
representing	O
267	O
cases	B-T169
of	O
benign disease	B-T191
,	O
244	O
malignancies	B-T191
,	O
and	O
39	O
borderline tumors	B-T191
.	O
The	O
most	O
common	O
procedure	B-T061
was	O
laparoscopic left pancreatectomy	B-T061
,	O
followed	O
by	O
resection	B-T061
of	O
the	O
head of the pancreas	B-T023
and	O
tumor	B-T191
enucleation	B-T061
.	O
The	O
most	O
common	O
intraoperative complication	B-T046
was	O
hemorrhage	B-T046
,	O
with	O
a	O
frequency	O
of	O
3%.	O
The	O
rate	B-T081
of	O
conversion	B-T169
to	O
open surgery	B-T061
was	O
35%;	O
if	O
minilaparotomies	B-T058
are	O
excluded,	O
the	O
conversion	B-T169
rate	B-T081
was	O
only	O
16%.	O
39%	O
of	O
patients	B-T101
developed	O
a	O
pancreatic fistula	B-T047
after	O
surgery	B-T061
(usually	O
grade	O
A	O
or	O
B,	O
with	O
1.5%	O
grade	O
C)	O
and	O
3%	O
underwent	O
reoperation	B-T061
because	O
of	O
postoperative hemorrhage	B-T046
.	O
The	O
procedure-related mortality	B-T033
was	O
1.3%.	O
91%	O
of	O
the	O
patients	B-T101
reported	O
only	O
very	O
mild	O
postoperative pain	B-T184
.	O
6.7%	O
newly	O
developed	O
diabetes mellitus	B-T047
after	O
the	O
procedure	B-T061
.	O
The	O
patient	B-T101
cohort	B-T098
in	O
the	O
registry	B-T170
consists	O
of	O
persons	B-T098
who	O
were	O
selected	O
to	O
undergo	O
laparoscopic pancreatectomy	B-T061
by	O
the	O
participating	O
hospital	B-T073
teams	B-T096
,	O
and	O
the	O
data	B-T078
are	O
thus	O
inherently	O
affected	O
by	O
selection bias	B-T081
.	O
The	O
operative procedures	B-T061
that	O
they	O
underwent	O
reflect	O
the	O
current	O
practice	O
of	O
laparoscopic pancreatectomy	B-T061
in	O
Germany	B-T083
.	O
The	O
complication	B-T046
rates	B-T081
are	O
similar	O
to	O
those	O
of	O
open surgery	B-T061
.	O
Selection bias	B-T081
can	O
be	O
avoided	O
only	O
by	O
a	O
randomized trial	B-T062
.	O

Associations	O
of	O
NEUROD2	B-T028
polymorphisms	B-T045
and	O
change	B-T169
of	O
cognitive dysfunctions	B-T048
in	O
schizophrenia	B-T048
and	O
schizoaffective disorder	B-T048
after	O
eight	O
weeks	B-T079
of	O
antipsychotic	B-T121
treatment	B-T061
NEUROD2	B-T028
is	O
a	O
neurospecific helix-loop-helix	B-T082
transcription factor	B-T116
which	O
has	O
an	O
impact	B-T080
on	O
the	O
regulation	B-T045
of	O
glutamatergic	B-T116
and	O
GABAergic	B-T116
genes	B-T028
.	O
We	O
investigated	B-T169
an	O
association	O
of	O
NEUROD2	B-T028
with	O
neurocognitive dysfunctions	B-T048
in	O
schizophrenia	B-T048
and	O
schizoaffective disorder	B-T048
patients	B-T101
before	O
and	O
during	O
treatment	B-T061
with	O
different	O
second-generation antipsychotics	B-T121
.	O
Patients	B-T101
were	O
genotyped	B-T032
for	O
four	O
different	O
polymorphisms	B-T045
of	O
the	O
NEUROD2	B-T028
gene	B-T028
((	O
rs9889354(A/G	B-T045
),	O
rs1877032(C/T)	B-T045
,	O
rs12453682(C/T)	B-T045
and	O
rs11078918(C/G)	B-T045
).	O
Cognitive function	B-T041
was	O
assessed	B-T052
at	O
baseline	B-T081
and	O
week	B-T079
8.	O
Results	B-T169
of	O
individual	O
neuropsychological tests	B-T060
were	O
assigned	O
to	O
six	O
cognitive domains	B-T170
(reaction time	B-T079
and	O
quality	B-T080
;	O
executive function	B-T041
;	O
working	B-T078
,	O
verbal	B-T041
and	O
visual memory	B-T041
)	O
and	O
a	O
general	O
cognitive	B-T169
index	B-T170
.	O
167	O
patients	B-T101
were	O
included	O
in	O
the	O
study	B-T062
.	O
The	O
NEUROD2	B-T028
exonic polymorphism rs11078918	B-T045
showed	O
significant	O
associations	O
with	O
verbal memory	B-T041
and	O
executive functions	B-T041
,	O
whereas	O
the	O
NEUROD2	B-T028
polymorphism rs12453682	B-T045
was	O
significantly	O
associated	O
with	O
working	B-T078
and	O
verbal memory	B-T041
,	O
executive functions	B-T041
and	O
with	O
a	O
cognitive	B-T169
index	B-T170
.	O
Significant	O
associations	O
were	O
found	O
at	O
baseline	B-T081
and	O
after	O
eight	O
weeks	B-T079
.	O
Moreover,	O
significant	O
associations	O
between	O
the	O
change	B-T169
in	O
neuropsychological test	B-T060
results	B-T169
during	O
antipsychotic	B-T121
treatment	B-T061
and	O
the	O
NEUROD2	B-T028
polymorphisms	B-T045
rs11078918	B-T045
and	O
rs12453682	B-T045
were	O
observed.	O
Our	O
findings	O
suggest	O
that	O
the	O
NEUROD2 gene	B-T028
could	O
play	O
a	O
role	O
in	O
the	O
pathophysiology	B-T169
of	O
neurocognitive dysfunctions	B-T048
as	O
well	O
as	O
in	O
the	O
change	B-T169
of	O
cognitive symptoms	B-T184
under	O
antipsychotic	B-T121
treatment	B-T061
in	O
schizophrenia	B-T048
and	O
schizoaffective disorder	B-T048
.	O

New	B-T080
Diterpenoids	B-T109
from	O
Clerodendranthus spicatus	B-T002
Two	O
new	B-T080
diterpenoids	B-T109
,	O
neoorthosiphonones B	B-T109
and	O
C	B-T109
(	O
1	B-T109
and	O
2	B-T109
),	O
and	O
one	O
known	O
diterpenoid	B-T109
,	O
were	O
isolated	B-T169
from	O
the	O
aerial parts	B-T002
of	O
Clerodendranthus spicatus	B-T002
.	O
Their	O
structures	B-T082
including	O
absolute	B-T080
configurations	B-T082
were	O
determined by	B-T080
comprehensive	O
spectroscopic analyses	B-T059
and	O
X-ray crystallographic methods	B-T059
.	O
No	O
compound	B-T080
was	O
found	O
to	O
inhibit	B-T080
fibronectin	B-T116
production	B-T057
at	O
the	O
concentration	B-T081
of	O
20	O
μM.	O

Stalk	B-T017
versus	O
base	B-T017
invasion	B-T033
in	O
pT1	B-T033
papillary cancers of the bladder	B-T191
:	O
improved	O
substaging	O
system	O
predicting	O
risk	B-T078
of	O
progression	B-T046
Pathologic stage T1	B-T033
(	O
pT1	B-T033
)	O
bladder cancers	B-T191
are	O
a	O
clinically	B-T080
heterogeneous group	B-T080
.	O
However,	O
current	O
staging	B-T185
guidelines	O
for	O
superficially	B-T082
invasive cancers	B-T191
do	O
not	O
acknowledge	O
the	O
variability	B-T077
in	O
type	O
and	O
extent	O
of	O
lamina propria invasion	B-T033
in	O
papillary urothelial carcinomas	B-T191
(	O
PUC	B-T191
),	O
and	O
historically	O
proposed	O
substaging	O
systems	O
showed	O
either	O
high	O
inter-observer variation	B-T081
or	O
limited value	B-T169
in	O
predicting	O
patient outcomes	B-T058
.	O
Herein	O
we	O
reappraise	B-T058
pT1	B-T033
PUC	B-T191
substaging,	O
aiming	B-T078
to	O
identify	B-T080
a	O
novel	B-T080
scheme	B-T170
which	O
is	O
reproducible	B-T080
and	O
prognostically	B-T170
meaningful.	O
Stage pT1	B-T033
PUC	B-T191
diagnosed	B-T033
during	O
years	B-T079
1999-2015	O
were	O
retrospectively reviewed	B-T062
and	O
characterized	B-T052
as	O
focal	B-T082
invasion	B-T046
confined	O
to	O
papillary stalk	B-T017
,	O
focal	B-T082
invasion	B-T033
of	O
tumor	B-T191
base	B-T017
,	O
or	O
extensive	O
invasion	B-T033
of	O
tumor	B-T191
base	B-T017
.	O
Cases	B-T169
with	O
concurrent	B-T079
flat carcinoma in-situ	B-T033
,	O
angiolymphatic invasion	B-T033
,	O
absent	B-T169
muscularis propria	B-T024
,	O
or	O
clinically	B-T080
advanced disease	B-UnknownType
were	O
excluded	B-T169
.	O
We	O
calculated	O
cumulative	B-T080
incidence	B-T081
of	O
recurrence	B-T033
,	O
progression	B-T046
,	O
and	O
death	B-T040
by	O
tumor subtype	B-T185
and	O
evaluated	B-T058
differential risks	B-T033
using	O
log-rank tests	B-T170
and	O
Kaplan-Meier curves	B-T081
stratified	B-T080
by	O
type	B-T080
and	O
extent of invasion	B-T201
.	O
Among	O
62	O
patients	B-T101
satisfying	O
inclusion	B-T080
criteria	B-T078
,	O
22	O
of	O
29	O
patients	B-T101
with	O
base	B-T017
extensive	B-T080
invasion	B-T033
progressed	B-T169
while	O
4	O
of	O
13	O
with	O
base	B-T017
focal	B-T082
and	O
0	O
of	O
20	O
with	O
stalk	B-T017
only	O
invasion	B-T033
progressed	B-T169
.	O
There	O
was	O
strong	O
evidence	O
that	O
base	B-T017
extensive	O
patients	B-T101
had	O
higher	O
risk	B-T078
of	O
progression	B-T046
and	O
death	B-T040
due	O
to	O
bladder cancer	B-T191
than	O
base	B-T017
focal	B-T082
or	O
stalk	B-T017
only	O
counterparts	O
(P<0.0001).	O
However,	O
tumor subtype	B-T185
was	O
not	O
significantly	O
associated	O
with	O
risk	B-T078
of	O
recurrence	B-T033
(P=0.21).	O
We	O
propose	O
an	O
innovative	O
substaging	O
approach	O
for	O
reporting	O
site	O
and	O
extent	O
of	O
lamina propria invasion	B-T033
in	O
patients	B-T101
with	O
pT1	B-T033
PUC	B-T191
allowing	O
patient	B-T101
stratification	B-T080
for	O
risk	B-T078
of	O
progression	B-T046
.	O
This	O
article	O
is	O
protected	O
by	O
copyright.	O
All	O
rights	O
reserved.	O

Basic science	B-T062
and	O
pathogenesis	B-T046
of	O
ageing	B-T040
with	O
HIV	B-T047
:	O
potential	O
mechanisms	B-T169
and	O
biomarkers	B-T201
:	O
The	O
increased	O
prevalence	B-T081
of	O
age	B-T032
-related	O
comorbidities	B-T078
and	O
mortality	B-T081
is	O
worrisome	B-T033
in	O
ageing	B-T040
HIV-infected	B-T047
patients	B-T101
.	O
Here,	O
we	O
aim	B-T078
to	O
analyse	B-T062
the	O
different	O
ageing	B-T040
mechanisms	B-T169
with	O
regard	O
to	O
HIV infection	B-T047
.	O
Ageing	B-T040
results	O
from	O
the	O
time	B-T079
-	O
dependent	B-T169
accumulation	B-T033
of	O
random	O
cellular damage	B-T049
.	O
Epigenetic modifications	B-T045
and	O
mitochondrial DNA	B-T114
haplogroups	B-T032
modulate	B-T082
ageing	B-T040
.	O
In	O
antiretroviral treatment	B-T061
-controlled	O
patients	B-T101
,	O
epigenetic clock	B-T040
appears	O
to	O
be	O
advanced,	O
and	O
some	O
haplogroups	B-T032
are	O
associated	O
with	O
HIV infection	B-T047
severity	B-T080
.	O
Telomere shortening	B-T049
is	O
enhanced	O
in	O
HIV-infected	B-T047
patients	B-T101
because	O
of	O
HIV	B-T005
and	O
some	O
nucleoside analogue	B-T114
reverse transcriptase inhibitors	B-T121
.	O
Mitochondria	B-T026
-related	O
oxidative stress	B-T049
and	O
mitochondrial DNA	B-T114
mutations	B-T045
are	O
increased	O
during	O
ageing	B-T040
and	O
also	O
by	O
some	O
nucleoside analogue	B-T114
reverse transcriptase inhibitors	B-T121
.	O
Overall,	O
increased	O
inflammation	B-T046
or	O
'	O
inflammageing	B-T046
'	O
is	O
a	O
major	O
driver	O
of	O
ageing	B-T040
and	O
could	O
result	O
from	O
cell senescence	B-T043
with	O
secreted	O
proinflammatory mediators	B-T121
,	O
altered	O
gut microbiota	B-T001
,	O
and	O
coinfections	B-T047
.	O
In	O
HIV-infected	B-T047
patients	B-T101
,	O
the	O
level	B-T080
of	O
inflammation	B-T046
and	O
innate immunity	B-T032
activation	B-T052
is	O
enhanced	O
and	O
related	O
to	O
most	O
comorbidities	B-T078
and	O
to	O
mortality	B-T081
.	O
This	O
status	O
could	O
result,	O
in	O
addition	O
to	O
age	B-T032
,	O
from	O
the	O
virus	B-T005
itself	O
or	O
viral protein	B-T116
released	O
from	O
reservoirs	B-T078
,	O
from	O
HIV	B-T005
-enhanced	O
gut	B-T023
permeability	B-T070
and	O
dysbiosis	B-T046
,	O
from	O
antiretroviral treatment	B-T061
,	O
from	O
frequent	O
cytomegalovirus	B-T005
and	O
hepatitis C virus	B-T005
coinfections	B-T047
,	O
and	O
also	O
from	O
personal	O
and	O
environmental factors	B-T169
,	O
as	O
central	O
fat accumulation	B-T033
or	O
smoking	B-T055
.	O
Adaptive immune	B-T039
activation	B-T052
and	O
immunosenescence	B-T039
are	O
associated	O
with	O
comorbidities	B-T078
and	O
mortality	B-T081
in	O
the	O
general population	B-T098
but	O
are	O
less	O
predictive	B-T080
in	O
HIV-infected	B-T047
patients	B-T101
.	O
Biomarkers	B-T201
to	O
evaluate	B-T058
ageing	B-T040
in	O
HIV-infected	B-T047
patients	B-T101
are	O
required.	O
Numerous	O
systemic	B-T169
or	O
cellular inflammatory	B-T025
,	O
immune	B-T169
activation	B-T052
,	O
oxidative stress	B-T049
,	O
or	O
senescence	O
markers	B-T201
can	O
be	O
tested	B-T169
in	O
serum	B-T031
or	O
peripheral blood mononuclear cells	B-T025
.	O
The	O
novel	O
European	B-T083
Study	B-T062
to	O
Establish	O
Biomarkers	B-T201
of	O
Human Ageing MARK-AGE algorithm	B-T170
,	O
evaluating	B-T058
the	O
biological	B-T080
age	B-T032
,	O
is	O
currently	O
assessed	O
in	O
HIV-infected	B-T047
patients	B-T101
and	O
reveals	O
an	O
advanced	O
biological	B-T080
age	B-T032
.	O
Some	O
enhanced	O
inflammatory	B-T169
or	O
innate immune	B-T032
activation	B-T052
markers	B-T201
are	O
interesting	O
but	O
still	O
not	O
validated	O
for	O
the	O
patient's	B-T101
follow-up	B-T058
.	O
To	O
be	O
able	O
to	O
assess	O
patients	B-T101
'	O
biological	B-T080
age	B-T032
is	O
an	O
important	O
objective	O
to	O
improve	O
their	O
healthspan	B-T078
.	O

MESOTHELIAL CELL	B-T025
ADHERENCE	B-T169
TO	O
VASCULAR PROSTHESES	B-T074
AND	O
THEIR	O
SUBSEQUENT	B-T079
GROWTH	B-T040
IN VITRO	B-T080
Cell	B-T025
seeding	B-T059
may	O
decrease	B-T081
the	O
thrombogenicity	B-T046
of	O
implanted	B-T074
vascular grafts	B-T074
,	O
but	O
its	O
application	O
is	O
hampered	O
by	O
the	O
limited	O
availability of	B-T169
autologous	B-T080
endothelial cells	B-T025
.	O
Human	B-T016
peritoneal	B-T029
mesothelial cells	B-T025
have	O
blood flow	B-T039
supporting qualities	B-T080
and	O
are	O
readily available	B-T169
.	O
This	O
study	O
investigated	B-T169
the	O
adherence	B-T169
of	O
mesothelial cells	B-T025
to	O
vascular prostheses	B-T074
and	O
their	O
subsequent	B-T079
growth	B-T040
in vitro	B-T080
.	O
Circular	B-T082
pieces	B-T081
of	O
various	O
vascular	B-T080
prosthetic materials	B-T122
were	O
seeded	B-T059
with	O
51Chromium-labeled	B-T121
mesothelial	B-T025
and	O
endothelial cells	B-T025
and	O
left	O
for	O
either	O
5,	O
15,	O
30,	O
60,	O
and	O
120	O
minutes	B-T079
.	O
The	O
unattached	B-T033
cells	B-T025
were	O
removed	B-T080
and	O
the	O
degree	B-T081
of	O
cell	B-T025
attachment	B-T052
was	O
measured	B-T080
.	O
The	O
number	B-T081
of	O
mesothelial cells	B-T025
to	O
Dacron	B-T109
increased	B-T081
during	O
the	O
first	O
60	O
min	B-T079
up	O
to	O
35.2	O
%	O
of	O
the	O
seeded	B-T059
inoculum	B-T167
where	O
after	O
a	O
plateau	B-T081
was	O
reached	B-T033
.	O
Scanning electron microscopy	B-T059
showed	O
spreaded	B-T080
mesothelial cells	B-T025
adherent	B-T169
to	O
the	O
Dacron fibers	B-T109
.	O
A	O
significant	B-T078
increase	B-T169
in	O
adherence	B-T169
was	O
observed	B-T169
after	O
preincubation	B-T059
of	O
Dacron	B-T109
with	O
10	O
μg/mL	O
fibronectin	B-T116
,	O
but	O
no improvement	B-T033
was	O
found	B-T033
after	O
preincubation	B-T059
with	O
human	B-T016
serum albumin	B-T116
or	O
gelatin	B-T116
.	O
Mesothelial cells	B-T025
adhered	B-T067
better	O
to	O
Gelcoated	B-T080
than	O
to	O
Gelsealed	B-T080
or	O
plain Dacron	B-T109
.	O
The	O
adherence	B-T169
of	O
mesothelial cells	B-T025
to	O
ePTFE	B-T109
(	O
Teflon	B-T109
)	O
was	O
significantly	B-T078
poorer	B-T080
.	O
No significant	B-T033
differences	B-T080
in	O
adherence	B-T169
were	O
found	B-T033
between	O
mesothelial	B-T025
and	O
endothelial cells	B-T025
.	O
Mesothelial cell	B-T025
growth	B-T040
on	O
Dacron	B-T109
resulted	B-T169
in	O
a	O
modest increase	B-T169
in	O
the	O
number	B-T081
of	O
viable cells	B-T025
during	O
27	O
days	B-T079
,	O
which	O
implies	O
biocompatibility	B-T044
of	O
Dacron	B-T109
and	O
mesothelial cells	B-T025
in vitro	B-T080
.	O

Anterolateral	B-T082
entorhinal cortex	B-T023
volume	B-T081
predicted	O
by	O
altered	O
intra-item configural processing	B-T170
Recent	O
functional	O
imaging studies	B-T060
have	O
proposed	O
that	O
the	O
human	B-T016
entorhinal cortex	B-T023
is	O
subdivided	O
into	O
functionally	O
distinct	O
anterolateral	B-T082
(	O
alERC	B-T023
)	O
and	O
posteromedial	B-T082
(	O
pmERC	B-T023
)	O
subregions	B-T029
.	O
The	O
alERC	B-T023
overlaps	O
with	O
regions	O
that	O
are	O
affected	O
earliest	O
by	O
Alzheimer's disease	B-T047
pathology	B-T046
,	O
yet	O
its	O
cognitive function	B-T041
remains	O
poorly	O
understood.	O
Previous	O
human	B-T016
fMRI studies	B-T060
have	O
focused	O
on	O
its	O
role	O
in	O
object	B-T072
memory	B-T041
,	O
but	O
rodent	B-T015
studies	B-T008
on	O
the	O
putatively	O
homologous	O
lateral	O
entorhinal cortex	B-T023
suggest	O
that	O
it	O
also	O
plays	O
an	O
important	O
role	O
in	O
representing	O
spatial properties	B-T082
of	O
objects	B-T072
.	O
In	O
order	O
to	O
investigate	O
the	O
cognitive effects	B-T033
of	O
human	B-T016
alERC	B-T023
volume	B-T081
differences,	O
we	O
developed	O
an	O
eyetracking-based	O
task	O
to	O
evaluate	B-T058
intra-item configural processing	B-T170
(i.e.,	O
processing	B-T052
the	O
arrangement	B-T082
of	O
an	O
object's	B-T072
features),	O
and	O
used	O
manual segmentation	B-T058
based	O
on	O
a	O
recently-	O
developed protocol	B-T170
to	O
delineate	O
the	O
alERC	B-T023
/	O
pmERC	B-T023
as	O
well	O
as	O
other	O
medial temporal lobe	B-T023
(	O
MTL	B-T023
)	O
subregions	B-T029
.	O
In	O
a	O
group	O
of	O
older	O
adult	B-T100
men	B-T098
and	O
women	B-T098
at	O
varying	O
stages	B-T079
of	O
brain atrophy	B-T047
and	O
cognitive decline	B-T046
,	O
we	O
found	O
that	O
intra-item configural processing	B-T170
-	O
regardless	O
of	O
an	O
object's	B-T072
novelty	O
-	O
was	O
strongly	O
predicted	O
by	O
alERC	B-T023
volume	B-T081
,	O
but	O
not	O
by	O
the	O
volume	B-T081
of	O
any	O
other	O
MTL subregion	B-T023
.	O
These	O
results	O
provide	O
the	O
first	O
evidence	O
that	O
the	O
human	B-T016
alERC	B-T023
plays	O
a	O
role	O
in	O
supporting	O
a	O
distinct	O
aspect	O
of	O
object	B-T072
processing	B-T052
,	O
namely	O
attending	O
to	O
the	O
arrangement	B-T082
of	O
an	O
object's	B-T072
component	O
features.SIGNIFICANCE	O
STATEMENT	O
Alzheimer's disease	B-T047
pathology	B-T046
appears	O
earliest	O
in	O
brain regions	B-T029
that	O
overlap	O
with	O
the	O
anterolateral	B-T082
entorhinal cortex	B-T023
(	O
alERC	B-T023
).	O
However,	O
the	O
cognitive role	B-T041
of	O
the	O
alERC	B-T023
is	O
poorly	O
understood.	O
Previous	O
human studies	B-T062
treat	B-T061
the	O
alERC	B-T023
as	O
an	O
extension	O
of	O
the	O
neighboring	O
perirhinal cortex	B-T029
,	O
supporting	O
object	B-T072
memory	B-T041
.	O
Animal studies	B-T008
suggest	O
that	O
the	O
alERC	B-T023
may	O
support	O
the	O
spatial properties	B-T082
of	O
objects	B-T072
.	O
In	O
a	O
group	O
of	O
older	O
adult	B-T100
humans	B-T016
at	O
the	O
earliest stages	B-T079
of	O
cognitive decline	B-T046
,	O
we	O
show	O
that	O
alERC	B-T023
volume	B-T081
selectively	O
predicted	O
configural processing	B-T170
(	O
attention	B-T041
to	O
the	O
spatial arrangement	B-T082
of	O
an	O
object's	B-T072
parts).	O
This	O
is	O
the	O
first	O
study	O
to	O
demonstrate	O
a	O
cognitive role	B-T041
related	O
to	O
alERC	B-T023
volume	B-T081
in	O
humans	B-T016
.	O
This	O
task	O
can	O
be	O
adapted	O
to	O
serve	O
as	O
an	O
early detection method	B-T170
for	O
Alzheimer's disease	B-T047
pathology	B-T046
.	O

Alcohol brief intervention	B-T058
in	O
primary care	B-T058
:	O
Blood pressure	B-T040
outcomes	B-T033
in	O
hypertensive	B-T047
patients	B-T101
In	O
clinical trials	B-T062
alcohol brief intervention	B-T058
(	O
BI	B-T058
)	O
in	O
adult	B-T100
primary care	B-T058
has	O
been	O
efficacious	B-T080
in	O
reducing	B-T080
alcohol consumption	B-T055
,	O
but	O
we	O
know	O
little	O
about	O
its	O
impact	B-T080
on	O
health outcomes	B-T080
.	O
Hypertension	B-T047
is	O
a	O
prevalent	O
and	O
costly	O
chronic condition	B-T033
in	O
the	O
U.S.	B-T083
and	O
worldwide	B-T080
,	O
and	O
alcohol use	B-T055
is	O
a	O
modifiable	O
hypertension	B-T047
risk factor	B-T033
.	O
To	O
evaluate	O
the	O
effect	B-T080
of	O
receiving	O
BI	B-T058
for	O
unhealthy drinking	B-T055
on	O
blood pressure (BP) control	B-T040
among	O
adult	B-T100
hypertensive	B-T047
patients	B-T101
by	O
analyzing secondary data	B-UnknownType
from	O
a	O
clustered	B-T062
,	O
randomized controlled trial	B-T062
on	O
alcohol screening	B-T058
,	O
brief intervention	B-T058
and	O
referral to treatment	B-UnknownType
(	O
SBIRT	B-T058
)	O
implementation	B-T052
by	O
primary care physicians	B-T097
(	O
PCP intervention arm	B-T097
)	O
and	O
non-physician providers	B-T097
and	O
medical assistants	B-T097
(	O
NPP	B-T097
&	O
MA intervention arm	B-T097
)	O
in	O
a	O
large,	O
integrated health care delivery system	B-T093
.	O
Observational	B-T062
,	O
prospective cohort study	B-T062
.	O
3811	O
adult	B-T100
hypertensive	B-T047
primary care patients	B-T101
screening	B-T058
positive	O
for	O
past-year	B-T079
heavy drinking	B-T048
at	O
baseline	B-T081
,	O
of	O
which	O
1422	O
(37%)	O
had	O
an	O
electronic health record	B-T170
BP	B-T040
measure	O
at	O
baseline	B-T081
and	O
18-month	B-T079
follow-up	B-T058
.	O
Change in BP	B-T033
and	O
controlled BP	B-T040
(	O
systolic/diastolic BP	B-T032
<140/90	O
mmHg	B-T081
).	O
Overall	O
no	O
significant	O
associations	B-T080
were	O
found	O
between	O
alcohol BI	B-T058
and	O
BP change	B-T033
at	O
18-month	B-T079
follow-up	B-T058
when	O
analyzing	O
the	O
combined	O
sample	O
of	O
subjects	B-T098
in	O
both	O
intervention arms	B-T097
.	O
However,	O
moderation	O
analyses	O
found	O
that	O
receiving	O
BI	B-T058
for	O
positive	O
past-year	B-T079
unhealthy drinking	B-T055
was	O
positively	O
associated with	B-T080
better	O
BP control	B-T040
at	O
18months	B-T079
in	O
the	O
PCP intervention arm	B-T097
,	O
and	O
for	O
those	O
with	O
lower	O
heavy drinking	B-T048
frequency	B-T079
and	O
poor	O
BP control	B-T040
at	O
the	O
index screening	B-T058
.	O
Our	O
findings	O
suggest	O
that	O
hypertensive	B-T047
patients	B-T101
may	O
benefit	B-T081
from	O
receiving	O
physician	B-T097
brief intervention	B-T058
for	O
unhealthy alcohol use	B-T055
in	O
primary care	B-T058
.	O
Findings	O
also	O
highlight	O
potential	O
population-level benefits	B-T081
of	O
alcohol BI	B-T058
if	O
widely	O
applied,	O
suggesting	O
a	O
need	O
for	O
the	O
development	O
of	O
innovative	O
strategies	O
to	O
facilitate	O
SBIRT delivery	B-T058
in	O
primary care	B-T058
settings.	O

Unusual	B-T080
asymptomatic presentation	B-T047
of	O
bladder cancer	B-T191
metastatic to the penis	B-T191
Penile metastasis	B-T191
is	O
an	O
extremely rare event	B-T047
and	O
mainly	O
originate	O
from	O
primary	O
pelvic	B-T023
tumor sites	B-T082
such	O
us	O
urinary bladder	B-T023
,	O
gastro-intestinal tract	B-T022
and	O
prostate	B-T023
and	O
more	O
rarely	O
from	O
respiratory system	B-T022
,	O
bone tumors	B-T191
and	O
melanoma	B-T191
.	O
Here	O
we	O
describe	O
the	O
unusual	B-T080
presentation	B-T078
of	O
two	O
bladder urothelial cancer	B-T191
metastatic to	B-T169
the	O
penis	B-T023
with	O
no relevant clinical symptoms	B-T033
.	O
Namely,	O
a	O
69	O
years-old	O
man	O
with	O
a	O
warthy	O
lesions	B-T033
of	O
the	O
foreskin and the glans	B-UnknownType
misunderstood	O
for	O
a	O
condylomata	B-T047
that	O
at	O
histological	B-T059
and	O
immunohistochemical analysis	B-T059
showed	O
a	O
bladder urothelial carcinoma	B-T191
;	O
and	O
a	O
71	O
years-old	O
man	O
with	O
reddish	B-T080
skin lesion of the glans	B-T033
,	O
a	O
previous	O
history of bladder	B-T033
and	O
urethral carcinoma	B-T191
and	O
histological pagetoid spread	B-T033
of	O
urothelial cancer	B-T191
to the glans	B-T023
.	O
Recurrent bladder urothelial carcinoma	B-T191
is	O
usually	O
a	O
visceral	B-T023
disease	B-T047
that	O
rarely	O
presents	O
as	O
a	O
superficial	O
asymptomatic	B-T033
skin lesion	B-T047
.	O
The	O
two	O
reported	O
cases were asymptomatic	B-T033
superficial penis metastases	B-T191
with	O
a	O
relatively	O
slow	O
growth	O
and	O
a	O
fairy good prognosis	B-T033
after	O
conservative surgical approach	B-T169
.	O
Accurate	O
clinical examination of the penis is mandatory for males	B-T064
with	O
history of bladder cancer	B-T033
.	O

The	O
bachelorette:	O
Female	B-T032
Siamese fighting fish	B-T013
avoid	B-T169
males	B-T032
exposed to	B-T080
an	O
estrogen	B-T109
mimic	B-T169
Due	O
to	O
improper	B-T080
disposal	B-T052
and	O
a	O
lack	B-T080
of	O
removal	B-T052
during	O
the	O
wastewater	B-T069
treatment process	B-T169
,	O
endocrine	B-T169
disrupting	B-T080
chemicals	B-T103
enter	O
aquatic ecosystems	B-T067
where	O
they	O
exert	O
detrimental	O
effects	B-T080
on	O
fish	B-T013
behavior	B-T053
and	O
physiology	B-T039
.	O
Perhaps	O
the	O
most	O
well-studied	O
and	O
prevalent	B-T081
EDC	B-T103
is	O
17α-ethinylestradiol	B-T109
(	O
EE2	B-T109
),	O
an	O
active	O
ingredient	B-T120
in	O
oral contraceptives	B-T121
,	O
which	O
is	O
known	O
to	O
cause	O
dramatic	O
reductions	B-T080
in	O
male	B-T032
-typical	O
behaviors	B-T053
.	O
While	O
it	O
is	O
likely	O
that	O
alterations	B-T078
in	O
male	B-T032
courtship	B-T054
behavior	B-T053
decrease	B-T081
reproductive fitness	B-T045
,	O
this	O
is	O
rarely	O
explicitly	O
examined.	O
To	O
this	O
end,	O
whether	O
EE2	B-T109
exposure	B-T080
reduces	B-T080
male	B-T032
attractiveness	B-T032
to	O
female	B-T032
Siamese fighting fish	B-T013
,	O
Betta splendens	B-T013
,	O
was	O
investigated	B-T169
by	O
showing	O
females	B-T032
video	B-T170
images	B-T170
of	O
exposed	B-T098
and	O
unexposed	B-T098
males	B-T032
.	O
Females	B-T032
were	O
randomly	O
assigned	O
to	O
one	O
of	O
two	O
exposure	B-T080
conditions	B-T080
(	O
exposed to	B-T080
EE2	B-T109
,	O
control	B-T096
)	O
and	O
each	O
subject	B-T096
then	O
viewed	O
four	B-T081
different	B-T080
video	B-T170
combinations	B-T080
of	O
male	B-T032
conspecifics	B-T078
(	O
courting	B-T054
exposed	B-T098
+	O
exposed	B-T098
;	O
courting	B-T054
unexposed	B-T098
+	O
unexposed	B-T098
;	O
courting	B-T054
unexposed	B-T098
+	O
exposed	B-T098
;	O
swimming	B-T056
unexposed	B-T098
+	O
exposed	B-T098
).	O
Females	B-T032
,	O
regardless	O
of	O
whether	O
or	O
not	O
they	O
were	O
exposed to	B-T080
EE2	B-T109
,	O
directed	O
markedly	O
less	O
behavior	B-T053
towards	O
exposed	B-T098
males	B-T032
,	O
especially	O
when	O
they	O
viewed	O
an	O
exposed	B-T098
male	B-T032
and	O
an	O
unexposed	B-T098
male	B-T032
simultaneously	B-T079
.	O
These	O
findings	O
demonstrate	O
that	O
EE2	B-T109
can	O
have	O
significant	B-T078
individual	B-T081
-	O
and	O
population-level	B-T098
consequences	B-T169
on	O
fitness	B-T078
by	O
disrupting	B-T080
sexual selection	B-T054
and,	O
ultimately,	O
the	O
success	B-T054
of	O
exposed	B-T098
males	B-T032
males	B-T032
.	O

Targeting	B-T169
accuracy	B-T080
of	O
single-isocenter	B-T082
intensity-modulated	B-T061
radiosurgery	B-T061
for	O
multiple	O
lesions	B-T033
To	O
investigate	B-T169
the	O
targeting	B-T169
accuracy	B-T080
of	O
intensity-modulated	B-T061
SRS	B-T061
(	O
IMRS	B-T061
)	O
plans	B-T170
designed	O
to	O
simultaneously	O
treat	O
multiple	O
brain	B-T023
metastases	B-T046
with	O
a	O
single isocenter	B-T082
.	O
A	O
home-made acrylic	B-T122
phantom	B-T073
able	O
to	O
support	O
a	O
film	B-T167
(	O
EBT3	B-T167
)	O
in	O
its	O
coronal plane	B-T082
was	O
used.	O
The	O
phantom	B-T073
was	O
CT scanned	B-T060
and	O
three	O
coplanar	O
small	O
targets	B-T169
(a	O
central	B-T082
and	O
two	O
peripheral	B-T082
)	O
were	O
outlined	O
in	O
the	O
Eclipse system	B-T061
.	O
Peripheral	B-T082
targets	B-T169
were	O
6	O
cm	O
apart	O
from	O
the	O
central	B-T082
one.	O
A	O
reference	O
IMRS	B-T061
plan	B-T170
was	O
designed	O
to	O
simultaneously	O
treat	O
the	O
three	O
targets	B-T169
,	O
but	O
only	O
a	O
single isocenter	B-T082
located	O
at	O
the	O
center	O
of	O
the	O
central	B-T082
target	B-T169
was	O
used.	O
After	O
positioning	B-T082
the	O
phantom	B-T073
on	O
the	O
linac	B-T074
using	O
the	O
room	B-T082
lasers	B-T073
,	O
a	O
CBCT scan	B-T060
was	O
acquired	O
and	O
the	O
reference	O
plan	B-T170
were	O
mapped	B-T052
on	O
it,	O
by	O
placing	O
the	O
planned	O
isocenter	B-T082
at	O
the	O
intersection	B-T078
of	O
the	O
landmarks	O
used	O
in	O
the	O
film	B-T167
showing	O
the	O
linac	B-T074
isocenter	B-T082
.	O
The	O
mapped	B-T052
plan	B-T170
was	O
then	O
recalculated	B-T052
and	O
delivered	B-T169
.	O
The	O
film	B-T167
dose distribution	B-T061
was	O
derived	O
using	O
a	O
cloud computing application	B-T170
(	O
www.radiochromic.com	B-T170
)	O
that	O
uses	O
a	O
triple-channel	O
dosimetry	B-T059
algorithm	B-T170
.	O
Comparison	O
of	O
dose distributions	B-T061
using	O
the	O
gamma index	B-T081
(5%/1	O
mm)	O
were	O
performed	O
over	O
a	O
5	O
×	O
5	O
cm(2)	O
region	O
centered	O
over	O
each	O
target	B-T169
.	O
2D shifts	B-T169
required	O
to	O
get	O
the	O
best	O
gamma	B-T070
passing	O
rates	O
on	O
the	O
peripheral	B-T082
target	B-T169
regions	O
were	O
compared	O
with	O
the	O
reported	O
ones	O
for	O
the	O
central	B-T082
target	B-T169
.	O
The	O
experiment	B-T062
was	O
repeated	O
ten	O
times	O
in	O
different	O
sessions	B-T061
.	O
Average	O
2D shifts	B-T169
required	O
to	O
achieve	O
optimal	O
gamma	B-T070
passing	O
rates	O
(99%,	O
97%,	O
99%)	O
were	O
0.7	O
mm	O
(SD:	O
0.3	O
mm),	O
0.8	O
mm	O
(SD:	O
0.4	O
mm)	O
and	O
0.8	O
mm	O
(SD:	O
0.3	O
mm),	O
for	O
the	O
central	B-T082
and	O
the	O
two	O
peripheral	B-T082
targets	B-T169
,	O
respectively.	O
No	O
statistical	O
differences	O
(p	O
>	O
0.05)	O
were	O
found	O
for	O
targeting	B-T169
accuracy	B-T080
between	O
the	O
central	B-T082
and	O
the	O
two	O
peripheral	B-T082
targets	B-T169
.	O
The	O
study	B-T062
revealed	O
a	O
targeting	B-T169
accuracy	B-T080
within	O
1	O
mm	O
for	O
off-	O
isocenter	B-T082
targets	B-T169
within	O
6	O
cm	O
of	O
the	O
linac	B-T074
isocenter	B-T082
,	O
when	O
a	O
single-isocenter	B-T082
IMRS	B-T061
plan	B-T170
is	O
designed.	O

Physical activity	B-T056
limits	B-T169
the	O
effects of	B-T080
age	B-T032
and	O
Alzheimer's disease	B-T047
on	O
postural control	B-T042
The	O
aim	B-T078
was	O
to	O
study	O
the	O
possible	O
influence	B-T077
of	O
physical activity	B-T056
on	O
the	O
postural	B-T169
performance	B-T052
of	O
subjects	B-T098
with	O
Alzheimer's disease	B-T047
(	O
AD	B-T047
).	O
The	O
postural	B-T169
performance	B-T052
(i.e.	O
surface area	B-T081
of	O
the	O
center of foot pressure displacement	B-T082
)	O
of	O
3	O
groups	B-T078
was	O
compared	B-T052
:	O
Alzheimer active group	B-T078
(	O
AA	B-T078
),	O
Alzheimer non-active group	B-T078
(	O
ANA	B-T078
)	O
and	O
healthy non-active group	B-T078
(	O
HNA	B-T078
).	O
The	O
AA group's	B-T098
postural	B-T169
performance	B-T052
was	O
superior	B-T082
to	O
that	O
of	O
the	O
ANA	B-T078
and	O
HNA groups	B-T078
.	O
AD	B-T047
disturbed	O
postural	B-T169
performance	B-T052
but	O
participation	B-T169
in	O
regular	B-T080
physical activity	B-T056
made	O
it	O
possible	O
to	O
limit	B-T169
the	O
disturbing effects	B-T080
of	O
AD	B-T047
to	O
a	O
surprising	O
extent,	O
since	O
the	O
postural	B-T169
performance	B-T052
of	O
active AD subjects	B-T098
was	O
also	O
superior	B-T082
to	O
that	O
of	O
healthy subjects	B-T098
.	O

LAMP-2	B-T116
mediates	O
oxidative stress	B-T049
-dependent	O
cell death	B-T043
in	O
Zn(2+)	B-T121
-	O
treated	B-T061
lung	B-T023
epithelium cells	B-T025
Zinc	B-T121
is	O
an	O
essential	O
element	B-T196
for	O
the	O
biological system	B-T022
.	O
However,	O
excessive	O
exogenous	B-T169
Zn(2+)	B-T121
would	O
disrupt	O
cellular Zn(2+) homeostasis	B-T043
and	O
cause toxicity	B-T037
.	O
In	O
particular,	O
Zinc salts	B-T121
or	O
ZnO	B-T121
nanoparticles	B-T073
exposure	O
could	O
induce	O
respiratory injury	B-T037
.	O
Although	O
previous	O
studies	O
have	O
indicated	O
that	O
organelle	B-T026
damage	B-T049
(including	O
mitochondria	B-T026
or	O
lysosomes	B-T026
)	O
and	O
reactive oxygen species	B-T123
(	O
ROS	B-T123
)	O
production	O
are	O
involved	O
in	O
Zn(2+)	B-T121
-induced	O
toxicity	B-T037
,	O
the	O
interplay	O
between	O
mitochondria	B-T026
/	O
lysosomes	B-T026
damage	B-T049
and	O
ROS	B-T123
production	O
is	O
obscure.	O
Herein,	O
we	O
demonstrated	O
that	O
Zn(2+)	B-T121
could	O
induce	O
deglycosylation	B-T044
of	O
lysosome-associated membrane protein 1	B-T116
and	O
2	B-T116
(	O
LAMP-1	B-T116
and	O
LAMP-2	B-T116
),	O
which	O
primarily	O
locate	O
in	O
late	O
endosomes	B-T026
/	O
lysosomes	B-T026
,	O
in	O
A549 lung epithelium cells	B-T025
.	O
Intriguingly,	O
LAMP-2	B-T028
knockdown	B-T063
further	O
aggravated	B-T080
Zn(2+)	B-T121
-mediated	O
ROS	B-T123
production	O
and	O
cell death	B-T043
,	O
indicating	O
LAMP-2	B-T116
(not	O
LAMP-1	B-T116
)	O
was	O
involved	O
in	O
Zn(2+)	B-T121
-induced	O
toxicity	B-T037
.	O
Our	O
results	O
provide	O
a	O
new	O
insight	O
that	O
LAMP-2	B-T116
contributes	O
to	O
the	O
ROS	B-T123
clearance	O
and	O
cell death	B-T043
induced	O
by	O
Zn(2+)	B-T121
treatment	B-T061
,	O
which	O
would	O
help	O
us	O
to	O
get	O
a	O
better	O
understanding	O
of	O
Zn(2+)	B-T121
-induced	O
toxicity	B-T037
in	O
respiratory system	B-T022
.	O

Fluorescence hyperspectral imaging	B-T060
(	O
fHSI	B-T060
)	O
using	O
a	O
spectrally	B-T080
resolved	B-T033
detector array	B-T074
The	O
ability	O
to	O
resolve	B-T077
multiple	B-T081
fluorescent emissions	B-T067
from	O
different	B-T080
biological	B-T080
targets	B-T169
in	O
video rate applications	B-UnknownType
,	O
such	O
as	O
endoscopy	B-T060
and	O
intraoperative imaging	B-T060
,	O
has	O
traditionally	O
been	O
limited	B-T169
by	O
the	O
use	O
of	O
filter-based	B-T080
imaging systems.	B-T074
Hyperspectral imaging	B-T060
(	O
HSI	B-T060
)	O
facilitates	O
the	O
detection	B-T061
of	O
both	O
spatial	B-T082
and	O
spectral	B-T081
information	B-T078
in	O
a	O
single data acquisition	B-T052
,	O
however,	O
instrumentation	B-T080
for	O
HSI	B-T060
is	O
typically	O
complex	B-T080
,	O
bulky	B-T081
and	O
expensive	B-T080
.	O
We	O
sought	O
to	O
overcome	B-T052
these	O
limitations	B-T169
using	O
a	O
novel	B-T080
robust	B-T080
and	O
low cost	B-T081
HSI	B-T060
camera	B-T074
based	O
on	O
a	O
spectrally resolved detector array	B-T074
(	O
SRDA	B-T074
).	O
We	O
integrated	B-T066
this	O
HSI	B-T060
camera	B-T074
into	O
a	O
wide-field	B-T033
reflectance-based	B-T059
imaging system	B-T073
operating	B-T169
in	O
the	O
near-infrared	B-T080
range	B-T081
to	O
assess	B-T058
the	O
suitability	O
for	O
in vivo imaging	B-T059
of	O
exogenous	B-T169
fluorescent contrast agents	B-T130
.	O
Using	O
this	O
fluorescence HSI	B-T060
(	O
fHSI	B-T060
)	O
system	B-T169
,	O
we	O
were	O
able	O
to	O
accurately	B-T080
resolve	B-T077
the	O
presence	B-T080
and	O
concentration	B-T081
of	O
at	O
least	O
7	O
fluorescent dyes	B-T130
in	O
solution	B-T167
.	O
We	O
also	O
demonstrate	O
high	B-T080
spectral unmixing	B-T066
precision	B-T080
,	O
signal	B-T067
linearity	B-T080
with	O
dye	B-T130
concentration	B-T081
and	O
at	O
depth	B-T082
in	O
tissue	B-T024
mimicking	B-T070
phantoms	B-T073
,	O
and	O
delineate	B-T033
4	O
fluorescent dyes	B-T130
in vivo	B-T082
.	O
Our	O
approach,	O
including	B-T169
statistical	B-T080
background	B-T077
removal,	O
could	O
be	O
directly	B-T080
generalised	B-T082
to	O
broader spectral	B-T074
ranges	B-T081
,	O
for	O
example,	O
to	O
resolve	B-T077
tissue	B-T024
reflectance	B-T059
or	O
autofluorescence	B-T059
and	O
in	O
future	B-T079
be	O
tailored	O
to	O
video rate applications	B-UnknownType
requiring	O
snapshot	O
HSI	B-T060
data acquisition	B-T052
.	O

Biochemical	B-T169
studies	B-T062
of	O
amylase	B-T116
,	O
lipase	B-T116
and	O
protease	B-T116
in	O
Callosobruchus maculatus	B-T204
(	O
Coleoptera	B-T204
:	O
Chrysomelidae	B-T204
)	O
populations	B-T098
fed	O
with	O
Vigna unguiculata	B-T002
grain	B-T168
cultivated	B-T062
with	O
diazotrophic bacteria strains	B-T007
The	O
objective	O
of	O
this	O
study	B-T062
was	O
to	O
evaluate	O
the	O
enzymatic activity	B-T044
of	O
homogenates	B-T072
of	O
insects	B-T204
fed	O
on	O
grain	B-T168
of	O
cowpea	B-T002
,	O
Vigna unguiculata (L.)	B-T002
,	O
cultivars	B-T002
grown	O
with	O
different	O
nitrogen	B-T123
sources.	O
For	O
the	O
experiment	O
we	O
used	O
aliquots	O
of	O
the	O
homogenate	B-T072
of	O
100	O
unsexed	O
adult	B-T100
insects	B-T204
,	O
emerged	O
from	O
10	O
g	O
of	O
grain	B-T168
obtained	O
from	O
four	O
cowpea	B-T002
cultivars	B-T002
:	O
'	O
BRS Acauã	B-T002
',	O
'	O
BRS Carijó	B-T002
',	O
'	O
BRS Pujante	B-T002
',	O
and	O
'	O
BRS Tapaihum	B-T002
'	O
grown	O
under	O
different	O
regimes	O
of	O
nitrogen	B-T123
sources:	O
mineral	B-T197
fertilizer	B-T073
,	O
inoculation	B-T059
with	O
strains of diazotrophs	B-T007
(	O
BR 3267	B-T007
,	O
BR 3262	B-T007
,	O
BR 3299	B-T007
;	O
INPA 03-11B	B-T007
,	O
03-84 UFLA	B-T007
,	O
as	O
well	O
as	O
the	O
control	B-T096
(with	O
soil	B-T167
nitrogen	B-T123
).	O
The	O
parameters	O
evaluated	O
were	O
enzymatic activities	B-T044
of	O
insect	B-T204
protease	B-T116
,	O
amylase	B-T116
and	O
lipase	B-T116
and	O
the	O
starch	B-T109
content	O
of	O
the	O
grains	B-T168
.	O
There	O
were	O
differences	O
in	O
the	O
enzymatic activity	B-T044
of	O
amylase	B-T116
,	O
lipase	B-T116
and	O
protease	B-T116
of	O
insect	B-T204
homogenate	B-T072
according	O
to	O
the	O
food	B-T168
source.	O
A	O
lower	O
activity of the enzyme	B-T044
amylase	B-T116
from	O
C. maculatus	B-T204
homogenate	B-T072
was	O
observed	O
when	O
insects	B-T204
were	O
fed	O
grain	B-T168
of	O
the	O
cultivar BRS Carijó	B-T002
.	O
A	O
lower	O
activity of lipase enzyme	B-T044
from	O
C. maculatus	B-T204
homogenate	B-T072
was	O
observed	O
when	O
the	O
insects	B-T204
fed	O
on	O
grain	B-T168
from	O
the	O
interaction	O
of	O
the	O
cultivar Tapaihum	B-T002
inoculated	O
with	O
BR 3262 diazotrophs	B-T007
.	O
The	O
lowest	O
proteolytic activity	B-T044
was	O
observed	O
in	O
homogenate	B-T072
of	O
insects	B-T204
fed	O
on	O
interaction	O
of	O
'	O
BRS Carijó	B-T002
'	O
inoculated	O
with	O
BR 3262 diazotroph	B-T007
s.	O
Starch	B-T109
content	O
correlated	O
positively	O
with	O
the	O
amylase activity	B-T044
of	O
C. maculatus	B-T204
homogenate	B-T072
.	O
The	O
cultivar BRS Carijó	B-T002
had	O
a	O
different	O
behavior	O
from	O
the	O
other	O
cultivars	B-T002
,	O
according	O
to	O
the	O
cluster analysis	B-T062
.	O

The	O
correlation of the results	B-T081
of	O
the	O
survey SNOT-20	B-T170
of	O
objective studies	B-T078
of	O
nasal obstruction	B-T033
and	O
the	O
geometry	O
of	O
the	O
nasal cavities	B-T030
In	O
this	O
paper	O
were	O
verified	O
the	O
correlation between the results	B-T081
of	O
the	O
survey SNOT-20	B-T170
and	O
the	O
results of the objective tests	B-T033
of	O
nasal obstruction	B-T033
which	O
are	O
rhinomanometry	B-T060
and	O
acoustic rhinometry	B-T060
before	O
and	O
after	O
surgical treatment	B-T061
,	O
such	O
as	O
septoplasty	B-T061
,	O
septoconchoplasty	B-T060
,	O
ethmoidectomy	B-T061
and	O
septoethmoidectomy	B-T060
.	O
The	O
material	O
used	O
in	O
this	O
study	O
was	O
233	O
patients	B-T101
diagnosed	B-T033
routinely	O
in	O
the	O
Rhinomanometry	B-T060
Laboratory	B-T073
of	O
the	O
Department of Otolaryngology	B-T093
at	O
the	O
Medical University	B-T073
of	O
Warsaw	B-UnknownType
,	O
reporting	O
rhinological problems	B-T047
.	O
Data	B-T078
were	O
obtained	O
from	O
70	O
women	B-T098
(31,4%)	O
ranging	O
in	O
ages	O
from	O
18	O
to	O
81	O
years	O
of	O
age	O
and	O
153	O
men	B-T098
(68,6%)	O
ranging	O
in	O
ages	O
from	O
16	O
to	O
81	O
years	O
of	O
age.	O
The	O
researches	O
presented	O
in	O
the	O
study	O
were	O
made	O
using	O
the	O
device	O
RhinoMetrics SRE 2100	B-T074
which	O
combines	O
the	O
Rhinomanometer	B-T074
(	O
RhinoStream	B-T074
)	O
and	O
Acoustic Rhinometer	B-T074
(	O
RhinoScan	B-T074
)	O
Interacoustics AS	B-T074
(	O
Denmark	B-T083
).	O
Survey SNOT-20	B-T170
(	O
Sino-Nasal Outcome Test-20	B-T170
)	O
in	O
Polish	B-UnknownType
was	O
completed	O
by	O
patients	B-T101
before surgery	B-T079
and	O
during the postoperative control visits	B-T079
.	O
The	O
calculated	O
correlations	O
between	O
the	O
objective parameter	B-T033
,	O
which	O
was	O
the	O
resistance	B-T169
to	O
the	O
flow of air through the nasal cavity	B-T033
,	O
and	O
the	O
subjective feelings of respondents	B-T033
expressed	O
in	O
the	O
survey SNOT-20	B-T170
were	O
generally weak	B-T080
,	O
and	O
statistical significance	B-T081
was	O
achieved	O
with	O
respect	O
to	O
the	O
first question survey	B-T062
(the	O
severity of the nose obstruction	B-T033
)	O
for	O
all	O
components	O
of	O
resistance flow	B-T169
.	O
The	O
feeling	O
of	O
nasal obstruction	B-T033
is	O
the	O
most	O
reproducible	O
and	O
reliable	O
complaint	O
reported	O
by	O
the	O
patient	B-T101
with	O
rhinological problems	B-T047
.	O

Emergency department	B-T073
use	B-T169
and	O
barriers	B-T080
to	O
wellness	B-T078
:	O
a	O
survey	B-T170
of	O
emergency department	B-T073
frequent	B-T079
users	B-T098
There	O
is	O
no	O
common	O
understanding	O
of	O
how	O
needs	B-T080
of	O
emergency department	B-T073
(	O
ED	B-T073
)	O
frequent	B-T079
users	B-T098
differ	O
from	O
other	O
patients	B-T101
.	O
This	O
study	B-T062
sought	O
to	O
examine	O
how	O
to	O
best	O
serve	O
this	O
population	B-T098
.	O
Examinations	B-T058
of	O
why	O
ED	B-T073
frequent	B-T079
users	B-T098
present	B-T033
to	O
the	O
ED	B-T073
,	O
what	O
barriers	B-T080
to	O
care	B-T058
exist	B-T077
,	O
and	O
what	O
service	B-T057
offerings	O
may	O
help	O
these	O
patients	B-T101
achieve	O
an	O
optimal	B-T080
level	B-T080
of	O
health	B-T078
were	O
conducted.	O
We	O
performed	O
a	O
prospective study	B-T062
of	O
frequent	B-T079
ED	B-T073
users	B-T098
in	O
an	O
adult	B-T100
only,	O
level 1 trauma center	B-T073
with	O
approximately	B-T080
90,000	O
visits	B-T058
per year	B-T079
.	O
Frequent	B-T079
ED	B-T073
users	B-T098
were	O
defined	O
as	O
those	O
who	O
make	O
four	O
or	O
more	O
ED visits	B-T058
in	O
a	O
12	O
month	B-T079
period	B-T079
.	O
Participants	B-T098
were	O
administered	B-T169
a	O
piloted structured interview	B-UnknownType
by	O
a	O
trained researcher	B-T097
querying	B-T170
demographics	B-T090
,	O
ED	B-T073
usage	B-T169
,	O
perceived barriers	B-T080
to	O
care	B-T058
,	O
and	O
potential	O
aids	B-T080
to	O
maintaining health	B-T055
.	O
Of	O
1,523	O
screened	B-T058
patients	B-T101
,	O
297	O
were	O
identified	B-T080
as	O
frequent	B-T079
ED	B-T073
users	B-T098
.	O
One	O
hundred	O
frequent	B-T079
ED	B-T073
users	B-T098
were	O
enrolled.	O
The	O
mean age	B-T032
was	O
48	O
years	B-T079
(95%	O
CI	B-T081
45-51).	O
The	O
majority	O
of	O
subjects	B-T098
were	O
female	B-T098
(64%,	O
64/100,	O
95%	O
CI	B-T081
55-73%),	O
white	B-T098
(61%,	O
60/98,	O
95%	O
CI	B-T081
52-71%)	O
and	O
insured	B-T170
by	O
Medicaid	B-T064
(55%,	O
47/86,	O
95%	O
CI	B-T081
44-65%)	O
or	O
Medicare	B-T064
(23%,	O
20/86,	O
95%	O
CI	B-T081
14-32%).	O
Subjects	B-T098
had	O
a	O
median	B-T081
of	O
6	O
ED visits	B-T058
,	O
and	O
2	O
inpatient admissions	B-T169
in	O
the	O
past	B-T079
12	O
months	B-T079
at	O
this	O
hospital	B-T073
.	O
Most	O
frequent	B-T079
ED	B-T073
users	B-T098
(61%,	O
59/96,	O
95%	O
CI	B-T081
52-71%)	O
stated	O
the	O
primary reason	B-T078
for	O
their	O
visit	B-T058
was	O
that	O
they	O
felt	O
that	O
their	O
health problem	B-T033
could	O
only	O
be	O
treated	B-T169
in	O
an	O
ED	B-T073
.	O
Transportation	B-T078
presented	O
as	O
a	O
major	B-T080
barrier	B-T080
to	O
few	B-T081
patients	B-T101
(7%,	O
7/95,	O
95%	O
CI	B-T081
3-14%).	O
Subjects	B-T098
stated	O
that	O
"	O
after-hours options	B-T058
,	O
besides	O
the	O
ED	B-T073
for	O
minor	B-T080
health issues	B-T078
"	O
(63%,	O
60/95,	O
95%	O
CI	B-T081
53-73%)	O
and	O
having	O
"a	O
nurse	B-T097
to	O
work	B-T057
with	O
you	O
one-on-one	B-T061
to	O
help	O
manage	B-T058
health care	B-T058
needs	B-T080
"	O
(53%,	O
50/95,	O
95%	O
CI	B-T081
43-63%)	O
would	O
be	O
most	O
helpful	O
in	O
achieving	O
optimal	B-T080
health	B-T078
.	O
This	O
study	B-T062
characterized	B-T052
ED	B-T073
frequent	B-T079
users	B-T098
and	O
identified	B-T080
several	B-T081
opportunities	B-T062
to	O
better	O
serve	O
this	O
population	B-T098
.	O
By	O
understanding	O
barriers	B-T080
to	O
care	B-T058
from	O
the	O
patient	B-T101
perspective,	O
health systems	B-T064
can	O
potentially	O
address	O
unmet	O
needs	B-T080
that	O
prevent	B-T080
wellness	B-T078
in	O
this	O
population	B-T098
.	O

Contralateral	B-T082
Superior Cerebellar Artery Syndrome	B-T046
:	O
A	O
Consequence of	B-T169
Brain Herniation	B-T190
Vascular	B-T023
compromise	B-T033
is	O
a	O
well-known	O
consequence of	B-T169
brain herniation	B-T190
syndromes	B-T047
.	O
Transtentorial	B-T082
brain herniation	B-T190
most	O
often	O
involves	O
posterior cerebral arteries	B-T023
.	O
However,	O
isolated	B-T169
involvement	B-T169
of	O
contralateral	B-T082
superior cerebellar artery	B-T023
(	O
SCA	B-T023
)	O
during	O
unilateral	B-T082
impending	B-T079
brain herniation	B-T190
is	O
reported	B-T058
only	O
once	O
and	O
we	O
present	O
another	O
case	O
of	O
this	O
exceedingly	O
rare	B-T080
entity	B-T071
.	O
A	O
24-year-old	O
man	B-T098
was	O
referred	O
to	O
us	O
with	O
impending	B-T079
herniation	B-T190
due	O
to	O
a	O
multiloculated	B-T082
hydrocephalus	B-T047
,	O
and	O
during	O
the	O
course of illness	B-T046
,	O
he	O
developed	O
an	O
isolated	B-T169
SCA	B-T023
ischemia	B-T046
in	O
the	O
opposite	O
side	O
of	O
the	O
most	O
dilated	B-T033
entrapped	O
horn	B-T023
.	O
In	O
the	O
current	O
article	B-T170
we	O
discuss	O
the	O
probable	O
pathophysiologic	B-T169
mechanisms	B-T169
of	O
this	O
phenomenon	B-T067
,	O
as	O
well	O
as	O
recommending	O
more	O
inclusive	B-T169
brain	B-T023
studies	O
in	O
cases	O
suspected	B-T078
of	O
Kernohan-Woltman notch phenomenon	B-T046
in	O
unilateral	B-T082
brain herniation	B-T190
.	O
The	O
rationale	B-T078
for	O
this	O
commentary	B-T170
is	O
that	O
contralateral	B-T082
SCA	B-T023
transient ischemia	B-T047
or	O
infarct	B-T046
might	O
be	O
the	O
underdiagnosed	B-T033
underlying	O
pathomechanism	B-T046
of	O
ipsilateral	B-T082
hemiparesis	B-T184
occurring	O
in	O
many	O
cases	O
of	O
this	O
somehow	O
vague	B-T080
phenomenon	B-T067
.	O

The	O
effects of	B-T080
clinical supervision	B-T057
on	O
supervisees	B-T098
and	O
patients	B-T101
in	O
cognitive-behavioral therapy	B-T061
:	O
a	O
study protocol	B-T170
for	O
a	O
systematic review	B-T170
Clinical supervision	B-T057
by	O
a	O
senior therapist	B-T097
is	O
a	O
very	O
common	O
practice	B-T041
in	O
psychotherapist	B-T097
training	B-T065
and	O
psychiatric care	B-T061
settings.	O
Though	O
clinical supervision	B-T057
is	O
advocated	O
by	O
most	O
educational and governing institutions	B-UnknownType
,	O
the	O
effects	O
of	O
clinical supervision	B-T057
on	O
the	O
supervisees	B-T098
'	O
competence	B-T080
,	O
e.g.,	O
attitudes	B-T041
,	O
behaviors	B-T053
,	O
and	O
skills	B-T055
,	O
as	O
well	O
as	O
on	O
treatment outcomes	B-T080
and	O
other	O
patient	B-T101
variables	O
are	O
debated	O
and	O
largely	O
unknown.	O
Evidence-based practice	B-T169
is	O
advocated	O
in	O
clinical settings	B-T082
but	O
has	O
not	O
yet	O
been	O
fully	O
implemented	O
in	O
educational	O
or	O
clinical	O
training	O
settings.	O
The	O
aim	O
of	O
this	O
systematic review	B-T170
is	O
to	O
synthesize	O
and	O
present	O
the	O
empirical literature	B-T170
regarding	O
effects	O
of	O
clinical supervision	B-T057
in	O
cognitive-behavioral therapy	B-T061
.	O
This	O
study	O
will	O
include	O
a	O
systematic review	B-T170
of	O
the	O
literature	B-T170
to	O
identify	O
studies	O
that	O
have	O
empirically	O
investigated	O
the	O
effects	O
of	O
supervision	O
on	O
supervised psychotherapists	B-T097
and/or	O
the	O
supervisees'	O
patients	B-T101
.	O
A	O
comprehensive	O
search	O
strategy	O
will	O
be	O
conducted	O
to	O
identify	O
published	O
controlled	O
studies	O
indexed	B-T170
in	O
the	O
MEDLINE	B-T170
,	O
EMBASE	B-T170
,	O
PsycINFO	B-T170
,	O
and	O
Cochrane Library databases	B-T170
.	O
Data	B-T078
on	O
supervision	O
outcomes	O
in	O
both	O
psychotherapists	B-T097
and	O
their	O
patients	B-T101
will	O
be	O
extracted,	O
synthesized,	O
and	O
reported	B-T170
.	O
Risk	O
of	O
bias	O
and	O
quality	O
of	O
the	O
included	O
studies	O
will	O
be	O
assessed	O
systematically.	O
This	O
systematic review	B-T170
will	O
rigorously	O
follow	O
established	O
guidelines	B-T170
for	O
systematic reviews	B-T170
in	O
order	O
to	O
summarize	O
and	O
present	O
the	O
evidence	O
base	O
for	O
clinical supervision	B-T057
in	O
cognitive-behavioral therapy	B-T061
and	O
may	O
aid	O
further	O
research	B-T062
and	O
discussion	O
in	O
this	O
area.	O
PROSPERO	O
CRD42016046834.	O

Higher risk of	B-T033
revision	B-T079
for	O
infection	B-T046
using	O
systemic	B-T169
clindamycin	B-T109
prophylaxis	B-T061
than	O
with	O
cloxacillin	B-T109
Background	O
and	O
purpose	O
-	O
Clindamycin	B-T109
has	O
not	O
been	O
compared	O
with	O
other	O
antibiotics	B-T195
for	O
prophylaxis	B-T061
in	O
arthroplasty	B-T061
.	O
Since	O
2009,	O
the	O
Swedish Knee Arthroplasty Register	B-T170
Knee Arthroplasty	B-T061
Register	O
(	O
SKAR	B-T170
)	O
has	O
been	O
collecting	B-T169
information	B-T078
on	O
the	O
prophylactic antibiotic regime	B-T061
used	O
at	O
every	O
individual	B-T098
operation	B-T169
.	O
In	O
Sweden	B-T083
,	O
when	O
there	O
is	O
allergy	B-T046
to	O
penicillin	B-T109
,	O
clindamycin	B-T109
has	O
been	O
the	O
recommended	B-T078
alternative	B-T077
.	O
We	O
examined	O
whether	O
there	O
were	O
differences	O
in	O
the	O
rate	O
of	O
revision	B-T079
due	O
to	O
infection	B-T046
depending	O
on	O
which	O
antibiotic	B-T195
was	O
used	O
as	O
systemic	B-T169
prophylaxis	B-T061
.	O
Patients	B-T101
and	O
methods	O
-	O
Patients	B-T101
who	O
had	O
a	O
total knee arthroplasty	B-T061
(	O
TKA	B-T061
)	O
performed	O
due	O
to	O
osteoarthritis	B-T047
(	O
OA	B-T047
)	O
during	O
the	O
years	O
2009-2015	O
were	O
included	O
in	O
the	O
study.	O
Information	O
on	O
which	O
antibiotic	B-T195
was	O
used	O
was	O
available	O
for	O
80,018	O
operations	B-T169
(55,530	O
patients	B-T101
).	O
Survival statistics	B-T170
were	O
used	O
to	O
calculate	O
the	O
rate	O
of	O
revision	B-T079
due	O
to	O
infection	B-T046
until	O
the	O
end	O
of	O
2015,	O
comparing	O
the	O
group	O
of	O
patients	B-T101
who	O
received	O
cloxacillin	B-T109
with	O
those	O
who	O
received	O
clindamycin	B-T109
as	O
systemic	B-T169
prophylaxis	B-T061
.	O
Results	O
-	O
Cloxacillin	B-T109
was	O
used	O
in	O
90%	O
of	O
the	O
cases,	O
clindamycin	B-T109
in	O
7%,	O
and	O
cephalosporins	B-T109
in	O
2%.	O
The	O
risk	O
of	O
being	O
revised	O
due	O
to	O
infection	B-T046
was	O
higher	O
when	O
clindamycin	B-T109
was	O
used	O
than	O
when	O
cloxacillin	B-T109
was	O
used	O
(RR	O
=1.5,	O
95%	O
CI:	O
1.2-2.0;	O
p	O
=	O
0.001).	O
There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
revision	B-T079
rate	O
for	O
other	O
causes	B-T169
(p	O
=	O
0.2).	O
Interpretation	B-T170
-	O
We	O
advise	O
that	O
patients	B-T101
reporting	O
allergic reaction	B-T046
to	O
penicillin	B-T109
should	O
have	O
their	O
allergic history	B-T184
explored.	O
In	O
the	O
absence	O
of	O
a	O
clear	O
history	B-T184
of	O
type-I allergic reaction	B-T046
(e.g.	O
urticaria	B-T047
,	O
anaphylaxis	B-T047
,	O
or	O
bronchospasm	B-T047
),	O
we	O
suggest	O
the	O
use	O
of	O
a	O
third-generation cephalosporin	B-T109
instead	O
of	O
clindamycin	B-T109
as	O
perioperative	B-T079
prophylaxis	B-T061
when	O
undergoing	O
a	O
TKR	B-T061
.	O
No	O
recommendation	B-T078
can	O
be	O
given	O
regarding	O
patients	B-T101
with	O
type-1 allergy	B-T046
.	O

PCVMZM	B-T062
:	O
Using	O
the	O
Probabilistic Classification Vector Machines Model Combined with a Zernike Moments	B-T062
Descriptor	O
to	O
Predict	B-T078
Protein-Protein Interactions	B-T044
from	O
Protein Sequences	B-T087
Protein-protein interactions	B-T044
(	O
PPIs	B-T044
)	O
are	O
essential	O
for	O
most	O
living organisms	B-T001
'	O
process.	O
Thus,	O
detecting	O
PPIs	B-T044
is	O
extremely	O
important	O
to	O
understand	O
the	O
molecular	B-T080
mechanisms	B-T169
of	O
biological systems	B-T169
.	O
Although	O
many	O
PPIs	B-T044
data	O
have	O
been	O
generated	O
by	O
high-throughput technologies	B-T170
for	O
a	O
variety	O
of	O
organisms	B-T001
,	O
the	O
whole	O
interatom	O
is	O
still	O
far	O
from	O
complete.	O
In	O
addition,	O
the	O
high-throughput technologies	B-T170
for	O
detecting	O
PPIs	B-T044
has	O
some	O
unavoidable defects	B-T169
,	O
including	O
time consumption	B-T079
,	O
high	O
cost	B-T081
,	O
and	O
high	O
error rate	B-T081
.	O
In	O
recent	O
years,	O
with	O
the	O
development	O
of	O
machine learning	B-T066
,	O
computational methods	B-T062
have	O
been	O
broadly	O
used	O
to	O
predict	O
PPIs	B-T044
,	O
and	O
can	O
achieve	O
good	O
prediction	B-T078
rate.	O
In	O
this	O
paper,	O
we	O
present	O
here	O
PCVMZM	B-T062
,	O
a	O
computational method	B-T062
based	O
on	O
a	O
Probabilistic Classification Vector Machines (PCVM) model	B-T081
and	O
Zernike moments (ZM) descriptor	B-T081
for	O
predicting	B-T078
the	O
PPIs	B-T044
from	O
protein	B-T116
amino acids sequences	B-T087
.	O
Specifically,	O
a	O
Zernike moments (ZM) descriptor	B-T081
is	O
used	O
to	O
extract	O
protein	B-T116
evolutionary	O
information	B-T078
from	O
Position-Specific Scoring Matrix	B-T081
(	O
PSSM	B-T081
)	O
generated	O
by	O
Position-Specific Iterated Basic Local Alignment Search Tool (PSI-BLAST)	B-T170
.	O
Then,	O
PCVM classifier	B-T081
is	O
used	O
to	O
infer	O
the	O
interactions	B-T044
among	O
protein	B-T116
.	O
When	O
performed	O
on	O
PPIs	B-T044
datasets	O
of	O
Yeast	B-T004
and	O
H. Pylori	B-T007
,	O
the	O
proposed	O
method	O
can	O
achieve	O
the	O
average	O
prediction	B-T078
accuracy	B-T080
of	O
94.48%	O
and	O
91.25%,	O
respectively.	O
In	O
order	O
to	O
further	O
evaluate	O
the	O
performance	O
of	O
the	O
proposed	O
method,	O
the	O
state-of-the-art	B-T170
support vector machines	B-T081
(	O
SVM) classifier	B-T081
is	O
used	O
and	O
compares	O
with	O
the	O
PCVM model	B-T081
.	O
Experimental results	B-T033
on	O
the	O
Yeast	B-T004
dataset	O
show	O
that	O
the	O
performance	O
of	O
PCVM classifier	B-T081
is	O
better	O
than	O
that	O
of	O
SVM classifier	B-T081
.	O
The	O
experimental results	B-T033
indicate	O
that	O
our	O
proposed	O
method	O
is	O
robust,	O
powerful	O
and	O
feasible,	O
which	O
can	O
be	O
used	O
as	O
a	O
helpful	O
tool	O
for	O
proteomics research	B-T062
.	O

Conditional	B-T080
Knockdown	B-T063
of	O
Endogenous	B-T169
MicroRNAs	B-T114
in	O
CHO Cells	B-T025
Using	O
TET-ON-SanDI Sponge Vectors	B-T114
MicroRNAs	B-T114
(	O
miRNAs	B-T114
)	O
are	O
small,	O
noncoding RNAs	B-T114
of	O
about	O
22	O
nucleotides	B-T114
in	O
length	O
and	O
have	O
proven	O
to	O
be	O
useful	O
targets	B-T169
for	O
genetic modifications	B-T063
for	O
desirable	O
phenotype	B-T032
in	O
the	O
biotech	B-T091
industry	B-T057
.	O
The	O
use	O
of	O
constitutively	O
expressed	O
"	O
miRNA sponge" vectors	B-T114
in	O
which	O
multiple,	O
tandem miRNA	B-T114
binding sites	B-T192
containing	O
transcripts	B-T114
are	O
transcriptionally regulated	B-T045
by	O
a	O
constitutive	O
promoter	B-T114
for	O
down regulating	B-T044
the	O
levels	O
of	O
endogenous	B-T169
microRNAs	B-T114
in	O
Chinese hamster ovary (CHO) cells	B-T025
has	O
shown	O
to	O
be	O
more	O
advantageous	O
than	O
using	O
synthetic	O
antisense oligonucleotides	B-T114
.	O
The	O
application	O
of	O
miRNA sponges	B-T114
in	O
biotechnological	B-T091
processes	B-T067
,	O
however,	O
could	O
be	O
more	O
effective	B-T080
,	O
if	O
expression	B-T045
of	O
miRNA sponges	B-T114
could	O
be	O
tuned.	O
In	O
this	O
chapter,	O
we	O
present	O
a	O
method	O
for	O
the	O
generation	O
of	O
stable	O
CHO cell lines	B-T025
expressing	B-T045
a	O
TET-ON-SanDI-miRNA-sponge	B-T114
that	O
is	O
in	O
theory	O
expressed	O
only	O
in	O
the	O
presence	O
of	O
an	O
inducer	B-T167
.	O

Forest	B-T070
protected areas	B-T083
governance	B-T080
in	O
Zimbabwe	B-T083
:	O
Shift	B-T067
needed	O
away	O
from	O
a	O
long history	B-T033
of	O
local	B-T082
community	B-T096
exclusion	B-T052
In	O
this	O
literature	O
review	O
based	O
paper	O
we	O
explored	O
the	O
concept	B-T078
of	O
exclusion	B-T052
of	O
local	B-T082
communities	B-T096
from	O
accessing	B-T078
resources	B-T078
in	O
forest	B-T070
protected areas	B-T083
(	O
FPAs	B-T083
)	O
in	O
Zimbabwe	B-T083
.	O
We	O
discussed	O
the	O
colonial	B-T170
and	O
post	B-T079
-	O
colonial forms	B-T170
,	O
causes	O
and	O
mechanisms	B-T169
of	O
exclusion	B-T052
and	O
their	O
social	B-T078
,	O
economic	B-T081
and	O
ecological outcomes	B-T077
.	O
We	O
examined	B-T033
the	O
range	B-T081
of	O
powers	B-T068
embodied	O
in	O
and	O
exercised	O
through	O
various	O
mechanisms,	O
processes	B-T067
and	O
social relations	B-T054
and	O
their	O
impact	B-T080
on	O
local	B-T082
communities	B-T096
'	O
access	B-T078
to	O
FPA	B-T083
resources	B-T078
and	O
associated	O
benefits	B-T081
along	O
the	O
historical	B-T079
trajectory	B-T169
of	O
forest	B-T070
governance	B-T080
in	O
Zimbabwe	B-T083
.	O
Results	O
showed	O
that	O
the	O
forms	B-T080
and	O
extent	B-T082
of	O
exclusion	B-T052
changed	B-T081
over	B-T079
time	B-T079
in	O
tandem	O
with	O
the	O
shifting	B-T169
political	B-T078
and	O
economic landscape	B-T064
.	O
During	O
the	O
colonial period	B-T079
,	O
it	O
was	O
total	O
exclusion	B-T052
whereby	O
people	B-T098
were	O
evicted	B-T052
from	O
forest	B-T070
land	B-T073
as	O
well	O
as	O
being	O
denied	B-T080
access	B-T078
to	O
basic	B-T169
resources	B-T078
for	O
their	O
livelihoods.	O
Local	B-T082
communities	B-T096
'	O
access	B-T078
to	O
low	B-T080
value	B-T081
FPA	B-T083
resources	B-T078
improved	B-T033
during	O
the	O
post-colonial period	B-T079
but	O
access	B-T078
to	O
high	B-T080
value	B-T081
resources	B-T078
like	O
commercial timber	B-T167
as	O
well	O
as	O
sharing	B-T054
income	B-T081
benefits	B-T081
derived	B-T080
from	O
FPA	B-T083
commercial activities	B-T052
remained	O
a	O
pipe dream	B-T077
.	O
Regulation	B-T064
,	O
legitimation	B-T064
,	O
force	O
and	O
markets	O
constituted	O
the	O
mixture	O
of	O
the	O
power	O
elements	O
that	O
FPA	B-T083
governing	B-T080
authorities	B-T054
used	O
to	O
exclude	B-T052
local	B-T082
communities	B-T096
.	O
These	O
powers	O
remained	O
intact	B-T080
despite	O
attempts	O
at	O
collaborative	B-T054
governance	B-T080
in	O
the	O
1990s.	O
However,	O
from	O
the	O
year	O
2000,	O
local	B-T082
communities	B-T096
expressed	B-T055
their	O
dissatisfaction	B-T041
with	O
the	O
centralised exclusionary governance system	B-T064
by	O
invading	O
the	O
FPAs	B-T083
rendering	O
them	O
ungovernable	B-T033
.	O
There	O
is	O
therefore	O
a	O
need	O
for	O
policy	B-T170
reform	B-T169
within	O
the	O
FPA	B-T083
sector	B-T083
to	O
improve	B-T033
the	O
current	B-T079
dire situation	B-T067
.	O

Renal arterial mycotic aneurysm	B-T047
after	O
kidney transplantation	B-T061
Mycotic aneurysm	B-T047
is	O
a	O
rare	O
condition	O
mostly	O
attributable	B-T078
to	O
Candida	B-T004
or	O
Aspergillus species	B-T004
.	O
About	O
20	O
cases	O
of	O
Candida	B-T004
-related	O
arteritis	B-T046
have	O
been	O
reported	O
in	O
kidney transplant	B-T061
patients	B-T101
.	O
Herein,	O
we	O
report	B-T170
the	O
case	O
of	O
a	O
40-year-	O
old	O
man	O
who	O
received	O
a	O
kidney	B-T023
from	O
a	O
deceased	O
donor	B-T098
in	O
whom	O
an	O
accidental	B-T169
digestive wound	B-T037
was	O
made	O
during	O
organ retrieval	B-T058
.	O
He	O
presented	O
with	O
sudden	O
anuria	B-T047
47	O
days	O
after	O
renal transplantation	B-T061
revealing	O
a	O
large	O
mycotic aneurysm	B-T047
of	O
the	O
kidney graft	B-T024
renal artery	B-T023
.	O
Organs	B-T023
derived	O
from	O
donors	B-T098
in	O
whom	O
a	O
digestive breach	B-T037
is	O
noticed	O
should	O
be	O
used with caution	B-T169
.	O

Risk of cancer	B-T081
in	O
patients	B-T101
with	O
heart failure	B-T047
who	O
use	O
digoxin	B-T109
:	O
a	O
10-year	O
follow-up study	B-T062
and	O
cell	B-T025
-based	O
verification	B-T169
Heart failure	B-T047
(	O
HF	B-T047
)	O
is	O
the	O
leading	O
cause of death	B-T033
in	O
the	O
world	B-T098
and	O
digoxin	B-T109
remains	O
one	O
of	O
the	O
oldest	O
therapies	B-T061
for	O
HF	B-T047
.	O
However,	O
its	O
safety	B-T068
and	O
efficacy	B-T080
have	O
been	O
controversial	O
since	O
its	O
initial	O
use	B-T169
and	O
there	O
is	O
uncertainty	B-T033
about	O
its	O
long-term	B-T079
efficacy	B-T080
and	O
safety	B-T068
.	O
Recently,	O
the	O
repositioning	B-T061
of	O
cardiac glycosides	B-T109
is	O
to	O
function	B-T169
in	O
anti-tumor activity	B-T061
via	O
multiple	B-T081
working pathways	B-T077
.	O
It	O
is	O
interesting	O
to	O
compare	B-T052
the	O
potential	B-T080
effects	B-T080
of	O
digoxin	B-T109
in	O
clinical	B-T080
patients	B-T101
and	O
cell lines	B-T025
.	O
First,	O
we	O
analyze	O
patient information	B-T170
retrieved	O
from	O
the	O
National Health Insurance Research database	B-T170
of	O
Taiwan	B-T083
between	O
January	O
1,	O
2000	O
and	O
December	O
31,	O
2000.	O
This	O
retrospective study	B-T062
included	O
a	O
study	O
cohort	B-T098
(1,219	O
patients	B-T101
)	O
and	O
a	O
comparison	B-T052
cohort	B-T098
.	O
Our	O
analytical data	B-T078
suggested	O
that	O
patients	B-T101
taking	O
digoxin	B-T109
are	O
at	O
an	O
increased	B-T081
risk of cancers	B-T081
,	O
including	O
breast	B-T191
,	O
liver	B-T191
,	O
and	O
lung cancers	B-T191
,	O
during	O
the	O
10-year	O
follow-up period	B-T058
.	O
In	O
contrast	O
to	O
the	O
anti-tumor function	B-T061
of	O
digoxin	B-T109
,	O
we	O
further	O
examined	O
the	O
potential	B-T080
pathway	B-T169
of	O
digoxin	B-T109
via	O
the	O
cell	B-T025
-based	O
strategy	B-T041
using	O
several	O
breast cancer	B-T191
cell lines	B-T025
,	O
including	O
MCF-7	B-T025
,	O
BT-474	B-T025
,	O
MAD-MB-231	B-T025
,	O
and	O
ZR-75-1	B-T025
.	O
Digoxin	B-T109
consistently	O
exerted	O
its	O
cytotoxicity	B-T049
to	O
these	O
four	O
cell lines	B-T025
with	O
various	O
range	O
of	O
concentration	B-T081
.	O
However,	O
the	O
proliferation	B-T169
of	O
ZR-75-1 cells	B-T025
was	O
the	O
only	O
cell lines	B-T025
induced	O
by	O
digoxin	B-T109
and	O
the	O
others	O
were	O
dramatically	O
suppressed	B-T169
by	O
digoxin	B-T109
.	O
The	O
responsiveness	B-T169
of	O
SRSF3	B-T028
to	O
digoxin	B-T109
might	O
be	O
involved	O
with	O
cell-type	B-T170
differences	B-T080
.	O
In	O
summary,	O
we	O
combined	O
a	O
cohort study	B-T081
for	O
digoxin	B-T109
treatment	B-T061
for	O
HF	B-T047
patients	B-T101
with	O
a	O
cell	B-T025
-based	O
strategy	B-T041
that	O
addresses	O
the	O
translation	O
issue,	O
which	O
revealed	O
the	O
complexity	B-T080
of	O
personalized medicine	B-T061
.	O

Comparison	O
and	O
Outcome	O
Analysis of Patients	B-T058
with	O
Takotsubo Cardiomyopathy	B-T047
Triggered by	B-T080
Emotional Stress	B-T048
or	O
Physical Stress	B-T046
Background:	O
Previous	O
studies	O
revealed	O
that	O
takotsubo cardiomyopathy	B-T047
(	O
TTC	B-T047
)	O
is	O
triggered by	B-T080
physical	B-T046
and	O
emotional stresses	B-T048
.	O
This	O
study	O
was	O
performed	O
to	O
determine	O
the	O
short-	B-T079
and	O
long-term	B-T079
prognostic	O
impact	O
of	O
emotional-	B-T048
and	O
physical stress	B-T046
associated with	B-T080
TTC	B-T047
.	O
Methods	O
and	O
results:	O
Our	O
institutional database	B-T170
constituted	O
a	O
collective	O
of	O
84	O
patients	B-T101
diagnosed	B-T033
with	O
TTC	B-T047
between	O
2003	O
and	O
2015.	O
The	O
patients	B-T101
were	O
divided	O
into	O
two	O
groups	B-T078
as	O
per	O
the	O
presence	O
of	O
emotional stress	B-T048
(n	O
=	O
24,	O
21%)	O
or	O
physical stress	B-T046
(n	O
=	O
60,	O
52.6%).	O
The	O
endpoint	B-T080
was	O
a	O
composite	B-T080
of	O
in-hospital events	B-T033
(	O
thromboembolic events	B-T046
and	O
life-threatening	B-T033
arrhythmias	B-T033
),	O
myocardial infarction	B-T047
,	O
all-	O
cause of mortality	B-T033
,	O
re-hospitalization	B-T058
due	O
to	O
heart failure	B-T047
,	O
stroke	B-T047
,	O
and	O
recurrence	B-T067
of	O
TTC	B-T047
.	O
A	O
Kaplan-Meier analysis	B-T081
indicated	O
a	O
significantly	O
lower	O
event-free	O
survival rate	B-T081
over	O
a	O
mean	O
follow-up	B-T058
of	O
5	O
years	O
in	O
the	O
emotional	B-T048
group	B-T078
than	O
the	O
physical stress	B-T046
group	B-T078
(log-rank,	O
p	O
<	O
0.01).	O
Multivariate Cox regression analysis	B-T170
revealed	O
only	O
emotional stress	B-T048
(HR	O
0.4,	O
95%	O
CI:	O
0.2-0.9,	O
p	O
<	O
0.05)	O
as	O
a	O
negative independent predictor	B-T033
of	O
the	O
primary	O
endpoint	B-T080
.	O
Conclusion:	O
Rates	O
of	O
in-hospital events	B-T033
and	O
short-	B-T079
as	O
well	O
as	O
long-term	B-T079
events	O
were	O
significantly	O
lower	O
in	O
TTC	B-T047
patients	B-T101
suffering	B-T048
from	O
emotional stress	B-T048
as	O
compared	O
to	O
patients	B-T101
with	O
physical stress	B-T046
.	O

Surviving	B-T169
moment	B-T079
to	O
moment	B-T079
:	O
The	O
experience	B-T041
of	O
living	B-T078
in	O
a	O
state	B-T033
of	O
ambivalence	B-T041
for	O
those	O
with	O
recurrent	B-T079
suicide attempts	B-T033
This	O
qualitative study	B-T062
aimed	O
to	O
capture	O
the	O
experience	B-T041
of	O
living	B-T078
in	O
the	O
ambivalent space	B-T041
between	O
life	B-T078
and	O
death	B-T078
for	O
adults	B-T100
with	O
recurrent	B-T079
suicide attempts	B-T033
(	O
RSA	B-T033
).	O
It	O
sought	O
to	O
expand	B-T082
upon	O
an	O
earlier	O
study	B-T062
that	O
explored	O
the	O
processes	B-T041
involved	B-T169
in	O
transitioning	B-T052
away	O
from	O
RSA	B-T033
among	O
adults	B-T100
,	O
which	O
revealed	B-T080
that	O
occupying	O
this	O
ambivalent space	B-T041
is	O
a	O
crucial	O
part	O
of	O
this	O
process	B-T067
.	O
Interpretive phenomenological analysis	B-T062
(	O
IPA	B-T062
)	O
was	O
used.	O
This	O
methodology	B-T078
was	O
designed	B-T052
to	O
explore	O
the	O
lived experiences	B-T041
and	O
meaning making	B-T041
and	O
enabled	O
interpretation	B-T062
of	O
the	O
multidimensional	B-T082
subjective	B-T080
experiences	B-T041
of	O
RSA	B-T033
participants	B-T098
.	O
In-depth	O
semi-structured interviews	B-UnknownType
were	O
conducted	B-T052
with	O
eight	O
adult women	B-T098
with	O
a	O
history	B-T169
of	O
RSA	B-T033
who	O
had	O
participated	B-T169
in	O
a	O
therapeutic intervention	B-T061
at	O
the	O
research	B-T062
site	B-T082
(	O
Skills	B-T055
for	O
Safer Living	B-T078
:	O
A	O
Psychosocial	B-T169
/	O
Psychoeducational Intervention	B-T065
for	O
People	B-T098
with	O
Recurrent	B-T079
Suicide Attempts	B-T033
[	O
SfSL	B-T078
/	O
PISA	B-T033
]).	O
The	O
six	O
stages	B-T079
of	O
IPA	B-T062
were	O
followed	O
to	O
analyse	B-T062
the	O
interview	B-T058
data	B-T078
.	O
Analysis	B-T062
revealed	B-T080
the	O
superordinate theme	B-UnknownType
,	O
'	O
surviving	B-T169
moment	B-T079
to	O
moment	B-T079
',	O
which	O
refers	O
to	O
a	O
precarious state	B-T033
of	O
making decisions	B-T041
about	O
one's	O
life	B-T078
and	O
destiny	B-T079
on	O
a	O
moment	B-T079
-to-	O
moment	B-T079
basis	O
without	O
clear	O
commitment	B-T041
to	O
either	O
life	B-T078
or	O
death	B-T078
.	O
Two	O
subordinate themes	B-UnknownType
were	O
identified	B-T080
:	O
'	O
deciding	B-T080
not	O
to	O
die	B-T033
in	O
the	O
moment	B-T079
'	O
when	O
the	O
participants	B-T098
were	O
more	O
invested	B-T169
in	O
dying	B-T033
than	O
living	B-T078
and	O
'	O
deciding	B-T080
to	O
live	B-T078
in	O
the	O
moment	B-T079
'	O
when	O
they	O
were	O
more	O
invested	B-T169
in	O
living	B-T078
than	O
dying	B-T033
.	O
The	O
study	B-T062
illuminated	O
the	O
complex	B-T080
process	B-T067
of	O
making decisions	B-T041
about	O
ones'	O
destiny	B-T079
on	O
a	O
moment	B-T079
-to-	O
moment	B-T079
basis.	O
It	O
revealed	B-T080
the	O
torment	O
experienced	B-T041
when	O
occupying	O
this	O
state	B-T033
,	O
while	O
paradoxically	B-T080
,	O
also	O
revealing	O
how	O
indecision	B-T033
about	O
life	B-T078
and	O
death	B-T078
provided	B-T052
a	O
lifeline	B-T078
opportunity	B-T080
for	O
those	O
with	O
RSA	B-T033
.	O
Clinicians	B-T097
who	O
recognize	O
the	O
subtle	O
distinctions	O
associated with	B-T080
this	O
in-between	O
state	B-T033
can	O
tailor	O
their	O
interventions	B-T061
accordingly.	O
Surviving	B-T169
moment	B-T079
to	O
moment	B-T079
is	O
characterized	B-T052
by	O
a	O
state	B-T033
of	O
emotional flux	B-T033
and	O
uncertainty	B-T033
about	O
one's	O
destiny	B-T079
,	O
where	O
the	O
person	B-T098
has	O
not	O
fully	O
committed	O
to	O
either	O
life	B-T078
or	O
death	B-T078
.	O
Within	O
this	O
state	B-T033
,	O
there	O
are	O
two	O
interlinked subprocesses	B-T041
,	O
whereby	O
the	O
person	B-T098
is	O
leaning	B-T078
more	O
towards	O
death	B-T078
or	O
life	B-T078
.	O
A	O
critical	O
feature	B-T080
in	O
working	B-T057
with	O
this	O
client group	B-T096
is	O
to	O
recognize	O
their	O
ambiguity	B-T080
and	O
the	O
fragility	B-T033
and	O
temporality	B-T041
of	O
their	O
decisions	B-T041
about	O
their	O
destiny	B-T079
.	O
The	O
practitioner	B-T097
has	O
an	O
opportunity	B-T080
to	O
be	O
a	O
catalyst	O
in	O
the	O
momentum	O
towards	O
life	B-T078
by	O
demonstrating	O
understanding	B-T041
of	O
this	O
survival	B-T169
struggle	B-T033
and	O
tailoring intervention	B-T061
to	O
fit	O
with	O
the	O
nuanced processes	B-T041
within	O
this	O
state	B-T033
.	O

Does	O
a	O
policy	B-T170
of	O
earlier induction	B-T061
affect	O
labour	B-T040
outcomes	B-T169
in	O
women	B-T098
induced	B-T169
for	O
postmaturity	B-T047
?	O
A	O
retrospective	B-T080
analysis	B-T062
in	O
a	O
tertiary hospital	B-T073
in	O
the	O
North	B-T082
of	O
England	B-T083
to	O
investigate	B-T169
whether	O
a	O
change	B-T169
in	O
the	O
management	B-T057
of	O
postmature pregnancy	B-T046
to	O
earlier induction	B-T061
affects	O
the	O
length of labour	B-T201
and	O
the	O
induction process	B-T061
.	O
Secondly,	O
to	O
assess	B-T052
the	O
feasibility	B-T062
of	O
the	O
research process	B-T062
to	O
inform	O
a	O
future	B-T079
larger study	B-T062
.	O
a	O
change	B-T169
in	O
management	B-T057
of	O
postmature pregnancy	B-T046
in	O
an	O
NHS	B-T058
hospital	B-T073
in	O
October	B-T079
2013,	O
from	O
induction	B-T061
at	O
42	O
weeks	B-T079
gestation	B-T040
to	O
induction	B-T061
between	O
41-42	O
weeks	B-T079
,	O
provided	B-T052
an	O
opportunity	B-T062
to	O
conduct	O
a	O
retrospective	B-T080
analysis	B-T062
.	O
Pre-existing	B-T080
data	B-T078
from	O
the	O
maternity	B-T054
database	B-T170
and	O
casenotes	B-T170
were	O
collected	B-T169
and	O
primary outcomes	B-T062
analysed	B-T062
using	O
the	O
Mann-Whitney test	B-T170
and	O
the	O
Hodges-Lehman confidence interval	B-T081
for	O
differences	B-T080
in	O
medians	B-T081
.	O
a	O
large city	B-T083
based	O
tertiary referral hospital	B-T073
in	O
the	O
North	B-T082
of	O
England	B-T083
.	O
125	O
women	B-T098
induced	B-T169
before	O
the	O
change	B-T169
in	O
policy	B-T170
were	O
compared	B-T052
with	O
309	O
women	B-T098
induced	B-T169
after	O
the	O
change	B-T169
.	O
primary outcomes	B-T062
were	O
length	B-T081
of	O
1st	B-T079
and	O
2nd stage of labour	B-T079
,	O
overall	O
length of labour	B-T201
,	O
length	B-T081
of	O
induction	B-T061
to	O
established	B-T080
labour	B-T040
and	O
length	B-T081
of	O
induction	B-T061
to	O
birth	B-T040
.	O
the	O
median	B-T081
overall	O
length of labour	B-T201
for	O
women	B-T098
induced	B-T169
at	O
42	O
weeks	B-T079
was	O
6.5	O
hours	B-T079
,	O
while	O
for	O
women	B-T098
induced	B-T169
at	O
41-42	O
weeks	B-T079
this	O
was	O
5.2	O
hours	B-T079
.	O
The	O
difference	B-T080
was	O
not	O
statistically significant	B-T081
(p=0.15,	O
95%	O
CI	B-T081
for	O
median	B-T081
difference	B-T080
-0.27	O
to	O
1.93	O
hours	B-T079
)	O
with	O
a	O
small effect size	B-T081
(	O
Pearson's	B-T081
r=-0.08).	O
The	O
median	B-T081
length	B-T081
of	O
induction	B-T061
to	O
birth	B-T040
was	O
13.6	O
hours	B-T079
for	O
women	B-T098
induced	B-T169
at	O
42	O
weeks	B-T079
and	O
16.5	O
hours	B-T079
for	O
women	B-T098
induced	B-T169
at	O
41-42	O
weeks	B-T079
.	O
This	O
difference	B-T080
was	O
also	O
not	O
statistically significant	B-T081
(p=0.14,	O
95%	O
CI	B-T081
for	O
median	B-T081
difference	B-T080
-7.25	O
to	O
1.20	O
hours	B-T079
)	O
with	O
a	O
small effect size	B-T081
(	O
Pearson's	B-T081
r=-0.13).	O
This	O
study	B-T062
demonstrated	O
no	O
statistically significant	B-T081
difference	B-T080
s	O
in	O
length of labour	B-T201
and	O
induction	B-T061
following	O
a	O
change	B-T169
in	O
the	O
management	B-T057
of	O
postmature pregnancy	B-T046
to	O
earlier induction	B-T061
.	O
A	O
large study	B-T062
is	O
needed	O
to	O
establish	B-T080
definitively	O
the	O
effects of	B-T080
earlier induction	B-T061
on	O
labour	B-T040
outcomes	B-T169
.	O

Liquid chromatography-mass spectrometry	B-T059
-based	O
quantitative proteomics analysis	B-T059
proteomics	B-T091
analysis	O
reveals	O
chondroprotective effects	B-T033
of	O
astragaloside IV	B-T109
in	O
interleukin-1β	B-T116
-	O
induced	B-T169
SW1353 chondrocyte-like cells	B-T025
Chondrocyte	B-T025
apoptosis	B-T043
played	O
a	O
key	O
role	O
on	O
the	O
progression	B-T046
of	O
Osteoarthritis	B-T047
(	O
OA	B-T047
).	O
Safe	O
and	O
effective	O
drugs	B-T061
are	O
urgently	O
needed	O
for	O
the	O
treatment	B-T169
of	O
OA	B-T047
.	O
Previous	O
study	B-T077
reported	O
that	O
Astragaloside IV	B-T109
(	O
ASG-IV	B-T109
)	O
had	O
exerted	O
a	O
protective effect	B-UnknownType
against	O
articular cartilage degeneration	B-T047
by	O
promoting	O
rapid	O
proliferation	B-T169
of	O
chondrocyte	B-T025
.	O
Therefore,	O
the	O
aim	O
of	O
our	O
study	B-T077
is	O
to	O
explore	O
the	O
effects	B-T169
and	O
mechanisms	B-T169
of	O
ASG-IV	B-T109
in	O
chondrocyte	B-T025
apoptosis	B-T043
.	O
Isobaric Tags For Relative And Absolute Quantitation (iTRAQ)-based quantitative proteomics	B-T059
proteomics	B-T091
was	O
used	O
to	O
quantitatively	O
detect	B-T033
and	O
map	B-T052
proteins	B-T116
in	O
SW1353 chondrocyte-like cells	B-T025
pre-treated	B-T169
with	O
ASG-IV	B-T109
or	O
interleukin-1β	B-T116
(	O
IL-1β	B-T116
)	O
or	O
ASG-IV	B-T109
+	O
IL-1β	B-T116
.	O
The	O
iTRAQ-labeled peptides	B-T116
were	O
fractionated	B-T080
by	O
high-accuracy liquid chromatography-mass spectrometry	B-T059
(	O
LC-MS	B-T059
).	O
Cell apoptosis	B-T043
and	O
differentially expressed proteins	B-T116
was	O
detected	B-T033
by	O
flow cytometry	B-T059
(	O
FCM	B-T059
),	O
quantitative real-time polymerase chain reaction	B-T063
(	O
qRT-PCR	B-T063
),	O
and	O
western blotting	B-T059
,	O
respectively.	O
The	O
apoptosis	B-T043
of	O
the	O
IL-1β	B-T116
-	O
induced	B-T169
SW1353 cells	B-T025
treated	B-T169
with	O
ASG-IV	B-T109
was	O
greatly	O
inhibited	B-T080
.	O
Bioinformatics	B-T091
Bioinformatics analysis	B-T059
revealed	O
that	O
gamma actin 1	B-T116
(	O
ACTG1	B-T116
)	O
and	O
Yes Associated Protein 1	B-T116
(	O
YAP1	B-T116
),	O
participating	O
in	O
the	O
Hippo signaling pathway	B-T043
and	O
Vitronectin	B-T116
(	O
VTN	B-T116
)	O
and	O
Collagen Type I Alpha 1 Chain	B-T116
(	O
COL1A1	B-T116
),	O
involving	O
in	O
the	O
extracellular matrix (ECM)-receptor interaction signaling pathway	B-T169
,	O
were	O
all	O
significantly	O
up-regulated	B-T044
in	O
the	O
IL-1β	B-T116
-	O
induced	B-T169
SW1353 cells	B-T025
after	O
treatment	B-T169
with	O
ASG-IV	B-T109
.	O
The	O
qRT-PCR	B-T063
and	O
Western blotting	B-T059
results	O
confirmed	O
the	O
up-regulation	B-T044
of	O
these	O
four	O
genes	B-T028
.	O
ASG-IV	B-T109
played	O
a	O
positive role	B-T033
in	O
human	B-T016
osteoarthritic chondrocyte apoptosis	B-T043
chondrocyte	B-T025
apoptosis,	O
possibly	O
through	O
modulation	B-UnknownType
of	O
the	O
Hippo signaling pathway	B-T043
by	O
up-regulating	B-T044
YAP1	B-T116
and	O
ACTG1	B-T116
expression	B-T045
,	O
and	O
also	O
by	O
up-regulating	B-T044
VTN	B-T116
and	O
COL1A1	B-T116
,	O
which	O
are	O
involved	O
in	O
the	O
ECM-receptor interaction pathway	B-T169
.	O
Taken	O
together,	O
all	O
the	O
results	O
suggested	O
that	O
ASG-IV	B-T109
had	O
a	O
novel	O
therapeutic	B-T169
potential	B-T080
for	O
the	O
treatment	B-T169
of	O
OA	B-T047
.	O

Open-label, multicentre safety study	B-T062
of	O
vemurafenib	B-T109
in	O
3219	O
patients	B-T101
with	O
BRAF(V600) mutation	B-T049
-	O
positive	B-T033
metastatic melanoma	B-T191
:	O
2-year	O
follow-up	B-T058
data	B-T078
and	O
long-term	B-T079
responders' analysis	B-T062
The	O
orally	B-T082
available	O
BRAF kinase inhibitor	B-T116
vemurafenib	B-T109
is	O
an	O
effective	B-T080
and	O
tolerable	B-T080
treatment option	B-T061
for	O
patients	B-T101
with	O
metastatic melanoma	B-T191
harbouring	O
BRAF(V600) mutations	B-T049
.	O
We	O
assessed	B-T052
the	O
safety	B-T080
of	O
vemurafenib	B-T109
in	O
a	O
large	B-T081
population	B-T098
of	O
patients	B-T101
with	O
few	O
alternative	B-T077
treatment options	B-T061
;	O
we	O
report	O
updated	O
2-year	O
safety	B-T080
.	O
This	O
was	O
an	O
open-label, multicentre study	B-T062
of	O
vemurafenib	B-T109
(960	O
mg	O
bid)	O
in	O
patients	B-T101
with	O
previously	O
treated	B-T169
or	O
untreated	B-T033
BRAF mutation	B-T049
-	O
positive	B-T033
metastatic melanoma	B-T191
(	O
cobas(®) 4800	B-T074
BRAF V600 Mutation Test	B-T059
).	O
The	O
primary	B-T080
end-point	B-T080
was	O
safety	B-T080
;	O
efficacy	O
end-points	B-T080
were	O
secondary	B-T080
.	O
An	O
exploratory analysis	B-T062
was	O
performed	O
to	O
assess	B-T058
safety	B-T080
outcomes	B-T080
in	O
patients	B-T101
with	O
long	B-T080
duration of response	B-T079
(	O
DOR	B-T079
)	O
(≥12	O
or	O
≥24	O
months	B-T079
).	O
After	O
a	O
median	B-T082
follow-up	B-T058
of	O
32.2	O
months	B-T079
(95%	O
CI,	O
31.1-33.2	O
months	B-T079
),	O
3079/3219	O
patients	B-T101
(96%)	O
had	O
discontinued treatment	B-T033
.	O
Adverse events	B-T046
(	O
AEs	B-T046
)	O
were	O
largely	O
consistent with	B-T078
previous	O
reports;	O
the	O
most	O
common	O
all-grade	O
treatment	B-T169
-related	O
AEs	B-T046
were	O
arthralgia	B-T184
(37%),	O
alopecia	B-T047
(25%)	O
and	O
hyperkeratosis	B-T047
(23%);	O
the	O
most	O
common	O
grade	O
3/4	O
treatment	B-T169
-related	O
AEs	B-T046
were	O
squamous cell carcinoma of the skin	B-T191
(8%)	O
and	O
keratoacanthoma	B-T191
(8%).	O
In	O
the	O
exploratory analysis	B-T062
,	O
patients	B-T101
with	O
DOR	B-T079
≥12	O
months	B-T079
(n	O
=	O
287)	O
or	O
≥24	O
months	B-T079
(n	O
=	O
133)	O
were	O
more	O
likely	O
to	O
experience	O
grade	O
3/4	O
AEs	B-T046
than	O
the	O
overall	B-T080
population	B-T098
.	O
No	O
new	O
specific	B-T080
safety signals	B-T073
were	O
observed	O
with	O
longer	O
vemurafenib	B-T109
vemurafenib exposure	B-T033
.	O
After	O
2	O
years'	O
follow-up	B-T058
,	O
safety	B-T080
was	O
maintained	O
in	O
this	O
large group	B-UnknownType
of	O
patients	B-T101
with	O
BRAF(V600) mutation	B-T049
-	O
positive	B-T033
metastatic melanoma	B-T191
who	O
are	O
more	O
representative	O
of	O
routine	O
clinical practice	B-T057
than	O
typical	O
clinical trial	B-T062
populations	B-T098
.	O
These	O
data	O
suggest	O
that	O
long-term	B-T079
vemurafenib	B-T109
treatment	B-T169
is	O
effective	B-T080
and	O
tolerable	B-T080
without	O
the	O
development	O
of	O
new	O
safety signals	B-T073
.	O

Collecting	B-T062
and	O
Reporting Safety Data	B-T062
and	O
Monitoring Trial Conduct	B-T062
In	O
Pragmatic Trials	B-T062
Pragmatic trials	B-T062
offer	O
the	O
opportunity	B-T062
to	O
obtain	O
real-life	B-T078
data	B-T078
on	O
the	O
relative	O
effectiveness	B-T080
and	O
safety	B-T068
of	O
a	O
treatment	B-T061
before	O
or	O
after	O
market authorisation	B-T064
.	O
This	O
is	O
the	O
penultimate paper	B-T078
in	O
a	O
series	O
of	O
eight,	O
describing	O
the	O
impact	O
of	O
design	B-T090
choices	B-T052
on	O
the	O
practical	O
implementation	B-T052
of	O
pragmatic trials	B-T062
.	O
This	O
paper	B-T078
focuses	O
on	O
the	O
practical	O
challenges	O
of	O
collecting	B-T062
and	O
reporting safety data	B-T062
and	O
of	O
monitoring trial conduct	B-T062
while	O
maintaining	O
routine	O
clinical care practice	B-T061
.	O
Current	O
ICH	B-T170
guidance	O
recommends	O
that,	O
all	O
serious adverse events	B-T033
(	O
SAEs	B-T033
)	O
and	O
all	O
drug	B-T121
-related	O
events	O
must	O
be	O
reported	O
in	O
an	O
interventional	B-T061
trial	B-T062
.	O
In	O
line	O
with	O
current	O
guidance,	O
we	O
propose	O
a	O
risk	B-T078
based	O
approach	B-T082
to	O
the	O
collection	B-T062
of	O
non	B-T033
-	O
drug	B-T121
related	O
non-serious AEs	B-T033
,	O
and	O
even	O
serious events	B-T080
not	O
related	O
to	O
treatment	B-T061
based	O
on	O
the	O
risk	B-T078
profile	B-T169
of	O
the	O
medicine	B-T121
/class	O
in	O
the	O
patient	B-T101
population	B-T098
of	O
interest.	O
Different	O
options	O
available	O
to	O
support	O
the	O
collection	B-T062
and	O
reporting of safety data	B-T062
whilst	O
minimizing	O
study	B-T062
-related	O
follow-up visits	B-T058
are	O
discussed.	O
A	O
risk	B-T078
-based	O
approach	B-T082
to	O
monitoring trial conduct	B-T062
is	O
also	O
discussed,	O
highlighting	O
the	O
difference	O
in	O
the	O
balance	O
of	O
risks	B-T078
likely	O
to	O
occur	O
in	O
a	O
pragmatic trial	B-T062
compared	O
to	O
traditional	O
clinical trials	B-T062
,	O
and	O
the	O
careful	O
consideration	O
that	O
must	O
be	O
given	O
to	O
the	O
mitigation	B-T067
and	O
management of these risks	B-T058
in	O
order	O
to	O
maintain	O
routine	O
care	B-T052
.	O

A	O
pilot study	B-T062
of	O
intraocular lens explantation	B-T061
in	O
69	O
eyes	B-T023
in	O
Chinese patients	B-T101
To	O
study	O
the	O
effects	O
of	O
intraocular lens (IOL) explantation	B-T061
and	O
demographic characteristics	B-T102
.	O
Retrospective	B-T080
non-comparative case series	B-T062
.	O
Clinical data	B-T170
recorded	O
from	O
patient charts	B-T073
included	O
the	O
following:	O
demographic	B-T102
,	O
preoperative	B-T058
and	O
postoperative	B-T079
characteristics	B-T080
;	O
complications	B-T046
;	O
surgical methods	B-UnknownType
,	O
and	O
changes	O
in	O
visual acuity	B-T060
.	O
A	O
total	O
of	O
69	O
eyes	B-T023
in	O
67	O
Chinese	B-T098
patients	B-T101
who	O
received	O
IOL explants	B-T061
were	O
studied.	O
The	O
patients	B-T101
'	O
mean	O
age	B-T032
at	O
the	O
time of explantation	B-T079
was	O
46.1	O
years	O
old	O
[SD	O
22.5	O
(6-85)],	O
and	O
37	O
patients were female	B-T032
(55.2%).	O
Regarding	O
employment	B-T080
,	O
47.8%	O
were	O
farmers	B-T097
,	O
23.9%	O
were	O
retired	B-T097
,	O
16.4%	O
were	O
students	B-T098
,	O
4.5%	O
were	O
unemployed	B-T033
,	O
3%	O
were	O
workers	B-T098
,	O
and	O
4.5%	O
were	O
other	O
(including	O
staff members	B-T097
,	O
teachers	B-T097
and	O
officers	B-T078
).	O
The	O
main	O
reasons	O
for	O
explantation	B-T061
were	O
dislocation	B-T037
/	O
decentration	B-T033
in	O
41	O
cases	O
(59.4%)	O
and	O
retinal detachment	B-T047
in	O
10	O
cases	O
(14.5%).	O
The	O
third	O
most	O
prevalent cause	B-T169
was	O
incorrect lens power	B-T033
in	O
7	O
eyes	B-T023
(10.1%).	O
The	O
remaining	O
reasons	O
were	O
endophthalmitis	B-T047
in	O
6	O
cases	O
(8.7%),	O
posterior capsular opacity	B-T047
in	O
3	O
eyes	B-T023
(4.3%),	O
and	O
impacting	B-T080
retinal surgery operation	B-T061
in	O
2	O
cases	O
(2.9%).	O
The	O
main	O
comorbidities	B-T078
were	O
high myopia	B-T047
in	O
18	O
eyes	B-T023
(26.1%),	O
trauma	B-T037
in	O
8	O
eyes	B-T023
(11.6%),	O
retinal detachment	B-T047
in	O
6	O
eyes	B-T023
(8.7%),	O
congenital cataracts	B-T019
in	O
8	O
eyes	B-T023
(11.6%),	O
and	O
Marfan's syndrome	B-T047
in	O
2	O
eyes	B-T023
(2.9%).	O
The	O
mean time from implantation to explantation	B-T079
was	O
4.0y	O
[SD	O
4.2	O
(0.005-15)].	O
Treatment after explantation	B-T058
included	O
posterior chamber IOL implantation	B-T061
in	O
44	O
eyes	B-T023
(63.8%)	O
and	O
aphakia	B-T190
in	O
25	O
eyes	B-T023
(36.2%).	O
After surgery	B-T033
,	O
the	O
best corrected visual ability	B-T033
(	O
BCVA	B-T033
)	O
was	O
improved	O
in	O
50	O
cases	O
(72.5%),	O
including	O
28	O
patients	B-T101
(40.6%)	O
in	O
whom	O
visual ability	B-T201
was	O
improved	O
by	O
more	O
than	O
two	O
lines.	O
Dislocation	B-T037
/	O
decentration	B-T033
is	O
the	O
main cause	B-T169
for	O
explantation	B-T061
,	O
and	O
high myopia	B-T047
is	O
a	O
main risk factor	B-T033
.	O
Posterior chamber IOL implantation	B-T061
remains	O
the	O
most	O
elected	O
treatment after explantation	B-T058
.	O

Improvement	B-T077
of	O
older	B-T098
-	O
person	B-T098
-	O
specific	B-T080
QOL	B-T078
after	O
hearing aid	B-T074
fitting	B-T061
and	O
its	O
relation	B-T080
to	O
social interaction	B-T033
This	O
study	B-T062
aimed	B-T078
to	O
investigate	B-T169
whether	O
hearing aids	B-T074
use	O
is	O
associated with	B-T080
improvement	B-T077
of	O
older	B-T098
-	O
person	B-T098
-	O
specific	B-T080
QOL	B-T078
and	O
whether	O
social interactions	B-T033
modify	B-T169
the	O
association	B-T080
.	O
The	O
WHOQOL-OLD questionnaire	B-T170
was	O
answered	B-T170
by	O
105	O
older adults	B-T098
aged	B-T032
60	O
to	O
90	O
years	O
who	O
were	O
newly	B-T078
fitted	B-T061
hearing aids	B-T074
on	O
the	O
day	O
of	O
fitting	B-T061
and	O
at	O
2	O
-	O
6	O
months	O
afterward	B-T079
.	O
The	O
associations	B-T080
between	O
the	O
daily	O
hours	O
of	O
hearing aid	B-T074
usage	B-T169
and	O
social relations	B-UnknownType
with	O
changes	B-T169
in	O
the	O
WHOQOL-OLD	B-T170
total score	B-T081
after	O
hearing aids	B-T074
fitting	B-T061
were	O
estimated	B-T081
adjusting	B-T061
for	O
possible	B-T033
confounders	B-T169
.	O
Older	B-T098
persons	B-T098
with	O
hearing loss	B-T033
experienced	B-T052
significant	B-T078
increases	B-T169
in	O
WHOQOL-OLD	B-T170
total score	B-T081
after	O
hearing aid	B-T074
fitting	B-T061
.	O
Regular	B-T080
use of	B-T169
hearing aid	B-T074
was	O
associated with	B-T080
a	O
greater	B-T081
increase	B-T169
in	O
the	O
total score	B-T081
.	O
The	O
combined	B-T080
categorical	B-T170
variable	B-T080
of	O
social relations	B-UnknownType
and	O
hearing aid	B-T074
usage	B-T169
revealed	B-T080
no	O
separate	B-T080
effects	B-T080
of	O
these	O
two	O
variables	B-T080
,	O
but	O
a	O
combined	B-T080
effect	B-T080
;	O
only	O
those	O
with	O
frequent	B-T079
social interactions	B-T033
who	O
used	O
their	O
hearing aid	B-T074
regularly	B-T080
had	O
a	O
significantly	B-T078
greater	B-T081
increase	B-T169
in	O
WHOQOL-OLD	B-T170
total score	B-T081
.	O
This	O
study's	B-T062
findings	B-T169
indicate	B-T080
that	O
hearing aid	B-T074
fitting	B-T061
may	O
be	O
associated with	B-T080
a	O
subsequent	B-T079
improvement	B-T077
in	O
older	B-T098
-	O
person	B-T098
-	O
specific	B-T080
QOL	B-T078
by	O
improvements	B-T077
in	O
hearing	B-T039
due	O
to	O
the	O
hearing aid	B-T074
,	O
and	O
possibly	B-T033
enhanced	B-T052
communication	B-T054
opportunities	B-T080
.	O

Enhancing	O
Comparative Effectiveness Research	B-T062
With	O
Automated	B-T169
Pediatric	B-T080
Pneumonia	B-T047
Detection	B-T061
in	O
a	O
Multi-Institutional	B-T093
Clinical	B-T080
Repository	B-T073
:	O
A	O
PHIS	B-T170
+	O
Pilot Study	B-T062
Community-acquired pneumonia	B-T047
is	O
a	O
leading	O
cause	O
of	O
pediatric	B-T080
morbidity	B-T081
.	O
Administrative	B-T169
data	B-T078
are	O
often	O
used	O
to	O
conduct	O
comparative effectiveness research	B-T062
(	O
CER	B-T062
)	O
with	O
sufficient	O
sample sizes	B-T081
to	O
enhance	O
detection	B-T033
of	O
important	B-T080
outcomes	B-T169
.	O
However,	O
such	O
studies	O
are	O
prone	O
to	O
misclassification errors	B-T080
because	O
of	O
the	O
variable	B-T080
accuracy	B-T080
of	O
discharge diagnosis	B-T033
codes	B-T170
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
develop	O
an	O
automated	B-T169
,	O
scalable	B-T169
,	O
and	O
accurate	B-T080
method	B-T170
to	O
determine	B-T080
the	O
presence	B-T033
or	O
absence	B-T169
of	O
pneumonia	B-T047
in	O
children	B-T100
using	O
chest imaging	B-T060
reports	B-T170
.	O
The	O
multi-institutional	B-T093
PHIS	B-T170
+	O
clinical	B-T080
repository	B-T073
was	O
developed	O
to	O
support	O
pediatric	B-T080
CER	B-T062
by	O
expanding	O
an	O
administrative	B-T169
database	B-T170
of	O
children's hospitals	B-T093
with	O
detailed	O
clinical	B-T080
data	B-T078
.	O
To	O
develop	O
a	O
scalable	B-T169
approach	O
to	O
find	B-T033
patients	B-T101
with	O
bacterial pneumonia	B-T047
more	O
accurately,	O
we	O
developed	O
a	O
Natural Language Processing	B-T066
(	O
NLP	B-T066
)	O
application	B-T080
to	O
extract	O
relevant	B-T080
information	B-T078
from	O
chest diagnostic imaging	B-T060
reports	B-T170
.	O
Domain	B-T169
experts	B-T097
established	B-T080
a	O
reference standard	B-T081
by	O
manually	B-T033
annotating	B-T169
282	O
reports	B-T170
to	O
train	O
and	O
then	O
test	O
the	O
NLP	B-T066
application	B-T080
.	O
Findings	O
of	O
pleural effusion	B-T047
,	O
pulmonary infiltrate	B-T033
,	O
and	O
pneumonia	B-T047
were	O
automatically	B-T033
extracted	O
from	O
the	O
reports	B-T170
and	O
then	O
used	O
to	O
automatically	B-T033
classify	B-T185
whether	O
a	O
report	B-T170
was	O
consistent with	B-T078
bacterial pneumonia	B-T047
.	O
Compared	B-T052
with	O
the	O
annotated	O
diagnostic imaging	B-T060
reports	B-T170
reference standard	B-T081
,	O
the	O
most	O
accurate	B-T080
implementation	B-T052
of	O
machine learning	B-T066
algorithms	B-T170
in	O
our	O
NLP	B-T066
application	B-T080
allowed	O
extracting	O
relevant	B-T080
findings	B-T169
with	O
a	O
sensitivity	B-T081
of	O
.939	O
and	O
a	O
positive	B-T033
predictive value	B-T080
of	O
.925.	O
It	O
allowed	O
classifying	B-T185
reports	B-T170
with	O
a	O
sensitivity	B-T081
of	O
.71,	O
a	O
positive	B-T033
predictive value	B-T080
of	O
.86,	O
and	O
a	O
specificity	B-T081
of	O
.962.	O
When	O
compared	B-T052
with	O
each	O
of	O
the	O
domain	B-T169
experts	B-T097
manually	B-T033
annotating	B-T169
these	O
reports	B-T170
,	O
the	O
NLP	B-T066
application	B-T080
allowed	O
for	O
significantly higher	B-T081
sensitivity	B-T081
(.71	O
vs	O
.527)	O
and	O
similar	O
positive	B-T033
predictive value	B-T080
and	O
specificity	B-T081
.	O
NLP	B-T066
-based	O
pneumonia	B-T047
information	B-T078
extraction	O
of	O
pediatric	B-T080
diagnostic imaging	B-T060
reports	B-T170
performed	B-T169
better	O
than	O
domain	B-T169
experts	B-T097
in	O
this	O
pilot study	B-T062
.	O
NLP	B-T066
is	O
an	O
efficient	O
method	O
to	O
extract	O
information	B-T078
from	O
a	O
large	O
collection	B-T169
of	O
imaging reports	B-T170
to	O
facilitate	O
CER	B-T062
.	O

Determination	B-T058
of	O
volatile organic compounds	B-T109
exhaled	B-T040
by	O
cell lines	B-T025
derived	B-T080
from	O
hematological malignancies	B-T191
Background:	O
The	O
gas	B-T104
human	B-T016
exhaled	B-T040
contains	O
many	O
volatile organic compounds	B-T109
(	O
VOCs	B-T109
),	O
which	O
is	O
related	O
to	O
the	O
health status	B-T080
of	O
body	B-T016
.	O
Analysis	B-T062
of	O
VOCs	B-T109
has	O
been	O
proposed	O
as	O
a	O
noninvasive	B-T185
diagnostic tool	B-T060
for	O
certain	O
cancers	B-T191
.	O
Detailed	O
research	O
on	O
the	O
VOCs	B-T109
in	O
gas	B-T104
exhaled	B-T040
by	O
cell	B-T025
can	O
characterize	O
cell type	B-T170
specific	O
metabolites	B-T123
and	O
may	O
be	O
helpful	O
to	O
detect	O
the	O
cancer markers	B-T123
in	O
clinical practice	B-T057
.	O
Methods:	O
Solid phase microextraction	B-T059
-	O
gas chromatography	B-T059
-	O
mass spectrometry	B-T059
was	O
used	O
to	O
detect	O
VOCs	B-T109
in	O
the	O
headspace	O
of	O
tissue culture flask	B-T074
in	O
non-Hodgkin's lymphoma	B-T191
cell line JEKO	B-T025
and	O
acute mononuclear leukemia	B-T191
cell line SHI-1	B-T025
,	O
to	O
elaborate	O
the	O
characteristic	O
gaseous	B-T104
biomarkers	B-T123
of	O
hematological malignancies	B-T191
.	O
While	O
macrophage cells	B-T025
and	O
lymphocytic cells	B-T025
were	O
acted	O
as	O
control	B-T096
.	O
The	O
blank group	B-T078
was	O
only	O
the	O
RPMI 1640 medium	B-T130
containing	O
10%	O
fetal calf serum	B-T130
that	O
without	O
cells	B-T025
.	O
Results:	O
Comparing	O
to	O
control group	B-T096
,	O
the	O
concentration	B-T081
of	O
dimethyl sulphide	B-T123
,	O
2,4-dimethyl-heptane	B-T123
,	O
methylbenzene	B-T109
,	O
o-xylene	B-T109
,	O
dodecane	B-T109
and	O
1,3-ditert-butylbenzene	B-T123
in	O
JEKO cells	B-T025
were	O
relatively	O
higher,	O
while	O
the	O
concentration	O
of	O
ethanol	B-T109
,	O
hexanal	B-T109
and	O
benzaldehyde	B-T109
was	O
lower.	O
In	O
SHI-1 cells	B-T025
,	O
the	O
levels	O
of	O
2,4-dimethyl-heptane	B-T123
,	O
benzene	B-T109
,	O
4-methyldecane	B-T123
,	O
chloroform	B-T109
,	O
3,7-dimethyl dodecane	B-T123
and	O
hexadecane	B-T109
were	O
significantly	O
elevated,	O
but	O
the	O
levels	O
of	O
hexanol	B-T109
and	O
cyclohexanol	B-T109
were	O
distinctly	O
reduced.	O
Conclusions:	O
This	O
pilot study	B-T062
revealed	O
that	O
the	O
malignant hematological	B-T191
cells	B-T025
could	O
change	O
the	O
components	O
of	O
VOCs	B-T109
in	O
the	O
cell culture flask	B-T059
in	O
a	O
cell type	B-T170
specific	O
pattern.	O
The	O
traits	O
of	O
VOCs	B-T109
in	O
our	O
setting	O
offered	O
new	O
strategy	O
for	O
hematological malignancies	B-T191
tracing,	O
and	O
would	O
act	O
as	O
potential	O
biomarkers	B-T123
in	O
diagnosis	B-T033
of	O
malignant	B-T080
hematological diseases	B-T047
.	O

Intratympanic steroid delivery	B-T169
steroid	B-T109
delivery	O
by	O
an	O
indwelling catheter	B-T074
in	O
refractory severe sudden sensorineural hearing loss	B-T047
Many	O
studies	O
over	O
the	O
last	O
decade	B-T081
showed	O
favorable	O
outcomes	B-T080
with	O
intratympanic	B-T169
(	O
IT	B-T169
)	O
steroid	B-T109
steroid treatment	B-T061
,	O
alone	O
as	O
salvage treatment	B-T061
or	O
in	O
combination	O
with	O
conventional	O
systemic therapy	B-T061
(	O
ST	B-T061
).	O
However,	O
in	O
severe	O
to	O
profound	O
sensorineural hearing loss	B-T047
resistant	B-T169
to	O
ST	B-T061
,	O
the	O
optimal	O
infusion mode	B-T061
,	O
the	O
type	B-T080
and	O
concentration	B-T081
of	O
the	O
solution	B-T167
,	O
the	O
preferable	O
drug	B-T121
,	O
its	O
total amount	B-T081
,	O
and	O
the	O
duration	B-T079
and	O
fractionation	B-T061
of	O
the	O
treatment	B-T061
are	O
still	O
debated.	O
Aim	O
of	O
the	O
study	O
was	O
to	O
investigate	B-T169
the	O
feasibility	O
and	O
the	O
outcomes	B-T080
of	O
a	O
direct and constant IT delivery	B-T169
of	O
dexamethasone	B-T109
(	O
DEX	B-T109
)	O
by	O
means	O
of	O
a	O
new	O
indwelling catheter	B-T074
.	O
A	O
prospective case-control study	B-T062
in	O
a	O
tertiary referral university hospital	B-T073
.	O
Ninety-nine	O
subjects	B-T098
treated	B-T169
with	O
ST	B-T061
only	O
and	O
28	O
with	O
additional	O
IT	B-T169
DEX	B-T109
have	O
been	O
included	O
in	O
the	O
study.	O
A	O
4 Fr catheter	B-T074
inserted	B-T058
in	O
a	O
sub-annular fashion	B-T080
with	O
a	O
minimal	O
postero-inferior	B-T082
tympanotomy	B-T061
through	O
and	O
endocanalar approach	B-T082
under	O
local anesthesia	B-T061
.	O
DEX	B-T109
4mg/ml	O
delivered	O
daily,	O
up	O
to	O
7	O
days	B-T079
.	O
Daily	O
bone and air-conducted pure tone	B-T060
and	O
speech audiometry	B-T060
were	O
performed	O
with	O
a	O
follow-up	O
at	O
1,	O
3,	O
6	O
months	B-T079
after	O
treatment	B-T061
.	O
Twenty-one	O
out	O
of	O
28	O
patients	B-T101
(75%)	O
refractory	B-T169
to	O
ST	B-T061
gained	O
on	O
average	O
24.0dB±20.5dB	O
HL	B-T033
after	O
IT	B-T169
-	O
DEX	B-T109
,	O
compared	O
to	O
35.4%	O
(average	O
6.7dB±16.6dB	O
HL	B-T033
)	O
of	O
those	O
receiving	O
only	O
medical	O
ST	B-T061
(p<0.001).	O
No	O
significant	O
side effects	B-T046
were	O
noted.	O
In	O
severe	O
to	O
profound	O
sudden deafness	B-T184
refractory	B-T169
to	O
conventional	O
ST	B-T061
,	O
the	O
daily	O
perfusion	B-T061
of	O
4mg/ml	O
DEX	B-T109
through	O
an	O
intratympanic	B-T169
catheter	B-T074
is	O
an	O
easy,	O
well	O
accepted	O
procedure	O
that	O
enables	O
patients	B-T101
to	O
receive	O
a	O
drug	B-T121
in	O
the	O
middle ear	B-T030
in	O
a	O
repeatable	B-T061
or	O
sustained form	B-T122
,	O
with	O
minimal	O
discomfort and a partial rescue	B-T062
(67.86%)	O
and	O
a	O
speech recognition	B-T041
gain	O
of	O
39%.	O

Design	B-T052
,	O
synthesis	B-T052
and	O
anti-tumor activity	B-T044
study	B-T062
of	O
novel	O
histone deacetylase inhibitors	B-T116
containing	O
isatin	B-T109
-based	O
caps	B-T104
and	O
o-phenylenediamine	B-T109
-based	O
zinc binding groups	B-T104
As	O
a	O
hot	O
topic	O
of	O
epigenetic studies	B-T091
,	O
histone deacetylases	B-T116
(	O
HDACs	B-T116
)	O
are	O
related	O
to	O
lots	O
of	O
diseases	B-T047
,	O
especially	O
cancer	B-T191
.	O
Further	O
researches	B-T062
indicated	O
that	O
different	B-T080
HDAC isoforms	B-T116
played	O
various	O
roles	B-T077
in	O
a	O
wide	O
range	O
of	O
tumor types	B-T033
.	O
Herein	O
a	O
novel	O
series	B-T081
of	O
HDAC inhibitors	B-T116
with	O
isatin	B-T109
-based	O
caps	B-T104
and	O
o-phenylenediamine	B-T109
-based	O
zinc binding groups	B-T104
have	O
been	O
designed	B-T052
and	O
synthesized	B-T052
through	B-T169
scaffold hopping strategy	B-T059
.	O
Among	O
these	O
compounds	B-T103
,	O
the	O
most	O
potent	O
compound 9n	B-T103
exhibited	O
similar	O
if	O
not	O
better	B-T080
HDAC	B-T116
inhibition	B-T039
and	O
antiproliferative activities	B-T044
against	O
multiple	B-T081
tumor cell lines	B-T025
compared	B-T052
with	O
the	O
positive control	B-T077
entinostat	B-T109
(	O
MS-275	B-T109
).	O
Additionally,	O
compared	B-T052
with	O
MS-275	B-T109
(	O
IC50	B-T081
values	B-T081
for	O
HDAC1	B-T116
,	O
2	B-T116
and	O
3	B-T116
were	O
0.163,	O
0.396	O
and	O
0.605µM,	O
respectively),	O
compound 9n	B-T103
with	O
IC50	B-T081
values	B-T081
of	O
0.032,	O
0.256	O
and	O
0.311µM	O
for	O
HDAC1	B-T116
,	O
2	B-T116
and	O
3	B-T116
respectively,	O
showed	O
a	O
moderate	O
HDAC1	B-T116
selectivity	B-T080
.	O

Efficacy	B-T080
of	O
42	O
Pharmacologic	B-T121
Cotreatment	B-T061
Strategies	O
Added	O
to	O
Antipsychotic	B-T121
Monotherapy	B-T061
in	O
Schizophrenia	B-T048
:	O
Systematic	O
Overview	O
and	O
Quality	B-T080
Appraisal	O
of	O
the	O
Meta-analytic	B-T062
Evidence	B-T078
Limited	O
treatment	B-T061
responses	B-T032
in	O
schizophrenia	B-T048
prompted	O
the	O
testing	O
of	O
combining	O
an	O
antipsychotic drug	B-T121
treatment	B-T061
with	O
a	O
second	O
psychotropic	B-T121
medication	B-T121
.	O
A	O
comprehensive	O
evaluation	B-T058
of	O
the	O
efficacy	B-T080
of	O
multiple	O
medication	B-T121
combinations	B-T121
is	O
missing.	O
To	O
summarize	O
and	O
compare	O
the	O
meta-analytically	B-T062
determined	O
efficacy	B-T080
of	O
pharmacologic	B-T121
combination	B-T121
strategies	O
of	O
antipsychotic drugs	B-T121
in	O
adults	B-T100
with	O
schizophrenia	B-T048
.	O
Systematic	O
search	O
of	O
PubMed	B-T170
and	O
PsycInfo	B-T170
until	O
May	O
13,	O
2016.	O
Meta-analyses	B-T062
of	O
randomized clinical trials	B-T062
comparing	O
the	O
efficacy	B-T080
of	O
antipsychotic drugs	B-T121
combined	O
with	O
other	O
antipsychotic	B-T121
or	O
nonantipsychotic medications	B-T121
vs	O
placebos	B-T122
or	O
antipsychotic	B-T121
monotherapy	B-T061
among	O
adults	B-T100
with	O
schizophrenia	B-T048
.	O
Independent	O
reviewers	B-T098
extracted	O
the	O
data	B-T078
and	O
assessed	O
the	O
quality	B-T080
of	O
the	O
methods	B-T170
of	O
the	O
included	O
meta-analyses	B-T062
using	O
A	O
Measurement Tool to Assess Systematic Reviews	B-T170
(	O
AMSTAR	B-T170
),	O
adding	O
6	O
new	O
items	O
to	O
rate	O
their	O
quality	B-T080
.	O
Effect sizes	B-T081
,	O
expressed	O
as	O
standardized mean difference	B-T201
/Hedges	O
g	O
or	O
risk ratio	B-T081
,	O
were	O
compared	O
separately	O
for	O
combinations	B-T121
with	O
any	O
antipsychotic drug	B-T121
and	O
for	O
combinations	B-T121
with	O
clozapine	B-T109
.	O
The	O
primary	O
outcome	O
was	O
total	O
symptom	B-T184
reduction	B-T080
.	O
Secondary	O
outcomes	O
included	O
positive	B-T033
and	O
negative	B-T033
symptoms	B-T184
,	O
treatment recommendations	B-T058
by	O
authors,	O
study-defined	O
inefficacies	B-T033
,	O
cognitive	B-T169
and	O
depressive symptoms	B-T184
,	O
discontinuation	B-T058
of	O
treatment	B-T061
because	O
of	O
any	O
cause,	O
and	O
inefficacies	B-T033
or	O
intolerabilities.	O
Of	O
3397	O
publications,	O
29	O
meta-analyses	B-T062
testing	O
42	O
combination	B-T121
strategies	O
in	O
381	O
individual	B-T098
trials	O
and	O
among	O
19	O
833	O
participants	B-T098
were	O
included.	O
For	O
total	O
symptom	B-T184
reductions	B-T061
,	O
32	O
strategies	O
that	O
augmented	O
any	O
antipsychotic drug	B-T121
and	O
5	O
strategies	O
that	O
augmented	O
clozapine	B-T109
were	O
examined.	O
Fourteen	O
combination	B-T121
treatments	B-T061
outperformed	O
controls	O
(	O
standard mean difference	B-T201
/Hedges	O
g,	O
-1.27	O
[95%	O
CI	B-T081
,	O
-2.35	O
to	O
-0.19]	O
to	O
-0.23	O
[95%	O
CI	B-T081
,	O
-0.44	O
to	O
-0.02];	O
P	O
=	O
.05).	O
No	O
combination	B-T121
strategies	O
with	O
clozapine	B-T109
outperformed	O
controls.	O
The	O
quality	B-T080
of	O
the	O
methods	B-T170
of	O
the	O
meta-analyses	B-T062
was	O
generally	O
high	B-T080
(	O
mean score	B-T033
,	O
9	O
of	O
a	O
maximum score	B-T081
of	O
11)	O
but	O
the	O
quality	B-T080
of	O
the	O
meta-analyzed studies	B-T062
was	O
low	B-T080
(	O
mean score	B-T033
,	O
2.8	O
of	O
a	O
maximum score	B-T081
of	O
8).	O
Treatment recommendations	B-T058
correlated	O
with	O
the	O
effect size	B-T081
(	O
correlation coefficient	B-T081
,	O
0.22;	O
95%	O
CI	B-T081
,	O
0.35-0.10;	O
P	O
<	O
.001),	O
yet	O
effect sizes	B-T081
were	O
inversely	O
correlated	O
with	O
study	O
quality	B-T080
(	O
correlation coefficient	B-T081
,	O
-0.06;	O
95%	O
CI	B-T081
,	O
0.01	O
to	O
-0.12;	O
P	O
=	O
.02).	O
Meta-analyses	B-T062
of	O
21	O
interventions	O
fully	O
or	O
partially	O
recommended	O
their	O
use,	O
with	O
recommendations	B-T078
being	O
positively	B-T033
correlated	O
with	O
the	O
effect sizes	B-T081
of	O
the	O
pooled	O
intervention.	O
However,	O
the	O
effect sizes	B-T081
were	O
inversely	O
correlated	O
with	O
meta-analyzed study	B-T062
quality	B-T080
,	O
reducing	B-T080
confidence	B-T041
in	O
these	O
recommendations	B-T078
.	O
Higher	B-T080
-	O
quality	B-T080
trials	O
and	O
patient	B-T101
-based	O
meta-analyses	B-T062
are	O
needed	O
to	O
determine	O
whether	O
subpopulations	B-T098
might	O
benefit	O
from	O
combination	B-T121
treatment	B-T061
,	O
as	O
no	O
single	O
strategy	O
can	O
be	O
recommended	O
for	O
patients	B-T101
with	O
schizophrenia	B-T048
based	O
on	O
the	O
current	O
meta-analytic	B-T062
literature	B-T170
.	O

Involvement	B-T169
Of	O
Vascular	B-T023
Aldosterone Synthase	B-T116
In	O
Phosphate	B-T121
-	O
Induced	B-T169
Osteogenic Transformation	B-T033
Of	O
Vascular	B-T023
Smooth Muscle Cells	B-T025
Vascular calcification	B-T046
resulting	O
from	O
hyperphosphatemia	B-T047
is	O
a	O
major	O
determinant	O
of	O
mortality	B-T081
in	O
chronic kidney disease	B-T047
(	O
CKD	B-T047
).	O
Vascular calcification	B-T046
is	O
driven	O
by	O
aldosterone	B-T109
-sensitive	O
osteogenic transformation	B-T033
of	O
vascular	B-T023
smooth muscle cells	B-T025
(	O
VSMCs	B-T025
).	O
We	O
show	O
that	O
even	O
in	O
absence	B-T169
of	O
exogenous	B-T169
aldosterone	B-T109
,	O
silencing	B-T044
and	O
pharmacological inhibition	B-T044
(	O
spironolactone	B-T109
,	O
eplerenone	B-T109
)	O
of	O
the	O
mineralocorticoid receptor	B-T116
(	O
MR	B-T116
)	O
ameliorated	O
phosphate	B-T121
-	O
induced	B-T169
osteo-	B-T033
/	O
chondrogenic transformation	B-T033
of	O
primary	B-T080
human	B-T016
aortic	B-T023
smooth muscle cells	B-T025
(	O
HAoSMCs	B-T025
).	O
High	O
phosphate	B-T121
concentrations	B-T081
up-regulated	B-T044
aldosterone synthase	B-T116
(	O
CYP11B2	B-T116
)	O
expression	B-T045
in	O
HAoSMCs	B-T025
.	O
Silencing	B-T044
and	O
deficiency	B-T047
of	O
CYP11B2	B-T116
in	O
VSMCs	B-T025
ameliorated	O
phosphate	B-T121
-	O
induced	B-T169
osteogenic reprogramming	B-T042
and	O
calcification	B-T042
.	O
Phosphate	B-T121
treatment	B-T169
was	O
followed	O
by	O
nuclear export	B-T043
of	O
APEX1	B-T116
,	O
a	O
CYP11B2	B-T028
transcriptional repressor	B-T116
.	O
APEX1	B-T116
silencing	B-T044
up-regulated	B-T044
CYP11B2	B-T028
expression	B-T045
and	O
stimulated	O
osteo-	B-T033
/	O
chondrogenic transformation	B-T033
.	O
APEX1	B-T116
overexpression	B-T045
blunted	O
the	O
phosphate	B-T121
-	O
induced	B-T169
osteo-	B-T033
/	O
chondrogenic transformation	B-T033
and	O
calcification	B-T042
of	O
HAoSMCs	B-T025
.	O
Cyp11b2	B-T028
expression	B-T045
was	O
higher	O
in	O
aortic	B-T023
tissue	B-T024
of	O
hyperphosphatemic	B-T047
klotho-hypomorphic (kl/kl) mice	B-T015
than	O
in	O
wild-type	B-T028
mice	B-T015
.	O
In	O
adrenalectomized kl/kl mice	B-T015
,	O
spironolactone	B-T109
treatment	B-T169
still	O
significantly	O
ameliorated	O
aortic	B-T023
osteoinductive reprogramming	B-T042
.	O
Our	O
findings	B-T169
suggest	O
that	O
VSMCs	B-T025
express	O
aldosterone synthase	B-T116
,	O
which	O
is	O
up-regulated	B-T044
by	O
phosphate	B-T121
-	O
induced	B-T169
disruption	B-T169
of	O
APEX1	B-T116
-dependent	O
gene suppression	B-T045
.	O
Vascular	B-T023
CYP11B2	B-T116
may	O
contribute	O
to	O
stimulation	O
of	O
VSMCs	B-T025
osteo-	B-T033
/	O
chondrogenic transformation	B-T033
during	O
hyperphosphatemia	B-T047
.	O

Fairness	B-T080
:	O
the	O
hidden	O
challenge	B-T058
for	O
competency-based postgraduate medical education programs	B-T065
Competency-based medical education systems	B-UnknownType
allow	O
institutions	B-UnknownType
to	O
individualize	B-T169
teaching practices	B-T065
to	O
meet	B-T067
the	O
needs	B-T080
of	O
diverse learners	B-T098
.	O
Yet,	O
the	O
focus	O
on	O
continuous	O
improvement	B-T077
and	O
individualization	B-T169
of	O
curricula	B-T170
does	O
not	O
exempt	O
programs	B-T169
from	O
treating	O
learners	B-T098
in	O
a	O
fair manner	B-T033
.	O
When	O
learners	B-T098
fail	O
to	O
meet	O
key	O
competencies	B-T080
and	O
are	O
placed	O
on	O
probation	B-T089
or	O
dismissed	B-T052
from	O
training programs	B-T065
,	O
issues	B-T033
of	O
fairness	B-T080
may	O
form	O
the	O
basis	O
of	O
their	O
legal claims	B-T170
.	O
In	O
a	O
literature	O
search,	O
we	O
found	O
no	O
in-depth	O
examination	B-T057
of	O
fairness	B-T080
.	O
In	O
this	O
paper,	O
we	O
utilize	O
a	O
systems	O
lens	O
to	O
examine	B-T033
fairness	B-T080
within	O
postgraduate medical education	B-T065
contexts	B-T078
,	O
focusing	O
on	O
educational opportunities	B-T033
,	O
assessment practices	B-T058
,	O
decision-making processes	B-T057
,	O
fairness	B-T080
from	O
a	O
legal standpoint	B-T169
,	O
and	O
fairness	B-T080
in	O
the	O
context	B-T078
of	O
the	O
learning environment	B-T082
.	O
While	O
we	O
provide	O
examples	O
of	O
fairness	B-T080
issues	B-T033
within	O
US	B-T083
training programs	B-T065
,	O
concerns	O
regarding	O
fairness	B-T080
are	O
relevant	O
in	O
any	O
medical education system	B-UnknownType
which	O
utilizes	O
a	O
competency-based education framework	B-T078
.	O
Assessment	B-T057
oversight	O
committees	B-T097
and	O
annual programmatic evaluations	B-T057
,	O
while	O
recommended,	O
will	O
not	O
guarantee	O
fairness	B-T080
within	O
postgraduate medical education programs	B-T065
,	O
but	O
they	O
can	O
provide	O
a	O
window	O
into	O
'hidden'	O
threats	O
to	O
fairness	B-T080
,	O
as	O
everything	O
from	O
training experiences	B-T065
to	O
assessment practices	B-T058
may	O
be	O
examined	B-T033
by	O
these	O
committees	B-T097
.	O
One	O
of	O
the	O
first	O
steps	O
programs	B-T169
can	O
take	O
is	O
to	O
recognize	O
that	O
threats	O
to	O
fairness	B-T080
may	O
exist	O
in	O
any	O
educational program	B-T065
,	O
including	O
their	O
own,	O
and	O
begin	O
conversations	B-T054
about	O
how	O
to	O
address	O
these	O
issues	B-T033
.	O

Us3	B-T116
and	O
Us9	B-T116
proteins	B-T116
contribute	O
to	O
the	O
stromal invasion	B-T033
of	O
bovine herpesvirus 1	B-T005
in	O
the	O
respiratory mucosa	B-T024
Bovine herpesvirus 1 (BHV-1) infection	B-T047
may	O
lead	O
to	O
conjunctivitis	B-T047
,	O
upper respiratory tract	B-T023
problems	B-T033
,	O
pneumonia	B-T047
,	O
genital disorders	B-T047
and	O
abortion	B-T033
.	O
BHV-1	B-T005
is	O
able	O
to	O
spread	B-T080
quickly	O
in	O
a	O
plaque	B-T033
-wise	O
manner	B-T169
and	O
invade	B-T169
by	O
breaching	B-T037
the	O
basement membrane	B-T024
(BM)	B-T024
barrier	B-UnknownType
in	O
the	O
respiratory mucosa	B-T024
.	O
BHV-1	B-T005
Us3	B-T116
,	O
a	O
serine/threonine kinase	B-T116
,	O
induces	B-T169
a	O
dramatic	O
cytoskeletal reorganization	B-T043
and	O
BHV-1	B-T005
Us9	B-T116
,	O
a	O
tail-anchored membrane protein	B-T116
,	O
is	O
required	O
for	O
axonal transport	B-T043
of	O
viruses	B-T005
in	O
neurons	B-T025
.	O
In	O
this	O
study	B-T062
,	O
we	O
investigated	B-T169
the	O
role	B-T077
of	O
Us3	B-T116
and	O
Us9	B-T116
during	O
BHV-1 infection	B-T047
in	O
the	O
respiratory mucosa	B-T024
.	O
First,	O
we	O
constructed	O
and	O
characterized	B-T052
BHV-1	B-T005
Us3	B-T028
null	B-T005
,	O
Us9	B-T028
null	B-T005
and	O
revertant viruses	B-T005
.	O
Then,	O
we	O
analysed	B-T062
the	O
viral replication	B-T043
and	O
plaque	B-T033
size	B-T082
(latitude)	O
in	O
Madin-Darby bovine kidney	B-T025
(	O
MDBK	B-T025
)	O
cells	B-T025
and	O
the	O
respiratory mucosa	B-T024
as	O
well	O
as	O
viral penetration	B-T043
depth	O
underneath	O
the	O
BM	B-T024
of	O
the	O
respiratory mucosa	B-T024
when	O
inoculated	B-T061
with	O
these	O
recombinant viruses	B-T005
.	O
Knockout	B-T050
of	O
Us3	B-T028
resulted	O
in	O
a	O
1	O
log10	O
reduction	B-T080
in	O
viral titre	B-T081
and	O
plaque	B-T033
size	B-T082
(	O
latitude	B-T081
)	O
in	O
MDBK cells	B-T025
and	O
the	O
trachea mucosa	B-T023
.	O
There	O
were	O
no	B-T033
defects	B-T169
in	O
the	O
cell-to-cell spread	B-T040
observed	B-T169
for	O
BHV-1	B-T005
Us9	B-T028
null virus	B-T005
.	O
Both	O
BHV-1	B-T005
Us3	B-T028
null	B-T005
and	O
Us9	B-T028
null viruses	B-T005
showed	O
a	O
significant	B-T078
reduction	B-T080
of	O
plaque	B-T033
penetration	B-T169
underneath	O
the	O
BM	B-T024
;	O
however,	O
penetration	B-T169
was	O
not	O
completely	O
inhibited	B-T052
.	O
In	O
conclusion	B-T078
,	O
the	O
current	O
findings	B-T062
demonstrated	O
that	O
Us3	B-T028
and	O
Us9	B-T028
play	O
an	O
important	O
role	B-T077
in	O
the	O
invasion	B-T033
of	O
BHV-1	B-T005
through	O
the	O
BM	B-T024
of	O
the	O
respiratory mucosa	B-T024
,	O
which	O
shows	O
the	O
way	O
forward	O
for	O
research	B-T062
-based	O
attenuation	B-T052
of	O
viruses	B-T005
in	O
order	O
to	O
make	O
safer	O
and	O
better	B-T080
-	O
performing	B-T169
vaccines	B-T121
.	O

Traumatic Brain Injury	B-T037
and	O
Depression	B-T048
in	O
a	O
Community	B-T096
-	O
Based	B-T169
Sample:	O
A	O
Cohort Study	B-T081
Across	O
the	O
Adult	B-T100
Life Span	B-T102
To	O
determine	O
whether	O
self-reported	O
traumatic brain injuries	B-T037
(	O
TBIs	B-T037
)	O
are	O
associated with	B-T080
"	O
cases	B-T077
"	O
of	O
clinically significant	B-T033
depression	B-T048
in	O
the	O
general community	B-T096
.	O
To	O
examine	O
interactions	B-T169
between	O
variables	B-T081
previously	O
linked	O
to	O
depression	B-T048
after	O
a	O
TBI	B-T037
.	O
Population	B-T098
-based	O
community	B-T096
study	B-T062
(	O
Canberra	B-T083
and	O
Queanbeyan	B-UnknownType
,	O
Australia	B-T083
).	O
Three	B-T081
age cohorts	B-T098
:	O
young	B-T079
,	O
middle-aged	B-T100
,	O
and	O
older	B-T098
adults	B-T100
(	O
aged	B-T032
20-24,	O
40-44,	O
and	O
60-64 years	B-T100
at	O
baseline	B-T081
)	O
randomly	B-T080
selected	B-T052
from	O
the	O
electoral	O
roll	O
and	O
followed	B-T079
across	O
3	O
waves	O
(4	O
years apart	B-T079
).	O
A	O
total	O
of	O
7397,	O
6621,	O
and	O
6042	O
people	B-T098
provided	O
their	O
TBI	B-T037
history	O
in	O
waves	O
1	O
to	O
3.	O
Lifetime	B-T079
(TBIlifetime:	O
sustained	B-T169
at	O
any	O
time	B-T079
since	B-T079
birth	B-T040
),	O
recent	B-T079
(TBIrecent:	O
in	O
the	O
preceding	B-T079
4	O
years	B-T079
),	O
and	O
multiple	B-T081
(TBImultiple:	O
more	O
than	O
1)	O
TBIs	B-T037
,	O
current	B-T079
depression	B-T048
,	O
and	O
known	O
risk factors	B-T033
for	O
depression	B-T048
(	O
age	B-T032
,	O
sex	B-T032
,	O
marital	B-T102
/	O
employment status	B-T033
,	O
prior history	B-T033
of	O
depression	B-T048
,	O
medical conditions	B-T033
,	O
recent	O
life events	B-T051
,	O
alcohol consumption	B-T055
,	O
social support	B-T054
,	O
physical activity	B-T056
).	O
Generalized	O
estimating	O
equations	B-T077
demonstrated	O
a	O
significant	O
association	B-T080
between	O
sustaining	O
a	O
TBI	B-T037
and	O
experiencing	O
clinically significant	B-T033
depression	B-T048
(	O
cases	B-T077
),	O
even	O
after	O
controlling	B-T067
for	O
multiple	B-T081
demographic	B-T078
and	O
health	B-T078
/	O
lifestyle	B-T054
factors	B-T169
.	O
There	O
is	O
an	O
enduring	O
association	B-T080
between	O
depression	B-T048
and	O
TBI	B-T037
,	O
suggesting	O
that,	O
following	O
a	O
TBI	B-T037
,	O
individuals	B-T098
should	O
be	O
monitored	B-T097
and	O
supported	O
to	O
optimize	O
their	O
long-term	B-T079
psychological health	B-T041
.	O

CS	B-T109
-	O
PEG	B-T109
decorated	O
PLGA nano-prototype	B-T109
for	O
delivery	B-T070
of	O
bioactive compounds	B-T123
:	O
A	O
novel	B-T080
approach	B-T082
for	O
induction	B-T169
of	O
apoptosis	B-T043
in	O
HepG2 cell line	B-T025
Polymer	B-T104
-	O
based	B-T169
nanoparticles	B-T073
are	O
used	B-T169
as	O
vectors	B-T082
for	O
cancer	B-T191
drug delivery	B-T169
.	O
The	O
bioactive compounds	B-T123
(	O
quercetin	B-T109
,	O
ellagic acid	B-T109
and	O
gallic acid	B-T109
)	O
are	O
well	O
known	O
to	O
be	O
not	O
only	O
antioxidants	B-T121
but	O
also	O
chemopreventive candidates	B-T121
against	B-T080
various	B-T081
types	B-T080
of	O
cancers	B-T191
.	O
To	O
circumvent	O
the	O
low	B-T080
bioavailability	B-T081
and	O
the	O
short	B-T081
half-life	B-T079
time	B-T079
obstacles	B-T169
,	O
we	O
hypothesized	O
a	O
novel	B-T080
PLGA nano-platform	B-T109
functionalized	B-T169
with	O
CS	B-T109
and	O
PEG	B-T109
to	O
encapsulate	B-T080
these	O
phytochemicals	B-T109
.	O
This	O
encapsulation	B-T067
will	O
protect	B-T033
the	O
compounds	B-T121
from	O
the	O
phagocytic uptake	B-T043
and	O
deliver	B-T070
PLGA-CS-PEG nano-prototype	B-T121
with	O
high	O
biodegradability	B-T080
and	O
biosafety	B-T080
.	O
Three	O
consequent	O
types	B-T080
of	O
PLGA-based nanocomposites	B-T121
were	O
prepared	B-T052
and	O
characterized	B-T052
.	O
Furthermore,	O
we	O
investigated	B-T169
the	O
newly	O
synthesized	B-T052
nano-formulations	B-T073
against	B-T080
human	B-T016
hepatocellular carcinoma	B-T191
(	O
HepG2	B-T025
)	O
and	O
colorectal cancer	B-T191
(	O
HCT 116	B-T025
)	O
cell lines	B-T025
using	B-T169
cell growth inhibition	B-T043
assays	B-T059
,	O
followed by	B-T079
apoptosis	B-T043
and	O
necrosis	B-T042
assays	B-T059
using	B-T169
flow cytometry	B-T059
to	O
detect	B-T059
the	O
underlying	O
mechanism	B-T169
of	O
HepG2	B-T025
cell death	B-T043
.	O
Through	O
Malvern	O
Zeta	O
Sizer,	O
we	O
recorded	O
that	O
the	O
average	B-T081
diameters	B-T081
of	O
the	O
nano-prototypes	B-T073
ranged	O
from	O
150	O
to	O
300nm.	O
The	O
cytotoxic activity	B-T059
of	O
quercetin	B-T109
,	O
ellagic acid	B-T109
,	O
and	O
gallic acid	B-T109
-	O
encapsulated	B-T080
PLGA	B-T109
,	O
PLGA-CS	B-T121
,	O
and	O
PLGA-CS-PEG nano-prototypes	B-T121
it	O
has	O
been	O
found	B-T033
that	O
they	O
reduce	B-T080
the	O
IC50s	B-T081
of	O
the	O
HepG2 cells	B-T025
values	B-T081
by	O
2.2,	O
2.9,	O
2.8-	O
folds	B-T081
,	O
1,	O
1.5,	O
2.7-	O
folds	B-T081
,	O
and	O
0.9,	O
0.7,	O
1.5-	O
folds	B-T081
,	O
respectively.	O
Mechanistically,	O
the	O
nano-platforms	O
of	O
quercetin	B-T109
seem	O
to	O
be	O
dependent	B-T080
on	O
both	O
apoptosis	B-T043
and	O
necrosis	B-T042
,	O
while	O
those	O
of	O
ellagic acid	B-T109
and	O
gallic acid	B-T109
are	O
mainly	O
dependent	B-T080
on	O
apoptosis	B-T043
.	O
CS	B-T109
-	O
PEG	B-T109
-blended	O
PLGA	B-T109
nano-delivery system	B-T169
of	O
quercetin	B-T109
,	O
ellagic acid	B-T109
and	O
gallic acid	B-T109
can	O
potentiate	B-T052
apoptosis-mediated	B-T043
cell death	B-T043
in	O
HepG2 cell line	B-T025
.	O

Fingerprint	B-T073
-based	O
background checks	B-T033
for	O
personal care workers	B-T097
:	O
Stakeholder	B-T098
views	B-T078
of	O
policy	B-T170
criteria	B-T078
Decision makers	B-T098
face	O
difficult	O
choices	O
when	O
tasked	O
with	O
identifying	O
and	O
implementing	B-T052
appropriate	O
mechanisms	B-T169
for	O
protecting	B-T033
the	O
elderly	B-T098
and	O
other	O
vulnerable adults	B-T033
from	O
abuse	B-T051
.	O
A	O
pilot project	B-T062
involving	O
fingerprint	B-T073
-based	O
criminal	B-T098
history	O
background checks	B-T033
for	O
personal care workers	B-T097
in	O
Michigan	B-T083
has	O
supplied	O
an	O
opportunity	B-T062
to	O
examine	O
one	O
such	O
mechanism	B-T169
.	O
In	O
conjunction	B-T078
with	O
the	O
pilot project	B-T062
,	O
we	O
have	O
conducted	O
a	O
stakeholder	B-T097
analysis	B-T062
with	O
the	O
aim	O
of	O
informing	O
decision makers	B-T098
about	O
stakeholder	B-T098
perceptions	B-T041
of	O
standard	B-T170
policy	B-T170
criteria	B-T078
like	O
effectiveness	B-T080
,	O
efficiency	B-T081
,	O
and	O
equity	B-T080
.	O
We	O
employed	O
focus groups	B-UnknownType
and	O
a	O
web-based survey	B-T170
to	O
collect	B-T062
data	B-T078
from	O
stakeholders	B-T098
.	O
While	O
stakeholders	B-T098
generally	O
see	O
fingerprint	B-T073
-based	O
background checks	B-T033
for	O
personal care workers	B-T097
as	O
potentially	O
effective	B-T080
and	O
as	O
a	O
net benefit	B-T081
,	O
they	O
also	O
point	O
to	O
a	O
variety	O
of	O
contingencies	B-T051
.	O
They	O
also	O
recognize	O
difficulties	B-T033
and	O
constraints	B-T169
for	O
government	B-T092
involvement	B-T169
.	O
This	O
preliminary analysis	B-T062
provides	O
solid	O
foundational information	B-T078
for	O
decision makers	B-T098
and	O
for	O
more	O
extensive	O
benefit-cost analysis	B-T057
.	O

Penetrating	B-T169
Craniomaxillofacial Injury	B-T037
Craniomaxillofacial Injury Caused by a Pneumatic Nail Gun	B-T037
Pneumatic Nail Gun	B-T073
Craniomaxillofacial	O
injuries	O
can	O
be	O
complex,	O
requiring	O
a	O
multidisciplinary	O
approach.	O
The	O
primary	O
survey	O
is	O
always	O
the	O
first	O
step	O
in	O
trauma	O
management	O
prior	O
to	O
proceeding	O
with	O
further	O
evaluation	O
and	O
treatment	B-T169
.	O
A	O
26-	O
year	O
-old	O
man	O
presented	O
with	O
a	O
penetrating	B-T169
nail	O
gun	O
injury	O
through	O
the	O
oral	B-T030
and	O
nasal cavities	B-T030
.	O
He	O
did	O
not	O
present	O
in	O
extremis	O
but	O
required	O
elective	O
endotracheal	O
intubation	O
for	O
intraoperative	O
assessment	O
and	O
treatment	B-T169
.	O
Airway	O
management	O
was	O
enhanced	B-T052
by	O
the	O
use	O
of	O
lingual nerve	B-T061
and	O
inferior alveolar nerve blocks	B-T061
via	O
the	O
Vazirani-Akinosi	O
technique	O
to	O
maintain	B-T052
spontaneous respiration	B-T033
while	O
the	O
tongue	B-T023
was	O
distracted	B-T033
from	O
the	O
palate	B-T023
.	O
The	O
nail	O
was	O
removed	O
and	O
rapid	O
sequence	O
induction	O
initiated	O
for	O
orotracheal	O
intubation.	O
Local	O
nerve	O
blocks	O
can	O
be	O
an	O
effective	O
tool	O
in	O
the	O
armamentarium	O
of	O
the	O
craniomaxillofacial	O
trauma	O
surgeon	O
in	O
managing	O
blunt	O
and	O
penetrating	O
injuries.	O
We	O
demonstrate	O
its	O
utility	O
in	O
airway	O
management	O
when	O
a	O
penetrating	O
foreign	O
body	O
in	O
the	O
upper airway	B-T023
precludes	O
orotracheal	O
or	O
nasotracheal	O
intubation.	O

Design	O
of	O
a	O
candidate	O
vibrational signal	B-T067
for	O
mating	B-T040
disruption	B-T169
against	O
the	O
glassy-winged sharpshooter	B-T204
,	O
Homalodisca vitripennis	B-T204
The	O
glassy-winged sharpshooter	B-T204
(	O
GWSS	B-T204
),	O
Homalodisca vitripennis	B-T204
,	O
is	O
an	O
important	O
pest	B-T204
of	O
grapevines	B-T002
due	O
to	O
its	O
ability	O
to	O
transmit	B-T169
Xylella fastidiosa	B-T007
,	O
the	O
causal agent	B-T001
of	O
Pierce's disease	B-T047
.	O
GWSS	B-T204
mating	B-T040
communication	B-T054
is	O
based	O
on	O
vibrational signals	B-T067
;	O
therefore,	O
vibrational	B-T080
mating	B-T040
disruption	B-T169
could	O
be	O
an	O
alternative	B-T077
to	O
insecticides	B-T131
for	O
suppression	B-UnknownType
of	O
GWSS	B-T204
population	B-T098
.	O
Our	O
objectives	B-T170
were	O
to	O
identify	O
spectral	B-T081
features	B-T080
of	O
female	B-T032
signal	B-T067
that	O
elicit	O
male	B-T032
signaling	B-T040
,	O
design	O
disruptive	B-T080
signals	B-T067
able	O
to	O
alter	B-T169
male	B-T032
perception	B-T041
and	O
acceptance	B-T055
of	O
a	O
female	B-T032
,	O
and	O
determine	O
the	O
signal intensity	B-T081
required	O
for	O
future	O
field	O
applications.	O
Results	B-T033
showed	O
that	O
male	B-T032
responses	B-T032
to	O
playback	B-T052
of	O
modified	B-T169
female	B-T032
signals	B-T067
were	O
significantly	B-T078
reduced	B-T080
by	O
60-75%when	O
part	O
of	O
the	O
female	B-T032
signal spectral components	B-T077
above	O
or	O
below	O
400	O
Hz	O
were	O
deleted.	O
Playback	B-T052
bioassays	B-T059
showed	O
that	O
transmission	B-T070
of	O
an	O
80	O
Hz	O
pure	O
frequency tone	B-T079
to	O
plants	B-T002
completely	O
suppressed	B-T169
male	B-T032
signaling	B-T040
to	O
female	B-T032
signal playback	B-T052
,	O
even	O
if	O
the	O
disruptive	B-T080
signal amplitude	B-T082
was	O
10	O
dB	O
lower	O
than	O
the	O
female	B-T032
signal playback	B-T052
.	O
Although	O
the	O
mechanism	B-T169
underlying	O
cessation	B-T052
of	O
male	B-T032
signaling	B-T040
activity	O
in	O
the	O
presence	B-T033
of	O
disruption	B-T169
is	O
not	O
yet	O
understood,	O
results	B-T033
suggest	O
that	O
an	O
80	O
Hz	O
vibrational signal	B-T067
should	O
be	O
tested	O
in	O
laboratory	B-T073
and	O
field experiments	B-T062
to	O
assess	B-T052
its	O
efficacy	B-T080
in	O
disrupting	O
mating	B-T040
of	O
GWSS	B-T204
.	O

Barriers	B-T080
and	O
facilitators	B-T080
to	O
smoking cessation	B-T055
in	O
a	O
cancer	B-T191
context	B-T078
:	O
A	O
qualitative study	B-T062
of	O
patient	B-T101
,	O
family	B-T099
and	O
professional	B-T097
views	B-T080
Continued	B-T078
smoking	B-T055
after	O
cancer	B-T191
adversely affects	B-T046
quality of life	B-T184
and	O
survival	B-T169
,	O
but	O
one	O
fifth	O
of	O
cancer	B-T191
survivors	B-T101
still	O
smoke	B-T055
.	O
Despite	O
its	O
demands,	O
cancer	B-T191
presents	O
an	O
opportunity	O
for	O
positive	B-T033
behaviour change	B-T055
.	O
Smoking	B-T055
often	O
occurs	O
in	O
social groups	B-T098
,	O
therefore	O
interventions	B-T061
which	O
target	B-T169
families	B-T099
and	O
individuals	B-T098
may	O
be	O
more	O
successful	B-T080
.	O
This	O
qualitative study	B-T062
explored	O
patients	B-T101
,	O
family members	B-T099
and	O
health professionals	B-T097
'	O
views	B-T080
and	O
experiences	B-T041
of	O
smoking	B-T055
and	O
smoking cessation	B-T055
after	O
cancer	B-T191
,	O
in	O
order	O
to	O
inform	O
future	O
interventions	B-T061
.	O
In-depth qualitative interviews	B-T058
(n	O
=	O
67)	O
with	O
29	O
patients	B-T101
,	O
14	O
family members	B-T099
and	O
24	O
health professionals	B-T097
.	O
Data	B-T078
were	O
analysed	O
using	O
the	O
'Framework' method	B-T169
.	O
Few	O
patient	B-T101
s	O
and	O
family members	B-T099
had	O
used	O
National Health Service	B-T058
(	O
NHS	B-T058
)	O
smoking cessation	B-T055
services	B-T058
and	O
more	O
than	O
half	O
still	O
smoked	B-T055
.	O
Most	O
recalled	O
little	O
'	O
smoking	B-T055
-related'	O
discussion	B-T061
with	O
clinicians	B-T097
but	O
were	O
receptive	O
to	O
talking	O
openly.	O
Clinicians	B-T097
revealed	O
several	O
barriers	B-T080
to	O
discussion	B-T061
.	O
Participants	B-T098
'	O
continued	B-T078
smoking	B-T055
was	O
explained	O
by	O
the	O
stress	B-T033
of	O
diagnosis	B-T060
;	O
desire	O
to	O
maintain	O
personal	B-T032
control	B-T080
;	O
and	O
lack	B-T080
of	O
connection	O
between	O
smoking	B-T055
,	O
cancer	B-T191
and	O
health	B-T078
.	O
A	O
range	O
of	O
barriers	B-T080
to	O
smoking cessation	B-T055
exist	O
for	O
patients	B-T101
and	O
family members	B-T099
.	O
These	O
are	O
insufficiently	B-T080
assessed	B-T052
and	O
considered	O
by	O
clinicians	B-T097
.	O
Interventions	B-T061
must	O
be	O
more	O
effectively	O
integrated	O
into	O
routine	O
practice.	O

Improving	B-T080
the	O
Sexual Health	B-T032
of	O
Young People	B-T100
With	O
Mobility Impairments	B-T033
:	O
Challenges	B-T058
and	O
Recommendations	B-T078
This	O
mixed-method study	B-T062
(a)	O
describes	O
challenges	B-T058
to	O
providing	B-T052
sexual health	B-T032
services	B-T058
to	O
youth	B-T100
with	O
mobility impairments	B-T033
from	O
the	O
perspective	B-T082
of	O
health care providers	B-T097
and	O
experts	B-T097
and	O
(b)	O
describes	O
and	O
compares	B-T052
sexual health	B-T032
-related	O
experiences	B-T041
of	O
youth	B-T100
with	O
mobility impairments	B-T033
.	O
Secondary data analysis of My Path	B-UnknownType
,	O
a	O
study	B-T062
focused	B-T169
on	O
the	O
transition	B-T052
to	O
adulthood	B-T079
for	O
youth	B-T100
with	O
mobility impairments	B-T033
.	O
Using	O
an	O
exploratory sequential design	B-T062
,	O
qualitative data	B-UnknownType
(n	O
=	O
10)	O
were	O
analyzed	B-T062
using	O
systematic	B-T169
content analysis	B-T062
followed	O
by	O
quantitative analysis of survey data	B-UnknownType
(N	O
=	O
337).	O
Challenges	B-T058
included	B-T169
not talking	B-T080
about	O
sex	B-T032
,	O
managing	O
sexual development	B-T040
,	O
adaptation	B-T040
and	O
instruction	B-T170
,	O
parent roles	B-T054
,	O
and	O
safety	B-T068
.	O
Survey	B-T170
data	B-T078
showed	O
that	O
youth	B-T100
with	O
mobility impairments	B-T033
are	O
diverse	B-T080
in	O
their	O
experiences	B-T041
with	O
sexual behavior	B-T053
and	O
sources	B-T033
of	O
sexual health	B-T032
information	B-T078
.	O
Although	O
connected	B-T052
with	O
primary care providers	B-T097
,	O
few	O
received	B-T080
information	B-T078
about	O
sexual health	B-T032
.	O
Interventions	B-T058
to	O
improve	B-T033
youths	B-T100
'	O
well-being	B-T078
should	O
include	B-T052
comprehensive care	B-T058
and	O
education	B-T065
that	O
promotes	B-T052
and	O
supports	B-T077
healthy	B-T080
sexual development	B-T040
.	O

Understanding	B-T041
the	O
interrelationship	B-T080
between	O
the	O
synthesis	B-T038
of	O
urea	B-T109
and	O
gluconeogenesis	B-T044
by	O
formulating	O
an	O
overall	B-T080
balanced equation	B-T077
It	O
is	O
well	O
known	O
that	O
a	O
strong	O
metabolic	B-T169
interrelationship	B-T080
exists	O
between	O
ureagenesis	B-T044
and	O
gluconeogenesis	B-T044
.	O
In	O
this	O
paper,	O
we	O
present	O
a	O
detailed,	O
overall	B-T080
equation	B-T077
,	O
describing	O
a	O
possible	O
metabolic	B-T169
link	B-T082
between	O
ureagenesis	B-T044
and	O
gluconeogenesis	B-T044
.	O
We	O
adopted	O
a	O
guided approach	B-T082
in	O
which	O
we	O
strongly	O
suggest	O
that	O
students	B-T098
,	O
when	O
faced	O
with	O
the	O
problem	B-T033
of	O
obtaining	B-T052
the	O
overall	B-T080
equation	B-T077
of	O
a	O
metabolic pathway	B-T169
,	O
carefully	O
account	O
for	O
all	O
atoms	B-T196
and	O
charges	B-T032
of	O
the	O
single	O
reactions	B-T169
,	O
as	O
well	O
as	O
the	O
cellular localizations	B-T043
of	O
the	O
substrates	B-T167
,	O
and	O
the	O
related	O
transport	B-T044
systems	B-T169
.	O
If	O
this	O
suggestion	O
is	O
always	O
taken	O
into	O
account,	O
a	O
balanced	B-T169
,	O
overall	B-T080
equation	B-T077
of	O
a	O
metabolic pathway	B-T169
will	O
be	O
obtained,	O
which	O
strongly	O
facilitates	O
the	O
discussion	O
of	O
its	O
physiological	B-T169
role.	O
Unfortunately,	O
textbooks	B-T073
often	O
report	B-T170
unbalanced	O
overall	B-T080
equations	B-T077
of	O
metabolic pathways	B-T169
,	O
including	O
ureagenesis	B-T044
and	O
gluconeogenesis	B-T044
.	O
Most	O
likely	O
the	O
reason	O
is	O
that	O
metabolism	B-T040
and	O
enzymology	B-T169
have	O
been	O
neglected	O
for	O
about	O
three	O
decades,	O
owing	O
to	O
the	O
remarkable	O
advances	O
of	O
molecular biology	B-T091
and	O
molecular genetics	B-T091
.	O
In	O
this	O
paper	B-T170
,	O
we	O
strongly	O
suggest	O
that	O
students	B-T098
,	O
when	O
faced	O
with	O
the	O
problem	O
of	O
obtaining	O
the	O
overall	B-T080
reaction	B-T169
of	O
a	O
metabolic pathway	B-T169
,	O
carefully	O
control	O
if	O
the	O
single	O
reactions	B-T169
are	O
properly	O
balanced	B-T169
for	O
atoms	B-T196
and	O
charges	B-T032
.	O
Following	O
this	O
suggestion	B-T078
,	O
we	O
were	O
able	O
to	O
obtain	O
an	O
overall	B-T080
equation	B-T077
describing	O
the	O
metabolic	B-T169
interrelationship	B-T080
between	O
ureagenesis	B-T044
and	O
gluconeogenesis	B-T044
,	O
in	O
which	O
urea	B-T109
and	O
glucose	B-T109
are	O
the	O
final	B-T079
products	B-T071
.	O
The	O
aim	O
is	O
to	O
better	O
rationalize	B-T169
this	O
topic	B-T078
and	O
to	O
convince	O
students	B-T098
and	O
teachers	B-T097
that	O
metabolism	B-T040
is	O
an	O
important	O
and	O
rewarding	O
chapter	B-T078
of	O
human physiology	B-T091
.	O

Delineation	O
of	O
B-cell	B-T025
Epitopes	B-T129
of	O
Salmonella enterica serovar Typhi	B-T007
Hemolysin E	B-T116
:	O
Potential	B-T080
antibody	B-T116
therapeutic	B-T061
target	B-T169
Hemolysin E	B-T116
(	O
HlyE	B-T116
)	O
is	O
an	O
immunogenic	B-T169
novel	B-T080
pore	B-T026
-forming	O
toxin	B-T109
involved	O
in	O
the	O
pathogenesis	B-T046
of	O
typhoid fever	B-T047
.	O
Thus,	O
mapping	B-T052
of	O
B-cell	B-T025
epitopes	B-T129
of	O
Salmonella enterica serovar Typhi	B-T007
(	O
S. Typhi	B-T007
)	O
is	O
critical	B-T080
to	O
identify	O
key	O
immunogenic regions	B-T082
of	O
HlyE	B-T116
.	O
A	O
random	O
20-mer	O
peptide library	B-T116
was	O
used	O
for	O
biopanning	O
with	O
enriched	O
anti-HlyE polyclonal antibodies	B-T116
from	O
typhoid	B-T047
patient	B-T101
sera	B-T031
.	O
Bioinformatic	B-T091
tools	B-T170
were	O
used	O
to	O
refine,	O
analyze	B-T062
and	O
map	B-T052
the	O
enriched	O
peptide sequences	B-T087
against	O
the	O
protein	B-T116
to	O
identify	O
the	O
epitopes	B-T129
.	O
The	O
analysis	B-T062
identified	O
both	O
linear	B-T082
and	O
conformational	B-T082
epitopes	B-T129
on	O
the	O
HlyE protein	B-T116
.	O
The	O
predicted	B-T078
linear	B-T082
GAAAGIVAG	B-T087
and	O
conformational	B-T082
epitope	B-T129
PYSQESVLSADSQNQK	B-T087
were	O
further	O
validated	O
against	O
the	O
pooled	O
sera	B-T031
.	O
The	O
identified	O
epitopes	B-T129
were	O
then	O
used	O
to	O
isolate	B-T061
epitope	B-T129
specific	O
monoclonal antibodies	B-T116
by	O
antibody	B-T116
phage display	B-T063
.	O
Monoclonal scFv	B-T116
antibodies	B-T116
were	O
enriched	O
for	O
both	O
linear	B-T082
and	O
conformational	B-T082
epitopes	B-T129
.	O
Molecular docking	B-T170
was	O
performed	O
to	O
elucidate	O
the	O
antigen-antibody interaction	B-T039
of	O
the	O
monoclonal antibodies	B-T116
against	O
the	O
epitopes	B-T129
on	O
the	O
HlyE	B-T116
monomer	B-T116
and	O
oligomer structure	B-T087
.	O
An	O
in-depth	O
view	O
of	O
the	O
mechanistic	O
and	O
positional	B-T033
characteristics	B-T080
of	O
the	O
antibodies	B-T116
and	O
epitope	B-T129
for	O
HlyE	B-T116
was	O
successfully	O
accomplished	O
by	O
a	O
combination	B-T080
of	O
phage display	B-T063
and	O
bioinformatic	B-T091
analysis	B-T062
.	O
The	O
predicted	B-T078
function	B-T169
and	O
structure	B-T082
of	O
the	O
antibodies	B-T116
highlights	O
the	O
possibility	O
of	O
utilizing	O
the	O
antibodies	B-T116
as	O
neutralizing agents	B-T121
for	O
typhoid fever	B-T047
.	O

Comparison	B-T052
of	O
electrospun	B-T067
and	O
solvent cast	B-T067
polylactic acid	B-T109
(	O
PLA	B-T109
)/	O
poly(vinyl alcohol)	B-T122
(	O
PVA	B-T122
)	O
inserts	B-T122
as	O
potential	O
ocular	B-T023
drug delivery vehicles	B-T122
The	O
purpose	O
of	O
this	O
work	O
was	O
to	O
develop,	O
characterize	O
and	O
compare	O
electrospun nanofiber	B-T073
inserts	B-T122
(	O
ENIs	B-T073
)	O
and	O
solvent cast	B-T067
polymeric	B-T104
inserts	B-T122
(	O
SCIs	B-T104
)	O
for	O
ocular	B-T023
drug delivery	B-T074
.	O
ENI	B-T073
and	O
SCI	B-T104
of	O
1%,	O
5%	O
and	O
10%	O
w/w	O
dexamethasone	B-T109
were	O
fabricated	B-T067
using	O
a	O
blend	B-T068
of	O
poly-lactic acid	B-T109
(	O
PLA	B-T109
)	O
and	O
poly-vinyl alcohol	B-T122
(	O
PVA	B-T122
).	O
Inserts	B-T122
were	O
characterized	O
for	O
morphology	B-T080
,	O
thickness	B-T080
,	O
pH	B-T081
,	O
drug content	B-T077
,	O
drug crystallinity	B-T080
,	O
in vitro	B-T080
drug release	B-T070
,	O
sterility	B-T080
,	O
dimethylformamide	B-T109
(	O
DMF	B-T109
)	O
and	O
chloroform	B-T109
content	B-T077
,	O
and	O
cytotoxicity	B-T049
.	O
The	O
thickness	B-T080
of	O
1%,	O
5%,	O
and	O
10%	O
dexamethasone	B-T109
-loaded	O
ENIs	B-T073
were	O
found	O
to	O
be	O
50μm,	O
62.5μm,	O
and	O
93.3μm,	O
respectively,	O
with	O
good	O
folding endurance	B-T033
.	O
SCIs	B-T104
were	O
brittle	B-T033
,	O
with	O
thickness	B-T080
values	O
>200μm.	O
Drug release	B-T070
rates	B-T081
from	O
1%,	O
5%	O
and	O
10%	O
ENIs	B-T073
were	O
found	O
to	O
be	O
0.62μg/h,	O
1.46μg/h,	O
and	O
2.30μg/h,	O
respectively,	O
while	O
those	O
from	O
SCIs	B-T104
were	O
erratic.	O
DMF	B-T109
content	B-T077
in	O
ENIs	B-T073
and	O
SCIs	B-T104
were	O
0.007%	O
w/w	O
and	O
0.123%	O
w/w,	O
respectively,	O
while	O
chloroform	B-T109
was	O
not detected	B-T033
.	O
No	B-T033
cytotoxicity	B-T049
was	O
observed	O
from	O
ENIs	B-T073
in	O
cultured	B-T025
bovine	B-T015
corneal endothelial cells	B-T025
for	O
up	O
to	O
24h.	O
We	O
conclude	O
that	O
ENIs	B-T073
are	O
better	O
than	O
SCIs	B-T104
and	O
could	O
be	O
utilized	O
as	O
a	O
potential	O
delivery system	B-T074
for	O
treating	B-T169
anterior segment	B-T082
ocular diseases	B-T047
.	O

Quantitative	B-T081
regulation	B-T038
of	O
histone variant H2A.Z	B-T116
during	B-T079
cell cycle	B-T043
by	O
ubiquitin proteasome system	B-T044
and	O
SUMO-targeted ubiquitin ligases	B-T026
Quantitative	B-T081
control	B-T169
of	O
histones	B-T116
and	O
histone variants	B-T116
during	B-T079
cell cycle	B-T043
is	O
relevant	B-T080
to	O
their	O
epigenetic functions	B-T043
.	O
We	O
found	O
that	O
the	O
level	B-T080
of	O
yeast histone variant H2A.Z	B-T116
in	O
the	O
G2/M-phase	B-T043
is	O
actively	B-T169
kept	O
low	O
by	O
the	O
ubiquitin proteasome system	B-T044
and	O
SUMO-targeted ubiquitin ligases	B-T026
.	O
Overexpression	B-T045
of	O
H2A.Z	B-T116
induced defects in mitotic progression	B-T043
,	O
suggesting	B-T078
functional	B-T169
importance	B-T080
of	O
this	O
quantitative	B-T081
control	B-T169
.	O

Tyrphostin AG-related compounds	B-T121
attenuate	O
H2O2	B-T121
-	O
induced	B-T169
TRPM2	B-T116
-	O
dependent	B-T080
and	O
-	O
independent	B-T169
cellular	B-T025
responses	B-T032
TRPM2	B-T116
is	O
a	O
Ca(2+)-permeable channel	B-T116
that	O
is	O
activated	B-T052
by	O
H2O2	B-T121
.	O
TRPM2	B-T116
-mediated	O
Ca(2+) signaling	B-T043
has	O
been	O
implicated	O
in	O
the	O
aggravation	B-T033
of	O
inflammatory diseases	B-T047
.	O
Therefore,	O
the	O
development	B-T169
of	O
TRPM2	B-T116
inhibitors	B-T121
to	O
prevent	O
the	O
aggravation	B-T033
of	O
these	O
diseases	B-T047
is	O
expected.	O
We	O
recently	O
reported	O
that	O
some	O
Tyrphostin AG-related compounds	B-T121
inhibited	B-T080
the	O
H2O2	B-T121
-	O
induced	B-T169
activation	B-T052
of	O
TRPM2	B-T116
by	O
scavenging the intracellular hydroxyl radical	B-T044
.	O
In	O
the	O
present	O
study,	O
we	O
examined	O
the	O
effects of	B-T080
AG-related compounds	B-T121
on	O
H2O2	B-T121
-	O
induced	B-T169
cellular	B-T025
responses	B-T032
in	O
human	B-T016
monocytic	B-T025
U937 cells	B-T025
,	O
which	O
functionally	B-T169
express	B-T045
TRPM2	B-T116
.	O
The	O
effects of	B-T080
AG-related compounds	B-T121
on	O
H2O2	B-T121
-	O
induced	B-T169
changes	B-T169
in	O
intracellular	B-T082
Ca(2+)	B-T121
concentrations	B-T081
,	O
extracellular signal-regulated kinase	B-T116
(	O
ERK	B-T116
)	O
activation	B-T052
,	O
and	O
CXCL8	B-T116
secretion	B-T043
were	O
assessed	O
using	O
U937 cells	B-T025
.	O
Ca(2+) influxes	B-T043
via	O
TRPM2	B-T116
in	O
response	O
to	O
H2O2	B-T121
were	O
blocked	B-T046
by	O
AG-related compounds	B-T121
.	O
AG-related compounds	B-T121
also	O
inhibited	B-T080
the	O
H2O2	B-T121
-	O
induced	B-T169
activation	B-T052
of	O
ERK	B-T116
,	O
and	O
subsequent	O
secretion	B-T043
of	O
CXCL8	B-T116
mediated	O
by	O
TRPM2	B-T116
-	O
dependent	B-T080
and	O
-	O
independent	B-T169
mechanisms	B-T169
.	O
Our	O
results	O
show	O
that	O
AG-related compounds	B-T121
inhibit	B-T080
H2O2	B-T121
-	O
induced	B-T169
CXCL8	B-T116
secretion	B-T043
following	O
ERK	B-T116
activation	B-T052
,	O
which	O
is	O
mediated	O
by	O
TRPM2	B-T116
-	O
dependent	B-T080
and	O
-	O
independent	B-T169
mechanisms	B-T169
in	O
U937 cells	B-T025
.	O
We	O
previously	O
reported	O
that	O
AG-related compounds	B-T121
blocked	B-T046
H2O2	B-T121
-	O
induced	B-T169
TRPM2	B-T116
activation	B-T052
by	O
scavenging the hydroxyl radical	B-T044
.	O
The	O
inhibitory	B-T052
effects	B-T080
of	O
AG-related compounds	B-T121
on	O
TRPM2	B-T116
-	O
independent	B-T169
responses	B-T032
may	O
be	O
due	O
to	O
scavenging of the hydroxyl radical	B-T044
.	O

Shared decision making	B-T041
in	O
the	O
UK	B-T083
:	O
Moving	O
towards	O
wider	O
uptake	O
Shared decision making	B-T041
(	O
SDM	B-T041
)	O
is	O
firmly	O
on	O
the	O
policy	B-T170
agenda	B-T170
in	O
the	O
UK	B-T083
and	O
a	O
recent	O
legal	B-T169
ruling	B-T064
has	O
confirmed	O
its	O
importance.	O
Policymakers	B-T097
,	O
ethicists	B-T097
,	O
professional regulators	B-T097
and	O
societies	B-T092
,	O
patient organisations	B-T092
and	O
now	O
the	O
courts	B-T092
are	O
committed	O
to	O
ensuring	O
that	O
SDM	B-T041
becomes	O
the	O
norm	B-T080
throughout	O
the	O
NHS	B-T058
,	O
but	O
an	O
unfavourable	O
economic climate	B-UnknownType
makes	O
this	O
especially	O
challenging.	O
Considerable	O
progress	B-T169
has	O
been	O
made	O
over	O
the	O
last	O
few	O
years	B-T079
,	O
with	O
new	O
learning	B-T041
from	O
demonstration	B-T054
sites	B-T082
,	O
various	O
initiatives	B-T041
in	O
capacity building	B-T058
and	O
training	B-T065
,	O
wider	O
availability	O
of	O
patient	B-T101
decision aids	B-T170
,	O
and	O
important	O
leadership	B-T054
initiatives	B-T041
.	O
Enthusiasm	B-T041
for	O
this	O
way	O
of	O
working	B-T057
is	O
growing	O
among	O
clinicians	B-T097
,	O
patients	B-T101
and	O
managers	B-T097
,	O
but	O
it	O
could	O
be	O
undermined	O
if	O
SDM	B-T041
comes	O
to	O
be	O
seen	O
primarily	O
as	O
a	O
means	B-T077
of	O
cost control	B-T064
.	O

Lactate	B-T109
induces	O
osteoblast differentiation	B-T043
by	O
stabilization	B-T044
of	O
HIF1α	B-T116
Aerobic glycolysis	B-T044
is	O
involved	O
in	O
osteoblast differentiation	B-T043
induced	O
by	O
Wnt signaling	B-T044
or	O
PTH	B-T116
treatment	B-T169
.	O
However,	O
it	O
is	O
still	O
unclear	O
whether	O
lactate	B-T109
,	O
the	O
end	O
product	O
of	O
aerobic glycolysis	B-T044
,	O
plays	O
any	O
role	O
in	O
osteoblast differentiation	B-T043
.	O
Herein	O
we	O
report	O
that	O
in	O
cultures	B-T059
of	O
osteoblast-lineage cells	B-T025
,	O
lactate	B-T109
promoted	O
alkaline phosphatase	B-T116
-positive	O
cell formation	B-T043
,	O
increased	O
the	O
activity	B-T044
of	O
alkaline phosphatase	B-T116
,	O
and	O
induced	O
the	O
expression	B-T045
of	O
osteocalcin	B-T116
.	O
This	O
osteoblast differentiation	B-T043
-inducing	O
effect	O
of	O
lactate	B-T109
can	O
be	O
inhibited	B-T080
by	O
blocking	B-T169
its	O
entry	O
into	O
cells	B-T025
with	O
MCT1	B-T116
siRNA	B-T114
or	O
inhibitors	B-T121
,	O
and	O
by	O
interfering	O
with	O
its	O
metabolism	B-T040
by	O
using	O
specific	O
siRNAs	B-T114
for	O
LDHB	B-T116
and	O
PDH	B-T116
.	O
Moreover,	O
lactate	B-T109
stabilized	O
HIF1α	B-T116
expression	B-T045
and	O
inhibited	B-T080
HIF1α	B-T116
activity	B-T044
,	O
with	O
BAY87-2243	B-T121
lowering	O
the	O
osteoblast differentiation	B-T043
-inducing	O
effect	O
of	O
lactate	B-T109
.	O
Thus,	O
these	O
findings	B-T033
reveal	O
an	O
unrecognized	O
role	O
for	O
aerobic glycolysis	B-T044
in	O
osteoblast differentiation	B-T043
via	O
its	O
end	O
product,	O
lactate	B-T109
.	O

Committee	B-T096
Opinion	O
No.	O
701	O
Summary:	O
Choosing	O
The	O
Route	B-T082
Of	O
Hysterectomy	B-T061
For	O
Benign	B-T080
Disease	B-T047
Hysterectomy	B-T061
is	O
one	O
of	O
the	O
most	O
frequently	O
performed	O
surgical procedures	B-T061
in	O
the	O
United States	B-T083
.	O
Selection	B-T052
of	O
the	O
route	B-T082
of	O
hysterectomy	B-T061
for	O
benign	B-T080
causes	O
can	O
be	O
influenced	O
by	O
the	O
size	B-T082
and	O
shape	B-T082
of	O
the	O
vagina	B-T023
and	O
uterus	B-T023
;	O
accessibility	O
to	O
the	O
uterus	B-T023
;	O
extent	O
of	O
extrauterine disease	B-T047
;	O
the	O
need	O
for	O
concurrent	O
procedures;	O
surgeon	B-T097
training	B-T065
and	O
experience	B-T041
;	O
average	O
case volume	B-T081
;	O
available	O
hospital	B-T073
technology	B-T058
,	O
devices	B-T074
,	O
and	O
support;	O
whether	O
the	O
case	O
is	O
emergent	O
or	O
scheduled;	O
and	O
preference	O
of	O
the	O
informed	O
patient	B-T101
.	O
Vaginal	B-T061
and	O
laparoscopic procedures	B-T061
are	O
considered	O
"	O
minimally invasive	B-T169
"	O
surgical approaches	B-T169
because	O
they	O
do	O
not	O
require	O
a	O
large	O
abdominal incision	B-T061
and,	O
thus,	O
typically	O
are	O
associated	O
with	O
shortened	O
hospitalization	B-T058
and	O
postoperative recovery times	B-T033
compared	O
with	O
open	O
abdominal hysterectomy	B-T061
.	O
Minimally invasive approaches	B-T169
to	O
hysterectomy	B-T061
should	O
be	O
performed,	O
whenever	O
feasible,	O
based	O
on	O
their	O
well-documented	O
advantages	O
over	O
abdominal hysterectomy	B-T061
.	O
The	O
vaginal approach	B-T082
is	O
preferred	O
among	O
the	O
minimally invasive approaches	B-T169
.	O
Laparoscopic hysterectomy	B-T061
is	O
a	O
preferable	O
alternative	O
to	O
open	O
abdominal hysterectomy	B-T061
for	O
those	O
patients	B-T101
in	O
whom	O
a	O
vaginal hysterectomy	B-T061
is	O
not	O
indicated	O
or	O
feasible.	O
Although	O
minimally invasive approaches	B-T169
to	O
hysterectomy	B-T061
are	O
the	O
preferred	O
route	B-T082
,	O
open	B-T061
abdominal hysterectomy	B-T061
remains	O
an	O
important	O
surgical	O
option	O
for	O
some	O
patients	B-T101
.	O
The	O
obstetrician	B-T097
-	O
gynecologist	B-T097
should	O
discuss	O
the	O
options	O
with	O
patients	B-T101
and	O
make	O
clear	O
recommendations	O
on	O
which	O
route	B-T082
of	O
hysterectomy	B-T061
will	O
maximize	O
benefits	B-T081
and	O
minimize	O
risks	B-T078
given	O
the	O
specific	O
clinical	O
situation.	O
The	O
relative	O
advantages	O
and	O
disadvantages	O
of	O
the	O
approaches	B-T169
to	O
hysterectomy	B-T061
should	O
be	O
discussed	O
in	O
the	O
context	O
of	O
the	O
patient	B-T101
's	O
values	O
and	O
preferences	B-T080
,	O
and	O
the	O
patient	B-T101
and	O
health care provider	B-T097
should	O
together	O
determine	O
the	O
best	O
course	O
of	O
action	O
after	O
this	O
discussion.	O

Measuring	B-T080
nonlinear	B-T080
signal	B-T067
combination	B-T080
using	O
EEG	B-T060
Relatively	B-T080
little	O
is	O
known	O
about	O
the	O
processes	B-T067
,	O
both	O
linear	B-T082
and	O
nonlinear	B-T080
,	O
by	O
which	O
signals	B-T067
are	O
combined	B-T080
beyond	O
V1	B-T029
.	O
By	O
presenting	O
two	O
stimulus	B-T067
components	B-T077
simultaneously	B-T079
,	O
flickering	B-T033
at	O
different	B-T080
temporal frequencies	B-T079
(	O
frequency	B-T081
tagging	B-T074
)	O
while	O
measuring	B-T080
steady-state	B-T070
visual evoked potentials	B-T042
,	O
we	O
can	O
assess	B-T058
responses	B-T032
to	O
the	O
individual	O
components	B-T077
,	O
including	O
direct	B-T080
measurements	B-T169
of	O
suppression	B-T046
on	O
each	O
other,	O
and	O
various	O
nonlinear	B-T080
responses	B-T032
to	O
their	O
combination	B-T080
found	O
at	O
intermodulation	B-T080
frequencies	B-T081
.	O
The	O
result	B-T034
is	O
a	O
rather	O
rich	O
dataset	B-T170
of	O
frequencies	B-T081
at	O
which	O
responses	B-T032
can	O
be	O
found.	O
We	O
presented	O
pairs	B-T080
of	O
sinusoidal gratings	B-T082
at	O
different	B-T080
temporal frequencies	B-T079
,	O
forming	O
plaid patterns	B-T033
that	O
were	O
"	O
coherent	B-T033
"	O
(	O
looking like a checkerboar	B-T082
d)	O
and	O
"	O
noncoherent	B-T033
"	O
(looking	O
like	O
a	O
pair	B-T080
of	O
transparently	B-T080
overlaid gratings	B-T082
),	O
and	O
found	O
clear	O
intermodulation	B-T080
responses	B-T032
to	O
compound	B-T080
stimuli	B-T067
,	O
indicating	O
nonlinear	B-T080
summation	B-T042
.	O
This	O
might	O
have	O
been	O
attributed	O
to	O
cross-orientation	B-T082
suppression	B-T046
except	O
that	O
the	O
pattern	B-T082
of	O
intermodulation	B-T080
responses	B-T032
differed	B-T080
for	O
coherent	B-T033
and	O
noncoherent	B-T033
patterns	B-T082
,	O
whereas	O
the	O
effects of	B-T080
suppression	B-T046
(measured	O
at	O
the	O
component	B-T077
frequencies	B-T081
)	O
did	O
not.	O
A	O
two-stage model	B-T170
of	O
nonlinear	B-T080
summation	B-T042
involving	O
conjunction	B-T078
detection	B-T061
with	O
a	O
logical	B-T077
AND gate	B-T170
described	O
the	O
data	B-T078
well,	O
capturing	O
the	O
difference	B-T081
between	O
coherent	B-T033
and	O
noncoherent	B-T033
plaids	B-T082
over	O
a	O
wide	O
array	B-T082
of	O
possible	B-T033
response frequencies	B-T079
.	O
Multistimulus	B-T080
frequency	B-T081
-tagged	O
EEG	B-T060
in	O
combination	B-T080
with	O
computational modeling	B-T066
may	O
be	O
a	O
very	O
valuable	O
tool	O
in	O
studying	O
the	O
conjunction	B-T078
of	O
these	O
signals	B-T067
.	O
In	O
the	O
current	O
study	B-T062
the	O
results	B-T034
suggest	O
a	O
second-order mechanism	B-T042
responding	O
selectively	B-T080
to	O
coherent	B-T033
plaid patterns	B-T033
.	O

Sleep Loss	B-T033
Promotes	B-T052
Astrocytic	B-T029
Phagocytosis	B-T043
and	O
Microglial Activation	B-T043
in	O
Mouse Cerebral Cortex	B-T024
We	O
previously	O
found	O
that	O
Mertk	B-T116
and	O
its	O
ligand Gas6	B-T116
,	O
astrocytic	B-T029
genes	B-T028
involved	O
in	O
phagocytosis	B-T043
,	O
are	O
upregulated	B-T044
after	B-T079
acute	B-T079
sleep deprivation	B-T033
.	O
These	O
results	O
suggested	O
that	O
astrocytes	B-T025
may	O
engage	O
in	O
phagocytic activity	B-T043
during	B-T079
extended	B-T082
wake	B-T039
,	O
but	O
direct	B-T080
evidence	B-T078
was	O
lacking	B-T080
.	O
Studies	B-T062
in	O
humans	B-T016
and	O
rodents	B-T015
also	O
found	B-T033
that	O
sleep loss	B-T033
increases	B-T169
peripheral	B-T082
markers	B-T201
of	O
inflammation	B-T046
,	O
but	O
whether	O
these	O
changes	B-T169
are	O
associated with	B-T080
neuroinflammation	B-UnknownType
and/or	O
activation	B-T043
of	O
microglia	B-T025
,	O
the	O
brain's	B-T023
resident	O
innate immune cells	B-T025
,	O
was	O
unknown	B-T080
.	O
Here	O
we	O
used	B-T169
serial block-face scanning electron microscopy	B-T059
to	O
obtain	O
3D	O
volume	B-T081
measurements	B-T169
of	O
synapses	B-T030
and	O
surrounding	B-T082
astrocytic	B-T029
processes	B-T038
in	O
mouse	B-T015
frontal cortex	B-T023
after	B-T079
6-8	O
h	O
of	O
sleep	B-T040
,	O
spontaneous	B-T169
wake	B-T039
,	O
or	O
sleep deprivation	B-T033
(	O
SD	B-T033
)	O
and	O
after	B-T079
chronic (∼5 d) sleep restriction	B-T169
(	O
CSR	B-T169
).	O
Astrocytic	B-T029
phagocytosis	B-T043
,	O
mainly	O
of	O
presynaptic components of large synapses	B-T026
,	O
increased	B-T081
after	B-T079
both	B-T080
acute	B-T079
and	O
chronic	B-T079
sleep loss	B-T033
relative	B-T080
to	O
sleep	B-T040
and	O
wake	B-T039
.	O
MERTK	B-T116
expression	B-T045
and	O
lipid peroxidation	B-T044
in	O
synaptoneurosomes	B-T026
also	O
increased	B-T081
to	O
a	O
similar	B-T080
extent	B-T082
after	B-T079
short	B-T081
and	O
long	B-T080
sleep loss	B-T033
,	O
suggesting	O
that	O
astrocytic	B-T029
phagocytosis	B-T043
may	O
represent	B-T052
the	O
brain's	B-T023
response	B-T032
to	O
the	O
increase	B-T169
in	O
synaptic activity	B-T043
associated with	B-T080
prolonged	B-T079
wake	B-T039
,	O
clearing	B-T080
worn	O
components	O
of	O
heavily	O
used	B-T169
synapses	B-T030
.	O
Using	B-T169
confocal microscopy	B-T059
,	O
we	O
then	O
found	B-T033
that	O
CSR	B-T169
but	O
not	B-T169
SD	B-T033
mice	B-T015
show	O
morphological	B-T082
signs	B-T184
of	O
microglial activation	B-T043
and	O
enhanced	B-T052
microglial	B-T029
phagocytosis	B-T043
of	O
synaptic elements	B-T026
,	O
without	B-T080
obvious	O
signs	B-T184
of	O
neuroinflammation	B-UnknownType
in	O
the	O
CSF	B-T031
.	O
Because	O
low	B-T080
-	O
level	B-T080
sustained	B-T169
microglia activation	B-T043
can	O
lead	O
to	O
abnormal	B-T033
responses	B-T032
to	O
a	O
secondary	B-T080
insult	B-T037
,	O
these	O
results	B-T169
suggest	B-T078
that	O
chronic	B-T079
sleep loss	B-T033
,	O
through	B-T169
microglia	B-T025
priming	B-T043
,	O
may	O
predispose	O
the	O
brain	B-T023
to	O
further	B-T082
damage	B-T169
.SIGNIFICANCE	O
STATEMENT	O
We	O
find	B-T033
that	O
astrocytic	B-T029
phagocytosis	B-T043
of	O
synaptic elements	B-T026
,	O
mostly	O
of	O
presynaptic origin	B-T026
and	O
in	O
large	B-T081
synapses	B-T030
,	O
is	O
upregulated	B-T044
already	O
after	B-T079
a	O
few	B-T081
hours	B-T079
of	O
sleep deprivation	B-T033
and	O
shows	O
a	O
further	B-T082
significant	B-T078
increase	B-T169
after	B-T079
prolonged	B-T079
and	O
severe	B-T080
sleep loss	B-T033
,	O
suggesting	O
that	O
it	O
may	O
promote	B-T052
the	O
housekeeping	B-T057
of	O
heavily	O
used	B-T169
and	O
strong	B-T080
synapses	B-T030
in	O
response	B-T032
to	O
the	O
increased	B-T081
neuronal	B-T025
activity	B-T043
of	O
extended	B-T082
wake	B-T039
.	O
By	O
contrast	B-T080
,	O
chronic sleep restriction	B-T169
but	O
not	B-T169
acute	B-T079
sleep loss	B-T033
activates	B-T043
microglia	B-T025
,	O
promotes	B-T052
their	O
phagocytic activity	B-T043
,	O
and	O
does	O
so	O
in	O
the	O
absence	B-T169
of	O
overt	O
signs	B-T184
of	O
neuroinflammation	B-UnknownType
,	O
suggesting	O
that	O
like	O
many	O
other	B-T080
stressors	B-T078
,	O
extended	B-T082
sleep disruption	B-T033
may	O
lead	O
to	O
a	O
state	B-T169
of	O
sustained	B-T169
microglia activation	B-T043
,	O
perhaps	O
increasing	B-T169
the	O
brain's	B-T023
susceptibility	B-T169
to	O
other	B-T080
forms	B-T169
of	O
damage	B-T169
.	O

Reflections	B-T062
on	O
Hip Fracture Recovery	B-T061
From	O
Older Adults	B-T098
Enrolled	O
in	O
a	O
Clinical Trial	B-T062
This	O
study	B-T062
describes	O
patients'	B-T101
perspectives	B-UnknownType
on	O
recovery	B-T052
during	O
participation	B-T169
in	O
a	O
randomized controlled trial	B-T062
that	O
tested	B-T170
a	O
postoperative	B-T079
hip fracture	B-T037
management program	B-T169
(	O
B4 Clinic	B-T073
),	O
compared	B-T052
with	O
usual care	B-T058
,	O
on	O
mobility	B-T080
.	O
Semistructured	B-T082
qualitative	B-T080
interviews	B-T052
were	O
conducted	O
with	O
50	O
older adults	B-T098
with	O
hip fracture	B-T037
(from	O
both	O
groups	B-T098
)	O
twice	O
over	O
12	O
months.	O
A	O
total	B-T080
of	O
32	O
women	B-T098
(64%)	O
and	O
18	O
men	B-T098
(36%)	O
participated	B-T169
in	O
the	O
study	B-T062
with	O
a	O
mean	B-T081
age	B-T032
at	O
baseline	B-T081
of	O
82	O
(	O
range	B-T081
=	O
65-98)	O
years.	O
A	O
total	B-T080
of	O
40	O
participants	B-T098
reported	B-T058
recovery	B-T052
goals	B-T170
at	O
some	O
point	O
during	O
their	O
recovery	B-T052
from	O
hip fracture	B-T037
but	O
only	O
18	O
participants	B-T098
realized	B-T078
their	O
goals	B-T170
within	O
12	O
months.	O
Recovering	B-T040
mobility	B-T080
,	O
returning	B-T080
to	O
prefracture activities	B-T052
,	O
and	O
obtaining	B-T169
stable	B-T080
health	B-T078
were	O
the	O
most	B-T081
commonly	B-T081
reported	B-T058
goals	B-T170
.	O
Participants	B-T098
described	O
good	B-T080
social support	B-T058
,	O
access	B-T082
to	O
physiotherapy	B-T061
,	O
and	O
positive	B-T033
perspective	B-UnknownType
as	O
most	B-T081
important	B-T080
to	O
recovery	B-T052
.	O
These	O
factors	B-T169
were	O
influenced	B-T077
by	O
participants	B-T098
'	O
knowledge	B-T170
,	O
resources	B-T078
,	O
and	O
monthly	O
contact	B-T078
with	O
study	B-T062
staff	B-T097
(	O
perceived	B-T041
as	O
a	O
form	O
of	O
social support	B-T058
).	O
The	O
most	B-T081
frequently	B-T079
reported	B-T058
barriers	B-T080
to	O
participants	B-T098
'	O
recovery	B-T052
were	O
the	O
onset of	B-T080
complications	B-T046
,	O
pain	B-T184
,	O
and	O
limited access	B-T033
to	O
physiotherapy	B-T061
.	O
Potential	B-T080
implications	B-T078
of	O
these	O
findings	B-T033
include	B-T052
design	B-T052
and	O
modification	B-T033
of	O
new	O
or	O
preexisting	B-T080
fracture	B-T037
programs	B-T169
,	O
prioritizing	B-T079
patient engagement	B-T058
and	O
enhanced	B-T052
knowledge	B-T170
for	O
future	B-T079
clinical research	B-T062
in	O
hip fracture recovery	B-T061
.	O

It	O
takes	O
biking	O
to	O
learn	B-T041
:	O
Physical activity	B-T056
improves	B-T033
learning	B-T041
a	O
second language	B-T033
Recent	O
studies	B-T062
have	O
shown	O
that	O
concurrent	B-T079
physical activity	B-T056
enhances	B-T052
learning	B-T041
a	O
completely	O
unfamiliar	O
L2	B-T033
vocabulary	B-T170
as	O
compared	O
to	O
learning	B-T041
it	O
in	O
a	O
static	B-T080
condition	B-T080
.	O
In	O
this	O
paper	O
we	O
report	O
a	O
study	B-T062
whose	O
aim	O
is	O
twofold:	O
to	O
test	O
for	O
possible	B-T033
positive	B-T033
effects of	B-T080
physical activity	B-T056
when	O
L2	B-T033
learning	B-T041
has	O
already	O
reached	O
some	O
level	B-T080
of	O
proficiency	B-T080
,	O
and	O
to	O
test	O
whether	O
the	O
assumed	O
better	B-T080
performance	B-T052
when	O
engaged	O
in	O
physical activity	B-T056
is	O
limited	O
to	O
the	O
linguistic	B-T090
level	B-T080
probed	O
at	O
training	B-T080
(i.e.	O
L2	B-T033
vocabulary	B-T170
tested	B-T169
by	O
means	O
of	O
a	O
Word-Picture Verification task	B-T062
),	O
or	O
whether	O
it	O
extends	O
also	O
to	O
the	O
sentence	B-T170
level	B-T080
(which	O
was	O
tested	B-T169
by	O
means	O
of	O
a	O
Sentence Semantic Judgment Task	B-T062
).	O
The	O
results	O
show	O
that	O
Chinese speakers	B-T098
with	O
basic knowledge	B-T033
of	O
English	B-T171
benefited	B-T081
from	O
physical activity	B-T056
while	O
learning	B-T041
a	O
set	O
of	O
new	O
words	B-T170
.	O
Furthermore,	O
their	O
better	B-T080
performance	B-T052
emerged	O
also	O
at	O
the	O
sentential	B-T170
level,	B-T080
as	O
shown	O
by	O
their	O
performance	B-T052
in	O
a	O
Semantic Judgment task	B-T062
.	O
Finally,	O
an	O
interesting	O
temporal	O
asymmetry	O
between	O
the	O
lexical	B-T078
and	O
the	O
sentential	B-T170
level	B-T080
emerges,	O
with	O
the	O
difference	O
between	O
the	O
experimental	B-T078
and	O
control group	B-T096
emerging	O
from	O
the	O
1st	O
testing session	B-T051
at	O
the	O
lexical	B-T078
level	B-T080
but	O
after	O
several	O
weeks	O
at	O
the	O
sentential	B-T170
level	B-T080
.	O

The	O
added	B-T169
value	B-T081
of	O
cardiac index	B-T033
and	O
pulse pressure	B-T040
variation	B-T080
monitoring	B-T058
to	O
mean arterial pressure	B-T033
-	O
guided volume therapy	B-T061
in	O
moderate-risk abdominal surgery	B-T061
(	O
COGUIDE	B-T061
):	O
a	O
pragmatic	B-T062
multicentre	B-T062
randomised controlled trial	B-T062
There	O
is	O
disagreement	B-UnknownType
regarding	O
the	O
benefits	B-T081
of	O
goal-directed therapy	B-T061
in	O
moderate-risk abdominal surgery	B-T061
.	O
Therefore,	O
we	O
tested	B-T170
the	O
hypothesis	B-T078
that	O
the	O
addition	B-T169
of	O
non-invasive	B-T169
cardiac index	B-T033
and	O
pulse pressure	B-T040
variation	B-T080
monitoring	B-T058
to	O
mean arterial pressure	B-T033
-based	O
goal-directed therapy	B-T061
would	O
reduce	B-T080
the	O
incidence	B-T081
of	O
postoperative complications	B-T046
in	O
patients	B-T101
having	O
moderate-risk abdominal surgery	B-T061
.	O
In	O
this	O
pragmatic	B-T062
multicentre	B-T062
randomised controlled trial	B-T062
,	O
we	O
randomly allocated	B-T062
244	O
patients	B-T101
by	O
envelope drawing	B-T170
in	O
a	O
1:1	O
fashion,	O
stratified	B-T080
per	O
centre.	O
All	O
patients	B-T101
had	O
mean arterial pressure	B-T033
,	O
cardiac index	B-T033
and	O
pulse pressure	B-T040
variation	B-T080
measured	B-T080
continuously	B-T078
.	O
In	O
one	O
group	B-T078
,	O
healthcare professionals	B-T097
were	O
blinded	B-T062
to	O
cardiac index	B-T033
and	O
pulse pressure	B-T040
variation	B-T080
values	B-T081
and	O
were	O
asked	O
to	O
guide	O
haemodynamic therapy	B-T061
only	O
based	O
on	O
mean arterial pressure	B-T033
(	O
control group	B-T096
).	O
In	O
the	O
second	O
group	B-T078
,	O
cardiac index	B-T033
and	O
pulse pressure	B-T040
variation	B-T080
values	B-T081
were	O
displayed	B-T169
and	O
kept	O
within	O
target	B-T169
ranges	B-T081
following	O
a	O
pre-defined algorithm	B-T170
(	O
CI-PPV group	B-T078
).	O
The	O
primary endpoint	B-T130
was	O
the	O
incidence	B-T081
of	O
postoperative complications	B-T046
within 30 days	B-T033
.	O
One	O
hundred	O
and	O
seventy-five	O
patients	B-T101
were	O
eligible	B-T080
for	O
final	B-T079
analysis	B-T062
.	O
Overall	B-T080
complication rates	B-T046
were	O
similar	O
(42/94	O
(44.7%)	O
vs.	O
38/81	O
(46.9%)	O
in	O
the	O
control	B-T096
and	O
CI-PPV groups	B-T078
,	O
respectively;	O
p	O
=	O
0.95).	O
The	O
CI-PPV group	B-T078
had	O
lower	B-T080
mean	B-T081
(	O
SD	B-T081
)	O
pulse pressure	B-T040
variation	B-T080
values	B-T081
(9.5	O
(2.0)%	O
vs.	O
11.9	O
(4.6)%;	O
p	O
=	O
0.003)	O
and	O
higher	B-T080
mean	B-T081
(	O
SD	B-T081
)	O
cardiac indices	B-T033
(2.76	O
(0.62)	O
l	O
min(-1)	O
.m(-2)	O
vs.	O
2.53	O
(0.66)	O
l	O
min(-1)	O
.m(-2);	O
p	O
=	O
0.004)	O
than	O
the	O
control group	B-T096
.	O
In	O
moderate-risk abdominal surgery	B-T061
,	O
we	O
observed	B-T169
no	O
additional value	B-T170
of	O
cardiac index	B-T033
and	O
pulse pressure	B-T040
variation	B-T080
-	O
guided haemodynamic therapy	B-T061
to	O
mean arterial pressure	B-T033
-	O
guided volume therapy	B-T061
with	O
regard	O
to	O
postoperative complications	B-T046
.	O

Anterior single implants	B-T074
with	O
different	O
neck	B-T082
designs	B-T052
:	O
5	O
Year	B-T079
results	O
of	O
a	O
randomized clinical trial	B-T062
The	O
design	B-T052
of	O
the	O
implant neck	B-T074
might	O
be	O
significant	O
for	O
preservation	B-T059
of	O
marginal	B-T082
bone	B-T024
.	O
To	O
compare	O
the	O
5-year	B-T079
radiographic	B-T070
and	O
clinical	B-T080
outcome	B-T169
of	O
single anterior implants	B-T074
provided	O
with	O
a	O
smooth	B-T080
smooth neck	B-T082
,	O
a	O
rough neck	B-T082
or	O
a	O
scalloped	O
rough neck	B-T082
.	O
93	O
Patients	B-T101
with	O
a	O
missing	O
anterior	B-T082
tooth	B-T023
in	O
the	O
maxilla	B-T023
were	O
included.	O
At	O
random,	O
patients	B-T101
received	O
an	O
implant	B-T074
with	O
a	O
1.5	O
mm	O
smooth	B-T080
neck	B-T082
("	O
smooth group	B-T078
"),	O
a	O
rough neck	B-T082
with	O
grooves	O
("	O
rough group	B-T078
")	O
or	O
a	O
scalloped	O
rough neck	B-T082
with	O
grooves	O
("	O
scalloped group	B-T078
").	O
Implants	B-T074
were	O
installed	O
in	O
healed sites	B-T029
.	O
Follow-up visits	B-T058
were	O
conducted	O
after	O
final	O
crown delivery	B-T169
and	O
1	O
year	B-T079
and	O
5	O
years	B-T079
later.	O
Scalloped	O
implants	B-T074
showed	O
significantly	O
more	O
initial	O
marginal	B-T082
bone resorption	B-T042
.	O
The	O
total	O
amount	O
of	O
bone loss	B-T042
was	O
1.26	O
±	O
0.90	O
mm	O
in	O
the	O
smooth group	B-T078
,	O
1.20	O
±	O
1.1	O
mm	O
in	O
the	O
rough group	B-T078
and	O
2.28	O
±	O
0.97	O
mm	O
in	O
the	O
scalloped group	B-T078
(P	O
<	O
.05).	O
Survival rates	B-T081
were	O
96.2%	O
for	O
the	O
smooth	B-T078
and	O
scalloped group	B-T078
and	O
100%	O
for	O
the	O
rough group	B-T078
.	O
Scalloped	O
implants	B-T074
showed	O
deeper pocket depths	B-T082
,	O
more	O
bleeding	B-T046
and	O
more	O
technical	O
complications	B-T078
.	O
There	O
were	O
no	O
differences	O
in	O
esthetic outcome	B-T169
nor	O
in	O
patient satisfaction	B-T080
.	O
For	O
anterior	B-T082
single	O
tooth replacements	B-T042
,	O
scalloped	O
implants	B-T074
show	O
less	O
favorable	O
radiographic	B-T070
and	O
clinical	B-T080
outcome	B-T169
compared	O
to	O
regular	O
implants	B-T074
with	O
a	O
smooth	B-T080
neck	B-T082
or	O
rough neck	B-T082
.	O

Recessive mutations	B-T045
in	O
MSTO1	B-T116
cause	O
mitochondrial dynamics	B-T043
impairment	B-T169
,	O
leading	O
to	O
myopathy	B-T047
and	O
ataxia	B-T184
We	O
report	O
here	O
the	O
first	O
families	B-T099
carrying	O
recessive	O
variants	B-T080
in	O
the	O
MSTO1 gene	B-T028
:	O
compound heterozygous	B-T033
mutations	B-T045
mutations	B-T045
were	O
identified	B-T080
in	O
two	O
sisters	B-T099
and	O
in	O
an	O
unrelated	B-T033
singleton	B-T099
case,	O
who	O
presented	B-T078
a	O
multisystem	O
complex	B-T080
phenotype	B-T032
mainly	O
characterized	B-T052
by	O
myopathy	B-T047
and	O
cerebellar ataxia	B-T184
.	O
Human MSTO1	B-T116
is	O
a	O
poorly	O
studied	O
protein,	O
suggested	B-T078
to	O
have	O
mitochondrial localization	B-T038
and	O
to	O
regulate	B-T038
morphology	B-T080
and	O
distribution of mitochondria	B-T043
.	O
As	O
for	O
other	O
mutations	B-T045
affecting	B-T169
genes	B-T028
involved	O
in	O
mitochondrial dynamics	B-T043
,	O
no	O
biochemical	B-T169
defects	B-T169
typical	O
of	O
mitochondrial disorders	B-T047
were	O
reported	B-T058
.	O
Studies	O
in	O
patients	B-T101
'	O
fibroblasts	B-T025
revealed	B-T080
that	O
MSTO1 protein	B-T116
levels	B-T080
were	O
strongly	O
reduced	B-T080
,	O
the	O
mitochondrial network was fragmented	B-T033
and	O
the	O
fusion	B-T169
events	O
among	O
mitochondria	B-T026
were	O
decreased	B-T081
,	O
confirming	O
the	O
deleterious effect	B-T049
of	O
the	O
identified	B-T080
variants	B-T080
and	O
the	O
role	O
of	O
MSTO1	B-T116
in	O
modulating	B-T082
mitochondrial dynamics	B-T043
.	O
We	O
also	O
found	O
that	O
MSTO1	O
is	O
mainly	O
a	O
cytosolic protein	B-T116
.	O
These	O
findings	O
indicate	O
recessive mutations	B-T045
in	O
MSTO1	B-T116
as	O
a	O
new	O
cause	O
for	O
inherited	B-T169
neuromuscular disorders	B-T047
with	O
multisystem	O
features.	O
This	O
article	O
is	O
protected	O
by	O
copyright.	O
All	O
rights	O
reserved.	O

A	O
miniature	O
bird	B-T012
-borne	O
passive air sampler	B-T074
for	O
monitoring	B-T058
halogenated flame retardants	B-T120
Birds	B-T012
have	O
been	O
used	O
intensively	O
as	O
biomonitors	B-T074
of	O
halogenated flame retardants	B-T120
(	O
HFRs	B-T120
),	O
and	O
several	O
studies	B-T062
have	O
reported	O
elevated	O
tissue	B-T024
concentrations	B-T081
and	O
inter-	O
individual	B-T098
variability	B-T077
for	O
these	O
contaminants	B-T167
.	O
While	O
diet	B-T168
is	O
known	O
to	O
be	O
an	O
important	O
exposure	B-T080
pathway	B-T077
for	O
HFRs	B-T120
in	O
birds	B-T012
,	O
it	O
has	O
been	O
suggested	B-T078
that	O
exposure	B-T080
through	O
air	B-T167
may	O
represent	B-T052
an	O
underestimated	O
source	B-T033
of	O
HFRs	B-T120
for	O
certain	O
species	B-T185
.	O
However,	O
a	O
method	B-T170
was	O
not available	B-T080
for	O
measuring	B-T080
the	O
atmospheric	B-T070
exposure	B-T080
of	O
individual	B-T098
birds	B-T012
to	O
HFRs	B-T120
or	O
other	O
semi-volatile	B-T080
contaminants	B-T167
.	O
The	O
goal	B-T170
of	O
this	O
study	B-T062
was	O
to	O
develop	O
a	O
bird	B-T012
-borne	O
passive air sampler	B-T074
(	O
PAS	B-T074
)	O
enabling	O
the	O
determination	B-T059
of	O
individual	B-T098
atmospheric	B-T070
exposure	B-T080
to	O
gas	B-T104
-	O
and	O
particle-phase	B-T104
HFRs	B-T120
using	O
the	O
ring-billed gull	B-T012
(	O
Larus delawarensis	B-T012
)	O
nesting	B-T053
in	O
the	O
Montreal area	B-UnknownType
(	O
QC	B-T083
,	O
Canada	B-T083
).	O
The	O
new	O
miniaturized	O
elliptical-shaped	B-T082
PAS	B-T074
(	O
mean weight	B-T081
:	O
2.72g)	O
was	O
tested	B-T169
using	O
two sorbent types	B-T059
during	O
three	O
exposure periods	B-T079
(one,	O
two	O
and	O
three	O
weeks).	O
Results	B-T169
showed	O
that	O
PAS	B-T074
using	O
polyurethane foam	B-T109
(	O
PUF	B-T109
)	O
combined	O
with	O
a	O
glass fiber	B-T122
filter collected	B-UnknownType
all	O
major	O
polybrominated diphenyl ethers	B-T109
(	O
PBDEs	B-T109
)	O
and	O
exhibited	O
better performance	B-T052
for	O
collecting	B-T169
highly hydrophobic	B-T080
DecaBDE	B-T109
mixture	B-T167
congeners	B-T104
compared to	B-T052
the	O
PAS	B-T074
using	O
polydimethylsiloxane	B-T109
(	O
PDMS	B-T109
).	O
Emerging	O
HFRs	B-T120
including	O
hexabromobenzene	B-T109
,	O
Dechlorane 604 Component B	B-T109
,	O
and	O
Dechlorane plus	B-T109
(	O
DP	B-T109
)	O
isomers	B-T070
also	O
were	O
sampled	B-T060
by	O
the	O
PUF	B-T109
-based	O
PAS	B-T074
.	O
Sampling	B-T060
rates	B-T081
for	O
most	O
HFRs	B-T120
were	O
comparable	B-T052
between	O
the	O
three	O
exposure periods	B-T079
.	O
This	O
novel	O
bird	B-T012
-borne	O
PAS	B-T074
provides	O
valuable information	B-T078
on	O
the	O
non-dietary exposure	B-T080
of	O
free-ranging	B-T033
birds	B-T012
to	O
HFRs	B-T120
.	O

Post	B-T079
endodontic pain	B-T184
following	O
single-visit	O
root canal preparation	B-T061
with	O
rotary	B-T074
vs	O
reciprocating instruments	B-T074
:	O
a	O
meta-analysis	B-T062
of	O
randomized clinical trials	B-T062
In	O
endodontic therapy	B-T061
,	O
continuous	O
rotary instrumentation	B-UnknownType
reduced	O
debris	B-T167
compared	O
to	O
reciprocal instrumentation	B-UnknownType
,	O
which	O
might	O
affect	O
the	O
incidence	B-T081
of	O
post-endodontic pain	B-T184
(	O
PP	B-T184
).	O
The	O
aim	O
of	O
our	O
study	B-T062
was	O
to	O
assess	O
whether	O
PP	B-T184
incidence	B-T081
and	O
levels	O
were	O
influenced	O
by	O
the	O
choice	O
of	O
rotary	B-T074
or	O
reciprocal instruments	B-T074
.	O
In	O
this	O
meta-analysis	B-T062
the	O
Pubmed	B-T170
and	O
EM databases	B-T170
were	O
searched	O
for	O
prospective	O
clinical randomized trials	B-T062
published	O
before	O
April	O
20,	O
2016,	O
using	O
combinations	O
of	O
the	O
keywords:	O
root canal preparation	B-T061
/	O
instrumentation	B-UnknownType
/	O
treatment	B-T061
/	O
therapy	B-T061
;	O
post-operative	B-T079
/	O
endodontic pain	B-T184
;	O
reciprocal	B-T074
and	O
rotary instruments	B-T074
.	O
Three	O
studies	B-T062
were	O
included,	O
involving	O
a	O
total	O
of	O
1,317	O
patients	B-T101
,	O
659	O
treated	O
with	O
reciprocating instruments	B-T074
and	O
658	O
treated	O
with	O
rotary instruments	B-T074
.	O
PP	B-T184
was	O
reported	O
in	O
139	O
patients	B-T101
in	O
the	O
reciprocating group	B-T098
and	O
172	O
in	O
the	O
rotary group	B-T098
.	O
The	O
PP	B-T184
incidence	B-T081
odds	O
ratio	O
was	O
1.27	O
with	O
95%	O
confidence interval	B-T081
(	O
CI	B-T081
)	O
(0.25,	O
6.52)	O
favoring	O
rotary instruments	B-T074
.	O
The	O
mild	B-T080
,	O
moderate	B-T080
and	O
severe	B-T080
PP	B-T184
levels	O
odds	O
ratios	O
were	O
0.31	O
(0.11,	O
0.84),	O
2.24	O
(0.66,	O
7.59)	O
and	O
11.71	O
(0.63,	O
218.15),	O
respectively.	O
No	O
evidence	O
of	O
publication	O
bias	O
was	O
found.	O
Rotary instrument	B-T074
choice	O
in	O
endodontic therapy	B-T061
is	O
associated with	B-T080
a	O
lower	O
incidence	B-T081
of	O
PP	B-T184
than	O
reciprocating instruments	B-T074
,	O
while	O
reciprocating instruments	B-T074
are	O
associated with	B-T080
less	O
mild	O
PP	B-T184
incidence	B-T081
.	O

High	O
throughput	O
resistance	B-T039
profiling	B-T169
of	O
Plasmodium falciparum	B-T204
Plasmodium falciparum infections	B-T046
based	O
on	O
custom dual indexing	B-T062
and	O
Illumina next generation sequencing-technology	B-T062
Genetic polymorphisms	B-T045
in	O
P. falciparum	B-T204
can	O
be	O
used	O
to	O
indicate	O
the	O
parasite's	B-T204
susceptibility	B-T033
to	O
antimalarial drugs	B-T121
as	O
well	O
as	O
its	O
geographical origin	B-T082
.	O
Both	O
of	O
these	O
factors	O
are	O
key	O
to	O
monitoring	B-T058
development	B-T169
and	O
spread	B-T080
of	O
antimalarial	B-T121
antimalarial drug resistance	B-T038
.	O
In	O
this	O
study,	O
we	O
combine	O
multiplex PCR	B-T059
,	O
custom designed dual indexing	B-T062
and	O
Miseq	B-T170
sequencing	B-T059
for	O
high	O
throughput	O
SNP	B-T086
-	O
profiling	B-T169
of	O
457	O
malaria	B-T047
infections	B-T046
from	O
Guinea-Bissau	B-T083
,	O
at	O
the	O
cost	B-T081
of	O
10	O
USD	O
per	O
sample.	O
By	O
amplifying	B-T045
and	O
sequencing	B-T059
15	O
genetic	B-T169
fragments	B-T080
,	O
we	O
cover	O
20	O
resistance	B-T039
-conferring	O
SNPs	B-T086
occurring	O
in	O
pfcrt	B-T028
,	O
pfmdr1	B-T028
,	O
pfdhfr	B-T028
,	O
pfdhps	B-T028
,	O
as	O
well	O
as	O
the	O
entire	O
length	B-T081
of	O
pfK13	B-T028
,	O
and	O
the	O
mitochondrial	B-T026
barcode	B-T170
for	O
parasite	B-T204
origin	B-T033
.	O
SNPs	B-T086
of	O
interest	O
were	O
sequenced	O
with	O
an	O
average	B-T081
depth	O
of	O
2,043	O
reads,	O
and	O
bases	O
were	O
called	O
for	O
the	O
various	O
SNP	B-T086
-	O
positions	B-T082
with	O
a	O
p-value	O
below	O
0.05,	O
for	O
89.8-100%	O
of	O
samples.	O
The	O
SNP	B-T086
data	O
indicates	O
that	O
artemisinin	B-T109
artemisinin resistance	B-T038
-conferring	O
SNPs	B-T086
in	O
pfK13	B-T028
are	O
absent	B-T169
from	O
the	O
studied	O
area	O
of	O
Guinea-Bissau	B-T083
,	O
while	O
the	O
pfmdr1	B-T028
86	O
N	O
allele	O
is	O
found	O
at	O
a	O
high	O
prevalence	B-T081
.	O
The	O
mitochondrial	B-T026
barcodes	B-T170
are	O
unanimous	O
and	O
accommodate	O
a	O
West African	B-T098
West African origin	B-T033
of	O
the	O
parasites	B-T204
.	O
With	O
this	O
method	B-T170
,	O
very	O
reliable	B-T170
high	O
throughput	O
surveillance	B-T061
of	O
antimalarial	B-T121
antimalarial drug resistance	B-T038
becomes	O
more	O
affordable	O
than	O
ever	O
before.	O

A	O
systematic review	B-T170
investigating	B-T169
psychosocial aspects	B-T078
of	O
egg sharing	B-T061
in	O
the	O
United Kingdom	B-T083
and	O
their	O
potential	B-T080
effects	B-T080
on	O
egg donation	B-T061
numbers	B-T081
This	O
review	B-T170
aims	O
to	O
provide	O
an	O
up-to-date	O
knowledge	B-T170
of	O
the	O
psychosocial aspects	B-T078
of	O
egg donation	B-T061
from	O
the	O
perspectives	O
of	O
the	O
egg share donor	B-T098
and	O
their	O
recipient	B-T098
.	O
It	O
explores	O
the	O
motives	B-UnknownType
,	O
experiences	B-T041
and	O
attitudes	B-T041
of	O
egg sharers	B-T098
and	O
their	O
views	O
towards	O
donor	B-T098
anonymity	B-T078
and	O
disclosure	B-T055
.	O
Conclusions	B-T078
are	O
made	O
on	O
how	O
these	O
findings	B-T033
can	O
guide clinical practice	B-T170
and	O
improve	O
egg sharing	B-T061
numbers	B-T081
.	O
A	O
systematic	B-T169
search	B-T052
of	O
peer-reviewed journals	B-T170
of	O
four	O
computerized databases	B-T170
was	O
undertaken.	O
Eleven	O
studies	B-T062
were	O
included	O
in	O
the	O
review	B-T170
.	O
Psychosocial aspects	B-T078
towards	O
donation	B-T061
were	O
positive	B-T033
from	O
the	O
egg share donor	B-T098
and	O
recipient	B-T098
.	O
Concerns	B-T078
raised	B-T080
were	O
whether	O
participating	B-T169
in	O
the	O
egg sharing	B-T061
scheme	B-T170
would	O
impact	B-T080
on	O
their	O
success	B-T080
rates	B-T081
,	O
as	O
well	O
as	O
frustration	B-T041
expressed	B-T078
by	O
a	O
minority	B-T098
regarding	O
the	O
lack of knowledge	B-T033
of	O
egg sharing	B-T061
outside	O
of	O
fertility	B-T040
clinics	B-T073
.	O
The	O
2005	O
legislative	B-T170
changes	B-T169
in	O
the	O
UK	B-T083
have	O
not	O
caused	O
the	O
anticipated	O
dramatic	O
decrease	B-T081
in	O
egg donation	B-T061
;	O
however,	O
oocyte donation	B-T061
still	O
falls	O
short	O
of	O
demand	B-T061
.	O
Egg sharing	B-T061
provides	O
a	O
practical option	B-T169
for	O
more	O
patients	B-T101
to	O
access	B-T169
IVF	B-T061
,	O
whilst	O
also	O
providing	O
more	O
donor oocytes	B-T098
.	O
Improved	O
information provision	B-UnknownType
will	O
result	B-T169
in	O
greater	O
awareness	B-T041
of	O
egg sharing	B-T061
,	O
with	O
the	O
potential	B-T080
to	O
recruit	B-T052
more	O
donors	O
and	O
meet	B-T067
the	O
needs	O
of	O
recipients	B-T098
currently	B-T079
on	O
long	O
waiting lists	B-T170
.	O

Medication regimen	B-T061
complexity	B-T078
and	O
prevalence	B-T081
of	O
potentially inappropriate medicines	B-T080
in	O
older	B-T098
patients	B-T101
after	O
hospitalisation	B-T058
Background	O
There	O
is	O
a	O
relative	B-T080
paucity	O
of	O
information	B-T078
to	O
characterise	O
potential	B-T080
changes	B-T169
in	O
medication regimen	B-T061
complexity	B-T078
and	O
prevalence	B-T081
of	O
prescribing	B-T058
of	O
potentially inappropriate medications	B-T080
after	O
hospitalisation	B-T058
,	O
both	O
in	O
Australia	B-T083
and	O
elsewhere.	O
Objective	B-T170
To	O
evaluate	B-T058
medication regimen	B-T061
complexity	B-T078
and	O
the	O
prevalence	B-T081
of	O
potentially inappropriate medications	B-T080
before	B-T079
and	O
after	O
admission to hospital	B-T058
.	O
Setting	O
General medical units	B-T093
of	O
a	O
tertiary care hospital	B-T073
in	O
Australia	B-T083
.	O
Methods	O
Retrospective cohort study	B-T062
of	O
patients	B-T101
aged	B-T032
65	O
years	O
and	O
above.	O
Medication	B-T058
complexity	B-T078
was	O
measured	B-T080
by	O
using	O
the	O
Medication Regimen Complexity Index	B-T170
(	O
MRCI	B-T170
).	O
Main outcome measure	B-T080
The	O
primary outcome	B-T080
was	O
the	O
change	B-T169
in	O
the	O
Medication Regimen Complexity Index	B-T170
for	O
all	O
prescribed medications	B-T121
after	O
hospitalization	B-T058
.	O
Results	B-T034
A	O
convenience sample	B-T062
of	O
100	O
patients	B-T101
was	O
included	B-T169
in	O
the	O
study	B-T062
.	O
There	O
was	O
a	O
significant	B-T078
change	B-T169
in	O
the	O
mean	B-T081
medication	B-T058
complexity	B-T078
score	B-T081
(as	O
measured	B-T080
using	O
the	O
MRCI	B-T170
),	O
increasing	B-T081
from	O
29	O
at	O
the	O
time of admission	B-T079
to	O
32	O
at	O
the	O
time of discharge	B-T079
(p	O
<	O
0.05).	O
Factors	B-T169
such	O
as	O
baseline	B-T081
medication regimen	B-T061
complexity	B-T078
(	O
pre-admission	B-T079
MRCI	B-T170
)	O
and	O
length of stay in the hospitals	B-T079
appear	B-T080
to	O
influence	B-T077
the	O
change	B-T169
in	O
medication	B-T058
complexity	B-T078
.	O
However,	O
the	O
proportion	B-T081
of	O
patients	B-T101
prescribed	B-T058
at	O
least	O
one	O
potentially inappropriate medicine	B-T080
(	O
PIM	B-T080
)	O
decreased significantly	B-T081
,	O
from	O
52%	O
pre-hospitalization	B-T058
to	O
42%	O
at discharge	B-T079
(p	O
=	O
0.04).	O
Conclusions	O
Relative	B-T080
to	O
the	O
time of admission	B-T079
,	O
overall	B-T080
medication	B-T058
complexity	B-T078
increased	B-T081
and	O
the	O
proportion	B-T081
of	O
patients	B-T101
who	O
were	O
prescribed	B-T058
PIMs	B-T080
decreased	B-T081
after	O
hospitalisation	B-T058
.	O

